{"c182210e8c864335b72c529d72291601f998918d": [["SummaryBetanodaviruses, members of the family Nodaviridae, have small positive-stranded bipartite RNA genomes and are the causal agent of viral nervous necrosis (VNN) in many species of marine farmed fish.", [["viral nervous necrosis", "DISEASE", 138, 160], ["VNN", "DISEASE", 162, 165], ["Betanodaviruses", "GENE_OR_GENE_PRODUCT", 7, 22], ["Nodaviridae", "GENE_OR_GENE_PRODUCT", 46, 57], ["nervous", "ANATOMICAL_SYSTEM", 144, 151], ["VNN", "CANCER", 162, 165], ["fish", "ORGANISM", 200, 204], ["small positive-stranded bipartite RNA genomes", "DNA", 64, 109], ["small positive-stranded bipartite RNA genomes", "PROBLEM", 64, 109], ["viral nervous necrosis", "PROBLEM", 138, 160], ["small", "OBSERVATION_MODIFIER", 64, 69], ["positive", "OBSERVATION", 70, 78], ["stranded bipartite", "OBSERVATION_MODIFIER", 79, 97], ["RNA genomes", "OBSERVATION", 98, 109], ["viral nervous necrosis", "OBSERVATION", 138, 160], ["marine farmed", "OBSERVATION", 186, 199]]], ["In the aquaculture industry, outbreaks of betanodavirus infection and spread in larval and juvenile fish result in devastating damage and heavy economic loss.", [["betanodavirus infection", "DISEASE", 42, 65], ["heavy economic loss", "DISEASE", 138, 157], ["betanodavirus", "SPECIES", 42, 55], ["betanodavirus infection", "PROBLEM", 42, 65], ["devastating damage", "PROBLEM", 115, 133], ["heavy economic loss", "PROBLEM", 138, 157], ["betanodavirus", "OBSERVATION_MODIFIER", 42, 55], ["infection", "OBSERVATION", 56, 65], ["spread", "OBSERVATION_MODIFIER", 70, 76], ["juvenile fish", "OBSERVATION", 91, 104], ["devastating", "OBSERVATION_MODIFIER", 115, 126], ["damage", "OBSERVATION", 127, 133], ["heavy", "OBSERVATION_MODIFIER", 138, 143], ["economic loss", "OBSERVATION", 144, 157]]], ["Although an urgent need exists to develop drugs that inhibit betanodavirus infection, there have been no reports about anti-betanodavirus drugs.", [["betanodavirus infection", "DISEASE", 61, 84], ["anti-betanodavirus drugs", "SIMPLE_CHEMICAL", 119, 143], ["drugs", "TREATMENT", 42, 47], ["betanodavirus infection", "PROBLEM", 61, 84], ["anti-betanodavirus drugs", "TREATMENT", 119, 143]]], ["Recently, it was reported that betanodaviruses were detected in the endosomes of infected cells, suggesting that betanodaviruses enter fish cells by endocytosis.", [["endosomes", "ANATOMY", 68, 77], ["cells", "ANATOMY", 90, 95], ["cells", "ANATOMY", 140, 145], ["betanodaviruses", "GENE_OR_GENE_PRODUCT", 31, 46], ["endosomes", "CELLULAR_COMPONENT", 68, 77], ["cells", "CELL", 90, 95], ["betanodaviruses", "SIMPLE_CHEMICAL", 113, 128], ["fish cells", "CELL", 135, 145], ["betanodaviruses", "PROTEIN", 31, 46], ["infected cells", "CELL_TYPE", 81, 95], ["betanodaviruses", "CELL_TYPE", 113, 128], ["fish cells", "CELL_TYPE", 135, 145], ["betanodaviruses", "PROBLEM", 31, 46], ["infected cells", "PROBLEM", 81, 95], ["betanodaviruses enter fish cells", "PROBLEM", 113, 145], ["infected cells", "OBSERVATION", 81, 95], ["fish cells", "OBSERVATION", 135, 145]]], ["This finding prompted us to examine whether blocking this endosomal pathway could provide a target for antiviral drug development.", [["endosomal", "ANATOMY", 58, 67], ["endosomal", "CELLULAR_COMPONENT", 58, 67], ["blocking this endosomal pathway", "PROBLEM", 44, 75], ["antiviral drug development", "TREATMENT", 103, 129]]], ["In this study, we examined the inhibitory effect of several lysosomotropic agents against betanodavirus infection in fish E-11 cells.", [["E-11 cells", "ANATOMY", 122, 132], ["betanodavirus infection", "DISEASE", 90, 113], ["lysosomotropic agents", "SIMPLE_CHEMICAL", 60, 81], ["betanodavirus", "SIMPLE_CHEMICAL", 90, 103], ["E-11 cells", "CELL", 122, 132], ["fish E-11 cells", "CELL_LINE", 117, 132], ["betanodavirus", "SPECIES", 90, 103], ["E-11", "SPECIES", 122, 126], ["this study", "TEST", 3, 13], ["several lysosomotropic agents", "TREATMENT", 52, 81], ["betanodavirus infection", "PROBLEM", 90, 113]]], ["The pres-IntroductionThe family Nodaviridae is comprised of the genera Alphanodavirus and Betanodavirus, which predominantly infect insects and fish, respectively.", [["Alphanodavirus", "GENE_OR_GENE_PRODUCT", 71, 85], ["Betanodavirus", "GENE_OR_GENE_PRODUCT", 90, 103], ["fish", "ORGANISM_SUBDIVISION", 144, 148], ["the genera Alphanodavirus", "PROBLEM", 60, 85], ["Betanodavirus", "TREATMENT", 90, 103], ["predominantly", "OBSERVATION_MODIFIER", 111, 124], ["infect", "OBSERVATION", 125, 131]]], ["Viruses belonging to the genus Betanodavirus are the causative agents of viral encephalopathy and retinopathy, also known as viral nervous necrosis (VNN).", [["viral encephalopathy", "DISEASE", 73, 93], ["retinopathy", "DISEASE", 98, 109], ["viral nervous necrosis", "DISEASE", 125, 147], ["VNN", "DISEASE", 149, 152], ["Betanodavirus", "GENE_OR_GENE_PRODUCT", 31, 44], ["viral nervous necrosis", "CANCER", 125, 147], ["VNN", "CANCER", 149, 152], ["Viruses", "PROBLEM", 0, 7], ["viral encephalopathy", "PROBLEM", 73, 93], ["retinopathy", "PROBLEM", 98, 109], ["viral nervous necrosis", "PROBLEM", 125, 147], ["viral encephalopathy", "OBSERVATION", 73, 93], ["retinopathy", "OBSERVATION", 98, 109], ["viral nervous necrosis", "OBSERVATION", 125, 147]]], ["Nodaviruses are small (25-30 nm diameter), spherical, non-enveloped viruses with a genome that is composed of two single-stranded, positive-sense RNA molecules [17] .", [["Nodaviruses", "DISEASE", 0, 11], ["Nodaviruses", "GENE_OR_GENE_PRODUCT", 0, 11], ["positive-sense RNA molecules", "PROTEIN", 131, 159], ["spherical, non-enveloped viruses", "PROBLEM", 43, 75], ["small", "OBSERVATION_MODIFIER", 16, 21], ["spherical", "OBSERVATION_MODIFIER", 43, 52], ["non-enveloped viruses", "OBSERVATION", 54, 75]]], ["The larger genomic segment, RNA1 (3.1 Kb), encodes the RNA-dependent RNA polymerase (RdRp) [10, 19, 31] , and the smaller genomic segment, RNA2 (1.4 Kb), encodes the coat protein [20] .", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 55, 83], ["genomic segment", "DNA", 11, 26], ["RNA1", "DNA", 28, 32], ["RNA-dependent RNA polymerase", "PROTEIN", 55, 83], ["RdRp", "PROTEIN", 85, 89], ["genomic segment", "DNA", 122, 137], ["RNA2", "DNA", 139, 143], ["coat protein", "PROTEIN", 166, 178], ["RNA1", "TEST", 28, 32], ["Kb", "TEST", 38, 40], ["the RNA", "TEST", 51, 58], ["RdRp", "TEST", 85, 89], ["RNA2", "TEST", 139, 143], ["the coat protein", "TEST", 162, 178], ["larger", "OBSERVATION_MODIFIER", 4, 10], ["genomic", "OBSERVATION_MODIFIER", 11, 18], ["segment", "ANATOMY_MODIFIER", 19, 26], ["RNA1", "OBSERVATION_MODIFIER", 28, 32], ["RNA", "OBSERVATION_MODIFIER", 55, 58], ["dependent", "OBSERVATION_MODIFIER", 59, 68], ["RNA polymerase", "OBSERVATION", 69, 83], ["smaller", "OBSERVATION_MODIFIER", 114, 121], ["segment", "ANATOMY_MODIFIER", 130, 137]]], ["It has recently been determined that a subgenomic RNA transcribed from the 3 0 end of RNA1, termed RNA3, encodes a protein, B2.", [["RNA1", "GENE_OR_GENE_PRODUCT", 86, 90], ["RNA3", "GENE_OR_GENE_PRODUCT", 99, 103], ["B2", "GENE_OR_GENE_PRODUCT", 124, 126], ["subgenomic RNA", "RNA", 39, 53], ["3 0 end", "DNA", 75, 82], ["RNA1", "DNA", 86, 90], ["RNA3", "DNA", 99, 103], ["B2", "PROTEIN", 124, 126], ["a subgenomic RNA", "PROBLEM", 37, 53], ["subgenomic RNA", "OBSERVATION", 39, 53], ["RNA3", "OBSERVATION", 99, 103]]], ["This protein is highly conserved among the betanodaviruses and is an RNAi antagonist [7, 8, 13] .IntroductionVNN devastates many species of marine fish culture worldwide [12] .", [["an RNAi antagonist", "TREATMENT", 66, 84], ["IntroductionVNN", "TREATMENT", 97, 112], ["marine fish culture", "TEST", 140, 159]]], ["Betanodaviruses have been isolated from more than 30 marine fish species from 14 families and are classified into four genotypes based on a phylogenetic analysis of the coat protein sequences.", [["Betanodaviruses", "CHEMICAL", 0, 15], ["Betanodaviruses", "GENE_OR_GENE_PRODUCT", 0, 15], ["coat protein sequences", "DNA", 169, 191], ["Betanodaviruses", "TREATMENT", 0, 15], ["a phylogenetic analysis", "TEST", 138, 161], ["the coat protein sequences", "TEST", 165, 191]]], ["The genotypes are: striped jack nervous necrosis virus (SJNNV), barfin flounder nervous necrosis virus (BFNNV), tiger puffer nervous necrosis virus (TPNNV) and redspotted grouper nervous necrosis virus (RGNNV) [18, 20, 21] .", [["nervous necrosis", "DISEASE", 32, 48], ["nervous necrosis", "DISEASE", 80, 96], ["nervous necrosis", "DISEASE", 125, 141], ["nervous necrosis", "DISEASE", 179, 195], ["striped jack nervous necrosis virus", "ORGANISM", 19, 54], ["SJNNV", "ORGANISM", 56, 61], ["barfin flounder nervous necrosis virus", "ORGANISM", 64, 102], ["tiger puffer nervous necrosis virus", "ORGANISM", 112, 147], ["redspotted grouper nervous necrosis virus", "ORGANISM", 160, 201], ["barfin", "SPECIES", 64, 70], ["flounder nervous necrosis virus", "SPECIES", 71, 102], ["puffer nervous necrosis virus", "SPECIES", 118, 147], ["grouper nervous necrosis virus", "SPECIES", 171, 201], ["striped jack nervous necrosis virus", "SPECIES", 19, 54], ["SJNNV", "SPECIES", 56, 61], ["barfin flounder nervous necrosis virus", "SPECIES", 64, 102], ["BFNNV", "SPECIES", 104, 109], ["tiger puffer nervous necrosis virus", "SPECIES", 112, 147], ["TPNNV", "SPECIES", 149, 154], ["redspotted grouper nervous necrosis virus", "SPECIES", 160, 201], ["The genotypes", "TEST", 0, 13], ["striped jack nervous necrosis virus (SJNNV)", "PROBLEM", 19, 62], ["barfin flounder nervous necrosis virus", "PROBLEM", 64, 102], ["tiger puffer nervous necrosis virus", "PROBLEM", 112, 147], ["redspotted grouper nervous necrosis virus", "PROBLEM", 160, 201], ["nervous", "ANATOMY", 32, 39], ["necrosis", "OBSERVATION", 40, 48], ["nervous", "ANATOMY", 80, 87], ["necrosis", "OBSERVATION", 88, 96], ["nervous", "ANATOMY", 125, 132], ["necrosis", "OBSERVATION", 133, 141], ["nervous", "ANATOMY", 179, 186]]], ["Effective control of betanodavirus infection is urgently needed to reduce the significant economic loss caused by the virus in the fish industry.", [["betanodavirus infection", "DISEASE", 21, 44], ["betanodavirus", "ORGANISM", 21, 34], ["betanodavirus", "SPECIES", 21, 34], ["betanodavirus infection", "PROBLEM", 21, 44], ["the significant economic loss", "PROBLEM", 74, 103], ["the virus", "PROBLEM", 114, 123], ["infection", "OBSERVATION", 35, 44], ["significant", "OBSERVATION_MODIFIER", 78, 89], ["economic loss", "OBSERVATION", 90, 103], ["virus", "OBSERVATION", 118, 123]]], ["It is widely accepted that a vaccine capable of preventing VNN would be a major improvement.", [["VNN", "DISEASE", 59, 62], ["VNN", "CANCER", 59, 62], ["VNN", "SPECIES", 59, 62], ["a vaccine", "TREATMENT", 27, 36], ["VNN", "TREATMENT", 59, 62]]], ["Partial immunity has been obtained using recombinant betanodavirus coat protein expressed in E. coli [11, 32] .", [["betanodavirus coat protein", "GENE_OR_GENE_PRODUCT", 53, 79], ["E. coli", "ORGANISM", 93, 100], ["recombinant betanodavirus coat protein", "PROTEIN", 41, 79], ["E. coli", "SPECIES", 93, 100], ["E. coli", "SPECIES", 93, 100], ["recombinant betanodavirus coat protein", "TREATMENT", 41, 79], ["E. coli", "PROBLEM", 93, 100], ["E. coli", "OBSERVATION", 93, 100]]], ["Immunization with virus-like particles (VLPs) of betanodavirus has been reported to induce a protective immune response against VNN [33] .", [["betanodavirus", "CHEMICAL", 49, 62], ["virus-like particles", "ORGANISM", 18, 38], ["VLPs", "ORGANISM", 40, 44], ["betanodavirus", "ORGANISM", 49, 62], ["Immunization", "TREATMENT", 0, 12], ["virus", "PROBLEM", 18, 23], ["betanodavirus", "TREATMENT", 49, 62]]], ["However, in most cases, VNN occurs in larval and juvenile fish that cannot be easily vaccinated due to their small size.", [["VNN", "CHEMICAL", 24, 27], ["VNN", "CANCER", 24, 27], ["fish", "ORGANISM", 58, 62], ["small", "OBSERVATION_MODIFIER", 109, 114], ["size", "OBSERVATION_MODIFIER", 115, 119]]], ["Therefore, the development of drugs that inhibit betanodavirus infection is of critical importance.", [["infection", "DISEASE", 63, 72], ["betanodavirus", "GENE_OR_GENE_PRODUCT", 49, 62], ["drugs", "TREATMENT", 30, 35], ["betanodavirus infection", "PROBLEM", 49, 72]]], ["The mechanism of betanodavirus infection is still unclear.", [["betanodavirus", "CHEMICAL", 17, 30], ["infection", "DISEASE", 31, 40], ["betanodavirus", "GENE_OR_GENE_PRODUCT", 17, 30], ["betanodavirus infection", "PROBLEM", 17, 40], ["betanodavirus", "OBSERVATION_MODIFIER", 17, 30], ["infection", "OBSERVATION", 31, 40]]], ["An electron-microscopic study of betanodavirus-infected cells suggested that the entry of the betanodavirus into a fish cell line depends on the endocytic pathway [16] .IntroductionThe use of inhibitors of endosomal acidification such as NH 4 Cl and chloroquine has been applied against many viruses [14, 26] .", [["cells", "ANATOMY", 56, 61], ["cell line", "ANATOMY", 120, 129], ["endosomal", "ANATOMY", 206, 215], ["NH 4 Cl", "CHEMICAL", 238, 245], ["chloroquine", "CHEMICAL", 250, 261], ["NH 4 Cl", "CHEMICAL", 238, 245], ["chloroquine", "CHEMICAL", 250, 261], ["betanodavirus", "GENE_OR_GENE_PRODUCT", 33, 46], ["cells", "CELL", 56, 61], ["betanodavirus", "GENE_OR_GENE_PRODUCT", 94, 107], ["fish cell line", "CELL", 115, 129], ["endosomal", "CELLULAR_COMPONENT", 206, 215], ["NH 4 Cl", "SIMPLE_CHEMICAL", 238, 245], ["chloroquine", "SIMPLE_CHEMICAL", 250, 261], ["betanodavirus-infected cells", "CELL_LINE", 33, 61], ["betanodavirus", "PROTEIN", 94, 107], ["fish cell line", "CELL_LINE", 115, 129], ["An electron-microscopic study", "TEST", 0, 29], ["betanodavirus", "TEST", 33, 46], ["infected cells", "PROBLEM", 47, 61], ["the betanodavirus", "TREATMENT", 90, 107], ["a fish cell line", "TREATMENT", 113, 129], ["inhibitors", "TREATMENT", 192, 202], ["endosomal acidification", "TREATMENT", 206, 229], ["NH 4 Cl", "TREATMENT", 238, 245], ["chloroquine", "TREATMENT", 250, 261], ["fish cell line", "OBSERVATION", 115, 129]]], ["In this study, we examined the inhibitory effect of lysosomotropic agents (NH 4 Cl, chloroquine, bafilomycin A1, and monensin) on betanodavirus infection.", [["lysosomotropic agents", "CHEMICAL", 52, 73], ["NH 4 Cl", "CHEMICAL", 75, 82], ["chloroquine", "CHEMICAL", 84, 95], ["bafilomycin A1", "CHEMICAL", 97, 111], ["monensin", "CHEMICAL", 117, 125], ["betanodavirus infection", "DISEASE", 130, 153], ["NH 4 Cl", "CHEMICAL", 75, 82], ["chloroquine", "CHEMICAL", 84, 95], ["bafilomycin A1", "CHEMICAL", 97, 111], ["monensin", "CHEMICAL", 117, 125], ["lysosomotropic agents", "SIMPLE_CHEMICAL", 52, 73], ["NH 4 Cl", "SIMPLE_CHEMICAL", 75, 82], ["chloroquine", "SIMPLE_CHEMICAL", 84, 95], ["bafilomycin A1", "SIMPLE_CHEMICAL", 97, 111], ["monensin", "SIMPLE_CHEMICAL", 117, 125], ["betanodavirus", "ORGANISM", 130, 143], ["this study", "TEST", 3, 13], ["lysosomotropic agents", "TREATMENT", 52, 73], ["NH", "TREATMENT", 75, 77], ["chloroquine", "TREATMENT", 84, 95], ["bafilomycin A1", "TREATMENT", 97, 111], ["monensin", "TREATMENT", 117, 125], ["betanodavirus infection", "PROBLEM", 130, 153], ["infection", "OBSERVATION", 144, 153]]], ["Our results demonstrate that these agents inhibit the entry of betanodavirus into cells.Materials and methodsCells, viruses and chemicals E-11 cells were maintained in Leibovitz's L-15 medium (Invitrogen, Carlsbad, CA) supplemented with 5% fetal bovine serum (FBS) at 25 C. The fish nodavirus used in this study was isolated in 2001 from a seven-band grouper in Nagasaki, Japan.", [["cells", "ANATOMY", 82, 87], ["Cells", "ANATOMY", 109, 114], ["E-11 cells", "ANATOMY", 138, 148], ["fetal bovine serum", "ANATOMY", 240, 258], ["FBS", "ANATOMY", 260, 263], ["betanodavirus", "GENE_OR_GENE_PRODUCT", 63, 76], ["cells", "CELL", 82, 87], ["Cells", "CELL", 109, 114], ["E-11 cells", "CELL", 138, 148], ["bovine", "ORGANISM", 246, 252], ["serum", "ORGANISM_SUBSTANCE", 253, 258], ["FBS", "ORGANISM_SUBSTANCE", 260, 263], ["fish", "ORGANISM", 278, 282], ["grouper", "ORGANISM", 351, 358], ["betanodavirus", "PROTEIN", 63, 76], ["E-11 cells", "CELL_LINE", 138, 148], ["bovine", "SPECIES", 246, 252], ["bovine", "SPECIES", 246, 252], ["Cells", "TEST", 109, 114], ["viruses", "TEST", 116, 123], ["chemicals E", "TEST", 128, 139], ["cells", "TEST", 143, 148], ["Leibovitz", "TEST", 168, 177], ["Invitrogen", "TEST", 193, 203], ["Carlsbad", "TEST", 205, 213], ["5% fetal bovine serum", "TEST", 237, 258], ["FBS", "TEST", 260, 263], ["The fish nodavirus", "PROBLEM", 274, 292], ["this study", "TEST", 301, 311]]], ["This virus belongs to the RGNNV genotype, determined by our own RNA2 nucleotide sequence analysis.", [["nucleotide", "CHEMICAL", 69, 79], ["RGNNV", "GENE_OR_GENE_PRODUCT", 26, 31], ["RNA2 nucleotide sequence", "DNA", 64, 88], ["This virus", "PROBLEM", 0, 10], ["our own RNA2 nucleotide sequence analysis", "TEST", 56, 97]]], ["E-11 cells were inoculated with the betanodavirus for propagation, and viruses were harvested when nearly all of the cells in the monolayer showed a cytopathic effect (CPE).", [["E-11 cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 117, 122], ["monolayer", "ANATOMY", 130, 139], ["E-11 cells", "CELL", 0, 10], ["cells", "CELL", 117, 122], ["monolayer", "CELL", 130, 139], ["E-11 cells", "CELL_LINE", 0, 10], ["viruses", "PROBLEM", 71, 78], ["a cytopathic effect (CPE", "PROBLEM", 147, 171], ["cytopathic effect", "OBSERVATION", 149, 166]]], ["NH 4 Cl, chloroquine, bafilomycin A1, and chlorpromazine were purchased from Sigma (St. Louis, Mo.), and monensin was purchased from Wako (Osaka, Japan).Virus infection and titrationE-11 cells were inoculated with virus, either in the presence or absence of chemicals at 28 C for 1 h.", [["titrationE-11 cells", "ANATOMY", 173, 192], ["NH 4 Cl", "CHEMICAL", 0, 7], ["chloroquine", "CHEMICAL", 9, 20], ["bafilomycin A1", "CHEMICAL", 22, 36], ["chlorpromazine", "CHEMICAL", 42, 56], ["monensin", "CHEMICAL", 105, 113], ["Virus infection", "DISEASE", 153, 168], ["NH 4 Cl", "CHEMICAL", 0, 7], ["chloroquine", "CHEMICAL", 9, 20], ["bafilomycin A1", "CHEMICAL", 22, 36], ["chlorpromazine", "CHEMICAL", 42, 56], ["monensin", "CHEMICAL", 105, 113], ["NH 4 Cl", "SIMPLE_CHEMICAL", 0, 7], ["chloroquine", "SIMPLE_CHEMICAL", 9, 20], ["bafilomycin A1", "SIMPLE_CHEMICAL", 22, 36], ["chlorpromazine", "SIMPLE_CHEMICAL", 42, 56], ["St. Louis", "ORGANISM", 84, 93], ["monensin", "SIMPLE_CHEMICAL", 105, 113], ["Wako", "ORGANISM_SUBSTANCE", 133, 137], ["Virus", "ORGANISM", 153, 158], ["titrationE-11 cells", "CELL", 173, 192], ["titrationE-11 cells", "CELL_LINE", 173, 192], ["NH", "TREATMENT", 0, 2], ["chloroquine", "TREATMENT", 9, 20], ["bafilomycin A1", "TREATMENT", 22, 36], ["chlorpromazine", "TREATMENT", 42, 56], ["monensin", "TREATMENT", 105, 113], ["Virus infection", "PROBLEM", 153, 168], ["titrationE-11 cells", "TREATMENT", 173, 192], ["virus", "PROBLEM", 214, 219], ["infection", "OBSERVATION", 159, 168]]], ["The cells were then maintained in growth medium containing 2% FBS at 28 C. Unless otherwise described, cells were pretreated with an agent for 1 h at 28 C and inoculated with virus at a multiplicity of infection (M.O.I.) of 1.", [["cells", "ANATOMY", 4, 9], ["FBS", "ANATOMY", 62, 65], ["cells", "ANATOMY", 103, 108], ["infection", "DISEASE", 202, 211], ["cells", "CELL", 4, 9], ["FBS", "ORGANISM_SUBSTANCE", 62, 65], ["cells", "CELL", 103, 108], ["2% FBS", "TREATMENT", 59, 65], ["an agent", "TREATMENT", 130, 138], ["virus", "PROBLEM", 175, 180], ["infection", "PROBLEM", 202, 211], ["infection", "OBSERVATION", 202, 211]]], ["The virus titer was expressed as 50% tissue culture infectious dose (TCID 50 ), assayed using E-11 cells.Detection of viral RNA by RT-PCRTotal RNA was prepared from RGNNV-infected cells (5\u00c2 10 5 ) using Trizol reagent (Invitrogen).", [["tissue", "ANATOMY", 37, 43], ["E-11 cells", "ANATOMY", 94, 104], ["cells", "ANATOMY", 180, 185], ["tissue", "TISSUE", 37, 43], ["E-11 cells", "CELL", 94, 104], ["cells", "CELL", 180, 185], ["E-11 cells", "CELL_LINE", 94, 104], ["viral RNA", "RNA", 118, 127], ["RT-PCRTotal RNA", "RNA", 131, 146], ["RGNNV-infected cells", "CELL_LINE", 165, 185], ["The virus titer", "PROBLEM", 0, 15], ["viral RNA", "PROBLEM", 118, 127], ["PCRTotal RNA", "PROBLEM", 134, 146], ["RGNNV", "TEST", 165, 170], ["infected cells", "PROBLEM", 171, 185], ["Trizol reagent (Invitrogen)", "TREATMENT", 203, 230], ["virus", "OBSERVATION", 4, 9], ["viral RNA", "OBSERVATION", 118, 127], ["infected cells", "OBSERVATION", 171, 185]]], ["To detect (\u00fe) RNA1, (\u00c0) RNA1, and 18S rRNA, the RNA samples were reverse-transcribed with M-MLV reverse transcriptase (Invitrogen) using RGRNA1-2490RDetection of viral RNA by RT-PCR, and 18S rRNA-R (5 0 -GCTGGAATTACCGCGGCT-3 0 ) (for 18S rRNA).", [["samples", "ANATOMY", 52, 59], ["(\u00c0) RNA1", "GENE_OR_GENE_PRODUCT", 20, 28], ["18S", "GENE_OR_GENE_PRODUCT", 34, 37], ["rRNA", "CELLULAR_COMPONENT", 38, 42], ["M-MLV reverse transcriptase", "GENE_OR_GENE_PRODUCT", 90, 117], ["18S", "GENE_OR_GENE_PRODUCT", 187, 190], ["rRNA-R", "GENE_OR_GENE_PRODUCT", 191, 197], ["18S rRNA", "GENE_OR_GENE_PRODUCT", 234, 242], ["(\u00fe) RNA1, (\u00c0) RNA1", "RNA", 10, 28], ["18S rRNA", "RNA", 34, 42], ["MLV reverse transcriptase", "PROTEIN", 92, 117], ["RGRNA1", "PROTEIN", 137, 143], ["viral RNA", "RNA", 162, 171], ["18S rRNA", "DNA", 187, 195], ["18S rRNA", "DNA", 234, 242], ["RNA1", "TEST", 14, 18], ["RNA1", "TEST", 24, 28], ["18S rRNA", "TEST", 34, 42], ["the RNA samples", "TEST", 44, 59], ["RGRNA1", "TEST", 137, 143], ["viral RNA", "TEST", 162, 171], ["RT", "TEST", 175, 177], ["PCR", "TEST", 178, 181], ["18S rRNA", "TEST", 187, 195], ["GCTGGAATTACCGCGGCT", "TEST", 204, 222]]], ["PCR amplification was performed with a primer pair (RGRNA1-1868F and RGRNA1-2490R for RNA1 and 18S rRNA-F [5 0 -CGGCTACCACATCCAAGGAA-3 0 ] and 18S rRNA-R for 18S rRNA).", [["RGRNA1-2490R", "GENE_OR_GENE_PRODUCT", 69, 81], ["18S", "GENE_OR_GENE_PRODUCT", 143, 146], ["rRNA-R", "GENE_OR_GENE_PRODUCT", 147, 153], ["18S rRNA", "GENE_OR_GENE_PRODUCT", 158, 166], ["primer pair", "DNA", 39, 50], ["RGRNA1", "DNA", 52, 58], ["1868F", "DNA", 59, 64], ["RGRNA1", "DNA", 69, 75], ["RNA1", "DNA", 86, 90], ["18S rRNA", "DNA", 95, 103], ["18S rRNA", "DNA", 143, 151], ["18S rRNA", "DNA", 158, 166], ["PCR amplification", "TEST", 0, 17], ["a primer pair", "TEST", 37, 50], ["RGRNA1", "TEST", 52, 58], ["RGRNA1", "TEST", 69, 75], ["RNA1", "TEST", 86, 90], ["rRNA", "TEST", 99, 103], ["CGGCTACCACATCCAAGGAA", "TEST", 112, 132], ["18S rRNA", "TEST", 143, 151]]], ["PCR products were analyzed by agarose gel electrophoresis and visualized by ethidium bromide staining.", [["ethidium bromide", "CHEMICAL", 76, 92], ["ethidium bromide", "CHEMICAL", 76, 92], ["agarose", "SIMPLE_CHEMICAL", 30, 37], ["ethidium bromide", "SIMPLE_CHEMICAL", 76, 92], ["PCR products", "TREATMENT", 0, 12], ["agarose gel electrophoresis", "TEST", 30, 57], ["ethidium bromide staining", "TEST", 76, 101]]], ["The band intensities were semi-quantitated using the Image J software program (NIH).Effects of NH 4 Cl and chloroquine on the development of betanodavirus-induced CPEThe effect of the lysosomotropic agents on betanodavirus infection was initially examined by the appearance of virus-induced CPE.", [["NH 4 Cl", "CHEMICAL", 95, 102], ["chloroquine", "CHEMICAL", 107, 118], ["betanodavirus", "CHEMICAL", 141, 154], ["betanodavirus", "CHEMICAL", 209, 222], ["infection", "DISEASE", 223, 232], ["NH 4 Cl", "CHEMICAL", 95, 102], ["chloroquine", "CHEMICAL", 107, 118], ["NH 4 Cl", "SIMPLE_CHEMICAL", 95, 102], ["chloroquine", "SIMPLE_CHEMICAL", 107, 118], ["betanodavirus", "SIMPLE_CHEMICAL", 141, 154], ["lysosomotropic agents", "SIMPLE_CHEMICAL", 184, 205], ["betanodavirus", "SIMPLE_CHEMICAL", 209, 222], ["The band intensities", "TEST", 0, 20], ["NH", "TREATMENT", 95, 97], ["chloroquine", "TREATMENT", 107, 118], ["betanodavirus", "TREATMENT", 141, 154], ["induced CPE", "PROBLEM", 155, 166], ["the lysosomotropic agents", "TREATMENT", 180, 205], ["betanodavirus infection", "PROBLEM", 209, 232], ["virus", "PROBLEM", 277, 282], ["CPE", "PROBLEM", 291, 294], ["CPE", "OBSERVATION", 163, 166], ["virus", "OBSERVATION", 277, 282], ["CPE", "OBSERVATION", 291, 294]]], ["NH 4 Cl and chloroquine diffused into the endosome and served as a proton sink, which inhibited endosome acidification [22] .", [["endosome", "ANATOMY", 42, 50], ["endosome", "ANATOMY", 96, 104], ["NH 4 Cl", "CHEMICAL", 0, 7], ["chloroquine", "CHEMICAL", 12, 23], ["NH 4 Cl", "CHEMICAL", 0, 7], ["chloroquine", "CHEMICAL", 12, 23], ["NH 4 Cl", "SIMPLE_CHEMICAL", 0, 7], ["chloroquine", "SIMPLE_CHEMICAL", 12, 23], ["endosome", "CELLULAR_COMPONENT", 42, 50], ["endosome", "CELLULAR_COMPONENT", 96, 104], ["chloroquine", "TREATMENT", 12, 23], ["a proton sink", "TREATMENT", 65, 78]]], ["E-11 cells were inoculated with RGNNV at an M.O.I. of 1 in the presence of different concentrations of the agents (Fig. 1) .", [["E-11 cells", "ANATOMY", 0, 10], ["E-11 cells", "CELL", 0, 10], ["E-11 cells", "CELL_LINE", 0, 10], ["RGNNV", "PROBLEM", 32, 37], ["the agents", "TREATMENT", 103, 113]]], ["The uninfected E-11 cells showed a flat adherent shape (Fig. 1A) , and virus-infected cells showed a typical CPE shape and detached from the dish by 6 days after inoculation (Fig. 1B) .", [["E-11 cells", "ANATOMY", 15, 25], ["cells", "ANATOMY", 86, 91], ["E-11 cells", "CELL", 15, 25], ["cells", "CELL", 86, 91], ["uninfected E-11 cells", "CELL_LINE", 4, 25], ["virus-infected cells", "CELL_TYPE", 71, 91], ["E-11", "SPECIES", 15, 19], ["The uninfected E-11 cells", "TEST", 0, 25], ["a flat adherent shape", "PROBLEM", 33, 54], ["virus", "PROBLEM", 71, 76], ["infected cells", "PROBLEM", 77, 91], ["a typical CPE shape", "PROBLEM", 99, 118], ["flat adherent", "OBSERVATION_MODIFIER", 35, 48], ["shape", "OBSERVATION_MODIFIER", 49, 54], ["infected cells", "OBSERVATION", 77, 91], ["typical", "OBSERVATION_MODIFIER", 101, 108], ["CPE shape", "OBSERVATION", 109, 118]]], ["In contrast, when E-11 cells were infected with RGNNV in the presence of NH 4 Cl ( Fig. 1C -E) or chloroquine ( Fig. 1F-H) , the development of CPE was suppressed in a dose-dependent manner.", [["E-11 cells", "ANATOMY", 18, 28], ["RGNNV", "CHEMICAL", 48, 53], ["NH 4 Cl", "CHEMICAL", 73, 80], ["1C -E", "CHEMICAL", 88, 93], ["chloroquine", "CHEMICAL", 98, 109], ["Fig. 1F-H", "CHEMICAL", 112, 121], ["NH 4 Cl", "CHEMICAL", 73, 80], ["chloroquine", "CHEMICAL", 98, 109], ["Fig. 1F-H", "CHEMICAL", 112, 121], ["E-11 cells", "CELL", 18, 28], ["NH 4 Cl", "SIMPLE_CHEMICAL", 73, 80], ["1C -E", "SIMPLE_CHEMICAL", 88, 93], ["chloroquine", "SIMPLE_CHEMICAL", 98, 109], ["Fig. 1F-H", "SIMPLE_CHEMICAL", 112, 121], ["E-11 cells", "CELL_LINE", 18, 28], ["RGNNV", "PROTEIN", 48, 53], ["chloroquine", "TREATMENT", 98, 109], ["CPE", "PROBLEM", 144, 147], ["CPE", "OBSERVATION", 144, 147]]], ["CPE was completely suppressed at a concentration of 1 mM NH 4 Cl (Fig. 1E ) and 1 mM chloroquine (Fig. 1H) , respectively.", [["CPE", "CHEMICAL", 0, 3], ["NH 4 Cl", "CHEMICAL", 57, 64], ["chloroquine", "CHEMICAL", 85, 96], ["NH 4 Cl", "CHEMICAL", 57, 64], ["chloroquine", "CHEMICAL", 85, 96], ["1H", "CHEMICAL", 103, 105], ["NH 4 Cl", "SIMPLE_CHEMICAL", 57, 64], ["chloroquine", "SIMPLE_CHEMICAL", 85, 96], ["CPE", "PROBLEM", 0, 3], ["1 mM chloroquine", "TREATMENT", 80, 96], ["completely", "OBSERVATION_MODIFIER", 8, 18], ["suppressed", "OBSERVATION_MODIFIER", 19, 29]]], ["The effect of NH 4 Cl and chloroquine on viral infection may result from the cytotoxicity of these agents.", [["NH 4 Cl", "CHEMICAL", 14, 21], ["chloroquine", "CHEMICAL", 26, 37], ["viral infection", "DISEASE", 41, 56], ["NH 4 Cl", "CHEMICAL", 14, 21], ["chloroquine", "CHEMICAL", 26, 37], ["NH 4 Cl", "SIMPLE_CHEMICAL", 14, 21], ["chloroquine", "SIMPLE_CHEMICAL", 26, 37], ["NH 4 Cl", "TREATMENT", 14, 21], ["chloroquine", "TREATMENT", 26, 37], ["viral infection", "PROBLEM", 41, 56], ["these agents", "TREATMENT", 93, 105]]], ["Therefore, we investigated the cytotoxicity of these agents to E-11 cells by WST-1 assay.", [["E-11 cells", "ANATOMY", 63, 73], ["E-11 cells", "CELL", 63, 73], ["WST-1", "GENE_OR_GENE_PRODUCT", 77, 82], ["E-11 cells", "CELL_LINE", 63, 73], ["WST", "TEST", 77, 80]]], ["The degree of cell proliferation and morphologic change with NH 4 Cl and chloroquine was not affected at a concentration of up to 12.5 mM and 25 mM, respectively (data not shown).Lysosomotropic agents do not affect the attachment of betanodavirus to cellsTo investigate the mechanism of the inhibitory effect on betanodavirus infection by agents, we next examined the effect of inhibitors on the attachment of betanodavirus to E-11 cells.", [["cell", "ANATOMY", 14, 18], ["cells", "ANATOMY", 250, 255], ["E-11 cells", "ANATOMY", 427, 437], ["NH 4 Cl", "CHEMICAL", 61, 68], ["chloroquine", "CHEMICAL", 73, 84], ["infection", "DISEASE", 326, 335], ["NH 4 Cl", "CHEMICAL", 61, 68], ["chloroquine", "CHEMICAL", 73, 84], ["cell", "CELL", 14, 18], ["NH 4 Cl", "SIMPLE_CHEMICAL", 61, 68], ["chloroquine", "SIMPLE_CHEMICAL", 73, 84], ["betanodavirus", "GENE_OR_GENE_PRODUCT", 233, 246], ["cells", "CELL", 250, 255], ["betanodavirus", "SIMPLE_CHEMICAL", 312, 325], ["E-11 cells", "CELL", 427, 437], ["E-11 cells", "CELL_LINE", 427, 437], ["cell proliferation", "PROBLEM", 14, 32], ["morphologic change", "PROBLEM", 37, 55], ["NH", "TREATMENT", 61, 63], ["chloroquine", "TREATMENT", 73, 84], ["Lysosomotropic agents", "TREATMENT", 179, 200], ["betanodavirus infection", "PROBLEM", 312, 335], ["agents", "TREATMENT", 339, 345], ["inhibitors", "TREATMENT", 378, 388], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["cell proliferation", "OBSERVATION", 14, 32], ["morphologic", "OBSERVATION_MODIFIER", 37, 48], ["change", "OBSERVATION_MODIFIER", 49, 55]]], ["As shown in Fig. 2A and B, the genomic (\u00fe) RNA1 band was detected in cells that were inoculated with RGNNV in a dose-dependent manner.", [["cells", "ANATOMY", 69, 74], ["2A", "GENE_OR_GENE_PRODUCT", 17, 19], ["B", "GENE_OR_GENE_PRODUCT", 24, 25], ["cells", "CELL", 69, 74], ["genomic (\u00fe) RNA1 band", "DNA", 31, 52], ["RGNNV", "PROTEIN", 101, 106], ["RNA1 band", "TEST", 43, 52]]], ["When E-11 cells were inoculated with virus in the presence of 1 mM NH 4 Cl or 1 mM chloroquine, the viral (\u00fe) RNA1 was still detected in the cells (Fig. 2C ).", [["E-11 cells", "ANATOMY", 5, 15], ["cells", "ANATOMY", 141, 146], ["NH 4 Cl", "CHEMICAL", 67, 74], ["chloroquine", "CHEMICAL", 83, 94], ["NH 4 Cl", "CHEMICAL", 67, 74], ["chloroquine", "CHEMICAL", 83, 94], ["E-11 cells", "CELL", 5, 15], ["NH 4 Cl", "SIMPLE_CHEMICAL", 67, 74], ["chloroquine", "SIMPLE_CHEMICAL", 83, 94], ["cells", "CELL", 141, 146], ["E-11 cells", "CELL_LINE", 5, 15], ["viral (\u00fe) RNA1", "DNA", 100, 114], ["virus", "PROBLEM", 37, 42], ["chloroquine", "TREATMENT", 83, 94], ["the viral (\u00fe) RNA1", "PROBLEM", 96, 114]]], ["The intensity of (\u00fe) RNA1 detected in the presence of drugs was comparable to that of the control cells (Fig. 2D ).", [["cells", "ANATOMY", 98, 103], ["cells", "CELL", 98, 103], ["RNA1", "DNA", 21, 25], ["control cells", "CELL_TYPE", 90, 103], ["RNA1", "PROBLEM", 21, 25], ["drugs", "TREATMENT", 54, 59]]], ["This result suggested that neither of the agents inhibited the attachment of betanodavirus to the cells.NH 4 Cl inhibits the entry of betanodavirus into cellsTo further determine the detailed mechanism of the inhibitory effect of NH 4 Cl and chloroquine, we next analyzed the viral genomic (\u00fe) RNA1 and template (\u00c0) RNA1 accumulation in infected cells.", [["cells", "ANATOMY", 98, 103], ["cells", "ANATOMY", 153, 158], ["cells", "ANATOMY", 346, 351], ["NH 4 Cl", "CHEMICAL", 104, 111], ["NH 4 Cl", "CHEMICAL", 230, 237], ["chloroquine", "CHEMICAL", 242, 253], ["NH 4 Cl", "CHEMICAL", 104, 111], ["NH 4 Cl", "CHEMICAL", 230, 237], ["chloroquine", "CHEMICAL", 242, 253], ["betanodavirus", "GENE_OR_GENE_PRODUCT", 77, 90], ["cells", "CELL", 98, 103], ["NH 4 Cl", "SIMPLE_CHEMICAL", 104, 111], ["betanodavirus", "GENE_OR_GENE_PRODUCT", 134, 147], ["cells", "CELL", 153, 158], ["NH 4 Cl", "SIMPLE_CHEMICAL", 230, 237], ["chloroquine", "SIMPLE_CHEMICAL", 242, 253], ["cells", "CELL", 346, 351], ["betanodavirus", "PROTEIN", 134, 147], ["viral genomic (\u00fe) RNA1 and template (\u00c0) RNA1", "DNA", 276, 320], ["infected cells", "CELL_TYPE", 337, 351], ["the agents", "TREATMENT", 38, 48], ["betanodavirus", "TREATMENT", 77, 90], ["betanodavirus into cells", "TREATMENT", 134, 158], ["NH", "TREATMENT", 230, 232], ["chloroquine", "TREATMENT", 242, 253], ["the viral genomic (\u00fe) RNA1 and template (\u00c0) RNA1 accumulation in infected cells", "PROBLEM", 272, 351], ["RNA1 accumulation", "OBSERVATION", 316, 333], ["infected cells", "OBSERVATION", 337, 351]]], ["E-11 cells were inoculated with virus in the presence or absence of these agents, and the infected cells were incubated for specific periods of time, and the total RNA was subsequently prepared from the cells.", [["E-11 cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 99, 104], ["cells", "ANATOMY", 203, 208], ["E-11 cells", "CELL", 0, 10], ["cells", "CELL", 99, 104], ["cells", "CELL", 203, 208], ["E-11 cells", "CELL_LINE", 0, 10], ["infected cells", "CELL_TYPE", 90, 104], ["virus", "PROBLEM", 32, 37], ["these agents", "TREATMENT", 68, 80], ["the infected cells", "PROBLEM", 86, 104], ["the total RNA", "PROBLEM", 154, 167], ["infected cells", "OBSERVATION", 90, 104]]], ["(\u00c0) RNA1 was synthesized from (\u00fe) RNA1 as the replication template; thus the presence of (\u00c0) RNA1 in the cells indicated that the replication of viral genomes had occurred.", [["cells", "ANATOMY", 105, 110], ["RNA1", "GENE_OR_GENE_PRODUCT", 4, 8], ["(\u00c0) RNA1", "GENE_OR_GENE_PRODUCT", 89, 97], ["cells", "CELL", 105, 110], ["RNA1", "DNA", 4, 8], ["RNA1", "DNA", 34, 38], ["replication template", "DNA", 46, 66], ["RNA1", "DNA", 93, 97], ["viral genomes", "DNA", 145, 158], ["RNA1", "PROBLEM", 4, 8], ["RNA1", "TREATMENT", 34, 38], ["the replication template", "TREATMENT", 42, 66], ["(\u00c0) RNA1 in the cells", "PROBLEM", 89, 110], ["viral genomes", "PROBLEM", 145, 158], ["viral genomes", "OBSERVATION", 145, 158]]], ["As shown in Fig. 3A and B, the detection of (\u00fe) RNA1 bands in the control cells gradually increased and reached a maximum level at 18 h post-inoculation.", [["cells", "ANATOMY", 74, 79], ["B", "CELL", 24, 25], ["cells", "CELL", 74, 79], ["control cells", "CELL_TYPE", 66, 79], ["the detection", "TEST", 27, 40], ["RNA1 bands in the control cells", "PROBLEM", 48, 79], ["RNA1 bands", "OBSERVATION", 48, 58], ["increased", "OBSERVATION_MODIFIER", 90, 99]]], ["No significant (\u00c0) RNA1 bands were detected in the cells at 1 h post-inoculation, but their intensity gradually increased until 9 h post-inoculation and significantly increased from 9 to 12 h post-inoculation.", [["cells", "ANATOMY", 51, 56], ["cells", "CELL", 51, 56], ["RNA1 bands", "DNA", 19, 29], ["significant (\u00c0) RNA1 bands", "PROBLEM", 3, 29], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["RNA1 bands", "OBSERVATION", 19, 29], ["cells", "ANATOMY", 51, 56], ["intensity", "OBSERVATION_MODIFIER", 92, 101], ["gradually", "OBSERVATION_MODIFIER", 102, 111], ["increased", "OBSERVATION_MODIFIER", 112, 121], ["significantly", "OBSERVATION_MODIFIER", 153, 166], ["increased", "OBSERVATION_MODIFIER", 167, 176]]], ["These data imply that, after attaching to the cell membrane, the betanodavirus enters the cell, and the synthesis of the (\u00c0) RNA1 begins immediately thereafter.", [["cell membrane", "ANATOMY", 46, 59], ["cell", "ANATOMY", 90, 94], ["cell membrane", "CELLULAR_COMPONENT", 46, 59], ["betanodavirus", "GENE_OR_GENE_PRODUCT", 65, 78], ["cell", "CELL", 90, 94], ["betanodavirus", "PROTEIN", 65, 78], ["RNA1", "DNA", 125, 129], ["the cell membrane", "TREATMENT", 42, 59], ["cell membrane", "OBSERVATION", 46, 59]]], ["No significant (\u00c0) RNA1 bands were detected in cells that were inoculated and cultured in the presence of 1 mM NH 4 Cl or 1 mM chloroquine.", [["cells", "ANATOMY", 47, 52], ["NH 4 Cl", "CHEMICAL", 111, 118], ["chloroquine", "CHEMICAL", 127, 138], ["NH 4 Cl", "CHEMICAL", 111, 118], ["chloroquine", "CHEMICAL", 127, 138], ["cells", "CELL", 47, 52], ["NH 4 Cl", "SIMPLE_CHEMICAL", 111, 118], ["chloroquine", "SIMPLE_CHEMICAL", 127, 138], ["RNA1 bands", "DNA", 19, 29], ["significant (\u00c0) RNA1 bands", "PROBLEM", 3, 29], ["1 mM chloroquine", "TREATMENT", 122, 138], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["RNA1 bands", "OBSERVATION", 19, 29]]], ["In addition, the band intensity of (\u00fe) RNA1 was steady over the sampling period.", [["the band intensity of (\u00fe) RNA1", "PROBLEM", 13, 43]]], ["NH 4 Cl was next added to virus-infected E-11 cells at various times after infection (Fig. 3C) .", [["E-11 cells", "ANATOMY", 41, 51], ["NH 4 Cl", "CHEMICAL", 0, 7], ["NH 4 Cl", "CHEMICAL", 0, 7], ["NH 4 Cl", "SIMPLE_CHEMICAL", 0, 7], ["E-11 cells", "CELL", 41, 51], ["E-11 cells", "CELL_LINE", 41, 51], ["E-11", "SPECIES", 41, 45], ["virus", "TEST", 26, 31], ["infection", "PROBLEM", 75, 84], ["infection", "OBSERVATION", 75, 84]]], ["With the continuous presence of 1 mM NH 4 Cl during the assay, no (\u00fe) RNA1 accumulation was detected in comparison to the control, as shown in panel B. However, a significant accumulation of (\u00fe) RNA1 was detected when NH 4 Cl was added to the cells 1 h after inoculation.", [["cells", "ANATOMY", 243, 248], ["NH 4 Cl", "CHEMICAL", 37, 44], ["NH 4 Cl", "CHEMICAL", 218, 225], ["NH 4 Cl", "CHEMICAL", 37, 44], ["NH 4 Cl", "CHEMICAL", 218, 225], ["NH 4 Cl", "SIMPLE_CHEMICAL", 37, 44], ["NH 4 Cl", "SIMPLE_CHEMICAL", 218, 225], ["cells", "CELL", 243, 248], ["the assay", "TEST", 52, 61], ["(\u00fe) RNA1 accumulation", "PROBLEM", 66, 87], ["a significant accumulation of (\u00fe) RNA1", "PROBLEM", 161, 199], ["NH 4 Cl", "TREATMENT", 218, 225], ["inoculation", "PROBLEM", 259, 270], ["RNA1 accumulation", "OBSERVATION", 70, 87], ["significant", "OBSERVATION_MODIFIER", 163, 174], ["accumulation", "OBSERVATION_MODIFIER", 175, 187]]], ["When NH 4 Cl was added at 3 h post-inoculation, the amount of (\u00fe) RNA1 that accumulated in the cells was almost equal to the level of (\u00fe) RNA1 in the untreated cells.", [["cells", "ANATOMY", 95, 100], ["cells", "ANATOMY", 160, 165], ["NH 4 Cl", "CHEMICAL", 5, 12], ["NH 4 Cl", "CHEMICAL", 5, 12], ["NH 4 Cl", "SIMPLE_CHEMICAL", 5, 12], ["(\u00fe) RNA1", "GENE_OR_GENE_PRODUCT", 62, 70], ["cells", "CELL", 95, 100], ["cells", "CELL", 160, 165], ["untreated cells", "CELL_TYPE", 150, 165], ["RNA1", "PROBLEM", 66, 70], ["RNA1 in the untreated cells", "PROBLEM", 138, 165], ["cells", "ANATOMY", 95, 100], ["RNA1", "OBSERVATION", 138, 142], ["untreated cells", "OBSERVATION", 150, 165]]], ["Taking these results into consideration, NH 4 Cl inhibits an early step of betanodavirus entry into cells and has no effect on viral replication once the virus has entered the cells.", [["betanodavirus", "ANATOMY", 75, 88], ["cells", "ANATOMY", 100, 105], ["cells", "ANATOMY", 176, 181], ["NH 4 Cl", "CHEMICAL", 41, 48], ["NH 4 Cl", "CHEMICAL", 41, 48], ["NH 4 Cl", "SIMPLE_CHEMICAL", 41, 48], ["betanodavirus", "GENE_OR_GENE_PRODUCT", 75, 88], ["cells", "CELL", 100, 105], ["cells", "CELL", 176, 181], ["viral replication", "TREATMENT", 127, 144], ["the virus", "PROBLEM", 150, 159], ["no", "UNCERTAINTY", 114, 116]]], ["At the indicated times after inoculation, total RNA was extracted, and the (\u00fe) RNA1, (\u00c0) RNA1 and 18S rRNA were detected by RT-PCR.", [["RNA1", "GENE_OR_GENE_PRODUCT", 79, 83], ["(\u00c0) RNA1", "GENE_OR_GENE_PRODUCT", 85, 93], ["18S rRNA", "GENE_OR_GENE_PRODUCT", 98, 106], ["(\u00fe) RNA1, (\u00c0) RNA1", "RNA", 75, 93], ["18S rRNA", "RNA", 98, 106], ["inoculation", "PROBLEM", 29, 40], ["total RNA", "TEST", 42, 51], ["RNA1", "TEST", 79, 83], ["RNA1", "TEST", 89, 93], ["18S rRNA", "TEST", 98, 106], ["RT", "TEST", 124, 126], ["PCR", "TEST", 127, 130], ["18S rRNA", "OBSERVATION", 98, 106]]], ["(B) The band intensity of RNA1s was normalized and calculated as the relative value of (\u00fe) RNA1 (closed circle) and (\u00c0) RNA1 (open circle) to that of (\u00fe) RNA1 which was seen at 1 h post-inoculation.", [["RNA1s", "GENE_OR_GENE_PRODUCT", 26, 31], ["(\u00fe) RNA1", "GENE_OR_GENE_PRODUCT", 150, 158], ["RNA1s", "PROTEIN", 26, 31], ["RNA1", "DNA", 154, 158], ["The band intensity of RNA1s", "TEST", 4, 31], ["RNA1", "PROBLEM", 154, 158], ["RNA1", "OBSERVATION", 154, 158]]], ["(C) Cells were inoculated with virus and incubated in the presence (gray bar) or absence (open bar) of 1 mM NH 4 Cl throughout the experiment.", [["Cells", "ANATOMY", 4, 9], ["NH 4 Cl", "CHEMICAL", 108, 115], ["NH 4 Cl", "CHEMICAL", 108, 115], ["Cells", "CELL", 4, 9], ["NH 4 Cl", "SIMPLE_CHEMICAL", 108, 115], ["(C) Cells", "PROBLEM", 0, 9], ["virus", "PROBLEM", 31, 36]]], ["NH 4 Cl was added to virus-infected cells to a final concentration of 1 mM at the indicated time post-inoculation (black bar).", [["cells", "ANATOMY", 36, 41], ["NH 4 Cl", "CHEMICAL", 0, 7], ["NH 4 Cl", "CHEMICAL", 0, 7], ["NH 4 Cl", "SIMPLE_CHEMICAL", 0, 7], ["cells", "CELL", 36, 41], ["virus-infected cells", "CELL_TYPE", 21, 41], ["virus", "PROBLEM", 21, 26], ["infected cells", "PROBLEM", 27, 41], ["infected cells", "OBSERVATION", 27, 41], ["1 mM", "OBSERVATION_MODIFIER", 70, 74]]], ["At 12 h postinoculation, total RNA was extracted and subjected to RT-PCR.", [["total RNA", "TREATMENT", 25, 34], ["RT-PCR", "TEST", 66, 72]]], ["The band intensity of (\u00fe) RNA1 were normalized and expressed as the ratio of (\u00fe) RNA1 compared to that of the cells that were only infected with virus (only adsorption).", [["cells", "ANATOMY", 110, 115], ["cells", "CELL", 110, 115], ["The band intensity of (\u00fe) RNA1", "PROBLEM", 0, 30], ["the ratio of (\u00fe) RNA1", "PROBLEM", 64, 85], ["virus", "PROBLEM", 145, 150], ["band", "OBSERVATION_MODIFIER", 4, 8], ["intensity", "OBSERVATION_MODIFIER", 9, 18], ["infected", "OBSERVATION", 131, 139]]], ["The data represent the means and standard deviations from three independent experimentsInhibitory effect on viral replication by lysosomotropic agentsWe examined the amount of infective virus released into the culture supernatant after betanodavirus infection in the presence of lysosomotropic agents.", [["supernatant", "ANATOMY", 218, 229], ["lysosomotropic agents", "CHEMICAL", 129, 150], ["betanodavirus", "CHEMICAL", 236, 249], ["infection", "DISEASE", 250, 259], ["lysosomotropic agents", "SIMPLE_CHEMICAL", 129, 150], ["lysosomotropic agents", "SIMPLE_CHEMICAL", 279, 300], ["betanodavirus", "SPECIES", 236, 249], ["Inhibitory effect", "PROBLEM", 87, 104], ["viral replication", "TREATMENT", 108, 125], ["lysosomotropic agents", "TREATMENT", 129, 150], ["infective virus", "PROBLEM", 176, 191], ["the culture", "TEST", 206, 217], ["betanodavirus infection", "PROBLEM", 236, 259], ["lysosomotropic agents", "TREATMENT", 279, 300], ["viral replication", "OBSERVATION", 108, 125], ["infective virus", "OBSERVATION", 176, 191], ["lysosomotropic agents", "OBSERVATION", 279, 300]]], ["As shown in Fig. 4A , incubation of the cells with increasing concentrations of NH 4 Cl resulted in a reduction in infectious virus.", [["cells", "ANATOMY", 40, 45], ["NH 4 Cl", "CHEMICAL", 80, 87], ["NH 4 Cl", "CHEMICAL", 80, 87], ["cells", "CELL", 40, 45], ["NH 4 Cl", "SIMPLE_CHEMICAL", 80, 87], ["the cells", "TREATMENT", 36, 45], ["increasing concentrations of NH", "TREATMENT", 51, 82], ["a reduction in infectious virus", "PROBLEM", 100, 131], ["reduction", "OBSERVATION_MODIFIER", 102, 111], ["infectious virus", "OBSERVATION", 115, 131]]], ["At a concentration of 160 mM NH 4 Cl, the number of infectious viruses decreased to about 90% of the control.", [["NH 4 Cl", "CHEMICAL", 29, 36], ["NH 4 Cl", "CHEMICAL", 29, 36], ["infectious viruses", "PROBLEM", 52, 70], ["infectious", "OBSERVATION_MODIFIER", 52, 62], ["viruses", "OBSERVATION", 63, 70]]], ["An almost complete inhibition of virus production was observed when cells were treated with 630 mM NH 4 Cl.", [["cells", "ANATOMY", 68, 73], ["NH 4 Cl", "CHEMICAL", 99, 106], ["NH 4 Cl", "CHEMICAL", 99, 106], ["cells", "CELL", 68, 73], ["NH 4 Cl", "SIMPLE_CHEMICAL", 99, 106], ["virus production", "PROBLEM", 33, 49], ["virus", "OBSERVATION", 33, 38]]], ["Chloroquine had an effect identical to NH 4 Cl on the reduction of virus production (Fig. 4B) .", [["Chloroquine", "CHEMICAL", 0, 11], ["NH 4 Cl", "CHEMICAL", 39, 46], ["Chloroquine", "CHEMICAL", 0, 11], ["NH 4 Cl", "CHEMICAL", 39, 46], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["NH 4 Cl", "SIMPLE_CHEMICAL", 39, 46], ["Chloroquine", "TREATMENT", 0, 11], ["virus production", "PROBLEM", 67, 83], ["virus", "OBSERVATION", 67, 72]]], ["The amount of infectious virus was reduced to less than 5% of the control in the presence of 200 nM chloroquine.", [["chloroquine", "CHEMICAL", 100, 111], ["chloroquine", "CHEMICAL", 100, 111], ["chloroquine", "SIMPLE_CHEMICAL", 100, 111], ["infectious virus", "PROBLEM", 14, 30], ["200 nM chloroquine", "TREATMENT", 93, 111], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["infectious", "OBSERVATION_MODIFIER", 14, 24], ["virus", "OBSERVATION", 25, 30]]], ["Treatment with bafilomycin A1, a lysosomotropic agent that is a specific inhibitor of the vacuolar H \u00fe -ATPase [24] , also showed an inhibitory effect against viral production in a dose-dependent manner (Fig. 4C) .", [["vacuolar", "ANATOMY", 90, 98], ["bafilomycin A1", "CHEMICAL", 15, 29], ["bafilomycin A1", "CHEMICAL", 15, 29], ["H", "CHEMICAL", 99, 100], ["bafilomycin A1", "SIMPLE_CHEMICAL", 15, 29], ["vacuolar H \u00fe -ATPase", "GENE_OR_GENE_PRODUCT", 90, 110], ["vacuolar H \u00fe -ATPase", "PROTEIN", 90, 110], ["bafilomycin A1", "TREATMENT", 15, 29], ["a lysosomotropic agent", "TREATMENT", 31, 53], ["an inhibitory effect", "PROBLEM", 130, 150], ["viral production", "PROBLEM", 159, 175]]], ["No virus-induced CPE was observed with cells that were treated with 1 nM bafi-lomycin A1 for 6 days after inoculation (Table 1 ).", [["cells", "ANATOMY", 39, 44], ["bafi-lomycin A1", "CHEMICAL", 73, 88], ["bafi-lomycin A1", "CHEMICAL", 73, 88], ["cells", "CELL", 39, 44], ["virus", "PROBLEM", 3, 8], ["induced CPE", "PROBLEM", 9, 20], ["1 nM bafi-lomycin A1", "TREATMENT", 68, 88], ["virus", "OBSERVATION", 3, 8], ["CPE", "OBSERVATION", 17, 20]]], ["In addition, monensin, another lysosomotropic agent, and chlorpromazine also inhibited the development of virus-induced CPE at the concentrations listed in Table 1 .", [["monensin", "CHEMICAL", 13, 21], ["chlorpromazine", "CHEMICAL", 57, 71], ["CPE", "CHEMICAL", 120, 123], ["monensin", "CHEMICAL", 13, 21], ["chlorpromazine", "CHEMICAL", 57, 71], ["monensin", "SIMPLE_CHEMICAL", 13, 21], ["chlorpromazine", "SIMPLE_CHEMICAL", 57, 71], ["monensin", "TREATMENT", 13, 21], ["another lysosomotropic agent", "TREATMENT", 23, 51], ["chlorpromazine", "TREATMENT", 57, 71], ["virus", "PROBLEM", 106, 111], ["induced CPE", "PROBLEM", 112, 123], ["virus", "OBSERVATION", 106, 111]]], ["These results strongly suggested that the various lysosomotropic agents could be utilized as inhibitors against betanodavirus infection.DiscussionWe have identified lysosomotropic agents as effective antiviral agents against betanodavirus infection in fish cell cultures.", [["cell cultures", "ANATOMY", 257, 270], ["betanodavirus infection", "DISEASE", 112, 135], ["betanodavirus infection", "DISEASE", 225, 248], ["lysosomotropic agents", "SIMPLE_CHEMICAL", 50, 71], ["betanodavirus", "SIMPLE_CHEMICAL", 112, 125], ["lysosomotropic agents", "SIMPLE_CHEMICAL", 165, 186], ["betanodavirus", "SIMPLE_CHEMICAL", 225, 238], ["fish cell cultures", "CELL", 252, 270], ["fish cell cultures", "CELL_LINE", 252, 270], ["betanodavirus", "SPECIES", 112, 125], ["betanodavirus", "SPECIES", 225, 238], ["the various lysosomotropic agents", "TREATMENT", 38, 71], ["inhibitors", "TREATMENT", 93, 103], ["betanodavirus infection", "PROBLEM", 112, 135], ["lysosomotropic agents", "TREATMENT", 165, 186], ["antiviral agents", "TREATMENT", 200, 216], ["betanodavirus infection", "PROBLEM", 225, 248], ["fish cell cultures", "TEST", 252, 270]]], ["We utilized these agents because the electron microscopic study by Liu et al. [16] suggested that the entry of betanodavirus into cells depends on the endocytic pathway.", [["cells", "ANATOMY", 130, 135], ["betanodavirus", "GENE_OR_GENE_PRODUCT", 111, 124], ["cells", "CELL", 130, 135], ["betanodavirus", "PROTEIN", 111, 124], ["these agents", "TREATMENT", 12, 24], ["the electron microscopic study", "TEST", 33, 63], ["betanodavirus into cells", "PROBLEM", 111, 135]]], ["We initially used NH 4 Cl and chloroquine to examine whether they can inhibit the development of CPE after betanodavirus infection.", [["NH 4 Cl", "CHEMICAL", 18, 25], ["chloroquine", "CHEMICAL", 30, 41], ["CPE", "CHEMICAL", 97, 100], ["betanodavirus infection", "DISEASE", 107, 130], ["NH 4 Cl", "CHEMICAL", 18, 25], ["chloroquine", "CHEMICAL", 30, 41], ["NH 4 Cl", "SIMPLE_CHEMICAL", 18, 25], ["chloroquine", "SIMPLE_CHEMICAL", 30, 41], ["betanodavirus", "SPECIES", 107, 120], ["NH 4 Cl", "TREATMENT", 18, 25], ["chloroquine", "TREATMENT", 30, 41], ["CPE", "PROBLEM", 97, 100], ["betanodavirus infection", "PROBLEM", 107, 130]]], ["Both agents completely inhibited virus-induced CPE at non-cytotoxic concentrations (Fig. 1) .", [["CPE", "CHEMICAL", 47, 50], ["virus", "PROBLEM", 33, 38], ["CPE", "PROBLEM", 47, 50]]], ["NH 4 Cl and chloroquine had no affect on virus attachment to the cells (Fig. 2C and D) .", [["cells", "ANATOMY", 65, 70], ["NH 4 Cl", "CHEMICAL", 0, 7], ["chloroquine", "CHEMICAL", 12, 23], ["NH 4 Cl", "CHEMICAL", 0, 7], ["chloroquine", "CHEMICAL", 12, 23], ["NH 4 Cl", "SIMPLE_CHEMICAL", 0, 7], ["chloroquine", "SIMPLE_CHEMICAL", 12, 23], ["cells", "CELL", 65, 70], ["chloroquine", "TREATMENT", 12, 23]]], ["We also showed that NH 4 Cl inhibited a very early step of infection rather than blocking polymerase activity, since the level of (\u00fe) RNA1 accumulation was not affected when NH 4 Cl was added to the culture medium at 1 h post-inoculation (Fig. 3C) .", [["NH 4 Cl", "CHEMICAL", 20, 27], ["infection", "DISEASE", 59, 68], ["NH 4 Cl", "CHEMICAL", 174, 181], ["NH 4 Cl", "CHEMICAL", 20, 27], ["NH 4 Cl", "CHEMICAL", 174, 181], ["NH 4 Cl", "SIMPLE_CHEMICAL", 20, 27], ["NH 4 Cl", "SIMPLE_CHEMICAL", 174, 181], ["NH 4 Cl", "PROBLEM", 20, 27], ["infection", "PROBLEM", 59, 68], ["blocking polymerase activity", "PROBLEM", 81, 109], ["RNA1 accumulation", "PROBLEM", 134, 151], ["NH 4 Cl", "TREATMENT", 174, 181], ["the culture", "TEST", 195, 206], ["very", "OBSERVATION_MODIFIER", 40, 44], ["early", "OBSERVATION_MODIFIER", 45, 50], ["step of", "OBSERVATION_MODIFIER", 51, 58], ["infection", "OBSERVATION", 59, 68]]], ["The effective doses of NH 4 Cl (1 mM) and chloroquine (1 mM) in this experiment were more than 10-fold lower than those used for other viruses [1, 2, 15, 29] .", [["NH 4 Cl", "CHEMICAL", 23, 30], ["chloroquine", "CHEMICAL", 42, 53], ["NH 4 Cl", "CHEMICAL", 23, 30], ["chloroquine", "CHEMICAL", 42, 53], ["NH 4 Cl", "SIMPLE_CHEMICAL", 23, 30], ["chloroquine", "SIMPLE_CHEMICAL", 42, 53], ["The effective doses of NH", "TREATMENT", 0, 25], ["chloroquine", "TREATMENT", 42, 53]]], ["The infection of betanodavirus was also inhibited by bafilomycin A1 and monensin ( Fig. 4 and Table 1 ), thus confirming that lysosomotropic agents can be useful for the prevention of betanodavirus infection.", [["infection", "DISEASE", 4, 13], ["bafilomycin A1", "CHEMICAL", 53, 67], ["monensin", "CHEMICAL", 72, 80], ["betanodavirus infection", "DISEASE", 184, 207], ["bafilomycin A1", "CHEMICAL", 53, 67], ["monensin", "CHEMICAL", 72, 80], ["betanodavirus", "ORGANISM", 17, 30], ["bafilomycin A1", "SIMPLE_CHEMICAL", 53, 67], ["monensin", "SIMPLE_CHEMICAL", 72, 80], ["lysosomotropic agents", "SIMPLE_CHEMICAL", 126, 147], ["betanodavirus", "CANCER", 184, 197], ["betanodavirus", "SPECIES", 184, 197], ["The infection of betanodavirus", "PROBLEM", 0, 30], ["bafilomycin A1", "TREATMENT", 53, 67], ["monensin", "TREATMENT", 72, 80], ["lysosomotropic agents", "TREATMENT", 126, 147], ["betanodavirus infection", "PROBLEM", 184, 207], ["infection", "OBSERVATION", 4, 13], ["infection", "OBSERVATION", 198, 207]]], ["Chloroquine, first synthesized as an anti-malarial drug, has been shown to have an antiviral effect on a wide range of viruses, including human immunodeficiency virus (HIV) [25, 27] , influenza virus [23] , and the SARS coronavirus (SARS-CoV) [4] .", [["Chloroquine", "CHEMICAL", 0, 11], ["human immunodeficiency virus (HIV)", "DISEASE", 138, 172], ["influenza virus", "DISEASE", 184, 199], ["SARS coronavirus", "DISEASE", 215, 231], ["SARS", "DISEASE", 233, 237], ["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["human immunodeficiency virus", "ORGANISM", 138, 166], ["HIV", "ORGANISM", 168, 171], ["influenza virus", "ORGANISM", 184, 199], ["SARS coronavirus", "ORGANISM", 215, 231], ["SARS-CoV", "ORGANISM", 233, 241], ["human immunodeficiency virus (HIV", "SPECIES", 138, 171], ["influenza virus", "SPECIES", 184, 199], ["SARS coronavirus", "SPECIES", 215, 231], ["human immunodeficiency virus", "SPECIES", 138, 166], ["HIV", "SPECIES", 168, 171], ["SARS coronavirus", "SPECIES", 215, 231], ["SARS-CoV", "SPECIES", 233, 241], ["Chloroquine", "TREATMENT", 0, 11], ["an anti-malarial drug", "TREATMENT", 34, 55], ["an antiviral effect", "PROBLEM", 80, 99], ["a wide range of viruses", "PROBLEM", 103, 126], ["human immunodeficiency virus", "PROBLEM", 138, 166], ["influenza virus", "PROBLEM", 184, 199], ["the SARS coronavirus", "PROBLEM", 211, 231], ["antiviral", "OBSERVATION", 83, 92]]], ["As for the enveloped viruses, chloroquine and NH 4 Cl inhibit the glycosylation of viral envelope proteins [34] , the transportation of glycoprotein to the plasma membrane [6, 9] , and the envelopment of viral nucleocapsids [14] .", [["plasma membrane", "ANATOMY", 156, 171], ["chloroquine", "CHEMICAL", 30, 41], ["NH 4 Cl", "CHEMICAL", 46, 53], ["chloroquine", "CHEMICAL", 30, 41], ["NH 4 Cl", "CHEMICAL", 46, 53], ["chloroquine", "SIMPLE_CHEMICAL", 30, 41], ["NH 4 Cl", "SIMPLE_CHEMICAL", 46, 53], ["plasma membrane", "CELLULAR_COMPONENT", 156, 171], ["viral envelope proteins", "PROTEIN", 83, 106], ["glycoprotein", "PROTEIN", 136, 148], ["the enveloped viruses", "PROBLEM", 7, 28], ["chloroquine", "TREATMENT", 30, 41], ["NH", "TREATMENT", 46, 48], ["viral envelope proteins", "TREATMENT", 83, 106], ["viral nucleocapsids", "TREATMENT", 204, 223], ["viruses", "OBSERVATION", 21, 28]]], ["It has also been suggested that the terminal glycosylation of angiotensin-converting enzyme-2 (ACE-2), a functional receptor of SARS-CoV, is inhibited by chloroquine and NH 4 Cl [34] .DiscussionRecently, in betanodavirus, sialic acid on the fish SSN-1 cell line has been demonstrated to be involved in binding of virus to the cell [16] , although the specific functional cellular receptors for the virus have not yet been identified.", [["SSN-1 cell line", "ANATOMY", 246, 261], ["cell", "ANATOMY", 326, 330], ["cellular", "ANATOMY", 371, 379], ["angiotensin", "CHEMICAL", 62, 73], ["chloroquine", "CHEMICAL", 154, 165], ["NH 4 Cl", "CHEMICAL", 170, 177], ["sialic acid", "CHEMICAL", 222, 233], ["chloroquine", "CHEMICAL", 154, 165], ["NH 4 Cl [34]", "CHEMICAL", 170, 182], ["sialic acid", "CHEMICAL", 222, 233], ["angiotensin-converting enzyme-2", "GENE_OR_GENE_PRODUCT", 62, 93], ["ACE-2", "GENE_OR_GENE_PRODUCT", 95, 100], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 128, 136], ["chloroquine", "SIMPLE_CHEMICAL", 154, 165], ["NH 4 Cl [34]", "SIMPLE_CHEMICAL", 170, 182], ["sialic acid", "SIMPLE_CHEMICAL", 222, 233], ["SSN-1 cell line", "CELL", 246, 261], ["cell", "CELL", 326, 330], ["cellular", "CELL", 371, 379], ["angiotensin-converting enzyme-2", "PROTEIN", 62, 93], ["ACE", "PROTEIN", 95, 98], ["fish SSN-1 cell line", "CELL_LINE", 241, 261], ["cellular receptors", "PROTEIN", 371, 389], ["SARS-CoV", "SPECIES", 128, 136], ["the terminal glycosylation of angiotensin", "TREATMENT", 32, 73], ["converting enzyme-2 (ACE", "TREATMENT", 74, 98], ["chloroquine", "TREATMENT", 154, 165], ["sialic acid", "TEST", 222, 233], ["the fish SSN", "TREATMENT", 237, 249], ["1 cell line", "TREATMENT", 250, 261], ["the virus", "PROBLEM", 394, 403]]], ["Our data suggested that the inhibitory effect against an early step of betanodavirus infection (binding to the cell surface) was not affected by the agents (Fig. 2C and D) .", [["cell surface", "ANATOMY", 111, 123], ["betanodavirus", "CHEMICAL", 71, 84], ["infection", "DISEASE", 85, 94], ["betanodavirus", "GENE_OR_GENE_PRODUCT", 71, 84], ["cell surface", "CELLULAR_COMPONENT", 111, 123], ["betanodavirus", "SPECIES", 71, 84], ["Our data", "TEST", 0, 8], ["betanodavirus infection", "PROBLEM", 71, 94], ["infection", "OBSERVATION", 85, 94]]], ["Feline calicivirus (FCV), a member of the family Caliciviridae and a non-enveloped virus, also requires the acidification in endosomes for its entry pathway [29] .", [["endosomes", "ANATOMY", 125, 134], ["Feline calicivirus", "DISEASE", 0, 18], ["Feline calicivirus", "ORGANISM", 0, 18], ["FCV", "ORGANISM", 20, 23], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 49, 62], ["endosomes", "CELLULAR_COMPONENT", 125, 134], ["Feline calicivirus", "SPECIES", 0, 18], ["Feline calicivirus", "SPECIES", 0, 18], ["FCV", "SPECIES", 20, 23], ["Feline calicivirus", "PROBLEM", 0, 18], ["the family Caliciviridae", "TREATMENT", 38, 62], ["a non-enveloped virus", "PROBLEM", 67, 88]]], ["The a2,6-linked sialic acid present on an N-linked glycoprotein acts as a receptor for FCV infection [30] , and it has been suggested that the inhibitory mechanism of chloroquine against FCV entry into the cells is not due to a defect of the functional cellular receptor [29] .DiscussionTreatment of E-11 cells with chlorpromazine inhibited the development of betanodavirus-induced CPE (Table 1) , which suggested clathrin-mediated endocytosis as an entry pathway of betanodavirus into cells.", [["cells", "ANATOMY", 206, 211], ["cellular", "ANATOMY", 253, 261], ["E-11 cells", "ANATOMY", 300, 310], ["cells", "ANATOMY", 486, 491], ["a2,6-linked sialic acid", "CHEMICAL", 4, 27], ["FCV infection", "DISEASE", 87, 100], ["chloroquine", "CHEMICAL", 167, 178], ["chlorpromazine", "CHEMICAL", 316, 330], ["betanodavirus", "CHEMICAL", 360, 373], ["sialic acid", "CHEMICAL", 16, 27], ["N", "CHEMICAL", 42, 43], ["chloroquine", "CHEMICAL", 167, 178], ["chlorpromazine", "CHEMICAL", 316, 330], ["a2,6-linked sialic acid", "SIMPLE_CHEMICAL", 4, 27], ["FCV", "ORGANISM", 87, 90], ["chloroquine", "SIMPLE_CHEMICAL", 167, 178], ["FCV", "ORGANISM", 187, 190], ["cells", "CELL", 206, 211], ["cellular", "CELL", 253, 261], ["E-11 cells", "CELL", 300, 310], ["chlorpromazine", "SIMPLE_CHEMICAL", 316, 330], ["betanodavirus", "SIMPLE_CHEMICAL", 360, 373], ["clathrin", "GENE_OR_GENE_PRODUCT", 414, 422], ["cells", "CELL", 486, 491], ["N-linked glycoprotein", "PROTEIN", 42, 63], ["E-11 cells", "CELL_LINE", 300, 310], ["clathrin", "PROTEIN", 414, 422], ["FCV", "SPECIES", 87, 90], ["FCV", "SPECIES", 187, 190], ["an N-linked glycoprotein acts", "TREATMENT", 39, 68], ["FCV infection", "PROBLEM", 87, 100], ["chloroquine", "TREATMENT", 167, 178], ["a defect", "PROBLEM", 226, 234], ["chlorpromazine", "TREATMENT", 316, 330], ["betanodavirus", "PROBLEM", 360, 373], ["induced CPE", "PROBLEM", 374, 385], ["clathrin-mediated endocytosis", "PROBLEM", 414, 443], ["betanodavirus into cells", "PROBLEM", 467, 491], ["not due to", "UNCERTAINTY", 215, 225], ["defect", "OBSERVATION", 228, 234]]], ["This agent is a cationic, amphiphilic molecule that inhibits viral infection by shifting clathrin and the AP-2 complex to the late endosomal compartment [28, 36] .", [["endosomal compartment", "ANATOMY", 131, 152], ["viral infection", "DISEASE", 61, 76], ["clathrin", "GENE_OR_GENE_PRODUCT", 89, 97], ["AP-2", "GENE_OR_GENE_PRODUCT", 106, 110], ["endosomal compartment", "CELLULAR_COMPONENT", 131, 152], ["clathrin", "PROTEIN", 89, 97], ["AP-2 complex", "PROTEIN", 106, 118], ["a cationic, amphiphilic molecule", "PROBLEM", 14, 46], ["viral infection", "PROBLEM", 61, 76], ["shifting clathrin", "PROBLEM", 80, 97], ["amphiphilic molecule", "OBSERVATION", 26, 46], ["viral", "OBSERVATION_MODIFIER", 61, 66], ["infection", "OBSERVATION", 67, 76], ["late", "OBSERVATION_MODIFIER", 126, 130], ["endosomal compartment", "OBSERVATION", 131, 152]]], ["Many non-enveloped viruses have been shown to use the clathrin-mediated endocytic route to infect cells [3, 5, 35] , and this pathway requires an acidic environment in the endosomes.", [["cells", "ANATOMY", 98, 103], ["endosomes", "ANATOMY", 172, 181], ["clathrin", "GENE_OR_GENE_PRODUCT", 54, 62], ["cells", "CELL", 98, 103], ["endosomes", "CELLULAR_COMPONENT", 172, 181], ["clathrin", "PROTEIN", 54, 62], ["Many non-enveloped viruses", "PROBLEM", 0, 26], ["the clathrin", "TREATMENT", 50, 62], ["non-enveloped", "OBSERVATION_MODIFIER", 5, 18], ["viruses", "OBSERVATION", 19, 26], ["acidic environment", "OBSERVATION", 146, 164]]], ["Further detailed experiments are needed to clarify the mechanism of the endocytic pathway utilized in betanodavirus infection.DiscussionAt present, to prevent the spread of betanodavirus, the selection of putative virus-free spawners and disinfection procedures are used, however these procedures are not enough to prevent re-emergence of betanodavirus infection on the same farms.DiscussionIn conclusion, we have demonstrated for the first time that lysosomotropic agents can inhibit the infection of betanodavirus in vitro.", [["betanodavirus infection", "DISEASE", 102, 125], ["betanodavirus", "DISEASE", 173, 186], ["infection", "DISEASE", 353, 362], ["infection", "DISEASE", 489, 498], ["betanodavirus", "CANCER", 102, 115], ["betanodavirus", "CANCER", 173, 186], ["betanodavirus", "ORGANISM", 339, 352], ["lysosomotropic agents", "SIMPLE_CHEMICAL", 451, 472], ["betanodavirus", "SPECIES", 339, 352], ["betanodavirus infection", "PROBLEM", 102, 125], ["betanodavirus", "TREATMENT", 173, 186], ["putative virus", "PROBLEM", 205, 219], ["free spawners", "TREATMENT", 220, 233], ["disinfection procedures", "TREATMENT", 238, 261], ["these procedures", "TREATMENT", 280, 296], ["betanodavirus infection", "PROBLEM", 339, 362], ["lysosomotropic agents", "TREATMENT", 451, 472], ["the infection of betanodavirus", "PROBLEM", 485, 515], ["infection", "OBSERVATION", 116, 125], ["infection", "OBSERVATION", 353, 362], ["infection", "OBSERVATION", 489, 498]]], ["These agents can be considered candidate anti-betanodavirus drugs.", [["anti-betanodavirus drugs", "SIMPLE_CHEMICAL", 41, 65], ["anti-betanodavirus drugs", "TREATMENT", 41, 65]]], ["However, the agents discussed in this paper have not yet been approved for application in fish culture.", [["fish", "ORGANISM", 90, 94], ["fish culture", "TEST", 90, 102]]], ["Further studies are thus called for to explore this question.", [["Further studies", "TEST", 0, 15]]]], "962108b211b3b68cc111aaac63b64aeacfa017ef": [["SARS-CoV-2 (COVID-19) requires little introduction.", [["SARS", "DISEASE", 0, 4], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["COVID", "TEST", 12, 17]]], ["COVID-19 has already had, and will progressively have, profound consequences on our practice during the pandemic and beyond.", [["COVID-19", "CHEMICAL", 0, 8]]], ["We aim to discuss how the pandemic is currently affecting our patients, multidisciplinary working and treatment choices, and consider the longer term consequences.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["treatment choices", "TREATMENT", 102, 119], ["the longer term consequences", "PROBLEM", 134, 162]]]], "53572f9cb278e30b679e9bcc1780e27be4f24681": [["Answer: Large Fundal VaricesThe CT scan (with i.v. contrast, Fig. 27 .1) demonstrates large varices filling in the proximal stomach which are confirmed on the EGD image ( Fig. 27.2) .", [["varices", "ANATOMY", 92, 99], ["proximal stomach", "ANATOMY", 115, 131], ["varices", "DISEASE", 92, 99], ["varices", "PATHOLOGICAL_FORMATION", 92, 99], ["stomach", "ORGAN", 124, 131], ["Large Fundal Varices", "PROBLEM", 8, 28], ["The CT scan (with i.v. contrast", "TEST", 28, 59], ["Fig.", "TEST", 61, 65], ["large varices filling in the proximal stomach", "PROBLEM", 86, 131], ["the EGD image", "TEST", 155, 168], ["Fig.", "TEST", 171, 175], ["Large", "OBSERVATION_MODIFIER", 8, 13], ["Fundal", "ANATOMY", 14, 20], ["Varices", "OBSERVATION", 21, 28], ["large", "OBSERVATION_MODIFIER", 86, 91], ["varices", "OBSERVATION", 92, 99], ["proximal", "ANATOMY_MODIFIER", 115, 123], ["stomach", "ANATOMY", 124, 131]]], ["The liver has a nodular contour consistent with cirrhosis and there is minimal ascites.", [["liver", "ANATOMY", 4, 9], ["ascites", "ANATOMY", 79, 86], ["cirrhosis", "DISEASE", 48, 57], ["ascites", "DISEASE", 79, 86], ["liver", "ORGAN", 4, 9], ["a nodular contour", "PROBLEM", 14, 31], ["cirrhosis", "PROBLEM", 48, 57], ["minimal ascites", "PROBLEM", 71, 86], ["liver", "ANATOMY", 4, 9], ["nodular", "OBSERVATION", 16, 23], ["consistent with", "UNCERTAINTY", 32, 47], ["cirrhosis", "OBSERVATION", 48, 57], ["minimal", "OBSERVATION_MODIFIER", 71, 78], ["ascites", "OBSERVATION", 79, 86]]], ["The endoscopic image has the scope in a retroflexed position and shows a mass in the fundus which could be confused with a tumor.Answer: Large Fundal VaricesThe differential diagnosis is essentially all causes of GI bleeding, but these should be separated into portal hypertensive and non-portal hypertensive causes in a patient with known cirrhosis.", [["fundus", "ANATOMY", 85, 91], ["tumor", "ANATOMY", 123, 128], ["GI", "ANATOMY", 213, 215], ["portal", "ANATOMY", 261, 267], ["tumor", "DISEASE", 123, 128], ["bleeding", "DISEASE", 216, 224], ["hypertensive", "DISEASE", 268, 280], ["hypertensive", "DISEASE", 296, 308], ["cirrhosis", "DISEASE", 340, 349], ["fundus", "MULTI-TISSUE_STRUCTURE", 85, 91], ["tumor", "CANCER", 123, 128], ["GI", "ORGANISM_SUBDIVISION", 213, 215], ["patient", "ORGANISM", 321, 328], ["patient", "SPECIES", 321, 328], ["The endoscopic image", "TEST", 0, 20], ["a mass in the fundus", "PROBLEM", 71, 91], ["a tumor", "PROBLEM", 121, 128], ["Large Fundal Varices", "PROBLEM", 137, 157], ["GI bleeding", "PROBLEM", 213, 224], ["portal hypertensive and non-portal hypertensive causes", "PROBLEM", 261, 315], ["known cirrhosis", "PROBLEM", 334, 349], ["mass", "OBSERVATION", 73, 77], ["fundus", "ANATOMY", 85, 91], ["could be", "UNCERTAINTY", 98, 106], ["tumor", "OBSERVATION", 123, 128], ["Large", "OBSERVATION_MODIFIER", 137, 142], ["Fundal", "ANATOMY", 143, 149], ["Varices", "OBSERVATION", 150, 157], ["GI", "ANATOMY", 213, 215], ["bleeding", "OBSERVATION", 216, 224], ["portal", "ANATOMY", 261, 267], ["hypertensive", "OBSERVATION", 268, 280], ["hypertensive", "OBSERVATION", 296, 308], ["cirrhosis", "OBSERVATION", 340, 349]]], ["The latter will include ulcer disease, malignancy, and a Dieulafoy lesion, while the former includes variceal bleeding (esophageal or gastric) and severe portal hypertensive gastropathy.Answer: Large Fundal VaricesThe laboratory values suggest well-compensated disease but this does not exclude significant portal hypertension.Answer: Large Fundal VaricesThe initial work up should include an imaging study such as a CT scan or ultrasound scan (USS) (with Doppler).", [["ulcer", "ANATOMY", 24, 29], ["Dieulafoy lesion", "ANATOMY", 57, 73], ["variceal", "ANATOMY", 101, 109], ["esophageal", "ANATOMY", 120, 130], ["gastric", "ANATOMY", 134, 141], ["portal", "ANATOMY", 307, 313], ["ulcer disease", "DISEASE", 24, 37], ["malignancy", "DISEASE", 39, 49], ["Dieulafoy lesion", "DISEASE", 57, 73], ["variceal bleeding", "DISEASE", 101, 118], ["esophageal or gastric)", "DISEASE", 120, 142], ["portal hypertensive gastropathy", "DISEASE", 154, 185], ["hypertension", "DISEASE", 314, 326], ["ulcer", "PATHOLOGICAL_FORMATION", 24, 29], ["esophageal", "CANCER", 120, 130], ["gastric", "ORGAN", 134, 141], ["portal", "MULTI-TISSUE_STRUCTURE", 307, 313], ["ulcer disease", "PROBLEM", 24, 37], ["malignancy", "PROBLEM", 39, 49], ["a Dieulafoy lesion", "PROBLEM", 55, 73], ["variceal bleeding", "PROBLEM", 101, 118], ["esophageal or gastric) and severe portal hypertensive gastropathy", "PROBLEM", 120, 185], ["Large Fundal Varices", "PROBLEM", 194, 214], ["The laboratory values", "TEST", 214, 235], ["well-compensated disease", "PROBLEM", 244, 268], ["significant portal hypertension", "PROBLEM", 295, 326], ["Large Fundal Varices", "PROBLEM", 335, 355], ["an imaging study", "TEST", 390, 406], ["a CT scan or ultrasound scan (USS)", "TEST", 415, 449], ["Doppler", "TEST", 456, 463], ["ulcer", "OBSERVATION", 24, 29], ["malignancy", "OBSERVATION", 39, 49], ["Dieulafoy", "OBSERVATION_MODIFIER", 57, 66], ["lesion", "OBSERVATION", 67, 73], ["variceal", "OBSERVATION_MODIFIER", 101, 109], ["bleeding", "OBSERVATION", 110, 118], ["esophageal", "ANATOMY", 120, 130], ["gastric", "ANATOMY", 134, 141], ["severe", "OBSERVATION_MODIFIER", 147, 153], ["portal", "ANATOMY", 154, 160], ["hypertensive gastropathy", "OBSERVATION", 161, 185], ["Large", "OBSERVATION_MODIFIER", 194, 199], ["Fundal", "ANATOMY", 200, 206], ["Varices", "OBSERVATION", 207, 214], ["well-compensated", "OBSERVATION_MODIFIER", 244, 260], ["disease", "OBSERVATION", 261, 268], ["portal", "ANATOMY", 307, 313], ["hypertension", "OBSERVATION", 314, 326], ["Large", "OBSERVATION_MODIFIER", 335, 340], ["Fundal", "ANATOMY", 341, 347], ["Varices", "OBSERVATION", 348, 355]]], ["The latter is important to document the patency of the portal vein.", [["portal vein", "ANATOMY", 55, 66], ["portal vein", "MULTI-TISSUE_STRUCTURE", 55, 66], ["patency", "OBSERVATION", 40, 47], ["portal vein", "ANATOMY", 55, 66]]], ["However, after adequate resuscitation, repeat EGD is required.", [["adequate resuscitation", "TREATMENT", 15, 37], ["repeat EGD", "TEST", 39, 49]]], ["Pharmacological therapy with intravenous octreotide should be standard in patients with suspected portal hypertensive bleeding and should be started prior to the EGD, and antibiotics have also been shown to reduce mortality in this situation.Answer: Large Fundal VaricesThe patient has isolated gastric varices and several red spots are seen on the EGD image which are indicative of recent bleeding.", [["intravenous", "ANATOMY", 29, 40], ["portal", "ANATOMY", 98, 104], ["gastric varices", "ANATOMY", 295, 310], ["red spots", "ANATOMY", 323, 332], ["octreotide", "CHEMICAL", 41, 51], ["portal hypertensive bleeding", "DISEASE", 98, 126], ["gastric varices", "DISEASE", 295, 310], ["bleeding", "DISEASE", 390, 398], ["octreotide", "CHEMICAL", 41, 51], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 29, 40], ["octreotide", "SIMPLE_CHEMICAL", 41, 51], ["patients", "ORGANISM", 74, 82], ["patient", "ORGANISM", 274, 281], ["gastric varices", "CANCER", 295, 310], ["patients", "SPECIES", 74, 82], ["patient", "SPECIES", 274, 281], ["Pharmacological therapy", "TREATMENT", 0, 23], ["intravenous octreotide", "TREATMENT", 29, 51], ["portal hypertensive bleeding", "PROBLEM", 98, 126], ["the EGD", "TEST", 158, 165], ["antibiotics", "TREATMENT", 171, 182], ["Large Fundal Varices", "PROBLEM", 250, 270], ["isolated gastric varices", "PROBLEM", 286, 310], ["several red spots", "PROBLEM", 315, 332], ["the EGD image", "TEST", 345, 358], ["recent bleeding", "PROBLEM", 383, 398], ["portal", "ANATOMY", 98, 104], ["hypertensive", "OBSERVATION_MODIFIER", 105, 117], ["bleeding", "OBSERVATION", 118, 126], ["Large", "OBSERVATION_MODIFIER", 250, 255], ["Fundal", "ANATOMY", 256, 262], ["Varices", "OBSERVATION", 263, 270], ["isolated", "OBSERVATION_MODIFIER", 286, 294], ["gastric", "ANATOMY", 295, 302], ["varices", "OBSERVATION", 303, 310], ["several", "OBSERVATION_MODIFIER", 315, 322], ["red spots", "OBSERVATION", 323, 332], ["indicative of", "UNCERTAINTY", 369, 382], ["bleeding", "OBSERVATION", 390, 398]]], ["Endoscopic treatment of isolated gastric varices is of limited benefit, although cyanoacrylate has shown some promise (but is not available in the United States).", [["gastric varices", "ANATOMY", 33, 48], ["gastric varices", "DISEASE", 33, 48], ["cyanoacrylate", "CHEMICAL", 81, 94], ["cyanoacrylate", "CHEMICAL", 81, 94], ["gastric varices", "PATHOLOGICAL_FORMATION", 33, 48], ["cyanoacrylate", "SIMPLE_CHEMICAL", 81, 94], ["Endoscopic treatment", "TREATMENT", 0, 20], ["isolated gastric varices", "PROBLEM", 24, 48], ["cyanoacrylate", "TREATMENT", 81, 94], ["isolated", "OBSERVATION_MODIFIER", 24, 32], ["gastric", "ANATOMY", 33, 40], ["varices", "OBSERVATION", 41, 48], ["some", "OBSERVATION_MODIFIER", 105, 109], ["promise", "OBSERVATION_MODIFIER", 110, 117]]], ["Band ligation of such large varices would be inadvisable but could be tried if the varices were smaller (which is a judgment call).Answer: Large Fundal VaricesIf the portal vein is open, the patient should undergo transjugular intrahepatic portosystemic shunting (TIPS) which controls bleeding in the majority of cases.", [["varices", "ANATOMY", 28, 35], ["varices", "ANATOMY", 83, 90], ["portal vein", "ANATOMY", 166, 177], ["varices", "DISEASE", 28, 35], ["varices", "DISEASE", 83, 90], ["transjugular intrahepatic portosystemic shunting", "DISEASE", 214, 262], ["bleeding", "DISEASE", 285, 293], ["varices", "PATHOLOGICAL_FORMATION", 28, 35], ["varices", "PATHOLOGICAL_FORMATION", 83, 90], ["portal vein", "MULTI-TISSUE_STRUCTURE", 166, 177], ["patient", "ORGANISM", 191, 198], ["transjugular intrahepatic portosystemic", "MULTI-TISSUE_STRUCTURE", 214, 253], ["patient", "SPECIES", 191, 198], ["Band ligation", "TREATMENT", 0, 13], ["such large varices", "PROBLEM", 17, 35], ["the varices", "PROBLEM", 79, 90], ["Large Fundal Varices", "PROBLEM", 139, 159], ["transjugular intrahepatic portosystemic shunting (TIPS", "TREATMENT", 214, 268], ["bleeding", "PROBLEM", 285, 293], ["ligation", "OBSERVATION", 5, 13], ["large", "OBSERVATION_MODIFIER", 22, 27], ["varices", "OBSERVATION", 28, 35], ["varices", "OBSERVATION", 83, 90], ["smaller", "OBSERVATION_MODIFIER", 96, 103], ["Large", "OBSERVATION_MODIFIER", 139, 144], ["Fundal", "ANATOMY", 145, 151], ["Varices", "OBSERVATION", 152, 159], ["portal vein", "ANATOMY", 166, 177], ["open", "OBSERVATION", 181, 185], ["transjugular", "ANATOMY_MODIFIER", 214, 226], ["intrahepatic", "ANATOMY_MODIFIER", 227, 239], ["portosystemic shunting", "OBSERVATION", 240, 262], ["TIPS", "OBSERVATION_MODIFIER", 264, 268], ["bleeding", "OBSERVATION", 285, 293]]], ["Hence, it is important to document portal vein patency prior to EGD if possible since this will influence how aggressive you should be with endoscopic treatment.", [["portal vein", "ANATOMY", 35, 46], ["portal vein", "MULTI-TISSUE_STRUCTURE", 35, 46], ["portal vein patency", "TREATMENT", 35, 54], ["EGD", "TEST", 64, 67], ["endoscopic treatment", "TREATMENT", 140, 160], ["portal vein", "ANATOMY", 35, 46], ["patency", "OBSERVATION", 47, 54]]], ["Aa gradient (on room air) = (150 \u2212 5/4(PaCO 2 )) \u2212 PaO 2 = 61 mmHgAnswer: Hepatopulmonary SyndromeThis patient's O 2 saturation on room air in the absence of lung or heart disease is suggestive of hepatopulmonary syndrome (HPS) which is a diagnosis that is frequently undetected.", [["lung", "ANATOMY", 158, 162], ["heart", "ANATOMY", 166, 171], ["Hepatopulmonary Syndrome", "DISEASE", 74, 98], ["lung or heart disease", "DISEASE", 158, 179], ["hepatopulmonary syndrome", "DISEASE", 197, 221], ["HPS", "DISEASE", 223, 226], ["O 2", "CHEMICAL", 113, 116], ["patient", "ORGANISM", 103, 110], ["lung", "ORGAN", 158, 162], ["heart", "ORGAN", 166, 171], ["patient", "SPECIES", 103, 110], ["Aa gradient", "TEST", 0, 11], ["PaCO", "TEST", 39, 43], ["PaO", "TEST", 51, 54], ["Hepatopulmonary Syndrome", "PROBLEM", 74, 98], ["This patient's O 2 saturation", "TEST", 98, 127], ["lung or heart disease", "PROBLEM", 158, 179], ["hepatopulmonary syndrome", "PROBLEM", 197, 221], ["gradient", "OBSERVATION_MODIFIER", 3, 11], ["Hepatopulmonary", "ANATOMY", 74, 89], ["Syndrome", "OBSERVATION", 90, 98], ["air", "OBSERVATION", 136, 139], ["lung", "ANATOMY", 158, 162], ["heart", "ANATOMY", 166, 171], ["disease", "OBSERVATION", 172, 179], ["suggestive of", "UNCERTAINTY", 183, 196], ["hepatopulmonary syndrome", "OBSERVATION", 197, 221]]], ["Patients undergoing liver transplant evaluation should have an arterial blood gas.Answer: Hepatopulmonary SyndromeHPS is defined by an increased alveolar-arterial gradient on room air with evidence of intrapulmonary vascular abnormalities or dilatations (IPVDs) occurring in patients with liver disease and in the absence of intrinsic lung disease.", [["liver", "ANATOMY", 20, 25], ["arterial blood", "ANATOMY", 63, 77], ["Hepatopulmonary", "ANATOMY", 90, 105], ["alveolar", "ANATOMY", 145, 153], ["arterial", "ANATOMY", 154, 162], ["intrapulmonary vascular", "ANATOMY", 201, 224], ["liver", "ANATOMY", 289, 294], ["lung", "ANATOMY", 335, 339], ["Hepatopulmonary SyndromeHPS", "DISEASE", 90, 117], ["intrapulmonary vascular abnormalities", "DISEASE", 201, 238], ["IPVDs", "DISEASE", 255, 260], ["liver disease", "DISEASE", 289, 302], ["lung disease", "DISEASE", 335, 347], ["Patients", "ORGANISM", 0, 8], ["liver", "ORGAN", 20, 25], ["arterial", "MULTI-TISSUE_STRUCTURE", 63, 71], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["alveolar", "TISSUE", 145, 153], ["arterial", "MULTI-TISSUE_STRUCTURE", 154, 162], ["intrapulmonary vascular", "MULTI-TISSUE_STRUCTURE", 201, 224], ["patients", "ORGANISM", 275, 283], ["liver", "ORGAN", 289, 294], ["lung", "ORGAN", 335, 339], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 275, 283], ["liver transplant evaluation", "TEST", 20, 47], ["an arterial blood gas", "TEST", 60, 81], ["Hepatopulmonary SyndromeHPS", "PROBLEM", 90, 117], ["an increased alveolar-arterial gradient", "PROBLEM", 132, 171], ["intrapulmonary vascular abnormalities", "PROBLEM", 201, 238], ["dilatations (IPVDs)", "PROBLEM", 242, 261], ["liver disease", "PROBLEM", 289, 302], ["intrinsic lung disease", "PROBLEM", 325, 347], ["liver", "ANATOMY", 20, 25], ["transplant", "OBSERVATION", 26, 36], ["arterial", "ANATOMY", 63, 71], ["Hepatopulmonary", "ANATOMY", 90, 105], ["SyndromeHPS", "OBSERVATION", 106, 117], ["increased", "OBSERVATION_MODIFIER", 135, 144], ["alveolar", "ANATOMY_MODIFIER", 145, 153], ["arterial", "ANATOMY", 154, 162], ["gradient", "OBSERVATION_MODIFIER", 163, 171], ["evidence of", "UNCERTAINTY", 189, 200], ["intrapulmonary", "ANATOMY_MODIFIER", 201, 215], ["vascular", "ANATOMY", 216, 224], ["abnormalities", "OBSERVATION", 225, 238], ["dilatations", "OBSERVATION", 242, 253], ["liver", "ANATOMY", 289, 294], ["disease", "OBSERVATION", 295, 302], ["intrinsic", "OBSERVATION_MODIFIER", 325, 334], ["lung", "ANATOMY", 335, 339], ["disease", "OBSERVATION", 340, 347]]], ["IPVDs are thought to arise due to poor clearance or excess production of pulmonary vasodilators and inhibition of circulating vasoconstrictors by the cirrhotic liver likely mediated through nitric oxide.", [["pulmonary", "ANATOMY", 73, 82], ["liver", "ANATOMY", 160, 165], ["IPVDs", "DISEASE", 0, 5], ["cirrhotic", "DISEASE", 150, 159], ["nitric oxide", "CHEMICAL", 190, 202], ["nitric oxide", "CHEMICAL", 190, 202], ["IPVDs", "SIMPLE_CHEMICAL", 0, 5], ["pulmonary", "ORGAN", 73, 82], ["liver", "ORGAN", 160, 165], ["nitric oxide", "SIMPLE_CHEMICAL", 190, 202], ["IPVDs", "TREATMENT", 0, 5], ["poor clearance", "PROBLEM", 34, 48], ["pulmonary vasodilators", "TREATMENT", 73, 95], ["circulating vasoconstrictors", "TREATMENT", 114, 142], ["the cirrhotic liver", "PROBLEM", 146, 165], ["nitric oxide", "TREATMENT", 190, 202], ["pulmonary", "ANATOMY", 73, 82], ["vasodilators", "OBSERVATION", 83, 95], ["cirrhotic", "OBSERVATION", 150, 159], ["liver", "ANATOMY", 160, 165], ["nitric oxide", "OBSERVATION", 190, 202]]], ["The resultant dilation of the pulmonary vasculature leads to a large right to left shunt, which is not a true anatomical shunt as it partially responds to increased FiO 2 .Answer: Hepatopulmonary SyndromeThe prevalence of HPS varies but it is thought to be 5-50% in cirrhotic patients.", [["pulmonary vasculature", "ANATOMY", 30, 51], ["Hepatopulmonary Syndrome", "DISEASE", 180, 204], ["HPS", "DISEASE", 222, 225], ["cirrhotic", "DISEASE", 266, 275], ["FiO 2", "CHEMICAL", 165, 170], ["pulmonary vasculature", "MULTI-TISSUE_STRUCTURE", 30, 51], ["FiO 2", "GENE_OR_GENE_PRODUCT", 165, 170], ["patients", "ORGANISM", 276, 284], ["FiO 2", "PROTEIN", 165, 170], ["patients", "SPECIES", 276, 284], ["The resultant dilation of the pulmonary vasculature", "PROBLEM", 0, 51], ["a large right to left shunt", "TREATMENT", 61, 88], ["a true anatomical shunt", "PROBLEM", 103, 126], ["Hepatopulmonary Syndrome", "PROBLEM", 180, 204], ["HPS varies", "PROBLEM", 222, 232], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["dilation", "OBSERVATION", 14, 22], ["pulmonary vasculature", "ANATOMY", 30, 51], ["large", "OBSERVATION_MODIFIER", 63, 68], ["right", "ANATOMY_MODIFIER", 69, 74], ["left", "ANATOMY_MODIFIER", 78, 82], ["shunt", "OBSERVATION", 83, 88], ["not a true", "UNCERTAINTY", 99, 109], ["anatomical shunt", "OBSERVATION", 110, 126], ["Hepatopulmonary", "ANATOMY", 180, 195], ["Syndrome", "OBSERVATION", 196, 204], ["HPS varies", "OBSERVATION", 222, 232], ["thought to be", "UNCERTAINTY", 243, 256], ["cirrhotic", "OBSERVATION", 266, 275]]], ["HPS can also occur in non-cirrhotic portal hypertension and occasionally acute liver disease.", [["portal", "ANATOMY", 36, 42], ["liver", "ANATOMY", 79, 84], ["HPS", "DISEASE", 0, 3], ["non-cirrhotic portal hypertension", "DISEASE", 22, 55], ["acute liver disease", "DISEASE", 73, 92], ["portal", "MULTI-TISSUE_STRUCTURE", 36, 42], ["liver", "ORGAN", 79, 84], ["non-cirrhotic portal hypertension", "PROBLEM", 22, 55], ["occasionally acute liver disease", "PROBLEM", 60, 92], ["non-cirrhotic", "OBSERVATION", 22, 35], ["portal", "ANATOMY", 36, 42], ["hypertension", "OBSERVATION", 43, 55], ["occasionally", "OBSERVATION_MODIFIER", 60, 72], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["liver", "ANATOMY", 79, 84], ["disease", "OBSERVATION", 85, 92]]], ["Mild abnormalities are very common.", [["Mild abnormalities", "PROBLEM", 0, 18], ["abnormalities", "OBSERVATION", 5, 18]]], ["If the PaO 2 is less than 60 mmHg, this is very suggestive of HPS in patients with cirrhosis and no underlying cardiopulmonary disease.Answer: Hepatopulmonary SyndromeHPS typically presents with dyspnea but often is initially asymptomatic and underdiagnosed.", [["cardiopulmonary", "ANATOMY", 111, 126], ["Hepatopulmonary", "ANATOMY", 143, 158], ["HPS", "DISEASE", 62, 65], ["cirrhosis", "DISEASE", 83, 92], ["cardiopulmonary disease", "DISEASE", 111, 134], ["Hepatopulmonary SyndromeHPS", "DISEASE", 143, 170], ["dyspnea", "DISEASE", 195, 202], ["PaO 2", "CHEMICAL", 7, 12], ["PaO 2", "GENE_OR_GENE_PRODUCT", 7, 12], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["the PaO", "TEST", 3, 10], ["HPS", "PROBLEM", 62, 65], ["cirrhosis", "PROBLEM", 83, 92], ["underlying cardiopulmonary disease", "PROBLEM", 100, 134], ["Hepatopulmonary SyndromeHPS", "PROBLEM", 143, 170], ["dyspnea", "PROBLEM", 195, 202], ["asymptomatic", "PROBLEM", 226, 238], ["very suggestive of", "UNCERTAINTY", 43, 61], ["HPS", "OBSERVATION", 62, 65], ["cirrhosis", "OBSERVATION", 83, 92], ["no underlying", "UNCERTAINTY", 97, 110], ["cardiopulmonary", "ANATOMY", 111, 126], ["disease", "OBSERVATION", 127, 134], ["Hepatopulmonary", "ANATOMY", 143, 158], ["dyspnea", "OBSERVATION", 195, 202]]], ["There does not appear to be a correlation between severity of liver disease and degree of hypoxemia although HPS is an independent predictor of death in patients with cirrhosis.Answer: Hepatopulmonary SyndromeThis patient's cardiac exam shows evidence of a hyperdynamic circulation and in HPS there is usually an elevated cardiac output, decreased systemic and pulmonary vascular resistance, and decreased arterial-mixed venous oxygen content difference.", [["liver", "ANATOMY", 62, 67], ["cardiac", "ANATOMY", 224, 231], ["cardiac", "ANATOMY", 322, 329], ["pulmonary vascular", "ANATOMY", 361, 379], ["arterial", "ANATOMY", 406, 414], ["venous", "ANATOMY", 421, 427], ["liver disease", "DISEASE", 62, 75], ["hypoxemia", "DISEASE", 90, 99], ["HPS", "DISEASE", 109, 112], ["death", "DISEASE", 144, 149], ["cirrhosis", "DISEASE", 167, 176], ["HPS", "DISEASE", 289, 292], ["elevated cardiac output", "DISEASE", 313, 336], ["oxygen", "CHEMICAL", 428, 434], ["oxygen", "CHEMICAL", 428, 434], ["liver", "ORGAN", 62, 67], ["patients", "ORGANISM", 153, 161], ["patient", "ORGANISM", 214, 221], ["cardiac", "ORGAN", 224, 231], ["cardiac", "ORGAN", 322, 329], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 361, 379], ["arterial", "MULTI-TISSUE_STRUCTURE", 406, 414], ["venous", "IMMATERIAL_ANATOMICAL_ENTITY", 421, 427], ["oxygen", "SIMPLE_CHEMICAL", 428, 434], ["patients", "SPECIES", 153, 161], ["patient", "SPECIES", 214, 221], ["liver disease", "PROBLEM", 62, 75], ["hypoxemia", "PROBLEM", 90, 99], ["cirrhosis", "PROBLEM", 167, 176], ["Hepatopulmonary SyndromeThis", "PROBLEM", 185, 213], ["patient's cardiac exam", "TEST", 214, 236], ["a hyperdynamic circulation", "PROBLEM", 255, 281], ["an elevated cardiac output", "PROBLEM", 310, 336], ["decreased systemic and pulmonary vascular resistance", "PROBLEM", 338, 390], ["decreased arterial-mixed venous oxygen content difference", "PROBLEM", 396, 453], ["liver", "ANATOMY", 62, 67], ["disease", "OBSERVATION", 68, 75], ["hypoxemia", "OBSERVATION", 90, 99], ["cirrhosis", "OBSERVATION", 167, 176], ["Hepatopulmonary", "ANATOMY", 185, 200], ["hyperdynamic", "OBSERVATION", 257, 269], ["elevated", "OBSERVATION", 313, 321], ["cardiac output", "OBSERVATION", 322, 336], ["decreased", "OBSERVATION_MODIFIER", 338, 347], ["systemic", "OBSERVATION_MODIFIER", 348, 356], ["pulmonary vascular", "ANATOMY", 361, 379], ["resistance", "OBSERVATION", 380, 390], ["decreased", "OBSERVATION_MODIFIER", 396, 405], ["arterial", "OBSERVATION_MODIFIER", 406, 414], ["mixed", "OBSERVATION_MODIFIER", 415, 420], ["venous", "ANATOMY", 421, 427], ["oxygen content", "OBSERVATION", 428, 442]]], ["As HPS progresses it can lead to decreased oxygenation induced by changes in posture such as platypnea -increase in dyspnea when sitting or standing upright and relieved by lying down or orthodeoxia -desaturation in the upright position relieved in a recumbent position.Answer: Hepatopulmonary SyndromeThe reason it is important to make a diagnosis of HPS is that it negatively impacts outcome after liver transplantation, particularly with a PaO 2 less than 60 mmHg.Answer: Hepatopulmonary SyndromeThe diagnosis can be confirmed in several ways.", [["liver", "ANATOMY", 400, 405], ["HPS", "DISEASE", 3, 6], ["dyspnea", "DISEASE", 116, 123], ["desaturation", "DISEASE", 200, 212], ["Hepatopulmonary Syndrome", "DISEASE", 278, 302], ["HPS", "DISEASE", 352, 355], ["Hepatopulmonary Syndrome", "DISEASE", 475, 499], ["liver", "ORGAN", 400, 405], ["decreased oxygenation", "PROBLEM", 33, 54], ["changes in posture", "PROBLEM", 66, 84], ["platypnea", "PROBLEM", 93, 102], ["dyspnea", "PROBLEM", 116, 123], ["orthodeoxia", "PROBLEM", 187, 198], ["desaturation in the upright position", "PROBLEM", 200, 236], ["Hepatopulmonary Syndrome", "PROBLEM", 278, 302], ["HPS", "PROBLEM", 352, 355], ["liver transplantation", "TREATMENT", 400, 421], ["a PaO", "TEST", 441, 446], ["Hepatopulmonary Syndrome", "PROBLEM", 475, 499], ["decreased", "OBSERVATION_MODIFIER", 33, 42], ["oxygenation", "OBSERVATION", 43, 54], ["increase", "OBSERVATION_MODIFIER", 104, 112], ["dyspnea", "OBSERVATION", 116, 123], ["desaturation", "OBSERVATION", 200, 212], ["Hepatopulmonary", "ANATOMY", 278, 293], ["Syndrome", "OBSERVATION", 294, 302], ["liver", "ANATOMY", 400, 405], ["transplantation", "OBSERVATION", 406, 421], ["Hepatopulmonary", "ANATOMY", 475, 490], ["Syndrome", "OBSERVATION", 491, 499]]], ["Contrast-enhanced echocardiography is used to document the presence of IVPDs.", [["IVPDs", "DISEASE", 71, 76], ["IVPDs", "PATHOLOGICAL_FORMATION", 71, 76], ["Contrast-enhanced echocardiography", "TEST", 0, 34], ["IVPDs", "PROBLEM", 71, 76]]], ["This can be performed with dye (indocyanine green) or agitated saline producing bubbles (bubble echo).", [["indocyanine green", "CHEMICAL", 32, 49], ["indocyanine green", "CHEMICAL", 32, 49], ["dye", "SIMPLE_CHEMICAL", 27, 30], ["indocyanine green", "SIMPLE_CHEMICAL", 32, 49], ["saline", "SIMPLE_CHEMICAL", 63, 69], ["dye (indocyanine green", "TREATMENT", 27, 49], ["agitated saline", "TREATMENT", 54, 69], ["bubble echo", "TEST", 89, 100]]], ["In the absence of shunts, the dye/bubbles should only be seen in the right heart as the dye/ bubbles do not clear the pulmonary capillary circulation.", [["right heart", "ANATOMY", 69, 80], ["pulmonary capillary", "ANATOMY", 118, 137], ["heart", "ORGAN", 75, 80], ["pulmonary capillary", "MULTI-TISSUE_STRUCTURE", 118, 137], ["shunts", "TREATMENT", 18, 24], ["the dye/bubbles", "TREATMENT", 26, 41], ["the dye/ bubbles", "TEST", 84, 100], ["shunts", "OBSERVATION", 18, 24], ["bubbles", "OBSERVATION", 34, 41], ["should only be seen", "UNCERTAINTY", 42, 61], ["right", "ANATOMY_MODIFIER", 69, 74], ["heart", "ANATOMY", 75, 80], ["bubbles", "OBSERVATION", 93, 100], ["clear", "OBSERVATION", 108, 113], ["pulmonary", "ANATOMY", 118, 127], ["capillary", "ANATOMY_MODIFIER", 128, 137]]], ["With a right to left shunt, the dye/bubbles will be seen in the left heart, within 3 heartbeats for an intracardiac shunt and 3-6 heartbeats for an intrapulmonary shunt.Answer: Hepatopulmonary SyndromeOther methods for the detection of shunting include technetium labeled macroaggregated albumin (MAA) scanning.", [["left heart", "ANATOMY", 64, 74], ["intracardiac", "ANATOMY", 103, 115], ["intrapulmonary", "ANATOMY", 148, 162], ["Hepatopulmonary", "ANATOMY", 177, 192], ["technetium", "CHEMICAL", 253, 263], ["technetium", "CHEMICAL", 253, 263], ["heart", "ORGAN", 69, 74], ["intrapulmonary", "ORGAN", 148, 162], ["technetium labeled macroaggregated albumin", "SIMPLE_CHEMICAL", 253, 295], ["MAA", "SIMPLE_CHEMICAL", 297, 300], ["a right to left shunt", "TREATMENT", 5, 26], ["the dye/bubbles", "TREATMENT", 28, 43], ["an intracardiac shunt", "TREATMENT", 100, 121], ["an intrapulmonary shunt", "TREATMENT", 145, 168], ["shunting", "PROBLEM", 236, 244], ["technetium labeled macroaggregated albumin (MAA) scanning", "TEST", 253, 310], ["right", "ANATOMY_MODIFIER", 7, 12], ["left", "ANATOMY_MODIFIER", 16, 20], ["shunt", "OBSERVATION", 21, 26], ["bubbles", "OBSERVATION", 36, 43], ["left", "ANATOMY_MODIFIER", 64, 68], ["heart", "ANATOMY", 69, 74], ["intracardiac", "ANATOMY", 103, 115], ["shunt", "OBSERVATION", 116, 121], ["intrapulmonary", "ANATOMY", 148, 162], ["shunt", "OBSERVATION", 163, 168], ["Hepatopulmonary", "ANATOMY", 177, 192], ["shunting", "OBSERVATION", 236, 244]]], ["The labeled MAA should not traverse the pulmonary capillary bed but will be seen in the kidneys or brain, if intracardiac or intrapulmonary shunting is present.", [["pulmonary capillary bed", "ANATOMY", 40, 63], ["kidneys", "ANATOMY", 88, 95], ["brain", "ANATOMY", 99, 104], ["intracardiac", "ANATOMY", 109, 121], ["intrapulmonary", "ANATOMY", 125, 139], ["MAA", "CHEMICAL", 12, 15], ["MAA", "CHEMICAL", 12, 15], ["MAA", "SIMPLE_CHEMICAL", 12, 15], ["pulmonary capillary bed", "TISSUE", 40, 63], ["kidneys", "ORGAN", 88, 95], ["brain", "ORGAN", 99, 104], ["intrapulmonary", "MULTI-TISSUE_STRUCTURE", 125, 139], ["The labeled MAA", "TREATMENT", 0, 15], ["intracardiac or intrapulmonary shunting", "PROBLEM", 109, 148], ["pulmonary", "ANATOMY", 40, 49], ["capillary", "ANATOMY_MODIFIER", 50, 59], ["kidneys", "ANATOMY", 88, 95], ["brain", "ANATOMY", 99, 104], ["intracardiac", "ANATOMY", 109, 121], ["intrapulmonary", "ANATOMY", 125, 139], ["shunting", "OBSERVATION", 140, 148]]], ["Pulmonary angiography should be reserved for cases where the diagnosis is still not certain after contrast echocardiography or MAA scan.Answer: Hepatopulmonary SyndromeRoutine chest imaging is typically normal in HPS.", [["Pulmonary", "ANATOMY", 0, 9], ["HPS", "DISEASE", 213, 216], ["Pulmonary", "ORGAN", 0, 9], ["MAA", "SIMPLE_CHEMICAL", 127, 130], ["Pulmonary angiography", "TEST", 0, 21], ["contrast echocardiography", "TEST", 98, 123], ["MAA scan", "TEST", 127, 135], ["Hepatopulmonary SyndromeRoutine chest imaging", "TEST", 144, 189], ["Hepatopulmonary", "ANATOMY", 144, 159], ["chest", "ANATOMY", 176, 181], ["normal", "OBSERVATION", 203, 209]]], ["Lung function assessments can be abnormal although in a non-specific pattern.", [["Lung", "ANATOMY", 0, 4], ["Lung", "ORGAN", 0, 4], ["Lung function assessments", "TEST", 0, 25], ["non-specific", "OBSERVATION_MODIFIER", 56, 68]]], ["The diffusion capacity for carbon monoxide (DLCO) is usually decreased.", [["carbon monoxide", "CHEMICAL", 27, 42], ["carbon monoxide", "CHEMICAL", 27, 42], ["DLCO", "CHEMICAL", 44, 48], ["carbon monoxide", "SIMPLE_CHEMICAL", 27, 42], ["The diffusion capacity", "TEST", 0, 22], ["carbon monoxide", "TEST", 27, 42], ["decreased", "OBSERVATION_MODIFIER", 61, 70]]], ["Arterial blood gases in HPS are abnormal.", [["Arterial blood", "ANATOMY", 0, 14], ["HPS", "DISEASE", 24, 27], ["Arterial blood", "MULTI-TISSUE_STRUCTURE", 0, 14], ["Arterial blood gases", "TEST", 0, 20], ["HPS", "TEST", 24, 27], ["abnormal", "PROBLEM", 32, 40], ["abnormal", "OBSERVATION", 32, 40]]], ["A PaO 2 of less than 80 mmHg on room air is usual and the Aa gradient is usually greater than 20 mmHg.Answer: Hepatopulmonary SyndromeThe shunt fraction gives an estimate of the degree of shunting and requires measuring the PaO 2 while breathing 100% O 2 for 20 min.", [["Hepatopulmonary Syndrome", "DISEASE", 110, 134], ["PaO 2", "CHEMICAL", 224, 229], ["O 2", "CHEMICAL", 251, 254], ["PaO 2", "GENE_OR_GENE_PRODUCT", 2, 7], ["A PaO", "TEST", 0, 5], ["the Aa gradient", "TEST", 54, 69], ["Hepatopulmonary Syndrome", "PROBLEM", 110, 134], ["The shunt fraction", "TREATMENT", 134, 152], ["the degree of shunting", "PROBLEM", 174, 196], ["the PaO", "TEST", 220, 227], ["Hepatopulmonary", "ANATOMY", 110, 125], ["Syndrome", "OBSERVATION", 126, 134], ["shunt fraction", "OBSERVATION", 138, 152], ["degree", "OBSERVATION_MODIFIER", 178, 184], ["shunting", "OBSERVATION", 188, 196]]], ["The formula is: where Qs is the shunt flow and Qt is the total flow and PAO 2 is the alveolar partial pressure of oxygen and PaO 2 is the arterial partial pressure of oxygen.", [["alveolar", "ANATOMY", 85, 93], ["arterial", "ANATOMY", 138, 146], ["oxygen", "CHEMICAL", 114, 120], ["oxygen", "CHEMICAL", 167, 173], ["PAO 2", "CHEMICAL", 72, 77], ["oxygen", "CHEMICAL", 114, 120], ["PaO 2", "CHEMICAL", 125, 130], ["oxygen", "CHEMICAL", 167, 173], ["alveolar", "MULTI-TISSUE_STRUCTURE", 85, 93], ["oxygen", "SIMPLE_CHEMICAL", 114, 120], ["PaO 2", "GENE_OR_GENE_PRODUCT", 125, 130], ["arterial", "MULTI-TISSUE_STRUCTURE", 138, 146], ["oxygen", "SIMPLE_CHEMICAL", 167, 173], ["the shunt flow", "TEST", 28, 42], ["Qt", "TEST", 47, 49], ["the total flow", "TEST", 53, 67], ["PAO", "TEST", 72, 75], ["the alveolar partial pressure of oxygen", "TREATMENT", 81, 120], ["PaO", "TREATMENT", 125, 128], ["the arterial partial pressure of oxygen", "TREATMENT", 134, 173], ["shunt", "OBSERVATION", 32, 37], ["alveolar", "ANATOMY_MODIFIER", 85, 93], ["partial", "OBSERVATION_MODIFIER", 94, 101], ["pressure", "OBSERVATION_MODIFIER", 102, 110], ["arterial", "ANATOMY", 138, 146], ["partial", "OBSERVATION_MODIFIER", 147, 154], ["pressure", "OBSERVATION_MODIFIER", 155, 163], ["oxygen", "OBSERVATION_MODIFIER", 167, 173]]], ["The normal shunt fraction is 5%.", [["normal", "OBSERVATION", 4, 10], ["shunt fraction", "OBSERVATION", 11, 25]]], ["Anything above 20-30% increases the risk of poor outcome after transplantation.Answer: Hepatopulmonary SyndromeThe only effective treatment for HPS is liver transplantation.", [["liver", "ANATOMY", 151, 156], ["Hepatopulmonary Syndrome", "DISEASE", 87, 111], ["HPS", "DISEASE", 144, 147], ["liver", "ORGAN", 151, 156], ["transplantation", "TREATMENT", 63, 78], ["Hepatopulmonary Syndrome", "PROBLEM", 87, 111], ["effective treatment", "TREATMENT", 120, 139], ["HPS", "PROBLEM", 144, 147], ["liver transplantation", "TREATMENT", 151, 172], ["Hepatopulmonary", "ANATOMY", 87, 102], ["Syndrome", "OBSERVATION", 103, 111], ["effective", "OBSERVATION_MODIFIER", 120, 129], ["liver", "ANATOMY", 151, 156], ["transplantation", "OBSERVATION", 157, 172]]], ["Case reports detail the use of various agents including somatostatin analogues, methylene blue and indomethacin and are usually unsuccessful.", [["methylene blue", "CHEMICAL", 80, 94], ["indomethacin", "CHEMICAL", 99, 111], ["somatostatin", "CHEMICAL", 56, 68], ["methylene blue", "CHEMICAL", 80, 94], ["indomethacin", "CHEMICAL", 99, 111], ["somatostatin analogues", "SIMPLE_CHEMICAL", 56, 78], ["methylene blue", "SIMPLE_CHEMICAL", 80, 94], ["indomethacin", "SIMPLE_CHEMICAL", 99, 111], ["various agents", "TREATMENT", 31, 45], ["somatostatin analogues", "TREATMENT", 56, 78], ["methylene blue", "TREATMENT", 80, 94], ["indomethacin", "TREATMENT", 99, 111]]], ["TIPS has also been tried with limited improvement.Answer: Hepatopulmonary SyndromeSeveral case series have documented good outcome after liver transplantation in selected patients with HPS.", [["liver", "ANATOMY", 137, 142], ["HPS", "DISEASE", 185, 188], ["liver", "ORGAN", 137, 142], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["TIPS", "TREATMENT", 0, 4], ["Hepatopulmonary SyndromeSeveral case series", "PROBLEM", 58, 101], ["liver transplantation", "TREATMENT", 137, 158], ["HPS", "PROBLEM", 185, 188], ["Hepatopulmonary", "ANATOMY", 58, 73], ["liver", "ANATOMY", 137, 142], ["transplantation", "OBSERVATION", 143, 158]]], ["Although survival is not at levels seen in patients without HPS, the survival benefit of transplant is significant.", [["HPS", "DISEASE", 60, 63], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["HPS", "PROBLEM", 60, 63], ["transplant", "TREATMENT", 89, 99], ["transplant", "OBSERVATION", 89, 99], ["significant", "OBSERVATION_MODIFIER", 103, 114]]], ["Resolution of HPS after transplant is variable and can be seen after a few days or up to a year.Answer: Hepatopulmonary SyndromeMost patients will need a model for end stage liver disease (MELD) exception as biological MELD scores are seldom at a level where transplant is likely, particularly in patients with blood type A or O.Answer: Esophageal Stricture Secondary to Band LigationThis man is not doing himself any favors.", [["liver", "ANATOMY", 174, 179], ["blood", "ANATOMY", 311, 316], ["Esophageal", "ANATOMY", 337, 347], ["HPS", "DISEASE", 14, 17], ["liver disease", "DISEASE", 174, 187], ["patients", "ORGANISM", 133, 141], ["liver", "ORGAN", 174, 179], ["patients", "ORGANISM", 297, 305], ["blood", "ORGANISM_SUBSTANCE", 311, 316], ["Esophageal", "ORGAN", 337, 347], ["patients", "SPECIES", 133, 141], ["patients", "SPECIES", 297, 305], ["man", "SPECIES", 389, 392], ["HPS", "PROBLEM", 14, 17], ["transplant", "TREATMENT", 24, 34], ["Hepatopulmonary SyndromeMost", "PROBLEM", 104, 132], ["a model", "TREATMENT", 152, 159], ["end stage liver disease", "PROBLEM", 164, 187], ["MELD)", "TREATMENT", 189, 194], ["biological MELD scores", "PROBLEM", 208, 230], ["transplant", "TREATMENT", 259, 269], ["Esophageal Stricture", "PROBLEM", 337, 357], ["Band Ligation", "TREATMENT", 371, 384], ["HPS", "OBSERVATION", 14, 17], ["transplant", "OBSERVATION", 24, 34], ["Hepatopulmonary", "ANATOMY", 104, 119], ["liver", "ANATOMY", 174, 179], ["disease", "OBSERVATION", 180, 187], ["Esophageal", "ANATOMY", 337, 347], ["Stricture", "OBSERVATION", 348, 357], ["Band Ligation", "OBSERVATION", 371, 384]]], ["He has decompensated cirrhosis and yet continues to drink.", [["cirrhosis", "DISEASE", 21, 30], ["decompensated cirrhosis", "PROBLEM", 7, 30], ["decompensated", "OBSERVATION_MODIFIER", 7, 20], ["cirrhosis", "OBSERVATION", 21, 30]]], ["He has developed dysphagia and the sudden onset is suggestive of a food bolus impaction.", [["dysphagia", "DISEASE", 17, 26], ["He", "ORGANISM", 0, 2], ["dysphagia", "PROBLEM", 17, 26], ["a food bolus impaction", "PROBLEM", 65, 87], ["dysphagia", "OBSERVATION", 17, 26], ["suggestive of", "UNCERTAINTY", 51, 64], ["food", "OBSERVATION", 67, 71], ["bolus impaction", "OBSERVATION", 72, 87]]], ["A contrast study in this situation would be inadvisable due to the risk of aspiration.", [["A contrast study", "TEST", 0, 16], ["aspiration", "PROBLEM", 75, 85], ["aspiration", "OBSERVATION", 75, 85]]], ["This will also be an issue in terms of sedating the patient if an EGD is planned.Answer: Esophageal Stricture Secondary to Band LigationThe patient actually underwent EGD under general anesthesia, since we were concerned about airway protection in the event of a bolus impaction, but also given his inebriated state.", [["Esophageal", "ANATOMY", 89, 99], ["airway", "ANATOMY", 227, 233], ["patient", "ORGANISM", 52, 59], ["Esophageal", "ORGAN", 89, 99], ["patient", "ORGANISM", 140, 147], ["airway", "MULTI-TISSUE_STRUCTURE", 227, 233], ["patient", "SPECIES", 52, 59], ["patient", "SPECIES", 140, 147], ["sedating", "TREATMENT", 39, 47], ["an EGD", "TEST", 63, 69], ["Esophageal Stricture", "PROBLEM", 89, 109], ["Band Ligation", "TREATMENT", 123, 136], ["EGD", "TEST", 167, 170], ["general anesthesia", "TREATMENT", 177, 195], ["airway protection", "TREATMENT", 227, 244], ["a bolus impaction", "TREATMENT", 261, 278], ["his inebriated state", "PROBLEM", 295, 315], ["Esophageal", "ANATOMY", 89, 99], ["Stricture", "OBSERVATION", 100, 109], ["Band Ligation", "OBSERVATION", 123, 136], ["impaction", "OBSERVATION", 269, 278]]], ["In general, anesthesiologists I have worked with would much prefer to intubate a patient like this rather than use moderate sedation.", [["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["moderate sedation", "TREATMENT", 115, 132]]], ["This patient may have proved particularly difficult to sedate using midazolam.", [["midazolam", "CHEMICAL", 68, 77], ["midazolam", "CHEMICAL", 68, 77], ["patient", "ORGANISM", 5, 12], ["midazolam", "SIMPLE_CHEMICAL", 68, 77], ["patient", "SPECIES", 5, 12], ["midazolam", "TREATMENT", 68, 77]]], ["Propofol would be an option but the airway would not be protected.", [["airway", "ANATOMY", 36, 42], ["Propofol", "CHEMICAL", 0, 8], ["Propofol", "CHEMICAL", 0, 8], ["Propofol", "SIMPLE_CHEMICAL", 0, 8], ["airway", "MULTI-TISSUE_STRUCTURE", 36, 42], ["Propofol", "TREATMENT", 0, 8], ["an option", "TREATMENT", 18, 27], ["airway", "ANATOMY", 36, 42]]], ["There is some literature comparing moderate sedation with general anesthesia in this situation that suggests no real difference in outcome, but I would caution against sedation without airway protection in such a patient.Answer: Esophageal Stricture Secondary to Band LigationThe images show a food bolus ( Fig. 29.1 ; he was eating chicken wings with the beer) that was easily removed but there was an underlying stricture as seen in Fig. 29 .2 with the arrow pointing to a pressure ulcer.", [["airway", "ANATOMY", 185, 191], ["Esophageal", "ANATOMY", 229, 239], ["ulcer", "ANATOMY", 484, 489], ["stricture", "DISEASE", 414, 423], ["ulcer", "DISEASE", 484, 489], ["airway", "MULTI-TISSUE_STRUCTURE", 185, 191], ["patient", "ORGANISM", 213, 220], ["Esophageal", "ORGAN", 229, 239], ["chicken", "ORGANISM", 333, 340], ["wings", "ORGANISM_SUBDIVISION", 341, 346], ["stricture", "PATHOLOGICAL_FORMATION", 414, 423], ["ulcer", "PATHOLOGICAL_FORMATION", 484, 489], ["patient", "SPECIES", 213, 220], ["chicken", "SPECIES", 333, 340], ["chicken", "SPECIES", 333, 340], ["moderate sedation", "TREATMENT", 35, 52], ["general anesthesia", "TREATMENT", 58, 76], ["sedation", "TREATMENT", 168, 176], ["airway protection", "TREATMENT", 185, 202], ["Esophageal Stricture", "PROBLEM", 229, 249], ["Band Ligation", "TREATMENT", 263, 276], ["The images", "TEST", 276, 286], ["a food bolus", "TREATMENT", 292, 304], ["an underlying stricture", "PROBLEM", 400, 423], ["a pressure ulcer", "PROBLEM", 473, 489], ["moderate", "OBSERVATION_MODIFIER", 35, 43], ["no", "UNCERTAINTY", 109, 111], ["Esophageal", "ANATOMY", 229, 239], ["Stricture", "OBSERVATION", 240, 249], ["Band Ligation", "OBSERVATION", 263, 276], ["stricture", "OBSERVATION", 414, 423], ["pressure", "OBSERVATION_MODIFIER", 475, 483], ["ulcer", "OBSERVATION", 484, 489]]], ["The stricture was from repeated banding, which is actually surprisingly uncommon.", [["stricture", "DISEASE", 4, 13], ["stricture", "PATHOLOGICAL_FORMATION", 4, 13], ["The stricture", "PROBLEM", 0, 13], ["repeated banding", "TREATMENT", 23, 39], ["stricture", "OBSERVATION", 4, 13], ["repeated banding", "OBSERVATION", 23, 39]]], ["Reviewing the literature on many studies of banding, strictures are very uncommon, particularly compared to sclerotherapy.Answer: Esophageal Stricture Secondary to Band LigationThe patient still had varices proximal to the stricture and underwent dilation using a 10 mm pneumatic balloon with some relief.", [["Esophageal", "ANATOMY", 130, 140], ["varices", "ANATOMY", 199, 206], ["strictures", "DISEASE", 53, 63], ["varices proximal to the stricture", "DISEASE", 199, 232], ["strictures", "PATHOLOGICAL_FORMATION", 53, 63], ["Esophageal", "ORGAN", 130, 140], ["patient", "ORGANISM", 181, 188], ["stricture", "PATHOLOGICAL_FORMATION", 223, 232], ["patient", "SPECIES", 181, 188], ["banding", "TREATMENT", 44, 51], ["strictures", "PROBLEM", 53, 63], ["sclerotherapy", "TREATMENT", 108, 121], ["Esophageal Stricture", "PROBLEM", 130, 150], ["Band Ligation", "TREATMENT", 164, 177], ["varices proximal to the stricture", "PROBLEM", 199, 232], ["dilation", "TREATMENT", 247, 255], ["a 10 mm pneumatic balloon", "TREATMENT", 262, 287], ["banding", "OBSERVATION", 44, 51], ["strictures", "OBSERVATION", 53, 63], ["very", "OBSERVATION_MODIFIER", 68, 72], ["uncommon", "OBSERVATION", 73, 81], ["sclerotherapy", "OBSERVATION", 108, 121], ["Esophageal", "ANATOMY", 130, 140], ["Stricture", "OBSERVATION", 141, 150], ["Band Ligation", "OBSERVATION", 164, 177], ["varices", "OBSERVATION", 199, 206], ["stricture", "OBSERVATION", 223, 232], ["dilation", "OBSERVATION", 247, 255], ["relief", "OBSERVATION_MODIFIER", 298, 304]]], ["He was instructed to chew thoroughly and drink plenty of fluid with meals (not alcohol!).", [["alcohol", "CHEMICAL", 79, 86], ["alcohol", "CHEMICAL", 79, 86], ["He", "ORGANISM", 0, 2], ["alcohol", "SIMPLE_CHEMICAL", 79, 86]]], ["There is no literature on the best way to dilate such a stricture but we felt it was safer to use a balloon and avoid the proximal varices rather than Savary or Maloney push dilators.Answer: Multifocal Hepatocellular CarcinomaThis gentleman has developed at least three lesions in the liver.", [["varices", "ANATOMY", 131, 138], ["Hepatocellular CarcinomaThis", "ANATOMY", 202, 230], ["lesions", "ANATOMY", 270, 277], ["liver", "ANATOMY", 285, 290], ["stricture", "DISEASE", 56, 65], ["varices", "DISEASE", 131, 138], ["stricture", "PATHOLOGICAL_FORMATION", 56, 65], ["varices", "PATHOLOGICAL_FORMATION", 131, 138], ["Hepatocellular CarcinomaThis", "CANCER", 202, 230], ["lesions", "PATHOLOGICAL_FORMATION", 270, 277], ["liver", "ORGAN", 285, 290], ["a stricture", "PROBLEM", 54, 65], ["a balloon", "TREATMENT", 98, 107], ["the proximal varices", "PROBLEM", 118, 138], ["Savary", "TREATMENT", 151, 157], ["Maloney push dilators", "TREATMENT", 161, 182], ["Multifocal Hepatocellular CarcinomaThis", "PROBLEM", 191, 230], ["at least three lesions in the liver", "PROBLEM", 255, 290], ["no", "UNCERTAINTY", 9, 11], ["stricture", "OBSERVATION", 56, 65], ["balloon", "OBSERVATION", 100, 107], ["proximal", "OBSERVATION_MODIFIER", 122, 130], ["varices", "OBSERVATION", 131, 138], ["push dilators", "OBSERVATION", 169, 182], ["Multifocal", "OBSERVATION_MODIFIER", 191, 201], ["Hepatocellular CarcinomaThis", "OBSERVATION", 202, 230], ["at least", "OBSERVATION_MODIFIER", 255, 263], ["three", "OBSERVATION_MODIFIER", 264, 269], ["lesions", "OBSERVATION", 270, 277], ["liver", "ANATOMY", 285, 290]]], ["The largest is hypervascular and is shown in the first image.", [["hypervascular", "ANATOMY", 15, 28], ["hypervascular", "CANCER", 15, 28], ["hypervascular", "PROBLEM", 15, 28], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["hypervascular", "OBSERVATION", 15, 28]]], ["It measures 4 cm in diameter.", [["4 cm", "OBSERVATION_MODIFIER", 12, 16], ["diameter", "OBSERVATION_MODIFIER", 20, 28]]], ["Two smaller lesions are seen in the lower image and appear not to enhance but still are suspicious for hepatocellular carcinoma (HCC).", [["lesions", "ANATOMY", 12, 19], ["hepatocellular carcinoma", "ANATOMY", 103, 127], ["HCC", "ANATOMY", 129, 132], ["hepatocellular carcinoma", "DISEASE", 103, 127], ["HCC", "DISEASE", 129, 132], ["lesions", "CANCER", 12, 19], ["hepatocellular carcinoma", "CANCER", 103, 127], ["HCC", "CANCER", 129, 132], ["Two smaller lesions", "PROBLEM", 0, 19], ["hepatocellular carcinoma", "PROBLEM", 103, 127], ["smaller", "OBSERVATION_MODIFIER", 4, 11], ["lesions", "OBSERVATION", 12, 19], ["lower", "ANATOMY_MODIFIER", 36, 41], ["appear not to", "UNCERTAINTY", 52, 65], ["suspicious for", "UNCERTAINTY", 88, 102], ["hepatocellular", "ANATOMY", 103, 117], ["carcinoma", "OBSERVATION", 118, 127], ["HCC", "OBSERVATION", 129, 132]]], ["The liver has a nodular contour and the spleen is enlarged consistent with cirrhosis and portal hypertension.Answer: Multifocal Hepatocellular CarcinomaThe approach to HCC is well described in American Association for the Study of Liver Diseases (AASLD) guidelines (referenced below).", [["liver", "ANATOMY", 4, 9], ["nodular", "ANATOMY", 16, 23], ["spleen", "ANATOMY", 40, 46], ["portal", "ANATOMY", 89, 95], ["Hepatocellular CarcinomaThe", "ANATOMY", 128, 155], ["HCC", "ANATOMY", 168, 171], ["Liver", "ANATOMY", 231, 236], ["cirrhosis", "DISEASE", 75, 84], ["portal hypertension", "DISEASE", 89, 108], ["HCC", "DISEASE", 168, 171], ["Liver Diseases", "DISEASE", 231, 245], ["liver", "ORGAN", 4, 9], ["spleen", "ORGAN", 40, 46], ["portal", "MULTI-TISSUE_STRUCTURE", 89, 95], ["Hepatocellular CarcinomaThe", "CANCER", 128, 155], ["HCC", "CANCER", 168, 171], ["Liver", "ORGAN", 231, 236], ["enlarged", "PROBLEM", 50, 58], ["cirrhosis", "PROBLEM", 75, 84], ["portal hypertension", "PROBLEM", 89, 108], ["Multifocal Hepatocellular CarcinomaThe approach", "PROBLEM", 117, 164], ["HCC", "PROBLEM", 168, 171], ["the Study", "TEST", 218, 227], ["Liver Diseases", "PROBLEM", 231, 245], ["liver", "ANATOMY", 4, 9], ["nodular", "OBSERVATION", 16, 23], ["contour", "OBSERVATION_MODIFIER", 24, 31], ["spleen", "ANATOMY", 40, 46], ["enlarged", "OBSERVATION", 50, 58], ["consistent with", "UNCERTAINTY", 59, 74], ["cirrhosis", "OBSERVATION", 75, 84], ["portal", "ANATOMY", 89, 95], ["hypertension", "OBSERVATION", 96, 108], ["Multifocal", "OBSERVATION_MODIFIER", 117, 127], ["Hepatocellular", "ANATOMY", 128, 142], ["HCC", "OBSERVATION", 168, 171], ["Liver", "ANATOMY", 231, 236], ["Diseases", "OBSERVATION", 237, 245]]], ["The important points to remember are that biopsy is seldom required to make a diagnosis.", [["biopsy", "TEST", 42, 48]]], ["Any hypervascular lesion in a cirrhotic liver is considered to be HCC until proven otherwise and biopsy runs the risk of seeding the needle track with HCC cells.", [["hypervascular lesion", "ANATOMY", 4, 24], ["liver", "ANATOMY", 40, 45], ["HCC", "ANATOMY", 66, 69], ["HCC cells", "ANATOMY", 151, 160], ["cirrhotic liver", "DISEASE", 30, 45], ["HCC", "DISEASE", 66, 69], ["HCC", "DISEASE", 151, 154], ["hypervascular lesion", "CANCER", 4, 24], ["liver", "ORGAN", 40, 45], ["HCC", "CANCER", 66, 69], ["HCC cells", "CELL", 151, 160], ["HCC cells", "CELL_TYPE", 151, 160], ["Any hypervascular lesion", "PROBLEM", 0, 24], ["a cirrhotic liver", "PROBLEM", 28, 45], ["HCC", "PROBLEM", 66, 69], ["biopsy", "TEST", 97, 103], ["HCC cells", "PROBLEM", 151, 160], ["hypervascular", "OBSERVATION_MODIFIER", 4, 17], ["lesion", "OBSERVATION", 18, 24], ["cirrhotic", "OBSERVATION", 30, 39], ["liver", "ANATOMY", 40, 45], ["considered to be", "UNCERTAINTY", 49, 65], ["HCC", "OBSERVATION", 66, 69]]], ["I have seen a case of recurrent HCC in the abdominal wall of a patient after liver transplant that had had a liver biopsy a year prior to transplant.Answer: Multifocal Hepatocellular CarcinomaThe size and number of lesions are important.", [["HCC", "ANATOMY", 32, 35], ["abdominal wall", "ANATOMY", 43, 57], ["liver", "ANATOMY", 77, 82], ["liver", "ANATOMY", 109, 114], ["Multifocal Hepatocellular Carcinoma", "ANATOMY", 157, 192], ["lesions", "ANATOMY", 215, 222], ["HCC", "DISEASE", 32, 35], ["Hepatocellular Carcinoma", "DISEASE", 168, 192], ["HCC", "CANCER", 32, 35], ["abdominal wall", "MULTI-TISSUE_STRUCTURE", 43, 57], ["patient", "ORGANISM", 63, 70], ["liver", "ORGAN", 77, 82], ["liver", "ORGAN", 109, 114], ["Hepatocellular Carcinoma", "CANCER", 168, 192], ["lesions", "PATHOLOGICAL_FORMATION", 215, 222], ["patient", "SPECIES", 63, 70], ["recurrent HCC", "PROBLEM", 22, 35], ["liver transplant", "TREATMENT", 77, 93], ["a liver biopsy", "TEST", 107, 121], ["transplant", "TREATMENT", 138, 148], ["Multifocal Hepatocellular Carcinoma", "PROBLEM", 157, 192], ["lesions", "PROBLEM", 215, 222], ["HCC", "OBSERVATION", 32, 35], ["abdominal wall", "ANATOMY", 43, 57], ["liver", "ANATOMY", 77, 82], ["transplant", "OBSERVATION", 83, 93], ["liver", "ANATOMY", 109, 114], ["biopsy", "OBSERVATION", 115, 121], ["Multifocal", "OBSERVATION_MODIFIER", 157, 167], ["Hepatocellular", "ANATOMY", 168, 182], ["Carcinoma", "OBSERVATION", 183, 192], ["size", "OBSERVATION_MODIFIER", 196, 200], ["number", "OBSERVATION_MODIFIER", 205, 211], ["lesions", "OBSERVATION", 215, 222]]], ["A seminal paper published in the 1990s established the Milan criteria that determined that patients with a single lesion less than 5 cm, or three lesions less than 3 cm without vascular invasion or metastases, had good 4-year survival after liver transplant, compared to patients transplanted beyond these criteria.", [["lesion", "ANATOMY", 114, 120], ["lesions", "ANATOMY", 146, 153], ["vascular", "ANATOMY", 177, 185], ["metastases", "ANATOMY", 198, 208], ["liver", "ANATOMY", 241, 246], ["metastases", "DISEASE", 198, 208], ["patients", "ORGANISM", 91, 99], ["lesions", "CANCER", 146, 153], ["vascular", "MULTI-TISSUE_STRUCTURE", 177, 185], ["liver", "ORGAN", 241, 246], ["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 271, 279], ["a single lesion", "PROBLEM", 105, 120], ["three lesions", "PROBLEM", 140, 153], ["vascular invasion", "PROBLEM", 177, 194], ["metastases", "PROBLEM", 198, 208], ["liver transplant", "TREATMENT", 241, 257], ["seminal", "ANATOMY", 2, 9], ["lesion", "OBSERVATION", 114, 120], ["than 5 cm", "OBSERVATION_MODIFIER", 126, 135], ["three", "OBSERVATION_MODIFIER", 140, 145], ["lesions", "OBSERVATION", 146, 153], ["less than 3 cm", "OBSERVATION_MODIFIER", 154, 168], ["without", "UNCERTAINTY", 169, 176], ["vascular", "ANATOMY", 177, 185], ["invasion", "OBSERVATION", 186, 194], ["metastases", "OBSERVATION", 198, 208], ["good", "OBSERVATION_MODIFIER", 214, 218], ["liver", "ANATOMY", 241, 246], ["transplant", "OBSERVATION", 247, 257]]], ["Based on this, the current MELD organ allocation system in the USA allows for an exception of 22 points if the patient's actual MELD score is lower than this (which is invariably the case) in patients who have a T2 tumor (so within Milan criteria but also a single lesion needs to be greater than 2 cm in diameter).Answer: Multifocal Hepatocellular CarcinomaOther studies have suggested that the Milan criteria are too strict and lesions up to 6.5 cm should be considered for transplant (the UCSF criteria) and some regions in the USA would provide a MELD exception for lesions this size.Answer: Multifocal Hepatocellular CarcinomaThe options for this patient are limited.", [["organ", "ANATOMY", 32, 37], ["T2 tumor", "ANATOMY", 212, 220], ["lesion", "ANATOMY", 265, 271], ["Hepatocellular", "ANATOMY", 334, 348], ["lesions", "ANATOMY", 430, 437], ["lesions", "ANATOMY", 570, 577], ["Multifocal Hepatocellular Carcinoma", "ANATOMY", 596, 631], ["tumor", "DISEASE", 215, 220], ["Hepatocellular Carcinoma", "DISEASE", 607, 631], ["organ", "ORGAN", 32, 37], ["patient", "ORGANISM", 111, 118], ["patients", "ORGANISM", 192, 200], ["T2 tumor", "CANCER", 212, 220], ["Hepatocellular CarcinomaOther", "CANCER", 334, 363], ["lesions", "PATHOLOGICAL_FORMATION", 430, 437], ["lesions", "PATHOLOGICAL_FORMATION", 570, 577], ["Hepatocellular Carcinoma", "CANCER", 607, 631], ["patient", "ORGANISM", 652, 659], ["patient", "SPECIES", 111, 118], ["patients", "SPECIES", 192, 200], ["patient", "SPECIES", 652, 659], ["the patient's actual MELD score", "TEST", 107, 138], ["a T2 tumor", "PROBLEM", 210, 220], ["a single lesion", "PROBLEM", 256, 271], ["Multifocal Hepatocellular CarcinomaOther studies", "TEST", 323, 371], ["lesions", "PROBLEM", 430, 437], ["transplant", "TREATMENT", 476, 486], ["the UCSF criteria", "TEST", 488, 505], ["lesions this size", "PROBLEM", 570, 587], ["Multifocal Hepatocellular Carcinoma", "PROBLEM", 596, 631], ["tumor", "OBSERVATION", 215, 220], ["lesion", "OBSERVATION", 265, 271], ["Multifocal", "OBSERVATION_MODIFIER", 323, 333], ["Hepatocellular", "ANATOMY", 334, 348], ["lesions", "OBSERVATION", 430, 437], ["6.5 cm", "OBSERVATION_MODIFIER", 444, 450], ["lesions", "OBSERVATION", 570, 577], ["size", "OBSERVATION_MODIFIER", 583, 587], ["Multifocal", "OBSERVATION_MODIFIER", 596, 606], ["Hepatocellular", "ANATOMY", 607, 621], ["Carcinoma", "OBSERVATION", 622, 631]]], ["He could get chemoembolization or radiofrequency ablation of the larger lesion.", [["lesion", "ANATOMY", 72, 78], ["lesion", "CANCER", 72, 78], ["chemoembolization", "TREATMENT", 13, 30], ["radiofrequency ablation", "TREATMENT", 34, 57], ["the larger lesion", "PROBLEM", 61, 78], ["larger", "OBSERVATION_MODIFIER", 65, 71], ["lesion", "OBSERVATION", 72, 78]]], ["Systemic chemotherapy is rarely effective for HCC.Answer: Multifocal Hepatocellular CarcinomaA live donor liver transplant is still an option for this patient since he would not need a MELD exception for a deceased donor organ.", [["HCC", "ANATOMY", 46, 49], ["Hepatocellular", "ANATOMY", 69, 83], ["liver", "ANATOMY", 106, 111], ["organ", "ANATOMY", 221, 226], ["HCC", "DISEASE", 46, 49], ["HCC", "CANCER", 46, 49], ["Hepatocellular CarcinomaA", "CANCER", 69, 94], ["liver", "ORGAN", 106, 111], ["patient", "ORGANISM", 151, 158], ["organ", "ORGAN", 221, 226], ["patient", "SPECIES", 151, 158], ["Systemic chemotherapy", "TREATMENT", 0, 21], ["HCC", "PROBLEM", 46, 49], ["Multifocal Hepatocellular CarcinomaA", "PROBLEM", 58, 94], ["donor liver transplant", "TREATMENT", 100, 122], ["a deceased donor organ", "PROBLEM", 204, 226], ["chemotherapy", "OBSERVATION", 9, 21], ["Multifocal", "OBSERVATION_MODIFIER", 58, 68], ["Hepatocellular", "ANATOMY", 69, 83], ["liver", "ANATOMY", 106, 111], ["transplant", "OBSERVATION", 112, 122]]], ["However, it should be made clear to the patient and the donor that there is a very significant risk of HCC recurrence.Case 31A 46-year-old male presents to the ER with pain and abdominal distension.", [["HCC", "ANATOMY", 103, 106], ["abdominal", "ANATOMY", 177, 186], ["HCC", "DISEASE", 103, 106], ["pain", "DISEASE", 168, 172], ["abdominal distension", "DISEASE", 177, 197], ["patient", "ORGANISM", 40, 47], ["HCC", "CANCER", 103, 106], ["male", "ORGANISM", 139, 143], ["ER", "GENE_OR_GENE_PRODUCT", 160, 162], ["abdominal", "ORGANISM_SUBDIVISION", 177, 186], ["patient", "SPECIES", 40, 47], ["HCC recurrence", "PROBLEM", 103, 117], ["pain", "PROBLEM", 168, 172], ["abdominal distension", "PROBLEM", 177, 197], ["HCC", "OBSERVATION_MODIFIER", 103, 106], ["recurrence", "OBSERVATION", 107, 117], ["pain", "OBSERVATION", 168, 172], ["abdominal", "ANATOMY", 177, 186], ["distension", "OBSERVATION", 187, 197]]], ["He has a history of alcoholic cirrhosis that has been complicated by ascites, encephalopathy and the presence of esophageal varices on endoscopy although he denies any bleeding.Case 31For the last 24 h, he has experienced increasing abdominal pain, mainly periumbilical with nausea and vomiting.", [["ascites", "ANATOMY", 69, 76], ["esophageal varices", "ANATOMY", 113, 131], ["abdominal", "ANATOMY", 233, 242], ["alcoholic cirrhosis", "DISEASE", 20, 39], ["ascites", "DISEASE", 69, 76], ["encephalopathy", "DISEASE", 78, 92], ["esophageal varices", "DISEASE", 113, 131], ["bleeding", "DISEASE", 168, 176], ["abdominal pain", "DISEASE", 233, 247], ["nausea", "DISEASE", 275, 281], ["vomiting", "DISEASE", 286, 294], ["esophageal varices", "PATHOLOGICAL_FORMATION", 113, 131], ["abdominal", "ORGANISM_SUBDIVISION", 233, 242], ["alcoholic cirrhosis", "PROBLEM", 20, 39], ["ascites", "PROBLEM", 69, 76], ["encephalopathy", "PROBLEM", 78, 92], ["esophageal varices", "PROBLEM", 113, 131], ["endoscopy", "TEST", 135, 144], ["any bleeding", "PROBLEM", 164, 176], ["increasing abdominal pain", "PROBLEM", 222, 247], ["nausea", "PROBLEM", 275, 281], ["vomiting", "PROBLEM", 286, 294], ["alcoholic", "OBSERVATION_MODIFIER", 20, 29], ["cirrhosis", "OBSERVATION", 30, 39], ["ascites", "OBSERVATION", 69, 76], ["encephalopathy", "OBSERVATION", 78, 92], ["esophageal", "ANATOMY", 113, 123], ["varices", "OBSERVATION", 124, 131], ["bleeding", "OBSERVATION", 168, 176], ["increasing", "OBSERVATION_MODIFIER", 222, 232], ["abdominal", "ANATOMY", 233, 242], ["pain", "OBSERVATION", 243, 247], ["periumbilical", "ANATOMY", 256, 269], ["nausea", "OBSERVATION", 275, 281]]], ["He has had no fever.Case 31He is currently on a small dose of diuretics, lactulose, and nadolol.", [["fever", "DISEASE", 14, 19], ["lactulose", "CHEMICAL", 73, 82], ["nadolol", "CHEMICAL", 88, 95], ["lactulose", "CHEMICAL", 73, 82], ["nadolol", "CHEMICAL", 88, 95], ["He", "ORGANISM", 0, 2], ["diuretics", "SIMPLE_CHEMICAL", 62, 71], ["lactulose", "SIMPLE_CHEMICAL", 73, 82], ["nadolol", "SIMPLE_CHEMICAL", 88, 95], ["fever", "PROBLEM", 14, 19], ["diuretics", "TREATMENT", 62, 71], ["lactulose", "TREATMENT", 73, 82], ["nadolol", "TREATMENT", 88, 95], ["no", "UNCERTAINTY", 11, 13], ["fever", "OBSERVATION", 14, 19]]], ["He has no children.Case 31On exam, he has mild tachycardia but normal blood pressure.", [["blood", "ANATOMY", 70, 75], ["tachycardia", "DISEASE", 47, 58], ["children", "ORGANISM", 10, 18], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["children", "SPECIES", 10, 18], ["exam", "TEST", 29, 33], ["mild tachycardia", "PROBLEM", 42, 58], ["no", "UNCERTAINTY", 7, 9], ["mild", "OBSERVATION_MODIFIER", 42, 46], ["tachycardia", "OBSERVATION", 47, 58], ["normal", "OBSERVATION", 63, 69], ["blood pressure", "OBSERVATION", 70, 84]]], ["He is afebrile.", [["afebrile", "PROBLEM", 6, 14], ["afebrile", "OBSERVATION", 6, 14]]], ["He has mild scleral icterus.Case 31His cardiovascular and respiratory systems are normal.", [["scleral", "ANATOMY", 12, 19], ["cardiovascular", "ANATOMY", 39, 53], ["respiratory", "ANATOMY", 58, 69], ["scleral icterus", "DISEASE", 12, 27], ["mild scleral icterus", "PROBLEM", 7, 27], ["mild", "OBSERVATION_MODIFIER", 7, 11], ["scleral", "ANATOMY", 12, 19], ["icterus", "OBSERVATION", 20, 27], ["cardiovascular", "ANATOMY", 39, 53], ["respiratory systems", "ANATOMY", 58, 77], ["normal", "OBSERVATION", 82, 88]]], ["His abdomen is distended with a fluid thrill but is tympanitic with increased bowel sounds.", [["abdomen", "ANATOMY", 4, 11], ["fluid", "ANATOMY", 32, 37], ["bowel", "ANATOMY", 78, 83], ["abdomen", "ORGAN", 4, 11], ["bowel", "ORGAN", 78, 83], ["distended", "PROBLEM", 15, 24], ["a fluid thrill", "PROBLEM", 30, 44], ["tympanitic", "PROBLEM", 52, 62], ["increased bowel sounds", "PROBLEM", 68, 90], ["abdomen", "ANATOMY", 4, 11], ["distended", "OBSERVATION", 15, 24], ["fluid", "OBSERVATION", 32, 37], ["tympanitic", "OBSERVATION", 52, 62], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["bowel", "ANATOMY", 78, 83], ["sounds", "OBSERVATION", 84, 90]]], ["He has a 4-5 cm umbilical hernia that is tender and can be reduced with difficulty.Laboratory StudiesHb 12.", [["umbilical hernia", "DISEASE", 16, 32], ["a 4-5 cm umbilical hernia", "PROBLEM", 7, 32], ["tender", "PROBLEM", 41, 47], ["Laboratory StudiesHb", "TEST", 83, 103], ["4-5 cm", "OBSERVATION_MODIFIER", 9, 15], ["umbilical", "ANATOMY", 16, 25], ["hernia", "OBSERVATION", 26, 32], ["tender", "OBSERVATION", 41, 47], ["reduced", "OBSERVATION_MODIFIER", 59, 66]]], ["4Answer: Risk Assessment in Cirrhotic Patients Undergoing SurgeryThis is a common scenario in a busy hospital.", [["Patients", "ORGANISM", 38, 46], ["Patients", "SPECIES", 38, 46], ["Surgery", "TREATMENT", 58, 65], ["Cirrhotic", "OBSERVATION", 28, 37]]], ["A patient with liver disease who has a condition that likely needs surgery, in this case small bowel obstruction from his umbilical hernia.Answer: Risk Assessment in Cirrhotic Patients Undergoing SurgeryHe really does not need any other investigation but he needs nasogastric suction, intravenous fluids and analgesia as required and hopefully he will improve with these conservative measures.", [["liver", "ANATOMY", 15, 20], ["bowel", "ANATOMY", 95, 100], ["umbilical hernia", "ANATOMY", 122, 138], ["nasogastric", "ANATOMY", 264, 275], ["intravenous", "ANATOMY", 285, 296], ["liver disease", "DISEASE", 15, 28], ["bowel obstruction", "DISEASE", 95, 112], ["umbilical hernia", "DISEASE", 122, 138], ["patient", "ORGANISM", 2, 9], ["liver", "ORGAN", 15, 20], ["bowel", "ORGAN", 95, 100], ["Patients", "ORGANISM", 176, 184], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 285, 296], ["patient", "SPECIES", 2, 9], ["Patients", "SPECIES", 176, 184], ["liver disease", "PROBLEM", 15, 28], ["surgery", "TREATMENT", 67, 74], ["small bowel obstruction", "PROBLEM", 89, 112], ["his umbilical hernia", "PROBLEM", 118, 138], ["Surgery", "TREATMENT", 196, 203], ["nasogastric suction", "TREATMENT", 264, 283], ["intravenous fluids", "TREATMENT", 285, 303], ["analgesia", "TREATMENT", 308, 317], ["these conservative measures", "TREATMENT", 365, 392], ["liver", "ANATOMY", 15, 20], ["disease", "OBSERVATION", 21, 28], ["bowel", "ANATOMY", 95, 100], ["obstruction", "OBSERVATION", 101, 112], ["umbilical", "ANATOMY", 122, 131], ["hernia", "OBSERVATION", 132, 138], ["Cirrhotic", "OBSERVATION", 166, 175]]], ["The problem will arise if he does not improve or if the clinical situation deteriorates such as strangulation of the hernia.Answer: Risk Assessment in Cirrhotic Patients Undergoing SurgeryIn general, elective surgery should be avoided in patients with decompensated liver disease.", [["hernia", "ANATOMY", 117, 123], ["liver", "ANATOMY", 266, 271], ["hernia", "DISEASE", 117, 123], ["decompensated liver disease", "DISEASE", 252, 279], ["hernia", "PATHOLOGICAL_FORMATION", 117, 123], ["Patients", "ORGANISM", 161, 169], ["patients", "ORGANISM", 238, 246], ["liver", "ORGAN", 266, 271], ["Patients", "SPECIES", 161, 169], ["patients", "SPECIES", 238, 246], ["the clinical situation", "PROBLEM", 52, 74], ["strangulation of the hernia", "PROBLEM", 96, 123], ["Surgery", "TREATMENT", 181, 188], ["elective surgery", "TREATMENT", 200, 216], ["decompensated liver disease", "PROBLEM", 252, 279], ["strangulation", "OBSERVATION", 96, 109], ["hernia", "OBSERVATION", 117, 123], ["Cirrhotic", "OBSERVATION", 151, 160], ["liver", "ANATOMY", 266, 271], ["disease", "OBSERVATION", 272, 279]]], ["Several predictive models exist to determine the risk of morbidity and mortality after surgery in such patients, but the risk depends on the severity of liver disease and also the type and urgency of the surgery.", [["liver", "ANATOMY", 153, 158], ["liver disease", "DISEASE", 153, 166], ["patients", "ORGANISM", 103, 111], ["liver", "ORGAN", 153, 158], ["patients", "SPECIES", 103, 111], ["Several predictive models", "TEST", 0, 25], ["morbidity", "PROBLEM", 57, 66], ["surgery", "TREATMENT", 87, 94], ["liver disease", "PROBLEM", 153, 166], ["the surgery", "TREATMENT", 200, 211], ["morbidity", "OBSERVATION", 57, 66], ["liver", "ANATOMY", 153, 158], ["disease", "OBSERVATION", 159, 166], ["surgery", "OBSERVATION", 204, 211]]], ["This patient has a Child-Pugh score of 10 or 11 making him a Child's C and his MELD score is given as 24.", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["Pugh score", "TEST", 25, 35], ["his MELD score", "TEST", 75, 89]]], ["He is at very high risk of decompensation and surgery should be avoided if at all possible.", [["decompensation", "DISEASE", 27, 41], ["decompensation", "PROBLEM", 27, 41], ["surgery", "TREATMENT", 46, 53], ["decompensation", "OBSERVATION", 27, 41]]], ["However, if he worsens and has a potentially fatal disorder (strangulated hernia would count), then he needs to be operated on.Answer: Risk Assessment in Cirrhotic Patients Undergoing SurgerySeveral studies have quantified the risk depending on the type or surgery and its urgency.", [["hernia", "ANATOMY", 74, 80], ["strangulated hernia", "DISEASE", 61, 80], ["hernia", "ORGAN", 74, 80], ["Patients", "ORGANISM", 164, 172], ["Patients", "SPECIES", 164, 172], ["a potentially fatal disorder", "PROBLEM", 31, 59], ["strangulated hernia", "PROBLEM", 61, 80], ["Surgery", "TREATMENT", 184, 191], ["Several studies", "TEST", 191, 206], ["surgery", "TREATMENT", 257, 264], ["its urgency", "PROBLEM", 269, 280], ["strangulated", "OBSERVATION_MODIFIER", 61, 73], ["hernia", "OBSERVATION", 74, 80], ["Cirrhotic", "OBSERVATION", 154, 163]]], ["In cirrhotic patients undergoing abdominal surgery, Child's class A, B, and C correspond to postoperative mortality of 10, 30, and 80%, respectively.", [["abdominal", "ANATOMY", 33, 42], ["cirrhotic", "DISEASE", 3, 12], ["patients", "ORGANISM", 13, 21], ["abdominal", "ORGANISM_SUBDIVISION", 33, 42], ["B", "CELL", 69, 70], ["patients", "SPECIES", 13, 21], ["abdominal surgery", "TREATMENT", 33, 50], ["postoperative mortality", "TEST", 92, 115], ["cirrhotic", "OBSERVATION_MODIFIER", 3, 12], ["abdominal", "ANATOMY", 33, 42], ["surgery", "OBSERVATION", 43, 50]]], ["The Child-Pugh score is somewhat subjective and in recent years, the MELD score has been used to assess mortality in liver patients.", [["liver", "ANATOMY", 117, 122], ["liver", "ORGAN", 117, 122], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["somewhat subjective", "PROBLEM", 24, 43], ["the MELD score", "TEST", 65, 79], ["liver", "ANATOMY", 117, 122]]], ["The MELD score incorporates three biochemical measurements into a complex logarithmic formula -the total bilirubin concentration, serum creatinine, and the international normalized ration (INR).", [["serum", "ANATOMY", 130, 135], ["bilirubin", "CHEMICAL", 105, 114], ["creatinine", "CHEMICAL", 136, 146], ["bilirubin", "CHEMICAL", 105, 114], ["creatinine", "CHEMICAL", 136, 146], ["bilirubin", "SIMPLE_CHEMICAL", 105, 114], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["creatinine", "SIMPLE_CHEMICAL", 136, 146], ["INR", "PROTEIN", 189, 192], ["The MELD score", "TEST", 0, 14], ["the total bilirubin concentration", "TEST", 95, 128], ["serum creatinine", "TEST", 130, 146], ["INR", "TEST", 189, 192]]], ["Patient scores range from 6 to 40, with 6 reflecting \"early\" disease and 40 \"severe\" disease.", [["Patient", "SPECIES", 0, 7], ["\"early\" disease", "PROBLEM", 53, 68], ["40 \"severe\" disease", "PROBLEM", 73, 92], ["disease", "OBSERVATION", 85, 92]]], ["The largest study of almost 800 cirrhotic patients undergoing major digestive, orthopedic, or cardiac surgery demonstrated that the MELD score correlated with short-term and long-term mortality extending out to 20 years.", [["digestive", "ANATOMY", 68, 77], ["cardiac", "ANATOMY", 94, 101], ["cirrhotic", "DISEASE", 32, 41], ["patients", "ORGANISM", 42, 50], ["digestive", "ORGAN", 68, 77], ["cardiac", "ORGAN", 94, 101], ["patients", "SPECIES", 42, 50], ["The largest study", "TEST", 0, 17], ["cardiac surgery", "TREATMENT", 94, 109], ["the MELD score", "PROBLEM", 128, 142], ["largest", "OBSERVATION_MODIFIER", 4, 11]]], ["For each point increase in the MELD score above 8, there was a 14% increase in 30-day and 90-day mortality.", [["the MELD score", "TEST", 27, 41], ["increase", "OBSERVATION_MODIFIER", 15, 23]]], ["The type of surgery is important but all emergent surgery increases the risk.Answer: Risk Assessment in Cirrhotic Patients Undergoing SurgeryUnfortunately, it is all too common to see a patient in the liver clinic who was referred for decompensated liver disease who states that they were completely well until they underwent elective surgery several months ago, or worse still, someone is transferred from another institution as an inpatient and had a recent umbilical hernia repair and now is draining ascites from the wound and has developed hepatorenal syndrome (HRS).Answer: Risk Assessment in Cirrhotic Patients Undergoing SurgeryThe reasons for worsening of liver disease after surgery are unclear but may reflect circulatory changes brought on by surgery or anesthesia resulting in impaired hepatic vascular flow.Case 32A 30-year-old Filipino woman presents with a 4-month history of progressive fatigue, jaundice, severe, generalized pruritus, dark urine, and pale stool.", [["liver", "ANATOMY", 201, 206], ["liver", "ANATOMY", 249, 254], ["umbilical hernia", "ANATOMY", 460, 476], ["ascites", "ANATOMY", 504, 511], ["wound", "ANATOMY", 521, 526], ["liver", "ANATOMY", 665, 670], ["hepatic vascular", "ANATOMY", 799, 815], ["urine", "ANATOMY", 958, 963], ["decompensated liver disease", "DISEASE", 235, 262], ["umbilical hernia", "DISEASE", 460, 476], ["ascites", "DISEASE", 504, 511], ["hepatorenal syndrome", "DISEASE", 545, 565], ["HRS", "DISEASE", 567, 570], ["liver disease", "DISEASE", 665, 678], ["impaired hepatic vascular flow", "DISEASE", 790, 820], ["fatigue", "DISEASE", 904, 911], ["jaundice", "DISEASE", 913, 921], ["pruritus", "DISEASE", 943, 951], ["Patients", "ORGANISM", 114, 122], ["patient", "ORGANISM", 186, 193], ["liver", "ORGAN", 201, 206], ["liver", "ORGAN", 249, 254], ["wound", "PATHOLOGICAL_FORMATION", 521, 526], ["Patients", "ORGANISM", 609, 617], ["liver", "ORGAN", 665, 670], ["hepatic vascular", "MULTI-TISSUE_STRUCTURE", 799, 815], ["Filipino", "ORGANISM", 842, 850], ["woman", "ORGANISM", 851, 856], ["urine", "ORGANISM_SUBSTANCE", 958, 963], ["stool", "ORGANISM_SUBSTANCE", 974, 979], ["Patients", "SPECIES", 114, 122], ["patient", "SPECIES", 186, 193], ["Patients", "SPECIES", 609, 617], ["woman", "SPECIES", 851, 856], ["surgery", "TREATMENT", 12, 19], ["all emergent surgery", "TREATMENT", 37, 57], ["Surgery", "TREATMENT", 134, 141], ["decompensated liver disease", "PROBLEM", 235, 262], ["elective surgery", "TREATMENT", 326, 342], ["a recent umbilical hernia repair", "TREATMENT", 451, 483], ["draining ascites", "PROBLEM", 495, 511], ["the wound", "PROBLEM", 517, 526], ["hepatorenal syndrome", "PROBLEM", 545, 565], ["Surgery", "TREATMENT", 629, 636], ["liver disease", "PROBLEM", 665, 678], ["surgery", "TREATMENT", 685, 692], ["circulatory changes", "PROBLEM", 721, 740], ["anesthesia", "TREATMENT", 766, 776], ["impaired hepatic vascular flow", "PROBLEM", 790, 820], ["progressive fatigue", "PROBLEM", 892, 911], ["jaundice", "PROBLEM", 913, 921], ["generalized pruritus", "PROBLEM", 931, 951], ["dark urine", "PROBLEM", 953, 963], ["pale stool", "PROBLEM", 969, 979], ["surgery", "OBSERVATION", 12, 19], ["Cirrhotic", "OBSERVATION", 104, 113], ["liver", "ANATOMY", 201, 206], ["liver", "ANATOMY", 249, 254], ["disease", "OBSERVATION", 255, 262], ["umbilical", "ANATOMY", 460, 469], ["hernia", "OBSERVATION", 470, 476], ["repair", "OBSERVATION", 477, 483], ["draining", "OBSERVATION_MODIFIER", 495, 503], ["ascites", "OBSERVATION", 504, 511], ["wound", "OBSERVATION", 521, 526], ["hepatorenal syndrome", "OBSERVATION", 545, 565], ["Cirrhotic", "OBSERVATION", 599, 608], ["worsening", "OBSERVATION_MODIFIER", 652, 661], ["liver", "ANATOMY", 665, 670], ["disease", "OBSERVATION", 671, 678], ["impaired", "OBSERVATION", 790, 798], ["hepatic", "ANATOMY_MODIFIER", 799, 806], ["vascular", "ANATOMY", 807, 815], ["flow", "OBSERVATION", 816, 820], ["progressive", "OBSERVATION_MODIFIER", 892, 903], ["fatigue", "OBSERVATION", 904, 911], ["jaundice", "OBSERVATION", 913, 921], ["severe", "OBSERVATION_MODIFIER", 923, 929], ["generalized", "OBSERVATION_MODIFIER", 931, 942], ["pruritus", "OBSERVATION", 943, 951], ["dark urine", "OBSERVATION", 953, 963], ["pale", "OBSERVATION_MODIFIER", 969, 973], ["stool", "OBSERVATION", 974, 979]]], ["She has no history of abdominal pain, nausea, vomiting, no prior history of jaundice or viral hepatitis.", [["abdominal", "ANATOMY", 22, 31], ["abdominal pain", "DISEASE", 22, 36], ["nausea", "DISEASE", 38, 44], ["vomiting", "DISEASE", 46, 54], ["jaundice", "DISEASE", 76, 84], ["viral hepatitis", "DISEASE", 88, 103], ["abdominal", "ORGANISM_SUBDIVISION", 22, 31], ["abdominal pain", "PROBLEM", 22, 36], ["nausea", "PROBLEM", 38, 44], ["vomiting", "PROBLEM", 46, 54], ["jaundice", "PROBLEM", 76, 84], ["viral hepatitis", "PROBLEM", 88, 103], ["no", "UNCERTAINTY", 8, 10], ["abdominal", "ANATOMY", 22, 31], ["pain", "OBSERVATION", 32, 36], ["nausea", "OBSERVATION", 38, 44], ["jaundice", "OBSERVATION", 76, 84], ["viral hepatitis", "OBSERVATION", 88, 103]]], ["She takes no medications and there is no family history of liver disease.", [["liver", "ANATOMY", 59, 64], ["liver disease", "DISEASE", 59, 72], ["liver", "ORGAN", 59, 64], ["medications", "TREATMENT", 13, 24], ["liver disease", "PROBLEM", 59, 72], ["no", "UNCERTAINTY", 38, 40], ["liver", "ANATOMY", 59, 64], ["disease", "OBSERVATION", 65, 72]]], ["She has had a prior cholecystectomy.Case 32Physical examination reveals excoriations on skin from scratching.", [["skin", "ANATOMY", 88, 92], ["skin", "ORGAN", 88, 92], ["a prior cholecystectomy", "TREATMENT", 12, 35], ["Case 32Physical examination", "TEST", 36, 63], ["excoriations on skin", "PROBLEM", 72, 92], ["scratching", "PROBLEM", 98, 108], ["cholecystectomy", "OBSERVATION", 20, 35], ["excoriations", "OBSERVATION", 72, 84], ["skin", "ANATOMY", 88, 92], ["scratching", "OBSERVATION", 98, 108]]], ["She has marked scleral icterus, no hepatosplenomegaly or ascites.", [["scleral icterus", "ANATOMY", 15, 30], ["ascites", "ANATOMY", 57, 64], ["scleral icterus", "DISEASE", 15, 30], ["hepatosplenomegaly", "DISEASE", 35, 53], ["ascites", "DISEASE", 57, 64], ["marked scleral icterus", "PROBLEM", 8, 30], ["hepatosplenomegaly", "PROBLEM", 35, 53], ["ascites", "PROBLEM", 57, 64], ["marked", "OBSERVATION_MODIFIER", 8, 14], ["scleral", "ANATOMY", 15, 22], ["icterus", "OBSERVATION", 23, 30], ["no", "UNCERTAINTY", 32, 34], ["hepatosplenomegaly", "OBSERVATION", 35, 53], ["ascites", "OBSERVATION", 57, 64]]], ["No cutaneous stigmata of chronic liver disease.Lab ResultsTotal bilirubin 19 mg/dl Direct bilirubin 13.7 mg/dl ALP 1833 iu/l GGTP 1756 iu/l ALT 194 iu/l AST 216 iu/l Albumin 3.2 g/dl Prothrombin time 21 seconds Ultrasound shows mild hepatomegaly.", [["liver", "ANATOMY", 33, 38], ["chronic liver disease", "DISEASE", 25, 46], ["bilirubin", "CHEMICAL", 64, 73], ["bilirubin", "CHEMICAL", 90, 99], ["hepatomegaly", "DISEASE", 233, 245], ["bilirubin", "CHEMICAL", 64, 73], ["bilirubin", "CHEMICAL", 90, 99], ["liver", "ORGAN", 33, 38], ["bilirubin", "GENE_OR_GENE_PRODUCT", 64, 73], ["bilirubin", "GENE_OR_GENE_PRODUCT", 90, 99], ["Albumin", "GENE_OR_GENE_PRODUCT", 166, 173], ["Prothrombin", "GENE_OR_GENE_PRODUCT", 183, 194], ["ALP", "PROTEIN", 111, 114], ["chronic liver disease", "PROBLEM", 25, 46], ["Total bilirubin", "TEST", 58, 73], ["Direct bilirubin", "TEST", 83, 99], ["ALP", "TEST", 111, 114], ["iu", "TEST", 120, 122], ["GGTP", "TEST", 125, 129], ["iu", "TEST", 135, 137], ["ALT", "TEST", 140, 143], ["iu", "TEST", 148, 150], ["AST", "TEST", 153, 156], ["iu", "TEST", 161, 163], ["Albumin", "TEST", 166, 173], ["dl", "TEST", 180, 182], ["Prothrombin time", "TEST", 183, 199], ["seconds Ultrasound", "TEST", 203, 221], ["mild hepatomegaly", "PROBLEM", 228, 245], ["cutaneous", "ANATOMY", 3, 12], ["stigmata", "OBSERVATION", 13, 21], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["liver", "ANATOMY", 33, 38], ["disease", "OBSERVATION", 39, 46], ["mild", "OBSERVATION_MODIFIER", 228, 232], ["hepatomegaly", "OBSERVATION", 233, 245]]], ["There is no biliary ductal dilation, patent hepatic vessels, absent gall bladder, no splenomegaly or ascites.Questions1.", [["biliary ductal", "ANATOMY", 12, 26], ["hepatic vessels", "ANATOMY", 44, 59], ["gall bladder", "ANATOMY", 68, 80], ["splenomegaly", "ANATOMY", 85, 97], ["ascites", "ANATOMY", 101, 108], ["gall bladder", "DISEASE", 68, 80], ["splenomegaly", "DISEASE", 85, 97], ["ascites", "DISEASE", 101, 108], ["biliary ductal", "MULTI-TISSUE_STRUCTURE", 12, 26], ["hepatic vessels", "MULTI-TISSUE_STRUCTURE", 44, 59], ["gall bladder", "ORGAN", 68, 80], ["biliary ductal dilation", "PROBLEM", 12, 35], ["absent gall bladder", "PROBLEM", 61, 80], ["splenomegaly", "PROBLEM", 85, 97], ["ascites", "PROBLEM", 101, 108], ["no", "UNCERTAINTY", 9, 11], ["biliary ductal", "ANATOMY", 12, 26], ["dilation", "OBSERVATION", 27, 35], ["patent", "OBSERVATION", 37, 43], ["hepatic vessels", "ANATOMY", 44, 59], ["gall bladder", "ANATOMY", 68, 80], ["no", "UNCERTAINTY", 82, 84], ["splenomegaly", "OBSERVATION", 85, 97], ["ascites", "OBSERVATION", 101, 108]]], ["How would one classify the pattern of this patient's jaundice and abnormal liver enzyme elevation? 2.", [["liver", "ANATOMY", 75, 80], ["jaundice", "DISEASE", 53, 61], ["abnormal liver enzyme elevation", "DISEASE", 66, 97], ["patient", "ORGANISM", 43, 50], ["liver", "ORGAN", 75, 80], ["patient", "SPECIES", 43, 50], ["this patient's jaundice", "PROBLEM", 38, 61], ["abnormal liver enzyme elevation", "PROBLEM", 66, 97], ["jaundice", "OBSERVATION", 53, 61], ["liver", "ANATOMY", 75, 80], ["enzyme elevation", "OBSERVATION", 81, 97]]], ["What additional diagnostic procedure should be performed?Answer: Idiopathic Adulthood DuctopeniaThis patient has cholestatic jaundice and more specifically intrahepatic cholestasis by virtue of the fact that the ultrasound does not demonstrate biliary ductal dilation.Answer: Idiopathic Adulthood DuctopeniaAdditional blood tests showed negative ANA, ASMA, and AMA.", [["intrahepatic cholestasis", "ANATOMY", 156, 180], ["biliary ductal", "ANATOMY", 244, 258], ["blood", "ANATOMY", 318, 323], ["cholestatic jaundice", "DISEASE", 113, 133], ["intrahepatic cholestasis", "DISEASE", 156, 180], ["biliary ductal dilation", "DISEASE", 244, 267], ["patient", "ORGANISM", 101, 108], ["intrahepatic cholestasis", "PATHOLOGICAL_FORMATION", 156, 180], ["biliary ductal", "MULTI-TISSUE_STRUCTURE", 244, 258], ["blood", "ORGANISM_SUBSTANCE", 318, 323], ["ANA", "PROTEIN", 346, 349], ["ASMA", "PROTEIN", 351, 355], ["AMA", "PROTEIN", 361, 364], ["patient", "SPECIES", 101, 108], ["diagnostic procedure", "TREATMENT", 16, 36], ["Idiopathic Adulthood DuctopeniaThis", "PROBLEM", 65, 100], ["cholestatic jaundice", "PROBLEM", 113, 133], ["intrahepatic cholestasis", "PROBLEM", 156, 180], ["the ultrasound", "TEST", 208, 222], ["biliary ductal dilation", "PROBLEM", 244, 267], ["Idiopathic Adulthood", "PROBLEM", 276, 296], ["DuctopeniaAdditional blood tests", "TEST", 297, 329], ["Idiopathic", "OBSERVATION_MODIFIER", 65, 75], ["cholestatic", "OBSERVATION_MODIFIER", 113, 124], ["jaundice", "OBSERVATION", 125, 133], ["intrahepatic", "ANATOMY", 156, 168], ["cholestasis", "OBSERVATION", 169, 180], ["biliary ductal", "ANATOMY", 244, 258], ["dilation", "OBSERVATION", 259, 267]]], ["Her serum ACE level was normal and quantitative immunoglobulins revealed normal IgG and IgM levels.Answer: Idiopathic Adulthood DuctopeniaDue to concern for a biliary process despite the negative ultrasound, she underwent an ERCP but the cholangiogram was normal without evidence of biliary duct beading or strictures.Answer: Idiopathic Adulthood DuctopeniaThe images show her liver biopsy.", [["serum", "ANATOMY", 4, 9], ["biliary", "ANATOMY", 159, 166], ["biliary duct", "ANATOMY", 283, 295], ["liver", "ANATOMY", 377, 382], ["biliary duct beading", "DISEASE", 283, 303], ["strictures", "DISEASE", 307, 317], ["Ductopenia", "DISEASE", 347, 357], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["ACE", "GENE_OR_GENE_PRODUCT", 10, 13], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 48, 63], ["IgG", "GENE_OR_GENE_PRODUCT", 80, 83], ["IgM", "GENE_OR_GENE_PRODUCT", 88, 91], ["biliary", "ORGAN", 159, 166], ["biliary duct", "MULTI-TISSUE_STRUCTURE", 283, 295], ["strictures", "PATHOLOGICAL_FORMATION", 307, 317], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 377, 389], ["serum ACE", "PROTEIN", 4, 13], ["immunoglobulins", "PROTEIN", 48, 63], ["IgG", "PROTEIN", 80, 83], ["IgM", "PROTEIN", 88, 91], ["Her serum ACE level", "TEST", 0, 19], ["quantitative immunoglobulins", "TEST", 35, 63], ["IgM levels", "TEST", 88, 98], ["Idiopathic Adulthood DuctopeniaDue", "PROBLEM", 107, 141], ["a biliary process", "PROBLEM", 157, 174], ["the negative ultrasound", "TEST", 183, 206], ["an ERCP", "TEST", 222, 229], ["the cholangiogram", "TEST", 234, 251], ["biliary duct beading", "PROBLEM", 283, 303], ["strictures", "PROBLEM", 307, 317], ["Idiopathic Adulthood Ductopenia", "PROBLEM", 326, 357], ["The images", "TEST", 357, 367], ["her liver biopsy", "TEST", 373, 389], ["IgM levels", "OBSERVATION", 88, 98], ["biliary", "ANATOMY", 159, 166], ["normal", "OBSERVATION", 256, 262], ["without evidence of", "UNCERTAINTY", 263, 282], ["biliary duct", "ANATOMY", 283, 295], ["beading", "OBSERVATION", 296, 303], ["strictures", "OBSERVATION", 307, 317], ["liver", "ANATOMY", 377, 382], ["biopsy", "OBSERVATION", 383, 389]]], ["The first is at low power ( Fig. 32.1 ) demonstrating brownish deposits, consistent with severe chronic cholestasis.", [["cholestasis", "DISEASE", 104, 115], ["brownish deposits", "PROBLEM", 54, 71], ["severe chronic cholestasis", "PROBLEM", 89, 115], ["brownish deposits", "OBSERVATION", 54, 71], ["consistent with", "UNCERTAINTY", 73, 88], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["cholestasis", "OBSERVATION", 104, 115]]], ["There is also an absence of interlobular bile ducts in the portal area.Answer: Idiopathic Adulthood DuctopeniaAt higher power ( Fig. 32.", [["interlobular bile ducts", "ANATOMY", 28, 51], ["portal area", "ANATOMY", 59, 70], ["interlobular bile ducts", "MULTI-TISSUE_STRUCTURE", 28, 51], ["portal area", "MULTI-TISSUE_STRUCTURE", 59, 70], ["interlobular bile ducts in the portal area", "PROBLEM", 28, 70], ["Idiopathic Adulthood", "PROBLEM", 79, 99], ["interlobular", "ANATOMY_MODIFIER", 28, 40], ["bile ducts", "ANATOMY", 41, 51], ["portal", "ANATOMY", 59, 65], ["area", "ANATOMY_MODIFIER", 66, 70]]], ["2), a portal tract is seen and confirms the absence of bile ducts and the presence of a mild chronic inflammatory infiltrate, including lymphocytes, neutrophils, and plasma cells.", [["portal tract", "ANATOMY", 6, 18], ["bile ducts", "ANATOMY", 55, 65], ["lymphocytes", "ANATOMY", 136, 147], ["neutrophils", "ANATOMY", 149, 160], ["plasma cells", "ANATOMY", 166, 178], ["portal tract", "MULTI-TISSUE_STRUCTURE", 6, 18], ["bile ducts", "MULTI-TISSUE_STRUCTURE", 55, 65], ["lymphocytes", "CELL", 136, 147], ["neutrophils", "CELL", 149, 160], ["plasma cells", "CELL", 166, 178], ["lymphocytes", "CELL_TYPE", 136, 147], ["neutrophils", "CELL_TYPE", 149, 160], ["plasma cells", "CELL_TYPE", 166, 178], ["a portal tract", "PROBLEM", 4, 18], ["bile ducts", "PROBLEM", 55, 65], ["a mild chronic inflammatory infiltrate", "PROBLEM", 86, 124], ["lymphocytes", "TEST", 136, 147], ["neutrophils", "TEST", 149, 160], ["plasma cells", "PROBLEM", 166, 178], ["portal tract", "ANATOMY", 6, 18], ["bile ducts", "ANATOMY", 55, 65], ["mild", "OBSERVATION_MODIFIER", 88, 92], ["chronic", "OBSERVATION_MODIFIER", 93, 100], ["inflammatory", "OBSERVATION_MODIFIER", 101, 113], ["infiltrate", "OBSERVATION", 114, 124], ["lymphocytes", "ANATOMY", 136, 147], ["plasma cells", "OBSERVATION", 166, 178]]], ["The differential diagnosis is lengthy and includes: As can be seen, all autoimmune serologies were negative and many of the other possible diagnoses were excluded as they were not clinically applicable.Answer: Idiopathic Adulthood DuctopeniaA liver biopsy confirmed extreme paucity of bile ducts and a diagnosis of idiopathic adulthood ductopenia was made.", [["liver", "ANATOMY", 243, 248], ["bile ducts", "ANATOMY", 285, 295], ["paucity of bile ducts", "DISEASE", 274, 295], ["idiopathic adulthood ductopenia", "DISEASE", 315, 346], ["liver", "ORGAN", 243, 248], ["bile ducts", "MULTI-TISSUE_STRUCTURE", 285, 295], ["all autoimmune serologies", "TEST", 68, 93], ["Idiopathic Adulthood", "PROBLEM", 210, 230], ["liver biopsy", "TEST", 243, 255], ["extreme paucity of bile ducts", "PROBLEM", 266, 295], ["idiopathic adulthood ductopenia", "PROBLEM", 315, 346], ["liver", "ANATOMY", 243, 248], ["biopsy", "OBSERVATION", 249, 255], ["extreme", "OBSERVATION_MODIFIER", 266, 273], ["paucity", "OBSERVATION", 274, 281], ["bile ducts", "ANATOMY", 285, 295], ["idiopathic", "OBSERVATION_MODIFIER", 315, 325]]], ["The patient underwent successful orthotopic liver transplantation.Answer: Idiopathic Adulthood DuctopeniaThis condition was first described by Jurgen Ludwig in 1988, is similar to the infantile condition, Alagille's syndrome and has an obscure natural history.", [["liver", "ANATOMY", 44, 49], ["Idiopathic Adulthood DuctopeniaThis condition", "DISEASE", 74, 119], ["infantile condition", "DISEASE", 184, 203], ["Alagille's syndrome", "DISEASE", 205, 224], ["patient", "ORGANISM", 4, 11], ["liver", "ORGAN", 44, 49], ["patient", "SPECIES", 4, 11], ["successful orthotopic liver transplantation", "TREATMENT", 22, 65], ["Idiopathic Adulthood DuctopeniaThis condition", "PROBLEM", 74, 119], ["the infantile condition", "PROBLEM", 180, 203], ["Alagille's syndrome", "PROBLEM", 205, 224], ["orthotopic", "OBSERVATION", 33, 43], ["liver", "ANATOMY", 44, 49], ["transplantation", "OBSERVATION", 50, 65]]], ["Orthotopic liver transplantation is the only effective treatment.", [["liver", "ANATOMY", 11, 16], ["liver", "ORGAN", 11, 16], ["Orthotopic liver transplantation", "TREATMENT", 0, 32], ["effective treatment", "TREATMENT", 45, 64], ["liver", "ANATOMY", 11, 16], ["transplantation", "OBSERVATION", 17, 32], ["effective", "OBSERVATION_MODIFIER", 45, 54], ["treatment", "OBSERVATION", 55, 64]]], ["It is diagnosed in an adult patient with biochemical cholestasis, biopsy evidence of ductopenia (loss of interlobular or septal bile ducts in at least 50% of portal tracts).", [["interlobular", "ANATOMY", 105, 117], ["septal bile ducts", "ANATOMY", 121, 138], ["portal tracts", "ANATOMY", 158, 171], ["cholestasis", "DISEASE", 53, 64], ["ductopenia", "DISEASE", 85, 95], ["loss of interlobular or septal bile ducts", "DISEASE", 97, 138], ["patient", "ORGANISM", 28, 35], ["interlobular", "MULTI-TISSUE_STRUCTURE", 105, 117], ["septal bile ducts", "MULTI-TISSUE_STRUCTURE", 121, 138], ["portal tracts", "MULTI-TISSUE_STRUCTURE", 158, 171], ["patient", "SPECIES", 28, 35], ["biochemical cholestasis", "PROBLEM", 41, 64], ["biopsy", "TEST", 66, 72], ["ductopenia", "PROBLEM", 85, 95], ["loss of interlobular or septal bile ducts", "PROBLEM", 97, 138], ["cholestasis", "OBSERVATION", 53, 64], ["ductopenia", "OBSERVATION", 85, 95], ["interlobular", "ANATOMY_MODIFIER", 105, 117], ["septal", "ANATOMY_MODIFIER", 121, 127], ["bile ducts", "ANATOMY", 128, 138], ["portal tracts", "ANATOMY", 158, 171]]], ["The diagnosis also requires a negative AMA, normal cholangiogram, no history of infantile cholestasis, no exposure to drugs or toxins that could produce cholangitis and no evidence of sarcoidosis or malignancy.Case 33A 47-year-old male presents with several episodes of hematemesis and melena.", [["infantile cholestasis", "DISEASE", 80, 101], ["cholangitis", "DISEASE", 153, 164], ["sarcoidosis", "DISEASE", 184, 195], ["malignancy", "DISEASE", 199, 209], ["hematemesis", "DISEASE", 270, 281], ["melena", "DISEASE", 286, 292], ["malignancy", "CANCER", 199, 209], ["male", "ORGANISM", 231, 235], ["melena", "PATHOLOGICAL_FORMATION", 286, 292], ["infantile cholestasis", "PROBLEM", 80, 101], ["drugs", "TREATMENT", 118, 123], ["toxins", "PROBLEM", 127, 133], ["cholangitis", "PROBLEM", 153, 164], ["sarcoidosis", "PROBLEM", 184, 195], ["malignancy", "PROBLEM", 199, 209], ["hematemesis", "PROBLEM", 270, 281], ["melena", "PROBLEM", 286, 292], ["cholestasis", "OBSERVATION", 90, 101], ["cholangitis", "OBSERVATION", 153, 164], ["no evidence of", "UNCERTAINTY", 169, 183], ["sarcoidosis", "OBSERVATION", 184, 195], ["malignancy", "OBSERVATION", 199, 209], ["hematemesis", "OBSERVATION", 270, 281], ["melena", "OBSERVATION", 286, 292]]], ["He has a history of cirrhosis secondary to alcohol and hepatitis C, which has been complicated in the past by multiple admissions for variceal hemorrhage, encephalopathy, and ascites.", [["variceal", "ANATOMY", 134, 142], ["ascites", "ANATOMY", 175, 182], ["cirrhosis", "DISEASE", 20, 29], ["alcohol", "CHEMICAL", 43, 50], ["hepatitis C", "DISEASE", 55, 66], ["variceal hemorrhage", "DISEASE", 134, 153], ["encephalopathy", "DISEASE", 155, 169], ["ascites", "DISEASE", 175, 182], ["alcohol", "CHEMICAL", 43, 50], ["alcohol", "SIMPLE_CHEMICAL", 43, 50], ["hepatitis C", "ORGANISM", 55, 66], ["cirrhosis", "PROBLEM", 20, 29], ["hepatitis C", "PROBLEM", 55, 66], ["variceal hemorrhage", "PROBLEM", 134, 153], ["encephalopathy", "PROBLEM", 155, 169], ["ascites", "PROBLEM", 175, 182], ["cirrhosis", "OBSERVATION", 20, 29], ["alcohol", "OBSERVATION", 43, 50], ["hepatitis", "OBSERVATION", 55, 64], ["variceal", "ANATOMY", 134, 142], ["hemorrhage", "OBSERVATION", 143, 153], ["encephalopathy", "OBSERVATION", 155, 169], ["ascites", "OBSERVATION", 175, 182]]], ["He continues to drink alcohol and has been very noncompliant in terms of follow-up.Case 33He has previously undergone band ligation of esophageal varices and a TIPS was placed 2 years ago.", [["esophageal varices", "ANATOMY", 135, 153], ["alcohol", "CHEMICAL", 22, 29], ["esophageal varices", "DISEASE", 135, 153], ["alcohol", "CHEMICAL", 22, 29], ["alcohol", "SIMPLE_CHEMICAL", 22, 29], ["esophageal varices", "PATHOLOGICAL_FORMATION", 135, 153], ["band ligation", "TREATMENT", 118, 131], ["esophageal varices", "PROBLEM", 135, 153], ["a TIPS", "TREATMENT", 158, 164], ["band", "OBSERVATION_MODIFIER", 118, 122], ["ligation", "OBSERVATION", 123, 131], ["esophageal", "ANATOMY", 135, 145], ["varices", "OBSERVATION", 146, 153], ["TIPS", "OBSERVATION_MODIFIER", 160, 164]]], ["He has also undergone coil embolization of gastric varices and several revisions of his TIPS, the last being several months ago.Case 33He has not taken any prescribed medication for more than a month after his prescriptions ran out.Case 33Exam demonstrates a disheveled looking man with a BP of 120/80 and pulse 104 beats per minute, regular.Case 33He is alert and oriented and his abdomen is mildly distended.", [["gastric varices", "ANATOMY", 43, 58], ["abdomen", "ANATOMY", 382, 389], ["gastric varices", "DISEASE", 43, 58], ["gastric varices", "PATHOLOGICAL_FORMATION", 43, 58], ["man", "ORGANISM", 278, 281], ["abdomen", "ORGAN", 382, 389], ["man", "SPECIES", 278, 281], ["coil embolization", "TREATMENT", 22, 39], ["gastric varices", "PROBLEM", 43, 58], ["his TIPS", "TREATMENT", 84, 92], ["any prescribed medication", "TREATMENT", 152, 177], ["a BP", "TEST", 287, 291], ["pulse", "TEST", 306, 311], ["mildly distended", "PROBLEM", 393, 409], ["coil", "OBSERVATION_MODIFIER", 22, 26], ["embolization", "OBSERVATION", 27, 39], ["gastric", "ANATOMY", 43, 50], ["varices", "OBSERVATION", 51, 58], ["several", "OBSERVATION_MODIFIER", 63, 70], ["revisions", "OBSERVATION", 71, 80], ["TIPS", "OBSERVATION_MODIFIER", 88, 92], ["abdomen", "ANATOMY", 382, 389], ["mildly", "OBSERVATION_MODIFIER", 393, 399], ["distended", "OBSERVATION", 400, 409]]], ["Melena is noted on rectal exam.Laboratory ParametersHb 7.6 g/dl Platelets 62,000/\u03bcl INR 1.5 Creatinine 0.8 mg/dl Tbili 2.5 mg/dl AST 88 iu/l ALT 48 iu/l GGTP 495 iu/l After adequate resuscitation, he undergoes upper GI endoscopy that demonstrates small esophageal varices but large varices in the cardia with red wale signs but no active bleeding.", [["rectal", "ANATOMY", 19, 25], ["esophageal varices", "ANATOMY", 253, 271], ["varices", "ANATOMY", 282, 289], ["cardia", "ANATOMY", 297, 303], ["Creatinine", "CHEMICAL", 92, 102], ["esophageal varices", "DISEASE", 253, 271], ["varices", "DISEASE", 282, 289], ["bleeding", "DISEASE", 338, 346], ["Creatinine", "CHEMICAL", 92, 102], ["rectal", "ORGAN", 19, 25], ["Creatinine", "SIMPLE_CHEMICAL", 92, 102], ["upper GI", "ORGANISM_SUBDIVISION", 210, 218], ["esophageal varices", "PATHOLOGICAL_FORMATION", 253, 271], ["varices", "PATHOLOGICAL_FORMATION", 282, 289], ["cardia", "ORGAN", 297, 303], ["Melena", "PROBLEM", 0, 6], ["rectal exam", "TEST", 19, 30], ["Laboratory ParametersHb", "TEST", 31, 54], ["Platelets", "TEST", 64, 73], ["\u03bcl", "TEST", 81, 83], ["INR", "TEST", 84, 87], ["Creatinine", "TEST", 92, 102], ["mg", "TEST", 107, 109], ["dl", "TEST", 110, 112], ["Tbili", "TEST", 113, 118], ["mg", "TEST", 123, 125], ["dl", "TEST", 126, 128], ["AST", "TEST", 129, 132], ["iu", "TEST", 136, 138], ["ALT", "TEST", 141, 144], ["iu", "TEST", 148, 150], ["GGTP", "TEST", 153, 157], ["adequate resuscitation", "TREATMENT", 173, 195], ["upper GI endoscopy", "TEST", 210, 228], ["small esophageal varices", "PROBLEM", 247, 271], ["large varices in the cardia", "PROBLEM", 276, 303], ["red wale signs", "PROBLEM", 309, 323], ["active bleeding", "PROBLEM", 331, 346], ["rectal", "ANATOMY", 19, 25], ["small", "OBSERVATION_MODIFIER", 247, 252], ["esophageal", "ANATOMY", 253, 263], ["varices", "OBSERVATION", 264, 271], ["large", "OBSERVATION_MODIFIER", 276, 281], ["varices", "OBSERVATION", 282, 289], ["cardia", "ANATOMY", 297, 303], ["red wale", "OBSERVATION", 309, 317], ["no", "UNCERTAINTY", 328, 330], ["active", "OBSERVATION_MODIFIER", 331, 337], ["bleeding", "OBSERVATION", 338, 346]]], ["Imaging a month ago had shown a patent TIPS and a significant splenorenal shunt.Question1.", [["Imaging", "TEST", 0, 7], ["a patent TIPS", "PROBLEM", 30, 43], ["a significant splenorenal shunt", "TREATMENT", 48, 79], ["patent", "OBSERVATION", 32, 38], ["TIPS", "OBSERVATION_MODIFIER", 39, 43], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["splenorenal shunt", "OBSERVATION", 62, 79]]], ["What treatment options are available for this patient (in the USA)?Answer: Balloon Occluded Retrograde Transvenous Obliteration of VaricesThis gentleman continues to bleed despite aggressive treatment.", [["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["Balloon Occluded Retrograde Transvenous Obliteration", "TREATMENT", 75, 127], ["Varices", "PROBLEM", 131, 138], ["bleed", "PROBLEM", 166, 171], ["aggressive treatment", "TREATMENT", 180, 200], ["Transvenous", "ANATOMY", 103, 114], ["Obliteration", "OBSERVATION", 115, 127], ["Varices", "OBSERVATION", 131, 138], ["bleed", "OBSERVATION", 166, 171]]], ["He has undergone endoscopic therapy and also TIPS and then an attempt at coil embolization of gastric varices with access through the TIPS.", [["gastric varices", "ANATOMY", 94, 109], ["gastric varices", "DISEASE", 94, 109], ["gastric varices", "PATHOLOGICAL_FORMATION", 94, 109], ["endoscopic therapy", "TREATMENT", 17, 35], ["TIPS", "TREATMENT", 45, 49], ["an attempt at coil embolization", "TREATMENT", 59, 90], ["gastric varices", "PROBLEM", 94, 109], ["access through the TIPS", "TREATMENT", 115, 138], ["endoscopic therapy", "OBSERVATION", 17, 35], ["gastric", "ANATOMY", 94, 101], ["varices", "OBSERVATION", 102, 109], ["TIPS", "OBSERVATION_MODIFIER", 134, 138]]], ["His endoscopy shows gastric varices with stigmata of recent bleeding and he has a low hemoglobin.", [["gastric varices", "ANATOMY", 20, 35], ["gastric varices", "DISEASE", 20, 35], ["bleeding", "DISEASE", 60, 68], ["gastric varices", "PATHOLOGICAL_FORMATION", 20, 35], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 86, 96], ["hemoglobin", "PROTEIN", 86, 96], ["His endoscopy", "TEST", 0, 13], ["gastric varices", "PROBLEM", 20, 35], ["recent bleeding", "PROBLEM", 53, 68], ["a low hemoglobin", "PROBLEM", 80, 96], ["gastric", "ANATOMY", 20, 27], ["varices", "OBSERVATION", 28, 35], ["bleeding", "OBSERVATION", 60, 68], ["low hemoglobin", "OBSERVATION_MODIFIER", 82, 96]]], ["His continued drinking and poor compliance mean that he is not a good transplant candidate.Answer: Balloon Occluded Retrograde Transvenous Obliteration of VaricesHis options are limited, particularly in the USA, where cyanoacrylate is not available outside of a study setting.Answer: Balloon Occluded Retrograde Transvenous Obliteration of VaricesOne potential solution that is increasingly used in Asia is balloon occluded retrograde transvenous obliteration (BRTO).", [["cyanoacrylate", "CHEMICAL", 218, 231], ["cyanoacrylate", "CHEMICAL", 218, 231], ["cyanoacrylate", "SIMPLE_CHEMICAL", 218, 231], ["Balloon Occluded Retrograde Transvenous Obliteration", "TREATMENT", 99, 151], ["Varices", "PROBLEM", 155, 162], ["cyanoacrylate", "TREATMENT", 218, 231], ["a study setting", "TEST", 260, 275], ["Balloon Occluded Retrograde Transvenous Obliteration", "TREATMENT", 284, 336], ["Varices", "PROBLEM", 340, 347], ["balloon occluded retrograde transvenous obliteration", "TREATMENT", 407, 459], ["Transvenous", "ANATOMY", 127, 138], ["Obliteration", "OBSERVATION", 139, 151], ["Varices", "OBSERVATION", 155, 162], ["Transvenous", "ANATOMY", 312, 323], ["Obliteration", "OBSERVATION", 324, 336], ["Varices", "OBSERVATION", 340, 347], ["balloon", "OBSERVATION_MODIFIER", 407, 414], ["occluded", "OBSERVATION", 415, 423], ["transvenous", "OBSERVATION_MODIFIER", 435, 446], ["obliteration", "OBSERVATION", 447, 459]]], ["This procedure involves passing a catheter into the inferior vena cava through the femoral vein.", [["inferior vena cava", "ANATOMY", 52, 70], ["femoral vein", "ANATOMY", 83, 95], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 52, 70], ["femoral vein", "MULTI-TISSUE_STRUCTURE", 83, 95], ["This procedure", "TREATMENT", 0, 14], ["a catheter", "TREATMENT", 32, 42], ["catheter", "OBSERVATION", 34, 42], ["inferior vena cava", "ANATOMY", 52, 70], ["femoral vein", "ANATOMY", 83, 95]]], ["The catheter is passed into the left renal vein and then the splenic vein through a splenorenal shunt.", [["left renal vein", "ANATOMY", 32, 47], ["splenic vein", "ANATOMY", 61, 73], ["renal vein", "MULTI-TISSUE_STRUCTURE", 37, 47], ["splenic vein", "MULTI-TISSUE_STRUCTURE", 61, 73], ["The catheter", "TREATMENT", 0, 12], ["a splenorenal shunt", "TREATMENT", 82, 101], ["catheter", "OBSERVATION", 4, 12], ["left", "ANATOMY_MODIFIER", 32, 36], ["renal vein", "ANATOMY", 37, 47], ["splenic vein", "ANATOMY", 61, 73], ["splenorenal shunt", "OBSERVATION", 84, 101]]], ["The gastric varices can be identified coming off the splenic vein and a balloon is inflated and foam or coils can be deployed to prevent retrograde flow.Answer: Balloon Occluded Retrograde Transvenous Obliteration of VaricesIn Figs.", [["gastric varices", "ANATOMY", 4, 19], ["splenic vein", "ANATOMY", 53, 65], ["gastric varices", "DISEASE", 4, 19], ["gastric varices", "CANCER", 4, 19], ["splenic vein", "MULTI-TISSUE_STRUCTURE", 53, 65], ["The gastric varices", "PROBLEM", 0, 19], ["a balloon", "TREATMENT", 70, 79], ["coils", "TREATMENT", 104, 109], ["Balloon Occluded Retrograde Transvenous Obliteration", "TREATMENT", 161, 213], ["VaricesIn Figs", "PROBLEM", 217, 231], ["gastric", "ANATOMY", 4, 11], ["varices", "OBSERVATION", 12, 19], ["splenic vein", "ANATOMY", 53, 65], ["balloon", "OBSERVATION", 72, 79], ["inflated", "OBSERVATION", 83, 91], ["foam", "OBSERVATION_MODIFIER", 96, 100], ["retrograde", "OBSERVATION_MODIFIER", 137, 147], ["flow", "OBSERVATION", 148, 152], ["Transvenous", "ANATOMY", 189, 200], ["Obliteration", "OBSERVATION", 201, 213], ["VaricesIn Figs", "OBSERVATION", 217, 231]]], ["33.1 and 33.2, previously place coils can be seen.", [["previously place coils", "TREATMENT", 15, 37]]], ["A catheter is visible with a balloon inflated and filling of large gastric varices is readily apparent.", [["gastric varices", "ANATOMY", 67, 82], ["gastric varices", "DISEASE", 67, 82], ["gastric varices", "PATHOLOGICAL_FORMATION", 67, 82], ["A catheter", "TREATMENT", 0, 10], ["a balloon inflated", "TREATMENT", 27, 45], ["large gastric varices", "PROBLEM", 61, 82], ["catheter", "OBSERVATION", 2, 10], ["visible", "OBSERVATION_MODIFIER", 14, 21], ["balloon inflated", "OBSERVATION", 29, 45], ["filling", "OBSERVATION_MODIFIER", 50, 57], ["large", "OBSERVATION_MODIFIER", 61, 66], ["gastric", "ANATOMY", 67, 74], ["varices", "OBSERVATION", 75, 82]]], ["Figure 33 .2 was taken 20 min after the injection of a foam sclerosant into the varices and markedly reduced flow is seen.Answer: Balloon Occluded Retrograde Transvenous Obliteration of VaricesThe patient did well for several months after this but expired from other complications of his liver disease.Answer: Balloon Occluded Retrograde Transvenous Obliteration of VaricesThere is limited data comparing BRTO with other modalities of treatment.", [["varices", "ANATOMY", 80, 87], ["liver", "ANATOMY", 288, 293], ["foam sclerosant", "CHEMICAL", 55, 70], ["varices", "DISEASE", 80, 87], ["liver disease", "DISEASE", 288, 301], ["varices", "PATHOLOGICAL_FORMATION", 80, 87], ["patient", "ORGANISM", 197, 204], ["liver", "ORGAN", 288, 293], ["BRTO", "SIMPLE_CHEMICAL", 405, 409], ["patient", "SPECIES", 197, 204], ["a foam sclerosant", "TREATMENT", 53, 70], ["the varices", "PROBLEM", 76, 87], ["markedly reduced flow", "PROBLEM", 92, 113], ["Balloon Occluded Retrograde Transvenous Obliteration", "TREATMENT", 130, 182], ["Varices", "PROBLEM", 186, 193], ["his liver disease", "PROBLEM", 284, 301], ["Balloon Occluded Retrograde Transvenous Obliteration of Varices", "TREATMENT", 310, 373], ["treatment", "TREATMENT", 435, 444], ["varices", "OBSERVATION", 80, 87], ["markedly", "OBSERVATION_MODIFIER", 92, 100], ["reduced", "OBSERVATION_MODIFIER", 101, 108], ["flow", "OBSERVATION", 109, 113], ["Transvenous", "ANATOMY", 158, 169], ["Obliteration", "OBSERVATION", 170, 182], ["Varices", "OBSERVATION", 186, 193], ["liver", "ANATOMY", 288, 293], ["disease", "OBSERVATION", 294, 301], ["Transvenous", "ANATOMY", 338, 349], ["Obliteration", "OBSERVATION", 350, 362], ["Varices", "OBSERVATION", 366, 373]]], ["One study compared BRTO to cyanoacrylate injection and found similar initial success rates but noted increased rebleeding with injection therapy.Answer: Balloon Occluded Retrograde Transvenous Obliteration of VaricesComplications of BRTO include balloon rupture such that sclerosant can leak into the systemic circulation and can cause pulmonary embolism or recurrent gastric variceal bleeding due to the sclerosant not obliterating the varices.", [["balloon", "ANATOMY", 246, 253], ["pulmonary", "ANATOMY", 336, 345], ["gastric", "ANATOMY", 368, 375], ["varices", "ANATOMY", 437, 444], ["BRTO", "CHEMICAL", 19, 23], ["cyanoacrylate", "CHEMICAL", 27, 40], ["rebleeding", "DISEASE", 111, 121], ["BRTO", "DISEASE", 233, 237], ["balloon rupture", "DISEASE", 246, 261], ["pulmonary embolism", "DISEASE", 336, 354], ["gastric variceal bleeding", "DISEASE", 368, 393], ["varices", "DISEASE", 437, 444], ["cyanoacrylate", "CHEMICAL", 27, 40], ["BRTO", "SIMPLE_CHEMICAL", 19, 23], ["cyanoacrylate", "SIMPLE_CHEMICAL", 27, 40], ["pulmonary", "ORGAN", 336, 345], ["gastric variceal", "PATHOLOGICAL_FORMATION", 368, 384], ["varices", "PATHOLOGICAL_FORMATION", 437, 444], ["One study", "TEST", 0, 9], ["cyanoacrylate injection", "TREATMENT", 27, 50], ["increased rebleeding", "PROBLEM", 101, 121], ["injection therapy", "TREATMENT", 127, 144], ["Balloon Occluded Retrograde Transvenous Obliteration", "TREATMENT", 153, 205], ["VaricesComplications of BRTO", "PROBLEM", 209, 237], ["balloon rupture", "PROBLEM", 246, 261], ["leak into the systemic circulation", "PROBLEM", 287, 321], ["pulmonary embolism", "PROBLEM", 336, 354], ["recurrent gastric variceal bleeding", "PROBLEM", 358, 393], ["the sclerosant", "TREATMENT", 401, 415], ["the varices", "PROBLEM", 433, 444], ["increased", "OBSERVATION_MODIFIER", 101, 110], ["rebleeding", "OBSERVATION", 111, 121], ["Transvenous", "OBSERVATION_MODIFIER", 181, 192], ["Obliteration", "OBSERVATION", 193, 205], ["balloon rupture", "OBSERVATION", 246, 261], ["sclerosant", "OBSERVATION", 272, 282], ["systemic circulation", "ANATOMY", 301, 321], ["pulmonary", "ANATOMY", 336, 345], ["embolism", "OBSERVATION", 346, 354], ["recurrent", "OBSERVATION_MODIFIER", 358, 367], ["gastric", "ANATOMY", 368, 375], ["variceal bleeding", "OBSERVATION", 376, 393], ["sclerosant", "OBSERVATION", 405, 415], ["varices", "OBSERVATION", 437, 444]]], ["In addition, there is some data that the portosystemic pressure gradient can rise following BRTO with concomitant worsening of esophageal varices.Case 34A 28-year-old woman is admitted to the ICU with a 2-week history of abdominal pain, nausea, vomiting, generalized malaise, and fevers to 103\u00b0F. There is no history of bleeding or confusion.Case 34There is no relevant prior medical problems and no history of prescription or over the counter/herbal medications, including no acetaminophen.", [["portosystemic", "ANATOMY", 41, 54], ["esophageal varices", "ANATOMY", 127, 145], ["abdominal", "ANATOMY", 221, 230], ["esophageal varices", "DISEASE", 127, 145], ["abdominal pain", "DISEASE", 221, 235], ["nausea", "DISEASE", 237, 243], ["vomiting", "DISEASE", 245, 253], ["fevers", "DISEASE", 280, 286], ["bleeding", "DISEASE", 320, 328], ["confusion", "DISEASE", 332, 341], ["acetaminophen", "CHEMICAL", 477, 490], ["acetaminophen", "CHEMICAL", 477, 490], ["esophageal varices", "PATHOLOGICAL_FORMATION", 127, 145], ["woman", "ORGANISM", 167, 172], ["abdominal", "ORGANISM_SUBDIVISION", 221, 230], ["acetaminophen", "SIMPLE_CHEMICAL", 477, 490], ["woman", "SPECIES", 167, 172], ["the portosystemic pressure gradient", "PROBLEM", 37, 72], ["esophageal varices", "PROBLEM", 127, 145], ["abdominal pain", "PROBLEM", 221, 235], ["nausea", "PROBLEM", 237, 243], ["vomiting", "PROBLEM", 245, 253], ["generalized malaise", "PROBLEM", 255, 274], ["fevers", "PROBLEM", 280, 286], ["bleeding", "PROBLEM", 320, 328], ["confusion", "PROBLEM", 332, 341], ["relevant prior medical problems", "PROBLEM", 361, 392], ["prescription", "TREATMENT", 411, 423], ["herbal medications", "TREATMENT", 444, 462], ["acetaminophen", "TREATMENT", 477, 490], ["portosystemic pressure", "OBSERVATION", 41, 63], ["concomitant", "OBSERVATION_MODIFIER", 102, 113], ["worsening", "OBSERVATION_MODIFIER", 114, 123], ["esophageal", "ANATOMY", 127, 137], ["varices", "OBSERVATION", 138, 145], ["abdominal", "ANATOMY", 221, 230], ["pain", "OBSERVATION", 231, 235], ["nausea", "OBSERVATION", 237, 243], ["malaise", "OBSERVATION", 267, 274], ["fevers", "OBSERVATION", 280, 286], ["no history of", "UNCERTAINTY", 306, 319], ["bleeding", "OBSERVATION", 320, 328], ["confusion", "OBSERVATION", 332, 341], ["no", "UNCERTAINTY", 358, 360]]], ["There is no history of alcohol, drugs, tattoos, or blood transfusions.Case 34Physical examination reveals a young woman with mild icterus, no oral mucocutaneous lesions, no stigmata of chronic liver disease.", [["blood", "ANATOMY", 51, 56], ["oral mucocutaneous lesions", "ANATOMY", 142, 168], ["liver", "ANATOMY", 193, 198], ["alcohol", "CHEMICAL", 23, 30], ["icterus", "DISEASE", 130, 137], ["mucocutaneous lesions", "DISEASE", 147, 168], ["chronic liver disease", "DISEASE", 185, 206], ["alcohol", "CHEMICAL", 23, 30], ["alcohol", "SIMPLE_CHEMICAL", 23, 30], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["woman", "ORGANISM", 114, 119], ["oral mucocutaneous lesions", "PATHOLOGICAL_FORMATION", 142, 168], ["liver", "ORGAN", 193, 198], ["woman", "SPECIES", 114, 119], ["drugs", "TREATMENT", 32, 37], ["tattoos", "TREATMENT", 39, 46], ["blood transfusions", "TREATMENT", 51, 69], ["Case 34Physical examination", "TEST", 70, 97], ["mild icterus", "PROBLEM", 125, 137], ["oral mucocutaneous lesions", "PROBLEM", 142, 168], ["chronic liver disease", "PROBLEM", 185, 206], ["no", "UNCERTAINTY", 9, 11], ["mild", "OBSERVATION_MODIFIER", 125, 129], ["icterus", "OBSERVATION", 130, 137], ["no", "UNCERTAINTY", 139, 141], ["mucocutaneous", "ANATOMY", 147, 160], ["lesions", "OBSERVATION", 161, 168], ["no stigmata of", "UNCERTAINTY", 170, 184], ["chronic", "OBSERVATION_MODIFIER", 185, 192], ["liver", "ANATOMY", 193, 198], ["disease", "OBSERVATION", 199, 206]]], ["Vital signs show she is febrile to 102\u00b0F, blood pressure 110/60, HR 95.Case 34Her abdomen has mild diffuse tenderness with no guarding or rebound.", [["blood", "ANATOMY", 42, 47], ["abdomen", "ANATOMY", 82, 89], ["febrile", "DISEASE", 24, 31], ["tenderness", "DISEASE", 107, 117], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["Vital signs", "TEST", 0, 11], ["febrile", "PROBLEM", 24, 31], ["blood pressure", "TEST", 42, 56], ["HR", "TEST", 65, 67], ["mild diffuse tenderness", "PROBLEM", 94, 117], ["guarding", "PROBLEM", 126, 134], ["rebound", "PROBLEM", 138, 145], ["abdomen", "ANATOMY", 82, 89], ["mild", "OBSERVATION_MODIFIER", 94, 98], ["diffuse", "OBSERVATION_MODIFIER", 99, 106], ["tenderness", "OBSERVATION", 107, 117], ["no", "UNCERTAINTY", 123, 125], ["guarding", "OBSERVATION", 126, 134], ["rebound", "OBSERVATION", 138, 145]]], ["No hepatosplenomegaly or ascites is appreciated.", [["ascites", "ANATOMY", 25, 32], ["hepatosplenomegaly", "DISEASE", 3, 21], ["ascites", "DISEASE", 25, 32], ["hepatosplenomegaly", "PROBLEM", 3, 21], ["ascites", "PROBLEM", 25, 32], ["hepatosplenomegaly", "OBSERVATION", 3, 21], ["ascites", "OBSERVATION", 25, 32]]], ["She is alert and oriented without asterixis.Admission Lab ResultsTotal bilirubin 2.9 mg/dl AST 20,300 iu/l ALT 14,050 iu/l ALP 93 iu/l GGTP 250 iu/l Albumin 3.0 g/dl INR 10.6 (PT 117 s) WBC 23.2 (25% bands) Platelets 55 \u00d7 10 9 Hgb 13.4 g/dl Creatinine 0.7 mg/dl Questions 1.", [["asterixis", "DISEASE", 34, 43], ["bilirubin", "CHEMICAL", 71, 80], ["Creatinine", "CHEMICAL", 241, 251], ["bilirubin", "CHEMICAL", 71, 80], ["Creatinine", "CHEMICAL", 241, 251], ["bilirubin", "SIMPLE_CHEMICAL", 71, 80], ["Creatinine", "SIMPLE_CHEMICAL", 241, 251], ["ALP", "PROTEIN", 123, 126], ["asterixis", "PROBLEM", 34, 43], ["Total bilirubin", "TEST", 65, 80], ["mg", "TEST", 85, 87], ["AST", "TEST", 91, 94], ["iu", "TEST", 102, 104], ["ALT", "TEST", 107, 110], ["iu", "TEST", 118, 120], ["ALP", "TEST", 123, 126], ["iu", "TEST", 130, 132], ["GGTP", "TEST", 135, 139], ["iu", "TEST", 144, 146], ["Albumin", "TEST", 149, 156], ["g", "TEST", 161, 162], ["INR", "TEST", 166, 169], ["PT", "TEST", 176, 178], ["s", "TEST", 183, 184], ["WBC", "TEST", 186, 189], ["bands", "TEST", 200, 205], ["Platelets", "TEST", 207, 216], ["Hgb", "TEST", 227, 230], ["g", "TEST", 236, 237], ["Creatinine", "TEST", 241, 251]]], ["What is this patient's clinical diagnosis? 2.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20]]], ["What is the differential diagnosis for her elevated LFT's? 3.", [["her elevated LFT's", "PROBLEM", 39, 57]]], ["How should she be managed?Answer: Acute Herpes Simplex Virus (HSV) HepatitisThe clinical diagnosis is that of \"acute severe hepatitis\".", [["Herpes Simplex Virus (HSV) Hepatitis", "DISEASE", 40, 76], ["hepatitis", "DISEASE", 124, 133], ["Acute", "ORGANISM", 34, 39], ["Herpes Simplex Virus", "ORGANISM", 40, 60], ["HSV", "ORGANISM", 62, 65], ["Herpes Simplex Virus", "SPECIES", 40, 60], ["HSV", "SPECIES", 62, 65], ["Acute Herpes Simplex Virus (HSV) Hepatitis", "PROBLEM", 34, 76], ["acute severe hepatitis\"", "PROBLEM", 111, 134], ["Acute", "OBSERVATION_MODIFIER", 34, 39], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["hepatitis", "OBSERVATION", 124, 133]]], ["The liver enzymes are indicative of a marked hepatocellular or necroinflammatory injury pattern.Answer: Acute Herpes Simplex Virus (HSV) HepatitisBy definition, the patient does not yet fulfill criteria for \"fulminant hepatic failure\" as she has no clinical encephalopathy.", [["liver", "ANATOMY", 4, 9], ["hepatocellular", "ANATOMY", 45, 59], ["hepatic", "ANATOMY", 218, 225], ["Herpes Simplex Virus (HSV) HepatitisBy", "DISEASE", 110, 148], ["fulminant hepatic failure", "DISEASE", 208, 233], ["encephalopathy", "DISEASE", 258, 272], ["liver", "ORGAN", 4, 9], ["hepatocellular", "CANCER", 45, 59], ["Acute", "ORGANISM", 104, 109], ["Herpes Simplex Virus", "ORGANISM", 110, 130], ["HSV", "ORGANISM", 132, 135], ["patient", "ORGANISM", 165, 172], ["hepatic", "ORGAN", 218, 225], ["liver enzymes", "PROTEIN", 4, 17], ["Herpes Simplex Virus", "SPECIES", 110, 130], ["patient", "SPECIES", 165, 172], ["HSV", "SPECIES", 132, 135], ["The liver enzymes", "TEST", 0, 17], ["a marked hepatocellular or necroinflammatory injury pattern", "PROBLEM", 36, 95], ["Acute Herpes Simplex Virus (HSV) HepatitisBy definition", "PROBLEM", 104, 159], ["fulminant hepatic failure", "PROBLEM", 208, 233], ["clinical encephalopathy", "PROBLEM", 249, 272], ["liver", "ANATOMY", 4, 9], ["indicative of", "UNCERTAINTY", 22, 35], ["marked", "OBSERVATION_MODIFIER", 38, 44], ["hepatocellular", "OBSERVATION", 45, 59], ["necroinflammatory", "OBSERVATION_MODIFIER", 63, 80], ["injury", "OBSERVATION", 81, 87], ["Acute", "OBSERVATION_MODIFIER", 104, 109], ["hepatic", "ANATOMY", 218, 225], ["failure", "OBSERVATION", 226, 233], ["no", "UNCERTAINTY", 246, 248], ["encephalopathy", "OBSERVATION", 258, 272]]], ["The original description of fulminant hepatic failure by Trey and Davidson in 1970 was that of the onset of altered mental status (hepatic encephalopathy) within 8 weeks of initial symptoms in an otherwise healthy individual without preexisting liver disease.", [["hepatic", "ANATOMY", 38, 45], ["hepatic", "ANATOMY", 131, 138], ["liver", "ANATOMY", 245, 250], ["fulminant hepatic failure", "DISEASE", 28, 53], ["hepatic encephalopathy", "DISEASE", 131, 153], ["liver disease", "DISEASE", 245, 258], ["hepatic", "ORGAN", 38, 45], ["hepatic", "ORGAN", 131, 138], ["liver", "ORGAN", 245, 250], ["fulminant hepatic failure", "PROBLEM", 28, 53], ["altered mental status", "PROBLEM", 108, 129], ["hepatic encephalopathy", "PROBLEM", 131, 153], ["initial symptoms", "PROBLEM", 173, 189], ["preexisting liver disease", "PROBLEM", 233, 258], ["fulminant", "OBSERVATION_MODIFIER", 28, 37], ["hepatic", "ANATOMY", 38, 45], ["failure", "OBSERVATION", 46, 53], ["altered", "OBSERVATION_MODIFIER", 108, 115], ["mental status", "OBSERVATION", 116, 129], ["hepatic", "ANATOMY", 131, 138], ["encephalopathy", "OBSERVATION", 139, 153], ["liver", "ANATOMY", 245, 250], ["disease", "OBSERVATION", 251, 258]]], ["The differential diagnosis for acute, severe hepatitis includes:Answer: Acute Herpes Simplex Virus (HSV) HepatitisAcetaminophen overdose -Autoimmune hepatitis -Viral hepatitis (hepatitis A, B, E, HSV, CMV, EBV) -Drug-induced -Ischemic hepatitis (shock liver) -Answer: Acute Herpes Simplex Virus (HSV) HepatitisWilson's disease -Answer: Acute Herpes Simplex Virus (HSV) HepatitisThe patient is at high risk of progressing to fulminant hepatic failure and should be managed in a liver transplant center and monitored closely for the development of hepatic encephalopathy, which could indicate the presence of cerebral edema.", [["liver", "ANATOMY", 252, 257], ["hepatic", "ANATOMY", 434, 441], ["liver", "ANATOMY", 477, 482], ["hepatic", "ANATOMY", 546, 553], ["cerebral", "ANATOMY", 607, 615], ["hepatitis", "DISEASE", 45, 54], ["Herpes Simplex Virus", "DISEASE", 78, 98], ["Hepatitis", "DISEASE", 105, 114], ["Acetaminophen", "CHEMICAL", 114, 127], ["overdose", "DISEASE", 128, 136], ["Autoimmune hepatitis -Viral hepatitis", "DISEASE", 138, 175], ["hepatitis A", "DISEASE", 177, 188], ["HSV, CMV, EBV) -Drug-induced -Ischemic hepatitis", "DISEASE", 196, 244], ["shock", "DISEASE", 246, 251], ["Herpes Simplex Virus (HSV) HepatitisWilson's disease", "DISEASE", 274, 326], ["Acute Herpes Simplex Virus (HSV) Hepatitis", "DISEASE", 336, 378], ["fulminant hepatic failure", "DISEASE", 424, 449], ["hepatic encephalopathy", "DISEASE", 546, 568], ["cerebral edema", "DISEASE", 607, 621], ["Acetaminophen", "CHEMICAL", 114, 127], ["Acute", "ORGANISM", 72, 77], ["Herpes Simplex Virus", "ORGANISM", 78, 98], ["HSV) HepatitisAcetaminophen", "ORGANISM", 100, 127], ["HSV", "ORGANISM", 196, 199], ["CMV", "ORGANISM", 201, 204], ["EBV", "ORGANISM", 206, 209], ["liver", "ORGAN", 252, 257], ["Herpes Simplex Virus", "ORGANISM", 274, 294], ["HSV", "ORGANISM", 296, 299], ["Acute", "ORGANISM", 336, 341], ["Herpes Simplex Virus", "ORGANISM", 342, 362], ["HSV", "ORGANISM", 364, 367], ["patient", "ORGANISM", 382, 389], ["hepatic", "ORGAN", 434, 441], ["liver", "ORGAN", 477, 482], ["hepatic", "ORGAN", 546, 553], ["cerebral edema", "PATHOLOGICAL_FORMATION", 607, 621], ["Herpes Simplex Virus", "SPECIES", 78, 98], ["Herpes Simplex Virus", "SPECIES", 274, 294], ["Herpes Simplex Virus", "SPECIES", 342, 362], ["patient", "SPECIES", 382, 389], ["HSV", "SPECIES", 100, 103], ["HSV", "SPECIES", 196, 199], ["CMV", "SPECIES", 201, 204], ["EBV", "SPECIES", 206, 209], ["HSV", "SPECIES", 296, 299], ["HSV", "SPECIES", 364, 367], ["acute, severe hepatitis", "PROBLEM", 31, 54], ["Acute Herpes Simplex Virus (HSV)", "PROBLEM", 72, 104], ["HepatitisAcetaminophen overdose", "PROBLEM", 105, 136], ["Autoimmune hepatitis", "PROBLEM", 138, 158], ["Viral hepatitis", "PROBLEM", 160, 175], ["hepatitis A", "TEST", 177, 188], ["HSV", "TEST", 196, 199], ["CMV", "TEST", 201, 204], ["EBV", "TEST", 206, 209], ["Ischemic hepatitis (shock liver)", "PROBLEM", 226, 258], ["Acute Herpes Simplex Virus (HSV)", "PROBLEM", 268, 300], ["HepatitisWilson's disease", "PROBLEM", 301, 326], ["Acute Herpes Simplex Virus (HSV) Hepatitis", "PROBLEM", 336, 378], ["fulminant hepatic failure", "PROBLEM", 424, 449], ["hepatic encephalopathy", "PROBLEM", 546, 568], ["cerebral edema", "PROBLEM", 607, 621], ["differential diagnosis for", "UNCERTAINTY", 4, 30], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["hepatitis", "OBSERVATION", 45, 54], ["Viral hepatitis", "OBSERVATION", 160, 175], ["Ischemic", "OBSERVATION_MODIFIER", 226, 234], ["hepatitis", "OBSERVATION", 235, 244], ["liver", "ANATOMY", 252, 257], ["Acute", "OBSERVATION_MODIFIER", 336, 341], ["fulminant", "OBSERVATION_MODIFIER", 424, 433], ["hepatic", "ANATOMY", 434, 441], ["failure", "OBSERVATION", 442, 449], ["liver", "ANATOMY", 477, 482], ["transplant", "OBSERVATION", 483, 493], ["hepatic", "ANATOMY", 546, 553], ["encephalopathy", "OBSERVATION", 554, 568], ["cerebral", "ANATOMY", 607, 615], ["edema", "OBSERVATION", 616, 621]]], ["Frequent neurologic checks are required.Answer: Acute Herpes Simplex Virus (HSV) HepatitisHospital course: within 18 h of admission, the patient had a rapid deterioration in her clinical condition with the development of grade 4 encephalopathy requiring intubation, ARDS requiring mechanical ventilation, acute renal failure, pancreatitis (amylase 9,600, lipase 8,300), DIC, gastrointestinal bleeding, and severe acidosis.", [["neurologic", "ANATOMY", 9, 19], ["renal", "ANATOMY", 311, 316], ["gastrointestinal", "ANATOMY", 375, 391], ["Herpes Simplex Virus (HSV) Hepatitis", "DISEASE", 54, 90], ["encephalopathy", "DISEASE", 229, 243], ["ARDS", "DISEASE", 266, 270], ["acute renal failure", "DISEASE", 305, 324], ["pancreatitis", "DISEASE", 326, 338], ["DIC", "DISEASE", 370, 373], ["gastrointestinal bleeding", "DISEASE", 375, 400], ["acidosis", "DISEASE", 413, 421], ["Acute", "ORGANISM", 48, 53], ["Herpes Simplex Virus", "ORGANISM", 54, 74], ["HSV", "ORGANISM", 76, 79], ["patient", "ORGANISM", 137, 144], ["renal", "ORGAN", 311, 316], ["amylase", "GENE_OR_GENE_PRODUCT", 340, 347], ["gastrointestinal", "ORGANISM_SUBDIVISION", 375, 391], ["Herpes Simplex Virus", "SPECIES", 54, 74], ["patient", "SPECIES", 137, 144], ["HSV", "SPECIES", 76, 79], ["Frequent neurologic checks", "TEST", 0, 26], ["Acute Herpes Simplex Virus", "PROBLEM", 48, 74], ["a rapid deterioration", "PROBLEM", 149, 170], ["her clinical condition", "PROBLEM", 174, 196], ["grade 4 encephalopathy", "PROBLEM", 221, 243], ["intubation", "TREATMENT", 254, 264], ["ARDS", "PROBLEM", 266, 270], ["mechanical ventilation", "TREATMENT", 281, 303], ["acute renal failure", "PROBLEM", 305, 324], ["pancreatitis", "PROBLEM", 326, 338], ["amylase", "TEST", 340, 347], ["lipase", "TEST", 355, 361], ["DIC", "PROBLEM", 370, 373], ["gastrointestinal bleeding", "PROBLEM", 375, 400], ["severe acidosis", "PROBLEM", 406, 421], ["Acute", "OBSERVATION_MODIFIER", 48, 53], ["rapid", "OBSERVATION_MODIFIER", 151, 156], ["deterioration", "OBSERVATION", 157, 170], ["grade 4", "OBSERVATION_MODIFIER", 221, 228], ["encephalopathy", "OBSERVATION", 229, 243], ["ARDS", "OBSERVATION", 266, 270], ["mechanical ventilation", "OBSERVATION", 281, 303], ["acute", "OBSERVATION_MODIFIER", 305, 310], ["renal", "ANATOMY", 311, 316], ["failure", "OBSERVATION", 317, 324], ["pancreatitis", "OBSERVATION", 326, 338], ["gastrointestinal", "ANATOMY", 375, 391], ["bleeding", "OBSERVATION", 392, 400], ["severe", "OBSERVATION_MODIFIER", 406, 412], ["acidosis", "OBSERVATION", 413, 421]]], ["The patient ultimately died despite aggressive medical care.Answer: Acute Herpes Simplex Virus (HSV) HepatitisA postmortem examination revealed massive, hemorrhagic hepatic necrosis involving 99% of the parenchyma as seen in Fig. 34 .1.", [["hepatic", "ANATOMY", 165, 172], ["parenchyma", "ANATOMY", 203, 213], ["Herpes Simplex Virus", "DISEASE", 74, 94], ["hemorrhagic hepatic necrosis", "DISEASE", 153, 181], ["patient", "ORGANISM", 4, 11], ["Acute", "ORGANISM", 68, 73], ["Herpes Simplex Virus", "ORGANISM", 74, 94], ["HSV", "ORGANISM", 96, 99], ["hepatic", "PATHOLOGICAL_FORMATION", 165, 172], ["parenchyma", "TISSUE", 203, 213], ["patient", "SPECIES", 4, 11], ["Herpes Simplex Virus", "SPECIES", 74, 94], ["HSV", "SPECIES", 96, 99], ["HepatitisA", "SPECIES", 101, 111], ["aggressive medical care", "TREATMENT", 36, 59], ["Acute Herpes Simplex Virus", "PROBLEM", 68, 94], ["HepatitisA postmortem examination", "TEST", 101, 134], ["massive, hemorrhagic hepatic necrosis", "PROBLEM", 144, 181], ["Acute", "OBSERVATION_MODIFIER", 68, 73], ["massive", "OBSERVATION_MODIFIER", 144, 151], ["hemorrhagic", "OBSERVATION_MODIFIER", 153, 164], ["hepatic", "ANATOMY", 165, 172], ["necrosis", "OBSERVATION", 173, 181], ["parenchyma", "ANATOMY", 203, 213]]], ["There were intranuclear inclusions (arrowed in Fig. 34 .2) and an immunostain was positive for herpes simplex virus ( Fig. 34.3 ).", [["herpes simplex virus", "DISEASE", 95, 115], ["herpes simplex virus", "ORGANISM", 95, 115], ["herpes simplex virus", "SPECIES", 95, 115], ["herpes simplex virus", "SPECIES", 95, 115], ["intranuclear inclusions", "PROBLEM", 11, 34], ["Fig.", "TEST", 47, 51], ["an immunostain", "TEST", 63, 77], ["herpes simplex virus", "PROBLEM", 95, 115], ["intranuclear", "OBSERVATION_MODIFIER", 11, 23], ["inclusions", "OBSERVATION", 24, 34]]], ["Serologies yielded a (+) HSV-1 IgM antibody.Answer: Acute Herpes Simplex Virus (HSV) HepatitisHSV-1 and HSV-2 produce a wide variety of illnesses including mucocutaneous infections, CNS infections, and occasional infections of visceral organs (which could be life threatening).", [["mucocutaneous", "ANATOMY", 156, 169], ["CNS", "ANATOMY", 182, 185], ["visceral organs", "ANATOMY", 227, 242], ["Herpes Simplex Virus", "DISEASE", 58, 78], ["mucocutaneous infections", "DISEASE", 156, 180], ["CNS infections", "DISEASE", 182, 196], ["infections", "DISEASE", 213, 223], ["Acute", "ORGANISM", 52, 57], ["Herpes Simplex Virus", "ORGANISM", 58, 78], ["HSV) HepatitisHSV-1", "ORGANISM", 80, 99], ["HSV-2", "ORGANISM", 104, 109], ["CNS", "ANATOMICAL_SYSTEM", 182, 185], ["visceral organs", "ORGAN", 227, 242], ["IgM antibody", "PROTEIN", 31, 43], ["HSV-1", "SPECIES", 25, 30], ["Herpes Simplex Virus", "SPECIES", 58, 78], ["HepatitisHSV-1", "SPECIES", 85, 99], ["HSV-2", "SPECIES", 104, 109], ["HSV-1", "SPECIES", 25, 30], ["HSV", "SPECIES", 80, 83], ["HepatitisHSV-1", "SPECIES", 85, 99], ["HSV-2", "SPECIES", 104, 109], ["Serologies", "TEST", 0, 10], ["HSV", "TEST", 25, 28], ["IgM antibody", "TEST", 31, 43], ["Acute Herpes Simplex Virus", "PROBLEM", 52, 78], ["HSV", "TEST", 80, 83], ["HepatitisHSV", "TEST", 85, 97], ["HSV", "TEST", 104, 107], ["illnesses", "PROBLEM", 136, 145], ["mucocutaneous infections", "PROBLEM", 156, 180], ["CNS infections", "PROBLEM", 182, 196], ["occasional infections of visceral organs", "PROBLEM", 202, 242], ["Acute", "OBSERVATION_MODIFIER", 52, 57], ["mucocutaneous infections", "OBSERVATION", 156, 180], ["CNS", "ANATOMY", 182, 185], ["infections", "OBSERVATION", 186, 196], ["occasional", "OBSERVATION_MODIFIER", 202, 212], ["infections", "OBSERVATION", 213, 223], ["visceral organs", "ANATOMY", 227, 242]]], ["HSV hepatitis is a rare disease in adults, but does have a high mortality, especially if not diagnosed early.", [["HSV hepatitis", "DISEASE", 0, 13], ["HSV hepatitis", "ORGANISM", 0, 13], ["HSV", "SPECIES", 0, 3], ["HSV hepatitis", "PROBLEM", 0, 13], ["a rare disease in adults", "PROBLEM", 17, 41], ["a high mortality", "PROBLEM", 57, 73], ["hepatitis", "OBSERVATION", 4, 13], ["rare", "OBSERVATION_MODIFIER", 19, 23], ["disease", "OBSERVATION", 24, 31]]], ["The disease can occur in immunocompetent patients, often characterized by the absence of mucocutaneous involvement.Answer: Acute Herpes Simplex Virus (HSV) HepatitisOther clues to the diagnosis:Answer: Acute Herpes Simplex Virus (HSV) HepatitisHigh fevers -Marked liver transaminase elevation -Relatively low total bilirubin level -Leukopenia (although not seen in the case presented here) -When suspected, IV acyclovir should be administered immediately.", [["mucocutaneous", "ANATOMY", 89, 102], ["liver", "ANATOMY", 264, 269], ["Herpes Simplex Virus", "DISEASE", 129, 149], ["Herpes Simplex Virus", "DISEASE", 208, 228], ["HepatitisHigh fevers", "DISEASE", 235, 255], ["bilirubin", "CHEMICAL", 315, 324], ["Leukopenia", "DISEASE", 332, 342], ["acyclovir", "CHEMICAL", 410, 419], ["bilirubin", "CHEMICAL", 315, 324], ["acyclovir", "CHEMICAL", 410, 419], ["patients", "ORGANISM", 41, 49], ["Acute", "ORGANISM", 123, 128], ["Herpes Simplex Virus", "ORGANISM", 129, 149], ["HSV", "ORGANISM", 151, 154], ["Acute", "ORGANISM", 202, 207], ["Herpes Simplex Virus", "ORGANISM", 208, 228], ["HSV", "ORGANISM", 230, 233], ["liver", "ORGAN", 264, 269], ["bilirubin", "SIMPLE_CHEMICAL", 315, 324], ["acyclovir", "SIMPLE_CHEMICAL", 410, 419], ["patients", "SPECIES", 41, 49], ["Herpes Simplex Virus", "SPECIES", 129, 149], ["Herpes Simplex Virus", "SPECIES", 208, 228], ["HSV", "SPECIES", 151, 154], ["HSV", "SPECIES", 230, 233], ["The disease", "PROBLEM", 0, 11], ["mucocutaneous involvement", "PROBLEM", 89, 114], ["Acute Herpes Simplex Virus", "PROBLEM", 123, 149], ["Acute Herpes Simplex Virus (HSV)", "PROBLEM", 202, 234], ["HepatitisHigh fevers", "PROBLEM", 235, 255], ["Marked liver transaminase elevation", "PROBLEM", 257, 292], ["Relatively low total bilirubin level", "PROBLEM", 294, 330], ["Leukopenia", "PROBLEM", 332, 342], ["IV acyclovir", "TREATMENT", 407, 419], ["disease", "OBSERVATION", 4, 11], ["mucocutaneous involvement", "OBSERVATION", 89, 114], ["liver", "ANATOMY", 264, 269], ["transaminase elevation", "OBSERVATION", 270, 292], ["Leukopenia", "OBSERVATION", 332, 342]]], ["Liver transplant ought to be considered in patients where medical management fails to improve the disease course.Case 35A 58-year-old woman was admitted with a 2-week history of progressive jaundice, dark urine, acholic stool, and abdominal distension.", [["Liver", "ANATOMY", 0, 5], ["urine", "ANATOMY", 205, 210], ["acholic stool", "ANATOMY", 212, 225], ["abdominal", "ANATOMY", 231, 240], ["jaundice", "DISEASE", 190, 198], ["acholic stool", "DISEASE", 212, 225], ["abdominal distension", "DISEASE", 231, 251], ["Liver", "ORGAN", 0, 5], ["patients", "ORGANISM", 43, 51], ["woman", "ORGANISM", 134, 139], ["urine", "ORGANISM_SUBSTANCE", 205, 210], ["abdominal", "ORGANISM_SUBDIVISION", 231, 240], ["patients", "SPECIES", 43, 51], ["woman", "SPECIES", 134, 139], ["Liver transplant", "TREATMENT", 0, 16], ["medical management", "TREATMENT", 58, 76], ["the disease course", "PROBLEM", 94, 112], ["progressive jaundice", "PROBLEM", 178, 198], ["dark urine", "PROBLEM", 200, 210], ["acholic stool", "PROBLEM", 212, 225], ["abdominal distension", "PROBLEM", 231, 251], ["transplant", "OBSERVATION", 6, 16], ["disease", "OBSERVATION", 98, 105], ["progressive", "OBSERVATION_MODIFIER", 178, 189], ["jaundice", "OBSERVATION", 190, 198], ["dark urine", "OBSERVATION", 200, 210], ["acholic", "ANATOMY", 212, 219], ["stool", "OBSERVATION", 220, 225], ["abdominal", "ANATOMY", 231, 240], ["distension", "OBSERVATION", 241, 251]]], ["There was no personal or family history of liver disease, no risk factors for viral hepatitis, no history of alcohol use.", [["liver", "ANATOMY", 43, 48], ["liver disease", "DISEASE", 43, 56], ["viral hepatitis", "DISEASE", 78, 93], ["alcohol", "CHEMICAL", 109, 116], ["alcohol", "CHEMICAL", 109, 116], ["liver", "ORGAN", 43, 48], ["alcohol", "SIMPLE_CHEMICAL", 109, 116], ["liver disease", "PROBLEM", 43, 56], ["viral hepatitis", "PROBLEM", 78, 93], ["no", "UNCERTAINTY", 10, 12], ["liver", "ANATOMY", 43, 48], ["disease", "OBSERVATION", 49, 56], ["hepatitis", "OBSERVATION", 84, 93]]], ["Medical history was significant for locally invasive infiltrating ductal Ca of the left breast 6 years previously (estrogen receptor (ER) positive, progesterone receptor (PR) negative), for which she underwent mastectomy with axillary node clearance followed by adjuvant chemotherapy and tamoxifen.Case 35Physical examination revealed scleral icterus, mild hepatomegaly with a liver edge three fingers below right costal margin, no splenomegaly and moderate ascites.", [["invasive infiltrating ductal Ca", "ANATOMY", 44, 75], ["left breast", "ANATOMY", 83, 94], ["axillary node", "ANATOMY", 226, 239], ["scleral icterus", "ANATOMY", 335, 350], ["liver edge", "ANATOMY", 377, 387], ["fingers", "ANATOMY", 394, 401], ["right costal margin", "ANATOMY", 408, 427], ["splenomegaly", "ANATOMY", 432, 444], ["ascites", "ANATOMY", 458, 465], ["Ca", "CHEMICAL", 73, 75], ["estrogen", "CHEMICAL", 115, 123], ["progesterone", "CHEMICAL", 148, 160], ["tamoxifen", "CHEMICAL", 288, 297], ["scleral icterus", "DISEASE", 335, 350], ["hepatomegaly", "DISEASE", 357, 369], ["splenomegaly", "DISEASE", 432, 444], ["ascites", "DISEASE", 458, 465], ["estrogen", "CHEMICAL", 115, 123], ["progesterone", "CHEMICAL", 148, 160], ["tamoxifen", "CHEMICAL", 288, 297], ["ductal Ca", "CANCER", 66, 75], ["breast", "ORGAN", 88, 94], ["estrogen receptor", "GENE_OR_GENE_PRODUCT", 115, 132], ["ER", "GENE_OR_GENE_PRODUCT", 134, 136], ["progesterone receptor", "GENE_OR_GENE_PRODUCT", 148, 169], ["PR", "GENE_OR_GENE_PRODUCT", 171, 173], ["axillary node", "MULTI-TISSUE_STRUCTURE", 226, 239], ["tamoxifen", "SIMPLE_CHEMICAL", 288, 297], ["liver", "ORGAN", 377, 382], ["costal margin", "MULTI-TISSUE_STRUCTURE", 414, 427], ["estrogen receptor", "PROTEIN", 115, 132], ["ER", "PROTEIN", 134, 136], ["progesterone receptor", "PROTEIN", 148, 169], ["PR", "PROTEIN", 171, 173], ["locally invasive infiltrating ductal Ca of the left breast", "PROBLEM", 36, 94], ["progesterone receptor", "TEST", 148, 169], ["mastectomy", "TREATMENT", 210, 220], ["axillary node clearance", "TREATMENT", 226, 249], ["adjuvant chemotherapy", "TREATMENT", 262, 283], ["tamoxifen", "TREATMENT", 288, 297], ["Case 35Physical examination", "TEST", 298, 325], ["scleral icterus", "PROBLEM", 335, 350], ["mild hepatomegaly", "PROBLEM", 352, 369], ["splenomegaly", "PROBLEM", 432, 444], ["moderate ascites", "PROBLEM", 449, 465], ["significant for", "UNCERTAINTY", 20, 35], ["locally", "OBSERVATION_MODIFIER", 36, 43], ["invasive", "OBSERVATION_MODIFIER", 44, 52], ["infiltrating", "OBSERVATION", 53, 65], ["ductal", "ANATOMY_MODIFIER", 66, 72], ["Ca", "OBSERVATION", 73, 75], ["left", "ANATOMY_MODIFIER", 83, 87], ["breast", "ANATOMY", 88, 94], ["mastectomy", "OBSERVATION", 210, 220], ["axillary", "ANATOMY", 226, 234], ["node", "OBSERVATION", 235, 239], ["scleral", "ANATOMY", 335, 342], ["icterus", "OBSERVATION", 343, 350], ["mild", "OBSERVATION_MODIFIER", 352, 356], ["hepatomegaly", "OBSERVATION", 357, 369], ["liver", "ANATOMY", 377, 382], ["edge", "ANATOMY_MODIFIER", 383, 387], ["fingers", "ANATOMY_MODIFIER", 394, 401], ["below", "ANATOMY_MODIFIER", 402, 407], ["right", "ANATOMY_MODIFIER", 408, 413], ["costal", "ANATOMY", 414, 420], ["margin", "ANATOMY_MODIFIER", 421, 427], ["no", "UNCERTAINTY", 429, 431], ["splenomegaly", "OBSERVATION", 432, 444], ["moderate", "OBSERVATION_MODIFIER", 449, 457], ["ascites", "OBSERVATION", 458, 465]]], ["There were no cutaneous stigmata of chronic liver disease and no asterixis.Lab ResultsTotal bilirubin 6.8 mg/dl Direct bilirubin 4.0 mg/dl AST 250 iu/l ALT 100 iu/l ALP 260 iu/l GGTP 451 iu/l Albumin 2.4 g/dl INR 1.5 Plt 95,000/\u03bcl Hb 13.5 g/dl Questions 1.", [["liver", "ANATOMY", 44, 49], ["chronic liver disease", "DISEASE", 36, 57], ["asterixis", "DISEASE", 65, 74], ["bilirubin", "CHEMICAL", 92, 101], ["bilirubin", "CHEMICAL", 119, 128], ["bilirubin", "CHEMICAL", 92, 101], ["bilirubin", "CHEMICAL", 119, 128], ["liver", "ORGAN", 44, 49], ["bilirubin", "SIMPLE_CHEMICAL", 92, 101], ["bilirubin", "SIMPLE_CHEMICAL", 119, 128], ["Albumin", "GENE_OR_GENE_PRODUCT", 192, 199], ["ALP", "PROTEIN", 165, 168], ["chronic liver disease", "PROBLEM", 36, 57], ["asterixis", "PROBLEM", 65, 74], ["Total bilirubin", "TEST", 86, 101], ["bilirubin", "TEST", 119, 128], ["AST", "TEST", 139, 142], ["iu", "TEST", 147, 149], ["ALT", "TEST", 152, 155], ["iu", "TEST", 160, 162], ["ALP", "TEST", 165, 168], ["iu", "TEST", 173, 175], ["GGTP", "TEST", 178, 182], ["iu", "TEST", 187, 189], ["Albumin", "TEST", 192, 199], ["g", "TEST", 204, 205], ["INR", "TEST", 209, 212], ["Plt", "TEST", 217, 220], ["\u03bcl", "TEST", 228, 230], ["Hb", "TEST", 231, 233], ["no", "UNCERTAINTY", 11, 13], ["cutaneous", "OBSERVATION_MODIFIER", 14, 23], ["stigmata", "OBSERVATION", 24, 32], ["chronic", "OBSERVATION_MODIFIER", 36, 43], ["liver", "ANATOMY", 44, 49], ["disease", "OBSERVATION", 50, 57], ["no", "UNCERTAINTY", 62, 64], ["asterixis", "OBSERVATION", 65, 74]]], ["How would you evaluate this patient further for the etiology of her liver disease? 2.", [["liver", "ANATOMY", 68, 73], ["liver disease", "DISEASE", 68, 81], ["patient", "ORGANISM", 28, 35], ["liver", "ORGAN", 68, 73], ["patient", "SPECIES", 28, 35], ["her liver disease", "PROBLEM", 64, 81], ["liver", "ANATOMY", 68, 73], ["disease", "OBSERVATION", 74, 81]]], ["What is the differential diagnosis for the radiographic appearance shown?Answer: Metastatic Breast Cancer Leading to PseudocirrhosisThe triphasic CT scan of the abdomen reveals a nodular contour of the liver with heterogeneous attenuation consistent with cirrhosis as well as moderate ascites, but no biliary ductal dilation or splenomegaly.Answer: Metastatic Breast Cancer Leading to PseudocirrhosisAt first glance, this case appears to be that of decompensated cirrhosis.", [["Metastatic Breast Cancer", "ANATOMY", 81, 105], ["abdomen", "ANATOMY", 161, 168], ["liver", "ANATOMY", 202, 207], ["ascites", "ANATOMY", 285, 292], ["biliary ductal", "ANATOMY", 301, 315], ["Metastatic Breast Cancer", "ANATOMY", 349, 373], ["Breast Cancer", "DISEASE", 92, 105], ["Pseudocirrhosis", "DISEASE", 117, 132], ["cirrhosis", "DISEASE", 255, 264], ["ascites", "DISEASE", 285, 292], ["biliary ductal dilation", "DISEASE", 301, 324], ["splenomegaly", "DISEASE", 328, 340], ["Breast Cancer", "DISEASE", 360, 373], ["cirrhosis", "DISEASE", 463, 472], ["Metastatic Breast Cancer", "CANCER", 81, 105], ["abdomen", "ORGAN", 161, 168], ["liver", "ORGAN", 202, 207], ["biliary ductal", "MULTI-TISSUE_STRUCTURE", 301, 315], ["Metastatic Breast Cancer", "CANCER", 349, 373], ["the radiographic appearance", "PROBLEM", 39, 66], ["Metastatic Breast Cancer", "PROBLEM", 81, 105], ["Pseudocirrhosis", "PROBLEM", 117, 132], ["The triphasic CT scan of the abdomen", "TEST", 132, 168], ["a nodular contour of the liver", "PROBLEM", 177, 207], ["heterogeneous attenuation", "PROBLEM", 213, 238], ["cirrhosis", "PROBLEM", 255, 264], ["moderate ascites", "PROBLEM", 276, 292], ["biliary ductal dilation", "PROBLEM", 301, 324], ["splenomegaly", "PROBLEM", 328, 340], ["Metastatic Breast Cancer", "PROBLEM", 349, 373], ["decompensated cirrhosis", "PROBLEM", 449, 472], ["Metastatic", "OBSERVATION_MODIFIER", 81, 91], ["Breast", "ANATOMY", 92, 98], ["Cancer", "OBSERVATION", 99, 105], ["abdomen", "ANATOMY", 161, 168], ["nodular", "OBSERVATION", 179, 186], ["liver", "ANATOMY", 202, 207], ["heterogeneous", "OBSERVATION_MODIFIER", 213, 226], ["attenuation", "OBSERVATION", 227, 238], ["consistent with", "UNCERTAINTY", 239, 254], ["cirrhosis", "OBSERVATION", 255, 264], ["moderate", "OBSERVATION_MODIFIER", 276, 284], ["ascites", "OBSERVATION", 285, 292], ["no", "UNCERTAINTY", 298, 300], ["biliary ductal", "ANATOMY", 301, 315], ["dilation", "OBSERVATION", 316, 324], ["splenomegaly", "OBSERVATION", 328, 340], ["Metastatic", "OBSERVATION_MODIFIER", 349, 359], ["Breast", "ANATOMY", 360, 366], ["Cancer", "OBSERVATION", 367, 373], ["decompensated", "OBSERVATION_MODIFIER", 449, 462], ["cirrhosis", "OBSERVATION", 463, 472]]], ["The patient presents with features of liver failure: jaundice, hypoalbuminemia, prolonged INR, and a cirrhotic appearing liver with evidence of portal hypertension (ascites).Answer: Metastatic Breast Cancer Leading to PseudocirrhosisThe puzzling issues are that she has no clear risk factors for chronic liver disease, the onset of liver failure has been rather rapid, and she does carry a history of prior malignancy.Answer: Metastatic Breast Cancer Leading to PseudocirrhosisFurther work-up included: Serologies for viral, autoimmune, and metabolic etiologies of cirrhosis: all negative.", [["liver", "ANATOMY", 38, 43], ["liver", "ANATOMY", 121, 126], ["portal", "ANATOMY", 144, 150], ["ascites", "ANATOMY", 165, 172], ["Metastatic Breast Cancer", "ANATOMY", 182, 206], ["liver", "ANATOMY", 304, 309], ["liver", "ANATOMY", 332, 337], ["Metastatic Breast Cancer", "ANATOMY", 426, 450], ["liver failure", "DISEASE", 38, 51], ["jaundice", "DISEASE", 53, 61], ["hypoalbuminemia", "DISEASE", 63, 78], ["cirrhotic appearing liver", "DISEASE", 101, 126], ["portal hypertension", "DISEASE", 144, 163], ["ascites", "DISEASE", 165, 172], ["Breast Cancer", "DISEASE", 193, 206], ["Pseudocirrhosis", "DISEASE", 218, 233], ["chronic liver disease", "DISEASE", 296, 317], ["liver failure", "DISEASE", 332, 345], ["malignancy", "DISEASE", 407, 417], ["Breast Cancer", "DISEASE", 437, 450], ["cirrhosis", "DISEASE", 565, 574], ["patient", "ORGANISM", 4, 11], ["liver", "ORGAN", 38, 43], ["liver", "ORGAN", 121, 126], ["portal", "MULTI-TISSUE_STRUCTURE", 144, 150], ["Metastatic Breast Cancer", "CANCER", 182, 206], ["liver", "ORGAN", 304, 309], ["liver", "ORGAN", 332, 337], ["malignancy", "CANCER", 407, 417], ["Metastatic Breast Cancer", "CANCER", 426, 450], ["patient", "SPECIES", 4, 11], ["liver failure", "PROBLEM", 38, 51], ["jaundice", "PROBLEM", 53, 61], ["hypoalbuminemia", "PROBLEM", 63, 78], ["prolonged INR", "PROBLEM", 80, 93], ["a cirrhotic appearing liver", "PROBLEM", 99, 126], ["portal hypertension", "PROBLEM", 144, 163], ["ascites", "PROBLEM", 165, 172], ["Metastatic Breast Cancer", "PROBLEM", 182, 206], ["Pseudocirrhosis", "PROBLEM", 218, 233], ["The puzzling issues", "PROBLEM", 233, 252], ["clear risk factors", "PROBLEM", 273, 291], ["chronic liver disease", "PROBLEM", 296, 317], ["liver failure", "PROBLEM", 332, 345], ["prior malignancy", "PROBLEM", 401, 417], ["Metastatic Breast Cancer", "PROBLEM", 426, 450], ["Serologies", "TEST", 503, 513], ["viral", "PROBLEM", 518, 523], ["autoimmune", "PROBLEM", 525, 535], ["cirrhosis", "PROBLEM", 565, 574], ["liver", "ANATOMY", 38, 43], ["failure", "OBSERVATION", 44, 51], ["jaundice", "OBSERVATION", 53, 61], ["hypoalbuminemia", "OBSERVATION", 63, 78], ["prolonged", "OBSERVATION_MODIFIER", 80, 89], ["INR", "OBSERVATION", 90, 93], ["cirrhotic", "OBSERVATION", 101, 110], ["liver", "ANATOMY", 121, 126], ["portal", "ANATOMY", 144, 150], ["hypertension", "OBSERVATION", 151, 163], ["ascites", "OBSERVATION", 165, 172], ["Metastatic", "OBSERVATION_MODIFIER", 182, 192], ["Breast", "ANATOMY", 193, 199], ["Cancer", "OBSERVATION", 200, 206], ["chronic", "OBSERVATION_MODIFIER", 296, 303], ["liver", "ANATOMY", 304, 309], ["disease", "OBSERVATION", 310, 317], ["liver", "ANATOMY", 332, 337], ["failure", "OBSERVATION", 338, 345], ["rapid", "OBSERVATION_MODIFIER", 362, 367], ["malignancy", "OBSERVATION", 407, 417], ["Metastatic", "OBSERVATION_MODIFIER", 426, 436], ["Breast", "ANATOMY", 437, 443], ["Cancer", "OBSERVATION", 444, 450], ["cirrhosis", "OBSERVATION", 565, 574]]], ["CEA 250 ng/ml (normal < 5): markedly elevated, raising suspicion of metastatic breast cancer.", [["metastatic breast cancer", "ANATOMY", 68, 92], ["breast cancer", "DISEASE", 79, 92], ["CEA", "GENE_OR_GENE_PRODUCT", 0, 3], ["breast cancer", "CANCER", 79, 92], ["CEA", "PROTEIN", 0, 3], ["CEA", "TEST", 0, 3], ["markedly elevated", "PROBLEM", 28, 45], ["metastatic breast cancer", "PROBLEM", 68, 92], ["markedly", "OBSERVATION_MODIFIER", 28, 36], ["elevated", "OBSERVATION", 37, 45], ["raising suspicion of", "UNCERTAINTY", 47, 67], ["metastatic", "OBSERVATION_MODIFIER", 68, 78], ["breast", "ANATOMY", 79, 85], ["cancer", "OBSERVATION", 86, 92]]], ["Ascitic fluid analysis showed a high serum-ascites albumin gradient (SAAG) >1.1 (indicating portal hypertension) and negative cytology.", [["Ascitic fluid", "ANATOMY", 0, 13], ["serum", "ANATOMY", 37, 42], ["ascites", "ANATOMY", 43, 50], ["portal", "ANATOMY", 92, 98], ["ascites", "DISEASE", 43, 50], ["hypertension", "DISEASE", 99, 111], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["albumin", "GENE_OR_GENE_PRODUCT", 51, 58], ["portal", "MULTI-TISSUE_STRUCTURE", 92, 98], ["Ascitic fluid analysis", "TEST", 0, 22], ["a high serum-ascites albumin gradient", "PROBLEM", 30, 67], ["SAAG", "TEST", 69, 73], ["portal hypertension", "PROBLEM", 92, 111], ["cytology", "TEST", 126, 134], ["fluid", "OBSERVATION", 8, 13], ["high", "OBSERVATION_MODIFIER", 32, 36], ["ascites", "OBSERVATION", 43, 50], ["portal", "ANATOMY", 92, 98], ["hypertension", "OBSERVATION", 99, 111], ["negative cytology", "OBSERVATION", 117, 134]]], ["A liver biopsy was planned; however, the patient had a massive variceal bleed that could not be controlled endoscopically.", [["liver", "ANATOMY", 2, 7], ["variceal", "ANATOMY", 63, 71], ["variceal bleed", "DISEASE", 63, 77], ["liver", "ORGAN", 2, 7], ["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48], ["A liver biopsy", "TEST", 0, 14], ["a massive variceal bleed", "PROBLEM", 53, 77], ["liver", "ANATOMY", 2, 7], ["biopsy", "OBSERVATION", 8, 14], ["massive", "OBSERVATION_MODIFIER", 55, 62], ["variceal bleed", "OBSERVATION", 63, 77], ["could not be", "UNCERTAINTY", 83, 95]]], ["An emergent TIPS reduced the hepatic portal venous pressure gradient from 30 to 9 mmHg.", [["hepatic portal venous", "ANATOMY", 29, 50], ["hepatic portal venous", "MULTI-TISSUE_STRUCTURE", 29, 50], ["An emergent TIPS", "TEST", 0, 16], ["the hepatic portal venous pressure gradient", "TEST", 25, 68], ["TIPS", "OBSERVATION_MODIFIER", 12, 16], ["reduced", "OBSERVATION", 17, 24], ["hepatic", "ANATOMY_MODIFIER", 29, 36], ["portal venous", "ANATOMY", 37, 50], ["pressure", "OBSERVATION_MODIFIER", 51, 59], ["gradient", "OBSERVATION_MODIFIER", 60, 68]]], ["Despite this, the patient later died and an autopsy revealed the cause of death to be related to the massive variceal hemorrhage and diffuse pulmonary alveolar damage.Answer: Metastatic Breast Cancer Leading to PseudocirrhosisThe autopsy also revealed grossly evident tumor infiltration of the liver by metastatic tumor (pale, confluent areas in Fig. 35 .2).", [["variceal", "ANATOMY", 109, 117], ["pulmonary alveolar", "ANATOMY", 141, 159], ["Metastatic Breast Cancer", "ANATOMY", 175, 199], ["tumor", "ANATOMY", 268, 273], ["liver", "ANATOMY", 294, 299], ["metastatic tumor", "ANATOMY", 303, 319], ["death", "DISEASE", 74, 79], ["variceal hemorrhage", "DISEASE", 109, 128], ["pulmonary alveolar damage", "DISEASE", 141, 166], ["Breast Cancer", "DISEASE", 186, 199], ["Pseudocirrhosis", "DISEASE", 211, 226], ["tumor infiltration of the liver", "DISEASE", 268, 299], ["tumor", "DISEASE", 314, 319], ["patient", "ORGANISM", 18, 25], ["pulmonary alveolar", "MULTI-TISSUE_STRUCTURE", 141, 159], ["Metastatic Breast Cancer", "CANCER", 175, 199], ["tumor", "CANCER", 268, 273], ["liver", "ORGAN", 294, 299], ["tumor", "CANCER", 314, 319], ["patient", "SPECIES", 18, 25], ["an autopsy", "TEST", 41, 51], ["death", "PROBLEM", 74, 79], ["the massive variceal hemorrhage", "PROBLEM", 97, 128], ["diffuse pulmonary alveolar damage", "PROBLEM", 133, 166], ["Metastatic Breast Cancer", "PROBLEM", 175, 199], ["Pseudocirrhosis", "PROBLEM", 211, 226], ["The autopsy", "TEST", 226, 237], ["grossly evident tumor infiltration of the liver", "PROBLEM", 252, 299], ["metastatic tumor", "PROBLEM", 303, 319], ["pale, confluent areas in Fig.", "PROBLEM", 321, 350], ["massive", "OBSERVATION_MODIFIER", 101, 108], ["variceal hemorrhage", "OBSERVATION", 109, 128], ["diffuse", "OBSERVATION_MODIFIER", 133, 140], ["pulmonary", "ANATOMY", 141, 150], ["alveolar", "ANATOMY_MODIFIER", 151, 159], ["damage", "OBSERVATION", 160, 166], ["Metastatic", "OBSERVATION_MODIFIER", 175, 185], ["Breast", "ANATOMY", 186, 192], ["Cancer", "OBSERVATION", 193, 199], ["grossly", "OBSERVATION_MODIFIER", 252, 259], ["evident", "OBSERVATION_MODIFIER", 260, 267], ["tumor", "OBSERVATION", 268, 273], ["infiltration", "OBSERVATION", 274, 286], ["liver", "ANATOMY", 294, 299], ["metastatic", "OBSERVATION_MODIFIER", 303, 313], ["tumor", "OBSERVATION", 314, 319], ["pale", "OBSERVATION_MODIFIER", 321, 325], ["confluent", "OBSERVATION_MODIFIER", 327, 336], ["areas", "OBSERVATION_MODIFIER", 337, 342]]], ["3) shows diffuse liver infiltration by a poorly differentiated, highly desmoplastic adenocarcinoma.", [["liver", "ANATOMY", 17, 22], ["desmoplastic adenocarcinoma", "ANATOMY", 71, 98], ["liver infiltration", "DISEASE", 17, 35], ["adenocarcinoma", "DISEASE", 84, 98], ["liver", "ORGAN", 17, 22], ["desmoplastic adenocarcinoma", "CANCER", 71, 98], ["diffuse liver infiltration", "PROBLEM", 9, 35], ["a poorly differentiated, highly desmoplastic adenocarcinoma", "PROBLEM", 39, 98], ["diffuse", "OBSERVATION_MODIFIER", 9, 16], ["liver", "ANATOMY", 17, 22], ["infiltration", "OBSERVATION", 23, 35], ["poorly differentiated", "OBSERVATION_MODIFIER", 41, 62], ["highly", "OBSERVATION_MODIFIER", 64, 70], ["desmoplastic", "OBSERVATION_MODIFIER", 71, 83], ["adenocarcinoma", "OBSERVATION", 84, 98]]], ["Immunohistochemical stains were positive for CEA and ER, but negative for PR.Answer: Metastatic Breast Cancer Leading to PseudocirrhosisThe differential diagnosis for a nodular-appearing liver on CT imaging includes: cirrhosis, nodular regenerative hyperplasia (NRH), and \"pseudocirrhosis\", where the hepatic histology shows evidence of extensive fibrosis, representing a profound desmoplastic response to the infiltrating tumor.", [["ER", "ANATOMY", 53, 55], ["Metastatic Breast Cancer", "ANATOMY", 85, 109], ["liver", "ANATOMY", 187, 192], ["nodular regenerative hyperplasia", "ANATOMY", 228, 260], ["NRH", "ANATOMY", 262, 265], ["pseudocirrhosis", "ANATOMY", 273, 288], ["hepatic", "ANATOMY", 301, 308], ["infiltrating tumor", "ANATOMY", 410, 428], ["Breast Cancer", "DISEASE", 96, 109], ["Pseudocirrhosis", "DISEASE", 121, 136], ["cirrhosis", "DISEASE", 217, 226], ["nodular regenerative hyperplasia", "DISEASE", 228, 260], ["NRH", "DISEASE", 262, 265], ["pseudocirrhosis", "DISEASE", 273, 288], ["fibrosis", "DISEASE", 347, 355], ["tumor", "DISEASE", 423, 428], ["CEA", "GENE_OR_GENE_PRODUCT", 45, 48], ["ER", "GENE_OR_GENE_PRODUCT", 53, 55], ["PR", "GENE_OR_GENE_PRODUCT", 74, 76], ["Metastatic Breast Cancer", "CANCER", 85, 109], ["Pseudocirrhosis", "CANCER", 121, 136], ["liver", "ORGAN", 187, 192], ["nodular regenerative hyperplasia", "CANCER", 228, 260], ["NRH", "CANCER", 262, 265], ["hepatic", "ORGAN", 301, 308], ["infiltrating tumor", "CANCER", 410, 428], ["CEA", "PROTEIN", 45, 48], ["ER", "PROTEIN", 53, 55], ["PR", "PROTEIN", 74, 76], ["Immunohistochemical stains", "TEST", 0, 26], ["CEA", "TEST", 45, 48], ["PR", "PROBLEM", 74, 76], ["Metastatic Breast Cancer", "PROBLEM", 85, 109], ["Pseudocirrhosis", "PROBLEM", 121, 136], ["a nodular-appearing liver", "PROBLEM", 167, 192], ["CT imaging", "TEST", 196, 206], ["cirrhosis", "PROBLEM", 217, 226], ["nodular regenerative hyperplasia", "PROBLEM", 228, 260], ["\"pseudocirrhosis\"", "PROBLEM", 272, 289], ["the hepatic histology", "TEST", 297, 318], ["extensive fibrosis", "PROBLEM", 337, 355], ["a profound desmoplastic response", "PROBLEM", 370, 402], ["the infiltrating tumor", "PROBLEM", 406, 428], ["Metastatic", "OBSERVATION_MODIFIER", 85, 95], ["Breast", "ANATOMY", 96, 102], ["Cancer", "OBSERVATION", 103, 109], ["nodular", "OBSERVATION_MODIFIER", 169, 176], ["liver", "ANATOMY", 187, 192], ["cirrhosis", "OBSERVATION", 217, 226], ["nodular", "OBSERVATION_MODIFIER", 228, 235], ["regenerative", "OBSERVATION_MODIFIER", 236, 248], ["hyperplasia", "OBSERVATION", 249, 260], ["hepatic", "ANATOMY", 301, 308], ["evidence of", "UNCERTAINTY", 325, 336], ["extensive", "OBSERVATION_MODIFIER", 337, 346], ["fibrosis", "OBSERVATION", 347, 355], ["profound", "OBSERVATION_MODIFIER", 372, 380], ["desmoplastic", "OBSERVATION_MODIFIER", 381, 393], ["infiltrating", "OBSERVATION_MODIFIER", 410, 422], ["tumor", "OBSERVATION", 423, 428]]], ["This case is an example of \"pseudocirrhosis.\"", [["pseudocirrhosis", "DISEASE", 28, 43], ["pseudocirrhosis", "CANCER", 28, 43], ["\"pseudocirrhosis", "PROBLEM", 27, 43]]], ["The only way to differentiate these three entities is via liver biopsy.Answer: Metastatic Breast Cancer Leading to PseudocirrhosisIt is interesting that the PET-CT did not unequivocally demonstrate metastatic breast cancer in our patient's liver.", [["liver", "ANATOMY", 58, 63], ["Metastatic Breast Cancer", "ANATOMY", 79, 103], ["metastatic breast cancer", "ANATOMY", 198, 222], ["liver", "ANATOMY", 240, 245], ["Breast Cancer", "DISEASE", 90, 103], ["Pseudocirrhosis", "DISEASE", 115, 130], ["breast cancer", "DISEASE", 209, 222], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 58, 70], ["Metastatic Breast Cancer", "CANCER", 79, 103], ["breast cancer", "CANCER", 209, 222], ["patient", "ORGANISM", 230, 237], ["liver", "ORGAN", 240, 245], ["patient", "SPECIES", 230, 237], ["liver biopsy", "TEST", 58, 70], ["Metastatic Breast Cancer", "PROBLEM", 79, 103], ["Pseudocirrhosis", "PROBLEM", 115, 130], ["the PET-CT", "TEST", 153, 163], ["metastatic breast cancer", "PROBLEM", 198, 222], ["liver", "ANATOMY", 58, 63], ["biopsy", "OBSERVATION", 64, 70], ["Metastatic", "OBSERVATION_MODIFIER", 79, 89], ["Breast", "ANATOMY", 90, 96], ["Cancer", "OBSERVATION", 97, 103], ["metastatic", "OBSERVATION_MODIFIER", 198, 208], ["breast", "ANATOMY", 209, 215], ["cancer", "OBSERVATION", 216, 222], ["liver", "ANATOMY", 240, 245]]], ["In one study, this radiologic modality has a 93% sensitivity, 79% specificity, 82% positive predictive value, and 92% negative predictive value.Case 36A 52-year-old Caucasian male presents to his primary care physician with a 1-week history of fatigue, malaise, and anorexia.", [["fatigue", "DISEASE", 244, 251], ["anorexia", "DISEASE", 266, 274], ["one study", "TEST", 3, 12], ["specificity", "TEST", 66, 77], ["fatigue", "PROBLEM", 244, 251], ["malaise", "PROBLEM", 253, 260], ["anorexia", "PROBLEM", 266, 274], ["fatigue", "OBSERVATION", 244, 251], ["malaise", "OBSERVATION", 253, 260], ["anorexia", "OBSERVATION", 266, 274]]], ["Over the last 2 days, he has noticed darkening of his urine and lightening in the color of his stools.", [["urine", "ANATOMY", 54, 59], ["stools", "ANATOMY", 95, 101], ["urine", "ORGANISM_SUBSTANCE", 54, 59], ["darkening of his urine", "PROBLEM", 37, 59], ["darkening", "OBSERVATION_MODIFIER", 37, 46], ["stools", "OBSERVATION", 95, 101]]], ["He denies any fevers or chills, abdominal pain or pruritus.", [["abdominal", "ANATOMY", 32, 41], ["fevers", "DISEASE", 14, 20], ["chills", "DISEASE", 24, 30], ["abdominal pain", "DISEASE", 32, 46], ["pruritus", "DISEASE", 50, 58], ["abdominal", "ORGANISM_SUBDIVISION", 32, 41], ["fevers", "PROBLEM", 14, 20], ["chills", "PROBLEM", 24, 30], ["abdominal pain", "PROBLEM", 32, 46], ["pruritus", "PROBLEM", 50, 58], ["abdominal", "ANATOMY", 32, 41], ["pain", "OBSERVATION", 42, 46], ["pruritus", "OBSERVATION", 50, 58]]], ["Remainder of review of symptoms is negative.", [["symptoms", "PROBLEM", 23, 31], ["negative", "OBSERVATION", 35, 43]]], ["He has a medical history significant for noninsulin-dependent diabetes.", [["noninsulin", "CHEMICAL", 41, 51], ["diabetes", "DISEASE", 62, 70], ["noninsulin", "CHEMICAL", 41, 51], ["noninsulin", "SIMPLE_CHEMICAL", 41, 51], ["noninsulin-dependent diabetes", "PROBLEM", 41, 70], ["dependent", "OBSERVATION_MODIFIER", 52, 61], ["diabetes", "OBSERVATION", 62, 70]]], ["He has been on metformin and pioglitazone for over 3 years and is on no over the counter or herbal medications.", [["metformin", "CHEMICAL", 15, 24], ["pioglitazone", "CHEMICAL", 29, 41], ["metformin", "CHEMICAL", 15, 24], ["pioglitazone", "CHEMICAL", 29, 41], ["metformin", "SIMPLE_CHEMICAL", 15, 24], ["pioglitazone", "SIMPLE_CHEMICAL", 29, 41], ["metformin", "TREATMENT", 15, 24], ["pioglitazone", "TREATMENT", 29, 41], ["herbal medications", "TREATMENT", 92, 110]]], ["He has not been on any recent antibiotics.", [["any recent antibiotics", "TREATMENT", 19, 41]]], ["He is married with three healthy children and works full time as an automotive mechanic.", [["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41]]], ["His father died at the age of 59 from a sudden heart attack.Case 36Physical exam is notable for a middle aged male in no apparent distress.", [["heart", "ANATOMY", 47, 52], ["sudden heart attack", "DISEASE", 40, 59], ["heart", "ORGAN", 47, 52], ["a sudden heart attack", "PROBLEM", 38, 59], ["Case 36Physical exam", "TEST", 60, 80], ["apparent distress", "PROBLEM", 121, 138], ["heart", "ANATOMY", 47, 52], ["attack", "OBSERVATION", 53, 59], ["no apparent", "UNCERTAINTY", 118, 129], ["distress", "OBSERVATION", 130, 138]]], ["He is afebrile with a heart rate of 98 beats per minute.", [["heart", "ANATOMY", 22, 27], ["He", "ORGANISM", 0, 2], ["heart", "ORGAN", 22, 27], ["afebrile", "PROBLEM", 6, 14], ["a heart rate", "TEST", 20, 32], ["afebrile", "OBSERVATION", 6, 14]]], ["His BMI is 29.5 kg/m 2 .", [["His BMI", "TEST", 0, 7]]], ["He is jaundiced with scleral icterus.", [["scleral", "ANATOMY", 21, 28], ["scleral icterus", "DISEASE", 21, 36], ["scleral icterus", "PROBLEM", 21, 36], ["jaundiced", "OBSERVATION", 6, 15], ["scleral", "ANATOMY", 21, 28], ["icterus", "OBSERVATION", 29, 36]]], ["Abdominal exam is soft and nontender without hepatosplenomegaly.", [["Abdominal", "ANATOMY", 0, 9], ["hepatosplenomegaly", "DISEASE", 45, 63], ["Abdominal exam", "TEST", 0, 14], ["nontender", "PROBLEM", 27, 36], ["hepatosplenomegaly", "PROBLEM", 45, 63], ["soft", "OBSERVATION", 18, 22], ["nontender", "OBSERVATION", 27, 36], ["without", "UNCERTAINTY", 37, 44], ["hepatosplenomegaly", "OBSERVATION", 45, 63]]], ["He has no lymphadenopathy.", [["lymphadenopathy", "DISEASE", 10, 25], ["lymphadenopathy", "PROBLEM", 10, 25], ["no", "UNCERTAINTY", 7, 9], ["lymphadenopathy", "OBSERVATION", 10, 25]]], ["He is mentating well and has no asterixis.", [["asterixis", "PROBLEM", 32, 41], ["no", "UNCERTAINTY", 29, 31], ["asterixis", "OBSERVATION", 32, 41]]], ["There are no stigmata to suggest chronic liver disease.Laboratory ParametersTbili 8.", [["liver", "ANATOMY", 41, 46], ["chronic liver disease", "DISEASE", 33, 54], ["liver", "ORGAN", 41, 46], ["stigmata", "PROBLEM", 13, 21], ["chronic liver disease", "PROBLEM", 33, 54], ["Laboratory Parameters", "TEST", 55, 76], ["Tbili", "TEST", 76, 81], ["no stigmata to suggest", "UNCERTAINTY", 10, 32], ["chronic", "OBSERVATION_MODIFIER", 33, 40], ["liver", "ANATOMY", 41, 46], ["disease", "OBSERVATION", 47, 54]]], ["5Answer: De Novo Acute Hepatitis B InfectionThe liver enzyme abnormalities in this case are primarily hepatocellular in nature.", [["liver", "ANATOMY", 48, 53], ["hepatocellular", "ANATOMY", 102, 116], ["Hepatitis B", "DISEASE", 23, 34], ["liver enzyme abnormalities", "DISEASE", 48, 74], ["De Novo Acute Hepatitis B", "ORGANISM", 9, 34], ["liver", "ORGAN", 48, 53], ["hepatocellular", "CANCER", 102, 116], ["liver enzyme", "PROTEIN", 48, 60], ["Acute Hepatitis B Infection", "PROBLEM", 17, 44], ["The liver enzyme abnormalities", "PROBLEM", 44, 74], ["Acute", "OBSERVATION_MODIFIER", 17, 22], ["Hepatitis", "OBSERVATION", 23, 32], ["Infection", "OBSERVATION", 35, 44], ["liver", "ANATOMY", 48, 53], ["enzyme", "OBSERVATION_MODIFIER", 54, 60], ["abnormalities", "OBSERVATION", 61, 74], ["primarily", "OBSERVATION_MODIFIER", 92, 101], ["hepatocellular", "OBSERVATION", 102, 116]]], ["The extreme elevations in transaminases with marked elevation in bilirubin narrow the differential diagnosis to a handful of disease entities, including: acute viral, autoimmune hepatitis, and drug-induced liver injury.", [["liver", "ANATOMY", 206, 211], ["bilirubin", "CHEMICAL", 65, 74], ["acute viral, autoimmune hepatitis", "DISEASE", 154, 187], ["liver injury", "DISEASE", 206, 218], ["bilirubin", "CHEMICAL", 65, 74], ["transaminases", "SIMPLE_CHEMICAL", 26, 39], ["bilirubin", "SIMPLE_CHEMICAL", 65, 74], ["liver", "ORGAN", 206, 211], ["The extreme elevations in transaminases", "PROBLEM", 0, 39], ["marked elevation in bilirubin", "PROBLEM", 45, 74], ["disease entities", "PROBLEM", 125, 141], ["acute viral, autoimmune hepatitis", "PROBLEM", 154, 187], ["drug-induced liver injury", "PROBLEM", 193, 218], ["extreme", "OBSERVATION_MODIFIER", 4, 11], ["elevations", "OBSERVATION_MODIFIER", 12, 22], ["transaminases", "ANATOMY", 26, 39], ["marked", "OBSERVATION_MODIFIER", 45, 51], ["elevation", "OBSERVATION_MODIFIER", 52, 61], ["bilirubin narrow", "OBSERVATION_MODIFIER", 65, 81], ["disease", "OBSERVATION", 125, 132], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["viral", "OBSERVATION", 160, 165], ["autoimmune hepatitis", "OBSERVATION", 167, 187], ["liver", "ANATOMY", 206, 211], ["injury", "OBSERVATION", 212, 218]]], ["Although the degree of injury would be categorized as \"severe\" based on the elevation in liver function tests and bilirubin, the patient does not fulfill criteria for acute liver failure as there is no evidence of encephalopathy or coagulopathy.", [["liver", "ANATOMY", 89, 94], ["liver", "ANATOMY", 173, 178], ["bilirubin", "CHEMICAL", 114, 123], ["acute liver failure", "DISEASE", 167, 186], ["encephalopathy", "DISEASE", 214, 228], ["coagulopathy", "DISEASE", 232, 244], ["bilirubin", "CHEMICAL", 114, 123], ["liver", "ORGAN", 89, 94], ["bilirubin", "SIMPLE_CHEMICAL", 114, 123], ["patient", "ORGANISM", 129, 136], ["liver", "ORGAN", 173, 178], ["patient", "SPECIES", 129, 136], ["injury", "PROBLEM", 23, 29], ["the elevation", "PROBLEM", 72, 85], ["liver function tests", "TEST", 89, 109], ["bilirubin", "TEST", 114, 123], ["acute liver failure", "PROBLEM", 167, 186], ["encephalopathy", "PROBLEM", 214, 228], ["coagulopathy", "PROBLEM", 232, 244], ["injury", "OBSERVATION", 23, 29], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["elevation", "OBSERVATION", 76, 85], ["liver", "ANATOMY", 89, 94], ["acute", "OBSERVATION_MODIFIER", 167, 172], ["liver", "ANATOMY", 173, 178], ["failure", "OBSERVATION", 179, 186], ["no evidence of", "UNCERTAINTY", 199, 213], ["encephalopathy", "OBSERVATION", 214, 228], ["coagulopathy", "OBSERVATION", 232, 244]]], ["In addition to supportive care and careful monitoring for evidence of impending liver failure, laboratory testing should be sent for hepatitis A, B, C and an autoimmune panel.", [["liver", "ANATOMY", 80, 85], ["liver failure", "DISEASE", 80, 93], ["hepatitis A", "DISEASE", 133, 144], ["liver", "ORGAN", 80, 85], ["B, C", "CELL", 146, 150], ["hepatitis A", "SPECIES", 133, 144], ["supportive care", "TREATMENT", 15, 30], ["careful monitoring", "TEST", 35, 53], ["impending liver failure", "PROBLEM", 70, 93], ["laboratory testing", "TEST", 95, 113], ["hepatitis A", "TEST", 133, 144], ["an autoimmune panel", "TEST", 155, 174], ["liver", "ANATOMY", 80, 85], ["failure", "OBSERVATION", 86, 93]]], ["A right upper quadrant ultrasound would be reasonable to ensure no evidence of underlying chronic liver disease.Answer: De Novo Acute Hepatitis B InfectionThe patient's serologies indicate acute hepatitis B infection.", [["right upper quadrant", "ANATOMY", 2, 22], ["liver", "ANATOMY", 98, 103], ["chronic liver disease", "DISEASE", 90, 111], ["Hepatitis B", "DISEASE", 134, 145], ["acute hepatitis B infection", "DISEASE", 189, 216], ["liver", "ORGAN", 98, 103], ["De Novo Acute Hepatitis B", "ORGANISM", 120, 145], ["patient", "ORGANISM", 159, 166], ["acute hepatitis B", "ORGANISM", 189, 206], ["patient", "SPECIES", 159, 166], ["A right upper quadrant ultrasound", "TEST", 0, 33], ["underlying chronic liver disease", "PROBLEM", 79, 111], ["Acute Hepatitis B Infection", "PROBLEM", 128, 155], ["The patient's serologies", "TEST", 155, 179], ["acute hepatitis B infection", "PROBLEM", 189, 216], ["right", "ANATOMY_MODIFIER", 2, 7], ["upper", "ANATOMY_MODIFIER", 8, 13], ["no evidence of", "UNCERTAINTY", 64, 78], ["chronic", "OBSERVATION_MODIFIER", 90, 97], ["liver", "ANATOMY", 98, 103], ["disease", "OBSERVATION", 104, 111], ["Hepatitis", "OBSERVATION", 134, 143], ["Infection", "OBSERVATION", 146, 155], ["acute", "OBSERVATION_MODIFIER", 189, 194], ["hepatitis", "OBSERVATION", 195, 204], ["infection", "OBSERVATION", 207, 216]]], ["The first detectable viral marker is HBsAg followed by hepatitis B e antigen (HBeAg) and HBV DNA.", [["HBsAg", "CHEMICAL", 37, 42], ["hepatitis B e antigen", "CHEMICAL", 55, 76], ["HBeAg", "CHEMICAL", 78, 83], ["HBsAg", "GENE_OR_GENE_PRODUCT", 37, 42], ["hepatitis B e antigen", "GENE_OR_GENE_PRODUCT", 55, 76], ["HBeAg", "GENE_OR_GENE_PRODUCT", 78, 83], ["HBV", "ORGANISM", 89, 92], ["DNA", "CELLULAR_COMPONENT", 93, 96], ["HBsAg", "PROTEIN", 37, 42], ["hepatitis B e antigen (HBeAg) and HBV DNA", "DNA", 55, 96], ["HBV", "SPECIES", 89, 92], ["HBsAg", "TEST", 37, 42], ["hepatitis B e antigen", "TEST", 55, 76], ["HBeAg", "TEST", 78, 83], ["HBV DNA", "PROBLEM", 89, 96], ["viral marker", "OBSERVATION", 21, 33], ["HBsAg", "OBSERVATION", 37, 42], ["HBV DNA", "OBSERVATION", 89, 96]]], ["Titers may be high during the incubation period, but HBV DNA and HBeAg levels begin to fall at the onset of illness and may be undetectable at the time of peak clinical illness.", [["HBeAg", "CHEMICAL", 65, 70], ["illness", "DISEASE", 108, 115], ["HBV", "ORGANISM", 53, 56], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["HBeAg", "GENE_OR_GENE_PRODUCT", 65, 70], ["HBV", "SPECIES", 53, 56], ["Titers", "TEST", 0, 6], ["HBV DNA", "PROBLEM", 53, 60], ["HBeAg levels", "TEST", 65, 77], ["illness", "PROBLEM", 108, 115], ["high", "OBSERVATION_MODIFIER", 14, 18]]], ["Core antigen does not appear in blood, but antibody to this antigen (anti-HBc) is detectable with the onset of clinical symptoms.", [["blood", "ANATOMY", 32, 37], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["antibody to this antigen", "GENE_OR_GENE_PRODUCT", 43, 67], ["anti-HBc", "GENE_OR_GENE_PRODUCT", 69, 77], ["HBc", "PROTEIN", 74, 77], ["Core antigen", "TEST", 0, 12], ["blood", "PROBLEM", 32, 37], ["antibody", "TEST", 43, 51], ["this antigen", "TEST", 55, 67], ["anti-HBc", "TEST", 69, 77], ["clinical symptoms", "PROBLEM", 111, 128], ["does not appear", "UNCERTAINTY", 13, 28]]], ["The positive IgM antibody is the hallmark of an acute hepatitis B infection.Answer: De Novo Acute Hepatitis B InfectionThe Center for Diseases Control estimate between 140 and 320,000 cases of acute hepatitis B yearly in the USA.", [["acute hepatitis B infection", "DISEASE", 48, 75], ["Hepatitis B", "DISEASE", 98, 109], ["acute hepatitis B", "DISEASE", 193, 210], ["IgM", "GENE_OR_GENE_PRODUCT", 13, 16], ["hepatitis B", "ORGANISM", 54, 65], ["positive IgM antibody", "PROTEIN", 4, 25], ["hepatitis B", "SPECIES", 54, 65], ["The positive IgM antibody", "TEST", 0, 25], ["an acute hepatitis B infection", "PROBLEM", 45, 75], ["Acute Hepatitis B Infection", "PROBLEM", 92, 119], ["Diseases Control estimate", "TEST", 134, 159], ["acute hepatitis B", "PROBLEM", 193, 210], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["IgM antibody", "OBSERVATION", 13, 25], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["hepatitis", "OBSERVATION", 54, 63], ["infection", "OBSERVATION", 66, 75], ["Acute", "OBSERVATION_MODIFIER", 92, 97], ["Hepatitis", "OBSERVATION", 98, 107], ["Infection", "OBSERVATION", 110, 119], ["acute", "OBSERVATION_MODIFIER", 193, 198], ["hepatitis", "OBSERVATION", 199, 208]]], ["About 30% of patients develop symptoms with nearly 15,000 requiring hospitalization.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["symptoms", "PROBLEM", 30, 38]]], ["Symptoms usually develop 2-4 months following exposure to the virus.", [["Symptoms", "PROBLEM", 0, 8], ["the virus", "PROBLEM", 58, 67]]], ["Transmission of the virus is predominantly via sexual contact, percutaneous exposure (IVDU), or vertical transmission (mother to child).", [["percutaneous", "ANATOMY", 63, 75], ["the virus", "PROBLEM", 16, 25], ["virus", "OBSERVATION", 20, 25]]], ["As is the case in the patient above, a significant number of times the etiology of transmission is never determined.", [["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["significant", "OBSERVATION_MODIFIER", 39, 50]]], ["The highest concentration of the virus is found in blood, semen, vaginal discharge, breast milk, and saliva.", [["blood", "ANATOMY", 51, 56], ["semen", "ANATOMY", 58, 63], ["vaginal", "ANATOMY", 65, 72], ["breast milk", "ANATOMY", 84, 95], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["semen", "ORGANISM_SUBSTANCE", 58, 63], ["vaginal", "ORGANISM_SUBDIVISION", 65, 72], ["breast milk", "ORGANISM_SUBSTANCE", 84, 95], ["saliva", "ORGANISM_SUBSTANCE", 101, 107], ["the virus", "PROBLEM", 29, 38], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["concentration", "OBSERVATION_MODIFIER", 12, 25], ["virus", "OBSERVATION", 33, 38], ["vaginal", "ANATOMY", 65, 72], ["breast", "ANATOMY", 84, 90]]], ["The time period between exposure and onset of symptoms is referred to the \"incubation period.\"", [["symptoms", "PROBLEM", 46, 54]]], ["The most common symptoms are fatigue, anorexia, abdominal pain, and jaundice.", [["abdominal", "ANATOMY", 48, 57], ["fatigue", "DISEASE", 29, 36], ["anorexia", "DISEASE", 38, 46], ["abdominal pain", "DISEASE", 48, 62], ["jaundice", "DISEASE", 68, 76], ["abdominal", "ORGANISM_SUBDIVISION", 48, 57], ["The most common symptoms", "PROBLEM", 0, 24], ["fatigue", "PROBLEM", 29, 36], ["anorexia", "PROBLEM", 38, 46], ["abdominal pain", "PROBLEM", 48, 62], ["jaundice", "PROBLEM", 68, 76], ["fatigue", "OBSERVATION", 29, 36], ["anorexia", "OBSERVATION", 38, 46], ["abdominal", "ANATOMY", 48, 57], ["pain", "OBSERVATION", 58, 62], ["jaundice", "OBSERVATION", 68, 76]]], ["As opposed to hepatitis A infection, fever is uncommon in HBV.Answer: De Novo Acute Hepatitis B InfectionAST and ALT levels increase to between 500 and 5,000 iu/l and fall after the acute phase.", [["hepatitis A infection", "DISEASE", 14, 35], ["fever", "DISEASE", 37, 42], ["Hepatitis B", "DISEASE", 84, 95], ["hepatitis A", "ORGANISM", 14, 25], ["HBV", "ORGANISM", 58, 61], ["De Novo Acute Hepatitis B", "ORGANISM", 70, 95], ["ALT", "SIMPLE_CHEMICAL", 113, 116], ["hepatitis A", "SPECIES", 14, 25], ["HBV", "SPECIES", 58, 61], ["hepatitis A infection", "PROBLEM", 14, 35], ["fever", "PROBLEM", 37, 42], ["HBV", "PROBLEM", 58, 61], ["De Novo Acute Hepatitis B InfectionAST", "PROBLEM", 70, 108], ["ALT levels", "TEST", 113, 123], ["fall", "PROBLEM", 167, 171], ["hepatitis", "OBSERVATION", 14, 23], ["infection", "OBSERVATION", 26, 35], ["Acute", "OBSERVATION_MODIFIER", 78, 83], ["Hepatitis", "OBSERVATION", 84, 93]]], ["Serum bilirubin seldom increases above 10 mg/dl.", [["Serum", "ANATOMY", 0, 5], ["bilirubin", "CHEMICAL", 6, 15], ["bilirubin", "CHEMICAL", 6, 15], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["bilirubin", "GENE_OR_GENE_PRODUCT", 6, 15], ["Serum bilirubin seldom", "TEST", 0, 22]]], ["Alkaline phosphatase and prothrombin time are usually normal or mildly elevated.Answer: De Novo Acute Hepatitis B InfectionThe virus is spontaneously cleared in 95% of adults with acute infection, with the remainder of individuals developing chronic infection.", [["Hepatitis B", "DISEASE", 102, 113], ["acute infection", "DISEASE", 180, 195], ["chronic infection", "DISEASE", 242, 259], ["Alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 0, 20], ["prothrombin", "GENE_OR_GENE_PRODUCT", 25, 36], ["De Novo Acute Hepatitis B", "ORGANISM", 88, 113], ["Alkaline phosphatase", "PROTEIN", 0, 20], ["prothrombin", "PROTEIN", 25, 36], ["Alkaline phosphatase", "TEST", 0, 20], ["prothrombin time", "TEST", 25, 41], ["mildly elevated", "PROBLEM", 64, 79], ["Acute Hepatitis B Infection", "PROBLEM", 96, 123], ["The virus", "PROBLEM", 123, 132], ["acute infection", "PROBLEM", 180, 195], ["chronic infection", "PROBLEM", 242, 259], ["mildly", "OBSERVATION_MODIFIER", 64, 70], ["elevated", "OBSERVATION_MODIFIER", 71, 79], ["Hepatitis", "OBSERVATION", 102, 111], ["Infection", "OBSERVATION", 114, 123], ["virus", "OBSERVATION", 127, 132], ["spontaneously", "OBSERVATION_MODIFIER", 136, 149], ["cleared", "OBSERVATION_MODIFIER", 150, 157], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["infection", "OBSERVATION", 186, 195], ["chronic", "OBSERVATION_MODIFIER", 242, 249], ["infection", "OBSERVATION", 250, 259]]], ["This is in contrast to neonates and children infected with hepatitis B where a majority will develop chronic infection.", [["hepatitis B", "DISEASE", 59, 70], ["chronic infection", "DISEASE", 101, 118], ["neonates", "ORGANISM", 23, 31], ["children", "ORGANISM", 36, 44], ["hepatitis B", "ORGANISM", 59, 70], ["children", "SPECIES", 36, 44], ["hepatitis B", "SPECIES", 59, 70], ["hepatitis B", "PROBLEM", 59, 70], ["chronic infection", "PROBLEM", 101, 118], ["hepatitis", "OBSERVATION", 59, 68], ["chronic", "OBSERVATION_MODIFIER", 101, 108], ["infection", "OBSERVATION", 109, 118]]], ["Because of the natural history and spontaneous clearance, treatment is almost never needed in adults with acute hepatitis B infection.", [["acute hepatitis B infection", "DISEASE", 106, 133], ["acute hepatitis B", "ORGANISM", 106, 123], ["spontaneous clearance", "PROBLEM", 35, 56], ["treatment", "TREATMENT", 58, 67], ["acute hepatitis B infection", "PROBLEM", 106, 133], ["acute", "OBSERVATION_MODIFIER", 106, 111], ["hepatitis", "OBSERVATION", 112, 121], ["infection", "OBSERVATION", 124, 133]]], ["Although some small studies suggest that antivirals such as lamivudine may prevent the progression of severe infection to fulminant status and because of their excellent safety profile may be considered in rare, severe cases.", [["lamivudine", "CHEMICAL", 60, 70], ["infection", "DISEASE", 109, 118], ["lamivudine", "CHEMICAL", 60, 70], ["lamivudine", "SIMPLE_CHEMICAL", 60, 70], ["some small studies", "TEST", 9, 27], ["antivirals", "TREATMENT", 41, 51], ["lamivudine", "TREATMENT", 60, 70], ["severe infection to fulminant status", "PROBLEM", 102, 138], ["small", "OBSERVATION_MODIFIER", 14, 19], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["infection", "OBSERVATION", 109, 118]]], ["Acute liver failure develops in 0.5-2% and is associated with fatality in up to 93% of cases without liver transplantation.Answer: De Novo Acute Hepatitis B InfectionFrom 1990 to 2002, the incidence of reported cases of acute hepatitis B declined by 67% secondary to routine vaccination in children and adolescents.", [["liver", "ANATOMY", 6, 11], ["liver", "ANATOMY", 101, 106], ["Acute liver failure", "DISEASE", 0, 19], ["Hepatitis B", "DISEASE", 145, 156], ["acute hepatitis B", "DISEASE", 220, 237], ["liver", "ORGAN", 6, 11], ["liver", "ORGAN", 101, 106], ["children", "ORGANISM", 290, 298], ["children", "SPECIES", 290, 298], ["adolescents", "SPECIES", 303, 314], ["Acute liver failure", "PROBLEM", 0, 19], ["liver transplantation", "TREATMENT", 101, 122], ["Acute Hepatitis B InfectionFrom", "PROBLEM", 139, 170], ["acute hepatitis B", "PROBLEM", 220, 237], ["routine vaccination", "TREATMENT", 267, 286], ["liver", "ANATOMY", 6, 11], ["failure", "OBSERVATION", 12, 19], ["liver", "ANATOMY", 101, 106], ["transplantation", "OBSERVATION", 107, 122], ["Acute", "OBSERVATION_MODIFIER", 139, 144], ["Hepatitis", "OBSERVATION", 145, 154], ["acute", "OBSERVATION_MODIFIER", 220, 225], ["hepatitis", "OBSERVATION", 226, 235]]], ["The incidence, however, has increased by 5% in men above the age of 19, 20% in men above the age of 40, and 30% in women above the age of 40.", [["men", "ORGANISM", 47, 50], ["men", "ORGANISM", 79, 82], ["women", "ORGANISM", 115, 120], ["men", "SPECIES", 47, 50], ["men", "SPECIES", 79, 82], ["women", "SPECIES", 115, 120], ["increased", "OBSERVATION_MODIFIER", 28, 37]]], ["The highest incidence is seen in African Americans and Hispanics.Answer: De Novo Acute Hepatitis B InfectionThe gentleman in this case was discharged on hospital day 4 when his enzymes began a downward trend.", [["Hepatitis B", "DISEASE", 87, 98], ["De Novo Acute Hepatitis B", "ORGANISM", 73, 98], ["Acute Hepatitis B Infection", "PROBLEM", 81, 108], ["his enzymes", "TEST", 173, 184], ["a downward trend", "PROBLEM", 191, 207], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["Hepatitis", "OBSERVATION", 87, 96], ["Infection", "OBSERVATION", 99, 108]]], ["Recommendations were given to the patient and his family to avoid sharing of razor blades and toothbrushes.", [["patient", "ORGANISM", 34, 41], ["patient", "SPECIES", 34, 41], ["razor blades", "TREATMENT", 77, 89], ["toothbrushes", "TREATMENT", 94, 106]]], ["His spouse was vaccinated against HBV.Answer: De Novo Acute Hepatitis B InfectionThe patient was seen in follow-up and at 4 months he developed complete normalization of his enzymes and seroconversion with the appearance of surface antibody:Answer: De Novo Acute Hepatitis B InfectionHBsAg \u2212, anti HBs 290 miu/ml, anti HBcore total +, anti HBcore IgM \u2212, HBeAg \u2212, HBeAb +, HBV DNA undetectable.Case 37A 53-year-old man presents to the emergency room with hematemesis.", [["surface", "ANATOMY", 224, 231], ["Hepatitis B", "DISEASE", 60, 71], ["Hepatitis B", "DISEASE", 263, 274], ["HBeAg", "CHEMICAL", 354, 359], ["hematemesis", "DISEASE", 454, 465], ["HBV", "ORGANISM", 34, 37], ["De Novo Acute Hepatitis B", "ORGANISM", 46, 71], ["patient", "ORGANISM", 85, 92], ["Hepatitis B", "ORGANISM", 263, 274], ["HBs", "ORGANISM", 298, 301], ["HBeAg", "GENE_OR_GENE_PRODUCT", 354, 359], ["HBeAb", "SIMPLE_CHEMICAL", 363, 368], ["HBV", "ORGANISM", 372, 375], ["DNA", "CELLULAR_COMPONENT", 376, 379], ["man", "ORGANISM", 414, 417], ["surface antibody", "PROTEIN", 224, 240], ["IgM", "PROTEIN", 347, 350], ["HBeAb", "PROTEIN", 363, 368], ["patient", "SPECIES", 85, 92], ["man", "SPECIES", 414, 417], ["HBV", "SPECIES", 34, 37], ["HBV", "SPECIES", 372, 375], ["HBV", "PROBLEM", 34, 37], ["Acute Hepatitis B Infection", "PROBLEM", 54, 81], ["his enzymes", "TEST", 170, 181], ["seroconversion", "TREATMENT", 186, 200], ["De Novo Acute Hepatitis B InfectionHBsAg", "PROBLEM", 249, 289], ["anti HBs", "TEST", 293, 301], ["anti HBcore total", "TEST", 314, 331], ["anti HBcore IgM", "TEST", 335, 350], ["HBeAg", "TEST", 354, 359], ["HBeAb", "TEST", 363, 368], ["HBV DNA", "PROBLEM", 372, 379], ["hematemesis", "PROBLEM", 454, 465], ["Hepatitis", "OBSERVATION", 60, 69], ["Infection", "OBSERVATION", 72, 81], ["Hepatitis", "OBSERVATION", 263, 272], ["hematemesis", "OBSERVATION", 454, 465]]], ["He has a history of cryptogenic cirrhosis and has been evaluated for liver transplant in the past but was felt to be early based on a low MELD score.Case 37His wife is with him and states that he was feeling fine up until a few hours ago when he started complaining of some abdominal discomfort.", [["liver", "ANATOMY", 69, 74], ["abdominal", "ANATOMY", 274, 283], ["cirrhosis", "DISEASE", 32, 41], ["abdominal discomfort", "DISEASE", 274, 294], ["liver", "ORGAN", 69, 74], ["abdominal", "ORGANISM_SUBDIVISION", 274, 283], ["cryptogenic cirrhosis", "PROBLEM", 20, 41], ["liver transplant", "TREATMENT", 69, 85], ["a low MELD score", "PROBLEM", 132, 148], ["some abdominal discomfort", "PROBLEM", 269, 294], ["cryptogenic", "OBSERVATION_MODIFIER", 20, 31], ["cirrhosis", "OBSERVATION", 32, 41], ["liver", "ANATOMY", 69, 74], ["transplant", "OBSERVATION", 75, 85], ["abdominal", "ANATOMY", 274, 283], ["discomfort", "OBSERVATION", 284, 294]]], ["There has been no fever or chills and as far as she is aware, his bowels have been moving normally without blood or change in stool color.", [["bowels", "ANATOMY", 66, 72], ["blood", "ANATOMY", 107, 112], ["fever", "DISEASE", 18, 23], ["chills", "DISEASE", 27, 33], ["bowels", "ORGANISM_SUBDIVISION", 66, 72], ["blood", "ORGANISM_SUBSTANCE", 107, 112], ["stool", "ORGANISM_SUBDIVISION", 126, 131], ["fever", "PROBLEM", 18, 23], ["chills", "PROBLEM", 27, 33], ["blood", "PROBLEM", 107, 112], ["change in stool color", "PROBLEM", 116, 137], ["no", "UNCERTAINTY", 15, 17], ["fever", "OBSERVATION_MODIFIER", 18, 23], ["chills", "OBSERVATION", 27, 33], ["bowels", "ANATOMY", 66, 72], ["stool color", "OBSERVATION", 126, 137]]], ["His appetite has been good and there has been no weight loss.Case 37His liver disease has been well compensated in the past and his only medication includes a small dose of beta-blocker.Case 37He does not smoke or drink and works fulltime.Case 37In the ER, he looks comfortable but anxious.", [["liver", "ANATOMY", 72, 77], ["weight loss", "DISEASE", 49, 60], ["liver disease", "DISEASE", 72, 85], ["liver", "ORGAN", 72, 77], ["ER", "GENE_OR_GENE_PRODUCT", 253, 255], ["ER", "PROTEIN", 253, 255], ["weight loss", "PROBLEM", 49, 60], ["liver disease", "PROBLEM", 72, 85], ["medication", "TREATMENT", 137, 147], ["a small dose of beta-blocker", "TREATMENT", 157, 185], ["anxious", "PROBLEM", 282, 289], ["good", "OBSERVATION_MODIFIER", 22, 26], ["no", "UNCERTAINTY", 46, 48], ["weight loss", "OBSERVATION", 49, 60], ["liver", "ANATOMY", 72, 77], ["disease", "OBSERVATION", 78, 85], ["compensated", "OBSERVATION_MODIFIER", 100, 111]]], ["His vital signs are BP 110-75, pulse 64 and he is afebrile.Case 37He has a few spider nevi but no scleral icterus.", [["nevi", "ANATOMY", 86, 90], ["scleral", "ANATOMY", 98, 105], ["spider nevi", "DISEASE", 79, 90], ["scleral icterus", "DISEASE", 98, 113], ["BP 110-75", "CHEMICAL", 20, 29], ["His vital signs", "TEST", 0, 15], ["BP", "TEST", 20, 22], ["pulse", "TEST", 31, 36], ["afebrile", "PROBLEM", 50, 58], ["scleral icterus", "PROBLEM", 98, 113], ["afebrile", "OBSERVATION", 50, 58], ["few", "OBSERVATION_MODIFIER", 75, 78], ["spider nevi", "OBSERVATION", 79, 90], ["no", "UNCERTAINTY", 95, 97], ["scleral", "ANATOMY", 98, 105], ["icterus", "OBSERVATION", 106, 113]]], ["His heart and lungs are normal.", [["heart", "ANATOMY", 4, 9], ["lungs", "ANATOMY", 14, 19], ["heart", "ORGAN", 4, 9], ["lungs", "ORGAN", 14, 19], ["heart", "ANATOMY", 4, 9], ["lungs", "ANATOMY", 14, 19], ["normal", "OBSERVATION", 24, 30]]], ["Abdominal examination demonstrates an enlarged liver and spleen but no ascites or ankle edema.", [["Abdominal", "ANATOMY", 0, 9], ["liver", "ANATOMY", 47, 52], ["spleen", "ANATOMY", 57, 63], ["ascites", "ANATOMY", 71, 78], ["ankle edema", "ANATOMY", 82, 93], ["enlarged liver and spleen", "DISEASE", 38, 63], ["ascites", "DISEASE", 71, 78], ["ankle edema", "DISEASE", 82, 93], ["liver", "ORGAN", 47, 52], ["spleen", "ORGAN", 57, 63], ["ankle edema", "PATHOLOGICAL_FORMATION", 82, 93], ["Abdominal examination", "TEST", 0, 21], ["an enlarged liver and spleen", "PROBLEM", 35, 63], ["ascites", "PROBLEM", 71, 78], ["ankle edema", "PROBLEM", 82, 93], ["enlarged", "OBSERVATION", 38, 46], ["liver", "ANATOMY", 47, 52], ["spleen", "ANATOMY", 57, 63], ["no", "UNCERTAINTY", 68, 70], ["ascites", "OBSERVATION", 71, 78], ["ankle", "ANATOMY", 82, 87], ["edema", "OBSERVATION", 88, 93]]], ["While being examined, he has another episode of hematemesis with what appears to be a very large amount of fresh blood and clots.Initial Laboratory StudiesHb 7.4 g/dl Platelets 56,000/\u03bcl INR 1.5 Tbili 1.9 mg/dl AST 38 iu/l ALT 32 iu/l ALP 101 iu/l GGT 49 iu/l Albumin 2.9 g/dl Creatinine 0.8 mg/dl He is emergently intubated, resuscitated and transferred to the intensive care unit and started on a somatostatin analogue, and antibiotics.", [["blood", "ANATOMY", 113, 118], ["clots", "ANATOMY", 123, 128], ["hematemesis", "DISEASE", 48, 59], ["Creatinine", "CHEMICAL", 277, 287], ["Creatinine", "CHEMICAL", 277, 287], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["clots", "ORGANISM_SUBSTANCE", 123, 128], ["Albumin", "GENE_OR_GENE_PRODUCT", 260, 267], ["Creatinine", "SIMPLE_CHEMICAL", 277, 287], ["He", "ORGANISM", 298, 300], ["somatostatin", "GENE_OR_GENE_PRODUCT", 399, 411], ["ALP", "PROTEIN", 235, 238], ["hematemesis", "PROBLEM", 48, 59], ["fresh blood", "PROBLEM", 107, 118], ["clots", "PROBLEM", 123, 128], ["StudiesHb", "TEST", 148, 157], ["Platelets", "TEST", 167, 176], ["\u03bcl", "TEST", 184, 186], ["INR", "TEST", 187, 190], ["Tbili", "TEST", 195, 200], ["mg", "TEST", 205, 207], ["dl", "TEST", 208, 210], ["AST", "TEST", 211, 214], ["iu", "TEST", 218, 220], ["ALT", "TEST", 223, 226], ["iu", "TEST", 230, 232], ["ALP", "TEST", 235, 238], ["iu", "TEST", 243, 245], ["GGT", "TEST", 248, 251], ["iu", "TEST", 255, 257], ["Albumin", "TEST", 260, 267], ["Creatinine", "TEST", 277, 287], ["intubated", "TREATMENT", 315, 324], ["a somatostatin analogue", "TREATMENT", 397, 420], ["antibiotics", "TREATMENT", 426, 437], ["hematemesis", "OBSERVATION", 48, 59], ["very", "OBSERVATION_MODIFIER", 86, 90], ["large", "OBSERVATION_MODIFIER", 91, 96], ["amount", "OBSERVATION_MODIFIER", 97, 103], ["fresh blood", "OBSERVATION", 107, 118], ["clots", "OBSERVATION", 123, 128]]], ["Endoscopy shows actively bleeding large esophageal varices and a large amount of fresh blood and clot in the stomach obscuring the fundus.", [["esophageal varices", "ANATOMY", 40, 58], ["blood", "ANATOMY", 87, 92], ["clot", "ANATOMY", 97, 101], ["stomach", "ANATOMY", 109, 116], ["fundus", "ANATOMY", 131, 137], ["bleeding", "DISEASE", 25, 33], ["esophageal varices", "DISEASE", 40, 58], ["esophageal varices", "PATHOLOGICAL_FORMATION", 40, 58], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["clot", "ORGANISM_SUBSTANCE", 97, 101], ["stomach", "ORGAN", 109, 116], ["fundus", "MULTI-TISSUE_STRUCTURE", 131, 137], ["Endoscopy", "TEST", 0, 9], ["actively bleeding large esophageal varices", "PROBLEM", 16, 58], ["fresh blood", "PROBLEM", 81, 92], ["clot in the stomach", "PROBLEM", 97, 116], ["actively", "OBSERVATION_MODIFIER", 16, 24], ["bleeding", "OBSERVATION_MODIFIER", 25, 33], ["large", "OBSERVATION_MODIFIER", 34, 39], ["esophageal", "ANATOMY", 40, 50], ["varices", "OBSERVATION", 51, 58], ["large", "OBSERVATION_MODIFIER", 65, 70], ["amount", "OBSERVATION_MODIFIER", 71, 77], ["fresh blood", "OBSERVATION", 81, 92], ["clot", "OBSERVATION", 97, 101], ["stomach", "ANATOMY", 109, 116], ["fundus", "ANATOMY", 131, 137]]], ["Despite several attempts at endoscopic treatment, the bleeding cannot be controlled.Questions1.", [["bleeding", "DISEASE", 54, 62], ["endoscopic treatment", "TREATMENT", 28, 48], ["the bleeding", "PROBLEM", 50, 62], ["bleeding", "OBSERVATION", 54, 62]]], ["What imaging is required in the ICU?Answer: Transjugular Intrahepatic Portosystemic Shunt (TIPS) as Salvage Therapy for Variceal BleedingThis gentleman has a life-threatening problem.", [["Variceal", "ANATOMY", 120, 128], ["Transjugular Intrahepatic Portosystemic Shunt", "DISEASE", 44, 89], ["Bleeding", "DISEASE", 129, 137], ["What imaging", "TEST", 0, 12], ["Transjugular Intrahepatic Portosystemic Shunt (TIPS)", "TREATMENT", 44, 96], ["Salvage Therapy", "TREATMENT", 100, 115], ["Variceal Bleeding", "PROBLEM", 120, 137], ["Transjugular", "ANATOMY_MODIFIER", 44, 56], ["Intrahepatic", "ANATOMY", 57, 69], ["Portosystemic Shunt", "OBSERVATION", 70, 89]]], ["He has actively bleeding esophageal varices that cannot be controlled despite pharmacological therapy with a somatostatin analogue (in the USA this would typically be octreotide) and endoscopic therapy.", [["esophageal varices", "ANATOMY", 25, 43], ["bleeding esophageal varices", "DISEASE", 16, 43], ["octreotide", "CHEMICAL", 167, 177], ["somatostatin", "CHEMICAL", 109, 121], ["octreotide", "CHEMICAL", 167, 177], ["esophageal varices", "PATHOLOGICAL_FORMATION", 25, 43], ["somatostatin analogue", "SIMPLE_CHEMICAL", 109, 130], ["octreotide", "SIMPLE_CHEMICAL", 167, 177], ["actively bleeding esophageal varices", "PROBLEM", 7, 43], ["pharmacological therapy", "TREATMENT", 78, 101], ["a somatostatin analogue", "TREATMENT", 107, 130], ["octreotide", "TREATMENT", 167, 177], ["endoscopic therapy", "TREATMENT", 183, 201], ["actively", "OBSERVATION_MODIFIER", 7, 15], ["bleeding", "OBSERVATION_MODIFIER", 16, 24], ["esophageal", "ANATOMY", 25, 35], ["varices", "OBSERVATION", 36, 43]]], ["In addition, he may have bleeding gastric varices but the fundus is obscured.", [["gastric varices", "ANATOMY", 34, 49], ["fundus", "ANATOMY", 58, 64], ["bleeding gastric varices", "DISEASE", 25, 49], ["gastric varices", "PATHOLOGICAL_FORMATION", 34, 49], ["fundus", "MULTI-TISSUE_STRUCTURE", 58, 64], ["bleeding gastric varices", "PROBLEM", 25, 49], ["bleeding", "OBSERVATION_MODIFIER", 25, 33], ["gastric", "ANATOMY", 34, 41], ["varices", "OBSERVATION", 42, 49], ["fundus", "ANATOMY", 58, 64], ["obscured", "OBSERVATION_MODIFIER", 68, 76]]], ["Endoscopic treatment of bleeding esophageal varices is successful 80-90% of the time, but this figure is not nearly as high with gastric variceal bleeding.Answer: Transjugular Intrahepatic Portosystemic Shunt (TIPS) as Salvage Therapy for Variceal BleedingThe definition of failure of endoscopic therapy is controversial but most authorities would agree that inability to stop bleeding with two endoscopies within 14 days is reasonable.", [["bleeding esophageal varices", "ANATOMY", 24, 51], ["gastric", "ANATOMY", 129, 136], ["Variceal", "ANATOMY", 239, 247], ["bleeding esophageal varices", "DISEASE", 24, 51], ["gastric variceal bleeding", "DISEASE", 129, 154], ["Transjugular Intrahepatic Portosystemic Shunt", "DISEASE", 163, 208], ["Variceal Bleeding", "DISEASE", 239, 256], ["bleeding", "DISEASE", 377, 385], ["esophageal varices", "PATHOLOGICAL_FORMATION", 33, 51], ["gastric variceal", "PATHOLOGICAL_FORMATION", 129, 145], ["Endoscopic treatment", "TREATMENT", 0, 20], ["bleeding esophageal varices", "PROBLEM", 24, 51], ["gastric variceal bleeding", "PROBLEM", 129, 154], ["Transjugular Intrahepatic Portosystemic Shunt (TIPS)", "TREATMENT", 163, 215], ["Salvage Therapy", "TREATMENT", 219, 234], ["Variceal Bleeding", "PROBLEM", 239, 256], ["endoscopic therapy", "TREATMENT", 285, 303], ["inability to stop bleeding", "PROBLEM", 359, 385], ["two endoscopies", "TEST", 391, 406], ["bleeding", "OBSERVATION_MODIFIER", 24, 32], ["esophageal", "ANATOMY", 33, 43], ["varices", "OBSERVATION", 44, 51], ["gastric", "ANATOMY", 129, 136], ["variceal bleeding", "OBSERVATION", 137, 154], ["Transjugular", "ANATOMY_MODIFIER", 163, 175], ["Intrahepatic", "ANATOMY", 176, 188], ["Portosystemic Shunt", "OBSERVATION", 189, 208]]], ["This patient has failed endoscopic therapy since he continues to bleed even after the first procedure.", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["endoscopic therapy", "TREATMENT", 24, 42], ["bleed", "PROBLEM", 65, 70], ["the first procedure", "TREATMENT", 82, 101], ["bleed", "OBSERVATION", 65, 70]]], ["An appropriate intervention for short-term cessation of bleeding at this time would be balloon tamponade.", [["bleeding", "DISEASE", 56, 64], ["An appropriate intervention", "TREATMENT", 0, 27], ["bleeding", "PROBLEM", 56, 64], ["balloon tamponade", "PROBLEM", 87, 104], ["bleeding", "OBSERVATION", 56, 64], ["balloon", "OBSERVATION_MODIFIER", 87, 94], ["tamponade", "OBSERVATION", 95, 104]]], ["Several balloons are available including the Sengstaken-Blakemore tube (which has gastric and esophageal balloons and a single gastric suction port), the Minnesota tube (a Sengstaken-Blakemore tube with an esophageal suction port as well), and the Linton-Nachlas tube (which has a single gastric balloon).", [["gastric", "ANATOMY", 82, 89], ["esophageal", "ANATOMY", 94, 104], ["gastric", "ANATOMY", 127, 134], ["esophageal", "ANATOMY", 206, 216], ["gastric", "ANATOMY", 288, 295], ["tube", "TISSUE", 66, 70], ["gastric", "MULTI-TISSUE_STRUCTURE", 82, 89], ["esophageal", "ORGAN", 94, 104], ["gastric", "ORGAN", 127, 134], ["tube", "TISSUE", 164, 168], ["tube", "TISSUE", 193, 197], ["esophageal", "ORGAN", 206, 216], ["Nachlas tube", "TISSUE", 255, 267], ["gastric", "ORGAN", 288, 295], ["Several balloons", "TREATMENT", 0, 16], ["the Sengstaken-Blakemore tube", "TREATMENT", 41, 70], ["gastric and esophageal balloons", "TREATMENT", 82, 113], ["a single gastric suction port", "TREATMENT", 118, 147], ["the Minnesota tube", "TREATMENT", 150, 168], ["a Sengstaken-Blakemore tube", "TREATMENT", 170, 197], ["an esophageal suction port", "TREATMENT", 203, 229], ["the Linton-Nachlas tube", "TREATMENT", 244, 267], ["a single gastric balloon", "TREATMENT", 279, 303], ["balloons", "OBSERVATION", 8, 16], ["Blakemore tube", "OBSERVATION", 56, 70], ["gastric", "ANATOMY", 82, 89], ["esophageal", "ANATOMY", 94, 104], ["balloons", "OBSERVATION", 105, 113], ["gastric", "ANATOMY", 127, 134], ["suction", "OBSERVATION", 135, 142], ["Minnesota tube", "OBSERVATION", 154, 168], ["tube", "OBSERVATION", 193, 197], ["esophageal", "ANATOMY", 206, 216], ["suction", "OBSERVATION", 217, 224], ["Nachlas tube", "OBSERVATION", 255, 267], ["gastric", "ANATOMY", 288, 295], ["balloon", "OBSERVATION", 296, 303]]], ["These can be used for 12-24 h to control ongoing bleeding.", [["bleeding", "DISEASE", 49, 57], ["ongoing bleeding", "PROBLEM", 41, 57], ["bleeding", "OBSERVATION", 49, 57]]], ["At some point, the patient should get a bedside ultrasound to ensure that the portal vein is patent.Answer: Transjugular Intrahepatic Portosystemic Shunt (TIPS) as Salvage Therapy for Variceal BleedingFigures 37.1-37.3 show insertion of a TIPS which involves the creation of a lowresistance connection between the hepatic vein and the intrahepatic portion of the portal vein by an interventional radiologist.", [["portal vein", "ANATOMY", 78, 89], ["hepatic vein", "ANATOMY", 314, 326], ["intrahepatic portion", "ANATOMY", 335, 355], ["portal vein", "ANATOMY", 363, 374], ["patient", "ORGANISM", 19, 26], ["portal vein", "MULTI-TISSUE_STRUCTURE", 78, 89], ["hepatic vein", "MULTI-TISSUE_STRUCTURE", 314, 326], ["intrahepatic portion", "MULTI-TISSUE_STRUCTURE", 335, 355], ["portal vein", "MULTI-TISSUE_STRUCTURE", 363, 374], ["patient", "SPECIES", 19, 26], ["a bedside ultrasound", "TEST", 38, 58], ["Transjugular Intrahepatic Portosystemic Shunt (TIPS)", "TREATMENT", 108, 160], ["Salvage Therapy", "TREATMENT", 164, 179], ["Variceal BleedingFigures", "TEST", 184, 208], ["a TIPS", "TREATMENT", 237, 243], ["portal vein", "ANATOMY", 78, 89], ["patent", "OBSERVATION", 93, 99], ["Transjugular", "ANATOMY_MODIFIER", 108, 120], ["Intrahepatic", "ANATOMY", 121, 133], ["Portosystemic Shunt", "OBSERVATION", 134, 153], ["TIPS", "OBSERVATION_MODIFIER", 239, 243], ["lowresistance", "OBSERVATION", 277, 290], ["hepatic vein", "ANATOMY", 314, 326], ["intrahepatic", "ANATOMY_MODIFIER", 335, 347], ["portal vein", "ANATOMY", 363, 374]]], ["The connection is kept patent by the deployment of an expandable metal stent across it, so that some of the portal venous blood flow is shunted to the systemic circulation, thereby decreasing portal pressure and decreasing variceal bleeding.", [["portal venous blood", "ANATOMY", 108, 127], ["portal", "ANATOMY", 192, 198], ["variceal", "ANATOMY", 223, 231], ["bleeding", "DISEASE", 232, 240], ["portal venous", "MULTI-TISSUE_STRUCTURE", 108, 121], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["portal", "MULTI-TISSUE_STRUCTURE", 192, 198], ["an expandable metal stent", "TREATMENT", 51, 76], ["the portal venous blood flow", "TEST", 104, 132], ["decreasing portal pressure", "PROBLEM", 181, 207], ["decreasing variceal bleeding", "PROBLEM", 212, 240], ["patent", "OBSERVATION", 23, 29], ["expandable", "OBSERVATION_MODIFIER", 54, 64], ["metal stent", "OBSERVATION", 65, 76], ["portal venous", "ANATOMY", 108, 121], ["blood flow", "OBSERVATION", 122, 132], ["systemic circulation", "ANATOMY", 151, 171], ["decreasing", "OBSERVATION_MODIFIER", 181, 191], ["portal pressure", "OBSERVATION", 192, 207], ["decreasing", "OBSERVATION_MODIFIER", 212, 222], ["variceal bleeding", "OBSERVATION", 223, 240]]], ["Several studies have shown that TIPS is very effective for refractory variceal hemorrhage.", [["variceal", "ANATOMY", 70, 78], ["variceal hemorrhage", "DISEASE", 70, 89], ["variceal hemorrhage", "PATHOLOGICAL_FORMATION", 70, 89], ["Several studies", "TEST", 0, 15], ["TIPS", "TREATMENT", 32, 36], ["refractory variceal hemorrhage", "PROBLEM", 59, 89], ["TIPS", "OBSERVATION_MODIFIER", 32, 36], ["variceal", "OBSERVATION_MODIFIER", 70, 78], ["hemorrhage", "OBSERVATION", 79, 89]]], ["The TIPS is formed by passing a needle catheter via the transjugular route into the hepatic vein and wedging it there.", [["transjugular", "ANATOMY", 56, 68], ["hepatic vein", "ANATOMY", 84, 96], ["hepatic vein", "MULTI-TISSUE_STRUCTURE", 84, 96], ["The TIPS", "TREATMENT", 0, 8], ["a needle catheter", "TREATMENT", 30, 47], ["the transjugular route", "TREATMENT", 52, 74], ["TIPS", "OBSERVATION_MODIFIER", 4, 8], ["needle catheter", "OBSERVATION", 32, 47], ["transjugular", "OBSERVATION", 56, 68], ["hepatic vein", "ANATOMY", 84, 96], ["wedging", "OBSERVATION", 101, 108]]], ["The needle is then extruded into the liver parenchyma and attempts are made to find a branch of the intrahepatic portion of the portal vein.", [["liver parenchyma", "ANATOMY", 37, 53], ["intrahepatic portion", "ANATOMY", 100, 120], ["portal vein", "ANATOMY", 128, 139], ["liver parenchyma", "MULTI-TISSUE_STRUCTURE", 37, 53], ["intrahepatic portion", "MULTI-TISSUE_STRUCTURE", 100, 120], ["portal vein", "MULTI-TISSUE_STRUCTURE", 128, 139], ["The needle", "TREATMENT", 0, 10], ["needle", "OBSERVATION", 4, 10], ["liver", "ANATOMY", 37, 42], ["parenchyma", "ANATOMY_MODIFIER", 43, 53], ["branch", "ANATOMY_MODIFIER", 86, 92], ["intrahepatic", "ANATOMY_MODIFIER", 100, 112], ["portal vein", "ANATOMY", 128, 139]]], ["Figure 37 .1 shows the catheter in place in the portal vein.", [["portal vein", "ANATOMY", 48, 59], ["portal vein", "MULTI-TISSUE_STRUCTURE", 48, 59], ["Figure", "TEST", 0, 6], ["the catheter", "TREATMENT", 19, 31], ["catheter", "OBSERVATION", 23, 31], ["portal vein", "ANATOMY", 48, 59]]], ["A series of balloon catheters are then used to dilate the tract from the hepatic vein to the portal vein ( Fig. 37.", [["balloon", "ANATOMY", 12, 19], ["tract", "ANATOMY", 58, 63], ["hepatic vein", "ANATOMY", 73, 85], ["portal vein", "ANATOMY", 93, 104], ["tract", "ORGANISM_SUBDIVISION", 58, 63], ["hepatic vein", "MULTI-TISSUE_STRUCTURE", 73, 85], ["portal vein", "MULTI-TISSUE_STRUCTURE", 93, 104], ["A series of balloon catheters", "TREATMENT", 0, 29], ["balloon catheters", "OBSERVATION", 12, 29], ["tract", "ANATOMY_MODIFIER", 58, 63], ["hepatic vein", "ANATOMY", 73, 85], ["portal vein", "ANATOMY", 93, 104]]], ["2) and the stent, which is typically a 10-mm diameter covered wire mesh device, is inserted ( Fig. 37.3) .Answer: Transjugular Intrahepatic Portosystemic Shunt (TIPS) as Salvage Therapy for Variceal BleedingTo assess the response, pressures are measured.", [["Variceal", "ANATOMY", 190, 198], ["the stent", "TREATMENT", 7, 16], ["a 10-mm diameter covered wire mesh device", "TREATMENT", 37, 78], ["Transjugular Intrahepatic Portosystemic Shunt (TIPS)", "TREATMENT", 114, 166], ["Salvage Therapy", "TREATMENT", 170, 185], ["Variceal Bleeding", "PROBLEM", 190, 207], ["pressures", "TEST", 231, 240], ["stent", "OBSERVATION", 11, 16], ["10-mm", "OBSERVATION_MODIFIER", 39, 44], ["diameter", "OBSERVATION_MODIFIER", 45, 53], ["wire", "OBSERVATION_MODIFIER", 62, 66], ["mesh device", "OBSERVATION", 67, 78], ["Transjugular", "ANATOMY_MODIFIER", 114, 126], ["Intrahepatic", "ANATOMY", 127, 139], ["Portosystemic Shunt", "OBSERVATION", 140, 159], ["pressures", "OBSERVATION_MODIFIER", 231, 240]]], ["In this patient, the pre-TIPS angiogram demonstrated hepatofugal flow from the portal system into a prominent paraumbilical vein and left coronary vein (top right of first image).", [["hepatofugal", "ANATOMY", 53, 64], ["portal system", "ANATOMY", 79, 92], ["paraumbilical vein", "ANATOMY", 110, 128], ["left coronary vein", "ANATOMY", 133, 151], ["patient", "ORGANISM", 8, 15], ["portal system", "MULTI-TISSUE_STRUCTURE", 79, 92], ["paraumbilical vein", "MULTI-TISSUE_STRUCTURE", 110, 128], ["coronary vein", "MULTI-TISSUE_STRUCTURE", 138, 151], ["patient", "SPECIES", 8, 15], ["the pre-TIPS angiogram", "TEST", 17, 39], ["hepatofugal flow", "OBSERVATION", 53, 69], ["portal system", "ANATOMY", 79, 92], ["prominent", "OBSERVATION", 100, 109], ["paraumbilical vein", "ANATOMY", 110, 128], ["left coronary vein", "ANATOMY", 133, 151], ["right", "ANATOMY_MODIFIER", 157, 162]]], ["The wedged pressure in the hepatic vein was 40 mmHg (a measure of portal pressure) and the free hepatic vein pressure was 16 mmHg giving a portosystemic gradient of 24 mmHg pre-TIPS consistent with portal hypertension.", [["hepatic vein", "ANATOMY", 27, 39], ["portal", "ANATOMY", 66, 72], ["hepatic vein", "ANATOMY", 96, 108], ["portal", "ANATOMY", 198, 204], ["portal hypertension", "DISEASE", 198, 217], ["hepatic vein", "MULTI-TISSUE_STRUCTURE", 27, 39], ["portal", "MULTI-TISSUE_STRUCTURE", 66, 72], ["hepatic vein", "MULTI-TISSUE_STRUCTURE", 96, 108], ["portal", "MULTI-TISSUE_STRUCTURE", 198, 204], ["The wedged pressure", "TEST", 0, 19], ["portal pressure", "TEST", 66, 81], ["the free hepatic vein pressure", "TEST", 87, 117], ["a portosystemic gradient", "TEST", 137, 161], ["portal hypertension", "PROBLEM", 198, 217], ["wedged", "OBSERVATION_MODIFIER", 4, 10], ["pressure", "OBSERVATION_MODIFIER", 11, 19], ["hepatic vein", "ANATOMY", 27, 39], ["40 mmHg", "OBSERVATION", 44, 51], ["portal", "ANATOMY", 66, 72], ["hepatic vein", "ANATOMY", 96, 108], ["16 mmHg", "OBSERVATION", 122, 129], ["portosystemic gradient", "OBSERVATION", 139, 161], ["24 mmHg", "OBSERVATION", 165, 172], ["consistent with", "UNCERTAINTY", 182, 197], ["portal", "ANATOMY", 198, 204], ["hypertension", "OBSERVATION", 205, 217]]], ["After the TIPS, the gradient dropped to 9 mmHg and the post-TIPS angiogram demonstrated flow through the TIPS shunt with decreased filling of the paraumbilical vein and left coronary vein.Answer: Transjugular Intrahepatic Portosystemic Shunt (TIPS) as Salvage Therapy for Variceal BleedingThe main complication of TIPS is the development of portosystemic encephalopathy (PSE), which occurs 30% of the time and can be debilitating.", [["paraumbilical vein", "ANATOMY", 146, 164], ["left coronary vein", "ANATOMY", 169, 187], ["Variceal", "ANATOMY", 272, 280], ["Transjugular Intrahepatic Portosystemic Shunt", "DISEASE", 196, 241], ["Variceal Bleeding", "DISEASE", 272, 289], ["portosystemic encephalopathy", "DISEASE", 341, 369], ["PSE", "DISEASE", 371, 374], ["paraumbilical vein", "MULTI-TISSUE_STRUCTURE", 146, 164], ["left coronary vein", "MULTI-TISSUE_STRUCTURE", 169, 187], ["the TIPS", "TREATMENT", 6, 14], ["the gradient", "TEST", 16, 28], ["the post-TIPS angiogram", "TEST", 51, 74], ["the TIPS shunt", "TREATMENT", 101, 115], ["decreased filling of the paraumbilical vein", "PROBLEM", 121, 164], ["Transjugular Intrahepatic Portosystemic Shunt (TIPS)", "TREATMENT", 196, 248], ["Salvage Therapy", "TREATMENT", 252, 267], ["Variceal Bleeding", "PROBLEM", 272, 289], ["TIPS", "TREATMENT", 314, 318], ["portosystemic encephalopathy", "PROBLEM", 341, 369], ["debilitating", "PROBLEM", 417, 429], ["TIPS", "OBSERVATION_MODIFIER", 10, 14], ["gradient", "OBSERVATION_MODIFIER", 20, 28], ["flow", "OBSERVATION", 88, 92], ["TIPS shunt", "OBSERVATION", 105, 115], ["decreased", "OBSERVATION_MODIFIER", 121, 130], ["filling", "OBSERVATION", 131, 138], ["paraumbilical vein", "ANATOMY", 146, 164], ["left coronary vein", "ANATOMY", 169, 187], ["Transjugular", "ANATOMY_MODIFIER", 196, 208], ["Intrahepatic", "ANATOMY", 209, 221], ["Portosystemic Shunt", "OBSERVATION", 222, 241], ["main", "OBSERVATION_MODIFIER", 293, 297], ["complication", "OBSERVATION", 298, 310], ["TIPS", "OBSERVATION_MODIFIER", 314, 318], ["portosystemic", "OBSERVATION_MODIFIER", 341, 354], ["encephalopathy", "OBSERVATION", 355, 369], ["debilitating", "OBSERVATION", 417, 429]]], ["We typically will start the patient on lactulose prior to TIPS.", [["lactulose", "CHEMICAL", 39, 48], ["lactulose", "CHEMICAL", 39, 48], ["patient", "ORGANISM", 28, 35], ["lactulose", "SIMPLE_CHEMICAL", 39, 48], ["patient", "SPECIES", 28, 35], ["lactulose", "TREATMENT", 39, 48], ["TIPS", "TREATMENT", 58, 62]]], ["Very occasionally, a TIPS needs to be deliberately occluded due to severe PSE (usually in elderly patients).", [["PSE", "DISEASE", 74, 77], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["a TIPS", "TREATMENT", 19, 25], ["severe PSE", "PROBLEM", 67, 77], ["occluded", "OBSERVATION", 51, 59], ["severe", "OBSERVATION_MODIFIER", 67, 73]]], ["Regular imaging is suggested after TIPS with Doppler sonography to ensure patency, although newer covered stents have lower stenosis rates.Case 38A 31-year-old Caucasian female nurse of Spanish/Portuguese descent was evaluated by her primary care physician for complaints of fatigue and lower extremity paresthesiae.", [["lower extremity paresthesiae", "ANATOMY", 287, 315], ["stenosis", "DISEASE", 124, 132], ["fatigue", "DISEASE", 275, 282], ["lower extremity paresthesiae", "DISEASE", 287, 315], ["female", "ORGANISM", 170, 176], ["Regular imaging", "TEST", 0, 15], ["TIPS with Doppler sonography", "TEST", 35, 63], ["patency", "TEST", 74, 81], ["newer covered stents", "TREATMENT", 92, 112], ["lower stenosis rates", "PROBLEM", 118, 138], ["fatigue", "PROBLEM", 275, 282], ["lower extremity paresthesiae", "PROBLEM", 287, 315], ["patency", "OBSERVATION", 74, 81], ["stents", "OBSERVATION", 106, 112], ["lower", "OBSERVATION_MODIFIER", 118, 123], ["stenosis", "OBSERVATION", 124, 132], ["lower extremity", "ANATOMY", 287, 302], ["paresthesiae", "OBSERVATION", 303, 315]]], ["A thyroid mass was palpated on exam that prompted a biopsy revealing papillary thyroid cancer.", [["thyroid mass", "ANATOMY", 2, 14], ["papillary thyroid cancer", "ANATOMY", 69, 93], ["papillary thyroid cancer", "DISEASE", 69, 93], ["thyroid", "ORGAN", 2, 9], ["papillary thyroid cancer", "CANCER", 69, 93], ["A thyroid mass", "PROBLEM", 0, 14], ["exam", "TEST", 31, 35], ["a biopsy", "TEST", 50, 58], ["papillary thyroid cancer", "PROBLEM", 69, 93], ["thyroid", "ANATOMY", 2, 9], ["mass", "OBSERVATION", 10, 14], ["papillary", "ANATOMY_MODIFIER", 69, 78], ["thyroid", "ANATOMY", 79, 86], ["cancer", "OBSERVATION", 87, 93]]], ["Her only other medical history is heterozygosity for factor V Leiden deficiency without prior thrombus, for which she is maintained on 81 mg of aspirin daily.", [["thrombus", "ANATOMY", 94, 102], ["factor V Leiden deficiency", "DISEASE", 53, 79], ["thrombus", "DISEASE", 94, 102], ["aspirin", "CHEMICAL", 144, 151], ["aspirin", "CHEMICAL", 144, 151], ["factor V Leiden", "GENE_OR_GENE_PRODUCT", 53, 68], ["thrombus", "PATHOLOGICAL_FORMATION", 94, 102], ["aspirin", "SIMPLE_CHEMICAL", 144, 151], ["factor V Leiden", "PROTEIN", 53, 68], ["heterozygosity", "PROBLEM", 34, 48], ["factor V Leiden deficiency", "PROBLEM", 53, 79], ["prior thrombus", "PROBLEM", 88, 102], ["aspirin", "TREATMENT", 144, 151], ["thrombus", "OBSERVATION", 94, 102]]], ["The patient was employed full time as a nurse; however, she was no longer able to work due to her current symptoms.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["her current symptoms", "PROBLEM", 94, 114]]], ["She is separated and has one healthy 7-year-old son.", [["She", "ORGANISM", 0, 3]]], ["She has two tattoos, the first obtained 12 years ago.", [["two", "OBSERVATION_MODIFIER", 8, 11], ["tattoos", "OBSERVATION", 12, 19]]], ["Her mother died at the age of 37 from sudden cardiac death, which was thought to be related to heart failure.", [["cardiac", "ANATOMY", 45, 52], ["heart", "ANATOMY", 95, 100], ["sudden cardiac death", "DISEASE", 38, 58], ["heart failure", "DISEASE", 95, 108], ["cardiac", "ORGAN", 45, 52], ["heart", "ORGAN", 95, 100], ["sudden cardiac death", "PROBLEM", 38, 58], ["heart failure", "PROBLEM", 95, 108], ["cardiac", "ANATOMY", 45, 52], ["death", "OBSERVATION", 53, 58], ["thought to be related to", "UNCERTAINTY", 70, 94], ["heart", "ANATOMY", 95, 100], ["failure", "OBSERVATION", 101, 108]]], ["Several other family members on her mother's side have had early death from a variety of diseases and all had the same fatigue and paresthesiae, and were thin (with some suggestion of a bulimia type eating disorder due to constant vomiting).", [["death", "DISEASE", 65, 70], ["fatigue", "DISEASE", 119, 126], ["paresthesiae", "DISEASE", 131, 143], ["bulimia type eating disorder", "DISEASE", 186, 214], ["vomiting", "DISEASE", 231, 239], ["early death", "PROBLEM", 59, 70], ["diseases", "PROBLEM", 89, 97], ["the same fatigue", "PROBLEM", 110, 126], ["paresthesiae", "PROBLEM", 131, 143], ["a bulimia type eating disorder", "PROBLEM", 184, 214], ["constant vomiting", "PROBLEM", 222, 239]]], ["Review of systems is positive for constipation, light headedness, and blurred vision from her right eye.", [["right eye", "ANATOMY", 94, 103], ["constipation", "DISEASE", 34, 46], ["blurred vision", "DISEASE", 70, 84], ["eye", "ORGAN", 100, 103], ["Review of systems", "TEST", 0, 17], ["constipation", "PROBLEM", 34, 46], ["light headedness", "PROBLEM", 48, 64], ["blurred vision from her right eye", "PROBLEM", 70, 103], ["right", "ANATOMY_MODIFIER", 94, 99], ["eye", "ANATOMY", 100, 103]]], ["The patient undergoes thryoidectomy and removal of 2.2 cm papillary thyroid cancer with no evidence of vascular invasion or lymph node metastases.", [["papillary thyroid cancer", "ANATOMY", 58, 82], ["vascular", "ANATOMY", 103, 111], ["lymph node metastases", "ANATOMY", 124, 145], ["papillary thyroid cancer", "DISEASE", 58, 82], ["patient", "ORGANISM", 4, 11], ["papillary thyroid cancer", "CANCER", 58, 82], ["vascular", "MULTI-TISSUE_STRUCTURE", 103, 111], ["lymph node", "MULTI-TISSUE_STRUCTURE", 124, 134], ["patient", "SPECIES", 4, 11], ["thryoidectomy", "TREATMENT", 22, 35], ["removal", "TREATMENT", 40, 47], ["2.2 cm papillary thyroid cancer", "PROBLEM", 51, 82], ["vascular invasion", "PROBLEM", 103, 120], ["lymph node metastases", "PROBLEM", 124, 145], ["thryoidectomy", "OBSERVATION", 22, 35], ["removal", "OBSERVATION_MODIFIER", 40, 47], ["2.2 cm", "OBSERVATION_MODIFIER", 51, 57], ["papillary", "OBSERVATION_MODIFIER", 58, 67], ["thyroid", "ANATOMY", 68, 75], ["cancer", "OBSERVATION", 76, 82], ["no evidence of", "UNCERTAINTY", 88, 102], ["vascular", "ANATOMY", 103, 111], ["invasion", "OBSERVATION", 112, 120], ["lymph node metastases", "OBSERVATION", 124, 145]]], ["She is treated successfully with postoperative radiation.Case 38She is referred to the liver clinic by her oncologist because of abnormal liver tests in a mixed pattern.Case 38Physical exam is notable for a healthy young female with a BMI of 25.8 kg/m 2 .", [["liver", "ANATOMY", 87, 92], ["liver", "ANATOMY", 138, 143], ["abnormal liver tests", "DISEASE", 129, 149], ["liver", "ORGAN", 87, 92], ["liver", "ORGAN", 138, 143], ["postoperative radiation", "TREATMENT", 33, 56], ["abnormal liver tests", "PROBLEM", 129, 149], ["liver", "ANATOMY", 87, 92], ["liver", "ANATOMY", 138, 143]]], ["Her supine blood pressure is 118/62 with a heart rate of 62, upon standing she does complain of light headedness and her repeat blood pressure is 88/42 with a heart rate of 96.", [["blood", "ANATOMY", 11, 16], ["heart", "ANATOMY", 43, 48], ["blood", "ANATOMY", 128, 133], ["heart", "ANATOMY", 159, 164], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["heart", "ORGAN", 43, 48], ["blood", "ORGANISM_SUBSTANCE", 128, 133], ["heart", "ORGAN", 159, 164], ["Her supine blood pressure", "TEST", 0, 25], ["a heart rate", "TEST", 41, 53], ["light headedness", "PROBLEM", 96, 112], ["her repeat blood pressure", "TEST", 117, 142], ["a heart rate", "TEST", 157, 169]]], ["She has no stigmata to suggest chronic liver disease.", [["liver", "ANATOMY", 39, 44], ["chronic liver disease", "DISEASE", 31, 52], ["liver", "ORGAN", 39, 44], ["stigmata", "PROBLEM", 11, 19], ["chronic liver disease", "PROBLEM", 31, 52], ["no stigmata to suggest", "UNCERTAINTY", 8, 30], ["chronic", "OBSERVATION_MODIFIER", 31, 38], ["liver", "ANATOMY", 39, 44], ["disease", "OBSERVATION", 45, 52]]], ["Her abdominal exam is normal.Case 38She has normal renal function and hemogram.Questions1.", [["abdominal", "ANATOMY", 4, 13], ["renal", "ANATOMY", 51, 56], ["abdominal", "ORGAN", 4, 13], ["renal", "ORGAN", 51, 56], ["Her abdominal exam", "TEST", 0, 18], ["hemogram", "TEST", 70, 78], ["abdominal", "ANATOMY", 4, 13], ["normal", "OBSERVATION", 22, 28], ["normal", "OBSERVATION", 44, 50], ["renal", "ANATOMY", 51, 56], ["function", "OBSERVATION", 57, 65]]], ["Is liver transplantation a viable option? 3.", [["liver", "ANATOMY", 3, 8], ["liver", "ORGAN", 3, 8], ["liver transplantation", "TREATMENT", 3, 24], ["liver", "ANATOMY", 3, 8], ["transplantation", "OBSERVATION", 9, 24]]], ["How would the diagnosis of thyroid cancer affect her status as a candidate?Answer: Familal Amyloidosis and Liver TransplantationThis patient has familial amyloid polyneuropathy (FAP).", [["thyroid cancer", "ANATOMY", 27, 41], ["Liver", "ANATOMY", 107, 112], ["thyroid cancer", "DISEASE", 27, 41], ["Amyloidosis", "DISEASE", 91, 102], ["familial amyloid polyneuropathy", "DISEASE", 145, 176], ["FAP", "DISEASE", 178, 181], ["thyroid cancer", "CANCER", 27, 41], ["Liver", "ORGAN", 107, 112], ["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140], ["thyroid cancer", "PROBLEM", 27, 41], ["Familal Amyloidosis", "PROBLEM", 83, 102], ["Liver Transplantation", "TREATMENT", 107, 128], ["familial amyloid polyneuropathy", "PROBLEM", 145, 176], ["thyroid", "ANATOMY", 27, 34], ["cancer", "OBSERVATION", 35, 41], ["Amyloidosis", "OBSERVATION", 91, 102], ["Liver", "ANATOMY", 107, 112], ["Transplantation", "OBSERVATION", 113, 128], ["familial", "OBSERVATION_MODIFIER", 145, 153], ["amyloid polyneuropathy", "OBSERVATION", 154, 176]]], ["FAP is an autosomal dominant multisystemic fatal disorder, characterized by a progressive peripheral neuropathy and autonomic neuropathy with neural and systemic amyloid deposits.", [["neural", "ANATOMY", 142, 148], ["FAP", "DISEASE", 0, 3], ["multisystemic fatal disorder", "DISEASE", 29, 57], ["peripheral neuropathy", "DISEASE", 90, 111], ["autonomic neuropathy", "DISEASE", 116, 136], ["an autosomal dominant multisystemic fatal disorder", "PROBLEM", 7, 57], ["a progressive peripheral neuropathy", "PROBLEM", 76, 111], ["autonomic neuropathy", "PROBLEM", 116, 136], ["neural and systemic amyloid deposits", "PROBLEM", 142, 178], ["autosomal", "OBSERVATION_MODIFIER", 10, 19], ["dominant", "OBSERVATION_MODIFIER", 20, 28], ["multisystemic", "OBSERVATION_MODIFIER", 29, 42], ["fatal disorder", "OBSERVATION", 43, 57], ["progressive", "OBSERVATION_MODIFIER", 78, 89], ["peripheral", "ANATOMY_MODIFIER", 90, 100], ["neuropathy", "OBSERVATION", 101, 111], ["autonomic neuropathy", "OBSERVATION", 116, 136], ["neural", "ANATOMY_MODIFIER", 142, 148], ["systemic", "OBSERVATION_MODIFIER", 153, 161], ["amyloid deposits", "OBSERVATION", 162, 178]]], ["The disease is caused by a mutant gene on chromosome 18.", [["chromosome", "ANATOMY", 42, 52], ["chromosome 18", "CELLULAR_COMPONENT", 42, 55], ["mutant gene", "DNA", 27, 38], ["chromosome 18", "DNA", 42, 55], ["The disease", "PROBLEM", 0, 11], ["a mutant gene on chromosome 18", "PROBLEM", 25, 55], ["disease", "OBSERVATION", 4, 11]]], ["The amyloid protein in type 1 FAP (the most common form) is the variant transthyretin in which methionine is a substitute for valine at position 30 (TTR Met 30).", [["FAP", "DISEASE", 30, 33], ["methionine", "CHEMICAL", 95, 105], ["valine", "CHEMICAL", 126, 132], ["methionine", "CHEMICAL", 95, 105], ["valine", "CHEMICAL", 126, 132], ["amyloid protein in type 1 FAP", "GENE_OR_GENE_PRODUCT", 4, 33], ["transthyretin", "GENE_OR_GENE_PRODUCT", 72, 85], ["methionine", "AMINO_ACID", 95, 105], ["valine", "AMINO_ACID", 126, 132], ["amyloid protein", "PROTEIN", 4, 19], ["transthyretin", "PROTEIN", 72, 85], ["TTR Met 30", "PROTEIN", 149, 159], ["The amyloid protein", "TEST", 0, 19], ["the variant transthyretin", "PROBLEM", 60, 85], ["methionine", "TREATMENT", 95, 105], ["valine at position", "TREATMENT", 126, 144], ["amyloid protein", "OBSERVATION", 4, 19]]], ["More than 90% of TTR Met 30 is produced by the liver.", [["liver", "ANATOMY", 47, 52], ["Met", "CHEMICAL", 21, 24], ["Met", "CHEMICAL", 21, 24], ["TTR Met 30", "GENE_OR_GENE_PRODUCT", 17, 27], ["liver", "ORGAN", 47, 52], ["TTR Met 30", "PROTEIN", 17, 27], ["TTR Met", "TEST", 17, 24], ["liver", "ANATOMY", 47, 52]]], ["Amyloidosis is a generic term that refers to the extracellular tissue deposition of fibrils composed of low molecular weight subunits of a variety of proteins, many of which circulate as a constituent of plasma.", [["extracellular tissue", "ANATOMY", 49, 69], ["fibrils", "ANATOMY", 84, 91], ["plasma", "ANATOMY", 204, 210], ["Amyloidosis", "DISEASE", 0, 11], ["extracellular tissue", "TISSUE", 49, 69], ["plasma", "ORGANISM_SUBSTANCE", 204, 210], ["low molecular weight subunits", "PROTEIN", 104, 133], ["Amyloidosis", "PROBLEM", 0, 11], ["the extracellular tissue deposition of fibrils", "PROBLEM", 45, 91], ["generic term", "OBSERVATION_MODIFIER", 17, 29], ["extracellular tissue", "OBSERVATION_MODIFIER", 49, 69], ["deposition", "OBSERVATION", 70, 80], ["fibrils", "OBSERVATION_MODIFIER", 84, 91], ["low molecular", "OBSERVATION_MODIFIER", 104, 117]]], ["There are at least 25 different human protein precursors of amyloid fibrils known.Answer: Familal Amyloidosis and Liver TransplantationAs in this particular case, a majority of patients with FAP present with peripheral polyneuropathy: pain, sensory loss, and motor disability.", [["Liver", "ANATOMY", 114, 119], ["Amyloidosis", "DISEASE", 98, 109], ["Liver TransplantationAs", "DISEASE", 114, 137], ["FAP", "DISEASE", 191, 194], ["peripheral polyneuropathy", "DISEASE", 208, 233], ["pain", "DISEASE", 235, 239], ["sensory loss", "DISEASE", 241, 253], ["motor disability", "DISEASE", 259, 275], ["human", "ORGANISM", 32, 37], ["amyloid fibrils", "GENE_OR_GENE_PRODUCT", 60, 75], ["Liver", "ORGAN", 114, 119], ["patients", "ORGANISM", 177, 185], ["FAP", "CANCER", 191, 194], ["human protein precursors", "PROTEIN", 32, 56], ["amyloid fibrils", "PROTEIN", 60, 75], ["human", "SPECIES", 32, 37], ["patients", "SPECIES", 177, 185], ["human", "SPECIES", 32, 37], ["amyloid fibrils", "PROBLEM", 60, 75], ["Familal Amyloidosis", "PROBLEM", 90, 109], ["Liver TransplantationAs", "PROBLEM", 114, 137], ["FAP", "PROBLEM", 191, 194], ["peripheral polyneuropathy", "PROBLEM", 208, 233], ["pain", "PROBLEM", 235, 239], ["sensory loss", "PROBLEM", 241, 253], ["motor disability", "PROBLEM", 259, 275], ["amyloid fibrils", "OBSERVATION", 60, 75], ["Amyloidosis", "OBSERVATION", 98, 109], ["Liver", "ANATOMY", 114, 119], ["peripheral", "ANATOMY_MODIFIER", 208, 218], ["polyneuropathy", "OBSERVATION", 219, 233], ["sensory loss", "OBSERVATION", 241, 253]]], ["Gastrointestinal dysfunction may also develop, including constipation, diarrhea, and sometimes fecal incontinence.", [["Gastrointestinal", "ANATOMY", 0, 16], ["fecal", "ANATOMY", 95, 100], ["Gastrointestinal dysfunction", "DISEASE", 0, 28], ["constipation", "DISEASE", 57, 69], ["diarrhea", "DISEASE", 71, 79], ["fecal incontinence", "DISEASE", 95, 113], ["Gastrointestinal", "ORGAN", 0, 16], ["fecal", "ORGANISM_SUBDIVISION", 95, 100], ["Gastrointestinal dysfunction", "PROBLEM", 0, 28], ["constipation", "PROBLEM", 57, 69], ["diarrhea", "PROBLEM", 71, 79], ["sometimes fecal incontinence", "PROBLEM", 85, 113], ["dysfunction", "OBSERVATION", 17, 28], ["diarrhea", "OBSERVATION", 71, 79], ["fecal", "ANATOMY", 95, 100], ["incontinence", "OBSERVATION", 101, 113]]], ["A rectal biopsy can show amyloid, particularly on a congo red stain, but can also be seen on a standard H&E stain as shown in Fig. 38 .1 with the amorphous pink material between the smooth muscle fibers in the muscularis mucosa.", [["rectal", "ANATOMY", 2, 8], ["smooth muscle fibers", "ANATOMY", 182, 202], ["muscularis mucosa", "ANATOMY", 210, 227], ["amyloid", "DISEASE", 25, 32], ["rectal biopsy", "MULTI-TISSUE_STRUCTURE", 2, 15], ["amyloid", "GENE_OR_GENE_PRODUCT", 25, 32], ["smooth muscle fibers", "TISSUE", 182, 202], ["muscularis mucosa", "MULTI-TISSUE_STRUCTURE", 210, 227], ["A rectal biopsy", "TEST", 0, 15], ["amyloid", "PROBLEM", 25, 32], ["a congo red stain", "TEST", 50, 67], ["a standard H&E stain", "TEST", 93, 113], ["the amorphous pink material", "PROBLEM", 142, 169], ["rectal", "ANATOMY", 2, 8], ["biopsy", "OBSERVATION", 9, 15], ["amyloid", "OBSERVATION", 25, 32], ["amorphous", "OBSERVATION_MODIFIER", 146, 155], ["pink material", "OBSERVATION", 156, 169], ["smooth muscle", "ANATOMY", 182, 195], ["fibers", "ANATOMY_MODIFIER", 196, 202], ["muscularis mucosa", "ANATOMY", 210, 227]]], ["Difficulty in gastric emptying with nausea and vomiting are also frequent.", [["gastric", "ANATOMY", 14, 21], ["nausea", "DISEASE", 36, 42], ["vomiting", "DISEASE", 47, 55], ["gastric", "ORGAN", 14, 21], ["Difficulty in gastric emptying", "PROBLEM", 0, 30], ["nausea", "PROBLEM", 36, 42], ["vomiting", "PROBLEM", 47, 55], ["gastric", "ANATOMY", 14, 21], ["emptying", "OBSERVATION", 22, 30]]], ["Cardiovascular symptoms range from orthostatic hypotension to different arrhythmias and first and second degree atrioventricular block.", [["Cardiovascular", "ANATOMY", 0, 14], ["Cardiovascular symptoms", "DISEASE", 0, 23], ["orthostatic hypotension", "DISEASE", 35, 58], ["arrhythmias", "DISEASE", 72, 83], ["atrioventricular block", "DISEASE", 112, 134], ["Cardiovascular symptoms", "PROBLEM", 0, 23], ["orthostatic hypotension", "PROBLEM", 35, 58], ["different arrhythmias", "PROBLEM", 62, 83], ["second degree atrioventricular block", "PROBLEM", 98, 134], ["orthostatic hypotension", "OBSERVATION", 35, 58], ["arrhythmias", "OBSERVATION", 72, 83], ["atrioventricular block", "OBSERVATION", 112, 134]]], ["Kidney involvement typically manifests as proteinuria with the reduction of the glomerular filtration rate and decreased creatinine clearance.Answer: Familal Amyloidosis and Liver TransplantationAlthough cases of FAP type 1 may be found all over the world, the most important clusters are in Portugal and Sweden.", [["Kidney", "ANATOMY", 0, 6], ["glomerular", "ANATOMY", 80, 90], ["Liver", "ANATOMY", 174, 179], ["proteinuria", "DISEASE", 42, 53], ["creatinine", "CHEMICAL", 121, 131], ["Amyloidosis", "DISEASE", 158, 169], ["Liver TransplantationAlthough", "DISEASE", 174, 203], ["FAP", "DISEASE", 213, 216], ["creatinine", "CHEMICAL", 121, 131], ["Kidney", "ORGAN", 0, 6], ["glomerular", "TISSUE", 80, 90], ["creatinine", "SIMPLE_CHEMICAL", 121, 131], ["Liver", "ORGAN", 174, 179], ["FAP type 1", "GENE_OR_GENE_PRODUCT", 213, 223], ["Kidney involvement", "PROBLEM", 0, 18], ["proteinuria", "PROBLEM", 42, 53], ["the glomerular filtration rate", "TEST", 76, 106], ["decreased creatinine clearance", "PROBLEM", 111, 141], ["Familal Amyloidosis", "PROBLEM", 150, 169], ["FAP type 1", "PROBLEM", 213, 223], ["proteinuria", "OBSERVATION", 42, 53], ["reduction", "OBSERVATION_MODIFIER", 63, 72], ["glomerular", "ANATOMY", 80, 90], ["filtration rate", "OBSERVATION", 91, 106], ["decreased", "OBSERVATION_MODIFIER", 111, 120], ["creatinine clearance", "OBSERVATION", 121, 141], ["Amyloidosis", "OBSERVATION", 158, 169], ["Liver", "ANATOMY", 174, 179]]], ["Frequently, the disease is present in either the father or the mother and there are also other family members affected.Answer: Familal Amyloidosis and Liver TransplantationSince more than 90% of TTR Met 30 is produced within the liver, it is expected that liver transplantation will stop disease progression and that TTR Met 30 will clear from the serum.", [["Liver", "ANATOMY", 151, 156], ["liver", "ANATOMY", 229, 234], ["liver", "ANATOMY", 256, 261], ["serum", "ANATOMY", 348, 353], ["Amyloidosis", "DISEASE", 135, 146], ["Met", "CHEMICAL", 199, 202], ["Met", "CHEMICAL", 321, 324], ["Liver", "ORGAN", 151, 156], ["TTR Met 30", "GENE_OR_GENE_PRODUCT", 195, 205], ["liver", "ORGAN", 229, 234], ["liver", "ORGAN", 256, 261], ["TTR Met 30", "GENE_OR_GENE_PRODUCT", 317, 327], ["serum", "ORGANISM_SUBSTANCE", 348, 353], ["TTR", "PROTEIN", 195, 198], ["TTR", "PROTEIN", 317, 320], ["Familal Amyloidosis", "PROBLEM", 127, 146], ["Liver TransplantationSince", "PROBLEM", 151, 177], ["TTR", "TEST", 195, 198], ["liver transplantation", "TREATMENT", 256, 277], ["disease progression", "PROBLEM", 288, 307], ["TTR", "TEST", 317, 320], ["the serum", "TEST", 344, 353], ["disease", "OBSERVATION", 16, 23], ["Amyloidosis", "OBSERVATION", 135, 146], ["Liver", "ANATOMY", 151, 156], ["liver", "ANATOMY", 229, 234], ["liver", "ANATOMY", 256, 261], ["transplantation", "OBSERVATION", 262, 277]]], ["The first orthotopic liver transplantation for FAP patients was performed in 1990.", [["liver", "ANATOMY", 21, 26], ["FAP", "DISEASE", 47, 50], ["liver", "ORGAN", 21, 26], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["The first orthotopic liver transplantation", "TREATMENT", 0, 42], ["liver", "ANATOMY", 21, 26], ["transplantation", "OBSERVATION", 27, 42]]], ["Since 1995, over 1,500 liver transplantations for FAP have been performed, on average 110 patients with FAP are transplanted per year (http://www.fapwtr.org/ram1.htm).Answer: Familal Amyloidosis and Liver TransplantationIt is now established that liver transplantation for symptomatic patients with FAP is an acceptable treatment for the disease and at the current time the only way to halt disease progression.", [["liver", "ANATOMY", 23, 28], ["Liver", "ANATOMY", 199, 204], ["liver", "ANATOMY", 247, 252], ["FAP", "DISEASE", 50, 53], ["FAP", "DISEASE", 104, 107], ["Amyloidosis", "DISEASE", 183, 194], ["FAP", "DISEASE", 299, 302], ["liver", "ORGAN", 23, 28], ["FAP", "CANCER", 50, 53], ["patients", "ORGANISM", 90, 98], ["Liver", "ORGAN", 199, 204], ["liver", "ORGAN", 247, 252], ["patients", "ORGANISM", 285, 293], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 285, 293], ["liver transplantations", "TREATMENT", 23, 45], ["FAP", "PROBLEM", 50, 53], ["FAP", "PROBLEM", 104, 107], ["Familal Amyloidosis", "PROBLEM", 175, 194], ["Liver Transplantation", "TREATMENT", 199, 220], ["liver transplantation", "TREATMENT", 247, 268], ["FAP", "PROBLEM", 299, 302], ["an acceptable treatment", "TREATMENT", 306, 329], ["the disease", "PROBLEM", 334, 345], ["halt disease progression", "PROBLEM", 386, 410], ["liver", "ANATOMY", 23, 28], ["transplantations", "OBSERVATION", 29, 45], ["Amyloidosis", "OBSERVATION", 183, 194], ["Liver", "ANATOMY", 199, 204], ["Transplantation", "OBSERVATION", 205, 220], ["liver", "ANATOMY", 247, 252], ["transplantation", "OBSERVATION", 253, 268], ["disease", "OBSERVATION", 338, 345], ["disease", "OBSERVATION", 391, 398]]], ["Key points which have been gained from the experience with transplantation in these patients include:Answer: Familal Amyloidosis and Liver Transplantation1.", [["Liver", "ANATOMY", 133, 138], ["Amyloidosis", "DISEASE", 117, 128], ["Liver Transplantation1", "DISEASE", 133, 155], ["patients", "ORGANISM", 84, 92], ["Liver", "ORGAN", 133, 138], ["patients", "SPECIES", 84, 92], ["transplantation", "TREATMENT", 59, 74], ["Familal Amyloidosis", "PROBLEM", 109, 128], ["Liver Transplantation1", "TREATMENT", 133, 155], ["Amyloidosis", "OBSERVATION", 117, 128], ["Liver", "ANATOMY", 133, 138]]], ["The earlier the transplant after the onset of symptoms the better the outcome.", [["the transplant", "TREATMENT", 12, 26], ["symptoms", "PROBLEM", 46, 54], ["transplant", "OBSERVATION", 16, 26]]], ["Caution should be warranted before listing patients with longstanding disease (greater than 6 years) as many of these patients will not have regression of their signs and symptoms.", [["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 118, 126], ["longstanding disease", "PROBLEM", 57, 77], ["their signs and symptoms", "PROBLEM", 155, 179]]], ["Consideration should be given to combined heart-liver transplantation in those patients with orthostatic hypotension and cardiac arrhythmias 4.", [["heart", "ANATOMY", 42, 47], ["liver", "ANATOMY", 48, 53], ["cardiac", "ANATOMY", 121, 128], ["orthostatic hypotension", "DISEASE", 93, 116], ["cardiac arrhythmias", "DISEASE", 121, 140], ["heart", "ORGAN", 42, 47], ["liver", "ORGAN", 48, 53], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["combined heart-liver transplantation", "TREATMENT", 33, 69], ["orthostatic hypotension", "PROBLEM", 93, 116], ["cardiac arrhythmias", "PROBLEM", 121, 140], ["heart", "ANATOMY", 42, 47], ["liver", "ANATOMY", 48, 53], ["transplantation", "OBSERVATION", 54, 69], ["hypotension", "OBSERVATION", 105, 116], ["cardiac", "ANATOMY", 121, 128], ["arrhythmias", "OBSERVATION", 129, 140]]], ["A complete screening of renal function should be performed and combined liverkidney transplantation should be considered in patients with moderate-to-severe kidney involvement.Domino transplant seems to be a safe way to increase donor offers and so farthere is no evidence of FAP de novo in the recipient.Domino transplant seems to be a safe way to increase donor offers and so farAt the present time, there is no consensus on the optimum window of time between presumed cure of various extrahepatic malignancies and liver transplantation, and each case needs to taken individually.", [["renal", "ANATOMY", 24, 29], ["kidney", "ANATOMY", 157, 163], ["extrahepatic malignancies", "ANATOMY", 487, 512], ["liver", "ANATOMY", 517, 522], ["FAP", "DISEASE", 276, 279], ["extrahepatic malignancies", "DISEASE", 487, 512], ["renal", "ORGAN", 24, 29], ["patients", "ORGANISM", 124, 132], ["kidney", "ORGAN", 157, 163], ["extrahepatic malignancies", "CANCER", 487, 512], ["liver", "ORGAN", 517, 522], ["patients", "SPECIES", 124, 132], ["A complete screening of renal function", "TEST", 0, 38], ["combined liverkidney transplantation", "TREATMENT", 63, 99], ["moderate-to-severe kidney involvement", "PROBLEM", 138, 175], ["Domino transplant", "TREATMENT", 176, 193], ["FAP", "PROBLEM", 276, 279], ["Domino transplant", "TREATMENT", 305, 322], ["various extrahepatic malignancies", "PROBLEM", 479, 512], ["liver transplantation", "TREATMENT", 517, 538], ["renal", "ANATOMY", 24, 29], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["kidney", "ANATOMY", 157, 163], ["involvement", "OBSERVATION", 164, 175], ["transplant", "OBSERVATION", 183, 193], ["no evidence of", "UNCERTAINTY", 261, 275], ["no", "UNCERTAINTY", 411, 413], ["extrahepatic", "ANATOMY", 487, 499], ["malignancies", "OBSERVATION", 500, 512], ["liver", "ANATOMY", 517, 522], ["transplantation", "OBSERVATION", 523, 538]]], ["As recommended in the current AASLD guidelines on liver transplantation, close consultation was obtained with oncology before listing this patient for liver transplantation.Domino transplant seems to be a safe way to increase donor offers and so farThe patient in this case received a living donor liver transplant from her 27-year-old sister who tested negative for FAP.", [["liver", "ANATOMY", 50, 55], ["liver", "ANATOMY", 151, 156], ["liver", "ANATOMY", 298, 303], ["FAP", "DISEASE", 367, 370], ["liver", "ORGAN", 50, 55], ["patient", "ORGANISM", 139, 146], ["liver", "ORGAN", 151, 156], ["patient", "ORGANISM", 253, 260], ["liver", "ORGAN", 298, 303], ["patient", "SPECIES", 139, 146], ["patient", "SPECIES", 253, 260], ["liver transplantation", "TREATMENT", 50, 71], ["liver transplantation", "TREATMENT", 151, 172], ["Domino transplant", "TREATMENT", 173, 190], ["a living donor liver transplant", "TREATMENT", 283, 314], ["FAP", "PROBLEM", 367, 370], ["liver", "ANATOMY", 50, 55], ["liver", "ANATOMY", 151, 156], ["transplantation", "OBSERVATION", 157, 172], ["transplant", "OBSERVATION", 180, 190], ["liver", "ANATOMY", 298, 303], ["transplant", "OBSERVATION", 304, 314]]], ["The patient's liver upon explant showed intact architecture with predominantly portal-based amyloid deposits and was used in a domino fashion to transplant a 67-year-old woman with HCV cirrhosis and HCC.Case 39A 25-year-old Caucasian female is admitted to the hospital with a 2-week history of right upper quadrant pain, bloating, nausea, vomiting, and malaise.", [["liver", "ANATOMY", 14, 19], ["HCC", "ANATOMY", 199, 202], ["right upper quadrant", "ANATOMY", 294, 314], ["HCV cirrhosis", "DISEASE", 181, 194], ["HCC", "DISEASE", 199, 202], ["right upper quadrant pain", "DISEASE", 294, 319], ["bloating", "DISEASE", 321, 329], ["nausea", "DISEASE", 331, 337], ["vomiting", "DISEASE", 339, 347], ["patient", "ORGANISM", 4, 11], ["liver", "ORGAN", 14, 19], ["woman", "ORGANISM", 170, 175], ["HCV", "ORGANISM", 181, 184], ["HCC", "CANCER", 199, 202], ["Caucasian", "ORGANISM", 224, 233], ["female", "ORGANISM", 234, 240], ["upper quadrant", "ORGANISM_SUBDIVISION", 300, 314], ["patient", "SPECIES", 4, 11], ["woman", "SPECIES", 170, 175], ["HCV", "SPECIES", 181, 184], ["predominantly portal-based amyloid deposits", "PROBLEM", 65, 108], ["a domino fashion", "TREATMENT", 125, 141], ["HCV cirrhosis", "PROBLEM", 181, 194], ["HCC", "PROBLEM", 199, 202], ["right upper quadrant pain", "PROBLEM", 294, 319], ["bloating", "PROBLEM", 321, 329], ["nausea", "PROBLEM", 331, 337], ["vomiting", "PROBLEM", 339, 347], ["malaise", "PROBLEM", 353, 360], ["liver", "ANATOMY", 14, 19], ["intact", "OBSERVATION", 40, 46], ["predominantly", "OBSERVATION_MODIFIER", 65, 78], ["portal", "ANATOMY", 79, 85], ["amyloid deposits", "OBSERVATION", 92, 108], ["HCV", "OBSERVATION_MODIFIER", 181, 184], ["cirrhosis", "OBSERVATION", 185, 194], ["HCC", "OBSERVATION", 199, 202], ["right", "ANATOMY_MODIFIER", 294, 299], ["upper", "ANATOMY_MODIFIER", 300, 305], ["quadrant", "ANATOMY", 306, 314], ["pain", "OBSERVATION", 315, 319], ["bloating", "OBSERVATION", 321, 329], ["nausea", "OBSERVATION", 331, 337], ["malaise", "OBSERVATION", 353, 360]]], ["She endorses chills, but no fevers and has noticed that her urine has become \"cola colored.\"", [["urine", "ANATOMY", 60, 65], ["chills", "DISEASE", 13, 19], ["fevers", "DISEASE", 28, 34], ["urine", "ORGANISM_SUBSTANCE", 60, 65], ["cola", "ORGANISM_SUBDIVISION", 78, 82], ["chills", "PROBLEM", 13, 19], ["fevers", "PROBLEM", 28, 34], ["chills", "OBSERVATION", 13, 19], ["no", "UNCERTAINTY", 25, 27], ["fevers", "OBSERVATION", 28, 34]]], ["The patient is single and is sexually active in a monogamous relationship.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["active", "OBSERVATION", 38, 44]]], ["She has three tattoos and a prior stint with IV heroin; however, she has been clean for several years.", [["heroin", "CHEMICAL", 48, 54], ["heroin", "CHEMICAL", 48, 54], ["IV heroin", "TREATMENT", 45, 54], ["tattoos", "OBSERVATION", 14, 21], ["clean", "OBSERVATION", 78, 83]]], ["She has been drinking a moderate amount of alcohol for the last 7 years, and very heavy amounts for the last 1 year, consuming 5-7 mixed drinks including vodka daily.", [["alcohol", "CHEMICAL", 43, 50], ["alcohol", "CHEMICAL", 43, 50], ["alcohol", "SIMPLE_CHEMICAL", 43, 50], ["vodka", "ORGANISM_SUBDIVISION", 154, 159]]], ["She has been told in the past that she has hepatitis C, although she has never been treated.", [["hepatitis C", "DISEASE", 43, 54], ["hepatitis C", "ORGANISM", 43, 54], ["hepatitis C", "PROBLEM", 43, 54], ["hepatitis", "OBSERVATION", 43, 52]]], ["She has no other significant medical history.", [["no", "UNCERTAINTY", 8, 10]]], ["She takes a daily oral contraceptive pill.", [["oral", "ANATOMY", 18, 22], ["oral contraceptive", "CHEMICAL", 18, 36], ["oral", "ORGANISM_SUBDIVISION", 18, 22], ["a daily oral contraceptive pill", "TREATMENT", 10, 41]]], ["Her parents and younger brother are in good health.Case 39Physical exam reveals a young female who is profoundly jaundiced with deep scleral icterus.", [["scleral", "ANATOMY", 133, 140], ["scleral icterus", "DISEASE", 133, 148], ["female", "ORGANISM", 88, 94], ["Case 39Physical exam", "TEST", 51, 71], ["profoundly jaundiced", "PROBLEM", 102, 122], ["deep scleral icterus", "PROBLEM", 128, 148], ["jaundiced", "OBSERVATION", 113, 122], ["deep", "ANATOMY_MODIFIER", 128, 132], ["scleral", "ANATOMY", 133, 140], ["icterus", "OBSERVATION", 141, 148]]], ["Temperature is 100.2\u00b0F with a heart rate of 106 beats per minute; her BMI is 26.2 kg/m 2 .", [["heart", "ANATOMY", 30, 35], ["heart", "ORGAN", 30, 35], ["Temperature", "TEST", 0, 11], ["a heart rate", "TEST", 28, 40], ["her BMI", "TEST", 66, 73]]], ["She is in no distress and answers questions appropriately although she is lethargic and drifts to sleep several times during your exam.", [["distress", "PROBLEM", 13, 21], ["lethargic", "PROBLEM", 74, 83], ["your exam", "TEST", 125, 134], ["no", "UNCERTAINTY", 10, 12], ["distress", "OBSERVATION", 13, 21]]], ["Her abdomen is distended and she has pain to palpation in the right upper quadrant.", [["abdomen", "ANATOMY", 4, 11], ["right upper quadrant", "ANATOMY", 62, 82], ["pain", "DISEASE", 37, 41], ["abdomen", "ORGAN", 4, 11], ["upper", "ORGANISM_SUBDIVISION", 68, 73], ["distended", "PROBLEM", 15, 24], ["pain", "PROBLEM", 37, 41], ["palpation", "TEST", 45, 54], ["abdomen", "ANATOMY", 4, 11], ["distended", "OBSERVATION", 15, 24], ["pain", "OBSERVATION", 37, 41], ["palpation", "OBSERVATION", 45, 54], ["right", "ANATOMY_MODIFIER", 62, 67], ["upper", "ANATOMY_MODIFIER", 68, 73], ["quadrant", "ANATOMY", 74, 82]]], ["Her liver is palpable 5 cm below her right costal margin.", [["liver", "ANATOMY", 4, 9], ["right costal margin", "ANATOMY", 37, 56], ["liver", "ORGAN", 4, 9], ["costal margin", "MULTI-TISSUE_STRUCTURE", 43, 56], ["liver", "ANATOMY", 4, 9], ["palpable", "OBSERVATION", 13, 21], ["5 cm", "OBSERVATION_MODIFIER", 22, 26], ["right", "ANATOMY_MODIFIER", 37, 42], ["costal", "ANATOMY", 43, 49], ["margin", "ANATOMY_MODIFIER", 50, 56]]], ["A hepatic bruit is auscultated in the right upper quadrant.", [["hepatic bruit", "ANATOMY", 2, 15], ["right upper quadrant", "ANATOMY", 38, 58], ["hepatic bruit", "DISEASE", 2, 15], ["hepatic", "ORGAN", 2, 9], ["upper quadrant", "ORGANISM_SUBDIVISION", 44, 58], ["A hepatic bruit", "PROBLEM", 0, 15], ["hepatic", "ANATOMY", 2, 9], ["bruit", "OBSERVATION", 10, 15], ["auscultated", "OBSERVATION", 19, 30], ["right", "ANATOMY_MODIFIER", 38, 43], ["upper", "ANATOMY_MODIFIER", 44, 49], ["quadrant", "ANATOMY", 50, 58]]], ["She has no splenomegaly, but shifting dullness is positive.", [["splenomegaly", "DISEASE", 11, 23], ["dullness", "DISEASE", 38, 46], ["splenomegaly", "PROBLEM", 11, 23], ["shifting dullness", "PROBLEM", 29, 46], ["positive", "PROBLEM", 50, 58], ["no", "UNCERTAINTY", 8, 10], ["splenomegaly", "OBSERVATION", 11, 23], ["shifting", "OBSERVATION_MODIFIER", 29, 37], ["dullness", "OBSERVATION", 38, 46], ["positive", "OBSERVATION", 50, 58]]], ["She has 1+ pitting edema bilaterally, palmar erythema but no asterixis.Answer: Severe Acute Alcoholic HepatitisThis young patient has the hallmark clinical features of severe acute alcoholic hepatitis: low-grade fever, jaundice, tender hepatomegaly, leuckocytosis, and moderate elevation of AST compared to ALT.", [["edema", "ANATOMY", 19, 24], ["palmar erythema", "ANATOMY", 38, 53], ["edema", "DISEASE", 19, 24], ["erythema", "DISEASE", 45, 53], ["asterixis", "DISEASE", 61, 70], ["Alcoholic Hepatitis", "DISEASE", 92, 111], ["alcoholic hepatitis", "DISEASE", 181, 200], ["low-grade fever", "DISEASE", 202, 217], ["jaundice", "DISEASE", 219, 227], ["hepatomegaly", "DISEASE", 236, 248], ["leuckocytosis", "DISEASE", 250, 263], ["patient", "ORGANISM", 122, 129], ["AST", "SIMPLE_CHEMICAL", 291, 294], ["ALT", "SIMPLE_CHEMICAL", 307, 310], ["AST", "PROTEIN", 291, 294], ["ALT", "PROTEIN", 307, 310], ["patient", "SPECIES", 122, 129], ["pitting edema bilaterally", "PROBLEM", 11, 36], ["palmar erythema", "PROBLEM", 38, 53], ["asterixis", "PROBLEM", 61, 70], ["Severe Acute Alcoholic Hepatitis", "PROBLEM", 79, 111], ["severe acute alcoholic hepatitis", "PROBLEM", 168, 200], ["low-grade fever", "PROBLEM", 202, 217], ["jaundice", "PROBLEM", 219, 227], ["tender hepatomegaly", "PROBLEM", 229, 248], ["leuckocytosis", "PROBLEM", 250, 263], ["moderate elevation of AST", "PROBLEM", 269, 294], ["ALT", "TEST", 307, 310], ["pitting", "OBSERVATION_MODIFIER", 11, 18], ["edema", "OBSERVATION", 19, 24], ["bilaterally", "ANATOMY_MODIFIER", 25, 36], ["palmar", "ANATOMY", 38, 44], ["erythema", "OBSERVATION", 45, 53], ["no", "UNCERTAINTY", 58, 60], ["asterixis", "OBSERVATION", 61, 70], ["Severe", "OBSERVATION_MODIFIER", 79, 85], ["Acute", "OBSERVATION_MODIFIER", 86, 91], ["Alcoholic Hepatitis", "OBSERVATION", 92, 111], ["severe", "OBSERVATION_MODIFIER", 168, 174], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["alcoholic hepatitis", "OBSERVATION", 181, 200], ["low-grade", "OBSERVATION_MODIFIER", 202, 211], ["fever", "OBSERVATION", 212, 217], ["jaundice", "OBSERVATION", 219, 227], ["tender", "OBSERVATION_MODIFIER", 229, 235], ["hepatomegaly", "OBSERVATION", 236, 248], ["moderate", "OBSERVATION_MODIFIER", 269, 277], ["elevation", "OBSERVATION_MODIFIER", 278, 287]]], ["Other physical exam findings may include a hepatic bruit, which is reported in >50% of cases and if heard is pathognomonic for the disease.", [["hepatic bruit", "ANATOMY", 43, 56], ["hepatic bruit", "DISEASE", 43, 56], ["hepatic", "ORGAN", 43, 50], ["Other physical exam", "TEST", 0, 19], ["a hepatic bruit", "PROBLEM", 41, 56], ["pathognomonic", "PROBLEM", 109, 122], ["the disease", "PROBLEM", 127, 138], ["hepatic", "ANATOMY", 43, 50], ["bruit", "OBSERVATION", 51, 56], ["disease", "OBSERVATION", 131, 138]]], ["Approximately 25-30% of patients with alcoholic hepatitis present with manifestations of portal hypertension (ascites, varices, encephalopathy), which may be a consequence of advanced fibrosis and cirrhosis or the result of transient portal venous obstruction from hepatic swelling.", [["portal", "ANATOMY", 89, 95], ["ascites", "ANATOMY", 110, 117], ["varices", "ANATOMY", 119, 126], ["portal venous", "ANATOMY", 234, 247], ["hepatic", "ANATOMY", 265, 272], ["alcoholic hepatitis", "DISEASE", 38, 57], ["portal hypertension", "DISEASE", 89, 108], ["ascites", "DISEASE", 110, 117], ["varices", "DISEASE", 119, 126], ["encephalopathy", "DISEASE", 128, 142], ["fibrosis", "DISEASE", 184, 192], ["cirrhosis", "DISEASE", 197, 206], ["portal venous obstruction", "DISEASE", 234, 259], ["hepatic swelling", "DISEASE", 265, 281], ["patients", "ORGANISM", 24, 32], ["portal", "MULTI-TISSUE_STRUCTURE", 89, 95], ["varices", "PATHOLOGICAL_FORMATION", 119, 126], ["portal venous obstruction", "PATHOLOGICAL_FORMATION", 234, 259], ["hepatic", "ORGAN", 265, 272], ["patients", "SPECIES", 24, 32], ["alcoholic hepatitis", "PROBLEM", 38, 57], ["portal hypertension", "PROBLEM", 89, 108], ["ascites", "PROBLEM", 110, 117], ["varices", "PROBLEM", 119, 126], ["encephalopathy", "PROBLEM", 128, 142], ["advanced fibrosis", "PROBLEM", 175, 192], ["cirrhosis", "PROBLEM", 197, 206], ["transient portal venous obstruction", "PROBLEM", 224, 259], ["hepatic swelling", "PROBLEM", 265, 281], ["alcoholic hepatitis", "OBSERVATION", 38, 57], ["portal", "ANATOMY", 89, 95], ["hypertension", "OBSERVATION", 96, 108], ["ascites", "OBSERVATION", 110, 117], ["varices", "OBSERVATION", 119, 126], ["encephalopathy", "OBSERVATION", 128, 142], ["may be a consequence of", "UNCERTAINTY", 151, 174], ["advanced", "OBSERVATION_MODIFIER", 175, 183], ["fibrosis", "OBSERVATION", 184, 192], ["cirrhosis", "OBSERVATION", 197, 206], ["transient", "OBSERVATION_MODIFIER", 224, 233], ["portal venous", "ANATOMY", 234, 247], ["obstruction", "OBSERVATION", 248, 259], ["hepatic", "ANATOMY", 265, 272], ["swelling", "OBSERVATION", 273, 281]]], ["Up to 50% of patients presenting with acute alcoholic hepatitis will have underlying cirrhosis.", [["acute alcoholic hepatitis", "DISEASE", 38, 63], ["cirrhosis", "DISEASE", 85, 94], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["acute alcoholic hepatitis", "PROBLEM", 38, 63], ["underlying cirrhosis", "PROBLEM", 74, 94], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["alcoholic hepatitis", "OBSERVATION", 44, 63], ["cirrhosis", "OBSERVATION", 85, 94]]], ["The spectrum of alcoholic liver disease ranges from asymptomatic fatty liver to alcoholic hepatitis to decompensated cirrhosis.", [["liver", "ANATOMY", 26, 31], ["fatty liver", "ANATOMY", 65, 76], ["alcoholic liver disease", "DISEASE", 16, 39], ["fatty liver", "DISEASE", 65, 76], ["alcoholic hepatitis", "DISEASE", 80, 99], ["decompensated cirrhosis", "DISEASE", 103, 126], ["liver", "ORGAN", 26, 31], ["liver", "ORGAN", 71, 76], ["alcoholic liver disease ranges", "PROBLEM", 16, 46], ["asymptomatic fatty liver", "PROBLEM", 52, 76], ["alcoholic hepatitis", "PROBLEM", 80, 99], ["decompensated cirrhosis", "PROBLEM", 103, 126], ["alcoholic", "OBSERVATION_MODIFIER", 16, 25], ["liver", "ANATOMY", 26, 31], ["disease", "OBSERVATION", 32, 39], ["asymptomatic", "OBSERVATION_MODIFIER", 52, 64], ["fatty", "OBSERVATION", 65, 70], ["liver", "ANATOMY", 71, 76], ["alcoholic hepatitis", "OBSERVATION", 80, 99], ["decompensated", "OBSERVATION_MODIFIER", 103, 116], ["cirrhosis", "OBSERVATION", 117, 126]]], ["Fatty liver or hepatic steatosis is the most common form of alcoholic liver disease and is reversible with abstinence from alcohol intake.", [["Fatty liver", "ANATOMY", 0, 11], ["hepatic", "ANATOMY", 15, 22], ["liver", "ANATOMY", 70, 75], ["Fatty liver", "DISEASE", 0, 11], ["hepatic steatosis", "DISEASE", 15, 32], ["alcoholic liver disease", "DISEASE", 60, 83], ["alcohol", "CHEMICAL", 123, 130], ["alcohol", "CHEMICAL", 123, 130], ["liver", "ORGAN", 6, 11], ["hepatic", "ORGAN", 15, 22], ["liver", "ORGAN", 70, 75], ["alcohol", "SIMPLE_CHEMICAL", 123, 130], ["Fatty liver", "PROBLEM", 0, 11], ["hepatic steatosis", "PROBLEM", 15, 32], ["alcoholic liver disease", "PROBLEM", 60, 83], ["liver", "ANATOMY", 6, 11], ["hepatic", "ANATOMY", 15, 22], ["steatosis", "OBSERVATION", 23, 32], ["most common", "OBSERVATION_MODIFIER", 40, 51], ["alcoholic", "OBSERVATION", 60, 69], ["liver", "ANATOMY", 70, 75], ["disease", "OBSERVATION", 76, 83], ["reversible", "OBSERVATION_MODIFIER", 91, 101], ["alcohol intake", "OBSERVATION", 123, 137]]], ["Its first clinical manifestation is typically asymptomatic hepatomegaly.", [["hepatomegaly", "DISEASE", 59, 71], ["typically asymptomatic hepatomegaly", "PROBLEM", 36, 71], ["typically", "OBSERVATION_MODIFIER", 36, 45], ["asymptomatic", "OBSERVATION_MODIFIER", 46, 58], ["hepatomegaly", "OBSERVATION", 59, 71]]], ["As a consequence of preferential alcohol oxidation, the liver develops fatty deposition.", [["liver", "ANATOMY", 56, 61], ["alcohol", "CHEMICAL", 33, 40], ["alcohol", "CHEMICAL", 33, 40], ["alcohol", "SIMPLE_CHEMICAL", 33, 40], ["liver", "ORGAN", 56, 61], ["fatty", "SIMPLE_CHEMICAL", 71, 76], ["fatty deposition", "PROBLEM", 71, 87], ["preferential", "OBSERVATION_MODIFIER", 20, 32], ["alcohol oxidation", "OBSERVATION", 33, 50], ["liver", "ANATOMY", 56, 61], ["fatty deposition", "OBSERVATION", 71, 87]]], ["Alcoholic fatty liver is rarely diagnosed clinically because most patients are asymptomatic and do not seek medical attention.", [["Alcoholic fatty liver", "ANATOMY", 0, 21], ["Alcoholic", "DISEASE", 0, 9], ["fatty liver", "DISEASE", 10, 21], ["liver", "ORGAN", 16, 21], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["Alcoholic fatty liver", "PROBLEM", 0, 21], ["asymptomatic", "PROBLEM", 79, 91], ["fatty", "OBSERVATION", 10, 15], ["liver", "ANATOMY", 16, 21]]], ["However, up to 90% of alcoholics have steatosis.", [["alcoholics", "DISEASE", 22, 32], ["steatosis", "DISEASE", 38, 47], ["alcoholics", "ORGANISM", 22, 32], ["steatosis", "PROBLEM", 38, 47], ["steatosis", "OBSERVATION", 38, 47]]], ["Fatty liver can occur within hours after a large alcohol binge.", [["Fatty liver", "ANATOMY", 0, 11], ["Fatty liver", "DISEASE", 0, 11], ["alcohol", "CHEMICAL", 49, 56], ["alcohol", "CHEMICAL", 49, 56], ["liver", "ORGAN", 6, 11], ["alcohol", "SIMPLE_CHEMICAL", 49, 56], ["Fatty liver", "PROBLEM", 0, 11], ["liver", "ANATOMY", 6, 11], ["large", "OBSERVATION_MODIFIER", 43, 48], ["alcohol binge", "OBSERVATION", 49, 62]]], ["It represents a direct effect of ethanol and can occur despite an adequate nutritional state.", [["ethanol", "CHEMICAL", 33, 40], ["ethanol", "CHEMICAL", 33, 40], ["ethanol", "SIMPLE_CHEMICAL", 33, 40], ["ethanol", "TREATMENT", 33, 40]]], ["The CT scan image ( Fig. 39.1 ), in this case, reveals an enlarged fatty liver (Hounsfield units of the liver are much lower when compared with the spleen; i.e., the liver is less dense, correlating with severe fatty infiltration).Answer: Severe Acute Alcoholic HepatitisThe diagnosis of acute alcoholic hepatitis can almost always be made on clinical grounds and rarely is a liver biopsy needed.", [["fatty liver", "ANATOMY", 67, 78], ["liver", "ANATOMY", 104, 109], ["spleen", "ANATOMY", 148, 154], ["liver", "ANATOMY", 166, 171], ["liver", "ANATOMY", 376, 381], ["fatty liver", "DISEASE", 67, 78], ["fatty infiltration", "DISEASE", 211, 229], ["Alcoholic Hepatitis", "DISEASE", 252, 271], ["alcoholic hepatitis", "DISEASE", 294, 313], ["liver", "ORGAN", 73, 78], ["liver", "ORGAN", 104, 109], ["spleen", "ORGAN", 148, 154], ["liver", "ORGAN", 166, 171], ["liver", "ORGAN", 376, 381], ["The CT scan image", "TEST", 0, 17], ["an enlarged fatty liver", "PROBLEM", 55, 78], ["severe fatty infiltration", "PROBLEM", 204, 229], ["Severe Acute Alcoholic Hepatitis", "PROBLEM", 239, 271], ["acute alcoholic hepatitis", "PROBLEM", 288, 313], ["a liver biopsy", "TEST", 374, 388], ["enlarged", "OBSERVATION_MODIFIER", 58, 66], ["fatty", "OBSERVATION", 67, 72], ["liver", "ANATOMY", 73, 78], ["Hounsfield units", "OBSERVATION_MODIFIER", 80, 96], ["liver", "ANATOMY", 104, 109], ["much", "OBSERVATION_MODIFIER", 114, 118], ["lower", "OBSERVATION_MODIFIER", 119, 124], ["spleen", "ANATOMY", 148, 154], ["liver", "ANATOMY", 166, 171], ["less", "OBSERVATION_MODIFIER", 175, 179], ["dense", "OBSERVATION", 180, 185], ["severe", "OBSERVATION_MODIFIER", 204, 210], ["fatty infiltration", "OBSERVATION", 211, 229], ["Severe", "OBSERVATION_MODIFIER", 239, 245], ["Acute", "OBSERVATION_MODIFIER", 246, 251], ["Alcoholic Hepatitis", "OBSERVATION", 252, 271], ["acute", "OBSERVATION_MODIFIER", 288, 293], ["alcoholic hepatitis", "OBSERVATION", 294, 313], ["liver", "ANATOMY", 376, 381], ["biopsy", "OBSERVATION", 382, 388]]], ["In the rare case, where the diagnosis is uncertain a liver biopsy may be obtained revealing hepatoceullular disarray; polymorphonuclear cell infiltration in the parenchyma; Mallory's hyaline bodies (seen in approximately one-third of cases), which are clumps of intermediary cytokeratin filaments due to tubulin-acetaldehyde adducts; and some degree of steatosis, cholestasis, fibrosis, and necrosis.", [["liver", "ANATOMY", 53, 58], ["hepatoceullular", "ANATOMY", 92, 107], ["polymorphonuclear cell", "ANATOMY", 118, 140], ["parenchyma", "ANATOMY", 161, 171], ["hyaline bodies", "ANATOMY", 183, 197], ["filaments", "ANATOMY", 287, 296], ["tubulin-acetaldehyde", "CHEMICAL", 304, 324], ["steatosis", "DISEASE", 353, 362], ["cholestasis", "DISEASE", 364, 375], ["fibrosis", "DISEASE", 377, 385], ["necrosis", "DISEASE", 391, 399], ["tubulin-acetaldehyde", "CHEMICAL", 304, 324], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 53, 65], ["polymorphonuclear cell", "CELL", 118, 140], ["parenchyma", "TISSUE", 161, 171], ["Mallory's hyaline bodies", "TISSUE", 173, 197], ["cytokeratin", "GENE_OR_GENE_PRODUCT", 275, 286], ["tubulin-acetaldehyde adducts", "SIMPLE_CHEMICAL", 304, 332], ["tubulin", "PROTEIN", 304, 311], ["a liver biopsy", "TEST", 51, 65], ["hepatoceullular disarray", "PROBLEM", 92, 116], ["polymorphonuclear cell infiltration in the parenchyma", "PROBLEM", 118, 171], ["Mallory's hyaline bodies", "PROBLEM", 173, 197], ["intermediary cytokeratin filaments", "PROBLEM", 262, 296], ["tubulin-acetaldehyde adducts", "PROBLEM", 304, 332], ["steatosis", "PROBLEM", 353, 362], ["cholestasis", "PROBLEM", 364, 375], ["fibrosis", "PROBLEM", 377, 385], ["necrosis", "PROBLEM", 391, 399], ["liver", "ANATOMY", 53, 58], ["polymorphonuclear cell infiltration", "OBSERVATION", 118, 153], ["parenchyma", "ANATOMY", 161, 171], ["Mallory", "OBSERVATION_MODIFIER", 173, 180], ["hyaline bodies", "OBSERVATION", 183, 197], ["clumps", "OBSERVATION_MODIFIER", 252, 258], ["intermediary cytokeratin filaments", "OBSERVATION", 262, 296], ["acetaldehyde adducts", "OBSERVATION", 312, 332], ["some degree", "OBSERVATION_MODIFIER", 338, 349], ["steatosis", "OBSERVATION", 353, 362], ["cholestasis", "OBSERVATION", 364, 375], ["fibrosis", "OBSERVATION", 377, 385], ["necrosis", "OBSERVATION", 391, 399]]], ["The presence of neutrophils is a hallmark of alcoholic hepatitis and is unusual in chronic viral hepatitis.Answer: Severe Acute Alcoholic HepatitisAlcohol is metabolized primarily through the liver.", [["neutrophils", "ANATOMY", 16, 27], ["liver", "ANATOMY", 192, 197], ["alcoholic hepatitis", "DISEASE", 45, 64], ["chronic viral hepatitis", "DISEASE", 83, 106], ["HepatitisAlcohol", "CHEMICAL", 138, 154], ["neutrophils", "CELL", 16, 27], ["liver", "ORGAN", 192, 197], ["neutrophils", "CELL_TYPE", 16, 27], ["neutrophils", "PROBLEM", 16, 27], ["alcoholic hepatitis", "PROBLEM", 45, 64], ["chronic viral hepatitis", "PROBLEM", 83, 106], ["Severe Acute Alcoholic HepatitisAlcohol", "PROBLEM", 115, 154], ["neutrophils", "OBSERVATION", 16, 27], ["hallmark", "OBSERVATION_MODIFIER", 33, 41], ["alcoholic hepatitis", "OBSERVATION", 45, 64], ["chronic", "OBSERVATION_MODIFIER", 83, 90], ["viral hepatitis", "OBSERVATION", 91, 106], ["Severe", "OBSERVATION_MODIFIER", 115, 121], ["Acute", "OBSERVATION_MODIFIER", 122, 127], ["Alcoholic HepatitisAlcohol", "OBSERVATION", 128, 154], ["liver", "ANATOMY", 192, 197]]], ["Once alcohol is ingested and absorbed through the gut, it is metabolized by both gastric and hepatic alcohol dehydrogenase to acetaldehyde.", [["gut", "ANATOMY", 50, 53], ["gastric", "ANATOMY", 81, 88], ["hepatic", "ANATOMY", 93, 100], ["alcohol", "CHEMICAL", 5, 12], ["alcohol", "CHEMICAL", 101, 108], ["acetaldehyde", "CHEMICAL", 126, 138], ["alcohol", "CHEMICAL", 5, 12], ["alcohol", "CHEMICAL", 101, 108], ["acetaldehyde", "CHEMICAL", 126, 138], ["alcohol", "SIMPLE_CHEMICAL", 5, 12], ["gut", "ORGANISM_SUBDIVISION", 50, 53], ["gastric", "MULTI-TISSUE_STRUCTURE", 81, 88], ["hepatic", "ORGAN", 93, 100], ["alcohol dehydrogenase", "GENE_OR_GENE_PRODUCT", 101, 122], ["acetaldehyde", "SIMPLE_CHEMICAL", 126, 138], ["hepatic alcohol dehydrogenase", "PROTEIN", 93, 122], ["gastric", "ANATOMY", 81, 88], ["hepatic", "ANATOMY", 93, 100], ["alcohol dehydrogenase", "OBSERVATION", 101, 122]]], ["Acetaldehyde is in turn oxidized by the liver using aldehyde dehydrogenase and the microsomal ethanol-oxidizing system, cytochrome P450 2E1 (CYP2E1).Answer: Severe Acute Alcoholic HepatitisHeavy alcohol consumption is considered >20 g/day in women and >80 g/day in men.", [["liver", "ANATOMY", 40, 45], ["Acetaldehyde", "CHEMICAL", 0, 12], ["aldehyde", "CHEMICAL", 52, 60], ["ethanol", "CHEMICAL", 94, 101], ["Alcoholic Hepatitis", "DISEASE", 170, 189], ["alcohol", "CHEMICAL", 195, 202], ["Acetaldehyde", "CHEMICAL", 0, 12], ["aldehyde", "CHEMICAL", 52, 60], ["ethanol", "CHEMICAL", 94, 101], ["alcohol", "CHEMICAL", 195, 202], ["Acetaldehyde", "SIMPLE_CHEMICAL", 0, 12], ["liver", "ORGAN", 40, 45], ["aldehyde dehydrogenase", "GENE_OR_GENE_PRODUCT", 52, 74], ["ethanol", "SIMPLE_CHEMICAL", 94, 101], ["cytochrome P450 2E1", "GENE_OR_GENE_PRODUCT", 120, 139], ["CYP2E1", "GENE_OR_GENE_PRODUCT", 141, 147], ["alcohol", "SIMPLE_CHEMICAL", 195, 202], ["women", "ORGANISM", 242, 247], ["men", "ORGANISM", 265, 268], ["aldehyde dehydrogenase", "PROTEIN", 52, 74], ["cytochrome P450 2E1", "PROTEIN", 120, 139], ["CYP2E1", "PROTEIN", 141, 147], ["women", "SPECIES", 242, 247], ["men", "SPECIES", 265, 268], ["Acetaldehyde", "TREATMENT", 0, 12], ["aldehyde dehydrogenase", "TREATMENT", 52, 74], ["the microsomal ethanol-oxidizing system", "TREATMENT", 79, 118], ["Severe Acute Alcoholic Hepatitis", "PROBLEM", 157, 189], ["liver", "ANATOMY", 40, 45], ["Severe", "OBSERVATION_MODIFIER", 157, 163], ["Acute", "OBSERVATION_MODIFIER", 164, 169], ["Alcoholic Hepatitis", "OBSERVATION", 170, 189]]], ["The incidence of cirrhosis is significantly increased in men who consume >40-60 g/day.", [["cirrhosis", "DISEASE", 17, 26], ["men", "ORGANISM", 57, 60], ["men", "SPECIES", 57, 60], ["cirrhosis", "PROBLEM", 17, 26], ["cirrhosis", "OBSERVATION", 17, 26], ["significantly", "OBSERVATION_MODIFIER", 30, 43], ["increased", "OBSERVATION_MODIFIER", 44, 53]]], ["Approximately 20% of men drinking >12 beers/day will go on to develop cirrhosis in 10 years.Answer: Severe Acute Alcoholic HepatitisIt is estimated that 30% of patients with alcoholic hepatitis are infected with HCV.Answer: Severe Acute Alcoholic HepatitisA high prevalence (25-65%) of hepatitis C virus infection has been recognized in alcoholics.", [["cirrhosis", "DISEASE", 70, 79], ["Alcoholic Hepatitis", "DISEASE", 113, 132], ["alcoholic hepatitis", "DISEASE", 174, 193], ["HCV", "DISEASE", 212, 215], ["Alcoholic HepatitisA", "DISEASE", 237, 257], ["hepatitis C virus infection", "DISEASE", 286, 313], ["men", "ORGANISM", 21, 24], ["patients", "ORGANISM", 160, 168], ["HCV", "ORGANISM", 212, 215], ["hepatitis C virus", "ORGANISM", 286, 303], ["men", "SPECIES", 21, 24], ["patients", "SPECIES", 160, 168], ["hepatitis C virus", "SPECIES", 286, 303], ["HCV", "SPECIES", 212, 215], ["hepatitis C virus", "SPECIES", 286, 303], ["cirrhosis", "PROBLEM", 70, 79], ["Severe Acute Alcoholic Hepatitis", "PROBLEM", 100, 132], ["alcoholic hepatitis", "PROBLEM", 174, 193], ["HCV", "PROBLEM", 212, 215], ["Severe Acute Alcoholic HepatitisA", "PROBLEM", 224, 257], ["hepatitis C virus infection", "PROBLEM", 286, 313], ["cirrhosis", "OBSERVATION", 70, 79], ["Severe", "OBSERVATION_MODIFIER", 100, 106], ["Acute", "OBSERVATION_MODIFIER", 107, 112], ["Alcoholic Hepatitis", "OBSERVATION", 113, 132], ["alcoholic", "OBSERVATION_MODIFIER", 174, 183], ["hepatitis", "OBSERVATION", 184, 193], ["infected", "OBSERVATION", 198, 206], ["Severe", "OBSERVATION_MODIFIER", 224, 230], ["Acute", "OBSERVATION_MODIFIER", 231, 236], ["Alcoholic", "OBSERVATION", 237, 246], ["hepatitis", "OBSERVATION", 286, 295], ["virus infection", "OBSERVATION", 298, 313]]], ["Such patients tend to have more severe disease, decreased survival, and an increased risk of HCC.Answer: Severe Acute Alcoholic HepatitisThere are several characteristic laboratory abnormalities in patients with alcoholic liver disease, but no lab test in particular is diagnostic.", [["HCC", "ANATOMY", 93, 96], ["liver", "ANATOMY", 222, 227], ["HCC", "DISEASE", 93, 96], ["Alcoholic Hepatitis", "DISEASE", 118, 137], ["alcoholic liver disease", "DISEASE", 212, 235], ["patients", "ORGANISM", 5, 13], ["HCC", "CANCER", 93, 96], ["patients", "ORGANISM", 198, 206], ["liver", "ORGAN", 222, 227], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 198, 206], ["more severe disease", "PROBLEM", 27, 46], ["decreased survival", "PROBLEM", 48, 66], ["HCC", "PROBLEM", 93, 96], ["Severe Acute Alcoholic Hepatitis", "PROBLEM", 105, 137], ["several characteristic laboratory abnormalities", "PROBLEM", 147, 194], ["alcoholic liver disease", "PROBLEM", 212, 235], ["lab test", "TEST", 244, 252], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["disease", "OBSERVATION", 39, 46], ["decreased", "OBSERVATION_MODIFIER", 48, 57], ["survival", "OBSERVATION_MODIFIER", 58, 66], ["increased", "OBSERVATION_MODIFIER", 75, 84], ["HCC", "OBSERVATION", 93, 96], ["Severe", "OBSERVATION_MODIFIER", 105, 111], ["Acute", "OBSERVATION_MODIFIER", 112, 117], ["Alcoholic Hepatitis", "OBSERVATION", 118, 137], ["several", "OBSERVATION_MODIFIER", 147, 154], ["characteristic", "OBSERVATION_MODIFIER", 155, 169], ["laboratory abnormalities", "OBSERVATION", 170, 194], ["alcoholic", "OBSERVATION_MODIFIER", 212, 221], ["liver", "ANATOMY", 222, 227], ["disease", "OBSERVATION", 228, 235]]], ["The most common pattern of LFT abnormality is a disproportionate elevation of serum AST to ALT.", [["serum", "ANATOMY", 78, 83], ["serum", "ORGANISM_SUBSTANCE", 78, 83], ["AST", "SIMPLE_CHEMICAL", 84, 87], ["ALT", "SIMPLE_CHEMICAL", 91, 94], ["serum AST", "PROTEIN", 78, 87], ["ALT", "PROTEIN", 91, 94], ["LFT abnormality", "PROBLEM", 27, 42], ["a disproportionate elevation", "PROBLEM", 46, 74], ["serum AST", "TEST", 78, 87], ["ALT", "TEST", 91, 94], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["LFT", "ANATOMY", 27, 30], ["abnormality", "OBSERVATION", 31, 42], ["disproportionate", "OBSERVATION_MODIFIER", 48, 64], ["elevation", "OBSERVATION_MODIFIER", 65, 74]]], ["This ratio is usually greater than 2, a value that is rarely seen in other forms of liver disease.", [["liver", "ANATOMY", 84, 89], ["liver disease", "DISEASE", 84, 97], ["liver", "ORGAN", 84, 89], ["This ratio", "TEST", 0, 10], ["liver disease", "PROBLEM", 84, 97], ["greater", "OBSERVATION_MODIFIER", 22, 29], ["liver", "ANATOMY", 84, 89], ["disease", "OBSERVATION", 90, 97]]], ["The absolute value of serum AST and ALT are usually less than 500 iu/l (and typically less than 300).", [["serum", "ANATOMY", 22, 27], ["serum", "ORGANISM_SUBSTANCE", 22, 27], ["AST", "SIMPLE_CHEMICAL", 28, 31], ["ALT", "SIMPLE_CHEMICAL", 36, 39], ["serum AST", "PROTEIN", 22, 31], ["ALT", "PROTEIN", 36, 39], ["The absolute value", "TEST", 0, 18], ["serum AST", "TEST", 22, 31], ["ALT", "TEST", 36, 39], ["absolute", "OBSERVATION_MODIFIER", 4, 12]]], ["The unusual variant \"alcoholic foamy degeneration\" which is characterized by jaundice and hyperlipidemia can elevate AST as high as 700.Answer: Severe Acute Alcoholic HepatitisOther lab abnormalities include: marked elevation in GGTP, macrocytosis as a result of poor nutritional status and B12 and folate deficiencies; thrombocytopenia as a result of primary bone marrow hypoplasia or splenic sequestration due to splenomegaly from portal hypertension.", [["bone marrow", "ANATOMY", 360, 371], ["splenic", "ANATOMY", 386, 393], ["portal", "ANATOMY", 433, 439], ["alcoholic foamy degeneration", "DISEASE", 21, 49], ["jaundice", "DISEASE", 77, 85], ["hyperlipidemia", "DISEASE", 90, 104], ["Alcoholic HepatitisOther lab abnormalities", "DISEASE", 157, 199], ["macrocytosis", "DISEASE", 235, 247], ["B12", "CHEMICAL", 291, 294], ["folate", "CHEMICAL", 299, 305], ["thrombocytopenia", "DISEASE", 320, 336], ["primary bone marrow hypoplasia", "DISEASE", 352, 382], ["splenic sequestration", "DISEASE", 386, 407], ["splenomegaly", "DISEASE", 415, 427], ["portal hypertension", "DISEASE", 433, 452], ["B12", "CHEMICAL", 291, 294], ["folate", "CHEMICAL", 299, 305], ["GGTP", "SIMPLE_CHEMICAL", 229, 233], ["B12", "SIMPLE_CHEMICAL", 291, 294], ["folate", "SIMPLE_CHEMICAL", 299, 305], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 360, 371], ["splenic", "ORGAN", 386, 393], ["splenomegaly", "PATHOLOGICAL_FORMATION", 415, 427], ["portal", "MULTI-TISSUE_STRUCTURE", 433, 439], ["AST", "PROTEIN", 117, 120], ["alcoholic foamy degeneration", "PROBLEM", 21, 49], ["jaundice", "PROBLEM", 77, 85], ["hyperlipidemia", "PROBLEM", 90, 104], ["AST", "TEST", 117, 120], ["Severe Acute Alcoholic HepatitisOther lab abnormalities", "PROBLEM", 144, 199], ["marked elevation in GGTP", "PROBLEM", 209, 233], ["macrocytosis", "PROBLEM", 235, 247], ["poor nutritional status", "PROBLEM", 263, 286], ["B12 and folate deficiencies", "PROBLEM", 291, 318], ["thrombocytopenia", "PROBLEM", 320, 336], ["primary bone marrow hypoplasia", "PROBLEM", 352, 382], ["splenic sequestration", "PROBLEM", 386, 407], ["splenomegaly", "PROBLEM", 415, 427], ["portal hypertension", "PROBLEM", 433, 452], ["alcoholic foamy degeneration", "OBSERVATION", 21, 49], ["jaundice", "OBSERVATION", 77, 85], ["hyperlipidemia", "OBSERVATION", 90, 104], ["Severe", "OBSERVATION_MODIFIER", 144, 150], ["Acute", "OBSERVATION_MODIFIER", 151, 156], ["Alcoholic", "OBSERVATION", 157, 166], ["marked", "OBSERVATION_MODIFIER", 209, 215], ["elevation", "OBSERVATION_MODIFIER", 216, 225], ["macrocytosis", "OBSERVATION", 235, 247], ["folate deficiencies", "OBSERVATION", 299, 318], ["thrombocytopenia", "OBSERVATION", 320, 336], ["primary", "OBSERVATION_MODIFIER", 352, 359], ["bone marrow hypoplasia", "OBSERVATION", 360, 382], ["splenic", "ANATOMY", 386, 393], ["sequestration", "OBSERVATION", 394, 407], ["splenomegaly", "OBSERVATION", 415, 427], ["portal", "ANATOMY", 433, 439], ["hypertension", "OBSERVATION", 440, 452]]], ["Leuckocytosis is a hallmark lab finding and correlates closely with the severity of the hepatic injury.Answer: Severe Acute Alcoholic HepatitisThe presentation of alcoholic hepatitis can be dramatic and many times carries a grave prognosis.", [["hepatic", "ANATOMY", 88, 95], ["Leuckocytosis", "DISEASE", 0, 13], ["hepatic injury", "DISEASE", 88, 102], ["Alcoholic Hepatitis", "DISEASE", 124, 143], ["alcoholic hepatitis", "DISEASE", 163, 182], ["hepatic", "ORGAN", 88, 95], ["the hepatic injury", "PROBLEM", 84, 102], ["Severe Acute Alcoholic Hepatitis", "PROBLEM", 111, 143], ["alcoholic hepatitis", "PROBLEM", 163, 182], ["hepatic", "ANATOMY", 88, 95], ["injury", "OBSERVATION", 96, 102], ["Severe", "OBSERVATION_MODIFIER", 111, 117], ["Acute", "OBSERVATION_MODIFIER", 118, 123], ["Alcoholic Hepatitis", "OBSERVATION", 124, 143], ["alcoholic hepatitis", "OBSERVATION", 163, 182]]], ["The prognosis of alcoholic liver disease depends upon its severity.", [["liver", "ANATOMY", 27, 32], ["alcoholic liver disease", "DISEASE", 17, 40], ["liver", "ORGAN", 27, 32], ["alcoholic liver disease", "PROBLEM", 17, 40], ["alcoholic", "OBSERVATION_MODIFIER", 17, 26], ["liver", "ANATOMY", 27, 32], ["disease", "OBSERVATION", 33, 40]]], ["Several predictive models have been proposed, which can also help to guide therapy.", [["therapy", "TREATMENT", 75, 82]]], ["The Maddrey's discriminant function is perhaps the most widely used.", [["most widely", "OBSERVATION_MODIFIER", 51, 62]]], ["It takes into account the elevation in prothrombin time and Bilirubin: 4.6 \u00d7 (patient's PT -control PT) + total bilirubin.", [["bilirubin", "CHEMICAL", 112, 121], ["Bilirubin", "CHEMICAL", 60, 69], ["bilirubin", "CHEMICAL", 112, 121], ["prothrombin", "GENE_OR_GENE_PRODUCT", 39, 50], ["Bilirubin", "SIMPLE_CHEMICAL", 60, 69], ["patient", "ORGANISM", 78, 85], ["bilirubin", "GENE_OR_GENE_PRODUCT", 112, 121], ["prothrombin", "PROTEIN", 39, 50], ["patient", "SPECIES", 78, 85], ["the elevation", "PROBLEM", 22, 35], ["prothrombin time", "TEST", 39, 55], ["Bilirubin", "TEST", 60, 69], ["patient's PT", "TEST", 78, 90], ["PT", "TEST", 100, 102], ["total bilirubin", "TEST", 106, 121], ["elevation", "OBSERVATION", 26, 35]]], ["Scores \u00b332 are considered severe and warrant consideration for treatment.", [["Scores", "TEST", 0, 6], ["treatment", "TREATMENT", 63, 72], ["severe", "OBSERVATION_MODIFIER", 26, 32]]], ["More recently, the MELD score has been used to prognosticate outcome, with a score of >11 considered severe disease.Answer: Severe Acute Alcoholic HepatitisTherapy is generally supportive and many times futile.", [["Alcoholic Hepatitis", "DISEASE", 137, 156], ["the MELD score", "TEST", 15, 29], ["a score", "TEST", 75, 82], ["severe disease", "PROBLEM", 101, 115], ["Severe Acute Alcoholic Hepatitis", "PROBLEM", 124, 156], ["Therapy", "TREATMENT", 156, 163], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["disease", "OBSERVATION", 108, 115], ["Severe", "OBSERVATION_MODIFIER", 124, 130], ["Acute", "OBSERVATION_MODIFIER", 131, 136], ["Alcoholic Hepatitis", "OBSERVATION", 137, 156]]], ["Survival in patients admitted to an intensive care unit is approximately 5%, This is especially true when there is concomitant renal failure.", [["renal", "ANATOMY", 127, 132], ["renal failure", "DISEASE", 127, 140], ["patients", "ORGANISM", 12, 20], ["renal", "ORGAN", 127, 132], ["patients", "SPECIES", 12, 20], ["concomitant renal failure", "PROBLEM", 115, 140], ["concomitant", "OBSERVATION_MODIFIER", 115, 126], ["renal", "ANATOMY", 127, 132], ["failure", "OBSERVATION", 133, 140]]], ["In addition to strict abstinence, aggressive nutrition and supplementation, treatment of withdrawal, several studies have shown a role for steroids (prednisolone) or pentoxyfylline.", [["steroids", "CHEMICAL", 139, 147], ["prednisolone", "CHEMICAL", 149, 161], ["pentoxyfylline", "CHEMICAL", 166, 180], ["steroids", "CHEMICAL", 139, 147], ["prednisolone", "CHEMICAL", 149, 161], ["pentoxyfylline", "CHEMICAL", 166, 180], ["steroids", "SIMPLE_CHEMICAL", 139, 147], ["prednisolone", "SIMPLE_CHEMICAL", 149, 161], ["pentoxyfylline", "SIMPLE_CHEMICAL", 166, 180], ["aggressive nutrition", "TREATMENT", 34, 54], ["supplementation", "TREATMENT", 59, 74], ["withdrawal", "PROBLEM", 89, 99], ["several studies", "TEST", 101, 116], ["steroids (prednisolone)", "TREATMENT", 139, 162], ["pentoxyfylline", "TREATMENT", 166, 180]]], ["Appropriate patients who have been abstinent for at least 6 months should be considered for liver transplantation.Answer: Severe Acute Alcoholic HepatitisThe patient in the case presented was started on pentoxyfylline 400 mg po TID.", [["liver", "ANATOMY", 92, 97], ["Alcoholic Hepatitis", "DISEASE", 135, 154], ["pentoxyfylline", "CHEMICAL", 203, 217], ["TID", "CHEMICAL", 228, 231], ["pentoxyfylline", "CHEMICAL", 203, 217], ["TID", "CHEMICAL", 228, 231], ["patients", "ORGANISM", 12, 20], ["liver", "ORGAN", 92, 97], ["patient", "ORGANISM", 158, 165], ["pentoxyfylline", "SIMPLE_CHEMICAL", 203, 217], ["patients", "SPECIES", 12, 20], ["patient", "SPECIES", 158, 165], ["liver transplantation", "TREATMENT", 92, 113], ["Severe Acute Alcoholic Hepatitis", "PROBLEM", 122, 154], ["pentoxyfylline", "TREATMENT", 203, 217], ["liver", "ANATOMY", 92, 97], ["transplantation", "OBSERVATION", 98, 113], ["Severe", "OBSERVATION_MODIFIER", 122, 128], ["Acute", "OBSERVATION_MODIFIER", 129, 134], ["Alcoholic Hepatitis", "OBSERVATION", 135, 154]]], ["Despite treatment, however, over the next several months, the patient deteriorated with the onset of ascites, renal failure, and eventually variceal bleeding requiring endoscopic band ligation.", [["ascites", "ANATOMY", 101, 108], ["renal", "ANATOMY", 110, 115], ["variceal", "ANATOMY", 140, 148], ["ascites", "DISEASE", 101, 108], ["renal failure", "DISEASE", 110, 123], ["bleeding", "DISEASE", 149, 157], ["patient", "ORGANISM", 62, 69], ["renal", "ORGAN", 110, 115], ["patient", "SPECIES", 62, 69], ["treatment", "TREATMENT", 8, 17], ["ascites", "PROBLEM", 101, 108], ["renal failure", "PROBLEM", 110, 123], ["eventually variceal bleeding", "PROBLEM", 129, 157], ["endoscopic band ligation", "TREATMENT", 168, 192], ["ascites", "OBSERVATION", 101, 108], ["renal", "ANATOMY", 110, 115], ["failure", "OBSERVATION", 116, 123], ["variceal bleeding", "OBSERVATION", 140, 157], ["band ligation", "OBSERVATION", 179, 192]]], ["After 6 months of abstinence and formal alcohol rehab, the patient underwent successful liver transplantation.", [["liver", "ANATOMY", 88, 93], ["alcohol", "CHEMICAL", 40, 47], ["alcohol", "CHEMICAL", 40, 47], ["alcohol", "SIMPLE_CHEMICAL", 40, 47], ["patient", "ORGANISM", 59, 66], ["liver", "ORGAN", 88, 93], ["patient", "SPECIES", 59, 66], ["abstinence", "TREATMENT", 18, 28], ["formal alcohol rehab", "TREATMENT", 33, 53], ["successful liver transplantation", "TREATMENT", 77, 109], ["liver", "ANATOMY", 88, 93], ["transplantation", "OBSERVATION", 94, 109]]], ["She was seen in the clinic 1 year after her transplant and is doing well and has remained abstinent from all drugs and alcohol.Case 40A 33-year-old Caucasian male with a past medical history significant only for psoriasis, presents to a local emergency room with progressively worsening right flank pain over the last 1 month.", [["right flank", "ANATOMY", 287, 298], ["alcohol", "CHEMICAL", 119, 126], ["psoriasis", "DISEASE", 212, 221], ["right flank pain", "DISEASE", 287, 303], ["alcohol", "CHEMICAL", 119, 126], ["alcohol", "SIMPLE_CHEMICAL", 119, 126], ["flank", "ORGANISM_SUBDIVISION", 293, 298], ["her transplant", "TREATMENT", 40, 54], ["psoriasis", "PROBLEM", 212, 221], ["progressively worsening right flank pain", "PROBLEM", 263, 303], ["transplant", "OBSERVATION", 44, 54], ["psoriasis", "OBSERVATION", 212, 221], ["worsening", "OBSERVATION_MODIFIER", 277, 286], ["right", "ANATOMY_MODIFIER", 287, 292], ["flank", "ANATOMY", 293, 298], ["pain", "OBSERVATION", 299, 303]]], ["He also reports some mild nausea and early satiety.", [["nausea", "DISEASE", 26, 32], ["some mild nausea", "PROBLEM", 16, 32], ["early satiety", "PROBLEM", 37, 50], ["mild", "OBSERVATION_MODIFIER", 21, 25], ["nausea", "OBSERVATION", 26, 32]]], ["The remainder of his review of systems is negative.", [["his review of systems", "TEST", 17, 38], ["negative", "OBSERVATION", 42, 50]]], ["Specifically he denies any dysuria, fevers, or chills.", [["dysuria", "DISEASE", 27, 34], ["fevers", "DISEASE", 36, 42], ["chills", "DISEASE", 47, 53], ["any dysuria", "PROBLEM", 23, 34], ["fevers", "PROBLEM", 36, 42], ["chills", "PROBLEM", 47, 53], ["dysuria", "OBSERVATION", 27, 34], ["fevers", "OBSERVATION", 36, 42], ["chills", "OBSERVATION", 47, 53]]], ["The patient takes a proton pump inhibitor as required for reflux.", [["reflux", "DISEASE", 58, 64], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["a proton pump inhibitor", "TREATMENT", 18, 41], ["reflux", "PROBLEM", 58, 64], ["reflux", "OBSERVATION", 58, 64]]], ["He has undergone an appendectomy and left inguinal hernia repair over 20 years ago.", [["left inguinal hernia", "ANATOMY", 37, 57], ["an appendectomy", "TREATMENT", 17, 32], ["left inguinal hernia repair", "TREATMENT", 37, 64], ["appendectomy", "OBSERVATION", 20, 32], ["left", "ANATOMY_MODIFIER", 37, 41], ["inguinal", "ANATOMY", 42, 50], ["hernia", "OBSERVATION", 51, 57]]], ["The patient works in a shipping yard.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["He smokes 1/2 pack of cigarettes for 15 years.", [["He", "ORGANISM", 0, 2]]], ["He drinks socially.", [["He", "ORGANISM", 0, 2]]], ["There is no history of blood transfusions or tattoos.", [["blood", "ANATOMY", 23, 28], ["blood", "ORGANISM_SUBSTANCE", 23, 28], ["blood transfusions", "TREATMENT", 23, 41], ["tattoos", "PROBLEM", 45, 52], ["no", "UNCERTAINTY", 9, 11], ["tattoos", "OBSERVATION", 45, 52]]], ["He admits to experimenting with nasal cocaine in high school.Case 40Physical exam is notable for a young gentleman who is slightly anxious, but otherwise appears well.", [["nasal", "ANATOMY", 32, 37], ["cocaine", "CHEMICAL", 38, 45], ["cocaine", "CHEMICAL", 38, 45], ["nasal", "ORGANISM_SUBDIVISION", 32, 37], ["slightly anxious", "PROBLEM", 122, 138]]], ["His BMI is 26.7 kg/m 2 .", [["His BMI", "TEST", 0, 7]]], ["He has no stigmata to suggest chronic liver disease.", [["liver", "ANATOMY", 38, 43], ["chronic liver disease", "DISEASE", 30, 51], ["liver", "ORGAN", 38, 43], ["stigmata", "PROBLEM", 10, 18], ["chronic liver disease", "PROBLEM", 30, 51], ["no stigmata to suggest", "UNCERTAINTY", 7, 29], ["chronic", "OBSERVATION_MODIFIER", 30, 37], ["liver", "ANATOMY", 38, 43], ["disease", "OBSERVATION", 44, 51]]], ["The patient is tender in his right upper and lower quadrant.", [["right upper", "ANATOMY", 29, 40], ["lower quadrant", "ANATOMY", 45, 59], ["patient", "ORGANISM", 4, 11], ["right upper", "ORGANISM_SUBDIVISION", 29, 40], ["patient", "SPECIES", 4, 11], ["tender", "PROBLEM", 15, 21], ["tender", "OBSERVATION", 15, 21], ["right", "ANATOMY_MODIFIER", 29, 34], ["upper", "ANATOMY_MODIFIER", 35, 40], ["lower", "ANATOMY_MODIFIER", 45, 50], ["quadrant", "ANATOMY", 51, 59]]], ["Liver edge is palpable 4 cm below the right costal margin.", [["Liver edge", "ANATOMY", 0, 10], ["right costal margin", "ANATOMY", 38, 57], ["Liver edge", "MULTI-TISSUE_STRUCTURE", 0, 10], ["costal margin", "MULTI-TISSUE_STRUCTURE", 44, 57], ["edge", "ANATOMY_MODIFIER", 6, 10], ["palpable", "OBSERVATION", 14, 22], ["4 cm", "OBSERVATION_MODIFIER", 23, 27], ["right", "ANATOMY_MODIFIER", 38, 43], ["costal", "ANATOMY", 44, 50], ["margin", "ANATOMY_MODIFIER", 51, 57]]], ["There is no splenomegaly.", [["splenomegaly", "DISEASE", 12, 24], ["splenomegaly", "PATHOLOGICAL_FORMATION", 12, 24], ["splenomegaly", "PROBLEM", 12, 24], ["no", "UNCERTAINTY", 9, 11], ["splenomegaly", "OBSERVATION", 12, 24]]], ["The remainder of the physical exam is normal.Answer: Fibrolamellar Hepatocellular CarcinomaThis patient presented in this case is relatively young with no evidence to suggest chronic liver disease.", [["Fibrolamellar Hepatocellular CarcinomaThis", "ANATOMY", 53, 95], ["liver", "ANATOMY", 183, 188], ["Fibrolamellar Hepatocellular CarcinomaThis", "DISEASE", 53, 95], ["chronic liver disease", "DISEASE", 175, 196], ["Fibrolamellar Hepatocellular CarcinomaThis", "CANCER", 53, 95], ["patient", "ORGANISM", 96, 103], ["liver", "ORGAN", 183, 188], ["patient", "SPECIES", 96, 103], ["the physical exam", "TEST", 17, 34], ["Fibrolamellar Hepatocellular CarcinomaThis", "PROBLEM", 53, 95], ["chronic liver disease", "PROBLEM", 175, 196], ["remainder", "ANATOMY_MODIFIER", 4, 13], ["normal", "OBSERVATION", 38, 44], ["Fibrolamellar", "OBSERVATION_MODIFIER", 53, 66], ["Hepatocellular CarcinomaThis", "OBSERVATION", 67, 95], ["no evidence to suggest", "UNCERTAINTY", 152, 174], ["chronic", "OBSERVATION_MODIFIER", 175, 182], ["liver", "ANATOMY", 183, 188], ["disease", "OBSERVATION", 189, 196]]], ["Tumor markers are normal and CT scan shows a large heterogenous mass with central scar in what otherwise appears to be normal liver parenchyma (Fig. 40.1 ).", [["Tumor", "ANATOMY", 0, 5], ["mass", "ANATOMY", 64, 68], ["scar", "ANATOMY", 82, 86], ["liver parenchyma", "ANATOMY", 126, 142], ["Tumor", "CANCER", 0, 5], ["scar", "PATHOLOGICAL_FORMATION", 82, 86], ["liver parenchyma", "MULTI-TISSUE_STRUCTURE", 126, 142], ["Tumor markers", "PROTEIN", 0, 13], ["Tumor markers", "TEST", 0, 13], ["CT scan", "TEST", 29, 36], ["a large heterogenous mass", "PROBLEM", 43, 68], ["central scar", "PROBLEM", 74, 86], ["normal", "OBSERVATION", 18, 24], ["large", "OBSERVATION_MODIFIER", 45, 50], ["heterogenous", "OBSERVATION_MODIFIER", 51, 63], ["mass", "OBSERVATION", 64, 68], ["central", "OBSERVATION_MODIFIER", 74, 81], ["scar", "OBSERVATION", 82, 86], ["otherwise appears to be", "UNCERTAINTY", 95, 118], ["normal", "OBSERVATION", 119, 125], ["liver", "ANATOMY", 126, 131], ["parenchyma", "ANATOMY_MODIFIER", 132, 142]]], ["Although the differential would include typical HCC, focal nodular hyperplasia, metastatic tumor, hepatic abscess, and giant cavernous hemangioma, the most likely diagnosis given the clues would be fibrolamellar hepatocellular carcinoma (FLHCC).Answer: Fibrolamellar Hepatocellular CarcinomaFLHCC was first described in 1965 as a distinctive form of primary HCC.", [["HCC", "ANATOMY", 48, 51], ["focal nodular hyperplasia", "ANATOMY", 53, 78], ["metastatic tumor", "ANATOMY", 80, 96], ["hepatic abscess", "ANATOMY", 98, 113], ["giant cavernous hemangioma", "ANATOMY", 119, 145], ["fibrolamellar hepatocellular carcinoma", "ANATOMY", 198, 236], ["FLHCC", "ANATOMY", 238, 243], ["Fibrolamellar Hepatocellular CarcinomaFLHCC", "ANATOMY", 253, 296], ["primary HCC", "ANATOMY", 350, 361], ["HCC", "DISEASE", 48, 51], ["nodular hyperplasia", "DISEASE", 59, 78], ["tumor", "DISEASE", 91, 96], ["hepatic abscess", "DISEASE", 98, 113], ["cavernous hemangioma", "DISEASE", 125, 145], ["fibrolamellar hepatocellular carcinoma", "DISEASE", 198, 236], ["FLHCC", "DISEASE", 238, 243], ["Fibrolamellar Hepatocellular CarcinomaFLHCC", "DISEASE", 253, 296], ["primary HCC", "DISEASE", 350, 361], ["HCC", "CANCER", 48, 51], ["focal nodular hyperplasia", "CANCER", 53, 78], ["metastatic tumor", "CANCER", 80, 96], ["hepatic abscess", "CANCER", 98, 113], ["giant cavernous hemangioma", "CANCER", 119, 145], ["fibrolamellar hepatocellular carcinoma", "CANCER", 198, 236], ["FLHCC", "CANCER", 238, 243], ["Fibrolamellar Hepatocellular CarcinomaFLHCC", "CANCER", 253, 296], ["HCC", "CANCER", 358, 361], ["typical HCC", "PROBLEM", 40, 51], ["focal nodular hyperplasia", "PROBLEM", 53, 78], ["metastatic tumor", "PROBLEM", 80, 96], ["hepatic abscess", "PROBLEM", 98, 113], ["giant cavernous hemangioma", "PROBLEM", 119, 145], ["fibrolamellar hepatocellular carcinoma", "PROBLEM", 198, 236], ["Fibrolamellar Hepatocellular CarcinomaFLHCC", "PROBLEM", 253, 296], ["primary HCC", "PROBLEM", 350, 361], ["differential would include", "UNCERTAINTY", 13, 39], ["typical", "OBSERVATION_MODIFIER", 40, 47], ["HCC", "OBSERVATION", 48, 51], ["focal", "OBSERVATION_MODIFIER", 53, 58], ["nodular", "OBSERVATION_MODIFIER", 59, 66], ["hyperplasia", "OBSERVATION", 67, 78], ["metastatic", "OBSERVATION_MODIFIER", 80, 90], ["tumor", "OBSERVATION", 91, 96], ["hepatic", "ANATOMY", 98, 105], ["abscess", "OBSERVATION", 106, 113], ["giant", "OBSERVATION_MODIFIER", 119, 124], ["cavernous", "ANATOMY", 125, 134], ["hemangioma", "OBSERVATION", 135, 145], ["most likely", "UNCERTAINTY", 151, 162], ["fibrolamellar", "OBSERVATION_MODIFIER", 198, 211], ["hepatocellular carcinoma", "OBSERVATION", 212, 236], ["Hepatocellular", "ANATOMY", 267, 281], ["HCC", "OBSERVATION", 358, 361]]], ["Controversy exists as to whether FLHCC is a distinct entity or a morphological variant of HCC.", [["HCC", "ANATOMY", 90, 93], ["FLHCC", "DISEASE", 33, 38], ["HCC", "DISEASE", 90, 93], ["FLHCC", "CANCER", 33, 38], ["HCC", "CANCER", 90, 93], ["HCC", "PROBLEM", 90, 93], ["HCC", "OBSERVATION", 90, 93]]], ["The two differ in many ways including patient demographics, risk factors, tumor markers, and prognosis.Answer: Fibrolamellar Hepatocellular CarcinomaThe reported incidence of FLHCC seems to vary by geographical region.", [["tumor", "ANATOMY", 74, 79], ["Fibrolamellar Hepatocellular Carcinoma", "ANATOMY", 111, 149], ["tumor", "DISEASE", 74, 79], ["Fibrolamellar Hepatocellular Carcinoma", "DISEASE", 111, 149], ["FLHCC", "DISEASE", 175, 180], ["patient", "ORGANISM", 38, 45], ["tumor", "CANCER", 74, 79], ["Fibrolamellar Hepatocellular Carcinoma", "CANCER", 111, 149], ["FLHCC", "CANCER", 175, 180], ["tumor markers", "PROTEIN", 74, 87], ["patient", "SPECIES", 38, 45], ["risk factors", "PROBLEM", 60, 72], ["tumor markers", "TEST", 74, 87], ["Fibrolamellar Hepatocellular Carcinoma", "PROBLEM", 111, 149], ["FLHCC", "PROBLEM", 175, 180], ["Fibrolamellar", "OBSERVATION_MODIFIER", 111, 124], ["Hepatocellular", "ANATOMY", 125, 139], ["Carcinoma", "OBSERVATION", 140, 149]]], ["The incidence of FLHCC in the USA was reported to be 1-2% of the total HCC cases versus 5.8% of all liver cancers in a Mexican cohort.Answer: Fibrolamellar Hepatocellular CarcinomaMore than 85% of all FLHCC cases occur in individuals aged <35 years with the average age being 25.", [["FLHCC", "ANATOMY", 17, 22], ["HCC", "ANATOMY", 71, 74], ["liver cancers", "ANATOMY", 100, 113], ["Fibrolamellar Hepatocellular CarcinomaMore", "ANATOMY", 142, 184], ["FLHCC", "DISEASE", 17, 22], ["HCC", "DISEASE", 71, 74], ["liver cancers", "DISEASE", 100, 113], ["FLHCC", "DISEASE", 201, 206], ["FLHCC", "CANCER", 17, 22], ["HCC", "CANCER", 71, 74], ["liver cancers", "CANCER", 100, 113], ["Fibrolamellar Hepatocellular CarcinomaMore", "CANCER", 142, 184], ["FLHCC", "CANCER", 201, 206], ["FLHCC in the USA", "PROBLEM", 17, 33], ["the total HCC cases", "PROBLEM", 61, 80], ["all liver cancers", "PROBLEM", 96, 113], ["Fibrolamellar Hepatocellular CarcinomaMore", "PROBLEM", 142, 184], ["HCC", "OBSERVATION", 71, 74], ["liver", "ANATOMY", 100, 105], ["cancers", "OBSERVATION", 106, 113], ["Hepatocellular", "ANATOMY", 156, 170]]], ["This is in contrast to primary HCC where the mean age at diagnosis is between 50 and 65 years of age.", [["primary HCC", "ANATOMY", 23, 34], ["HCC", "DISEASE", 31, 34], ["HCC", "CANCER", 31, 34], ["primary HCC", "PROBLEM", 23, 34], ["HCC", "OBSERVATION", 31, 34]]], ["Also in apposition to HCC where males are affected nearly 2:1 compared to females, FLHCC shows an equal frequency among gender.Answer: Fibrolamellar Hepatocellular CarcinomaThe etiology of FLHCC is still unknown, although some reports have linked occult HBV and focal nodular hyperplasia and long-term oral contraceptive and estrogen use to the formation of FLHCC there is no solid evidence to suggest causality.", [["HCC", "ANATOMY", 22, 25], ["Fibrolamellar Hepatocellular Carcinoma", "ANATOMY", 135, 173], ["FLHCC", "ANATOMY", 189, 194], ["focal nodular hyperplasia", "ANATOMY", 262, 287], ["oral", "ANATOMY", 302, 306], ["HCC", "DISEASE", 22, 25], ["Fibrolamellar Hepatocellular Carcinoma", "DISEASE", 135, 173], ["FLHCC", "DISEASE", 189, 194], ["nodular hyperplasia", "DISEASE", 268, 287], ["oral contraceptive", "CHEMICAL", 302, 320], ["estrogen", "CHEMICAL", 325, 333], ["FLHCC", "DISEASE", 358, 363], ["estrogen", "CHEMICAL", 325, 333], ["HCC", "CANCER", 22, 25], ["FLHCC", "CANCER", 83, 88], ["Fibrolamellar Hepatocellular Carcinoma", "CANCER", 135, 173], ["FLHCC", "CANCER", 189, 194], ["HBV", "ORGANISM", 254, 257], ["focal nodular hyperplasia", "PATHOLOGICAL_FORMATION", 262, 287], ["oral", "ORGANISM_SUBDIVISION", 302, 306], ["estrogen", "SIMPLE_CHEMICAL", 325, 333], ["FLHCC", "CANCER", 358, 363], ["HBV", "SPECIES", 254, 257], ["FLHCC", "TEST", 83, 88], ["Fibrolamellar Hepatocellular Carcinoma", "PROBLEM", 135, 173], ["FLHCC", "PROBLEM", 189, 194], ["occult HBV", "PROBLEM", 247, 257], ["focal nodular hyperplasia", "PROBLEM", 262, 287], ["long-term oral contraceptive", "TREATMENT", 292, 320], ["FLHCC", "PROBLEM", 358, 363], ["solid evidence", "PROBLEM", 376, 390], ["HCC", "OBSERVATION", 22, 25], ["Fibrolamellar", "OBSERVATION_MODIFIER", 135, 148], ["Hepatocellular", "ANATOMY", 149, 163], ["Carcinoma", "OBSERVATION", 164, 173], ["occult", "OBSERVATION_MODIFIER", 247, 253], ["HBV", "OBSERVATION", 254, 257], ["focal", "OBSERVATION_MODIFIER", 262, 267], ["nodular", "OBSERVATION_MODIFIER", 268, 275], ["hyperplasia", "OBSERVATION", 276, 287], ["long-term", "OBSERVATION_MODIFIER", 292, 301], ["no solid evidence to suggest", "UNCERTAINTY", 373, 401]]], ["In contrast to typical HCC, FLHCC generally occurs in patients without chronic liver disease and cirrhosis.Answer: Fibrolamellar Hepatocellular CarcinomaThe diagnosis of FLHCC is made on the combination of clinical presentation, imaging studies, and negative tumor marker, however, pathological diagnosis remains the gold standard.", [["HCC", "ANATOMY", 23, 26], ["FLHCC", "ANATOMY", 28, 33], ["liver", "ANATOMY", 79, 84], ["Fibrolamellar Hepatocellular Carcinoma", "ANATOMY", 115, 153], ["tumor", "ANATOMY", 259, 264], ["HCC", "DISEASE", 23, 26], ["FLHCC", "DISEASE", 28, 33], ["chronic liver disease", "DISEASE", 71, 92], ["cirrhosis", "DISEASE", 97, 106], ["Fibrolamellar Hepatocellular Carcinoma", "DISEASE", 115, 153], ["FLHCC", "DISEASE", 170, 175], ["tumor", "DISEASE", 259, 264], ["HCC", "CANCER", 23, 26], ["FLHCC", "CANCER", 28, 33], ["patients", "ORGANISM", 54, 62], ["liver", "ORGAN", 79, 84], ["Fibrolamellar Hepatocellular Carcinoma", "CANCER", 115, 153], ["FLHCC", "CANCER", 170, 175], ["tumor", "CANCER", 259, 264], ["patients", "SPECIES", 54, 62], ["typical HCC", "PROBLEM", 15, 26], ["FLHCC", "PROBLEM", 28, 33], ["chronic liver disease", "PROBLEM", 71, 92], ["cirrhosis", "PROBLEM", 97, 106], ["Fibrolamellar Hepatocellular Carcinoma", "PROBLEM", 115, 153], ["FLHCC", "PROBLEM", 170, 175], ["imaging studies", "TEST", 229, 244], ["typical", "OBSERVATION_MODIFIER", 15, 22], ["HCC", "OBSERVATION", 23, 26], ["without", "UNCERTAINTY", 63, 70], ["chronic", "OBSERVATION_MODIFIER", 71, 78], ["liver", "ANATOMY", 79, 84], ["disease", "OBSERVATION", 85, 92], ["cirrhosis", "OBSERVATION", 97, 106], ["Fibrolamellar", "OBSERVATION_MODIFIER", 115, 128], ["Hepatocellular", "ANATOMY", 129, 143], ["Carcinoma", "OBSERVATION", 144, 153], ["tumor", "OBSERVATION", 259, 264]]], ["Macroscopically, about 75% of cases have a prominent central scar.", [["scar", "ANATOMY", 61, 65], ["central scar", "PATHOLOGICAL_FORMATION", 53, 65], ["Macroscopically", "TEST", 0, 15], ["a prominent central scar", "PROBLEM", 41, 65], ["prominent", "OBSERVATION_MODIFIER", 43, 52], ["central", "OBSERVATION_MODIFIER", 53, 60], ["scar", "OBSERVATION", 61, 65]]], ["Microscopically, FLHCC usually consists of malignant hepatocytes that are well differentiated in a background of noncirrhotic liver.", [["FLHCC", "ANATOMY", 17, 22], ["malignant hepatocytes", "ANATOMY", 43, 64], ["liver", "ANATOMY", 126, 131], ["noncirrhotic liver", "DISEASE", 113, 131], ["FLHCC", "CANCER", 17, 22], ["malignant hepatocytes", "CELL", 43, 64], ["liver", "ORGAN", 126, 131], ["malignant hepatocytes", "CELL_TYPE", 43, 64], ["malignant hepatocytes", "PROBLEM", 43, 64], ["noncirrhotic liver", "PROBLEM", 113, 131], ["malignant", "OBSERVATION_MODIFIER", 43, 52], ["hepatocytes", "OBSERVATION", 53, 64], ["well differentiated", "OBSERVATION_MODIFIER", 74, 93], ["noncirrhotic", "OBSERVATION", 113, 125], ["liver", "ANATOMY", 126, 131]]], ["The pathological diagnosis of FLHCC is based upon the following: large tumor cells with deeply eosinophilic cytoplasm, the presence of macronucleoli and abundant fibrous stroma arranged in thin parallel lamellae around tumor cells and is cleary distinguishable from conventional HCC in the hands of an experienced pathologist.Answer: Fibrolamellar Hepatocellular CarcinomaAt presentation, 70% of FLHCC patients have metastatic lymphadenopathy.", [["FLHCC", "ANATOMY", 30, 35], ["tumor cells", "ANATOMY", 71, 82], ["eosinophilic cytoplasm", "ANATOMY", 95, 117], ["macronucleoli", "ANATOMY", 135, 148], ["fibrous stroma", "ANATOMY", 162, 176], ["lamellae", "ANATOMY", 203, 211], ["tumor cells", "ANATOMY", 219, 230], ["HCC", "ANATOMY", 279, 282], ["Fibrolamellar Hepatocellular CarcinomaAt", "ANATOMY", 334, 374], ["FLHCC", "ANATOMY", 396, 401], ["metastatic lymphadenopathy", "ANATOMY", 416, 442], ["FLHCC", "DISEASE", 30, 35], ["tumor", "DISEASE", 71, 76], ["tumor", "DISEASE", 219, 224], ["HCC", "DISEASE", 279, 282], ["Fibrolamellar Hepatocellular CarcinomaAt", "DISEASE", 334, 374], ["FLHCC", "DISEASE", 396, 401], ["lymphadenopathy", "DISEASE", 427, 442], ["FLHCC", "CANCER", 30, 35], ["tumor cells", "CELL", 71, 82], ["cytoplasm", "ORGANISM_SUBSTANCE", 108, 117], ["fibrous stroma", "TISSUE", 162, 176], ["lamellae", "CELLULAR_COMPONENT", 203, 211], ["tumor cells", "CELL", 219, 230], ["HCC", "CANCER", 279, 282], ["Fibrolamellar Hepatocellular CarcinomaAt", "CANCER", 334, 374], ["FLHCC", "CANCER", 396, 401], ["patients", "ORGANISM", 402, 410], ["lymphadenopathy", "CANCER", 427, 442], ["tumor cells", "CELL_TYPE", 71, 82], ["tumor cells", "CELL_TYPE", 219, 230], ["patients", "SPECIES", 402, 410], ["FLHCC", "PROBLEM", 30, 35], ["large tumor cells", "PROBLEM", 65, 82], ["deeply eosinophilic cytoplasm", "PROBLEM", 88, 117], ["macronucleoli", "PROBLEM", 135, 148], ["abundant fibrous stroma", "PROBLEM", 153, 176], ["thin parallel lamellae around tumor cells", "PROBLEM", 189, 230], ["conventional HCC", "PROBLEM", 266, 282], ["Fibrolamellar Hepatocellular CarcinomaAt presentation", "PROBLEM", 334, 387], ["metastatic lymphadenopathy", "PROBLEM", 416, 442], ["large", "OBSERVATION_MODIFIER", 65, 70], ["tumor cells", "OBSERVATION", 71, 82], ["deeply", "OBSERVATION_MODIFIER", 88, 94], ["eosinophilic cytoplasm", "OBSERVATION", 95, 117], ["macronucleoli", "ANATOMY", 135, 148], ["abundant", "OBSERVATION_MODIFIER", 153, 161], ["fibrous stroma", "OBSERVATION", 162, 176], ["thin parallel", "OBSERVATION_MODIFIER", 189, 202], ["lamellae", "OBSERVATION_MODIFIER", 203, 211], ["tumor cells", "OBSERVATION", 219, 230], ["HCC", "OBSERVATION", 279, 282], ["Fibrolamellar", "OBSERVATION_MODIFIER", 334, 347], ["Hepatocellular", "ANATOMY", 348, 362], ["metastatic", "OBSERVATION_MODIFIER", 416, 426], ["lymphadenopathy", "OBSERVATION", 427, 442]]], ["Nearly half of patients develop distant metastasis.Answer: Fibrolamellar Hepatocellular CarcinomaLiver function tests are typically normal or only mildly elevated.", [["Fibrolamellar Hepatocellular CarcinomaLiver", "ANATOMY", 59, 102], ["patients", "ORGANISM", 15, 23], ["Fibrolamellar Hepatocellular CarcinomaLiver", "CANCER", 59, 102], ["patients", "SPECIES", 15, 23], ["distant metastasis", "PROBLEM", 32, 50], ["Fibrolamellar Hepatocellular CarcinomaLiver function tests", "TEST", 59, 117], ["mildly elevated", "PROBLEM", 147, 162], ["distant", "OBSERVATION_MODIFIER", 32, 39], ["metastasis", "OBSERVATION", 40, 50], ["Hepatocellular", "ANATOMY", 73, 87], ["mildly", "OBSERVATION_MODIFIER", 147, 153], ["elevated", "OBSERVATION", 154, 162]]], ["Commonly used markers for HCC such as alpha fetoprotein are of little help in diagnosing FLHCC, as only a small proportion of patients show minor elevations.Answer: Fibrolamellar Hepatocellular CarcinomaOn CT scan, tumors are typically sharply demarcated with a central scar, sometimes with calcification, usually occurring in an otherwise noncirrhotic, normal appearing liver.", [["HCC", "ANATOMY", 26, 29], ["FLHCC", "ANATOMY", 89, 94], ["Hepatocellular", "ANATOMY", 179, 193], ["tumors", "ANATOMY", 215, 221], ["scar", "ANATOMY", 270, 274], ["liver", "ANATOMY", 371, 376], ["HCC", "DISEASE", 26, 29], ["FLHCC", "DISEASE", 89, 94], ["tumors", "DISEASE", 215, 221], ["calcification", "DISEASE", 291, 304], ["HCC", "CANCER", 26, 29], ["alpha fetoprotein", "GENE_OR_GENE_PRODUCT", 38, 55], ["FLHCC", "CANCER", 89, 94], ["patients", "ORGANISM", 126, 134], ["Fibrolamellar Hepatocellular CarcinomaOn CT", "CANCER", 165, 208], ["tumors", "CANCER", 215, 221], ["scar", "PATHOLOGICAL_FORMATION", 270, 274], ["liver", "ORGAN", 371, 376], ["alpha fetoprotein", "PROTEIN", 38, 55], ["patients", "SPECIES", 126, 134], ["HCC", "PROBLEM", 26, 29], ["alpha fetoprotein", "TEST", 38, 55], ["minor elevations", "PROBLEM", 140, 156], ["Fibrolamellar Hepatocellular CarcinomaOn CT scan", "TEST", 165, 213], ["tumors", "PROBLEM", 215, 221], ["a central scar", "PROBLEM", 260, 274], ["calcification", "PROBLEM", 291, 304], ["minor", "OBSERVATION_MODIFIER", 140, 145], ["elevations", "OBSERVATION", 146, 156], ["Hepatocellular", "ANATOMY", 179, 193], ["tumors", "OBSERVATION", 215, 221], ["sharply", "OBSERVATION_MODIFIER", 236, 243], ["demarcated", "OBSERVATION_MODIFIER", 244, 254], ["central", "OBSERVATION_MODIFIER", 262, 269], ["scar", "OBSERVATION", 270, 274], ["calcification", "OBSERVATION", 291, 304], ["otherwise", "OBSERVATION_MODIFIER", 330, 339], ["noncirrhotic", "OBSERVATION", 340, 352], ["normal", "OBSERVATION", 354, 360], ["liver", "ANATOMY", 371, 376]]], ["The lesion seen on CT scan is usually hypodense, which may show marked enhancement after contrast injection.Answer: Fibrolamellar Hepatocellular CarcinomaOverall, the key to successful management of FLHCC is early diagnosis.", [["lesion", "ANATOMY", 4, 10], ["Fibrolamellar Hepatocellular CarcinomaOverall", "ANATOMY", 116, 161], ["FLHCC", "ANATOMY", 199, 204], ["FLHCC", "DISEASE", 199, 204], ["Fibrolamellar Hepatocellular CarcinomaOverall", "CANCER", 116, 161], ["FLHCC", "CANCER", 199, 204], ["The lesion", "PROBLEM", 0, 10], ["CT scan", "TEST", 19, 26], ["hypodense", "PROBLEM", 38, 47], ["marked enhancement", "PROBLEM", 64, 82], ["contrast injection", "TREATMENT", 89, 107], ["Fibrolamellar Hepatocellular CarcinomaOverall", "PROBLEM", 116, 161], ["FLHCC", "PROBLEM", 199, 204], ["lesion", "OBSERVATION", 4, 10], ["hypodense", "OBSERVATION", 38, 47], ["may show", "UNCERTAINTY", 55, 63], ["marked", "OBSERVATION_MODIFIER", 64, 70], ["enhancement", "OBSERVATION_MODIFIER", 71, 82], ["Hepatocellular", "ANATOMY", 130, 144]]], ["As is being considered for the patient in the current case, the cornerstone for treatment is surgical resection and lymph node dissection.", [["lymph node", "ANATOMY", 116, 126], ["patient", "ORGANISM", 31, 38], ["lymph node", "MULTI-TISSUE_STRUCTURE", 116, 126], ["patient", "SPECIES", 31, 38], ["treatment", "TREATMENT", 80, 89], ["surgical resection", "TREATMENT", 93, 111], ["lymph node dissection", "TREATMENT", 116, 137], ["surgical resection", "OBSERVATION", 93, 111], ["lymph node dissection", "OBSERVATION", 116, 137]]], ["The outcome of patients with FLHCC after surgical resection is usually good.", [["FLHCC", "ANATOMY", 29, 34], ["FLHCC", "DISEASE", 29, 34], ["patients", "ORGANISM", 15, 23], ["FLHCC", "CANCER", 29, 34], ["patients", "SPECIES", 15, 23], ["FLHCC", "TREATMENT", 29, 34], ["surgical resection", "TREATMENT", 41, 59], ["resection", "OBSERVATION", 50, 59]]], ["A 50-75% cure rate has been reported after complete surgical resection.", [["complete surgical resection", "TREATMENT", 43, 70], ["surgical", "OBSERVATION_MODIFIER", 52, 60], ["resection", "OBSERVATION", 61, 70]]], ["In cases in which partial hepatectomy is not technically feasible because of size or extension, liver transplantation should be considered.", [["liver", "ANATOMY", 96, 101], ["liver", "ORGAN", 96, 101], ["partial hepatectomy", "TREATMENT", 18, 37], ["liver transplantation", "TREATMENT", 96, 117], ["partial", "OBSERVATION_MODIFIER", 18, 25], ["hepatectomy", "OBSERVATION", 26, 37], ["size", "OBSERVATION_MODIFIER", 77, 81], ["liver", "ANATOMY", 96, 101], ["transplantation", "OBSERVATION", 102, 117]]], ["However, recurrence occurs in about half of patients within 3.5 years of transplant.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["recurrence", "PROBLEM", 9, 19], ["transplant", "TREATMENT", 73, 83], ["recurrence", "OBSERVATION", 9, 19], ["transplant", "OBSERVATION", 73, 83]]], ["If resection and liver transplantation are not options, chemotherapy or hepatic artery chemoembolization can be used as an alternative treatment approach.Case 41A 43-year-old Caucasian female with no significant past medical history was in her usual state of health until 1 week prior to presentation when she developed what she described as \"flu-like symptoms,\" including fever up to 102\u00b0F, anorexia, diarrhea, epigastric fullness and discomfort (mostly in her right quadrant), malaiase, and myalgias.", [["liver", "ANATOMY", 17, 22], ["hepatic artery", "ANATOMY", 72, 86], ["epigastric", "ANATOMY", 412, 422], ["right quadrant", "ANATOMY", 462, 476], ["flu-like symptoms", "DISEASE", 343, 360], ["fever", "DISEASE", 373, 378], ["anorexia", "DISEASE", 392, 400], ["diarrhea", "DISEASE", 402, 410], ["epigastric fullness", "DISEASE", 412, 431], ["malaiase", "DISEASE", 479, 487], ["myalgias", "DISEASE", 493, 501], ["liver", "ORGAN", 17, 22], ["hepatic artery", "MULTI-TISSUE_STRUCTURE", 72, 86], ["female", "ORGANISM", 185, 191], ["epigastric", "ORGANISM_SUBDIVISION", 412, 422], ["resection", "TREATMENT", 3, 12], ["liver transplantation", "TREATMENT", 17, 38], ["chemotherapy", "TREATMENT", 56, 68], ["hepatic artery chemoembolization", "TREATMENT", 72, 104], ["an alternative treatment approach", "TREATMENT", 120, 153], ["flu-like symptoms", "PROBLEM", 343, 360], ["fever", "PROBLEM", 373, 378], ["anorexia", "PROBLEM", 392, 400], ["diarrhea", "PROBLEM", 402, 410], ["epigastric fullness", "PROBLEM", 412, 431], ["discomfort", "PROBLEM", 436, 446], ["malaiase", "PROBLEM", 479, 487], ["myalgias", "PROBLEM", 493, 501], ["resection", "OBSERVATION", 3, 12], ["liver", "ANATOMY", 17, 22], ["transplantation", "OBSERVATION", 23, 38], ["hepatic artery", "ANATOMY", 72, 86], ["chemoembolization", "OBSERVATION", 87, 104], ["anorexia", "OBSERVATION", 392, 400], ["diarrhea", "OBSERVATION", 402, 410], ["epigastric", "ANATOMY", 412, 422], ["fullness", "OBSERVATION", 423, 431], ["discomfort", "OBSERVATION", 436, 446], ["right", "ANATOMY_MODIFIER", 462, 467], ["quadrant", "ANATOMY", 468, 476], ["myalgias", "OBSERVATION", 493, 501]]], ["At the onset of her symptoms, the patient did take approximately 2 g of acetaminophen daily for three days.", [["acetaminophen", "CHEMICAL", 72, 85], ["acetaminophen", "CHEMICAL", 72, 85], ["patient", "ORGANISM", 34, 41], ["acetaminophen", "SIMPLE_CHEMICAL", 72, 85], ["patient", "SPECIES", 34, 41], ["her symptoms", "PROBLEM", 16, 28], ["acetaminophen", "TREATMENT", 72, 85]]], ["Her fevers subsided, but the remainder of her symptoms persisted which prompted a visit to her local emergency room.", [["fevers", "DISEASE", 4, 10], ["Her fevers", "PROBLEM", 0, 10], ["her symptoms", "PROBLEM", 42, 54], ["fevers", "OBSERVATION", 4, 10]]], ["After admission into the hospital and administration of intravenous fluids, the patient states that she feels much better.", [["intravenous", "ANATOMY", 56, 67], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 67], ["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["intravenous fluids", "TREATMENT", 56, 74]]], ["She denies any cough, her urine appears darker than normal, but she denies any dysuria.", [["urine", "ANATOMY", 26, 31], ["cough", "DISEASE", 15, 20], ["dysuria", "DISEASE", 79, 86], ["urine", "ORGANISM_SUBSTANCE", 26, 31], ["any cough", "PROBLEM", 11, 20], ["her urine", "TEST", 22, 31], ["any dysuria", "PROBLEM", 75, 86], ["cough", "OBSERVATION", 15, 20], ["dysuria", "OBSERVATION", 79, 86]]], ["The patient and her family returned from visiting her in-laws over the Christmas holiday in Monterrey, Mexico 2 weeks prior to the onset of her symptoms.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["her symptoms", "PROBLEM", 140, 152]]], ["Her only surgical history is the removal of a benign ovarian cyst over 4 years ago.", [["benign ovarian cyst", "ANATOMY", 46, 65], ["ovarian cyst", "DISEASE", 53, 65], ["ovarian cyst", "CANCER", 53, 65], ["the removal", "TREATMENT", 29, 40], ["a benign ovarian cyst", "PROBLEM", 44, 65], ["surgical", "OBSERVATION", 9, 17], ["benign", "OBSERVATION_MODIFIER", 46, 52], ["ovarian", "ANATOMY", 53, 60], ["cyst", "OBSERVATION", 61, 65]]], ["She takes a daily multivitamin, oral contraceptive (which she has been on since the age of 32) and as needed ibuprofen and acetaminophen.", [["oral", "ANATOMY", 32, 36], ["multivitamin", "CHEMICAL", 18, 30], ["oral contraceptive", "CHEMICAL", 32, 50], ["ibuprofen", "CHEMICAL", 109, 118], ["acetaminophen", "CHEMICAL", 123, 136], ["ibuprofen", "CHEMICAL", 109, 118], ["acetaminophen", "CHEMICAL", 123, 136], ["multivitamin", "SIMPLE_CHEMICAL", 18, 30], ["oral", "ORGANISM_SUBDIVISION", 32, 36], ["ibuprofen", "SIMPLE_CHEMICAL", 109, 118], ["acetaminophen", "SIMPLE_CHEMICAL", 123, 136], ["a daily multivitamin", "TREATMENT", 10, 30], ["oral contraceptive", "TREATMENT", 32, 50], ["ibuprofen", "TREATMENT", 109, 118], ["acetaminophen", "TREATMENT", 123, 136]]], ["She denies any herbal medications or recent antibiotics.", [["herbal medications", "TREATMENT", 15, 33], ["recent antibiotics", "TREATMENT", 37, 55]]], ["The patient works as an accountant at a pediatric hospital.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["She has been married for over 20 years now and has three young children all in good health.", [["children", "ORGANISM", 63, 71], ["children", "SPECIES", 63, 71]]], ["The patient works part-time as a babysitter/nanny.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["The patient's husband owns a local seafood restaurant, and occasionally, the patient helps in the preparation of food products.", [["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 77, 84]]], ["The patient occasionally drinks wine.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["There are no other habits or high risk behavior.", [["high risk behavior", "PROBLEM", 29, 47], ["no", "UNCERTAINTY", 10, 12], ["high", "OBSERVATION_MODIFIER", 29, 33]]], ["The patient's father died of colon cancer at the age of 81.Case 41Physical examination is notable for a generally well-appearing, middle-aged female in no distress accompanied by her entire family.", [["colon cancer", "ANATOMY", 29, 41], ["colon cancer", "DISEASE", 29, 41], ["patient", "ORGANISM", 4, 11], ["father", "ORGANISM", 14, 20], ["colon cancer", "CANCER", 29, 41], ["female", "ORGANISM", 142, 148], ["patient", "SPECIES", 4, 11], ["colon cancer", "PROBLEM", 29, 41], ["Case 41Physical examination", "TEST", 59, 86], ["distress", "PROBLEM", 155, 163], ["colon", "ANATOMY", 29, 34], ["cancer", "OBSERVATION", 35, 41], ["no", "UNCERTAINTY", 152, 154], ["distress", "OBSERVATION", 155, 163]]], ["Temperature is 100.8\u00b0F and vital signs are stable.", [["Temperature", "TEST", 0, 11], ["vital signs", "TEST", 27, 38], ["stable", "OBSERVATION_MODIFIER", 43, 49]]], ["She has mild scleral icterus.", [["scleral", "ANATOMY", 13, 20], ["scleral icterus", "DISEASE", 13, 28], ["mild scleral icterus", "PROBLEM", 8, 28], ["mild", "OBSERVATION_MODIFIER", 8, 12], ["scleral", "ANATOMY", 13, 20], ["icterus", "OBSERVATION", 21, 28]]], ["She has no stigmata of chronic liver disease.", [["liver", "ANATOMY", 31, 36], ["chronic liver disease", "DISEASE", 23, 44], ["liver", "ORGAN", 31, 36], ["chronic liver disease", "PROBLEM", 23, 44], ["no stigmata of", "UNCERTAINTY", 8, 22], ["chronic", "OBSERVATION_MODIFIER", 23, 30], ["liver", "ANATOMY", 31, 36], ["disease", "OBSERVATION", 37, 44]]], ["Her lungs and heart are normal.", [["lungs", "ANATOMY", 4, 9], ["heart", "ANATOMY", 14, 19], ["lungs", "ORGAN", 4, 9], ["heart", "ORGAN", 14, 19], ["lungs", "ANATOMY", 4, 9], ["heart", "ANATOMY", 14, 19], ["normal", "OBSERVATION", 24, 30]]], ["Her abdomen is soft, although she is mildly tender in her right upper quadrant.", [["abdomen", "ANATOMY", 4, 11], ["right upper quadrant", "ANATOMY", 58, 78], ["abdomen", "ORGAN", 4, 11], ["upper quadrant", "ORGANISM_SUBDIVISION", 64, 78], ["mildly tender in her right upper quadrant", "PROBLEM", 37, 78], ["abdomen", "ANATOMY", 4, 11], ["soft", "OBSERVATION", 15, 19], ["mildly", "OBSERVATION_MODIFIER", 37, 43], ["tender", "OBSERVATION", 44, 50], ["right", "ANATOMY_MODIFIER", 58, 63], ["upper", "ANATOMY_MODIFIER", 64, 69], ["quadrant", "ANATOMY", 70, 78]]], ["Her liver edge is smooth and is palpable three fingerbreadths below her right costo vertebral angle.", [["liver edge", "ANATOMY", 4, 14], ["right costo vertebral angle", "ANATOMY", 72, 99], ["liver", "ORGAN", 4, 9], ["liver", "ANATOMY", 4, 9], ["edge", "ANATOMY_MODIFIER", 10, 14], ["smooth", "OBSERVATION", 18, 24], ["palpable", "OBSERVATION", 32, 40], ["right", "ANATOMY_MODIFIER", 72, 77], ["costo vertebral angle", "ANATOMY", 78, 99]]], ["She has no shifting dullness, and extremities are without edema.", [["extremities", "ANATOMY", 34, 45], ["edema", "ANATOMY", 58, 63], ["edema", "DISEASE", 58, 63], ["extremities", "ORGANISM_SUBDIVISION", 34, 45], ["edema", "PATHOLOGICAL_FORMATION", 58, 63], ["shifting dullness", "PROBLEM", 11, 28], ["edema", "PROBLEM", 58, 63], ["no", "UNCERTAINTY", 8, 10], ["shifting", "OBSERVATION_MODIFIER", 11, 19], ["dullness", "OBSERVATION", 20, 28], ["extremities", "ANATOMY", 34, 45], ["without", "UNCERTAINTY", 50, 57], ["edema", "OBSERVATION", 58, 63]]], ["She is mentating well and has no asterixis.Laboratory DataTbili 3.0 mg/dl (direct 2.2); bilirubin peaked at 6.", [["bilirubin", "CHEMICAL", 88, 97], ["bilirubin", "CHEMICAL", 88, 97], ["bilirubin", "SIMPLE_CHEMICAL", 88, 97], ["asterixis", "PROBLEM", 33, 42], ["Laboratory DataTbili", "TEST", 43, 63], ["direct", "TEST", 75, 81], ["bilirubin", "TEST", 88, 97], ["no", "UNCERTAINTY", 30, 32], ["asterixis", "OBSERVATION", 33, 42]]], ["5 Increased perioportal echogenicity throughout the liver; no focal hepatic masses and no intrahepatic biliary dilation.", [["liver", "ANATOMY", 52, 57], ["focal hepatic masses", "ANATOMY", 62, 82], ["intrahepatic biliary", "ANATOMY", 90, 110], ["intrahepatic biliary dilation", "DISEASE", 90, 119], ["liver", "ORGAN", 52, 57], ["hepatic masses", "CANCER", 68, 82], ["intrahepatic biliary", "MULTI-TISSUE_STRUCTURE", 90, 110], ["Increased perioportal echogenicity throughout the liver", "PROBLEM", 2, 57], ["focal hepatic masses", "PROBLEM", 62, 82], ["intrahepatic biliary dilation", "PROBLEM", 90, 119], ["Increased", "OBSERVATION_MODIFIER", 2, 11], ["perioportal", "OBSERVATION_MODIFIER", 12, 23], ["echogenicity", "OBSERVATION", 24, 36], ["liver", "ANATOMY", 52, 57], ["no", "UNCERTAINTY", 59, 61], ["focal", "OBSERVATION_MODIFIER", 62, 67], ["hepatic", "ANATOMY", 68, 75], ["masses", "OBSERVATION", 76, 82], ["no", "UNCERTAINTY", 87, 89], ["intrahepatic", "ANATOMY_MODIFIER", 90, 102], ["biliary", "ANATOMY", 103, 110], ["dilation", "OBSERVATION", 111, 119]]], ["Marked circumfrential gallbladder wall thickening which almost completely obliterates the lumen of the gallbladder.", [["circumfrential gallbladder wall", "ANATOMY", 7, 38], ["lumen", "ANATOMY", 90, 95], ["gallbladder", "ANATOMY", 103, 114], ["gallbladder wall", "PATHOLOGICAL_FORMATION", 22, 38], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 90, 95], ["gallbladder", "ORGAN", 103, 114], ["Marked circumfrential gallbladder wall thickening", "PROBLEM", 0, 49], ["circumfrential", "OBSERVATION_MODIFIER", 7, 21], ["gallbladder", "ANATOMY", 22, 33], ["wall", "ANATOMY_MODIFIER", 34, 38], ["thickening", "OBSERVATION", 39, 49], ["lumen", "ANATOMY_MODIFIER", 90, 95], ["gallbladder", "ANATOMY", 103, 114]]], ["No discrete shadowing stone is identified.", [["discrete shadowing stone", "PROBLEM", 3, 27], ["discrete", "OBSERVATION_MODIFIER", 3, 11], ["shadowing", "OBSERVATION_MODIFIER", 12, 21], ["stone", "OBSERVATION", 22, 27]]], ["Patent and appropriately directed flow within the hepatic vasculature.Answer: Acute Hepatitis A InfectionThis patient has an acute severe hepatitis but no evidence of coagulopathy or encephalopathy to categorize it as acute liver failure.", [["hepatic vasculature", "ANATOMY", 50, 69], ["liver", "ANATOMY", 224, 229], ["Hepatitis A InfectionThis", "DISEASE", 84, 109], ["hepatitis", "DISEASE", 138, 147], ["coagulopathy", "DISEASE", 167, 179], ["encephalopathy", "DISEASE", 183, 197], ["acute liver failure", "DISEASE", 218, 237], ["hepatic vasculature", "MULTI-TISSUE_STRUCTURE", 50, 69], ["patient", "ORGANISM", 110, 117], ["liver", "ORGAN", 224, 229], ["patient", "SPECIES", 110, 117], ["Acute Hepatitis A InfectionThis", "PROBLEM", 78, 109], ["an acute severe hepatitis", "PROBLEM", 122, 147], ["coagulopathy", "PROBLEM", 167, 179], ["encephalopathy", "PROBLEM", 183, 197], ["acute liver failure", "PROBLEM", 218, 237], ["appropriately", "OBSERVATION_MODIFIER", 11, 24], ["directed", "OBSERVATION_MODIFIER", 25, 33], ["flow", "OBSERVATION", 34, 38], ["hepatic", "ANATOMY", 50, 57], ["vasculature", "ANATOMY_MODIFIER", 58, 69], ["Acute", "OBSERVATION_MODIFIER", 78, 83], ["Hepatitis", "OBSERVATION", 84, 93], ["acute", "OBSERVATION_MODIFIER", 125, 130], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["hepatitis", "OBSERVATION", 138, 147], ["no evidence of", "UNCERTAINTY", 152, 166], ["coagulopathy", "OBSERVATION", 167, 179], ["encephalopathy", "OBSERVATION", 183, 197], ["acute", "OBSERVATION_MODIFIER", 218, 223], ["liver", "ANATOMY", 224, 229], ["failure", "OBSERVATION", 230, 237]]], ["The degree of hepatocellular injury and the onset of fever and diarrhea, in addition to the multiple risk factors (travel, work exposure) would place acute hepatitis A virus (HAV) at the top of the differential diagnosis.", [["hepatocellular", "ANATOMY", 14, 28], ["hepatocellular injury", "DISEASE", 14, 35], ["fever", "DISEASE", 53, 58], ["diarrhea", "DISEASE", 63, 71], ["acute hepatitis A", "DISEASE", 150, 167], ["HAV", "DISEASE", 175, 178], ["hepatocellular", "ORGAN", 14, 28], ["acute hepatitis A virus", "ORGANISM", 150, 173], ["HAV", "ORGANISM", 175, 178], ["hepatitis A virus", "SPECIES", 156, 173], ["hepatitis A virus", "SPECIES", 156, 173], ["HAV", "SPECIES", 175, 178], ["hepatocellular injury", "PROBLEM", 14, 35], ["fever", "PROBLEM", 53, 58], ["diarrhea", "PROBLEM", 63, 71], ["the multiple risk factors", "PROBLEM", 88, 113], ["acute hepatitis A virus (HAV", "PROBLEM", 150, 178], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["hepatocellular", "ANATOMY", 14, 28], ["injury", "OBSERVATION", 29, 35], ["fever", "OBSERVATION", 53, 58], ["diarrhea", "OBSERVATION", 63, 71], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["hepatitis", "OBSERVATION", 156, 165]]], ["The presence of HAV IgM confirms the diagnosis.Answer: Acute Hepatitis A InfectionHAV is a nonenveloped RNA virus in the hepatovirus genus of the picornavirus family.", [["Hepatitis A InfectionHAV", "DISEASE", 61, 85], ["HAV", "ORGANISM", 16, 19], ["hepatovirus genus", "ORGANISM", 121, 138], ["picornavirus", "ORGANISM", 146, 158], ["HAV IgM", "PROTEIN", 16, 23], ["HAV", "SPECIES", 16, 19], ["HAV IgM", "TEST", 16, 23], ["Acute Hepatitis", "PROBLEM", 55, 70], ["a nonenveloped RNA virus", "PROBLEM", 89, 113], ["IgM", "OBSERVATION", 20, 23], ["Acute", "OBSERVATION_MODIFIER", 55, 60], ["Hepatitis", "OBSERVATION", 61, 70]]], ["Hepatitis A has an incubation period of approximately 4 weeks.", [["Hepatitis A", "CHEMICAL", 0, 11], ["Hepatitis A", "ORGANISM", 0, 11], ["Hepatitis A", "SPECIES", 0, 11], ["Hepatitis A", "PROBLEM", 0, 11]]], ["Its replication is limited to the liver, but the virus is also present in bile, stool, and blood during the late incubation period and acute preicteric phase of illness.", [["liver", "ANATOMY", 34, 39], ["bile", "ANATOMY", 74, 78], ["stool", "ANATOMY", 80, 85], ["blood", "ANATOMY", 91, 96], ["illness", "DISEASE", 161, 168], ["liver", "ORGAN", 34, 39], ["bile", "MULTI-TISSUE_STRUCTURE", 74, 78], ["stool", "ORGANISM_SUBSTANCE", 80, 85], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["the virus", "PROBLEM", 45, 54], ["acute preicteric phase of illness", "PROBLEM", 135, 168], ["replication", "OBSERVATION", 4, 15], ["liver", "ANATOMY", 34, 39], ["virus", "OBSERVATION", 49, 54], ["bile", "ANATOMY", 74, 78], ["stool", "OBSERVATION", 80, 85], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["preicteric phase", "OBSERVATION_MODIFIER", 141, 157], ["illness", "OBSERVATION", 161, 168]]], ["Despite persistence of virus in the liver, viral shedding in feces, viremia, and infectivity diminish rapidly once jaundice is apparent.Answer: Acute Hepatitis A InfectionHAV is transmitted almost exclusively by the fecal-oral route.", [["liver", "ANATOMY", 36, 41], ["feces", "ANATOMY", 61, 66], ["oral", "ANATOMY", 222, 226], ["viremia", "DISEASE", 68, 75], ["jaundice", "DISEASE", 115, 123], ["Hepatitis A InfectionHAV", "DISEASE", 150, 174], ["liver", "ORGAN", 36, 41], ["feces", "ORGANISM_SUBSTANCE", 61, 66], ["fecal", "ORGANISM_SUBDIVISION", 216, 221], ["oral", "ORGANISM_SUBDIVISION", 222, 226], ["virus in the liver", "PROBLEM", 23, 41], ["viral shedding in feces", "PROBLEM", 43, 66], ["viremia", "PROBLEM", 68, 75], ["infectivity diminish", "PROBLEM", 81, 101], ["jaundice", "PROBLEM", 115, 123], ["Acute Hepatitis", "PROBLEM", 144, 159], ["virus", "OBSERVATION", 23, 28], ["liver", "ANATOMY", 36, 41], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["viremia", "OBSERVATION", 68, 75], ["infectivity", "OBSERVATION_MODIFIER", 81, 92], ["diminish", "OBSERVATION_MODIFIER", 93, 101], ["rapidly", "OBSERVATION_MODIFIER", 102, 109], ["jaundice", "OBSERVATION", 115, 123], ["Acute", "OBSERVATION_MODIFIER", 144, 149], ["Hepatitis", "OBSERVATION", 150, 159], ["fecal", "ANATOMY", 216, 221]]], ["Person-to-person spread of HAV is enhanced by poor personal hygiene and overcrowding: large ouTbilieaks as well as sporadic cases have been traced to contaminated food, water, milk, frozen fruit, and shellfish.Answer: Acute Hepatitis A InfectionIn developing countries, exposure, infection, and subsequent immunity are almost universal in childhood.", [["milk", "ANATOMY", 176, 180], ["fruit", "ANATOMY", 189, 194], ["HAV", "DISEASE", 27, 30], ["Hepatitis A InfectionIn", "DISEASE", 224, 247], ["infection", "DISEASE", 280, 289], ["HAV", "ORGANISM", 27, 30], ["milk", "ORGANISM_SUBSTANCE", 176, 180], ["person", "SPECIES", 10, 16], ["milk", "SPECIES", 176, 180], ["HAV", "SPECIES", 27, 30], ["large ouTbilieaks", "PROBLEM", 86, 103], ["sporadic cases", "PROBLEM", 115, 129], ["Acute Hepatitis A InfectionIn", "PROBLEM", 218, 247], ["infection", "PROBLEM", 280, 289], ["large", "OBSERVATION_MODIFIER", 86, 91], ["Acute", "OBSERVATION_MODIFIER", 218, 223], ["Hepatitis", "OBSERVATION", 224, 233], ["infection", "OBSERVATION", 280, 289]]], ["With improvements in personal hygiene and sanitation, the frequency of subclinical childhood HAV infection will continue to decline ( Fig. 41.1) .", [["HAV infection", "DISEASE", 93, 106], ["HAV", "ORGANISM", 93, 96], ["HAV", "SPECIES", 93, 96], ["personal hygiene", "TREATMENT", 21, 37], ["sanitation", "TREATMENT", 42, 52], ["subclinical childhood HAV infection", "PROBLEM", 71, 106], ["infection", "OBSERVATION", 97, 106]]], ["In turn, a susceptible cohort of adults emerges and the likelihood of clinically apparent and severe HAV infection may increase.", [["HAV infection", "DISEASE", 101, 114], ["adults", "ORGANISM", 33, 39], ["HAV", "ORGANISM", 101, 104], ["HAV", "SPECIES", 101, 104], ["severe HAV infection", "PROBLEM", 94, 114], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["HAV", "OBSERVATION_MODIFIER", 101, 104], ["infection", "OBSERVATION", 105, 114]]], ["Hepatitis A infection tends to be more symptomatic in adults.", [["Hepatitis A infection", "DISEASE", 0, 21], ["Hepatitis A", "ORGANISM", 0, 11], ["Hepatitis A", "SPECIES", 0, 11], ["Hepatitis A infection", "PROBLEM", 0, 21], ["infection", "OBSERVATION", 12, 21]]], ["Travel to endemic areas is a common source of infection for adults of nonendemic areas.Answer: Acute Hepatitis A InfectionAntibodies to HAV (anti-HAV) can be detected during acute illness when serum aminotransferase activity is elevated and fecal HAV shedding is still occurring.", [["serum", "ANATOMY", 193, 198], ["fecal", "ANATOMY", 241, 246], ["infection", "DISEASE", 46, 55], ["Hepatitis A InfectionAntibodies", "DISEASE", 101, 132], ["HAV", "DISEASE", 136, 139], ["Hepatitis A InfectionAntibodies", "ORGANISM", 101, 132], ["HAV", "ORGANISM", 136, 139], ["anti-HAV", "ORGANISM", 141, 149], ["serum", "ORGANISM_SUBSTANCE", 193, 198], ["aminotransferase", "SIMPLE_CHEMICAL", 199, 215], ["fecal", "ORGANISM_SUBSTANCE", 241, 246], ["HAV", "ORGANISM", 247, 250], ["HAV", "SPECIES", 136, 139], ["HAV", "SPECIES", 146, 149], ["HAV", "SPECIES", 247, 250], ["infection", "PROBLEM", 46, 55], ["nonendemic areas", "PROBLEM", 70, 86], ["Acute Hepatitis A InfectionAntibodies", "PROBLEM", 95, 132], ["HAV", "PROBLEM", 136, 139], ["acute illness", "PROBLEM", 174, 187], ["serum aminotransferase activity", "TEST", 193, 224], ["elevated", "PROBLEM", 228, 236], ["fecal HAV shedding", "PROBLEM", 241, 259], ["endemic", "OBSERVATION_MODIFIER", 10, 17], ["infection", "OBSERVATION", 46, 55], ["Acute", "OBSERVATION_MODIFIER", 95, 100], ["Hepatitis", "OBSERVATION", 101, 110], ["fecal HAV", "OBSERVATION_MODIFIER", 241, 250]]], ["This early antibody response is predominantly of the IgM subclass and persists for several months.", [["IgM", "GENE_OR_GENE_PRODUCT", 53, 56], ["IgM subclass", "PROTEIN", 53, 65], ["the IgM subclass", "PROBLEM", 49, 65], ["predominantly", "OBSERVATION_MODIFIER", 32, 45], ["IgM subclass", "OBSERVATION_MODIFIER", 53, 65]]], ["The detection of acute hepatitis A is made by demonstrating anti-HAV IgM.", [["acute hepatitis A", "DISEASE", 17, 34], ["hepatitis A", "SPECIES", 23, 34], ["acute hepatitis A", "PROBLEM", 17, 34], ["anti-HAV IgM.", "TEST", 60, 73], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["hepatitis", "OBSERVATION", 23, 32]]], ["During convalescence, however, anti-HAV of the IgG subclass becomes the predominant antibody.", [["IgG", "GENE_OR_GENE_PRODUCT", 47, 50], ["anti-HAV", "PROTEIN", 31, 39], ["IgG subclass", "PROTEIN", 47, 59], ["the IgG subclass", "TEST", 43, 59], ["predominant", "OBSERVATION_MODIFIER", 72, 83], ["antibody", "OBSERVATION", 84, 92]]], ["IgG antibodies will remain detectable indefinitely and are thought by most experts to provide lifelong immunity to the host.Answer: Acute Hepatitis A InfectionThe incubation period for HAV ranges from 15 to 45 days (mean 4 weeks).", [["Hepatitis A Infection", "DISEASE", 138, 159], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 0, 14], ["HAV", "ORGANISM", 185, 188], ["IgG antibodies", "PROTEIN", 0, 14], ["HAV", "SPECIES", 185, 188], ["IgG antibodies", "TEST", 0, 14], ["Acute Hepatitis A Infection", "PROBLEM", 132, 159], ["HAV ranges", "PROBLEM", 185, 195], ["Acute", "OBSERVATION_MODIFIER", 132, 137], ["Hepatitis", "OBSERVATION", 138, 147], ["Infection", "OBSERVATION", 150, 159]]], ["The prodromal symptoms of acute viral hepatitis are generally systemic and quite variable.", [["acute viral hepatitis", "DISEASE", 26, 47], ["The prodromal symptoms", "PROBLEM", 0, 22], ["acute viral hepatitis", "PROBLEM", 26, 47], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["viral hepatitis", "OBSERVATION", 32, 47]]], ["Constitutional symptoms of anorexia, nausea and vomiting, fatigue, malaise, arthralgias, myalgias, and headache may precede the onset of jaundice by 1-2 weeks.", [["anorexia", "DISEASE", 27, 35], ["nausea", "DISEASE", 37, 43], ["vomiting", "DISEASE", 48, 56], ["fatigue", "DISEASE", 58, 65], ["arthralgias", "DISEASE", 76, 87], ["myalgias", "DISEASE", 89, 97], ["headache", "DISEASE", 103, 111], ["jaundice", "DISEASE", 137, 145], ["Constitutional symptoms", "PROBLEM", 0, 23], ["anorexia", "PROBLEM", 27, 35], ["nausea", "PROBLEM", 37, 43], ["vomiting", "PROBLEM", 48, 56], ["fatigue", "PROBLEM", 58, 65], ["malaise", "PROBLEM", 67, 74], ["arthralgias", "PROBLEM", 76, 87], ["myalgias", "PROBLEM", 89, 97], ["headache", "PROBLEM", 103, 111], ["jaundice", "PROBLEM", 137, 145], ["anorexia", "OBSERVATION", 27, 35], ["arthralgias", "OBSERVATION", 76, 87], ["myalgias", "OBSERVATION", 89, 97], ["jaundice", "OBSERVATION", 137, 145]]], ["A low-grade fever (100-102\u00b0F) is often present in hepatitis A. With the onset of clinical jaundice, the constitutional symptoms usually diminish.", [["low-grade fever", "DISEASE", 2, 17], ["hepatitis", "DISEASE", 50, 59], ["jaundice", "DISEASE", 90, 98], ["hepatitis A.", "SPECIES", 50, 62], ["A low-grade fever", "PROBLEM", 0, 17], ["hepatitis A.", "PROBLEM", 50, 62], ["clinical jaundice", "PROBLEM", 81, 98], ["the constitutional symptoms", "PROBLEM", 100, 127], ["low-grade", "OBSERVATION_MODIFIER", 2, 11], ["fever", "OBSERVATION", 12, 17], ["hepatitis", "OBSERVATION", 50, 59], ["jaundice", "OBSERVATION", 90, 98]]], ["A substantial proportion of patients with acute hepatitis A never become icteric.", [["acute hepatitis A", "DISEASE", 42, 59], ["icteric", "DISEASE", 73, 80], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["acute hepatitis A", "PROBLEM", 42, 59], ["icteric", "PROBLEM", 73, 80], ["substantial", "OBSERVATION_MODIFIER", 2, 13], ["proportion", "OBSERVATION_MODIFIER", 14, 24], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["hepatitis", "OBSERVATION", 48, 57], ["icteric", "OBSERVATION", 73, 80]]], ["Patients may complain of abdominal discomfort as the result of tender hepatomegaly.", [["abdominal", "ANATOMY", 25, 34], ["abdominal discomfort", "DISEASE", 25, 45], ["hepatomegaly", "DISEASE", 70, 82], ["Patients", "ORGANISM", 0, 8], ["abdominal", "ORGANISM_SUBDIVISION", 25, 34], ["Patients", "SPECIES", 0, 8], ["abdominal discomfort", "PROBLEM", 25, 45], ["tender hepatomegaly", "PROBLEM", 63, 82], ["abdominal", "ANATOMY", 25, 34], ["discomfort", "OBSERVATION", 35, 45], ["tender", "OBSERVATION_MODIFIER", 63, 69], ["hepatomegaly", "OBSERVATION", 70, 82]]], ["Complete clinical and biochemical recovery is expected within 1-2 months in nearly all cases of hepatitis A.Answer: Acute Hepatitis A InfectionThe serum aminotransferases show variable increase during the prodromal phase and precede the rise in bilirubin level.", [["serum", "ANATOMY", 147, 152], ["hepatitis", "DISEASE", 96, 105], ["Hepatitis A Infection", "DISEASE", 122, 143], ["bilirubin", "CHEMICAL", 245, 254], ["bilirubin", "CHEMICAL", 245, 254], ["serum", "ORGANISM_SUBSTANCE", 147, 152], ["bilirubin", "SIMPLE_CHEMICAL", 245, 254], ["serum aminotransferases", "PROTEIN", 147, 170], ["hepatitis", "PROBLEM", 96, 105], ["Acute Hepatitis A Infection", "PROBLEM", 116, 143], ["The serum aminotransferases", "TEST", 143, 170], ["variable increase", "PROBLEM", 176, 193], ["the prodromal phase", "TEST", 201, 220], ["the rise in bilirubin level", "PROBLEM", 233, 260], ["hepatitis", "OBSERVATION", 96, 105], ["Acute", "OBSERVATION_MODIFIER", 116, 121], ["Hepatitis", "OBSERVATION", 122, 131], ["Infection", "OBSERVATION", 134, 143], ["variable", "OBSERVATION_MODIFIER", 176, 184], ["increase", "OBSERVATION_MODIFIER", 185, 193], ["rise", "OBSERVATION_MODIFIER", 237, 241]]], ["The level of elevation in these enzymes does not correlate well with the severity of illness or degree of liver cell damage.", [["liver cell", "ANATOMY", 106, 116], ["illness", "DISEASE", 85, 92], ["liver cell damage", "DISEASE", 106, 123], ["liver cell", "CELL", 106, 116], ["enzymes", "PROTEIN", 32, 39], ["elevation", "PROBLEM", 13, 22], ["these enzymes", "TEST", 26, 39], ["illness", "PROBLEM", 85, 92], ["liver cell damage", "PROBLEM", 106, 123], ["elevation", "OBSERVATION", 13, 22], ["liver", "ANATOMY", 106, 111], ["cell damage", "OBSERVATION", 112, 123]]], ["Peak levels vary from 400 to 4,000 iu or more.", [["Peak levels", "TEST", 0, 11]]], ["These levels are usually reached at the time the patient is clinically jaundiced.", [["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["clinically jaundiced", "PROBLEM", 60, 80], ["clinically", "OBSERVATION_MODIFIER", 60, 70], ["jaundiced", "OBSERVATION", 71, 80]]], ["The serum bilirubin may continue to rise despite falling aminotransferase levels.", [["serum", "ANATOMY", 4, 9], ["bilirubin", "CHEMICAL", 10, 19], ["bilirubin", "CHEMICAL", 10, 19], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["bilirubin", "SIMPLE_CHEMICAL", 10, 19], ["aminotransferase", "SIMPLE_CHEMICAL", 57, 73], ["The serum bilirubin", "TEST", 0, 19], ["falling aminotransferase levels", "PROBLEM", 49, 80]]], ["In most instances, the total bilirubin is equally divided between the conjugated and unconjugated fractions.", [["bilirubin", "CHEMICAL", 29, 38], ["bilirubin", "CHEMICAL", 29, 38], ["bilirubin", "GENE_OR_GENE_PRODUCT", 29, 38], ["conjugated", "SIMPLE_CHEMICAL", 70, 80], ["the total bilirubin", "TEST", 19, 38], ["most instances", "OBSERVATION_MODIFIER", 3, 17], ["unconjugated fractions", "OBSERVATION", 85, 107]]], ["As in this case, virtually all previously healthy patients with hepatitis A recover completely from their illness with no clinical sequelae.", [["hepatitis A", "DISEASE", 64, 75], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["hepatitis A", "SPECIES", 64, 75], ["hepatitis A", "PROBLEM", 64, 75], ["clinical sequelae", "PROBLEM", 122, 139], ["hepatitis", "OBSERVATION", 64, 73]]], ["The case fatality in hepatitis A is very low (approximately 0.1%) and almost always occurs in the setting of advanced age or underlying debilitating disease.", [["hepatitis A", "DISEASE", 21, 32], ["hepatitis A", "SPECIES", 21, 32], ["hepatitis A", "TEST", 21, 32], ["very low", "PROBLEM", 36, 44], ["underlying debilitating disease", "PROBLEM", 125, 156], ["hepatitis", "OBSERVATION", 21, 30], ["very", "OBSERVATION_MODIFIER", 36, 40], ["low", "OBSERVATION_MODIFIER", 41, 44], ["debilitating", "OBSERVATION_MODIFIER", 136, 148], ["disease", "OBSERVATION", 149, 156]]], ["A small proportion of patients with hepatitis A experience relapsing hepatitis weeks to months after apparent recovery from acute infection.", [["hepatitis A", "DISEASE", 36, 47], ["hepatitis", "DISEASE", 69, 78], ["infection", "DISEASE", 130, 139], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["hepatitis A", "SPECIES", 36, 47], ["hepatitis", "PROBLEM", 36, 45], ["relapsing hepatitis weeks", "PROBLEM", 59, 84], ["acute infection", "PROBLEM", 124, 139], ["small", "OBSERVATION_MODIFIER", 2, 7], ["hepatitis", "OBSERVATION", 36, 45], ["acute", "OBSERVATION_MODIFIER", 124, 129], ["infection", "OBSERVATION", 130, 139]]], ["Relapses are characterized by recurrence of symptoms, aminotransferase elevations, occasionally jaundice, and fecal excretion of HAV.", [["fecal", "ANATOMY", 110, 115], ["jaundice", "DISEASE", 96, 104], ["HAV", "DISEASE", 129, 132], ["aminotransferase", "SIMPLE_CHEMICAL", 54, 70], ["fecal", "ORGANISM_SUBSTANCE", 110, 115], ["HAV", "ORGANISM", 129, 132], ["HAV", "SPECIES", 129, 132], ["Relapses", "PROBLEM", 0, 8], ["recurrence of symptoms", "PROBLEM", 30, 52], ["aminotransferase elevations", "PROBLEM", 54, 81], ["occasionally jaundice", "PROBLEM", 83, 104], ["fecal excretion of HAV", "PROBLEM", 110, 132], ["recurrence", "OBSERVATION_MODIFIER", 30, 40], ["aminotransferase elevations", "OBSERVATION", 54, 81], ["occasionally", "OBSERVATION_MODIFIER", 83, 95], ["jaundice", "OBSERVATION", 96, 104], ["fecal excretion", "OBSERVATION_MODIFIER", 110, 125]]], ["Another unusual variant of acute hepatitis A is cholestatic hepatitis, characterized by protracted cholestatic jaundice and pruritus.", [["acute hepatitis A", "DISEASE", 27, 44], ["cholestatic hepatitis", "DISEASE", 48, 69], ["cholestatic jaundice", "DISEASE", 99, 119], ["pruritus", "DISEASE", 124, 132], ["hepatitis A", "SPECIES", 33, 44], ["acute hepatitis", "PROBLEM", 27, 42], ["cholestatic hepatitis", "PROBLEM", 48, 69], ["protracted cholestatic jaundice", "PROBLEM", 88, 119], ["pruritus", "PROBLEM", 124, 132], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["hepatitis", "OBSERVATION", 33, 42], ["cholestatic", "OBSERVATION_MODIFIER", 48, 59], ["hepatitis", "OBSERVATION", 60, 69], ["protracted", "OBSERVATION_MODIFIER", 88, 98], ["cholestatic", "OBSERVATION_MODIFIER", 99, 110], ["jaundice", "OBSERVATION", 111, 119], ["pruritus", "OBSERVATION", 124, 132]]], ["Rarely, liver test abnormalities may persist for months or even up to a year.", [["liver", "ANATOMY", 8, 13], ["liver test abnormalities", "DISEASE", 8, 32], ["liver", "ORGAN", 8, 13], ["liver test abnormalities", "PROBLEM", 8, 32], ["liver", "ANATOMY", 8, 13]]], ["Even when these complications of hepatitis A occur, it remains a self-limiting disease and does not progress to chronic liver disease.Answer: Acute Hepatitis A InfectionPhysical isolation of patients with hepatitis A is rarely necessary except in the case of fecal incontinence.", [["liver", "ANATOMY", 120, 125], ["fecal", "ANATOMY", 259, 264], ["hepatitis A", "DISEASE", 33, 44], ["chronic liver disease", "DISEASE", 112, 133], ["hepatitis A", "DISEASE", 205, 216], ["fecal incontinence", "DISEASE", 259, 277], ["liver", "ORGAN", 120, 125], ["patients", "ORGANISM", 191, 199], ["fecal", "ORGANISM_SUBDIVISION", 259, 264], ["patients", "SPECIES", 191, 199], ["hepatitis A", "SPECIES", 33, 44], ["hepatitis A", "PROBLEM", 33, 44], ["a self-limiting disease", "PROBLEM", 63, 86], ["chronic liver disease", "PROBLEM", 112, 133], ["Acute Hepatitis", "PROBLEM", 142, 157], ["hepatitis A", "PROBLEM", 205, 216], ["fecal incontinence", "PROBLEM", 259, 277], ["hepatitis", "OBSERVATION", 33, 42], ["chronic", "OBSERVATION_MODIFIER", 112, 119], ["liver", "ANATOMY", 120, 125], ["disease", "OBSERVATION", 126, 133], ["Acute", "OBSERVATION_MODIFIER", 142, 147], ["Hepatitis", "OBSERVATION", 148, 157], ["fecal", "ANATOMY", 259, 264], ["incontinence", "OBSERVATION", 265, 277]]], ["Because most patients hospitalized with hepatitis A excrete little if any HAV, the likelihood of transmission from these patients during their hospitalizations is low.", [["hepatitis A", "DISEASE", 40, 51], ["HAV", "DISEASE", 74, 77], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 121, 129], ["hepatitis A", "SPECIES", 40, 51], ["HAV", "SPECIES", 74, 77], ["hepatitis", "PROBLEM", 40, 49], ["any HAV", "PROBLEM", 70, 77], ["hepatitis", "OBSERVATION", 40, 49]]], ["Hospitalized patients may be discharged when there is substantial symptomatic improvement, a significant downward trend in the ezymes levels, and normalization of PT.", [["patients", "ORGANISM", 13, 21], ["PT", "GENE_OR_GENE_PRODUCT", 163, 165], ["patients", "SPECIES", 13, 21], ["a significant downward trend", "PROBLEM", 91, 119], ["the ezymes levels", "TEST", 123, 140], ["PT", "TEST", 163, 165], ["substantial", "OBSERVATION_MODIFIER", 54, 65], ["symptomatic", "OBSERVATION_MODIFIER", 66, 77], ["improvement", "OBSERVATION", 78, 89], ["significant", "OBSERVATION_MODIFIER", 93, 104], ["downward", "OBSERVATION_MODIFIER", 105, 113], ["trend", "OBSERVATION_MODIFIER", 114, 119]]], ["Mild aminotransferease elevation should not be considered a contraindication to the gradual resumption of normal activity.Case 42A 19-year-old white male with a past medical history significant for attention deficit-hyperactivity disorder (ADHD) presents to his local emergency room with a one day history of severe nausea and nonbloody emesis.", [["attention deficit-hyperactivity disorder", "DISEASE", 198, 238], ["ADHD", "DISEASE", 240, 244], ["nausea", "DISEASE", 316, 322], ["emesis", "DISEASE", 337, 343], ["Mild aminotransferease elevation", "PROBLEM", 0, 32], ["attention deficit", "PROBLEM", 198, 215], ["hyperactivity disorder", "PROBLEM", 216, 238], ["ADHD", "PROBLEM", 240, 244], ["severe nausea", "PROBLEM", 309, 322], ["nonbloody emesis", "PROBLEM", 327, 343], ["elevation", "OBSERVATION", 23, 32], ["normal activity", "OBSERVATION", 106, 121], ["hyperactivity disorder", "OBSERVATION", 216, 238], ["severe", "OBSERVATION_MODIFIER", 309, 315], ["nausea", "OBSERVATION", 316, 322], ["nonbloody emesis", "OBSERVATION", 327, 343]]], ["The patient reported some abdominal discomfort and fatigue.", [["abdominal", "ANATOMY", 26, 35], ["abdominal discomfort", "DISEASE", 26, 46], ["fatigue", "DISEASE", 51, 58], ["patient", "ORGANISM", 4, 11], ["abdominal", "ORGANISM_SUBDIVISION", 26, 35], ["patient", "SPECIES", 4, 11], ["some abdominal discomfort", "PROBLEM", 21, 46], ["fatigue", "PROBLEM", 51, 58], ["abdominal", "ANATOMY", 26, 35], ["discomfort", "OBSERVATION", 36, 46], ["fatigue", "OBSERVATION", 51, 58]]], ["Remainder of review of systems was negative, although the patient did report feeling depressed after a \"big-time fight\" with his girlfriend.", [["depressed", "DISEASE", 85, 94], ["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["review of systems", "TEST", 13, 30], ["feeling depressed", "PROBLEM", 77, 94], ["negative", "OBSERVATION", 35, 43]]], ["The patient denied any suicidal or homicidal ideation.", [["homicidal ideation", "DISEASE", 35, 53], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["homicidal ideation", "PROBLEM", 35, 53]]], ["He had his tonsils and adenoids removed 3 years ago.", [["tonsils", "ANATOMY", 11, 18], ["adenoids", "ANATOMY", 23, 31], ["He", "ORGANISM", 0, 2], ["tonsils", "ORGAN", 11, 18], ["adenoids", "ORGAN", 23, 31], ["his tonsils and adenoids", "PROBLEM", 7, 31], ["tonsils", "ANATOMY", 11, 18], ["adenoids", "OBSERVATION", 23, 31]]], ["His prescription medications include amphetamine and dextroamphetamine for ADHD and venlafaxine which he has recently started on for anxiety.", [["amphetamine", "CHEMICAL", 37, 48], ["dextroamphetamine", "CHEMICAL", 53, 70], ["ADHD", "DISEASE", 75, 79], ["venlafaxine", "CHEMICAL", 84, 95], ["anxiety", "DISEASE", 133, 140], ["amphetamine", "CHEMICAL", 37, 48], ["dextroamphetamine", "CHEMICAL", 53, 70], ["venlafaxine", "CHEMICAL", 84, 95], ["amphetamine", "SIMPLE_CHEMICAL", 37, 48], ["dextroamphetamine", "SIMPLE_CHEMICAL", 53, 70], ["venlafaxine", "SIMPLE_CHEMICAL", 84, 95], ["His prescription medications", "TREATMENT", 0, 28], ["amphetamine", "TREATMENT", 37, 48], ["dextroamphetamine", "TREATMENT", 53, 70], ["ADHD", "TREATMENT", 75, 79], ["venlafaxine", "TREATMENT", 84, 95], ["anxiety", "PROBLEM", 133, 140]]], ["He denied any recent antibiotics, herbal, or over-the-counter medications.", [["antibiotics", "TREATMENT", 21, 32], ["herbal", "TREATMENT", 34, 40], ["medications", "TREATMENT", 62, 73]]], ["The patient lives with his mother and is coping with the recent separation of his parents.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["He denies alcohol, but he does smoke one pack of cigarettes per day and smokes marijuana on weekends.", [["alcohol", "CHEMICAL", 10, 17], ["marijuana", "CHEMICAL", 79, 88], ["alcohol", "CHEMICAL", 10, 17], ["He", "ORGANISM", 0, 2], ["alcohol", "SIMPLE_CHEMICAL", 10, 17]]], ["He denies any intravenous drug use.", [["intravenous", "ANATOMY", 14, 25], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 25]]], ["He has a tattoo of his girlfriend's name which he obtained 1 year ago.", [["tattoo", "OBSERVATION", 9, 15]]], ["He has a family history significant for alcohol abuse and depression.Case 42Physical examination is notable for a thin (BMI 19.1 kg/m 2 ) somewhat illappearing Caucasian male.", [["alcohol abuse", "DISEASE", 40, 53], ["depression", "DISEASE", 58, 68], ["alcohol", "CHEMICAL", 40, 47], ["alcohol", "SIMPLE_CHEMICAL", 40, 47], ["depression", "PROBLEM", 58, 68], ["Case 42Physical examination", "TEST", 69, 96]]], ["He is afebrile, heart rate is 101 per minute, and blood pressure is 142/66.", [["heart", "ANATOMY", 16, 21], ["blood", "ANATOMY", 50, 55], ["heart", "ORGAN", 16, 21], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["afebrile", "PROBLEM", 6, 14], ["heart rate", "TEST", 16, 26], ["blood pressure", "TEST", 50, 64], ["afebrile", "OBSERVATION", 6, 14], ["heart", "ANATOMY", 16, 21]]], ["He answers questions appropriately, and there is no asterixis.", [["asterixis", "PROBLEM", 52, 61], ["no", "UNCERTAINTY", 49, 51], ["asterixis", "OBSERVATION", 52, 61]]], ["He has no stigmata of chronic liver disease.", [["liver", "ANATOMY", 30, 35], ["chronic liver disease", "DISEASE", 22, 43], ["liver", "ORGAN", 30, 35], ["chronic liver disease", "PROBLEM", 22, 43], ["no stigmata of", "UNCERTAINTY", 7, 21], ["chronic", "OBSERVATION_MODIFIER", 22, 29], ["liver", "ANATOMY", 30, 35], ["disease", "OBSERVATION", 36, 43]]], ["He is nonicteric.", [["nonicteric", "PROBLEM", 6, 16], ["nonicteric", "OBSERVATION", 6, 16]]], ["Cardiac and pulmonary exam are normal.", [["Cardiac", "ANATOMY", 0, 7], ["pulmonary", "ANATOMY", 12, 21], ["Cardiac", "MULTI-TISSUE_STRUCTURE", 0, 7], ["pulmonary", "ORGAN", 12, 21], ["Cardiac and pulmonary exam", "TEST", 0, 26], ["pulmonary", "ANATOMY", 12, 21], ["normal", "OBSERVATION", 31, 37]]], ["His abdomen is soft; bowel sounds are normal, but he is mildly tender in right quadrant.", [["abdomen", "ANATOMY", 4, 11], ["bowel", "ANATOMY", 21, 26], ["right quadrant", "ANATOMY", 73, 87], ["abdomen", "ORGAN", 4, 11], ["bowel", "ORGAN", 21, 26], ["mildly tender in right quadrant", "PROBLEM", 56, 87], ["abdomen", "ANATOMY", 4, 11], ["soft", "OBSERVATION", 15, 19], ["bowel", "ANATOMY", 21, 26], ["sounds", "OBSERVATION", 27, 33], ["normal", "OBSERVATION", 38, 44], ["mildly", "OBSERVATION_MODIFIER", 56, 62], ["tender", "OBSERVATION", 63, 69], ["right", "ANATOMY_MODIFIER", 73, 78], ["quadrant", "ANATOMY", 79, 87]]], ["There is no appreciable hepatosplenomegaly. pH 7.27; lactate 2.9 WBC 9,400/\u03bcl Amylase 350 iu/l, Lipase 780 iu/l Acetaminophen level 12 (44 h after ingestion) Right Upper Quadrant US with Dopplers Normal liver, normal hepatic flowAnswer: Acute Hepatitis Secondary to Intentional Acetaminophen IngestionInitially, this patient adamantly denied taking any excessive medications.", [["liver", "ANATOMY", 203, 208], ["hepatic", "ANATOMY", 217, 224], ["hepatosplenomegaly", "DISEASE", 24, 42], ["lactate", "CHEMICAL", 53, 60], ["Acetaminophen", "CHEMICAL", 112, 125], ["Hepatitis", "DISEASE", 243, 252], ["Acetaminophen", "CHEMICAL", 278, 291], ["lactate", "CHEMICAL", 53, 60], ["Acetaminophen", "CHEMICAL", 112, 125], ["Acetaminophen", "CHEMICAL", 278, 291], ["lactate", "SIMPLE_CHEMICAL", 53, 60], ["liver", "ORGAN", 203, 208], ["hepatic", "ORGAN", 217, 224], ["Acetaminophen", "SIMPLE_CHEMICAL", 278, 291], ["patient", "ORGANISM", 317, 324], ["patient", "SPECIES", 317, 324], ["appreciable hepatosplenomegaly", "PROBLEM", 12, 42], ["pH", "TEST", 44, 46], ["lactate", "TEST", 53, 60], ["WBC", "TEST", 65, 68], ["\u03bcl", "TEST", 75, 77], ["Amylase", "TEST", 78, 85], ["iu", "TEST", 90, 92], ["Lipase", "TEST", 96, 102], ["iu/l Acetaminophen level", "TEST", 107, 131], ["Right Upper Quadrant US", "TEST", 158, 181], ["Dopplers", "TEST", 187, 195], ["Acute Hepatitis", "PROBLEM", 237, 252], ["Intentional Acetaminophen IngestionInitially", "TREATMENT", 266, 310], ["any excessive medications", "TREATMENT", 349, 374], ["no", "UNCERTAINTY", 9, 11], ["appreciable", "OBSERVATION_MODIFIER", 12, 23], ["hepatosplenomegaly", "OBSERVATION", 24, 42], ["Lipase", "ANATOMY", 96, 102], ["Right", "ANATOMY_MODIFIER", 158, 163], ["Upper", "ANATOMY_MODIFIER", 164, 169], ["Quadrant", "ANATOMY", 170, 178], ["Normal", "OBSERVATION", 196, 202], ["liver", "ANATOMY", 203, 208], ["normal", "OBSERVATION", 210, 216], ["hepatic", "ANATOMY", 217, 224], ["Acute", "OBSERVATION_MODIFIER", 237, 242], ["Hepatitis", "OBSERVATION", 243, 252]]], ["When his liver tests returned and he was further questioned, he eventually admitted to ingesting a \"fistful\" of Tylenol\u00ae, estimated to be just over 16 g (50 \u00d7 325 mg tablets).Answer: Acute Hepatitis Secondary to Intentional Acetaminophen IngestionThe massive elevations (nearly 1,000\u00d7 upper limits of normal) and exclusively hepatocellular injury, elevated INR, and development of acute tubular necrosis all point towards acetaminophen toxicity as the cause of liver injury.Answer: Acute Hepatitis Secondary to Intentional Acetaminophen IngestionAcetaminophen (N-acetyl-p-aminophenol; APAP; paracetamol) is the most widely used analgesic-antipyretic in the United States.", [["liver", "ANATOMY", 9, 14], ["hepatocellular", "ANATOMY", 325, 339], ["tubular", "ANATOMY", 387, 394], ["liver", "ANATOMY", 461, 466], ["Tylenol\u00ae", "CHEMICAL", 112, 120], ["Hepatitis", "DISEASE", 189, 198], ["Acetaminophen", "CHEMICAL", 224, 237], ["hepatocellular injury", "DISEASE", 325, 346], ["acute tubular necrosis", "DISEASE", 381, 403], ["acetaminophen", "CHEMICAL", 422, 435], ["toxicity", "DISEASE", 436, 444], ["liver injury", "DISEASE", 461, 473], ["Hepatitis", "DISEASE", 488, 497], ["Acetaminophen", "CHEMICAL", 523, 536], ["IngestionAcetaminophen", "CHEMICAL", 537, 559], ["N-acetyl-p-aminophenol", "CHEMICAL", 561, 583], ["APAP", "CHEMICAL", 585, 589], ["paracetamol", "CHEMICAL", 591, 602], ["Acetaminophen", "CHEMICAL", 224, 237], ["acetaminophen", "CHEMICAL", 422, 435], ["Acetaminophen", "CHEMICAL", 523, 536], ["N-acetyl-p-aminophenol", "CHEMICAL", 561, 583], ["APAP", "CHEMICAL", 585, 589], ["paracetamol", "CHEMICAL", 591, 602], ["liver", "ORGAN", 9, 14], ["Tylenol\u00ae", "SIMPLE_CHEMICAL", 112, 120], ["Acetaminophen", "SIMPLE_CHEMICAL", 224, 237], ["hepatocellular", "ORGAN", 325, 339], ["tubular", "ORGAN", 387, 394], ["acetaminophen", "SIMPLE_CHEMICAL", 422, 435], ["liver", "ORGAN", 461, 466], ["Acetaminophen IngestionAcetaminophen", "SIMPLE_CHEMICAL", 523, 559], ["N-acetyl-p-aminophenol", "SIMPLE_CHEMICAL", 561, 583], ["APAP", "SIMPLE_CHEMICAL", 585, 589], ["paracetamol", "SIMPLE_CHEMICAL", 591, 602], ["INR", "PROTEIN", 357, 360], ["his liver tests", "TEST", 5, 20], ["Tylenol\u00ae", "TREATMENT", 112, 120], ["Acute Hepatitis", "PROBLEM", 183, 198], ["Intentional Acetaminophen Ingestion", "PROBLEM", 212, 247], ["The massive elevations", "PROBLEM", 247, 269], ["hepatocellular injury", "PROBLEM", 325, 346], ["elevated INR", "PROBLEM", 348, 360], ["acute tubular necrosis", "PROBLEM", 381, 403], ["acetaminophen toxicity", "PROBLEM", 422, 444], ["liver injury", "PROBLEM", 461, 473], ["Acute Hepatitis", "PROBLEM", 482, 497], ["Intentional Acetaminophen IngestionAcetaminophen", "TREATMENT", 511, 559], ["N-acetyl", "TREATMENT", 561, 569], ["aminophenol", "TREATMENT", 572, 583], ["APAP", "TREATMENT", 585, 589], ["paracetamol", "TREATMENT", 591, 602], ["analgesic-antipyretic", "TREATMENT", 628, 649], ["liver", "ANATOMY", 9, 14], ["Acute", "OBSERVATION_MODIFIER", 183, 188], ["Hepatitis", "OBSERVATION", 189, 198], ["massive", "OBSERVATION_MODIFIER", 251, 258], ["elevations", "OBSERVATION_MODIFIER", 259, 269], ["upper limits", "OBSERVATION_MODIFIER", 285, 297], ["normal", "OBSERVATION", 301, 307], ["hepatocellular", "ANATOMY", 325, 339], ["injury", "OBSERVATION", 340, 346], ["elevated", "OBSERVATION_MODIFIER", 348, 356], ["INR", "OBSERVATION", 357, 360], ["acute", "OBSERVATION_MODIFIER", 381, 386], ["tubular", "ANATOMY_MODIFIER", 387, 394], ["necrosis", "OBSERVATION", 395, 403], ["liver", "ANATOMY", 461, 466], ["injury", "OBSERVATION", 467, 473], ["Acute", "OBSERVATION_MODIFIER", 482, 487], ["Hepatitis", "OBSERVATION", 488, 497]]], ["Although safe when taken at prescribed doses, overdose can cause severe and sometimes life-threatening hepatic injury.", [["hepatic", "ANATOMY", 103, 110], ["overdose", "DISEASE", 46, 54], ["hepatic injury", "DISEASE", 103, 117], ["hepatic", "ORGAN", 103, 110], ["overdose", "PROBLEM", 46, 54], ["severe and sometimes life-threatening hepatic injury", "PROBLEM", 65, 117], ["severe", "OBSERVATION_MODIFIER", 65, 71], ["hepatic", "ANATOMY", 103, 110], ["injury", "OBSERVATION", 111, 117]]], ["Acetaminophen has become the most common etiology of acute liver failure in the United States and accounts for more intentional and unintentional overdoses and overdose deaths each year in the US than any other pharmaceutical agent.Answer: Acute Hepatitis Secondary to Intentional Acetaminophen IngestionThe maximum recommended dose in a 24 h period in adults is 4 g.", [["liver", "ANATOMY", 59, 64], ["Acetaminophen", "CHEMICAL", 0, 13], ["acute liver failure", "DISEASE", 53, 72], ["overdoses", "DISEASE", 146, 155], ["overdose", "DISEASE", 160, 168], ["deaths", "DISEASE", 169, 175], ["Hepatitis", "DISEASE", 246, 255], ["Acetaminophen", "CHEMICAL", 281, 294], ["Acetaminophen", "CHEMICAL", 0, 13], ["Acetaminophen", "CHEMICAL", 281, 294], ["Acetaminophen", "SIMPLE_CHEMICAL", 0, 13], ["liver", "ORGAN", 59, 64], ["Acetaminophen", "SIMPLE_CHEMICAL", 281, 294], ["Acetaminophen", "TREATMENT", 0, 13], ["acute liver failure", "PROBLEM", 53, 72], ["Acute Hepatitis", "PROBLEM", 240, 255], ["Intentional Acetaminophen Ingestion", "TREATMENT", 269, 304], ["most common", "OBSERVATION_MODIFIER", 29, 40], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["liver", "ANATOMY", 59, 64], ["failure", "OBSERVATION", 65, 72], ["Acute", "OBSERVATION_MODIFIER", 240, 245], ["Hepatitis", "OBSERVATION", 246, 255]]], ["Toxicity is likely to occur with a single ingestion >12 g over a 24 h period.", [["Toxicity", "DISEASE", 0, 8], ["likely to", "UNCERTAINTY", 12, 21]]], ["Virtually all patients who ingest doses >350 mg/kg develop severe liver toxicity unless appropriately treated.Answer: Acute Hepatitis Secondary to Intentional Acetaminophen IngestionAcetaminophen is rapidly and completely absorbed from the intestinal tract.", [["liver", "ANATOMY", 66, 71], ["intestinal tract", "ANATOMY", 240, 256], ["liver toxicity", "DISEASE", 66, 80], ["Hepatitis", "DISEASE", 124, 133], ["Acetaminophen", "CHEMICAL", 159, 172], ["Acetaminophen", "CHEMICAL", 182, 195], ["Acetaminophen", "CHEMICAL", 159, 172], ["Acetaminophen", "CHEMICAL", 182, 195], ["patients", "ORGANISM", 14, 22], ["liver", "ORGAN", 66, 71], ["Acetaminophen", "SIMPLE_CHEMICAL", 159, 172], ["Acetaminophen", "SIMPLE_CHEMICAL", 182, 195], ["intestinal tract", "ORGAN", 240, 256], ["patients", "SPECIES", 14, 22], ["severe liver toxicity", "PROBLEM", 59, 80], ["Acute Hepatitis", "PROBLEM", 118, 133], ["Intentional Acetaminophen Ingestion", "TREATMENT", 147, 182], ["Acetaminophen", "TREATMENT", 182, 195], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["liver", "ANATOMY", 66, 71], ["toxicity", "OBSERVATION", 72, 80], ["Acute", "OBSERVATION_MODIFIER", 118, 123], ["Hepatitis", "OBSERVATION", 124, 133], ["intestinal tract", "ANATOMY", 240, 256]]], ["Serum concentrations peak between one-half and 2 h after an oral dose.", [["Serum", "ANATOMY", 0, 5], ["oral", "ANATOMY", 60, 64], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["oral", "ORGANISM_SUBDIVISION", 60, 64], ["Serum concentrations", "TEST", 0, 20]]], ["At therapeutic doses, 90% of acetaminophen is metabolized in the liver to sulfate and glucuronide conjugates, which are then excreted in the urine.", [["liver", "ANATOMY", 65, 70], ["urine", "ANATOMY", 141, 146], ["acetaminophen", "CHEMICAL", 29, 42], ["glucuronide", "CHEMICAL", 86, 97], ["acetaminophen", "CHEMICAL", 29, 42], ["sulfate", "CHEMICAL", 74, 81], ["glucuronide", "CHEMICAL", 86, 97], ["acetaminophen", "SIMPLE_CHEMICAL", 29, 42], ["liver", "ORGAN", 65, 70], ["sulfate", "SIMPLE_CHEMICAL", 74, 81], ["glucuronide conjugates", "SIMPLE_CHEMICAL", 86, 108], ["urine", "ORGANISM_SUBSTANCE", 141, 146], ["acetaminophen", "TREATMENT", 29, 42], ["the liver to sulfate", "TREATMENT", 61, 81], ["glucuronide conjugates", "TREATMENT", 86, 108], ["liver", "ANATOMY", 65, 70]]], ["Approximately 2% is excreted in the urine unchanged.", [["urine", "ANATOMY", 36, 41], ["urine", "ORGANISM_SUBSTANCE", 36, 41], ["the urine", "TEST", 32, 41], ["urine", "OBSERVATION", 36, 41], ["unchanged", "OBSERVATION_MODIFIER", 42, 51]]], ["The remaining acetaminophen is metabolized via the hepatic cytochrome P450 mixed function oxidase pathway to a toxic, highly reactive intermediate N-acetyl-p-benzoquinoneimine (NAPQ1).", [["hepatic", "ANATOMY", 51, 58], ["acetaminophen", "CHEMICAL", 14, 27], ["N-acetyl-p-benzoquinoneimine", "CHEMICAL", 147, 175], ["NAPQ1", "CHEMICAL", 177, 182], ["acetaminophen", "CHEMICAL", 14, 27], ["N-acetyl-p-benzoquinoneimine", "CHEMICAL", 147, 175], ["NAPQ1", "CHEMICAL", 177, 182], ["acetaminophen", "SIMPLE_CHEMICAL", 14, 27], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 59, 74], ["oxidase", "GENE_OR_GENE_PRODUCT", 90, 97], ["N-acetyl-p-benzoquinoneimine", "SIMPLE_CHEMICAL", 147, 175], ["NAPQ1", "SIMPLE_CHEMICAL", 177, 182], ["hepatic cytochrome P450 mixed function oxidase", "PROTEIN", 51, 97], ["The remaining acetaminophen", "TREATMENT", 0, 27], ["the hepatic cytochrome", "TREATMENT", 47, 69], ["mixed function oxidase pathway", "PROBLEM", 75, 105], ["a toxic", "PROBLEM", 109, 116], ["acetyl", "TREATMENT", 149, 155], ["p-benzoquinoneimine", "TREATMENT", 156, 175], ["hepatic", "ANATOMY", 51, 58], ["reactive", "OBSERVATION_MODIFIER", 125, 133]]], ["Appropriate acetaminophen doses produce a small amount of NAPQ1 which is rapidly conjugated with hepatic glutathione, forming nontoxic cysteine and mercaptate compounds that are excreted in the urine.", [["hepatic", "ANATOMY", 97, 104], ["urine", "ANATOMY", 194, 199], ["acetaminophen", "CHEMICAL", 12, 25], ["NAPQ1", "CHEMICAL", 58, 63], ["glutathione", "CHEMICAL", 105, 116], ["cysteine", "CHEMICAL", 135, 143], ["mercaptate", "CHEMICAL", 148, 158], ["acetaminophen", "CHEMICAL", 12, 25], ["NAPQ1", "CHEMICAL", 58, 63], ["glutathione", "CHEMICAL", 105, 116], ["cysteine", "CHEMICAL", 135, 143], ["mercaptate", "CHEMICAL", 148, 158], ["acetaminophen", "SIMPLE_CHEMICAL", 12, 25], ["NAPQ1", "SIMPLE_CHEMICAL", 58, 63], ["glutathione", "SIMPLE_CHEMICAL", 105, 116], ["nontoxic cysteine", "SIMPLE_CHEMICAL", 126, 143], ["mercaptate compounds", "SIMPLE_CHEMICAL", 148, 168], ["urine", "ORGANISM_SUBSTANCE", 194, 199], ["Appropriate acetaminophen doses", "TREATMENT", 0, 31], ["a small amount of NAPQ1", "PROBLEM", 40, 63], ["hepatic glutathione", "TREATMENT", 97, 116], ["nontoxic cysteine", "TREATMENT", 126, 143], ["mercaptate compounds", "TREATMENT", 148, 168], ["small", "OBSERVATION_MODIFIER", 42, 47], ["amount", "OBSERVATION_MODIFIER", 48, 54], ["hepatic", "ANATOMY", 97, 104], ["nontoxic cysteine", "OBSERVATION", 126, 143], ["urine", "ANATOMY", 194, 199]]], ["However, with toxic doses of acetaminophen, the sulfation and glucuronidation pathways become saturated, and more acetaminophen is metabolized to NAPQ1 via cytochrome P450.", [["acetaminophen", "CHEMICAL", 29, 42], ["acetaminophen", "CHEMICAL", 114, 127], ["NAPQ1", "CHEMICAL", 146, 151], ["acetaminophen", "CHEMICAL", 29, 42], ["acetaminophen", "CHEMICAL", 114, 127], ["NAPQ1", "CHEMICAL", 146, 151], ["acetaminophen", "SIMPLE_CHEMICAL", 29, 42], ["acetaminophen", "SIMPLE_CHEMICAL", 114, 127], ["NAPQ1", "SIMPLE_CHEMICAL", 146, 151], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 156, 171], ["cytochrome P450", "PROTEIN", 156, 171], ["acetaminophen", "TREATMENT", 29, 42], ["the sulfation", "TREATMENT", 44, 57], ["glucuronidation pathways", "TREATMENT", 62, 86], ["acetaminophen", "TREATMENT", 114, 127], ["NAPQ1 via cytochrome P450", "TREATMENT", 146, 171]]], ["When hepatic glutathione stores are depleted by approximately 75%, NAPQ1 begins to react with hepatocytes and leads to injury and necrosis.", [["hepatic", "ANATOMY", 5, 12], ["hepatocytes", "ANATOMY", 94, 105], ["glutathione", "CHEMICAL", 13, 24], ["NAPQ1", "CHEMICAL", 67, 72], ["necrosis", "DISEASE", 130, 138], ["glutathione", "CHEMICAL", 13, 24], ["hepatic", "MULTI-TISSUE_STRUCTURE", 5, 12], ["glutathione", "SIMPLE_CHEMICAL", 13, 24], ["NAPQ1", "SIMPLE_CHEMICAL", 67, 72], ["hepatocytes", "CELL", 94, 105], ["NAPQ1", "PROTEIN", 67, 72], ["hepatocytes", "CELL_TYPE", 94, 105], ["hepatic glutathione stores", "PROBLEM", 5, 31], ["injury", "PROBLEM", 119, 125], ["necrosis", "PROBLEM", 130, 138], ["hepatic", "ANATOMY", 5, 12], ["glutathione stores", "OBSERVATION", 13, 31], ["depleted", "OBSERVATION_MODIFIER", 36, 44], ["hepatocytes", "ANATOMY", 94, 105], ["injury", "OBSERVATION", 119, 125], ["necrosis", "OBSERVATION", 130, 138]]], ["There is evidence that conditions that deplete stores of glutathione, such as malnutrition and a period of fasting may predispose patients to acetaminophen toxicity.Answer: Acute Hepatitis Secondary to Intentional Acetaminophen IngestionClinical manifestations of acetaminophen poisoning are divided into four stages: Histological changes in the liver vary from cytolysis to centrilobular necrosis.", [["liver", "ANATOMY", 346, 351], ["centrilobular", "ANATOMY", 375, 388], ["glutathione", "CHEMICAL", 57, 68], ["malnutrition", "DISEASE", 78, 90], ["acetaminophen", "CHEMICAL", 142, 155], ["toxicity", "DISEASE", 156, 164], ["Hepatitis", "DISEASE", 179, 188], ["Acetaminophen", "CHEMICAL", 214, 227], ["acetaminophen", "CHEMICAL", 264, 277], ["poisoning", "DISEASE", 278, 287], ["cytolysis", "DISEASE", 362, 371], ["necrosis", "DISEASE", 389, 397], ["glutathione", "CHEMICAL", 57, 68], ["acetaminophen", "CHEMICAL", 142, 155], ["Acetaminophen", "CHEMICAL", 214, 227], ["acetaminophen", "CHEMICAL", 264, 277], ["glutathione", "SIMPLE_CHEMICAL", 57, 68], ["patients", "ORGANISM", 130, 138], ["acetaminophen", "SIMPLE_CHEMICAL", 142, 155], ["acetaminophen", "SIMPLE_CHEMICAL", 264, 277], ["liver", "ORGAN", 346, 351], ["patients", "SPECIES", 130, 138], ["glutathione", "TREATMENT", 57, 68], ["malnutrition", "PROBLEM", 78, 90], ["acetaminophen toxicity", "PROBLEM", 142, 164], ["Acute Hepatitis", "PROBLEM", 173, 188], ["Intentional Acetaminophen", "TREATMENT", 202, 227], ["acetaminophen poisoning", "TREATMENT", 264, 287], ["Histological changes in the liver", "PROBLEM", 318, 351], ["cytolysis", "PROBLEM", 362, 371], ["centrilobular necrosis", "PROBLEM", 375, 397], ["Acute", "OBSERVATION_MODIFIER", 173, 178], ["Hepatitis", "OBSERVATION", 179, 188], ["liver", "ANATOMY", 346, 351], ["cytolysis", "OBSERVATION", 362, 371], ["centrilobular", "OBSERVATION_MODIFIER", 375, 388], ["necrosis", "OBSERVATION", 389, 397]]], ["The centrilobular region (zone III) is preferentially involved because it is the greatest area of concentration of CYP2E1 and therefore the site of maximal production of NAPQ1.", [["centrilobular region", "ANATOMY", 4, 24], ["NAPQ1", "CHEMICAL", 170, 175], ["NAPQ1", "CHEMICAL", 170, 175], ["centrilobular region", "PATHOLOGICAL_FORMATION", 4, 24], ["CYP2E1", "GENE_OR_GENE_PRODUCT", 115, 121], ["NAPQ1", "GENE_OR_GENE_PRODUCT", 170, 175], ["CYP2E1", "PROTEIN", 115, 121], ["NAPQ1", "PROTEIN", 170, 175], ["centrilobular", "ANATOMY_MODIFIER", 4, 17], ["zone III", "OBSERVATION_MODIFIER", 26, 34], ["greatest", "OBSERVATION_MODIFIER", 81, 89], ["area", "OBSERVATION_MODIFIER", 90, 94], ["concentration", "OBSERVATION_MODIFIER", 98, 111], ["CYP2E1", "OBSERVATION", 115, 121], ["maximal", "OBSERVATION_MODIFIER", 148, 155], ["production", "OBSERVATION_MODIFIER", 156, 166]]], ["Acute renal failure due primarily to acute tubular necrosis occurs in 25% of patients with significant hepatotoxicity and in more than 50% of those with frank hepatic failure.Answer: Acute Hepatitis Secondary to Intentional Acetaminophen IngestionAll patients with a clear history of acetaminophen or suspected of overdose should undergo measurement of serum acetaminophen concentration.", [["renal", "ANATOMY", 6, 11], ["tubular", "ANATOMY", 43, 50], ["hepatic", "ANATOMY", 159, 166], ["serum", "ANATOMY", 353, 358], ["Acute renal failure", "DISEASE", 0, 19], ["acute tubular necrosis", "DISEASE", 37, 59], ["hepatotoxicity", "DISEASE", 103, 117], ["hepatic failure", "DISEASE", 159, 174], ["Hepatitis", "DISEASE", 189, 198], ["Acetaminophen", "CHEMICAL", 224, 237], ["acetaminophen", "CHEMICAL", 284, 297], ["overdose", "DISEASE", 314, 322], ["acetaminophen", "CHEMICAL", 359, 372], ["Acetaminophen", "CHEMICAL", 224, 237], ["acetaminophen", "CHEMICAL", 284, 297], ["acetaminophen", "CHEMICAL", 359, 372], ["renal", "ORGAN", 6, 11], ["tubular", "MULTI-TISSUE_STRUCTURE", 43, 50], ["patients", "ORGANISM", 77, 85], ["hepatic", "ORGAN", 159, 166], ["Acetaminophen", "SIMPLE_CHEMICAL", 224, 237], ["patients", "ORGANISM", 251, 259], ["acetaminophen", "SIMPLE_CHEMICAL", 284, 297], ["serum", "ORGANISM_SUBSTANCE", 353, 358], ["acetaminophen", "SIMPLE_CHEMICAL", 359, 372], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 251, 259], ["Acute renal failure", "PROBLEM", 0, 19], ["acute tubular necrosis", "PROBLEM", 37, 59], ["significant hepatotoxicity", "PROBLEM", 91, 117], ["frank hepatic failure", "PROBLEM", 153, 174], ["Acute Hepatitis", "PROBLEM", 183, 198], ["Intentional Acetaminophen Ingestion", "TREATMENT", 212, 247], ["acetaminophen", "TREATMENT", 284, 297], ["overdose", "PROBLEM", 314, 322], ["serum acetaminophen concentration", "TREATMENT", 353, 386], ["renal", "ANATOMY", 6, 11], ["failure", "OBSERVATION", 12, 19], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["tubular", "ANATOMY_MODIFIER", 43, 50], ["necrosis", "OBSERVATION", 51, 59], ["25%", "OBSERVATION_MODIFIER", 70, 73], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["hepatotoxicity", "OBSERVATION", 103, 117], ["hepatic", "ANATOMY", 159, 166], ["failure", "OBSERVATION", 167, 174], ["Acute", "OBSERVATION_MODIFIER", 183, 188], ["Hepatitis", "OBSERVATION", 189, 198]]], ["If any doubt exists about the time of ingestion, a serum concentration should be obtained immediately at the time of presentation.", [["serum", "ANATOMY", 51, 56], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["a serum concentration", "TEST", 49, 70]]], ["A serum concentration should also be obtained 4 h following the time of acute ingestion or presentation.Answer: Acute Hepatitis Secondary to Intentional Acetaminophen IngestionManagement consists of supportive care, prevention of drug absorption, and, when appropriate, the administration of antidotes, namely, N-acetylcysteine (NAC).Answer: Acute Hepatitis Secondary to Intentional Acetaminophen IngestionTreatment with NAC is recommended for all patients with liver tenderness, elevations of aminotransferases, supratherapeutic serum acetaminophen concentrations (greater than 20 mcg/ml), and those with history of excessive ingestion, risk factors for toxicity, and acetaminophen concentrations >10 mcg/ml.", [["serum", "ANATOMY", 2, 7], ["liver", "ANATOMY", 462, 467], ["serum", "ANATOMY", 530, 535], ["Hepatitis", "DISEASE", 118, 127], ["Acetaminophen", "CHEMICAL", 153, 166], ["N-acetylcysteine", "CHEMICAL", 311, 327], ["NAC", "CHEMICAL", 329, 332], ["Hepatitis", "DISEASE", 348, 357], ["Acetaminophen", "CHEMICAL", 383, 396], ["NAC", "CHEMICAL", 421, 424], ["liver tenderness", "DISEASE", 462, 478], ["acetaminophen", "CHEMICAL", 536, 549], ["toxicity", "DISEASE", 655, 663], ["acetaminophen", "CHEMICAL", 669, 682], ["Acetaminophen", "CHEMICAL", 153, 166], ["N-acetylcysteine", "CHEMICAL", 311, 327], ["NAC", "CHEMICAL", 329, 332], ["Acetaminophen", "CHEMICAL", 383, 396], ["NAC", "CHEMICAL", 421, 424], ["acetaminophen", "CHEMICAL", 536, 549], ["acetaminophen", "CHEMICAL", 669, 682], ["serum", "ORGANISM_SUBSTANCE", 2, 7], ["Acetaminophen", "SIMPLE_CHEMICAL", 153, 166], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 311, 327], ["NAC", "SIMPLE_CHEMICAL", 329, 332], ["Acetaminophen", "SIMPLE_CHEMICAL", 383, 396], ["NAC", "SIMPLE_CHEMICAL", 421, 424], ["patients", "ORGANISM", 448, 456], ["liver", "ORGAN", 462, 467], ["aminotransferases", "SIMPLE_CHEMICAL", 494, 511], ["serum", "ORGANISM_SUBSTANCE", 530, 535], ["acetaminophen", "SIMPLE_CHEMICAL", 536, 549], ["acetaminophen", "SIMPLE_CHEMICAL", 669, 682], ["patients", "SPECIES", 448, 456], ["A serum concentration", "TEST", 0, 21], ["acute ingestion", "PROBLEM", 72, 87], ["Acute Hepatitis", "PROBLEM", 112, 127], ["Intentional Acetaminophen IngestionManagement", "TREATMENT", 141, 186], ["supportive care", "TREATMENT", 199, 214], ["drug absorption", "PROBLEM", 230, 245], ["antidotes", "TREATMENT", 292, 301], ["N-acetylcysteine (NAC)", "TREATMENT", 311, 333], ["Acute Hepatitis", "PROBLEM", 342, 357], ["Intentional Acetaminophen IngestionTreatment", "TREATMENT", 371, 415], ["NAC", "TREATMENT", 421, 424], ["liver tenderness", "PROBLEM", 462, 478], ["elevations of aminotransferases", "PROBLEM", 480, 511], ["supratherapeutic serum acetaminophen concentrations", "TREATMENT", 513, 564], ["excessive ingestion", "PROBLEM", 617, 636], ["toxicity", "PROBLEM", 655, 663], ["acetaminophen concentrations", "TREATMENT", 669, 697], ["Acute", "OBSERVATION_MODIFIER", 112, 117], ["Hepatitis", "OBSERVATION", 118, 127], ["Acute", "OBSERVATION_MODIFIER", 342, 347], ["Hepatitis", "OBSERVATION", 348, 357], ["liver", "ANATOMY", 462, 467], ["tenderness", "OBSERVATION", 468, 478]]], ["If a patient has a detectable acetaminophen concentration but is without signs, symptoms, or risk factors for toxicity and without elevations of aminotransferases, then treatment is likely not necessary.Answer: Acute Hepatitis Secondary to Intentional Acetaminophen IngestionThe outcome of acetaminophen intoxication is nearly always good if NAC is given in a timely fashion.", [["acetaminophen", "CHEMICAL", 30, 43], ["toxicity", "DISEASE", 110, 118], ["Hepatitis", "DISEASE", 217, 226], ["Acetaminophen", "CHEMICAL", 252, 265], ["acetaminophen", "CHEMICAL", 290, 303], ["NAC", "CHEMICAL", 342, 345], ["acetaminophen", "CHEMICAL", 30, 43], ["Acetaminophen", "CHEMICAL", 252, 265], ["acetaminophen", "CHEMICAL", 290, 303], ["NAC", "CHEMICAL", 342, 345], ["patient", "ORGANISM", 5, 12], ["acetaminophen", "SIMPLE_CHEMICAL", 30, 43], ["aminotransferases", "GENE_OR_GENE_PRODUCT", 145, 162], ["Acetaminophen", "SIMPLE_CHEMICAL", 252, 265], ["acetaminophen", "SIMPLE_CHEMICAL", 290, 303], ["NAC", "SIMPLE_CHEMICAL", 342, 345], ["aminotransferases", "PROTEIN", 145, 162], ["patient", "SPECIES", 5, 12], ["a detectable acetaminophen concentration", "TREATMENT", 17, 57], ["symptoms", "PROBLEM", 80, 88], ["risk factors", "PROBLEM", 93, 105], ["toxicity", "PROBLEM", 110, 118], ["elevations of aminotransferases", "PROBLEM", 131, 162], ["treatment", "TREATMENT", 169, 178], ["Acute Hepatitis", "PROBLEM", 211, 226], ["Intentional Acetaminophen Ingestion", "TREATMENT", 240, 275], ["acetaminophen intoxication", "PROBLEM", 290, 316], ["NAC", "TREATMENT", 342, 345], ["without", "UNCERTAINTY", 65, 72], ["likely not", "UNCERTAINTY", 182, 192], ["Acute", "OBSERVATION_MODIFIER", 211, 216], ["Hepatitis", "OBSERVATION", 217, 226]]], ["No deaths have been reported in any of the large studies of acetaminophen overdose provided NAC was given within 10 h of ingestion, regardless of the initial serum acetaminophen concentration.Answer: Acute Hepatitis Secondary to Intentional Acetaminophen IngestionSeveral statistical models have been developed for predicting the outcome in patients with acute liver failure, including the MELD.", [["serum", "ANATOMY", 158, 163], ["liver", "ANATOMY", 361, 366], ["deaths", "DISEASE", 3, 9], ["acetaminophen", "CHEMICAL", 60, 73], ["overdose", "DISEASE", 74, 82], ["NAC", "CHEMICAL", 92, 95], ["acetaminophen", "CHEMICAL", 164, 177], ["Hepatitis", "DISEASE", 206, 215], ["Acetaminophen", "CHEMICAL", 241, 254], ["acute liver failure", "DISEASE", 355, 374], ["acetaminophen", "CHEMICAL", 60, 73], ["NAC", "CHEMICAL", 92, 95], ["acetaminophen", "CHEMICAL", 164, 177], ["Acetaminophen", "CHEMICAL", 241, 254], ["acetaminophen", "SIMPLE_CHEMICAL", 60, 73], ["NAC", "SIMPLE_CHEMICAL", 92, 95], ["serum", "ORGANISM_SUBSTANCE", 158, 163], ["acetaminophen", "SIMPLE_CHEMICAL", 164, 177], ["patients", "ORGANISM", 341, 349], ["liver", "ORGAN", 361, 366], ["patients", "SPECIES", 341, 349], ["deaths", "PROBLEM", 3, 9], ["acetaminophen overdose", "PROBLEM", 60, 82], ["NAC", "TREATMENT", 92, 95], ["the initial serum acetaminophen concentration", "TREATMENT", 146, 191], ["Acute Hepatitis", "PROBLEM", 200, 215], ["Intentional Acetaminophen", "TREATMENT", 229, 254], ["acute liver failure", "PROBLEM", 355, 374], ["the MELD", "TEST", 386, 394], ["deaths", "OBSERVATION", 3, 9], ["Acute", "OBSERVATION_MODIFIER", 200, 205], ["Hepatitis", "OBSERVATION", 206, 215], ["acute", "OBSERVATION_MODIFIER", 355, 360], ["liver", "ANATOMY", 361, 366], ["failure", "OBSERVATION", 367, 374]]], ["Perhaps the most widely recognized of these models, however, is the King's College Criteria (see table above).", [["most widely", "OBSERVATION_MODIFIER", 12, 23]]], ["This model was developed in a cohort of over 500 patients who were managed between 1973 and 1985.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]], ["Recommendations for liver transplantation were based upon the results.", [["liver", "ANATOMY", 20, 25], ["liver", "ORGAN", 20, 25], ["liver transplantation", "TREATMENT", 20, 41], ["liver", "ANATOMY", 20, 25], ["transplantation", "OBSERVATION", 26, 41]]], ["The predictors of outcome were stratified according to whether the ALF was caused by acetaminophen or \"other\" causes.", [["ALF", "DISEASE", 67, 70], ["acetaminophen", "CHEMICAL", 85, 98], ["ALF", "CHEMICAL", 67, 70], ["acetaminophen", "CHEMICAL", 85, 98], ["acetaminophen", "SIMPLE_CHEMICAL", 85, 98], ["the ALF", "PROBLEM", 63, 70], ["acetaminophen", "TREATMENT", 85, 98]]], ["The positive and negative predictive values of the Kings College Criteria for mortality in patients with acetaminophen-induced ALF (not including patients who were transplanted) are 88 and 65%, respectivelyAnswer: Acute Hepatitis Secondary to Intentional Acetaminophen IngestionThe patient in this case was administered NAC as soon as his enzyme elevation was noted.", [["acetaminophen", "CHEMICAL", 105, 118], ["ALF", "DISEASE", 127, 130], ["Hepatitis", "DISEASE", 220, 229], ["Acetaminophen", "CHEMICAL", 255, 268], ["NAC", "CHEMICAL", 320, 323], ["acetaminophen", "CHEMICAL", 105, 118], ["ALF", "CHEMICAL", 127, 130], ["Acetaminophen", "CHEMICAL", 255, 268], ["NAC", "CHEMICAL", 320, 323], ["patients", "ORGANISM", 91, 99], ["acetaminophen", "SIMPLE_CHEMICAL", 105, 118], ["patients", "ORGANISM", 146, 154], ["Acetaminophen", "SIMPLE_CHEMICAL", 255, 268], ["patient", "ORGANISM", 282, 289], ["NAC", "SIMPLE_CHEMICAL", 320, 323], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 146, 154], ["patient", "SPECIES", 282, 289], ["acetaminophen", "TREATMENT", 105, 118], ["Acute Hepatitis", "PROBLEM", 214, 229], ["Intentional Acetaminophen Ingestion", "TREATMENT", 243, 278], ["NAC", "TREATMENT", 320, 323], ["his enzyme elevation", "TEST", 335, 355], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["negative predictive values", "OBSERVATION_MODIFIER", 17, 43], ["Acute", "OBSERVATION_MODIFIER", 214, 219], ["Hepatitis", "OBSERVATION", 220, 229], ["elevation", "OBSERVATION", 346, 355]]], ["His transaminases dramatically normalized, and although he developed oliguric renal failure secondary to ATN, he never required renal replacement therapy.", [["renal", "ANATOMY", 78, 83], ["renal", "ANATOMY", 128, 133], ["oliguric renal failure", "DISEASE", 69, 91], ["ATN", "DISEASE", 105, 108], ["His", "CHEMICAL", 0, 3], ["renal", "ORGAN", 78, 83], ["renal", "ORGAN", 128, 133], ["His transaminases", "TEST", 0, 17], ["oliguric renal failure", "PROBLEM", 69, 91], ["ATN", "PROBLEM", 105, 108], ["renal replacement therapy", "TREATMENT", 128, 153], ["oliguric", "OBSERVATION_MODIFIER", 69, 77], ["renal", "ANATOMY", 78, 83], ["failure", "OBSERVATION", 84, 91], ["ATN", "OBSERVATION", 105, 108], ["renal", "ANATOMY", 128, 133], ["replacement therapy", "OBSERVATION", 134, 153]]], ["He was eventually discharged to an inpatient psychiatric ward on hospital day 6.Case 43A 43-year-old male presents to the emergency room with confusion and jaundice.", [["psychiatric", "DISEASE", 45, 56], ["confusion", "DISEASE", 142, 151], ["jaundice", "DISEASE", 156, 164], ["male", "ORGANISM", 101, 105], ["confusion", "PROBLEM", 142, 151], ["jaundice", "PROBLEM", 156, 164], ["confusion", "OBSERVATION", 142, 151], ["jaundice", "OBSERVATION", 156, 164]]], ["He is a heavy drinker and has been drinking even more heavily recently following separation from his wife.", [["He", "ORGANISM", 0, 2]]], ["He complains of abdominal discomfort and nausea.", [["abdominal", "ANATOMY", 16, 25], ["abdominal discomfort", "DISEASE", 16, 36], ["nausea", "DISEASE", 41, 47], ["abdominal", "ORGANISM_SUBDIVISION", 16, 25], ["abdominal discomfort", "PROBLEM", 16, 36], ["nausea", "PROBLEM", 41, 47], ["abdominal", "ANATOMY", 16, 25], ["discomfort", "OBSERVATION", 26, 36], ["nausea", "OBSERVATION", 41, 47]]], ["He has no other medical history.", [["no", "UNCERTAINTY", 7, 9]]], ["He has been laid off work recently due to his alcoholism.Case 43He smokes and admits to drinking 20-30 beers on a daily basis and has been drinking vodka in addition over the last 2 weeks.Case 43He is cirrhotic based on imaging from 2 years ago when he presented to the outpatient clinic with abnormal liver tests.Case 43He is on no prescribed medication.", [["liver", "ANATOMY", 302, 307], ["alcoholism", "DISEASE", 46, 56], ["cirrhotic", "DISEASE", 201, 210], ["abnormal liver tests", "DISEASE", 293, 313], ["vodka", "ORGANISM_SUBDIVISION", 148, 153], ["liver", "ORGAN", 302, 307], ["his alcoholism", "PROBLEM", 42, 56], ["cirrhotic", "PROBLEM", 201, 210], ["imaging", "TEST", 220, 227], ["abnormal liver tests", "PROBLEM", 293, 313], ["prescribed medication", "TREATMENT", 333, 354], ["alcoholism", "OBSERVATION", 46, 56], ["cirrhotic", "OBSERVATION", 201, 210], ["liver", "ANATOMY", 302, 307]]], ["On examination, vital signs are stable.", [["examination", "TEST", 3, 14], ["vital signs", "TEST", 16, 27], ["stable", "OBSERVATION_MODIFIER", 32, 38]]], ["He is obviously confused with asterixis.", [["asterixis", "DISEASE", 30, 39], ["He", "ORGANISM", 0, 2], ["obviously confused", "PROBLEM", 6, 24], ["asterixis", "PROBLEM", 30, 39], ["asterixis", "OBSERVATION", 30, 39]]], ["He has palmar erythema, scleral icterus, and an enlarged liver and spleen.", [["palmar", "ANATOMY", 7, 13], ["scleral icterus", "ANATOMY", 24, 39], ["liver", "ANATOMY", 57, 62], ["spleen", "ANATOMY", 67, 73], ["erythema", "DISEASE", 14, 22], ["scleral icterus", "DISEASE", 24, 39], ["liver", "ORGAN", 57, 62], ["spleen", "ORGAN", 67, 73], ["palmar erythema", "PROBLEM", 7, 22], ["scleral icterus", "PROBLEM", 24, 39], ["an enlarged liver and spleen", "PROBLEM", 45, 73], ["palmar", "ANATOMY", 7, 13], ["erythema", "OBSERVATION", 14, 22], ["scleral", "ANATOMY", 24, 31], ["icterus", "OBSERVATION", 32, 39], ["enlarged", "OBSERVATION", 48, 56], ["liver", "ANATOMY", 57, 62], ["spleen", "ANATOMY", 67, 73]]], ["Skin reveals jaundice and multiple 5-10 mm lesions as shown in the photographs.Laboratory StudiesTotal bilirubin 25.6 mg/dl Direct bilirubin 19.7 mg/dl AST 154 iu/l ALT 47 iu/l ALP 135 iu/l GGTP 657 iu/l Albumin 2.2 g/dl INR 1.9 Questions 1.", [["Skin", "ANATOMY", 0, 4], ["lesions", "ANATOMY", 43, 50], ["jaundice", "DISEASE", 13, 21], ["bilirubin", "CHEMICAL", 103, 112], ["bilirubin", "CHEMICAL", 131, 140], ["bilirubin", "CHEMICAL", 103, 112], ["bilirubin", "CHEMICAL", 131, 140], ["Skin", "ORGAN", 0, 4], ["lesions", "PATHOLOGICAL_FORMATION", 43, 50], ["bilirubin", "SIMPLE_CHEMICAL", 103, 112], ["bilirubin", "SIMPLE_CHEMICAL", 131, 140], ["Albumin", "GENE_OR_GENE_PRODUCT", 204, 211], ["ALP", "PROTEIN", 177, 180], ["jaundice", "PROBLEM", 13, 21], ["multiple 5-10 mm lesions", "PROBLEM", 26, 50], ["Laboratory Studies", "TEST", 79, 97], ["Total bilirubin", "TEST", 97, 112], ["bilirubin", "TEST", 131, 140], ["AST", "TEST", 152, 155], ["iu", "TEST", 160, 162], ["ALT", "TEST", 165, 168], ["iu", "TEST", 172, 174], ["ALP", "TEST", 177, 180], ["iu", "TEST", 185, 187], ["GGTP", "TEST", 190, 194], ["iu", "TEST", 199, 201], ["Albumin", "TEST", 204, 211], ["dl INR", "TEST", 218, 224], ["jaundice", "OBSERVATION", 13, 21], ["multiple", "OBSERVATION_MODIFIER", 26, 34], ["5-10 mm", "OBSERVATION_MODIFIER", 35, 42], ["lesions", "OBSERVATION", 43, 50]]], ["What is the relevance of the skin lesions -are they always pathological? 2.", [["skin lesions", "ANATOMY", 29, 41], ["skin lesions", "CANCER", 29, 41], ["the skin lesions", "PROBLEM", 25, 41], ["skin", "ANATOMY", 29, 33], ["lesions", "OBSERVATION", 34, 41]]], ["How many lesions are considered significant? 3.", [["lesions", "ANATOMY", 9, 16], ["lesions", "PATHOLOGICAL_FORMATION", 9, 16], ["many lesions", "PROBLEM", 4, 16], ["many", "OBSERVATION_MODIFIER", 4, 8], ["lesions", "OBSERVATION", 9, 16]]], ["Is there a recognized distribution in patients with liver disease? 4.", [["liver", "ANATOMY", 52, 57], ["liver disease", "DISEASE", 52, 65], ["patients", "ORGANISM", 38, 46], ["liver", "ORGAN", 52, 57], ["patients", "SPECIES", 38, 46], ["liver disease", "PROBLEM", 52, 65], ["distribution", "OBSERVATION_MODIFIER", 22, 34], ["liver", "ANATOMY", 52, 57], ["disease", "OBSERVATION", 58, 65]]], ["Is the etiology of his liver disease relevant? 4 show the classic appearance of a spider nevus.", [["liver", "ANATOMY", 23, 28], ["nevus", "ANATOMY", 89, 94], ["liver disease", "DISEASE", 23, 36], ["spider nevus", "DISEASE", 82, 94], ["liver", "ORGAN", 23, 28], ["his liver disease", "PROBLEM", 19, 36], ["a spider nevus", "PROBLEM", 80, 94], ["liver", "ANATOMY", 23, 28], ["disease", "OBSERVATION", 29, 36], ["spider nevus", "OBSERVATION", 82, 94]]], ["There is a central arteriole and capillaries extending outwards.", [["central arteriole", "ANATOMY", 11, 28], ["capillaries", "ANATOMY", 33, 44], ["arteriole", "MULTI-TISSUE_STRUCTURE", 19, 28], ["capillaries", "TISSUE", 33, 44], ["central", "ANATOMY_MODIFIER", 11, 18], ["arteriole", "ANATOMY_MODIFIER", 19, 28], ["capillaries", "ANATOMY_MODIFIER", 33, 44]]], ["They blanch with pressure and then refill from centrally when the pressure is released.Laboratory StudiesThey are seen in 10-15% of healthy children and young adults.", [["children", "ORGANISM", 140, 148], ["children", "SPECIES", 140, 148], ["pressure", "TREATMENT", 17, 25], ["Laboratory Studies", "TEST", 87, 105], ["pressure", "OBSERVATION_MODIFIER", 17, 25], ["pressure", "OBSERVATION", 66, 74]]], ["They are commonly seen in pregnancy, and in women where there appears to be a relationship with the menstrual cycle, and in high output states such as thyrotoxicosis.", [["thyrotoxicosis", "DISEASE", 151, 165], ["women", "ORGANISM", 44, 49], ["women", "SPECIES", 44, 49], ["thyrotoxicosis", "PROBLEM", 151, 165], ["thyrotoxicosis", "OBSERVATION", 151, 165]]], ["In liver disease, they are common in cirrhosis, particularly if alcohol is the etiology.Laboratory StudiesThe number is thought to be relevant with more than 5-7 indicative of pathology.", [["liver", "ANATOMY", 3, 8], ["liver disease", "DISEASE", 3, 16], ["cirrhosis", "DISEASE", 37, 46], ["alcohol", "CHEMICAL", 64, 71], ["alcohol", "CHEMICAL", 64, 71], ["liver", "ORGAN", 3, 8], ["alcohol", "SIMPLE_CHEMICAL", 64, 71], ["liver disease", "PROBLEM", 3, 16], ["cirrhosis", "PROBLEM", 37, 46], ["Laboratory Studies", "TEST", 88, 106], ["pathology", "PROBLEM", 176, 185], ["liver", "ANATOMY", 3, 8], ["disease", "OBSERVATION", 9, 16], ["common", "OBSERVATION_MODIFIER", 27, 33], ["cirrhosis", "OBSERVATION", 37, 46], ["thought to be", "UNCERTAINTY", 120, 133], ["pathology", "OBSERVATION", 176, 185]]], ["The distribution follows that of the superior vena cava, so lesions are seen above the nipple line, face, shoulders, and upper extremities.Laboratory StudiesThe pathogenesis is unclear but is related to dilation of existing vessels rather than neoproliferation.Laboratory StudiesSome studies have suggested that their presence together with other markers of liver disease is indicative of increased hepatic fibrosis in patients with chronic hepatitis C.Case 44A 64-year-old woman presents to your outpatient office because of worsening ankle edema.", [["superior vena cava", "ANATOMY", 37, 55], ["lesions", "ANATOMY", 60, 67], ["nipple line", "ANATOMY", 87, 98], ["face", "ANATOMY", 100, 104], ["shoulders", "ANATOMY", 106, 115], ["upper extremities", "ANATOMY", 121, 138], ["vessels", "ANATOMY", 224, 231], ["liver", "ANATOMY", 358, 363], ["hepatic", "ANATOMY", 399, 406], ["ankle edema", "ANATOMY", 536, 547], ["liver disease", "DISEASE", 358, 371], ["hepatic fibrosis", "DISEASE", 399, 415], ["chronic hepatitis", "DISEASE", 433, 450], ["ankle edema", "DISEASE", 536, 547], ["superior", "MULTI-TISSUE_STRUCTURE", 37, 45], ["vena cava", "MULTI-TISSUE_STRUCTURE", 46, 55], ["lesions", "PATHOLOGICAL_FORMATION", 60, 67], ["nipple line", "TISSUE", 87, 98], ["face", "ORGANISM_SUBDIVISION", 100, 104], ["shoulders", "ORGANISM_SUBDIVISION", 106, 115], ["upper extremities", "ORGANISM_SUBDIVISION", 121, 138], ["vessels", "MULTI-TISSUE_STRUCTURE", 224, 231], ["liver", "ORGAN", 358, 363], ["hepatic", "ORGAN", 399, 406], ["patients", "ORGANISM", 419, 427], ["woman", "ORGANISM", 474, 479], ["ankle edema", "PATHOLOGICAL_FORMATION", 536, 547], ["patients", "SPECIES", 419, 427], ["woman", "SPECIES", 474, 479], ["lesions", "PROBLEM", 60, 67], ["Laboratory Studies", "TEST", 139, 157], ["dilation of existing vessels", "PROBLEM", 203, 231], ["neoproliferation", "PROBLEM", 244, 260], ["Laboratory Studies", "TEST", 261, 279], ["Some studies", "TEST", 279, 291], ["liver disease", "PROBLEM", 358, 371], ["increased hepatic fibrosis", "PROBLEM", 389, 415], ["chronic hepatitis C.", "PROBLEM", 433, 453], ["worsening ankle edema", "PROBLEM", 526, 547], ["superior vena cava", "ANATOMY", 37, 55], ["lesions", "OBSERVATION", 60, 67], ["nipple line", "OBSERVATION", 87, 98], ["face", "ANATOMY_MODIFIER", 100, 104], ["shoulders", "ANATOMY", 106, 115], ["upper extremities", "ANATOMY", 121, 138], ["dilation", "OBSERVATION", 203, 211], ["vessels", "ANATOMY", 224, 231], ["neoproliferation", "OBSERVATION", 244, 260], ["liver", "ANATOMY", 358, 363], ["disease", "OBSERVATION", 364, 371], ["indicative of", "UNCERTAINTY", 375, 388], ["increased", "OBSERVATION_MODIFIER", 389, 398], ["hepatic", "ANATOMY", 399, 406], ["fibrosis", "OBSERVATION", 407, 415], ["chronic", "OBSERVATION_MODIFIER", 433, 440], ["hepatitis", "OBSERVATION", 441, 450], ["worsening", "OBSERVATION_MODIFIER", 526, 535], ["ankle", "ANATOMY", 536, 541], ["edema", "OBSERVATION", 542, 547]]], ["She has a history of cirrhosis likely from significant alcohol use but quit drinking several years ago.", [["cirrhosis", "DISEASE", 21, 30], ["alcohol", "CHEMICAL", 55, 62], ["alcohol", "CHEMICAL", 55, 62], ["alcohol", "ORGANISM_SUBDIVISION", 55, 62], ["cirrhosis", "PROBLEM", 21, 30], ["cirrhosis", "OBSERVATION", 21, 30], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["alcohol", "OBSERVATION", 55, 62]]], ["Her liver disease has been complicated by encephalopathy, and she has mild portal hypertension based on imaging and endoscopy.Case 44Her past medical history is significant for hypertension and a hysterectomy many years ago for a nonmalignant condition.Case 44Her current medications include a thiazide diuretic and lactulose.", [["liver", "ANATOMY", 4, 9], ["portal", "ANATOMY", 75, 81], ["liver disease", "DISEASE", 4, 17], ["encephalopathy", "DISEASE", 42, 56], ["portal hypertension", "DISEASE", 75, 94], ["hypertension", "DISEASE", 177, 189], ["thiazide diuretic", "CHEMICAL", 294, 311], ["lactulose", "CHEMICAL", 316, 325], ["thiazide", "CHEMICAL", 294, 302], ["lactulose", "CHEMICAL", 316, 325], ["liver", "ORGAN", 4, 9], ["portal", "MULTI-TISSUE_STRUCTURE", 75, 81], ["thiazide", "SIMPLE_CHEMICAL", 294, 302], ["lactulose", "SIMPLE_CHEMICAL", 316, 325], ["Her liver disease", "PROBLEM", 0, 17], ["encephalopathy", "PROBLEM", 42, 56], ["mild portal hypertension", "PROBLEM", 70, 94], ["imaging", "TEST", 104, 111], ["endoscopy", "TEST", 116, 125], ["hypertension", "PROBLEM", 177, 189], ["a hysterectomy", "TREATMENT", 194, 208], ["a nonmalignant condition", "PROBLEM", 228, 252], ["current medications", "TREATMENT", 264, 283], ["a thiazide diuretic", "TREATMENT", 292, 311], ["lactulose", "TREATMENT", 316, 325], ["liver", "ANATOMY", 4, 9], ["disease", "OBSERVATION", 10, 17], ["encephalopathy", "OBSERVATION", 42, 56], ["mild", "OBSERVATION_MODIFIER", 70, 74], ["portal", "ANATOMY", 75, 81], ["hypertension", "OBSERVATION", 82, 94], ["significant for", "UNCERTAINTY", 161, 176], ["hypertension", "OBSERVATION", 177, 189], ["hysterectomy", "OBSERVATION", 196, 208]]], ["She is an ex-smoker but denies drug use.", [["ex-smoker", "OBSERVATION", 10, 19]]], ["Her alcohol history is significant for daily drinking including spirits and beer up until 4 years ago.Case 44She is widowed and comes to the appointment with an adult daughter.", [["alcohol", "CHEMICAL", 4, 11], ["alcohol", "CHEMICAL", 4, 11]]], ["Her family history is notable for several family members with alcoholic liver disease.Case 44Her review of symptoms is significant for the ankle edema and some shortness of breath on exertion but no chest pain, weight loss, or abdominal distension.", [["liver", "ANATOMY", 72, 77], ["ankle edema", "ANATOMY", 139, 150], ["chest", "ANATOMY", 199, 204], ["abdominal", "ANATOMY", 227, 236], ["alcoholic liver disease", "DISEASE", 62, 85], ["edema", "DISEASE", 145, 150], ["shortness of breath", "DISEASE", 160, 179], ["chest pain", "DISEASE", 199, 209], ["weight loss", "DISEASE", 211, 222], ["abdominal distension", "DISEASE", 227, 247], ["liver", "ORGAN", 72, 77], ["ankle", "ORGANISM_SUBDIVISION", 139, 144], ["edema", "PATHOLOGICAL_FORMATION", 145, 150], ["chest", "ORGANISM_SUBDIVISION", 199, 204], ["abdominal", "ORGANISM_SUBDIVISION", 227, 236], ["alcoholic liver disease", "PROBLEM", 62, 85], ["symptoms", "PROBLEM", 107, 115], ["the ankle edema", "PROBLEM", 135, 150], ["some shortness of breath", "PROBLEM", 155, 179], ["chest pain", "PROBLEM", 199, 209], ["weight loss", "PROBLEM", 211, 222], ["abdominal distension", "PROBLEM", 227, 247], ["alcoholic", "OBSERVATION", 62, 71], ["liver", "ANATOMY", 72, 77], ["disease", "OBSERVATION", 78, 85], ["ankle", "ANATOMY", 139, 144], ["edema", "OBSERVATION", 145, 150], ["no", "UNCERTAINTY", 196, 198], ["chest", "ANATOMY", 199, 204], ["abdominal", "ANATOMY", 227, 236], ["distension", "OBSERVATION", 237, 247]]], ["She does feel very fatigued.Case 44On exam, she is alert and oriented.", [["very fatigued", "PROBLEM", 14, 27], ["exam", "TEST", 38, 42]]], ["Her vital signs show BP 140/85, pulse 82 and regular, and she is afebrile.", [["Her vital signs", "TEST", 0, 15], ["BP", "TEST", 21, 23], ["pulse", "TEST", 32, 37], ["afebrile", "PROBLEM", 65, 73], ["afebrile", "OBSERVATION", 65, 73]]], ["She has mild palmar erythema and a few spider nevi.", [["palmar erythema", "ANATOMY", 13, 28], ["nevi", "ANATOMY", 46, 50], ["palmar erythema", "DISEASE", 13, 28], ["spider nevi", "DISEASE", 39, 50], ["palmar erythema", "PATHOLOGICAL_FORMATION", 13, 28], ["mild palmar erythema", "PROBLEM", 8, 28], ["a few spider nevi", "PROBLEM", 33, 50], ["mild", "OBSERVATION_MODIFIER", 8, 12], ["palmar", "ANATOMY", 13, 19], ["erythema", "OBSERVATION", 20, 28], ["few", "OBSERVATION_MODIFIER", 35, 38], ["spider nevi", "OBSERVATION", 39, 50]]], ["There is no scleral icterus.Case 44Cardiovascular system reveals normal heart sounds with a pansystolic murmur heard best at the left sternal edge, and chest reveals a few bibasilar crackles.", [["scleral", "ANATOMY", 12, 19], ["heart", "ANATOMY", 72, 77], ["left sternal edge", "ANATOMY", 129, 146], ["chest", "ANATOMY", 152, 157], ["icterus", "DISEASE", 20, 27], ["heart", "ORGAN", 72, 77], ["sternal edge", "MULTI-TISSUE_STRUCTURE", 134, 146], ["chest", "ORGAN", 152, 157], ["scleral icterus", "PROBLEM", 12, 27], ["a pansystolic murmur", "PROBLEM", 90, 110], ["a few bibasilar crackles", "PROBLEM", 166, 190], ["no", "UNCERTAINTY", 9, 11], ["scleral", "ANATOMY", 12, 19], ["icterus", "OBSERVATION", 20, 27], ["normal", "OBSERVATION", 65, 71], ["heart", "ANATOMY", 72, 77], ["sounds", "OBSERVATION", 78, 84], ["pansystolic", "OBSERVATION_MODIFIER", 92, 103], ["murmur", "OBSERVATION", 104, 110], ["left", "ANATOMY_MODIFIER", 129, 133], ["sternal", "ANATOMY", 134, 141], ["edge", "ANATOMY_MODIFIER", 142, 146], ["chest", "ANATOMY", 152, 157], ["few", "OBSERVATION_MODIFIER", 168, 171], ["bibasilar", "ANATOMY_MODIFIER", 172, 181], ["crackles", "OBSERVATION", 182, 190]]], ["Her abdomen is soft and nontender.", [["abdomen", "ANATOMY", 4, 11], ["abdomen", "ORGAN", 4, 11], ["nontender", "PROBLEM", 24, 33], ["abdomen", "ANATOMY", 4, 11], ["soft", "OBSERVATION", 15, 19], ["nontender", "OBSERVATION", 24, 33]]], ["The liver is palpable several cms below the right costal margin and she has a spleen tip in the left upper quadrant.", [["liver", "ANATOMY", 4, 9], ["cms", "ANATOMY", 30, 33], ["right costal margin", "ANATOMY", 44, 63], ["spleen", "ANATOMY", 78, 84], ["left upper quadrant", "ANATOMY", 96, 115], ["liver", "ORGAN", 4, 9], ["costal margin", "MULTI-TISSUE_STRUCTURE", 50, 63], ["spleen tip", "MULTI-TISSUE_STRUCTURE", 78, 88], ["upper quadrant", "ORGANISM_SUBDIVISION", 101, 115], ["liver", "ANATOMY", 4, 9], ["palpable", "OBSERVATION", 13, 21], ["several", "OBSERVATION_MODIFIER", 22, 29], ["cms", "OBSERVATION", 30, 33], ["right", "ANATOMY_MODIFIER", 44, 49], ["costal", "ANATOMY", 50, 56], ["margin", "ANATOMY_MODIFIER", 57, 63], ["spleen", "ANATOMY", 78, 84], ["tip", "OBSERVATION_MODIFIER", 85, 88], ["left", "ANATOMY_MODIFIER", 96, 100], ["upper", "ANATOMY_MODIFIER", 101, 106], ["quadrant", "ANATOMY", 107, 115]]], ["There is some dullness in the flanks, and she has 2+ ankle edema.Answer: Portopulmonary HypertensionThis lady has symptoms and signs suggestive of portopulmonary hypertension (PPHTN).", [["portopulmonary", "ANATOMY", 147, 161], ["edema", "DISEASE", 59, 64], ["Hypertension", "DISEASE", 88, 100], ["portopulmonary hypertension", "DISEASE", 147, 174], ["PPHTN", "DISEASE", 176, 181], ["flanks", "ORGANISM_SUBDIVISION", 30, 36], ["ankle", "ORGANISM_SUBDIVISION", 53, 58], ["edema", "PATHOLOGICAL_FORMATION", 59, 64], ["some dullness in the flanks", "PROBLEM", 9, 36], ["ankle edema", "PROBLEM", 53, 64], ["Portopulmonary Hypertension", "PROBLEM", 73, 100], ["symptoms", "PROBLEM", 114, 122], ["portopulmonary hypertension", "PROBLEM", 147, 174], ["some", "OBSERVATION_MODIFIER", 9, 13], ["dullness", "OBSERVATION", 14, 22], ["flanks", "ANATOMY", 30, 36], ["ankle", "ANATOMY", 53, 58], ["edema", "OBSERVATION", 59, 64], ["Portopulmonary", "ANATOMY", 73, 87], ["Hypertension", "OBSERVATION", 88, 100], ["suggestive of", "UNCERTAINTY", 133, 146], ["portopulmonary", "ANATOMY", 147, 161], ["hypertension", "OBSERVATION", 162, 174]]], ["This condition is defined by pulmonary arterial hypertension in the setting of portal hypertension in the absence of other causes of pulmonary hypertension.Answer: Portopulmonary HypertensionThe pulmonary symptoms typically include dyspnea on exertion, chest pain, fatigue, orthopnea, and syncope.", [["pulmonary arterial", "ANATOMY", 29, 47], ["portal", "ANATOMY", 79, 85], ["pulmonary", "ANATOMY", 133, 142], ["pulmonary", "ANATOMY", 195, 204], ["chest", "ANATOMY", 253, 258], ["pulmonary arterial hypertension", "DISEASE", 29, 60], ["portal hypertension", "DISEASE", 79, 98], ["pulmonary hypertension", "DISEASE", 133, 155], ["Hypertension", "DISEASE", 179, 191], ["pulmonary symptoms", "DISEASE", 195, 213], ["dyspnea", "DISEASE", 232, 239], ["chest pain", "DISEASE", 253, 263], ["fatigue", "DISEASE", 265, 272], ["orthopnea", "DISEASE", 274, 283], ["syncope", "DISEASE", 289, 296], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 29, 47], ["portal", "MULTI-TISSUE_STRUCTURE", 79, 85], ["pulmonary", "ORGAN", 133, 142], ["pulmonary", "ORGAN", 195, 204], ["chest", "ORGANISM_SUBDIVISION", 253, 258], ["pulmonary arterial hypertension", "PROBLEM", 29, 60], ["portal hypertension", "PROBLEM", 79, 98], ["pulmonary hypertension", "PROBLEM", 133, 155], ["Portopulmonary Hypertension", "PROBLEM", 164, 191], ["The pulmonary symptoms", "PROBLEM", 191, 213], ["dyspnea", "PROBLEM", 232, 239], ["chest pain", "PROBLEM", 253, 263], ["fatigue", "PROBLEM", 265, 272], ["orthopnea", "PROBLEM", 274, 283], ["syncope", "PROBLEM", 289, 296], ["pulmonary arterial", "ANATOMY", 29, 47], ["hypertension", "OBSERVATION", 48, 60], ["portal", "ANATOMY", 79, 85], ["hypertension", "OBSERVATION", 86, 98], ["pulmonary", "ANATOMY", 133, 142], ["hypertension", "OBSERVATION", 143, 155], ["Portopulmonary", "ANATOMY", 164, 178], ["Hypertension", "OBSERVATION", 179, 191], ["pulmonary", "ANATOMY", 195, 204], ["chest", "ANATOMY", 253, 258], ["orthopnea", "OBSERVATION", 274, 283], ["syncope", "OBSERVATION", 289, 296]]], ["Exam can demonstrate right ventricular overload with tricuspid incompetence (as in this case), worsening ascites, and dependent edema.", [["right ventricular", "ANATOMY", 21, 38], ["tricuspid", "ANATOMY", 53, 62], ["ascites", "ANATOMY", 105, 112], ["edema", "ANATOMY", 128, 133], ["ventricular overload", "DISEASE", 27, 47], ["tricuspid incompetence", "DISEASE", 53, 75], ["ascites", "DISEASE", 105, 112], ["edema", "DISEASE", 128, 133], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 21, 38], ["tricuspid", "MULTI-TISSUE_STRUCTURE", 53, 62], ["edema", "PATHOLOGICAL_FORMATION", 128, 133], ["Exam", "TEST", 0, 4], ["right ventricular overload", "PROBLEM", 21, 47], ["tricuspid incompetence", "PROBLEM", 53, 75], ["worsening ascites", "PROBLEM", 95, 112], ["dependent edema", "PROBLEM", 118, 133], ["right ventricular", "ANATOMY", 21, 38], ["overload", "OBSERVATION", 39, 47], ["tricuspid", "ANATOMY", 53, 62], ["incompetence", "OBSERVATION", 63, 75], ["worsening", "OBSERVATION_MODIFIER", 95, 104], ["ascites", "OBSERVATION", 105, 112], ["dependent", "OBSERVATION_MODIFIER", 118, 127], ["edema", "OBSERVATION", 128, 133]]], ["Her laboratory studies also suggest some hepatic congestion.Answer: Portopulmonary HypertensionThe diagnosis cannot be made clinically but is suspected on echocardiography and confirmed by right heart catheterization.", [["hepatic", "ANATOMY", 41, 48], ["right heart", "ANATOMY", 189, 200], ["hepatic congestion", "DISEASE", 41, 59], ["Hypertension", "DISEASE", 83, 95], ["hepatic", "ORGAN", 41, 48], ["heart", "ORGAN", 195, 200], ["Her laboratory studies", "TEST", 0, 22], ["some hepatic congestion", "PROBLEM", 36, 59], ["Portopulmonary Hypertension", "PROBLEM", 68, 95], ["echocardiography", "TEST", 155, 171], ["right heart catheterization", "TEST", 189, 216], ["some", "OBSERVATION_MODIFIER", 36, 40], ["hepatic", "ANATOMY", 41, 48], ["congestion", "OBSERVATION", 49, 59], ["Portopulmonary", "ANATOMY", 68, 82], ["Hypertension", "OBSERVATION", 83, 95], ["right", "ANATOMY_MODIFIER", 189, 194], ["heart", "ANATOMY", 195, 200], ["catheterization", "OBSERVATION", 201, 216]]], ["This lady should undergo a stress echocardiogram, which is a good screening test for pulmonary hypertension.", [["pulmonary", "ANATOMY", 85, 94], ["pulmonary hypertension", "DISEASE", 85, 107], ["pulmonary", "ORGAN", 85, 94], ["a stress echocardiogram", "TEST", 25, 48], ["a good screening test", "TEST", 59, 80], ["pulmonary hypertension", "PROBLEM", 85, 107], ["pulmonary", "ANATOMY", 85, 94], ["hypertension", "OBSERVATION", 95, 107]]], ["The right ventricular pressure is elevated and should prompt referral to a cardiopulmonary specialist and right heart catheterization to make a diagnosis.", [["right ventricular", "ANATOMY", 4, 21], ["right heart", "ANATOMY", 106, 117], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 4, 21], ["heart", "ORGAN", 112, 117], ["The right ventricular pressure", "TEST", 0, 30], ["elevated", "PROBLEM", 34, 42], ["a cardiopulmonary specialist", "TEST", 73, 101], ["right heart catheterization", "TEST", 106, 133], ["right ventricular", "ANATOMY", 4, 21], ["pressure", "OBSERVATION_MODIFIER", 22, 30], ["elevated", "OBSERVATION", 34, 42], ["right", "ANATOMY_MODIFIER", 106, 111], ["heart", "ANATOMY", 112, 117], ["catheterization", "OBSERVATION", 118, 133]]], ["Pulmonary artery hypertension is defined by a mean pulmonary artery pressure (MPAP) >25 mmHg at rest and a pulmonary capillary wedge pressure (PCWP) <15 mmHg.Answer: Portopulmonary HypertensionThe pathogenesis of PPHTN is unclear but may occur on the background of genetic susceptibility as there are cases of familial pulmonary hypertension related to dysfunction of the bone morphogenetic protein receptor type II.", [["Pulmonary artery", "ANATOMY", 0, 16], ["pulmonary artery", "ANATOMY", 51, 67], ["pulmonary capillary", "ANATOMY", 107, 126], ["pulmonary", "ANATOMY", 319, 328], ["bone", "ANATOMY", 372, 376], ["Pulmonary artery hypertension", "DISEASE", 0, 29], ["Hypertension", "DISEASE", 181, 193], ["PPHTN", "DISEASE", 213, 218], ["pulmonary hypertension", "DISEASE", 319, 341], ["Pulmonary artery", "MULTI-TISSUE_STRUCTURE", 0, 16], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 51, 67], ["pulmonary capillary", "MULTI-TISSUE_STRUCTURE", 107, 126], ["PPHTN", "CANCER", 213, 218], ["pulmonary", "ORGAN", 319, 328], ["bone morphogenetic protein receptor type II", "GENE_OR_GENE_PRODUCT", 372, 415], ["bone morphogenetic protein receptor type II", "PROTEIN", 372, 415], ["Pulmonary artery hypertension", "PROBLEM", 0, 29], ["a mean pulmonary artery pressure", "TEST", 44, 76], ["MPAP", "TEST", 78, 82], ["a pulmonary capillary wedge pressure", "TEST", 105, 141], ["PCWP", "TEST", 143, 147], ["Portopulmonary Hypertension", "PROBLEM", 166, 193], ["The pathogenesis of PPHTN", "PROBLEM", 193, 218], ["genetic susceptibility", "PROBLEM", 265, 287], ["familial pulmonary hypertension", "PROBLEM", 310, 341], ["dysfunction of the bone morphogenetic protein receptor type II", "PROBLEM", 353, 415], ["artery", "ANATOMY", 10, 16], ["hypertension", "OBSERVATION", 17, 29], ["pulmonary artery", "ANATOMY", 51, 67], ["pulmonary capillary", "ANATOMY", 107, 126], ["wedge pressure", "OBSERVATION", 127, 141], ["Portopulmonary", "ANATOMY", 166, 180], ["Hypertension", "OBSERVATION", 181, 193], ["PPHTN", "OBSERVATION", 213, 218], ["familial", "OBSERVATION_MODIFIER", 310, 318], ["pulmonary", "ANATOMY", 319, 328], ["hypertension", "OBSERVATION", 329, 341], ["bone", "ANATOMY", 372, 376]]], ["Some studies suggest that the underlying portal hypertension leads to porto-systemic collaterals and substances that normally would be metabolized in the liver mediate the pulmonary hypertension.", [["portal", "ANATOMY", 41, 47], ["porto-systemic collaterals", "ANATOMY", 70, 96], ["liver", "ANATOMY", 154, 159], ["pulmonary", "ANATOMY", 172, 181], ["hypertension", "DISEASE", 48, 60], ["pulmonary hypertension", "DISEASE", 172, 194], ["portal", "MULTI-TISSUE_STRUCTURE", 41, 47], ["liver", "ORGAN", 154, 159], ["pulmonary", "ORGAN", 172, 181], ["Some studies", "TEST", 0, 12], ["the underlying portal hypertension", "PROBLEM", 26, 60], ["the pulmonary hypertension", "PROBLEM", 168, 194], ["portal", "ANATOMY", 41, 47], ["hypertension", "OBSERVATION", 48, 60], ["porto-systemic", "OBSERVATION_MODIFIER", 70, 84], ["collaterals", "OBSERVATION", 85, 96], ["liver", "ANATOMY", 154, 159], ["pulmonary", "ANATOMY", 172, 181], ["hypertension", "OBSERVATION", 182, 194]]], ["Multiple cytokines and hormones have been implicated including serotonin, IL-1, vasoactive intestinal peptide, glucagon, endothelin-1, and thromboxane B2.Answer: Portopulmonary HypertensionThe hyperdynamic circulation seen in cirrhosis and chronic thromboembolism may also play a role.", [["serotonin", "CHEMICAL", 63, 72], ["thromboxane B2", "CHEMICAL", 139, 153], ["Hypertension", "DISEASE", 177, 189], ["cirrhosis", "DISEASE", 226, 235], ["thromboembolism", "DISEASE", 248, 263], ["serotonin", "CHEMICAL", 63, 72], ["thromboxane B2", "CHEMICAL", 139, 153], ["serotonin", "SIMPLE_CHEMICAL", 63, 72], ["IL-1", "GENE_OR_GENE_PRODUCT", 74, 78], ["vasoactive intestinal peptide", "GENE_OR_GENE_PRODUCT", 80, 109], ["glucagon", "GENE_OR_GENE_PRODUCT", 111, 119], ["endothelin-1", "GENE_OR_GENE_PRODUCT", 121, 133], ["thromboxane B2", "GENE_OR_GENE_PRODUCT", 139, 153], ["cytokines", "PROTEIN", 9, 18], ["Multiple cytokines and hormones", "TREATMENT", 0, 31], ["serotonin, IL", "TREATMENT", 63, 76], ["vasoactive intestinal peptide", "TREATMENT", 80, 109], ["glucagon", "TREATMENT", 111, 119], ["endothelin", "TEST", 121, 131], ["thromboxane B2", "TREATMENT", 139, 153], ["Portopulmonary Hypertension", "PROBLEM", 162, 189], ["The hyperdynamic circulation", "PROBLEM", 189, 217], ["cirrhosis", "PROBLEM", 226, 235], ["chronic thromboembolism", "PROBLEM", 240, 263], ["cytokines", "OBSERVATION", 9, 18], ["intestinal", "ANATOMY", 91, 101], ["Portopulmonary", "ANATOMY", 162, 176], ["Hypertension", "OBSERVATION", 177, 189], ["hyperdynamic circulation", "OBSERVATION", 193, 217], ["cirrhosis", "OBSERVATION", 226, 235], ["chronic", "OBSERVATION_MODIFIER", 240, 247], ["thromboembolism", "OBSERVATION", 248, 263]]], ["Pulmonary histology in PPHTN demonstrates in situ thrombosis, pulmonary arteriopathy, and vasoconstriction.Answer: Portopulmonary HypertensionIt is important to make a diagnosis of PPHTN as it negatively impacts outcome after liver transplantation, particularly with a MPAP >35 mmHg.Answer: Portopulmonary HypertensionTreatment can be by liver transplantation, which has a good outcome in patients with a MPAP below 35 mmHg.", [["Pulmonary", "ANATOMY", 0, 9], ["pulmonary", "ANATOMY", 62, 71], ["liver", "ANATOMY", 226, 231], ["Portopulmonary", "ANATOMY", 291, 305], ["liver", "ANATOMY", 338, 343], ["thrombosis", "DISEASE", 50, 60], ["pulmonary arteriopathy", "DISEASE", 62, 84], ["Hypertension", "DISEASE", 130, 142], ["PPHTN", "DISEASE", 181, 186], ["Hypertension", "DISEASE", 306, 318], ["Pulmonary", "ORGAN", 0, 9], ["pulmonary", "ORGAN", 62, 71], ["PPHTN", "CANCER", 181, 186], ["liver", "ORGAN", 226, 231], ["liver", "ORGAN", 338, 343], ["patients", "ORGANISM", 389, 397], ["patients", "SPECIES", 389, 397], ["Pulmonary histology", "TEST", 0, 19], ["PPHTN", "TEST", 23, 28], ["situ thrombosis", "PROBLEM", 45, 60], ["pulmonary arteriopathy", "PROBLEM", 62, 84], ["vasoconstriction", "PROBLEM", 90, 106], ["Portopulmonary Hypertension", "PROBLEM", 115, 142], ["PPHTN", "TREATMENT", 181, 186], ["liver transplantation", "TREATMENT", 226, 247], ["a MPAP", "TEST", 267, 273], ["Portopulmonary Hypertension", "PROBLEM", 291, 318], ["liver transplantation", "TREATMENT", 338, 359], ["a MPAP", "TEST", 403, 409], ["histology", "OBSERVATION", 10, 19], ["situ", "OBSERVATION_MODIFIER", 45, 49], ["thrombosis", "OBSERVATION", 50, 60], ["pulmonary", "ANATOMY", 62, 71], ["arteriopathy", "OBSERVATION", 72, 84], ["vasoconstriction", "OBSERVATION", 90, 106], ["Portopulmonary", "ANATOMY", 115, 129], ["Hypertension", "OBSERVATION", 130, 142], ["liver", "ANATOMY", 226, 231], ["transplantation", "OBSERVATION", 232, 247], ["Portopulmonary", "ANATOMY", 291, 305], ["Hypertension", "OBSERVATION", 306, 318], ["liver", "ANATOMY", 338, 343], ["transplantation", "OBSERVATION", 344, 359]]], ["Higher MPAP and increased peripheral vascular resisitance (PVR) (>250 dynes s cm \u22125 ) are associated with significant mortality after transplantation, and MPAP >50 mmHg is an absolute contraindication to transplant.Answer: Portopulmonary HypertensionThe medical therapy of PPHTN has increased over the last few years and involves vasodilatory agents including epoprostenol (Flolan), sildenafil (Revatio), iloprost, and bosentan, best administered in the setting of a pulmonary hypertension clinic.", [["peripheral vascular", "ANATOMY", 26, 45], ["pulmonary", "ANATOMY", 467, 476], ["Hypertension", "DISEASE", 238, 250], ["PPHTN", "DISEASE", 273, 278], ["epoprostenol", "CHEMICAL", 360, 372], ["Flolan", "CHEMICAL", 374, 380], ["sildenafil", "CHEMICAL", 383, 393], ["iloprost", "CHEMICAL", 405, 413], ["bosentan", "CHEMICAL", 419, 427], ["pulmonary hypertension", "DISEASE", 467, 489], ["epoprostenol", "CHEMICAL", 360, 372], ["Flolan", "CHEMICAL", 374, 380], ["sildenafil", "CHEMICAL", 383, 393], ["iloprost", "CHEMICAL", 405, 413], ["bosentan", "CHEMICAL", 419, 427], ["peripheral vascular", "MULTI-TISSUE_STRUCTURE", 26, 45], ["epoprostenol", "SIMPLE_CHEMICAL", 360, 372], ["Flolan", "SIMPLE_CHEMICAL", 374, 380], ["sildenafil", "SIMPLE_CHEMICAL", 383, 393], ["Revatio", "SIMPLE_CHEMICAL", 395, 402], ["iloprost", "SIMPLE_CHEMICAL", 405, 413], ["bosentan", "SIMPLE_CHEMICAL", 419, 427], ["pulmonary", "ORGAN", 467, 476], ["Higher MPAP", "PROBLEM", 0, 11], ["increased peripheral vascular resisitance", "PROBLEM", 16, 57], ["PVR", "TEST", 59, 62], ["transplantation", "TREATMENT", 134, 149], ["MPAP", "TEST", 155, 159], ["transplant", "TREATMENT", 204, 214], ["Portopulmonary Hypertension", "PROBLEM", 223, 250], ["The medical therapy", "TREATMENT", 250, 269], ["PPHTN", "TREATMENT", 273, 278], ["vasodilatory agents", "TREATMENT", 330, 349], ["epoprostenol (Flolan)", "TREATMENT", 360, 381], ["sildenafil (Revatio)", "TREATMENT", 383, 403], ["iloprost", "TREATMENT", 405, 413], ["bosentan", "TREATMENT", 419, 427], ["a pulmonary hypertension", "PROBLEM", 465, 489], ["MPAP", "OBSERVATION", 7, 11], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["peripheral", "ANATOMY_MODIFIER", 26, 36], ["vascular", "ANATOMY", 37, 45], ["resisitance", "OBSERVATION", 46, 57], ["PVR", "OBSERVATION", 59, 62], ["significant", "OBSERVATION_MODIFIER", 106, 117], ["mortality", "OBSERVATION", 118, 127], ["transplantation", "OBSERVATION", 134, 149], ["transplant", "OBSERVATION", 204, 214], ["Portopulmonary", "ANATOMY", 223, 237], ["Hypertension", "OBSERVATION", 238, 250], ["increased", "OBSERVATION_MODIFIER", 283, 292], ["pulmonary", "ANATOMY", 467, 476], ["hypertension", "OBSERVATION", 477, 489]]], ["The data is based on case series rather than randomized controlled trials, but the goal is to reduce MPAP and decrease PVR to acceptable levels for transplant.", [["MPAP", "SIMPLE_CHEMICAL", 101, 105], ["randomized controlled trials", "TREATMENT", 45, 73], ["MPAP", "TEST", 101, 105], ["PVR", "TEST", 119, 122], ["transplant", "TREATMENT", 148, 158], ["PVR", "OBSERVATION", 119, 122]]], ["There is very limited data to demonstrate improved outcome after transplant in patients treated with these agents.Answer: Portopulmonary HypertensionSeveral case series have documented good outcome after liver transplantation in selected patients with PPHTN.", [["liver", "ANATOMY", 204, 209], ["Hypertension", "DISEASE", 137, 149], ["PPHTN", "DISEASE", 252, 257], ["patients", "ORGANISM", 79, 87], ["liver", "ORGAN", 204, 209], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 238, 246], ["transplant", "TREATMENT", 65, 75], ["these agents", "TREATMENT", 101, 113], ["Portopulmonary Hypertension", "PROBLEM", 122, 149], ["liver transplantation", "TREATMENT", 204, 225], ["PPHTN", "TREATMENT", 252, 257], ["Portopulmonary", "ANATOMY", 122, 136], ["Hypertension", "OBSERVATION", 137, 149], ["liver", "ANATOMY", 204, 209], ["transplantation", "OBSERVATION", 210, 225]]], ["Although survival is not at levels seen in patients without PPHTN, the survival benefit of transplant is significant.", [["PPHTN", "DISEASE", 60, 65], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["PPHTN", "PROBLEM", 60, 65], ["transplant", "TREATMENT", 91, 101], ["transplant", "OBSERVATION", 91, 101], ["significant", "OBSERVATION_MODIFIER", 105, 116]]], ["Resolution of PPHTN after transplant is usual, and there is no evidence that it recurs.Case 45A 57-year-old Asian male presents to the emergency room with hematemesis.", [["PPHTN", "DISEASE", 14, 19], ["hematemesis", "DISEASE", 155, 166], ["PPHTN", "CANCER", 14, 19], ["Asian", "ORGANISM", 108, 113], ["PPHTN", "PROBLEM", 14, 19], ["transplant", "TREATMENT", 26, 36], ["hematemesis", "PROBLEM", 155, 166], ["PPHTN", "OBSERVATION", 14, 19], ["transplant", "OBSERVATION", 26, 36], ["no evidence that", "UNCERTAINTY", 60, 76], ["hematemesis", "OBSERVATION", 155, 166]]], ["The patient has been recently diagnosed with non-small cell lung cancer.", [["non-small cell lung cancer", "ANATOMY", 45, 71], ["non-small cell lung cancer", "DISEASE", 45, 71], ["patient", "ORGANISM", 4, 11], ["non-small cell lung cancer", "CANCER", 45, 71], ["patient", "SPECIES", 4, 11], ["non-small cell lung cancer", "PROBLEM", 45, 71], ["non-small cell", "OBSERVATION", 45, 59], ["lung", "ANATOMY", 60, 64], ["cancer", "OBSERVATION", 65, 71]]], ["The cancer has not yet been treated.", [["cancer", "ANATOMY", 4, 10], ["cancer", "DISEASE", 4, 10], ["cancer", "CANCER", 4, 10], ["The cancer", "PROBLEM", 0, 10], ["cancer", "OBSERVATION", 4, 10]]], ["He is not known to have liver disease.Case 45His current medications include aspirin and atenolol for hypertension.", [["liver", "ANATOMY", 24, 29], ["liver disease", "DISEASE", 24, 37], ["aspirin", "CHEMICAL", 77, 84], ["atenolol", "CHEMICAL", 89, 97], ["hypertension", "DISEASE", 102, 114], ["aspirin", "CHEMICAL", 77, 84], ["atenolol", "CHEMICAL", 89, 97], ["liver", "ORGAN", 24, 29], ["aspirin", "SIMPLE_CHEMICAL", 77, 84], ["atenolol", "SIMPLE_CHEMICAL", 89, 97], ["liver disease", "PROBLEM", 24, 37], ["current medications", "TREATMENT", 49, 68], ["aspirin", "TREATMENT", 77, 84], ["atenolol", "TREATMENT", 89, 97], ["hypertension", "PROBLEM", 102, 114], ["not known to", "UNCERTAINTY", 6, 18], ["liver", "ANATOMY", 24, 29], ["disease", "OBSERVATION", 30, 37], ["hypertension", "OBSERVATION", 102, 114]]], ["The patient also reports a history of intermittent dysphagia to solid food for the last several weeks.Case 45He is a heavy smoker with a 42 pack-year smoking history.", [["dysphagia", "DISEASE", 51, 60], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["intermittent dysphagia to solid food", "PROBLEM", 38, 74], ["intermittent", "OBSERVATION_MODIFIER", 38, 50], ["dysphagia", "OBSERVATION", 51, 60]]], ["He denies use of alcohol or drugs.Case 45The patient is admitted to the intensive care unit and intubated for airway protection.", [["airway", "ANATOMY", 110, 116], ["alcohol", "CHEMICAL", 17, 24], ["alcohol", "CHEMICAL", 17, 24], ["alcohol", "SIMPLE_CHEMICAL", 17, 24], ["patient", "ORGANISM", 45, 52], ["airway", "MULTI-TISSUE_STRUCTURE", 110, 116], ["patient", "SPECIES", 45, 52], ["intubated", "TREATMENT", 96, 105], ["airway protection", "TREATMENT", 110, 127], ["airway", "ANATOMY", 110, 116]]], ["He undergoes an emergent upper endoscopy which shows large masses starting right below the upper esophageal sphincter.", [["masses", "ANATOMY", 59, 65], ["upper esophageal sphincter", "ANATOMY", 91, 117], ["upper", "ORGANISM_SUBDIVISION", 25, 30], ["masses", "CANCER", 59, 65], ["upper esophageal", "ORGANISM_SUBDIVISION", 91, 107], ["sphincter", "ORGAN", 108, 117], ["an emergent upper endoscopy", "TEST", 13, 40], ["large masses", "PROBLEM", 53, 65], ["large", "OBSERVATION_MODIFIER", 53, 58], ["masses", "OBSERVATION", 59, 65], ["right", "ANATOMY_MODIFIER", 75, 80], ["upper", "ANATOMY_MODIFIER", 91, 96], ["esophageal sphincter", "ANATOMY", 97, 117]]], ["The masses progressively became thinner distally.Laboratory Parameters ShowWBC 9 \u00d7 10 3 /uL Hb 9.0 g/dl Tbili 0.9 mg/dl AST 34 U/l ALT 45 U/l Creatinine 1.2 mg/dl Questions 1.", [["masses", "ANATOMY", 4, 10], ["Creatinine", "CHEMICAL", 142, 152], ["Creatinine", "CHEMICAL", 142, 152], ["masses", "CANCER", 4, 10], ["The masses", "PROBLEM", 0, 10], ["Laboratory Parameters", "TEST", 49, 70], ["ShowWBC", "TEST", 71, 78], ["uL", "TEST", 89, 91], ["Hb", "TEST", 92, 94], ["g", "TEST", 99, 100], ["dl", "TEST", 101, 103], ["Tbili", "TEST", 104, 109], ["mg", "TEST", 114, 116], ["dl", "TEST", 117, 119], ["AST", "TEST", 120, 123], ["U", "TEST", 127, 128], ["ALT", "TEST", 131, 134], ["U", "TEST", 138, 139], ["Creatinine", "TEST", 142, 152], ["masses", "OBSERVATION", 4, 10], ["progressively", "OBSERVATION_MODIFIER", 11, 24], ["thinner", "OBSERVATION_MODIFIER", 32, 39], ["distally", "OBSERVATION_MODIFIER", 40, 48]]], ["What is the pathogenesis of these lesions? 2.", [["lesions", "ANATOMY", 34, 41], ["lesions", "PATHOLOGICAL_FORMATION", 34, 41], ["these lesions", "PROBLEM", 28, 41], ["lesions", "OBSERVATION", 34, 41]]], ["What is the long-term prognosis?", [["long-term", "OBSERVATION_MODIFIER", 12, 21]]], ["Band ligation and sclerotherapy can be attempted, but data on their efficacy is limited and would be expected to cause significant discomfort this high in the esophagus.Case 46A 47-year-old man presents to your outpatient clinic for follow-up.", [["esophagus", "ANATOMY", 159, 168], ["esophagus", "ORGAN", 159, 168], ["man", "ORGANISM", 190, 193], ["man", "SPECIES", 190, 193], ["Band ligation", "TREATMENT", 0, 13], ["sclerotherapy", "TREATMENT", 18, 31], ["significant discomfort this high in the esophagus", "PROBLEM", 119, 168], ["ligation", "OBSERVATION", 5, 13], ["sclerotherapy", "OBSERVATION", 18, 31], ["significant", "OBSERVATION_MODIFIER", 119, 130], ["discomfort", "OBSERVATION", 131, 141], ["esophagus", "ANATOMY", 159, 168]]], ["He has a history of cirrhosis secondary to hepatitis C. He attempted treatment in the past but could not tolerate the side effects and developed worsening depression.Case 46His disease has been well compensated with minimal ascites controlled on diuretics and no encephalopathy.", [["ascites", "ANATOMY", 224, 231], ["cirrhosis", "DISEASE", 20, 29], ["hepatitis", "DISEASE", 43, 52], ["depression", "DISEASE", 155, 165], ["ascites", "DISEASE", 224, 231], ["encephalopathy", "DISEASE", 263, 277], ["cirrhosis", "PROBLEM", 20, 29], ["hepatitis C.", "PROBLEM", 43, 55], ["treatment", "TREATMENT", 69, 78], ["worsening depression", "PROBLEM", 145, 165], ["minimal ascites", "PROBLEM", 216, 231], ["diuretics", "TREATMENT", 246, 255], ["encephalopathy", "PROBLEM", 263, 277], ["cirrhosis", "OBSERVATION", 20, 29], ["hepatitis", "OBSERVATION", 43, 52], ["worsening", "OBSERVATION_MODIFIER", 145, 154], ["depression", "OBSERVATION", 155, 165], ["minimal", "OBSERVATION_MODIFIER", 216, 223], ["ascites", "OBSERVATION", 224, 231], ["no", "UNCERTAINTY", 260, 262], ["encephalopathy", "OBSERVATION", 263, 277]]], ["He has grade 1 esophageal varices on endoscopy.Case 46His past medical history is significant for hypertension and some mild depression.", [["esophageal varices", "ANATOMY", 15, 33], ["esophageal varices", "DISEASE", 15, 33], ["hypertension", "DISEASE", 98, 110], ["depression", "DISEASE", 125, 135], ["esophageal varices", "PATHOLOGICAL_FORMATION", 15, 33], ["grade 1 esophageal varices", "PROBLEM", 7, 33], ["endoscopy", "TEST", 37, 46], ["hypertension", "PROBLEM", 98, 110], ["some mild depression", "PROBLEM", 115, 135], ["esophageal", "ANATOMY", 15, 25], ["varices", "OBSERVATION", 26, 33], ["significant for", "UNCERTAINTY", 82, 97], ["hypertension", "OBSERVATION", 98, 110], ["mild", "OBSERVATION_MODIFIER", 120, 124], ["depression", "OBSERVATION", 125, 135]]], ["He denies current tobacco or alcohol but has a remote history of intranasal cocaine use.Case 46His current medications include paroxetine, furosemide 40 mg daily, spironolactone 100 mg daily, and metoprolol 25 mg daily.Case 46On exam, his vital signs demonstrate weight 165 pounds, BP 135/75, and pulse 62, and he is afebrile.", [["alcohol", "CHEMICAL", 29, 36], ["cocaine", "CHEMICAL", 76, 83], ["paroxetine", "CHEMICAL", 127, 137], ["furosemide", "CHEMICAL", 139, 149], ["spironolactone", "CHEMICAL", 163, 177], ["metoprolol", "CHEMICAL", 196, 206], ["alcohol", "CHEMICAL", 29, 36], ["cocaine", "CHEMICAL", 76, 83], ["paroxetine", "CHEMICAL", 127, 137], ["furosemide", "CHEMICAL", 139, 149], ["spironolactone", "CHEMICAL", 163, 177], ["metoprolol", "CHEMICAL", 196, 206], ["He", "ORGANISM", 0, 2], ["tobacco", "ORGANISM", 18, 25], ["alcohol", "SIMPLE_CHEMICAL", 29, 36], ["cocaine", "SIMPLE_CHEMICAL", 76, 83], ["paroxetine", "SIMPLE_CHEMICAL", 127, 137], ["furosemide", "SIMPLE_CHEMICAL", 139, 149], ["spironolactone", "SIMPLE_CHEMICAL", 163, 177], ["metoprolol", "SIMPLE_CHEMICAL", 196, 206], ["tobacco", "SPECIES", 18, 25], ["current medications", "TREATMENT", 99, 118], ["paroxetine", "TREATMENT", 127, 137], ["furosemide", "TREATMENT", 139, 149], ["spironolactone", "TREATMENT", 163, 177], ["metoprolol", "TREATMENT", 196, 206], ["exam", "TEST", 229, 233], ["his vital signs", "TEST", 235, 250], ["weight", "TEST", 263, 269], ["BP", "TEST", 282, 284], ["pulse", "TEST", 297, 302], ["afebrile", "PROBLEM", 317, 325], ["afebrile", "OBSERVATION", 317, 325]]], ["He has no scleral icterus and normal cardiovascular and respiratory systems.Case 46Abdominal exam demonstrates a soft nontender abdomen without organomegaly and no ascites and no ankle edema.", [["scleral icterus", "ANATOMY", 10, 25], ["cardiovascular", "ANATOMY", 37, 51], ["abdomen", "ANATOMY", 128, 135], ["ascites", "ANATOMY", 164, 171], ["ankle edema", "ANATOMY", 179, 190], ["icterus", "DISEASE", 18, 25], ["cardiovascular and respiratory systems", "DISEASE", 37, 75], ["organomegaly", "DISEASE", 144, 156], ["ascites", "DISEASE", 164, 171], ["ankle edema", "DISEASE", 179, 190], ["cardiovascular", "ANATOMICAL_SYSTEM", 37, 51], ["abdomen", "ORGAN", 128, 135], ["ankle edema", "PATHOLOGICAL_FORMATION", 179, 190], ["scleral icterus", "PROBLEM", 10, 25], ["Case 46Abdominal exam", "TEST", 76, 97], ["a soft nontender abdomen", "PROBLEM", 111, 135], ["organomegaly", "PROBLEM", 144, 156], ["ascites", "PROBLEM", 164, 171], ["ankle edema", "PROBLEM", 179, 190], ["no", "UNCERTAINTY", 7, 9], ["scleral", "ANATOMY", 10, 17], ["icterus", "OBSERVATION", 18, 25], ["normal", "OBSERVATION", 30, 36], ["cardiovascular", "ANATOMY", 37, 51], ["respiratory systems", "ANATOMY", 56, 75], ["soft", "ANATOMY", 113, 117], ["nontender", "OBSERVATION", 118, 127], ["abdomen", "ANATOMY", 128, 135], ["without", "UNCERTAINTY", 136, 143], ["organomegaly", "OBSERVATION", 144, 156], ["no", "UNCERTAINTY", 161, 163], ["ascites", "OBSERVATION", 164, 171], ["no", "UNCERTAINTY", 176, 178], ["ankle", "ANATOMY", 179, 184], ["edema", "OBSERVATION", 185, 190]]], ["He has no asterixis.Laboratory StudiesHb 12.5 g/dl Platelets 64,000/\u03bcl INR 1.5 Creatinine 1.2 mg/dl Tbili 1.9 mg/dl AST 47 iu/l ALT 34 iu/l ALP 112 iu/l Albumin 2.7 g/dl AFP 257 mcg/l Questions 1.", [["Creatinine", "CHEMICAL", 79, 89], ["Creatinine", "CHEMICAL", 79, 89], ["Creatinine", "SIMPLE_CHEMICAL", 79, 89], ["Albumin", "GENE_OR_GENE_PRODUCT", 153, 160], ["ALP", "PROTEIN", 140, 143], ["asterixis", "PROBLEM", 10, 19], ["Laboratory StudiesHb", "TEST", 20, 40], ["Platelets", "TEST", 51, 60], ["\u03bcl", "TEST", 68, 70], ["INR", "TEST", 71, 74], ["Creatinine", "TEST", 79, 89], ["mg", "TEST", 94, 96], ["dl", "TEST", 97, 99], ["Tbili", "TEST", 100, 105], ["mg", "TEST", 110, 112], ["dl", "TEST", 113, 115], ["AST", "TEST", 116, 119], ["iu", "TEST", 123, 125], ["ALT", "TEST", 128, 131], ["iu", "TEST", 135, 137], ["ALP", "TEST", 140, 143], ["iu", "TEST", 148, 150], ["Albumin", "TEST", 153, 160], ["AFP", "TEST", 170, 173], ["no", "UNCERTAINTY", 7, 9], ["asterixis", "OBSERVATION", 10, 19]]], ["What options if any are available to this patient? 2.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49]]], ["Is he a candidate for liver transplant?Answer: Treatment of Solitary Hepatocellular Carcinoma (HCC)This man has developed HCC, which is increasingly common in the United States in people with cirrhosis secondary to hepatitis C. Some studies suggest that the yearly incidence of HCC may be anywhere from 3 to 8% in patients with hepatitis C cirrhosis.Answer: Treatment of Solitary Hepatocellular Carcinoma (HCC)The MRI images (Figs.", [["liver", "ANATOMY", 22, 27], ["Solitary Hepatocellular Carcinoma", "ANATOMY", 60, 93], ["HCC", "ANATOMY", 95, 98], ["HCC", "ANATOMY", 122, 125], ["HCC", "ANATOMY", 278, 281], ["Solitary Hepatocellular Carcinoma", "ANATOMY", 371, 404], ["HCC", "ANATOMY", 406, 409], ["Solitary Hepatocellular Carcinoma", "DISEASE", 60, 93], ["HCC", "DISEASE", 95, 98], ["HCC", "DISEASE", 122, 125], ["cirrhosis", "DISEASE", 192, 201], ["hepatitis", "DISEASE", 215, 224], ["HCC", "DISEASE", 278, 281], ["hepatitis C cirrhosis", "DISEASE", 328, 349], ["Solitary Hepatocellular Carcinoma", "DISEASE", 371, 404], ["HCC", "DISEASE", 406, 409], ["liver", "ORGAN", 22, 27], ["Solitary Hepatocellular Carcinoma", "CANCER", 60, 93], ["HCC", "CANCER", 95, 98], ["man", "ORGANISM", 104, 107], ["HCC", "CANCER", 122, 125], ["people", "ORGANISM", 180, 186], ["HCC", "CANCER", 278, 281], ["patients", "ORGANISM", 314, 322], ["hepatitis C", "ORGANISM", 328, 339], ["Solitary Hepatocellular Carcinoma", "CANCER", 371, 404], ["HCC", "CANCER", 406, 409], ["man", "SPECIES", 104, 107], ["people", "SPECIES", 180, 186], ["patients", "SPECIES", 314, 322], ["liver transplant", "TREATMENT", 22, 38], ["Solitary Hepatocellular Carcinoma", "PROBLEM", 60, 93], ["HCC", "PROBLEM", 122, 125], ["cirrhosis", "PROBLEM", 192, 201], ["hepatitis C.", "PROBLEM", 215, 227], ["Some studies", "TEST", 228, 240], ["HCC", "PROBLEM", 278, 281], ["hepatitis C cirrhosis", "PROBLEM", 328, 349], ["Solitary Hepatocellular Carcinoma", "PROBLEM", 371, 404], ["The MRI images", "TEST", 410, 424], ["liver", "ANATOMY", 22, 27], ["transplant", "OBSERVATION", 28, 38], ["Solitary", "OBSERVATION_MODIFIER", 60, 68], ["Hepatocellular", "ANATOMY", 69, 83], ["Carcinoma", "OBSERVATION", 84, 93], ["HCC", "OBSERVATION", 122, 125], ["increasingly", "OBSERVATION_MODIFIER", 136, 148], ["common", "OBSERVATION_MODIFIER", 149, 155], ["cirrhosis", "OBSERVATION", 192, 201], ["hepatitis", "OBSERVATION", 215, 224], ["HCC", "OBSERVATION", 278, 281], ["hepatitis", "OBSERVATION", 328, 337], ["cirrhosis", "OBSERVATION", 340, 349], ["Solitary", "OBSERVATION_MODIFIER", 371, 379], ["Hepatocellular", "ANATOMY", 380, 394], ["Carcinoma", "OBSERVATION", 395, 404]]], ["46.1-46.3) show a 3 cm lesion in the posterior right lobe (arrowed in Fig. 46.1) .", [["cm lesion", "ANATOMY", 20, 29], ["posterior right lobe", "ANATOMY", 37, 57], ["posterior right lobe", "MULTI-TISSUE_STRUCTURE", 37, 57], ["a 3 cm lesion in the posterior right lobe", "PROBLEM", 16, 57], ["3 cm", "OBSERVATION_MODIFIER", 18, 22], ["lesion", "OBSERVATION", 23, 29], ["posterior", "ANATOMY_MODIFIER", 37, 46], ["right lobe", "ANATOMY", 47, 57]]], ["Figure 46 .2 shows the lesion after transarterial chemoembolization has been administered, and the third image (Fig. 46.3, CT) shows a radiofrequency ablation probe being placed into the lesion.", [["lesion", "ANATOMY", 23, 29], ["transarterial", "ANATOMY", 36, 49], ["lesion", "ANATOMY", 187, 193], ["lesion", "CANCER", 23, 29], ["lesion", "CANCER", 187, 193], ["Figure", "TEST", 0, 6], ["the lesion", "PROBLEM", 19, 29], ["transarterial chemoembolization", "TREATMENT", 36, 67], ["the third image", "TEST", 95, 110], ["CT", "TEST", 123, 125], ["a radiofrequency ablation probe", "TREATMENT", 133, 164], ["the lesion", "PROBLEM", 183, 193], ["lesion", "OBSERVATION", 23, 29], ["lesion", "OBSERVATION", 187, 193]]], ["The follow-up MRI 2 months later ( Fig. 46.4) shows the treated lesion which did not enhance, suggesting successful treatment.", [["lesion", "ANATOMY", 64, 70], ["The follow-up MRI", "TEST", 0, 17], ["the treated lesion", "PROBLEM", 52, 70], ["successful treatment", "TREATMENT", 105, 125], ["lesion", "OBSERVATION", 64, 70], ["successful", "OBSERVATION_MODIFIER", 105, 115], ["treatment", "OBSERVATION", 116, 125]]], ["Multiple treatment modalities exist for HCC including: The basic algorithm for management of HCC is shown in the first reference below, but essentially, the decision to use which treatment modality is based on center preference and also severity of underlying liver disease.Answer: Treatment of Solitary Hepatocellular Carcinoma (HCC)Resection is a good treatment option for HCC as it can be potentially curative.", [["HCC", "ANATOMY", 40, 43], ["HCC", "ANATOMY", 93, 96], ["liver", "ANATOMY", 260, 265], ["Solitary Hepatocellular Carcinoma", "ANATOMY", 295, 328], ["HCC", "ANATOMY", 330, 333], ["HCC", "ANATOMY", 375, 378], ["HCC", "DISEASE", 40, 43], ["HCC", "DISEASE", 93, 96], ["liver disease", "DISEASE", 260, 273], ["Solitary Hepatocellular Carcinoma", "DISEASE", 295, 328], ["HCC", "DISEASE", 330, 333], ["HCC", "DISEASE", 375, 378], ["HCC", "CANCER", 40, 43], ["HCC", "CANCER", 93, 96], ["liver", "ORGAN", 260, 265], ["Solitary Hepatocellular Carcinoma", "CANCER", 295, 328], ["HCC", "CANCER", 330, 333], ["HCC", "CANCER", 375, 378], ["Multiple treatment modalities", "TREATMENT", 0, 29], ["HCC", "PROBLEM", 40, 43], ["The basic algorithm", "TEST", 55, 74], ["management", "TREATMENT", 79, 89], ["HCC", "PROBLEM", 93, 96], ["treatment modality", "TREATMENT", 179, 197], ["underlying liver disease", "PROBLEM", 249, 273], ["Solitary Hepatocellular Carcinoma", "PROBLEM", 295, 328], ["Resection", "TREATMENT", 334, 343], ["a good treatment option", "TREATMENT", 347, 370], ["HCC", "PROBLEM", 375, 378], ["HCC", "OBSERVATION", 40, 43], ["HCC", "OBSERVATION", 93, 96], ["liver", "ANATOMY", 260, 265], ["disease", "OBSERVATION", 266, 273], ["Solitary", "OBSERVATION_MODIFIER", 295, 303], ["Hepatocellular", "ANATOMY", 304, 318], ["Carcinoma", "OBSERVATION", 319, 328], ["Resection", "OBSERVATION", 334, 343]]], ["A single HCC confined to the liver without evidence of vascular invasion in a patient without portal hypertension, and well-preserved hepatic function would be an ideal candidate.", [["HCC", "ANATOMY", 9, 12], ["liver", "ANATOMY", 29, 34], ["vascular", "ANATOMY", 55, 63], ["portal", "ANATOMY", 94, 100], ["hepatic", "ANATOMY", 134, 141], ["HCC confined to the liver", "DISEASE", 9, 34], ["vascular invasion", "DISEASE", 55, 72], ["portal hypertension", "DISEASE", 94, 113], ["HCC", "CANCER", 9, 12], ["liver", "ORGAN", 29, 34], ["vascular", "MULTI-TISSUE_STRUCTURE", 55, 63], ["patient", "ORGANISM", 78, 85], ["portal", "MULTI-TISSUE_STRUCTURE", 94, 100], ["hepatic", "ORGAN", 134, 141], ["patient", "SPECIES", 78, 85], ["A single HCC", "PROBLEM", 0, 12], ["vascular invasion", "PROBLEM", 55, 72], ["portal hypertension", "PROBLEM", 94, 113], ["HCC", "OBSERVATION", 9, 12], ["liver", "ANATOMY", 29, 34], ["without evidence of", "UNCERTAINTY", 35, 54], ["vascular", "ANATOMY", 55, 63], ["invasion", "OBSERVATION", 64, 72], ["without", "UNCERTAINTY", 86, 93], ["portal", "ANATOMY", 94, 100], ["hypertension", "OBSERVATION", 101, 113], ["hepatic", "ANATOMY", 134, 141]]], ["Very good 5-year survival rates have been reported.Answer: Treatment of Solitary Hepatocellular Carcinoma (HCC)Liver transplant for HCC is discussed in another case.", [["Solitary Hepatocellular Carcinoma", "ANATOMY", 72, 105], ["HCC", "ANATOMY", 107, 110], ["Liver", "ANATOMY", 111, 116], ["HCC", "ANATOMY", 132, 135], ["Solitary Hepatocellular Carcinoma", "DISEASE", 72, 105], ["HCC", "DISEASE", 107, 110], ["HCC", "DISEASE", 132, 135], ["Solitary Hepatocellular Carcinoma", "CANCER", 72, 105], ["HCC", "CANCER", 107, 110], ["Liver", "ORGAN", 111, 116], ["HCC", "CANCER", 132, 135], ["Solitary Hepatocellular Carcinoma", "PROBLEM", 72, 105], ["Liver transplant", "TREATMENT", 111, 127], ["HCC", "PROBLEM", 132, 135], ["Solitary", "OBSERVATION_MODIFIER", 72, 80], ["Hepatocellular", "ANATOMY", 81, 95], ["Carcinoma", "OBSERVATION", 96, 105], ["Liver", "ANATOMY", 111, 116], ["transplant", "OBSERVATION", 117, 127], ["HCC", "OBSERVATION", 132, 135]]], ["TACE uses the fact that the majority of the blood supply to HCCs is derived from the hepatic artery so that eliminating hepatic arterial supply to the tumor should cause ischemia.", [["blood", "ANATOMY", 44, 49], ["HCCs", "ANATOMY", 60, 64], ["hepatic artery", "ANATOMY", 85, 99], ["hepatic arterial", "ANATOMY", 120, 136], ["tumor", "ANATOMY", 151, 156], ["HCCs", "DISEASE", 60, 64], ["tumor", "DISEASE", 151, 156], ["ischemia", "DISEASE", 170, 178], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["HCCs", "CANCER", 60, 64], ["hepatic artery", "MULTI-TISSUE_STRUCTURE", 85, 99], ["hepatic arterial", "MULTI-TISSUE_STRUCTURE", 120, 136], ["tumor", "CANCER", 151, 156], ["TACE", "PROTEIN", 0, 4], ["TACE", "TREATMENT", 0, 4], ["the tumor", "PROBLEM", 147, 156], ["ischemia", "PROBLEM", 170, 178], ["HCCs", "OBSERVATION", 60, 64], ["hepatic artery", "ANATOMY", 85, 99], ["hepatic", "ANATOMY", 120, 127], ["arterial", "ANATOMY_MODIFIER", 128, 136], ["tumor", "OBSERVATION", 151, 156], ["ischemia", "OBSERVATION", 170, 178]]], ["In addition, chemotherapy can be given directly to the tumor.", [["tumor", "ANATOMY", 55, 60], ["tumor", "DISEASE", 55, 60], ["tumor", "CANCER", 55, 60], ["chemotherapy", "TREATMENT", 13, 25], ["tumor", "OBSERVATION", 55, 60]]], ["The chemotherapy is often given with lipiodol, which promotes intratumoral retention of chemotherapy drugs.", [["intratumoral", "ANATOMY", 62, 74], ["lipiodol", "CHEMICAL", 37, 45], ["lipiodol", "CHEMICAL", 37, 45], ["lipiodol", "SIMPLE_CHEMICAL", 37, 45], ["The chemotherapy", "TREATMENT", 0, 16], ["lipiodol", "TREATMENT", 37, 45], ["chemotherapy drugs", "TREATMENT", 88, 106], ["chemotherapy", "OBSERVATION", 4, 16], ["intratumoral retention", "OBSERVATION", 62, 84]]], ["After the chemotherapy has been delivered, the hepatic artery branch can be occluded in a variety of ways.", [["hepatic artery", "ANATOMY", 47, 61], ["hepatic artery", "MULTI-TISSUE_STRUCTURE", 47, 61], ["the chemotherapy", "TREATMENT", 6, 22], ["the hepatic artery branch", "TREATMENT", 43, 68], ["hepatic artery", "ANATOMY", 47, 61], ["branch", "ANATOMY_MODIFIER", 62, 68], ["occluded", "OBSERVATION", 76, 84]]], ["TACE is usually not curative but is used as a bridge to transplant for larger tumors, but there is limited data on its efficacy compared to other modalities.Answer: Treatment of Solitary Hepatocellular Carcinoma (HCC)RFA involves the application of radiofrequency thermal energy directly to the lesion.", [["tumors", "ANATOMY", 78, 84], ["Solitary Hepatocellular Carcinoma", "ANATOMY", 178, 211], ["HCC", "ANATOMY", 213, 216], ["lesion", "ANATOMY", 295, 301], ["tumors", "DISEASE", 78, 84], ["Solitary Hepatocellular Carcinoma", "DISEASE", 178, 211], ["HCC", "DISEASE", 213, 216], ["tumors", "CANCER", 78, 84], ["Solitary Hepatocellular Carcinoma", "CANCER", 178, 211], ["HCC", "CANCER", 213, 216], ["TACE", "TREATMENT", 0, 4], ["a bridge to transplant", "TREATMENT", 44, 66], ["larger tumors", "PROBLEM", 71, 84], ["Solitary Hepatocellular Carcinoma", "PROBLEM", 178, 211], ["RFA", "TREATMENT", 217, 220], ["radiofrequency thermal energy", "TREATMENT", 249, 278], ["the lesion", "PROBLEM", 291, 301], ["larger", "OBSERVATION_MODIFIER", 71, 77], ["tumors", "OBSERVATION", 78, 84], ["Solitary", "OBSERVATION_MODIFIER", 178, 186], ["Hepatocellular", "ANATOMY", 187, 201], ["Carcinoma", "OBSERVATION", 202, 211], ["lesion", "OBSERVATION", 295, 301]]], ["This causes the temperature of the tissue to rise, and when it reaches beyond 60\u00b0C, cells begin to die, resulting in a necrosis of tumor cells.Answer: Treatment of Solitary Hepatocellular Carcinoma (HCC)RFA is a reasonable option for patients who are not candidates for resection but typically only works well for lesions less than 4 cm.", [["tissue", "ANATOMY", 35, 41], ["cells", "ANATOMY", 84, 89], ["tumor cells", "ANATOMY", 131, 142], ["Solitary Hepatocellular Carcinoma", "ANATOMY", 164, 197], ["HCC", "ANATOMY", 199, 202], ["lesions", "ANATOMY", 314, 321], ["necrosis", "DISEASE", 119, 127], ["tumor", "DISEASE", 131, 136], ["Solitary Hepatocellular Carcinoma", "DISEASE", 164, 197], ["HCC", "DISEASE", 199, 202], ["tissue", "TISSUE", 35, 41], ["cells", "CELL", 84, 89], ["tumor cells", "CELL", 131, 142], ["Solitary Hepatocellular Carcinoma", "CANCER", 164, 197], ["HCC", "CANCER", 199, 202], ["patients", "ORGANISM", 234, 242], ["lesions", "PATHOLOGICAL_FORMATION", 314, 321], ["tumor cells", "CELL_TYPE", 131, 142], ["patients", "SPECIES", 234, 242], ["a necrosis of tumor cells", "PROBLEM", 117, 142], ["Solitary Hepatocellular Carcinoma", "PROBLEM", 164, 197], ["RFA", "TREATMENT", 203, 206], ["resection", "TREATMENT", 270, 279], ["lesions", "PROBLEM", 314, 321], ["necrosis", "OBSERVATION", 119, 127], ["tumor cells", "OBSERVATION", 131, 142], ["Solitary", "OBSERVATION_MODIFIER", 164, 172], ["Hepatocellular", "ANATOMY", 173, 187], ["Carcinoma", "OBSERVATION", 188, 197], ["resection", "OBSERVATION", 270, 279]]], ["Again, it is often used as a bridge to transplant, but there is limited data for outcome after RFA compared to other treatments.Case 47A 52-year-old man presents with bright red blood per rectum.", [["red blood", "ANATOMY", 174, 183], ["rectum", "ANATOMY", 188, 194], ["man", "ORGANISM", 149, 152], ["blood", "ORGANISM_SUBSTANCE", 178, 183], ["rectum", "ORGAN", 188, 194], ["man", "SPECIES", 149, 152], ["transplant", "TREATMENT", 39, 49], ["RFA", "TREATMENT", 95, 98], ["other treatments", "TREATMENT", 111, 127], ["bright red blood per rectum", "PROBLEM", 167, 194], ["rectum", "ANATOMY", 188, 194]]], ["He has a history of cirrhosis secondary to alcohol and is still drinking.", [["cirrhosis", "DISEASE", 20, 29], ["alcohol", "CHEMICAL", 43, 50], ["alcohol", "CHEMICAL", 43, 50], ["alcohol", "SIMPLE_CHEMICAL", 43, 50], ["cirrhosis", "PROBLEM", 20, 29], ["cirrhosis", "OBSERVATION", 20, 29]]], ["His liver disease has been complicated by ascites, but he denies encephalopathy or spontaneous bacterial peritonitis (SBP).", [["liver", "ANATOMY", 4, 9], ["ascites", "ANATOMY", 42, 49], ["liver disease", "DISEASE", 4, 17], ["ascites", "DISEASE", 42, 49], ["encephalopathy", "DISEASE", 65, 79], ["bacterial peritonitis", "DISEASE", 95, 116], ["liver", "ORGAN", 4, 9], ["His liver disease", "PROBLEM", 0, 17], ["ascites", "PROBLEM", 42, 49], ["encephalopathy", "PROBLEM", 65, 79], ["spontaneous bacterial peritonitis", "PROBLEM", 83, 116], ["SBP", "TEST", 118, 121], ["liver", "ANATOMY", 4, 9], ["disease", "OBSERVATION", 10, 17], ["ascites", "OBSERVATION", 42, 49], ["spontaneous", "OBSERVATION_MODIFIER", 83, 94], ["bacterial", "OBSERVATION_MODIFIER", 95, 104], ["peritonitis", "OBSERVATION", 105, 116]]], ["He has undergone endoscopy and colonoscopy in the last year at his local hospital and states that they were \"OK\".Case 47His bowels have been moving normally with a normal stool color up until yesterday when he noticed blood in the toilet bowl.", [["bowels", "ANATOMY", 124, 130], ["blood", "ANATOMY", 218, 223], ["blood", "ORGANISM_SUBSTANCE", 218, 223], ["endoscopy", "TEST", 17, 26], ["colonoscopy", "TEST", 31, 42], ["blood in the toilet bowl", "PROBLEM", 218, 242], ["bowels", "ANATOMY", 124, 130], ["toilet bowl", "OBSERVATION", 231, 242]]], ["He denies abdominal pain or fever.Case 47Upon presentation to the emergency room he is witnessed to have further bleeding per rectum with bright red blood but also several large clots.Case 47He has been taking diuretics but no other medications.", [["abdominal", "ANATOMY", 10, 19], ["rectum", "ANATOMY", 126, 132], ["blood", "ANATOMY", 149, 154], ["clots", "ANATOMY", 178, 183], ["abdominal pain", "DISEASE", 10, 24], ["fever", "DISEASE", 28, 33], ["bleeding", "DISEASE", 113, 121], ["abdominal", "ORGANISM_SUBDIVISION", 10, 19], ["rectum", "ORGAN", 126, 132], ["blood", "ORGANISM_SUBSTANCE", 149, 154], ["clots", "ORGANISM_SUBSTANCE", 178, 183], ["abdominal pain", "PROBLEM", 10, 24], ["fever", "PROBLEM", 28, 33], ["further bleeding per rectum", "PROBLEM", 105, 132], ["bright red blood", "PROBLEM", 138, 154], ["several large clots", "PROBLEM", 164, 183], ["diuretics", "TREATMENT", 210, 219], ["other medications", "TREATMENT", 227, 244], ["abdominal", "ANATOMY", 10, 19], ["pain", "OBSERVATION", 20, 24], ["fever", "OBSERVATION", 28, 33], ["bleeding", "OBSERVATION", 113, 121], ["rectum", "ANATOMY", 126, 132], ["bright red blood", "OBSERVATION", 138, 154], ["several", "OBSERVATION_MODIFIER", 164, 171], ["large", "OBSERVATION_MODIFIER", 172, 177], ["clots", "OBSERVATION", 178, 183]]], ["On exam, he looks comfortable and is alert and oriented.", [["exam", "TEST", 3, 7]]], ["Pulse is 110 beats per minute, regular, blood pressure 95/60 His abdomen is soft, and the flanks are dull.", [["blood", "ANATOMY", 40, 45], ["abdomen", "ANATOMY", 65, 72], ["flanks", "ANATOMY", 90, 96], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["abdomen", "ORGAN", 65, 72], ["flanks", "ORGANISM_SUBDIVISION", 90, 96], ["Pulse", "TEST", 0, 5], ["blood pressure", "TEST", 40, 54], ["dull", "PROBLEM", 101, 105], ["abdomen", "ANATOMY", 65, 72], ["soft", "OBSERVATION", 76, 80], ["flanks", "ANATOMY", 90, 96], ["dull", "OBSERVATION", 101, 105]]], ["Extremities reveal mild ankle edema.Case 47Rectal exam demonstrates dark red clots.Answer: Rectal VaricesThe endoscopic image (Fig. 47.1 ) demonstrates significant rectal varices seen on retroflexion (the black tube on the right is the scope).", [["ankle edema", "ANATOMY", 24, 35], ["red clots", "ANATOMY", 73, 82], ["Rectal Varices", "ANATOMY", 91, 105], ["rectal varices", "ANATOMY", 164, 178], ["Extremities", "DISEASE", 0, 11], ["ankle edema", "DISEASE", 24, 35], ["varices", "DISEASE", 171, 178], ["ankle edema", "PATHOLOGICAL_FORMATION", 24, 35], ["clots", "ORGANISM_SUBSTANCE", 77, 82], ["rectal varices", "PATHOLOGICAL_FORMATION", 164, 178], ["tube", "TISSUE", 211, 215], ["mild ankle edema", "PROBLEM", 19, 35], ["Case 47Rectal exam", "TEST", 36, 54], ["dark red clots", "PROBLEM", 68, 82], ["Rectal Varices", "PROBLEM", 91, 105], ["The endoscopic image", "TEST", 105, 125], ["Fig.", "TEST", 127, 131], ["significant rectal varices", "PROBLEM", 152, 178], ["retroflexion", "TREATMENT", 187, 199], ["the black tube", "TREATMENT", 201, 215], ["mild", "OBSERVATION_MODIFIER", 19, 23], ["ankle", "ANATOMY", 24, 29], ["edema", "OBSERVATION", 30, 35], ["dark red", "OBSERVATION_MODIFIER", 68, 76], ["clots", "OBSERVATION", 77, 82], ["Rectal", "ANATOMY", 91, 97], ["Varices", "OBSERVATION", 98, 105], ["significant", "OBSERVATION_MODIFIER", 152, 163], ["rectal", "ANATOMY", 164, 170], ["varices", "OBSERVATION", 171, 178], ["black", "OBSERVATION_MODIFIER", 205, 210], ["tube", "OBSERVATION", 211, 215], ["right", "ANATOMY_MODIFIER", 223, 228]]], ["The CT image of the pelvis (Fig. 47.2) shows the varices around the distal rectum (arrowed).", [["pelvis", "ANATOMY", 20, 26], ["varices", "ANATOMY", 49, 56], ["distal rectum", "ANATOMY", 68, 81], ["varices", "DISEASE", 49, 56], ["pelvis", "ORGAN", 20, 26], ["varices", "PATHOLOGICAL_FORMATION", 49, 56], ["rectum", "ORGAN", 75, 81], ["The CT image of the pelvis (Fig.", "TEST", 0, 32], ["the varices around the distal rectum", "PROBLEM", 45, 81], ["pelvis", "ANATOMY", 20, 26], ["varices", "OBSERVATION", 49, 56], ["distal", "ANATOMY_MODIFIER", 68, 74], ["rectum", "ANATOMY", 75, 81]]], ["Scrolling up through the images showed a single vessel running all the way from the perirectal varices up to the splenic vein.", [["vessel", "ANATOMY", 48, 54], ["perirectal varices", "ANATOMY", 84, 102], ["splenic vein", "ANATOMY", 113, 125], ["varices", "DISEASE", 95, 102], ["vessel", "MULTI-TISSUE_STRUCTURE", 48, 54], ["perirectal varices", "PATHOLOGICAL_FORMATION", 84, 102], ["splenic vein", "MULTI-TISSUE_STRUCTURE", 113, 125], ["the images", "TEST", 21, 31], ["the perirectal varices", "PROBLEM", 80, 102], ["vessel", "ANATOMY", 48, 54], ["perirectal", "ANATOMY", 84, 94], ["varices", "OBSERVATION", 95, 102], ["splenic vein", "ANATOMY", 113, 125]]], ["The differential diagnosis here is essentially all the causes of bright red blood per rectum including hemorrhoids, diverticular bleeding, arteriovenous malformations and tumor.Answer: Rectal VaricesIn a patient with portal hypertension, ectopic varices also have to be considered.", [["red blood", "ANATOMY", 72, 81], ["rectum", "ANATOMY", 86, 92], ["diverticular", "ANATOMY", 116, 128], ["arteriovenous", "ANATOMY", 139, 152], ["tumor", "ANATOMY", 171, 176], ["Rectal", "ANATOMY", 185, 191], ["portal", "ANATOMY", 217, 223], ["ectopic varices", "ANATOMY", 238, 253], ["hemorrhoids", "DISEASE", 103, 114], ["diverticular bleeding", "DISEASE", 116, 137], ["arteriovenous malformations", "DISEASE", 139, 166], ["tumor", "DISEASE", 171, 176], ["portal hypertension", "DISEASE", 217, 236], ["ectopic varices", "DISEASE", 238, 253], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["rectum", "ORGAN", 86, 92], ["diverticular bleeding", "PATHOLOGICAL_FORMATION", 116, 137], ["arteriovenous malformations", "PATHOLOGICAL_FORMATION", 139, 166], ["tumor", "CANCER", 171, 176], ["patient", "ORGANISM", 204, 211], ["portal", "MULTI-TISSUE_STRUCTURE", 217, 223], ["varices", "PATHOLOGICAL_FORMATION", 246, 253], ["patient", "SPECIES", 204, 211], ["bright red blood per rectum", "PROBLEM", 65, 92], ["hemorrhoids", "PROBLEM", 103, 114], ["diverticular bleeding", "PROBLEM", 116, 137], ["arteriovenous malformations", "PROBLEM", 139, 166], ["tumor", "PROBLEM", 171, 176], ["portal hypertension", "PROBLEM", 217, 236], ["ectopic varices", "PROBLEM", 238, 253], ["bright red blood", "OBSERVATION", 65, 81], ["rectum", "ANATOMY", 86, 92], ["hemorrhoids", "OBSERVATION", 103, 114], ["diverticular", "OBSERVATION_MODIFIER", 116, 128], ["bleeding", "OBSERVATION", 129, 137], ["arteriovenous malformations", "OBSERVATION", 139, 166], ["tumor", "OBSERVATION", 171, 176], ["Rectal", "ANATOMY", 185, 191], ["VaricesIn", "OBSERVATION", 192, 201], ["portal", "ANATOMY", 217, 223], ["hypertension", "OBSERVATION", 224, 236], ["ectopic varices", "OBSERVATION", 238, 253]]], ["An upper source of GI bleeding could be a possibility but is unlikely given the relatively well-maintained hemodynamics and hemoglobin.Answer: Rectal VaricesThe usual algorithm for lower GI bleeding includes resuscitation and then colonoscopy.", [["GI", "ANATOMY", 19, 21], ["Rectal Varices", "ANATOMY", 143, 157], ["lower GI", "ANATOMY", 181, 189], ["GI bleeding", "DISEASE", 19, 30], ["GI bleeding", "DISEASE", 187, 198], ["GI", "ORGANISM_SUBDIVISION", 19, 21], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 124, 134], ["GI", "ORGANISM_SUBDIVISION", 187, 189], ["hemoglobin", "PROTEIN", 124, 134], ["GI bleeding", "PROBLEM", 19, 30], ["hemoglobin", "TEST", 124, 134], ["Rectal Varices", "PROBLEM", 143, 157], ["The usual algorithm", "TEST", 157, 176], ["lower GI bleeding", "PROBLEM", 181, 198], ["resuscitation", "TREATMENT", 208, 221], ["colonoscopy", "TEST", 231, 242], ["upper", "ANATOMY_MODIFIER", 3, 8], ["GI", "ANATOMY", 19, 21], ["bleeding", "OBSERVATION", 22, 30], ["could be a possibility", "UNCERTAINTY", 31, 53], ["Rectal", "ANATOMY", 143, 149], ["Varices", "OBSERVATION", 150, 157], ["GI", "ANATOMY", 187, 189], ["bleeding", "OBSERVATION", 190, 198]]], ["The timing of the colonoscopy will depend on the degree of bleeding.Answer: Rectal VaricesIn this patient, there was significant bleeding, and we elected to proceed with colonoscopy after a rapid purgative preparation.Answer: Rectal VaricesThe rectal varices were immediately evident, and there was no evidence of any blood proximal to the rectum.Answer: Rectal VaricesTreatment of rectal varices is based on very limited data.", [["Rectal Varices", "ANATOMY", 76, 90], ["Rectal Varices", "ANATOMY", 226, 240], ["rectal varices", "ANATOMY", 244, 258], ["blood", "ANATOMY", 318, 323], ["rectum", "ANATOMY", 340, 346], ["Rectal Varices", "ANATOMY", 355, 369], ["rectal varices", "ANATOMY", 382, 396], ["bleeding", "DISEASE", 59, 67], ["bleeding", "DISEASE", 129, 137], ["rectal varices", "DISEASE", 244, 258], ["rectal varices", "DISEASE", 382, 396], ["patient", "ORGANISM", 98, 105], ["rectal varices", "PATHOLOGICAL_FORMATION", 244, 258], ["blood", "ORGANISM_SUBSTANCE", 318, 323], ["rectum", "ORGAN", 340, 346], ["rectal varices", "PATHOLOGICAL_FORMATION", 382, 396], ["patient", "SPECIES", 98, 105], ["the colonoscopy", "TEST", 14, 29], ["bleeding", "PROBLEM", 59, 67], ["Rectal Varices", "PROBLEM", 76, 90], ["significant bleeding", "PROBLEM", 117, 137], ["colonoscopy", "TEST", 170, 181], ["a rapid purgative preparation", "TREATMENT", 188, 217], ["Rectal Varices", "PROBLEM", 226, 240], ["The rectal varices", "PROBLEM", 240, 258], ["any blood proximal to the rectum", "PROBLEM", 314, 346], ["Rectal Varices", "PROBLEM", 355, 369], ["rectal varices", "PROBLEM", 382, 396], ["bleeding", "OBSERVATION", 59, 67], ["Rectal", "ANATOMY", 76, 82], ["Varices", "OBSERVATION", 83, 90], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["bleeding", "OBSERVATION", 129, 137], ["Rectal", "ANATOMY", 226, 232], ["Varices", "OBSERVATION", 233, 240], ["rectal", "ANATOMY", 244, 250], ["varices", "OBSERVATION", 251, 258], ["no evidence of", "UNCERTAINTY", 299, 313], ["blood", "OBSERVATION", 318, 323], ["proximal", "ANATOMY_MODIFIER", 324, 332], ["rectum", "ANATOMY", 340, 346], ["Rectal", "ANATOMY", 355, 361], ["Varices", "OBSERVATION", 362, 369], ["rectal", "ANATOMY", 382, 388], ["varices", "OBSERVATION", 389, 396]]], ["Banding or sclerotherapy does not appear to be effective.", [["Banding", "TREATMENT", 0, 7], ["sclerotherapy", "TREATMENT", 11, 24], ["sclerotherapy", "OBSERVATION", 11, 24], ["not appear to be", "UNCERTAINTY", 30, 46], ["effective", "OBSERVATION", 47, 56]]], ["I have on one occasion used the gastric balloon of a Blakemore tube inserted into the rectum to control torrential bleeding from huge rectal varices.", [["gastric", "ANATOMY", 32, 39], ["rectum", "ANATOMY", 86, 92], ["rectal varices", "ANATOMY", 134, 148], ["bleeding", "DISEASE", 115, 123], ["rectal varices", "DISEASE", 134, 148], ["gastric", "ORGAN", 32, 39], ["Blakemore tube", "TISSUE", 53, 67], ["rectum", "ORGAN", 86, 92], ["rectal varices", "PATHOLOGICAL_FORMATION", 134, 148], ["the gastric balloon", "TREATMENT", 28, 47], ["a Blakemore tube", "TREATMENT", 51, 67], ["torrential bleeding", "PROBLEM", 104, 123], ["huge rectal varices", "PROBLEM", 129, 148], ["gastric", "ANATOMY", 32, 39], ["balloon", "OBSERVATION", 40, 47], ["Blakemore tube", "OBSERVATION", 53, 67], ["rectum", "ANATOMY", 86, 92], ["torrential", "OBSERVATION_MODIFIER", 104, 114], ["bleeding", "OBSERVATION", 115, 123], ["huge", "OBSERVATION_MODIFIER", 129, 133], ["rectal", "ANATOMY", 134, 140], ["varices", "OBSERVATION", 141, 148]]], ["Unfortunately, the patient died after a prolonged intensivecare course.Answer: Rectal VaricesThere is anecdotal data that in bleeding ectopic varices -treatment with TIPS and/or embolisation by a radiologist can control bleeding.", [["Rectal Varices", "ANATOMY", 79, 93], ["bleeding", "DISEASE", 125, 133], ["varices", "DISEASE", 142, 149], ["bleeding", "DISEASE", 220, 228], ["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26], ["a prolonged intensivecare course", "TREATMENT", 38, 70], ["Rectal Varices", "PROBLEM", 79, 93], ["anecdotal data", "TEST", 102, 116], ["bleeding ectopic varices", "PROBLEM", 125, 149], ["TIPS", "TREATMENT", 166, 170], ["embolisation", "TREATMENT", 178, 190], ["bleeding", "PROBLEM", 220, 228], ["Rectal", "ANATOMY", 79, 85], ["Varices", "OBSERVATION", 86, 93], ["bleeding", "OBSERVATION_MODIFIER", 125, 133], ["ectopic", "OBSERVATION_MODIFIER", 134, 141], ["varices", "OBSERVATION", 142, 149]]], ["In this case, the bleeding stopped spontaneously, and we elected not to try a TIPS due to his elevated MELD score although the patient may have had some decompression based on the CT images showing a single vessel supplying the rectal varices from the splenic vein.Case 48A 25-year-old man presents with jaundice.", [["vessel", "ANATOMY", 207, 213], ["rectal varices", "ANATOMY", 228, 242], ["splenic vein", "ANATOMY", 252, 264], ["bleeding", "DISEASE", 18, 26], ["varices", "DISEASE", 235, 242], ["jaundice", "DISEASE", 304, 312], ["patient", "ORGANISM", 127, 134], ["vessel", "MULTI-TISSUE_STRUCTURE", 207, 213], ["rectal varices", "PATHOLOGICAL_FORMATION", 228, 242], ["splenic vein", "MULTI-TISSUE_STRUCTURE", 252, 264], ["man", "ORGANISM", 286, 289], ["patient", "SPECIES", 127, 134], ["man", "SPECIES", 286, 289], ["the bleeding", "PROBLEM", 14, 26], ["a TIPS", "TREATMENT", 76, 82], ["his elevated MELD score", "PROBLEM", 90, 113], ["some decompression", "TREATMENT", 148, 166], ["the CT images", "TEST", 176, 189], ["a single vessel supplying the rectal varices", "PROBLEM", 198, 242], ["jaundice", "PROBLEM", 304, 312], ["bleeding", "OBSERVATION", 18, 26], ["decompression", "OBSERVATION", 153, 166], ["vessel", "ANATOMY", 207, 213], ["rectal", "ANATOMY", 228, 234], ["varices", "OBSERVATION", 235, 242], ["splenic vein", "ANATOMY", 252, 264], ["jaundice", "OBSERVATION", 304, 312]]], ["He is otherwise asymptomatic but does admit to dark urine and pale stool.", [["urine", "ANATOMY", 52, 57], ["He", "ORGANISM", 0, 2], ["urine", "ORGANISM_SUBSTANCE", 52, 57], ["pale stool", "ORGANISM_SUBSTANCE", 62, 72], ["asymptomatic", "PROBLEM", 16, 28], ["dark urine", "PROBLEM", 47, 57], ["pale stool", "PROBLEM", 62, 72], ["asymptomatic", "OBSERVATION", 16, 28], ["pale", "OBSERVATION_MODIFIER", 62, 66], ["stool", "OBSERVATION", 67, 72]]], ["The jaundice has gradually worsened over the last few weeks and he is now complaining of itching.", [["jaundice", "DISEASE", 4, 12], ["itching", "DISEASE", 89, 96], ["The jaundice", "PROBLEM", 0, 12], ["itching", "PROBLEM", 89, 96], ["jaundice", "OBSERVATION", 4, 12], ["gradually", "OBSERVATION_MODIFIER", 17, 26], ["worsened", "OBSERVATION_MODIFIER", 27, 35], ["itching", "OBSERVATION", 89, 96]]], ["No one else has been sick, and he denies any foreign travel.Case 48He denies fever or abdominal pain, and his appetite is good with a stable weight.Case 48He has no other past medical history that he is aware of but knows he has had an abdominal surgery as an infant.", [["abdominal", "ANATOMY", 86, 95], ["abdominal", "ANATOMY", 236, 245], ["fever", "DISEASE", 77, 82], ["abdominal pain", "DISEASE", 86, 100], ["abdominal", "ORGANISM_SUBDIVISION", 86, 95], ["abdominal", "ORGANISM_SUBDIVISION", 236, 245], ["infant", "SPECIES", 260, 266], ["fever", "PROBLEM", 77, 82], ["abdominal pain", "PROBLEM", 86, 100], ["an abdominal surgery", "TREATMENT", 233, 253], ["abdominal", "ANATOMY", 86, 95], ["pain", "OBSERVATION", 96, 100], ["stable", "OBSERVATION", 134, 140], ["no", "UNCERTAINTY", 162, 164], ["abdominal", "ANATOMY", 236, 245], ["surgery", "OBSERVATION", 246, 253]]], ["He takes no medications.Case 48He does not smoke or drink.", [["medications", "TREATMENT", 12, 23]]], ["He is married with a young child.", [["child", "ORGANISM", 27, 32]]], ["He is not aware of his birth parents and is not in contact with his foster parents.Case 48On exam, he looks comfortable and is alert and oriented.", [["exam", "TEST", 93, 97]]], ["He is obviously jaundiced.Case 48Pulse is 70 beats per minute, regular, blood pressure 115/60, and he is afebrile.", [["blood", "ANATOMY", 72, 77], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["obviously jaundiced", "PROBLEM", 6, 25], ["blood pressure", "TEST", 72, 86], ["afebrile", "PROBLEM", 105, 113], ["obviously", "OBSERVATION_MODIFIER", 6, 15], ["jaundiced", "OBSERVATION", 16, 25]]], ["His abdomen is soft and nontender.", [["abdomen", "ANATOMY", 4, 11], ["abdomen", "ORGAN", 4, 11], ["nontender", "PROBLEM", 24, 33], ["abdomen", "ANATOMY", 4, 11], ["soft", "OBSERVATION", 15, 19], ["nontender", "OBSERVATION", 24, 33]]], ["There is a midline scar in the epigastric area extending into the right upper quadrant.", [["midline scar", "ANATOMY", 11, 23], ["epigastric area", "ANATOMY", 31, 46], ["right upper quadrant", "ANATOMY", 66, 86], ["midline scar", "PATHOLOGICAL_FORMATION", 11, 23], ["epigastric area", "MULTI-TISSUE_STRUCTURE", 31, 46], ["upper", "ORGANISM_SUBDIVISION", 72, 77], ["a midline scar in the epigastric area", "PROBLEM", 9, 46], ["midline", "OBSERVATION_MODIFIER", 11, 18], ["scar", "OBSERVATION", 19, 23], ["epigastric", "ANATOMY", 31, 41], ["area", "ANATOMY_MODIFIER", 42, 46], ["right", "ANATOMY_MODIFIER", 66, 71], ["upper", "ANATOMY_MODIFIER", 72, 77], ["quadrant", "ANATOMY", 78, 86]]], ["Extremities reveal no edema.Answer: Biliary Cirrhosis After Kasai Procedure for Extra-Hepatic Biliary Atresia as a ChildThis young man has an obstructive picture with jaundice and pale stool and dark urine.", [["edema", "ANATOMY", 22, 27], ["Biliary", "ANATOMY", 36, 43], ["Hepatic Biliary Atresia", "ANATOMY", 86, 109], ["urine", "ANATOMY", 200, 205], ["Extremities", "DISEASE", 0, 11], ["edema", "DISEASE", 22, 27], ["Biliary Cirrhosis", "DISEASE", 36, 53], ["Hepatic Biliary Atresia", "DISEASE", 86, 109], ["jaundice", "DISEASE", 167, 175], ["edema", "PATHOLOGICAL_FORMATION", 22, 27], ["Biliary", "ORGAN", 36, 43], ["man", "ORGANISM", 131, 134], ["stool", "ORGANISM_SUBSTANCE", 185, 190], ["urine", "ORGANISM_SUBSTANCE", 200, 205], ["man", "SPECIES", 131, 134], ["edema", "PROBLEM", 22, 27], ["Biliary Cirrhosis", "PROBLEM", 36, 53], ["Kasai Procedure", "TREATMENT", 60, 75], ["Extra-Hepatic Biliary Atresia", "TREATMENT", 80, 109], ["an obstructive picture", "PROBLEM", 139, 161], ["jaundice", "PROBLEM", 167, 175], ["pale stool", "PROBLEM", 180, 190], ["dark urine", "PROBLEM", 195, 205], ["no", "UNCERTAINTY", 19, 21], ["edema", "OBSERVATION", 22, 27], ["Biliary", "ANATOMY", 36, 43], ["Cirrhosis", "OBSERVATION", 44, 53], ["Hepatic", "ANATOMY", 86, 93], ["Biliary", "ANATOMY", 94, 101], ["Atresia", "OBSERVATION", 102, 109], ["obstructive", "OBSERVATION", 142, 153], ["jaundice", "OBSERVATION", 167, 175], ["pale stool", "OBSERVATION", 180, 190], ["dark urine", "OBSERVATION", 195, 205]]], ["The differential diagnosis includes posthepatic causes of jaundice such as biliary obstruction from stones or tumor, on intrahepatic causes such as cholestatic liver disease.", [["posthepatic", "ANATOMY", 36, 47], ["biliary", "ANATOMY", 75, 82], ["stones", "ANATOMY", 100, 106], ["tumor", "ANATOMY", 110, 115], ["intrahepatic", "ANATOMY", 120, 132], ["liver", "ANATOMY", 160, 165], ["jaundice", "DISEASE", 58, 66], ["biliary obstruction", "DISEASE", 75, 94], ["tumor", "DISEASE", 110, 115], ["cholestatic liver disease", "DISEASE", 148, 173], ["biliary obstruction", "PATHOLOGICAL_FORMATION", 75, 94], ["tumor", "CANCER", 110, 115], ["liver", "ORGAN", 160, 165], ["posthepatic causes", "PROBLEM", 36, 54], ["jaundice", "PROBLEM", 58, 66], ["biliary obstruction", "PROBLEM", 75, 94], ["stones", "PROBLEM", 100, 106], ["tumor", "PROBLEM", 110, 115], ["intrahepatic causes", "PROBLEM", 120, 139], ["cholestatic liver disease", "PROBLEM", 148, 173], ["differential diagnosis includes", "UNCERTAINTY", 4, 35], ["jaundice", "OBSERVATION", 58, 66], ["biliary", "ANATOMY", 75, 82], ["obstruction", "OBSERVATION", 83, 94], ["stones", "OBSERVATION", 100, 106], ["tumor", "OBSERVATION", 110, 115], ["intrahepatic", "ANATOMY", 120, 132], ["cholestatic", "OBSERVATION_MODIFIER", 148, 159], ["liver", "ANATOMY", 160, 165], ["disease", "OBSERVATION", 166, 173]]], ["In this case, he states he had surgery as an infant.", [["infant", "SPECIES", 45, 51], ["surgery", "TREATMENT", 31, 38]]], ["A cholecystectomy would be unusual at that age, but inadvertent damage to the biliary tree during such a procedure could lead to secondary biliary cirrhosis.", [["biliary tree", "ANATOMY", 78, 90], ["biliary", "ANATOMY", 139, 146], ["biliary cirrhosis", "DISEASE", 139, 156], ["biliary tree", "MULTI-TISSUE_STRUCTURE", 78, 90], ["biliary", "ORGAN", 139, 146], ["A cholecystectomy", "TREATMENT", 0, 17], ["inadvertent damage to the biliary tree", "PROBLEM", 52, 90], ["a procedure", "TREATMENT", 103, 114], ["secondary biliary cirrhosis", "PROBLEM", 129, 156], ["cholecystectomy", "OBSERVATION", 2, 17], ["damage", "OBSERVATION", 64, 70], ["biliary", "ANATOMY", 78, 85], ["tree", "ANATOMY_MODIFIER", 86, 90], ["biliary", "ANATOMY", 139, 146], ["cirrhosis", "OBSERVATION", 147, 156]]], ["Typically, this would occur after only a few years and not 20-25 years as in this case.Answer: Biliary Cirrhosis After Kasai Procedure for Extra-Hepatic Biliary Atresia as a ChildHe does have some evidence of portal hypertension given the low platelet count but looks to be relatively well compensated.Answer: Biliary Cirrhosis After Kasai Procedure for Extra-Hepatic Biliary Atresia as a ChildThe next best test would be imaging.", [["Biliary", "ANATOMY", 95, 102], ["portal", "ANATOMY", 209, 215], ["platelet", "ANATOMY", 243, 251], ["Biliary", "ANATOMY", 310, 317], ["Hepatic Biliary Atresia", "ANATOMY", 360, 383], ["Biliary Cirrhosis", "DISEASE", 95, 112], ["Hepatic Biliary Atresia", "DISEASE", 145, 168], ["hypertension", "DISEASE", 216, 228], ["Biliary Cirrhosis", "DISEASE", 310, 327], ["Hepatic Biliary Atresia", "DISEASE", 360, 383], ["Biliary", "ORGAN", 95, 102], ["portal", "MULTI-TISSUE_STRUCTURE", 209, 215], ["platelet", "CELL", 243, 251], ["Biliary", "ORGAN", 310, 317], ["Biliary Cirrhosis", "PROBLEM", 95, 112], ["Kasai Procedure", "TREATMENT", 119, 134], ["Extra-Hepatic Biliary Atresia", "TREATMENT", 139, 168], ["portal hypertension", "PROBLEM", 209, 228], ["the low platelet count", "PROBLEM", 235, 257], ["Biliary Cirrhosis", "PROBLEM", 310, 327], ["Kasai Procedure", "TREATMENT", 334, 349], ["Extra-Hepatic Biliary Atresia", "TREATMENT", 354, 383], ["imaging", "TEST", 422, 429], ["Biliary", "ANATOMY", 95, 102], ["Cirrhosis", "OBSERVATION", 103, 112], ["Hepatic", "ANATOMY", 145, 152], ["Biliary", "ANATOMY", 153, 160], ["Atresia", "OBSERVATION", 161, 168], ["portal", "ANATOMY", 209, 215], ["hypertension", "OBSERVATION", 216, 228], ["low platelet count", "OBSERVATION", 239, 257], ["compensated", "OBSERVATION", 290, 301], ["Biliary", "ANATOMY", 310, 317], ["Cirrhosis", "OBSERVATION", 318, 327], ["Hepatic", "ANATOMY", 360, 367], ["Biliary", "ANATOMY", 368, 375], ["Atresia", "OBSERVATION", 376, 383]]], ["The MRI (Fig. 48.1) shows evidence of biliary ductal dilation, and there are stones and sludge within the biliary tree (arrowed).", [["biliary ductal", "ANATOMY", 38, 52], ["stones", "ANATOMY", 77, 83], ["biliary tree", "ANATOMY", 106, 118], ["biliary ductal dilation", "DISEASE", 38, 61], ["biliary ductal", "MULTI-TISSUE_STRUCTURE", 38, 52], ["stones", "PATHOLOGICAL_FORMATION", 77, 83], ["biliary tree", "MULTI-TISSUE_STRUCTURE", 106, 118], ["The MRI (Fig.", "TEST", 0, 13], ["biliary ductal dilation", "PROBLEM", 38, 61], ["stones", "PROBLEM", 77, 83], ["sludge within the biliary tree", "PROBLEM", 88, 118], ["biliary ductal", "ANATOMY", 38, 52], ["dilation", "OBSERVATION", 53, 61], ["stones", "OBSERVATION", 77, 83], ["sludge", "OBSERVATION", 88, 94], ["biliary", "ANATOMY", 106, 113], ["tree", "ANATOMY_MODIFIER", 114, 118]]], ["On other cuts, it was evident that there was a biliary-enteric anastomosis, and the spleen is big consistent with portal hypertension.Answer: Biliary Cirrhosis After Kasai Procedure for Extra-Hepatic Biliary Atresia as a ChildThis was actually a patient who had undergone a Kasai procedure (hepatoportoenterostomy) for extra-hepatic biliary atresia (EHBA) at the age of 1 month.", [["biliary", "ANATOMY", 47, 54], ["spleen", "ANATOMY", 84, 90], ["portal", "ANATOMY", 114, 120], ["Biliary", "ANATOMY", 142, 149], ["Hepatic Biliary Atresia", "ANATOMY", 192, 215], ["extra-hepatic biliary atresia", "ANATOMY", 319, 348], ["portal hypertension", "DISEASE", 114, 133], ["Biliary Cirrhosis", "DISEASE", 142, 159], ["Hepatic Biliary Atresia", "DISEASE", 192, 215], ["extra-hepatic biliary atresia", "DISEASE", 319, 348], ["EHBA", "DISEASE", 350, 354], ["spleen", "ORGAN", 84, 90], ["portal", "MULTI-TISSUE_STRUCTURE", 114, 120], ["Biliary", "ORGAN", 142, 149], ["patient", "ORGANISM", 246, 253], ["extra-hepatic biliary atresia", "PATHOLOGICAL_FORMATION", 319, 348], ["patient", "SPECIES", 246, 253], ["portal hypertension", "PROBLEM", 114, 133], ["Biliary Cirrhosis", "PROBLEM", 142, 159], ["Kasai Procedure", "TREATMENT", 166, 181], ["Extra-Hepatic Biliary Atresia", "TREATMENT", 186, 215], ["a Kasai procedure", "TREATMENT", 272, 289], ["hepatoportoenterostomy", "TREATMENT", 291, 313], ["extra-hepatic biliary atresia", "PROBLEM", 319, 348], ["biliary", "ANATOMY", 47, 54], ["enteric", "ANATOMY", 55, 62], ["anastomosis", "OBSERVATION", 63, 74], ["spleen", "ANATOMY", 84, 90], ["big", "OBSERVATION", 94, 97], ["consistent with", "UNCERTAINTY", 98, 113], ["portal", "ANATOMY", 114, 120], ["hypertension", "OBSERVATION", 121, 133], ["Biliary", "ANATOMY", 142, 149], ["Cirrhosis", "OBSERVATION", 150, 159], ["Hepatic", "ANATOMY", 192, 199], ["Biliary", "ANATOMY", 200, 207], ["Atresia", "OBSERVATION", 208, 215], ["extra-hepatic", "ANATOMY_MODIFIER", 319, 332], ["biliary", "ANATOMY", 333, 340], ["atresia", "OBSERVATION", 341, 348]]], ["He has developed secondary biliary cirrhosis which is seen in the majority of cases.Answer: Biliary Cirrhosis After Kasai Procedure for Extra-Hepatic Biliary Atresia as a ChildThis patient was being worked up for liver transplant, and we decided to obtain a tranjugular liver biopsy to assess the degree of liver damage since he had so much biliary obstruction.", [["biliary", "ANATOMY", 27, 34], ["Biliary", "ANATOMY", 92, 99], ["Hepatic Biliary Atresia", "ANATOMY", 142, 165], ["liver", "ANATOMY", 213, 218], ["liver", "ANATOMY", 270, 275], ["liver", "ANATOMY", 307, 312], ["biliary", "ANATOMY", 341, 348], ["biliary cirrhosis", "DISEASE", 27, 44], ["Biliary Cirrhosis", "DISEASE", 92, 109], ["Hepatic Biliary Atresia", "DISEASE", 142, 165], ["liver damage", "DISEASE", 307, 319], ["biliary obstruction", "DISEASE", 341, 360], ["biliary cirrhosis", "PATHOLOGICAL_FORMATION", 27, 44], ["Biliary", "ORGAN", 92, 99], ["patient", "ORGANISM", 181, 188], ["liver", "ORGAN", 213, 218], ["liver", "ORGAN", 270, 275], ["liver", "ORGAN", 307, 312], ["biliary obstruction", "PATHOLOGICAL_FORMATION", 341, 360], ["patient", "SPECIES", 181, 188], ["secondary biliary cirrhosis", "PROBLEM", 17, 44], ["Biliary Cirrhosis", "PROBLEM", 92, 109], ["Kasai Procedure", "TREATMENT", 116, 131], ["Extra-Hepatic Biliary Atresia", "TREATMENT", 136, 165], ["liver transplant", "TREATMENT", 213, 229], ["a tranjugular liver biopsy", "TEST", 256, 282], ["liver damage", "PROBLEM", 307, 319], ["much biliary obstruction", "PROBLEM", 336, 360], ["secondary", "OBSERVATION_MODIFIER", 17, 26], ["biliary", "ANATOMY", 27, 34], ["cirrhosis", "OBSERVATION", 35, 44], ["Biliary", "ANATOMY", 92, 99], ["Cirrhosis", "OBSERVATION", 100, 109], ["Hepatic", "ANATOMY", 142, 149], ["Biliary", "ANATOMY", 150, 157], ["Atresia", "OBSERVATION", 158, 165], ["liver", "ANATOMY", 213, 218], ["transplant", "OBSERVATION", 219, 229], ["liver", "ANATOMY", 270, 275], ["biopsy", "OBSERVATION", 276, 282], ["liver", "ANATOMY", 307, 312], ["damage", "OBSERVATION", 313, 319], ["biliary", "ANATOMY", 341, 348], ["obstruction", "OBSERVATION", 349, 360]]], ["The low power image (Fig. 48.2) shows a cirrhotic nodule and at higher power (Fig. 48.", [["cirrhotic nodule", "ANATOMY", 40, 56], ["cirrhotic nodule", "CANCER", 40, 56], ["The low power image", "TEST", 0, 19], ["a cirrhotic nodule", "PROBLEM", 38, 56], ["low power", "OBSERVATION_MODIFIER", 4, 13], ["cirrhotic", "OBSERVATION_MODIFIER", 40, 49], ["nodule", "OBSERVATION", 50, 56]]], ["3) the cholestasis is readily apparent.Answer: Biliary Cirrhosis After Kasai Procedure for Extra-Hepatic Biliary Atresia as a ChildEHBA has an incidence of approximately 1 in 10,000-20,000 births and is characterized by inflammation of the bile ducts leading to progressive obliteration of the extrahepatic biliary tract.", [["Biliary", "ANATOMY", 47, 54], ["Biliary", "ANATOMY", 105, 112], ["bile ducts", "ANATOMY", 240, 250], ["extrahepatic biliary tract", "ANATOMY", 294, 320], ["cholestasis", "DISEASE", 7, 18], ["Biliary Cirrhosis", "DISEASE", 47, 64], ["Extra-Hepatic Biliary Atresia", "DISEASE", 91, 120], ["ChildEHBA", "CHEMICAL", 126, 135], ["inflammation of the bile ducts", "DISEASE", 220, 250], ["obliteration of the extrahepatic biliary tract", "DISEASE", 274, 320], ["Biliary", "ORGAN", 47, 54], ["bile ducts", "MULTI-TISSUE_STRUCTURE", 240, 250], ["extrahepatic biliary tract", "MULTI-TISSUE_STRUCTURE", 294, 320], ["the cholestasis", "PROBLEM", 3, 18], ["Biliary Cirrhosis", "PROBLEM", 47, 64], ["Kasai Procedure", "TREATMENT", 71, 86], ["Extra-Hepatic Biliary Atresia", "PROBLEM", 91, 120], ["inflammation of the bile ducts", "PROBLEM", 220, 250], ["progressive obliteration of the extrahepatic biliary tract", "PROBLEM", 262, 320], ["cholestasis", "OBSERVATION", 7, 18], ["Biliary", "ANATOMY", 47, 54], ["Cirrhosis", "OBSERVATION", 55, 64], ["Hepatic", "ANATOMY_MODIFIER", 97, 104], ["Biliary", "ANATOMY", 105, 112], ["Atresia", "OBSERVATION", 113, 120], ["inflammation", "OBSERVATION", 220, 232], ["bile ducts", "ANATOMY", 240, 250], ["progressive", "OBSERVATION_MODIFIER", 262, 273], ["obliteration", "OBSERVATION", 274, 286], ["extrahepatic", "ANATOMY_MODIFIER", 294, 306], ["biliary tract", "ANATOMY", 307, 320]]], ["The diagnosis of BA should ideally be made within the first month of life as multiple studies have demonstrated that the success of biliary drainage using the Kasai procedure is poor after 3 months of age.Answer: Biliary Cirrhosis After Kasai Procedure for Extra-Hepatic Biliary Atresia as a ChildThe Kasai procedure attempts to restore bile flow from the liver to the proximal small bowel by using a roux-en-Y loop of bowel and a direct anastomosis to the capsule of the liver following excision of the biliary remnant and portal fibrous plate.Answer: Biliary Cirrhosis After Kasai Procedure for Extra-Hepatic Biliary Atresia as a ChildIf the procedure is successful, the small patent bile ducts drain into the small bowel and relieve the biliary obstruction and prevent nutritional issues from cholestasis.Answer: Biliary Cirrhosis After Kasai Procedure for Extra-Hepatic Biliary Atresia as a ChildBiliary cirrhosis usually occurs within 5-10 years, and liver transplantation is required.", [["biliary", "ANATOMY", 132, 139], ["Biliary", "ANATOMY", 213, 220], ["Biliary", "ANATOMY", 271, 278], ["bile", "ANATOMY", 337, 341], ["liver", "ANATOMY", 356, 361], ["proximal small bowel", "ANATOMY", 369, 389], ["bowel", "ANATOMY", 419, 424], ["capsule", "ANATOMY", 457, 464], ["liver", "ANATOMY", 472, 477], ["biliary remnant", "ANATOMY", 504, 519], ["portal fibrous plate", "ANATOMY", 524, 544], ["Biliary", "ANATOMY", 553, 560], ["bile ducts", "ANATOMY", 686, 696], ["small bowel", "ANATOMY", 712, 723], ["biliary", "ANATOMY", 740, 747], ["Biliary", "ANATOMY", 816, 823], ["Hepatic Biliary Atresia", "ANATOMY", 866, 889], ["liver", "ANATOMY", 956, 961], ["BA", "CHEMICAL", 17, 19], ["Biliary Cirrhosis", "DISEASE", 213, 230], ["Hepatic Biliary Atresia", "DISEASE", 263, 286], ["Biliary Cirrhosis", "DISEASE", 553, 570], ["Hepatic Biliary Atresia", "DISEASE", 603, 626], ["biliary obstruction", "DISEASE", 740, 759], ["cholestasis", "DISEASE", 796, 807], ["Biliary Cirrhosis", "DISEASE", 816, 833], ["Extra-Hepatic Biliary Atresia", "DISEASE", 860, 889], ["cirrhosis", "DISEASE", 908, 917], ["BA", "MULTI-TISSUE_STRUCTURE", 17, 19], ["biliary", "MULTI-TISSUE_STRUCTURE", 132, 139], ["Biliary", "ORGAN", 213, 220], ["bile", "MULTI-TISSUE_STRUCTURE", 337, 341], ["liver", "ORGAN", 356, 361], ["small", "ORGAN", 378, 383], ["bowel", "ORGAN", 384, 389], ["bowel", "ORGAN", 419, 424], ["capsule", "CANCER", 457, 464], ["liver", "ORGAN", 472, 477], ["biliary remnant", "MULTI-TISSUE_STRUCTURE", 504, 519], ["portal fibrous plate", "TISSUE", 524, 544], ["Biliary", "ORGAN", 553, 560], ["bile ducts", "MULTI-TISSUE_STRUCTURE", 686, 696], ["bowel", "ORGAN", 718, 723], ["biliary obstruction", "PATHOLOGICAL_FORMATION", 740, 759], ["Biliary", "ORGAN", 816, 823], ["liver", "ORGAN", 956, 961], ["multiple studies", "TEST", 77, 93], ["biliary drainage", "TREATMENT", 132, 148], ["the Kasai procedure", "TREATMENT", 155, 174], ["Biliary Cirrhosis", "PROBLEM", 213, 230], ["Kasai Procedure", "TREATMENT", 237, 252], ["Extra-Hepatic Biliary Atresia", "TREATMENT", 257, 286], ["The Kasai procedure", "TREATMENT", 297, 316], ["a roux-en-Y loop of bowel", "TREATMENT", 399, 424], ["a direct anastomosis", "TREATMENT", 429, 449], ["excision", "TREATMENT", 488, 496], ["the biliary remnant", "PROBLEM", 500, 519], ["portal fibrous plate", "PROBLEM", 524, 544], ["Biliary Cirrhosis", "PROBLEM", 553, 570], ["Kasai Procedure", "TREATMENT", 577, 592], ["Extra-Hepatic Biliary Atresia", "TREATMENT", 597, 626], ["the procedure", "TREATMENT", 640, 653], ["the small patent bile ducts drain", "TREATMENT", 669, 702], ["the biliary obstruction", "PROBLEM", 736, 759], ["nutritional issues", "PROBLEM", 772, 790], ["cholestasis", "PROBLEM", 796, 807], ["Biliary Cirrhosis", "PROBLEM", 816, 833], ["Kasai Procedure", "TREATMENT", 840, 855], ["Extra-Hepatic Biliary Atresia", "PROBLEM", 860, 889], ["a ChildBiliary cirrhosis", "PROBLEM", 893, 917], ["liver transplantation", "TREATMENT", 956, 977], ["biliary", "ANATOMY", 132, 139], ["drainage", "OBSERVATION", 140, 148], ["Biliary", "ANATOMY", 213, 220], ["Cirrhosis", "OBSERVATION", 221, 230], ["Hepatic", "ANATOMY", 263, 270], ["Biliary", "ANATOMY", 271, 278], ["Atresia", "OBSERVATION", 279, 286], ["bile", "ANATOMY", 337, 341], ["flow", "OBSERVATION", 342, 346], ["liver", "ANATOMY", 356, 361], ["proximal", "ANATOMY_MODIFIER", 369, 377], ["small bowel", "ANATOMY", 378, 389], ["bowel", "ANATOMY", 419, 424], ["anastomosis", "OBSERVATION", 438, 449], ["capsule", "ANATOMY_MODIFIER", 457, 464], ["liver", "ANATOMY", 472, 477], ["excision", "OBSERVATION", 488, 496], ["biliary", "ANATOMY", 504, 511], ["remnant", "OBSERVATION", 512, 519], ["portal", "ANATOMY", 524, 530], ["fibrous plate", "OBSERVATION", 531, 544], ["Biliary", "ANATOMY", 553, 560], ["Cirrhosis", "OBSERVATION", 561, 570], ["Hepatic", "ANATOMY", 603, 610], ["Biliary", "ANATOMY", 611, 618], ["Atresia", "OBSERVATION", 619, 626], ["small", "OBSERVATION_MODIFIER", 673, 678], ["patent", "OBSERVATION", 679, 685], ["bile ducts", "ANATOMY", 686, 696], ["drain", "OBSERVATION", 697, 702], ["small bowel", "ANATOMY", 712, 723], ["biliary", "ANATOMY", 740, 747], ["obstruction", "OBSERVATION", 748, 759], ["nutritional issues", "OBSERVATION", 772, 790], ["cholestasis", "OBSERVATION", 796, 807], ["Biliary", "ANATOMY", 816, 823], ["Cirrhosis", "OBSERVATION", 824, 833], ["Hepatic", "ANATOMY", 866, 873], ["Biliary", "ANATOMY", 874, 881], ["Atresia", "OBSERVATION", 882, 889], ["ChildBiliary", "OBSERVATION_MODIFIER", 895, 907], ["cirrhosis", "OBSERVATION", 908, 917], ["liver", "ANATOMY", 956, 961], ["transplantation", "OBSERVATION", 962, 977]]], ["The outcome after transplant is good with overall survival of approximately 70-80% long term survival.", [["transplant", "TREATMENT", 18, 28]]], ["More recent case series have suggested better long-term outcome with early Kasai procedures and perhaps explains this patient's later presentation.Case 49A 45-year-old male presents to the emergency room brought in by his family.", [["patient", "ORGANISM", 118, 125], ["male", "ORGANISM", 168, 172], ["patient", "SPECIES", 118, 125], ["early Kasai procedures", "TREATMENT", 69, 91]]], ["He has become increasingly jaundiced over the last several days and is mildly confused.", [["increasingly jaundiced", "PROBLEM", 14, 36], ["mildly confused", "PROBLEM", 71, 86], ["increasingly", "OBSERVATION_MODIFIER", 14, 26], ["jaundiced", "OBSERVATION", 27, 36], ["mildly", "OBSERVATION_MODIFIER", 71, 77], ["confused", "OBSERVATION", 78, 86]]], ["His last alcohol was yesterday.Case 49He complains of some mild abdominal pain but otherwise denies fever or chills.", [["abdominal", "ANATOMY", 64, 73], ["alcohol", "CHEMICAL", 9, 16], ["abdominal pain", "DISEASE", 64, 78], ["fever", "DISEASE", 100, 105], ["chills", "DISEASE", 109, 115], ["alcohol", "CHEMICAL", 9, 16], ["alcohol", "SIMPLE_CHEMICAL", 9, 16], ["abdominal", "ORGANISM_SUBDIVISION", 64, 73], ["some mild abdominal pain", "PROBLEM", 54, 78], ["fever", "PROBLEM", 100, 105], ["chills", "PROBLEM", 109, 115], ["mild", "OBSERVATION_MODIFIER", 59, 63], ["abdominal", "ANATOMY", 64, 73], ["pain", "OBSERVATION", 74, 78], ["chills", "OBSERVATION", 109, 115]]], ["His bowels move normally without blood, and he denies dysuria.Case 49His past medical history is significant for diabetes and hypertension, but he has been off medication for several months after he lost his job and his medical insurance.", [["bowels", "ANATOMY", 4, 10], ["blood", "ANATOMY", 33, 38], ["dysuria", "DISEASE", 54, 61], ["diabetes", "DISEASE", 113, 121], ["hypertension", "DISEASE", 126, 138], ["bowels", "ORGAN", 4, 10], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["dysuria", "PROBLEM", 54, 61], ["diabetes", "PROBLEM", 113, 121], ["hypertension", "PROBLEM", 126, 138], ["medication", "TREATMENT", 160, 170], ["bowels", "ANATOMY", 4, 10], ["dysuria", "OBSERVATION", 54, 61], ["significant for", "UNCERTAINTY", 97, 112], ["diabetes", "OBSERVATION", 113, 121], ["hypertension", "OBSERVATION", 126, 138]]], ["He denies any over-the-counter medications.Case 49His family history is notable for alcohol-related liver disease in his father and several male siblings.Case 49Exam demonstrates an obese male, looking older than stated, with vital signs weight 257 pounds, BP 120/80, pulse 104 regular, and temperature 100\u00b0F.Case 49He is not in distress but has mild asterixis.", [["liver", "ANATOMY", 100, 105], ["alcohol", "CHEMICAL", 84, 91], ["liver disease", "DISEASE", 100, 113], ["asterixis", "DISEASE", 351, 360], ["alcohol", "CHEMICAL", 84, 91], ["alcohol", "SIMPLE_CHEMICAL", 84, 91], ["liver", "ORGAN", 100, 105], ["medications", "TREATMENT", 31, 42], ["liver disease", "PROBLEM", 100, 113], ["vital signs", "TEST", 226, 237], ["weight", "TEST", 238, 244], ["BP", "TEST", 257, 259], ["pulse", "TEST", 268, 273], ["temperature", "TEST", 291, 302], ["distress", "PROBLEM", 329, 337], ["mild asterixis", "PROBLEM", 346, 360], ["liver", "ANATOMY", 100, 105], ["disease", "OBSERVATION", 106, 113], ["obese", "OBSERVATION", 182, 187], ["not in", "UNCERTAINTY", 322, 328], ["mild", "OBSERVATION_MODIFIER", 346, 350], ["asterixis", "OBSERVATION", 351, 360]]], ["He is obviously icteric and has multiple spider nevi.", [["icteric", "DISEASE", 16, 23], ["spider nevi", "DISEASE", 41, 52], ["He", "ORGANISM", 0, 2], ["obviously icteric", "PROBLEM", 6, 23], ["multiple spider nevi", "PROBLEM", 32, 52], ["icteric", "OBSERVATION", 16, 23], ["multiple", "OBSERVATION_MODIFIER", 32, 40], ["spider nevi", "OBSERVATION", 41, 52]]], ["He has temporal wasting.", [["wasting", "DISEASE", 16, 23], ["temporal wasting", "PROBLEM", 7, 23], ["temporal", "OBSERVATION_MODIFIER", 7, 15], ["wasting", "OBSERVATION", 16, 23]]], ["His heart and lungs are normal but his abdomen is distended with dilated abdominal veins.", [["heart", "ANATOMY", 4, 9], ["lungs", "ANATOMY", 14, 19], ["abdomen", "ANATOMY", 39, 46], ["abdominal veins", "ANATOMY", 73, 88], ["heart", "ORGAN", 4, 9], ["lungs", "ORGAN", 14, 19], ["abdomen", "ORGAN", 39, 46], ["abdominal veins", "MULTI-TISSUE_STRUCTURE", 73, 88], ["distended", "PROBLEM", 50, 59], ["dilated abdominal veins", "PROBLEM", 65, 88], ["heart", "ANATOMY", 4, 9], ["lungs", "ANATOMY", 14, 19], ["normal", "OBSERVATION", 24, 30], ["abdomen", "ANATOMY", 39, 46], ["distended", "OBSERVATION", 50, 59], ["dilated", "OBSERVATION", 65, 72], ["abdominal veins", "ANATOMY", 73, 88]]], ["His liver is markedly enlarged and tender, but his spleen is impalpable.", [["liver", "ANATOMY", 4, 9], ["spleen", "ANATOMY", 51, 57], ["liver", "ORGAN", 4, 9], ["spleen", "ORGAN", 51, 57], ["markedly enlarged", "PROBLEM", 13, 30], ["tender", "PROBLEM", 35, 41], ["liver", "ANATOMY", 4, 9], ["markedly", "OBSERVATION_MODIFIER", 13, 21], ["enlarged", "OBSERVATION", 22, 30], ["tender", "OBSERVATION", 35, 41], ["spleen", "ANATOMY", 51, 57], ["impalpable", "OBSERVATION", 61, 71]]], ["Extremities show ++ ankle edema, and his skin demonstrates jaundice.Answer: Type I Hepatorenal Syndrome (HRS)This man presents with classic alcoholic hepatitis, but it has been complicated by type 1 HRS.", [["ankle", "ANATOMY", 20, 25], ["skin", "ANATOMY", 41, 45], ["edema", "DISEASE", 26, 31], ["jaundice", "DISEASE", 59, 67], ["Type I Hepatorenal Syndrome", "DISEASE", 76, 103], ["HRS", "DISEASE", 105, 108], ["alcoholic hepatitis", "DISEASE", 140, 159], ["HRS", "DISEASE", 199, 202], ["skin", "ORGAN", 41, 45], ["man", "ORGANISM", 114, 117], ["man", "SPECIES", 114, 117], ["ankle edema", "PROBLEM", 20, 31], ["jaundice", "PROBLEM", 59, 67], ["Type I Hepatorenal Syndrome", "PROBLEM", 76, 103], ["classic alcoholic hepatitis", "PROBLEM", 132, 159], ["+", "OBSERVATION", 17, 18], ["ankle", "ANATOMY", 20, 25], ["edema", "OBSERVATION", 26, 31], ["skin", "ANATOMY", 41, 45], ["jaundice", "OBSERVATION", 59, 67], ["Hepatorenal Syndrome", "OBSERVATION", 83, 103], ["alcoholic hepatitis", "OBSERVATION", 140, 159]]], ["This is a diagnosis that is actually quite difficult to make (according to the international ascites club) since several other disorders need to be excluded.", [["ascites", "ANATOMY", 93, 100], ["ascites", "DISEASE", 93, 100], ["several other disorders", "PROBLEM", 113, 136], ["ascites", "OBSERVATION", 93, 100]]], ["There are two types of HRS which by definition occur in patients with cirrhosis, severe alcoholic hepatitis, or fulminant hepatic failure.", [["hepatic", "ANATOMY", 122, 129], ["HRS", "DISEASE", 23, 26], ["cirrhosis", "DISEASE", 70, 79], ["alcoholic hepatitis", "DISEASE", 88, 107], ["fulminant hepatic failure", "DISEASE", 112, 137], ["HRS", "CANCER", 23, 26], ["patients", "ORGANISM", 56, 64], ["hepatic", "ORGAN", 122, 129], ["patients", "SPECIES", 56, 64], ["HRS", "TREATMENT", 23, 26], ["cirrhosis", "PROBLEM", 70, 79], ["severe alcoholic hepatitis", "PROBLEM", 81, 107], ["fulminant hepatic failure", "PROBLEM", 112, 137], ["cirrhosis", "OBSERVATION", 70, 79], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["alcoholic hepatitis", "OBSERVATION", 88, 107], ["fulminant", "OBSERVATION_MODIFIER", 112, 121], ["hepatic", "ANATOMY", 122, 129], ["failure", "OBSERVATION", 130, 137]]], ["Type I is defined as at least a 50% lowering of the creatinine clearance to a value below 20 ml/min in less than a 2 week period or at least a twofold increase in serum creatinine to a level >2.5 mg/dl (221 \u03bcmol/l).", [["serum", "ANATOMY", 163, 168], ["creatinine", "CHEMICAL", 52, 62], ["creatinine", "CHEMICAL", 169, 179], ["creatinine", "CHEMICAL", 52, 62], ["creatinine", "CHEMICAL", 169, 179], ["creatinine", "SIMPLE_CHEMICAL", 52, 62], ["serum", "ORGANISM_SUBSTANCE", 163, 168], ["creatinine", "SIMPLE_CHEMICAL", 169, 179], ["the creatinine clearance", "TEST", 48, 72], ["serum creatinine", "TEST", 163, 179], ["increase", "OBSERVATION_MODIFIER", 151, 159]]], ["Hence, the lab values shown from 2 weeks ago would fulfill this criterion.", [["the lab values", "TEST", 7, 21]]], ["Patients do not need to be oliguric although most are.", [["oliguric", "DISEASE", 27, 35], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["oliguric", "PROBLEM", 27, 35], ["oliguric", "OBSERVATION", 27, 35]]], ["Type II is defined as any renal insufficiency in a patient that has the above liver diseases but does not meet criteria for type I. In general, this is essentially similar to diuretic-resistant ascites.", [["renal", "ANATOMY", 26, 31], ["liver", "ANATOMY", 78, 83], ["ascites", "ANATOMY", 194, 201], ["Type II", "DISEASE", 0, 7], ["renal insufficiency", "DISEASE", 26, 45], ["liver diseases", "DISEASE", 78, 92], ["ascites", "DISEASE", 194, 201], ["renal", "ORGAN", 26, 31], ["patient", "ORGANISM", 51, 58], ["liver", "ORGAN", 78, 83], ["patient", "SPECIES", 51, 58], ["Type II", "PROBLEM", 0, 7], ["any renal insufficiency", "PROBLEM", 22, 45], ["the above liver diseases", "PROBLEM", 68, 92], ["type I.", "PROBLEM", 124, 131], ["diuretic", "TREATMENT", 175, 183], ["resistant ascites", "PROBLEM", 184, 201], ["renal", "ANATOMY", 26, 31], ["insufficiency", "OBSERVATION", 32, 45], ["liver", "ANATOMY", 78, 83], ["diseases", "OBSERVATION", 84, 92], ["resistant", "OBSERVATION_MODIFIER", 184, 193], ["ascites", "OBSERVATION", 194, 201]]], ["The absolute definition of HRS is:Answer: Type I Hepatorenal Syndrome (HRS)Patient with liver disease/failure and portal hypertension.Answer: Type I Hepatorenal Syndrome (HRS)-Plasma creatinine >1.5 mg/dl (133 -mmol/l) that progresses over days to weeks.", [["liver", "ANATOMY", 88, 93], ["portal", "ANATOMY", 114, 120], ["HRS", "DISEASE", 27, 30], ["Type I Hepatorenal Syndrome", "DISEASE", 42, 69], ["HRS", "DISEASE", 71, 74], ["liver disease/failure", "DISEASE", 88, 109], ["portal hypertension", "DISEASE", 114, 133], ["Type I Hepatorenal Syndrome", "DISEASE", 142, 169], ["HRS", "DISEASE", 171, 174], ["creatinine", "CHEMICAL", 183, 193], ["creatinine", "CHEMICAL", 183, 193], ["liver", "ORGAN", 88, 93], ["portal", "MULTI-TISSUE_STRUCTURE", 114, 120], ["Plasma", "ORGANISM_SUBSTANCE", 176, 182], ["creatinine", "SIMPLE_CHEMICAL", 183, 193], ["Patient", "SPECIES", 75, 82], ["Type I Hepatorenal Syndrome", "PROBLEM", 42, 69], ["liver disease", "PROBLEM", 88, 101], ["failure", "PROBLEM", 102, 109], ["portal hypertension", "PROBLEM", 114, 133], ["Type I Hepatorenal Syndrome", "PROBLEM", 142, 169], ["Plasma creatinine", "TEST", 176, 193], ["Hepatorenal", "ANATOMY", 49, 60], ["Syndrome", "OBSERVATION", 61, 69], ["liver", "ANATOMY", 88, 93], ["disease", "OBSERVATION", 94, 101], ["failure", "OBSERVATION", 102, 109], ["portal", "ANATOMY", 114, 120], ["hypertension", "OBSERVATION", 121, 133], ["Hepatorenal", "ANATOMY", 149, 160], ["Syndrome", "OBSERVATION", 161, 169]]], ["Absence of any other apparent cause for renal disease, including shock, ongoing bacterial infection, current or recent treatment with nephrotoxic drugs, and the absence of ultrasonographic evidence of obstruction or parenchymal renal disease.", [["renal", "ANATOMY", 40, 45], ["parenchymal renal", "ANATOMY", 216, 233], ["renal disease", "DISEASE", 40, 53], ["shock", "DISEASE", 65, 70], ["bacterial infection", "DISEASE", 80, 99], ["nephrotoxic", "DISEASE", 134, 145], ["obstruction", "DISEASE", 201, 212], ["parenchymal renal disease", "DISEASE", 216, 241], ["renal", "ORGAN", 40, 45], ["parenchymal renal", "MULTI-TISSUE_STRUCTURE", 216, 233], ["renal disease", "PROBLEM", 40, 53], ["shock", "PROBLEM", 65, 70], ["ongoing bacterial infection", "PROBLEM", 72, 99], ["nephrotoxic drugs", "TREATMENT", 134, 151], ["obstruction", "PROBLEM", 201, 212], ["parenchymal renal disease", "PROBLEM", 216, 241], ["renal", "ANATOMY", 40, 45], ["disease", "OBSERVATION", 46, 53], ["shock", "OBSERVATION", 65, 70], ["bacterial", "OBSERVATION_MODIFIER", 80, 89], ["infection", "OBSERVATION", 90, 99], ["obstruction", "OBSERVATION", 201, 212], ["parenchymal", "ANATOMY_MODIFIER", 216, 227], ["renal", "ANATOMY", 228, 233], ["disease", "OBSERVATION", 234, 241]]], ["Urine red cell excretion <50 cells per high power field. -Urine protein excretion <500 mg/day. -Lack of improvement in renal function after volume expansion with intravenous albumin (1 g/kg of body weight per day up to 100 g/day) for at least two days and withdrawal of diuretics.Answer: Type I Hepatorenal Syndrome (HRS)The pathogenesis is related to splanchnic arterial vasodilation in the setting of portal hypertension.", [["Urine red cell", "ANATOMY", 0, 14], ["cells", "ANATOMY", 29, 34], ["renal", "ANATOMY", 119, 124], ["intravenous", "ANATOMY", 162, 173], ["body", "ANATOMY", 193, 197], ["splanchnic arterial", "ANATOMY", 352, 371], ["portal", "ANATOMY", 403, 409], ["Type I Hepatorenal Syndrome", "DISEASE", 288, 315], ["HRS", "DISEASE", 317, 320], ["portal hypertension", "DISEASE", 403, 422], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["cell", "CELL", 10, 14], ["cells", "CELL", 29, 34], ["Urine", "ORGANISM_SUBSTANCE", 58, 63], ["renal", "ORGAN", 119, 124], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 162, 173], ["albumin", "GENE_OR_GENE_PRODUCT", 174, 181], ["body", "ORGANISM_SUBDIVISION", 193, 197], ["splanchnic arterial", "MULTI-TISSUE_STRUCTURE", 352, 371], ["portal", "MULTI-TISSUE_STRUCTURE", 403, 409], ["Urine protein", "PROTEIN", 58, 71], ["Urine red cell excretion", "TEST", 0, 24], ["Urine protein excretion", "TEST", 58, 81], ["volume expansion", "TREATMENT", 140, 156], ["intravenous albumin", "TREATMENT", 162, 181], ["diuretics", "TREATMENT", 270, 279], ["Type I Hepatorenal Syndrome", "PROBLEM", 288, 315], ["splanchnic arterial vasodilation", "PROBLEM", 352, 384], ["portal hypertension", "PROBLEM", 403, 422], ["red cell", "OBSERVATION", 6, 14], ["excretion", "OBSERVATION_MODIFIER", 15, 24], ["high power", "OBSERVATION_MODIFIER", 39, 49], ["improvement", "OBSERVATION_MODIFIER", 104, 115], ["renal", "ANATOMY", 119, 124], ["function", "OBSERVATION", 125, 133], ["Hepatorenal Syndrome", "OBSERVATION", 295, 315], ["splanchnic", "ANATOMY_MODIFIER", 352, 362], ["arterial", "ANATOMY", 363, 371], ["vasodilation", "OBSERVATION", 372, 384], ["portal", "ANATOMY", 403, 409], ["hypertension", "OBSERVATION", 410, 422]]], ["This is thought to be mediated by increased production or activity of vasodilators such as nitric oxide, mainly in the splanchnic circulation.", [["splanchnic", "ANATOMY", 119, 129], ["nitric oxide", "CHEMICAL", 91, 103], ["nitric oxide", "CHEMICAL", 91, 103], ["nitric oxide", "SIMPLE_CHEMICAL", 91, 103], ["splanchnic circulation", "MULTI-TISSUE_STRUCTURE", 119, 141], ["increased production", "PROBLEM", 34, 54], ["activity of vasodilators", "TREATMENT", 58, 82], ["nitric oxide", "TREATMENT", 91, 103], ["thought to be", "UNCERTAINTY", 8, 21], ["increased", "OBSERVATION_MODIFIER", 34, 43], ["production", "OBSERVATION", 44, 54], ["splanchnic circulation", "ANATOMY", 119, 141]]], ["In patients with significant liver disease, the cardiac output increases and the systemic vascular resistance decreases despite activation of the renin-angiotensin and sympathetic nervous systems.", [["liver", "ANATOMY", 29, 34], ["cardiac", "ANATOMY", 48, 55], ["vascular", "ANATOMY", 90, 98], ["sympathetic nervous systems", "ANATOMY", 168, 195], ["liver disease", "DISEASE", 29, 42], ["angiotensin", "CHEMICAL", 152, 163], ["patients", "ORGANISM", 3, 11], ["liver", "ORGAN", 29, 34], ["cardiac", "ORGAN", 48, 55], ["vascular", "MULTI-TISSUE_STRUCTURE", 90, 98], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 146, 163], ["sympathetic nervous systems", "ANATOMICAL_SYSTEM", 168, 195], ["renin", "PROTEIN", 146, 151], ["patients", "SPECIES", 3, 11], ["significant liver disease", "PROBLEM", 17, 42], ["the cardiac output", "TEST", 44, 62], ["the systemic vascular resistance", "PROBLEM", 77, 109], ["the renin", "TEST", 142, 151], ["sympathetic nervous systems", "PROBLEM", 168, 195], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["liver", "ANATOMY", 29, 34], ["disease", "OBSERVATION", 35, 42], ["cardiac", "ANATOMY", 48, 55], ["output", "OBSERVATION_MODIFIER", 56, 62], ["increases", "OBSERVATION_MODIFIER", 63, 72], ["systemic", "OBSERVATION_MODIFIER", 81, 89], ["vascular resistance", "OBSERVATION", 90, 109], ["sympathetic nervous", "ANATOMY", 168, 187]]], ["The glomerular filtration rate and sodium excretion (usually <10 mEq/day in advanced cirrhosis) decline in this setting along with a fall in mean arterial pressure, despite the intense renal vasoconstriction.Answer: Type I Hepatorenal Syndrome (HRS)HRS is best considered a reversible form of renal dysfunction in patients with liver failure (cirrhosis or acute liver failure), and treatment aims at improving the vasodilation by using vasoconstrictors.", [["glomerular", "ANATOMY", 4, 14], ["arterial", "ANATOMY", 146, 154], ["renal", "ANATOMY", 185, 190], ["renal", "ANATOMY", 293, 298], ["liver", "ANATOMY", 328, 333], ["liver", "ANATOMY", 362, 367], ["sodium", "CHEMICAL", 35, 41], ["cirrhosis", "DISEASE", 85, 94], ["Type I Hepatorenal Syndrome", "DISEASE", 216, 243], ["HRS", "DISEASE", 245, 248], ["HRS", "DISEASE", 249, 252], ["renal dysfunction", "DISEASE", 293, 310], ["liver failure", "DISEASE", 328, 341], ["cirrhosis", "DISEASE", 343, 352], ["acute liver failure", "DISEASE", 356, 375], ["sodium", "CHEMICAL", 35, 41], ["glomerular", "TISSUE", 4, 14], ["sodium", "SIMPLE_CHEMICAL", 35, 41], ["arterial", "MULTI-TISSUE_STRUCTURE", 146, 154], ["renal", "ORGAN", 185, 190], ["renal", "ORGAN", 293, 298], ["patients", "ORGANISM", 314, 322], ["liver", "ORGAN", 328, 333], ["liver", "ORGAN", 362, 367], ["patients", "SPECIES", 314, 322], ["The glomerular filtration rate", "TEST", 0, 30], ["sodium excretion", "TEST", 35, 51], ["advanced cirrhosis", "PROBLEM", 76, 94], ["a fall", "PROBLEM", 131, 137], ["mean arterial pressure", "TEST", 141, 163], ["the intense renal vasoconstriction", "PROBLEM", 173, 207], ["Type I Hepatorenal Syndrome", "PROBLEM", 216, 243], ["renal dysfunction", "PROBLEM", 293, 310], ["liver failure", "PROBLEM", 328, 341], ["cirrhosis", "PROBLEM", 343, 352], ["acute liver failure", "PROBLEM", 356, 375], ["treatment", "TREATMENT", 382, 391], ["the vasodilation", "TREATMENT", 410, 426], ["vasoconstrictors", "TREATMENT", 436, 452], ["glomerular", "ANATOMY", 4, 14], ["filtration", "OBSERVATION", 15, 25], ["cirrhosis", "OBSERVATION", 85, 94], ["fall", "OBSERVATION", 133, 137], ["mean arterial pressure", "OBSERVATION", 141, 163], ["intense", "OBSERVATION_MODIFIER", 177, 184], ["renal", "ANATOMY", 185, 190], ["vasoconstriction", "OBSERVATION", 191, 207], ["Hepatorenal", "ANATOMY", 223, 234], ["Syndrome", "OBSERVATION", 235, 243], ["reversible", "OBSERVATION", 274, 284], ["renal", "ANATOMY", 293, 298], ["dysfunction", "OBSERVATION", 299, 310], ["liver", "ANATOMY", 328, 333], ["failure", "OBSERVATION", 334, 341], ["cirrhosis", "OBSERVATION", 343, 352], ["acute", "OBSERVATION_MODIFIER", 356, 361], ["liver", "ANATOMY", 362, 367], ["failure", "OBSERVATION", 368, 375]]], ["However, the underlying liver disease needs to be taken care of, and this usually means patients with type I HRS need urgent liver transplant evaluation as long as there are no other contraindications.Answer: Type I Hepatorenal Syndrome (HRS)In the United States, we would typically use a combination of octreotide and midodrine (with intravenous albumin) or norepinephrine as vasoconstrictors.", [["liver", "ANATOMY", 24, 29], ["liver", "ANATOMY", 125, 130], ["intravenous", "ANATOMY", 335, 346], ["liver disease", "DISEASE", 24, 37], ["HRS", "DISEASE", 109, 112], ["Type I Hepatorenal Syndrome", "DISEASE", 209, 236], ["HRS", "DISEASE", 238, 241], ["octreotide", "CHEMICAL", 304, 314], ["midodrine", "CHEMICAL", 319, 328], ["norepinephrine", "CHEMICAL", 359, 373], ["octreotide", "CHEMICAL", 304, 314], ["midodrine", "CHEMICAL", 319, 328], ["norepinephrine", "CHEMICAL", 359, 373], ["liver", "ORGAN", 24, 29], ["patients", "ORGANISM", 88, 96], ["liver", "ORGAN", 125, 130], ["octreotide", "SIMPLE_CHEMICAL", 304, 314], ["midodrine", "SIMPLE_CHEMICAL", 319, 328], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 335, 346], ["albumin", "SIMPLE_CHEMICAL", 347, 354], ["norepinephrine", "SIMPLE_CHEMICAL", 359, 373], ["patients", "SPECIES", 88, 96], ["the underlying liver disease", "PROBLEM", 9, 37], ["type I HRS", "PROBLEM", 102, 112], ["urgent liver transplant evaluation", "TEST", 118, 152], ["Type I Hepatorenal Syndrome", "PROBLEM", 209, 236], ["octreotide", "TREATMENT", 304, 314], ["midodrine", "TREATMENT", 319, 328], ["intravenous albumin", "TREATMENT", 335, 354], ["norepinephrine", "TREATMENT", 359, 373], ["vasoconstrictors", "TREATMENT", 377, 393], ["liver", "ANATOMY", 24, 29], ["disease", "OBSERVATION", 30, 37], ["liver", "ANATOMY", 125, 130], ["transplant", "OBSERVATION", 131, 141], ["no other", "UNCERTAINTY", 174, 182], ["Hepatorenal Syndrome", "OBSERVATION", 216, 236]]], ["In countries where it is unavailable, the potent vasoconstrictor terlipression is used as it demonstrates a survival benefit in HRS.Answer: Type I Hepatorenal Syndrome (HRS)In this patient, the prognosis is poor since his discriminant function is greater than 32.", [["HRS", "DISEASE", 128, 131], ["Type I Hepatorenal Syndrome", "DISEASE", 140, 167], ["HRS", "DISEASE", 169, 172], ["patient", "ORGANISM", 181, 188], ["patient", "SPECIES", 181, 188], ["the potent vasoconstrictor terlipression", "TREATMENT", 38, 78], ["Type I Hepatorenal Syndrome", "PROBLEM", 140, 167], ["his discriminant function", "TEST", 218, 243], ["Hepatorenal", "ANATOMY", 147, 158], ["Syndrome", "OBSERVATION", 159, 167]]], ["In addition, several studies have shown that the MELD score is also a good predictor of mortality in such patients, and his score is >40.Answer: Type I Hepatorenal Syndrome (HRS)The cause of death in patients with alcoholic hepatitis is usually renal failure, and studies have shown that pentoxifylline is beneficial in this situation.Answer: Type I Hepatorenal Syndrome (HRS)In this patient, after a trial of fluid, we would typically start him on pentoxifylline along with intravenous albumin.Case 50A 49-year-old female is admitted with a chief complaint of \"I wasn't feeling well\".", [["renal", "ANATOMY", 245, 250], ["intravenous", "ANATOMY", 475, 486], ["Type I Hepatorenal Syndrome", "DISEASE", 145, 172], ["HRS", "DISEASE", 174, 177], ["death", "DISEASE", 191, 196], ["alcoholic hepatitis", "DISEASE", 214, 233], ["renal failure", "DISEASE", 245, 258], ["pentoxifylline", "CHEMICAL", 288, 302], ["Type I Hepatorenal Syndrome", "DISEASE", 343, 370], ["HRS", "DISEASE", 372, 375], ["pentoxifylline", "CHEMICAL", 449, 463], ["pentoxifylline", "CHEMICAL", 288, 302], ["pentoxifylline", "CHEMICAL", 449, 463], ["patients", "ORGANISM", 106, 114], ["patients", "ORGANISM", 200, 208], ["renal", "ORGAN", 245, 250], ["pentoxifylline", "SIMPLE_CHEMICAL", 288, 302], ["patient", "ORGANISM", 384, 391], ["fluid", "ORGANISM_SUBSTANCE", 410, 415], ["pentoxifylline", "SIMPLE_CHEMICAL", 449, 463], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 475, 486], ["albumin", "GENE_OR_GENE_PRODUCT", 487, 494], ["female", "ORGANISM", 516, 522], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 200, 208], ["patient", "SPECIES", 384, 391], ["several studies", "TEST", 13, 28], ["the MELD score", "TEST", 45, 59], ["his score", "TEST", 120, 129], ["Type I Hepatorenal Syndrome", "PROBLEM", 145, 172], ["death", "PROBLEM", 191, 196], ["alcoholic hepatitis", "PROBLEM", 214, 233], ["renal failure", "PROBLEM", 245, 258], ["studies", "TEST", 264, 271], ["pentoxifylline", "TREATMENT", 288, 302], ["Type I Hepatorenal Syndrome", "PROBLEM", 343, 370], ["a trial of fluid", "TREATMENT", 399, 415], ["pentoxifylline", "TREATMENT", 449, 463], ["intravenous albumin", "TREATMENT", 475, 494], ["Hepatorenal Syndrome", "OBSERVATION", 152, 172], ["alcoholic hepatitis", "OBSERVATION", 214, 233], ["renal", "ANATOMY", 245, 250], ["failure", "OBSERVATION", 251, 258], ["Hepatorenal", "ANATOMY", 350, 361], ["Syndrome", "OBSERVATION", 362, 370]]], ["The patient states she was in her usual state of health until 5 days prior to admission when she began to develop severe fatigue.", [["fatigue", "DISEASE", 121, 128], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["severe fatigue", "PROBLEM", 114, 128], ["severe", "OBSERVATION_MODIFIER", 114, 120], ["fatigue", "OBSERVATION", 121, 128]]], ["The next day she began to develop nausea, bilious emesis, and darkening of her urine.", [["bilious", "ANATOMY", 42, 49], ["urine", "ANATOMY", 79, 84], ["nausea", "DISEASE", 34, 40], ["bilious emesis", "DISEASE", 42, 56], ["darkening of her urine", "DISEASE", 62, 84], ["urine", "ORGANISM_SUBSTANCE", 79, 84], ["nausea", "PROBLEM", 34, 40], ["bilious emesis", "PROBLEM", 42, 56], ["darkening of her urine", "PROBLEM", 62, 84], ["nausea", "OBSERVATION", 34, 40], ["bilious emesis", "OBSERVATION", 42, 56]]], ["The patient thought she had the flu and continued to work.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["the flu", "PROBLEM", 28, 35]]], ["Over the next two days, she began to develop right upper quadrant pain, anorexia, chills, and light headedness and finally presented to her local emergency room.", [["right upper quadrant", "ANATOMY", 45, 65], ["right upper quadrant pain", "DISEASE", 45, 70], ["anorexia", "DISEASE", 72, 80], ["chills", "DISEASE", 82, 88], ["upper quadrant", "ORGANISM_SUBDIVISION", 51, 65], ["right upper quadrant pain", "PROBLEM", 45, 70], ["anorexia", "PROBLEM", 72, 80], ["chills", "PROBLEM", 82, 88], ["light headedness", "PROBLEM", 94, 110], ["right", "ANATOMY_MODIFIER", 45, 50], ["upper", "ANATOMY_MODIFIER", 51, 56], ["quadrant", "ANATOMY", 57, 65], ["pain", "OBSERVATION", 66, 70], ["anorexia", "OBSERVATION", 72, 80], ["chills", "OBSERVATION", 82, 88]]], ["She has a past medical history significant only for endometriosis.", [["endometriosis", "ANATOMY", 52, 65], ["endometriosis", "DISEASE", 52, 65], ["endometriosis", "PATHOLOGICAL_FORMATION", 52, 65], ["endometriosis", "PROBLEM", 52, 65], ["endometriosis", "OBSERVATION", 52, 65]]], ["Over the last several days, she did take a few tablets of acetaminophen and ibuprofen, but otherwise takes no prescription medications, herbals nor has she had any recent antibiotic exposure.", [["acetaminophen", "CHEMICAL", 58, 71], ["ibuprofen", "CHEMICAL", 76, 85], ["acetaminophen", "CHEMICAL", 58, 71], ["ibuprofen", "CHEMICAL", 76, 85], ["acetaminophen", "SIMPLE_CHEMICAL", 58, 71], ["ibuprofen", "SIMPLE_CHEMICAL", 76, 85], ["acetaminophen", "TREATMENT", 58, 71], ["ibuprofen", "TREATMENT", 76, 85], ["prescription medications", "TREATMENT", 110, 134], ["herbals", "TREATMENT", 136, 143]]], ["The patient lives with her husband of 25 years and their 15-year-old son.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["She has one tattoo which she obtained over 25 years ago.", [["tattoo", "OBSERVATION", 12, 18]]], ["She has no habits, and there has been no recent travel.", [["no", "UNCERTAINTY", 8, 10], ["no", "UNCERTAINTY", 38, 40]]], ["The patient's father died at the age of 69 of a pulmonary embolism following an open cholecystectomy.Case 50The patient's husband is being followed in the liver clinic for chronic hepatitis B which was diagnosed over 15 years ago.", [["pulmonary", "ANATOMY", 48, 57], ["liver", "ANATOMY", 155, 160], ["pulmonary embolism", "DISEASE", 48, 66], ["chronic hepatitis B", "DISEASE", 172, 191], ["patient", "ORGANISM", 4, 11], ["father", "ORGANISM", 14, 20], ["pulmonary", "ORGAN", 48, 57], ["patient", "ORGANISM", 112, 119], ["liver", "ORGAN", 155, 160], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 112, 119], ["a pulmonary embolism", "PROBLEM", 46, 66], ["an open cholecystectomy", "TREATMENT", 77, 100], ["chronic hepatitis B", "PROBLEM", 172, 191], ["pulmonary", "ANATOMY", 48, 57], ["embolism", "OBSERVATION", 58, 66], ["open", "OBSERVATION_MODIFIER", 80, 84], ["cholecystectomy", "OBSERVATION", 85, 100], ["liver", "ANATOMY", 155, 160], ["chronic", "OBSERVATION_MODIFIER", 172, 179], ["hepatitis", "OBSERVATION", 180, 189]]], ["He underwent a liver biopsy 3 years ago which revealed 1/6 fibrosis and minimal disease activity.", [["liver", "ANATOMY", 15, 20], ["fibrosis", "DISEASE", 59, 67], ["liver", "ORGAN", 15, 20], ["a liver biopsy", "TEST", 13, 27], ["1/6 fibrosis", "PROBLEM", 55, 67], ["minimal disease activity", "PROBLEM", 72, 96], ["liver", "ANATOMY", 15, 20], ["biopsy", "OBSERVATION", 21, 27], ["1/6", "OBSERVATION_MODIFIER", 55, 58], ["fibrosis", "OBSERVATION", 59, 67], ["minimal", "OBSERVATION_MODIFIER", 72, 79], ["disease", "OBSERVATION", 80, 87], ["activity", "OBSERVATION_MODIFIER", 88, 96]]], ["The patient was seen in the liver clinic 1 year ago and was a symptomatic; however, his AST and ALT were 64 and 140 respectively.", [["liver", "ANATOMY", 28, 33], ["patient", "ORGANISM", 4, 11], ["liver", "ORGAN", 28, 33], ["AST", "PROTEIN", 88, 91], ["patient", "SPECIES", 4, 11], ["a symptomatic", "PROBLEM", 60, 73], ["his AST", "TEST", 84, 91], ["ALT", "TEST", 96, 99], ["liver", "ANATOMY", 28, 33], ["symptomatic", "OBSERVATION", 62, 73], ["ALT", "ANATOMY", 96, 99]]], ["He was HBsAg +, sAb \u2212, core total +, eAg negative, and eAb +.", [["HBsAg", "CHEMICAL", 7, 12], ["He", "ORGANISM", 0, 2], ["HBsAg", "GENE_OR_GENE_PRODUCT", 7, 12], ["sAb", "GENE_OR_GENE_PRODUCT", 16, 19], ["eAg", "GENE_OR_GENE_PRODUCT", 37, 40], ["eAb +", "SIMPLE_CHEMICAL", 55, 60], ["HBsAg", "PROTEIN", 7, 12], ["sAb", "PROTEIN", 16, 19], ["eAb", "PROTEIN", 55, 58], ["HBsAg", "TEST", 7, 12], ["sAb", "TEST", 16, 19], ["core total", "TEST", 23, 33], ["eAg", "TEST", 37, 40]]], ["His viral load was 350,000 iu/ml and was being maintained on 10 mg of adefovir.", [["adefovir", "CHEMICAL", 70, 78], ["adefovir", "CHEMICAL", 70, 78], ["adefovir", "SIMPLE_CHEMICAL", 70, 78], ["His viral load", "TEST", 0, 14], ["adefovir", "TREATMENT", 70, 78], ["viral load", "OBSERVATION", 4, 14]]], ["Within the last 2 months, because of a lack of finances, the patient stopped taking his medication.", [["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["his medication", "TREATMENT", 84, 98]]], ["He was last seen about 6 weeks ago complaining of fatigue.", [["fatigue", "DISEASE", 50, 57], ["fatigue", "PROBLEM", 50, 57], ["fatigue", "OBSERVATION", 50, 57]]], ["His lab work showed ALT 156 and ALT 320, and his DNA was 11,360,000 iu/ml.", [["DNA", "CELLULAR_COMPONENT", 49, 52], ["His lab work", "TEST", 0, 12], ["ALT", "TEST", 20, 23], ["ALT", "TEST", 32, 35], ["his DNA", "TEST", 45, 52]]], ["A resistance panel was performed, revealing the presence of a precore tag mutation.", [["precore tag mutation", "DNA", 62, 82], ["A resistance panel", "TEST", 0, 18], ["a precore tag mutation", "PROBLEM", 60, 82]]], ["The patient was restarted on adefovir 10 mg in addition to 100 mg of lamivudine.Case 50On physical exam, the patient was febrile at 100.5\u00b0F with a heart rate of 90 and blood pressure of 100/50.", [["heart", "ANATOMY", 147, 152], ["blood", "ANATOMY", 168, 173], ["adefovir", "CHEMICAL", 29, 37], ["lamivudine", "CHEMICAL", 69, 79], ["febrile", "DISEASE", 121, 128], ["adefovir", "CHEMICAL", 29, 37], ["lamivudine", "CHEMICAL", 69, 79], ["patient", "ORGANISM", 4, 11], ["adefovir", "SIMPLE_CHEMICAL", 29, 37], ["lamivudine", "SIMPLE_CHEMICAL", 69, 79], ["patient", "ORGANISM", 109, 116], ["heart", "ORGAN", 147, 152], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 109, 116], ["adefovir", "TREATMENT", 29, 37], ["lamivudine", "TREATMENT", 69, 79], ["physical exam", "TEST", 90, 103], ["febrile", "PROBLEM", 121, 128], ["a heart rate", "TEST", 145, 157], ["blood pressure", "TEST", 168, 182], ["heart", "ANATOMY", 147, 152]]], ["She was lethargic and confused with asterixis.", [["asterixis", "DISEASE", 36, 45], ["lethargic", "PROBLEM", 8, 17], ["confused", "PROBLEM", 22, 30], ["asterixis", "PROBLEM", 36, 45], ["asterixis", "OBSERVATION", 36, 45]]], ["She was jaundiced with scleral icterus.", [["scleral", "ANATOMY", 23, 30], ["scleral icterus", "DISEASE", 23, 38], ["jaundiced", "PROBLEM", 8, 17], ["scleral icterus", "PROBLEM", 23, 38], ["jaundiced", "OBSERVATION", 8, 17], ["scleral", "ANATOMY", 23, 30], ["icterus", "OBSERVATION", 31, 38]]], ["Cardiac and lung exam were normal.", [["Cardiac", "ANATOMY", 0, 7], ["lung", "ANATOMY", 12, 16], ["Cardiac", "ORGAN", 0, 7], ["lung", "ORGAN", 12, 16], ["Cardiac and lung exam", "TEST", 0, 21], ["lung", "ANATOMY", 12, 16], ["normal", "OBSERVATION", 27, 33]]], ["Abdomen was flat with hypoactive bowel sounds.", [["bowel", "ANATOMY", 33, 38], ["bowel", "ORGAN", 33, 38], ["flat", "OBSERVATION", 12, 16], ["hypoactive", "OBSERVATION", 22, 32], ["bowel", "ANATOMY", 33, 38], ["sounds", "OBSERVATION", 39, 45]]], ["She was very tender in her right upper quadrant.", [["right upper quadrant", "ANATOMY", 27, 47], ["upper quadrant", "ORGANISM_SUBDIVISION", 33, 47], ["very tender in her right upper quadrant", "PROBLEM", 8, 47], ["very", "OBSERVATION_MODIFIER", 8, 12], ["tender", "OBSERVATION", 13, 19], ["right", "ANATOMY_MODIFIER", 27, 32], ["upper", "ANATOMY_MODIFIER", 33, 38], ["quadrant", "ANATOMY", 39, 47]]], ["There was no evidence of hepatosplenomegaly.", [["hepatosplenomegaly", "DISEASE", 25, 43], ["hepatosplenomegaly", "PROBLEM", 25, 43], ["no evidence of", "UNCERTAINTY", 10, 24], ["hepatosplenomegaly", "OBSERVATION", 25, 43]]], ["Extremities were without clubbing cyanosis or edema.", [["edema", "ANATOMY", 46, 51], ["Extremities", "DISEASE", 0, 11], ["clubbing cyanosis", "DISEASE", 25, 42], ["edema", "DISEASE", 46, 51], ["edema", "PATHOLOGICAL_FORMATION", 46, 51], ["clubbing cyanosis", "PROBLEM", 25, 42], ["edema", "PROBLEM", 46, 51], ["without", "UNCERTAINTY", 17, 24], ["clubbing", "OBSERVATION", 25, 33], ["edema", "OBSERVATION", 46, 51]]], ["There were no stigmata to suggest chronic liver disease.Answer: Acute Liver Failure Secondary to Acute De Novo Hepatitis B VirusThe patient fulfills criteria for acute liver failure (ALF): the onset of coagulopathy and encephalopathy in a previous healthy individual.", [["liver", "ANATOMY", 42, 47], ["Liver", "ANATOMY", 70, 75], ["liver", "ANATOMY", 168, 173], ["chronic liver disease", "DISEASE", 34, 55], ["Liver Failure", "DISEASE", 70, 83], ["Hepatitis B Virus", "DISEASE", 111, 128], ["acute liver failure", "DISEASE", 162, 181], ["ALF", "DISEASE", 183, 186], ["coagulopathy", "DISEASE", 202, 214], ["encephalopathy", "DISEASE", 219, 233], ["liver", "ORGAN", 42, 47], ["Liver", "ORGAN", 70, 75], ["De Novo Hepatitis B Virus", "ORGANISM", 103, 128], ["patient", "ORGANISM", 132, 139], ["liver", "ORGAN", 168, 173], ["patient", "SPECIES", 132, 139], ["stigmata", "PROBLEM", 14, 22], ["chronic liver disease", "PROBLEM", 34, 55], ["Acute Liver Failure", "PROBLEM", 64, 83], ["Acute De Novo Hepatitis B Virus", "PROBLEM", 97, 128], ["acute liver failure", "PROBLEM", 162, 181], ["coagulopathy", "PROBLEM", 202, 214], ["encephalopathy", "PROBLEM", 219, 233], ["no stigmata to suggest", "UNCERTAINTY", 11, 33], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["liver", "ANATOMY", 42, 47], ["disease", "OBSERVATION", 48, 55], ["Acute", "OBSERVATION_MODIFIER", 64, 69], ["Liver", "ANATOMY", 70, 75], ["Failure", "OBSERVATION", 76, 83], ["Acute", "OBSERVATION_MODIFIER", 97, 102], ["Novo Hepatitis", "OBSERVATION", 106, 120], ["acute", "OBSERVATION_MODIFIER", 162, 167], ["liver", "ANATOMY", 168, 173], ["failure", "OBSERVATION", 174, 181], ["coagulopathy", "OBSERVATION", 202, 214], ["encephalopathy", "OBSERVATION", 219, 233]]], ["An important point for clinicians to realize is that although many patients with ALF will have elevated bilirubin levels, jaundice is not included in the formal definition.", [["ALF", "DISEASE", 81, 84], ["bilirubin", "CHEMICAL", 104, 113], ["jaundice", "DISEASE", 122, 130], ["ALF", "CHEMICAL", 81, 84], ["bilirubin", "CHEMICAL", 104, 113], ["patients", "ORGANISM", 67, 75], ["bilirubin", "GENE_OR_GENE_PRODUCT", 104, 113], ["patients", "SPECIES", 67, 75], ["elevated bilirubin levels", "PROBLEM", 95, 120], ["jaundice", "PROBLEM", 122, 130], ["jaundice", "OBSERVATION", 122, 130]]], ["ALF is a rare condition with only approximately 2,000 cases per year in the United States.", [["ALF", "DISEASE", 0, 3], ["ALF", "CHEMICAL", 0, 3]]], ["The most common cause of ALF in the US is acetaminophen toxicity.", [["ALF", "DISEASE", 25, 28], ["acetaminophen", "CHEMICAL", 42, 55], ["toxicity", "DISEASE", 56, 64], ["ALF", "CHEMICAL", 25, 28], ["acetaminophen", "CHEMICAL", 42, 55], ["ALF", "CANCER", 25, 28], ["acetaminophen", "SIMPLE_CHEMICAL", 42, 55], ["ALF", "PROBLEM", 25, 28], ["acetaminophen toxicity", "PROBLEM", 42, 64], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["ALF", "OBSERVATION", 25, 28], ["acetaminophen toxicity", "OBSERVATION", 42, 64]]], ["ALF secondary to HBV develops in less than one percent of patients infected with the virus.", [["ALF", "DISEASE", 0, 3], ["ALF", "CHEMICAL", 0, 3], ["HBV", "ORGANISM", 17, 20], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["HBV", "SPECIES", 17, 20], ["ALF", "PROBLEM", 0, 3], ["HBV", "PROBLEM", 17, 20], ["the virus", "PROBLEM", 81, 90], ["HBV", "OBSERVATION", 17, 20], ["infected", "OBSERVATION", 67, 75], ["virus", "OBSERVATION", 85, 90]]], ["Without liver transplantation, the fatality rate in patients with ALF from HBV is 93%.", [["liver", "ANATOMY", 8, 13], ["ALF", "DISEASE", 66, 69], ["ALF", "CHEMICAL", 66, 69], ["liver", "ORGAN", 8, 13], ["patients", "ORGANISM", 52, 60], ["HBV", "ORGANISM", 75, 78], ["patients", "SPECIES", 52, 60], ["HBV", "SPECIES", 75, 78], ["liver transplantation", "TREATMENT", 8, 29], ["the fatality rate", "TEST", 31, 48], ["ALF", "PROBLEM", 66, 69], ["HBV", "PROBLEM", 75, 78], ["liver", "ANATOMY", 8, 13], ["transplantation", "OBSERVATION", 14, 29], ["HBV", "OBSERVATION", 75, 78]]], ["There are approximately 50 cases of ALF due to hepatitis B Virus (HBV) in the US each year.", [["ALF", "DISEASE", 36, 39], ["hepatitis B Virus", "DISEASE", 47, 64], ["ALF", "CHEMICAL", 36, 39], ["ALF", "CANCER", 36, 39], ["hepatitis B Virus", "ORGANISM", 47, 64], ["HBV", "ORGANISM", 66, 69], ["hepatitis B Virus", "SPECIES", 47, 64], ["hepatitis B Virus", "SPECIES", 47, 64], ["HBV", "SPECIES", 66, 69], ["ALF", "TREATMENT", 36, 39], ["hepatitis B Virus", "PROBLEM", 47, 64]]], ["If detected in time, transplantation can be live-saving, with a 1 year survival of approximately 85%.Answer: Acute Liver Failure Secondary to Acute De Novo Hepatitis B VirusThe injury in patients with severe hepatitis B infection is a consequence of the patient's violent immune response.", [["Liver", "ANATOMY", 115, 120], ["Liver Failure", "DISEASE", 115, 128], ["Hepatitis B", "DISEASE", 156, 167], ["hepatitis B infection", "DISEASE", 208, 229], ["Liver", "ORGAN", 115, 120], ["Hepatitis B Virus", "ORGANISM", 156, 173], ["patients", "ORGANISM", 187, 195], ["hepatitis B", "ORGANISM", 208, 219], ["patient", "ORGANISM", 254, 261], ["patients", "SPECIES", 187, 195], ["patient", "SPECIES", 254, 261], ["hepatitis B", "SPECIES", 208, 219], ["transplantation", "TREATMENT", 21, 36], ["Acute Liver Failure", "PROBLEM", 109, 128], ["Acute De Novo Hepatitis B Virus", "PROBLEM", 142, 173], ["The injury", "PROBLEM", 173, 183], ["severe hepatitis B infection", "PROBLEM", 201, 229], ["Acute", "OBSERVATION_MODIFIER", 109, 114], ["Liver", "ANATOMY", 115, 120], ["Failure", "OBSERVATION", 121, 128], ["Acute", "OBSERVATION_MODIFIER", 142, 147], ["Novo Hepatitis", "OBSERVATION", 151, 165], ["injury", "OBSERVATION", 177, 183], ["severe", "OBSERVATION_MODIFIER", 201, 207], ["hepatitis", "OBSERVATION", 208, 217], ["infection", "OBSERVATION", 220, 229]]], ["The patient's viral serologies in this case provide a unique but telling tale into this immune response.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["The patient's viral serologies", "TEST", 0, 30]]], ["It was during the process of fighting the infection and producing antibodies to the HBV that the patient became acutely ill.", [["infection", "DISEASE", 42, 51], ["acutely ill", "DISEASE", 112, 123], ["HBV", "ORGANISM", 84, 87], ["patient", "ORGANISM", 97, 104], ["antibodies", "PROTEIN", 66, 76], ["patient", "SPECIES", 97, 104], ["HBV", "SPECIES", 84, 87], ["the infection", "PROBLEM", 38, 51], ["the HBV", "PROBLEM", 80, 87], ["acutely ill", "PROBLEM", 112, 123], ["infection", "OBSERVATION", 42, 51], ["ill", "OBSERVATION", 120, 123]]], ["Unfortunately, the reaction and liver injury in this case was too far advanced for the patient to recover from.", [["liver", "ANATOMY", 32, 37], ["liver injury", "DISEASE", 32, 44], ["liver", "ORGAN", 32, 37], ["patient", "ORGANISM", 87, 94], ["patient", "SPECIES", 87, 94], ["the reaction", "PROBLEM", 15, 27], ["liver injury", "PROBLEM", 32, 44], ["liver", "ANATOMY", 32, 37], ["injury", "OBSERVATION", 38, 44]]], ["Antivirals would not reverse and would likely not stabilize the acute injury in this case.", [["Antivirals", "TREATMENT", 0, 10], ["the acute injury", "PROBLEM", 60, 76], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["injury", "OBSERVATION", 70, 76]]], ["An argument could be made to administer antivirals to decrease the patient's viral load pre LT in the hopes of decreasing the incidence of recurrent HBV post transplant.Answer: Acute Liver Failure Secondary to Acute De Novo Hepatitis B VirusAlthough the decision tree in patients with ALF secondary to HBV is somewhat easier given the high mortality, knowing when to \"pull the plug\" on a patient with ALF and send them for LT can be a difficult decision.", [["Liver", "ANATOMY", 183, 188], ["Liver Failure", "DISEASE", 183, 196], ["Hepatitis B", "DISEASE", 224, 235], ["ALF", "DISEASE", 285, 288], ["ALF", "DISEASE", 401, 404], ["ALF", "CHEMICAL", 285, 288], ["patient", "ORGANISM", 67, 74], ["HBV", "ORGANISM", 149, 152], ["Liver", "ORGAN", 183, 188], ["patients", "ORGANISM", 271, 279], ["HBV", "ORGANISM", 302, 305], ["patient", "ORGANISM", 388, 395], ["patient", "SPECIES", 67, 74], ["patients", "SPECIES", 271, 279], ["patient", "SPECIES", 388, 395], ["HBV", "SPECIES", 149, 152], ["HBV", "SPECIES", 302, 305], ["antivirals", "TREATMENT", 40, 50], ["the patient's viral load pre LT", "TREATMENT", 63, 94], ["recurrent HBV", "PROBLEM", 139, 152], ["transplant", "TREATMENT", 158, 168], ["Acute Liver Failure", "PROBLEM", 177, 196], ["Acute De Novo Hepatitis B VirusAlthough", "PROBLEM", 210, 249], ["ALF", "TREATMENT", 285, 288], ["HBV", "PROBLEM", 302, 305], ["ALF", "TREATMENT", 401, 404], ["recurrent", "OBSERVATION_MODIFIER", 139, 148], ["HBV", "OBSERVATION", 149, 152], ["transplant", "OBSERVATION", 158, 168], ["Acute", "OBSERVATION_MODIFIER", 177, 182], ["Liver", "ANATOMY", 183, 188], ["Failure", "OBSERVATION", 189, 196], ["Acute", "OBSERVATION_MODIFIER", 210, 215], ["Hepatitis", "OBSERVATION", 224, 233], ["HBV", "OBSERVATION", 302, 305]]], ["The clinician must weigh the chances of the patient's spontaneous recovery with the chances of progressive deterioration and multisystem organ failure.", [["organ", "ANATOMY", 137, 142], ["multisystem organ failure", "DISEASE", 125, 150], ["patient", "ORGANISM", 44, 51], ["organ", "ORGAN", 137, 142], ["patient", "SPECIES", 44, 51], ["progressive deterioration", "PROBLEM", 95, 120], ["multisystem organ failure", "PROBLEM", 125, 150], ["progressive", "OBSERVATION_MODIFIER", 95, 106], ["deterioration", "OBSERVATION", 107, 120], ["multisystem organ failure", "OBSERVATION", 125, 150]]], ["Many prognostic models have been proposed to help in this decision-making process.Answer: Acute Liver Failure Secondary to Acute De Novo Hepatitis B VirusTo the untrained eye, the precipitous fall in the patient's enzyme in the case above may be viewed as an improvement; however, in conjunction with the worsening coagulopathy, this is actually a sign of impending doom and is a consequence submassive hepatocellular necrosis.", [["Liver", "ANATOMY", 96, 101], ["eye", "ANATOMY", 171, 174], ["hepatocellular", "ANATOMY", 403, 417], ["Liver Failure", "DISEASE", 96, 109], ["Hepatitis B", "DISEASE", 137, 148], ["coagulopathy", "DISEASE", 315, 327], ["necrosis", "DISEASE", 418, 426], ["Liver", "ORGAN", 96, 101], ["Hepatitis B Virus", "ORGANISM", 137, 154], ["eye", "ORGAN", 171, 174], ["patient", "ORGANISM", 204, 211], ["hepatocellular", "CANCER", 403, 417], ["patient", "SPECIES", 204, 211], ["Acute Liver Failure", "PROBLEM", 90, 109], ["Acute De Novo Hepatitis B Virus", "PROBLEM", 123, 154], ["the precipitous fall", "PROBLEM", 176, 196], ["the patient's enzyme", "TEST", 200, 220], ["the worsening coagulopathy", "PROBLEM", 301, 327], ["impending doom", "PROBLEM", 356, 370], ["a consequence submassive hepatocellular necrosis", "PROBLEM", 378, 426], ["Acute", "OBSERVATION_MODIFIER", 90, 95], ["Liver", "ANATOMY", 96, 101], ["Failure", "OBSERVATION", 102, 109], ["Acute", "OBSERVATION_MODIFIER", 123, 128], ["Novo Hepatitis", "OBSERVATION", 132, 146], ["eye", "ANATOMY", 171, 174], ["precipitous", "OBSERVATION_MODIFIER", 180, 191], ["fall", "OBSERVATION", 192, 196], ["improvement", "OBSERVATION", 259, 270], ["worsening", "OBSERVATION_MODIFIER", 305, 314], ["coagulopathy", "OBSERVATION", 315, 327], ["submassive", "OBSERVATION_MODIFIER", 392, 402], ["hepatocellular", "ANATOMY", 403, 417], ["necrosis", "OBSERVATION", 418, 426]]], ["The gross pathology (Fig. 50.1 ) of the patients explant reveals a \"shriveled\" liver weighing only 525 g (normal weight of a female adult liver 1,200-1,400 g).", [["liver", "ANATOMY", 79, 84], ["liver", "ANATOMY", 138, 143], ["patients", "ORGANISM", 40, 48], ["liver", "ORGAN", 79, 84], ["liver", "ORGAN", 138, 143], ["patients", "SPECIES", 40, 48], ["The gross pathology", "TEST", 0, 19], ["gross", "OBSERVATION_MODIFIER", 4, 9], ["pathology", "OBSERVATION", 10, 19], ["liver", "ANATOMY", 79, 84], ["liver", "ANATOMY", 138, 143]]], ["Histology (Fig. 50.", [["Histology", "TEST", 0, 9]]], ["2) reveals lobular necrosis with hemorrhage involving over 90% of the liver.", [["lobular", "ANATOMY", 11, 18], ["liver", "ANATOMY", 70, 75], ["necrosis", "DISEASE", 19, 27], ["hemorrhage", "DISEASE", 33, 43], ["lobular necrosis", "CANCER", 11, 27], ["liver", "ORGAN", 70, 75], ["lobular necrosis", "PROBLEM", 11, 27], ["hemorrhage", "PROBLEM", 33, 43], ["lobular", "OBSERVATION_MODIFIER", 11, 18], ["necrosis", "OBSERVATION", 19, 27], ["hemorrhage", "OBSERVATION", 33, 43], ["liver", "ANATOMY", 70, 75]]], ["Almost no hepatocytes are recognized.Answer: Acute Liver Failure Secondary to Acute De Novo Hepatitis B VirusThe patient's husband in this case had an acute \"flare\" in his disease off of antiviral medications.", [["hepatocytes", "ANATOMY", 10, 21], ["Liver", "ANATOMY", 51, 56], ["Liver Failure", "DISEASE", 51, 64], ["Hepatitis B", "DISEASE", 92, 103], ["hepatocytes", "CELL", 10, 21], ["Liver", "ORGAN", 51, 56], ["De Novo Hepatitis B Virus", "ORGANISM", 84, 109], ["patient", "ORGANISM", 113, 120], ["hepatocytes", "CELL_TYPE", 10, 21], ["Hepatitis B Virus", "SPECIES", 92, 109], ["patient", "SPECIES", 113, 120], ["hepatocytes", "PROBLEM", 10, 21], ["Acute Liver Failure", "PROBLEM", 45, 64], ["Acute De Novo Hepatitis B Virus", "PROBLEM", 78, 109], ["an acute \"flare", "PROBLEM", 148, 163], ["his disease", "PROBLEM", 168, 179], ["antiviral medications", "TREATMENT", 187, 208], ["hepatocytes", "OBSERVATION", 10, 21], ["Acute", "OBSERVATION_MODIFIER", 45, 50], ["Liver", "ANATOMY", 51, 56], ["Failure", "OBSERVATION", 57, 64], ["Acute", "OBSERVATION_MODIFIER", 78, 83], ["Novo Hepatitis", "OBSERVATION", 87, 101], ["acute", "OBSERVATION_MODIFIER", 151, 156], ["flare", "OBSERVATION", 158, 163]]], ["The patient and her husband did have relations during this period.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Transmission of HBV among adults is predominantly through sexual contact.", [["HBV", "ORGANISM", 16, 19], ["HBV", "SPECIES", 16, 19], ["HBV", "OBSERVATION", 16, 19]]], ["HBV is a preventable disease, and all adults with potential exposure risk should be offered vaccination.Case 51A 55-year-old lady presents for elective outpatient endoscopy.", [["HBV", "ORGANISM", 0, 3], ["adults", "ORGANISM", 38, 44], ["HBV", "SPECIES", 0, 3], ["HBV", "PROBLEM", 0, 3], ["a preventable disease", "PROBLEM", 7, 28], ["elective outpatient endoscopy", "TEST", 143, 172], ["preventable", "OBSERVATION_MODIFIER", 9, 20], ["disease", "OBSERVATION", 21, 28]]], ["She has a history of alcoholic cirrhosis that has been complicated by variceal bleeding 2 months ago when she was first diagnosed with liver disease.", [["variceal", "ANATOMY", 70, 78], ["liver", "ANATOMY", 135, 140], ["alcoholic cirrhosis", "DISEASE", 21, 40], ["variceal bleeding", "DISEASE", 70, 87], ["liver disease", "DISEASE", 135, 148], ["liver", "ORGAN", 135, 140], ["alcoholic cirrhosis", "PROBLEM", 21, 40], ["variceal bleeding", "PROBLEM", 70, 87], ["liver disease", "PROBLEM", 135, 148], ["alcoholic", "OBSERVATION_MODIFIER", 21, 30], ["cirrhosis", "OBSERVATION", 31, 40], ["variceal", "OBSERVATION_MODIFIER", 70, 78], ["bleeding", "OBSERVATION", 79, 87], ["liver", "ANATOMY", 135, 140], ["disease", "OBSERVATION", 141, 148]]], ["She underwent band ligation.", [["band ligation", "TREATMENT", 14, 27], ["band ligation", "OBSERVATION", 14, 27]]], ["She developed encephalopathy while she was hospitalized with the bleeding but this is well controlled on lactulose.", [["encephalopathy", "DISEASE", 14, 28], ["bleeding", "DISEASE", 65, 73], ["lactulose", "CHEMICAL", 105, 114], ["lactulose", "CHEMICAL", 105, 114], ["lactulose", "SIMPLE_CHEMICAL", 105, 114], ["encephalopathy", "PROBLEM", 14, 28], ["the bleeding", "PROBLEM", 61, 73], ["lactulose", "TREATMENT", 105, 114], ["encephalopathy", "OBSERVATION", 14, 28], ["bleeding", "OBSERVATION", 65, 73]]], ["She has required a small dose of diuretics for ankle edema but has noticed some improvement in her overall condition with abstinence from alcohol.Case 51She has no other medical problems.Case 51Medications include nadolol, lactulose, furosemide, and aldactone.", [["ankle edema", "ANATOMY", 47, 58], ["edema", "DISEASE", 53, 58], ["alcohol", "CHEMICAL", 138, 145], ["nadolol", "CHEMICAL", 214, 221], ["lactulose", "CHEMICAL", 223, 232], ["furosemide", "CHEMICAL", 234, 244], ["aldactone", "CHEMICAL", 250, 259], ["alcohol", "CHEMICAL", 138, 145], ["nadolol", "CHEMICAL", 214, 221], ["lactulose", "CHEMICAL", 223, 232], ["furosemide", "CHEMICAL", 234, 244], ["aldactone", "CHEMICAL", 250, 259], ["ankle edema", "PATHOLOGICAL_FORMATION", 47, 58], ["alcohol", "SIMPLE_CHEMICAL", 138, 145], ["nadolol", "SIMPLE_CHEMICAL", 214, 221], ["lactulose", "SIMPLE_CHEMICAL", 223, 232], ["furosemide", "SIMPLE_CHEMICAL", 234, 244], ["aldactone", "SIMPLE_CHEMICAL", 250, 259], ["a small dose of diuretics", "TREATMENT", 17, 42], ["ankle edema", "PROBLEM", 47, 58], ["other medical problems", "PROBLEM", 164, 186], ["nadolol", "TREATMENT", 214, 221], ["lactulose", "TREATMENT", 223, 232], ["furosemide", "TREATMENT", 234, 244], ["aldactone", "TREATMENT", 250, 259], ["ankle", "ANATOMY", 47, 52], ["edema", "OBSERVATION", 53, 58], ["improvement", "OBSERVATION_MODIFIER", 80, 91], ["no", "UNCERTAINTY", 161, 163]]], ["She is also taking a multivitamin and folate.Case 51She is divorced and has no children.", [["multivitamin", "CHEMICAL", 21, 33], ["folate", "CHEMICAL", 38, 44], ["multivitamin", "CHEMICAL", 21, 33], ["folate", "CHEMICAL", 38, 44], ["multivitamin", "SIMPLE_CHEMICAL", 21, 33], ["folate", "SIMPLE_CHEMICAL", 38, 44], ["children", "ORGANISM", 79, 87], ["children", "SPECIES", 79, 87], ["a multivitamin and folate", "TREATMENT", 19, 44]]], ["She has a strong family history of alcoholism.", [["alcoholism", "DISEASE", 35, 45], ["alcoholism", "PROBLEM", 35, 45], ["alcoholism", "OBSERVATION", 35, 45]]], ["Her review of systems is significant for fatigue but is otherwise negative.", [["fatigue", "DISEASE", 41, 48], ["Her review of systems", "TEST", 0, 21], ["fatigue", "PROBLEM", 41, 48], ["negative", "OBSERVATION", 66, 74]]], ["On exam she looks well and is alert and oriented.", [["exam", "TEST", 3, 7]]], ["Vital signs show BP 105/65, pulse 58, and she is afebrile.", [["Vital signs", "TEST", 0, 11], ["BP", "TEST", 17, 19], ["pulse", "TEST", 28, 33], ["afebrile", "PROBLEM", 49, 57]]], ["There is mild scleral icterus and multiple spider nevi.", [["scleral icterus", "ANATOMY", 14, 29], ["nevi", "ANATOMY", 50, 54], ["icterus", "DISEASE", 22, 29], ["spider nevi", "DISEASE", 43, 54], ["mild scleral icterus", "PROBLEM", 9, 29], ["multiple spider nevi", "PROBLEM", 34, 54], ["mild", "OBSERVATION_MODIFIER", 9, 13], ["scleral", "ANATOMY", 14, 21], ["icterus", "OBSERVATION", 22, 29], ["multiple", "OBSERVATION_MODIFIER", 34, 42], ["spider nevi", "OBSERVATION", 43, 54]]], ["Heart reveals normal S1 and S2 without added sounds.", [["Heart", "ANATOMY", 0, 5], ["Heart", "ORGAN", 0, 5], ["S2", "PROTEIN", 28, 30], ["added sounds", "PROBLEM", 39, 51], ["normal", "OBSERVATION", 14, 20], ["S1", "ANATOMY", 21, 23], ["S2", "ANATOMY", 28, 30], ["without", "UNCERTAINTY", 31, 38], ["added", "OBSERVATION_MODIFIER", 39, 44], ["sounds", "OBSERVATION", 45, 51]]], ["Chest reveals lung fields.", [["lung", "ANATOMY", 14, 18], ["lung", "ORGAN", 14, 18], ["lung", "ANATOMY", 14, 18], ["fields", "ANATOMY_MODIFIER", 19, 25]]], ["His abdomen is soft and nontender with a spleen easily palpable.", [["abdomen", "ANATOMY", 4, 11], ["spleen", "ANATOMY", 41, 47], ["abdomen", "ORGAN", 4, 11], ["spleen", "ORGAN", 41, 47], ["nontender", "PROBLEM", 24, 33], ["abdomen", "ANATOMY", 4, 11], ["soft", "OBSERVATION", 15, 19], ["nontender", "OBSERVATION", 24, 33], ["spleen", "ANATOMY", 41, 47], ["palpable", "OBSERVATION", 55, 63]]], ["There is +ankle edema.Laboratory StudiesHb 9.6 g/dl Platelets 42,000/\u03bcl WBC 3.Questions1.", [["ankle edema", "ANATOMY", 10, 21], ["edema", "DISEASE", 16, 21], ["ankle edema", "PATHOLOGICAL_FORMATION", 10, 21], ["ankle edema", "PROBLEM", 10, 21], ["Laboratory StudiesHb", "TEST", 22, 42], ["Platelets", "TEST", 52, 61], ["\u03bcl", "TEST", 69, 71], ["WBC", "TEST", 72, 75], ["+", "UNCERTAINTY", 9, 10], ["ankle", "ANATOMY", 10, 15], ["edema", "OBSERVATION", 16, 21]]], ["Is there an advantage in treating her with band ligation in combination with a beta-blocker or is banding alone sufficient? 2.", [["beta-blocker", "GENE_OR_GENE_PRODUCT", 79, 91], ["band ligation", "TREATMENT", 43, 56], ["a beta-blocker", "TREATMENT", 77, 91]]], ["If she has to undergo TIPS, will this improve her survival? 3.", [["TIPS", "TREATMENT", 22, 26]]], ["Is she a candidate for shunt surgery?Answer: Secondary Prophylaxis of Variceal HemorrhageThis lady still has grade II esophageal varices with red wale signs at endoscopy (first image).", [["Variceal Hemorrhage", "ANATOMY", 70, 89], ["grade II esophageal varices", "ANATOMY", 109, 136], ["Hemorrhage", "DISEASE", 79, 89], ["esophageal varices", "DISEASE", 118, 136], ["esophageal varices", "PATHOLOGICAL_FORMATION", 118, 136], ["shunt surgery", "TREATMENT", 23, 36], ["Variceal Hemorrhage", "PROBLEM", 70, 89], ["grade II esophageal varices", "PROBLEM", 109, 136], ["red wale signs", "PROBLEM", 142, 156], ["endoscopy", "TEST", 160, 169], ["Variceal", "ANATOMY", 70, 78], ["Hemorrhage", "OBSERVATION", 79, 89], ["grade II", "OBSERVATION_MODIFIER", 109, 117], ["esophageal", "ANATOMY", 118, 128], ["varices", "OBSERVATION", 129, 136]]], ["She undergoes repeat band ligation as seen in the second image and likely will need further sessions to try and eradicate her varices.Answer: Secondary Prophylaxis of Variceal HemorrhageThere is a vast amount of literature on preventing rebleeding after an initial esophageal variceal bleed, and the American Association for the Study of Liver Diseases has published guidelines dealing with this topic.Answer: Secondary Prophylaxis of Variceal HemorrhageThe patient appears to be on an adequate dose of nadolol as evidenced by her pulse and blood pressure.", [["varices", "ANATOMY", 126, 133], ["Variceal Hemorrhage", "ANATOMY", 167, 186], ["esophageal", "ANATOMY", 265, 275], ["Liver", "ANATOMY", 338, 343], ["Variceal Hemorrhage", "ANATOMY", 435, 454], ["blood", "ANATOMY", 541, 546], ["varices", "DISEASE", 126, 133], ["Hemorrhage", "DISEASE", 176, 186], ["rebleeding", "DISEASE", 237, 247], ["esophageal variceal bleed", "DISEASE", 265, 290], ["Liver Diseases", "DISEASE", 338, 352], ["Hemorrhage", "DISEASE", 444, 454], ["nadolol", "CHEMICAL", 503, 510], ["nadolol", "CHEMICAL", 503, 510], ["varices", "PATHOLOGICAL_FORMATION", 126, 133], ["esophageal", "ORGAN", 265, 275], ["Liver", "ORGAN", 338, 343], ["patient", "ORGANISM", 458, 465], ["nadolol", "SIMPLE_CHEMICAL", 503, 510], ["blood", "ORGANISM_SUBSTANCE", 541, 546], ["patient", "SPECIES", 458, 465], ["repeat band ligation", "TREATMENT", 14, 34], ["further sessions", "TREATMENT", 84, 100], ["her varices", "PROBLEM", 122, 133], ["Variceal Hemorrhage", "PROBLEM", 167, 186], ["rebleeding", "PROBLEM", 237, 247], ["an initial esophageal variceal bleed", "PROBLEM", 254, 290], ["the Study", "TEST", 325, 334], ["Liver Diseases", "PROBLEM", 338, 352], ["Variceal Hemorrhage", "PROBLEM", 435, 454], ["nadolol", "TREATMENT", 503, 510], ["her pulse", "TEST", 527, 536], ["blood pressure", "TEST", 541, 555], ["band ligation", "OBSERVATION", 21, 34], ["varices", "OBSERVATION", 126, 133], ["Variceal", "ANATOMY", 167, 175], ["Hemorrhage", "OBSERVATION", 176, 186], ["vast", "OBSERVATION_MODIFIER", 197, 201], ["amount", "OBSERVATION_MODIFIER", 202, 208], ["rebleeding", "OBSERVATION", 237, 247], ["esophageal", "ANATOMY", 265, 275], ["variceal bleed", "OBSERVATION", 276, 290], ["Liver", "ANATOMY", 338, 343], ["Diseases", "OBSERVATION", 344, 352], ["Variceal", "ANATOMY", 435, 443], ["Hemorrhage", "OBSERVATION", 444, 454]]], ["Nonselective beta-blockers reduce the risk of a primary bleed, and several studies have shown that they reduce the risk of recurrent bleeding by about 40%.", [["primary bleed", "DISEASE", 48, 61], ["bleeding", "DISEASE", 133, 141], ["Nonselective beta-blockers", "TREATMENT", 0, 26], ["a primary bleed", "PROBLEM", 46, 61], ["several studies", "TEST", 67, 82], ["recurrent bleeding", "PROBLEM", 123, 141], ["primary", "OBSERVATION_MODIFIER", 48, 55], ["bleed", "OBSERVATION", 56, 61], ["recurrent", "OBSERVATION_MODIFIER", 123, 132], ["bleeding", "OBSERVATION", 133, 141]]], ["Ideally, the efficacy of beta-blockers should be measured by the reduction in hepatic venous pressure gradient, but this requires invasive testing, and most studies use a reduction of 25% in resting hear rate as a surrogate marker.Answer: Secondary Prophylaxis of Variceal HemorrhageA combination of beta-blocker and endoscopic therapy with band ligation is better than either treatment alone in preventing rebleeding but does not reduce mortality compared to either treatment.", [["hepatic venous", "ANATOMY", 78, 92], ["Variceal", "ANATOMY", 264, 272], ["beta-blocker", "CHEMICAL", 300, 312], ["rebleeding", "DISEASE", 407, 417], ["beta-blockers", "GENE_OR_GENE_PRODUCT", 25, 38], ["hepatic venous", "MULTI-TISSUE_STRUCTURE", 78, 92], ["beta-blocker", "GENE_OR_GENE_PRODUCT", 300, 312], ["beta", "PROTEIN", 25, 29], ["beta-blockers", "TREATMENT", 25, 38], ["hepatic venous pressure gradient", "TEST", 78, 110], ["invasive testing", "TEST", 130, 146], ["a reduction", "TREATMENT", 169, 180], ["Variceal HemorrhageA", "PROBLEM", 264, 284], ["beta-blocker", "TREATMENT", 300, 312], ["endoscopic therapy", "TREATMENT", 317, 335], ["band ligation", "TREATMENT", 341, 354], ["treatment", "TREATMENT", 377, 386], ["rebleeding", "PROBLEM", 407, 417], ["treatment", "TREATMENT", 467, 476], ["reduction", "OBSERVATION_MODIFIER", 65, 74], ["hepatic venous", "ANATOMY", 78, 92], ["pressure gradient", "OBSERVATION", 93, 110], ["Variceal", "OBSERVATION", 264, 272], ["rebleeding", "OBSERVATION", 407, 417]]], ["Hence, patients who have experienced variceal bleeding should undergo band ligation until eradication of varices (we typically repeat an endoscopy every 6-8 weeks until varices are no longer present or too small to band) as well as beta-blocker treatment.", [["variceal", "ANATOMY", 37, 45], ["varices", "ANATOMY", 105, 112], ["varices", "ANATOMY", 169, 176], ["bleeding", "DISEASE", 46, 54], ["varices", "DISEASE", 105, 112], ["varices", "DISEASE", 169, 176], ["patients", "ORGANISM", 7, 15], ["varices", "PATHOLOGICAL_FORMATION", 105, 112], ["beta-blocker", "GENE_OR_GENE_PRODUCT", 232, 244], ["beta", "PROTEIN", 232, 236], ["patients", "SPECIES", 7, 15], ["variceal bleeding", "PROBLEM", 37, 54], ["band ligation", "TREATMENT", 70, 83], ["varices", "PROBLEM", 105, 112], ["an endoscopy", "TEST", 134, 146], ["varices", "PROBLEM", 169, 176], ["beta-blocker treatment", "TREATMENT", 232, 254], ["variceal", "ANATOMY", 37, 45], ["bleeding", "OBSERVATION", 46, 54], ["varices", "OBSERVATION", 105, 112], ["varices", "OBSERVATION", 169, 176], ["no longer", "UNCERTAINTY", 181, 190], ["too small to band", "OBSERVATION_MODIFIER", 202, 219]]], ["If patients are intolerant to beta-blockers, band ligation alone is sufficient.Answer: Secondary Prophylaxis of Variceal HemorrhageTransjugular porto-systemic shunting (TIPS) can be considered, particularly in patients with continued bleeding despite these measures.", [["Variceal Hemorrhage", "ANATOMY", 112, 131], ["Transjugular", "ANATOMY", 131, 143], ["Hemorrhage", "DISEASE", 121, 131], ["bleeding", "DISEASE", 234, 242], ["patients", "ORGANISM", 3, 11], ["beta-blockers", "GENE_OR_GENE_PRODUCT", 30, 43], ["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 210, 218], ["beta-blockers", "TREATMENT", 30, 43], ["band ligation", "TREATMENT", 45, 58], ["Variceal Hemorrhage", "PROBLEM", 112, 131], ["Transjugular porto-systemic shunting (TIPS", "TREATMENT", 131, 173], ["continued bleeding", "PROBLEM", 224, 242], ["these measures", "TREATMENT", 251, 265], ["Variceal", "ANATOMY", 112, 120], ["Hemorrhage", "OBSERVATION", 121, 131], ["porto-systemic", "OBSERVATION_MODIFIER", 144, 158], ["shunting", "OBSERVATION", 159, 167], ["TIPS", "OBSERVATION_MODIFIER", 169, 173], ["bleeding", "OBSERVATION", 234, 242]]], ["Studies comparing TIPS with endoscopic therapy for the prevention of variceal rebleeding found an advantage for TIPS, but this did not extend to a survival benefit and TIPS was associated with more complications such as encephalopathy, liver failure, and repeat intervention for TIPS dysfunction (although these studies were with uncoated TIPS stents).Answer: Secondary Prophylaxis of Variceal HemorrhageAs illustrated in another case, shunt surgery such as a distal splenorenal shunt is an option to prevent rebleeding but should be reserved for patients with wellmaintained liver synthetic function which is not the case here.", [["variceal", "ANATOMY", 69, 77], ["liver", "ANATOMY", 236, 241], ["liver", "ANATOMY", 576, 581], ["rebleeding", "DISEASE", 78, 88], ["encephalopathy", "DISEASE", 220, 234], ["liver failure", "DISEASE", 236, 249], ["TIPS dysfunction", "DISEASE", 279, 295], ["HemorrhageAs", "DISEASE", 394, 406], ["rebleeding", "DISEASE", 509, 519], ["variceal", "PATHOLOGICAL_FORMATION", 69, 77], ["liver", "ORGAN", 236, 241], ["patients", "ORGANISM", 547, 555], ["liver", "ORGAN", 576, 581], ["patients", "SPECIES", 547, 555], ["Studies", "TEST", 0, 7], ["TIPS", "TREATMENT", 18, 22], ["endoscopic therapy", "TREATMENT", 28, 46], ["variceal rebleeding", "PROBLEM", 69, 88], ["TIPS", "TREATMENT", 112, 116], ["TIPS", "TREATMENT", 168, 172], ["more complications", "PROBLEM", 193, 211], ["encephalopathy", "PROBLEM", 220, 234], ["liver failure", "PROBLEM", 236, 249], ["repeat intervention", "TREATMENT", 255, 274], ["TIPS dysfunction", "PROBLEM", 279, 295], ["these studies", "TEST", 306, 319], ["uncoated TIPS stents", "TREATMENT", 330, 350], ["Variceal HemorrhageAs", "PROBLEM", 385, 406], ["shunt surgery", "TREATMENT", 436, 449], ["a distal splenorenal shunt", "TREATMENT", 458, 484], ["rebleeding", "PROBLEM", 509, 519], ["variceal", "ANATOMY", 69, 77], ["rebleeding", "OBSERVATION", 78, 88], ["encephalopathy", "OBSERVATION", 220, 234], ["liver", "ANATOMY", 236, 241], ["failure", "OBSERVATION", 242, 249], ["TIPS stents", "OBSERVATION", 339, 350], ["Variceal HemorrhageAs", "OBSERVATION", 385, 406], ["shunt", "OBSERVATION", 436, 441], ["distal", "ANATOMY_MODIFIER", 460, 466], ["splenorenal", "ANATOMY", 467, 478], ["shunt", "OBSERVATION", 479, 484], ["rebleeding", "OBSERVATION", 509, 519], ["liver", "ANATOMY", 576, 581]]], ["The ultimate treatment would be liver transplant, but this is contraindicated in patient with such short sobriety.Case 52A 25-year-old white female comes to the liver clinic to reestablish care.", [["liver", "ANATOMY", 32, 37], ["liver", "ANATOMY", 161, 166], ["liver", "ORGAN", 32, 37], ["patient", "ORGANISM", 81, 88], ["female", "ORGANISM", 141, 147], ["liver", "ORGAN", 161, 166], ["patient", "SPECIES", 81, 88], ["The ultimate treatment", "TREATMENT", 0, 22], ["liver transplant", "TREATMENT", 32, 48], ["liver", "ANATOMY", 32, 37], ["transplant", "OBSERVATION", 38, 48], ["liver", "ANATOMY", 161, 166]]], ["She initially presented to the children's hospital at the age of 9 with hematemesis.", [["hematemesis", "DISEASE", 72, 83], ["She", "ORGANISM", 0, 3], ["children", "ORGANISM", 31, 39], ["children", "SPECIES", 31, 39], ["hematemesis", "PROBLEM", 72, 83], ["hematemesis", "OBSERVATION", 72, 83]]], ["She underwent urgent EGD revealing bleeding esophageal varices and was treated with endoscopic sclerotherapy.", [["bleeding esophageal varices", "ANATOMY", 35, 62], ["bleeding esophageal varices", "DISEASE", 35, 62], ["esophageal varices", "PATHOLOGICAL_FORMATION", 44, 62], ["urgent EGD", "TEST", 14, 24], ["bleeding esophageal varices", "PROBLEM", 35, 62], ["endoscopic sclerotherapy", "TREATMENT", 84, 108], ["bleeding", "OBSERVATION_MODIFIER", 35, 43], ["esophageal", "ANATOMY", 44, 54], ["varices", "OBSERVATION", 55, 62], ["sclerotherapy", "OBSERVATION", 95, 108]]], ["She never had recurrent bleeding and never followed-up afterwards.", [["bleeding", "DISEASE", 24, 32], ["recurrent bleeding", "PROBLEM", 14, 32], ["recurrent", "OBSERVATION_MODIFIER", 14, 23], ["bleeding", "OBSERVATION", 24, 32]]], ["She has been recently diagnosed with a spontaneous left lower extremity blood clot and is found to have protein C deficiency.", [["left lower extremity blood clot", "ANATOMY", 51, 82], ["She", "ORGANISM", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["clot", "ORGANISM_SUBSTANCE", 78, 82], ["protein C", "GENE_OR_GENE_PRODUCT", 104, 113], ["protein C", "PROTEIN", 104, 113], ["a spontaneous left lower extremity blood clot", "PROBLEM", 37, 82], ["protein C deficiency", "PROBLEM", 104, 124], ["spontaneous", "OBSERVATION_MODIFIER", 39, 50], ["left", "ANATOMY_MODIFIER", 51, 55], ["lower extremity", "ANATOMY", 56, 71], ["blood", "ANATOMY", 72, 77], ["clot", "OBSERVATION", 78, 82], ["protein C deficiency", "OBSERVATION", 104, 124]]], ["Before starting her on chronic anticoagulation, given her history of GIB, hematology recommends consultation with you.Case 52The patient states she feels well.", [["GIB", "DISEASE", 69, 72], ["patient", "ORGANISM", 129, 136], ["patient", "SPECIES", 129, 136], ["chronic anticoagulation", "TREATMENT", 23, 46], ["GIB", "PROBLEM", 69, 72], ["GIB", "OBSERVATION", 69, 72]]], ["She has a history of anxiety and takes as needed benzodiazepines.", [["anxiety", "DISEASE", 21, 28], ["benzodiazepines", "CHEMICAL", 49, 64], ["benzodiazepines", "CHEMICAL", 49, 64], ["anxiety", "PROBLEM", 21, 28], ["benzodiazepines", "TREATMENT", 49, 64]]], ["Two years ago the patient underwent an uneventful laparoscopic cholecystectomy for symptomatic gallstones, an intraoperative liver biopsy revealed mild fibrosis and bile ductular proliferation.", [["gallstones", "ANATOMY", 95, 105], ["liver", "ANATOMY", 125, 130], ["bile ductular", "ANATOMY", 165, 178], ["gallstones", "DISEASE", 95, 105], ["fibrosis", "DISEASE", 152, 160], ["patient", "ORGANISM", 18, 25], ["gallstones", "PATHOLOGICAL_FORMATION", 95, 105], ["liver", "ORGAN", 125, 130], ["bile ductular", "PATHOLOGICAL_FORMATION", 165, 178], ["patient", "SPECIES", 18, 25], ["an uneventful laparoscopic cholecystectomy", "TREATMENT", 36, 78], ["symptomatic gallstones", "PROBLEM", 83, 105], ["an intraoperative liver biopsy", "TEST", 107, 137], ["mild fibrosis", "PROBLEM", 147, 160], ["bile ductular proliferation", "PROBLEM", 165, 192], ["cholecystectomy", "OBSERVATION", 63, 78], ["symptomatic", "OBSERVATION_MODIFIER", 83, 94], ["gallstones", "OBSERVATION", 95, 105], ["liver", "ANATOMY", 125, 130], ["biopsy", "OBSERVATION", 131, 137], ["mild", "OBSERVATION_MODIFIER", 147, 151], ["fibrosis", "OBSERVATION", 152, 160], ["bile", "ANATOMY", 165, 169], ["ductular proliferation", "OBSERVATION", 170, 192]]], ["Although the patient doesn't know details, she knows her mother is on lifelong warfarin for a history of blood clots.", [["blood clots", "ANATOMY", 105, 116], ["warfarin", "CHEMICAL", 79, 87], ["blood clots", "DISEASE", 105, 116], ["warfarin", "CHEMICAL", 79, 87], ["patient", "ORGANISM", 13, 20], ["warfarin", "SIMPLE_CHEMICAL", 79, 87], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["clots", "ORGANISM_SUBSTANCE", 111, 116], ["patient", "SPECIES", 13, 20], ["lifelong warfarin", "TREATMENT", 70, 87], ["blood clots", "PROBLEM", 105, 116], ["clots", "OBSERVATION", 111, 116]]], ["The patient lives with her fianc\u00e9 and works as a cashier at a convenience store.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["There is no history of high-risk behavior.Case 52On exam, she appears well and is not in distress.", [["high-risk behavior", "PROBLEM", 23, 41], ["exam", "TEST", 52, 56], ["distress", "PROBLEM", 89, 97], ["no", "UNCERTAINTY", 9, 11]]], ["Her heart rate is 80 beats per minute, blood pressure 110/50; BMI is 27.7 kg/m 2 .", [["heart", "ANATOMY", 4, 9], ["blood", "ANATOMY", 39, 44], ["heart", "ORGAN", 4, 9], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["Her heart rate", "TEST", 0, 14], ["blood pressure", "TEST", 39, 53], ["BMI", "TEST", 62, 65], ["heart", "ANATOMY", 4, 9]]], ["She has no evidence of scleral icterus or stigmata to suggest chronic liver disease.", [["scleral", "ANATOMY", 23, 30], ["liver", "ANATOMY", 70, 75], ["scleral icterus", "DISEASE", 23, 38], ["chronic liver disease", "DISEASE", 62, 83], ["liver", "ORGAN", 70, 75], ["scleral icterus", "PROBLEM", 23, 38], ["stigmata", "PROBLEM", 42, 50], ["chronic liver disease", "PROBLEM", 62, 83], ["no evidence of", "UNCERTAINTY", 8, 22], ["scleral", "ANATOMY", 23, 30], ["icterus", "OBSERVATION", 31, 38], ["stigmata", "OBSERVATION", 42, 50], ["suggest", "UNCERTAINTY", 54, 61], ["chronic", "OBSERVATION_MODIFIER", 62, 69], ["liver", "ANATOMY", 70, 75], ["disease", "OBSERVATION", 76, 83]]], ["Her lungs and cardiac exam are normal.", [["lungs", "ANATOMY", 4, 9], ["cardiac", "ANATOMY", 14, 21], ["lungs", "ORGAN", 4, 9], ["cardiac", "ORGAN", 14, 21], ["cardiac exam", "TEST", 14, 26], ["lungs", "ANATOMY", 4, 9], ["cardiac", "ANATOMY", 14, 21], ["normal", "OBSERVATION", 31, 37]]], ["Abdominal exam reveals some dilated umbilical veins, no hepatomegaly, but a palpable spleen tip.", [["Abdominal", "ANATOMY", 0, 9], ["dilated umbilical veins", "ANATOMY", 28, 51], ["spleen", "ANATOMY", 85, 91], ["hepatomegaly", "DISEASE", 56, 68], ["umbilical veins", "MULTI-TISSUE_STRUCTURE", 36, 51], ["spleen", "ORGAN", 85, 91], ["Abdominal exam", "TEST", 0, 14], ["some dilated umbilical veins", "PROBLEM", 23, 51], ["hepatomegaly", "PROBLEM", 56, 68], ["a palpable spleen tip", "PROBLEM", 74, 95], ["some", "OBSERVATION_MODIFIER", 23, 27], ["dilated", "OBSERVATION", 28, 35], ["umbilical veins", "ANATOMY", 36, 51], ["no", "UNCERTAINTY", 53, 55], ["hepatomegaly", "OBSERVATION", 56, 68], ["palpable", "OBSERVATION", 76, 84], ["spleen", "ANATOMY", 85, 91], ["tip", "OBSERVATION_MODIFIER", 92, 95]]], ["No appreciable ascites.", [["ascites", "ANATOMY", 15, 22], ["ascites", "DISEASE", 15, 22], ["appreciable ascites", "PROBLEM", 3, 22], ["appreciable", "OBSERVATION_MODIFIER", 3, 14], ["ascites", "OBSERVATION", 15, 22]]], ["Her left leg has some mild erythema and trace edema.Case 52An EGD was performed revealing mild-to-moderate portal hypertensive gastropathy (most notable in the fundus) and grade 1 esophageal varices but no evidence of gastric varices.Answer: Hypercoaguable State Leading to Portal Vein Thrombosis, Cavernous Transformation and Portal HypertensionThis young lady has portal hypertension, but interestingly, this was first noted as a child, and hence, congenital causes have to be high on the differential diagnosis.", [["left leg", "ANATOMY", 4, 12], ["fundus", "ANATOMY", 160, 166], ["grade 1 esophageal varices", "ANATOMY", 172, 198], ["gastric varices", "ANATOMY", 218, 233], ["Vein", "ANATOMY", 281, 285], ["erythema", "DISEASE", 27, 35], ["trace edema", "DISEASE", 40, 51], ["portal hypertensive gastropathy", "DISEASE", 107, 138], ["esophageal varices", "DISEASE", 180, 198], ["gastric varices", "DISEASE", 218, 233], ["Portal Vein Thrombosis", "DISEASE", 274, 296], ["Portal Hypertension", "DISEASE", 327, 346], ["hypertension", "DISEASE", 373, 385], ["leg", "ORGANISM_SUBDIVISION", 9, 12], ["erythema", "PATHOLOGICAL_FORMATION", 27, 35], ["edema", "PATHOLOGICAL_FORMATION", 46, 51], ["fundus", "MULTI-TISSUE_STRUCTURE", 160, 166], ["esophageal varices", "PATHOLOGICAL_FORMATION", 180, 198], ["gastric varices", "PATHOLOGICAL_FORMATION", 218, 233], ["Portal Vein", "MULTI-TISSUE_STRUCTURE", 274, 285], ["portal", "MULTI-TISSUE_STRUCTURE", 366, 372], ["some mild erythema", "PROBLEM", 17, 35], ["trace edema", "PROBLEM", 40, 51], ["EGD", "TEST", 62, 65], ["mild-to-moderate portal hypertensive gastropathy", "PROBLEM", 90, 138], ["grade 1 esophageal varices", "PROBLEM", 172, 198], ["gastric varices", "PROBLEM", 218, 233], ["Hypercoaguable State", "PROBLEM", 242, 262], ["Portal Vein Thrombosis", "PROBLEM", 274, 296], ["Cavernous Transformation", "PROBLEM", 298, 322], ["Portal Hypertension", "PROBLEM", 327, 346], ["portal hypertension", "PROBLEM", 366, 385], ["congenital causes", "PROBLEM", 450, 467], ["left", "ANATOMY_MODIFIER", 4, 8], ["leg", "ANATOMY", 9, 12], ["some", "OBSERVATION_MODIFIER", 17, 21], ["mild", "OBSERVATION_MODIFIER", 22, 26], ["erythema", "OBSERVATION", 27, 35], ["trace", "OBSERVATION_MODIFIER", 40, 45], ["edema", "OBSERVATION", 46, 51], ["mild", "OBSERVATION_MODIFIER", 90, 94], ["moderate", "OBSERVATION_MODIFIER", 98, 106], ["portal hypertensive", "ANATOMY", 107, 126], ["gastropathy", "OBSERVATION", 127, 138], ["fundus", "ANATOMY", 160, 166], ["esophageal", "ANATOMY", 180, 190], ["varices", "OBSERVATION", 191, 198], ["no evidence of", "UNCERTAINTY", 203, 217], ["gastric", "ANATOMY", 218, 225], ["varices", "OBSERVATION", 226, 233], ["Portal Vein", "ANATOMY", 274, 285], ["Thrombosis", "OBSERVATION", 286, 296], ["Cavernous", "ANATOMY", 298, 307], ["Portal", "ANATOMY", 327, 333], ["Hypertension", "OBSERVATION", 334, 346], ["portal", "ANATOMY", 366, 372], ["hypertension", "OBSERVATION", 373, 385]]], ["The main possibilities include portal vein atresia or portal vein thrombosis.", [["portal vein", "ANATOMY", 31, 42], ["portal vein", "ANATOMY", 54, 65], ["portal vein atresia", "DISEASE", 31, 50], ["portal vein thrombosis", "DISEASE", 54, 76], ["portal vein", "MULTI-TISSUE_STRUCTURE", 31, 42], ["portal vein", "MULTI-TISSUE_STRUCTURE", 54, 65], ["portal vein atresia", "PROBLEM", 31, 50], ["portal vein thrombosis", "PROBLEM", 54, 76], ["main", "OBSERVATION_MODIFIER", 4, 8], ["portal vein", "ANATOMY", 31, 42], ["atresia", "OBSERVATION", 43, 50], ["portal vein", "ANATOMY", 54, 65], ["thrombosis", "OBSERVATION", 66, 76]]], ["Cirrhosis is uncommon in young children and would be expected to worsen with time and yet this lady did well for many years.", [["Cirrhosis", "DISEASE", 0, 9], ["children", "ORGANISM", 31, 39], ["children", "SPECIES", 31, 39], ["Cirrhosis", "PROBLEM", 0, 9]]], ["The first test to obtain would be an imaging study to look at the liver and hepatic vasculature.", [["liver", "ANATOMY", 66, 71], ["hepatic vasculature", "ANATOMY", 76, 95], ["liver", "ORGAN", 66, 71], ["hepatic vasculature", "MULTI-TISSUE_STRUCTURE", 76, 95], ["an imaging study", "TEST", 34, 50], ["liver", "ANATOMY", 66, 71], ["hepatic", "ANATOMY", 76, 83], ["vasculature", "ANATOMY_MODIFIER", 84, 95]]], ["CT scan, MRI, or ultrasound all have a potential role.Answer: Hypercoaguable State Leading to Portal Vein Thrombosis, Cavernous Transformation and Portal HypertensionPortal hypertension is defined by a hepatic venous pressure gradient (HVPG) greater than 5 mmHg.", [["Vein", "ANATOMY", 101, 105], ["hepatic venous", "ANATOMY", 202, 216], ["Portal Vein Thrombosis", "DISEASE", 94, 116], ["Cavernous Transformation", "DISEASE", 118, 142], ["Portal HypertensionPortal hypertension", "DISEASE", 147, 185], ["Portal Vein", "MULTI-TISSUE_STRUCTURE", 94, 105], ["hepatic venous", "MULTI-TISSUE_STRUCTURE", 202, 216], ["CT scan", "TEST", 0, 7], ["MRI", "TEST", 9, 12], ["ultrasound", "TEST", 17, 27], ["Hypercoaguable State", "PROBLEM", 62, 82], ["Portal Vein Thrombosis", "PROBLEM", 94, 116], ["Cavernous Transformation", "PROBLEM", 118, 142], ["Portal HypertensionPortal hypertension", "PROBLEM", 147, 185], ["a hepatic venous pressure gradient", "TEST", 200, 234], ["HVPG", "TEST", 236, 240], ["Portal Vein", "ANATOMY", 94, 105], ["Thrombosis", "OBSERVATION", 106, 116], ["Cavernous Transformation", "OBSERVATION", 118, 142], ["Portal", "ANATOMY", 147, 153], ["HypertensionPortal hypertension", "OBSERVATION", 154, 185], ["hepatic venous", "ANATOMY", 202, 216], ["pressure", "OBSERVATION_MODIFIER", 217, 225], ["gradient", "OBSERVATION_MODIFIER", 226, 234]]], ["A variety of disorders can cause portal hypertension in the absence of cirrhosis, a condition referred to as \"noncirrhotic portal hypertension.\"Answer: Hypercoaguable State Leading to Portal Vein Thrombosis, Cavernous Transformation and Portal HypertensionPortal hypertension has been categorized as prehepatic, intrahepatic, or posthepatic based upon the site of obstruction to flow.", [["portal", "ANATOMY", 33, 39], ["portal", "ANATOMY", 123, 129], ["Vein", "ANATOMY", 191, 195], ["prehepatic", "ANATOMY", 300, 310], ["intrahepatic", "ANATOMY", 312, 324], ["portal hypertension", "DISEASE", 33, 52], ["cirrhosis", "DISEASE", 71, 80], ["noncirrhotic portal hypertension", "DISEASE", 110, 142], ["Portal Vein Thrombosis", "DISEASE", 184, 206], ["Portal HypertensionPortal hypertension", "DISEASE", 237, 275], ["obstruction", "DISEASE", 364, 375], ["portal", "MULTI-TISSUE_STRUCTURE", 33, 39], ["portal", "MULTI-TISSUE_STRUCTURE", 123, 129], ["Portal Vein", "MULTI-TISSUE_STRUCTURE", 184, 195], ["A variety of disorders", "PROBLEM", 0, 22], ["portal hypertension", "PROBLEM", 33, 52], ["cirrhosis", "PROBLEM", 71, 80], ["a condition", "PROBLEM", 82, 93], ["noncirrhotic portal hypertension", "PROBLEM", 110, 142], ["Hypercoaguable State", "PROBLEM", 152, 172], ["Portal Vein Thrombosis", "PROBLEM", 184, 206], ["Cavernous Transformation", "PROBLEM", 208, 232], ["Portal HypertensionPortal hypertension", "PROBLEM", 237, 275], ["obstruction to flow", "PROBLEM", 364, 383], ["portal", "ANATOMY", 33, 39], ["hypertension", "OBSERVATION", 40, 52], ["cirrhosis", "OBSERVATION", 71, 80], ["noncirrhotic", "OBSERVATION", 110, 122], ["portal", "ANATOMY", 123, 129], ["hypertension", "OBSERVATION", 130, 142], ["Portal Vein", "ANATOMY", 184, 195], ["Thrombosis", "OBSERVATION", 196, 206], ["Cavernous", "ANATOMY", 208, 217], ["Portal", "ANATOMY", 237, 243], ["HypertensionPortal hypertension", "OBSERVATION", 244, 275], ["intrahepatic", "ANATOMY", 312, 324], ["obstruction", "OBSERVATION", 364, 375], ["flow", "OBSERVATION", 379, 383]]], ["The clinical consequences of portal hypertension (ascites, varices, and encephalopathy) are similar regardless of the cause or site of obstruction.Answer: Hypercoaguable State Leading to Portal Vein Thrombosis, Cavernous Transformation and Portal HypertensionPresinusoidal portal hypertension is caused by obstruction to flow through the portal venous system in the extrahepatic portion of the portal vein (extrahepatic presinusoidal portal hypertension; see image one above) or at the level of portal vein branches within the liver (intrahepatic presinusoidal portal hypertension).Answer: Hypercoaguable State Leading to Portal Vein Thrombosis, Cavernous Transformation and Portal HypertensionThe causes of portal vein thrombosis (PVT) vary with age.", [["portal", "ANATOMY", 29, 35], ["ascites", "ANATOMY", 50, 57], ["varices", "ANATOMY", 59, 66], ["Vein", "ANATOMY", 194, 198], ["portal", "ANATOMY", 273, 279], ["portal venous system", "ANATOMY", 338, 358], ["extrahepatic portion", "ANATOMY", 366, 386], ["portal vein", "ANATOMY", 394, 405], ["extrahepatic presinusoidal portal", "ANATOMY", 407, 440], ["portal vein branches", "ANATOMY", 495, 515], ["liver", "ANATOMY", 527, 532], ["intrahepatic presinusoidal portal", "ANATOMY", 534, 567], ["Vein", "ANATOMY", 629, 633], ["portal vein", "ANATOMY", 708, 719], ["portal hypertension", "DISEASE", 29, 48], ["ascites", "DISEASE", 50, 57], ["varices", "DISEASE", 59, 66], ["encephalopathy", "DISEASE", 72, 86], ["obstruction", "DISEASE", 135, 146], ["Portal Vein Thrombosis", "DISEASE", 187, 209], ["Portal Hypertension", "DISEASE", 240, 259], ["portal hypertension", "DISEASE", 273, 292], ["hypertension", "DISEASE", 441, 453], ["intrahepatic presinusoidal portal hypertension", "DISEASE", 534, 580], ["Portal Vein Thrombosis", "DISEASE", 622, 644], ["Portal Hypertension", "DISEASE", 675, 694], ["portal vein thrombosis", "DISEASE", 708, 730], ["PVT", "DISEASE", 732, 735], ["portal", "MULTI-TISSUE_STRUCTURE", 29, 35], ["varices", "PATHOLOGICAL_FORMATION", 59, 66], ["obstruction", "PATHOLOGICAL_FORMATION", 135, 146], ["Portal Vein", "MULTI-TISSUE_STRUCTURE", 187, 198], ["portal", "MULTI-TISSUE_STRUCTURE", 273, 279], ["portal venous", "MULTI-TISSUE_STRUCTURE", 338, 351], ["extrahepatic portion", "MULTI-TISSUE_STRUCTURE", 366, 386], ["portal vein", "MULTI-TISSUE_STRUCTURE", 394, 405], ["extrahepatic presinusoidal portal", "MULTI-TISSUE_STRUCTURE", 407, 440], ["portal vein", "MULTI-TISSUE_STRUCTURE", 495, 506], ["liver", "ORGAN", 527, 532], ["intrahepatic presinusoidal portal", "MULTI-TISSUE_STRUCTURE", 534, 567], ["Portal Vein", "MULTI-TISSUE_STRUCTURE", 622, 633], ["portal vein", "MULTI-TISSUE_STRUCTURE", 708, 719], ["portal hypertension", "PROBLEM", 29, 48], ["ascites", "PROBLEM", 50, 57], ["varices", "PROBLEM", 59, 66], ["encephalopathy", "PROBLEM", 72, 86], ["obstruction", "PROBLEM", 135, 146], ["Hypercoaguable State", "PROBLEM", 155, 175], ["Portal Vein Thrombosis", "PROBLEM", 187, 209], ["Cavernous Transformation", "PROBLEM", 211, 235], ["Portal Hypertension", "PROBLEM", 240, 259], ["Presinusoidal portal hypertension", "PROBLEM", 259, 292], ["obstruction to flow through the portal venous system", "PROBLEM", 306, 358], ["extrahepatic presinusoidal portal hypertension", "PROBLEM", 407, 453], ["intrahepatic presinusoidal portal hypertension", "PROBLEM", 534, 580], ["Hypercoaguable State", "PROBLEM", 590, 610], ["Portal Vein Thrombosis", "PROBLEM", 622, 644], ["Cavernous Transformation", "PROBLEM", 646, 670], ["Portal Hypertension", "PROBLEM", 675, 694], ["portal vein thrombosis", "PROBLEM", 708, 730], ["portal", "ANATOMY", 29, 35], ["hypertension", "OBSERVATION", 36, 48], ["ascites", "OBSERVATION", 50, 57], ["varices", "OBSERVATION", 59, 66], ["encephalopathy", "OBSERVATION", 72, 86], ["obstruction", "OBSERVATION", 135, 146], ["Portal Vein", "ANATOMY", 187, 198], ["Thrombosis", "OBSERVATION", 199, 209], ["Cavernous", "ANATOMY", 211, 220], ["Portal", "ANATOMY", 240, 246], ["Hypertension", "OBSERVATION", 247, 259], ["portal", "ANATOMY", 273, 279], ["hypertension", "OBSERVATION", 280, 292], ["obstruction", "OBSERVATION", 306, 317], ["flow", "OBSERVATION", 321, 325], ["portal venous", "ANATOMY", 338, 351], ["system", "ANATOMY_MODIFIER", 352, 358], ["extrahepatic", "ANATOMY_MODIFIER", 366, 378], ["portal vein", "ANATOMY", 394, 405], ["extrahepatic", "ANATOMY_MODIFIER", 407, 419], ["portal", "ANATOMY", 434, 440], ["hypertension", "OBSERVATION", 441, 453], ["portal vein", "ANATOMY", 495, 506], ["branches", "ANATOMY_MODIFIER", 507, 515], ["liver", "ANATOMY", 527, 532], ["intrahepatic", "ANATOMY_MODIFIER", 534, 546], ["presinusoidal", "ANATOMY_MODIFIER", 547, 560], ["portal", "ANATOMY", 561, 567], ["hypertension", "OBSERVATION", 568, 580], ["Portal Vein", "ANATOMY", 622, 633], ["Thrombosis", "OBSERVATION", 634, 644], ["Cavernous", "ANATOMY", 646, 655], ["Portal", "ANATOMY", 675, 681], ["Hypertension", "OBSERVATION", 682, 694], ["portal vein", "ANATOMY", 708, 719], ["thrombosis", "OBSERVATION", 720, 730]]], ["In adults, approximately 25% of patients with PVT have underlying cirrhosis, with the prevalence correlating with the severity of underlying liver disease.", [["liver", "ANATOMY", 141, 146], ["PVT", "DISEASE", 46, 49], ["cirrhosis", "DISEASE", 66, 75], ["liver disease", "DISEASE", 141, 154], ["patients", "ORGANISM", 32, 40], ["liver", "ORGAN", 141, 146], ["patients", "SPECIES", 32, 40], ["PVT", "PROBLEM", 46, 49], ["underlying cirrhosis", "PROBLEM", 55, 75], ["underlying liver disease", "PROBLEM", 130, 154], ["cirrhosis", "OBSERVATION", 66, 75], ["liver", "ANATOMY", 141, 146], ["disease", "OBSERVATION", 147, 154]]], ["In children, the most common etiology of PVT is thrombophlebitis of the umbilical vein (omphalitis) and ultimately the portal vein.", [["umbilical vein", "ANATOMY", 72, 86], ["omphalitis", "ANATOMY", 88, 98], ["portal vein", "ANATOMY", 119, 130], ["PVT", "DISEASE", 41, 44], ["thrombophlebitis", "DISEASE", 48, 64], ["omphalitis", "DISEASE", 88, 98], ["children", "ORGANISM", 3, 11], ["PVT", "CANCER", 41, 44], ["umbilical vein", "MULTI-TISSUE_STRUCTURE", 72, 86], ["omphalitis", "CANCER", 88, 98], ["portal vein", "MULTI-TISSUE_STRUCTURE", 119, 130], ["children", "SPECIES", 3, 11], ["PVT", "PROBLEM", 41, 44], ["thrombophlebitis of the umbilical vein", "PROBLEM", 48, 86], ["PVT", "OBSERVATION", 41, 44], ["thrombophlebitis", "OBSERVATION", 48, 64], ["umbilical vein", "ANATOMY", 72, 86], ["portal vein", "ANATOMY", 119, 130]]], ["Omphalitis is a rare event in industrialized countries but is estimated to be as high as 6% in the developing world.Answer: Hypercoaguable State Leading to Portal Vein Thrombosis, Cavernous Transformation and Portal HypertensionNo apparent cause for portal vein thrombosis is evident in more than one-third of patients Many of these patients probably have an underlying hypercoagulable state.", [["Vein", "ANATOMY", 163, 167], ["portal vein", "ANATOMY", 250, 261], ["Omphalitis", "DISEASE", 0, 10], ["Portal Vein Thrombosis", "DISEASE", 156, 178], ["Portal HypertensionNo", "DISEASE", 209, 230], ["portal vein thrombosis", "DISEASE", 250, 272], ["Portal Vein", "MULTI-TISSUE_STRUCTURE", 156, 167], ["portal vein", "MULTI-TISSUE_STRUCTURE", 250, 261], ["patients", "ORGANISM", 310, 318], ["patients", "ORGANISM", 333, 341], ["patients", "SPECIES", 310, 318], ["patients", "SPECIES", 333, 341], ["Hypercoaguable State", "PROBLEM", 124, 144], ["Portal Vein Thrombosis", "PROBLEM", 156, 178], ["Cavernous Transformation", "PROBLEM", 180, 204], ["Portal HypertensionNo apparent cause", "PROBLEM", 209, 245], ["portal vein thrombosis", "PROBLEM", 250, 272], ["an underlying hypercoagulable state", "PROBLEM", 356, 391], ["Portal Vein", "ANATOMY", 156, 167], ["Thrombosis", "OBSERVATION", 168, 178], ["Cavernous", "OBSERVATION", 180, 189], ["Portal", "ANATOMY", 209, 215], ["portal vein", "ANATOMY", 250, 261], ["thrombosis", "OBSERVATION", 262, 272], ["hypercoagulable state", "OBSERVATION", 370, 391]]], ["The following hypercoagulable states have been identified in different studies comparing patients with portal vein thrombosis compared to various controls and should be tested for:Answer: Hypercoaguable State Leading to Portal Vein Thrombosis, Cavernous Transformation and Portal HypertensionFactor V Leiden Prothrombin gene mutation Protein C deficiency Protein S deficiency Antithrombin deficiency MTFR gene mutation that raises homocysteine Myeloproliferative disorders, in some cases diagnosed only by the presence of a JAK2 617F mutation Increased factor VIII levels Chronic portal vein thrombosis develops in patients whose thrombosis does not spontaneously resolve.", [["portal vein", "ANATOMY", 103, 114], ["Vein", "ANATOMY", 227, 231], ["portal vein", "ANATOMY", 580, 591], ["portal vein thrombosis", "DISEASE", 103, 125], ["Portal Vein Thrombosis", "DISEASE", 220, 242], ["Cavernous Transformation", "DISEASE", 244, 268], ["Hypertension", "DISEASE", 280, 292], ["homocysteine", "CHEMICAL", 431, 443], ["Myeloproliferative disorders", "DISEASE", 444, 472], ["portal vein thrombosis", "DISEASE", 580, 602], ["thrombosis", "DISEASE", 630, 640], ["homocysteine", "CHEMICAL", 431, 443], ["patients", "ORGANISM", 89, 97], ["portal vein", "MULTI-TISSUE_STRUCTURE", 103, 114], ["Portal Vein", "MULTI-TISSUE_STRUCTURE", 220, 231], ["Factor V Leiden Prothrombin", "GENE_OR_GENE_PRODUCT", 292, 319], ["Protein C", "GENE_OR_GENE_PRODUCT", 334, 343], ["Antithrombin", "GENE_OR_GENE_PRODUCT", 376, 388], ["MTFR", "GENE_OR_GENE_PRODUCT", 400, 404], ["homocysteine", "SIMPLE_CHEMICAL", 431, 443], ["JAK2 617F", "GENE_OR_GENE_PRODUCT", 524, 533], ["factor VIII", "GENE_OR_GENE_PRODUCT", 553, 564], ["portal vein", "MULTI-TISSUE_STRUCTURE", 580, 591], ["patients", "ORGANISM", 615, 623], ["Protein S deficiency Antithrombin deficiency MTFR gene", "DNA", 355, 409], ["JAK2 617F", "PROTEIN", 524, 533], ["factor VIII", "PROTEIN", 553, 564], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 615, 623], ["different studies", "TEST", 61, 78], ["portal vein thrombosis", "PROBLEM", 103, 125], ["Hypercoaguable State", "PROBLEM", 188, 208], ["Portal Vein Thrombosis", "PROBLEM", 220, 242], ["Cavernous Transformation", "PROBLEM", 244, 268], ["Portal Hypertension", "PROBLEM", 273, 292], ["Factor V Leiden", "TEST", 292, 307], ["Prothrombin gene mutation", "TEST", 308, 333], ["Protein C deficiency", "PROBLEM", 334, 354], ["Protein S deficiency", "PROBLEM", 355, 375], ["Antithrombin deficiency", "PROBLEM", 376, 399], ["MTFR gene mutation", "PROBLEM", 400, 418], ["homocysteine Myeloproliferative disorders", "PROBLEM", 431, 472], ["a JAK2 617F mutation", "PROBLEM", 522, 542], ["Increased factor VIII levels", "PROBLEM", 543, 571], ["Chronic portal vein thrombosis", "PROBLEM", 572, 602], ["thrombosis", "PROBLEM", 630, 640], ["portal vein", "ANATOMY", 103, 114], ["thrombosis", "OBSERVATION", 115, 125], ["Portal Vein", "ANATOMY", 220, 231], ["Thrombosis", "OBSERVATION", 232, 242], ["Cavernous", "ANATOMY", 244, 253], ["Portal", "ANATOMY", 273, 279], ["Hypertension", "OBSERVATION", 280, 292], ["homocysteine Myeloproliferative disorders", "OBSERVATION", 431, 472], ["portal vein", "ANATOMY", 580, 591], ["thrombosis", "OBSERVATION", 592, 602], ["thrombosis", "OBSERVATION", 630, 640]]], ["This may either produce a chronic noncavernous thrombosed portal vein or cavernous transformation of the portal vein.", [["portal vein", "ANATOMY", 58, 69], ["cavernous", "ANATOMY", 73, 82], ["portal vein", "ANATOMY", 105, 116], ["portal vein", "MULTI-TISSUE_STRUCTURE", 58, 69], ["portal vein", "MULTI-TISSUE_STRUCTURE", 105, 116], ["a chronic noncavernous thrombosed portal vein", "PROBLEM", 24, 69], ["cavernous transformation of the portal vein", "PROBLEM", 73, 116], ["may either produce", "UNCERTAINTY", 5, 23], ["chronic", "OBSERVATION_MODIFIER", 26, 33], ["noncavernous", "OBSERVATION_MODIFIER", 34, 46], ["thrombosed", "OBSERVATION", 47, 57], ["portal vein", "ANATOMY", 58, 69], ["cavernous transformation", "OBSERVATION", 73, 97], ["portal vein", "ANATOMY", 105, 116]]], ["Cavernous transformation refers to the development of collateral blood vessels that bring blood in a hepatopedal manner from the region of obstruction.", [["Cavernous", "ANATOMY", 0, 9], ["collateral blood vessels", "ANATOMY", 54, 78], ["blood", "ANATOMY", 90, 95], ["hepatopedal", "ANATOMY", 101, 112], ["Cavernous transformation", "DISEASE", 0, 24], ["obstruction", "DISEASE", 139, 150], ["collateral blood vessels", "MULTI-TISSUE_STRUCTURE", 54, 78], ["blood", "ORGANISM_SUBSTANCE", 90, 95], ["obstruction", "PATHOLOGICAL_FORMATION", 139, 150], ["Cavernous transformation", "PROBLEM", 0, 24], ["collateral blood vessels", "PROBLEM", 54, 78], ["obstruction", "PROBLEM", 139, 150], ["transformation", "OBSERVATION", 10, 24], ["collateral blood vessels", "OBSERVATION", 54, 78], ["obstruction", "OBSERVATION", 139, 150]]], ["When seen in a transverse section, as on a CT scan, cavernous transformation gives the appearance of multiple caveolar orifices (white arrows in image two above).", [["cavernous", "ANATOMY", 52, 61], ["caveolar", "ANATOMY", 110, 118], ["caveolar orifices", "MULTI-TISSUE_STRUCTURE", 110, 127], ["a CT scan", "TEST", 41, 50], ["cavernous transformation", "PROBLEM", 52, 76], ["multiple caveolar orifices (white arrows", "PROBLEM", 101, 141], ["cavernous", "ANATOMY", 52, 61], ["multiple", "OBSERVATION_MODIFIER", 101, 109], ["caveolar orifices", "OBSERVATION", 110, 127], ["white arrows", "OBSERVATION", 129, 141]]], ["Image one above reveals abrupt \"cut off\" of the portal vein (arrow) at the confluence secondary to extensive thrombus.Answer: Hypercoaguable State Leading to Portal Vein Thrombosis, Cavernous Transformation and Portal HypertensionMore than 85-90% of patients with chronic portal vein thrombosis have esophageal varices, while 30-40% have concomitant gastric varices with bleeding occurring in 50-70% of patients.", [["portal vein", "ANATOMY", 48, 59], ["thrombus", "ANATOMY", 109, 117], ["Vein", "ANATOMY", 165, 169], ["chronic portal vein", "ANATOMY", 264, 283], ["esophageal varices", "ANATOMY", 300, 318], ["gastric varices", "ANATOMY", 350, 365], ["thrombus", "DISEASE", 109, 117], ["Portal Vein Thrombosis", "DISEASE", 158, 180], ["Portal HypertensionMore", "DISEASE", 211, 234], ["chronic portal vein thrombosis", "DISEASE", 264, 294], ["esophageal varices", "DISEASE", 300, 318], ["gastric varices", "DISEASE", 350, 365], ["bleeding", "DISEASE", 371, 379], ["portal vein", "MULTI-TISSUE_STRUCTURE", 48, 59], ["thrombus", "PATHOLOGICAL_FORMATION", 109, 117], ["Portal Vein", "MULTI-TISSUE_STRUCTURE", 158, 169], ["patients", "ORGANISM", 250, 258], ["portal vein", "MULTI-TISSUE_STRUCTURE", 272, 283], ["esophageal varices", "PATHOLOGICAL_FORMATION", 300, 318], ["gastric varices", "PATHOLOGICAL_FORMATION", 350, 365], ["patients", "ORGANISM", 403, 411], ["patients", "SPECIES", 250, 258], ["patients", "SPECIES", 403, 411], ["Image", "TEST", 0, 5], ["extensive thrombus", "PROBLEM", 99, 117], ["Hypercoaguable State", "PROBLEM", 126, 146], ["Portal Vein Thrombosis", "PROBLEM", 158, 180], ["Cavernous Transformation", "PROBLEM", 182, 206], ["Portal HypertensionMore", "TEST", 211, 234], ["chronic portal vein thrombosis", "PROBLEM", 264, 294], ["esophageal varices", "PROBLEM", 300, 318], ["concomitant gastric varices", "PROBLEM", 338, 365], ["bleeding", "PROBLEM", 371, 379], ["abrupt", "OBSERVATION_MODIFIER", 24, 30], ["portal vein", "ANATOMY", 48, 59], ["confluence", "OBSERVATION_MODIFIER", 75, 85], ["extensive", "OBSERVATION_MODIFIER", 99, 108], ["thrombus", "OBSERVATION", 109, 117], ["Portal Vein", "ANATOMY", 158, 169], ["Thrombosis", "OBSERVATION", 170, 180], ["Cavernous", "ANATOMY", 182, 191], ["Portal", "ANATOMY", 211, 217], ["chronic", "OBSERVATION_MODIFIER", 264, 271], ["portal vein", "ANATOMY", 272, 283], ["thrombosis", "OBSERVATION", 284, 294], ["esophageal", "ANATOMY", 300, 310], ["varices", "OBSERVATION", 311, 318], ["gastric", "ANATOMY", 350, 357], ["varices", "OBSERVATION", 358, 365], ["bleeding", "OBSERVATION", 371, 379]]], ["In contrast to variceal bleeding in patients with cirrhosis, the risks of developing liver failure, encephalopathy, and death are much lower in patients with portal vein thrombosis or other causes of extrahepatic portal vein obstruction without underlying cirrhosis.Answer: Hypercoaguable State Leading to Portal Vein Thrombosis, Cavernous Transformation and Portal HypertensionSince the liver parenchyma is not directly involved in patients with portal vein thrombosis, a majority of patients have histologically normal livers.Answer: Hypercoaguable State Leading to Portal Vein Thrombosis, Cavernous Transformation and Portal HypertensionThere are few controlled data on which to base clinical decisions in patients with portal vein thrombosis.", [["variceal", "ANATOMY", 15, 23], ["liver", "ANATOMY", 85, 90], ["portal vein", "ANATOMY", 158, 169], ["extrahepatic portal vein", "ANATOMY", 200, 224], ["Vein", "ANATOMY", 313, 317], ["liver parenchyma", "ANATOMY", 388, 404], ["portal vein", "ANATOMY", 447, 458], ["livers", "ANATOMY", 521, 527], ["Vein", "ANATOMY", 575, 579], ["portal vein", "ANATOMY", 723, 734], ["variceal bleeding", "DISEASE", 15, 32], ["cirrhosis", "DISEASE", 50, 59], ["liver failure", "DISEASE", 85, 98], ["encephalopathy", "DISEASE", 100, 114], ["death", "DISEASE", 120, 125], ["portal vein thrombosis", "DISEASE", 158, 180], ["extrahepatic portal vein obstruction", "DISEASE", 200, 236], ["cirrhosis", "DISEASE", 256, 265], ["Portal Vein Thrombosis", "DISEASE", 306, 328], ["portal vein thrombosis", "DISEASE", 447, 469], ["Portal Vein Thrombosis", "DISEASE", 568, 590], ["Portal Hypertension", "DISEASE", 621, 640], ["portal vein thrombosis", "DISEASE", 723, 745], ["patients", "ORGANISM", 36, 44], ["liver", "ORGAN", 85, 90], ["patients", "ORGANISM", 144, 152], ["portal vein", "MULTI-TISSUE_STRUCTURE", 158, 169], ["extrahepatic portal vein", "MULTI-TISSUE_STRUCTURE", 200, 224], ["Portal Vein", "MULTI-TISSUE_STRUCTURE", 306, 317], ["liver parenchyma", "MULTI-TISSUE_STRUCTURE", 388, 404], ["patients", "ORGANISM", 433, 441], ["portal vein", "MULTI-TISSUE_STRUCTURE", 447, 458], ["patients", "ORGANISM", 485, 493], ["livers", "ORGAN", 521, 527], ["Portal Vein", "MULTI-TISSUE_STRUCTURE", 568, 579], ["patients", "ORGANISM", 709, 717], ["portal vein", "MULTI-TISSUE_STRUCTURE", 723, 734], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 144, 152], ["patients", "SPECIES", 433, 441], ["patients", "SPECIES", 485, 493], ["patients", "SPECIES", 709, 717], ["variceal bleeding", "PROBLEM", 15, 32], ["cirrhosis", "PROBLEM", 50, 59], ["developing liver failure", "PROBLEM", 74, 98], ["encephalopathy", "PROBLEM", 100, 114], ["death", "PROBLEM", 120, 125], ["portal vein thrombosis", "PROBLEM", 158, 180], ["extrahepatic portal vein obstruction", "PROBLEM", 200, 236], ["underlying cirrhosis", "PROBLEM", 245, 265], ["Hypercoaguable State", "PROBLEM", 274, 294], ["Portal Vein Thrombosis", "PROBLEM", 306, 328], ["Cavernous Transformation", "PROBLEM", 330, 354], ["Portal HypertensionSince the liver parenchyma", "PROBLEM", 359, 404], ["portal vein thrombosis", "PROBLEM", 447, 469], ["Hypercoaguable State", "PROBLEM", 536, 556], ["Portal Vein Thrombosis", "PROBLEM", 568, 590], ["Cavernous Transformation", "PROBLEM", 592, 616], ["Portal Hypertension", "PROBLEM", 621, 640], ["few controlled data", "PROBLEM", 650, 669], ["portal vein thrombosis", "PROBLEM", 723, 745], ["variceal", "ANATOMY", 15, 23], ["bleeding", "OBSERVATION", 24, 32], ["cirrhosis", "OBSERVATION", 50, 59], ["liver", "ANATOMY", 85, 90], ["failure", "OBSERVATION", 91, 98], ["encephalopathy", "OBSERVATION", 100, 114], ["lower", "OBSERVATION_MODIFIER", 135, 140], ["portal vein", "ANATOMY", 158, 169], ["thrombosis", "OBSERVATION", 170, 180], ["extrahepatic", "ANATOMY_MODIFIER", 200, 212], ["portal vein", "ANATOMY", 213, 224], ["obstruction", "OBSERVATION", 225, 236], ["without", "UNCERTAINTY", 237, 244], ["cirrhosis", "OBSERVATION", 256, 265], ["Portal Vein", "ANATOMY", 306, 317], ["Thrombosis", "OBSERVATION", 318, 328], ["Cavernous", "OBSERVATION", 330, 339], ["Portal", "ANATOMY", 359, 365], ["HypertensionSince", "OBSERVATION", 366, 383], ["liver", "ANATOMY", 388, 393], ["parenchyma", "ANATOMY_MODIFIER", 394, 404], ["not directly involved", "UNCERTAINTY", 408, 429], ["portal vein", "ANATOMY", 447, 458], ["thrombosis", "OBSERVATION", 459, 469], ["histologically", "OBSERVATION_MODIFIER", 499, 513], ["normal", "OBSERVATION", 514, 520], ["livers", "ANATOMY", 521, 527], ["Portal Vein", "ANATOMY", 568, 579], ["Thrombosis", "OBSERVATION", 580, 590], ["Cavernous", "ANATOMY", 592, 601], ["Portal", "ANATOMY", 621, 627], ["Hypertension", "OBSERVATION", 628, 640], ["few", "OBSERVATION_MODIFIER", 650, 653], ["portal vein", "ANATOMY", 723, 734], ["thrombosis", "OBSERVATION", 735, 745]]], ["Thus, treatment should be determined by an individual patient's clinical circumstances, the pathophysiology involved, and the available expertise.", [["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["treatment", "TREATMENT", 6, 15]]], ["A surgical approach can be considered for patients with correctable anatomic abnormalities causing extrahepatic portal vein obstruction, provided there is no cirrhosis.Answer: Hypercoaguable State Leading to Portal Vein Thrombosis, Cavernous Transformation and Portal HypertensionA 2009 guideline from the American Association for the Study of Liver Diseases recommends consideration of long-term anticoagulation in patients with chronic portal vein thrombosis without cirrhosis who have a permanent risk factor for venous thrombosis that cannot be corrected.", [["extrahepatic portal vein", "ANATOMY", 99, 123], ["Vein", "ANATOMY", 215, 219], ["Liver", "ANATOMY", 344, 349], ["chronic portal vein", "ANATOMY", 430, 449], ["venous", "ANATOMY", 516, 522], ["extrahepatic portal vein obstruction", "DISEASE", 99, 135], ["cirrhosis", "DISEASE", 158, 167], ["Portal Vein Thrombosis", "DISEASE", 208, 230], ["Liver Diseases", "DISEASE", 344, 358], ["chronic portal vein thrombosis", "DISEASE", 430, 460], ["cirrhosis", "DISEASE", 469, 478], ["venous thrombosis", "DISEASE", 516, 533], ["patients", "ORGANISM", 42, 50], ["extrahepatic portal vein", "MULTI-TISSUE_STRUCTURE", 99, 123], ["Liver", "ORGAN", 344, 349], ["patients", "ORGANISM", 416, 424], ["portal vein", "MULTI-TISSUE_STRUCTURE", 438, 449], ["venous", "MULTI-TISSUE_STRUCTURE", 516, 522], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 416, 424], ["A surgical approach", "TREATMENT", 0, 19], ["correctable anatomic abnormalities", "PROBLEM", 56, 90], ["extrahepatic portal vein obstruction", "PROBLEM", 99, 135], ["cirrhosis", "PROBLEM", 158, 167], ["Hypercoaguable State", "PROBLEM", 176, 196], ["Portal Vein Thrombosis", "PROBLEM", 208, 230], ["Cavernous Transformation", "PROBLEM", 232, 256], ["the Study", "TEST", 331, 340], ["Liver Diseases", "PROBLEM", 344, 358], ["long-term anticoagulation", "TREATMENT", 387, 412], ["chronic portal vein thrombosis", "PROBLEM", 430, 460], ["cirrhosis", "PROBLEM", 469, 478], ["a permanent risk factor", "PROBLEM", 488, 511], ["venous thrombosis", "PROBLEM", 516, 533], ["surgical", "OBSERVATION", 2, 10], ["extrahepatic", "ANATOMY_MODIFIER", 99, 111], ["portal vein", "ANATOMY", 112, 123], ["obstruction", "OBSERVATION", 124, 135], ["no", "UNCERTAINTY", 155, 157], ["cirrhosis", "OBSERVATION", 158, 167], ["Portal Vein", "ANATOMY", 208, 219], ["Thrombosis", "OBSERVATION", 220, 230], ["Portal", "ANATOMY", 261, 267], ["Liver", "ANATOMY", 344, 349], ["Diseases", "OBSERVATION", 350, 358], ["long-term", "OBSERVATION_MODIFIER", 387, 396], ["chronic", "OBSERVATION_MODIFIER", 430, 437], ["portal vein", "ANATOMY", 438, 449], ["thrombosis", "OBSERVATION", 450, 460], ["cirrhosis", "OBSERVATION", 469, 478], ["venous", "ANATOMY", 516, 522], ["thrombosis", "OBSERVATION", 523, 533]]], ["In patients with gastroesophageal varices, anticoagulation should not be initiated until adequate prophylaxis for variceal bleeding has been instituted.Answer: Hypercoaguable State Leading to Portal Vein Thrombosis, Cavernous Transformation and Portal HypertensionThe young lady in this case was \"cleared\" to remain on anticoagulation.", [["gastroesophageal varices", "ANATOMY", 17, 41], ["variceal", "ANATOMY", 114, 122], ["Vein", "ANATOMY", 199, 203], ["gastroesophageal varices", "DISEASE", 17, 41], ["variceal bleeding", "DISEASE", 114, 131], ["Portal Vein Thrombosis", "DISEASE", 192, 214], ["Portal Hypertension", "DISEASE", 245, 264], ["patients", "ORGANISM", 3, 11], ["gastroesophageal varices", "PATHOLOGICAL_FORMATION", 17, 41], ["Portal Vein", "MULTI-TISSUE_STRUCTURE", 192, 203], ["patients", "SPECIES", 3, 11], ["gastroesophageal varices", "PROBLEM", 17, 41], ["anticoagulation", "TREATMENT", 43, 58], ["adequate prophylaxis", "TREATMENT", 89, 109], ["variceal bleeding", "PROBLEM", 114, 131], ["Hypercoaguable State", "PROBLEM", 160, 180], ["Portal Vein Thrombosis", "PROBLEM", 192, 214], ["Cavernous Transformation", "PROBLEM", 216, 240], ["Portal Hypertension", "PROBLEM", 245, 264], ["anticoagulation", "TREATMENT", 319, 334], ["gastroesophageal", "ANATOMY", 17, 33], ["varices", "OBSERVATION", 34, 41], ["bleeding", "OBSERVATION", 123, 131], ["Portal Vein", "ANATOMY", 192, 203], ["Thrombosis", "OBSERVATION", 204, 214], ["Cavernous", "ANATOMY", 216, 225], ["Portal", "ANATOMY", 245, 251], ["Hypertension", "OBSERVATION", 252, 264]]], ["She was started on a nonselective beta blocker with titration to a heart rate of 55 beats per minute.", [["heart", "ANATOMY", 67, 72], ["heart", "ORGAN", 67, 72], ["a nonselective beta blocker", "TREATMENT", 19, 46], ["a heart rate", "TEST", 65, 77]]], ["Close follow-up was arranged in both the hematology and hepatology clinics given her prior history of noncompliance.Case 53A 53-year-old white female with a past medical history significant for hypertension and hypercholesterolemia is brought to the emergency room with chest pain and syncope.", [["chest", "ANATOMY", 270, 275], ["hypertension", "DISEASE", 194, 206], ["hypercholesterolemia", "DISEASE", 211, 231], ["chest pain", "DISEASE", 270, 280], ["syncope", "DISEASE", 285, 292], ["female", "ORGANISM", 143, 149], ["chest", "ORGANISM_SUBDIVISION", 270, 275], ["noncompliance", "PROBLEM", 102, 115], ["hypertension", "PROBLEM", 194, 206], ["hypercholesterolemia", "PROBLEM", 211, 231], ["chest pain", "PROBLEM", 270, 280], ["syncope", "PROBLEM", 285, 292], ["hypertension", "OBSERVATION", 194, 206], ["hypercholesterolemia", "OBSERVATION", 211, 231], ["chest", "ANATOMY", 270, 275], ["syncope", "OBSERVATION", 285, 292]]], ["The patient was \"found down\" in her kitchen by her 14-year-old son.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["She was diaphoretic, grasping for air, holding her chest, complaining of severe, crushing pain.", [["chest", "ANATOMY", 51, 56], ["pain", "DISEASE", 90, 94], ["chest", "ORGANISM_SUBDIVISION", 51, 56], ["diaphoretic", "PROBLEM", 8, 19], ["severe, crushing pain", "PROBLEM", 73, 94], ["chest", "ANATOMY", 51, 56], ["severe", "OBSERVATION_MODIFIER", 73, 79]]], ["Upon arrival, emergency medical service (EMS) documented her temperature as 99.1\u00b0F, heart rate 116, systolic blood pressure 82, and respiratory rate 22.", [["heart", "ANATOMY", 84, 89], ["blood", "ANATOMY", 109, 114], ["heart", "ORGAN", 84, 89], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["her temperature", "TEST", 57, 72], ["heart rate", "TEST", 84, 94], ["systolic blood pressure", "TEST", 100, 123], ["respiratory rate", "TEST", 132, 148]]], ["Her oxygen saturation was 83% on room air.", [["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["Her oxygen saturation", "TEST", 0, 21]]], ["The patient's only other medical history includes long standing hypothyroidism.", [["hypothyroidism", "DISEASE", 64, 78], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["long standing hypothyroidism", "PROBLEM", 50, 78], ["long standing", "OBSERVATION_MODIFIER", 50, 63], ["hypothyroidism", "OBSERVATION", 64, 78]]], ["She underwent a carpal tunnel release on her right hand 4 years ago.", [["carpal tunnel", "ANATOMY", 16, 29], ["right hand", "ANATOMY", 45, 55], ["carpal tunnel", "MULTI-TISSUE_STRUCTURE", 16, 29], ["a carpal tunnel release", "TREATMENT", 14, 37], ["carpal", "ANATOMY", 16, 22], ["tunnel release", "OBSERVATION", 23, 37], ["right", "ANATOMY_MODIFIER", 45, 50]]], ["Her prescription medications include hydrochlorothiazide and synthroid.", [["hydrochlorothiazide", "CHEMICAL", 37, 56], ["hydrochlorothiazide", "CHEMICAL", 37, 56], ["synthroid", "CHEMICAL", 61, 70], ["hydrochlorothiazide", "SIMPLE_CHEMICAL", 37, 56], ["synthroid", "SIMPLE_CHEMICAL", 61, 70], ["Her prescription medications", "TREATMENT", 0, 28], ["hydrochlorothiazide", "TREATMENT", 37, 56], ["synthroid", "TREATMENT", 61, 70]]], ["She stopped taking her cholesterol medication (rosuvastatin) months ago as she thought it was the cause of her \"aching muscles.\"", [["muscles", "ANATOMY", 119, 126], ["cholesterol", "CHEMICAL", 23, 34], ["rosuvastatin", "CHEMICAL", 47, 59], ["cholesterol", "CHEMICAL", 23, 34], ["rosuvastatin", "CHEMICAL", 47, 59], ["cholesterol", "SIMPLE_CHEMICAL", 23, 34], ["rosuvastatin", "SIMPLE_CHEMICAL", 47, 59], ["muscles", "ORGANISM_SUBDIVISION", 119, 126], ["her cholesterol medication", "TREATMENT", 19, 45], ["rosuvastatin)", "TREATMENT", 47, 60], ["her \"aching muscles", "PROBLEM", 107, 126]]], ["She does suffer from chronic low back pain and takes as needed ibuprofen and acetaminophen.", [["low back pain", "DISEASE", 29, 42], ["ibuprofen", "CHEMICAL", 63, 72], ["acetaminophen", "CHEMICAL", 77, 90], ["ibuprofen", "CHEMICAL", 63, 72], ["acetaminophen", "CHEMICAL", 77, 90], ["ibuprofen", "SIMPLE_CHEMICAL", 63, 72], ["acetaminophen", "SIMPLE_CHEMICAL", 77, 90], ["chronic low back pain", "PROBLEM", 21, 42], ["ibuprofen", "TREATMENT", 63, 72], ["acetaminophen", "TREATMENT", 77, 90], ["chronic", "OBSERVATION_MODIFIER", 21, 28], ["low", "OBSERVATION_MODIFIER", 29, 32], ["back", "ANATOMY", 33, 37], ["pain", "OBSERVATION", 38, 42]]], ["She took 3 g of acetaminophen two days prior to admission.", [["acetaminophen", "CHEMICAL", 16, 29], ["acetaminophen", "CHEMICAL", 16, 29], ["acetaminophen", "SIMPLE_CHEMICAL", 16, 29], ["acetaminophen", "TREATMENT", 16, 29]]], ["Her husband notes that she has been complaining of intermittent chest discomfort for the last month.", [["chest", "ANATOMY", 64, 69], ["chest discomfort", "DISEASE", 64, 80], ["chest", "ORGANISM_SUBDIVISION", 64, 69], ["intermittent chest discomfort", "PROBLEM", 51, 80], ["chest", "ANATOMY", 64, 69], ["discomfort", "OBSERVATION", 70, 80]]], ["She was scheduled for an evaluation with her primary care physician next week.", [["an evaluation", "TEST", 22, 35]]], ["The patient lives with her husband of 28 years and their three healthy children.", [["patient", "ORGANISM", 4, 11], ["children", "ORGANISM", 71, 79], ["patient", "SPECIES", 4, 11], ["children", "SPECIES", 71, 79]]], ["She has a 20 pack year smoking history and currently smokes ten cigarettes per day.", [["smoking", "CHEMICAL", 23, 30]]], ["She has two tattoos, the first of which she obtained 25 years ago.", [["two", "OBSERVATION_MODIFIER", 8, 11], ["tattoos", "OBSERVATION", 12, 19]]], ["Her father passed from pneumonia at the age of 59.", [["pneumonia", "DISEASE", 23, 32], ["pneumonia", "PROBLEM", 23, 32], ["pneumonia", "OBSERVATION", 23, 32]]], ["He suffered from a debilitating stroke 1 year prior.", [["stroke", "DISEASE", 32, 38], ["a debilitating stroke", "PROBLEM", 17, 38], ["debilitating", "OBSERVATION_MODIFIER", 19, 31], ["stroke", "OBSERVATION", 32, 38]]], ["Her mother died at the age of 66 from postoperative complications following an abdominal aortic aneurysm (AAA) repair.", [["abdominal aortic aneurysm", "ANATOMY", 79, 104], ["abdominal aortic aneurysm", "DISEASE", 79, 104], ["AAA", "DISEASE", 106, 109], ["abdominal aortic", "MULTI-TISSUE_STRUCTURE", 79, 95], ["postoperative complications", "PROBLEM", 38, 65], ["an abdominal aortic aneurysm", "PROBLEM", 76, 104], ["AAA) repair", "TREATMENT", 106, 117], ["postoperative complications", "OBSERVATION", 38, 65], ["abdominal aortic", "ANATOMY", 79, 95], ["aneurysm", "OBSERVATION", 96, 104], ["AAA", "OBSERVATION", 106, 109], ["repair", "OBSERVATION", 111, 117]]], ["The patient's 57-year-old brother has diabetes.Case 53Physical exam is notable for an obese, middle-aged white female with a BMI of 33.7 kg/m 2 .", [["diabetes", "DISEASE", 38, 46], ["patient", "ORGANISM", 4, 11], ["brother", "ORGANISM", 26, 33], ["female", "ORGANISM", 111, 117], ["patient", "SPECIES", 4, 11], ["diabetes", "PROBLEM", 38, 46], ["Case 53Physical exam", "TEST", 47, 67], ["diabetes", "OBSERVATION", 38, 46], ["obese", "OBSERVATION", 86, 91]]], ["She is awake, but confused.", [["confused", "PROBLEM", 18, 26]]], ["She is diaphoretic and very anxious.", [["diaphoretic", "PROBLEM", 7, 18], ["very anxious", "PROBLEM", 23, 35], ["diaphoretic", "OBSERVATION", 7, 18]]], ["Sclerae are nonicteric.", [["nonicteric", "PROBLEM", 12, 22], ["nonicteric", "OBSERVATION", 12, 22]]], ["JVP is measured at 13 cm.", [["JVP", "GENE_OR_GENE_PRODUCT", 0, 3], ["JVP", "PROTEIN", 0, 3], ["JVP", "TEST", 0, 3], ["13 cm", "OBSERVATION_MODIFIER", 19, 24]]], ["She has rales bilaterally, and an S3 is auscultated on cardiac exam.", [["cardiac", "ANATOMY", 55, 62], ["cardiac", "ORGAN", 55, 62], ["rales bilaterally", "PROBLEM", 8, 25], ["cardiac exam", "TEST", 55, 67], ["rales", "OBSERVATION", 8, 13], ["bilaterally", "ANATOMY_MODIFIER", 14, 25], ["S3", "OBSERVATION", 34, 36], ["auscultated", "OBSERVATION", 40, 51]]], ["Her abdomen is soft and nontender.", [["abdomen", "ANATOMY", 4, 11], ["abdomen", "ORGAN", 4, 11], ["nontender", "PROBLEM", 24, 33], ["abdomen", "ANATOMY", 4, 11], ["soft", "OBSERVATION", 15, 19], ["nontender", "OBSERVATION", 24, 33]]], ["Bowel sounds are normal.", [["Bowel", "ANATOMY", 0, 5], ["sounds", "OBSERVATION", 6, 12], ["normal", "OBSERVATION", 17, 23]]], ["Liver edge is smooth and palpable 2 cm below the right costo-vertebral angle.", [["Liver edge", "ANATOMY", 0, 10], ["right costo-vertebral angle", "ANATOMY", 49, 76], ["Liver edge", "MULTI-TISSUE_STRUCTURE", 0, 10], ["edge", "ANATOMY_MODIFIER", 6, 10], ["smooth", "OBSERVATION", 14, 20], ["palpable", "OBSERVATION", 25, 33], ["2 cm", "OBSERVATION_MODIFIER", 34, 38], ["right", "ANATOMY_MODIFIER", 49, 54], ["costo-vertebral angle", "ANATOMY", 55, 76]]], ["There is no appreciable splenomegaly.", [["splenomegaly", "DISEASE", 24, 36], ["splenomegaly", "PATHOLOGICAL_FORMATION", 24, 36], ["appreciable splenomegaly", "PROBLEM", 12, 36], ["no", "UNCERTAINTY", 9, 11], ["appreciable", "OBSERVATION_MODIFIER", 12, 23], ["splenomegaly", "OBSERVATION", 24, 36]]], ["She has trace lower extremitiy edema.", [["lower extremitiy edema", "ANATOMY", 14, 36], ["edema", "DISEASE", 31, 36], ["edema", "PATHOLOGICAL_FORMATION", 31, 36], ["trace lower extremitiy edema", "PROBLEM", 8, 36], ["trace", "OBSERVATION_MODIFIER", 8, 13], ["lower", "ANATOMY_MODIFIER", 14, 19], ["extremitiy", "ANATOMY", 20, 30], ["edema", "OBSERVATION", 31, 36]]], ["There are no stigmata suggestive of chronic liver disease.Case 53An EKG reveals ST elevations in the anterior leads.", [["liver", "ANATOMY", 44, 49], ["anterior", "ANATOMY", 101, 109], ["chronic liver disease", "DISEASE", 36, 57], ["liver", "ORGAN", 44, 49], ["anterior", "ORGAN", 101, 109], ["stigmata", "PROBLEM", 13, 21], ["chronic liver disease", "PROBLEM", 36, 57], ["EKG", "TEST", 68, 71], ["ST elevations in the anterior leads", "PROBLEM", 80, 115], ["no stigmata", "UNCERTAINTY", 10, 21], ["suggestive of", "UNCERTAINTY", 22, 35], ["chronic", "OBSERVATION_MODIFIER", 36, 43], ["liver", "ANATOMY", 44, 49], ["disease", "OBSERVATION", 50, 57], ["ST elevations", "OBSERVATION", 80, 93], ["anterior", "ANATOMY_MODIFIER", 101, 109]]], ["Troponin I is 125.6 ng/ml.", [["Troponin I", "GENE_OR_GENE_PRODUCT", 0, 10], ["Troponin I", "PROTEIN", 0, 10], ["Troponin I", "TEST", 0, 10]]], ["The remainder of initial laboratory data are shown below.Case 53The patient is taken emergently for cardiac catheterization.", [["cardiac", "ANATOMY", 100, 107], ["patient", "ORGANISM", 68, 75], ["cardiac", "ORGAN", 100, 107], ["patient", "SPECIES", 68, 75], ["initial laboratory data", "TEST", 17, 40], ["cardiac catheterization", "TEST", 100, 123], ["catheterization", "OBSERVATION", 108, 123]]], ["Coronary angiography reveals high grade, three vessel disease.", [["Coronary", "ANATOMY", 0, 8], ["vessel", "ANATOMY", 47, 53], ["Coronary", "MULTI-TISSUE_STRUCTURE", 0, 8], ["vessel", "MULTI-TISSUE_STRUCTURE", 47, 53], ["Coronary angiography", "TEST", 0, 20], ["high grade, three vessel disease", "PROBLEM", 29, 61], ["high grade", "OBSERVATION", 29, 39], ["three vessel disease", "OBSERVATION", 41, 61]]], ["Right heart catheterization reveals pressures consistent with severe biventricular congestive heart failure.", [["Right heart", "ANATOMY", 0, 11], ["heart", "ANATOMY", 94, 99], ["biventricular congestive heart failure", "DISEASE", 69, 107], ["heart", "ORGAN", 6, 11], ["heart", "ORGAN", 94, 99], ["Right heart catheterization", "TEST", 0, 27], ["pressures", "TEST", 36, 45], ["severe biventricular congestive heart failure", "PROBLEM", 62, 107], ["heart", "ANATOMY", 6, 11], ["catheterization", "OBSERVATION", 12, 27], ["pressures", "OBSERVATION_MODIFIER", 36, 45], ["consistent with", "UNCERTAINTY", 46, 61], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["biventricular", "ANATOMY_MODIFIER", 69, 82], ["congestive", "OBSERVATION", 83, 93], ["heart", "ANATOMY", 94, 99], ["failure", "OBSERVATION", 100, 107]]], ["An intraaortic balloon pump is inserted, and the patient is taken emergently to the operating room for coronary artery bypass (CABG).Case 53You are consulted on postoperative day 3 for a rising bilirubin.", [["intraaortic", "ANATOMY", 3, 14], ["coronary artery", "ANATOMY", 103, 118], ["bilirubin", "CHEMICAL", 194, 203], ["bilirubin", "CHEMICAL", 194, 203], ["patient", "ORGANISM", 49, 56], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 103, 118], ["bilirubin", "SIMPLE_CHEMICAL", 194, 203], ["patient", "SPECIES", 49, 56], ["An intraaortic balloon pump", "TREATMENT", 0, 27], ["coronary artery bypass", "TREATMENT", 103, 125], ["CABG", "TREATMENT", 127, 131], ["a rising bilirubin", "PROBLEM", 185, 203], ["intraaortic", "ANATOMY", 3, 14], ["balloon pump", "OBSERVATION", 15, 27], ["coronary artery", "ANATOMY", 103, 118], ["bypass", "OBSERVATION", 119, 125], ["CABG", "OBSERVATION", 127, 131]]], ["The primary team also asks you \"when would it be safe to restart her statin?\"", [["statin", "CHEMICAL", 69, 75], ["statin", "CHEMICAL", 69, 75], ["her statin", "TREATMENT", 65, 75]]], ["AST 874 iu/l ALT 290 iu/l ALP 118 iu/l Questions 1.", [["ALP", "PROTEIN", 26, 29], ["AST", "TEST", 0, 3], ["iu", "TEST", 8, 10], ["l ALT", "TEST", 11, 16], ["iu", "TEST", 21, 23], ["l ALP", "TEST", 24, 29]]], ["What is the differential for the abnormalities noted in liver function tests and the increasing bilirubin level? 2.", [["liver", "ANATOMY", 56, 61], ["bilirubin", "CHEMICAL", 96, 105], ["bilirubin", "CHEMICAL", 96, 105], ["liver", "ORGAN", 56, 61], ["bilirubin", "GENE_OR_GENE_PRODUCT", 96, 105], ["the abnormalities", "PROBLEM", 29, 46], ["liver function tests", "TEST", 56, 76], ["the increasing bilirubin level", "PROBLEM", 81, 111], ["abnormalities", "OBSERVATION", 33, 46], ["liver", "ANATOMY", 56, 61], ["increasing", "OBSERVATION_MODIFIER", 85, 95], ["bilirubin", "OBSERVATION", 96, 105]]], ["When would it be safe to start a statin?Answer: Ischemic/Hypoxic Liver InjuryThere are only a handful of liver injuries which will cause transaminase levels to be in the tens of thousands initially and then drop in half the next day.", [["Liver", "ANATOMY", 65, 70], ["liver", "ANATOMY", 105, 110], ["statin", "CHEMICAL", 33, 39], ["liver injuries", "DISEASE", 105, 119], ["statin", "CHEMICAL", 33, 39], ["Liver", "ORGAN", 65, 70], ["liver", "ORGAN", 105, 110], ["transaminase", "SIMPLE_CHEMICAL", 137, 149], ["a statin", "TREATMENT", 31, 39], ["Ischemic/Hypoxic Liver Injury", "PROBLEM", 48, 77], ["liver injuries", "PROBLEM", 105, 119], ["transaminase levels", "TEST", 137, 156], ["Ischemic", "OBSERVATION", 48, 56], ["Hypoxic", "OBSERVATION", 57, 64], ["Liver", "ANATOMY", 65, 70], ["Injury", "OBSERVATION", 71, 77], ["liver", "ANATOMY", 105, 110], ["injuries", "OBSERVATION", 111, 119]]], ["Perhaps the most commonly encountered of these in the United States is ischemic liver injury.", [["liver", "ANATOMY", 80, 85], ["ischemic liver injury", "DISEASE", 71, 92], ["liver", "ORGAN", 80, 85], ["ischemic liver injury", "PROBLEM", 71, 92], ["most commonly", "OBSERVATION_MODIFIER", 12, 25], ["ischemic", "OBSERVATION", 71, 79], ["liver", "ANATOMY", 80, 85], ["injury", "OBSERVATION", 86, 92]]], ["One study quoted a prevalence of 0.9% of all ICU admissions to suffer from ischemic liver injury.Answer: Ischemic/Hypoxic Liver InjuryThe case presentation here is quite classic.", [["liver", "ANATOMY", 84, 89], ["Liver", "ANATOMY", 122, 127], ["ischemic liver injury", "DISEASE", 75, 96], ["liver", "ORGAN", 84, 89], ["Liver", "ORGAN", 122, 127], ["One study", "TEST", 0, 9], ["ischemic liver injury", "PROBLEM", 75, 96], ["Ischemic/Hypoxic Liver Injury", "PROBLEM", 105, 134], ["ischemic", "OBSERVATION", 75, 83], ["liver", "ANATOMY", 84, 89], ["injury", "OBSERVATION", 90, 96], ["Ischemic", "OBSERVATION", 105, 113], ["Hypoxic", "OBSERVATION", 114, 121], ["Liver", "ANATOMY", 122, 127], ["Injury", "OBSERVATION", 128, 134]]], ["The transaminase levels are remarkably high in the setting of shock (in this case cardiogenic); there is concomitant kidney injury (likely the result of acute tubular necrosis).", [["kidney", "ANATOMY", 117, 123], ["tubular", "ANATOMY", 159, 166], ["shock", "DISEASE", 62, 67], ["cardiogenic", "DISEASE", 82, 93], ["kidney injury", "DISEASE", 117, 130], ["acute tubular necrosis", "DISEASE", 153, 175], ["transaminase", "SIMPLE_CHEMICAL", 4, 16], ["kidney", "ORGAN", 117, 123], ["tubular", "ORGAN", 159, 166], ["The transaminase levels", "TEST", 0, 23], ["shock", "PROBLEM", 62, 67], ["concomitant kidney injury", "PROBLEM", 105, 130], ["acute tubular necrosis", "PROBLEM", 153, 175], ["high", "OBSERVATION_MODIFIER", 39, 43], ["shock", "OBSERVATION", 62, 67], ["kidney", "ANATOMY", 117, 123], ["injury", "OBSERVATION", 124, 130], ["likely the result of", "UNCERTAINTY", 132, 152], ["acute", "OBSERVATION_MODIFIER", 153, 158], ["tubular", "ANATOMY_MODIFIER", 159, 166], ["necrosis", "OBSERVATION", 167, 175]]], ["The elevated LDH is also a clue and makes a viral etiology less likely.", [["LDH", "GENE_OR_GENE_PRODUCT", 13, 16], ["LDH", "PROTEIN", 13, 16], ["The elevated LDH", "PROBLEM", 0, 16], ["a viral etiology", "PROBLEM", 42, 58], ["elevated", "OBSERVATION_MODIFIER", 4, 12], ["LDH", "OBSERVATION", 13, 16]]], ["As the underlying insult resolves, the transaminase levels improve precipitously.Answer: Ischemic/Hypoxic Liver InjuryIt is not uncommon for the consult in these cases to be called in several days after admission.", [["Liver", "ANATOMY", 106, 111], ["Liver", "ORGAN", 106, 111], ["the underlying insult", "PROBLEM", 3, 24], ["the transaminase levels", "TEST", 35, 58], ["Ischemic/Hypoxic Liver Injury", "PROBLEM", 89, 118], ["insult", "OBSERVATION", 18, 24], ["Ischemic", "OBSERVATION", 89, 97], ["Hypoxic", "OBSERVATION", 98, 105], ["Liver", "ANATOMY", 106, 111], ["Injury", "OBSERVATION", 112, 118]]], ["The primary team is comforted by the rapid improvement in transaminase levels, but is concerned given the rising total bilirubin.Answer: Ischemic/Hypoxic Liver InjuryThe term \"ischemic hepatitis\" was first coined in 1979 to refer to liver injury characterized histologically by centrilobular liver cell necrosis with a sharp increase in serum aminotransferase levels in the setting of cardiac failure.Answer: Ischemic/Hypoxic Liver InjuryThe etiology of ischemic liver injury is a result of a reduction in hepatic perfusion leading to hepatic anoxia and necrosis.", [["Liver", "ANATOMY", 154, 159], ["liver", "ANATOMY", 233, 238], ["centrilobular liver cell", "ANATOMY", 278, 302], ["serum", "ANATOMY", 337, 342], ["cardiac", "ANATOMY", 385, 392], ["Liver", "ANATOMY", 426, 431], ["liver", "ANATOMY", 463, 468], ["hepatic", "ANATOMY", 506, 513], ["hepatic", "ANATOMY", 535, 542], ["bilirubin", "CHEMICAL", 119, 128], ["ischemic hepatitis", "DISEASE", 176, 194], ["liver injury", "DISEASE", 233, 245], ["centrilobular liver cell necrosis", "DISEASE", 278, 311], ["cardiac failure", "DISEASE", 385, 400], ["ischemic liver injury", "DISEASE", 454, 475], ["hepatic anoxia", "DISEASE", 535, 549], ["necrosis", "DISEASE", 554, 562], ["bilirubin", "CHEMICAL", 119, 128], ["transaminase", "SIMPLE_CHEMICAL", 58, 70], ["bilirubin", "GENE_OR_GENE_PRODUCT", 119, 128], ["Liver", "ORGAN", 154, 159], ["liver", "ORGAN", 233, 238], ["centrilobular liver cell", "CELL", 278, 302], ["serum", "ORGANISM_SUBSTANCE", 337, 342], ["aminotransferase", "SIMPLE_CHEMICAL", 343, 359], ["cardiac", "ORGAN", 385, 392], ["Liver", "ORGAN", 426, 431], ["liver", "ORGAN", 463, 468], ["hepatic", "ORGAN", 506, 513], ["hepatic", "ORGAN", 535, 542], ["serum aminotransferase", "PROTEIN", 337, 359], ["transaminase levels", "TEST", 58, 77], ["the rising total bilirubin", "PROBLEM", 102, 128], ["Ischemic/Hypoxic Liver Injury", "PROBLEM", 137, 166], ["The term \"ischemic hepatitis", "PROBLEM", 166, 194], ["liver injury", "PROBLEM", 233, 245], ["centrilobular liver cell necrosis", "PROBLEM", 278, 311], ["a sharp increase in serum aminotransferase levels", "PROBLEM", 317, 366], ["cardiac failure", "PROBLEM", 385, 400], ["Ischemic/Hypoxic Liver Injury", "PROBLEM", 409, 438], ["ischemic liver injury", "PROBLEM", 454, 475], ["a reduction in hepatic perfusion", "PROBLEM", 491, 523], ["hepatic anoxia", "PROBLEM", 535, 549], ["necrosis", "PROBLEM", 554, 562], ["Ischemic", "OBSERVATION", 137, 145], ["Hypoxic", "OBSERVATION", 146, 153], ["Liver", "ANATOMY", 154, 159], ["Injury", "OBSERVATION", 160, 166], ["ischemic", "OBSERVATION_MODIFIER", 176, 184], ["hepatitis", "OBSERVATION", 185, 194], ["liver", "ANATOMY", 233, 238], ["injury", "OBSERVATION", 239, 245], ["centrilobular", "ANATOMY_MODIFIER", 278, 291], ["liver", "ANATOMY", 292, 297], ["cell necrosis", "OBSERVATION", 298, 311], ["sharp", "OBSERVATION_MODIFIER", 319, 324], ["increase", "OBSERVATION_MODIFIER", 325, 333], ["serum aminotransferase", "OBSERVATION_MODIFIER", 337, 359], ["cardiac", "ANATOMY", 385, 392], ["failure", "OBSERVATION", 393, 400], ["Ischemic", "OBSERVATION", 409, 417], ["Hypoxic", "OBSERVATION", 418, 425], ["Liver", "ANATOMY", 426, 431], ["Injury", "OBSERVATION", 432, 438], ["ischemic", "OBSERVATION_MODIFIER", 454, 462], ["liver", "ANATOMY", 463, 468], ["injury", "OBSERVATION", 469, 475], ["reduction", "OBSERVATION_MODIFIER", 493, 502], ["hepatic", "ANATOMY", 506, 513], ["perfusion", "OBSERVATION", 514, 523], ["hepatic", "ANATOMY", 535, 542], ["anoxia", "OBSERVATION", 543, 549], ["necrosis", "OBSERVATION", 554, 562]]], ["The degree of liver injury is proportional to the amount of liver rendered ischemic.", [["liver", "ANATOMY", 14, 19], ["liver", "ANATOMY", 60, 65], ["liver injury", "DISEASE", 14, 26], ["liver", "ORGAN", 14, 19], ["liver", "ORGAN", 60, 65], ["liver injury", "PROBLEM", 14, 26], ["ischemic", "PROBLEM", 75, 83], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["liver", "ANATOMY", 14, 19], ["injury", "OBSERVATION", 20, 26], ["amount", "OBSERVATION_MODIFIER", 50, 56], ["liver", "ANATOMY", 60, 65], ["ischemic", "OBSERVATION", 75, 83]]], ["The outcome is dependent upon restoration in hepatic blood flow and oxygen delivery.", [["hepatic blood", "ANATOMY", 45, 58], ["oxygen", "CHEMICAL", 68, 74], ["oxygen", "CHEMICAL", 68, 74], ["hepatic", "MULTI-TISSUE_STRUCTURE", 45, 52], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["oxygen", "SIMPLE_CHEMICAL", 68, 74], ["hepatic blood flow", "TREATMENT", 45, 63], ["oxygen delivery", "TREATMENT", 68, 83], ["dependent", "OBSERVATION_MODIFIER", 15, 24], ["restoration", "OBSERVATION", 30, 41], ["hepatic", "ANATOMY", 45, 52], ["blood flow", "OBSERVATION", 53, 63], ["oxygen delivery", "OBSERVATION", 68, 83]]], ["Global hypotension (as seen in shock/ hypotension) typically leads to rapid recovery with no long-term effects, granted there is no significant underlying liver disease.", [["liver", "ANATOMY", 155, 160], ["hypotension", "DISEASE", 7, 18], ["shock", "DISEASE", 31, 36], ["hypotension", "DISEASE", 38, 49], ["liver disease", "DISEASE", 155, 168], ["liver", "ORGAN", 155, 160], ["Global hypotension", "PROBLEM", 0, 18], ["hypotension", "PROBLEM", 38, 49], ["long-term effects", "PROBLEM", 93, 110], ["significant underlying liver disease", "PROBLEM", 132, 168], ["hypotension", "OBSERVATION", 7, 18], ["hypotension", "OBSERVATION", 38, 49], ["long-term effects", "OBSERVATION_MODIFIER", 93, 110], ["no significant", "UNCERTAINTY", 129, 143], ["liver", "ANATOMY", 155, 160], ["disease", "OBSERVATION", 161, 168]]], ["Ischemia resulting from vascular occlusion or injury to the contrary can cause permanent injury and lead to fibrosis and ischemic cholangiopathy.Answer: Ischemic/Hypoxic Liver InjuryIn one of the larger studies to evaluate this entity, over a 10-year period, 142 episodes of ischemic hepatitis were identified.", [["vascular", "ANATOMY", 24, 32], ["Liver", "ANATOMY", 170, 175], ["Ischemia", "DISEASE", 0, 8], ["vascular occlusion", "DISEASE", 24, 42], ["fibrosis", "DISEASE", 108, 116], ["ischemic cholangiopathy", "DISEASE", 121, 144], ["ischemic hepatitis", "DISEASE", 275, 293], ["vascular", "MULTI-TISSUE_STRUCTURE", 24, 32], ["Liver", "ORGAN", 170, 175], ["Ischemia", "PROBLEM", 0, 8], ["vascular occlusion", "PROBLEM", 24, 42], ["injury", "PROBLEM", 46, 52], ["permanent injury", "PROBLEM", 79, 95], ["fibrosis", "PROBLEM", 108, 116], ["ischemic cholangiopathy", "PROBLEM", 121, 144], ["Ischemic/Hypoxic Liver Injury", "PROBLEM", 153, 182], ["the larger studies", "TEST", 192, 210], ["ischemic hepatitis", "PROBLEM", 275, 293], ["vascular", "ANATOMY", 24, 32], ["occlusion", "OBSERVATION", 33, 42], ["injury", "OBSERVATION", 46, 52], ["injury", "OBSERVATION", 89, 95], ["fibrosis", "OBSERVATION", 108, 116], ["ischemic", "OBSERVATION_MODIFIER", 121, 129], ["cholangiopathy", "OBSERVATION", 130, 144], ["Ischemic", "OBSERVATION", 153, 161], ["Hypoxic", "OBSERVATION", 162, 169], ["Liver", "ANATOMY", 170, 175], ["Injury", "OBSERVATION", 176, 182], ["ischemic", "OBSERVATION_MODIFIER", 275, 283], ["hepatitis", "OBSERVATION", 284, 293]]], ["Four main groups were identified: decompensated congestive heart failure, acute cardiac failure, exacerbated chronic respiratory failure, and toxic/septic shock.", [["heart", "ANATOMY", 59, 64], ["cardiac", "ANATOMY", 80, 87], ["respiratory", "ANATOMY", 117, 128], ["congestive heart failure", "DISEASE", 48, 72], ["acute cardiac failure", "DISEASE", 74, 95], ["chronic respiratory failure", "DISEASE", 109, 136], ["toxic/septic shock", "DISEASE", 142, 160], ["heart", "ORGAN", 59, 64], ["cardiac", "ORGAN", 80, 87], ["decompensated congestive heart failure", "PROBLEM", 34, 72], ["acute cardiac failure", "PROBLEM", 74, 95], ["exacerbated chronic respiratory failure", "PROBLEM", 97, 136], ["toxic/septic shock", "PROBLEM", 142, 160], ["decompensated", "OBSERVATION_MODIFIER", 34, 47], ["congestive", "OBSERVATION", 48, 58], ["heart", "ANATOMY", 59, 64], ["failure", "OBSERVATION", 65, 72], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["cardiac", "ANATOMY", 80, 87], ["failure", "OBSERVATION", 88, 95], ["exacerbated", "OBSERVATION_MODIFIER", 97, 108], ["chronic", "OBSERVATION_MODIFIER", 109, 116], ["respiratory failure", "OBSERVATION", 117, 136], ["toxic", "OBSERVATION_MODIFIER", 142, 147], ["septic shock", "OBSERVATION", 148, 160]]], ["The hemodynamic mechanisms responsible for liver injury were different in the four groups.", [["liver", "ANATOMY", 43, 48], ["liver injury", "DISEASE", 43, 55], ["liver", "ORGAN", 43, 48], ["The hemodynamic mechanisms", "PROBLEM", 0, 26], ["liver injury", "PROBLEM", 43, 55], ["hemodynamic mechanisms", "OBSERVATION", 4, 26], ["liver", "ANATOMY", 43, 48], ["injury", "OBSERVATION", 49, 55], ["different", "OBSERVATION_MODIFIER", 61, 70]]], ["In congestive heart failure and acute heart failure, the hypoxia of the liver resulted from decreased hepatic blood flow due to left-sided heart failure and from venous congestion secondary to right-sided heart failure.", [["heart", "ANATOMY", 14, 19], ["heart", "ANATOMY", 38, 43], ["liver", "ANATOMY", 72, 77], ["hepatic blood", "ANATOMY", 102, 115], ["heart", "ANATOMY", 139, 144], ["venous", "ANATOMY", 162, 168], ["heart", "ANATOMY", 205, 210], ["congestive heart failure", "DISEASE", 3, 27], ["heart failure", "DISEASE", 38, 51], ["hypoxia", "DISEASE", 57, 64], ["decreased hepatic blood flow", "DISEASE", 92, 120], ["heart failure", "DISEASE", 139, 152], ["venous congestion", "DISEASE", 162, 179], ["heart failure", "DISEASE", 205, 218], ["heart", "ORGAN", 14, 19], ["heart", "ORGAN", 38, 43], ["liver", "ORGAN", 72, 77], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["heart", "ORGAN", 139, 144], ["venous", "MULTI-TISSUE_STRUCTURE", 162, 168], ["heart", "ORGAN", 205, 210], ["congestive heart failure", "PROBLEM", 3, 27], ["acute heart failure", "PROBLEM", 32, 51], ["the hypoxia of the liver", "PROBLEM", 53, 77], ["decreased hepatic blood flow", "PROBLEM", 92, 120], ["left-sided heart failure", "PROBLEM", 128, 152], ["venous congestion", "PROBLEM", 162, 179], ["right-sided heart failure", "PROBLEM", 193, 218], ["congestive", "OBSERVATION_MODIFIER", 3, 13], ["heart", "ANATOMY", 14, 19], ["failure", "OBSERVATION", 20, 27], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["heart", "ANATOMY", 38, 43], ["failure", "OBSERVATION", 44, 51], ["hypoxia", "OBSERVATION", 57, 64], ["liver", "ANATOMY", 72, 77], ["decreased", "OBSERVATION_MODIFIER", 92, 101], ["hepatic", "ANATOMY", 102, 109], ["blood flow", "OBSERVATION", 110, 120], ["left", "ANATOMY_MODIFIER", 128, 132], ["sided", "ANATOMY_MODIFIER", 133, 138], ["heart", "ANATOMY", 139, 144], ["failure", "OBSERVATION", 145, 152], ["venous", "ANATOMY", 162, 168], ["congestion", "OBSERVATION", 169, 179], ["right", "ANATOMY_MODIFIER", 193, 198], ["sided", "ANATOMY_MODIFIER", 199, 204], ["heart", "ANATOMY", 205, 210], ["failure", "OBSERVATION", 211, 218]]], ["In chronic respiratory failure, liver hypoxia was mainly due to profound hypoxemia.", [["respiratory", "ANATOMY", 11, 22], ["liver", "ANATOMY", 32, 37], ["chronic respiratory failure", "DISEASE", 3, 30], ["liver hypoxia", "DISEASE", 32, 45], ["hypoxemia", "DISEASE", 73, 82], ["liver", "ORGAN", 32, 37], ["chronic respiratory failure", "PROBLEM", 3, 30], ["liver hypoxia", "PROBLEM", 32, 45], ["profound hypoxemia", "PROBLEM", 64, 82], ["chronic", "OBSERVATION_MODIFIER", 3, 10], ["respiratory failure", "OBSERVATION", 11, 30], ["liver", "ANATOMY", 32, 37], ["hypoxia", "OBSERVATION", 38, 45], ["profound", "OBSERVATION_MODIFIER", 64, 72], ["hypoxemia", "OBSERVATION", 73, 82]]], ["In toxic/septic shock, oxygen delivery to the liver was not decreased, but oxygen demands were increased.", [["liver", "ANATOMY", 46, 51], ["shock", "DISEASE", 16, 21], ["oxygen", "CHEMICAL", 23, 29], ["oxygen", "CHEMICAL", 75, 81], ["oxygen", "CHEMICAL", 23, 29], ["oxygen", "CHEMICAL", 75, 81], ["oxygen", "SIMPLE_CHEMICAL", 23, 29], ["liver", "ORGAN", 46, 51], ["oxygen", "SIMPLE_CHEMICAL", 75, 81], ["septic shock", "PROBLEM", 9, 21], ["oxygen delivery", "TREATMENT", 23, 38], ["oxygen demands", "PROBLEM", 75, 89], ["toxic", "OBSERVATION_MODIFIER", 3, 8], ["septic shock", "OBSERVATION", 9, 21], ["oxygen", "OBSERVATION_MODIFIER", 23, 29], ["liver", "ANATOMY", 46, 51], ["not", "UNCERTAINTY", 56, 59], ["decreased", "OBSERVATION_MODIFIER", 60, 69], ["oxygen demands", "OBSERVATION", 75, 89], ["increased", "OBSERVATION_MODIFIER", 95, 104]]], ["A \"shock\" state was present in only 55% of cases.", [["shock", "DISEASE", 3, 8], ["A \"shock\" state", "PROBLEM", 0, 15], ["shock", "OBSERVATION", 3, 8]]], ["We agree with the authors of this study that the commonly used term \"shock liver\" should be disregarded, and replaced with \"hypoxic liver injury.\"Answer: Ischemic/Hypoxic Liver InjuryThe workup in cases like this should be determined on a case-by-case basis but in most instances should be limited and cost-efficient.", [["liver", "ANATOMY", 75, 80], ["liver", "ANATOMY", 132, 137], ["Liver", "ANATOMY", 171, 176], ["shock", "DISEASE", 69, 74], ["liver injury", "DISEASE", 132, 144], ["liver", "ORGAN", 75, 80], ["liver", "ORGAN", 132, 137], ["Liver", "ORGAN", 171, 176], ["this study", "TEST", 29, 39], ["shock liver", "PROBLEM", 69, 80], ["hypoxic liver injury", "PROBLEM", 124, 144], ["Ischemic/Hypoxic Liver Injury", "PROBLEM", 154, 183], ["The workup", "TEST", 183, 193], ["liver", "ANATOMY", 75, 80], ["hypoxic", "OBSERVATION_MODIFIER", 124, 131], ["liver", "ANATOMY", 132, 137], ["injury", "OBSERVATION", 138, 144], ["Ischemic", "OBSERVATION", 154, 162], ["Hypoxic", "OBSERVATION", 163, 170], ["Liver", "ANATOMY", 171, 176], ["Injury", "OBSERVATION", 177, 183]]], ["A right upper quadrant ultrasound with Dopplers to rule out underlying liver disease and vascular occlusion should be performed.", [["right upper quadrant", "ANATOMY", 2, 22], ["liver", "ANATOMY", 71, 76], ["vascular", "ANATOMY", 89, 97], ["liver disease", "DISEASE", 71, 84], ["vascular occlusion", "DISEASE", 89, 107], ["liver", "ORGAN", 71, 76], ["vascular", "MULTI-TISSUE_STRUCTURE", 89, 97], ["A right upper quadrant ultrasound", "TEST", 0, 33], ["Dopplers", "TEST", 39, 47], ["underlying liver disease", "PROBLEM", 60, 84], ["vascular occlusion", "PROBLEM", 89, 107], ["right", "ANATOMY_MODIFIER", 2, 7], ["upper", "ANATOMY_MODIFIER", 8, 13], ["liver", "ANATOMY", 71, 76], ["disease", "OBSERVATION", 77, 84], ["vascular", "ANATOMY", 89, 97], ["occlusion", "OBSERVATION", 98, 107]]], ["Viral serologies are not unreasonable.", [["Viral", "ORGANISM", 0, 5], ["Viral serologies", "TEST", 0, 16]]], ["The bilirubin will typically \"lag\" behind the transaminase levels and will peak on days 3-5.", [["bilirubin", "CHEMICAL", 4, 13], ["bilirubin", "CHEMICAL", 4, 13], ["bilirubin", "SIMPLE_CHEMICAL", 4, 13], ["transaminase", "SIMPLE_CHEMICAL", 46, 58], ["The bilirubin", "TEST", 0, 13], ["the transaminase levels", "TEST", 42, 65]]], ["Avoiding additional hepatic insults is important.", [["hepatic", "ANATOMY", 20, 27], ["hepatic insults", "DISEASE", 20, 35], ["hepatic", "MULTI-TISSUE_STRUCTURE", 20, 27], ["additional hepatic insults", "PROBLEM", 9, 35], ["hepatic", "ANATOMY", 20, 27], ["insults", "OBSERVATION", 28, 35]]], ["Generally supportive care and improving the underlying cause of hypoxia will improve the liver injury.", [["liver", "ANATOMY", 89, 94], ["hypoxia", "DISEASE", 64, 71], ["liver injury", "DISEASE", 89, 101], ["liver", "ORGAN", 89, 94], ["supportive care", "TREATMENT", 10, 25], ["hypoxia", "PROBLEM", 64, 71], ["the liver injury", "PROBLEM", 85, 101], ["hypoxia", "OBSERVATION", 64, 71], ["liver", "ANATOMY", 89, 94], ["injury", "OBSERVATION", 95, 101]]], ["Liver failure is rare in these settings; when it does occur, it almost always occurs in the setting of severe cardiac disease or cirrhosis.Answer: Ischemic/Hypoxic Liver InjuryThe use of statins in patients with liver disease is a commonly asked question of primary care physicians.", [["Liver", "ANATOMY", 0, 5], ["cardiac", "ANATOMY", 110, 117], ["Liver", "ANATOMY", 164, 169], ["liver", "ANATOMY", 212, 217], ["Liver failure", "DISEASE", 0, 13], ["cardiac disease", "DISEASE", 110, 125], ["cirrhosis", "DISEASE", 129, 138], ["statins", "CHEMICAL", 187, 194], ["liver disease", "DISEASE", 212, 225], ["statins", "CHEMICAL", 187, 194], ["Liver", "ORGAN", 0, 5], ["cardiac", "ORGAN", 110, 117], ["Liver", "ORGAN", 164, 169], ["patients", "ORGANISM", 198, 206], ["liver", "ORGAN", 212, 217], ["patients", "SPECIES", 198, 206], ["Liver failure", "PROBLEM", 0, 13], ["severe cardiac disease", "PROBLEM", 103, 125], ["cirrhosis", "PROBLEM", 129, 138], ["Ischemic/Hypoxic Liver Injury", "PROBLEM", 147, 176], ["statins", "TREATMENT", 187, 194], ["liver disease", "PROBLEM", 212, 225], ["failure", "OBSERVATION", 6, 13], ["rare", "OBSERVATION_MODIFIER", 17, 21], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["cardiac", "ANATOMY", 110, 117], ["disease", "OBSERVATION", 118, 125], ["cirrhosis", "OBSERVATION", 129, 138], ["Ischemic", "OBSERVATION", 147, 155], ["Hypoxic", "OBSERVATION", 156, 163], ["Liver", "ANATOMY", 164, 169], ["Injury", "OBSERVATION", 170, 176], ["liver", "ANATOMY", 212, 217], ["disease", "OBSERVATION", 218, 225]]], ["Statins have become one of the most widely prescribed medications in the western world.", [["Statins", "CHEMICAL", 0, 7], ["Statins", "CHEMICAL", 0, 7], ["Statins", "TREATMENT", 0, 7], ["medications", "TREATMENT", 54, 65]]], ["Their beneficial effects in patients with cardiovascular disease are well established.", [["cardiovascular", "ANATOMY", 42, 56], ["cardiovascular disease", "DISEASE", 42, 64], ["patients", "ORGANISM", 28, 36], ["cardiovascular", "ANATOMICAL_SYSTEM", 42, 56], ["patients", "SPECIES", 28, 36], ["cardiovascular disease", "PROBLEM", 42, 64], ["cardiovascular", "ANATOMY", 42, 56], ["disease", "OBSERVATION", 57, 64]]], ["They have an excellent safety profile.", [["excellent", "OBSERVATION_MODIFIER", 13, 22]]], ["The most common clinical hepatic manifestation of statins is asymptomatic elevations in liver enzymes with an incidence of about 3%.", [["hepatic", "ANATOMY", 25, 32], ["liver", "ANATOMY", 88, 93], ["statins", "CHEMICAL", 50, 57], ["elevations in liver enzymes", "DISEASE", 74, 101], ["statins", "CHEMICAL", 50, 57], ["hepatic", "ORGAN", 25, 32], ["statins", "SIMPLE_CHEMICAL", 50, 57], ["liver", "ORGAN", 88, 93], ["liver enzymes", "PROTEIN", 88, 101], ["statins", "TREATMENT", 50, 57], ["asymptomatic elevations in liver enzymes", "PROBLEM", 61, 101], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["hepatic", "ANATOMY", 25, 32], ["statins", "OBSERVATION", 50, 57], ["asymptomatic", "OBSERVATION_MODIFIER", 61, 73], ["elevations", "OBSERVATION_MODIFIER", 74, 84], ["liver", "ANATOMY", 88, 93]]], ["In general, however, the incidence of liver enzymes elevations in statin-treated patients has not been consistently different than placebo.", [["liver", "ANATOMY", 38, 43], ["statin", "CHEMICAL", 66, 72], ["statin", "CHEMICAL", 66, 72], ["liver", "ORGAN", 38, 43], ["statin", "SIMPLE_CHEMICAL", 66, 72], ["patients", "ORGANISM", 81, 89], ["liver enzymes", "PROTEIN", 38, 51], ["patients", "SPECIES", 81, 89], ["liver enzymes elevations", "PROBLEM", 38, 62], ["statin", "TREATMENT", 66, 72], ["liver", "ANATOMY", 38, 43]]], ["The risk of \"significant\" liver injury is extremely rare, and the risk of acute liver failure has been limited to a handful of case reports.Answer: Ischemic/Hypoxic Liver InjuryUnderstanding the beneficial effects a statin would have for the patient in this particular case, we recommend starting the medication after liver enzymes were closer to normal values.", [["liver", "ANATOMY", 26, 31], ["liver", "ANATOMY", 80, 85], ["Liver", "ANATOMY", 165, 170], ["liver", "ANATOMY", 318, 323], ["liver injury", "DISEASE", 26, 38], ["acute liver failure", "DISEASE", 74, 93], ["Liver Injury", "DISEASE", 165, 177], ["statin", "CHEMICAL", 216, 222], ["liver", "ORGAN", 26, 31], ["liver", "ORGAN", 80, 85], ["Liver", "ORGAN", 165, 170], ["patient", "ORGANISM", 242, 249], ["liver", "ORGAN", 318, 323], ["liver enzymes", "PROTEIN", 318, 331], ["patient", "SPECIES", 242, 249], ["\"significant\" liver injury", "PROBLEM", 12, 38], ["acute liver failure", "PROBLEM", 74, 93], ["Ischemic/Hypoxic Liver Injury", "PROBLEM", 148, 177], ["a statin", "TREATMENT", 214, 222], ["the medication", "TREATMENT", 297, 311], ["liver enzymes", "TEST", 318, 331], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["liver", "ANATOMY", 26, 31], ["injury", "OBSERVATION", 32, 38], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["liver", "ANATOMY", 80, 85], ["failure", "OBSERVATION", 86, 93], ["Ischemic", "OBSERVATION", 148, 156], ["Hypoxic", "OBSERVATION_MODIFIER", 157, 164], ["Liver", "ANATOMY", 165, 170], ["Injury", "OBSERVATION", 171, 177], ["liver", "ANATOMY", 318, 323]]], ["The patient's enzymes returned to near normal after 2 weeks from her initial presentation.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["The patient's enzymes", "TEST", 0, 21]]], ["She was restarted on her statin medication and repeat enzymes 1 month later were completely normal.", [["statin", "CHEMICAL", 25, 31], ["statin", "CHEMICAL", 25, 31], ["her statin medication", "TREATMENT", 21, 42], ["repeat enzymes", "TEST", 47, 61], ["normal", "OBSERVATION", 92, 98]]], ["The patient has had no sequelae from her acute liver injury.Case 54A 41-year-old lady presents with several weeks of right upper quadrant pain, abdominal distension, and shortness of breath.", [["liver", "ANATOMY", 47, 52], ["right upper quadrant", "ANATOMY", 117, 137], ["abdominal", "ANATOMY", 144, 153], ["acute liver injury", "DISEASE", 41, 59], ["right upper quadrant pain", "DISEASE", 117, 142], ["abdominal distension", "DISEASE", 144, 164], ["shortness of breath", "DISEASE", 170, 189], ["patient", "ORGANISM", 4, 11], ["liver", "ORGAN", 47, 52], ["lady", "ORGANISM", 81, 85], ["upper quadrant", "ORGANISM_SUBDIVISION", 123, 137], ["abdominal", "ORGANISM_SUBDIVISION", 144, 153], ["patient", "SPECIES", 4, 11], ["sequelae", "PROBLEM", 23, 31], ["her acute liver injury", "PROBLEM", 37, 59], ["right upper quadrant pain", "PROBLEM", 117, 142], ["abdominal distension", "PROBLEM", 144, 164], ["shortness of breath", "PROBLEM", 170, 189], ["no", "UNCERTAINTY", 20, 22], ["sequelae", "OBSERVATION_MODIFIER", 23, 31], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["liver", "ANATOMY", 47, 52], ["injury", "OBSERVATION", 53, 59], ["right", "ANATOMY_MODIFIER", 117, 122], ["upper", "ANATOMY_MODIFIER", 123, 128], ["quadrant", "ANATOMY", 129, 137], ["pain", "OBSERVATION", 138, 142], ["abdominal", "ANATOMY", 144, 153], ["distension", "OBSERVATION", 154, 164]]], ["She denies any jaundice or change in urine or stool color.Case 54She is otherwise well and has no other medical problems.", [["urine", "ANATOMY", 37, 42], ["stool", "ANATOMY", 46, 51], ["jaundice", "DISEASE", 15, 23], ["urine", "ORGANISM_SUBSTANCE", 37, 42], ["stool", "ORGANISM_SUBSTANCE", 46, 51], ["any jaundice", "PROBLEM", 11, 23], ["change in urine or stool color", "PROBLEM", 27, 57], ["other medical problems", "PROBLEM", 98, 120], ["jaundice", "OBSERVATION", 15, 23], ["urine", "ANATOMY", 37, 42], ["stool", "OBSERVATION", 46, 51]]], ["She takes no medications and denies over-the-counter or herbal supplements.", [["medications", "TREATMENT", 13, 24], ["herbal supplements", "TREATMENT", 56, 74]]], ["She has two children who are alive and well.Case 54She denies tobacco or alcohol and does not use illicit drugs.Case 54There is no family history.", [["alcohol", "CHEMICAL", 73, 80], ["alcohol", "CHEMICAL", 73, 80], ["children", "ORGANISM", 12, 20], ["tobacco", "ORGANISM", 62, 69], ["alcohol", "SIMPLE_CHEMICAL", 73, 80], ["children", "SPECIES", 12, 20], ["tobacco", "SPECIES", 62, 69], ["no", "UNCERTAINTY", 128, 130]]], ["Exam shows a lady who is uncomfortable.", [["Exam", "TEST", 0, 4], ["uncomfortable", "PROBLEM", 25, 38]]], ["Vital signs show BP 125/80, pulse 104, respiratory rate 26 per minute, and she is afebrile.Case 54There is mild scleral icterus but no spider nevi or palmar erythema.", [["scleral icterus", "ANATOMY", 112, 127], ["nevi", "ANATOMY", 142, 146], ["palmar", "ANATOMY", 150, 156], ["scleral icterus", "DISEASE", 112, 127], ["spider nevi", "DISEASE", 135, 146], ["palmar erythema", "DISEASE", 150, 165], ["palmar erythema", "PATHOLOGICAL_FORMATION", 150, 165], ["Vital signs", "TEST", 0, 11], ["BP", "TEST", 17, 19], ["pulse", "TEST", 28, 33], ["respiratory rate", "TEST", 39, 55], ["afebrile", "PROBLEM", 82, 90], ["mild scleral icterus", "PROBLEM", 107, 127], ["spider nevi", "PROBLEM", 135, 146], ["palmar erythema", "PROBLEM", 150, 165], ["afebrile", "OBSERVATION", 82, 90], ["mild", "OBSERVATION_MODIFIER", 107, 111], ["scleral", "ANATOMY", 112, 119], ["icterus", "OBSERVATION", 120, 127], ["no", "UNCERTAINTY", 132, 134], ["spider nevi", "OBSERVATION", 135, 146], ["palmar", "ANATOMY", 150, 156], ["erythema", "OBSERVATION", 157, 165]]], ["Heart reveals normal S1 and S2 without added sounds.", [["Heart", "ANATOMY", 0, 5], ["Heart", "ORGAN", 0, 5], ["S2", "PROTEIN", 28, 30], ["added sounds", "PROBLEM", 39, 51], ["normal", "OBSERVATION", 14, 20], ["S1", "ANATOMY", 21, 23], ["S2", "ANATOMY", 28, 30], ["without", "UNCERTAINTY", 31, 38], ["added", "OBSERVATION_MODIFIER", 39, 44], ["sounds", "OBSERVATION", 45, 51]]], ["Chest reveals decreased air entry at the right base with a stony dull percussion note and decreased fremitus.Case 54Her abdomen is distended with a liver that is felt 6 cm below the right costal margin and is tender but not pulsatile.", [["right base", "ANATOMY", 41, 51], ["abdomen", "ANATOMY", 120, 127], ["liver", "ANATOMY", 148, 153], ["right costal margin", "ANATOMY", 182, 201], ["fremitus", "DISEASE", 100, 108], ["liver", "ORGAN", 148, 153], ["costal margin", "MULTI-TISSUE_STRUCTURE", 188, 201], ["decreased air entry at the right base", "PROBLEM", 14, 51], ["a stony dull percussion", "TEST", 57, 80], ["decreased fremitus", "PROBLEM", 90, 108], ["distended", "PROBLEM", 131, 140], ["tender", "PROBLEM", 209, 215], ["pulsatile", "PROBLEM", 224, 233], ["decreased", "OBSERVATION_MODIFIER", 14, 23], ["air entry", "OBSERVATION", 24, 33], ["right", "ANATOMY_MODIFIER", 41, 46], ["base", "ANATOMY_MODIFIER", 47, 51], ["stony", "OBSERVATION_MODIFIER", 59, 64], ["dull", "OBSERVATION_MODIFIER", 65, 69], ["percussion", "OBSERVATION", 70, 80], ["decreased", "OBSERVATION_MODIFIER", 90, 99], ["fremitus", "OBSERVATION", 100, 108], ["abdomen", "ANATOMY", 120, 127], ["distended", "OBSERVATION", 131, 140], ["liver", "ANATOMY", 148, 153], ["6 cm", "OBSERVATION_MODIFIER", 167, 171], ["right", "ANATOMY_MODIFIER", 182, 187], ["costal", "ANATOMY", 188, 194], ["margin", "ANATOMY_MODIFIER", 195, 201], ["tender", "OBSERVATION", 209, 215], ["not", "UNCERTAINTY", 220, 223], ["pulsatile", "OBSERVATION", 224, 233]]], ["There is a fluid thrill but no dilated abdominal veins.", [["fluid", "ANATOMY", 11, 16], ["abdominal veins", "ANATOMY", 39, 54], ["abdominal veins", "MULTI-TISSUE_STRUCTURE", 39, 54], ["a fluid thrill", "PROBLEM", 9, 23], ["dilated abdominal veins", "PROBLEM", 31, 54], ["fluid thrill", "OBSERVATION", 11, 23], ["no", "UNCERTAINTY", 28, 30], ["dilated", "OBSERVATION", 31, 38], ["abdominal veins", "ANATOMY", 39, 54]]], ["She has 2+ankle edema to the knees bilaterally.Answer: Budd-Chiari SyndromeThe ultrasound with Doppler(Figs.", [["knees", "ANATOMY", 29, 34], ["edema", "DISEASE", 16, 21], ["Budd-Chiari Syndrome", "DISEASE", 55, 75], ["ankle", "ORGANISM_SUBDIVISION", 10, 15], ["edema", "PATHOLOGICAL_FORMATION", 16, 21], ["knees", "ORGANISM_SUBDIVISION", 29, 34], ["Budd-Chiari Syndrome", "SPECIES", 55, 75], ["ankle edema to the knees bilaterally", "PROBLEM", 10, 46], ["Budd-Chiari Syndrome", "PROBLEM", 55, 75], ["The ultrasound", "TEST", 75, 89], ["Doppler", "TEST", 95, 102], ["ankle", "ANATOMY", 10, 15], ["edema", "OBSERVATION", 16, 21], ["knees", "ANATOMY", 29, 34], ["bilaterally", "ANATOMY_MODIFIER", 35, 46], ["Chiari Syndrome", "OBSERVATION", 60, 75]]], ["1-54.4) shows echogenic material in the inferior vena cava (IVC) that is arrowed (Fig. 54.1) , and all of the hepatic veins show no flow and are barely visible indicating complete thrombosis.Answer: Budd-Chiari SyndromeBudd-Chiari syndrome (BCS) is defined by obstruction of venous outflow from the liver.", [["inferior vena cava", "ANATOMY", 40, 58], ["IVC", "ANATOMY", 60, 63], ["hepatic veins", "ANATOMY", 110, 123], ["venous", "ANATOMY", 275, 281], ["liver", "ANATOMY", 299, 304], ["thrombosis", "DISEASE", 180, 190], ["Chiari SyndromeBudd-Chiari syndrome", "DISEASE", 204, 239], ["BCS", "DISEASE", 241, 244], ["obstruction of venous outflow from the liver", "DISEASE", 260, 304], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 40, 58], ["IVC", "MULTI-TISSUE_STRUCTURE", 60, 63], ["hepatic veins", "MULTI-TISSUE_STRUCTURE", 110, 123], ["venous outflow", "MULTI-TISSUE_STRUCTURE", 275, 289], ["liver", "ORGAN", 299, 304], ["echogenic material", "PROBLEM", 14, 32], ["Fig.", "TEST", 82, 86], ["complete thrombosis", "PROBLEM", 171, 190], ["Budd-Chiari SyndromeBudd-Chiari syndrome", "PROBLEM", 199, 239], ["obstruction of venous outflow from the liver", "PROBLEM", 260, 304], ["echogenic", "OBSERVATION_MODIFIER", 14, 23], ["material", "OBSERVATION", 24, 32], ["inferior vena cava", "ANATOMY", 40, 58], ["IVC", "ANATOMY", 60, 63], ["hepatic veins", "ANATOMY", 110, 123], ["no", "UNCERTAINTY", 129, 131], ["flow", "OBSERVATION", 132, 136], ["complete", "OBSERVATION_MODIFIER", 171, 179], ["thrombosis", "OBSERVATION", 180, 190], ["Chiari SyndromeBudd-Chiari syndrome", "OBSERVATION", 204, 239], ["obstruction", "OBSERVATION", 260, 271], ["venous", "ANATOMY", 275, 281], ["outflow", "ANATOMY_MODIFIER", 282, 289], ["liver", "ANATOMY", 299, 304]]], ["This is typically due to hepatic venous or inferior vena caval thrombosis.Answer: Budd-Chiari SyndromeThis lady has a classic presentation with a relatively acute onset of tender hepatomegaly, ascites and lower extremity edema.", [["hepatic venous", "ANATOMY", 25, 39], ["inferior vena caval", "ANATOMY", 43, 62], ["ascites", "ANATOMY", 193, 200], ["lower extremity edema", "ANATOMY", 205, 226], ["hepatic venous or inferior vena caval thrombosis", "DISEASE", 25, 73], ["Budd-Chiari SyndromeThis", "DISEASE", 82, 106], ["hepatomegaly", "DISEASE", 179, 191], ["ascites", "DISEASE", 193, 200], ["lower extremity edema", "DISEASE", 205, 226], ["hepatic venous", "MULTI-TISSUE_STRUCTURE", 25, 39], ["inferior vena caval", "MULTI-TISSUE_STRUCTURE", 43, 62], ["lower extremity", "ORGANISM_SUBDIVISION", 205, 220], ["edema", "PATHOLOGICAL_FORMATION", 221, 226], ["hepatic venous or inferior vena caval thrombosis", "PROBLEM", 25, 73], ["tender hepatomegaly", "PROBLEM", 172, 191], ["ascites", "PROBLEM", 193, 200], ["lower extremity edema", "PROBLEM", 205, 226], ["typically due to", "UNCERTAINTY", 8, 24], ["hepatic venous", "ANATOMY", 25, 39], ["inferior vena caval", "ANATOMY", 43, 62], ["thrombosis", "OBSERVATION", 63, 73], ["acute", "OBSERVATION_MODIFIER", 157, 162], ["tender", "OBSERVATION_MODIFIER", 172, 178], ["hepatomegaly", "OBSERVATION", 179, 191], ["ascites", "OBSERVATION", 193, 200], ["lower", "ANATOMY_MODIFIER", 205, 210], ["extremity", "ANATOMY", 211, 220], ["edema", "OBSERVATION", 221, 226]]], ["In several large case series, most patients will present in this fashion or with chronic disease characterized by portal hypertension and cirrhosis.", [["portal", "ANATOMY", 114, 120], ["portal hypertension", "DISEASE", 114, 133], ["cirrhosis", "DISEASE", 138, 147], ["patients", "ORGANISM", 35, 43], ["portal", "MULTI-TISSUE_STRUCTURE", 114, 120], ["patients", "SPECIES", 35, 43], ["chronic disease", "PROBLEM", 81, 96], ["portal hypertension", "PROBLEM", 114, 133], ["cirrhosis", "PROBLEM", 138, 147], ["large", "OBSERVATION_MODIFIER", 11, 16], ["chronic", "OBSERVATION_MODIFIER", 81, 88], ["disease", "OBSERVATION", 89, 96], ["portal", "ANATOMY", 114, 120], ["hypertension", "OBSERVATION", 121, 133], ["cirrhosis", "OBSERVATION", 138, 147]]], ["A few will have fulminant hepatic failure.", [["hepatic", "ANATOMY", 26, 33], ["fulminant hepatic failure", "DISEASE", 16, 41], ["hepatic", "ORGAN", 26, 33], ["fulminant hepatic failure", "PROBLEM", 16, 41], ["few", "OBSERVATION_MODIFIER", 2, 5], ["fulminant", "OBSERVATION_MODIFIER", 16, 25], ["hepatic", "ANATOMY", 26, 33], ["failure", "OBSERVATION", 34, 41]]], ["BCS is more common in women and a quarter of patients will have an overt myeloproliferative disorder (typically polycythemia vera).", [["myeloproliferative disorder", "DISEASE", 73, 100], ["polycythemia vera", "DISEASE", 112, 129], ["women", "ORGANISM", 22, 27], ["patients", "ORGANISM", 45, 53], ["women", "SPECIES", 22, 27], ["patients", "SPECIES", 45, 53], ["BCS", "TEST", 0, 3], ["an overt myeloproliferative disorder", "PROBLEM", 64, 100], ["polycythemia vera", "PROBLEM", 112, 129], ["more common", "OBSERVATION_MODIFIER", 7, 18], ["overt", "OBSERVATION_MODIFIER", 67, 72], ["myeloproliferative disorder", "OBSERVATION", 73, 100]]], ["This lady's elevated hemoglobin and platelet count are very suggestive and subsequent work-up confirmed this was indeed the case.Answer: Budd-Chiari SyndromeLaboratory studies typically show a mixed picture of enzyme elevation and mild hyperbilirubinemia.", [["platelet", "ANATOMY", 36, 44], ["hyperbilirubinemia", "DISEASE", 236, 254], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 21, 31], ["platelet", "CELL", 36, 44], ["hemoglobin", "PROTEIN", 21, 31], ["This lady's elevated hemoglobin", "TEST", 0, 31], ["platelet count", "TEST", 36, 50], ["Chiari SyndromeLaboratory studies", "TEST", 142, 175], ["enzyme elevation", "PROBLEM", 210, 226], ["mild hyperbilirubinemia", "PROBLEM", 231, 254], ["platelet count", "OBSERVATION", 36, 50], ["enzyme elevation", "OBSERVATION", 210, 226], ["mild", "OBSERVATION_MODIFIER", 231, 235], ["hyperbilirubinemia", "OBSERVATION", 236, 254]]], ["If the disease is not treated encephalopathy and liver failure can ensue.Answer: Budd-Chiari SyndromeThe diagnosis is typically made as in this case with Doppler imaging showing either thrombosis or lack of flow in the hepatic venous outflow tract.", [["liver", "ANATOMY", 49, 54], ["hepatic venous outflow tract", "ANATOMY", 219, 247], ["encephalopathy", "DISEASE", 30, 44], ["liver failure", "DISEASE", 49, 62], ["Budd-Chiari Syndrome", "DISEASE", 81, 101], ["thrombosis", "DISEASE", 185, 195], ["liver", "ORGAN", 49, 54], ["hepatic venous outflow tract", "ORGANISM_SUBDIVISION", 219, 247], ["Budd-Chiari Syndrome", "SPECIES", 81, 101], ["the disease", "PROBLEM", 3, 14], ["encephalopathy", "PROBLEM", 30, 44], ["liver failure", "PROBLEM", 49, 62], ["Budd-Chiari Syndrome", "PROBLEM", 81, 101], ["Doppler imaging", "TEST", 154, 169], ["thrombosis", "PROBLEM", 185, 195], ["lack of flow in the hepatic venous outflow tract", "PROBLEM", 199, 247], ["disease", "OBSERVATION", 7, 14], ["not", "UNCERTAINTY", 18, 21], ["liver", "ANATOMY", 49, 54], ["failure", "OBSERVATION", 55, 62], ["Chiari Syndrome", "OBSERVATION", 86, 101], ["thrombosis", "OBSERVATION", 185, 195], ["flow", "OBSERVATION", 207, 211], ["hepatic", "ANATOMY", 219, 226], ["venous", "ANATOMY_MODIFIER", 227, 233], ["outflow tract", "ANATOMY", 234, 247]]], ["Ct scan or MRI can also be employed and the gold standard is venography.", [["Ct scan", "TEST", 0, 7], ["MRI", "TEST", 11, 14], ["venography", "TEST", 61, 71]]], ["The differential diagnosis includes right heart failure and constrictive pericarditis so echocardiogram is a useful test, particularly as analysis of ascitic fluid can demonstrate a total protein >3.0 g/l, and the serum-ascites albumin concentration gradient can be >1.1 g/dl, as seen in patients with cardiac and pericardial disease.Answer: Budd-Chiari SyndromeLiver biopsy is not necessary to make a diagnosis but can be helpful for determining prognosis and for guiding therapy, since patients with advanced fibrosis or cirrhosis are unlikely to improve with revascularization.Answer: Budd-Chiari SyndromeTreatment can be medical, radiologic, or surgical depending on the acuity of presentation and severity of the obstruction but is also guided by local expertise.", [["right heart", "ANATOMY", 36, 47], ["ascitic fluid", "ANATOMY", 150, 163], ["serum", "ANATOMY", 214, 219], ["ascites", "ANATOMY", 220, 227], ["cardiac", "ANATOMY", 302, 309], ["pericardial", "ANATOMY", 314, 325], ["heart failure", "DISEASE", 42, 55], ["constrictive pericarditis", "DISEASE", 60, 85], ["ascites", "DISEASE", 220, 227], ["cardiac and pericardial disease", "DISEASE", 302, 333], ["fibrosis", "DISEASE", 511, 519], ["cirrhosis", "DISEASE", 523, 532], ["Budd-Chiari SyndromeTreatment", "DISEASE", 588, 617], ["obstruction", "DISEASE", 718, 729], ["heart", "ORGAN", 42, 47], ["ascitic fluid", "ORGANISM_SUBSTANCE", 150, 163], ["serum", "ORGANISM_SUBSTANCE", 214, 219], ["albumin", "GENE_OR_GENE_PRODUCT", 228, 235], ["patients", "ORGANISM", 288, 296], ["cardiac", "ORGAN", 302, 309], ["pericardial", "ORGAN", 314, 325], ["patients", "ORGANISM", 488, 496], ["patients", "SPECIES", 288, 296], ["patients", "SPECIES", 488, 496], ["right heart failure", "PROBLEM", 36, 55], ["constrictive pericarditis", "PROBLEM", 60, 85], ["echocardiogram", "TEST", 89, 103], ["a useful test", "TEST", 107, 120], ["ascitic fluid", "PROBLEM", 150, 163], ["a total protein", "TEST", 180, 195], ["the serum", "TEST", 210, 219], ["ascites albumin concentration gradient", "TEST", 220, 258], ["cardiac and pericardial disease", "PROBLEM", 302, 333], ["Chiari SyndromeLiver biopsy", "TEST", 347, 374], ["guiding therapy", "TREATMENT", 465, 480], ["advanced fibrosis", "PROBLEM", 502, 519], ["cirrhosis", "PROBLEM", 523, 532], ["revascularization", "TREATMENT", 562, 579], ["Chiari SyndromeTreatment", "PROBLEM", 593, 617], ["surgical", "TREATMENT", 649, 657], ["the obstruction", "PROBLEM", 714, 729], ["differential diagnosis includes", "UNCERTAINTY", 4, 35], ["right", "ANATOMY_MODIFIER", 36, 41], ["heart", "ANATOMY", 42, 47], ["failure", "OBSERVATION", 48, 55], ["constrictive", "OBSERVATION_MODIFIER", 60, 72], ["pericarditis", "OBSERVATION", 73, 85], ["ascitic", "ANATOMY", 150, 157], ["ascites", "OBSERVATION", 220, 227], ["cardiac", "ANATOMY", 302, 309], ["pericardial", "ANATOMY", 314, 325], ["disease", "OBSERVATION", 326, 333], ["advanced", "OBSERVATION_MODIFIER", 502, 510], ["fibrosis", "OBSERVATION", 511, 519], ["cirrhosis", "OBSERVATION", 523, 532], ["obstruction", "OBSERVATION", 718, 729]]], ["The goal is restore venous outflow and decompress the liver to prevent portal hypertension and its sequelae.", [["venous", "ANATOMY", 20, 26], ["liver", "ANATOMY", 54, 59], ["portal", "ANATOMY", 71, 77], ["hypertension", "DISEASE", 78, 90], ["venous outflow", "MULTI-TISSUE_STRUCTURE", 20, 34], ["liver", "ORGAN", 54, 59], ["portal", "MULTI-TISSUE_STRUCTURE", 71, 77], ["decompress the liver", "PROBLEM", 39, 59], ["portal hypertension", "PROBLEM", 71, 90], ["its sequelae", "PROBLEM", 95, 107], ["venous", "ANATOMY", 20, 26], ["outflow", "ANATOMY_MODIFIER", 27, 34], ["decompress", "OBSERVATION", 39, 49], ["liver", "ANATOMY", 54, 59], ["portal", "ANATOMY", 71, 77], ["hypertension", "OBSERVATION", 78, 90], ["sequelae", "OBSERVATION_MODIFIER", 99, 107]]], ["It is important to complete a hypercoaguable work up and involve a hematologist in the care of these patients so as not to delay use of anticoagulation or anti-platelet agents.", [["anti-platelet", "ANATOMY", 155, 168], ["patients", "ORGANISM", 101, 109], ["anti-platelet agents", "SIMPLE_CHEMICAL", 155, 175], ["patients", "SPECIES", 101, 109], ["anticoagulation", "TREATMENT", 136, 151], ["anti-platelet agents", "TREATMENT", 155, 175]]], ["In patients with an acute presentation, direct thrombolytic therapy into the thrombosed vessels has had some success.Answer: Budd-Chiari SyndromeThis patient was treated with diuretics with a good response and was started on heparin and aspirin while waiting for a diagnosis.Answer: Budd-Chiari SyndromeShe later underwent a TIPS placement.", [["thrombosed vessels", "ANATOMY", 77, 95], ["Budd-Chiari SyndromeThis", "DISEASE", 125, 149], ["heparin", "CHEMICAL", 225, 232], ["aspirin", "CHEMICAL", 237, 244], ["Budd-Chiari Syndrome", "DISEASE", 283, 303], ["aspirin", "CHEMICAL", 237, 244], ["patients", "ORGANISM", 3, 11], ["thrombosed vessels", "MULTI-TISSUE_STRUCTURE", 77, 95], ["patient", "ORGANISM", 150, 157], ["heparin", "SIMPLE_CHEMICAL", 225, 232], ["aspirin", "SIMPLE_CHEMICAL", 237, 244], ["patients", "SPECIES", 3, 11], ["patient", "SPECIES", 150, 157], ["Budd-Chiari Syndrome", "SPECIES", 283, 303], ["an acute presentation", "PROBLEM", 17, 38], ["direct thrombolytic therapy", "TREATMENT", 40, 67], ["the thrombosed vessels", "TREATMENT", 73, 95], ["Budd-Chiari SyndromeThis", "PROBLEM", 125, 149], ["diuretics", "TREATMENT", 175, 184], ["heparin", "TREATMENT", 225, 232], ["aspirin", "TREATMENT", 237, 244], ["Budd-Chiari Syndrome", "PROBLEM", 283, 303], ["a TIPS placement", "TREATMENT", 323, 339], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["thrombosed", "OBSERVATION", 77, 87], ["vessels", "ANATOMY", 88, 95], ["Chiari", "ANATOMY", 130, 136], ["Chiari Syndrome", "OBSERVATION", 288, 303], ["TIPS placement", "OBSERVATION", 325, 339]]], ["Recent data would suggest that longterm survival after TIPS is 80%, equivalent to that seen with transplant.", [["longterm survival after TIPS", "TREATMENT", 31, 59], ["transplant", "TREATMENT", 97, 107], ["transplant", "OBSERVATION", 97, 107]]], ["There are small case series illustrating the benefit of dilation or stent therapy without TIPS, but this runs the risk of restenosis or reocclusion.", [["restenosis", "DISEASE", 122, 132], ["reocclusion", "DISEASE", 136, 147], ["small case series", "PROBLEM", 10, 27], ["dilation", "TREATMENT", 56, 64], ["stent therapy", "TREATMENT", 68, 81], ["TIPS", "TREATMENT", 90, 94], ["restenosis", "PROBLEM", 122, 132], ["reocclusion", "PROBLEM", 136, 147], ["small", "OBSERVATION_MODIFIER", 10, 15], ["dilation", "OBSERVATION", 56, 64], ["stent", "OBSERVATION", 68, 73], ["TIPS", "OBSERVATION_MODIFIER", 90, 94], ["restenosis", "OBSERVATION", 122, 132], ["reocclusion", "OBSERVATION", 136, 147]]], ["Because of the improvement in interventional radiology over the last 10-15 years, nontransplant surgery for BCS is very rarely employed.Answer: Budd-Chiari SyndromeLiver transplant is an excellent option for patients with evidence of cirrhosis and decompensation who are not candidates for TIPS.", [["cirrhosis", "DISEASE", 234, 243], ["decompensation", "DISEASE", 248, 262], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216], ["nontransplant surgery", "TREATMENT", 82, 103], ["Chiari SyndromeLiver transplant", "TREATMENT", 149, 180], ["cirrhosis", "PROBLEM", 234, 243], ["decompensation", "PROBLEM", 248, 262], ["TIPS", "TREATMENT", 290, 294], ["improvement", "OBSERVATION_MODIFIER", 15, 26], ["Chiari", "ANATOMY", 149, 155], ["cirrhosis", "OBSERVATION", 234, 243], ["decompensation", "OBSERVATION", 248, 262]]], ["It also has the advantage of correctingCase 55A 41-year-old man presents to the emergency room with ascites and lower extremity edema.", [["ascites", "ANATOMY", 100, 107], ["lower extremity edema", "ANATOMY", 112, 133], ["ascites", "DISEASE", 100, 107], ["lower extremity edema", "DISEASE", 112, 133], ["man", "ORGANISM", 60, 63], ["lower extremity", "ORGANISM_SUBDIVISION", 112, 127], ["edema", "PATHOLOGICAL_FORMATION", 128, 133], ["man", "SPECIES", 60, 63], ["ascites", "PROBLEM", 100, 107], ["lower extremity edema", "PROBLEM", 112, 133], ["ascites", "OBSERVATION", 100, 107], ["lower", "ANATOMY_MODIFIER", 112, 117], ["extremity", "ANATOMY", 118, 127], ["edema", "OBSERVATION", 128, 133]]], ["He is not known to have liver disease and in fact was very healthy up until a motor vehicle accident 4 months ago where he was in the passenger seat and his car had a head-on collision with a minivan.", [["liver", "ANATOMY", 24, 29], ["head", "ANATOMY", 167, 171], ["liver disease", "DISEASE", 24, 37], ["liver", "ORGAN", 24, 29], ["head", "ORGANISM_SUBDIVISION", 167, 171], ["liver disease", "PROBLEM", 24, 37], ["a minivan", "TREATMENT", 190, 199], ["not known to", "UNCERTAINTY", 6, 18], ["liver", "ANATOMY", 24, 29], ["disease", "OBSERVATION", 30, 37], ["head", "ANATOMY", 167, 171]]], ["Fortunately, he was wearing a seatbelt then and suffered only a fractured tibia that has healed well.Case 55He has noticed increasing abdominal distension over the last few days and now cannot get his shoes on without difficulty.", [["tibia", "ANATOMY", 74, 79], ["abdominal", "ANATOMY", 134, 143], ["abdominal distension", "DISEASE", 134, 154], ["tibia", "ORGAN", 74, 79], ["abdominal", "ORGANISM_SUBDIVISION", 134, 143], ["a fractured tibia", "PROBLEM", 62, 79], ["increasing abdominal distension", "PROBLEM", 123, 154], ["difficulty", "PROBLEM", 218, 228], ["fractured", "OBSERVATION", 64, 73], ["tibia", "ANATOMY", 74, 79], ["healed", "OBSERVATION", 89, 95], ["increasing", "OBSERVATION_MODIFIER", 123, 133], ["abdominal", "ANATOMY", 134, 143], ["distension", "OBSERVATION", 144, 154]]], ["He denies GI bleeding or encephalopathy.Case 55There has been no fever or chills, but he has noticed some shortness of breath.", [["GI", "ANATOMY", 10, 12], ["GI bleeding", "DISEASE", 10, 21], ["encephalopathy", "DISEASE", 25, 39], ["fever", "DISEASE", 65, 70], ["chills", "DISEASE", 74, 80], ["shortness of breath", "DISEASE", 106, 125], ["GI", "ORGANISM_SUBDIVISION", 10, 12], ["GI bleeding", "PROBLEM", 10, 21], ["encephalopathy", "PROBLEM", 25, 39], ["fever", "PROBLEM", 65, 70], ["chills", "PROBLEM", 74, 80], ["some shortness of breath", "PROBLEM", 101, 125], ["GI", "ANATOMY", 10, 12], ["bleeding", "OBSERVATION", 13, 21], ["encephalopathy", "OBSERVATION", 25, 39], ["no", "UNCERTAINTY", 62, 64], ["fever", "OBSERVATION_MODIFIER", 65, 70], ["chills", "OBSERVATION", 74, 80]]], ["He denies any prescribed or over the counter medication.", [["the counter medication", "TREATMENT", 33, 55]]], ["He does not smoke or drink and is married.", [["He", "ORGANISM", 0, 2]]], ["He has no obvious risk factors for viral hepatitis and no family history of liver disease.Case 55On exam, he looks well with vital signs showing BP 120/75, pulse 92, and he is afebrile.", [["liver", "ANATOMY", 76, 81], ["viral hepatitis", "DISEASE", 35, 50], ["liver disease", "DISEASE", 76, 89], ["liver", "ORGAN", 76, 81], ["viral hepatitis", "PROBLEM", 35, 50], ["liver disease", "PROBLEM", 76, 89], ["exam", "TEST", 100, 104], ["vital signs", "TEST", 125, 136], ["BP", "TEST", 145, 147], ["pulse", "TEST", 156, 161], ["afebrile", "PROBLEM", 176, 184], ["no obvious", "UNCERTAINTY", 7, 17], ["viral hepatitis", "OBSERVATION", 35, 50], ["liver", "ANATOMY", 76, 81], ["disease", "OBSERVATION", 82, 89], ["afebrile", "OBSERVATION", 176, 184]]], ["His BMI is 23 kg/m 2 .", [["His BMI", "TEST", 0, 7]]], ["There is no scleral icterus, but he has several spider nevi.Case 55His heart exam is normal, and lungs reveal some decreased air entry at the right base.", [["scleral icterus", "ANATOMY", 12, 27], ["nevi", "ANATOMY", 55, 59], ["heart", "ANATOMY", 71, 76], ["lungs", "ANATOMY", 97, 102], ["right base", "ANATOMY", 142, 152], ["scleral icterus", "DISEASE", 12, 27], ["spider nevi", "DISEASE", 48, 59], ["heart", "ORGAN", 71, 76], ["lungs", "ORGAN", 97, 102], ["scleral icterus", "PROBLEM", 12, 27], ["several spider nevi", "PROBLEM", 40, 59], ["heart exam", "TEST", 71, 81], ["some decreased air entry at the right base", "PROBLEM", 110, 152], ["no", "UNCERTAINTY", 9, 11], ["scleral", "ANATOMY", 12, 19], ["icterus", "OBSERVATION", 20, 27], ["several", "OBSERVATION_MODIFIER", 40, 47], ["spider nevi", "OBSERVATION", 48, 59], ["heart", "ANATOMY", 71, 76], ["normal", "OBSERVATION", 85, 91], ["lungs", "ANATOMY", 97, 102], ["some", "OBSERVATION_MODIFIER", 110, 114], ["decreased", "OBSERVATION_MODIFIER", 115, 124], ["air entry", "OBSERVATION", 125, 134], ["right", "ANATOMY_MODIFIER", 142, 147], ["base", "ANATOMY_MODIFIER", 148, 152]]], ["His abdomen is distended with dullness in the flanks.", [["abdomen", "ANATOMY", 4, 11], ["flanks", "ANATOMY", 46, 52], ["dullness", "DISEASE", 30, 38], ["abdomen", "ORGAN", 4, 11], ["flanks", "ORGANISM_SUBDIVISION", 46, 52], ["distended", "PROBLEM", 15, 24], ["dullness in the flanks", "PROBLEM", 30, 52], ["abdomen", "ANATOMY", 4, 11], ["distended", "OBSERVATION", 15, 24], ["dullness", "OBSERVATION", 30, 38], ["flanks", "ANATOMY", 46, 52]]], ["His liver is palpable just below the right costal margin, and the spleen is easily felt.", [["liver", "ANATOMY", 4, 9], ["right costal margin", "ANATOMY", 37, 56], ["spleen", "ANATOMY", 66, 72], ["liver", "ORGAN", 4, 9], ["costal margin", "MULTI-TISSUE_STRUCTURE", 43, 56], ["spleen", "ORGAN", 66, 72], ["liver", "ANATOMY", 4, 9], ["palpable", "OBSERVATION", 13, 21], ["right", "ANATOMY_MODIFIER", 37, 42], ["costal", "ANATOMY", 43, 49], ["margin", "ANATOMY_MODIFIER", 50, 56], ["spleen", "ANATOMY", 66, 72], ["easily", "OBSERVATION_MODIFIER", 76, 82], ["felt", "OBSERVATION", 83, 87]]], ["He has ++ankle edema to the thighs.Answer: Hepatic Arterio-Portal Fistula as a Cause of Portal HypertensionThis is a very interesting case that shows not all portal hypertension is due to increased resistance in portal venous flow.", [["ankle", "ANATOMY", 9, 14], ["thighs", "ANATOMY", 28, 34], ["Hepatic Arterio-Portal Fistula", "ANATOMY", 43, 73], ["portal", "ANATOMY", 158, 164], ["portal venous", "ANATOMY", 212, 225], ["edema", "DISEASE", 15, 20], ["Portal Hypertension", "DISEASE", 88, 107], ["hypertension", "DISEASE", 165, 177], ["He", "ORGANISM", 0, 2], ["thighs", "ORGANISM_SUBDIVISION", 28, 34], ["portal", "MULTI-TISSUE_STRUCTURE", 158, 164], ["portal venous", "MULTI-TISSUE_STRUCTURE", 212, 225], ["ankle edema to the thighs", "PROBLEM", 9, 34], ["Portal Fistula", "PROBLEM", 59, 73], ["Portal Hypertension", "PROBLEM", 88, 107], ["all portal hypertension", "PROBLEM", 154, 177], ["increased resistance in portal venous flow", "PROBLEM", 188, 230], ["ankle", "ANATOMY", 9, 14], ["edema", "OBSERVATION", 15, 20], ["thighs", "ANATOMY", 28, 34], ["Hepatic", "ANATOMY", 43, 50], ["Arterio", "ANATOMY_MODIFIER", 51, 58], ["Portal", "ANATOMY", 59, 65], ["Fistula", "OBSERVATION", 66, 73], ["Portal", "ANATOMY", 88, 94], ["Hypertension", "OBSERVATION", 95, 107], ["portal", "ANATOMY", 158, 164], ["hypertension", "OBSERVATION", 165, 177], ["increased", "OBSERVATION_MODIFIER", 188, 197], ["resistance", "OBSERVATION", 198, 208], ["portal venous", "ANATOMY", 212, 225], ["flow", "OBSERVATION", 226, 230]]], ["The usual classification of portal hypertension is based on the site of the obstruction -prehepatic, intrahepatic, or posthepatic.", [["portal", "ANATOMY", 28, 34], ["prehepatic", "ANATOMY", 89, 99], ["intrahepatic", "ANATOMY", 101, 113], ["posthepatic", "ANATOMY", 118, 129], ["portal hypertension", "DISEASE", 28, 47], ["obstruction", "DISEASE", 76, 87], ["portal", "MULTI-TISSUE_STRUCTURE", 28, 34], ["portal hypertension", "PROBLEM", 28, 47], ["the obstruction", "PROBLEM", 72, 87], ["portal", "ANATOMY", 28, 34], ["hypertension", "OBSERVATION", 35, 47], ["obstruction", "OBSERVATION", 76, 87], ["prehepatic", "ANATOMY_MODIFIER", 89, 99], ["intrahepatic", "ANATOMY", 101, 113]]], ["The normal portal system is under very low pressure and a gradient of <5 mmHg is typical.", [["portal system", "MULTI-TISSUE_STRUCTURE", 11, 24], ["a gradient", "TEST", 56, 66], ["normal", "OBSERVATION", 4, 10], ["portal system", "ANATOMY", 11, 24], ["very", "OBSERVATION_MODIFIER", 34, 38], ["low pressure", "OBSERVATION", 39, 51]]], ["Clinical consequences arise when the pressure gradient between the portal and hepatic veins reaches 10-12 mmHg.", [["portal", "ANATOMY", 67, 73], ["hepatic veins", "ANATOMY", 78, 91], ["portal", "MULTI-TISSUE_STRUCTURE", 67, 73], ["hepatic veins", "MULTI-TISSUE_STRUCTURE", 78, 91], ["the pressure gradient", "TEST", 33, 54], ["portal", "ANATOMY", 67, 73], ["hepatic veins", "ANATOMY", 78, 91]]], ["Increases of portal blood flow can be significant in the postprandial state (from 700 to 1,500 ml/min) but due to the passive dilation of low resistance vessels in and around the liver, the portal pressure rises only marginally.Answer: Hepatic Arterio-Portal Fistula as a Cause of Portal HypertensionIn this patient, the trauma of the motor vehicle accident has led to the formation of a fistula between the hepatic artery and portal vein.", [["portal blood", "ANATOMY", 13, 25], ["vessels", "ANATOMY", 153, 160], ["liver", "ANATOMY", 179, 184], ["portal", "ANATOMY", 190, 196], ["fistula", "ANATOMY", 388, 395], ["hepatic artery", "ANATOMY", 408, 422], ["portal vein", "ANATOMY", 427, 438], ["Increases of portal blood flow", "DISEASE", 0, 30], ["Portal HypertensionIn", "DISEASE", 281, 302], ["trauma", "DISEASE", 321, 327], ["fistula", "DISEASE", 388, 395], ["portal", "MULTI-TISSUE_STRUCTURE", 13, 19], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["vessels", "MULTI-TISSUE_STRUCTURE", 153, 160], ["liver", "ORGAN", 179, 184], ["portal", "MULTI-TISSUE_STRUCTURE", 190, 196], ["patient", "ORGANISM", 308, 315], ["fistula", "PATHOLOGICAL_FORMATION", 388, 395], ["hepatic artery", "MULTI-TISSUE_STRUCTURE", 408, 422], ["portal vein", "MULTI-TISSUE_STRUCTURE", 427, 438], ["patient", "SPECIES", 308, 315], ["portal blood flow", "TEST", 13, 30], ["the passive dilation of low resistance vessels", "PROBLEM", 114, 160], ["the portal pressure", "TEST", 186, 205], ["Portal Fistula", "PROBLEM", 252, 266], ["Portal HypertensionIn", "PROBLEM", 281, 302], ["a fistula between the hepatic artery and portal vein", "PROBLEM", 386, 438], ["portal", "ANATOMY", 13, 19], ["blood flow", "OBSERVATION", 20, 30], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["passive", "OBSERVATION_MODIFIER", 118, 125], ["dilation", "OBSERVATION", 126, 134], ["low resistance vessels", "OBSERVATION", 138, 160], ["liver", "ANATOMY", 179, 184], ["portal", "ANATOMY", 190, 196], ["pressure", "OBSERVATION_MODIFIER", 197, 205], ["rises", "OBSERVATION_MODIFIER", 206, 211], ["Hepatic", "ANATOMY", 236, 243], ["Arterio", "ANATOMY_MODIFIER", 244, 251], ["Portal", "ANATOMY", 252, 258], ["Fistula", "OBSERVATION", 259, 266], ["Portal", "ANATOMY", 281, 287], ["HypertensionIn", "OBSERVATION", 288, 302], ["fistula", "OBSERVATION", 388, 395], ["hepatic artery", "ANATOMY", 408, 422], ["portal vein", "ANATOMY", 427, 438]]], ["The portal blood flow increases dramatically in this situation, beyond the capacity of low resistance vessels to accommodate and portal hypertension ensues.", [["portal blood", "ANATOMY", 4, 16], ["vessels", "ANATOMY", 102, 109], ["portal", "ANATOMY", 129, 135], ["hypertension", "DISEASE", 136, 148], ["portal", "MULTI-TISSUE_STRUCTURE", 4, 10], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["vessels", "MULTI-TISSUE_STRUCTURE", 102, 109], ["portal", "MULTI-TISSUE_STRUCTURE", 129, 135], ["The portal blood flow", "TEST", 0, 21], ["low resistance vessels", "PROBLEM", 87, 109], ["portal hypertension", "PROBLEM", 129, 148], ["portal blood", "ANATOMY", 4, 16], ["flow", "OBSERVATION_MODIFIER", 17, 21], ["increases", "OBSERVATION_MODIFIER", 22, 31], ["dramatically", "OBSERVATION_MODIFIER", 32, 44], ["capacity", "OBSERVATION_MODIFIER", 75, 83], ["low resistance vessels", "OBSERVATION", 87, 109], ["portal", "ANATOMY", 129, 135], ["hypertension", "OBSERVATION", 136, 148]]], ["It can also lead to significant fibrosis in the liver and cirrhosis.Answer: Hepatic Arterio-Portal Fistula as a Cause of Portal HypertensionThe CT images (Figs.", [["liver", "ANATOMY", 48, 53], ["Hepatic Arterio-Portal Fistula", "ANATOMY", 76, 106], ["fibrosis", "DISEASE", 32, 40], ["cirrhosis", "DISEASE", 58, 67], ["Portal Hypertension", "DISEASE", 121, 140], ["liver", "ORGAN", 48, 53], ["cirrhosis", "CANCER", 58, 67], ["significant fibrosis in the liver", "PROBLEM", 20, 53], ["cirrhosis", "PROBLEM", 58, 67], ["Portal Fistula", "PROBLEM", 92, 106], ["Portal Hypertension", "PROBLEM", 121, 140], ["The CT images", "TEST", 140, 153], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["fibrosis", "OBSERVATION", 32, 40], ["liver", "ANATOMY", 48, 53], ["cirrhosis", "OBSERVATION", 58, 67], ["Hepatic", "ANATOMY", 76, 83], ["Arterio", "ANATOMY_MODIFIER", 84, 91], ["Portal", "ANATOMY", 92, 98], ["Fistula", "OBSERVATION", 99, 106], ["Portal", "ANATOMY", 121, 127], ["Hypertension", "OBSERVATION", 128, 140]]], ["55.1 and 55.2) show the arterial phase and the hepatic artery fills, but a connection can be seen to the portal vein which is seen filling in Fig. 55 .2.", [["arterial", "ANATOMY", 24, 32], ["hepatic artery", "ANATOMY", 47, 61], ["portal vein", "ANATOMY", 105, 116], ["arterial", "MULTI-TISSUE_STRUCTURE", 24, 32], ["hepatic artery", "MULTI-TISSUE_STRUCTURE", 47, 61], ["portal vein", "MULTI-TISSUE_STRUCTURE", 105, 116], ["the arterial phase", "TEST", 20, 38], ["arterial", "ANATOMY", 24, 32], ["hepatic artery", "ANATOMY", 47, 61], ["portal vein", "ANATOMY", 105, 116]]], ["The angiogram (Figs.", [["The angiogram", "TEST", 0, 13]]], ["55.3-55.5) shows a catheter in the right hepatic artery and the portal vein can be seen filling rapidly (Fig. 55.3) .", [["right hepatic artery", "ANATOMY", 35, 55], ["portal vein", "ANATOMY", 64, 75], ["right hepatic artery", "MULTI-TISSUE_STRUCTURE", 35, 55], ["portal vein", "MULTI-TISSUE_STRUCTURE", 64, 75], ["a catheter in the right hepatic artery", "TREATMENT", 17, 55], ["Fig.", "TEST", 105, 109], ["catheter", "OBSERVATION", 19, 27], ["right", "ANATOMY_MODIFIER", 35, 40], ["hepatic artery", "ANATOMY", 41, 55], ["portal vein", "ANATOMY", 64, 75], ["rapidly", "OBSERVATION_MODIFIER", 96, 103]]], ["The magnified second image (Fig. 55.4) shows the catheter in the fistula and coils are being placed, and the third image (Fig. 55.5) shows closure of the fistula without flow into the portal system.Answer: Hepatic Arterio-Portal Fistula as a Cause of Portal HypertensionHepatic (or splenic) arterioportal fistula is a very rare cause of portal hypertension but illustrates the physiology of the portal system very well.", [["fistula", "ANATOMY", 65, 72], ["fistula", "ANATOMY", 154, 161], ["portal system", "ANATOMY", 184, 197], ["Hepatic Arterio-Portal Fistula", "ANATOMY", 206, 236], ["splenic", "ANATOMY", 282, 289], ["arterioportal fistula", "ANATOMY", 291, 312], ["portal", "ANATOMY", 337, 343], ["portal system", "ANATOMY", 395, 408], ["fistula", "DISEASE", 65, 72], ["fistula", "DISEASE", 154, 161], ["Portal HypertensionHepatic (or splenic) arterioportal fistula", "DISEASE", 251, 312], ["hypertension", "DISEASE", 344, 356], ["fistula", "PATHOLOGICAL_FORMATION", 65, 72], ["fistula", "PATHOLOGICAL_FORMATION", 154, 161], ["portal system", "MULTI-TISSUE_STRUCTURE", 184, 197], ["splenic", "ORGAN", 282, 289], ["portal", "MULTI-TISSUE_STRUCTURE", 337, 343], ["portal system", "MULTI-TISSUE_STRUCTURE", 395, 408], ["The magnified second image", "TEST", 0, 26], ["the catheter in the fistula", "TREATMENT", 45, 72], ["coils", "TREATMENT", 77, 82], ["the third image", "TEST", 105, 120], ["closure", "TREATMENT", 139, 146], ["the fistula", "PROBLEM", 150, 161], ["Portal Fistula", "PROBLEM", 222, 236], ["Portal HypertensionHepatic (or splenic) arterioportal fistula", "PROBLEM", 251, 312], ["portal hypertension", "PROBLEM", 337, 356], ["catheter", "OBSERVATION", 49, 57], ["fistula", "OBSERVATION", 65, 72], ["closure", "OBSERVATION", 139, 146], ["fistula", "OBSERVATION", 154, 161], ["without", "UNCERTAINTY", 162, 169], ["flow", "OBSERVATION", 170, 174], ["portal system", "ANATOMY", 184, 197], ["Hepatic", "ANATOMY", 206, 213], ["Arterio", "ANATOMY_MODIFIER", 214, 221], ["Portal", "ANATOMY", 222, 228], ["Fistula", "OBSERVATION", 229, 236], ["Portal", "ANATOMY", 251, 257], ["HypertensionHepatic", "OBSERVATION", 258, 277], ["splenic", "ANATOMY", 282, 289], ["arterioportal", "ANATOMY", 291, 304], ["fistula", "OBSERVATION", 305, 312], ["portal", "ANATOMY", 337, 343], ["hypertension", "OBSERVATION", 344, 356], ["portal system", "ANATOMY", 395, 408]]], ["It typically can occur after trauma or rupture of an arterial aneurysm, tumor invasion and has been reported as a complication of liver biopsy.", [["arterial aneurysm", "ANATOMY", 53, 70], ["tumor", "ANATOMY", 72, 77], ["liver", "ANATOMY", 130, 135], ["trauma", "DISEASE", 29, 35], ["rupture", "DISEASE", 39, 46], ["arterial aneurysm", "DISEASE", 53, 70], ["tumor", "DISEASE", 72, 77], ["arterial aneurysm", "PATHOLOGICAL_FORMATION", 53, 70], ["tumor", "CANCER", 72, 77], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 130, 142], ["trauma", "PROBLEM", 29, 35], ["rupture", "PROBLEM", 39, 46], ["an arterial aneurysm", "PROBLEM", 50, 70], ["tumor invasion", "PROBLEM", 72, 86], ["liver biopsy", "TEST", 130, 142], ["rupture", "OBSERVATION", 39, 46], ["arterial", "ANATOMY", 53, 61], ["aneurysm", "OBSERVATION", 62, 70], ["tumor", "OBSERVATION", 72, 77], ["invasion", "OBSERVATION_MODIFIER", 78, 86], ["liver", "ANATOMY", 130, 135], ["biopsy", "OBSERVATION", 136, 142]]], ["Congential causes include hereditary hemorrhagic telangiectasia.", [["hereditary hemorrhagic telangiectasia", "DISEASE", 26, 63], ["Congential causes", "PROBLEM", 0, 17], ["hereditary hemorrhagic telangiectasia", "PROBLEM", 26, 63], ["hereditary", "OBSERVATION_MODIFIER", 26, 36], ["hemorrhagic", "OBSERVATION_MODIFIER", 37, 48], ["telangiectasia", "OBSERVATION", 49, 63]]], ["There are reports in the older literature of surgical repair of fistulae, but most case reports and case series now detail successful radiologic treatment as in this case.", [["fistulae", "ANATOMY", 64, 72], ["fistulae", "DISEASE", 64, 72], ["fistulae", "PATHOLOGICAL_FORMATION", 64, 72], ["surgical repair", "TREATMENT", 45, 60], ["fistulae", "PROBLEM", 64, 72], ["radiologic treatment", "TREATMENT", 134, 154], ["surgical repair", "OBSERVATION", 45, 60], ["fistulae", "OBSERVATION", 64, 72]]], ["Occasionally, liver transplantation is required.Answer: Prevention of Recurrent Variceal Hemorrhage with Distal Splenorenal ShuntThis lady presents with another episode of variceal bleeding despite being on a beta-blocker and having undergone multiple endoscopies in the past.", [["liver", "ANATOMY", 14, 19], ["Variceal", "ANATOMY", 80, 88], ["variceal", "ANATOMY", 172, 180], ["Variceal Hemorrhage", "DISEASE", 80, 99], ["variceal bleeding", "DISEASE", 172, 189], ["liver", "ORGAN", 14, 19], ["liver transplantation", "TREATMENT", 14, 35], ["Recurrent Variceal Hemorrhage", "PROBLEM", 70, 99], ["Distal Splenorenal Shunt", "TREATMENT", 105, 129], ["variceal bleeding", "PROBLEM", 172, 189], ["a beta-blocker", "TREATMENT", 207, 221], ["multiple endoscopies", "TREATMENT", 243, 263], ["liver", "ANATOMY", 14, 19], ["transplantation", "OBSERVATION", 20, 35], ["Variceal", "ANATOMY", 80, 88], ["Hemorrhage", "OBSERVATION", 89, 99], ["Distal", "ANATOMY_MODIFIER", 105, 111], ["Splenorenal Shunt", "OBSERVATION", 112, 129], ["variceal", "ANATOMY", 172, 180], ["bleeding", "OBSERVATION", 181, 189], ["multiple", "OBSERVATION_MODIFIER", 243, 251], ["endoscopies", "OBSERVATION", 252, 263]]], ["Her liver synthetic function is normal and she appears to be active and is still working.", [["liver", "ANATOMY", 4, 9], ["liver", "ORGAN", 4, 9], ["Her liver synthetic function", "TEST", 0, 28], ["liver", "ANATOMY", 4, 9], ["normal", "OBSERVATION", 32, 38], ["active", "OBSERVATION", 61, 67]]], ["Liver transplant would fix the underlying portal hypertension, but she is early based on her MELD score, and most experts would not recommend this.Answer: Prevention of Recurrent Variceal Hemorrhage with Distal Splenorenal ShuntYou could continue with the current strategy but she has bled again despite adequate medical therapy.", [["Liver", "ANATOMY", 0, 5], ["portal", "ANATOMY", 42, 48], ["Variceal", "ANATOMY", 179, 187], ["hypertension", "DISEASE", 49, 61], ["Hemorrhage", "DISEASE", 188, 198], ["Liver", "ORGAN", 0, 5], ["portal", "MULTI-TISSUE_STRUCTURE", 42, 48], ["Liver transplant", "TREATMENT", 0, 16], ["the underlying portal hypertension", "PROBLEM", 27, 61], ["her MELD score", "TEST", 89, 103], ["Recurrent Variceal Hemorrhage", "PROBLEM", 169, 198], ["Distal Splenorenal Shunt", "TREATMENT", 204, 228], ["the current strategy", "TREATMENT", 252, 272], ["adequate medical therapy", "TREATMENT", 304, 328], ["transplant", "OBSERVATION", 6, 16], ["portal", "ANATOMY", 42, 48], ["hypertension", "OBSERVATION", 49, 61], ["Variceal", "ANATOMY", 179, 187], ["Hemorrhage", "OBSERVATION", 188, 198], ["Distal", "ANATOMY_MODIFIER", 204, 210], ["Splenorenal Shunt", "OBSERVATION", 211, 228]]], ["TIPS would be a consideration in this patient.", [["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["TIPS", "TREATMENT", 0, 4], ["would be a consideration", "UNCERTAINTY", 5, 29]]], ["Another option would be surgical decompression.Answer: Prevention of Recurrent Variceal Hemorrhage with Distal Splenorenal ShuntIn the 1980s, there were several trials comparing endoscopic therapy with portocaval shunting which showed similar efficacy, and this was in the days of sclerotherapy rather than band ligation.", [["Variceal", "ANATOMY", 79, 87], ["portocaval", "ANATOMY", 202, 212], ["Variceal Hemorrhage", "DISEASE", 79, 98], ["surgical decompression", "TREATMENT", 24, 46], ["Recurrent Variceal Hemorrhage", "PROBLEM", 69, 98], ["Distal Splenorenal ShuntIn", "TREATMENT", 104, 130], ["endoscopic therapy", "TREATMENT", 178, 196], ["portocaval shunting", "TREATMENT", 202, 221], ["sclerotherapy", "TREATMENT", 281, 294], ["band ligation", "TREATMENT", 307, 320], ["surgical decompression", "OBSERVATION", 24, 46], ["Variceal", "ANATOMY", 79, 87], ["Hemorrhage", "OBSERVATION", 88, 98], ["Distal", "ANATOMY_MODIFIER", 104, 110], ["Splenorenal", "ANATOMY", 111, 122], ["portocaval", "ANATOMY", 202, 212], ["shunting", "OBSERVATION", 213, 221], ["similar", "OBSERVATION_MODIFIER", 235, 242], ["efficacy", "OBSERVATION_MODIFIER", 243, 251], ["sclerotherapy", "OBSERVATION", 281, 294], ["ligation", "OBSERVATION", 312, 320]]], ["In addition, this type of surgery is complex and requires significant expertise and is only available in certain centers.", [["surgery", "TREATMENT", 26, 33], ["significant", "OBSERVATION_MODIFIER", 58, 69]]], ["Another study published in 1990 suggested that distal splenorenal shunt (DSRS) was superior to sclerotherapy in bleeding control but the sclerotherapy arm had improved survival, which was still apparent if sclerotherapy failed to control the bleeding and the patient needed salvage DSRS.Answer: Prevention of Recurrent Variceal Hemorrhage with Distal Splenorenal ShuntHowever, today a patient would undergo band ligation for esophageal varices rather than sclerotherapy, and TIPS would be a viable option.Answer: Prevention of Recurrent Variceal Hemorrhage with Distal Splenorenal ShuntA more recent study compared TIPS with DSRS and found that in Child's A and B patients, the control of recurrent bleeding was similar, but the TIPS group needed more intervention for TIPS stenosis or dysfunction.", [["Variceal", "ANATOMY", 319, 327], ["esophageal varices", "ANATOMY", 425, 443], ["Variceal", "ANATOMY", 537, 545], ["bleeding", "DISEASE", 112, 120], ["bleeding", "DISEASE", 242, 250], ["Hemorrhage", "DISEASE", 328, 338], ["esophageal varices", "DISEASE", 425, 443], ["Hemorrhage", "DISEASE", 546, 556], ["bleeding", "DISEASE", 699, 707], ["TIPS stenosis", "DISEASE", 769, 782], ["patient", "ORGANISM", 259, 266], ["patient", "ORGANISM", 385, 392], ["esophageal varices", "PATHOLOGICAL_FORMATION", 425, 443], ["patients", "ORGANISM", 664, 672], ["patient", "SPECIES", 259, 266], ["patient", "SPECIES", 385, 392], ["patients", "SPECIES", 664, 672], ["Another study", "TEST", 0, 13], ["distal splenorenal shunt (DSRS", "TREATMENT", 47, 77], ["sclerotherapy", "TREATMENT", 95, 108], ["bleeding control", "TREATMENT", 112, 128], ["the sclerotherapy arm", "TREATMENT", 133, 154], ["sclerotherapy", "TREATMENT", 206, 219], ["the bleeding", "PROBLEM", 238, 250], ["salvage DSRS", "TREATMENT", 274, 286], ["Recurrent Variceal Hemorrhage", "PROBLEM", 309, 338], ["Distal Splenorenal ShuntHowever", "TREATMENT", 344, 375], ["band ligation", "TREATMENT", 407, 420], ["esophageal varices", "PROBLEM", 425, 443], ["sclerotherapy", "TREATMENT", 456, 469], ["TIPS", "TREATMENT", 475, 479], ["a viable option", "TREATMENT", 489, 504], ["Recurrent Variceal Hemorrhage", "PROBLEM", 527, 556], ["Distal Splenorenal ShuntA", "TREATMENT", 562, 587], ["recent study", "TEST", 593, 605], ["DSRS", "TREATMENT", 625, 629], ["recurrent bleeding", "PROBLEM", 689, 707], ["the TIPS group", "TREATMENT", 725, 739], ["more intervention", "TREATMENT", 747, 764], ["TIPS stenosis", "PROBLEM", 769, 782], ["dysfunction", "PROBLEM", 786, 797], ["distal", "ANATOMY_MODIFIER", 47, 53], ["splenorenal shunt", "OBSERVATION", 54, 71], ["sclerotherapy", "OBSERVATION", 95, 108], ["bleeding", "OBSERVATION", 112, 120], ["sclerotherapy", "OBSERVATION", 137, 150], ["bleeding", "OBSERVATION", 242, 250], ["Variceal", "ANATOMY", 319, 327], ["Hemorrhage", "OBSERVATION", 328, 338], ["Distal", "ANATOMY_MODIFIER", 344, 350], ["Splenorenal", "ANATOMY", 351, 362], ["ligation", "OBSERVATION", 412, 420], ["esophageal", "ANATOMY", 425, 435], ["varices", "OBSERVATION", 436, 443], ["Variceal", "ANATOMY", 537, 545], ["Hemorrhage", "OBSERVATION", 546, 556], ["Distal", "ANATOMY_MODIFIER", 562, 568], ["Splenorenal", "ANATOMY", 569, 580], ["recurrent", "OBSERVATION_MODIFIER", 689, 698], ["bleeding", "OBSERVATION", 699, 707], ["stenosis", "OBSERVATION", 774, 782]]], ["This study was started in the era before covered TIPS which have lower stenosis rates.Answer: Prevention of Recurrent Variceal Hemorrhage with Distal Splenorenal ShuntThe ultrasound image (Fig. 56.1) shows a patent DSRS (the \"S\") between the splenic vein (\"SV\") and renal vein (\"RV\").", [["Variceal", "ANATOMY", 118, 126], ["splenic vein", "ANATOMY", 242, 254], ["SV", "ANATOMY", 257, 259], ["renal vein", "ANATOMY", 266, 276], ["RV", "ANATOMY", 279, 281], ["stenosis", "DISEASE", 71, 79], ["Hemorrhage", "DISEASE", 127, 137], ["splenic vein", "MULTI-TISSUE_STRUCTURE", 242, 254], ["renal vein", "MULTI-TISSUE_STRUCTURE", 266, 276], ["This study", "TEST", 0, 10], ["covered TIPS", "TREATMENT", 41, 53], ["lower stenosis rates", "PROBLEM", 65, 85], ["Recurrent Variceal Hemorrhage", "PROBLEM", 108, 137], ["Distal Splenorenal Shunt", "TREATMENT", 143, 167], ["The ultrasound image", "TEST", 167, 187], ["a patent DSRS", "TREATMENT", 206, 219], ["lower", "OBSERVATION_MODIFIER", 65, 70], ["stenosis", "OBSERVATION", 71, 79], ["Variceal", "ANATOMY", 118, 126], ["Hemorrhage", "OBSERVATION", 127, 137], ["Distal", "ANATOMY_MODIFIER", 143, 149], ["Splenorenal Shunt", "OBSERVATION", 150, 167], ["patent", "OBSERVATION", 208, 214], ["DSRS", "OBSERVATION_MODIFIER", 215, 219], ["splenic vein", "ANATOMY", 242, 254], ["renal vein", "ANATOMY", 266, 276], ["RV", "ANATOMY", 279, 281]]], ["Good flow is noted on the Doppler.", [["the Doppler", "TEST", 22, 33], ["flow", "OBSERVATION", 5, 9]]], ["This lady did well after DSRS and has not bled in the last 2 years.", [["DSRS", "TREATMENT", 25, 29]]], ["I have followed several other patients from the TIPS vs. DSRS trial that similarly have not bled in 10 years and are still early for transplant suggesting that in patients with wellpreserved liver synthetic function and significant portal hypertension, DSRS is a viable alternative if the anatomy is amenable, and the center has the expertise to perform the procedure.Answer: Cruveilhier-Baumgarten Disease or SyndromeThis patient obviously has portal hypertension.", [["liver", "ANATOMY", 191, 196], ["portal", "ANATOMY", 232, 238], ["portal hypertension", "DISEASE", 232, 251], ["DSRS", "DISEASE", 253, 257], ["hypertension", "DISEASE", 452, 464], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 163, 171], ["liver", "ORGAN", 191, 196], ["portal", "MULTI-TISSUE_STRUCTURE", 232, 238], ["patient", "ORGANISM", 423, 430], ["portal", "MULTI-TISSUE_STRUCTURE", 445, 451], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 163, 171], ["patient", "SPECIES", 423, 430], ["the TIPS vs. DSRS trial", "TREATMENT", 44, 67], ["transplant", "TREATMENT", 133, 143], ["wellpreserved liver synthetic function", "PROBLEM", 177, 215], ["significant portal hypertension", "PROBLEM", 220, 251], ["DSRS", "TREATMENT", 253, 257], ["the procedure", "TREATMENT", 354, 367], ["Baumgarten Disease", "PROBLEM", 388, 406], ["SyndromeThis", "PROBLEM", 410, 422], ["portal hypertension", "PROBLEM", 445, 464], ["liver", "ANATOMY", 191, 196], ["significant", "OBSERVATION_MODIFIER", 220, 231], ["portal", "ANATOMY", 232, 238], ["hypertension", "OBSERVATION", 239, 251], ["portal", "ANATOMY", 445, 451], ["hypertension", "OBSERVATION", 452, 464]]], ["He has ascites, splenomegaly, and dilated abdominal veins, and the sound in the epigastric area is a venous hum.", [["ascites", "ANATOMY", 7, 14], ["splenomegaly", "ANATOMY", 16, 28], ["abdominal veins", "ANATOMY", 42, 57], ["epigastric area", "ANATOMY", 80, 95], ["venous hum", "ANATOMY", 101, 111], ["ascites", "DISEASE", 7, 14], ["splenomegaly", "DISEASE", 16, 28], ["dilated abdominal veins", "DISEASE", 34, 57], ["He", "ORGANISM", 0, 2], ["abdominal veins", "MULTI-TISSUE_STRUCTURE", 42, 57], ["epigastric area", "MULTI-TISSUE_STRUCTURE", 80, 95], ["venous hum", "CANCER", 101, 111], ["ascites", "PROBLEM", 7, 14], ["splenomegaly", "PROBLEM", 16, 28], ["dilated abdominal veins", "PROBLEM", 34, 57], ["the sound in the epigastric area", "PROBLEM", 63, 95], ["ascites", "OBSERVATION", 7, 14], ["splenomegaly", "OBSERVATION", 16, 28], ["dilated", "OBSERVATION", 34, 41], ["abdominal veins", "ANATOMY", 42, 57], ["sound", "OBSERVATION_MODIFIER", 67, 72], ["epigastric", "ANATOMY", 80, 90], ["area", "ANATOMY_MODIFIER", 91, 95], ["venous", "ANATOMY", 101, 107], ["hum", "OBSERVATION", 108, 111]]], ["Some experts suggest that the direction of flow of blood in the dilated abdominal veins is indicative of either portal hypertension or vena caval obstruction, but the presence of valves can make it difficult to distinguish inferior flow (suggesting portal hypertension) or flow superiorly (vena caval obstruction).Answer: Cruveilhier-Baumgarten Disease or SyndromeThe ultrasound image (Fig. 57.1) shows a liver that is echogenic in echotexture (smallest arrow), and on other images was markedly decreased in size, and nodular in contour.", [["blood", "ANATOMY", 51, 56], ["abdominal veins", "ANATOMY", 72, 87], ["portal", "ANATOMY", 112, 118], ["vena caval", "ANATOMY", 135, 145], ["inferior", "ANATOMY", 223, 231], ["portal", "ANATOMY", 249, 255], ["vena caval", "ANATOMY", 290, 300], ["liver", "ANATOMY", 405, 410], ["hypertension", "DISEASE", 119, 131], ["vena caval obstruction", "DISEASE", 135, 157], ["hypertension", "DISEASE", 256, 268], ["vena caval obstruction", "DISEASE", 290, 312], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["abdominal veins", "MULTI-TISSUE_STRUCTURE", 72, 87], ["portal", "MULTI-TISSUE_STRUCTURE", 112, 118], ["vena caval", "MULTI-TISSUE_STRUCTURE", 135, 145], ["valves", "PATHOLOGICAL_FORMATION", 179, 185], ["portal", "MULTI-TISSUE_STRUCTURE", 249, 255], ["vena caval", "MULTI-TISSUE_STRUCTURE", 290, 300], ["liver", "ORGAN", 405, 410], ["blood in the dilated abdominal veins", "PROBLEM", 51, 87], ["portal hypertension", "PROBLEM", 112, 131], ["vena caval obstruction", "PROBLEM", 135, 157], ["valves", "TREATMENT", 179, 185], ["inferior flow", "PROBLEM", 223, 236], ["portal hypertension", "PROBLEM", 249, 268], ["flow superiorly (vena caval obstruction", "PROBLEM", 273, 312], ["Baumgarten Disease", "PROBLEM", 334, 352], ["Syndrome", "PROBLEM", 356, 364], ["The ultrasound image", "TEST", 364, 384], ["echogenic in echotexture", "PROBLEM", 419, 443], ["other images", "TEST", 469, 481], ["nodular in contour", "PROBLEM", 518, 536], ["flow", "OBSERVATION", 43, 47], ["blood", "OBSERVATION", 51, 56], ["dilated", "OBSERVATION", 64, 71], ["abdominal veins", "ANATOMY", 72, 87], ["indicative of", "UNCERTAINTY", 91, 104], ["portal", "ANATOMY", 112, 118], ["hypertension", "OBSERVATION", 119, 131], ["vena caval", "ANATOMY", 135, 145], ["obstruction", "OBSERVATION", 146, 157], ["valves", "OBSERVATION", 179, 185], ["inferior", "OBSERVATION_MODIFIER", 223, 231], ["flow", "OBSERVATION", 232, 236], ["portal", "ANATOMY", 249, 255], ["hypertension", "OBSERVATION", 256, 268], ["flow", "OBSERVATION_MODIFIER", 273, 277], ["superiorly", "OBSERVATION_MODIFIER", 278, 288], ["vena caval", "ANATOMY", 290, 300], ["obstruction", "OBSERVATION", 301, 312], ["liver", "ANATOMY", 405, 410], ["echogenic", "OBSERVATION", 419, 428], ["echotexture", "OBSERVATION", 432, 443], ["smallest", "OBSERVATION_MODIFIER", 445, 453], ["markedly", "OBSERVATION_MODIFIER", 486, 494], ["decreased", "OBSERVATION", 495, 504], ["size", "OBSERVATION_MODIFIER", 508, 512], ["nodular", "OBSERVATION_MODIFIER", 518, 525], ["contour", "OBSERVATION_MODIFIER", 529, 536]]], ["A large amount of abdominal ascites is present (large arrow) and there is a patent paraumbilical vein (long arrow).", [["abdominal ascites", "ANATOMY", 18, 35], ["paraumbilical vein", "ANATOMY", 83, 101], ["abdominal ascites", "DISEASE", 18, 35], ["abdominal ascites", "CANCER", 18, 35], ["paraumbilical vein", "MULTI-TISSUE_STRUCTURE", 83, 101], ["A large amount of abdominal ascites", "PROBLEM", 0, 35], ["a patent paraumbilical vein", "PROBLEM", 74, 101], ["large", "OBSERVATION_MODIFIER", 2, 7], ["amount", "OBSERVATION_MODIFIER", 8, 14], ["abdominal", "ANATOMY", 18, 27], ["ascites", "OBSERVATION", 28, 35], ["large", "OBSERVATION_MODIFIER", 48, 53], ["patent", "OBSERVATION", 76, 82], ["paraumbilical vein", "ANATOMY", 83, 101]]], ["The venous hum results from collateral connections between the portal system and the remnant of the umbilical vein and should increase with the Valsalva and decrease with pressure over the umbilicus.Answer: Cruveilhier-Baumgarten Disease or SyndromeThe term Cruveilhier-Baumgarten syndrome is based on a description by Cruveilhier in 1852 and then Baumgarten in 1908 and is characterized by portal hypertension, splenomegaly, and evidence of excessively prominent umbilical circulation -visible abdominal veins and a venous hum.", [["venous", "ANATOMY", 4, 10], ["collateral", "ANATOMY", 28, 38], ["portal system", "ANATOMY", 63, 76], ["umbilical vein", "ANATOMY", 100, 114], ["umbilicus", "ANATOMY", 189, 198], ["portal", "ANATOMY", 391, 397], ["umbilical", "ANATOMY", 464, 473], ["abdominal veins", "ANATOMY", 495, 510], ["venous hum", "ANATOMY", 517, 527], ["Cruveilhier-Baumgarten syndrome", "DISEASE", 258, 289], ["portal hypertension", "DISEASE", 391, 410], ["splenomegaly", "DISEASE", 412, 424], ["venous hum", "CANCER", 4, 14], ["collateral connections", "MULTI-TISSUE_STRUCTURE", 28, 50], ["portal system", "MULTI-TISSUE_STRUCTURE", 63, 76], ["umbilical vein", "MULTI-TISSUE_STRUCTURE", 100, 114], ["umbilicus", "PATHOLOGICAL_FORMATION", 189, 198], ["portal", "MULTI-TISSUE_STRUCTURE", 391, 397], ["abdominal veins", "MULTI-TISSUE_STRUCTURE", 495, 510], ["venous hum", "MULTI-TISSUE_STRUCTURE", 517, 527], ["The venous hum", "TEST", 0, 14], ["collateral connections between the portal system", "PROBLEM", 28, 76], ["the Valsalva", "TREATMENT", 140, 152], ["pressure over the umbilicus", "TREATMENT", 171, 198], ["Baumgarten Disease", "PROBLEM", 219, 237], ["Syndrome", "PROBLEM", 241, 249], ["Baumgarten syndrome", "PROBLEM", 270, 289], ["portal hypertension", "PROBLEM", 391, 410], ["splenomegaly", "PROBLEM", 412, 424], ["excessively prominent umbilical circulation", "PROBLEM", 442, 485], ["visible abdominal veins", "PROBLEM", 487, 510], ["a venous hum", "PROBLEM", 515, 527], ["venous", "ANATOMY", 4, 10], ["collateral connections", "OBSERVATION", 28, 50], ["portal system", "ANATOMY", 63, 76], ["remnant", "OBSERVATION", 85, 92], ["umbilical vein", "ANATOMY", 100, 114], ["increase", "OBSERVATION_MODIFIER", 126, 134], ["Valsalva", "OBSERVATION", 144, 152], ["decrease", "OBSERVATION_MODIFIER", 157, 165], ["pressure", "OBSERVATION_MODIFIER", 171, 179], ["umbilicus", "ANATOMY", 189, 198], ["Baumgarten syndrome", "OBSERVATION", 270, 289], ["portal", "ANATOMY", 391, 397], ["hypertension", "OBSERVATION", 398, 410], ["splenomegaly", "OBSERVATION", 412, 424], ["excessively", "OBSERVATION_MODIFIER", 442, 453], ["prominent", "OBSERVATION", 454, 463], ["umbilical circulation", "ANATOMY", 464, 485], ["visible", "ANATOMY_MODIFIER", 487, 494], ["abdominal veins", "ANATOMY", 495, 510], ["venous", "ANATOMY", 517, 523], ["hum", "OBSERVATION", 524, 527]]], ["The disease refers to these findings in a patient who has a patent umbilical vein, an atrophic liver but with little or no fibrosis on pathology, whereas the syndrome most commonly occurs in patients with cirrhosis.Answer: Cruveilhier-Baumgarten Disease or SyndromeThere is some suggestion that the presence of the collaterals in this syndrome makes typical varices in the distal esophagus and proximal stomach smaller (and less likely to bleed).Answer: Cruveilhier-Baumgarten Disease or SyndromeThe classic intrahepatic venous circulation found in the syndrome can be appreciated on Doppler sonography with hepatopetal flow in the segmental portal veins and hepatofugal flow leaving the liver in a paraumbilical vein in the falciform ligament which joins veins in the anterior abdominal wall around the umbilicus (causing the venous hum).Case 58A 37-year-old white male with a history of chronic lower back pain is admitted directly to the hospital from his scheduled pain clinic visit with new onset jaundice and abdominal distension.", [["patent umbilical vein", "ANATOMY", 60, 81], ["liver", "ANATOMY", 95, 100], ["collaterals", "ANATOMY", 315, 326], ["varices", "ANATOMY", 358, 365], ["distal esophagus", "ANATOMY", 373, 389], ["proximal stomach", "ANATOMY", 394, 410], ["intrahepatic venous", "ANATOMY", 508, 527], ["hepatopetal", "ANATOMY", 608, 619], ["segmental portal veins", "ANATOMY", 632, 654], ["hepatofugal", "ANATOMY", 659, 670], ["liver", "ANATOMY", 688, 693], ["paraumbilical vein", "ANATOMY", 699, 717], ["falciform ligament", "ANATOMY", 725, 743], ["veins", "ANATOMY", 756, 761], ["anterior abdominal wall", "ANATOMY", 769, 792], ["umbilicus", "ANATOMY", 804, 813], ["venous", "ANATOMY", 827, 833], ["lower back", "ANATOMY", 897, 907], ["abdominal", "ANATOMY", 1015, 1024], ["fibrosis", "DISEASE", 123, 131], ["cirrhosis", "DISEASE", 205, 214], ["varices", "DISEASE", 358, 365], ["lower back pain", "DISEASE", 897, 912], ["pain", "DISEASE", 969, 973], ["jaundice", "DISEASE", 1002, 1010], ["abdominal distension", "DISEASE", 1015, 1035], ["patient", "ORGANISM", 42, 49], ["umbilical vein", "MULTI-TISSUE_STRUCTURE", 67, 81], ["liver", "ORGAN", 95, 100], ["patients", "ORGANISM", 191, 199], ["varices", "PATHOLOGICAL_FORMATION", 358, 365], ["esophagus", "ORGAN", 380, 389], ["stomach", "ORGAN", 403, 410], ["intrahepatic venous", "MULTI-TISSUE_STRUCTURE", 508, 527], ["portal veins", "MULTI-TISSUE_STRUCTURE", 642, 654], ["liver", "ORGAN", 688, 693], ["paraumbilical vein", "MULTI-TISSUE_STRUCTURE", 699, 717], ["falciform ligament", "TISSUE", 725, 743], ["veins", "MULTI-TISSUE_STRUCTURE", 756, 761], ["anterior abdominal wall", "MULTI-TISSUE_STRUCTURE", 769, 792], ["umbilicus", "ORGAN", 804, 813], ["venous hum", "MULTI-TISSUE_STRUCTURE", 827, 837], ["male", "ORGANISM", 866, 870], ["abdominal", "ORGANISM_SUBDIVISION", 1015, 1024], ["patient", "SPECIES", 42, 49], ["patients", "SPECIES", 191, 199], ["The disease", "PROBLEM", 0, 11], ["a patent umbilical vein", "PROBLEM", 58, 81], ["an atrophic liver", "PROBLEM", 83, 100], ["fibrosis on pathology", "PROBLEM", 123, 144], ["the syndrome", "PROBLEM", 154, 166], ["cirrhosis", "PROBLEM", 205, 214], ["Baumgarten Disease", "PROBLEM", 235, 253], ["this syndrome", "PROBLEM", 330, 343], ["typical varices in the distal esophagus and proximal stomach", "PROBLEM", 350, 410], ["bleed", "PROBLEM", 439, 444], ["Baumgarten Disease", "PROBLEM", 466, 484], ["Syndrome", "PROBLEM", 488, 496], ["The classic intrahepatic venous circulation", "PROBLEM", 496, 539], ["the syndrome", "PROBLEM", 549, 561], ["Doppler sonography", "TEST", 584, 602], ["chronic lower back pain", "PROBLEM", 889, 912], ["new onset jaundice", "PROBLEM", 992, 1010], ["abdominal distension", "PROBLEM", 1015, 1035], ["disease", "OBSERVATION", 4, 11], ["patent", "OBSERVATION", 60, 66], ["umbilical vein", "ANATOMY", 67, 81], ["atrophic", "OBSERVATION", 86, 94], ["liver", "ANATOMY", 95, 100], ["no", "UNCERTAINTY", 120, 122], ["fibrosis", "OBSERVATION", 123, 131], ["pathology", "OBSERVATION", 135, 144], ["cirrhosis", "OBSERVATION", 205, 214], ["collaterals", "OBSERVATION", 315, 326], ["typical", "OBSERVATION_MODIFIER", 350, 357], ["varices", "OBSERVATION", 358, 365], ["distal", "ANATOMY_MODIFIER", 373, 379], ["esophagus", "ANATOMY", 380, 389], ["proximal", "ANATOMY_MODIFIER", 394, 402], ["stomach", "ANATOMY", 403, 410], ["smaller", "OBSERVATION_MODIFIER", 411, 418], ["less likely to", "UNCERTAINTY", 424, 438], ["bleed", "OBSERVATION", 439, 444], ["classic", "ANATOMY_MODIFIER", 500, 507], ["intrahepatic", "ANATOMY_MODIFIER", 508, 520], ["venous", "ANATOMY", 521, 527], ["circulation", "OBSERVATION", 528, 539], ["syndrome", "OBSERVATION", 553, 561], ["hepatopetal", "OBSERVATION_MODIFIER", 608, 619], ["flow", "OBSERVATION", 620, 624], ["segmental", "ANATOMY_MODIFIER", 632, 641], ["portal veins", "ANATOMY", 642, 654], ["hepatofugal flow", "OBSERVATION", 659, 675], ["liver", "ANATOMY", 688, 693], ["paraumbilical vein", "ANATOMY", 699, 717], ["falciform ligament", "ANATOMY", 725, 743], ["veins", "ANATOMY", 756, 761], ["anterior", "ANATOMY_MODIFIER", 769, 777], ["abdominal", "ANATOMY_MODIFIER", 778, 787], ["wall", "ANATOMY_MODIFIER", 788, 792], ["umbilicus", "ANATOMY", 804, 813], ["venous hum", "ANATOMY", 827, 837], ["chronic", "OBSERVATION_MODIFIER", 889, 896], ["lower", "ANATOMY_MODIFIER", 897, 902], ["back", "ANATOMY", 903, 907], ["pain", "OBSERVATION", 908, 912], ["jaundice", "OBSERVATION", 1002, 1010], ["abdominal", "ANATOMY", 1015, 1024], ["distension", "OBSERVATION", 1025, 1035]]], ["The patient has been experiencing increasing back pain for the last 2 weeks.", [["back", "ANATOMY", 45, 49], ["back pain", "DISEASE", 45, 54], ["patient", "ORGANISM", 4, 11], ["back", "ORGANISM_SUBDIVISION", 45, 49], ["patient", "SPECIES", 4, 11], ["increasing back pain", "PROBLEM", 34, 54], ["increasing", "OBSERVATION_MODIFIER", 34, 44], ["back", "ANATOMY", 45, 49], ["pain", "OBSERVATION", 50, 54]]], ["He states that the pain is higher than his chronic back pain.", [["back", "ANATOMY", 51, 55], ["pain", "DISEASE", 19, 23], ["chronic back pain", "DISEASE", 43, 60], ["back", "ORGANISM_SUBDIVISION", 51, 55], ["the pain", "PROBLEM", 15, 23], ["his chronic back pain", "PROBLEM", 39, 60], ["chronic", "OBSERVATION_MODIFIER", 43, 50], ["back", "ANATOMY", 51, 55], ["pain", "OBSERVATION", 56, 60]]], ["He also has developed new onset lower extremity edema in the last week.", [["lower extremity edema", "ANATOMY", 32, 53], ["lower extremity edema", "DISEASE", 32, 53], ["lower extremity", "ORGANISM_SUBDIVISION", 32, 47], ["edema", "PATHOLOGICAL_FORMATION", 48, 53], ["new onset lower extremity edema", "PROBLEM", 22, 53], ["new", "OBSERVATION_MODIFIER", 22, 25], ["onset", "OBSERVATION_MODIFIER", 26, 31], ["lower", "ANATOMY_MODIFIER", 32, 37], ["extremity", "ANATOMY", 38, 47], ["edema", "OBSERVATION", 48, 53]]], ["The patient's wife noticed some confusion and disorientation in the last several days.", [["confusion", "DISEASE", 32, 41], ["disorientation", "DISEASE", 46, 60], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["some confusion", "PROBLEM", 27, 41], ["disorientation", "PROBLEM", 46, 60], ["confusion", "OBSERVATION", 32, 41], ["disorientation", "OBSERVATION", 46, 60]]], ["One day prior to admission, she noticed yellowing of his eyes.", [["eyes", "ANATOMY", 57, 61], ["eyes", "ORGAN", 57, 61], ["yellowing of his eyes", "PROBLEM", 40, 61], ["yellowing", "OBSERVATION", 40, 49], ["eyes", "ANATOMY", 57, 61]]], ["Review of systems is notable for nausea, constipation with intermittent rectal bleeding in the last month, dyspnea on exertion, and diaphoresis.", [["rectal", "ANATOMY", 72, 78], ["nausea", "DISEASE", 33, 39], ["constipation", "DISEASE", 41, 53], ["intermittent rectal bleeding", "DISEASE", 59, 87], ["dyspnea", "DISEASE", 107, 114], ["diaphoresis", "DISEASE", 132, 143], ["rectal", "ORGANISM_SUBDIVISION", 72, 78], ["Review of systems", "TEST", 0, 17], ["nausea", "PROBLEM", 33, 39], ["constipation", "PROBLEM", 41, 53], ["intermittent rectal bleeding", "PROBLEM", 59, 87], ["dyspnea", "PROBLEM", 107, 114], ["diaphoresis", "PROBLEM", 132, 143], ["rectal", "ANATOMY", 72, 78], ["bleeding", "OBSERVATION", 79, 87], ["dyspnea", "OBSERVATION", 107, 114]]], ["One month prior, the patient and his wife were in South Carolina on vacation.", [["patient", "ORGANISM", 21, 28], ["patient", "SPECIES", 21, 28]]], ["There is no history of fevers, chills, sick contacts, or antibiotic use.", [["fevers", "DISEASE", 23, 29], ["chills", "DISEASE", 31, 37], ["fevers", "PROBLEM", 23, 29], ["chills", "PROBLEM", 31, 37], ["sick contacts", "PROBLEM", 39, 52], ["antibiotic use", "TREATMENT", 57, 71], ["no history of", "UNCERTAINTY", 9, 22], ["fevers", "OBSERVATION", 23, 29]]], ["The patient is a former police man and was involved in a workrelated injury 3 years ago.", [["patient", "ORGANISM", 4, 11], ["man", "ORGANISM", 31, 34], ["patient", "SPECIES", 4, 11], ["man", "SPECIES", 31, 34], ["a workrelated injury", "PROBLEM", 55, 75]]], ["Since then, he has been suffering with lower back pain.", [["lower back", "ANATOMY", 39, 49], ["lower back pain", "DISEASE", 39, 54], ["lower back pain", "PROBLEM", 39, 54], ["lower", "ANATOMY_MODIFIER", 39, 44], ["back", "ANATOMY", 45, 49], ["pain", "OBSERVATION", 50, 54]]], ["He is seen regularly in the chronic pain clinic and has been consistent with his physical therapy regimen.", [["chronic pain", "DISEASE", 28, 40], ["his physical therapy regimen", "TREATMENT", 77, 105]]], ["In the last several months, he has been able to wean to as needed narcotics, although in the last several weeks, his narcotic use had increased to hydrocodone/acetaminophen 7.5/750 up to 8 pills a day.", [["hydrocodone", "CHEMICAL", 147, 158], ["acetaminophen", "CHEMICAL", 159, 172], ["hydrocodone", "CHEMICAL", 147, 158], ["acetaminophen", "CHEMICAL", 159, 172], ["hydrocodone", "SIMPLE_CHEMICAL", 147, 158], ["acetaminophen", "SIMPLE_CHEMICAL", 159, 172], ["narcotics", "TREATMENT", 66, 75], ["his narcotic use", "TREATMENT", 113, 129], ["hydrocodone", "TREATMENT", 147, 158], ["acetaminophen", "TREATMENT", 159, 172]]], ["He also has recently been diagnosed with depression and insomnia and was started on a low dose of amitriptyline.", [["depression", "DISEASE", 41, 51], ["insomnia", "DISEASE", 56, 64], ["amitriptyline", "CHEMICAL", 98, 111], ["amitriptyline", "CHEMICAL", 98, 111], ["amitriptyline", "SIMPLE_CHEMICAL", 98, 111], ["depression", "PROBLEM", 41, 51], ["insomnia", "PROBLEM", 56, 64], ["a low dose of amitriptyline", "TREATMENT", 84, 111], ["depression", "OBSERVATION", 41, 51]]], ["The patient lives with his wife of 4 years.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["He is monogamous and has never used illicit drugs.", [["monogamous", "OBSERVATION", 6, 16]]], ["He drinks 10-14 beers per week.", [["He", "ORGANISM", 0, 2]]], ["He does not smoke.", [["smoke", "OBSERVATION", 12, 17]]], ["He has no tattoos nor has he ever had any blood transfusion.", [["blood", "ANATOMY", 42, 47], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["tattoos", "PROBLEM", 10, 17], ["any blood transfusion", "TREATMENT", 38, 59], ["no", "UNCERTAINTY", 7, 9], ["tattoos", "OBSERVATION", 10, 17]]], ["The patient's sister was diagnosed with leukemia at the age of 24.", [["leukemia", "ANATOMY", 40, 48], ["leukemia", "DISEASE", 40, 48], ["patient", "ORGANISM", 4, 11], ["leukemia", "CANCER", 40, 48], ["patient", "SPECIES", 4, 11], ["leukemia", "PROBLEM", 40, 48], ["leukemia", "OBSERVATION", 40, 48]]], ["She has been in remission for over 10 years.Case 58Physical exam was notable for a lethargic, ill-appearing white male.", [["Case 58Physical exam", "TEST", 44, 64], ["a lethargic", "PROBLEM", 81, 92], ["remission", "OBSERVATION", 16, 25]]], ["Vital signs reveal: temperature 37.2\u00b0C, heart rate 110, Blood pressure 98/54, respiratory rate 22, saturation 92%, and BMI 31.7 kg/m 2 .", [["heart", "ANATOMY", 40, 45], ["Blood", "ANATOMY", 56, 61], ["heart", "ORGAN", 40, 45], ["Blood", "ORGANISM_SUBSTANCE", 56, 61], ["Vital signs", "TEST", 0, 11], ["temperature", "TEST", 20, 31], ["C", "TEST", 37, 38], ["heart rate", "TEST", 40, 50], ["Blood pressure", "TEST", 56, 70], ["respiratory rate", "TEST", 78, 94], ["saturation", "TEST", 99, 109], ["BMI", "TEST", 119, 122]]], ["Sclerae were icteric.", [["icteric", "DISEASE", 13, 20], ["Sclerae", "SIMPLE_CHEMICAL", 0, 7], ["icteric", "PROBLEM", 13, 20], ["icteric", "OBSERVATION", 13, 20]]], ["Other than tachycardia, cardiac and pulmonary exam were normal.", [["cardiac", "ANATOMY", 24, 31], ["pulmonary", "ANATOMY", 36, 45], ["tachycardia", "DISEASE", 11, 22], ["cardiac", "ORGAN", 24, 31], ["pulmonary", "ORGAN", 36, 45], ["tachycardia", "PROBLEM", 11, 22], ["cardiac and pulmonary exam", "TEST", 24, 50], ["cardiac", "ANATOMY", 24, 31], ["pulmonary", "ANATOMY", 36, 45], ["normal", "OBSERVATION", 56, 62]]], ["Abdominal exam was notable for marked distension.", [["Abdominal", "ANATOMY", 0, 9], ["Abdominal", "ORGAN", 0, 9], ["Abdominal exam", "TEST", 0, 14], ["marked distension", "PROBLEM", 31, 48], ["marked", "OBSERVATION_MODIFIER", 31, 37], ["distension", "OBSERVATION", 38, 48]]], ["Liver edge was palpable 8 cm below right costovertebral angle and was tender.", [["Liver edge", "ANATOMY", 0, 10], ["right costovertebral angle", "ANATOMY", 35, 61], ["Liver edge", "MULTI-TISSUE_STRUCTURE", 0, 10], ["tender", "PROBLEM", 70, 76], ["edge", "OBSERVATION_MODIFIER", 6, 10], ["palpable", "OBSERVATION", 15, 23], ["8 cm", "OBSERVATION_MODIFIER", 24, 28], ["right", "ANATOMY_MODIFIER", 35, 40], ["costovertebral angle", "ANATOMY", 41, 61], ["tender", "OBSERVATION", 70, 76]]], ["There was no splenomegaly.", [["splenomegaly", "DISEASE", 13, 25], ["splenomegaly", "PATHOLOGICAL_FORMATION", 13, 25], ["splenomegaly", "PROBLEM", 13, 25], ["no", "UNCERTAINTY", 10, 12], ["splenomegaly", "OBSERVATION", 13, 25]]], ["Fluid wave was easily elicited.", [["Fluid wave", "TEST", 0, 10]]], ["Pitting edema was noted from ankles to mid thigh.", [["edema", "ANATOMY", 8, 13], ["ankles", "ANATOMY", 29, 35], ["thigh", "ANATOMY", 43, 48], ["edema", "DISEASE", 8, 13], ["edema", "PATHOLOGICAL_FORMATION", 8, 13], ["ankles", "ORGANISM_SUBDIVISION", 29, 35], ["thigh", "ORGANISM_SUBDIVISION", 43, 48], ["Pitting edema", "PROBLEM", 0, 13], ["edema", "OBSERVATION", 8, 13], ["ankles", "ANATOMY", 29, 35], ["mid", "ANATOMY_MODIFIER", 39, 42], ["thigh", "ANATOMY", 43, 48]]], ["Rectal exam revealed moderate external hemorrhoids one of which was thrombosed and oozing a small amount of blood, no internal masses were palpated.", [["Rectal", "ANATOMY", 0, 6], ["blood", "ANATOMY", 108, 113], ["internal masses", "ANATOMY", 118, 133], ["hemorrhoids", "DISEASE", 39, 50], ["Rectal", "ORGAN", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["masses", "CANCER", 127, 133], ["Rectal exam", "TEST", 0, 11], ["moderate external hemorrhoids", "PROBLEM", 21, 50], ["thrombosed", "PROBLEM", 68, 78], ["a small amount of blood", "PROBLEM", 90, 113], ["internal masses", "PROBLEM", 118, 133], ["moderate", "OBSERVATION_MODIFIER", 21, 29], ["external", "OBSERVATION_MODIFIER", 30, 38], ["hemorrhoids", "OBSERVATION", 39, 50], ["thrombosed", "OBSERVATION", 68, 78], ["oozing", "OBSERVATION", 83, 89], ["small", "OBSERVATION_MODIFIER", 92, 97], ["amount", "OBSERVATION_MODIFIER", 98, 104], ["no", "UNCERTAINTY", 115, 117], ["internal", "OBSERVATION_MODIFIER", 118, 126], ["masses", "OBSERVATION", 127, 133]]], ["There was no palpable adenopathy.Case 58A diagnostic tap was performed: hematocrit 22% A CT scan is performed (see Fig. 58.1 ).", [["palpable adenopathy", "ANATOMY", 13, 32], ["adenopathy", "DISEASE", 22, 32], ["palpable adenopathy", "PROBLEM", 13, 32], ["diagnostic tap", "TEST", 42, 56], ["hematocrit", "TEST", 72, 82], ["A CT scan", "TEST", 87, 96], ["no", "UNCERTAINTY", 10, 12], ["palpable", "OBSERVATION_MODIFIER", 13, 21], ["adenopathy", "OBSERVATION", 22, 32]]], ["In addition, a note is made of an enhancing lesion in the sigmoid colon.Answer: Metastatic Colon Cancer to the Liver presenting as Acute Liver FailureThis case fulfills criteria for acute liver failure (ALF): the rapid deterioration of liver function resulting in coagulopathy and alteration in the mental status of a previously healthy individual.", [["lesion", "ANATOMY", 44, 50], ["sigmoid colon", "ANATOMY", 58, 71], ["Metastatic Colon Cancer", "ANATOMY", 80, 103], ["Liver", "ANATOMY", 111, 116], ["Liver", "ANATOMY", 137, 142], ["liver", "ANATOMY", 188, 193], ["liver", "ANATOMY", 236, 241], ["Colon Cancer", "DISEASE", 91, 103], ["Liver Failure", "DISEASE", 137, 150], ["acute liver failure", "DISEASE", 182, 201], ["ALF", "DISEASE", 203, 206], ["deterioration of liver function", "DISEASE", 219, 250], ["coagulopathy", "DISEASE", 264, 276], ["lesion", "CANCER", 44, 50], ["sigmoid colon", "CANCER", 58, 71], ["Metastatic Colon Cancer", "CANCER", 80, 103], ["Liver", "ORGAN", 111, 116], ["Liver", "ORGAN", 137, 142], ["liver", "ORGAN", 188, 193], ["liver", "ORGAN", 236, 241], ["an enhancing lesion in the sigmoid colon", "PROBLEM", 31, 71], ["Metastatic Colon Cancer to the Liver", "PROBLEM", 80, 116], ["Acute Liver Failure", "PROBLEM", 131, 150], ["acute liver failure", "PROBLEM", 182, 201], ["the rapid deterioration of liver function", "PROBLEM", 209, 250], ["coagulopathy", "PROBLEM", 264, 276], ["alteration in the mental status", "PROBLEM", 281, 312], ["enhancing", "OBSERVATION_MODIFIER", 34, 43], ["lesion", "OBSERVATION", 44, 50], ["sigmoid", "ANATOMY_MODIFIER", 58, 65], ["colon", "ANATOMY", 66, 71], ["Metastatic", "OBSERVATION_MODIFIER", 80, 90], ["Colon", "ANATOMY", 91, 96], ["Cancer", "OBSERVATION", 97, 103], ["Liver", "ANATOMY", 111, 116], ["Acute", "OBSERVATION_MODIFIER", 131, 136], ["Liver", "ANATOMY", 137, 142], ["Failure", "OBSERVATION", 143, 150], ["liver", "ANATOMY", 188, 193], ["failure", "OBSERVATION", 194, 201], ["rapid", "OBSERVATION_MODIFIER", 213, 218], ["deterioration", "OBSERVATION", 219, 232], ["liver", "ANATOMY", 236, 241], ["coagulopathy", "OBSERVATION", 264, 276]]], ["The differential diagnosis in this case includes: acetaminophen/drug induced, viral, veno-occlusive, ischemic, and autoimmune hepatitis.", [["acetaminophen", "CHEMICAL", 50, 63], ["viral, veno-occlusive, ischemic, and autoimmune hepatitis", "DISEASE", 78, 135], ["acetaminophen", "CHEMICAL", 50, 63], ["acetaminophen", "SIMPLE_CHEMICAL", 50, 63], ["acetaminophen", "TREATMENT", 50, 63], ["viral, veno-occlusive", "PROBLEM", 78, 99], ["ischemic", "PROBLEM", 101, 109], ["autoimmune hepatitis", "PROBLEM", 115, 135], ["veno-occlusive", "OBSERVATION", 85, 99], ["ischemic", "OBSERVATION_MODIFIER", 101, 109], ["autoimmune hepatitis", "OBSERVATION", 115, 135]]], ["All of these, however, can reasonably be ruled out with history, exam, blood work, and imaging.", [["blood", "ANATOMY", 71, 76], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["exam", "TEST", 65, 69], ["blood work", "TEST", 71, 81], ["imaging", "TEST", 87, 94]]], ["The extreme elevations in iron studies seen in many cases of acute severe hepatitis can cause some confusion to the unseasoned clinician; however, these constitute a manifestation of hepatocellular damage and likely have no prognostic value.", [["hepatocellular", "ANATOMY", 183, 197], ["iron", "CHEMICAL", 26, 30], ["hepatitis", "DISEASE", 74, 83], ["confusion", "DISEASE", 99, 108], ["hepatocellular damage", "DISEASE", 183, 204], ["iron", "CHEMICAL", 26, 30], ["iron", "SIMPLE_CHEMICAL", 26, 30], ["hepatocellular", "CANCER", 183, 197], ["The extreme elevations", "PROBLEM", 0, 22], ["iron studies", "TEST", 26, 38], ["acute severe hepatitis", "PROBLEM", 61, 83], ["some confusion", "PROBLEM", 94, 108], ["hepatocellular damage", "PROBLEM", 183, 204], ["prognostic value", "PROBLEM", 224, 240], ["extreme", "OBSERVATION_MODIFIER", 4, 11], ["elevations", "OBSERVATION_MODIFIER", 12, 22], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["hepatitis", "OBSERVATION", 74, 83], ["hepatocellular", "ANATOMY", 183, 197]]], ["Moreover, hereditary hemochromatosis should never be on the differential of acute liver failure.Answer: Metastatic Colon Cancer to the Liver presenting as Acute Liver FailureThe presence of massive hepatomegaly, cholestatic pattern to the liver function tests, and bloody tap in a relatively young person make an infiltrative or malignant process the most likely cause.", [["liver", "ANATOMY", 82, 87], ["Metastatic Colon Cancer", "ANATOMY", 104, 127], ["Liver", "ANATOMY", 135, 140], ["Liver", "ANATOMY", 161, 166], ["liver", "ANATOMY", 239, 244], ["hereditary hemochromatosis", "DISEASE", 10, 36], ["acute liver failure", "DISEASE", 76, 95], ["Colon Cancer", "DISEASE", 115, 127], ["Liver Failure", "DISEASE", 161, 174], ["hepatomegaly", "DISEASE", 198, 210], ["liver", "ORGAN", 82, 87], ["Metastatic Colon Cancer", "CANCER", 104, 127], ["Liver", "ORGAN", 135, 140], ["Liver", "ORGAN", 161, 166], ["liver", "ORGAN", 239, 244], ["person", "SPECIES", 298, 304], ["hereditary hemochromatosis", "PROBLEM", 10, 36], ["acute liver failure", "PROBLEM", 76, 95], ["Metastatic Colon Cancer to the Liver", "PROBLEM", 104, 140], ["Acute Liver Failure", "PROBLEM", 155, 174], ["massive hepatomegaly", "PROBLEM", 190, 210], ["cholestatic pattern", "PROBLEM", 212, 231], ["the liver function tests", "TEST", 235, 259], ["bloody tap", "PROBLEM", 265, 275], ["an infiltrative or malignant process", "PROBLEM", 310, 346], ["hereditary", "OBSERVATION_MODIFIER", 10, 20], ["hemochromatosis", "OBSERVATION", 21, 36], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["liver", "ANATOMY", 82, 87], ["failure", "OBSERVATION", 88, 95], ["Metastatic", "OBSERVATION_MODIFIER", 104, 114], ["Colon", "ANATOMY", 115, 120], ["Cancer", "OBSERVATION", 121, 127], ["Liver", "ANATOMY", 135, 140], ["Acute", "OBSERVATION_MODIFIER", 155, 160], ["Liver", "ANATOMY", 161, 166], ["Failure", "OBSERVATION", 167, 174], ["massive", "OBSERVATION_MODIFIER", 190, 197], ["hepatomegaly", "OBSERVATION", 198, 210], ["cholestatic", "OBSERVATION_MODIFIER", 212, 223], ["liver", "ANATOMY", 239, 244], ["infiltrative", "OBSERVATION_MODIFIER", 313, 325], ["malignant", "OBSERVATION", 329, 338], ["most likely", "UNCERTAINTY", 351, 362]]], ["Prior to histology, given the elevated LDH and high uric acid, lymphoma was at the top of our list of possible causes.Answer: Metastatic Colon Cancer to the Liver presenting as Acute Liver FailureThe patient's hemodynamic instability was secondary to intraperitoneal hemorrhage.", [["lymphoma", "ANATOMY", 63, 71], ["Metastatic Colon Cancer", "ANATOMY", 126, 149], ["Liver", "ANATOMY", 157, 162], ["Liver", "ANATOMY", 183, 188], ["intraperitoneal", "ANATOMY", 251, 266], ["uric acid", "CHEMICAL", 52, 61], ["lymphoma", "DISEASE", 63, 71], ["Colon Cancer", "DISEASE", 137, 149], ["Liver Failure", "DISEASE", 183, 196], ["hemodynamic instability", "DISEASE", 210, 233], ["hemorrhage", "DISEASE", 267, 277], ["uric acid", "CHEMICAL", 52, 61], ["LDH", "GENE_OR_GENE_PRODUCT", 39, 42], ["uric acid", "SIMPLE_CHEMICAL", 52, 61], ["lymphoma", "CANCER", 63, 71], ["Metastatic Colon Cancer", "CANCER", 126, 149], ["Liver", "ORGAN", 157, 162], ["Liver", "ORGAN", 183, 188], ["patient", "ORGANISM", 200, 207], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 251, 266], ["LDH", "PROTEIN", 39, 42], ["patient", "SPECIES", 200, 207], ["histology", "TEST", 9, 18], ["the elevated LDH", "PROBLEM", 26, 42], ["high uric acid", "PROBLEM", 47, 61], ["lymphoma", "PROBLEM", 63, 71], ["Metastatic Colon Cancer to the Liver", "PROBLEM", 126, 162], ["Acute Liver Failure", "PROBLEM", 177, 196], ["The patient's hemodynamic instability", "PROBLEM", 196, 233], ["intraperitoneal hemorrhage", "PROBLEM", 251, 277], ["high", "OBSERVATION_MODIFIER", 47, 51], ["uric acid", "OBSERVATION", 52, 61], ["lymphoma", "OBSERVATION", 63, 71], ["Metastatic", "OBSERVATION_MODIFIER", 126, 136], ["Colon", "ANATOMY", 137, 142], ["Cancer", "OBSERVATION", 143, 149], ["Liver", "ANATOMY", 157, 162], ["Acute", "OBSERVATION_MODIFIER", 177, 182], ["Liver", "ANATOMY", 183, 188], ["Failure", "OBSERVATION", 189, 196], ["intraperitoneal", "ANATOMY", 251, 266], ["hemorrhage", "OBSERVATION", 267, 277]]], ["The equivalent ascites and serum hematocrit measured from the diagnostic paracentesis, in conjunction with inappropriate response to multiple blood transfusions were evidence of active bleeding.", [["ascites", "ANATOMY", 15, 22], ["serum", "ANATOMY", 27, 32], ["blood", "ANATOMY", 142, 147], ["ascites", "DISEASE", 15, 22], ["bleeding", "DISEASE", 185, 193], ["ascites", "CANCER", 15, 22], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["blood", "ORGANISM_SUBSTANCE", 142, 147], ["The equivalent ascites", "PROBLEM", 0, 22], ["serum hematocrit", "TEST", 27, 43], ["the diagnostic paracentesis", "TREATMENT", 58, 85], ["multiple blood transfusions", "TREATMENT", 133, 160], ["active bleeding", "PROBLEM", 178, 193], ["equivalent", "OBSERVATION_MODIFIER", 4, 14], ["ascites", "OBSERVATION", 15, 22], ["serum hematocrit", "OBSERVATION_MODIFIER", 27, 43], ["evidence of", "UNCERTAINTY", 166, 177], ["active", "OBSERVATION_MODIFIER", 178, 184], ["bleeding", "OBSERVATION", 185, 193]]], ["The CT scan (Fig. 58.1, white arrow) showed an actively bleeding lesion in the periphery of the right lobe.", [["lesion", "ANATOMY", 65, 71], ["periphery", "ANATOMY", 79, 88], ["right lobe", "ANATOMY", 96, 106], ["bleeding", "DISEASE", 56, 64], ["lobe", "ORGAN", 102, 106], ["The CT scan (Fig.", "TEST", 0, 17], ["white arrow", "TEST", 24, 35], ["an actively bleeding lesion in the periphery of the right lobe", "PROBLEM", 44, 106], ["actively", "OBSERVATION_MODIFIER", 47, 55], ["bleeding", "OBSERVATION_MODIFIER", 56, 64], ["lesion", "OBSERVATION", 65, 71], ["periphery", "ANATOMY_MODIFIER", 79, 88], ["right lobe", "ANATOMY", 96, 106]]], ["The patient was sent emergently to angiography where emoblization of a branch of the right hepatic artery was performed resulting in cessation of active bleeding.Answer: Metastatic Colon Cancer to the Liver presenting as Acute Liver FailureBoth a transjugular liver biopsy (peformed prior to knowledge of a questionable sigmoid lesion was discovered on CT scan) and flexible sigmoidoscopy were performed.", [["right hepatic artery", "ANATOMY", 85, 105], ["Metastatic Colon Cancer", "ANATOMY", 170, 193], ["Liver", "ANATOMY", 201, 206], ["Liver", "ANATOMY", 227, 232], ["liver", "ANATOMY", 260, 265], ["sigmoid lesion", "ANATOMY", 320, 334], ["bleeding", "DISEASE", 153, 161], ["Colon Cancer", "DISEASE", 181, 193], ["patient", "ORGANISM", 4, 11], ["hepatic artery", "MULTI-TISSUE_STRUCTURE", 91, 105], ["Metastatic Colon Cancer", "CANCER", 170, 193], ["Liver", "ORGAN", 201, 206], ["Liver", "ORGAN", 227, 232], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 260, 272], ["sigmoid lesion", "CANCER", 320, 334], ["patient", "SPECIES", 4, 11], ["angiography", "TEST", 35, 46], ["active bleeding", "PROBLEM", 146, 161], ["Metastatic Colon Cancer to the Liver", "PROBLEM", 170, 206], ["Acute Liver FailureBoth", "PROBLEM", 221, 244], ["a transjugular liver biopsy", "TEST", 245, 272], ["sigmoid lesion", "PROBLEM", 320, 334], ["CT scan", "TEST", 353, 360], ["flexible sigmoidoscopy", "TEST", 366, 388], ["branch", "ANATOMY_MODIFIER", 71, 77], ["right", "ANATOMY_MODIFIER", 85, 90], ["hepatic artery", "ANATOMY", 91, 105], ["active", "OBSERVATION_MODIFIER", 146, 152], ["bleeding", "OBSERVATION", 153, 161], ["Metastatic", "OBSERVATION_MODIFIER", 170, 180], ["Colon", "ANATOMY", 181, 186], ["Cancer", "OBSERVATION", 187, 193], ["Liver", "ANATOMY", 201, 206], ["Acute", "OBSERVATION_MODIFIER", 221, 226], ["Liver", "ANATOMY", 227, 232], ["FailureBoth", "OBSERVATION", 233, 244], ["transjugular", "ANATOMY_MODIFIER", 247, 259], ["liver", "ANATOMY", 260, 265], ["biopsy", "OBSERVATION", 266, 272], ["sigmoid", "ANATOMY", 320, 327], ["lesion", "OBSERVATION", 328, 334]]], ["Liver biopsy (Fig. 58.", [["Liver", "ANATOMY", 0, 5], ["Liver biopsy", "MULTI-TISSUE_STRUCTURE", 0, 12], ["Liver biopsy", "TEST", 0, 12], ["biopsy", "OBSERVATION", 6, 12]]], ["2) revealed normal liver parenchyma with tumor thrombus noted within branches of the portal vein (white arrow).", [["liver parenchyma", "ANATOMY", 19, 35], ["tumor thrombus", "ANATOMY", 41, 55], ["portal vein", "ANATOMY", 85, 96], ["tumor", "DISEASE", 41, 46], ["thrombus", "DISEASE", 47, 55], ["liver parenchyma", "MULTI-TISSUE_STRUCTURE", 19, 35], ["tumor", "CANCER", 41, 46], ["thrombus", "PATHOLOGICAL_FORMATION", 47, 55], ["portal vein", "MULTI-TISSUE_STRUCTURE", 85, 96], ["tumor thrombus", "PROBLEM", 41, 55], ["normal", "OBSERVATION", 12, 18], ["liver", "ANATOMY", 19, 24], ["parenchyma", "ANATOMY_MODIFIER", 25, 35], ["tumor", "OBSERVATION_MODIFIER", 41, 46], ["thrombus", "OBSERVATION", 47, 55], ["branches", "ANATOMY_MODIFIER", 69, 77], ["portal vein", "ANATOMY", 85, 96]]], ["Sigmoidoscopy revealed a 5 cm, bleeding, partially obstructing mass in the recto-sigmoid junction ( Fig. 58.3) .", [["mass", "ANATOMY", 63, 67], ["recto-sigmoid junction", "ANATOMY", 75, 97], ["bleeding", "DISEASE", 31, 39], ["recto-sigmoid junction", "MULTI-TISSUE_STRUCTURE", 75, 97], ["Sigmoidoscopy", "TEST", 0, 13], ["a 5 cm, bleeding, partially obstructing mass in the recto-sigmoid junction", "PROBLEM", 23, 97], ["5 cm", "OBSERVATION_MODIFIER", 25, 29], ["bleeding", "OBSERVATION_MODIFIER", 31, 39], ["partially", "OBSERVATION_MODIFIER", 41, 50], ["obstructing", "OBSERVATION_MODIFIER", 51, 62], ["mass", "OBSERVATION", 63, 67], ["recto-sigmoid junction", "ANATOMY", 75, 97]]], ["Pathological evaluation and special stains confirmed a diagnosis of colon cancer with metastatic spread to the liver.Answer: Metastatic Colon Cancer to the Liver presenting as Acute Liver FailureHematological malignancies (leukemia and lymphoma) aside, metastatic spread of solid organ cancers to the liver presenting as ALF is a very rare phenomenon with only a handful of cases described in the literature.", [["colon cancer", "ANATOMY", 68, 80], ["liver", "ANATOMY", 111, 116], ["Metastatic Colon Cancer", "ANATOMY", 125, 148], ["Liver", "ANATOMY", 156, 161], ["Liver", "ANATOMY", 182, 187], ["Hematological malignancies", "ANATOMY", 195, 221], ["leukemia", "ANATOMY", 223, 231], ["lymphoma", "ANATOMY", 236, 244], ["solid organ cancers", "ANATOMY", 274, 293], ["liver", "ANATOMY", 301, 306], ["colon cancer", "DISEASE", 68, 80], ["Colon Cancer", "DISEASE", 136, 148], ["Liver FailureHematological malignancies (leukemia and lymphoma", "DISEASE", 182, 244], ["solid organ cancers to the liver", "DISEASE", 274, 306], ["ALF", "DISEASE", 321, 324], ["colon cancer", "CANCER", 68, 80], ["liver", "ORGAN", 111, 116], ["Metastatic Colon Cancer", "CANCER", 125, 148], ["Liver", "ORGAN", 156, 161], ["Liver", "ORGAN", 182, 187], ["Hematological malignancies", "CANCER", 195, 221], ["leukemia", "CANCER", 223, 231], ["lymphoma", "CANCER", 236, 244], ["solid organ cancers", "CANCER", 274, 293], ["liver", "ORGAN", 301, 306], ["Pathological evaluation", "TEST", 0, 23], ["special stains", "TEST", 28, 42], ["colon cancer", "PROBLEM", 68, 80], ["metastatic spread to the liver", "PROBLEM", 86, 116], ["Metastatic Colon Cancer to the Liver", "PROBLEM", 125, 161], ["Acute Liver Failure", "PROBLEM", 176, 195], ["Hematological malignancies", "PROBLEM", 195, 221], ["leukemia", "PROBLEM", 223, 231], ["lymphoma", "PROBLEM", 236, 244], ["solid organ cancers to the liver", "PROBLEM", 274, 306], ["a very rare phenomenon", "PROBLEM", 328, 350], ["colon", "ANATOMY", 68, 73], ["cancer", "OBSERVATION", 74, 80], ["metastatic", "OBSERVATION", 86, 96], ["liver", "ANATOMY", 111, 116], ["Metastatic", "OBSERVATION_MODIFIER", 125, 135], ["Colon", "ANATOMY", 136, 141], ["Cancer", "OBSERVATION", 142, 148], ["Liver", "ANATOMY", 156, 161], ["Acute", "OBSERVATION_MODIFIER", 176, 181], ["Liver", "ANATOMY", 182, 187], ["Failure", "OBSERVATION", 188, 195], ["Hematological malignancies", "OBSERVATION", 195, 221], ["leukemia", "OBSERVATION", 223, 231], ["lymphoma", "OBSERVATION", 236, 244], ["metastatic", "OBSERVATION_MODIFIER", 253, 263], ["solid organ cancers", "OBSERVATION", 274, 293], ["liver", "ANATOMY", 301, 306], ["very", "OBSERVATION_MODIFIER", 330, 334], ["rare", "OBSERVATION_MODIFIER", 335, 339], ["phenomenon", "OBSERVATION", 340, 350]]], ["Given the unique blood supply of the liver, massive metastatic tumor burden in the liver is not an uncommon occurrence.", [["blood", "ANATOMY", 17, 22], ["liver", "ANATOMY", 37, 42], ["metastatic tumor", "ANATOMY", 52, 68], ["liver", "ANATOMY", 83, 88], ["tumor", "DISEASE", 63, 68], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["liver", "ORGAN", 37, 42], ["tumor", "CANCER", 63, 68], ["liver", "ORGAN", 83, 88], ["massive metastatic tumor burden in the liver", "PROBLEM", 44, 88], ["liver", "ANATOMY", 37, 42], ["massive", "OBSERVATION_MODIFIER", 44, 51], ["metastatic", "OBSERVATION_MODIFIER", 52, 62], ["tumor", "OBSERVATION", 63, 68], ["liver", "ANATOMY", 83, 88], ["not an", "UNCERTAINTY", 92, 98], ["uncommon", "OBSERVATION_MODIFIER", 99, 107], ["occurrence", "OBSERVATION", 108, 118]]], ["So, why then did this patient develop acute liver failure?", [["liver", "ANATOMY", 44, 49], ["acute liver failure", "DISEASE", 38, 57], ["patient", "ORGANISM", 22, 29], ["liver", "ORGAN", 44, 49], ["patient", "SPECIES", 22, 29], ["acute liver failure", "PROBLEM", 38, 57], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["liver", "ANATOMY", 44, 49], ["failure", "OBSERVATION", 50, 57]]], ["We hypothesize (given the presence of tumor only within the branches of the portal vein and not the hepatic parenchyma) that the tumor metastasis via the portal vein, in conjuction with the intraperitoneal hemorrhage, resulted in an ischemic liver injury; this in conjunction with massive tumor burden resulted in this patient's liver failure.Answer: Metastatic Colon Cancer to the Liver presenting as Acute Liver FailureIn every case of ALF with prodromal symptoms or abnormal imaging, hepatic histology should be obtained by liver biopsy as soon as possible to diagnose infiltrative hepatic disease and avoid futile transplantation.Answer: Metastatic Colon Cancer to the Liver presenting as Acute Liver FailureThe unfortunate gentleman in this case developed anuric renal failure and worsening mental status.", [["tumor", "ANATOMY", 38, 43], ["portal vein", "ANATOMY", 76, 87], ["hepatic parenchyma", "ANATOMY", 100, 118], ["tumor", "ANATOMY", 129, 134], ["portal vein", "ANATOMY", 154, 165], ["intraperitoneal", "ANATOMY", 190, 205], ["liver", "ANATOMY", 242, 247], ["tumor", "ANATOMY", 289, 294], ["liver", "ANATOMY", 329, 334], ["Metastatic Colon Cancer", "ANATOMY", 351, 374], ["Liver", "ANATOMY", 382, 387], ["Liver", "ANATOMY", 408, 413], ["hepatic", "ANATOMY", 487, 494], ["liver", "ANATOMY", 527, 532], ["hepatic", "ANATOMY", 585, 592], ["Metastatic Colon Cancer", "ANATOMY", 642, 665], ["Liver", "ANATOMY", 673, 678], ["Liver", "ANATOMY", 699, 704], ["renal", "ANATOMY", 768, 773], ["tumor", "DISEASE", 38, 43], ["tumor", "DISEASE", 129, 134], ["hemorrhage", "DISEASE", 206, 216], ["ischemic liver injury", "DISEASE", 233, 254], ["tumor", "DISEASE", 289, 294], ["liver failure", "DISEASE", 329, 342], ["Colon Cancer", "DISEASE", 362, 374], ["Liver FailureIn", "DISEASE", 408, 423], ["ALF", "DISEASE", 438, 441], ["hepatic disease", "DISEASE", 585, 600], ["Colon Cancer", "DISEASE", 653, 665], ["Liver Failure", "DISEASE", 699, 712], ["anuric renal failure", "DISEASE", 761, 781], ["tumor", "CANCER", 38, 43], ["portal vein", "MULTI-TISSUE_STRUCTURE", 76, 87], ["hepatic parenchyma", "MULTI-TISSUE_STRUCTURE", 100, 118], ["tumor", "CANCER", 129, 134], ["portal vein", "MULTI-TISSUE_STRUCTURE", 154, 165], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 190, 205], ["liver", "ORGAN", 242, 247], ["tumor", "CANCER", 289, 294], ["patient", "ORGANISM", 319, 326], ["liver", "ORGAN", 329, 334], ["Metastatic Colon Cancer", "CANCER", 351, 374], ["Liver", "ORGAN", 382, 387], ["Liver", "ORGAN", 408, 413], ["ALF", "CANCER", 438, 441], ["hepatic", "ORGAN", 487, 494], ["liver", "ORGAN", 527, 532], ["hepatic", "ORGAN", 585, 592], ["Metastatic Colon Cancer", "CANCER", 642, 665], ["Liver", "ORGAN", 673, 678], ["Liver", "ORGAN", 699, 704], ["renal", "ORGAN", 768, 773], ["patient", "SPECIES", 319, 326], ["tumor", "PROBLEM", 38, 43], ["the tumor metastasis", "PROBLEM", 125, 145], ["the intraperitoneal hemorrhage", "PROBLEM", 186, 216], ["an ischemic liver injury", "PROBLEM", 230, 254], ["massive tumor burden", "PROBLEM", 281, 301], ["this patient's liver failure", "PROBLEM", 314, 342], ["Metastatic Colon Cancer", "PROBLEM", 351, 374], ["Acute Liver FailureIn", "PROBLEM", 402, 423], ["ALF", "PROBLEM", 438, 441], ["prodromal symptoms", "PROBLEM", 447, 465], ["abnormal imaging", "PROBLEM", 469, 485], ["hepatic histology", "TEST", 487, 504], ["liver biopsy", "TEST", 527, 539], ["infiltrative hepatic disease", "PROBLEM", 572, 600], ["futile transplantation", "TREATMENT", 611, 633], ["Metastatic Colon Cancer to the Liver", "PROBLEM", 642, 678], ["Acute Liver Failure", "PROBLEM", 693, 712], ["anuric renal failure", "PROBLEM", 761, 781], ["worsening mental status", "PROBLEM", 786, 809], ["tumor", "OBSERVATION", 38, 43], ["branches", "ANATOMY_MODIFIER", 60, 68], ["portal vein", "ANATOMY", 76, 87], ["hepatic", "ANATOMY", 100, 107], ["parenchyma", "ANATOMY_MODIFIER", 108, 118], ["tumor", "OBSERVATION_MODIFIER", 129, 134], ["metastasis", "OBSERVATION", 135, 145], ["portal vein", "ANATOMY", 154, 165], ["intraperitoneal", "ANATOMY", 190, 205], ["hemorrhage", "OBSERVATION", 206, 216], ["ischemic", "OBSERVATION_MODIFIER", 233, 241], ["liver", "ANATOMY", 242, 247], ["injury", "OBSERVATION", 248, 254], ["massive", "OBSERVATION_MODIFIER", 281, 288], ["tumor", "OBSERVATION", 289, 294], ["liver", "ANATOMY", 329, 334], ["failure", "OBSERVATION", 335, 342], ["Metastatic", "OBSERVATION_MODIFIER", 351, 361], ["Colon", "ANATOMY", 362, 367], ["Cancer", "OBSERVATION", 368, 374], ["Liver", "ANATOMY", 382, 387], ["Acute", "OBSERVATION_MODIFIER", 402, 407], ["Liver", "ANATOMY", 408, 413], ["hepatic", "ANATOMY", 487, 494], ["liver", "ANATOMY", 527, 532], ["hepatic", "ANATOMY", 585, 592], ["disease", "OBSERVATION", 593, 600], ["Metastatic", "OBSERVATION_MODIFIER", 642, 652], ["Colon", "ANATOMY", 653, 658], ["Cancer", "OBSERVATION", 659, 665], ["Liver", "ANATOMY", 673, 678], ["Acute", "OBSERVATION_MODIFIER", 693, 698], ["Liver", "ANATOMY", 699, 704], ["Failure", "OBSERVATION", 705, 712], ["anuric", "OBSERVATION", 761, 767], ["renal", "ANATOMY", 768, 773], ["failure", "OBSERVATION", 774, 781], ["worsening", "OBSERVATION_MODIFIER", 786, 795], ["mental status", "OBSERVATION", 796, 809]]], ["He was made comfort measures only and died 7 days after admission.", [["He", "ORGANISM", 0, 2], ["comfort measures", "TREATMENT", 12, 28]]], ["Microsatellite instability was performed on the pathology of the colon cancer and was negative.", [["colon cancer", "ANATOMY", 65, 77], ["colon cancer", "DISEASE", 65, 77], ["colon cancer", "CANCER", 65, 77], ["Microsatellite instability", "PROBLEM", 0, 26], ["the colon cancer", "PROBLEM", 61, 77], ["instability", "OBSERVATION", 15, 26], ["colon", "ANATOMY", 65, 70], ["cancer", "OBSERVATION", 71, 77]]], ["Screening colonoscopies were performed on the patient's two sisters and were normal.", [["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["Screening colonoscopies", "TEST", 0, 23], ["normal", "OBSERVATION", 77, 83]]], ["What is the characteristic appearance of the liver biopsy in this condition? 2.", [["liver", "ANATOMY", 45, 50], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 45, 57], ["the liver biopsy", "TEST", 41, 57], ["liver", "ANATOMY", 45, 50], ["biopsy", "OBSERVATION", 51, 57]]], ["Is there a risk of this disease recurring in subsequent pregnancies?Answer: Acute Fatty Liver of PregnancyThis clinical scenario probably occurs a few times a year at a tertiary care liver transplant center.Answer: Acute Fatty Liver of PregnancyLiver disease in pregnancy can be separated into diseases that are unique to pregnancy, \"normal\" liver or biliary diseases occurring in a pregnant woman (viral hepatitis or gallstone disease), and pregnancy occurring in a patient with known liver disease (typically viral hepatitis or cirrhosis).Answer: Acute Fatty Liver of PregnancyThe approach to liver disease in pregnancy is guided by a few factors, namely, the trimester, the degree of liver enzyme elevation, the presence of itching, and the severity of disease.Answer: Acute Fatty Liver of PregnancyHyperemesis gravidarum occurs in the first trimester and presents with relatively mild elevation of liver enzymes and intractable nausea and vomiting.", [["Liver", "ANATOMY", 88, 93], ["liver", "ANATOMY", 183, 188], ["Liver", "ANATOMY", 227, 232], ["liver", "ANATOMY", 342, 347], ["biliary", "ANATOMY", 351, 358], ["gallstone", "ANATOMY", 418, 427], ["liver", "ANATOMY", 486, 491], ["Liver", "ANATOMY", 561, 566], ["liver", "ANATOMY", 595, 600], ["liver", "ANATOMY", 687, 692], ["Liver", "ANATOMY", 784, 789], ["liver", "ANATOMY", 902, 907], ["PregnancyLiver disease", "DISEASE", 236, 258], ["liver or biliary diseases", "DISEASE", 342, 367], ["viral hepatitis", "DISEASE", 399, 414], ["gallstone disease", "DISEASE", 418, 435], ["liver disease", "DISEASE", 486, 499], ["viral hepatitis", "DISEASE", 511, 526], ["cirrhosis", "DISEASE", 530, 539], ["liver disease", "DISEASE", 595, 608], ["itching", "DISEASE", 727, 734], ["Hyperemesis gravidarum", "DISEASE", 802, 824], ["elevation of liver enzymes", "DISEASE", 889, 915], ["nausea", "DISEASE", 932, 938], ["vomiting", "DISEASE", 943, 951], ["Liver", "ORGAN", 88, 93], ["liver", "ORGAN", 183, 188], ["Liver", "ORGAN", 227, 232], ["liver", "ORGAN", 342, 347], ["biliary", "ORGAN", 351, 358], ["woman", "ORGANISM", 392, 397], ["patient", "ORGANISM", 467, 474], ["liver", "ORGAN", 486, 491], ["Liver", "ORGAN", 561, 566], ["liver", "ORGAN", 595, 600], ["liver", "ORGAN", 687, 692], ["Liver", "ORGAN", 784, 789], ["liver", "ORGAN", 902, 907], ["liver enzyme", "PROTEIN", 687, 699], ["liver enzymes", "PROTEIN", 902, 915], ["woman", "SPECIES", 392, 397], ["patient", "SPECIES", 467, 474], ["this disease", "PROBLEM", 19, 31], ["subsequent pregnancies", "PROBLEM", 45, 67], ["Acute Fatty Liver of Pregnancy", "PROBLEM", 76, 106], ["Acute Fatty Liver of PregnancyLiver disease", "PROBLEM", 215, 258], ["biliary diseases", "PROBLEM", 351, 367], ["viral hepatitis", "PROBLEM", 399, 414], ["gallstone disease)", "PROBLEM", 418, 436], ["pregnancy", "PROBLEM", 442, 451], ["known liver disease", "PROBLEM", 480, 499], ["typically viral hepatitis", "PROBLEM", 501, 526], ["cirrhosis)", "PROBLEM", 530, 540], ["Acute Fatty Liver of Pregnancy", "PROBLEM", 549, 579], ["liver disease in pregnancy", "PROBLEM", 595, 621], ["liver enzyme elevation", "PROBLEM", 687, 709], ["itching", "PROBLEM", 727, 734], ["disease", "PROBLEM", 756, 763], ["Acute Fatty Liver of Pregnancy", "PROBLEM", 772, 802], ["Hyperemesis gravidarum", "PROBLEM", 802, 824], ["relatively mild elevation of liver enzymes", "PROBLEM", 873, 915], ["intractable nausea", "PROBLEM", 920, 938], ["vomiting", "PROBLEM", 943, 951], ["disease", "OBSERVATION", 24, 31], ["Acute", "OBSERVATION_MODIFIER", 76, 81], ["Fatty", "OBSERVATION", 82, 87], ["Liver", "ANATOMY", 88, 93], ["liver", "ANATOMY", 183, 188], ["transplant", "OBSERVATION", 189, 199], ["Acute", "OBSERVATION_MODIFIER", 215, 220], ["Fatty", "OBSERVATION", 221, 226], ["Liver", "ANATOMY", 227, 232], ["PregnancyLiver disease", "OBSERVATION", 236, 258], ["liver", "ANATOMY", 342, 347], ["biliary", "ANATOMY", 351, 358], ["diseases", "OBSERVATION", 359, 367], ["gallstone", "OBSERVATION", 418, 427], ["liver", "ANATOMY", 486, 491], ["disease", "OBSERVATION", 492, 499], ["viral", "OBSERVATION_MODIFIER", 511, 516], ["hepatitis", "OBSERVATION", 517, 526], ["cirrhosis", "OBSERVATION", 530, 539], ["Acute", "OBSERVATION_MODIFIER", 549, 554], ["Fatty", "OBSERVATION", 555, 560], ["Liver", "ANATOMY", 561, 566], ["liver", "ANATOMY", 595, 600], ["disease", "OBSERVATION", 601, 608], ["liver", "ANATOMY", 687, 692], ["enzyme elevation", "OBSERVATION", 693, 709], ["itching", "OBSERVATION", 727, 734], ["disease", "OBSERVATION", 756, 763], ["Acute", "OBSERVATION_MODIFIER", 772, 777], ["Fatty", "OBSERVATION", 778, 783], ["Liver", "ANATOMY", 784, 789], ["mild", "OBSERVATION_MODIFIER", 884, 888], ["elevation", "OBSERVATION", 889, 898], ["liver", "ANATOMY", 902, 907], ["intractable", "OBSERVATION_MODIFIER", 920, 931], ["nausea", "OBSERVATION", 932, 938]]], ["It can be confused with viral hepatitis.", [["viral hepatitis", "DISEASE", 24, 39], ["confused", "PROBLEM", 10, 18], ["viral hepatitis", "PROBLEM", 24, 39], ["viral hepatitis", "OBSERVATION", 24, 39]]], ["Intrahepatic cholestasis of pregnancy is a disorder of late pregnancy and presents with itching, cholestatic enzymes, and negative imaging for biliary dilation.", [["biliary", "ANATOMY", 143, 150], ["Intrahepatic cholestasis of pregnancy", "DISEASE", 0, 37], ["itching", "DISEASE", 88, 95], ["cholestatic", "DISEASE", 97, 108], ["biliary", "MULTI-TISSUE_STRUCTURE", 143, 150], ["cholestatic enzymes", "PROTEIN", 97, 116], ["Intrahepatic cholestasis of pregnancy", "PROBLEM", 0, 37], ["a disorder of late pregnancy", "PROBLEM", 41, 69], ["itching", "PROBLEM", 88, 95], ["cholestatic enzymes", "PROBLEM", 97, 116], ["imaging", "TEST", 131, 138], ["biliary dilation", "PROBLEM", 143, 159], ["cholestasis", "OBSERVATION", 13, 24], ["pregnancy", "OBSERVATION", 28, 37], ["biliary", "ANATOMY", 143, 150], ["dilation", "OBSERVATION", 151, 159]]], ["It often recurs in subsequent pregnancies and is associated with fetal loss.", [["fetal", "ANATOMY", 65, 70], ["fetal loss", "DISEASE", 65, 75], ["fetal", "ORGANISM_SUBDIVISION", 65, 70], ["fetal loss", "PROBLEM", 65, 75], ["pregnancies", "OBSERVATION", 30, 41], ["associated with", "UNCERTAINTY", 49, 64], ["fetal loss", "OBSERVATION", 65, 75]]], ["Treatment is delivery.", [["delivery", "TREATMENT", 13, 21]]], ["Acute fatty liver of pregnancy (AFLP), HELLP syndrome (hemolysis with a microangiopathic blood smear, elevated liver enzymes, and a low platelet count), and severe preeclampsia cause the most confusion in making a diagnosis since they can have a similar presentation.Answer: Acute Fatty Liver of PregnancyThis lady presents in the third trimester with nausea, vomiting, and abdominal pain, all of which are common in AFLP.", [["fatty liver", "ANATOMY", 6, 17], ["blood", "ANATOMY", 89, 94], ["liver", "ANATOMY", 111, 116], ["platelet", "ANATOMY", 136, 144], ["Liver", "ANATOMY", 287, 292], ["abdominal", "ANATOMY", 374, 383], ["fatty liver of pregnancy", "DISEASE", 6, 30], ["HELLP syndrome", "DISEASE", 39, 53], ["hemolysis", "DISEASE", 55, 64], ["low platelet count", "DISEASE", 132, 150], ["preeclampsia", "DISEASE", 164, 176], ["confusion", "DISEASE", 192, 201], ["nausea", "DISEASE", 352, 358], ["vomiting", "DISEASE", 360, 368], ["abdominal pain", "DISEASE", 374, 388], ["liver", "ORGAN", 12, 17], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["liver", "ORGAN", 111, 116], ["platelet", "CELL", 136, 144], ["Liver", "ORGAN", 287, 292], ["abdominal", "ORGANISM_SUBDIVISION", 374, 383], ["liver enzymes", "PROTEIN", 111, 124], ["Acute fatty liver of pregnancy", "PROBLEM", 0, 30], ["AFLP)", "PROBLEM", 32, 37], ["HELLP syndrome", "PROBLEM", 39, 53], ["hemolysis", "PROBLEM", 55, 64], ["a microangiopathic blood smear", "PROBLEM", 70, 100], ["elevated liver enzymes", "PROBLEM", 102, 124], ["a low platelet count", "PROBLEM", 130, 150], ["severe preeclampsia", "PROBLEM", 157, 176], ["the most confusion", "PROBLEM", 183, 201], ["Acute Fatty Liver of Pregnancy", "PROBLEM", 275, 305], ["nausea", "PROBLEM", 352, 358], ["vomiting", "PROBLEM", 360, 368], ["abdominal pain", "PROBLEM", 374, 388], ["fatty", "OBSERVATION", 6, 11], ["liver", "ANATOMY", 12, 17], ["liver", "ANATOMY", 111, 116], ["low platelet count", "OBSERVATION_MODIFIER", 132, 150], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["preeclampsia", "OBSERVATION", 164, 176], ["Acute", "OBSERVATION_MODIFIER", 275, 280], ["Fatty", "OBSERVATION", 281, 286], ["Liver", "ANATOMY", 287, 292], ["nausea", "OBSERVATION", 352, 358], ["abdominal", "ANATOMY", 374, 383], ["pain", "OBSERVATION", 384, 388]]], ["Her laboratory studies show elevated transaminases and hypoglycemia, which together with her mental status, are concerning for significant liver dysfunction.", [["liver", "ANATOMY", 139, 144], ["hypoglycemia", "DISEASE", 55, 67], ["liver dysfunction", "DISEASE", 139, 156], ["liver", "ORGAN", 139, 144], ["Her laboratory studies", "TEST", 0, 22], ["elevated transaminases", "PROBLEM", 28, 50], ["hypoglycemia", "PROBLEM", 55, 67], ["significant liver dysfunction", "PROBLEM", 127, 156], ["elevated", "OBSERVATION_MODIFIER", 28, 36], ["transaminases", "OBSERVATION", 37, 50], ["hypoglycemia", "OBSERVATION", 55, 67], ["concerning for", "UNCERTAINTY", 112, 126], ["significant", "OBSERVATION_MODIFIER", 127, 138], ["liver", "ANATOMY", 139, 144], ["dysfunction", "OBSERVATION", 145, 156]]], ["The low platelet count might suggest HELLP, but disseminated intravascular coagulopathy is not infrequent in AFLP.Answer: Acute Fatty Liver of PregnancyThe pathogenesis of AFLP is not completely understood, but several studies have shown an association with one of the inherited defects in mitochondrial betaoxidation of fatty acids, long-chain 3-hydroxyacyl CoA dehydrogenase deficiency (LCHAD).", [["platelet", "ANATOMY", 8, 16], ["intravascular", "ANATOMY", 61, 74], ["Liver", "ANATOMY", 134, 139], ["mitochondrial", "ANATOMY", 290, 303], ["HELLP", "DISEASE", 37, 42], ["intravascular coagulopathy", "DISEASE", 61, 87], ["fatty acids", "CHEMICAL", 321, 332], ["fatty acids", "CHEMICAL", 321, 332], ["3-hydroxyacyl CoA", "CHEMICAL", 345, 362], ["platelet", "CELL", 8, 16], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["Liver", "ORGAN", 134, 139], ["mitochondrial", "CELLULAR_COMPONENT", 290, 303], ["fatty acids", "SIMPLE_CHEMICAL", 321, 332], ["long-chain 3-hydroxyacyl CoA dehydrogenase", "GENE_OR_GENE_PRODUCT", 334, 376], ["long-chain 3-hydroxyacyl CoA dehydrogenase", "PROTEIN", 334, 376], ["The low platelet count", "TEST", 0, 22], ["HELLP", "PROBLEM", 37, 42], ["disseminated intravascular coagulopathy", "PROBLEM", 48, 87], ["AFLP", "PROBLEM", 109, 113], ["Acute Fatty Liver of Pregnancy", "PROBLEM", 122, 152], ["several studies", "TEST", 211, 226], ["the inherited defects", "PROBLEM", 265, 286], ["fatty acids", "TEST", 321, 332], ["long-chain", "PROBLEM", 334, 344], ["hydroxyacyl CoA dehydrogenase deficiency", "PROBLEM", 347, 387], ["low platelet count", "OBSERVATION", 4, 22], ["suggest", "UNCERTAINTY", 29, 36], ["HELLP", "OBSERVATION", 37, 42], ["disseminated", "OBSERVATION_MODIFIER", 48, 60], ["intravascular coagulopathy", "OBSERVATION", 61, 87], ["not infrequent", "UNCERTAINTY", 91, 105], ["Acute", "OBSERVATION_MODIFIER", 122, 127], ["Fatty", "OBSERVATION", 128, 133], ["Liver", "ANATOMY", 134, 139], ["inherited", "OBSERVATION_MODIFIER", 269, 278], ["defects", "OBSERVATION", 279, 286], ["mitochondrial betaoxidation", "OBSERVATION", 290, 317], ["fatty acids", "OBSERVATION", 321, 332], ["dehydrogenase deficiency", "OBSERVATION", 363, 387]]], ["This suggests that some affected women and their fetuses might have an inherited enzyme deficiency in beta-oxidation that predisposes the mother to AFLP.", [["fetuses", "ANATOMY", 49, 56], ["women", "ORGANISM", 33, 38], ["fetuses", "ORGANISM", 49, 56], ["women", "SPECIES", 33, 38], ["an inherited enzyme deficiency", "PROBLEM", 68, 98], ["AFLP", "PROBLEM", 148, 152], ["enzyme deficiency", "OBSERVATION", 81, 98]]], ["LCHAD catalyzes one of the steps in the beta-oxidation of fatty acids in mitochondria (the formation of 3-ketoacyl-CoA from 3-hydroxyacyl-CoA), and deficiency leads to the accumulation of long-chain 3-hydroxyacyl metabolites produced by the fetus or placenta which is toxic to the maternal liver.", [["mitochondria", "ANATOMY", 73, 85], ["fetus", "ANATOMY", 241, 246], ["placenta", "ANATOMY", 250, 258], ["liver", "ANATOMY", 290, 295], ["LCHAD", "CHEMICAL", 0, 5], ["fatty acids", "CHEMICAL", 58, 69], ["3-ketoacyl-CoA", "CHEMICAL", 104, 118], ["3-hydroxyacyl-CoA", "CHEMICAL", 124, 141], ["fatty acids", "CHEMICAL", 58, 69], ["3-ketoacyl-CoA", "CHEMICAL", 104, 118], ["3-hydroxyacyl-CoA", "CHEMICAL", 124, 141], ["3-hydroxyacyl", "CHEMICAL", 199, 212], ["LCHAD", "SIMPLE_CHEMICAL", 0, 5], ["fatty acids", "SIMPLE_CHEMICAL", 58, 69], ["mitochondria", "CELLULAR_COMPONENT", 73, 85], ["3-ketoacyl-CoA", "SIMPLE_CHEMICAL", 104, 118], ["3-hydroxyacyl-CoA", "SIMPLE_CHEMICAL", 124, 141], ["long-chain 3-hydroxyacyl metabolites", "SIMPLE_CHEMICAL", 188, 224], ["fetus", "ORGANISM", 241, 246], ["placenta", "ORGAN", 250, 258], ["liver", "ORGAN", 290, 295], ["fatty acids in mitochondria", "PROBLEM", 58, 85], ["CoA", "TEST", 115, 118], ["deficiency", "PROBLEM", 148, 158], ["fatty acids", "OBSERVATION", 58, 69], ["CoA", "ANATOMY", 115, 118], ["fetus", "ANATOMY", 241, 246], ["placenta", "ANATOMY", 250, 258], ["toxic", "OBSERVATION_MODIFIER", 268, 273], ["liver", "ANATOMY", 290, 295]]], ["Not all cases of AFLP have the enzyme deficiency.Answer: Acute Fatty Liver of PregnancyThe diagnosis of AFLP is based on an appropriate clinical presentation and supportive laboratory tests.", [["Liver", "ANATOMY", 69, 74], ["Liver", "ORGAN", 69, 74], ["AFLP", "PROBLEM", 17, 21], ["the enzyme deficiency", "PROBLEM", 27, 48], ["Acute Fatty Liver of Pregnancy", "PROBLEM", 57, 87], ["AFLP", "PROBLEM", 104, 108], ["supportive laboratory tests", "TEST", 162, 189], ["enzyme deficiency", "OBSERVATION", 31, 48], ["Acute", "OBSERVATION_MODIFIER", 57, 62], ["Fatty", "OBSERVATION", 63, 68], ["Liver", "ANATOMY", 69, 74]]], ["Liver biopsy is not necessary and will be risky because of the coagulopathy.", [["Liver", "ANATOMY", 0, 5], ["coagulopathy", "DISEASE", 63, 75], ["Liver", "ORGAN", 0, 5], ["Liver biopsy", "TEST", 0, 12], ["the coagulopathy", "PROBLEM", 59, 75], ["biopsy", "OBSERVATION", 6, 12], ["coagulopathy", "OBSERVATION", 63, 75]]], ["However, it is diagnostic, showing a characteristic microvesicular fatty infiltration of the hepatocytes.", [["hepatocytes", "ANATOMY", 93, 104], ["fatty infiltration", "DISEASE", 67, 85], ["hepatocytes", "CELL", 93, 104], ["hepatocytes", "CELL_TYPE", 93, 104], ["a characteristic microvesicular fatty infiltration of the hepatocytes", "PROBLEM", 35, 104], ["characteristic", "OBSERVATION_MODIFIER", 37, 51], ["microvesicular", "OBSERVATION_MODIFIER", 52, 66], ["fatty infiltration", "OBSERVATION", 67, 85], ["hepatocytes", "ANATOMY", 93, 104]]], ["There is a foamy cytoplasm due to fat droplets surrounding centrally located nuclei, and there is sparing of a sharply defined rim of cells around the portal tracts.Answer: Acute Fatty Liver of PregnancyTreatment is based on maternal support and emergent delivery.", [["cytoplasm", "ANATOMY", 17, 26], ["fat droplets", "ANATOMY", 34, 46], ["nuclei", "ANATOMY", 77, 83], ["cells", "ANATOMY", 134, 139], ["portal tracts", "ANATOMY", 151, 164], ["Liver", "ANATOMY", 185, 190], ["foamy", "ORGANISM_SUBSTANCE", 11, 16], ["cytoplasm", "ORGANISM_SUBSTANCE", 17, 26], ["fat droplets", "CELLULAR_COMPONENT", 34, 46], ["nuclei", "CELLULAR_COMPONENT", 77, 83], ["cells", "CELL", 134, 139], ["portal tracts", "MULTI-TISSUE_STRUCTURE", 151, 164], ["Liver", "ORGAN", 185, 190], ["a foamy cytoplasm", "PROBLEM", 9, 26], ["fat droplets", "PROBLEM", 34, 46], ["a sharply defined rim of cells", "PROBLEM", 109, 139], ["Acute Fatty Liver of Pregnancy", "PROBLEM", 173, 203], ["maternal support", "TREATMENT", 225, 241], ["emergent delivery", "TREATMENT", 246, 263], ["foamy cytoplasm", "OBSERVATION", 11, 26], ["fat droplets", "OBSERVATION", 34, 46], ["centrally", "OBSERVATION_MODIFIER", 59, 68], ["nuclei", "OBSERVATION_MODIFIER", 77, 83], ["sparing", "OBSERVATION_MODIFIER", 98, 105], ["sharply defined", "OBSERVATION_MODIFIER", 111, 126], ["rim", "OBSERVATION_MODIFIER", 127, 130], ["cells", "OBSERVATION", 134, 139], ["portal tracts", "ANATOMY", 151, 164], ["Acute", "OBSERVATION_MODIFIER", 173, 178], ["Fatty", "OBSERVATION", 179, 184], ["Liver", "ANATOMY", 185, 190]]], ["Maternal and fetal mortality has improved with better recognition of the disease but is still seen.", [["fetal", "ANATOMY", 13, 18], ["fetal", "ANATOMICAL_SYSTEM", 13, 18], ["Maternal and fetal mortality", "PROBLEM", 0, 28], ["the disease", "PROBLEM", 69, 80], ["fetal", "ANATOMY", 13, 18], ["mortality", "OBSERVATION", 19, 28], ["improved", "OBSERVATION_MODIFIER", 33, 41], ["disease", "OBSERVATION", 73, 80]]], ["Recurrence in subsequent pregnancies has been documented.Answer: Acute Variceal BleedingThe EGD pictures (Figs.", [["Variceal", "ANATOMY", 71, 79], ["Bleeding", "DISEASE", 80, 88], ["Recurrence in subsequent pregnancies", "PROBLEM", 0, 36], ["Acute Variceal Bleeding", "PROBLEM", 65, 88], ["pregnancies", "OBSERVATION", 25, 36], ["Acute", "OBSERVATION_MODIFIER", 65, 70], ["Variceal Bleeding", "OBSERVATION", 71, 88]]], ["2) demonstrate a large amount of fresh blood in the fundus and a gastric varix spurting blood along the greater curvature (GOVII).", [["blood", "ANATOMY", 39, 44], ["fundus", "ANATOMY", 52, 58], ["gastric varix", "ANATOMY", 65, 78], ["blood", "ANATOMY", 88, 93], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["fundus", "MULTI-TISSUE_STRUCTURE", 52, 58], ["gastric", "ORGAN", 65, 72], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["fresh blood in the fundus", "PROBLEM", 33, 58], ["a gastric varix spurting blood", "PROBLEM", 63, 93], ["large", "OBSERVATION_MODIFIER", 17, 22], ["amount", "OBSERVATION_MODIFIER", 23, 29], ["fresh blood", "OBSERVATION", 33, 44], ["fundus", "ANATOMY", 52, 58], ["gastric", "ANATOMY", 65, 72], ["varix", "OBSERVATION", 73, 78], ["greater", "OBSERVATION_MODIFIER", 104, 111], ["curvature", "OBSERVATION_MODIFIER", 112, 121]]], ["A sclerotherapy needle is being used to inject a sclerosant into the varix and the bleeding stops.", [["varix", "ANATOMY", 69, 74], ["varix", "DISEASE", 69, 74], ["bleeding", "DISEASE", 83, 91], ["A sclerotherapy needle", "TREATMENT", 0, 22], ["a sclerosant into the varix", "TREATMENT", 47, 74], ["the bleeding stops", "PROBLEM", 79, 97], ["sclerotherapy", "OBSERVATION", 2, 15], ["varix", "OBSERVATION", 69, 74], ["bleeding", "OBSERVATION", 83, 91]]], ["The patient has a known history of chronic hepatitis C infection.", [["chronic hepatitis C infection", "DISEASE", 35, 64], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["chronic hepatitis C infection", "PROBLEM", 35, 64], ["chronic", "OBSERVATION_MODIFIER", 35, 42], ["hepatitis", "OBSERVATION", 43, 52], ["infection", "OBSERVATION", 55, 64]]], ["From his social history, it is likely that he had had the infection for more than 30 years, which increases the likelihood of advanced liver disease such as cirrhosis.", [["liver", "ANATOMY", 135, 140], ["infection", "DISEASE", 58, 67], ["liver disease", "DISEASE", 135, 148], ["cirrhosis", "DISEASE", 157, 166], ["liver", "ORGAN", 135, 140], ["the infection", "PROBLEM", 54, 67], ["advanced liver disease", "PROBLEM", 126, 148], ["cirrhosis", "PROBLEM", 157, 166], ["infection", "OBSERVATION", 58, 67], ["advanced", "OBSERVATION_MODIFIER", 126, 134], ["liver", "ANATOMY", 135, 140], ["disease", "OBSERVATION", 141, 148], ["cirrhosis", "OBSERVATION", 157, 166]]], ["About one-third of patients with varices experience variceal hemorrhage, and each episode of hemorrhage can have 20-30% mortality.", [["varices", "ANATOMY", 33, 40], ["variceal", "ANATOMY", 52, 60], ["varices", "DISEASE", 33, 40], ["variceal hemorrhage", "DISEASE", 52, 71], ["hemorrhage", "DISEASE", 93, 103], ["patients", "ORGANISM", 19, 27], ["varices", "PATHOLOGICAL_FORMATION", 33, 40], ["patients", "SPECIES", 19, 27], ["varices", "PROBLEM", 33, 40], ["variceal hemorrhage", "PROBLEM", 52, 71], ["hemorrhage", "PROBLEM", 93, 103], ["varices", "OBSERVATION", 33, 40], ["variceal", "OBSERVATION_MODIFIER", 52, 60], ["hemorrhage", "OBSERVATION", 61, 71], ["hemorrhage", "OBSERVATION", 93, 103]]], ["In patients with acute variceal hemorrhage, diagnostic and therapeutic endoscopy should be done emergently once patients are hemodynamically stable.", [["acute variceal hemorrhage", "DISEASE", 17, 42], ["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 112, 120], ["acute variceal hemorrhage", "PROBLEM", 17, 42], ["therapeutic endoscopy", "TEST", 59, 80], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["variceal", "ANATOMY", 23, 31], ["hemorrhage", "OBSERVATION", 32, 42], ["stable", "OBSERVATION", 141, 147]]], ["Intravenous octreotide and antibiotics should be started promptly when variceal hemorrhage is suspected.", [["variceal", "ANATOMY", 71, 79], ["octreotide", "CHEMICAL", 12, 22], ["hemorrhage", "DISEASE", 80, 90], ["octreotide", "CHEMICAL", 12, 22], ["octreotide", "SIMPLE_CHEMICAL", 12, 22], ["Intravenous octreotide", "TREATMENT", 0, 22], ["antibiotics", "TREATMENT", 27, 38], ["variceal hemorrhage", "PROBLEM", 71, 90], ["hemorrhage", "OBSERVATION", 80, 90]]], ["Type I gastric varices (GOV I) are found along the lesser curve (usually 2-5 cm in length) which are potentially treatable with endoscopic band ligation therapy.", [["gastric varices", "ANATOMY", 7, 22], ["Type I gastric varices", "DISEASE", 0, 22], ["gastric varices", "CANCER", 7, 22], ["Type I gastric varices", "PROBLEM", 0, 22], ["endoscopic band ligation therapy", "TREATMENT", 128, 160], ["gastric", "ANATOMY", 7, 14], ["varices", "OBSERVATION", 15, 22], ["lesser", "OBSERVATION_MODIFIER", 51, 57], ["curve", "OBSERVATION_MODIFIER", 58, 63], ["2-5 cm", "OBSERVATION_MODIFIER", 73, 79], ["potentially treatable", "UNCERTAINTY", 101, 122], ["band ligation", "OBSERVATION", 139, 152]]], ["Type II (GOV II) are found along the greater curve extending toward the fundus of stomach.", [["fundus", "ANATOMY", 72, 78], ["stomach", "ANATOMY", 82, 89], ["Type II (GOV II", "GENE_OR_GENE_PRODUCT", 0, 15], ["fundus", "MULTI-TISSUE_STRUCTURE", 72, 78], ["stomach", "ORGAN", 82, 89], ["GOV II", "PROTEIN", 9, 15], ["Type II (GOV II)", "TREATMENT", 0, 16], ["fundus", "ANATOMY", 72, 78], ["stomach", "ANATOMY", 82, 89]]], ["Isolated gastric varices are found in the fundus (IGV I) or other parts of the stomach (IGV II).", [["gastric varices", "ANATOMY", 9, 24], ["fundus", "ANATOMY", 42, 48], ["stomach", "ANATOMY", 79, 86], ["gastric varices", "DISEASE", 9, 24], ["gastric varices", "CANCER", 9, 24], ["fundus", "MULTI-TISSUE_STRUCTURE", 42, 48], ["stomach", "ORGAN", 79, 86], ["IGV II", "CANCER", 88, 94], ["Isolated gastric varices", "PROBLEM", 0, 24], ["gastric", "ANATOMY", 9, 16], ["varices", "OBSERVATION", 17, 24], ["fundus", "ANATOMY", 42, 48], ["parts", "ANATOMY_MODIFIER", 66, 71], ["stomach", "ANATOMY", 79, 86]]], ["Band ligation is ineffective in GOV II and IGV.", [["GOV II", "CHEMICAL", 32, 38], ["GOV II", "GENE_OR_GENE_PRODUCT", 32, 38], ["IGV", "CANCER", 43, 46], ["IGV", "PROTEIN", 43, 46], ["Band ligation", "TREATMENT", 0, 13], ["ligation", "OBSERVATION", 5, 13], ["ineffective", "OBSERVATION_MODIFIER", 17, 28]]], ["The AASLD guidelines for variceal hemorrhage recommend: Acute GI hemorrhage in cirrhotic patients is an emergency that requires prompt intravascular volume support and blood transfusions, being careful to maintain a hemoglobin of approximately 8 g/dl.", [["variceal", "ANATOMY", 25, 33], ["GI", "ANATOMY", 62, 64], ["intravascular", "ANATOMY", 135, 148], ["blood", "ANATOMY", 168, 173], ["variceal hemorrhage", "DISEASE", 25, 44], ["GI hemorrhage", "DISEASE", 62, 75], ["cirrhotic", "DISEASE", 79, 88], ["patients", "ORGANISM", 89, 97], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 135, 148], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 216, 226], ["hemoglobin", "PROTEIN", 216, 226], ["patients", "SPECIES", 89, 97], ["The AASLD guidelines", "TREATMENT", 0, 20], ["variceal hemorrhage", "PROBLEM", 25, 44], ["Acute GI hemorrhage", "PROBLEM", 56, 75], ["prompt intravascular volume support", "TREATMENT", 128, 163], ["blood transfusions", "TREATMENT", 168, 186], ["a hemoglobin", "TEST", 214, 226], ["variceal", "ANATOMY", 25, 33], ["hemorrhage", "OBSERVATION", 34, 44], ["Acute", "OBSERVATION_MODIFIER", 56, 61], ["GI", "ANATOMY", 62, 64], ["hemorrhage", "OBSERVATION", 65, 75], ["cirrhotic", "OBSERVATION", 79, 88]]], ["7 days) antibiotic prophylaxis should be instituted in any patient with cirrhosis and GI hemorrhage with PO norfloxacin or IV ciprofloxacin.", [["GI", "ANATOMY", 86, 88], ["cirrhosis", "DISEASE", 72, 81], ["GI hemorrhage", "DISEASE", 86, 99], ["norfloxacin", "CHEMICAL", 108, 119], ["ciprofloxacin", "CHEMICAL", 126, 139], ["norfloxacin", "CHEMICAL", 108, 119], ["ciprofloxacin", "CHEMICAL", 126, 139], ["patient", "ORGANISM", 59, 66], ["GI", "ORGANISM_SUBDIVISION", 86, 88], ["PO", "SIMPLE_CHEMICAL", 105, 107], ["norfloxacin", "SIMPLE_CHEMICAL", 108, 119], ["IV", "SIMPLE_CHEMICAL", 123, 125], ["ciprofloxacin", "SIMPLE_CHEMICAL", 126, 139], ["patient", "SPECIES", 59, 66], ["antibiotic prophylaxis", "TREATMENT", 8, 30], ["cirrhosis", "PROBLEM", 72, 81], ["GI hemorrhage", "PROBLEM", 86, 99], ["PO norfloxacin", "TREATMENT", 105, 119], ["IV ciprofloxacin", "TREATMENT", 123, 139], ["cirrhosis", "OBSERVATION", 72, 81], ["GI", "ANATOMY", 86, 88], ["hemorrhage", "OBSERVATION", 89, 99]]], ["In patients with advanced cirrhosis, IV ceftriaxone (1 g/day) may be preferable, particularly in centers with a high prevalence of quinolone-resistant organisms.", [["cirrhosis", "DISEASE", 26, 35], ["ceftriaxone", "CHEMICAL", 40, 51], ["quinolone", "CHEMICAL", 131, 140], ["ceftriaxone", "CHEMICAL", 40, 51], ["quinolone", "CHEMICAL", 131, 140], ["patients", "ORGANISM", 3, 11], ["ceftriaxone", "SIMPLE_CHEMICAL", 40, 51], ["quinolone", "SIMPLE_CHEMICAL", 131, 140], ["patients", "SPECIES", 3, 11], ["advanced cirrhosis", "PROBLEM", 17, 35], ["IV ceftriaxone", "TREATMENT", 37, 51], ["quinolone", "PROBLEM", 131, 140], ["resistant organisms", "PROBLEM", 141, 160], ["advanced", "OBSERVATION_MODIFIER", 17, 25], ["cirrhosis", "OBSERVATION", 26, 35]]], ["Pharmacological therapy (somatostatin or its analogues octreotide and vap-reotide; terlipressin) should be initiated as soon as variceal hemorrhage is suspected and continued for 3-5 days after the diagnosis is confirmed.", [["variceal", "ANATOMY", 128, 136], ["octreotide", "CHEMICAL", 55, 65], ["vap-reotide", "CHEMICAL", 70, 81], ["terlipressin", "CHEMICAL", 83, 95], ["hemorrhage", "DISEASE", 137, 147], ["somatostatin", "CHEMICAL", 25, 37], ["octreotide", "CHEMICAL", 55, 65], ["vap-reotide", "CHEMICAL", 70, 81], ["terlipressin", "CHEMICAL", 83, 95], ["somatostatin", "GENE_OR_GENE_PRODUCT", 25, 37], ["octreotide", "SIMPLE_CHEMICAL", 55, 65], ["vap-reotide", "SIMPLE_CHEMICAL", 70, 81], ["terlipressin", "SIMPLE_CHEMICAL", 83, 95], ["Pharmacological therapy", "TREATMENT", 0, 23], ["somatostatin", "TREATMENT", 25, 37], ["its analogues octreotide", "TREATMENT", 41, 65], ["vap-reotide", "TREATMENT", 70, 81], ["terlipressin", "TREATMENT", 83, 95], ["variceal hemorrhage", "PROBLEM", 128, 147]]], ["EGD, performed within 12 h, should be used to make the diagnosis and to treat variceal hemorrhage either with band ligation or sclerotherapy.", [["variceal", "ANATOMY", 78, 86], ["variceal hemorrhage", "DISEASE", 78, 97], ["EGD", "TEST", 0, 3], ["variceal hemorrhage", "PROBLEM", 78, 97], ["band ligation", "TREATMENT", 110, 123], ["sclerotherapy", "TREATMENT", 127, 140], ["variceal", "ANATOMY", 78, 86], ["hemorrhage", "OBSERVATION", 87, 97], ["sclerotherapy", "OBSERVATION", 127, 140]]], ["TIPS is indicated in patients in whom hemorrhage from esophageal varices can-not be controlled or in whom bleeding recurs despite combined pharmacological and endoscopic therapy.", [["esophageal varices", "ANATOMY", 54, 72], ["hemorrhage", "DISEASE", 38, 48], ["esophageal varices", "DISEASE", 54, 72], ["bleeding", "DISEASE", 106, 114], ["patients", "ORGANISM", 21, 29], ["esophageal varices", "PATHOLOGICAL_FORMATION", 54, 72], ["patients", "SPECIES", 21, 29], ["TIPS", "TREATMENT", 0, 4], ["hemorrhage", "PROBLEM", 38, 48], ["esophageal varices", "PROBLEM", 54, 72], ["bleeding", "PROBLEM", 106, 114], ["combined pharmacological", "TREATMENT", 130, 154], ["endoscopic therapy", "TREATMENT", 159, 177], ["esophageal", "ANATOMY", 54, 64], ["varices", "OBSERVATION", 65, 72]]], ["Balloon tamponade should be used as a temporizing measure (max.", [["Balloon tamponade", "TREATMENT", 0, 17], ["a temporizing measure", "TREATMENT", 36, 57], ["tamponade", "OBSERVATION", 8, 17]]], ["24 h) in patients with uncontrollable bleeding for whom a more definitive therapy (e.g., TIPS or endoscopic therapy is planned).", [["bleeding", "DISEASE", 38, 46], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["uncontrollable bleeding", "PROBLEM", 23, 46], ["a more definitive therapy", "TREATMENT", 56, 81], ["TIPS", "TREATMENT", 89, 93], ["endoscopic therapy", "TREATMENT", 97, 115], ["uncontrollable", "OBSERVATION_MODIFIER", 23, 37], ["bleeding", "OBSERVATION", 38, 46]]], ["For gastric varices, endoscopic variceal obturation using tissue adhesives such as cyanoacrylate is preferred, where available.", [["gastric varices", "ANATOMY", 4, 19], ["variceal", "ANATOMY", 32, 40], ["tissue", "ANATOMY", 58, 64], ["gastric varices", "DISEASE", 4, 19], ["cyanoacrylate", "CHEMICAL", 83, 96], ["cyanoacrylate", "CHEMICAL", 83, 96], ["gastric varices", "PATHOLOGICAL_FORMATION", 4, 19], ["variceal", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 40], ["tissue", "TISSUE", 58, 64], ["cyanoacrylate", "SIMPLE_CHEMICAL", 83, 96], ["gastric varices", "PROBLEM", 4, 19], ["endoscopic variceal obturation", "TREATMENT", 21, 51], ["tissue adhesives", "TREATMENT", 58, 74], ["cyanoacrylate", "TREATMENT", 83, 96], ["gastric", "ANATOMY", 4, 11], ["varices", "OBSERVATION", 12, 19], ["variceal obturation", "OBSERVATION", 32, 51]]], ["Otherwise, EVL is an option.", [["EVL", "PATHOLOGICAL_FORMATION", 11, 14], ["EVL", "OBSERVATION", 11, 14]]], ["TIPS should be considered in patients in whom hemorrhage from fundal varices cannot be controlled or in whom bleeding recurs despite combined pharmacological and endoscopic therapy.Answer: Acute Variceal BleedingAs well as cyanoacrylate (that is not available outside of a study in the United States), intravariceal thrombin injection has also been shown to be useful.Case 63A 52-year-old African American male presents with a 4-week history of progressively worsening abdominal pain and distension.", [["fundal varices", "ANATOMY", 62, 76], ["abdominal", "ANATOMY", 469, 478], ["hemorrhage", "DISEASE", 46, 56], ["fundal varices", "DISEASE", 62, 76], ["bleeding", "DISEASE", 109, 117], ["Bleeding", "DISEASE", 204, 212], ["cyanoacrylate", "CHEMICAL", 223, 236], ["abdominal pain", "DISEASE", 469, 483], ["cyanoacrylate", "CHEMICAL", 223, 236], ["patients", "ORGANISM", 29, 37], ["fundal varices", "PATHOLOGICAL_FORMATION", 62, 76], ["cyanoacrylate", "SIMPLE_CHEMICAL", 223, 236], ["thrombin", "GENE_OR_GENE_PRODUCT", 316, 324], ["American", "ORGANISM", 397, 405], ["abdominal", "ORGANISM_SUBDIVISION", 469, 478], ["thrombin", "PROTEIN", 316, 324], ["patients", "SPECIES", 29, 37], ["TIPS", "TREATMENT", 0, 4], ["hemorrhage", "PROBLEM", 46, 56], ["fundal varices", "PROBLEM", 62, 76], ["bleeding", "PROBLEM", 109, 117], ["combined pharmacological", "TREATMENT", 133, 157], ["endoscopic therapy", "TREATMENT", 162, 180], ["Acute Variceal Bleeding", "PROBLEM", 189, 212], ["cyanoacrylate", "TREATMENT", 223, 236], ["a study", "TEST", 271, 278], ["intravariceal thrombin injection", "TREATMENT", 302, 334], ["progressively worsening abdominal pain", "PROBLEM", 445, 483], ["distension", "PROBLEM", 488, 498], ["fundal", "ANATOMY", 62, 68], ["varices", "OBSERVATION", 69, 76], ["Acute", "OBSERVATION_MODIFIER", 189, 194], ["Variceal", "ANATOMY", 195, 203], ["Bleeding", "OBSERVATION", 204, 212], ["cyanoacrylate", "OBSERVATION", 223, 236], ["worsening", "OBSERVATION_MODIFIER", 459, 468], ["abdominal", "ANATOMY", 469, 478], ["pain", "OBSERVATION", 479, 483], ["distension", "OBSERVATION", 488, 498]]], ["Four weeks ago, he began to develop diffuse, crampy abdominal pain which he describes as sharp and jabbing with radiation to his upper chest and back.", [["abdominal", "ANATOMY", 52, 61], ["upper chest", "ANATOMY", 129, 140], ["abdominal pain", "DISEASE", 52, 66], ["abdominal", "ORGANISM_SUBDIVISION", 52, 61], ["upper chest", "ORGANISM_SUBDIVISION", 129, 140], ["diffuse, crampy abdominal pain", "PROBLEM", 36, 66], ["sharp and jabbing", "PROBLEM", 89, 106], ["diffuse", "OBSERVATION_MODIFIER", 36, 43], ["crampy", "OBSERVATION_MODIFIER", 45, 51], ["abdominal", "ANATOMY", 52, 61], ["pain", "OBSERVATION", 62, 66], ["sharp", "OBSERVATION_MODIFIER", 89, 94], ["radiation", "OBSERVATION", 112, 121], ["upper", "ANATOMY_MODIFIER", 129, 134], ["chest", "ANATOMY", 135, 140], ["back", "ANATOMY", 145, 149]]], ["He also describes increasing abdominal distension and is no longer able to fit into his pants.", [["abdominal", "ANATOMY", 29, 38], ["abdominal distension", "DISEASE", 29, 49], ["abdominal", "ORGANISM_SUBDIVISION", 29, 38], ["increasing abdominal distension", "PROBLEM", 18, 49], ["increasing", "OBSERVATION_MODIFIER", 18, 28], ["abdominal", "ANATOMY", 29, 38], ["distension", "OBSERVATION", 39, 49]]], ["Over the last 2 weeks, he has reported constant nausea, intermittent nonbloody emesis, and nonbloody diarrhea.", [["nausea", "DISEASE", 48, 54], ["nonbloody emesis", "DISEASE", 69, 85], ["diarrhea", "DISEASE", 101, 109], ["constant nausea", "PROBLEM", 39, 54], ["intermittent nonbloody emesis", "PROBLEM", 56, 85], ["nonbloody diarrhea", "PROBLEM", 91, 109], ["constant", "OBSERVATION_MODIFIER", 39, 47], ["nausea", "OBSERVATION", 48, 54], ["nonbloody emesis", "OBSERVATION", 69, 85], ["nonbloody", "ANATOMY", 91, 100], ["diarrhea", "OBSERVATION", 101, 109]]], ["He also is very short of breath and has developed a new dry cough.", [["dry cough", "DISEASE", 56, 65], ["very short of breath", "PROBLEM", 11, 31], ["a new dry cough", "PROBLEM", 50, 65], ["very", "OBSERVATION_MODIFIER", 11, 15], ["short", "OBSERVATION_MODIFIER", 16, 21], ["new", "OBSERVATION_MODIFIER", 52, 55], ["dry", "OBSERVATION_MODIFIER", 56, 59], ["cough", "OBSERVATION", 60, 65]]], ["The patient has a history of poorly controlled diabetes and schizoaffective disorder and is on sertraline and quetiapine fumarate, although he admits to noncompliance.", [["diabetes", "DISEASE", 47, 55], ["schizoaffective disorder", "DISEASE", 60, 84], ["sertraline", "CHEMICAL", 95, 105], ["quetiapine fumarate", "CHEMICAL", 110, 129], ["sertraline", "CHEMICAL", 95, 105], ["quetiapine fumarate", "CHEMICAL", 110, 129], ["patient", "ORGANISM", 4, 11], ["sertraline", "SIMPLE_CHEMICAL", 95, 105], ["quetiapine", "SIMPLE_CHEMICAL", 110, 120], ["fumarate", "SIMPLE_CHEMICAL", 121, 129], ["patient", "SPECIES", 4, 11], ["poorly controlled diabetes", "PROBLEM", 29, 55], ["schizoaffective disorder", "PROBLEM", 60, 84], ["sertraline", "TREATMENT", 95, 105], ["quetiapine fumarate", "TREATMENT", 110, 129], ["noncompliance", "PROBLEM", 153, 166], ["poorly controlled", "OBSERVATION_MODIFIER", 29, 46], ["diabetes", "OBSERVATION", 47, 55], ["schizoaffective disorder", "OBSERVATION", 60, 84]]], ["He has a history of hepatitis C diagnosed 8 years ago but never treated due to his psychiatric history.", [["hepatitis C", "DISEASE", 20, 31], ["psychiatric", "DISEASE", 83, 94], ["hepatitis C", "ORGANISM", 20, 31], ["hepatitis C", "PROBLEM", 20, 31], ["hepatitis", "OBSERVATION", 20, 29]]], ["The patient currently lives with his girlfriend.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["He has seven children from previous relationships.", [["children", "ORGANISM", 13, 21], ["children", "SPECIES", 13, 21]]], ["He works as a construction worker but has been forced to quit given his recent illness.", [["his recent illness", "PROBLEM", 68, 86]]], ["He has drunk most of his adult life, averaging between 6 and 10 beers per day in addition to a pint of rum.", [["He", "ORGANISM", 0, 2]]], ["He uses IV drugs in the form of heroin, and his last use was 1 week prior to admission.", [["heroin", "CHEMICAL", 32, 38], ["heroin", "CHEMICAL", 32, 38], ["heroin", "SIMPLE_CHEMICAL", 32, 38], ["IV drugs", "TREATMENT", 8, 16]]], ["The patient is adopted and does not know details regarding the medical history of his biological family.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["On review of systems, he complains of chills, fatigue, light headedness, and darkening of his urine.Case 63Physical exam is notable for an ill-, lethargic-appearing male with a BMI of 21.8 kg/m 2 .", [["urine", "ANATOMY", 94, 99], ["chills", "DISEASE", 38, 44], ["fatigue", "DISEASE", 46, 53], ["headedness", "DISEASE", 61, 71], ["darkening of his urine", "DISEASE", 77, 99], ["urine", "ORGANISM_SUBSTANCE", 94, 99], ["chills", "PROBLEM", 38, 44], ["fatigue", "PROBLEM", 46, 53], ["light headedness", "PROBLEM", 55, 71], ["darkening of his urine", "PROBLEM", 77, 99], ["Case 63Physical exam", "TEST", 100, 120], ["an ill-, lethargic", "PROBLEM", 136, 154], ["chills", "OBSERVATION", 38, 44], ["ill-", "OBSERVATION", 139, 143]]], ["He is afebrile, with a heart rate of 98, and a blood pressure of 106/48.", [["heart", "ANATOMY", 23, 28], ["blood", "ANATOMY", 47, 52], ["heart", "ORGAN", 23, 28], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["afebrile", "PROBLEM", 6, 14], ["a heart rate", "TEST", 21, 33], ["a blood pressure", "TEST", 45, 61]]], ["Respiratory rate is 18 per minute and oxygen saturation is 91% on room air.", [["oxygen", "CHEMICAL", 38, 44], ["oxygen", "CHEMICAL", 38, 44], ["oxygen", "SIMPLE_CHEMICAL", 38, 44], ["Respiratory rate", "TEST", 0, 16], ["oxygen saturation", "TEST", 38, 55]]], ["He has temporal wasting and scleral icterus.", [["scleral", "ANATOMY", 28, 35], ["wasting", "DISEASE", 16, 23], ["scleral icterus", "DISEASE", 28, 43], ["temporal wasting", "PROBLEM", 7, 23], ["scleral icterus", "PROBLEM", 28, 43], ["temporal", "OBSERVATION_MODIFIER", 7, 15], ["wasting", "OBSERVATION", 16, 23], ["scleral", "ANATOMY", 28, 35], ["icterus", "OBSERVATION", 36, 43]]], ["His parotid glands are enlarged bilaterally.", [["parotid glands", "ANATOMY", 4, 18], ["parotid glands", "ORGAN", 4, 18], ["enlarged bilaterally", "PROBLEM", 23, 43], ["parotid glands", "ANATOMY", 4, 18], ["enlarged", "OBSERVATION", 23, 31], ["bilaterally", "ANATOMY_MODIFIER", 32, 43]]], ["His mucous membranes are dry.", [["mucous membranes", "ANATOMY", 4, 20], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 4, 20], ["mucous membranes", "ANATOMY", 4, 20], ["dry", "OBSERVATION", 25, 28]]], ["He has decreased breath sounds one-third of the way up on his right side.", [["He", "ORGANISM", 0, 2], ["decreased breath sounds", "PROBLEM", 7, 30], ["decreased", "OBSERVATION_MODIFIER", 7, 16], ["breath sounds", "OBSERVATION", 17, 30], ["right", "ANATOMY_MODIFIER", 62, 67]]], ["Heart sounds are distant.", [["Heart", "ANATOMY", 0, 5], ["Heart", "ORGAN", 0, 5], ["sounds", "OBSERVATION", 6, 12], ["distant", "OBSERVATION", 17, 24]]], ["His abdomen reveals dilated umbilical veins, a firm liver palpable 3 cm below the right costal margin.", [["abdomen", "ANATOMY", 4, 11], ["dilated umbilical veins", "ANATOMY", 20, 43], ["liver", "ANATOMY", 52, 57], ["right costal margin", "ANATOMY", 82, 101], ["abdomen", "ORGAN", 4, 11], ["umbilical veins", "MULTI-TISSUE_STRUCTURE", 28, 43], ["liver", "ORGAN", 52, 57], ["costal margin", "MULTI-TISSUE_STRUCTURE", 88, 101], ["dilated umbilical veins", "PROBLEM", 20, 43], ["abdomen", "ANATOMY", 4, 11], ["dilated", "OBSERVATION", 20, 27], ["umbilical veins", "ANATOMY", 28, 43], ["firm", "OBSERVATION_MODIFIER", 47, 51], ["liver", "ANATOMY", 52, 57], ["palpable", "OBSERVATION", 58, 66], ["3 cm", "OBSERVATION_MODIFIER", 67, 71], ["right", "ANATOMY_MODIFIER", 82, 87], ["costal", "ANATOMY", 88, 94], ["margin", "ANATOMY_MODIFIER", 95, 101]]], ["There is no audible hepatic bruit.", [["hepatic bruit", "ANATOMY", 20, 33], ["audible hepatic bruit", "DISEASE", 12, 33], ["hepatic", "ORGAN", 20, 27], ["audible hepatic bruit", "PROBLEM", 12, 33], ["no", "UNCERTAINTY", 9, 11], ["audible", "OBSERVATION_MODIFIER", 12, 19], ["hepatic", "ANATOMY", 20, 27], ["bruit", "OBSERVATION", 28, 33]]], ["He has full flanks and shifting dullness.", [["dullness", "DISEASE", 32, 40], ["flanks", "ORGANISM_SUBDIVISION", 12, 18], ["shifting dullness", "PROBLEM", 23, 40], ["full", "OBSERVATION_MODIFIER", 7, 11], ["flanks", "OBSERVATION_MODIFIER", 12, 18], ["shifting", "OBSERVATION_MODIFIER", 23, 31], ["dullness", "OBSERVATION", 32, 40]]], ["He is tender diffusely.", [["He", "ORGANISM", 0, 2], ["tender", "PROBLEM", 6, 12], ["tender", "OBSERVATION_MODIFIER", 6, 12], ["diffusely", "OBSERVATION_MODIFIER", 13, 22]]], ["Extremities reveal multiple needle tracks and trace lower extremity edema.", [["lower extremity edema", "ANATOMY", 52, 73], ["lower extremity edema", "DISEASE", 52, 73], ["lower extremity", "ORGANISM_SUBDIVISION", 52, 67], ["edema", "PATHOLOGICAL_FORMATION", 68, 73], ["multiple needle tracks", "PROBLEM", 19, 41], ["trace lower extremity edema", "PROBLEM", 46, 73], ["multiple", "OBSERVATION_MODIFIER", 19, 27], ["needle tracks", "OBSERVATION", 28, 41], ["trace", "OBSERVATION_MODIFIER", 46, 51], ["lower", "ANATOMY_MODIFIER", 52, 57], ["extremity", "ANATOMY", 58, 67], ["edema", "OBSERVATION", 68, 73]]], ["He has palmar erythema, Duputryen's contractures bilaterally and a few scattered spider nevi.", [["palmar", "ANATOMY", 7, 13], ["nevi", "ANATOMY", 88, 92], ["erythema", "DISEASE", 14, 22], ["Duputryen's contractures", "DISEASE", 24, 48], ["spider nevi", "DISEASE", 81, 92], ["palmar erythema", "PATHOLOGICAL_FORMATION", 7, 22], ["palmar erythema", "PROBLEM", 7, 22], ["Duputryen's contractures bilaterally", "PROBLEM", 24, 60], ["a few scattered spider nevi", "PROBLEM", 65, 92], ["palmar", "ANATOMY", 7, 13], ["erythema", "OBSERVATION", 14, 22], ["contractures", "OBSERVATION", 36, 48], ["bilaterally", "ANATOMY_MODIFIER", 49, 60], ["few", "OBSERVATION_MODIFIER", 67, 70], ["scattered", "OBSERVATION_MODIFIER", 71, 80], ["spider nevi", "OBSERVATION", 81, 92]]], ["He answers questions appropriately and is oriented but does have a liver flap.Laboratory DataWBC 25,0 \u00d7 103/\u03bcl00 with 19% bands Hg 9 g/dl, MCV 111 f/l Platelet count 71,000/\u03bclAnswer: HCV/ETOH Cirrhosis with Superimposed Acute Alcoholic Hepatitis and Multifocal HCCThe acute deterioration in this patient can be accounted for by both the development of HCC with hepatic/portal vein thrombus and superimposed acute alcoholic hepatitis.Answer: HCV/ETOH Cirrhosis with Superimposed Acute Alcoholic Hepatitis and Multifocal HCCThe symptoms of weight loss, night sweats, and new onset abdominal pain with radiation to the back are all concerning for malignancy.", [["liver flap", "ANATOMY", 67, 77], ["HCC", "ANATOMY", 352, 355], ["hepatic", "ANATOMY", 361, 368], ["portal vein thrombus", "ANATOMY", 369, 389], ["abdominal", "ANATOMY", 579, 588], ["back", "ANATOMY", 616, 620], ["ETOH", "CHEMICAL", 187, 191], ["Cirrhosis", "DISEASE", 192, 201], ["Alcoholic Hepatitis", "DISEASE", 226, 245], ["HCC", "DISEASE", 352, 355], ["hepatic/portal vein thrombus", "DISEASE", 361, 389], ["acute alcoholic hepatitis", "DISEASE", 407, 432], ["ETOH", "CHEMICAL", 445, 449], ["Cirrhosis", "DISEASE", 450, 459], ["Alcoholic Hepatitis", "DISEASE", 484, 503], ["weight loss", "DISEASE", 538, 549], ["night sweats", "DISEASE", 551, 563], ["abdominal pain", "DISEASE", 579, 593], ["malignancy", "DISEASE", 644, 654], ["Hg", "CHEMICAL", 128, 130], ["liver", "ORGAN", 67, 72], ["Platelet", "CELL", 151, 159], ["HCV", "ORGANISM", 183, 186], ["patient", "ORGANISM", 296, 303], ["HCC", "CANCER", 352, 355], ["hepatic", "ORGAN", 361, 368], ["portal vein", "MULTI-TISSUE_STRUCTURE", 369, 380], ["thrombus", "PATHOLOGICAL_FORMATION", 381, 389], ["HCV", "ORGANISM", 441, 444], ["abdominal", "ORGANISM_SUBDIVISION", 579, 588], ["malignancy", "CANCER", 644, 654], ["patient", "SPECIES", 296, 303], ["HCV", "SPECIES", 183, 186], ["HCV", "SPECIES", 441, 444], ["a liver flap", "TREATMENT", 65, 77], ["Laboratory DataWBC", "TEST", 78, 96], ["bands", "TEST", 122, 127], ["Hg", "TEST", 128, 130], ["g", "TEST", 133, 134], ["dl", "TEST", 135, 137], ["MCV", "TEST", 139, 142], ["f", "TEST", 147, 148], ["Platelet count", "TEST", 151, 165], ["\u03bclAnswer", "TEST", 173, 181], ["HCV", "PROBLEM", 183, 186], ["Cirrhosis", "PROBLEM", 192, 201], ["Superimposed Acute Alcoholic Hepatitis", "PROBLEM", 207, 245], ["Multifocal HCCThe acute deterioration", "PROBLEM", 250, 287], ["HCC", "PROBLEM", 352, 355], ["hepatic/portal vein thrombus", "PROBLEM", 361, 389], ["superimposed acute alcoholic hepatitis", "PROBLEM", 394, 432], ["HCV", "PROBLEM", 441, 444], ["Cirrhosis", "PROBLEM", 450, 459], ["Superimposed Acute Alcoholic Hepatitis", "PROBLEM", 465, 503], ["Multifocal HCCThe symptoms", "PROBLEM", 508, 534], ["weight loss", "PROBLEM", 538, 549], ["night sweats", "PROBLEM", 551, 563], ["new onset abdominal pain", "PROBLEM", 569, 593], ["radiation to the back", "PROBLEM", 599, 620], ["malignancy", "PROBLEM", 644, 654], ["liver", "ANATOMY", 67, 72], ["flap", "OBSERVATION", 73, 77], ["HCV", "OBSERVATION", 183, 186], ["ETOH Cirrhosis", "OBSERVATION", 187, 201], ["Superimposed", "OBSERVATION_MODIFIER", 207, 219], ["Acute", "OBSERVATION_MODIFIER", 220, 225], ["Alcoholic Hepatitis", "OBSERVATION", 226, 245], ["Multifocal", "OBSERVATION_MODIFIER", 250, 260], ["acute", "OBSERVATION_MODIFIER", 268, 273], ["deterioration", "OBSERVATION", 274, 287], ["HCC", "OBSERVATION", 352, 355], ["hepatic", "ANATOMY", 361, 368], ["portal vein", "ANATOMY", 369, 380], ["thrombus", "OBSERVATION", 381, 389], ["superimposed", "OBSERVATION_MODIFIER", 394, 406], ["acute", "OBSERVATION_MODIFIER", 407, 412], ["alcoholic hepatitis", "OBSERVATION", 413, 432], ["ETOH Cirrhosis", "OBSERVATION", 445, 459], ["Superimposed", "OBSERVATION_MODIFIER", 465, 477], ["Acute", "OBSERVATION_MODIFIER", 478, 483], ["Alcoholic Hepatitis", "OBSERVATION", 484, 503], ["Multifocal", "OBSERVATION_MODIFIER", 508, 518], ["weight loss", "OBSERVATION", 538, 549], ["new", "OBSERVATION_MODIFIER", 569, 572], ["onset", "OBSERVATION_MODIFIER", 573, 578], ["abdominal", "ANATOMY", 579, 588], ["pain", "OBSERVATION", 589, 593], ["back", "ANATOMY", 616, 620], ["concerning for", "UNCERTAINTY", 629, 643], ["malignancy", "OBSERVATION", 644, 654]]], ["In the setting of a cirrhotic liver with classic characteristics (hypervascular lesion with washout in the portal venous phase) and marked elevation in AFP, a liver biopsy is not needed to establish the diagnosis of HCC.Answer: HCV/ETOH Cirrhosis with Superimposed Acute Alcoholic Hepatitis and Multifocal HCCAlthough markedly elevated in this case, and solidifying the diagnosis, AFP is a notoriously poor marker for screening of HCC.", [["liver", "ANATOMY", 30, 35], ["hypervascular lesion", "ANATOMY", 66, 86], ["portal venous", "ANATOMY", 107, 120], ["liver", "ANATOMY", 159, 164], ["HCC", "ANATOMY", 216, 219], ["HCC", "ANATOMY", 431, 434], ["cirrhotic liver", "DISEASE", 20, 35], ["HCC", "DISEASE", 216, 219], ["ETOH", "CHEMICAL", 232, 236], ["Cirrhosis", "DISEASE", 237, 246], ["Alcoholic Hepatitis", "DISEASE", 271, 290], ["HCC", "DISEASE", 431, 434], ["liver", "ORGAN", 30, 35], ["hypervascular lesion", "CANCER", 66, 86], ["portal venous", "MULTI-TISSUE_STRUCTURE", 107, 120], ["AFP", "GENE_OR_GENE_PRODUCT", 152, 155], ["liver", "ORGAN", 159, 164], ["HCC", "CANCER", 216, 219], ["HCV", "ORGANISM", 228, 231], ["AFP", "GENE_OR_GENE_PRODUCT", 381, 384], ["HCC", "CANCER", 431, 434], ["AFP", "PROTEIN", 152, 155], ["AFP", "PROTEIN", 381, 384], ["HCV", "SPECIES", 228, 231], ["a cirrhotic liver", "PROBLEM", 18, 35], ["classic characteristics (hypervascular lesion", "PROBLEM", 41, 86], ["the portal venous phase", "TEST", 103, 126], ["marked elevation in AFP", "PROBLEM", 132, 155], ["a liver biopsy", "TEST", 157, 171], ["HCC", "PROBLEM", 216, 219], ["HCV", "PROBLEM", 228, 231], ["Cirrhosis", "PROBLEM", 237, 246], ["Superimposed Acute Alcoholic Hepatitis", "PROBLEM", 252, 290], ["Multifocal HCCAlthough", "PROBLEM", 295, 317], ["AFP", "TEST", 381, 384], ["HCC", "PROBLEM", 431, 434], ["cirrhotic", "OBSERVATION", 20, 29], ["liver", "ANATOMY", 30, 35], ["hypervascular", "OBSERVATION_MODIFIER", 66, 79], ["lesion", "OBSERVATION", 80, 86], ["washout", "OBSERVATION_MODIFIER", 92, 99], ["portal venous", "ANATOMY", 107, 120], ["phase", "OBSERVATION_MODIFIER", 121, 126], ["marked", "OBSERVATION_MODIFIER", 132, 138], ["elevation", "OBSERVATION_MODIFIER", 139, 148], ["AFP", "OBSERVATION_MODIFIER", 152, 155], ["liver", "ANATOMY", 159, 164], ["biopsy", "OBSERVATION", 165, 171], ["HCC", "OBSERVATION", 216, 219], ["ETOH Cirrhosis", "OBSERVATION", 232, 246], ["Superimposed", "OBSERVATION_MODIFIER", 252, 264], ["Acute", "OBSERVATION_MODIFIER", 265, 270], ["Alcoholic Hepatitis", "OBSERVATION", 271, 290], ["Multifocal", "OBSERVATION_MODIFIER", 295, 305], ["markedly", "OBSERVATION_MODIFIER", 318, 326], ["elevated", "OBSERVATION_MODIFIER", 327, 335], ["HCC", "OBSERVATION", 431, 434]]], ["The sensitivity of AFP is 41-65%, with a specificity of 80 to 94%.Answer: HCV/ETOH Cirrhosis with Superimposed Acute Alcoholic Hepatitis and Multifocal HCCThe acute onset of jaundice, elevated INR, WBC, 2:1 pattern of elevation of AST/ALT and marked elevation in GGT in the setting of excessive consumption of alcohol are consistent with acute alcoholic hepatitis.", [["ETOH", "CHEMICAL", 78, 82], ["Cirrhosis", "DISEASE", 83, 92], ["Alcoholic Hepatitis", "DISEASE", 117, 136], ["jaundice", "DISEASE", 174, 182], ["alcohol", "CHEMICAL", 310, 317], ["acute alcoholic hepatitis", "DISEASE", 338, 363], ["alcohol", "CHEMICAL", 310, 317], ["AFP", "GENE_OR_GENE_PRODUCT", 19, 22], ["HCV", "ORGANISM", 74, 77], ["AST", "SIMPLE_CHEMICAL", 231, 234], ["ALT", "SIMPLE_CHEMICAL", 235, 238], ["GGT", "SIMPLE_CHEMICAL", 263, 266], ["alcohol", "SIMPLE_CHEMICAL", 310, 317], ["AFP", "PROTEIN", 19, 22], ["INR", "PROTEIN", 193, 196], ["AST", "PROTEIN", 231, 234], ["ALT", "PROTEIN", 235, 238], ["GGT", "PROTEIN", 263, 266], ["HCV", "SPECIES", 74, 77], ["The sensitivity", "TEST", 0, 15], ["AFP", "TEST", 19, 22], ["a specificity", "TEST", 39, 52], ["HCV", "PROBLEM", 74, 77], ["Cirrhosis", "PROBLEM", 83, 92], ["Superimposed Acute Alcoholic Hepatitis", "PROBLEM", 98, 136], ["jaundice", "PROBLEM", 174, 182], ["elevated INR", "PROBLEM", 184, 196], ["WBC", "TEST", 198, 201], ["elevation of AST/ALT", "PROBLEM", 218, 238], ["marked elevation in GGT", "PROBLEM", 243, 266], ["acute alcoholic hepatitis", "PROBLEM", 338, 363], ["ETOH Cirrhosis", "OBSERVATION", 78, 92], ["Superimposed", "OBSERVATION_MODIFIER", 98, 110], ["Acute", "OBSERVATION_MODIFIER", 111, 116], ["Alcoholic Hepatitis", "OBSERVATION", 117, 136], ["Multifocal", "OBSERVATION_MODIFIER", 141, 151], ["acute", "OBSERVATION_MODIFIER", 159, 164], ["jaundice", "OBSERVATION", 174, 182], ["elevated", "OBSERVATION_MODIFIER", 184, 192], ["INR", "OBSERVATION", 193, 196], ["elevation", "OBSERVATION_MODIFIER", 218, 227], ["marked", "OBSERVATION_MODIFIER", 243, 249], ["elevation", "OBSERVATION_MODIFIER", 250, 259], ["excessive consumption", "OBSERVATION", 285, 306], ["consistent with", "UNCERTAINTY", 322, 337], ["acute", "OBSERVATION_MODIFIER", 338, 343], ["alcoholic hepatitis", "OBSERVATION", 344, 363]]], ["Acute alcoholic hepatitis occurs superimposed on cirrhosis in approximately 40% of individuals.Answer: HCV/ETOH Cirrhosis with Superimposed Acute Alcoholic Hepatitis and Multifocal HCCThe epidemic of fatty liver disease aside, alcoholic liver disease and HCV are the two most common causes chronic liver disease in the country and many times coexist in the same individual.", [["fatty liver", "ANATOMY", 200, 211], ["liver", "ANATOMY", 237, 242], ["liver", "ANATOMY", 298, 303], ["alcoholic hepatitis", "DISEASE", 6, 25], ["cirrhosis", "DISEASE", 49, 58], ["ETOH", "CHEMICAL", 107, 111], ["Cirrhosis", "DISEASE", 112, 121], ["Alcoholic Hepatitis", "DISEASE", 146, 165], ["fatty liver disease", "DISEASE", 200, 219], ["alcoholic liver disease", "DISEASE", 227, 250], ["HCV", "DISEASE", 255, 258], ["chronic liver disease", "DISEASE", 290, 311], ["HCV", "ORGANISM", 103, 106], ["liver", "ORGAN", 206, 211], ["liver", "ORGAN", 237, 242], ["HCV", "ORGANISM", 255, 258], ["liver", "ORGAN", 298, 303], ["HCV", "SPECIES", 103, 106], ["HCV", "SPECIES", 255, 258], ["Acute alcoholic hepatitis", "PROBLEM", 0, 25], ["cirrhosis", "PROBLEM", 49, 58], ["HCV", "PROBLEM", 103, 106], ["Cirrhosis", "PROBLEM", 112, 121], ["Superimposed Acute Alcoholic Hepatitis", "PROBLEM", 127, 165], ["fatty liver disease", "PROBLEM", 200, 219], ["alcoholic liver disease", "PROBLEM", 227, 250], ["HCV", "PROBLEM", 255, 258], ["chronic liver disease", "PROBLEM", 290, 311], ["alcoholic hepatitis", "OBSERVATION", 6, 25], ["cirrhosis", "OBSERVATION", 49, 58], ["ETOH Cirrhosis", "OBSERVATION", 107, 121], ["Superimposed", "OBSERVATION_MODIFIER", 127, 139], ["Acute", "OBSERVATION_MODIFIER", 140, 145], ["Alcoholic Hepatitis", "OBSERVATION", 146, 165], ["Multifocal", "OBSERVATION_MODIFIER", 170, 180], ["epidemic", "OBSERVATION_MODIFIER", 188, 196], ["fatty liver disease", "OBSERVATION", 200, 219], ["alcoholic", "OBSERVATION_MODIFIER", 227, 236], ["liver", "ANATOMY", 237, 242], ["disease", "OBSERVATION", 243, 250], ["HCV", "OBSERVATION", 255, 258], ["chronic", "OBSERVATION_MODIFIER", 290, 297], ["liver", "ANATOMY", 298, 303], ["disease", "OBSERVATION", 304, 311]]], ["The combination of insults seems to work in synergy in both the progression of fibrosis and the development of HCC.", [["HCC", "ANATOMY", 111, 114], ["fibrosis", "DISEASE", 79, 87], ["HCC", "DISEASE", 111, 114], ["HCC", "CANCER", 111, 114], ["insults", "PROBLEM", 19, 26], ["synergy", "PROBLEM", 44, 51], ["fibrosis", "PROBLEM", 79, 87], ["HCC", "PROBLEM", 111, 114], ["insults", "OBSERVATION", 19, 26], ["progression", "OBSERVATION_MODIFIER", 64, 75], ["fibrosis", "OBSERVATION", 79, 87], ["HCC", "OBSERVATION", 111, 114]]], ["A daily uptake of >80 g of alcohol alone increases HCC risk fivefold while the presence of HCV alone increases HCC 20-fold.", [["HCC", "ANATOMY", 51, 54], ["HCC", "ANATOMY", 111, 114], ["alcohol", "CHEMICAL", 27, 34], ["HCC", "DISEASE", 51, 54], ["HCC", "DISEASE", 111, 114], ["alcohol", "CHEMICAL", 27, 34], ["alcohol", "SIMPLE_CHEMICAL", 27, 34], ["HCC", "CANCER", 51, 54], ["HCV", "ORGANISM", 91, 94], ["HCC", "CANCER", 111, 114], ["HCV", "SPECIES", 91, 94], ["A daily uptake", "TEST", 0, 14], ["HCC risk fivefold", "PROBLEM", 51, 68], ["HCV", "PROBLEM", 91, 94], ["HCC", "PROBLEM", 111, 114], ["HCV", "OBSERVATION", 91, 94]]], ["The combination of both factors increases the risk of HCC development over 100-fold.Answer: HCV/ETOH Cirrhosis with Superimposed Acute Alcoholic Hepatitis and Multifocal HCCMen are far more likely to develop HCC.", [["HCC", "ANATOMY", 54, 57], ["HCC", "ANATOMY", 208, 211], ["HCC", "DISEASE", 54, 57], ["ETOH", "CHEMICAL", 96, 100], ["Cirrhosis", "DISEASE", 101, 110], ["Alcoholic Hepatitis", "DISEASE", 135, 154], ["HCC", "DISEASE", 208, 211], ["HCC", "CANCER", 54, 57], ["HCV", "ORGANISM", 92, 95], ["HCC", "CANCER", 208, 211], ["HCV", "SPECIES", 92, 95], ["both factors", "PROBLEM", 19, 31], ["HCC development", "PROBLEM", 54, 69], ["HCV", "PROBLEM", 92, 95], ["Cirrhosis", "PROBLEM", 101, 110], ["Superimposed Acute Alcoholic Hepatitis", "PROBLEM", 116, 154], ["Multifocal HCCMen", "PROBLEM", 159, 176], ["HCC", "PROBLEM", 208, 211], ["HCC", "OBSERVATION", 54, 57], ["ETOH Cirrhosis", "OBSERVATION", 96, 110], ["Superimposed", "OBSERVATION_MODIFIER", 116, 128], ["Acute", "OBSERVATION_MODIFIER", 129, 134], ["Alcoholic Hepatitis", "OBSERVATION", 135, 154], ["Multifocal", "OBSERVATION_MODIFIER", 159, 169], ["HCC", "OBSERVATION", 208, 211]]], ["Although not completely understood, these differences in sex distribution are thought to be due to variation in viral hepatitis carrier states, exposure to environmental toxins, and the trophic effect of androgens.", [["hepatitis", "DISEASE", 118, 127], ["androgens", "CHEMICAL", 204, 213], ["androgens", "SIMPLE_CHEMICAL", 204, 213], ["viral hepatitis carrier states", "PROBLEM", 112, 142], ["environmental toxins", "PROBLEM", 156, 176], ["androgens", "TREATMENT", 204, 213], ["thought to be due to", "UNCERTAINTY", 78, 98], ["viral hepatitis", "OBSERVATION", 112, 127]]], ["In addition, the incidence of HCC is greater in black Americans than white Americans.", [["HCC", "ANATOMY", 30, 33], ["HCC", "DISEASE", 30, 33], ["HCC", "CANCER", 30, 33], ["HCC", "PROBLEM", 30, 33], ["HCC", "OBSERVATION", 30, 33], ["greater", "OBSERVATION_MODIFIER", 37, 44]]], ["Other risk factors for HCC present in the case, but more controversial and less definitive in their association include smoking, diabetes, and the positive hepatitis B core antibody.Answer: HCV/ETOH Cirrhosis with Superimposed Acute Alcoholic Hepatitis and Multifocal HCCThe differential for frankly bloody ascites include: traumatic tap, cirrhosis, or malignancy.", [["HCC", "ANATOMY", 23, 26], ["bloody ascites", "ANATOMY", 300, 314], ["HCC", "DISEASE", 23, 26], ["diabetes", "DISEASE", 129, 137], ["hepatitis B", "DISEASE", 156, 167], ["ETOH", "CHEMICAL", 194, 198], ["Cirrhosis", "DISEASE", 199, 208], ["Alcoholic Hepatitis", "DISEASE", 233, 252], ["ascites", "DISEASE", 307, 314], ["cirrhosis", "DISEASE", 339, 348], ["malignancy", "DISEASE", 353, 363], ["HCC", "CANCER", 23, 26], ["HCV", "ORGANISM", 190, 193], ["positive hepatitis B core antibody", "PROTEIN", 147, 181], ["HCV", "SPECIES", 190, 193], ["Other risk factors", "PROBLEM", 0, 18], ["HCC", "PROBLEM", 23, 26], ["diabetes", "PROBLEM", 129, 137], ["the positive hepatitis B core antibody", "PROBLEM", 143, 181], ["HCV", "PROBLEM", 190, 193], ["Cirrhosis", "PROBLEM", 199, 208], ["Superimposed Acute Alcoholic Hepatitis", "PROBLEM", 214, 252], ["frankly bloody ascites", "PROBLEM", 292, 314], ["traumatic tap", "PROBLEM", 324, 337], ["cirrhosis", "PROBLEM", 339, 348], ["malignancy", "PROBLEM", 353, 363], ["hepatitis", "OBSERVATION", 156, 165], ["HCV", "OBSERVATION", 190, 193], ["ETOH Cirrhosis", "OBSERVATION", 194, 208], ["Superimposed", "OBSERVATION_MODIFIER", 214, 226], ["Acute", "OBSERVATION_MODIFIER", 227, 232], ["Alcoholic Hepatitis", "OBSERVATION", 233, 252], ["Multifocal", "OBSERVATION_MODIFIER", 257, 267], ["frankly", "OBSERVATION_MODIFIER", 292, 299], ["bloody", "OBSERVATION_MODIFIER", 300, 306], ["ascites", "OBSERVATION", 307, 314], ["traumatic", "OBSERVATION_MODIFIER", 324, 333], ["tap", "OBSERVATION", 334, 337], ["cirrhosis", "OBSERVATION", 339, 348], ["malignancy", "OBSERVATION", 353, 363]]], ["Ascites is bloody in approximately 50% of patients with HCC.Answer: HCV/ETOH Cirrhosis with Superimposed Acute Alcoholic Hepatitis and Multifocal HCCThe HCC in this case was multifocal with the largest lesion being 7 cm.", [["Ascites", "ANATOMY", 0, 7], ["HCC", "ANATOMY", 56, 59], ["HCC", "ANATOMY", 153, 156], ["lesion", "ANATOMY", 202, 208], ["Ascites", "DISEASE", 0, 7], ["HCC", "DISEASE", 56, 59], ["ETOH", "CHEMICAL", 72, 76], ["Cirrhosis", "DISEASE", 77, 86], ["Alcoholic Hepatitis", "DISEASE", 111, 130], ["HCC", "DISEASE", 153, 156], ["Ascites", "CANCER", 0, 7], ["patients", "ORGANISM", 42, 50], ["HCC", "CANCER", 56, 59], ["HCV", "ORGANISM", 68, 71], ["Multifocal HCCThe HCC", "CANCER", 135, 156], ["lesion", "CANCER", 202, 208], ["patients", "SPECIES", 42, 50], ["HCV", "SPECIES", 68, 71], ["Ascites", "PROBLEM", 0, 7], ["bloody", "PROBLEM", 11, 17], ["HCC", "PROBLEM", 56, 59], ["HCV", "PROBLEM", 68, 71], ["Cirrhosis", "PROBLEM", 77, 86], ["Superimposed Acute Alcoholic Hepatitis", "PROBLEM", 92, 130], ["Multifocal HCCThe HCC", "PROBLEM", 135, 156], ["the largest lesion", "PROBLEM", 190, 208], ["bloody", "OBSERVATION", 11, 17], ["50%", "OBSERVATION_MODIFIER", 35, 38], ["HCC", "OBSERVATION", 56, 59], ["ETOH Cirrhosis", "OBSERVATION", 72, 86], ["Superimposed", "OBSERVATION_MODIFIER", 92, 104], ["Acute", "OBSERVATION_MODIFIER", 105, 110], ["Alcoholic Hepatitis", "OBSERVATION", 111, 130], ["Multifocal", "OBSERVATION_MODIFIER", 135, 145], ["HCCThe", "OBSERVATION_MODIFIER", 146, 152], ["HCC", "OBSERVATION", 153, 156], ["multifocal", "OBSERVATION_MODIFIER", 174, 184], ["largest", "OBSERVATION_MODIFIER", 194, 201], ["lesion", "OBSERVATION", 202, 208], ["7 cm", "OBSERVATION_MODIFIER", 215, 219]]], ["The lesion was invading the right diaphragm and was actually abutting the right heart (see Fig. 63 .2; black arrow: HCC, white arrow right ventricle).", [["lesion", "ANATOMY", 4, 10], ["right diaphragm", "ANATOMY", 28, 43], ["right heart", "ANATOMY", 74, 85], ["HCC", "ANATOMY", 116, 119], ["right ventricle", "ANATOMY", 133, 148], ["HCC", "DISEASE", 116, 119], ["lesion", "CANCER", 4, 10], ["diaphragm", "ORGAN", 34, 43], ["heart", "ORGAN", 80, 85], ["HCC", "CANCER", 116, 119], ["right ventricle", "MULTI-TISSUE_STRUCTURE", 133, 148], ["The lesion", "PROBLEM", 0, 10], ["HCC", "PROBLEM", 116, 119], ["lesion", "OBSERVATION", 4, 10], ["right", "ANATOMY_MODIFIER", 28, 33], ["diaphragm", "ANATOMY", 34, 43], ["right", "ANATOMY_MODIFIER", 74, 79], ["heart", "ANATOMY", 80, 85], ["HCC", "OBSERVATION", 116, 119], ["right ventricle", "ANATOMY", 133, 148]]], ["There was subocclusive thrombosis of the inferior vena cava, middle hepatic, right and main portal veins.", [["inferior vena cava", "ANATOMY", 41, 59], ["middle hepatic", "ANATOMY", 61, 75], ["right", "ANATOMY", 77, 82], ["portal veins", "ANATOMY", 92, 104], ["thrombosis", "DISEASE", 23, 33], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 41, 59], ["hepatic", "ORGAN", 68, 75], ["portal veins", "MULTI-TISSUE_STRUCTURE", 92, 104], ["subocclusive thrombosis of the inferior vena cava", "PROBLEM", 10, 59], ["subocclusive", "OBSERVATION_MODIFIER", 10, 22], ["thrombosis", "OBSERVATION", 23, 33], ["inferior vena cava", "ANATOMY", 41, 59], ["middle", "ANATOMY_MODIFIER", 61, 67], ["hepatic", "ANATOMY", 68, 75], ["right", "ANATOMY_MODIFIER", 77, 82], ["main", "ANATOMY_MODIFIER", 87, 91], ["portal veins", "ANATOMY", 92, 104]]], ["Per the patient's wishes, he was made palliative care, sent home on hospice and died 8 days after his presentation.Answer: HCV/ETOH Cirrhosis with Superimposed Acute Alcoholic Hepatitis and Multifocal HCCVenous ammonia: 16 mmol/l MELD score: 23Answer: Hepatic Encephalopathy Following TIPSThis elderly patient has developed altered mental status after placement of a TIPS, likely related to hepatic encephalopathy (HE).", [["Hepatic", "ANATOMY", 252, 259], ["hepatic", "ANATOMY", 391, 398], ["ETOH", "CHEMICAL", 127, 131], ["Cirrhosis", "DISEASE", 132, 141], ["Alcoholic Hepatitis", "DISEASE", 166, 185], ["ammonia", "CHEMICAL", 211, 218], ["Hepatic Encephalopathy", "DISEASE", 252, 274], ["hepatic encephalopathy", "DISEASE", 391, 413], ["HE", "DISEASE", 415, 417], ["ammonia", "CHEMICAL", 211, 218], ["patient", "ORGANISM", 8, 15], ["HCV", "ORGANISM", 123, 126], ["patient", "ORGANISM", 302, 309], ["hepatic", "ORGAN", 391, 398], ["patient", "SPECIES", 8, 15], ["patient", "SPECIES", 302, 309], ["HCV", "SPECIES", 123, 126], ["palliative care", "TREATMENT", 38, 53], ["hospice", "TREATMENT", 68, 75], ["Cirrhosis", "PROBLEM", 132, 141], ["Superimposed Acute Alcoholic Hepatitis", "PROBLEM", 147, 185], ["Multifocal HCCVenous ammonia", "PROBLEM", 190, 218], ["MELD score", "TEST", 230, 240], ["Hepatic Encephalopathy", "PROBLEM", 252, 274], ["altered mental status", "PROBLEM", 324, 345], ["a TIPS", "TREATMENT", 365, 371], ["hepatic encephalopathy", "PROBLEM", 391, 413], ["ETOH Cirrhosis", "OBSERVATION", 127, 141], ["Acute", "OBSERVATION_MODIFIER", 160, 165], ["Alcoholic Hepatitis", "OBSERVATION", 166, 185], ["Multifocal", "OBSERVATION_MODIFIER", 190, 200], ["Hepatic", "ANATOMY", 252, 259], ["Encephalopathy", "OBSERVATION", 260, 274], ["likely related to", "UNCERTAINTY", 373, 390], ["hepatic", "ANATOMY", 391, 398], ["encephalopathy", "OBSERVATION", 399, 413]]], ["This is a diagnosis that can be difficult to make since it is defined by a variety of neuropsychiatric abnormalities seen in patients with liver disease, after excluding other unrelated neurologic and/or metabolic abnormalities.", [["liver", "ANATOMY", 139, 144], ["neurologic", "ANATOMY", 186, 196], ["neuropsychiatric abnormalities", "DISEASE", 86, 116], ["liver disease", "DISEASE", 139, 152], ["neurologic and/or metabolic abnormalities", "DISEASE", 186, 227], ["patients", "ORGANISM", 125, 133], ["liver", "ORGAN", 139, 144], ["patients", "SPECIES", 125, 133], ["neuropsychiatric abnormalities", "PROBLEM", 86, 116], ["liver disease", "PROBLEM", 139, 152], ["other unrelated neurologic and/or metabolic abnormalities", "PROBLEM", 170, 227], ["liver", "ANATOMY", 139, 144], ["disease", "OBSERVATION", 145, 152], ["metabolic abnormalities", "OBSERVATION", 204, 227]]], ["The severity of HE can be graded from stages I through IV with stage I representing mild symptoms and stage IV coma.", [["HE", "DISEASE", 16, 18], ["coma", "DISEASE", 111, 115], ["stage I representing mild symptoms", "PROBLEM", 63, 97], ["stage IV coma", "PROBLEM", 102, 115], ["mild", "OBSERVATION_MODIFIER", 84, 88], ["symptoms", "OBSERVATION", 89, 97], ["IV coma", "OBSERVATION_MODIFIER", 108, 115]]], ["More recently, there have been attempts to reclassify HE to enable better clinical studies.", [["clinical studies", "TEST", 74, 90]]], ["This new system uses the following:Answer: Hepatic Encephalopathy Following TIPSType A -HE associated with acute liver failure Type B -HE associated with porto-systemic bypass and no liver disease Type C -HE associated with cirrhosis and portal hypertension and/or shunts.", [["liver", "ANATOMY", 113, 118], ["porto-systemic", "ANATOMY", 154, 168], ["liver", "ANATOMY", 183, 188], ["portal", "ANATOMY", 238, 244], ["Hepatic Encephalopathy", "DISEASE", 43, 65], ["HE", "DISEASE", 88, 90], ["acute liver failure", "DISEASE", 107, 126], ["HE", "DISEASE", 135, 137], ["liver disease", "DISEASE", 183, 196], ["HE", "DISEASE", 205, 207], ["cirrhosis", "DISEASE", 224, 233], ["portal hypertension", "DISEASE", 238, 257], ["liver", "ORGAN", 113, 118], ["liver", "ORGAN", 183, 188], ["portal", "MULTI-TISSUE_STRUCTURE", 238, 244], ["Hepatic Encephalopathy", "PROBLEM", 43, 65], ["acute liver failure", "PROBLEM", 107, 126], ["Type B", "PROBLEM", 127, 133], ["porto-systemic bypass", "TREATMENT", 154, 175], ["liver disease", "PROBLEM", 183, 196], ["Type C", "PROBLEM", 197, 203], ["cirrhosis", "PROBLEM", 224, 233], ["portal hypertension", "PROBLEM", 238, 257], ["shunts", "PROBLEM", 265, 271], ["Hepatic", "ANATOMY", 43, 50], ["Encephalopathy", "OBSERVATION", 51, 65], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["liver", "ANATOMY", 113, 118], ["failure", "OBSERVATION", 119, 126], ["porto-systemic bypass", "OBSERVATION", 154, 175], ["no", "UNCERTAINTY", 180, 182], ["liver", "ANATOMY", 183, 188], ["disease", "OBSERVATION", 189, 196], ["cirrhosis", "OBSERVATION", 224, 233], ["portal", "ANATOMY", 238, 244], ["hypertension", "OBSERVATION", 245, 257], ["shunts", "OBSERVATION", 265, 271]]], ["Type C is subdivided into episodic, persistent and mild.", [["Type C", "GENE_OR_GENE_PRODUCT", 0, 6], ["Type C", "PROBLEM", 0, 6], ["persistent", "OBSERVATION_MODIFIER", 36, 46], ["mild", "OBSERVATION_MODIFIER", 51, 55]]], ["This last subdivision of minimal HE has gained attention since the diagnosis is based on psychometric testing and patients have no signs or symptoms (stage 0), and several studies have suggested that these patients are at increased risk of accidents while driving.Answer: Hepatic Encephalopathy Following TIPSThe diagnosis of HE should be made clinically and does not require an ammonia level.", [["Hepatic", "ANATOMY", 272, 279], ["HE", "DISEASE", 33, 35], ["accidents", "DISEASE", 240, 249], ["Hepatic Encephalopathy", "DISEASE", 272, 294], ["HE", "DISEASE", 326, 328], ["ammonia", "CHEMICAL", 379, 386], ["ammonia", "CHEMICAL", 379, 386], ["patients", "ORGANISM", 114, 122], ["patients", "ORGANISM", 206, 214], ["ammonia", "SIMPLE_CHEMICAL", 379, 386], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 206, 214], ["psychometric testing", "TEST", 89, 109], ["signs or symptoms", "PROBLEM", 131, 148], ["several studies", "TEST", 164, 179], ["Hepatic Encephalopathy", "PROBLEM", 272, 294], ["an ammonia level", "TEST", 376, 392], ["minimal", "OBSERVATION_MODIFIER", 25, 32], ["Hepatic", "ANATOMY", 272, 279], ["Encephalopathy", "OBSERVATION", 280, 294]]], ["Ammonia levels do not correlate well with the degree of HE and are difficult to measure accurately.", [["Ammonia", "CHEMICAL", 0, 7], ["Ammonia", "CHEMICAL", 0, 7], ["Ammonia", "SIMPLE_CHEMICAL", 0, 7], ["Ammonia levels", "TEST", 0, 14]]], ["Ammonia is produced in the gut from several sources including the breakdown of nitrogenous material by bacteria and also from glutamine in enterocytes.", [["gut", "ANATOMY", 27, 30], ["enterocytes", "ANATOMY", 139, 150], ["Ammonia", "CHEMICAL", 0, 7], ["glutamine", "CHEMICAL", 126, 135], ["Ammonia", "CHEMICAL", 0, 7], ["glutamine", "CHEMICAL", 126, 135], ["Ammonia", "SIMPLE_CHEMICAL", 0, 7], ["gut", "ORGANISM_SUBDIVISION", 27, 30], ["glutamine", "AMINO_ACID", 126, 135], ["enterocytes", "CELL", 139, 150], ["enterocytes", "CELL_TYPE", 139, 150], ["Ammonia", "TEST", 0, 7], ["the breakdown of nitrogenous material", "PROBLEM", 62, 99], ["bacteria", "PROBLEM", 103, 111], ["glutamine in enterocytes", "TREATMENT", 126, 150], ["several", "OBSERVATION_MODIFIER", 36, 43], ["sources", "OBSERVATION", 44, 51], ["nitrogenous material", "OBSERVATION", 79, 99], ["enterocytes", "ANATOMY", 139, 150]]], ["It enters the portal vein, and the liver metabolizes it back to glutamine or urea.", [["portal vein", "ANATOMY", 14, 25], ["liver", "ANATOMY", 35, 40], ["glutamine", "CHEMICAL", 64, 73], ["urea", "CHEMICAL", 77, 81], ["glutamine", "CHEMICAL", 64, 73], ["urea", "CHEMICAL", 77, 81], ["portal vein", "MULTI-TISSUE_STRUCTURE", 14, 25], ["liver", "ORGAN", 35, 40], ["glutamine", "AMINO_ACID", 64, 73], ["urea", "SIMPLE_CHEMICAL", 77, 81], ["portal vein", "ANATOMY", 14, 25], ["liver", "ANATOMY", 35, 40]]], ["In liver dysfunction, ammonia clearance is impaired, and shunting also occurs if there is portal hypertension.Answer: Hepatic Encephalopathy Following TIPSAccurate measurement of venous (or preferably arterial) ammonia requires the sample to be placed on ice and analyzed quickly.", [["liver", "ANATOMY", 3, 8], ["portal", "ANATOMY", 90, 96], ["Hepatic", "ANATOMY", 118, 125], ["venous", "ANATOMY", 179, 185], ["arterial", "ANATOMY", 201, 209], ["sample", "ANATOMY", 232, 238], ["liver dysfunction", "DISEASE", 3, 20], ["ammonia", "CHEMICAL", 22, 29], ["hypertension", "DISEASE", 97, 109], ["Hepatic Encephalopathy", "DISEASE", 118, 140], ["ammonia", "CHEMICAL", 211, 218], ["ammonia", "CHEMICAL", 22, 29], ["ammonia", "CHEMICAL", 211, 218], ["liver", "ORGAN", 3, 8], ["ammonia", "SIMPLE_CHEMICAL", 22, 29], ["portal", "MULTI-TISSUE_STRUCTURE", 90, 96], ["venous", "MULTI-TISSUE_STRUCTURE", 179, 185], ["arterial", "MULTI-TISSUE_STRUCTURE", 201, 209], ["ammonia", "SIMPLE_CHEMICAL", 211, 218], ["liver dysfunction", "PROBLEM", 3, 20], ["ammonia clearance", "TEST", 22, 39], ["shunting", "PROBLEM", 57, 65], ["portal hypertension", "PROBLEM", 90, 109], ["Hepatic Encephalopathy", "PROBLEM", 118, 140], ["TIPSAccurate measurement", "TEST", 151, 175], ["the sample", "TREATMENT", 228, 238], ["ice", "TREATMENT", 255, 258], ["liver", "ANATOMY", 3, 8], ["dysfunction", "OBSERVATION", 9, 20], ["ammonia clearance", "OBSERVATION", 22, 39], ["impaired", "OBSERVATION_MODIFIER", 43, 51], ["shunting", "OBSERVATION", 57, 65], ["portal", "ANATOMY", 90, 96], ["hypertension", "OBSERVATION", 97, 109], ["Hepatic", "ANATOMY", 118, 125], ["Encephalopathy", "OBSERVATION", 126, 140], ["venous", "ANATOMY", 179, 185]]], ["The partial pressure of ammonia is a better test since it is in this state that ammonia crosses the blood brain barrier, but again is difficult to measure directly.Answer: Hepatic Encephalopathy Following TIPSThe pathogenesis of HE is still unclear but likely involves ammonia as well as other neurotransmitters such as gamma-aminobutyric acid (GABA) in the central nervous system.Answer: Hepatic Encephalopathy Following TIPSAfter TIPS, HE is seen in up to 30% of patients and is more likely to occur in older patients, more severe liver disease and in patients with HE prior to the TIPS.", [["blood brain", "ANATOMY", 100, 111], ["Hepatic", "ANATOMY", 172, 179], ["central nervous system", "ANATOMY", 358, 380], ["Hepatic", "ANATOMY", 389, 396], ["liver", "ANATOMY", 533, 538], ["ammonia", "CHEMICAL", 24, 31], ["ammonia", "CHEMICAL", 80, 87], ["Hepatic Encephalopathy", "DISEASE", 172, 194], ["HE", "DISEASE", 229, 231], ["ammonia", "CHEMICAL", 269, 276], ["gamma-aminobutyric acid", "CHEMICAL", 320, 343], ["GABA", "CHEMICAL", 345, 349], ["Hepatic Encephalopathy", "DISEASE", 389, 411], ["HE", "DISEASE", 438, 440], ["liver disease", "DISEASE", 533, 546], ["HE", "DISEASE", 568, 570], ["ammonia", "CHEMICAL", 24, 31], ["ammonia", "CHEMICAL", 80, 87], ["ammonia", "CHEMICAL", 269, 276], ["gamma-aminobutyric acid", "CHEMICAL", 320, 343], ["GABA", "CHEMICAL", 345, 349], ["ammonia", "SIMPLE_CHEMICAL", 24, 31], ["ammonia", "SIMPLE_CHEMICAL", 80, 87], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 100, 119], ["ammonia", "SIMPLE_CHEMICAL", 269, 276], ["gamma-aminobutyric acid", "SIMPLE_CHEMICAL", 320, 343], ["GABA", "SIMPLE_CHEMICAL", 345, 349], ["central nervous system", "ANATOMICAL_SYSTEM", 358, 380], ["patients", "ORGANISM", 465, 473], ["patients", "ORGANISM", 511, 519], ["liver", "ORGAN", 533, 538], ["patients", "ORGANISM", 554, 562], ["patients", "SPECIES", 465, 473], ["patients", "SPECIES", 511, 519], ["patients", "SPECIES", 554, 562], ["The partial pressure of ammonia", "PROBLEM", 0, 31], ["Hepatic Encephalopathy", "PROBLEM", 172, 194], ["ammonia", "PROBLEM", 269, 276], ["other neurotransmitters", "PROBLEM", 288, 311], ["gamma-aminobutyric acid (GABA) in the central nervous system", "PROBLEM", 320, 380], ["Hepatic Encephalopathy", "PROBLEM", 389, 411], ["TIPSAfter TIPS", "TREATMENT", 422, 436], ["more severe liver disease", "PROBLEM", 521, 546], ["the TIPS", "TREATMENT", 580, 588], ["partial", "OBSERVATION_MODIFIER", 4, 11], ["pressure", "OBSERVATION_MODIFIER", 12, 20], ["blood brain", "ANATOMY", 100, 111], ["Hepatic", "ANATOMY", 172, 179], ["Encephalopathy", "OBSERVATION", 180, 194], ["central", "ANATOMY_MODIFIER", 358, 365], ["nervous system", "ANATOMY", 366, 380], ["Hepatic", "ANATOMY", 389, 396], ["Encephalopathy", "OBSERVATION", 397, 411], ["TIPS", "OBSERVATION_MODIFIER", 432, 436], ["more likely", "UNCERTAINTY", 481, 492], ["severe", "OBSERVATION_MODIFIER", 526, 532], ["liver", "ANATOMY", 533, 538], ["disease", "OBSERVATION", 539, 546]]], ["Prior to being used to prioritize organ allocation for liver transplant in the US, the MELD score was developed to predict mortality after TIPS.", [["organ", "ANATOMY", 34, 39], ["liver", "ANATOMY", 55, 60], ["organ", "ORGAN", 34, 39], ["liver", "ORGAN", 55, 60], ["organ allocation", "TREATMENT", 34, 50], ["liver transplant", "TREATMENT", 55, 71], ["the MELD score", "TEST", 83, 97], ["TIPS", "TREATMENT", 139, 143], ["liver", "ANATOMY", 55, 60], ["transplant", "OBSERVATION", 61, 71]]], ["A score of greater than 18 predicts poor outcome and this patient should not have undergone TIPS for this nonemergent indication.Answer: Hepatic Encephalopathy Following TIPSThe treatment of post-TIPS HE is the same as HE in other situations.", [["Hepatic", "ANATOMY", 137, 144], ["Hepatic Encephalopathy", "DISEASE", 137, 159], ["HE", "DISEASE", 219, 221], ["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["A score", "TEST", 0, 7], ["TIPS", "TREATMENT", 92, 96], ["this nonemergent indication", "TREATMENT", 101, 128], ["Hepatic Encephalopathy", "PROBLEM", 137, 159], ["TIPSThe treatment", "TREATMENT", 170, 187], ["post-TIPS", "TREATMENT", 191, 200], ["Hepatic", "ANATOMY", 137, 144], ["Encephalopathy", "OBSERVATION", 145, 159]]], ["Precipitating factors should be reversed if present such as constipation, GI bleeding, dehydration, electrolyte abnormalities, infections, and medications, and worsening hepatic function.", [["GI", "ANATOMY", 74, 76], ["hepatic", "ANATOMY", 170, 177], ["constipation", "DISEASE", 60, 72], ["GI bleeding", "DISEASE", 74, 85], ["dehydration", "DISEASE", 87, 98], ["electrolyte abnormalities", "DISEASE", 100, 125], ["infections", "DISEASE", 127, 137], ["GI", "ORGANISM_SUBDIVISION", 74, 76], ["hepatic", "ORGAN", 170, 177], ["Precipitating factors", "PROBLEM", 0, 21], ["constipation", "PROBLEM", 60, 72], ["GI bleeding", "PROBLEM", 74, 85], ["dehydration", "PROBLEM", 87, 98], ["electrolyte abnormalities", "PROBLEM", 100, 125], ["infections", "PROBLEM", 127, 137], ["medications", "TREATMENT", 143, 154], ["worsening hepatic function", "PROBLEM", 160, 186], ["GI", "ANATOMY", 74, 76], ["bleeding", "OBSERVATION", 77, 85], ["infections", "OBSERVATION", 127, 137], ["worsening", "OBSERVATION_MODIFIER", 160, 169], ["hepatic", "ANATOMY", 170, 177]]], ["Lactulose should be titrated to 3-4 soft bowel movements daily.", [["bowel", "ANATOMY", 41, 46], ["Lactulose", "CHEMICAL", 0, 9], ["Lactulose", "CHEMICAL", 0, 9], ["Lactulose", "SIMPLE_CHEMICAL", 0, 9], ["bowel", "ORGAN", 41, 46], ["Lactulose", "TREATMENT", 0, 9]]], ["Protein restriction is generally not recommended.", [["Protein restriction", "TEST", 0, 19]]], ["Other agents used include neomycin, metronidazole, and zinc although the data for their efficacy is limited.", [["neomycin", "CHEMICAL", 26, 34], ["metronidazole", "CHEMICAL", 36, 49], ["zinc", "CHEMICAL", 55, 59], ["neomycin", "CHEMICAL", 26, 34], ["metronidazole", "CHEMICAL", 36, 49], ["zinc", "CHEMICAL", 55, 59], ["neomycin", "SIMPLE_CHEMICAL", 26, 34], ["metronidazole", "SIMPLE_CHEMICAL", 36, 49], ["zinc", "SIMPLE_CHEMICAL", 55, 59], ["Other agents", "TREATMENT", 0, 12], ["neomycin", "TREATMENT", 26, 34], ["metronidazole", "TREATMENT", 36, 49], ["zinc", "TREATMENT", 55, 59], ["the data", "TEST", 69, 77]]], ["Recently, oral rifaximin has been shown to be effective but is very expensive in the US.", [["oral", "ANATOMY", 10, 14], ["rifaximin", "CHEMICAL", 15, 24], ["rifaximin", "CHEMICAL", 15, 24], ["oral", "ORGANISM_SUBDIVISION", 10, 14], ["rifaximin", "SIMPLE_CHEMICAL", 15, 24], ["oral rifaximin", "TREATMENT", 10, 24]]], ["As a last resort, the TIPS can be occluded or downsized, but this will very likely cause the ascites to reaccumulate.Questions1.", [["ascites", "ANATOMY", 93, 100], ["ascites", "DISEASE", 93, 100], ["the TIPS", "TREATMENT", 18, 26], ["occluded", "PROBLEM", 34, 42], ["the ascites", "PROBLEM", 89, 100], ["occluded", "OBSERVATION", 34, 42], ["ascites", "OBSERVATION", 93, 100]]], ["Does she need albumin/octreotide/hypertonic saline?Answer: Spontaneous Bacterial Peritonitis (SBP)This lady presents with a relatively acute onset of change in mental status, low-grade fever, and ascites in the setting of ongoing alcohol use.", [["ascites", "ANATOMY", 196, 203], ["octreotide", "CHEMICAL", 22, 32], ["Bacterial Peritonitis", "DISEASE", 71, 92], ["low-grade fever", "DISEASE", 175, 190], ["ascites", "DISEASE", 196, 203], ["alcohol", "CHEMICAL", 230, 237], ["octreotide", "CHEMICAL", 22, 32], ["alcohol", "CHEMICAL", 230, 237], ["albumin", "GENE_OR_GENE_PRODUCT", 14, 21], ["octreotide", "SIMPLE_CHEMICAL", 22, 32], ["hypertonic saline", "SIMPLE_CHEMICAL", 33, 50], ["alcohol", "ORGANISM_SUBDIVISION", 230, 237], ["albumin", "TREATMENT", 14, 21], ["octreotide", "TREATMENT", 22, 32], ["hypertonic saline", "TREATMENT", 33, 50], ["Spontaneous Bacterial Peritonitis", "PROBLEM", 59, 92], ["change in mental status", "PROBLEM", 150, 173], ["low-grade fever", "PROBLEM", 175, 190], ["ascites", "PROBLEM", 196, 203], ["Bacterial Peritonitis", "OBSERVATION", 71, 92], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["change", "OBSERVATION_MODIFIER", 150, 156], ["mental status", "OBSERVATION", 160, 173], ["low-grade", "OBSERVATION_MODIFIER", 175, 184], ["fever", "OBSERVATION", 185, 190], ["ascites", "OBSERVATION", 196, 203]]], ["She has not been seen for some time, and we are not told her baseline bilirubin.", [["bilirubin", "CHEMICAL", 70, 79], ["bilirubin", "CHEMICAL", 70, 79], ["bilirubin", "GENE_OR_GENE_PRODUCT", 70, 79], ["her baseline bilirubin", "TEST", 57, 79]]], ["However, she is coagulopathic, has an elevated white-cell count with abdominal tenderness in the setting of jaundice.", [["white-cell", "ANATOMY", 47, 57], ["abdominal", "ANATOMY", 69, 78], ["abdominal tenderness", "DISEASE", 69, 89], ["jaundice", "DISEASE", 108, 116], ["white-cell", "CELL", 47, 57], ["abdominal", "ORGANISM_SUBDIVISION", 69, 78], ["coagulopathic", "PROBLEM", 16, 29], ["an elevated white-cell count", "PROBLEM", 35, 63], ["abdominal tenderness", "PROBLEM", 69, 89], ["jaundice", "PROBLEM", 108, 116], ["coagulopathic", "OBSERVATION", 16, 29], ["elevated", "OBSERVATION_MODIFIER", 38, 46], ["white-cell count", "OBSERVATION", 47, 63], ["abdominal", "ANATOMY", 69, 78], ["tenderness", "OBSERVATION", 79, 89], ["jaundice", "OBSERVATION", 108, 116]]], ["She very likely has hepatic encephalopathy, but the question is what is the etiology?", [["hepatic", "ANATOMY", 20, 27], ["hepatic encephalopathy", "DISEASE", 20, 42], ["hepatic", "ORGAN", 20, 27], ["hepatic encephalopathy", "PROBLEM", 20, 42], ["very likely", "UNCERTAINTY", 4, 15], ["hepatic", "ANATOMY", 20, 27], ["encephalopathy", "OBSERVATION", 28, 42]]], ["The main differential diagnosis is between alcoholic hepatitis and SBP, but the development of HCC or another infection is also possible.", [["HCC", "ANATOMY", 95, 98], ["alcoholic hepatitis", "DISEASE", 43, 62], ["HCC", "DISEASE", 95, 98], ["infection", "DISEASE", 110, 119], ["HCC", "CANCER", 95, 98], ["alcoholic hepatitis", "PROBLEM", 43, 62], ["SBP", "PROBLEM", 67, 70], ["HCC", "PROBLEM", 95, 98], ["another infection", "PROBLEM", 102, 119], ["main", "OBSERVATION_MODIFIER", 4, 8], ["differential", "OBSERVATION_MODIFIER", 9, 21], ["alcoholic", "OBSERVATION_MODIFIER", 43, 52], ["hepatitis", "OBSERVATION", 53, 62], ["HCC", "OBSERVATION", 95, 98], ["infection", "OBSERVATION", 110, 119]]], ["Apart from SBP, which is defined as infection in the ascitic fluid without evidence of an intraabdominal surgically treatable source, the possibility of secondary bacterial peritonitis (from a ruptured viscus -gallbladder, colon, or peptic ulcer) should be considered and abdominal imaging is advisable.Answer: Spontaneous Bacterial Peritonitis (SBP)The first test that should be performed is a diagnostic ascitic tap.", [["ascitic fluid", "ANATOMY", 53, 66], ["intraabdominal", "ANATOMY", 90, 104], ["viscus", "ANATOMY", 202, 208], ["gallbladder", "ANATOMY", 210, 221], ["colon", "ANATOMY", 223, 228], ["peptic ulcer", "ANATOMY", 233, 245], ["abdominal", "ANATOMY", 272, 281], ["ascitic", "ANATOMY", 406, 413], ["infection", "DISEASE", 36, 45], ["peritonitis", "DISEASE", 173, 184], ["ruptured viscus -gallbladder, colon, or peptic ulcer", "DISEASE", 193, 245], ["Bacterial Peritonitis", "DISEASE", 323, 344], ["ascitic fluid", "ORGANISM_SUBSTANCE", 53, 66], ["gallbladder", "ORGAN", 210, 221], ["colon", "ORGAN", 223, 228], ["peptic ulcer", "PATHOLOGICAL_FORMATION", 233, 245], ["abdominal", "ORGANISM_SUBDIVISION", 272, 281], ["SBP", "PROBLEM", 11, 14], ["infection in the ascitic fluid", "PROBLEM", 36, 66], ["an intraabdominal surgically treatable source", "PROBLEM", 87, 132], ["secondary bacterial peritonitis", "PROBLEM", 153, 184], ["a ruptured viscus", "PROBLEM", 191, 208], ["gallbladder, colon", "PROBLEM", 210, 228], ["peptic ulcer", "PROBLEM", 233, 245], ["abdominal imaging", "TEST", 272, 289], ["Spontaneous Bacterial Peritonitis", "PROBLEM", 311, 344], ["a diagnostic ascitic tap", "TREATMENT", 393, 417], ["SBP", "OBSERVATION", 11, 14], ["infection", "OBSERVATION", 36, 45], ["ascitic", "ANATOMY", 53, 60], ["fluid", "OBSERVATION", 61, 66], ["without evidence of", "UNCERTAINTY", 67, 86], ["intraabdominal", "ANATOMY", 90, 104], ["surgically", "OBSERVATION", 105, 115], ["possibility of", "UNCERTAINTY", 138, 152], ["secondary", "OBSERVATION_MODIFIER", 153, 162], ["bacterial", "OBSERVATION_MODIFIER", 163, 172], ["peritonitis", "OBSERVATION", 173, 184], ["ruptured", "OBSERVATION_MODIFIER", 193, 201], ["viscus", "OBSERVATION", 202, 208], ["gallbladder", "ANATOMY", 210, 221], ["colon", "ANATOMY", 223, 228], ["peptic", "OBSERVATION_MODIFIER", 233, 239], ["ulcer", "OBSERVATION", 240, 245], ["Bacterial", "OBSERVATION_MODIFIER", 323, 332], ["Peritonitis", "OBSERVATION", 333, 344]]], ["Despite the thrombocytopenia and elevated INR, she does not need blood products prior to the tap.", [["blood", "ANATOMY", 65, 70], ["thrombocytopenia", "DISEASE", 12, 28], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["INR", "PROTEIN", 42, 45], ["the thrombocytopenia", "PROBLEM", 8, 28], ["elevated INR", "PROBLEM", 33, 45], ["blood products", "TREATMENT", 65, 79], ["the tap", "TREATMENT", 89, 96], ["thrombocytopenia", "OBSERVATION", 12, 28], ["elevated", "OBSERVATION_MODIFIER", 33, 41], ["INR", "OBSERVATION", 42, 45]]], ["Several studies have documented that a tap in this situation is very safe and guidelines from the AASLD do not recommend prophylactic platelet or plasma/cryoprecipitate transfusion.", [["platelet", "ANATOMY", 134, 142], ["plasma", "ANATOMY", 146, 152], ["cryoprecipitate", "ANATOMY", 153, 168], ["platelet", "CELL", 134, 142], ["plasma", "ORGANISM_SUBSTANCE", 146, 152], ["cryoprecipitate", "ORGANISM_SUBSTANCE", 153, 168], ["Several studies", "TEST", 0, 15], ["a tap", "TREATMENT", 37, 42], ["prophylactic platelet", "TREATMENT", 121, 142], ["plasma/cryoprecipitate transfusion", "TREATMENT", 146, 180]]], ["Apart from the tap, blood cultures and a sepsis workup are warranted, and abdominal imaging with ultrasound would not be unreasonable.Answer: Spontaneous Bacterial Peritonitis (SBP)The ascitic tap should be performed at the bedside, and antibiotics can be started while waiting for the result if the suspicion for SBP is high (as is the case in this patient).", [["blood cultures", "ANATOMY", 20, 34], ["abdominal", "ANATOMY", 74, 83], ["ascitic", "ANATOMY", 185, 192], ["sepsis", "DISEASE", 41, 47], ["Bacterial Peritonitis", "DISEASE", 154, 175], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["abdominal", "ORGANISM_SUBDIVISION", 74, 83], ["patient", "ORGANISM", 350, 357], ["patient", "SPECIES", 350, 357], ["the tap", "TEST", 11, 18], ["blood cultures", "TEST", 20, 34], ["a sepsis workup", "TEST", 39, 54], ["abdominal imaging", "TEST", 74, 91], ["ultrasound", "TEST", 97, 107], ["Spontaneous Bacterial Peritonitis", "PROBLEM", 142, 175], ["SBP", "TEST", 177, 180], ["The ascitic tap", "TREATMENT", 181, 196], ["antibiotics", "TREATMENT", 237, 248], ["SBP", "TEST", 314, 317], ["abdominal", "ANATOMY", 74, 83], ["Bacterial", "OBSERVATION_MODIFIER", 154, 163], ["Peritonitis", "OBSERVATION", 164, 175], ["ascitic", "ANATOMY", 185, 192]]], ["The diagnosis of SBP is made on a positive culture and an elevated absolute polymorphonuclear leucocyte (PMN) cell count of >250 cells/mm 3 .", [["polymorphonuclear leucocyte", "ANATOMY", 76, 103], ["PMN) cell", "ANATOMY", 105, 114], ["cells", "ANATOMY", 129, 134], ["polymorphonuclear leucocyte", "CELL", 76, 103], ["PMN) cell", "CELL", 105, 114], ["polymorphonuclear leucocyte", "CELL_TYPE", 76, 103], ["PMN", "CELL_TYPE", 105, 108], ["SBP", "PROBLEM", 17, 20], ["a positive culture", "PROBLEM", 32, 50], ["an elevated absolute polymorphonuclear leucocyte", "PROBLEM", 55, 103], ["PMN", "TEST", 105, 108], ["cell count", "TEST", 110, 120], ["elevated", "OBSERVATION_MODIFIER", 58, 66], ["absolute polymorphonuclear leucocyte", "OBSERVATION", 67, 103]]], ["A small amount of the fluid should be sent for chemistry to determine the albumin content.", [["fluid", "ORGANISM_SUBSTANCE", 22, 27], ["albumin", "GENE_OR_GENE_PRODUCT", 74, 81], ["albumin", "PROTEIN", 74, 81], ["A small amount of the fluid", "PROBLEM", 0, 27], ["chemistry", "TEST", 47, 56], ["the albumin content", "TEST", 70, 89], ["small", "OBSERVATION_MODIFIER", 2, 7], ["amount", "OBSERVATION_MODIFIER", 8, 14], ["fluid", "OBSERVATION", 22, 27]]], ["In this case, the difference between the serum albumin and ascites albumin (serum ascites albumin gradient or SAAG) was 1.4 g/dl, indicative of portal hypertension.", [["serum", "ANATOMY", 41, 46], ["ascites", "ANATOMY", 59, 66], ["serum ascites", "ANATOMY", 76, 89], ["portal", "ANATOMY", 144, 150], ["ascites", "DISEASE", 59, 66], ["portal hypertension", "DISEASE", 144, 163], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["albumin", "GENE_OR_GENE_PRODUCT", 47, 54], ["albumin", "GENE_OR_GENE_PRODUCT", 67, 74], ["serum", "ORGANISM_SUBSTANCE", 76, 81], ["albumin", "GENE_OR_GENE_PRODUCT", 90, 97], ["portal", "MULTI-TISSUE_STRUCTURE", 144, 150], ["serum albumin", "PROTEIN", 41, 54], ["ascites albumin", "PROTEIN", 59, 74], ["the serum albumin", "TEST", 37, 54], ["ascites albumin", "TEST", 59, 74], ["serum ascites albumin gradient", "TEST", 76, 106], ["SAAG", "TEST", 110, 114], ["portal hypertension", "PROBLEM", 144, 163], ["ascites", "OBSERVATION", 59, 66], ["indicative of", "UNCERTAINTY", 130, 143], ["portal", "ANATOMY", 144, 150], ["hypertension", "OBSERVATION", 151, 163]]], ["Another 10 ml should be inoculated into blood culture bottles at the bedside (rather than sent to the laboratory in a syringe since this reduces the sensitivity).", [["blood", "ANATOMY", 40, 45], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["blood culture", "TEST", 40, 53]]], ["The gram stain can be ordered but has a very low sensitivity in determining if bacteria are present.Answer: Spontaneous Bacterial Peritonitis (SBP)The cell count should be available within 1-2 h.", [["cell", "ANATOMY", 151, 155], ["Bacterial Peritonitis", "DISEASE", 120, 141], ["cell", "CELL", 151, 155], ["The gram stain", "TEST", 0, 14], ["a very low sensitivity", "PROBLEM", 38, 60], ["bacteria", "PROBLEM", 79, 87], ["Spontaneous Bacterial Peritonitis", "PROBLEM", 108, 141], ["SBP", "TEST", 143, 146], ["The cell count", "TEST", 147, 161], ["Bacterial", "OBSERVATION_MODIFIER", 120, 129], ["Peritonitis", "OBSERVATION", 130, 141]]], ["In this case, the tap was bloody and needs to be corrected by subtracting one PMN for every 250 red cells.", [["PMN", "ANATOMY", 78, 81], ["red cells", "ANATOMY", 96, 105], ["PMN", "CELL", 78, 81], ["cells", "CELL", 100, 105], ["PMN", "CELL_TYPE", 78, 81], ["250 red cells", "CELL_LINE", 92, 105], ["the tap", "TREATMENT", 14, 21], ["bloody", "PROBLEM", 26, 32], ["bloody", "OBSERVATION", 26, 32]]], ["The PMN count was 300, positive for SBP.", [["PMN", "ANATOMY", 4, 7], ["PMN", "CELL", 4, 7], ["PMN", "CELL_TYPE", 4, 7], ["SBP", "PROTEIN", 36, 39], ["The PMN count", "TEST", 0, 13], ["SBP", "TEST", 36, 39]]], ["The choice of antibiotic should cover gut organisms, as well as streptococcal species and the possibility of staphylococcal infection and a third generation cephalosporin such as cefotaxime 2 g intravenous every 8 h is reasonable, with 5-7 days of treatment usually sufficient.", [["gut", "ANATOMY", 38, 41], ["staphylococcal infection", "DISEASE", 109, 133], ["cephalosporin", "CHEMICAL", 157, 170], ["cefotaxime", "CHEMICAL", 179, 189], ["cephalosporin", "CHEMICAL", 157, 170], ["cefotaxime", "CHEMICAL", 179, 189], ["gut", "ORGANISM_SUBDIVISION", 38, 41], ["cephalosporin", "SIMPLE_CHEMICAL", 157, 170], ["cefotaxime", "SIMPLE_CHEMICAL", 179, 189], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 194, 205], ["staphylococcal", "SPECIES", 109, 123], ["antibiotic", "TREATMENT", 14, 24], ["gut organisms", "PROBLEM", 38, 51], ["streptococcal species", "PROBLEM", 64, 85], ["staphylococcal infection", "PROBLEM", 109, 133], ["a third generation cephalosporin", "TREATMENT", 138, 170], ["cefotaxime", "TREATMENT", 179, 189], ["treatment", "TREATMENT", 248, 257], ["staphylococcal", "OBSERVATION_MODIFIER", 109, 123], ["infection", "OBSERVATION", 124, 133]]], ["We also give intravenous albumin (1.5 g/kg of body weight on day 1 and 1 g/kg of body weight on day 3) on the basis of a study that showed very low mortality in SBP patients treated in this manner.Answer: Spontaneous Bacterial Peritonitis (SBP)There are several SBP variants based on cell count and culture.", [["intravenous", "ANATOMY", 13, 24], ["body", "ANATOMY", 46, 50], ["body", "ANATOMY", 81, 85], ["cell", "ANATOMY", 284, 288], ["Bacterial Peritonitis", "DISEASE", 217, 238], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 24], ["albumin", "GENE_OR_GENE_PRODUCT", 25, 32], ["body", "ORGANISM_SUBDIVISION", 46, 50], ["body", "ORGANISM_SUBDIVISION", 81, 85], ["patients", "ORGANISM", 165, 173], ["cell", "CELL", 284, 288], ["patients", "SPECIES", 165, 173], ["intravenous albumin", "TREATMENT", 13, 32], ["a study", "TEST", 119, 126], ["very low mortality", "PROBLEM", 139, 157], ["Spontaneous Bacterial Peritonitis", "PROBLEM", 205, 238], ["several SBP variants", "PROBLEM", 254, 274], ["cell count", "TEST", 284, 294], ["culture", "TEST", 299, 306], ["Bacterial", "OBSERVATION_MODIFIER", 217, 226], ["Peritonitis", "OBSERVATION", 227, 238], ["SBP variants", "OBSERVATION", 262, 274]]], ["In this patient, the ascitic fluid culture was negative, so she falls into the category of culture negative neutrocytic ascites, which may be related to poor culture technique.", [["ascitic fluid", "ANATOMY", 21, 34], ["neutrocytic ascites", "ANATOMY", 108, 127], ["ascites", "DISEASE", 120, 127], ["patient", "ORGANISM", 8, 15], ["ascitic fluid", "ORGANISM_SUBSTANCE", 21, 34], ["patient", "SPECIES", 8, 15], ["the ascitic fluid culture", "TEST", 17, 42], ["culture", "TEST", 91, 98], ["neutrocytic ascites", "PROBLEM", 108, 127], ["poor culture technique", "PROBLEM", 153, 175], ["ascitic", "ANATOMY", 21, 28], ["neutrocytic", "OBSERVATION_MODIFIER", 108, 119], ["ascites", "OBSERVATION", 120, 127], ["may be related to", "UNCERTAINTY", 135, 152]]], ["The opposite variant is monomicrobial, nonneutrocytic bacterascites where the culture is positive but the PMN count is <250.", [["monomicrobial", "ANATOMY", 24, 37], ["PMN", "ANATOMY", 106, 109], ["PMN", "CELL", 106, 109], ["monomicrobial", "PROBLEM", 24, 37], ["nonneutrocytic bacterascites", "PROBLEM", 39, 67], ["the culture", "TEST", 74, 85], ["the PMN count", "TEST", 102, 115], ["monomicrobial", "OBSERVATION", 24, 37], ["nonneutrocytic bacterascites", "OBSERVATION", 39, 67]]], ["Both should be treated as SBP, particularly if the clinical setting is convincing.", [["SBP", "TEST", 26, 29]]], ["It is also possible to get polymicrobial bacterascites from trauma to the bowel during paracentesis.", [["bowel", "ANATOMY", 74, 79], ["bacterascites", "DISEASE", 41, 54], ["trauma", "DISEASE", 60, 66], ["bowel", "ORGAN", 74, 79], ["polymicrobial bacterascites", "PROBLEM", 27, 54], ["trauma to the bowel", "PROBLEM", 60, 79], ["paracentesis", "TREATMENT", 87, 99], ["also possible", "UNCERTAINTY", 6, 19], ["polymicrobial", "OBSERVATION_MODIFIER", 27, 40], ["bacterascites", "OBSERVATION", 41, 54], ["trauma", "OBSERVATION", 60, 66], ["bowel", "ANATOMY", 74, 79], ["paracentesis", "OBSERVATION", 87, 99]]]], "76b09383740476d96a3e63ae0f265e2897e9a194": [["INTRODUCTIONMankind has held a centuries-long fascination with the cat.", [["cat", "ORGANISM", 67, 70]]], ["The earliest arch eological records that have been linked to the domestication of Felis catus date to approximately 9500 years ago from Cyprus, 1 with recent molecular genetic analyses in our laboratory suggesting a Middle Eastern origin for domestication (C. Driscoll et al., unpublished observations) .", [["Felis catus", "ORGANISM", 82, 93], ["Felis catus", "SPECIES", 82, 93], ["Felis catus", "SPECIES", 82, 93], ["recent molecular genetic analyses", "PROBLEM", 151, 184], ["arch", "ANATOMY", 13, 17], ["Middle", "ANATOMY_MODIFIER", 216, 222]]], ["Currently the most numerous of companion animals, numbering close to 90 million in households across the United States (http://www.appma.org/ press_industrytrends.asp), the cat enjoys a medical surveillance second only to the dog and humankind.", [["cat", "ORGANISM", 173, 176], ["dog", "ORGANISM", 226, 229], ["dog", "SPECIES", 226, 229], ["most numerous", "OBSERVATION_MODIFIER", 14, 27]]], ["In this chapter we review the promise of the cat as an important model for the advancement of human hereditary and infectious disease and the genomic tools that have been developed for the identification, and characterization of genes of interest.INTRODUCTIONFor many years we have sought to characterize genetic organization in the domestic cat and to develop genomic resources that establish F. catus as a useful animal model for human hereditary disease analogues, neoplasia, genetic factors associated with host response to infectious disease, and mammalian genome evolution.", [["neoplasia", "ANATOMY", 468, 477], ["hereditary and infectious disease", "DISEASE", 100, 133], ["hereditary disease", "DISEASE", 438, 456], ["neoplasia", "DISEASE", 468, 477], ["infectious disease", "DISEASE", 528, 546], ["cat", "ORGANISM", 45, 48], ["human", "ORGANISM", 94, 99], ["cat", "ORGANISM", 342, 345], ["F. catus", "ORGANISM", 394, 402], ["human", "ORGANISM", 432, 437], ["neoplasia", "CANCER", 468, 477], ["human", "SPECIES", 94, 99], ["cat", "SPECIES", 342, 345], ["human", "SPECIES", 432, 437], ["human", "SPECIES", 94, 99], ["F. catus", "SPECIES", 394, 402], ["human", "SPECIES", 432, 437], ["human hereditary and infectious disease", "PROBLEM", 94, 133], ["the genomic tools", "TEST", 138, 155], ["the identification", "TEST", 185, 203], ["human hereditary disease analogues", "PROBLEM", 432, 466], ["neoplasia", "PROBLEM", 468, 477], ["genetic factors", "PROBLEM", 479, 494], ["infectious disease", "PROBLEM", 528, 546], ["infectious", "OBSERVATION", 115, 125], ["infectious", "OBSERVATION", 528, 538], ["mammalian genome", "OBSERVATION", 552, 568]]], ["2, 3 To identify genes associated with inherited pathologies that mirror inherited human conditions and interesting pheno-types in the domestic cat, we have produced genetic maps of sufficient density to allow linkage or association-based mapping exercises.", [["inherited pathologies", "DISEASE", 39, 60], ["human", "ORGANISM", 83, 88], ["cat", "ORGANISM", 144, 147], ["human", "SPECIES", 83, 88], ["cat", "SPECIES", 144, 147], ["human", "SPECIES", 83, 88], ["inherited pathologies", "PROBLEM", 39, 60], ["mirror inherited human conditions", "PROBLEM", 66, 99], ["based mapping exercises", "TREATMENT", 233, 256]]], ["[4] [5] [6] [7] [8] [9] [10] [11] The first genetic map of the cat, a physical map generated from a somatic-cell hybrid panel, demonstrated the cat's high level of conserved synteny with the human genome, which offered much promise for the future application of comparative genomic inference in felid mapping and association exercises.", [["[4] [5] [6] [7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 0, 33], ["cat", "ORGANISM", 63, 66], ["cat", "ORGANISM", 144, 147], ["human", "ORGANISM", 191, 196], ["somatic-cell hybrid panel", "CELL_LINE", 100, 125], ["human genome", "DNA", 191, 203], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 191, 196], ["the cat", "TEST", 59, 66], ["a physical map", "TEST", 68, 82], ["a somatic-cell hybrid panel", "TEST", 98, 125], ["the human genome", "TREATMENT", 187, 203]]], ["12 Several radiation hybrid (RH) and genetic linkage (GL) maps have since been published.", [["Several radiation hybrid (RH", "TREATMENT", 3, 31], ["genetic linkage (GL) maps", "TREATMENT", 37, 62], ["radiation hybrid", "OBSERVATION", 11, 27]]], ["[4] [5] [6] [7] [8] [9] 11, 13, 14THE DOMESTIC CAT RADIATION HYBRID MAPAlthough previous versions of the cat gene map, based on somatic cell hybrid and ZOO FISH analysis, 15 ,16 revealed considerable conservation of synteny with the human genome, these maps provided no knowledge of gene order or intrachromosomal genome rearrangement between the two species, information that is critical to applying comparative map inference to gene dis covery in gene-poor model systems.", [["cell", "ANATOMY", 136, 140], ["[4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 0, 23], ["cat", "ORGANISM", 105, 108], ["somatic cell", "CELL", 128, 140], ["human", "ORGANISM", 233, 238], ["cat gene map", "DNA", 105, 117], ["human genome", "DNA", 233, 245], ["human", "SPECIES", 233, 238], ["human", "SPECIES", 233, 238], ["the cat gene map", "TEST", 101, 117], ["somatic cell hybrid", "TEST", 128, 147], ["ZOO FISH analysis", "TEST", 152, 169], ["the human genome", "TREATMENT", 229, 245], ["these maps", "TEST", 247, 257], ["intrachromosomal genome rearrangement", "PROBLEM", 297, 334], ["genome rearrangement", "OBSERVATION", 314, 334]]], ["Radiation hybrid (RH) mapping has emerged as a powerful tool for constructing moderate-to high-density gene maps in vertebrates by obviating the need to identify interspecific polymorphisms critical for the generation of genetic linkage maps.", [["Radiation hybrid (RH) mapping", "TREATMENT", 0, 29], ["interspecific polymorphisms", "PROBLEM", 162, 189]]], ["7 The most recent RH map of the cat 8 includes 1793 markers: 662 coding loci, 335 selected markers derived from the cat 2X whole genome sequence targeted at breakpoints in conserved synteny between human and cat, and 797 short tandem repeat (STR) loci.", [["cat", "ORGANISM", 32, 35], ["human", "ORGANISM", 198, 203], ["cat 8", "DNA", 32, 37], ["cat 2X whole genome sequence", "DNA", 116, 144], ["human and cat, and 797 short tandem repeat (STR) loci", "DNA", 198, 251], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 198, 203], ["The most recent RH map", "TEST", 2, 24], ["coding loci", "TEST", 65, 76], ["selected markers", "TEST", 82, 98], ["the cat 2X whole genome sequence", "TREATMENT", 112, 144], ["short tandem repeat (STR) loci", "PROBLEM", 221, 251]]], ["The strategy used in developing the current RH map was to target gaps in the feline-human comparative map, and to provide more definition in breakpoints in regions of conserved synteny between cat and human.", [["feline", "ORGANISM", 77, 83], ["human", "ORGANISM", 84, 89], ["cat", "ORGANISM", 193, 196], ["human", "ORGANISM", 201, 206], ["RH map", "DNA", 44, 50], ["feline-human comparative map", "DNA", 77, 105], ["human", "SPECIES", 84, 89], ["cat", "SPECIES", 193, 196], ["human", "SPECIES", 201, 206], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 201, 206], ["the current RH map", "TEST", 32, 50]]], ["The 1793 markers cover the length of the 18 feline autosomes and the X chromosome at an average spacing of one marker every 1.5 Mb (megabase), with fairly uniform marker density.", [["X chromosome", "ANATOMY", 69, 81], ["feline", "ORGANISM", 44, 50], ["autosomes", "CELLULAR_COMPONENT", 51, 60], ["X chromosome", "CELLULAR_COMPONENT", 69, 81], ["1793 markers", "DNA", 4, 16], ["18 feline autosomes", "DNA", 41, 60], ["X chromosome", "DNA", 69, 81], ["the 18 feline autosomes", "TREATMENT", 37, 60], ["the X chromosome", "TREATMENT", 65, 81], ["uniform", "OBSERVATION_MODIFIER", 155, 162], ["marker density", "OBSERVATION", 163, 177]]], ["8 An enhanced comparative map demonstrates that the current map provides 86% and 85% comparative coverage of the human and canine genomes, respectively.", [["human", "ORGANISM", 113, 118], ["canine", "ORGANISM", 123, 129], ["human and canine genomes", "DNA", 113, 137], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["canine", "SPECIES", 123, 129], ["the current map", "TEST", 48, 63]]], ["8 Ninety-six percent of the 1793 cat markers have identifi able orthologues in the canine and human genome sequences, providing a rich comparative tool, which is critical in linkage mapping exercises for the identification of genes controlling feline phenotypes.", [["cat", "ORGANISM", 33, 36], ["canine", "ORGANISM", 83, 89], ["human", "ORGANISM", 94, 99], ["feline", "ORGANISM", 244, 250], ["canine and human genome sequences", "DNA", 83, 116], ["canine", "SPECIES", 83, 89], ["human", "SPECIES", 94, 99], ["canine", "SPECIES", 83, 89], ["human", "SPECIES", 94, 99], ["linkage mapping exercises", "TREATMENT", 174, 199], ["genes controlling feline phenotypes", "PROBLEM", 226, 261]]], ["Figure 25 -1 presents a graphic display of each cat chromosome and blocks of conserved syntenic order with the human and canine genomes.", [["chromosome", "ANATOMY", 52, 62], ["cat", "ORGANISM", 48, 51], ["chromosome", "CELLULAR_COMPONENT", 52, 62], ["human", "ORGANISM", 111, 116], ["canine", "ORGANISM", 121, 127], ["cat chromosome", "DNA", 48, 62], ["human and canine genomes", "DNA", 111, 135], ["human", "SPECIES", 111, 116], ["canine", "SPECIES", 121, 127], ["human", "SPECIES", 111, 116], ["canine", "SPECIES", 121, 127]]], ["8 One hundred and fifty-two cat-human and 134 cat-dog homologous synteny blocks were identified.", [["cat-human", "CANCER", 28, 37], ["cat", "ORGANISM", 46, 49], ["dog", "ORGANISM", 50, 53], ["cat-human and 134 cat-dog homologous synteny blocks", "DNA", 28, 79], ["cat-dog", "SPECIES", 46, 53], ["134 cat-dog homologous synteny blocks", "TREATMENT", 42, 79]]], ["Alignment of cat, dog, and human chromosomes demonstrated different patterns of chromosomal rearrangement with a marked increase in interchromosomal rearrangements relative to human in the canid lineage (89% of all rearrangements), as opposed to the more frequent intrachromosomal rearrangements in the felid lineage (95% of all rearrangements) since divergence from a common carnivore ancestor 55 My ago.THE DOMESTIC CAT RADIATION HYBRID MAPWith an average spacing of 1 marker every 1.5 Mb in the feline euchromatic sequence, the map provided a solid framework for the chromosomal assignment of feline contigs and scaffolds during assembly of the cat genome assembly, 17 and served as a comparative tool to aid in the identification of genes controlling feline phenotypes.THE DOMESTIC CAT GENETIC LINKAGE MAPAs a complement to the RH map of the cat, a third generation linkage map of 625 STRs is currently nearing completion.", [["chromosomes", "ANATOMY", 33, 44], ["chromosomal", "ANATOMY", 80, 91], ["canid lineage", "ANATOMY", 189, 202], ["felid lineage", "ANATOMY", 303, 316], ["chromosomal", "ANATOMY", 570, 581], ["cat", "ORGANISM", 13, 16], ["dog", "ORGANISM", 18, 21], ["human", "ORGANISM", 27, 32], ["chromosomal", "CELLULAR_COMPONENT", 80, 91], ["interchromosomal", "CELLULAR_COMPONENT", 132, 148], ["human", "ORGANISM", 176, 181], ["canid lineage", "CELL", 189, 202], ["felid lineage", "CELL", 303, 316], ["feline", "ORGANISM", 498, 504], ["chromosomal", "CELLULAR_COMPONENT", 570, 581], ["feline", "ORGANISM", 596, 602], ["cat", "ORGANISM", 648, 651], ["feline", "ORGANISM", 755, 761], ["cat", "ORGANISM", 846, 849], ["cat, dog, and human chromosomes", "DNA", 13, 44], ["canid lineage", "CELL_TYPE", 189, 202], ["felid lineage", "CELL_TYPE", 303, 316], ["DOMESTIC CAT RADIATION HYBRID MAPWith", "DNA", 409, 446], ["feline euchromatic sequence", "DNA", 498, 525], ["feline contigs", "DNA", 596, 610], ["cat genome", "DNA", 648, 658], ["DOMESTIC CAT GENETIC LINKAGE MAPAs", "DNA", 777, 811], ["RH map", "DNA", 832, 838], ["625 STRs", "DNA", 885, 893], ["dog", "SPECIES", 18, 21], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 176, 181], ["chromosomal rearrangement", "PROBLEM", 80, 105], ["a marked increase in interchromosomal rearrangements", "PROBLEM", 111, 163], ["a solid framework", "TREATMENT", 544, 561], ["feline contigs", "TREATMENT", 596, 610], ["scaffolds", "TREATMENT", 615, 624], ["genes controlling feline phenotypes", "PROBLEM", 737, 772], ["the RH map", "TEST", 828, 838], ["a third generation linkage map", "TREATMENT", 851, 881], ["chromosomal rearrangement", "OBSERVATION", 80, 105], ["marked", "OBSERVATION_MODIFIER", 113, 119], ["increase", "OBSERVATION_MODIFIER", 120, 128], ["interchromosomal rearrangements", "OBSERVATION", 132, 163], ["intrachromosomal rearrangements", "OBSERVATION", 264, 295], ["felid lineage", "OBSERVATION", 303, 316], ["RADIATION HYBRID", "OBSERVATION", 422, 438], ["average", "OBSERVATION_MODIFIER", 450, 457], ["spacing", "OBSERVATION_MODIFIER", 458, 465]]], ["The map has been generated in a large multigeneration domestic cat pedigree (n = 483 informative meioses).", [["cat", "ORGANISM", 63, 66], ["The map", "TEST", 0, 7], ["large", "OBSERVATION_MODIFIER", 32, 37]]], ["18 Previous first-and second-generation linkage maps of the cat were generated in a multigeneration interspecies pedigree generated between the domestic cat and the Asian leopard cat, Prionailurus bengalensis, 7 to facilitate the mapping and integration of Type I (coding) and Type II (polymorphic STR) loci.", [["cat", "ORGANISM", 60, 63], ["cat", "ORGANISM", 153, 156], ["cat", "ORGANISM", 179, 182], ["Prionailurus bengalensis", "ORGANISM", 184, 208], ["Type I (coding)", "GENE_OR_GENE_PRODUCT", 257, 272], ["Type II", "GENE_OR_GENE_PRODUCT", 277, 284], ["Type I (coding) and Type II (polymorphic STR) loci", "DNA", 257, 307], ["cat", "SPECIES", 153, 156], ["cat", "SPECIES", 179, 182], ["Prionailurus bengalensis", "SPECIES", 184, 208], ["Asian leopard cat", "SPECIES", 165, 182], ["Prionailurus bengalensis", "SPECIES", 184, 208], ["Prionailurus bengalensis", "TREATMENT", 184, 208], ["the mapping", "TEST", 226, 237], ["Type I (coding)", "PROBLEM", 257, 272], ["Type II (polymorphic STR) loci", "PROBLEM", 277, 307]]], ["7 The current map, which spans all 18 autosomes with single linkage groups, has twice the STR density of previous maps, providing a 5-cM resolution.", [["autosomes", "DNA", 38, 47], ["The current map", "TEST", 2, 17], ["previous maps", "TEST", 105, 118], ["a 5-cM resolution", "TREATMENT", 130, 147], ["5-cM", "OBSERVATION_MODIFIER", 132, 136]]], ["There is also greatly expanded coverage of the X chromosome, with some 75 STR loci.", [["X chromosome", "ANATOMY", 47, 59], ["X chromosome", "CELLULAR_COMPONENT", 47, 59], ["X chromosome", "DNA", 47, 59], ["75 STR loci", "DNA", 71, 82], ["some 75 STR loci", "PROBLEM", 66, 82], ["greatly", "OBSERVATION_MODIFIER", 14, 21], ["expanded", "OBSERVATION_MODIFIER", 22, 30], ["coverage", "OBSERVATION_MODIFIER", 31, 39], ["X chromosome", "OBSERVATION_MODIFIER", 47, 59], ["STR loci", "OBSERVATION", 74, 82]]], ["Marker order between the current generation RH and GL maps is highly concordant.", [["GL maps", "DNA", 51, 58], ["GL maps", "TEST", 51, 58], ["concordant", "OBSERVATION", 69, 79]]], ["8 Approximately 85% of the STRs are mapped in the most current RH map of the cat, 8 which provides reference and integration with Type I loci.", [["cat", "ORGANISM", 77, 80], ["Type I loci", "DNA", 130, 141], ["the STRs", "TEST", 23, 31], ["Type I loci", "PROBLEM", 130, 141]]], ["Whereas the third-generation linkage map is composed entirely of STR loci, the sequence homology of extended genomic regions adjacent to the STR loci in the cat 2X whole genome sequence, 17 to the dog's homologous region, 19 has enabled us to obtain identifiable orthologues in the canine and human genome sequences for over 95% of the STRs.", [["cat 2X", "ORGANISM", 157, 163], ["canine", "ORGANISM", 282, 288], ["human", "ORGANISM", 293, 298], ["third-generation linkage map", "DNA", 12, 40], ["STR loci", "DNA", 65, 73], ["extended genomic regions", "DNA", 100, 124], ["STR loci", "DNA", 141, 149], ["cat 2X whole genome sequence", "DNA", 157, 185], ["dog's homologous region", "DNA", 197, 220], ["canine and human genome sequences", "DNA", 282, 315], ["STRs", "DNA", 336, 340], ["dog", "SPECIES", 197, 200], ["canine", "SPECIES", 282, 288], ["human", "SPECIES", 293, 298], ["canine", "SPECIES", 282, 288], ["human", "SPECIES", 293, 298], ["STR loci", "PROBLEM", 65, 73], ["the STRs", "TEST", 332, 340]]], ["Thus, practically every STR acts as a \"virtual\" Type 1 locus, with both comparative anchoring and linkage map utility.", [["STR", "CHEMICAL", 24, 27], ["STR", "DNA", 24, 27], ["Type 1 locus", "DNA", 48, 60]]], ["Combined with the cat RH map, these genomic tools provide us with the comparative reference to other mammalian genomes critical for linkage and association mapping.THE DOMESTIC CAT WHOLE GENOME (2X) SEQUENCEThe domestic cat is one of 26 mammalian species endorsed by the National Human Genome Research Institute (NHGRI) Human Genome Annotation committee for a \"light\" 2-fold whole genome sequence, largely to capture the pattern of genome variation and divergence that characterizes the mammalian radiations (http:// www.hgsc.bcm.tmc.edu/projects/bovine/, http://www.broad.mit. edu/mammals/).", [["cat", "ORGANISM", 220, 223], ["Human", "ORGANISM", 280, 285], ["Human", "ORGANISM", 320, 325], ["cat RH map", "DNA", 18, 28], ["mammalian genomes", "DNA", 101, 118], ["cat", "SPECIES", 220, 223], ["Human", "SPECIES", 280, 285], ["Human", "SPECIES", 320, 325], ["the cat RH map", "TEST", 14, 28], ["a \"light\" 2-fold whole genome sequence", "TREATMENT", 358, 396], ["genome variation", "PROBLEM", 432, 448], ["genome variation", "OBSERVATION", 432, 448]]], ["Although light genome coverage provides limited sequence representation, (\u223c80%), 20 one of the rationales for these light genome sequences included \"enhancing opportunities for research on species providing human medical models.\"", [["human", "ORGANISM", 207, 212], ["light genome sequences", "DNA", 116, 138], ["human", "SPECIES", 207, 212], ["human", "SPECIES", 207, 212], ["light genome coverage", "TREATMENT", 9, 30], ["these light genome sequences", "TEST", 110, 138]]], ["The 2-fold assembly of the domestic cat genome has recently been completed for a female Abyssinian cat, \"Cinnamon,\" 17 and a 7X whole genome sequencing effort is planned in the near future.THE DOMESTIC CAT WHOLE GENOME (2X) SEQUENCEA total of 9,161,674 reads were assembled to 817,956 contigs, covering 1.642 Gb with an N50 (i.e., half of the sequenced base pairs are in contigs <N50) contig length of 2378 bp.", [["cat", "ORGANISM", 36, 39], ["cat", "ORGANISM", 99, 102], ["domestic cat genome", "DNA", 27, 46], ["817,956 contigs", "DNA", 277, 292], ["N50", "DNA", 320, 323], ["sequenced base pairs", "DNA", 343, 363], ["cat", "SPECIES", 99, 102], ["Gb", "TEST", 309, 311], ["an N50", "TEST", 317, 323], ["contig length", "TEST", 385, 398], ["bp", "TEST", 407, 409]]], ["Assembled supercontigs (N = 217,790) had an N50 length of 117 kb 17 (http:// hosted. abcc.ncifcrf.gov/cgi-gin/gbrowse/cat/).", [["N50 length", "DNA", 44, 54], ["117 kb 17", "DNA", 58, 67], ["an N50 length", "TEST", 41, 54], ["kb", "TEST", 62, 64]]], ["The estimated size of the genome was 2.7 Gb and the genome coverage was approximately 2-fold, predicting an average inclusion of 80-85% of the eukaryotic genome sequence.", [["genome", "CELLULAR_COMPONENT", 26, 32], ["eukaryotic genome sequence", "DNA", 143, 169], ["the genome coverage", "TEST", 48, 67], ["size", "OBSERVATION_MODIFIER", 14, 18], ["genome", "OBSERVATION_MODIFIER", 26, 32], ["2.7 Gb", "OBSERVATION_MODIFIER", 37, 43], ["genome", "OBSERVATION_MODIFIER", 52, 58], ["coverage", "OBSERVATION_MODIFIER", 59, 67], ["average", "OBSERVATION_MODIFIER", 108, 115], ["eukaryotic genome", "OBSERVATION", 143, 160]]], ["21 Feline coding genes were identified using a comparative approach based upon sequence homology and syntenic orthology of neighboring gene homologues in the genomes of six index mammal species (human, chimp, mouse, rat, cow, and dog).", [["Feline", "ORGANISM", 3, 9], ["human", "ORGANISM", 195, 200], ["chimp", "ORGANISM", 202, 207], ["mouse", "ORGANISM", 209, 214], ["rat", "ORGANISM", 216, 219], ["cow", "ORGANISM", 221, 224], ["dog", "ORGANISM", 230, 233], ["Feline coding genes", "DNA", 3, 22], ["neighboring gene homologues", "DNA", 123, 150], ["human", "SPECIES", 195, 200], ["mouse", "SPECIES", 209, 214], ["rat", "SPECIES", 216, 219], ["cow", "SPECIES", 221, 224], ["dog", "SPECIES", 230, 233], ["human", "SPECIES", 195, 200], ["mouse", "SPECIES", 209, 214], ["rat", "SPECIES", 216, 219], ["cow", "SPECIES", 221, 224], ["a comparative approach", "TREATMENT", 45, 67]]], ["The results revealed nearly 21,080 feline genes plus 132,493 conserved sequence blocks (CSBs) used to build the gene map, 17 depending upon the framework RH map of 1794 ordered Type 1 markers.", [["feline", "ORGANISM", 35, 41], ["feline genes", "DNA", 35, 47], ["132,493 conserved sequence blocks", "DNA", 53, 86], ["CSBs", "DNA", 88, 92], ["1794 ordered Type 1 markers", "DNA", 164, 191], ["CSBs", "TEST", 88, 92], ["the framework RH map", "TEST", 140, 160]]], ["8 The 2X feline genome sequence detects 83% of human genes, 89% of chimp or cattle genes, and 92% of dog genes based upon sequence identity to approximately 1000 bp of reciprocal base match 17 between the cat sequence and the genome sequence of the six index mammals.THE DOMESTIC CAT WHOLE GENOME (2X) SEQUENCEA genome browser has been developed from the cat assembly, named Genome Annotation Region FIELD (GARFIELD), which provides a physical map of the 18 autosomes and the X chromosome, which can be inspected for sequence representation, including genes and the proportion of that gene available in the 2X cover, single nucleotide polymorphisms (SNPs), and STRs, which can be used in linkage and association mapping, and other genome features (http://ccr.cancer.gov/ labs/lab).", [["X chromosome", "ANATOMY", 476, 488], ["2X feline", "ORGANISM", 6, 15], ["human", "ORGANISM", 47, 52], ["chimp", "ORGANISM", 67, 72], ["cattle", "ORGANISM", 76, 82], ["dog", "ORGANISM", 101, 104], ["cat", "ORGANISM", 205, 208], ["cat", "ORGANISM", 355, 358], ["autosomes", "CELLULAR_COMPONENT", 458, 467], ["X chromosome", "CELLULAR_COMPONENT", 476, 488], ["2X feline genome sequence", "DNA", 6, 31], ["human genes", "DNA", 47, 58], ["chimp or cattle genes", "DNA", 67, 88], ["dog genes", "DNA", 101, 110], ["cat sequence", "DNA", 205, 217], ["DOMESTIC CAT WHOLE GENOME (2X) SEQUENCEA genome browser", "DNA", 271, 326], ["18 autosomes", "DNA", 455, 467], ["X chromosome", "DNA", 476, 488], ["2X cover", "DNA", 607, 615], ["SNPs", "DNA", 650, 654], ["STRs", "DNA", 661, 665], ["human", "SPECIES", 47, 52], ["cattle", "SPECIES", 76, 82], ["human", "SPECIES", 47, 52], ["cattle", "SPECIES", 76, 82], ["The 2X feline genome sequence", "TEST", 2, 31], ["human genes", "TEST", 47, 58], ["chimp", "TEST", 67, 72], ["the cat sequence", "TEST", 201, 217], ["a physical map", "TEST", 433, 447], ["the X chromosome", "TEST", 472, 488], ["sequence representation", "TEST", 517, 540], ["single nucleotide polymorphisms (SNPs)", "TREATMENT", 617, 655], ["STRs", "TREATMENT", 661, 665], ["association mapping", "TEST", 700, 719]]], ["FigureSINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS DEMONSTRATES POTENTIAL OF LINKAGE DISEQUILIBRIUM MAPPING IN CAT BREEDSA total of 421,000 SNP variants were identified in Cinnamon's sequence, representing an incidence of 1/600 bp.", [["SNP", "CHEMICAL", 135, 138], ["CAT BREEDSA total of 421,000 SNP variants", "DNA", 106, 147], ["Cinnamon's sequence", "DNA", 167, 186], ["FigureSINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS", "TEST", 0, 45], ["SNP variants", "PROBLEM", 135, 147], ["Cinnamon's sequence", "TEST", 167, 186], ["LINKAGE DISEQUILIBRIUM", "OBSERVATION", 72, 94]]], ["17 Approximately 43% of Cinnamon's genome was heterozygous and 57% homozygous, which was not unexpected in a breed cat that is also the member of a highly inbred pedigree for retinal atrophy.", [["retinal", "ANATOMY", 175, 182], ["retinal atrophy", "DISEASE", 175, 190], ["cat", "ORGANISM", 115, 118], ["retinal", "MULTI-TISSUE_STRUCTURE", 175, 182], ["Cinnamon's genome", "DNA", 24, 41], ["heterozygous", "PROBLEM", 46, 58], ["57% homozygous", "PROBLEM", 63, 77], ["retinal atrophy", "PROBLEM", 175, 190], ["43%", "OBSERVATION_MODIFIER", 17, 20], ["retinal", "ANATOMY", 175, 182], ["atrophy", "OBSERVATION", 183, 190]]], ["17, 22 Long stretches of alternating homozygous and heterozygous segments were observed ( Figure 25 -3), which represent the consequences of close inbreeding during the domestication process, and the more recent generation of fancy breeds and inbred disease pedigree.", [["alternating homozygous and heterozygous segments", "PROBLEM", 25, 73], ["fancy breeds", "PROBLEM", 226, 238], ["inbred disease pedigree", "PROBLEM", 243, 266], ["alternating homozygous", "OBSERVATION", 25, 47], ["heterozygous", "OBSERVATION", 52, 64], ["segments", "ANATOMY_MODIFIER", 65, 73]]], ["22 Similar patches of homozygous/heterozygous segments were observed in the recently released whole genome sequence of the dog.", [["dog", "ORGANISM", 123, 126], ["whole genome sequence", "DNA", 94, 115], ["dog", "SPECIES", 123, 126], ["homozygous/heterozygous segments", "PROBLEM", 22, 54], ["Similar", "OBSERVATION_MODIFIER", 3, 10], ["patches", "OBSERVATION_MODIFIER", 11, 18], ["homozygous", "OBSERVATION", 22, 32], ["heterozygous segments", "OBSERVATION", 33, 54], ["dog", "ANATOMY", 123, 126]]], ["19 The length of the segments is influenced by breedspecifi c history including effective population sizes, use of popular sires, and population bottlenecks.", [["effective population sizes", "TREATMENT", 80, 106], ["popular sires", "TREATMENT", 115, 128], ["length", "OBSERVATION_MODIFIER", 7, 13], ["segments", "ANATOMY_MODIFIER", 21, 29], ["effective", "OBSERVATION_MODIFIER", 80, 89], ["population", "OBSERVATION_MODIFIER", 90, 100], ["sizes", "OBSERVATION_MODIFIER", 101, 106], ["popular sires", "OBSERVATION", 115, 128]]], ["23, 24 Linkage disequilibrium (LD) mapping has recently emerged as a powerful approach in humans for association mapping.", [["humans", "ORGANISM", 90, 96], ["humans", "SPECIES", 90, 96], ["humans", "SPECIES", 90, 96], ["Linkage disequilibrium (LD) mapping", "PROBLEM", 7, 42]]], ["25 Long stretches of linkage disequilibrium in the target population greatly facilitate the success of the strategy and decrease the number of markers required for analysis.", [["Long stretches of linkage disequilibrium", "PROBLEM", 3, 43], ["the strategy", "TREATMENT", 103, 115], ["analysis", "TEST", 164, 172], ["linkage disequilibrium", "OBSERVATION", 21, 43]]], ["25 The extended LDs observed in dog breeds, up to one hundred times the length observed in human populations, 26 is proving to be a powerful mapping strategy for identification of genes associated with breedspecifi c phenotypes, 27 including hereditary pathologies.", [["hereditary pathologies", "DISEASE", 242, 264], ["dog", "ORGANISM", 32, 35], ["human", "ORGANISM", 91, 96], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["a powerful mapping strategy", "TREATMENT", 130, 157], ["breedspecifi c phenotypes", "PROBLEM", 202, 227], ["hereditary pathologies", "PROBLEM", 242, 264], ["dog breeds", "OBSERVATION", 32, 42]]], ["28, 29 The potential of this mapping approach in cat breeds was evaluated by examining breed-specific patterns of common segment homozygosity in 24 Cat Fancier Association (CFA) (http://www.cfainc.org) breeds.", [["cat", "ORGANISM", 49, 52], ["this mapping approach", "TREATMENT", 24, 45], ["common segment homozygosity", "PROBLEM", 114, 141], ["common segment", "ANATOMY", 114, 128]]], ["17 The level of homozygosity refl ected in a group of 665 SNPs was roughly half that seen in dogs, 26 likely reflecting a more extensive recent inbreeding within Heterozygosity across Cinnamon's chromosomes is represented in nonoverlapping windows of 100 kb.", [["chromosomes", "ANATOMY", 195, 206], ["chromosomes", "CELLULAR_COMPONENT", 195, 206], ["Cinnamon's chromosomes", "DNA", 184, 206], ["dogs", "SPECIES", 93, 97], ["a more extensive recent inbreeding within Heterozygosity", "PROBLEM", 120, 176], ["Cinnamon's chromosomes", "TREATMENT", 184, 206], ["extensive", "OBSERVATION_MODIFIER", 127, 136]]], ["Black represents regions with more than two SNPs per 100 kb while gray represents the homozygous region (less than two SNP, 0/100 kb).", [["homozygous region", "DNA", 86, 103], ["the homozygous region", "PROBLEM", 82, 103], ["homozygous", "OBSERVATION", 86, 96]]], ["White represents gaps in the chromosome assembly.SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS DEMONSTRATES POTENTIAL OF LINKAGE DISEQUILIBRIUM MAPPING IN CAT BREEDSdog versus cat breeds.", [["chromosome", "ANATOMY", 29, 39], ["chromosome", "CELLULAR_COMPONENT", 29, 39], ["cat", "ORGANISM", 170, 173], ["CAT BREEDSdog", "PROTEIN", 149, 162], ["SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS", "TEST", 49, 88], ["LINKAGE DISEQUILIBRIUM MAPPING", "PROBLEM", 115, 145], ["gaps", "OBSERVATION", 17, 21], ["LINKAGE DISEQUILIBRIUM", "OBSERVATION", 115, 137]]], ["30 This level of homozygosity was used to estimate 19 that some 45,000 equivalently spaced SNP variants would be required for a linkage disequilibrium/haplotype-based association genome search of a complex heritable disease within cat breeds.SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS DEMONSTRATES POTENTIAL OF LINKAGE DISEQUILIBRIUM MAPPING IN CAT BREEDSRecently, tyrosinase-related protein 1 (TYRP1), one of the key enzymes in the melanogenic pathway, was linked to two coat color variants in the cat by association mapping in 38 cat breeds due to extensive LD.", [["SNP", "CHEMICAL", 91, 94], ["cat", "ORGANISM", 231, 234], ["tyrosinase-related protein 1", "GENE_OR_GENE_PRODUCT", 362, 390], ["TYRP1", "GENE_OR_GENE_PRODUCT", 392, 397], ["cat", "ORGANISM", 496, 499], ["cat", "ORGANISM", 529, 532], ["CAT", "PROTEIN", 342, 345], ["tyrosinase-related protein 1", "PROTEIN", 362, 390], ["TYRP1", "PROTEIN", 392, 397], ["some 45,000 equivalently spaced SNP variants", "PROBLEM", 59, 103], ["a linkage disequilibrium/haplotype", "PROBLEM", 126, 160], ["a complex heritable disease", "PROBLEM", 196, 223], ["SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS", "TEST", 242, 281], ["LINKAGE DISEQUILIBRIUM MAPPING", "PROBLEM", 308, 338], ["CAT BREEDSRecently", "TEST", 342, 360], ["tyrosinase", "TEST", 362, 372], ["protein", "TEST", 381, 388], ["the key enzymes", "TEST", 407, 422], ["extensive LD", "PROBLEM", 547, 559], ["complex", "OBSERVATION_MODIFIER", 198, 205], ["heritable", "OBSERVATION_MODIFIER", 206, 215], ["disease", "OBSERVATION", 216, 223], ["LINKAGE DISEQUILIBRIUM", "OBSERVATION", 308, 330]]], ["31 Two DNA polymorphisms in TYRP1, an A3G substitution in the signal peptide and an in-frame insertion TYRP1-421ins17/18, were associated with the chocolate (b) allele.", [["DNA", "CELLULAR_COMPONENT", 7, 10], ["TYRP1", "GENE_OR_GENE_PRODUCT", 28, 33], ["A3G", "GENE_OR_GENE_PRODUCT", 38, 41], ["chocolate (b)", "GENE_OR_GENE_PRODUCT", 147, 160], ["TYRP1", "DNA", 28, 33], ["TYRP1", "DNA", 103, 108], ["421ins17/18", "DNA", 109, 120], ["chocolate (b) allele", "DNA", 147, 167], ["Two DNA polymorphisms in TYRP1", "PROBLEM", 3, 33], ["an A3G substitution", "TREATMENT", 35, 54], ["the signal peptide", "TEST", 58, 76], ["A3G substitution", "OBSERVATION", 38, 54]]], ["A premature UAG stop codon at position 100 of TYRP1 was associated with a second allele of the B locus, cinnamon (bl).", [["TYRP1", "GENE_OR_GENE_PRODUCT", 46, 51], ["B", "GENE_OR_GENE_PRODUCT", 95, 96], ["cinnamon", "SIMPLE_CHEMICAL", 104, 112], ["premature UAG stop codon", "DNA", 2, 26], ["TYRP1", "DNA", 46, 51], ["allele", "DNA", 81, 87], ["B locus", "DNA", 95, 102], ["cinnamon (bl)", "DNA", 104, 117], ["A premature UAG stop codon", "TREATMENT", 0, 26], ["TYRP1", "PROBLEM", 46, 51], ["premature", "OBSERVATION_MODIFIER", 2, 11], ["UAG", "OBSERVATION", 12, 15], ["stop codon", "OBSERVATION", 16, 26]]], ["32 SNP discovery is planned in the 7X whole genome sequencing of the cat through a resequencing strategy of selected genomic regions in several cat breeds as was recently performed in the 7X whole genome sequencing of the dog.", [["SNP", "CHEMICAL", 3, 6], ["cat", "ORGANISM", 69, 72], ["cat", "ORGANISM", 144, 147], ["dog", "ORGANISM", 222, 225], ["genomic regions", "DNA", 117, 132], ["dog", "SPECIES", 222, 225], ["cat breeds", "OBSERVATION", 144, 154]]], ["19THE MATURITY OF CURRENT FELID MAPPING RESOURCES DEMONSTRATED IN SUCCESSFUL WHOLE GENOME AND ASSOCIATION MAPPING EXERCISESThe majority of hereditary pathologies in the domestic cat for which the gene defect has been elucidated have resulted from the analysis of candidate genes (Table 25-1) .", [["hereditary pathologies", "DISEASE", 139, 161], ["cat", "ORGANISM", 178, 181], ["candidate genes", "DNA", 263, 278], ["Table 25-1", "DNA", 280, 290], ["cat", "SPECIES", 178, 181], ["hereditary pathologies", "PROBLEM", 139, 161], ["the gene defect", "PROBLEM", 192, 207], ["hereditary", "OBSERVATION_MODIFIER", 139, 149], ["pathologies", "OBSERVATION", 150, 161], ["defect", "OBSERVATION", 201, 207]]], ["However, with the availability of a detailed comparative map, and integration with developing GL and RH maps, and the cat 2X whole genome sequence, linkage and association-based mapping techniques have recently identified causative mutations for hereditary disease genes, 33, 34 as well as several feline phenotypes (Table 25-1) .", [["hereditary disease", "DISEASE", 246, 264], ["GL", "CELL", 94, 96], ["feline", "ORGANISM", 298, 304], ["GL and RH maps", "DNA", 94, 108], ["cat 2X whole genome sequence", "DNA", 118, 146], ["hereditary disease genes", "DNA", 246, 270], ["developing GL and RH maps", "TEST", 83, 108], ["the cat 2X whole genome sequence", "TEST", 114, 146], ["causative mutations", "PROBLEM", 222, 241], ["hereditary disease genes", "PROBLEM", 246, 270], ["several feline phenotypes", "TEST", 290, 315]]], ["18, 32, Once a genomic region is implicated from association-based or linkage mapping exercises, fine mapping has been accomplished by development of new STRs or SNPs in the targeted region using the cat 2X whole genome sequence data accessed sequence tagged sites (STS), utilizing sequence information from the cat 2X whole genome sequencing effort, which ultimately identifi ed an \u223c140 kb deletion and a novel gene candidate, LIX1 34 ( Figure 25-4) .", [["genomic region", "DNA", 15, 29], ["STRs", "DNA", 154, 158], ["SNPs", "DNA", 162, 166], ["cat 2X whole genome sequence", "DNA", 200, 228], ["\u223c140 kb deletion", "DNA", 383, 399], ["novel gene candidate", "DNA", 406, 426], ["LIX1 34", "DNA", 428, 435], ["Figure 25-4", "DNA", 438, 449], ["linkage mapping exercises", "TREATMENT", 70, 95], ["fine mapping", "TEST", 97, 109], ["new STRs or SNPs", "PROBLEM", 150, 166], ["LIX1", "TEST", 428, 432], ["new", "OBSERVATION_MODIFIER", 150, 153]]], ["Though the function of LIX1 is unknown, the predicted secondary structure is compatible with a role in RNA metabolism.", [["LIX1", "GENE_OR_GENE_PRODUCT", 23, 27], ["LIX1", "PROTEIN", 23, 27], ["a role in RNA metabolism", "PROBLEM", 93, 117], ["secondary structure", "OBSERVATION", 54, 73], ["compatible with", "UNCERTAINTY", 77, 92], ["RNA metabolism", "OBSERVATION", 103, 117]]], ["An exon sequence screen of 25 human SMA cases, not otherwise explicable by mutations at the SMN1 locus, failed to identify comparable LIX1 mutations.", [["human", "ORGANISM", 30, 35], ["SMA", "GENE_OR_GENE_PRODUCT", 36, 39], ["SMN1", "GENE_OR_GENE_PRODUCT", 92, 96], ["LIX1", "GENE_OR_GENE_PRODUCT", 134, 138], ["SMN1 locus", "DNA", 92, 102], ["LIX1", "DNA", 134, 138], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["An exon sequence screen", "TEST", 0, 23], ["mutations at the SMN1 locus", "PROBLEM", 75, 102], ["SMA", "ANATOMY", 36, 39]]], ["34 The SMN1 gene product, SMN, is a ubiquitously expressed protein member of multiple ribonucleoprotein complexes with diverse roles in RNA metabolism, splicing, and transport in all cells.", [["cells", "ANATOMY", 183, 188], ["SMN1", "GENE_OR_GENE_PRODUCT", 7, 11], ["SMN", "GENE_OR_GENE_PRODUCT", 26, 29], ["cells", "CELL", 183, 188], ["SMN1 gene product", "PROTEIN", 7, 24], ["SMN", "PROTEIN", 26, 29], ["ubiquitously expressed protein member", "PROTEIN", 36, 73], ["multiple ribonucleoprotein complexes", "PROTEIN", 77, 113], ["multiple ribonucleoprotein complexes", "PROBLEM", 77, 113], ["SMN", "ANATOMY", 26, 29], ["multiple", "OBSERVATION_MODIFIER", 77, 85], ["ribonucleoprotein complexes", "OBSERVATION", 86, 113], ["RNA metabolism", "OBSERVATION", 136, 150]]], ["62, 63 A central focus of SMA research remains to discern the disease mechanism(s) and to understand why the primary disease pathology is localized to spinal lower motor neurons when all cells require SMN function.", [["spinal lower motor neurons", "ANATOMY", 151, 177], ["cells", "ANATOMY", 187, 192], ["SMA", "MULTI-TISSUE_STRUCTURE", 26, 29], ["neurons", "CELL", 170, 177], ["cells", "CELL", 187, 192], ["SMN", "GENE_OR_GENE_PRODUCT", 201, 204], ["spinal lower motor neurons", "CELL_TYPE", 151, 177], ["SMN", "PROTEIN", 201, 204], ["the disease mechanism", "PROBLEM", 58, 79], ["the primary disease pathology", "PROBLEM", 105, 134], ["central", "OBSERVATION_MODIFIER", 9, 16], ["SMA", "ANATOMY", 26, 29], ["disease", "OBSERVATION", 62, 69], ["spinal", "ANATOMY", 151, 157], ["lower", "ANATOMY_MODIFIER", 158, 163], ["SMN function", "OBSERVATION", 201, 213]]], ["LIX1 expression is largely restricted to the central nervous system (CNS), primarily in spinal motor neurons, thus offering an explanation of the tissue restriction of pathology in feline SMA.", [["central nervous system", "ANATOMY", 45, 67], ["CNS", "ANATOMY", 69, 72], ["spinal motor neurons", "ANATOMY", 88, 108], ["tissue", "ANATOMY", 146, 152], ["feline SMA", "DISEASE", 181, 191], ["LIX1", "GENE_OR_GENE_PRODUCT", 0, 4], ["central nervous system", "ANATOMICAL_SYSTEM", 45, 67], ["CNS", "ANATOMICAL_SYSTEM", 69, 72], ["spinal motor neurons", "CELL", 88, 108], ["tissue", "TISSUE", 146, 152], ["feline", "ORGANISM", 181, 187], ["SMA", "GENE_OR_GENE_PRODUCT", 188, 191], ["LIX1", "PROTEIN", 0, 4], ["spinal motor neurons", "CELL_TYPE", 88, 108], ["central", "ANATOMY_MODIFIER", 45, 52], ["nervous system", "ANATOMY", 53, 67], ["spinal motor", "ANATOMY", 88, 100], ["SMA", "ANATOMY", 188, 191]]], ["Determination of LIX1 function may well provide fresh insight into the mechanisms of human SMA pathology, impetus for more targeted therapeutics, and answers to fundamental questions of motor neuron development, maintenance, and/or function. through the cat genome browser, GARFIELD.", [["motor neuron", "ANATOMY", 186, 198], ["LIX1", "GENE_OR_GENE_PRODUCT", 17, 21], ["human", "ORGANISM", 85, 90], ["SMA", "GENE_OR_GENE_PRODUCT", 91, 94], ["motor neuron", "MULTI-TISSUE_STRUCTURE", 186, 198], ["LIX1", "PROTEIN", 17, 21], ["cat genome browser", "DNA", 254, 272], ["GARFIELD", "DNA", 274, 282], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["LIX1 function", "PROBLEM", 17, 30], ["SMA", "ANATOMY", 91, 94]]], ["17 A recent report of the mapping and characterization of a novel gene causative of feline spinal muscular atrophy 34 marked the first identification of a disease gene purely from positional reasoning.", [["spinal muscular", "ANATOMY", 91, 106], ["spinal muscular atrophy", "DISEASE", 91, 114], ["feline", "ORGANISM", 84, 90], ["disease gene", "DNA", 155, 167], ["feline", "SPECIES", 84, 90], ["the mapping", "TEST", 22, 33], ["feline spinal muscular atrophy", "PROBLEM", 84, 114], ["a disease gene purely", "PROBLEM", 153, 174], ["spinal muscular", "ANATOMY", 91, 106], ["atrophy", "OBSERVATION", 107, 114], ["disease", "OBSERVATION", 155, 162]]], ["Human spinal muscular atrophies (SMAs) are a genetically heterogeneous group of neuropathies that varies in clinical severity, from lethal in infancy to onset of mild weakness in adulthood, but all are characterized by neurogenic muscle atrophy due to degeneration of lower motor neurons of the spinal cord.", [["spinal muscular atrophies", "ANATOMY", 6, 31], ["SMAs", "ANATOMY", 33, 37], ["muscle", "ANATOMY", 230, 236], ["lower motor neurons", "ANATOMY", 268, 287], ["spinal cord", "ANATOMY", 295, 306], ["spinal muscular atrophies", "DISEASE", 6, 31], ["SMAs", "DISEASE", 33, 37], ["neuropathies", "DISEASE", 80, 92], ["weakness", "DISEASE", 167, 175], ["muscle atrophy", "DISEASE", 230, 244], ["Human", "ORGANISM", 0, 5], ["spinal muscular atrophies", "CANCER", 6, 31], ["SMAs", "CANCER", 33, 37], ["muscle", "ORGAN", 230, 236], ["motor neurons", "MULTI-TISSUE_STRUCTURE", 274, 287], ["spinal cord", "ORGAN", 295, 306], ["lower motor neurons", "CELL_TYPE", 268, 287], ["Human", "SPECIES", 0, 5], ["Human spinal muscular atrophies", "PROBLEM", 0, 31], ["neuropathies", "PROBLEM", 80, 92], ["mild weakness in adulthood", "PROBLEM", 162, 188], ["neurogenic muscle atrophy", "PROBLEM", 219, 244], ["degeneration of lower motor neurons of the spinal cord", "PROBLEM", 252, 306], ["spinal muscular", "ANATOMY", 6, 21], ["atrophies", "OBSERVATION", 22, 31], ["SMAs", "ANATOMY", 33, 37], ["heterogeneous", "OBSERVATION_MODIFIER", 57, 70], ["neuropathies", "OBSERVATION", 80, 92], ["mild", "OBSERVATION_MODIFIER", 162, 166], ["weakness", "OBSERVATION", 167, 175], ["neurogenic", "OBSERVATION", 219, 229], ["muscle", "ANATOMY", 230, 236], ["atrophy", "OBSERVATION", 237, 244], ["degeneration", "OBSERVATION", 252, 264], ["lower", "ANATOMY_MODIFIER", 268, 273], ["motor neurons", "ANATOMY_MODIFIER", 274, 287], ["spinal cord", "ANATOMY", 295, 306]]], ["58 For approximately 97% of people affected with SMA, disease pathology is attributable to a mutation in the SMN1 gene, on human chromosome 5q13, which is subject to a high frequency of deletions and gene conversion events with the divergent and only partially functional centromeric copy/copies of the duplicated SMN2 locus.", [["chromosome 5q13", "ANATOMY", 129, 144], ["centromeric", "ANATOMY", 272, 283], ["SMA", "DISEASE", 49, 52], ["people", "ORGANISM", 28, 34], ["SMA", "GENE_OR_GENE_PRODUCT", 49, 52], ["SMN1", "GENE_OR_GENE_PRODUCT", 109, 113], ["human", "ORGANISM", 123, 128], ["chromosome 5q13", "CELLULAR_COMPONENT", 129, 144], ["centromeric", "CELLULAR_COMPONENT", 272, 283], ["SMN2", "GENE_OR_GENE_PRODUCT", 314, 318], ["SMN1 gene", "DNA", 109, 118], ["human chromosome 5q13", "DNA", 123, 144], ["SMN2 locus", "DNA", 314, 324], ["people", "SPECIES", 28, 34], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 123, 128], ["SMA, disease pathology", "PROBLEM", 49, 71], ["a mutation in the SMN1 gene", "PROBLEM", 91, 118], ["human chromosome", "TREATMENT", 123, 139], ["a high frequency of deletions", "PROBLEM", 166, 195], ["gene conversion events", "PROBLEM", 200, 222], ["the duplicated SMN2 locus", "PROBLEM", 299, 324], ["SMA", "ANATOMY", 49, 52], ["disease", "OBSERVATION", 54, 61], ["SMN2 locus", "OBSERVATION", 314, 324]]], ["59, 60 A domestic cat model of SMA has been described that is a model of autosomal recessive juvenile-onset SMA.", [["SMA", "DISEASE", 31, 34], ["autosomal recessive juvenile-onset SMA", "DISEASE", 73, 111], ["cat", "ORGANISM", 18, 21], ["SMA", "GENE_OR_GENE_PRODUCT", 31, 34], ["SMA", "CANCER", 108, 111], ["SMA", "PROTEIN", 31, 34], ["autosomal recessive juvenile-onset SMA", "PROBLEM", 73, 111], ["domestic cat", "OBSERVATION", 9, 21], ["SMA", "ANATOMY", 31, 34], ["autosomal", "OBSERVATION_MODIFIER", 73, 82], ["recessive", "OBSERVATION_MODIFIER", 83, 92], ["juvenile", "OBSERVATION", 93, 101], ["onset", "OBSERVATION_MODIFIER", 102, 107], ["SMA", "ANATOMY", 108, 111]]], ["61 With the feline SMN gene excluded as the disease locus, 61 a full genome linkage scan was conducted in a pedigree segregating for SMA.", [["feline", "ORGANISM", 12, 18], ["SMN", "GENE_OR_GENE_PRODUCT", 19, 22], ["feline SMN gene", "DNA", 12, 27], ["disease locus", "DNA", 44, 57], ["SMA", "PROTEIN", 133, 136], ["feline", "SPECIES", 12, 18], ["the disease locus", "PROBLEM", 40, 57], ["a full genome linkage scan", "TEST", 62, 88], ["SMA", "ANATOMY", 133, 136]]], ["61 The disease phenotype was linked to chromosome A1q, 34 in a region of conserved synteny to human chromosome 5q15.", [["chromosome A1q", "ANATOMY", 39, 53], ["chromosome 5q15", "ANATOMY", 100, 115], ["chromosome A1q", "CELLULAR_COMPONENT", 39, 53], ["human", "ORGANISM", 94, 99], ["chromosome 5q15", "CELLULAR_COMPONENT", 100, 115], ["chromosome A1q", "DNA", 39, 53], ["human chromosome 5q15", "DNA", 94, 115], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["The disease phenotype", "PROBLEM", 3, 24], ["disease", "OBSERVATION", 7, 14]]], ["Fine mapping was accomplished with development of new STRs andTHE CAT AS ANIMAL MODEL FOR HUMAN HEREDITARY DISEASEThe world's veterinary schools produce thousands of practitioners each year, most of whom carefully document genetic and chronic diseases of our pets.", [["Fine mapping", "TEST", 0, 12], ["new STRs", "TEST", 50, 58], ["HUMAN HEREDITARY DISEASE", "PROBLEM", 90, 114], ["genetic and chronic diseases of our pets", "PROBLEM", 223, 263], ["new", "OBSERVATION_MODIFIER", 50, 53], ["HEREDITARY DISEASE", "OBSERVATION", 96, 114], ["chronic", "OBSERVATION_MODIFIER", 235, 242], ["diseases", "OBSERVATION", 243, 251]]], ["The result is a comprehensive veterinary literature that has described over 200 feline hereditary pathologies 17 (http://www.angis.org.au/).", [["hereditary pathologies", "DISEASE", 87, 109], ["hereditary pathologies", "PROBLEM", 87, 109]]], ["The clinical and physiological study of these feline hereditary diseases provides a strong comparative medicine opportunity for prevention, diagnostics, and treatment studies in a laboratory setting.", [["hereditary diseases", "DISEASE", 53, 72], ["feline", "ORGANISM", 46, 52], ["physiological study", "TEST", 17, 36], ["these feline hereditary diseases", "PROBLEM", 40, 72], ["diagnostics", "TEST", 140, 151], ["treatment studies", "TEST", 157, 174]]], ["Additionally, large animal homologues are similar to humans in natural genetic diversity and offer the possibility of evaluating long-term effects of treatment.", [["humans", "ORGANISM", 53, 59], ["humans", "SPECIES", 53, 59], ["humans", "SPECIES", 53, 59], ["large animal homologues", "PROBLEM", 14, 37], ["treatment", "TREATMENT", 150, 159], ["large", "OBSERVATION_MODIFIER", 14, 19], ["animal homologues", "OBSERVATION", 20, 37]]], ["64 To date, causal mutations have been characterized in 19 felid genes that cause hereditary disease (Table 25 -1).", [["hereditary disease", "DISEASE", 82, 100], ["felid genes", "DNA", 59, 70], ["causal mutations", "PROBLEM", 12, 28], ["hereditary disease", "PROBLEM", 82, 100]]], ["The largest representation comes from lysosomal storage enzyme disorders that arise from defects in genes playing a role in degradation of macromolecules targeted to the lysosomes.", [["lysosomal", "ANATOMY", 38, 47], ["lysosomes", "ANATOMY", 170, 179], ["lysosomes", "CELLULAR_COMPONENT", 170, 179], ["lysosomal storage enzyme", "PROTEIN", 38, 62], ["lysosomal storage enzyme disorders", "PROBLEM", 38, 72], ["defects in genes", "PROBLEM", 89, 105], ["macromolecules", "TREATMENT", 139, 153], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["lysosomal storage", "OBSERVATION", 38, 55], ["enzyme disorders", "OBSERVATION", 56, 72], ["defects", "OBSERVATION", 89, 96]]], ["Many of the genes that cause these pathologies have been mapped in the cat.", [["cat", "ORGANISM", 71, 74], ["these pathologies", "PROBLEM", 29, 46], ["pathologies", "OBSERVATION", 35, 46]]], ["65 Corrective therapeutic strategies have been proposed and examined in the cat, including enzyme replacement, heterologous bone marrow transplantation, and substrate reduction therapy.", [["bone marrow", "ANATOMY", 124, 135], ["cat", "ORGANISM", 76, 79], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 124, 135], ["Corrective therapeutic strategies", "TREATMENT", 3, 36], ["enzyme replacement", "TREATMENT", 91, 109], ["heterologous bone marrow transplantation", "TREATMENT", 111, 151], ["substrate reduction therapy", "TREATMENT", 157, 184], ["bone marrow transplantation", "OBSERVATION", 124, 151]]], ["64, 66 Limitations to these treatment strategies include high morbidity and mortality, limited positive outcomes, incomplete response to therapy, cost, and in some cases requirements for continuous lifelong therapy.", [["these treatment strategies", "TREATMENT", 22, 48], ["high morbidity", "PROBLEM", 57, 71], ["limited positive outcomes", "PROBLEM", 87, 112], ["therapy", "TREATMENT", 137, 144], ["cost", "TREATMENT", 146, 150], ["continuous lifelong therapy", "TREATMENT", 187, 214]]], ["66 Gene therapy poses the most recent of intervention strategies.", [["Gene therapy", "TREATMENT", 3, 15], ["intervention strategies", "TREATMENT", 41, 64]]], ["Feline models have been important in elucidating molecular pathogenesis and are now playing a critical role in evaluating and optimizing the range of therapeutic strategies prior to clinical trials in humans.THE CAT AS ANIMAL MODEL FOR HUMAN HEREDITARY DISEASEThe mucopolysaccharidoses are disorders that result from the defi ciency of lysosomal enzymes involved in the degradation of mucopolysaccharides.", [["lysosomal", "ANATOMY", 336, 345], ["mucopolysaccharidoses", "DISEASE", 264, 285], ["Feline", "ORGANISM", 0, 6], ["humans", "ORGANISM", 201, 207], ["mucopolysaccharidoses", "SIMPLE_CHEMICAL", 264, 285], ["mucopolysaccharides", "SIMPLE_CHEMICAL", 385, 404], ["lysosomal enzymes", "PROTEIN", 336, 353], ["humans", "SPECIES", 201, 207], ["humans", "SPECIES", 201, 207], ["therapeutic strategies", "TREATMENT", 150, 172], ["HUMAN HEREDITARY DISEASE", "PROBLEM", 236, 260], ["The mucopolysaccharidoses", "PROBLEM", 260, 285], ["disorders", "PROBLEM", 290, 299], ["lysosomal enzymes", "TEST", 336, 353], ["the degradation of mucopolysaccharides", "PROBLEM", 366, 404], ["HEREDITARY DISEASE", "OBSERVATION", 242, 260], ["mucopolysaccharidoses", "OBSERVATION", 264, 285]]], ["The cat offers homologous models for mucopolysaccharidosis Types I, VI, and VII.THE CAT AS ANIMAL MODEL FOR HUMAN HEREDITARY DISEASEMucopolysaccharidosis Type I (MPS I), which results from a genetic deficient activity of the enzyme \u03b1-l-iduronidase (IDUA), can lead to mental retardation, growth abnormalities, and shortened life span in humans.", [["mucopolysaccharidosis", "DISEASE", 37, 58], ["DISEASEMucopolysaccharidosis Type I", "DISEASE", 125, 160], ["MPS", "DISEASE", 162, 165], ["mental retardation", "DISEASE", 268, 286], ["growth abnormalities", "DISEASE", 288, 308], ["cat", "ORGANISM", 4, 7], ["mucopolysaccharidosis Types I", "GENE_OR_GENE_PRODUCT", 37, 66], ["VII", "GENE_OR_GENE_PRODUCT", 76, 79], ["DISEASEMucopolysaccharidosis Type I", "GENE_OR_GENE_PRODUCT", 125, 160], ["MPS I", "GENE_OR_GENE_PRODUCT", 162, 167], ["\u03b1-l-iduronidase", "GENE_OR_GENE_PRODUCT", 232, 247], ["IDUA", "GENE_OR_GENE_PRODUCT", 249, 253], ["humans", "ORGANISM", 337, 343], ["mucopolysaccharidosis Types I, VI, and VII", "PROTEIN", 37, 79], ["enzyme \u03b1-l-iduronidase", "PROTEIN", 225, 247], ["IDUA", "PROTEIN", 249, 253], ["humans", "SPECIES", 337, 343], ["humans", "SPECIES", 337, 343], ["mucopolysaccharidosis", "PROBLEM", 37, 58], ["mental retardation", "PROBLEM", 268, 286], ["growth abnormalities", "PROBLEM", 288, 308], ["shortened life span in humans", "PROBLEM", 314, 343]]], ["67 Naturally occurring models have been characterized in the cat 68,69 and dog.", [["cat", "ORGANISM", 61, 64], ["dog", "ORGANISM", 75, 78], ["dog", "SPECIES", 75, 78]]], ["70 Immune responses can nullify the effect of gene corrective therapy.", [["gene corrective therapy", "TREATMENT", 46, 69]]], ["It has been demonstrated that cats, but not dogs, mount a potent CTL response to canine IDUA after neonatal gene therapy, which can be prevented with transient CTLA4-Ig.", [["IDUA", "CHEMICAL", 88, 92], ["cats", "ORGANISM", 30, 34], ["dogs", "ORGANISM", 44, 48], ["CTL", "CANCER", 65, 68], ["canine", "ORGANISM", 81, 87], ["IDUA", "CANCER", 88, 92], ["CTLA4", "GENE_OR_GENE_PRODUCT", 160, 165], ["CTLA4", "PROTEIN", 160, 165], ["cats", "SPECIES", 30, 34], ["dogs", "SPECIES", 44, 48], ["canine", "SPECIES", 81, 87], ["canine IDUA", "TREATMENT", 81, 92], ["neonatal gene therapy", "TREATMENT", 99, 120], ["transient CTLA4", "TREATMENT", 150, 165]]], ["71 The efficacy of neonatal retroviral therapy has also been explored in the cat.", [["retroviral", "ORGANISM", 28, 38], ["cat", "ORGANISM", 77, 80], ["neonatal retroviral therapy", "TREATMENT", 19, 46], ["retroviral therapy", "OBSERVATION", 28, 46]]], ["66 The cat model, additionally, provides an ideal system to study mechanisms of brain neurodegeneration and neural-directed strategies, especially given a large body of preexisting literature on cat neurology.", [["brain", "ANATOMY", 80, 85], ["neural", "ANATOMY", 108, 114], ["brain neurodegeneration", "DISEASE", 80, 103], ["cat", "ORGANISM", 7, 10], ["brain", "ORGAN", 80, 85], ["cat", "ORGANISM", 195, 198], ["brain neurodegeneration", "PROBLEM", 80, 103], ["brain", "ANATOMY", 80, 85], ["neurodegeneration", "OBSERVATION", 86, 103]]], ["MPS VI or Marteaux-Lamy disease, deficient activity of arylsulfatase B (ARSB), is characterized in humans and cats with growth retardation, coarse facial features, corneal opacity, and skeletal deformities.", [["facial", "ANATOMY", 147, 153], ["corneal", "ANATOMY", 164, 171], ["skeletal", "ANATOMY", 185, 193], ["MPS", "DISEASE", 0, 3], ["Lamy disease", "DISEASE", 19, 31], ["growth retardation", "DISEASE", 120, 138], ["corneal opacity", "DISEASE", 164, 179], ["skeletal deformities", "DISEASE", 185, 205], ["MPS VI", "GENE_OR_GENE_PRODUCT", 0, 6], ["arylsulfatase B", "GENE_OR_GENE_PRODUCT", 55, 70], ["ARSB", "GENE_OR_GENE_PRODUCT", 72, 76], ["humans", "ORGANISM", 99, 105], ["cats", "ORGANISM", 110, 114], ["corneal", "TISSUE", 164, 171], ["skeletal", "ORGAN", 185, 193], ["arylsulfatase B", "PROTEIN", 55, 70], ["ARSB", "PROTEIN", 72, 76], ["humans", "SPECIES", 99, 105], ["cats", "SPECIES", 110, 114], ["humans", "SPECIES", 99, 105], ["Marteaux", "TEST", 10, 18], ["Lamy disease", "PROBLEM", 19, 31], ["deficient activity of arylsulfatase B (ARSB)", "PROBLEM", 33, 77], ["growth retardation", "PROBLEM", 120, 138], ["coarse facial features", "PROBLEM", 140, 162], ["corneal opacity", "PROBLEM", 164, 179], ["skeletal deformities", "PROBLEM", 185, 205], ["Lamy disease", "OBSERVATION", 19, 31], ["activity", "OBSERVATION_MODIFIER", 43, 51], ["coarse", "OBSERVATION_MODIFIER", 140, 146], ["facial", "ANATOMY", 147, 153], ["corneal", "ANATOMY", 164, 171], ["opacity", "OBSERVATION", 172, 179], ["skeletal", "ANATOMY", 185, 193], ["deformities", "OBSERVATION", 194, 205]]], ["[72] [73] [74] [75] The feline model also exhibits abnormal lysosomal storage in occasional neurons and glia distributed throughout the cerebral cortex.", [["lysosomal", "ANATOMY", 60, 69], ["neurons", "ANATOMY", 92, 99], ["glia", "ANATOMY", 104, 108], ["cerebral cortex", "ANATOMY", 136, 151], ["[72] [73] [74] [75", "SIMPLE_CHEMICAL", 0, 18], ["feline", "ORGANISM", 24, 30], ["lysosomal", "CELLULAR_COMPONENT", 60, 69], ["neurons", "CELL", 92, 99], ["glia", "CELL", 104, 108], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 136, 151], ["occasional neurons", "CELL_TYPE", 81, 99], ["glia", "CELL_TYPE", 104, 108], ["The feline model", "TEST", 20, 36], ["abnormal lysosomal storage in occasional neurons", "PROBLEM", 51, 99], ["abnormal", "OBSERVATION_MODIFIER", 51, 59], ["lysosomal storage", "OBSERVATION", 60, 77], ["occasional neurons", "OBSERVATION", 81, 99], ["glia", "ANATOMY_MODIFIER", 104, 108], ["cerebral cortex", "ANATOMY", 136, 151]]], ["76 Fibroblast-mediated in vitro gene therapy has been examined in this cat model.", [["Fibroblast", "CELL", 3, 13], ["cat", "ORGANISM", 71, 74], ["Fibroblast", "TREATMENT", 3, 13], ["vitro gene therapy", "TREATMENT", 26, 44]]], ["77 Recently, an adeno-associated vector containing feline ARSB has demonstrated gene therapy-based correction of corneal clouding in the MPS VI cat.", [["corneal", "ANATOMY", 113, 120], ["corneal clouding", "DISEASE", 113, 129], ["MPS", "DISEASE", 137, 140], ["feline", "ORGANISM", 51, 57], ["ARSB", "CANCER", 58, 62], ["corneal", "TISSUE", 113, 120], ["feline ARSB", "DNA", 51, 62], ["feline", "SPECIES", 51, 57], ["MPS VI cat", "SPECIES", 137, 147], ["an adeno-associated vector", "TREATMENT", 13, 39], ["gene therapy", "TREATMENT", 80, 92], ["corneal clouding", "PROBLEM", 113, 129], ["gene therapy", "OBSERVATION", 80, 92], ["corneal", "ANATOMY", 113, 120], ["clouding", "OBSERVATION", 121, 129]]], ["78 MPS VII results from deficiency of \u03b2-glucuronidase (GUSB), which in humans manifests as cartilaginous and bony malformations, growth and mental retardation, abdominal organ enlargement, and corneal clouding.", [["cartilaginous", "ANATOMY", 91, 104], ["bony", "ANATOMY", 109, 113], ["abdominal organ", "ANATOMY", 160, 175], ["corneal", "ANATOMY", 193, 200], ["MPS VII", "DISEASE", 3, 10], ["bony malformations", "DISEASE", 109, 127], ["growth and mental retardation", "DISEASE", 129, 158], ["abdominal organ enlargement", "DISEASE", 160, 187], ["corneal clouding", "DISEASE", 193, 209], ["MPS VII", "GENE_OR_GENE_PRODUCT", 3, 10], ["\u03b2-glucuronidase", "GENE_OR_GENE_PRODUCT", 38, 53], ["GUSB", "GENE_OR_GENE_PRODUCT", 55, 59], ["humans", "ORGANISM", 71, 77], ["cartilaginous", "TISSUE", 91, 104], ["bony malformations", "PATHOLOGICAL_FORMATION", 109, 127], ["organ", "ORGAN", 170, 175], ["corneal", "TISSUE", 193, 200], ["MPS VII", "PROTEIN", 3, 10], ["\u03b2-glucuronidase", "PROTEIN", 38, 53], ["GUSB", "PROTEIN", 55, 59], ["humans", "SPECIES", 71, 77], ["humans", "SPECIES", 71, 77], ["MPS VII results", "TEST", 3, 18], ["deficiency of \u03b2-glucuronidase (GUSB)", "PROBLEM", 24, 60], ["cartilaginous and bony malformations", "PROBLEM", 91, 127], ["mental retardation", "PROBLEM", 140, 158], ["abdominal organ enlargement", "PROBLEM", 160, 187], ["corneal clouding", "PROBLEM", 193, 209], ["bony", "ANATOMY", 109, 113], ["malformations", "OBSERVATION", 114, 127], ["abdominal organ", "ANATOMY", 160, 175], ["enlargement", "OBSERVATION", 176, 187], ["corneal", "ANATOMY", 193, 200], ["clouding", "OBSERVATION", 201, 209]]], ["79 Naturally occurring animal models have been described in mice, 80 dogs, 81 and the cat.", [["mice", "ORGANISM", 60, 64], ["dogs", "ORGANISM", 69, 73], ["cat", "ORGANISM", 86, 89], ["mice", "SPECIES", 60, 64], ["dogs", "SPECIES", 69, 73], ["cat", "SPECIES", 86, 89], ["mice", "SPECIES", 60, 64]]], ["82 Enzymatic activity has been restored in fibroblasts and restored by retroviral gene transfer of rat GUSB cDNA.", [["fibroblasts", "ANATOMY", 43, 54], ["fibroblasts", "CELL", 43, 54], ["retroviral", "ORGANISM", 71, 81], ["rat", "ORGANISM", 99, 102], ["GUSB", "GENE_OR_GENE_PRODUCT", 103, 107], ["fibroblasts", "CELL_TYPE", 43, 54], ["rat GUSB cDNA", "DNA", 99, 112], ["rat", "SPECIES", 99, 102], ["rat", "SPECIES", 99, 102]]], ["As GUSB is an essential housekeeping enzyme, this feline model is important for examination of exogenous genes and gene product delivery to a variety of tissue types, and could prove especially valuable due to extensive research conducted on the anatomy and physiology of the cat central nervous and visual systems.", [["tissue", "ANATOMY", 153, 159], ["central nervous", "ANATOMY", 280, 295], ["GUSB", "GENE_OR_GENE_PRODUCT", 3, 7], ["feline", "ORGANISM", 50, 56], ["tissue", "TISSUE", 153, 159], ["cat", "ORGANISM", 276, 279], ["central nervous", "ANATOMICAL_SYSTEM", 280, 295], ["GUSB", "PROTEIN", 3, 7], ["housekeeping enzyme", "PROTEIN", 24, 43], ["exogenous genes", "DNA", 95, 110], ["examination", "TEST", 80, 91], ["exogenous genes", "PROBLEM", 95, 110], ["gene product delivery", "TREATMENT", 115, 136], ["central", "ANATOMY_MODIFIER", 280, 287], ["nervous", "ANATOMY", 288, 295]]], ["Three different serotypes of adeno-associated viral constructs of GUSB demonstrated the efficacy of this vector to achieve gene transfer in the normal cat brain, as a model for the efficacy of this construct in a large mammalian brain.", [["brain", "ANATOMY", 155, 160], ["brain", "ANATOMY", 229, 234], ["cat", "ORGANISM", 151, 154], ["brain", "ORGAN", 155, 160], ["brain", "ORGAN", 229, 234], ["adeno-associated viral constructs", "DNA", 29, 62], ["adeno-associated viral constructs of GUSB", "PROBLEM", 29, 70], ["this vector", "TREATMENT", 100, 111], ["a large mammalian brain", "PROBLEM", 211, 234], ["serotypes", "OBSERVATION_MODIFIER", 16, 25], ["adeno-associated", "OBSERVATION_MODIFIER", 29, 45], ["viral constructs", "OBSERVATION", 46, 62], ["normal", "OBSERVATION", 144, 150], ["brain", "ANATOMY", 155, 160], ["large", "OBSERVATION", 213, 218], ["brain", "ANATOMY", 229, 234]]], ["83 Defi ciency of lysosomal \u03b1-mannosidase leads to an accumulation of mannose-rich oligosaccharides, 84 which leads to mental retardation, recurrent infections, skeletal changes and hearing impairment.", [["lysosomal", "ANATOMY", 18, 27], ["skeletal", "ANATOMY", 161, 169], ["mental retardation", "DISEASE", 119, 137], ["infections", "DISEASE", 149, 159], ["hearing impairment", "DISEASE", 182, 200], ["mannose", "CHEMICAL", 70, 77], ["lysosomal \u03b1-mannosidase", "GENE_OR_GENE_PRODUCT", 18, 41], ["mannose-rich oligosaccharides", "SIMPLE_CHEMICAL", 70, 99], ["skeletal", "ORGAN", 161, 169], ["lysosomal \u03b1-mannosidase", "PROTEIN", 18, 41], ["lysosomal \u03b1-mannosidase", "TREATMENT", 18, 41], ["mental retardation", "PROBLEM", 119, 137], ["recurrent infections", "PROBLEM", 139, 159], ["skeletal changes", "PROBLEM", 161, 177], ["hearing impairment", "PROBLEM", 182, 200], ["lysosomal \u03b1-mannosidase", "OBSERVATION", 18, 41], ["accumulation", "OBSERVATION_MODIFIER", 54, 66], ["mental retardation", "OBSERVATION", 119, 137], ["recurrent", "OBSERVATION_MODIFIER", 139, 148], ["infections", "OBSERVATION", 149, 159], ["skeletal", "ANATOMY", 161, 169], ["hearing impairment", "OBSERVATION", 182, 200]]], ["85 This feline model was initially important in achieving bone marrow transplantation as corrective strategy for neuronal storage diseases of the CNS.", [["bone marrow", "ANATOMY", 58, 69], ["neuronal", "ANATOMY", 113, 121], ["CNS", "ANATOMY", 146, 149], ["neuronal storage diseases of the CNS", "DISEASE", 113, 149], ["feline", "ORGANISM", 8, 14], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 58, 69], ["neuronal", "CELL", 113, 121], ["CNS", "ANATOMICAL_SYSTEM", 146, 149], ["bone marrow transplantation", "TREATMENT", 58, 85], ["corrective strategy", "TREATMENT", 89, 108], ["neuronal storage diseases of the CNS", "PROBLEM", 113, 149], ["CNS", "ANATOMY", 146, 149]]], ["86, 87 Recently, adeno-associated viral (AAV) constructs of feline \u03b1-mannosidase were used to demonstrate the efficacy of CNS gene therapy.", [["CNS", "ANATOMY", 122, 125], ["adeno-associated viral", "ORGANISM", 17, 39], ["AAV", "ORGANISM", 41, 44], ["feline", "ORGANISM", 60, 66], ["\u03b1-mannosidase", "GENE_OR_GENE_PRODUCT", 67, 80], ["CNS", "ANATOMICAL_SYSTEM", 122, 125], ["adeno-associated viral (AAV) constructs", "DNA", 17, 56], ["feline \u03b1-mannosidase", "PROTEIN", 60, 80], ["feline", "SPECIES", 60, 66], ["AAV", "SPECIES", 41, 44], ["adeno-associated viral (AAV) constructs of feline \u03b1-mannosidase", "TREATMENT", 17, 80], ["CNS gene therapy", "TREATMENT", 122, 138]]], ["Treated cats exhibited widespread improvement of neuropathology, showing the effi cacy of this treatment in a large mammalian brain for CNS correction of human lysosomal enzyme defi ciencies.", [["brain", "ANATOMY", 126, 131], ["CNS", "ANATOMY", 136, 139], ["lysosomal", "ANATOMY", 160, 169], ["neuropathology", "DISEASE", 49, 63], ["cats", "ORGANISM", 8, 12], ["brain", "ORGAN", 126, 131], ["CNS", "ANATOMICAL_SYSTEM", 136, 139], ["human", "ORGANISM", 154, 159], ["human lysosomal enzyme", "PROTEIN", 154, 176], ["cats", "SPECIES", 8, 12], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 154, 159], ["neuropathology", "PROBLEM", 49, 63], ["this treatment", "TREATMENT", 90, 104], ["a large mammalian brain", "PROBLEM", 108, 131], ["CNS correction", "TREATMENT", 136, 150], ["human lysosomal enzyme defi ciencies", "PROBLEM", 154, 190], ["widespread", "OBSERVATION_MODIFIER", 23, 33], ["improvement", "OBSERVATION_MODIFIER", 34, 45], ["brain", "ANATOMY", 126, 131]]], ["88 Lipoprotein lipase (LPL) is a crucial enzyme involved in the regulation of lipoprotein and lipid metabolism ability to thrive.", [["Lipoprotein lipase", "GENE_OR_GENE_PRODUCT", 3, 21], ["LPL", "GENE_OR_GENE_PRODUCT", 23, 26], ["lipoprotein", "SIMPLE_CHEMICAL", 78, 89], ["lipid", "SIMPLE_CHEMICAL", 94, 99], ["Lipoprotein lipase", "PROTEIN", 3, 21], ["LPL", "PROTEIN", 23, 26], ["Lipoprotein lipase", "TEST", 3, 21], ["LPL", "TEST", 23, 26], ["a crucial enzyme", "TEST", 31, 47], ["lipid metabolism ability to thrive", "PROBLEM", 94, 128]]], ["89 Cats with LPL deficiency display a remarkably similar phenotype to humans, including severe pancreatitis, chylomicronemia, and failure to thrive.", [["LPL deficiency", "DISEASE", 13, 27], ["pancreatitis", "DISEASE", 95, 107], ["chylomicronemia", "DISEASE", 109, 124], ["LPL", "GENE_OR_GENE_PRODUCT", 13, 16], ["humans", "ORGANISM", 70, 76], ["LPL", "PROTEIN", 13, 16], ["humans", "SPECIES", 70, 76], ["humans", "SPECIES", 70, 76], ["LPL deficiency", "PROBLEM", 13, 27], ["severe pancreatitis", "PROBLEM", 88, 107], ["chylomicronemia", "PROBLEM", 109, 124], ["failure to thrive", "PROBLEM", 130, 147], ["similar phenotype", "OBSERVATION", 49, 66], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["pancreatitis", "OBSERVATION", 95, 107], ["chylomicronemia", "OBSERVATION", 109, 124], ["failure", "OBSERVATION", 130, 137]]], ["46 There is currently no adequate treatment for this pathology in humans.", [["humans", "ORGANISM", 66, 72], ["humans", "SPECIES", 66, 72], ["humans", "SPECIES", 66, 72], ["adequate treatment", "TREATMENT", 25, 43], ["this pathology in humans", "PROBLEM", 48, 72], ["no", "UNCERTAINTY", 22, 24], ["adequate", "OBSERVATION_MODIFIER", 25, 33], ["treatment", "OBSERVATION", 34, 43], ["pathology", "OBSERVATION", 53, 62]]], ["Cats could prove to be the most valuable animal model of LPL deficiency, as of numerous animal model systems examined including the mouse, the cat most closely resembles the lipoprotein pattern and lipid transport system of humans.", [["LPL deficiency", "DISEASE", 57, 71], ["Cats", "ORGANISM", 0, 4], ["LPL", "GENE_OR_GENE_PRODUCT", 57, 60], ["mouse", "ORGANISM", 132, 137], ["cat", "ORGANISM", 143, 146], ["lipid", "SIMPLE_CHEMICAL", 198, 203], ["humans", "ORGANISM", 224, 230], ["LPL", "PROTEIN", 57, 60], ["mouse", "SPECIES", 132, 137], ["humans", "SPECIES", 224, 230], ["mouse", "SPECIES", 132, 137], ["humans", "SPECIES", 224, 230], ["LPL deficiency", "PROBLEM", 57, 71], ["LPL deficiency", "OBSERVATION", 57, 71]]], ["Recently, AAV-mediated transfer of a human LPL S447X variant into feline muscle cells demonstrated correction of the hypertriglyceridemia associated with feline pathology; this offers much promise for treatment of human LPL defi ciency.", [["muscle cells", "ANATOMY", 73, 85], ["hypertriglyceridemia", "DISEASE", 117, 137], ["AAV", "ORGANISM", 10, 13], ["human", "ORGANISM", 37, 42], ["LPL", "GENE_OR_GENE_PRODUCT", 43, 46], ["S447X", "GENE_OR_GENE_PRODUCT", 47, 52], ["feline", "ORGANISM", 66, 72], ["muscle cells", "CELL", 73, 85], ["feline", "ORGANISM", 154, 160], ["human", "ORGANISM", 214, 219], ["LPL", "GENE_OR_GENE_PRODUCT", 220, 223], ["human LPL S447X variant", "PROTEIN", 37, 60], ["feline muscle cells", "CELL_TYPE", 66, 85], ["LPL", "PROTEIN", 220, 223], ["human", "SPECIES", 37, 42], ["feline", "SPECIES", 66, 72], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 214, 219], ["a human LPL", "TREATMENT", 35, 46], ["the hypertriglyceridemia", "PROBLEM", 113, 137], ["feline pathology", "PROBLEM", 154, 170], ["human LPL defi ciency", "TREATMENT", 214, 235], ["hypertriglyceridemia", "OBSERVATION", 117, 137], ["LPL", "ANATOMY", 220, 223]]], ["90 A separate class of lysosomal storage disorder characterized in the cat is the gangliosidoses, G M1 and G M2 , which are heritable neurodegenerative diseases.", [["lysosomal", "ANATOMY", 23, 32], ["gangliosidoses", "ANATOMY", 82, 96], ["lysosomal storage disorder", "DISEASE", 23, 49], ["neurodegenerative diseases", "DISEASE", 134, 160], ["cat", "ORGANISM", 71, 74], ["G M1", "GENE_OR_GENE_PRODUCT", 98, 102], ["G M2", "GENE_OR_GENE_PRODUCT", 107, 111], ["lysosomal storage disorder", "PROBLEM", 23, 49], ["heritable neurodegenerative diseases", "PROBLEM", 124, 160], ["lysosomal storage disorder", "OBSERVATION", 23, 49], ["cat", "ANATOMY_MODIFIER", 71, 74], ["gangliosidoses", "ANATOMY", 82, 96], ["M1", "ANATOMY_MODIFIER", 100, 102], ["G M2", "ANATOMY_MODIFIER", 107, 111], ["heritable", "OBSERVATION_MODIFIER", 124, 133], ["neurodegenerative", "OBSERVATION_MODIFIER", 134, 151], ["diseases", "OBSERVATION", 152, 160]]], ["A deficiency of lysosomal \u03b2-galactosidase results in the neuronal accumulation of the G M1 ganglioside, while the degradation of the G M2 ganglioside is initiated by coordinated action of at least three gene products, the \u03b1 and \u03b2 submits of \u03b2-N-acetylhexosaminidase and the G M2 activator (GM2A) protein.", [["lysosomal", "ANATOMY", 16, 25], ["neuronal", "ANATOMY", 57, 65], ["ganglioside", "CHEMICAL", 91, 102], ["ganglioside", "CHEMICAL", 138, 149], ["lysosomal \u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 16, 41], ["neuronal", "CELL", 57, 65], ["G M1 ganglioside", "GENE_OR_GENE_PRODUCT", 86, 102], ["G M2 ganglioside", "GENE_OR_GENE_PRODUCT", 133, 149], ["\u03b1", "GENE_OR_GENE_PRODUCT", 222, 223], ["\u03b2-N-acetylhexosaminidase", "GENE_OR_GENE_PRODUCT", 241, 265], ["G M2 activator", "GENE_OR_GENE_PRODUCT", 274, 288], ["GM2A", "GENE_OR_GENE_PRODUCT", 290, 294], ["lysosomal \u03b2-galactosidase", "PROTEIN", 16, 41], ["G M2 ganglioside", "PROTEIN", 133, 149], ["\u03b1", "PROTEIN", 222, 223], ["\u03b2", "PROTEIN", 228, 229], ["\u03b2-N-acetylhexosaminidase", "PROTEIN", 241, 265], ["G M2 activator (GM2A) protein", "PROTEIN", 274, 303], ["A deficiency of lysosomal \u03b2-galactosidase", "PROBLEM", 0, 41], ["the G M1 ganglioside", "TREATMENT", 82, 102], ["the G M2 ganglioside", "TREATMENT", 129, 149], ["\u03b2-N-acetylhexosaminidase", "TREATMENT", 241, 265], ["the G M2 activator", "TREATMENT", 270, 288], ["deficiency", "OBSERVATION", 2, 12], ["lysosomal \u03b2-galactosidase", "OBSERVATION", 16, 41], ["neuronal accumulation", "OBSERVATION", 57, 78]]], ["42, 91 Mutations in any of these enzymes result in an accumulation of gangliosides G M1 and G M2 in the lysosomes of affected neurons, resulting in progressive deterioration of the CNS.", [["lysosomes", "ANATOMY", 104, 113], ["neurons", "ANATOMY", 126, 133], ["CNS", "ANATOMY", 181, 184], ["deterioration of the CNS", "DISEASE", 160, 184], ["gangliosides G M1", "GENE_OR_GENE_PRODUCT", 70, 87], ["G M2", "GENE_OR_GENE_PRODUCT", 92, 96], ["lysosomes", "CELLULAR_COMPONENT", 104, 113], ["neurons", "CELL", 126, 133], ["CNS", "ANATOMICAL_SYSTEM", 181, 184], ["G M2", "PROTEIN", 92, 96], ["affected neurons", "CELL_TYPE", 117, 133], ["these enzymes", "TEST", 27, 40], ["an accumulation of gangliosides", "PROBLEM", 51, 82], ["affected neurons", "PROBLEM", 117, 133], ["progressive deterioration of the CNS", "PROBLEM", 148, 184], ["gangliosides G M1", "OBSERVATION_MODIFIER", 70, 87], ["affected neurons", "ANATOMY", 117, 133], ["progressive", "OBSERVATION_MODIFIER", 148, 159], ["deterioration", "OBSERVATION", 160, 173], ["CNS", "ANATOMY", 181, 184]]], ["Feline models have been especially important in characterizing the pathobiology and molecular biology of these diseases.", [["Feline", "ORGANISM", 0, 6], ["these diseases", "PROBLEM", 105, 119], ["diseases", "OBSERVATION", 111, 119]]], ["G M2 -gangliosidosis has been characterized in cat models defi cient in the G M2 activator protein and HexB, 40, 42, 92, 93 exhibiting remarkably similar pathology to human Sandhoff's disease.", [["gangliosidosis", "DISEASE", 6, 20], ["Sandhoff's disease", "DISEASE", 173, 191], ["G M2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cat", "ORGANISM", 47, 50], ["G M2 activator", "GENE_OR_GENE_PRODUCT", 76, 90], ["HexB", "GENE_OR_GENE_PRODUCT", 103, 107], ["human", "ORGANISM", 167, 172], ["G M2", "PROTEIN", 0, 4], ["G M2 activator protein", "PROTEIN", 76, 98], ["HexB", "PROTEIN", 103, 107], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["gangliosidosis", "PROBLEM", 6, 20], ["HexB", "TEST", 103, 107], ["human Sandhoff's disease", "PROBLEM", 167, 191], ["M2", "ANATOMY", 2, 4], ["gangliosidosis", "OBSERVATION", 6, 20], ["human Sandhoff", "OBSERVATION", 167, 181]]], ["91 Limited reduction in G M2 neuronal storage has been reported following bone marrow therapy.", [["neuronal", "ANATOMY", 29, 37], ["bone marrow", "ANATOMY", 74, 85], ["G M2", "GENE_OR_GENE_PRODUCT", 24, 28], ["neuronal", "CELL", 29, 37], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 74, 85], ["Limited reduction in G M2 neuronal storage", "PROBLEM", 3, 45], ["bone marrow therapy", "TREATMENT", 74, 93], ["reduction", "OBSERVATION_MODIFIER", 11, 20], ["G M2", "OBSERVATION_MODIFIER", 24, 28], ["bone", "ANATOMY", 74, 78], ["marrow therapy", "OBSERVATION", 79, 93]]], ["86 Feline models will be important in the development of therapeutic strategies for these disorders.THE CAT AS ANIMAL MODEL FOR HUMAN HEREDITARY DISEASEMucolipidosis II (I-cell disease) is caused by deficient activity of the enzyme N-acetylglucosamine-1-phosphotransferase, which leads to a failure to internalize enzymes into lysosomes.", [["cell", "ANATOMY", 172, 176], ["lysosomes", "ANATOMY", 327, 336], ["I-cell disease", "DISEASE", 170, 184], ["N-acetylglucosamine-1-phosphotransferase", "CHEMICAL", 232, 272], ["N-acetylglucosamine", "CHEMICAL", 232, 251], ["Feline", "ORGANISM", 3, 9], ["HEREDITARY DISEASEMucolipidosis II", "CANCER", 134, 168], ["I-cell", "CELL", 170, 176], ["N-acetylglucosamine-1-phosphotransferase", "GENE_OR_GENE_PRODUCT", 232, 272], ["lysosomes", "CELLULAR_COMPONENT", 327, 336], ["enzyme N-acetylglucosamine-1-phosphotransferase", "PROTEIN", 225, 272], ["enzymes", "PROTEIN", 314, 321], ["therapeutic strategies", "TREATMENT", 57, 79], ["these disorders", "PROBLEM", 84, 99], ["HUMAN HEREDITARY DISEASEMucolipidosis II (I-cell disease", "PROBLEM", 128, 184], ["the enzyme N-acetylglucosamine", "TEST", 221, 251], ["a failure to internalize enzymes into lysosomes", "PROBLEM", 289, 336], ["failure", "OBSERVATION", 291, 298]]], ["The cat is the only known animal model for this pathology.", [["cat", "ORGANISM", 4, 7], ["this pathology", "PROBLEM", 43, 57]]], ["94 Congenital diseases of feline muscle and neuromuscular junction have been reviewed by Gashen et al. 95 Some pathologies have been observed in isolated breeds, including hypokalemic myopathy of Burmese cats, 96 glycogen storage disease type IV in Norwegian Forest cats, 44 and myopathy observed in the Devon Rex.", [["muscle", "ANATOMY", 33, 39], ["neuromuscular junction", "ANATOMY", 44, 66], ["Congenital diseases of feline muscle", "DISEASE", 3, 39], ["hypokalemic myopathy", "DISEASE", 172, 192], ["glycogen", "CHEMICAL", 213, 221], ["myopathy", "DISEASE", 279, 287], ["feline", "ORGANISM", 26, 32], ["muscle", "ORGAN", 33, 39], ["neuromuscular junction", "MULTI-TISSUE_STRUCTURE", 44, 66], ["cats", "ORGANISM", 204, 208], ["glycogen", "SIMPLE_CHEMICAL", 213, 221], ["feline", "SPECIES", 26, 32], ["cats", "SPECIES", 204, 208], ["cats", "SPECIES", 266, 270], ["Congenital diseases of feline muscle and neuromuscular junction", "PROBLEM", 3, 66], ["Some pathologies", "PROBLEM", 106, 122], ["hypokalemic myopathy", "PROBLEM", 172, 192], ["Burmese cats", "PROBLEM", 196, 208], ["glycogen storage disease type IV", "PROBLEM", 213, 245], ["Norwegian Forest cats", "TEST", 249, 270], ["myopathy", "PROBLEM", 279, 287], ["Congenital", "OBSERVATION_MODIFIER", 3, 13], ["diseases", "OBSERVATION", 14, 22], ["feline muscle", "ANATOMY", 26, 39], ["neuromuscular junction", "ANATOMY", 44, 66], ["hypokalemic myopathy", "OBSERVATION", 172, 192], ["myopathy", "OBSERVATION", 279, 287], ["Devon Rex", "OBSERVATION", 304, 313]]], ["97 The cat is the only reported animal model for type IV glycogen storage disease.", [["type IV glycogen storage disease", "DISEASE", 49, 81], ["cat", "ORGANISM", 7, 10], ["glycogen", "SIMPLE_CHEMICAL", 57, 65], ["type IV glycogen storage disease", "PROBLEM", 49, 81], ["glycogen storage disease", "OBSERVATION", 57, 81]]], ["Myotonia congenital, 95,98 muscular dystrophy (dystrophin defi cient), 52 and laminin \u03b1 2 defi ciency 52, 99 have also been reported in the cat.THE CAT AS ANIMAL MODEL FOR HUMAN HEREDITARY DISEASEX-linked muscular dystrophy in humans is characterized by progressive degeneration of skeletal and cardiac muscle.", [["muscular", "ANATOMY", 27, 35], ["muscular", "ANATOMY", 205, 213], ["skeletal", "ANATOMY", 282, 290], ["cardiac muscle", "ANATOMY", 295, 309], ["Myotonia congenital", "DISEASE", 0, 19], ["muscular dystrophy", "DISEASE", 27, 45], ["muscular dystrophy", "DISEASE", 205, 223], ["degeneration of skeletal and cardiac muscle", "DISEASE", 266, 309], ["muscular", "ORGAN", 27, 35], ["dystrophin", "GENE_OR_GENE_PRODUCT", 47, 57], ["laminin \u03b1 2", "GENE_OR_GENE_PRODUCT", 78, 89], ["cat", "ORGANISM", 140, 143], ["muscular", "ORGAN", 205, 213], ["humans", "ORGANISM", 227, 233], ["skeletal", "TISSUE", 282, 290], ["cardiac muscle", "TISSUE", 295, 309], ["cat", "SPECIES", 140, 143], ["humans", "SPECIES", 227, 233], ["humans", "SPECIES", 227, 233], ["Myotonia congenital", "PROBLEM", 0, 19], ["muscular dystrophy", "PROBLEM", 27, 45], ["muscular dystrophy", "PROBLEM", 205, 223], ["progressive degeneration of skeletal and cardiac muscle", "PROBLEM", 254, 309], ["muscular dystrophy", "OBSERVATION", 27, 45], ["muscular dystrophy", "OBSERVATION", 205, 223], ["progressive", "OBSERVATION_MODIFIER", 254, 265], ["degeneration", "OBSERVATION", 266, 278], ["skeletal", "ANATOMY", 282, 290], ["cardiac muscle", "ANATOMY", 295, 309]]], ["Mutations in humans lead to either an absence of or abnormality in the protein product dystrophin.", [["humans", "ORGANISM", 13, 19], ["dystrophin", "GENE_OR_GENE_PRODUCT", 87, 97], ["protein product", "PROTEIN", 71, 86], ["dystrophin", "PROTEIN", 87, 97], ["humans", "SPECIES", 13, 19], ["humans", "SPECIES", 13, 19], ["Mutations in humans", "PROBLEM", 0, 19], ["abnormality in the protein product dystrophin", "PROBLEM", 52, 97]]], ["100, 101 A deletion in the dystrophin muscle promoter characterized in the cat eliminates expression of muscle and Purkinje neuronal dystrophin isoforms.", [["muscle", "ANATOMY", 38, 44], ["muscle", "ANATOMY", 104, 110], ["Purkinje neuronal", "ANATOMY", 115, 132], ["dystrophin", "GENE_OR_GENE_PRODUCT", 27, 37], ["muscle", "ORGAN", 38, 44], ["cat", "ORGANISM", 75, 78], ["muscle", "ORGAN", 104, 110], ["Purkinje neuronal dystrophin", "GENE_OR_GENE_PRODUCT", 115, 143], ["dystrophin muscle promoter", "DNA", 27, 53], ["muscle and Purkinje neuronal dystrophin isoforms", "PROTEIN", 104, 152], ["A deletion in the dystrophin muscle promoter", "PROBLEM", 9, 53], ["muscle and Purkinje neuronal dystrophin isoforms", "PROBLEM", 104, 152], ["deletion", "OBSERVATION", 11, 19], ["dystrophin muscle", "ANATOMY", 27, 44], ["muscle", "ANATOMY", 104, 110], ["Purkinje neuronal", "OBSERVATION", 115, 132], ["dystrophin isoforms", "OBSERVATION", 133, 152]]], ["52 Marked clinical heterogeneity is observed in these models, from severe disability exhibited in human and dog, to minor muscle fi brosis and an actual regenerative process leading to muscle hypertrophy in mouse and cat.", [["muscle", "ANATOMY", 122, 128], ["muscle", "ANATOMY", 185, 191], ["disability", "DISEASE", 74, 84], ["muscle hypertrophy", "DISEASE", 185, 203], ["human", "ORGANISM", 98, 103], ["dog", "ORGANISM_SUBDIVISION", 108, 111], ["muscle", "ORGAN", 122, 128], ["muscle", "ORGAN", 185, 191], ["mouse", "ORGANISM", 207, 212], ["cat", "ORGANISM", 217, 220], ["human", "SPECIES", 98, 103], ["dog", "SPECIES", 108, 111], ["mouse", "SPECIES", 207, 212], ["cat", "SPECIES", 217, 220], ["human", "SPECIES", 98, 103], ["mouse", "SPECIES", 207, 212], ["Marked clinical heterogeneity", "PROBLEM", 3, 32], ["severe disability", "PROBLEM", 67, 84], ["minor muscle fi brosis", "PROBLEM", 116, 138], ["an actual regenerative process", "PROBLEM", 143, 173], ["muscle hypertrophy in mouse and cat", "PROBLEM", 185, 220], ["Marked", "OBSERVATION_MODIFIER", 3, 9], ["heterogeneity", "OBSERVATION", 19, 32], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["disability", "OBSERVATION", 74, 84], ["muscle fi", "ANATOMY", 122, 131], ["brosis", "OBSERVATION", 132, 138], ["regenerative process", "OBSERVATION", 153, 173], ["muscle", "ANATOMY", 185, 191], ["hypertrophy", "OBSERVATION", 192, 203]]], ["[102] [103] [104] These different sequellae could be important in characterizing immediate and secondary consequences of the lack of dystrophin 105 and points out the importance of multiple animal models.THE CAT AS ANIMAL MODEL FOR HUMAN HEREDITARY DISEASEHypertrophic cardiomyopathy is a clinically heterogeneous myocardial disease contributing to one of the most common causes of sudden cardiac death in young adults.", [["myocardial", "ANATOMY", 314, 324], ["cardiac", "ANATOMY", 389, 396], ["DISEASEHypertrophic cardiomyopathy", "DISEASE", 249, 283], ["myocardial disease", "DISEASE", 314, 332], ["sudden cardiac death", "DISEASE", 382, 402], ["dystrophin 105", "GENE_OR_GENE_PRODUCT", 133, 147], ["myocardial", "MULTI-TISSUE_STRUCTURE", 314, 324], ["cardiac", "ORGAN", 389, 396], ["dystrophin 105", "PROTEIN", 133, 147], ["These different sequellae", "PROBLEM", 18, 43], ["dystrophin 105", "PROBLEM", 133, 147], ["HUMAN HEREDITARY DISEASEHypertrophic cardiomyopathy", "PROBLEM", 232, 283], ["a clinically heterogeneous myocardial disease", "PROBLEM", 287, 332], ["sudden cardiac death", "PROBLEM", 382, 402], ["cardiomyopathy", "OBSERVATION", 269, 283], ["heterogeneous", "OBSERVATION_MODIFIER", 300, 313], ["myocardial", "ANATOMY", 314, 324], ["disease", "OBSERVATION", 325, 332], ["cardiac", "ANATOMY", 389, 396], ["death", "OBSERVATION", 397, 402]]], ["106 The cat represent the first spontaneous large animal model for this familial disease 47 and will prove to be valuable for examining pathophysiological processes and therapeutic interventions.THE POTENTIAL FOR KNOCKOUT CATSThere is a continued demand for alternative mammalian models for studying human diseases.", [["familial disease", "DISEASE", 72, 88], ["cat", "ORGANISM", 8, 11], ["human", "ORGANISM", 300, 305], ["human", "SPECIES", 300, 305], ["human", "SPECIES", 300, 305], ["this familial disease", "PROBLEM", 67, 88], ["therapeutic interventions", "TREATMENT", 169, 194], ["KNOCKOUT CATSThere", "TREATMENT", 213, 231], ["alternative mammalian models", "TREATMENT", 258, 286], ["studying human diseases", "PROBLEM", 291, 314]]], ["Compared to traditional murine models, the cat's more similar physiology, increased size, and longevity have made it ideal for testing the safety and efficacy of some therapeutic modalities in naturally occurring feline disease models.", [["feline disease", "DISEASE", 213, 227], ["murine", "ORGANISM", 24, 30], ["cat", "ORGANISM", 43, 46], ["feline", "ORGANISM", 213, 219], ["murine", "SPECIES", 24, 30], ["testing", "TEST", 127, 134], ["some therapeutic modalities", "TREATMENT", 162, 189], ["feline disease models", "PROBLEM", 213, 234], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["size", "OBSERVATION_MODIFIER", 84, 88]]], ["[107] [108] [109] [110] Additionally, cats have a genetically heterogeneous background, similar to humans.", [["cats", "ORGANISM", 38, 42], ["humans", "ORGANISM", 99, 105], ["cats", "SPECIES", 38, 42], ["humans", "SPECIES", 99, 105], ["humans", "SPECIES", 99, 105], ["a genetically heterogeneous background", "PROBLEM", 48, 86], ["heterogeneous", "OBSERVATION_MODIFIER", 62, 75]]], ["A good example of a human disease in need of a better mammalian model is cystic fibrosis, as mice targeted with the most common human mutation (\u2206F508) in the cystic fibrosis transmembrane receptor (CFTR) fail to spontaneously develop the same opportunistic lung infections that plague human patients with cystic fi brosis.", [["cystic", "ANATOMY", 73, 79], ["lung", "ANATOMY", 257, 261], ["fibrosis", "DISEASE", 80, 88], ["fibrosis", "DISEASE", 165, 173], ["opportunistic lung infections", "DISEASE", 243, 272], ["cystic fi brosis", "DISEASE", 305, 321], ["human", "ORGANISM", 20, 25], ["cystic fibrosis", "PATHOLOGICAL_FORMATION", 73, 88], ["mice", "ORGANISM", 93, 97], ["human", "ORGANISM", 128, 133], ["\u2206F508", "ORGANISM", 144, 149], ["cystic fibrosis transmembrane receptor", "GENE_OR_GENE_PRODUCT", 158, 196], ["CFTR", "GENE_OR_GENE_PRODUCT", 198, 202], ["lung", "ORGAN", 257, 261], ["human", "ORGANISM", 285, 290], ["patients", "ORGANISM", 291, 299], ["cystic fibrosis transmembrane receptor", "PROTEIN", 158, 196], ["CFTR", "PROTEIN", 198, 202], ["human", "SPECIES", 20, 25], ["mice", "SPECIES", 93, 97], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 285, 290], ["patients", "SPECIES", 291, 299], ["human", "SPECIES", 20, 25], ["mice", "SPECIES", 93, 97], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 285, 290], ["a human disease", "PROBLEM", 18, 33], ["cystic fibrosis", "PROBLEM", 73, 88], ["the cystic fibrosis transmembrane receptor (CFTR)", "PROBLEM", 154, 203], ["the same opportunistic lung infections", "PROBLEM", 234, 272], ["cystic fi brosis", "PROBLEM", 305, 321], ["good", "OBSERVATION_MODIFIER", 2, 6], ["disease", "OBSERVATION", 26, 33], ["cystic", "OBSERVATION_MODIFIER", 73, 79], ["fibrosis", "OBSERVATION", 80, 88], ["cystic", "OBSERVATION_MODIFIER", 158, 164], ["fibrosis", "OBSERVATION", 165, 173], ["opportunistic", "OBSERVATION_MODIFIER", 243, 256], ["lung", "ANATOMY", 257, 261], ["infections", "OBSERVATION", 262, 272]]], ["111, 112 One group has been working to produce a ferret cystic fibrosis model through gene targeting of somatic cells for nuclear transfer.", [["cystic", "ANATOMY", 56, 62], ["somatic cells", "ANATOMY", 104, 117], ["nuclear", "ANATOMY", 122, 129], ["fibrosis", "DISEASE", 63, 71], ["ferret", "ORGANISM", 49, 55], ["cystic", "ORGAN", 56, 62], ["somatic cells", "CELL", 104, 117], ["nuclear", "CELLULAR_COMPONENT", 122, 129], ["somatic cells", "CELL_TYPE", 104, 117], ["a ferret cystic fibrosis model", "PROBLEM", 47, 77], ["somatic cells", "PROBLEM", 104, 117], ["cystic", "OBSERVATION_MODIFIER", 56, 62], ["fibrosis", "OBSERVATION", 63, 71]]], ["113, 114 While reproductive cloning has a consistently low success rate (1-4%) across mammalian species, 115 targeting genetic loci through homologous recombination in somatic cells is currently the only viable method for producing knockout models in all mammalian species other than the mouse, for which targeted embryonic stem cells are routinely used.", [["somatic cells", "ANATOMY", 168, 181], ["embryonic stem cells", "ANATOMY", 314, 334], ["somatic cells", "CELL", 168, 181], ["mouse", "ORGANISM", 288, 293], ["embryonic stem cells", "CELL", 314, 334], ["somatic cells", "CELL_TYPE", 168, 181], ["targeted embryonic stem cells", "CELL_TYPE", 305, 334], ["mouse", "SPECIES", 288, 293], ["mouse", "SPECIES", 288, 293], ["across mammalian species", "PROBLEM", 79, 103], ["genetic loci through homologous recombination in somatic cells", "PROBLEM", 119, 181], ["knockout models", "PROBLEM", 232, 247], ["all mammalian species", "PROBLEM", 251, 272], ["targeted embryonic stem cells", "TREATMENT", 305, 334], ["somatic cells", "OBSERVATION", 168, 181], ["embryonic stem cells", "OBSERVATION", 314, 334]]], ["Nuclear transfer of targeted fibroblasts has been successfully used to produce viable \u03b1-1,3-galactosyltransferase knockout pig and cow models for xenotransplantation studies.", [["Nuclear", "ANATOMY", 0, 7], ["fibroblasts", "ANATOMY", 29, 40], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["fibroblasts", "CELL", 29, 40], ["\u03b1-1,3-galactosyltransferase", "GENE_OR_GENE_PRODUCT", 86, 113], ["pig", "ORGANISM", 123, 126], ["cow", "ORGANISM", 131, 134], ["targeted fibroblasts", "CELL_TYPE", 20, 40], ["\u03b1-1,3-galactosyltransferase", "PROTEIN", 86, 113], ["pig", "SPECIES", 123, 126], ["pig", "SPECIES", 123, 126], ["cow", "SPECIES", 131, 134], ["targeted fibroblasts", "PROBLEM", 20, 40], ["xenotransplantation studies", "TEST", 146, 173]]], ["116, 117 With the successful reproductive cloning of cats by several groups, 118-120 the development of gene-targeted cat models through nuclear transfer is now feasible.", [["nuclear", "ANATOMY", 137, 144], ["cats", "ORGANISM", 53, 57], ["cat", "ORGANISM", 118, 121], ["nuclear", "CELLULAR_COMPONENT", 137, 144]]], ["121 The imminent release of the annotated feline genome project, 17 integration of recombination and radiation hybrid maps, [5] [6] [7] [8] [9] [10] 122 and availability of multiple PAC, BAC, 123 flow-sorted autosome, and Y-chromosome libraries 124, 125 (J. Pecon-Slattery et al., unpublished observations) at the Laboratory of Genomic Diversity will facilitate efforts by researchers to develop new cat models of specific human genetic diseases.COAT COLOR GENES IN THE DOMESTIC CATThe coat color loci influence the development, maturation, and migration of melanocytes as well as the synthesis of melanin and the formation, transport, and transfer of melanosomes.", [["melanocytes", "ANATOMY", 558, 569], ["melanosomes", "ANATOMY", 652, 663], ["[5] [6] [7] [8] [9] [10] 122", "CHEMICAL", 124, 152], ["PAC", "CHEMICAL", 182, 185], ["genetic diseases", "DISEASE", 429, 445], ["feline", "ORGANISM", 42, 48], ["[5] [6] [7] [8] [9] [10] 122", "SIMPLE_CHEMICAL", 124, 152], ["autosome", "CELLULAR_COMPONENT", 208, 216], ["cat", "ORGANISM", 400, 403], ["human", "ORGANISM", 423, 428], ["melanocytes", "CELL", 558, 569], ["melanin", "SIMPLE_CHEMICAL", 598, 605], ["melanosomes", "CELLULAR_COMPONENT", 652, 663], ["multiple PAC, BAC, 123 flow-sorted autosome", "DNA", 173, 216], ["CAT", "PROTEIN", 479, 482], ["coat color loci", "DNA", 486, 501], ["melanocytes", "CELL_TYPE", 558, 569], ["human", "SPECIES", 423, 428], ["human", "SPECIES", 423, 428], ["the annotated feline genome project", "TREATMENT", 28, 63], ["radiation hybrid maps", "TREATMENT", 101, 122], ["multiple PAC", "TEST", 173, 185], ["BAC", "TEST", 187, 190], ["flow", "TEST", 196, 200], ["Y-chromosome libraries", "TEST", 222, 244], ["specific human genetic diseases", "PROBLEM", 414, 445], ["The coat color loci", "PROBLEM", 482, 501], ["melanocytes", "PROBLEM", 558, 569], ["the synthesis of melanin", "PROBLEM", 581, 605], ["COLOR GENES", "OBSERVATION", 451, 462], ["coat", "OBSERVATION_MODIFIER", 486, 490], ["color loci", "OBSERVATION", 491, 501], ["maturation", "OBSERVATION_MODIFIER", 529, 539]]], ["Genes involved in these processes often have pleiotropic effects, which impact other important biochemical pathways.", [["pleiotropic effects", "PROBLEM", 45, 64]]], ["Coat color loci in the mouse have been known to be part of diverse cellular, developmental, and physiological processes and in some cases to be implicated in pathologies such as anemia, sterility, and neurological disorders.", [["cellular", "ANATOMY", 67, 75], ["neurological", "ANATOMY", 201, 213], ["anemia", "DISEASE", 178, 184], ["sterility", "DISEASE", 186, 195], ["neurological disorders", "DISEASE", 201, 223], ["mouse", "ORGANISM", 23, 28], ["cellular", "CELL", 67, 75], ["Coat color loci", "DNA", 0, 15], ["mouse", "SPECIES", 23, 28], ["mouse", "SPECIES", 23, 28], ["Coat color loci", "PROBLEM", 0, 15], ["diverse cellular, developmental, and physiological processes", "PROBLEM", 59, 119], ["pathologies", "PROBLEM", 158, 169], ["anemia", "PROBLEM", 178, 184], ["sterility", "PROBLEM", 186, 195], ["neurological disorders", "PROBLEM", 201, 223], ["color loci", "OBSERVATION", 5, 15], ["known to be", "UNCERTAINTY", 39, 50], ["diverse", "OBSERVATION_MODIFIER", 59, 66], ["cellular", "OBSERVATION", 67, 75], ["anemia", "OBSERVATION", 178, 184]]], ["[126] [127] [128] The cat is an excellent model system with which to study coat color phenotypes.", [["cat", "ORGANISM", 22, 25]]], ["At least nine different coat color loci have been identified in the cat, 129 and several are now characterized on a molecular genetic level including, a (nonagouti) responsible for melanism, 18 b (Brown), which changes black pigmentation to brown or variants of brown, 32 c (color), causing the darker pigmentation at extremities (i.e., ears, tail), observed in Siamese and Burmese cats 32,37 and albinism, 36 and d (dilute), which causes dilution of expected color (i.e., black pigmentation appears gray).", [["extremities", "ANATOMY", 318, 329], ["ears", "ANATOMY", 337, 341], ["tail", "ANATOMY", 343, 347], ["melanism", "DISEASE", 181, 189], ["albinism", "DISEASE", 397, 405], ["cat", "ORGANISM", 68, 71], ["extremities", "ORGANISM_SUBDIVISION", 318, 329], ["ears", "ORGAN", 337, 341], ["tail", "ORGANISM_SUBDIVISION", 343, 347], ["cats", "ORGANISM", 382, 386], ["coat color loci", "DNA", 24, 39], ["cats", "SPECIES", 382, 386], ["Burmese cats 32,37", "SPECIES", 374, 392], ["nine different coat color loci", "PROBLEM", 9, 39], ["melanism", "PROBLEM", 181, 189], ["black pigmentation to brown or variants of brown, 32 c (color)", "PROBLEM", 219, 281], ["the darker pigmentation at extremities", "PROBLEM", 291, 329], ["Burmese cats", "TEST", 374, 386], ["albinism", "TEST", 397, 405], ["least", "OBSERVATION_MODIFIER", 3, 8], ["nine", "OBSERVATION_MODIFIER", 9, 13], ["different", "OBSERVATION_MODIFIER", 14, 23], ["coat", "OBSERVATION_MODIFIER", 24, 28], ["color loci", "OBSERVATION", 29, 39], ["black", "OBSERVATION_MODIFIER", 219, 224], ["pigmentation", "OBSERVATION_MODIFIER", 225, 237], ["brown", "OBSERVATION_MODIFIER", 241, 246], ["brown", "OBSERVATION_MODIFIER", 262, 267], ["32 c", "OBSERVATION_MODIFIER", 269, 273], ["darker pigmentation", "OBSERVATION", 295, 314], ["extremities", "ANATOMY", 318, 329], ["ears", "ANATOMY", 337, 341], ["tail", "ANATOMY", 343, 347]]], ["35 The cat is also unique in mammalian species in exhibiting a variation in coat pattern, demonstrating agouti (A) (nonpatterned coat) and variants of the T (tabby) locus, which affect striping and spotting patterns.VIRAL PATHOGENS OF THE DOMESTIC CATThe cat has provided several useful models for infectious disease.", [["infectious disease", "DISEASE", 298, 316], ["cat", "ORGANISM", 7, 10], ["agouti (A)", "GENE_OR_GENE_PRODUCT", 104, 114], ["T (tabby)", "GENE_OR_GENE_PRODUCT", 155, 164], ["cat", "ORGANISM", 255, 258], ["T (tabby) locus", "DNA", 155, 170], ["a variation in coat pattern", "PROBLEM", 61, 88], ["agouti (A) (nonpatterned coat)", "PROBLEM", 104, 134], ["infectious disease", "PROBLEM", 298, 316], ["mammalian species", "OBSERVATION", 29, 46], ["variation", "OBSERVATION_MODIFIER", 63, 72], ["coat pattern", "OBSERVATION", 76, 88], ["infectious", "OBSERVATION", 298, 308]]], ["These include feline leukemia and feline sarcoma virus, feline coronavirus, and Type C retroviruses that interact with cellular oncogenes to induce leukemia, lymphoma, and sarcoma.", [["feline leukemia", "ANATOMY", 14, 29], ["cellular", "ANATOMY", 119, 127], ["leukemia", "ANATOMY", 148, 156], ["lymphoma", "ANATOMY", 158, 166], ["sarcoma", "ANATOMY", 172, 179], ["feline leukemia", "DISEASE", 14, 29], ["feline sarcoma", "DISEASE", 34, 48], ["feline coronavirus", "DISEASE", 56, 74], ["leukemia, lymphoma", "DISEASE", 148, 166], ["sarcoma", "DISEASE", 172, 179], ["feline", "ORGANISM", 14, 20], ["leukemia", "CANCER", 21, 29], ["feline sarcoma virus", "ORGANISM", 34, 54], ["feline coronavirus", "ORGANISM", 56, 74], ["Type C retroviruses", "ORGANISM", 80, 99], ["cellular", "CELL", 119, 127], ["leukemia", "CANCER", 148, 156], ["lymphoma", "CANCER", 158, 166], ["sarcoma", "CANCER", 172, 179], ["cellular oncogenes", "DNA", 119, 137], ["feline", "SPECIES", 14, 20], ["feline sarcoma virus", "SPECIES", 34, 54], ["feline coronavirus", "SPECIES", 56, 74], ["feline sarcoma virus", "SPECIES", 34, 54], ["feline coronavirus", "SPECIES", 56, 74], ["Type C retroviruses", "SPECIES", 80, 99], ["feline leukemia", "PROBLEM", 14, 29], ["feline sarcoma virus", "PROBLEM", 34, 54], ["feline coronavirus", "PROBLEM", 56, 74], ["Type C retroviruses", "PROBLEM", 80, 99], ["cellular oncogenes", "TREATMENT", 119, 137], ["leukemia", "PROBLEM", 148, 156], ["lymphoma", "PROBLEM", 158, 166], ["sarcoma", "PROBLEM", 172, 179], ["feline leukemia", "OBSERVATION", 14, 29], ["feline sarcoma virus", "OBSERVATION", 34, 54], ["feline coronavirus", "OBSERVATION", 56, 74], ["retroviruses", "OBSERVATION", 87, 99], ["leukemia", "OBSERVATION", 148, 156], ["lymphoma", "OBSERVATION", 158, 166], ["sarcoma", "OBSERVATION", 172, 179]]], ["[130] [131] [132] Historically, many of the human oncogenes that defi ne signal transduction pathways were originally discovered in the context of feline leukemia virus interaction in cat models.", [["leukemia", "ANATOMY", 154, 162], ["feline leukemia", "DISEASE", 147, 162], ["human", "ORGANISM", 44, 49], ["feline leukemia virus", "ORGANISM", 147, 168], ["cat", "ORGANISM", 184, 187], ["human oncogenes", "DNA", 44, 59], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["feline leukemia virus", "SPECIES", 147, 168], ["feline leukemia virus interaction in cat models", "PROBLEM", 147, 194], ["feline leukemia virus", "OBSERVATION", 147, 168]]], ["The cat provides the only naturally occurring model for human AIDS pathogenesis, in its endemic fatal transmissible feline immunodefi ciency virus (FIV).", [["AIDS", "DISEASE", 62, 66], ["feline immunodefi ciency", "DISEASE", 116, 140], ["cat", "ORGANISM", 4, 7], ["human", "ORGANISM", 56, 61], ["feline", "ORGANISM", 116, 122], ["immunodefi ciency virus", "ORGANISM", 123, 146], ["FIV", "ORGANISM", 148, 151], ["human", "SPECIES", 56, 61], ["feline immunodefi ciency virus", "SPECIES", 116, 146], ["human", "SPECIES", 56, 61], ["feline immunodefi ciency virus", "SPECIES", 116, 146], ["FIV", "SPECIES", 148, 151], ["human AIDS pathogenesis", "PROBLEM", 56, 79]]], ["133, 134 Similar to its close phylogenetic relative HIV, FIV induces CD4-T lymphocyte depletion in affected cats, an immune system collapse, and susceptibility to adventitious microbial agents as a prelude to wasting disease and death.", [["CD4-T lymphocyte", "ANATOMY", 69, 85], ["immune system", "ANATOMY", 117, 130], ["wasting disease", "DISEASE", 209, 224], ["death", "DISEASE", 229, 234], ["HIV", "ORGANISM", 52, 55], ["FIV", "ORGANISM", 57, 60], ["CD4", "GENE_OR_GENE_PRODUCT", 69, 72], ["T lymphocyte", "CELL", 73, 85], ["cats", "ORGANISM", 108, 112], ["CD4", "PROTEIN", 69, 72], ["cats", "SPECIES", 108, 112], ["HIV", "SPECIES", 52, 55], ["FIV", "SPECIES", 57, 60], ["CD4", "TEST", 69, 72], ["T lymphocyte depletion", "PROBLEM", 73, 95], ["affected cats", "PROBLEM", 99, 112], ["an immune system collapse", "PROBLEM", 114, 139], ["adventitious microbial agents", "TREATMENT", 163, 192], ["wasting disease", "PROBLEM", 209, 224], ["death", "PROBLEM", 229, 234], ["lymphocyte depletion", "OBSERVATION", 75, 95], ["immune system", "OBSERVATION", 117, 130], ["collapse", "OBSERVATION", 131, 139]]], ["133, 135 Interestingly, over 10 wildcat species (including lions, leopards, cheetahs, ocelots, pumas and other big cats) are endemic with their own species-specific strain of FIV [136] [137] [138] [139] [140] [141] ; however, unlike strains in domestic cats, the wildcat FIV strains do not appear to cause acute immunodeficiency in the wildcat species, perhaps a consequence of historic natural selection of host genetic resistance to the fatal virus.", [["ocelots", "ANATOMY", 86, 93], ["pumas", "ANATOMY", 95, 100], ["FIV [136] [137] [138] [139] [140] [141", "CHEMICAL", 175, 213], ["immunodeficiency", "DISEASE", 312, 328], ["cats", "ORGANISM", 115, 119], ["FIV", "ORGANISM", 175, 178], ["domestic cats", "ORGANISM", 244, 257], ["wildcat FIV", "ORGANISM", 263, 274], ["cats", "SPECIES", 115, 119], ["cats", "SPECIES", 253, 257], ["FIV", "SPECIES", 175, 178], ["ocelots", "TREATMENT", 86, 93], ["pumas", "TREATMENT", 95, 100], ["strains in domestic cats", "PROBLEM", 233, 257], ["the wildcat FIV strains", "PROBLEM", 259, 282], ["acute immunodeficiency in the wildcat species", "PROBLEM", 306, 351], ["the fatal virus", "PROBLEM", 435, 450], ["acute", "OBSERVATION_MODIFIER", 306, 311], ["immunodeficiency", "OBSERVATION", 312, 328], ["host genetic resistance", "OBSERVATION", 408, 431], ["fatal virus", "OBSERVATION", 439, 450]]], ["139, 142 Lion and puma-specific FIV strains have recently been demonstrated to utilize novel, more promiscuous mechanisms for cell entry than FIV, suggesting a divergent tropism and biological properties of these viruses.", [["cell", "ANATOMY", 126, 130], ["puma-specific FIV", "ORGANISM", 18, 35], ["cell", "CELL", 126, 130], ["FIV", "ORGANISM", 142, 145], ["FIV", "SPECIES", 142, 145], ["Lion", "TEST", 9, 13], ["puma-specific FIV strains", "TEST", 18, 43], ["cell entry than FIV", "PROBLEM", 126, 145], ["a divergent tropism", "PROBLEM", 158, 177], ["these viruses", "PROBLEM", 207, 220], ["divergent tropism", "OBSERVATION", 160, 177], ["viruses", "OBSERVATION", 213, 220]]], ["143 The World Health Organization reported a new human respiratory illness outbreak (severe acute respiratory syndrome, SARS) that emerged in Guangdong Province, China in 2003.", [["respiratory illness", "DISEASE", 55, 74], ["acute respiratory syndrome", "DISEASE", 92, 118], ["SARS", "DISEASE", 120, 124], ["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["a new human respiratory illness outbreak", "PROBLEM", 43, 83], ["severe acute respiratory syndrome", "PROBLEM", 85, 118], ["SARS", "PROBLEM", 120, 124], ["new", "OBSERVATION_MODIFIER", 45, 48], ["respiratory illness", "OBSERVATION", 55, 74], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["respiratory syndrome", "OBSERVATION", 98, 118]]], ["144, 145 Sequence analysis demonstrated that the infectious agent was a previously unrecognized coronavirus.", [["coronavirus", "DISEASE", 96, 107], ["coronavirus", "ORGANISM", 96, 107], ["Sequence analysis", "TEST", 9, 26], ["the infectious agent", "PROBLEM", 45, 65], ["a previously unrecognized coronavirus", "PROBLEM", 70, 107], ["infectious", "OBSERVATION", 49, 59], ["coronavirus", "OBSERVATION", 96, 107]]], ["146, 147 An animal model demonstrating clinical symptoms and pathology of SARS-infected patients has not been reported.", [["SARS-infected", "DISEASE", 74, 87], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["clinical symptoms", "PROBLEM", 39, 56], ["SARS", "PROBLEM", 74, 78]]], ["148 Of interest, the recent report of a highly virulent feline coronavirus epidemic in captive African cheetahs, a disease model for human SARS, illustrates the critical role of ancestral population genetic variation.", [["feline coronavirus", "DISEASE", 56, 74], ["SARS", "DISEASE", 139, 143], ["feline coronavirus", "ORGANISM", 56, 74], ["human", "ORGANISM", 133, 138], ["feline coronavirus", "SPECIES", 56, 74], ["human", "SPECIES", 133, 138], ["feline coronavirus", "SPECIES", 56, 74], ["African cheetahs", "SPECIES", 95, 111], ["human", "SPECIES", 133, 138], ["a highly virulent feline coronavirus", "PROBLEM", 38, 74], ["human SARS", "PROBLEM", 133, 143]]], ["132 In addition, cats injected with the SARS virus developed clinical symptoms, an important insight in implicating the virus in the SARS epidemic.", [["SARS", "DISEASE", 40, 44], ["SARS", "DISEASE", 133, 137], ["cats", "ORGANISM", 17, 21], ["cats", "SPECIES", 17, 21], ["SARS virus", "SPECIES", 40, 50], ["cats", "TREATMENT", 17, 21], ["the SARS virus", "PROBLEM", 36, 50], ["clinical symptoms", "PROBLEM", 61, 78], ["the virus", "PROBLEM", 116, 125]]], ["[149] [150] [151] [152] The feline panleukopenia (feline distemper) virus has revealed a natural history parable in its abrupt transformation of the cat virus to an epidemic, fatal canine parvovirus, that emerged in the world's puppy population in 1978.", [["feline panleukopenia", "DISEASE", 28, 48], ["feline distemper) virus", "DISEASE", 50, 73], ["canine parvovirus", "DISEASE", 181, 198], ["feline", "ORGANISM", 28, 34], ["panleukopenia", "ORGANISM", 35, 48], ["feline distemper", "ORGANISM", 50, 66], ["cat virus", "ORGANISM", 149, 158], ["canine parvovirus", "ORGANISM", 181, 198], ["feline distemper", "SPECIES", 50, 66], ["cat", "SPECIES", 149, 152], ["canine parvovirus", "SPECIES", 181, 198], ["feline panleukopenia (feline distemper) virus", "SPECIES", 28, 73], ["cat virus", "SPECIES", 149, 158], ["canine parvovirus", "SPECIES", 181, 198], ["The feline panleukopenia", "TEST", 24, 48], ["feline distemper) virus", "PROBLEM", 50, 73], ["the cat virus", "PROBLEM", 145, 158], ["fatal canine parvovirus", "PROBLEM", 175, 198], ["abrupt", "OBSERVATION_MODIFIER", 120, 126]]], ["153 In contrast, the canine distemper virus, which is normally restricted to canid species, precipitously adapted to and decimated East African lions in 1994, killing one-third of the lions in the Serengeti ecosystem within a 9-month outbreak.", [["canine distemper virus", "ORGANISM", 21, 43], ["canine distemper virus", "SPECIES", 21, 43], ["canine distemper virus", "SPECIES", 21, 43], ["the canine distemper virus", "PROBLEM", 17, 43], ["distemper virus", "OBSERVATION", 28, 43], ["lions", "OBSERVATION", 184, 189]]], ["154 A clear involvement of host defense mecha- nisms in these and other infectious disease episodes renders the cats and their pathogens an excellent candidate species for characterizing the interaction of microbial adaptation and host disease gene defenses.", [["infectious disease", "DISEASE", 72, 90], ["mecha- nisms", "GENE_OR_GENE_PRODUCT", 40, 52], ["cats", "ORGANISM", 112, 116], ["cats", "SPECIES", 112, 116], ["host defense mecha", "PROBLEM", 27, 45], ["nisms", "PROBLEM", 47, 52], ["other infectious disease episodes", "PROBLEM", 66, 99], ["host disease gene defenses", "PROBLEM", 231, 257], ["clear", "OBSERVATION", 6, 11], ["host", "OBSERVATION_MODIFIER", 27, 31], ["defense", "OBSERVATION_MODIFIER", 32, 39], ["mecha", "OBSERVATION_MODIFIER", 40, 45], ["infectious", "OBSERVATION_MODIFIER", 72, 82]]], ["Given the critical importance of infectious disease in scores of chronic and acute human disease, there are powerful research opportunities in the cat family.", [["infectious disease", "DISEASE", 33, 51], ["acute human disease", "DISEASE", 77, 96], ["human", "ORGANISM", 83, 88], ["cat", "ORGANISM", 147, 150], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["chronic and acute human disease", "PROBLEM", 65, 96], ["infectious", "OBSERVATION", 33, 43], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["human disease", "OBSERVATION", 83, 96]]], ["142, 155 Finally, recent concern over the emergence of avian flu H5N1 has shown a strong susceptibility of cats, both domestic and large cats, again raising possibilities for pathogenesis and therapy development.", [["flu H5N1", "DISEASE", 61, 69], ["avian flu H5N1", "ORGANISM", 55, 69], ["cats", "ORGANISM", 107, 111], ["cats", "ORGANISM", 137, 141], ["avian flu H5N1", "SPECIES", 55, 69], ["cats", "SPECIES", 107, 111], ["cats", "SPECIES", 137, 141], ["avian flu H5N1", "SPECIES", 55, 69], ["avian flu H5N1", "PROBLEM", 55, 69], ["pathogenesis", "PROBLEM", 175, 187], ["therapy development", "TREATMENT", 192, 211], ["large", "OBSERVATION_MODIFIER", 131, 136], ["cats", "OBSERVATION", 137, 141], ["raising possibilities for", "UNCERTAINTY", 149, 174]]], ["156, 157 With the development of genomic resources in the cat (Table 25 -2) and the application of complementary comparative tools developed in other species, the domestic cat is emerging as a promising resource of phenotypically defined genetic variation of biomedical significance.", [["cat", "ORGANISM", 58, 61], ["cat", "ORGANISM", 172, 175]]], ["Exploration of similar resources in other species, particularly the dog and mouse, has provided important insight into otherwise unexplained biomedical disorders.", [["dog", "ORGANISM", 68, 71], ["mouse", "ORGANISM", 76, 81], ["dog", "SPECIES", 68, 71], ["mouse", "SPECIES", 76, 81], ["mouse", "SPECIES", 76, 81], ["Exploration", "TREATMENT", 0, 11], ["otherwise unexplained biomedical disorders", "PROBLEM", 119, 161]]]], "571832d2f6244532b408fee0146ee1ba9c1db6a7": [["1 How have writing assessment practices and policies of the past and present either contributed to or challenged the systematic entrenchment of inequity? 2 How can research on writing assessment draw attention to the role of writing assessment in confronting inequity and promoting opportunity for all?", [["writing assessment", "TEST", 176, 194], ["writing assessment", "TEST", 225, 243]]]], "819493b7520b80b1e610c27ac9ecc73af0305194": [["Three stages of the epidemic, and the delay principle.", [["the epidemic", "PROBLEM", 16, 28], ["the delay principle", "PROBLEM", 34, 53], ["epidemic", "OBSERVATION_MODIFIER", 20, 28]]], ["In a first stage, the epidemic in a country grows exponentially.", [["epidemic", "OBSERVATION_MODIFIER", 22, 30]]], ["Weak countermeasures reduce the rate of growth, but will not stop the growth [5] .", [["Weak countermeasures", "PROBLEM", 0, 20]]], ["The other countries have implemented strong lockdown measures and managed to stop the growth.", [["strong lockdown measures", "TREATMENT", 37, 61]]]], "PMC7104229": [["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) moved rapidly through China, and the virus had spread to more than 60 countries and infected nearly 90 000 patients by March 5, 2020.", [["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["SARS-CoV-2", "ORGANISM", 49, 59], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["SARS-CoV-2", "SPECIES", 49, 59], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 45], ["SARS-CoV", "TEST", 49, 57], ["the virus", "PROBLEM", 94, 103], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33]]], ["Based on data for 72 314 cases of coronavirus disease 2019 (COVID-19), 14% of people have severe disease, 5% have critical illness, and 2\u00b73% die.1 COVID-19 is not a conventional disease, and rapid changes in the provision of critical care have been needed to meet the needs of patients.", [["coronavirus disease", "DISEASE", 34, 53], ["people", "ORGANISM", 78, 84], ["patients", "ORGANISM", 277, 285], ["people", "SPECIES", 78, 84], ["patients", "SPECIES", 277, 285], ["coronavirus disease", "PROBLEM", 34, 53], ["COVID", "TEST", 60, 65], ["severe disease", "PROBLEM", 90, 104], ["critical illness", "PROBLEM", 114, 130], ["COVID", "TEST", 147, 152], ["a conventional disease", "PROBLEM", 163, 185], ["critical care", "TREATMENT", 225, 238], ["coronavirus disease", "OBSERVATION", 34, 53], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["disease", "OBSERVATION", 97, 104], ["illness", "OBSERVATION", 123, 130], ["disease", "OBSERVATION", 178, 185]]], ["Health emergencies such as the COVID-19 outbreak can be a huge challenge for critical-care physicians, who need strong comprehensive skills to respond effectively.2 Critical-care-related continuing medical education has an important part to play in preparing for and responding to such emergencies.", [["continuing medical education", "TREATMENT", 187, 215]]]], "b67f51e05e40ae50e63345dea9fb046712035d24": [["Engineered AMPs do not inhibit Marburg virus (MARV) infection.", [["Marburg virus (MARV) infection", "DISEASE", 31, 61], ["AMPs", "GENE_OR_GENE_PRODUCT", 11, 15], ["Marburg virus", "ORGANISM", 31, 44], ["MARV", "ORGANISM", 46, 50], ["Marburg virus", "SPECIES", 31, 44], ["Marburg virus", "SPECIES", 31, 44], ["MARV", "SPECIES", 46, 50], ["Engineered AMPs", "TREATMENT", 0, 15], ["Marburg virus (MARV) infection", "PROBLEM", 31, 61], ["infection", "OBSERVATION", 52, 61]]], ["Related to Figure 3.Hela cells were preincubated with individual AMPs at different concentrations (16 serial dilutions from 50 \u00b5M) for two hrs at 37\u00b0C and then infected with MARV (Ci67) at MOI of 1.", [["Hela cells", "ANATOMY", 20, 30], ["Hela cells", "CELL", 20, 30], ["MARV", "ORGANISM", 174, 178], ["Hela cells", "CELL_LINE", 20, 30], ["MARV", "SPECIES", 174, 178], ["Hela cells", "PROBLEM", 20, 30], ["individual AMPs at different concentrations", "TREATMENT", 54, 97], ["serial dilutions", "TEST", 102, 118]]], ["At 24 hrs post-infection, cells were fixed, permeabilized, and immuno-stained with anti-Marburg GP antibodies followed by fluorescenceconjugated secondary antibody to identify the infected cells.", [["cells", "ANATOMY", 26, 31], ["cells", "ANATOMY", 189, 194], ["cells", "CELL", 26, 31], ["cells", "CELL", 189, 194], ["anti-Marburg GP antibodies", "PROTEIN", 83, 109], ["fluorescenceconjugated secondary antibody", "PROTEIN", 122, 163], ["infected cells", "CELL_TYPE", 180, 194], ["cells", "TEST", 26, 31], ["immuno", "TEST", 63, 69], ["anti-Marburg GP antibodies", "PROBLEM", 83, 109], ["fluorescenceconjugated secondary antibody", "PROBLEM", 122, 163], ["the infected cells", "PROBLEM", 176, 194], ["infected cells", "OBSERVATION", 180, 194]]], ["A) Representative immunostaining images (Red: cell nuclear staining; Green: anti-MARV GP staining).", [["cell", "ANATOMY", 46, 50], ["Green: anti-MARV GP", "GENE_OR_GENE_PRODUCT", 69, 88], ["Representative immunostaining images", "TEST", 3, 39], ["cell nuclear staining", "TEST", 46, 67]]], ["B) A summary of IC50 of AMPs.", [["AMPs", "TREATMENT", 24, 28]]], ["LL-37 and engineered AMPs inhibit the intrinsic enzymatic activity of CatB, but not CatL.", [["LL-37", "CHEMICAL", 0, 5], ["LL-37", "GENE_OR_GENE_PRODUCT", 0, 5], ["AMPs", "GENE_OR_GENE_PRODUCT", 21, 25], ["CatB", "GENE_OR_GENE_PRODUCT", 70, 74], ["CatL", "GENE_OR_GENE_PRODUCT", 84, 88], ["CatB", "PROTEIN", 70, 74], ["CatL", "PROTEIN", 84, 88], ["LL", "TEST", 0, 2], ["enzymatic activity", "OBSERVATION", 48, 66]]], ["A) CatB was pre-incubated with cathepsin B specific inhibitor CA-074Me (at 2.", [["CA-074Me", "CHEMICAL", 62, 70], ["CatB", "GENE_OR_GENE_PRODUCT", 3, 7], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 31, 42], ["CA-074Me", "GENE_OR_GENE_PRODUCT", 62, 70], ["CatB", "PROTEIN", 3, 7], ["cathepsin B", "PROTEIN", 31, 42], ["cathepsin B specific inhibitor CA", "TREATMENT", 31, 64]]], ["5, 5, and 10 \u00b5M) or AMPs (at 2.5, 5, and 10 \u00b5M) in reaction buffer for 30 min at 37\u00b0C before the addition of CatB substrate peptide, Z-Arg-Arg-AMC (100 \u00b5M).", [["Z-Arg-Arg", "CHEMICAL", 133, 142], ["Z-Arg-Arg-AMC", "CHEMICAL", 133, 146], ["CatB", "SIMPLE_CHEMICAL", 109, 113], ["Z-Arg-Arg-AMC", "SIMPLE_CHEMICAL", 133, 146], ["AMPs", "TEST", 20, 24], ["CatB substrate peptide", "TREATMENT", 109, 131], ["Z", "TEST", 133, 134]]], ["The reaction was incubated at room temperature for 1 hr.", [["The reaction", "PROBLEM", 0, 12]]], ["Fluorescence generated by the cleavage of CatB substrate was measured. **, p<0.001 by two-way ANOVA test.Peptide designHuman cathelicidin LL-37 has several limitations as a therapeutic molecule.", [["LL-37", "CHEMICAL", 138, 143], ["CatB", "GENE_OR_GENE_PRODUCT", 42, 46], ["LL-37", "GENE_OR_GENE_PRODUCT", 138, 143], ["CatB substrate", "PROTEIN", 42, 56], ["Fluorescence", "TEST", 0, 12], ["CatB substrate", "TEST", 42, 56], ["ANOVA test", "TEST", 94, 104], ["Peptide designHuman cathelicidin LL", "TEST", 105, 140], ["a therapeutic molecule", "PROBLEM", 171, 193], ["cathelicidin LL", "OBSERVATION", 125, 140], ["therapeutic molecule", "OBSERVATION", 173, 193]]], ["First, it is relatively long with 37 amino acids.", [["amino acids", "CHEMICAL", 37, 48], ["amino acids", "CHEMICAL", 37, 48], ["amino acids", "AMINO_ACID", 37, 48], ["37 amino acids", "TREATMENT", 34, 48]]], ["Second, it can be rapidly degraded by proteases.", [["proteases", "PROTEIN", 38, 47]]], ["The design of engineered LL-37 aimed to overcome these limitations.", [["engineered LL", "TEST", 14, 27]]], ["We have previously identified the major active region of LL-37 corresponding to residues 17-32 (Li et al., 2006 , Wang et al., 2008 .", [["LL-37", "GENE_OR_GENE_PRODUCT", 57, 62], ["LL-37", "PROTEIN", 57, 62], ["residues", "TEST", 80, 88], ["major", "OBSERVATION_MODIFIER", 34, 39], ["active", "OBSERVATION_MODIFIER", 40, 46], ["LL", "ANATOMY", 57, 59]]], ["Since numerous natural peptides starts with a glycine, we added a glycine to residues 17-32 of LL-37, leading to the generation of GF-17.", [["glycine", "CHEMICAL", 46, 53], ["glycine", "CHEMICAL", 66, 73], ["residues 17-32 of LL-37", "CHEMICAL", 77, 100], ["GF-17", "CHEMICAL", 131, 136], ["glycine", "CHEMICAL", 46, 53], ["glycine", "CHEMICAL", 66, 73], ["GF-17", "CHEMICAL", 131, 136], ["glycine", "SIMPLE_CHEMICAL", 46, 53], ["glycine", "SIMPLE_CHEMICAL", 66, 73], ["LL-37", "GENE_OR_GENE_PRODUCT", 95, 100], ["GF-17", "GENE_OR_GENE_PRODUCT", 131, 136], ["a glycine", "TREATMENT", 44, 53], ["a glycine to residues", "TREATMENT", 64, 85], ["LL", "TEST", 95, 97], ["natural peptides", "OBSERVATION", 15, 31]]], ["Based on GF-17, we designed multiple peptides and conducted a simultaneous screening of peptide activity and stability to proteases.", [["GF-17", "CHEMICAL", 9, 14], ["proteases", "PROTEIN", 122, 131], ["GF", "TEST", 9, 11], ["multiple peptides", "TREATMENT", 28, 45], ["a simultaneous screening", "TEST", 60, 84], ["peptide activity", "PROBLEM", 88, 104]]], ["The screening identified the GF-17d3 template, which incorporated three D-form leucine residues and was active in the presence of chymotrypsin.", [["leucine", "CHEMICAL", 79, 86], ["GF-17d3", "CHEMICAL", 29, 36], ["leucine", "CHEMICAL", 79, 86], ["leucine", "AMINO_ACID", 79, 86], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 130, 142], ["GF-17d3 template", "DNA", 29, 45], ["chymotrypsin", "PROTEIN", 130, 142], ["The screening", "TEST", 0, 13], ["chymotrypsin", "PROBLEM", 130, 142], ["leucine residues", "OBSERVATION", 79, 95], ["active", "OBSERVATION_MODIFIER", 104, 110]]], ["Three-dimensional structure analysis identified a structural defect in GF-17d3 (Li et al., 2006 , Wang et al., 2008 .", [["GF-17d3", "CHEMICAL", 71, 78], ["GF-17d3", "SIMPLE_CHEMICAL", 71, 78], ["a structural defect in GF", "PROBLEM", 48, 73], ["structural defect", "OBSERVATION", 50, 67]]], ["To fill in the structural defect, we replaced phenylalanine at positions 17 and 27 with biphenylalanine, leading to the generation of 17BIPHE2 which is stable to multiple proteases (Wang, 2008) (referred as \"17BI\" in this manuscript).", [["phenylalanine", "CHEMICAL", 46, 59], ["biphenylalanine", "CHEMICAL", 88, 103], ["17BIPHE2", "CHEMICAL", 134, 142], ["phenylalanine", "CHEMICAL", 46, 59], ["biphenylalanine", "CHEMICAL", 88, 103], ["17BIPHE2", "CHEMICAL", 134, 142], ["phenylalanine", "AMINO_ACID", 46, 59], ["biphenylalanine", "SIMPLE_CHEMICAL", 88, 103], ["17BIPHE2", "SIMPLE_CHEMICAL", 134, 142], ["17BIPHE2", "PROTEIN", 134, 142], ["proteases", "PROTEIN", 171, 180], ["the structural defect", "PROBLEM", 11, 32], ["phenylalanine at positions", "TREATMENT", 46, 72], ["biphenylalanine", "TREATMENT", 88, 103], ["defect", "OBSERVATION", 26, 32], ["stable", "OBSERVATION_MODIFIER", 152, 158]]], ["In another study, we found that GI-20 (with three amino acid-extension at the Nterminus of GF-17) had increased activity in inhibiting HIV-1 (Wang et al., 2014) .", [["GI-20", "CHEMICAL", 32, 37], ["amino acid-extension", "CHEMICAL", 50, 70], ["GF-17", "CHEMICAL", 91, 96], ["GI-20", "CHEMICAL", 32, 37], ["amino", "CHEMICAL", 50, 55], ["GF-17", "CHEMICAL", 91, 96], ["GI-20", "GENE_OR_GENE_PRODUCT", 32, 37], ["HIV-1", "ORGANISM", 135, 140], ["HIV", "SPECIES", 135, 138], ["HIV-1", "SPECIES", 135, 140], ["another study", "TEST", 3, 16], ["GI", "TEST", 32, 34], ["amino acid-extension", "TEST", 50, 70], ["increased activity in inhibiting HIV", "PROBLEM", 102, 138], ["GI", "ANATOMY", 32, 34], ["increased", "OBSERVATION_MODIFIER", 102, 111], ["activity", "OBSERVATION_MODIFIER", 112, 120]]], ["To increase GI-20 stability, we engineered GI-20 with all D-amino acids, leading to the generation of GI-20d.", [["D-amino acids", "CHEMICAL", 58, 71], ["GI-20", "CHEMICAL", 43, 48], ["D-amino acids", "CHEMICAL", 58, 71], ["GI-20d", "CHEMICAL", 102, 108], ["D-amino acids", "SIMPLE_CHEMICAL", 58, 71], ["GI-20d", "GENE_OR_GENE_PRODUCT", 102, 108], ["all D-amino acids", "TREATMENT", 54, 71], ["GI", "TEST", 102, 104], ["20 stability", "OBSERVATION_MODIFIER", 15, 27], ["GI", "ANATOMY", 102, 104]]], ["Further shortening of GF-17 made the peptide inactive.", [["GF-17", "CHEMICAL", 22, 27], ["GF-17", "CHEMICAL", 22, 27], ["GF-17", "GENE_OR_GENE_PRODUCT", 22, 27], ["GF-17", "PROTEIN", 22, 27], ["Further shortening of GF", "PROBLEM", 0, 24], ["the peptide inactive", "PROBLEM", 33, 53], ["shortening", "OBSERVATION_MODIFIER", 8, 18]]], ["One of the peptides is RI-10 (Li et al., 2006 , Wang et al., 2008 which was used as a negative control in this study.Peptide synthesisPeptides (0.1 mmol scale) were purchased from Genemed Synthesis, Inc. (San Antonio, TX, USA).", [["RI-10", "GENE_OR_GENE_PRODUCT", 23, 28], ["RI", "TEST", 23, 25], ["this study", "TEST", 106, 116], ["Peptide synthesisPeptides", "TREATMENT", 117, 142], ["RI", "OBSERVATION_MODIFIER", 23, 25]]], ["In brief, they were synthesized using the standard Fmoc Chemistry.", [["Fmoc", "CHEMICAL", 51, 55], ["the standard Fmoc Chemistry", "TREATMENT", 38, 65]]], ["After synthesis, peptides were deprotected and cleaved from the Wang resin (for LL-37) or rink amide resin (for other peptides) using trifluoroacetic acid (TFA).", [["LL-37", "CHEMICAL", 80, 85], ["trifluoroacetic acid", "CHEMICAL", 134, 154], ["TFA", "CHEMICAL", 156, 159], ["amide", "CHEMICAL", 95, 100], ["trifluoroacetic acid", "CHEMICAL", 134, 154], ["TFA", "CHEMICAL", 156, 159], ["rink amide resin", "SIMPLE_CHEMICAL", 90, 106], ["trifluoroacetic acid", "SIMPLE_CHEMICAL", 134, 154], ["TFA", "SIMPLE_CHEMICAL", 156, 159], ["peptides", "TREATMENT", 17, 25], ["the Wang resin", "TREATMENT", 60, 74], ["LL", "TEST", 80, 82], ["rink amide resin", "TREATMENT", 90, 106], ["other peptides", "TREATMENT", 112, 126], ["trifluoroacetic acid (TFA", "TREATMENT", 134, 159]]], ["The TFA was then be removed and peptide precipitated with dry ether.", [["TFA", "CHEMICAL", 4, 7], ["dry ether", "CHEMICAL", 58, 67], ["TFA", "CHEMICAL", 4, 7], ["ether", "CHEMICAL", 62, 67], ["TFA", "SIMPLE_CHEMICAL", 4, 7], ["dry ether", "SIMPLE_CHEMICAL", 58, 67], ["The TFA", "TREATMENT", 0, 7]]], ["After removal of ether, the peptide was lyophilized.", [["ether", "CHEMICAL", 17, 22], ["ether", "SIMPLE_CHEMICAL", 17, 22], ["removal of ether", "TREATMENT", 6, 22], ["the peptide", "TREATMENT", 24, 35], ["lyophilized", "OBSERVATION", 40, 51]]], ["The peptide was finally purified via preparative HPLC.", [["preparative HPLC", "TREATMENT", 37, 53]]], ["All peptides were purified to high quality (purity >95%) with correct masses by MS.Cells, viruses, and reagentsVero cells (ATCC, CCL-81) and Hela cells (ATCC, CCL-2) were maintained in Dulbecco's Modified Eagle Medium (DMEM, Hyclone Laboratories Inc., Logan, UT) supplemented with 10% Fetal Bovine Serum (FBS, Atlanta Biologicals, Inc., Flowery Branch, GA), 100 IU/ml penicillin, 100 g/ml streptomycin (Corning Life Sciences, Tewksbury, MA).", [["Cells", "ANATOMY", 83, 88], ["Vero cells", "ANATOMY", 111, 121], ["ATCC", "ANATOMY", 123, 127], ["CCL-81", "ANATOMY", 129, 135], ["Hela cells", "ANATOMY", 141, 151], ["ATCC", "ANATOMY", 153, 157], ["CCL-2", "ANATOMY", 159, 164], ["penicillin", "CHEMICAL", 368, 378], ["streptomycin", "CHEMICAL", 389, 401], ["penicillin", "CHEMICAL", 368, 378], ["streptomycin", "CHEMICAL", 389, 401], ["Cells", "CELL", 83, 88], ["Vero cells", "CELL", 111, 121], ["ATCC", "CELL", 123, 127], ["CCL-81", "CELL", 129, 135], ["Hela cells", "CELL", 141, 151], ["ATCC", "CELL", 153, 157], ["CCL-2", "CELL", 159, 164], ["Bovine", "ORGANISM", 291, 297], ["Serum", "ORGANISM_SUBSTANCE", 298, 303], ["FBS", "ORGANISM_SUBSTANCE", 305, 308], ["penicillin", "SIMPLE_CHEMICAL", 368, 378], ["streptomycin", "SIMPLE_CHEMICAL", 389, 401], ["Vero cells", "CELL_LINE", 111, 121], ["ATCC", "CELL_LINE", 123, 127], ["CCL-81", "CELL_LINE", 129, 135], ["Hela cells", "CELL_LINE", 141, 151], ["ATCC", "CELL_LINE", 153, 157], ["CCL-2", "CELL_LINE", 159, 164], ["Bovine", "SPECIES", 291, 297], ["Bovine", "SPECIES", 291, 297], ["All peptides", "TEST", 0, 12], ["purity", "TEST", 44, 50], ["correct masses", "PROBLEM", 62, 76], ["reagents", "TREATMENT", 103, 111], ["Vero cells", "TEST", 111, 121], ["ATCC", "TEST", 123, 127], ["CCL", "TEST", 129, 132], ["Hela cells", "TEST", 141, 151], ["ATCC", "TEST", 153, 157], ["CCL", "TEST", 159, 162], ["Fetal Bovine Serum", "TEST", 285, 303], ["FBS", "TEST", 305, 308], ["Atlanta Biologicals", "TREATMENT", 310, 329], ["penicillin", "TREATMENT", 368, 378], ["streptomycin", "TREATMENT", 389, 401], ["masses", "OBSERVATION", 70, 76], ["Hela cells", "ANATOMY", 141, 151]]], ["Recombinant vesicular stomatitis virus (rVSV)-EBOVgp-GFP was provided by Dr. Christopher L Cooper (United States Army Medical Research Institute of Infectious Diseases, (USAMRIID)) and used to perform all the BSL-2 assays.", [["vesicular stomatitis", "DISEASE", 12, 32], ["Infectious Diseases", "DISEASE", 148, 167], ["Recombinant", "ORGANISM", 0, 11], ["vesicular stomatitis virus", "ORGANISM", 12, 38], ["rVSV", "ORGANISM", 40, 44], ["GFP", "GENE_OR_GENE_PRODUCT", 53, 56], ["vesicular stomatitis virus", "SPECIES", 12, 38], ["stomatitis virus", "SPECIES", 22, 38], ["rVSV", "SPECIES", 40, 44], ["Recombinant vesicular stomatitis virus", "PROBLEM", 0, 38], ["the BSL", "TEST", 205, 212], ["vesicular stomatitis virus", "OBSERVATION", 12, 38]]], ["WT EBOV Kiwit strain were handled under BSL-4 containment at the USAMRIID.", [["WT EBOV", "ORGANISM", 0, 7], ["EBOV", "OBSERVATION", 3, 7]]], ["EBOV Zaire beta-lactamase VP40 expression plasmid was obtained from B.E.I Resources (Manassas, VA).", [["EBOV", "ORGANISM", 0, 4], ["VP40", "GENE_OR_GENE_PRODUCT", 26, 30], ["EBOV Zaire beta-lactamase VP40 expression plasmid", "DNA", 0, 49], ["EBOV", "SPECIES", 0, 4], ["EBOV Zaire beta-lactamase VP40 expression plasmid", "TREATMENT", 0, 49]]], ["EBOV Zaire GP expression plasmids were obtained from Addgene (Cambridge, MA). pCAGGS-NP-V5, pCAGGS-V5-VP30, and pcDNA3 vectors were generated at the USAMRIID. pCAGGS-FLAG-VP35 was a kind gift from Dr. Christopher F. Basler (Georgia State University). pCAGGS_L_EBOV and pCAGGS_3E5E_luciferase were gifts from Dr. Elke M\u00fchlberger (Addgene plasmid # 103052; # 103055) (Nelson et al., 2017) .", [["EBOV", "ORGANISM", 0, 4], ["Addgene", "GENE_OR_GENE_PRODUCT", 53, 60], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 78, 84], ["pCAGGS-V5-VP30", "GENE_OR_GENE_PRODUCT", 92, 106], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 112, 118], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 159, 165], ["FLAG", "GENE_OR_GENE_PRODUCT", 166, 170], ["VP35", "GENE_OR_GENE_PRODUCT", 171, 175], ["pCAGGS_L_EBOV", "GENE_OR_GENE_PRODUCT", 251, 264], ["pCAGGS_3E5E_luciferase", "GENE_OR_GENE_PRODUCT", 269, 291], ["EBOV Zaire GP expression plasmids", "DNA", 0, 33], ["pCAGGS", "DNA", 78, 84], ["NP", "DNA", 85, 87], ["V5", "DNA", 88, 90], ["pCAGGS", "DNA", 92, 98], ["V5", "DNA", 99, 101], ["VP30", "DNA", 102, 106], ["pcDNA3 vectors", "DNA", 112, 126], ["USAMRIID", "DNA", 149, 157], ["pCAGGS", "PROTEIN", 159, 165], ["FLAG", "PROTEIN", 166, 170], ["VP35", "PROTEIN", 171, 175], ["pCAGGS_L_EBOV", "DNA", 251, 264], ["pCAGGS_3E5E_luciferase", "PROTEIN", 269, 291], ["EBOV", "SPECIES", 0, 4], ["EBOV Zaire GP expression plasmids", "TREATMENT", 0, 33], ["pCAGGS", "TEST", 78, 84], ["pCAGGS", "TEST", 92, 98], ["pcDNA3 vectors", "TREATMENT", 112, 126]]], ["The pRL-TK plasmid was kindly provided by Dr. Tsung-Hsien Chang (Kaohsiung, Taiwan) (Tsai et al., 2017) .", [["pRL", "GENE_OR_GENE_PRODUCT", 4, 7], ["pRL-TK plasmid", "DNA", 4, 18], ["The pRL-TK plasmid", "TREATMENT", 0, 18], ["TK", "ANATOMY", 8, 10]]], ["Ebola GP protein and rabbit anti-EBOV GPddmuc polyclonal antibodies were purchased from IBT Bioservices (Rockville, MD).", [["Ebola GP", "ORGANISM", 0, 8], ["rabbit", "ORGANISM", 21, 27], ["Ebola GP protein", "PROTEIN", 0, 16], ["rabbit anti-EBOV GPddmuc polyclonal antibodies", "PROTEIN", 21, 67], ["Ebola", "SPECIES", 0, 5], ["rabbit", "SPECIES", 21, 27], ["rabbit", "SPECIES", 21, 27], ["Ebola GP protein", "TEST", 0, 16], ["rabbit anti-EBOV", "TEST", 21, 37], ["polyclonal antibodies", "TEST", 46, 67]]], ["Mouse monoclonal anti-EBOV GP antibody, 13C6 was provided by C.L.C. at USAMRIID.", [["Mouse", "ORGANISM", 0, 5], ["Mouse monoclonal anti-EBOV GP antibody", "PROTEIN", 0, 38], ["13C6", "PROTEIN", 40, 44], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse monoclonal anti-EBOV GP antibody", "TEST", 0, 38]]], ["Human Cathepsin B, Cathepsin L and Cathepsin S were obtained from Acrobiosystems Inc. (Newark, DE) or Millipore Sigma (St. Louis, MO).", [["Human", "ORGANISM", 0, 5], ["Cathepsin B", "GENE_OR_GENE_PRODUCT", 6, 17], ["Cathepsin L", "GENE_OR_GENE_PRODUCT", 19, 30], ["Cathepsin S", "GENE_OR_GENE_PRODUCT", 35, 46], ["St. Louis", "ORGANISM", 119, 128], ["Human Cathepsin B", "PROTEIN", 0, 17], ["Cathepsin L", "PROTEIN", 19, 30], ["Cathepsin S", "PROTEIN", 35, 46], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human Cathepsin B", "TREATMENT", 0, 17], ["Cathepsin L and Cathepsin S", "TREATMENT", 19, 46]]], ["Cathepsin B inhibitor CA-074 methyl ester (CA-074me) and Cathepsin L inhibitor III were purchased from Sigma -Aldrich (St. Louis, MO).", [["CA-074 methyl ester", "CHEMICAL", 22, 41], ["CA-074me", "CHEMICAL", 43, 51], ["CA-074 methyl ester", "CHEMICAL", 22, 41], ["CA-074me", "CHEMICAL", 43, 51], ["Cathepsin B", "GENE_OR_GENE_PRODUCT", 0, 11], ["CA-074 methyl ester", "SIMPLE_CHEMICAL", 22, 41], ["CA-074me", "SIMPLE_CHEMICAL", 43, 51], ["Cathepsin L inhibitor III", "GENE_OR_GENE_PRODUCT", 57, 82], ["Sigma -Aldrich", "ORGANISM", 103, 117], ["St. Louis, MO", "ORGANISM", 119, 132], ["Cathepsin B", "PROTEIN", 0, 11], ["Cathepsin B inhibitor CA", "TEST", 0, 24], ["methyl ester (CA", "TREATMENT", 29, 45], ["Cathepsin L inhibitor III", "TREATMENT", 57, 82]]], ["Cathepsin S inhibitor was purchased from APExBIO (Houston, TX).", [["Cathepsin S", "GENE_OR_GENE_PRODUCT", 0, 11], ["Cathepsin S inhibitor", "TREATMENT", 0, 21]]], ["Cathepsin B substrate was obtained from Millipore Sigma (St. Louis, MO).", [["Cathepsin B", "GENE_OR_GENE_PRODUCT", 0, 11], ["St. Louis", "ORGANISM", 57, 66], ["MO", "ORGANISM", 68, 70], ["Cathepsin B substrate", "PROTEIN", 0, 21], ["Cathepsin B substrate", "TEST", 0, 21]]], ["Cathepsin L substrate was purchased from Santa Cruz Biotechnology (Dallas, TX).Differentiation of MacrophagesPeripheral blood samples from healthy donors were obtained after informed consent in accordance with institutional review board approved protocols at the University of Nebraska Medical Center (UNMC).", [["MacrophagesPeripheral blood samples", "ANATOMY", 98, 133], ["Cathepsin L", "GENE_OR_GENE_PRODUCT", 0, 11], ["MacrophagesPeripheral blood samples", "ORGANISM_SUBSTANCE", 98, 133], ["donors", "ORGANISM", 147, 153], ["Cathepsin L substrate", "PROTEIN", 0, 21], ["Cathepsin L substrate", "TREATMENT", 0, 21], ["MacrophagesPeripheral blood samples", "TEST", 98, 133]]], ["Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient Centrifugation using Polymorphprep (Axis-Shield Poc, Oslo, Norway).", [["Peripheral blood mononuclear cells", "ANATOMY", 0, 34], ["PBMCs", "ANATOMY", 36, 41], ["Peripheral blood mononuclear cells", "CELL", 0, 34], ["PBMCs", "CELL", 36, 41], ["Peripheral blood mononuclear cells", "CELL_TYPE", 0, 34], ["PBMCs", "CELL_TYPE", 36, 41], ["Peripheral blood mononuclear cells", "TEST", 0, 34], ["PBMCs", "TEST", 36, 41], ["Ficoll density gradient Centrifugation", "TREATMENT", 60, 98], ["Polymorphprep", "TREATMENT", 105, 118], ["blood", "ANATOMY", 11, 16], ["mononuclear cells", "OBSERVATION", 17, 34], ["Ficoll density", "OBSERVATION", 60, 74]]], ["Monocytes were purified using anti-human CD14 antibody-labeled magnetic beads and iron-based MACS separation columns (Miltenyi Biotec, Auburn, CA).", [["Monocytes", "ANATOMY", 0, 9], ["Monocytes", "CELL", 0, 9], ["CD14", "GENE_OR_GENE_PRODUCT", 41, 45], ["Monocytes", "CELL_TYPE", 0, 9], ["anti-human CD14 antibody", "PROTEIN", 30, 54], ["Miltenyi Biotec", "PROTEIN", 118, 133], ["Monocytes", "TEST", 0, 9], ["anti-human CD14 antibody", "TEST", 30, 54], ["magnetic beads", "TREATMENT", 63, 77], ["iron-based MACS separation columns", "TREATMENT", 82, 116], ["Miltenyi Biotec", "TREATMENT", 118, 133]]], ["For macrophage differentiation, monocytes were plated in Minimum Essential Media (MEM, Hyclone Laboratories Inc., Logan, UT) supplemented with 10% FBS, non-essential amino acids (Hyclone Laboratories Inc., Logan, UT), 100 IU/ml penicillin, 100 \u00b5g/ml streptomycin, and 50 ng/ml human macrophage colony-stimulating factor (M-CSF; Peprotech, Rocky Hill, NJ) and incubated for 7 to 10 days.rVSV-EBOVgp-GFP (VSV-eGP) infectionOne day before infection, Vero cells or Hela cells were seeded at 1.25x10 5 /ml.", [["macrophage", "ANATOMY", 4, 14], ["monocytes", "ANATOMY", 32, 41], ["FBS", "ANATOMY", 147, 150], ["Vero cells", "ANATOMY", 447, 457], ["Hela cells", "ANATOMY", 461, 471], ["amino acids", "CHEMICAL", 166, 177], ["penicillin", "CHEMICAL", 228, 238], ["streptomycin", "CHEMICAL", 250, 262], ["infection", "DISEASE", 436, 445], ["amino acids", "CHEMICAL", 166, 177], ["penicillin", "CHEMICAL", 228, 238], ["streptomycin", "CHEMICAL", 250, 262], ["macrophage", "CELL", 4, 14], ["monocytes", "CELL", 32, 41], ["FBS", "ORGANISM_SUBSTANCE", 147, 150], ["amino acids", "AMINO_ACID", 166, 177], ["penicillin", "SIMPLE_CHEMICAL", 228, 238], ["streptomycin", "SIMPLE_CHEMICAL", 250, 262], ["human", "ORGANISM", 277, 282], ["macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 283, 319], ["M-CSF", "GENE_OR_GENE_PRODUCT", 321, 326], ["rVSV-EBOVgp-GFP", "GENE_OR_GENE_PRODUCT", 386, 401], ["VSV-eGP", "ORGANISM", 403, 410], ["Vero cells", "CELL", 447, 457], ["Hela cells", "CELL", 461, 471], ["monocytes", "CELL_TYPE", 32, 41], ["human macrophage colony-stimulating factor", "PROTEIN", 277, 319], ["CSF", "PROTEIN", 323, 326], ["Peprotech", "PROTEIN", 328, 337], ["Vero cells", "CELL_LINE", 447, 457], ["Hela cells", "CELL_LINE", 461, 471], ["human", "SPECIES", 277, 282], ["human", "SPECIES", 277, 282], ["VSV", "SPECIES", 403, 406], ["Vero", "SPECIES", 447, 451], ["macrophage differentiation", "PROBLEM", 4, 30], ["monocytes", "TEST", 32, 41], ["non-essential amino acids", "TREATMENT", 152, 177], ["penicillin", "TREATMENT", 228, 238], ["streptomycin", "TREATMENT", 250, 262], ["rVSV", "TEST", 386, 390], ["EBOVgp", "TEST", 391, 397], ["GFP", "PROBLEM", 398, 401], ["infectionOne", "PROBLEM", 412, 424], ["infection", "PROBLEM", 436, 445], ["Vero cells", "PROBLEM", 447, 457], ["Hela cells", "PROBLEM", 461, 471], ["macrophage differentiation", "OBSERVATION", 4, 30], ["monocytes", "ANATOMY", 32, 41], ["infection", "OBSERVATION", 436, 445], ["Vero cells", "OBSERVATION", 447, 457], ["Hela cells", "OBSERVATION", 461, 471]]], ["Cells were then infected with rVSV-eGFP at multiplicities of infection (MOI) of 0.5.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 61, 70], ["Cells", "CELL", 0, 5], ["eGFP", "GENE_OR_GENE_PRODUCT", 35, 39], ["rVSV", "PROTEIN", 30, 34], ["eGFP", "DNA", 35, 39], ["Cells", "TEST", 0, 5], ["rVSV", "TEST", 30, 34], ["infection", "PROBLEM", 61, 70], ["infection", "OBSERVATION", 61, 70]]], ["Human macrophages were infected with rVSV-eGFP at MOI of 5.", [["macrophages", "ANATOMY", 6, 17], ["Human", "ORGANISM", 0, 5], ["macrophages", "CELL", 6, 17], ["eGFP", "GENE_OR_GENE_PRODUCT", 42, 46], ["Human macrophages", "CELL_TYPE", 0, 17], ["rVSV", "PROTEIN", 37, 41], ["eGFP", "DNA", 42, 46], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human macrophages", "PROBLEM", 0, 17], ["rVSV", "TEST", 37, 41]]], ["After 20 hours of infection, cells are harvested and analyzed by a NovoCyte flow cytometer (ACEA Biosciences, San Diego, CA) for GFP expression.Wild-type EBOV and MARV infectionEBOV (Zaire-Kiwit) and MARV (Ci67) were obtained from the USAMRIID collection.", [["cells", "ANATOMY", 29, 34], ["infection", "DISEASE", 18, 27], ["cells", "CELL", 29, 34], ["GFP", "GENE_OR_GENE_PRODUCT", 129, 132], ["Wild-type EBOV", "ORGANISM", 144, 158], ["MARV infectionEBOV", "ORGANISM", 163, 181], ["Zaire-Kiwit", "ORGANISM", 183, 194], ["MARV", "ORGANISM", 200, 204], ["Ci67", "ORGANISM", 206, 210], ["MARV", "SPECIES", 163, 167], ["MARV", "SPECIES", 200, 204], ["EBOV", "SPECIES", 154, 158], ["MARV", "SPECIES", 163, 167], ["MARV", "SPECIES", 200, 204], ["infection", "PROBLEM", 18, 27], ["a NovoCyte flow cytometer", "TEST", 65, 90], ["GFP expression", "PROBLEM", 129, 143], ["type EBOV", "PROBLEM", 149, 158], ["MARV infectionEBOV", "PROBLEM", 163, 181], ["infection", "OBSERVATION", 18, 27], ["type EBOV", "OBSERVATION", 149, 158]]], ["All viruses were propagated in Vero cells.", [["Vero cells", "ANATOMY", 31, 41], ["Vero cells", "CELL", 31, 41], ["Vero cells", "CELL_LINE", 31, 41], ["All viruses", "PROBLEM", 0, 11], ["viruses", "OBSERVATION", 4, 11], ["Vero cells", "OBSERVATION", 31, 41]]], ["Virus-containing supernatant was clarified by centrifugation at 12,000g for 30 min prior to storage at -80\u00b0C. All virus stock titers were determined by plaque assay on Vero E6 cells as previously described.Wild-type EBOV and MARV infectionFilovirus infections were performed under BSL-4 laboratory conditions.", [["supernatant", "ANATOMY", 17, 28], ["plaque", "ANATOMY", 152, 158], ["Vero E6 cells", "ANATOMY", 168, 181], ["infectionFilovirus infections", "DISEASE", 230, 259], ["Virus", "ORGANISM", 0, 5], ["Vero E6 cells", "CELL", 168, 181], ["Wild-type EBOV", "ORGANISM", 206, 220], ["MARV", "ORGANISM", 225, 229], ["infectionFilovirus", "ORGANISM", 230, 248], ["Vero E6 cells", "CELL_LINE", 168, 181], ["MARV", "SPECIES", 225, 229], ["Vero E6", "SPECIES", 168, 175], ["EBOV", "SPECIES", 216, 220], ["MARV", "SPECIES", 225, 229], ["Virus", "PROBLEM", 0, 5], ["All virus stock titers", "TEST", 110, 132], ["plaque assay", "TEST", 152, 164], ["Vero E6 cells", "TREATMENT", 168, 181], ["type EBOV", "PROBLEM", 211, 220], ["MARV infectionFilovirus infections", "PROBLEM", 225, 259], ["BSL", "TEST", 281, 284], ["plaque", "OBSERVATION", 152, 158], ["E6 cells", "OBSERVATION", 173, 181]]], ["4000 HeLa cells were infected with viruses at MOI of 4.0 and 1.0 for EBOV and MARV respectively.", [["HeLa cells", "ANATOMY", 5, 15], ["HeLa cells", "CELL", 5, 15], ["EBOV", "ORGANISM", 69, 73], ["MARV", "ORGANISM", 78, 82], ["HeLa cells", "CELL_LINE", 5, 15], ["EBOV", "SPECIES", 69, 73], ["MARV", "SPECIES", 78, 82], ["HeLa cells", "PROBLEM", 5, 15], ["viruses", "PROBLEM", 35, 42], ["MOI", "TEST", 46, 49], ["EBOV", "PROBLEM", 69, 73], ["HeLa cells", "OBSERVATION", 5, 15]]], ["Infection was allowed to proceed for 24 hrs.", [["Infection", "PROBLEM", 0, 9]]], ["At the end of the incubation time, virus-infected cells were fixed in 10% neutral buffered Formalin (Sigma, St. Louis, MO) for a minimum of 24 hrs under BSL4 conditions.Wild-type EBOV and MARV infectionAn IFA was used to visualize virus-infected cells.", [["cells", "ANATOMY", 50, 55], ["cells", "ANATOMY", 246, 251], ["Formalin", "CHEMICAL", 91, 99], ["Formalin", "CHEMICAL", 91, 99], ["cells", "CELL", 50, 55], ["Formalin", "SIMPLE_CHEMICAL", 91, 99], ["Wild-type EBOV", "ORGANISM", 169, 183], ["MARV", "ORGANISM", 188, 192], ["cells", "CELL", 246, 251], ["virus-infected cells", "CELL_TYPE", 35, 55], ["virus-infected cells", "CELL_TYPE", 231, 251], ["MARV", "SPECIES", 188, 192], ["Wild-type EBOV", "SPECIES", 169, 183], ["MARV", "SPECIES", 188, 192], ["virus", "PROBLEM", 35, 40], ["infected cells", "PROBLEM", 41, 55], ["type EBOV", "PROBLEM", 174, 183], ["MARV infectionAn IFA", "TEST", 188, 208], ["infected cells", "PROBLEM", 237, 251], ["infected cells", "OBSERVATION", 41, 55], ["infected cells", "OBSERVATION", 237, 251]]], ["Several antibodies were tested with each virus, and the antibodies that gave the highest signal-to-noise ratio in the IFA were used for screening purposes.", [["antibodies", "PROTEIN", 8, 18], ["antibodies", "PROTEIN", 56, 66], ["Several antibodies", "TEST", 0, 18], ["each virus", "PROBLEM", 36, 46], ["the antibodies", "TEST", 52, 66], ["the IFA", "TEST", 114, 121], ["screening purposes", "TEST", 136, 154]]], ["Cells were washed three times with PBS, blocked in 3% bovine serum albumin/PBS, and treated with the corresponding primary antibody at 37 \u00b0C for 1 h followed by three additional washes with 1\u00d7 PBS and secondary antibody treatment.", [["Cells", "ANATOMY", 0, 5], ["serum", "ANATOMY", 61, 66], ["Cells", "CELL", 0, 5], ["bovine", "ORGANISM", 54, 60], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["albumin", "GENE_OR_GENE_PRODUCT", 67, 74], ["PBS", "SIMPLE_CHEMICAL", 75, 78], ["primary antibody", "PROTEIN", 115, 131], ["bovine", "SPECIES", 54, 60], ["bovine", "SPECIES", 54, 60], ["PBS", "TREATMENT", 35, 38], ["3% bovine serum albumin/PBS", "TREATMENT", 51, 78], ["the corresponding primary antibody", "TREATMENT", 97, 131], ["PBS", "TREATMENT", 193, 196], ["secondary antibody treatment", "TREATMENT", 201, 229], ["secondary", "OBSERVATION", 201, 210], ["antibody treatment", "OBSERVATION", 211, 229]]], ["The mouse monoclonal antibodies 6D8 and 9G4 were used to detect EBOV GP, and MARV GP respectively.", [["mouse", "ORGANISM", 4, 9], ["EBOV", "ORGANISM", 64, 68], ["MARV", "ORGANISM", 77, 81], ["mouse monoclonal antibodies", "PROTEIN", 4, 31], ["6D8", "PROTEIN", 32, 35], ["9G4", "PROTEIN", 40, 43], ["EBOV GP", "PROTEIN", 64, 71], ["MARV GP", "PROTEIN", 77, 84], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 4, 9], ["EBOV", "SPECIES", 64, 68], ["MARV", "SPECIES", 77, 81], ["The mouse monoclonal antibodies", "TEST", 0, 31], ["EBOV GP", "TEST", 64, 71]]], ["All antibodies to viral antigens were purified from the hybridoma stocks at USAMRIID.", [["hybridoma", "ANATOMY", 56, 65], ["antibodies", "PROTEIN", 4, 14], ["viral antigens", "PROTEIN", 18, 32], ["All antibodies to viral antigens", "PROBLEM", 0, 32], ["the hybridoma stocks", "TREATMENT", 52, 72], ["hybridoma stocks", "OBSERVATION", 56, 72]]], ["Cell nuclei and cytoplasm were labeled with Hoechst 33342 (Life Technologies, Carlsbad, CA) and HCS CellMask Red or Deep Red (Life Technologies, Carlsbad, CA), respectively, at a 1:10,000 dilution.", [["Cell nuclei", "ANATOMY", 0, 11], ["cytoplasm", "ANATOMY", 16, 25], ["Hoechst 33342", "CHEMICAL", 44, 57], ["Hoechst 33342", "CHEMICAL", 44, 57], ["Cell nuclei", "CELL", 0, 11], ["cytoplasm", "ORGANISM_SUBSTANCE", 16, 25], ["Hoechst 33342", "SIMPLE_CHEMICAL", 44, 57], ["HCS CellMask", "TEST", 96, 108]]], ["Alexa 488-conjugated goat anti-mouse secondary antibody (1:1000; Life Technologies, Carlsbad, CA) were used to visualize primary antibodies.Wild-type EBOV and MARV infectionFor image analysis, high-content quantitative imaging data were acquired and analyzed on an Opera confocal reader (model 3842 [Quadruple Excitation High Sensitivity] PerkinElmer, Waltham, MA) at two exposures using a 10X air objective.", [["MARV infection", "DISEASE", 159, 173], ["Alexa 488", "CHEMICAL", 0, 9], ["Alexa 488", "SIMPLE_CHEMICAL", 0, 9], ["Wild-type EBOV", "ORGANISM", 140, 154], ["MARV", "ORGANISM", 159, 163], ["Alexa 488-conjugated goat anti-mouse secondary antibody", "PROTEIN", 0, 55], ["primary antibodies", "PROTEIN", 121, 139], ["goat", "SPECIES", 21, 25], ["anti-mouse", "SPECIES", 26, 36], ["goat", "SPECIES", 21, 25], ["Wild-type EBOV", "SPECIES", 140, 154], ["MARV", "SPECIES", 159, 163], ["Alexa", "TEST", 0, 5], ["type EBOV", "PROBLEM", 145, 154], ["MARV infection", "PROBLEM", 159, 173], ["image analysis", "TEST", 177, 191], ["quantitative imaging data", "TEST", 206, 231], ["Quadruple Excitation", "TREATMENT", 300, 320]]], ["Analyses of the images were accomplished within the Opera or Columbus environment using standard vendor provided Acapella scripts.Wild-type EBOV and MARV infectionConcentration-response curve (CRC) analysis was applied to determine the potency of the hit compound's antiviral activity.", [["infection", "DISEASE", 154, 163], ["Wild-type EBOV", "ORGANISM", 130, 144], ["MARV", "ORGANISM", 149, 153], ["EBOV", "SPECIES", 140, 144], ["MARV", "SPECIES", 149, 153], ["the images", "TEST", 12, 22], ["Acapella scripts", "TREATMENT", 113, 129], ["type EBOV", "PROBLEM", 135, 144], ["MARV infection", "PROBLEM", 149, 163], ["CRC) analysis", "TEST", 193, 206], ["antiviral activity", "OBSERVATION", 266, 284]]], ["Briefly, cells were seeded at a concentration of 2 \u00d710 4 cells per well in a 384-well plate, and peptides were tested in a 16-point dose-response curve (twofold serial dilution from 100 \u00b5M).", [["cells", "ANATOMY", 9, 14], ["cells", "ANATOMY", 57, 62], ["cells", "CELL", 9, 14], ["cells", "CELL", 57, 62], ["peptides", "TEST", 97, 105], ["response curve", "TEST", 137, 151], ["twofold serial dilution", "TEST", 153, 176]]], ["Peptides were added to cells 2 hrs prior to the start of virus infection.", [["cells", "ANATOMY", 23, 28], ["infection", "DISEASE", 63, 72], ["cells", "CELL", 23, 28], ["Peptides", "TREATMENT", 0, 8], ["virus infection", "PROBLEM", 57, 72], ["infection", "OBSERVATION", 63, 72]]], ["Each concentration of peptide were tested in quadruplicate.", [["Each concentration of peptide", "TREATMENT", 0, 29]]], ["Data generated from the image analysis were plotted and analyzed using Genedata software (Basel, Switzerland) The IC50, defined as the effective concentration resulting in a 50% inhibition of viral infection, was used to evaluate peptide activity.", [["viral infection", "DISEASE", 192, 207], ["the image analysis", "TEST", 20, 38], ["The IC50", "TREATMENT", 110, 118], ["viral infection", "PROBLEM", 192, 207], ["viral infection", "OBSERVATION", 192, 207]]], ["Peptide toxicity was determined by normalizing the cell number of peptide treated + virus-infected cells with mock treated (0.5% DMSO) + virus-infected cells, which were considered as 100%.", [["cell", "ANATOMY", 51, 55], ["cells", "ANATOMY", 99, 104], ["cells", "ANATOMY", 152, 157], ["toxicity", "DISEASE", 8, 16], ["DMSO", "CHEMICAL", 129, 133], ["DMSO", "CHEMICAL", 129, 133], ["cell", "CELL", 51, 55], ["cells", "CELL", 99, 104], ["DMSO", "SIMPLE_CHEMICAL", 129, 133], ["cells", "CELL", 152, 157], ["infected cells", "CELL_TYPE", 90, 104], ["infected cells", "CELL_TYPE", 143, 157], ["Peptide toxicity", "PROBLEM", 0, 16], ["virus", "PROBLEM", 84, 89], ["infected cells", "PROBLEM", 90, 104], ["virus", "PROBLEM", 137, 142], ["infected cells", "PROBLEM", 143, 157], ["toxicity", "OBSERVATION", 8, 16], ["infected cells", "OBSERVATION", 90, 104], ["infected cells", "OBSERVATION", 143, 157]]], ["The TC50 value, defined as the compound concentration resulting in a 50% reduction in cell viability (based on normalized data) compared with mock infection, was used to evaluate cell toxicity.Cell Viability assayVero cells, Hela cells or macrophages were seeded into 96 well tissue culture plates (Greiner Bio-One, Monroe, NC) and treated with different concentrations of AMPs for 18 hrs at 37\u00b0C. Cell viability was examined by Vybrant\u00ae MTT Cell Proliferation Assay Kit (Thermo Fisher Scientific, Grand Island, NY) following the manufacturer's instructions.Virus-like particle productionThe \u03b2-lactamase enzyme was fused to the amino-terminus of the Zaire Ebola virus VP40 matrix gene.", [["cell", "ANATOMY", 86, 90], ["cell", "ANATOMY", 179, 183], ["Cell", "ANATOMY", 193, 197], ["Vero cells", "ANATOMY", 213, 223], ["Hela cells", "ANATOMY", 225, 235], ["macrophages", "ANATOMY", 239, 250], ["Cell", "ANATOMY", 398, 402], ["Cell", "ANATOMY", 442, 446], ["infection", "DISEASE", 147, 156], ["toxicity", "DISEASE", 184, 192], ["amino-terminus", "CHEMICAL", 628, 642], ["MTT", "CHEMICAL", 438, 441], ["amino", "CHEMICAL", 628, 633], ["cell", "CELL", 86, 90], ["cell", "CELL", 179, 183], ["Cell", "CELL", 193, 197], ["Vero cells", "CELL", 213, 223], ["Hela cells", "CELL", 225, 235], ["macrophages", "CELL", 239, 250], ["Cell", "CELL", 398, 402], ["\u03b2-lactamase enzyme", "GENE_OR_GENE_PRODUCT", 592, 610], ["Zaire Ebola virus", "ORGANISM", 650, 667], ["VP40 matrix", "CELLULAR_COMPONENT", 668, 679], ["Vero cells", "CELL_LINE", 213, 223], ["Hela cells", "CELL_LINE", 225, 235], ["macrophages", "CELL_TYPE", 239, 250], ["\u03b2-lactamase enzyme", "PROTEIN", 592, 610], ["amino-terminus", "PROTEIN", 628, 642], ["Zaire Ebola virus VP40 matrix gene", "DNA", 650, 684], ["Zaire Ebola virus", "SPECIES", 650, 667], ["Zaire Ebola virus", "SPECIES", 650, 667], ["The TC50 value", "TEST", 0, 14], ["the compound concentration", "PROBLEM", 27, 53], ["a 50% reduction in cell viability", "PROBLEM", 67, 100], ["mock infection", "PROBLEM", 142, 156], ["cell toxicity", "PROBLEM", 179, 192], ["Cell Viability assay", "TEST", 193, 213], ["Vero cells", "PROBLEM", 213, 223], ["Hela cells", "PROBLEM", 225, 235], ["macrophages", "PROBLEM", 239, 250], ["tissue culture plates", "TEST", 276, 297], ["Greiner Bio", "TEST", 299, 310], ["NC", "TREATMENT", 324, 326], ["AMPs", "TREATMENT", 373, 377], ["Cell viability", "TEST", 398, 412], ["Virus", "PROBLEM", 558, 563], ["particle production", "PROBLEM", 569, 588], ["The \u03b2-lactamase enzyme", "TEST", 588, 610], ["the Zaire Ebola virus VP40 matrix gene", "TREATMENT", 646, 684], ["reduction", "OBSERVATION_MODIFIER", 73, 82], ["cell viability", "OBSERVATION", 86, 100], ["infection", "OBSERVATION", 147, 156], ["Hela cells", "OBSERVATION", 225, 235], ["particle production", "OBSERVATION", 569, 588], ["Zaire Ebola", "OBSERVATION", 650, 661]]], ["This chimeric protein exhibited \u03b2-lactamase activity when expressed in Vero and 293T cells.", [["Vero", "ANATOMY", 71, 75], ["293T cells", "ANATOMY", 80, 90], ["\u03b2-lactamase", "GENE_OR_GENE_PRODUCT", 32, 43], ["Vero", "CELL", 71, 75], ["293T cells", "CELL", 80, 90], ["chimeric protein", "PROTEIN", 5, 21], ["\u03b2-lactamase", "PROTEIN", 32, 43], ["Vero", "CELL_LINE", 71, 75], ["293T cells", "CELL_LINE", 80, 90], ["This chimeric protein", "TEST", 0, 21], ["\u03b2-lactamase activity", "PROBLEM", 32, 52], ["293T cells", "OBSERVATION", 80, 90]]], ["VLPs were produced by co-transfecting 12 \u00b5g of EBOV Zaire beta-lactamaseVP40 expression plasmid and 6 \u00b5g of EBOV Zaire GP expression plasmids into 10 7 293T cells in 10 cm plates using polyethylenimine (PEI, Sigma -Aldrich, St. Louis, MO).", [["plasmids", "ANATOMY", 133, 141], ["293T cells", "ANATOMY", 152, 162], ["polyethylenimine", "CHEMICAL", 185, 201], ["PEI", "CHEMICAL", 203, 206], ["polyethylenimine", "CHEMICAL", 185, 201], ["PEI", "CHEMICAL", 203, 206], ["VLPs", "ORGANISM", 0, 4], ["EBOV", "ORGANISM", 47, 51], ["EBOV", "ORGANISM", 108, 112], ["293T cells", "CELL", 152, 162], ["polyethylenimine", "SIMPLE_CHEMICAL", 185, 201], ["PEI", "SIMPLE_CHEMICAL", 203, 206], ["St. Louis", "ORGANISM", 224, 233], ["EBOV Zaire beta-lactamaseVP40 expression plasmid", "DNA", 47, 95], ["EBOV Zaire GP expression plasmids", "DNA", 108, 141], ["293T cells", "CELL_LINE", 152, 162], ["EBOV Zaire beta-lactamaseVP40", "SPECIES", 47, 76], ["EBOV", "SPECIES", 108, 112], ["VLPs", "TREATMENT", 0, 4], ["EBOV Zaire beta-lactamaseVP40 expression plasmid", "TREATMENT", 47, 95], ["EBOV Zaire GP expression plasmids", "TREATMENT", 108, 141], ["polyethylenimine (PEI", "TREATMENT", 185, 206]]], ["48 hours post-transfection, VLP-containing supernatant was harvested by a cell spin to pellet away debris.", [["supernatant", "ANATOMY", 43, 54], ["cell", "ANATOMY", 74, 78], ["VLP", "ORGANISM", 28, 31], ["cell", "CELL", 74, 78], ["VLP", "PROTEIN", 28, 31], ["VLP-containing supernatant", "TREATMENT", 28, 54], ["debris", "PROBLEM", 99, 105], ["debris", "OBSERVATION", 99, 105]]], ["VLPs were centrifuged through a sucrose cushion at 26,000 rpm for 2 hours at 4\u00b0C, washed in ice-cold NTE buffer (10 mM Tris pH7.5, 100 mM NaCl, 1mM EDTA) by centrifuging at 26,000 rpm for 2 hrs at 4\u00b0C and then resuspended in NTE buffer.", [["sucrose", "CHEMICAL", 32, 39], ["NaCl", "CHEMICAL", 138, 142], ["sucrose", "CHEMICAL", 32, 39], ["Tris pH7.5", "CHEMICAL", 119, 129], ["NaCl", "CHEMICAL", 138, 142], ["EDTA", "CHEMICAL", 148, 152], ["VLPs", "ORGANISM", 0, 4], ["C", "SIMPLE_CHEMICAL", 199, 200], ["VLPs", "TREATMENT", 0, 4], ["a sucrose cushion", "TREATMENT", 30, 47], ["1mM EDTA", "TREATMENT", 144, 152], ["NTE buffer", "TREATMENT", 225, 235]]], ["VLP protein concentration was quantified by Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA).VLP Cell Entry assayThe introduction of beta-lactamase activity by VLPs into the cytoplasm of vero cells (entry of lactamase-VP40) can be measured by fluorescence emission of a membrane-permeable substrate (CCF-2AM, Invitrogen, Carlsbad, CA) that initially fluoresces green but when cleaved by beta-lactamase will fluoresce blue.", [["Cell", "ANATOMY", 117, 121], ["cytoplasm", "ANATOMY", 194, 203], ["vero cells", "ANATOMY", 207, 217], ["membrane", "ANATOMY", 290, 298], ["fluoresces green", "CHEMICAL", 370, 386], ["fluoresce blue", "CHEMICAL", 427, 441], ["VLP", "GENE_OR_GENE_PRODUCT", 0, 3], ["Cell", "CELL", 117, 121], ["beta-lactamase", "GENE_OR_GENE_PRODUCT", 153, 167], ["VLPs", "ORGANISM", 180, 184], ["cytoplasm", "ORGANISM_SUBSTANCE", 194, 203], ["vero cells", "CELL", 207, 217], ["lactamase-VP40", "GENE_OR_GENE_PRODUCT", 228, 242], ["membrane", "CELLULAR_COMPONENT", 290, 298], ["CA", "GENE_OR_GENE_PRODUCT", 351, 353], ["beta-lactamase", "GENE_OR_GENE_PRODUCT", 407, 421], ["VLP protein", "PROTEIN", 0, 11], ["beta-lactamase", "PROTEIN", 153, 167], ["vero cells", "CELL_TYPE", 207, 217], ["lactamase", "PROTEIN", 228, 237], ["VP40", "PROTEIN", 238, 242], ["CCF", "PROTEIN", 320, 323], ["2AM", "PROTEIN", 324, 327], ["beta-lactamase", "PROTEIN", 407, 421], ["VLP protein concentration", "TREATMENT", 0, 25], ["VLP Cell Entry assay", "TEST", 113, 133], ["beta-lactamase activity", "TREATMENT", 153, 176], ["lactamase", "TEST", 228, 237], ["a membrane", "TEST", 288, 298], ["CCF", "TEST", 320, 323], ["Invitrogen", "TEST", 329, 339], ["vero cells", "OBSERVATION", 207, 217]]], ["Vero cells, seeded in 96 well imaging microplate (Corning Life Sciences, Tewksbury, MA), were pretreated with different doses of AMPs at 37\u00b0C for 1 hr, and then were infected with VLPs by centrifuging at 2000 rpm for 1 hr at 4\u00b0C, and incubated at 37\u00b0C for 4 hrs.", [["Vero cells", "ANATOMY", 0, 10], ["Vero cells", "CELL", 0, 10], ["VLPs", "ORGANISM", 180, 184], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cells", "PROBLEM", 0, 10], ["AMPs", "TREATMENT", 129, 133], ["VLPs", "TREATMENT", 180, 184]]], ["Cells were then washed and added with the substrate and incubated for 1 hr at room temperature (RT).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["the substrate", "TREATMENT", 38, 51]]], ["The ratio of green to blue fluorescence was measured by a fluorescence plate reader (TECAN, Morrisville, NC).EBOV minigenome replicationA RNA polymerase-II driven EBOV minigenome was used as previously described 57 .", [["EBOV", "ORGANISM", 109, 113], ["RNA polymerase-II", "GENE_OR_GENE_PRODUCT", 138, 155], ["EBOV", "ORGANISM", 163, 167], ["EBOV minigenome replicationA RNA polymerase-II driven EBOV minigenome", "DNA", 109, 178], ["EBOV", "SPECIES", 109, 113], ["EBOV", "SPECIES", 163, 167], ["blue fluorescence", "TEST", 22, 39], ["a fluorescence plate", "TREATMENT", 56, 76], ["NC", "TREATMENT", 105, 107], ["EBOV minigenome", "TEST", 109, 124], ["RNA polymerase", "TEST", 138, 152]]], ["Briefly, HeLa cells (2.0 x 10 6 ) were seeded in 100 mm plates 24 hrs before transfection.", [["HeLa cells", "ANATOMY", 9, 19], ["HeLa cells", "CELL", 9, 19], ["HeLa cells", "CELL_LINE", 9, 19], ["HeLa cells", "TREATMENT", 9, 19], ["HeLa cells", "OBSERVATION", 9, 19]]], ["Cells were transfected with minigenome components (1.25 \u00b5g pCAGGS-NP-V5, 1.25 \u00b5g pCAGGS-FLAG-VP35, 0.5 \u00b5g pCAGGS-V5-VP30, 0.5 \u00b5g pCAGGS-L, and 7.5 \u00b5g of pCAGGS-3E5E-luciferase) along with 0.5 \u00b5g pRL-TK (for transfection efficiency control) using jetPRIME reagent (Polyplus-transfection; S.A., Illkirch, France) as per manufacturer's recommendation.", [["Cells", "ANATOMY", 0, 5], ["pRL-TK", "CHEMICAL", 195, 201], ["Cells", "CELL", 0, 5], ["VP35", "ORGANISM", 93, 97], ["luciferase", "GENE_OR_GENE_PRODUCT", 165, 175], ["Polyplus", "SIMPLE_CHEMICAL", 264, 272], ["V5", "PROTEIN", 69, 71], ["FLAG", "PROTEIN", 88, 92], ["VP35", "PROTEIN", 93, 97], ["pCAGGS", "PROTEIN", 106, 112], ["V5", "PROTEIN", 113, 115], ["VP30", "PROTEIN", 116, 120], ["pCAGGS", "PROTEIN", 153, 159], ["3E5E", "PROTEIN", 160, 164], ["luciferase", "PROTEIN", 165, 175], ["Cells", "TEST", 0, 5], ["minigenome components", "TEST", 28, 49], ["pCAGGS", "TEST", 59, 65], ["NP", "TEST", 66, 68], ["pCAGGS", "TEST", 81, 87], ["FLAG", "TEST", 88, 92], ["VP35", "TEST", 93, 97], ["pCAGGS", "TEST", 106, 112], ["VP30", "TEST", 116, 120], ["pCAGGS", "TEST", 129, 135], ["pCAGGS", "TEST", 153, 159], ["luciferase", "TEST", 165, 175], ["pRL", "TEST", 195, 198], ["transfection efficiency control", "TREATMENT", 207, 238], ["jetPRIME reagent", "TREATMENT", 246, 262], ["Polyplus", "TEST", 264, 272]]], ["For the no L control, total DNA levels were kept constant by complementing transfections with empty-vector pcDNA3.", [["DNA", "CELLULAR_COMPONENT", 28, 31], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 107, 113], ["empty-vector pcDNA3", "DNA", 94, 113], ["total DNA levels", "TEST", 22, 38], ["empty-vector pcDNA3", "TREATMENT", 94, 113]]], ["Six hrs post-transfection, cells were trypsinized and seeded in 96-well tissue culture plates at 4.0 x 10 4 cells/well with no treatment (L) or with the indicated compounds: vehicle control (VC), ribavirin (5, 25, 50 \u00b5M) , or the individual AMPs (5 \u00b5M).", [["cells", "ANATOMY", 27, 32], ["cells", "ANATOMY", 108, 113], ["ribavirin", "CHEMICAL", 196, 205], ["ribavirin", "CHEMICAL", 196, 205], ["cells", "CELL", 27, 32], ["cells", "CELL", 108, 113], ["ribavirin", "SIMPLE_CHEMICAL", 196, 205], ["cells", "TEST", 27, 32], ["tissue culture plates", "TEST", 72, 93], ["treatment", "TREATMENT", 127, 136], ["vehicle control (VC)", "TREATMENT", 174, 194], ["ribavirin", "TREATMENT", 196, 205]]], ["Reporter activity was measured 24 hrs post-transfection using the Dual-Glo Luciferase Assay System (Promega; Madison, WI, USA) and a Tecan Spark microplate luminometer (Tecan Trading AG, Switzerland).", [["a Tecan Spark microplate luminometer", "TREATMENT", 131, 167]]], ["To account for potential differences in transfection efficiency, firefly luciferase activity was normalized to Renilla luciferase values and plotted as fold activity calculated relative to the no L control.", [["luciferase", "GENE_OR_GENE_PRODUCT", 73, 83], ["luciferase", "GENE_OR_GENE_PRODUCT", 119, 129], ["luciferase", "PROTEIN", 73, 83], ["luciferase", "PROTEIN", 119, 129], ["potential differences in transfection efficiency", "PROBLEM", 15, 63], ["firefly luciferase activity", "TEST", 65, 92], ["Renilla luciferase values", "TEST", 111, 136], ["plotted as fold activity", "PROBLEM", 141, 165], ["transfection efficiency", "OBSERVATION", 40, 63]]], ["Mean \u00b1 standard error of the mean (SEM) values were calculated using GraphPad Prism 7.05 software (GraphPad Software, Inc.; San Diego, CA, USA).Assay for Cathepsin B/L enzymatic activityTo test the effects of AMPs on Cathepsin B/L activity, Cathepsin B/L (2 \u00b5g/ml) was pre-incubated with different doses of Cathepsin B inhibitor CA-074Me, or Cathepsin L inhibitor III, or AMPs in reaction buffer (100 mM sodium acetate pH 5, 1 mM EDTA, 5 mM dithiothreitol) for 30 min at 37\u00b0C, and then 100 \u00b5M of substrate peptide, Z-Arg-Arg-AMC for Cathepsin B, or Z-Phe-Arg-AMC for Cathepsin L (MilliporeSigma, Burlington, MA) was added.", [["sodium acetate", "CHEMICAL", 404, 418], ["dithiothreitol", "CHEMICAL", 441, 455], ["Z-Arg-Arg", "CHEMICAL", 515, 524], ["sodium acetate", "CHEMICAL", 404, 418], ["EDTA", "CHEMICAL", 430, 434], ["dithiothreitol", "CHEMICAL", 441, 455], ["Z-Arg-Arg-AMC", "CHEMICAL", 515, 528], ["Cathepsin B", "GENE_OR_GENE_PRODUCT", 154, 165], ["Cathepsin B", "GENE_OR_GENE_PRODUCT", 217, 228], ["Cathepsin B", "GENE_OR_GENE_PRODUCT", 241, 252], ["Cathepsin B", "GENE_OR_GENE_PRODUCT", 307, 318], ["CA-074Me", "SIMPLE_CHEMICAL", 329, 337], ["Cathepsin L inhibitor III", "SIMPLE_CHEMICAL", 342, 367], ["sodium acetate", "SIMPLE_CHEMICAL", 404, 418], ["EDTA", "SIMPLE_CHEMICAL", 430, 434], ["dithiothreitol", "SIMPLE_CHEMICAL", 441, 455], ["Z-Arg-Arg-AMC", "SIMPLE_CHEMICAL", 515, 528], ["Cathepsin B", "GENE_OR_GENE_PRODUCT", 533, 544], ["Z-Phe-Arg-AMC", "SIMPLE_CHEMICAL", 549, 562], ["Cathepsin L", "SIMPLE_CHEMICAL", 567, 578], ["MilliporeSigma", "SIMPLE_CHEMICAL", 580, 594], ["Cathepsin B", "PROTEIN", 154, 165], ["Cathepsin B", "PROTEIN", 217, 228], ["Cathepsin B", "PROTEIN", 241, 252], ["Cathepsin B", "PROTEIN", 307, 318], ["Cathepsin B", "PROTEIN", 533, 544], ["Mean", "TEST", 0, 4], ["GraphPad Prism", "TEST", 69, 83], ["GraphPad", "TEST", 99, 107], ["Software", "TEST", 108, 116], ["Assay", "TEST", 144, 149], ["Cathepsin B/L enzymatic activity", "TREATMENT", 154, 186], ["AMPs", "TEST", 209, 213], ["Cathepsin B/L activity", "TREATMENT", 217, 239], ["Cathepsin B/L (2 \u00b5g/ml", "TREATMENT", 241, 263], ["Cathepsin B inhibitor CA", "TREATMENT", 307, 331], ["Cathepsin L inhibitor III", "TREATMENT", 342, 367], ["AMPs in reaction buffer", "TREATMENT", 372, 395], ["mM sodium acetate pH", "TREATMENT", 401, 421], ["EDTA", "TEST", 430, 434], ["5 mM dithiothreitol", "TREATMENT", 436, 455], ["substrate peptide", "TREATMENT", 496, 513], ["Z-Arg-Arg", "TEST", 515, 524], ["Cathepsin B", "TREATMENT", 533, 544], ["Z-Phe-Arg", "TEST", 549, 558], ["Cathepsin L (MilliporeSigma, Burlington, MA", "TREATMENT", 567, 610]]], ["The reaction was incubated at room temperature for 1 h r, and fluorescence was measured (excitation 380 nm, emission 460 nm) by a fluorescence plate reader (TECAN, Morrisville NC)Cathepsin B/L cleavage of Ebola GP proteinCathepin B or Cathepsin L was pre-incubated with 50mM of its inhibitor or 5 mM AMPs in 100 mM sodium acetate buffer pH 5.0, containing 1 mM EDTA and 5 mM dithiothreitol at 37 \u00b0C for 30 min.", [["sodium acetate", "CHEMICAL", 315, 329], ["dithiothreitol", "CHEMICAL", 375, 389], ["proteinCathepin B", "CHEMICAL", 214, 231], ["sodium acetate", "CHEMICAL", 315, 329], ["EDTA", "CHEMICAL", 361, 365], ["dithiothreitol", "CHEMICAL", 375, 389], ["Cathepsin B", "GENE_OR_GENE_PRODUCT", 179, 190], ["Ebola", "ORGANISM", 205, 210], ["GP proteinCathepin B", "GENE_OR_GENE_PRODUCT", 211, 231], ["Cathepsin L", "GENE_OR_GENE_PRODUCT", 235, 246], ["sodium acetate", "SIMPLE_CHEMICAL", 315, 329], ["EDTA", "SIMPLE_CHEMICAL", 361, 365], ["dithiothreitol", "SIMPLE_CHEMICAL", 375, 389], ["Ebola GP proteinCathepin B", "PROTEIN", 205, 231], ["Cathepsin L", "PROTEIN", 235, 246], ["The reaction", "PROBLEM", 0, 12], ["a fluorescence plate reader (TECAN", "TREATMENT", 128, 162], ["Morrisville NC", "TREATMENT", 164, 178], ["Cathepsin B/L cleavage", "TREATMENT", 179, 201], ["Ebola GP proteinCathepin B", "TREATMENT", 205, 231], ["Cathepsin L", "TREATMENT", 235, 246], ["its inhibitor", "TREATMENT", 278, 291], ["5 mM AMPs", "TREATMENT", 295, 304], ["mM sodium acetate buffer pH", "TREATMENT", 312, 339], ["1 mM EDTA", "TREATMENT", 356, 365], ["5 mM dithiothreitol", "TREATMENT", 370, 389]]], ["Then, 1 \u03bcg of Ebola GP protein (IBT Bioservice, Rockville, MD) were added to the reaction and incubated at 37 \u00b0C for 1 hr.", [["Ebola", "ORGANISM", 14, 19], ["Ebola GP protein", "PROTEIN", 14, 30], ["Ebola GP protein", "TREATMENT", 14, 30]]], ["The reaction mixtures were boiled for 10 min and subjected to SDS PAGE followed by Western blot with anti-Ebola GP antibodies.", [["anti-Ebola GP antibodies", "GENE_OR_GENE_PRODUCT", 101, 125], ["anti-Ebola GP antibodies", "PROTEIN", 101, 125], ["The reaction mixtures", "TREATMENT", 0, 21]]]], "PMC7517055": [["Objectives of this study ::: IntroductionThe main objective of this work is to assist the victims and humanitarian organizations in the event of a disaster by designing a method for automatic identification of Need and Availability of Resource tweets (NAR) from Twitter.", [["this study", "TEST", 14, 24], ["humanitarian organizations", "TREATMENT", 102, 128], ["main", "OBSERVATION_MODIFIER", 45, 49]]], ["The problem of detecting NAR tweets can be treated as a multi-classification problem.", [["NAR", "MULTI-TISSUE_STRUCTURE", 25, 28], ["a multi-classification problem", "PROBLEM", 54, 84], ["NAR tweets", "OBSERVATION", 25, 35]]], ["None of both.Prior work with limitations ::: IntroductionOnly a few existing works [1, 3, 11] are only focused on extracting the need and availability of resource tweets during the disaster.", [["both", "ANATOMY_MODIFIER", 8, 12]]], ["Among them, most of the works used information-retrieval methodologies such as word2vec, a combination of word embeddings and character embeddings, etc. Specifically, the authors in [3] used both information-retrieval methodologies and classification methodologies (CNN with crisis word embeddings) to extract the Need and Availability of Resource tweets during the disaster.", [["word2vec", "PROTEIN", 79, 87], ["retrieval methodologies", "TREATMENT", 47, 70], ["word embeddings", "PROBLEM", 106, 121]]], ["The main drawback of CNN with crisis embeddings is that it does not work well if the number of training tweets is small and, in the case of information retrieval methodologies, keywords must be given manually to identify the need and availability of resource tweets during the disaster.Prior work with limitations ::: IntroductionTo overcome the above-mentioned issues, a novel method is proposed by using the stacking mechanism [44] to identify NAR tweets during the disaster.", [["NAR", "MULTI-TISSUE_STRUCTURE", 446, 449], ["crisis embeddings", "PROBLEM", 30, 47], ["main", "OBSERVATION_MODIFIER", 4, 8], ["crisis", "OBSERVATION", 30, 36], ["small", "OBSERVATION_MODIFIER", 114, 119]]], ["The stacking mechanism uses a two-level classifiers.", [["a two-level classifiers", "TREATMENT", 28, 51]]], ["The first level uses multiple classifiers and the classifier output is used as the second level classifier input, while the second level uses only one classifier.", [["multiple classifiers", "TREATMENT", 21, 41], ["the classifier output", "TEST", 46, 67]]], ["The stacking method does not produce improved results if the models used in the stacking method are stable.", [["stable", "OBSERVATION_MODIFIER", 100, 106]]], ["Therefore, different models such as CNN and KNN classifiers with domain-specific features are used in this work.", [["CNN", "DNA", 36, 39]]], ["CNN is used to capture the semantic similarity between words, and even vocabulary words are different in the testing phase.", [["CNN", "GENE_OR_GENE_PRODUCT", 0, 3], ["CNN", "PROTEIN", 0, 3], ["the testing phase", "TEST", 105, 122]]], ["In order to overcome the problem of a lower number of training tweets, new features are proposed and used in the KNN classifier to detect NAR tweets.", [["NAR", "MULTI-TISSUE_STRUCTURE", 138, 141], ["NAR tweets", "OBSERVATION", 138, 148]]], ["The output of these two models is given as input to the SVM (second level) classifier.", [["The output", "TEST", 0, 10], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["The reason for selecting the KNN and SVM classifiers as first and second level classifiers is clearly explained in Sections 4.4.2 and 4.5.2.Contributions of this work ::: IntroductionThe main contributions are summarized as:A Stacked Convolutional Neural Network is proposed to automatically identify the need and availability of resources tweets during the disaster.Crisis word embedding is used in a deep learning model and domain-specific features are used in a feature-based classification method.", [["KNN", "DNA", 29, 32], ["Sections", "TEST", 115, 123], ["Crisis word embedding", "TREATMENT", 367, 388], ["main", "OBSERVATION_MODIFIER", 187, 191]]], ["Various classification algorithms such as SVM, Bagging, gradient boosting, random forest, KNN, Decision tree and Naive Bayes classification are also used.Extensive experiments are carried out on real-time Twitter datasets such as the Nepal and Italy earthquakes in 2015 and 2016.The proposed model is compared to the existing methodologies by using different parameters.", [["Various classification algorithms", "PROBLEM", 0, 33], ["SVM", "TEST", 42, 45], ["Bagging", "TREATMENT", 47, 54], ["gradient boosting", "TREATMENT", 56, 73]]], ["In addition, statistical validation is performed to compare the methods using the MCNemar test.Contributions of this work ::: IntroductionThis paper is organized as follows.", [["statistical validation", "TEST", 13, 35], ["the MCNemar test", "TEST", 78, 94]]], ["The proposed approach for the detection of NAR tweets during a disaster is described in the third section.", [["NAR", "MULTI-TISSUE_STRUCTURE", 43, 46], ["NAR tweets", "OBSERVATION", 43, 53]]], ["Experimental results and analysis are discussed in the fourth section.", [["analysis", "TEST", 25, 33]]], ["The last section is the conclusion of the paper.Related workMany studies [22, 28, 32, 41] focused on the detection of the tweets related to a disaster.", [["Many studies", "TEST", 60, 72]]], ["Preliminary work [41] focused mainly on extracting the features such as uni-gram and bi-gram frequency, Parts-Of-Speech (POS), objective or subjective, personal or impersonal and formal or informal from tweets and used the classifiers for classifying the tweets based on the relevancy.", [["uni-gram", "TEST", 72, 80]]], ["Classifiers such as Naive Bayes and Max entropy classifiers are used for detection of the situational tweets related to the disaster.", [["Naive Bayes and Max entropy classifiers", "TREATMENT", 20, 59]]], ["To overcome the problem domain dependent, the authors in [28] proposed a novel framework for classifying the situational and non-situational information based on the low-level lexical and syntactical features.", [["the problem domain dependent", "PROBLEM", 12, 40]]], ["Several studies, for instance [2, 11, 21, 29] have been proposed on different specific classes.", [["Several studies", "TEST", 0, 15]]], ["The authors in [21], suggests that decision tree with context and content features give the best results for recall and F1-measure parameters among the classifiers such as SVM, AdaBoost and random forest.", [["AdaBoost", "TREATMENT", 177, 185], ["random forest", "TREATMENT", 190, 203]]], ["In AIDR, the uni-gram and bi-gram features are used for detecting the tweets related to the user-defined categories.", [["the uni-gram and bi-gram features", "TEST", 9, 42]]], ["In [2], the authors manually analyzed WhatsApp messages for the requirement of medical, human, infrastructural resources during a disaster by considering the case study of Nepal earthquake dataset 2015.", [["human", "ORGANISM", 88, 93], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93]]], ["In [11], the authors found that neural network retrieved models by integrating the character-level and word-level embeddings with pattern recognition techniques perform well than state-of-art models.", [["neural network", "ANATOMY", 32, 46], ["neural network", "MULTI-TISSUE_STRUCTURE", 32, 46]]], ["The authors applied information retrieval techniques for detecting the NAR tweets.", [["NAR tweets", "OBSERVATION", 71, 81]]], ["In [7], the authors used a novel vector training approach for clustering the tweets about the emergency situations and compared their method with Bag-Of-Words (BOW), word2vec-sum and doc2vec.", [["word2vec-sum", "GENE_OR_GENE_PRODUCT", 166, 178], ["doc2vec", "GENE_OR_GENE_PRODUCT", 183, 190], ["word2vec", "DNA", 166, 174], ["doc2vec", "DNA", 183, 190], ["a novel vector training approach", "TREATMENT", 25, 57], ["Bag", "TREATMENT", 146, 149]]], ["However, they are not proposed a method for identifying the NAR tweets during a disaster.Tokenization and pre-processing ::: Stacked convolutional neural network", [["neural network", "MULTI-TISSUE_STRUCTURE", 147, 161], ["Stacked convolutional neural network", "PROBLEM", 125, 161], ["neural network", "OBSERVATION", 147, 161]]]], "PMC7510728": [["Because of in vitro studies suggesting potential activity on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1,2), hydroxychloroquine has been one of the main candidate drugs evaluated for coronavirus disease (COVID-19), both as a curative treatment and as preexposure or postexposure prophylaxis.", [["acute respiratory syndrome coronavirus", "DISEASE", 68, 106], ["hydroxychloroquine", "CHEMICAL", 129, 147], ["coronavirus disease", "DISEASE", 203, 222], ["COVID-19", "CHEMICAL", 224, 232], ["hydroxychloroquine", "CHEMICAL", 129, 147], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 129, 147], ["coronavirus", "ORGANISM", 203, 214], ["severe acute respiratory syndrome coronavirus", "SPECIES", 61, 106], ["SARS-CoV-2", "SPECIES", 110, 120], ["vitro studies", "TEST", 14, 27], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 61, 106], ["SARS", "TEST", 110, 114], ["CoV", "TEST", 115, 118], ["hydroxychloroquine", "TREATMENT", 129, 147], ["drugs", "TREATMENT", 183, 188], ["coronavirus disease", "PROBLEM", 203, 222], ["COVID", "TEST", 224, 229], ["a curative treatment", "TREATMENT", 243, 263], ["postexposure prophylaxis", "TREATMENT", 286, 310], ["suggesting potential", "UNCERTAINTY", 28, 48], ["activity", "OBSERVATION_MODIFIER", 49, 57], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory syndrome", "OBSERVATION", 74, 94]]], ["We report a case of COVID-19 in a patient receiving long-term hydroxychloroquine treatment despite plasma concentrations within the therapeutic range for autoimmune diseases, such as systemic lupus erythematosus.", [["plasma", "ANATOMY", 99, 105], ["COVID-19", "CHEMICAL", 20, 28], ["hydroxychloroquine", "CHEMICAL", 62, 80], ["autoimmune diseases", "DISEASE", 154, 173], ["systemic lupus erythematosus", "DISEASE", 183, 211], ["COVID-19", "CHEMICAL", 20, 28], ["hydroxychloroquine", "CHEMICAL", 62, 80], ["patient", "ORGANISM", 34, 41], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 62, 80], ["plasma", "ORGANISM_SUBSTANCE", 99, 105], ["patient", "SPECIES", 34, 41], ["COVID", "TEST", 20, 25], ["long-term hydroxychloroquine treatment", "TREATMENT", 52, 90], ["plasma concentrations", "PROBLEM", 99, 120], ["autoimmune diseases", "PROBLEM", 154, 173], ["systemic lupus erythematosus", "PROBLEM", 183, 211], ["autoimmune diseases", "OBSERVATION", 154, 173], ["systemic", "OBSERVATION_MODIFIER", 183, 191], ["lupus erythematosus", "OBSERVATION", 192, 211]]]], "PMC7334988": [["Property 1 ::: IntroductionEach row or column of the MixColumns matrix has two elements that sum to zero.Property 2 ::: IntroductionEach row or column of the MixColumns matrix has three elements that sum to zero.Property 2 ::: IntroductionAt Crypto 2016, Sun et al. noticed Property 1 for the first time and established the first zero-correlation linear hull and the first integral distinguisher for the 5-round AES [15].", [["IntroductionEach row or column of the MixColumns matrix", "TREATMENT", 15, 70], ["IntroductionEach row or column of the MixColumns matrix", "TREATMENT", 120, 175]]], ["The two attacks exploited the existing 4-round corresponding properties and extended them one more round based on the MixColumns coefficient property.", [["round", "OBSERVATION_MODIFIER", 99, 104]]], ["As is well-known, the previous zero-correlation linear hull can cover at most 3.5 rounds of the AES (without last MixColumns) [4] which is illustrated in Fig. 11.", [["the AES", "PROBLEM", 92, 99]]]], "6e1f1359702c7246756a3816072ca48b49ff4803": [["The COVID-19 pandemic has driven unprecedented efforts to identify existing treatments that can be quickly and effectively repurposed to reduce morbidity and mortality.", [["The COVID", "TEST", 0, 9], ["existing treatments", "TREATMENT", 67, 86], ["morbidity", "PROBLEM", 144, 153]]], ["In this issue of Cell Metabolism, Zhang et al. (2020) report an association between statin use and improved outcomes in a large observational study of hospitalized COVID-19 patients.", [["Cell", "ANATOMY", 17, 21], ["statin", "CHEMICAL", 84, 90], ["statin", "CHEMICAL", 84, 90], ["Cell", "CELL", 17, 21], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["statin", "TREATMENT", 84, 90], ["Cell Metabolism", "OBSERVATION", 17, 32]]], ["Given the widespread availability, low cost, and safety of statins, this promising result should be further investigated in randomized controlled trials.", [["statins", "CHEMICAL", 59, 66], ["statins", "CHEMICAL", 59, 66], ["statins", "TREATMENT", 59, 66], ["widespread", "OBSERVATION_MODIFIER", 10, 20], ["low cost", "OBSERVATION_MODIFIER", 35, 43]]]], "d515d3944ae0e54d6ec0bd57a8bb4bec30f589ad": [["INTRODUCTIONCancer cells may escape immune surveillance through a variety of mechanisms, including the activation of immune checkpoint pathways that serve to suppress immune responses against tumor cells.", [["INTRODUCTIONCancer cells", "ANATOMY", 0, 24], ["tumor cells", "ANATOMY", 192, 203], ["tumor", "DISEASE", 192, 197], ["INTRODUCTIONCancer cells", "CELL", 0, 24], ["tumor cells", "CELL", 192, 203], ["tumor cells", "CELL_TYPE", 192, 203], ["INTRODUCTIONCancer cells", "PROBLEM", 0, 24], ["immune surveillance", "TEST", 36, 55], ["immune checkpoint pathways", "TREATMENT", 117, 143], ["tumor cells", "PROBLEM", 192, 203]]], ["Immune checkpoint inhibitors (ICI) boost antitumor immune responses by interrupting coinhibitory signaling pathways to promote immunemediated killing of tumor cells.", [["antitumor", "ANATOMY", 41, 50], ["tumor cells", "ANATOMY", 153, 164], ["ICI", "CHEMICAL", 30, 33], ["tumor", "DISEASE", 153, 158], ["ICI", "SIMPLE_CHEMICAL", 30, 33], ["antitumor", "CANCER", 41, 50], ["tumor cells", "CELL", 153, 164], ["tumor cells", "CELL_TYPE", 153, 164], ["Immune checkpoint inhibitors (ICI)", "TREATMENT", 0, 34], ["boost antitumor immune responses", "TREATMENT", 35, 67], ["interrupting coinhibitory signaling pathways", "TREATMENT", 71, 115], ["tumor cells", "PROBLEM", 153, 164], ["tumor cells", "OBSERVATION", 153, 164]]], ["The introduction of ICI in 2011 for therapy has been a revolutionary milestone in the management of many solid cancers and hematological malignancies (eg, melanoma, Merkel cell carcinoma, squamous cell carcinomas, colorectal cancer, renal cell carcinoma, urothelial cancer, Hodgkin lymphoma).", [["solid cancers", "ANATOMY", 105, 118], ["hematological malignancies", "ANATOMY", 123, 149], ["melanoma", "ANATOMY", 155, 163], ["Merkel cell carcinoma", "ANATOMY", 165, 186], ["squamous cell carcinomas", "ANATOMY", 188, 212], ["colorectal cancer", "ANATOMY", 214, 231], ["renal cell carcinoma", "ANATOMY", 233, 253], ["urothelial cancer", "ANATOMY", 255, 272], ["Hodgkin lymphoma", "ANATOMY", 274, 290], ["ICI", "CHEMICAL", 20, 23], ["cancers", "DISEASE", 111, 118], ["hematological malignancies", "DISEASE", 123, 149], ["melanoma", "DISEASE", 155, 163], ["Merkel cell carcinoma", "DISEASE", 165, 186], ["squamous cell carcinomas", "DISEASE", 188, 212], ["colorectal cancer", "DISEASE", 214, 231], ["renal cell carcinoma", "DISEASE", 233, 253], ["urothelial cancer", "DISEASE", 255, 272], ["Hodgkin lymphoma", "DISEASE", 274, 290], ["ICI", "CHEMICAL", 20, 23], ["ICI", "SIMPLE_CHEMICAL", 20, 23], ["solid cancers", "CANCER", 105, 118], ["hematological malignancies", "CANCER", 123, 149], ["melanoma", "CANCER", 155, 163], ["Merkel cell carcinoma", "CANCER", 165, 186], ["squamous cell carcinomas", "CANCER", 188, 212], ["colorectal cancer", "CANCER", 214, 231], ["renal cell carcinoma", "CANCER", 233, 253], ["urothelial cancer", "CANCER", 255, 272], ["Hodgkin lymphoma", "CANCER", 274, 290], ["The introduction of ICI", "TREATMENT", 0, 23], ["therapy", "TREATMENT", 36, 43], ["many solid cancers", "PROBLEM", 100, 118], ["hematological malignancies (eg", "PROBLEM", 123, 153], ["melanoma", "PROBLEM", 155, 163], ["Merkel cell carcinoma", "PROBLEM", 165, 186], ["squamous cell carcinomas", "PROBLEM", 188, 212], ["colorectal cancer", "PROBLEM", 214, 231], ["renal cell carcinoma", "PROBLEM", 233, 253], ["urothelial cancer", "PROBLEM", 255, 272], ["Hodgkin lymphoma", "PROBLEM", 274, 290], ["many", "OBSERVATION_MODIFIER", 100, 104], ["solid cancers", "OBSERVATION", 105, 118], ["hematological malignancies", "OBSERVATION", 123, 149], ["melanoma", "OBSERVATION", 155, 163], ["Merkel cell carcinoma", "OBSERVATION", 165, 186], ["squamous cell carcinomas", "OBSERVATION", 188, 212], ["colorectal cancer", "OBSERVATION", 214, 231], ["renal", "ANATOMY", 233, 238], ["cell carcinoma", "OBSERVATION", 239, 253], ["urothelial", "ANATOMY", 255, 265], ["cancer", "OBSERVATION", 266, 272], ["Hodgkin lymphoma", "OBSERVATION", 274, 290]]], ["[1] [2] [3] Currently, antibodies targeting three different inhibitory checkpoint proteins are approved as first-line, second-line or third-line treatments for various types of malignancies: cytotoxic T lymphocyte antigen-4 (CTLA-4; ipilimumab), programmed cell death protein-1 (PD-1; pembrolizumab, nivolumab, cemiplimab), and programmed cell death protein ligand-1 (PD-L1; durvalumab, atezolizumab, avelumab).", [["malignancies", "ANATOMY", 177, 189], ["cell", "ANATOMY", 339, 343], ["malignancies", "DISEASE", 177, 189], ["CTLA-4", "CHEMICAL", 225, 231], ["ipilimumab", "CHEMICAL", 233, 243], ["pembrolizumab", "CHEMICAL", 285, 298], ["nivolumab", "CHEMICAL", 300, 309], ["cemiplimab", "CHEMICAL", 311, 321], ["durvalumab", "CHEMICAL", 375, 385], ["atezolizumab", "CHEMICAL", 387, 399], ["avelumab", "CHEMICAL", 401, 409], ["pembrolizumab", "CHEMICAL", 285, 298], ["nivolumab", "CHEMICAL", 300, 309], ["cemiplimab", "CHEMICAL", 311, 321], ["atezolizumab", "CHEMICAL", 387, 399], ["avelumab", "CHEMICAL", 401, 409], ["malignancies", "CANCER", 177, 189], ["cytotoxic T lymphocyte antigen-4", "GENE_OR_GENE_PRODUCT", 191, 223], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 225, 231], ["ipilimumab", "SIMPLE_CHEMICAL", 233, 243], ["programmed cell death protein-1", "GENE_OR_GENE_PRODUCT", 246, 277], ["PD-1", "GENE_OR_GENE_PRODUCT", 279, 283], ["pembrolizumab", "SIMPLE_CHEMICAL", 285, 298], ["nivolumab", "SIMPLE_CHEMICAL", 300, 309], ["cemiplimab", "SIMPLE_CHEMICAL", 311, 321], ["programmed cell death protein ligand-1", "GENE_OR_GENE_PRODUCT", 328, 366], ["PD-L1", "GENE_OR_GENE_PRODUCT", 368, 373], ["durvalumab", "SIMPLE_CHEMICAL", 375, 385], ["atezolizumab", "SIMPLE_CHEMICAL", 387, 399], ["avelumab", "SIMPLE_CHEMICAL", 401, 409], ["inhibitory checkpoint proteins", "PROTEIN", 60, 90], ["antibodies", "TREATMENT", 23, 33], ["different inhibitory checkpoint proteins", "TREATMENT", 50, 90], ["second-line", "TREATMENT", 119, 130], ["third-line treatments", "TREATMENT", 134, 155], ["malignancies", "PROBLEM", 177, 189], ["cytotoxic T lymphocyte antigen", "TEST", 191, 221], ["CTLA", "TEST", 225, 229], ["ipilimumab", "TEST", 233, 243], ["programmed cell death protein", "TEST", 246, 275], ["PD", "TEST", 279, 281], ["pembrolizumab", "TEST", 285, 298], ["nivolumab", "TEST", 300, 309], ["cemiplimab", "TEST", 311, 321], ["programmed cell death protein ligand", "TEST", 328, 364], ["PD", "TEST", 368, 370], ["durvalumab", "TREATMENT", 375, 385], ["atezolizumab", "TREATMENT", 387, 399], ["malignancies", "OBSERVATION", 177, 189]]], ["[1] [2] [3] [4] Full activation of T lymphocytes predominantly depends on several different signals.", [["T lymphocytes", "ANATOMY", 35, 48], ["[1] [2] [3] [4] Full", "SIMPLE_CHEMICAL", 0, 20], ["T lymphocytes", "CELL", 35, 48], ["T lymphocytes", "CELL_TYPE", 35, 48], ["T lymphocytes", "PROBLEM", 35, 48]]], ["Indeed, T lymphocyte activation is regulated both by costimulators and coinhibitors known as immune checkpoints.", [["T lymphocyte", "ANATOMY", 8, 20], ["T lymphocyte", "CELL", 8, 20], ["costimulators", "PROTEIN", 53, 66], ["coinhibitors", "PROTEIN", 71, 83], ["T lymphocyte activation", "PROBLEM", 8, 31], ["coinhibitors", "TREATMENT", 71, 83], ["immune checkpoints", "TREATMENT", 93, 111], ["lymphocyte activation", "OBSERVATION", 10, 31], ["immune checkpoints", "OBSERVATION", 93, 111]]], ["5 Antigen-major histocompatibility complex (MHC) and T cell receptor (TCR) binding associated with the activation of costimulatory receptors (ie, CD28) enables T lymphocytes to proliferate, differentiate and migrate toward specific antigens.", [["T cell", "ANATOMY", 53, 59], ["T lymphocytes", "ANATOMY", 160, 173], ["Antigen-major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 2, 42], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 53, 68], ["TCR", "GENE_OR_GENE_PRODUCT", 70, 73], ["CD28", "GENE_OR_GENE_PRODUCT", 146, 150], ["T lymphocytes", "CELL", 160, 173], ["Antigen-major histocompatibility complex", "PROTEIN", 2, 42], ["MHC", "PROTEIN", 44, 47], ["T cell receptor", "PROTEIN", 53, 68], ["TCR", "PROTEIN", 70, 73], ["costimulatory receptors", "PROTEIN", 117, 140], ["CD28", "PROTEIN", 146, 150], ["T lymphocytes", "CELL_TYPE", 160, 173], ["T cell receptor (TCR) binding", "PROBLEM", 53, 82], ["costimulatory receptors", "TREATMENT", 117, 140]]], ["By contrast, when antigen-MHC and TCR binding is associated with signaling of coinhibitory receptors (ie, CTLA-4), T cell activation will be suppressed.", [["T cell", "ANATOMY", 115, 121], ["TCR", "CHEMICAL", 34, 37], ["antigen-MHC", "GENE_OR_GENE_PRODUCT", 18, 29], ["TCR", "GENE_OR_GENE_PRODUCT", 34, 37], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 106, 112], ["T cell", "CELL", 115, 121], ["MHC", "PROTEIN", 26, 29], ["TCR", "PROTEIN", 34, 37], ["coinhibitory receptors", "PROTEIN", 78, 100], ["CTLA-4", "PROTEIN", 106, 112], ["TCR binding", "PROBLEM", 34, 45], ["signaling of coinhibitory receptors", "PROBLEM", 65, 100], ["CTLA", "TEST", 106, 110], ["T cell activation", "PROBLEM", 115, 132]]], ["CTLA-4 is not expressed in na\u00efve T lymphocytes, but is quickly induced on T cell activation.", [["T lymphocytes", "ANATOMY", 33, 46], ["T cell", "ANATOMY", 74, 80], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 0, 6], ["na\u00efve T lymphocytes", "CELL", 27, 46], ["T cell", "CELL", 74, 80], ["CTLA-4", "PROTEIN", 0, 6], ["na\u00efve T lymphocytes", "CELL_TYPE", 27, 46], ["CTLA", "TEST", 0, 4], ["not", "UNCERTAINTY", 10, 13], ["lymphocytes", "ANATOMY", 35, 46]]], ["Importantly, CTLA-4 predominantly regulates the amplitude of T cell activation during the early priming phase in lymphoid organs.", [["T cell", "ANATOMY", 61, 67], ["lymphoid organs", "ANATOMY", 113, 128], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 13, 19], ["T cell", "CELL", 61, 67], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 113, 128], ["CTLA-4", "PROTEIN", 13, 19], ["CTLA", "TEST", 13, 17], ["T cell activation", "PROBLEM", 61, 78], ["amplitude", "OBSERVATION_MODIFIER", 48, 57], ["T cell activation", "OBSERVATION", 61, 78], ["lymphoid organs", "OBSERVATION", 113, 128]]], ["1 3 5 The binding of CTLA-4 to B7 proteins is in direct competition with CD28 costimulatory signals, and the ratio between CD28 and CTLA-4 binding determines activation of T lymphocytes versus anergy, and represents an important mechanism in the prevention of excessive immune responses.", [["T lymphocytes", "ANATOMY", 172, 185], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 21, 27], ["B7", "GENE_OR_GENE_PRODUCT", 31, 33], ["CD28", "GENE_OR_GENE_PRODUCT", 73, 77], ["CD28", "GENE_OR_GENE_PRODUCT", 123, 127], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 132, 138], ["T lymphocytes", "CELL", 172, 185], ["CTLA", "PROTEIN", 21, 25], ["B7 proteins", "PROTEIN", 31, 42], ["CD28", "PROTEIN", 73, 77], ["CD28", "PROTEIN", 123, 127], ["CTLA-4", "PROTEIN", 132, 138], ["T lymphocytes", "CELL_TYPE", 172, 185], ["CTLA", "TEST", 21, 25], ["CD28 costimulatory signals", "TEST", 73, 99], ["the ratio", "TEST", 105, 114], ["CD28", "TEST", 123, 127], ["CTLA", "TEST", 132, 136], ["T lymphocytes", "PROBLEM", 172, 185], ["anergy", "PROBLEM", 193, 199], ["excessive immune responses", "PROBLEM", 260, 286], ["lymphocytes", "OBSERVATION", 174, 185]]], ["Hence, the main task of CTLA-4 is to stop autoreactive T lymphocytes at the initial stages of activation, predominantly in lymphoid tissues, to prevent autoimmunity.", [["T lymphocytes", "ANATOMY", 55, 68], ["lymphoid tissues", "ANATOMY", 123, 139], ["autoimmunity", "DISEASE", 152, 164], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 24, 30], ["autoreactive T lymphocytes", "CELL", 42, 68], ["lymphoid tissues", "TISSUE", 123, 139], ["CTLA-4", "PROTEIN", 24, 30], ["autoreactive T lymphocytes", "CELL_TYPE", 42, 68], ["CTLA", "TEST", 24, 28], ["autoreactive T lymphocytes", "PROBLEM", 42, 68], ["autoimmunity", "PROBLEM", 152, 164], ["main", "OBSERVATION_MODIFIER", 11, 15], ["autoreactive T lymphocytes", "OBSERVATION", 42, 68], ["predominantly", "OBSERVATION_MODIFIER", 106, 119], ["lymphoid tissues", "OBSERVATION", 123, 139]]], ["5 Thus, it is not surprising that it is also expressed on regulatory T cells (Tregs).", [["regulatory T cells", "ANATOMY", 58, 76], ["Tregs", "ANATOMY", 78, 83], ["regulatory T cells", "CELL", 58, 76], ["Tregs", "CELL", 78, 83], ["regulatory T cells", "CELL_TYPE", 58, 76], ["Tregs", "CELL_TYPE", 78, 83]]], ["Similar to Tregs, PD-1 plays an important role in limiting immune responses in peripheral tissues.", [["Tregs", "ANATOMY", 11, 16], ["peripheral tissues", "ANATOMY", 79, 97], ["Tregs", "CELL", 11, 16], ["PD-1", "GENE_OR_GENE_PRODUCT", 18, 22], ["peripheral tissues", "TISSUE", 79, 97], ["Tregs", "CELL_TYPE", 11, 16], ["peripheral tissues", "ANATOMY", 79, 97]]], ["The interaction of PD-1 with its ligands (PD-L1/2) inhibits T cell proliferation and cytokine secretion mediated by TCRs.", [["T cell", "ANATOMY", 60, 66], ["PD-1", "GENE_OR_GENE_PRODUCT", 19, 23], ["PD-L1", "GENE_OR_GENE_PRODUCT", 42, 47], ["T cell", "CELL", 60, 66], ["TCRs", "GENE_OR_GENE_PRODUCT", 116, 120], ["cytokine", "PROTEIN", 85, 93], ["TCRs", "PROTEIN", 116, 120], ["PD", "TEST", 19, 21], ["PD", "TEST", 42, 44], ["T cell proliferation", "PROBLEM", 60, 80], ["cytokine secretion", "PROBLEM", 85, 103], ["cell proliferation", "OBSERVATION", 62, 80]]], ["1-3 5 The PD-1 receptor is physiologically expressed by activated T lymphocytes, B lymphocytes, monocytes, natural killer (NK) cells, and Tregs.", [["T lymphocytes", "ANATOMY", 66, 79], ["B lymphocytes", "ANATOMY", 81, 94], ["monocytes", "ANATOMY", 96, 105], ["natural killer (NK) cells", "ANATOMY", 107, 132], ["Tregs", "ANATOMY", 138, 143], ["PD-1 receptor", "GENE_OR_GENE_PRODUCT", 10, 23], ["T lymphocytes", "CELL", 66, 79], ["B lymphocytes", "CELL", 81, 94], ["monocytes", "CELL", 96, 105], ["natural killer (NK) cells", "CELL", 107, 132], ["Tregs", "CELL", 138, 143], ["PD-1 receptor", "PROTEIN", 10, 23], ["activated T lymphocytes", "CELL_TYPE", 56, 79], ["B lymphocytes", "CELL_TYPE", 81, 94], ["monocytes", "CELL_TYPE", 96, 105], ["natural killer (NK) cells", "CELL_TYPE", 107, 132], ["Tregs", "CELL_TYPE", 138, 143], ["The PD-1 receptor", "TEST", 6, 23], ["activated T lymphocytes", "TEST", 56, 79], ["B lymphocytes", "TEST", 81, 94], ["monocytes", "TEST", 96, 105], ["cells", "TEST", 127, 132], ["Tregs", "TEST", 138, 143], ["lymphocytes", "ANATOMY", 83, 94], ["monocytes", "ANATOMY", 96, 105]]], ["PD-L1 is expressed on several cells, including tumor cells and some host cells such as myeloid, lymphoid and epithelial cells.", [["cells", "ANATOMY", 30, 35], ["tumor cells", "ANATOMY", 47, 58], ["cells", "ANATOMY", 73, 78], ["myeloid", "ANATOMY", 87, 94], ["lymphoid", "ANATOMY", 96, 104], ["epithelial cells", "ANATOMY", 109, 125], ["tumor", "DISEASE", 47, 52], ["PD-L1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 30, 35], ["tumor cells", "CELL", 47, 58], ["host cells", "CELL", 68, 78], ["myeloid", "CELL", 87, 94], ["lymphoid", "CELL", 96, 104], ["epithelial cells", "CELL", 109, 125], ["PD-L1", "DNA", 0, 5], ["tumor cells", "CELL_TYPE", 47, 58], ["host cells", "CELL_TYPE", 68, 78], ["myeloid, lymphoid and epithelial cells", "CELL_TYPE", 87, 125], ["several cells", "PROBLEM", 22, 35], ["tumor cells", "PROBLEM", 47, 58], ["some host cells", "PROBLEM", 63, 78], ["myeloid, lymphoid and epithelial cells", "PROBLEM", 87, 125], ["L1", "ANATOMY", 3, 5], ["several cells", "OBSERVATION_MODIFIER", 22, 35], ["tumor cells", "OBSERVATION", 47, 58], ["host cells", "OBSERVATION", 68, 78], ["myeloid", "ANATOMY", 87, 94], ["lymphoid", "ANATOMY", 96, 104], ["epithelial cells", "OBSERVATION", 109, 125]]], ["The interaction between PD-1 and PD-L1 blocks CD8+INTRODUCTIONOpen access cytotoxic T cell proliferation and survival, leads to apoptosis of tumor-infiltrating lymphocytes, and promotes differentiation of CD4+ T lymphocytes into Tregs.", [["T cell", "ANATOMY", 84, 90], ["tumor-infiltrating lymphocytes", "ANATOMY", 141, 171], ["CD4+ T lymphocytes", "ANATOMY", 205, 223], ["Tregs", "ANATOMY", 229, 234], ["tumor", "DISEASE", 141, 146], ["PD-1", "GENE_OR_GENE_PRODUCT", 24, 28], ["PD-L1", "GENE_OR_GENE_PRODUCT", 33, 38], ["cytotoxic T cell", "CELL", 74, 90], ["tumor-infiltrating lymphocytes", "CELL", 141, 171], ["CD4", "GENE_OR_GENE_PRODUCT", 205, 208], ["Tregs", "CELL", 229, 234], ["tumor-infiltrating lymphocytes", "CELL_TYPE", 141, 171], ["CD4+ T lymphocytes", "CELL_TYPE", 205, 223], ["Tregs", "CELL_TYPE", 229, 234], ["PD", "TEST", 24, 26], ["PD-L1 blocks", "TREATMENT", 33, 45], ["cytotoxic T cell proliferation", "TREATMENT", 74, 104], ["survival", "TREATMENT", 109, 117], ["tumor", "PROBLEM", 141, 146], ["infiltrating lymphocytes", "PROBLEM", 147, 171], ["L1", "ANATOMY", 36, 38], ["cytotoxic T cell proliferation", "OBSERVATION", 74, 104], ["tumor", "OBSERVATION", 141, 146], ["infiltrating lymphocytes", "OBSERVATION", 147, 171]]], ["1 5 6 Most cancer cells possess the ability to express inhibitory ligands such as PD-L1, for example, in response to interferons (IFN).", [["cancer cells", "ANATOMY", 11, 23], ["cancer", "DISEASE", 11, 17], ["cancer cells", "CELL", 11, 23], ["PD-L1", "GENE_OR_GENE_PRODUCT", 82, 87], ["interferons", "GENE_OR_GENE_PRODUCT", 117, 128], ["IFN", "GENE_OR_GENE_PRODUCT", 130, 133], ["cancer cells", "CELL_TYPE", 11, 23], ["PD-L1", "PROTEIN", 82, 87], ["interferons", "PROTEIN", 117, 128], ["IFN", "PROTEIN", 130, 133], ["Most cancer cells", "PROBLEM", 6, 23], ["inhibitory ligands", "PROBLEM", 55, 73], ["PD-L1", "TREATMENT", 82, 87], ["interferons (IFN)", "TREATMENT", 117, 134], ["L1", "ANATOMY", 85, 87]]], ["This process can limit normal anticancer immune responses, thus assisting in immune escape.", [["anticancer", "ANATOMY", 30, 40], ["anticancer", "CANCER", 30, 40]]], ["Hence, ICI do not result in killing tumor cells directly but enhance or restore immune responses and endogenous antitumor activity.", [["tumor cells", "ANATOMY", 36, 47], ["antitumor", "ANATOMY", 112, 121], ["ICI", "CHEMICAL", 7, 10], ["tumor", "DISEASE", 36, 41], ["ICI", "CHEMICAL", 7, 10], ["ICI", "SIMPLE_CHEMICAL", 7, 10], ["tumor cells", "CELL", 36, 47], ["antitumor", "CANCER", 112, 121], ["killing tumor cells", "CELL_TYPE", 28, 47], ["ICI", "TREATMENT", 7, 10], ["killing tumor cells", "PROBLEM", 28, 47], ["tumor", "OBSERVATION", 36, 41], ["antitumor activity", "OBSERVATION", 112, 130]]], ["[1] [2] [3] [4] [5] [6] Exhaustion of T lymphocytes is the most important factor contributing to weakened T cell activity against both cancer and infectious agents.", [["T lymphocytes", "ANATOMY", 38, 51], ["T cell", "ANATOMY", 106, 112], ["cancer", "ANATOMY", 135, 141], ["cancer", "DISEASE", 135, 141], ["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 0, 23], ["T lymphocytes", "CELL", 38, 51], ["T cell", "CELL", 106, 112], ["cancer", "CANCER", 135, 141], ["T lymphocytes", "CELL_TYPE", 38, 51], ["Exhaustion of T lymphocytes", "PROBLEM", 24, 51], ["weakened T cell activity", "PROBLEM", 97, 121], ["both cancer", "PROBLEM", 130, 141], ["infectious agents", "TREATMENT", 146, 163], ["cancer", "OBSERVATION", 135, 141], ["infectious", "OBSERVATION", 146, 156]]], ["Notably, T cell exhaustion is a distinguishing feature of many chronic viral infections such as HIV and hepatitis B virus (HBV) infection.", [["T cell", "ANATOMY", 9, 15], ["viral infections", "DISEASE", 71, 87], ["HIV and hepatitis B virus (HBV) infection", "DISEASE", 96, 137], ["T cell", "CELL", 9, 15], ["HIV", "ORGANISM", 96, 99], ["hepatitis B virus", "ORGANISM", 104, 121], ["HBV", "ORGANISM", 123, 126], ["HIV", "SPECIES", 96, 99], ["hepatitis B virus", "SPECIES", 104, 121], ["HIV", "SPECIES", 96, 99], ["hepatitis B virus", "SPECIES", 104, 121], ["HBV", "SPECIES", 123, 126], ["T cell exhaustion", "PROBLEM", 9, 26], ["many chronic viral infections", "PROBLEM", 58, 87], ["HIV", "PROBLEM", 96, 99], ["hepatitis B virus (HBV) infection", "PROBLEM", 104, 137], ["cell exhaustion", "OBSERVATION", 11, 26], ["many", "OBSERVATION_MODIFIER", 58, 62], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["viral", "OBSERVATION_MODIFIER", 71, 76], ["infections", "OBSERVATION", 77, 87], ["infection", "OBSERVATION", 128, 137]]], ["Indeed, T cell exhaustion was first described in the context of chronic infections.", [["T cell", "ANATOMY", 8, 14], ["chronic infections", "DISEASE", 64, 82], ["T cell", "CELL", 8, 14], ["T cell exhaustion", "PROBLEM", 8, 25], ["chronic infections", "PROBLEM", 64, 82], ["cell exhaustion", "OBSERVATION", 10, 25], ["chronic", "OBSERVATION_MODIFIER", 64, 71], ["infections", "OBSERVATION", 72, 82]]], ["7 8 In the following, T lymphocytes with a similar phenotype were also detected in the tumor microenvironment.", [["T lymphocytes", "ANATOMY", 22, 35], ["tumor", "ANATOMY", 87, 92], ["tumor", "DISEASE", 87, 92], ["T lymphocytes", "CELL", 22, 35], ["tumor", "CANCER", 87, 92], ["T lymphocytes", "CELL_TYPE", 22, 35], ["a similar phenotype", "PROBLEM", 41, 60], ["tumor microenvironment", "OBSERVATION", 87, 109]]], ["2 7-9 Exhausted T lymphocytes are functionally characterized by a loss of interleukin 2 (IL-2) production, impaired proliferation, diminished cytotoxicity, and altered production of proinflammatory cytokines.", [["T lymphocytes", "ANATOMY", 16, 29], ["T lymphocytes", "CELL", 16, 29], ["interleukin 2", "GENE_OR_GENE_PRODUCT", 74, 87], ["IL-2", "GENE_OR_GENE_PRODUCT", 89, 93], ["T lymphocytes", "CELL_TYPE", 16, 29], ["interleukin 2", "PROTEIN", 74, 87], ["proinflammatory cytokines", "PROTEIN", 182, 207], ["Exhausted T lymphocytes", "PROBLEM", 6, 29], ["a loss of interleukin 2", "PROBLEM", 64, 87], ["impaired proliferation", "PROBLEM", 107, 129], ["diminished cytotoxicity", "PROBLEM", 131, 154], ["proinflammatory cytokines", "PROBLEM", 182, 207], ["loss", "OBSERVATION_MODIFIER", 66, 70], ["impaired", "OBSERVATION_MODIFIER", 107, 115], ["proliferation", "OBSERVATION_MODIFIER", 116, 129], ["diminished", "OBSERVATION_MODIFIER", 131, 141], ["cytotoxicity", "OBSERVATION_MODIFIER", 142, 154], ["altered", "OBSERVATION_MODIFIER", 160, 167], ["production", "OBSERVATION_MODIFIER", 168, 178], ["proinflammatory cytokines", "OBSERVATION", 182, 207]]], ["2 7-9 Moreover, the overexpression of immune checkpoint receptors, including PD-1 and CTLA-4, is a characteristic.", [["PD-1", "GENE_OR_GENE_PRODUCT", 77, 81], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 86, 92], ["immune checkpoint receptors", "PROTEIN", 38, 65], ["CTLA", "PROTEIN", 86, 90], ["immune checkpoint receptors", "TREATMENT", 38, 65], ["PD", "TEST", 77, 79], ["CTLA", "TEST", 86, 90], ["immune checkpoint", "OBSERVATION", 38, 55]]], ["Given the similarities between the immune response to cancer and chronic infections, one may hypothesize that the use of ICI should not be harmful for tumor patients with infections or may even provide a benefit.", [["cancer", "ANATOMY", 54, 60], ["tumor", "ANATOMY", 151, 156], ["cancer", "DISEASE", 54, 60], ["chronic infections", "DISEASE", 65, 83], ["ICI", "CHEMICAL", 121, 124], ["tumor", "DISEASE", 151, 156], ["infections", "DISEASE", 171, 181], ["ICI", "CHEMICAL", 121, 124], ["cancer", "CANCER", 54, 60], ["ICI", "SIMPLE_CHEMICAL", 121, 124], ["tumor", "CANCER", 151, 156], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["cancer", "PROBLEM", 54, 60], ["chronic infections", "PROBLEM", 65, 83], ["ICI", "TREATMENT", 121, 124], ["infections", "PROBLEM", 171, 181], ["cancer", "OBSERVATION", 54, 60], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["infections", "OBSERVATION", 73, 83]]], ["However, as of yet, tumor patients with existing viral infections are excluded from participation in many treatment protocols for ICI.", [["tumor", "ANATOMY", 20, 25], ["tumor", "DISEASE", 20, 25], ["viral infections", "DISEASE", 49, 65], ["ICI", "CHEMICAL", 130, 133], ["ICI", "CHEMICAL", 130, 133], ["tumor", "CANCER", 20, 25], ["patients", "ORGANISM", 26, 34], ["ICI", "SIMPLE_CHEMICAL", 130, 133], ["patients", "SPECIES", 26, 34], ["existing viral infections", "PROBLEM", 40, 65], ["many treatment protocols", "TREATMENT", 101, 125], ["ICI", "TREATMENT", 130, 133], ["tumor", "OBSERVATION", 20, 25], ["viral", "OBSERVATION_MODIFIER", 49, 54], ["infections", "OBSERVATION", 55, 65]]], ["7 8 With respect to acquired infectious diseases during ICI treatment, no increased risk was observed in clinical studies.", [["infectious diseases", "DISEASE", 29, 48], ["ICI", "CHEMICAL", 56, 59], ["ICI", "CHEMICAL", 56, 59], ["ICI", "SIMPLE_CHEMICAL", 56, 59], ["acquired infectious diseases", "PROBLEM", 20, 48], ["ICI treatment", "TREATMENT", 56, 69], ["increased risk", "PROBLEM", 74, 88], ["clinical studies", "TEST", 105, 121], ["infectious", "OBSERVATION", 29, 39], ["no", "UNCERTAINTY", 71, 73], ["increased", "OBSERVATION_MODIFIER", 74, 83]]], ["1-4 7 8 However, ICI treatment frequently results in activation of autoreactive T lymphocytes and disturbances in immune tolerance thereby causing autoimmune-like/inflammatory side effects.", [["T lymphocytes", "ANATOMY", 80, 93], ["ICI", "CHEMICAL", 17, 20], ["ICI", "CHEMICAL", 17, 20], ["ICI", "SIMPLE_CHEMICAL", 17, 20], ["T lymphocytes", "CELL", 80, 93], ["autoreactive T lymphocytes", "CELL_TYPE", 67, 93], ["ICI treatment", "TREATMENT", 17, 30], ["autoreactive T lymphocytes", "PROBLEM", 67, 93], ["disturbances in immune tolerance", "PROBLEM", 98, 130], ["autoimmune", "PROBLEM", 147, 157], ["inflammatory side effects", "PROBLEM", 163, 188], ["autoreactive T lymphocytes", "OBSERVATION", 67, 93], ["inflammatory", "OBSERVATION", 163, 175]]], ["These are summarized as immunerelated adverse events (irAEs) and include autoimmune colitis, pneumonitis, hypophysitis, hepatitis, thyroiditis and so on.", [["autoimmune colitis", "DISEASE", 73, 91], ["pneumonitis", "DISEASE", 93, 104], ["hypophysitis", "DISEASE", 106, 118], ["hepatitis", "DISEASE", 120, 129], ["thyroiditis", "DISEASE", 131, 142], ["immunerelated adverse events", "PROBLEM", 24, 52], ["autoimmune colitis", "PROBLEM", 73, 91], ["pneumonitis", "PROBLEM", 93, 104], ["hypophysitis", "PROBLEM", 106, 118], ["hepatitis", "PROBLEM", 120, 129], ["thyroiditis", "PROBLEM", 131, 142], ["autoimmune colitis", "OBSERVATION", 73, 91], ["pneumonitis", "OBSERVATION", 93, 104], ["hypophysitis", "OBSERVATION", 106, 118], ["hepatitis", "OBSERVATION", 120, 129], ["thyroiditis", "OBSERVATION", 131, 142]]], ["[10] [11] [12] Since irAEs may require immunosuppressive therapy, including high-dose corticosteroids and/or tumor necrosis factor (TNF)-\u03b1 blockers, the risk of infection or reactivation of chronic or latent viral infections (eg, HBV or hepatitis C virus (HCV)) may be secondarily increased.", [["tumor necrosis", "DISEASE", 109, 123], ["infection", "DISEASE", 161, 170], ["viral infections", "DISEASE", 208, 224], ["HBV or hepatitis C virus (HCV))", "DISEASE", 230, 261], ["[10] [11] [12]", "SIMPLE_CHEMICAL", 0, 14], ["tumor necrosis factor (TNF)-\u03b1", "GENE_OR_GENE_PRODUCT", 109, 138], ["HBV", "ORGANISM", 230, 233], ["hepatitis C virus", "ORGANISM", 237, 254], ["HCV", "ORGANISM", 256, 259], ["TNF", "PROTEIN", 132, 135], ["hepatitis C virus", "SPECIES", 237, 254], ["HBV", "SPECIES", 230, 233], ["hepatitis C virus", "SPECIES", 237, 254], ["HCV", "SPECIES", 256, 259], ["immunosuppressive therapy", "TREATMENT", 39, 64], ["high-dose corticosteroids", "TREATMENT", 76, 101], ["tumor necrosis factor", "PROBLEM", 109, 130], ["TNF)", "TREATMENT", 132, 136], ["blockers", "TREATMENT", 139, 147], ["infection", "PROBLEM", 161, 170], ["chronic or latent viral infections (eg", "PROBLEM", 190, 228], ["HBV", "PROBLEM", 230, 233], ["hepatitis C virus (HCV)", "PROBLEM", 237, 260], ["tumor", "OBSERVATION_MODIFIER", 109, 114], ["necrosis", "OBSERVATION", 115, 123], ["infection", "OBSERVATION", 161, 170], ["chronic", "OBSERVATION_MODIFIER", 190, 197], ["latent", "OBSERVATION_MODIFIER", 201, 207], ["viral", "OBSERVATION_MODIFIER", 208, 213], ["infections", "OBSERVATION", 214, 224], ["increased", "OBSERVATION_MODIFIER", 281, 290]]], ["[10] [11] [12] In this respect, it should also be noted that much of the morbidity of persistent viral diseases is caused by collateral damage caused by the chronic reactive inflammation associated with the inability of viral clearance; both may be boosted by ICI therapy.", [["collateral", "ANATOMY", 125, 135], ["viral diseases", "DISEASE", 97, 111], ["collateral damage", "DISEASE", 125, 142], ["inflammation", "DISEASE", 174, 186], ["ICI", "CHEMICAL", 260, 263], ["ICI", "CHEMICAL", 260, 263], ["collateral", "MULTI-TISSUE_STRUCTURE", 125, 135], ["ICI", "SIMPLE_CHEMICAL", 260, 263], ["persistent viral diseases", "PROBLEM", 86, 111], ["collateral damage", "PROBLEM", 125, 142], ["the chronic reactive inflammation", "PROBLEM", 153, 186], ["viral clearance", "PROBLEM", 220, 235], ["ICI therapy", "TREATMENT", 260, 271], ["persistent", "OBSERVATION_MODIFIER", 86, 96], ["viral diseases", "OBSERVATION", 97, 111], ["collateral damage", "OBSERVATION", 125, 142], ["chronic", "OBSERVATION_MODIFIER", 157, 164], ["reactive", "OBSERVATION_MODIFIER", 165, 173], ["inflammation", "OBSERVATION", 174, 186]]], ["In this review, we present information on the pros and cons of using ICI in patients with viral infections including COVID-19.HIV INFECTIONAntiretroviral therapy has significantly decreased the incidence of AIDS and thus the mortality of HIV infection.", [["ICI", "CHEMICAL", 69, 72], ["viral infections", "DISEASE", 90, 106], ["AIDS", "DISEASE", 207, 211], ["HIV infection", "DISEASE", 238, 251], ["ICI", "CHEMICAL", 69, 72], ["ICI", "SIMPLE_CHEMICAL", 69, 72], ["patients", "ORGANISM", 76, 84], ["HIV", "ORGANISM", 238, 241], ["patients", "SPECIES", 76, 84], ["HIV", "SPECIES", 238, 241], ["HIV", "SPECIES", 126, 129], ["HIV", "SPECIES", 238, 241], ["ICI", "TREATMENT", 69, 72], ["viral infections", "PROBLEM", 90, 106], ["COVID", "TEST", 117, 122], ["HIV INFECTIONAntiretroviral therapy", "TREATMENT", 126, 161], ["AIDS", "PROBLEM", 207, 211], ["HIV infection", "PROBLEM", 238, 251], ["decreased", "OBSERVATION_MODIFIER", 180, 189], ["HIV", "OBSERVATION_MODIFIER", 238, 241], ["infection", "OBSERVATION", 242, 251]]], ["However, complete eradication of HIV with antiviral agents has not yet been achieved, presumably because HIV persists in cellular reservoirs.", [["cellular", "ANATOMY", 121, 129], ["HIV", "DISEASE", 33, 36], ["HIV", "ORGANISM", 33, 36], ["HIV", "ORGANISM", 105, 108], ["cellular", "CELL", 121, 129], ["HIV", "SPECIES", 33, 36], ["HIV", "SPECIES", 105, 108], ["HIV", "PROBLEM", 33, 36], ["antiviral agents", "TREATMENT", 42, 58], ["HIV", "PROBLEM", 105, 108], ["cellular reservoirs", "OBSERVATION", 121, 140]]], ["The major HIV reservoir is a small pool of latently infected resting memory CD4+ lymphocytes carrying an integrated form of the viral genome that lacks the ability to produce viral proteins.", [["memory CD4+ lymphocytes", "ANATOMY", 69, 92], ["HIV", "ORGANISM", 10, 13], ["CD4", "GENE_OR_GENE_PRODUCT", 76, 79], ["resting memory CD4+ lymphocytes", "CELL_TYPE", 61, 92], ["viral genome", "DNA", 128, 140], ["viral proteins", "PROTEIN", 175, 189], ["HIV", "SPECIES", 10, 13], ["lymphocytes", "PROBLEM", 81, 92], ["the viral genome", "PROBLEM", 124, 140], ["viral proteins", "PROBLEM", 175, 189], ["major", "OBSERVATION_MODIFIER", 4, 9], ["HIV reservoir", "OBSERVATION", 10, 23], ["small", "OBSERVATION_MODIFIER", 29, 34], ["pool", "OBSERVATION_MODIFIER", 35, 39], ["latently", "OBSERVATION_MODIFIER", 43, 51], ["infected", "OBSERVATION_MODIFIER", 52, 60], ["resting memory CD4+ lymphocytes", "OBSERVATION", 61, 92], ["viral genome", "OBSERVATION", 128, 140]]], ["13 In HIV-infected subjects receiving highly active antiretroviral therapy (HAART), inhibitory checkpoint proteins such as PD-1 are expressed on persisting infected T cells.", [["T cells", "ANATOMY", 165, 172], ["HIV-infected", "DISEASE", 6, 18], ["HIV", "ORGANISM", 6, 9], ["subjects", "ORGANISM", 19, 27], ["PD-1", "GENE_OR_GENE_PRODUCT", 123, 127], ["T cells", "CELL", 165, 172], ["inhibitory checkpoint proteins", "PROTEIN", 84, 114], ["PD-1", "PROTEIN", 123, 127], ["persisting infected T cells", "CELL_TYPE", 145, 172], ["HIV", "SPECIES", 6, 9], ["HIV", "SPECIES", 6, 9], ["highly active antiretroviral therapy", "TREATMENT", 38, 74], ["HAART)", "TREATMENT", 76, 82], ["inhibitory checkpoint proteins", "TREATMENT", 84, 114], ["PD", "PROBLEM", 123, 125], ["persisting infected T cells", "PROBLEM", 145, 172], ["active", "OBSERVATION_MODIFIER", 45, 51], ["antiretroviral therapy", "OBSERVATION", 52, 74], ["persisting", "OBSERVATION_MODIFIER", 145, 155], ["infected T cells", "OBSERVATION", 156, 172]]], ["Indeed, there is a wealth of evidence that high expression of PD-1 on CD4+ lymphocytes clearly correlates with HIV persistence.", [["CD4+ lymphocytes", "ANATOMY", 70, 86], ["PD-1", "GENE_OR_GENE_PRODUCT", 62, 66], ["CD4", "GENE_OR_GENE_PRODUCT", 70, 73], ["HIV", "ORGANISM", 111, 114], ["PD-1", "PROTEIN", 62, 66], ["CD4", "PROTEIN", 70, 73], ["HIV", "SPECIES", 111, 114], ["PD", "TEST", 62, 64], ["CD4", "TEST", 70, 73], ["lymphocytes", "PROBLEM", 75, 86], ["HIV persistence", "PROBLEM", 111, 126], ["high", "OBSERVATION_MODIFIER", 43, 47]]], ["8 13 However, different inhibitory checkpoint proteins are differentially expressed by T cell subtypes; for example, PD-1 expression is increased in memory T cells and Tregs, whereas CTLA-4 is highly expressed in both memory T cells and Tregs.", [["T cell", "ANATOMY", 87, 93], ["memory T cells", "ANATOMY", 149, 163], ["Tregs", "ANATOMY", 168, 173], ["memory T cells", "ANATOMY", 218, 232], ["Tregs", "ANATOMY", 237, 242], ["T cell", "CELL", 87, 93], ["PD-1", "GENE_OR_GENE_PRODUCT", 117, 121], ["memory T cells", "CELL", 149, 163], ["Tregs", "CELL", 168, 173], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 183, 189], ["memory T cells", "CELL", 218, 232], ["Tregs", "CELL", 237, 242], ["inhibitory checkpoint proteins", "PROTEIN", 24, 54], ["T cell subtypes", "CELL_TYPE", 87, 102], ["memory T cells", "CELL_TYPE", 149, 163], ["Tregs", "CELL_TYPE", 168, 173], ["CTLA-4", "PROTEIN", 183, 189], ["memory T cells", "CELL_TYPE", 218, 232], ["Tregs", "CELL_TYPE", 237, 242], ["different inhibitory checkpoint proteins", "PROBLEM", 14, 54], ["T cell subtypes", "PROBLEM", 87, 102], ["PD", "TEST", 117, 119], ["Tregs", "TEST", 168, 173], ["CTLA", "TEST", 183, 187], ["cell subtypes", "OBSERVATION", 89, 102], ["increased", "OBSERVATION_MODIFIER", 136, 145], ["memory T cells", "OBSERVATION", 149, 163]]], ["8 14 Interestingly, the frequency of PD-1 expression on CD4+ and CD8+ lymphocytes appears to strongly correlate with disease outcome.", [["CD4+", "ANATOMY", 56, 60], ["CD8+ lymphocytes", "ANATOMY", 65, 81], ["PD-1", "GENE_OR_GENE_PRODUCT", 37, 41], ["CD4", "GENE_OR_GENE_PRODUCT", 56, 59], ["CD8", "GENE_OR_GENE_PRODUCT", 65, 68], ["CD4", "PROTEIN", 56, 59], ["CD8", "PROTEIN", 65, 68], ["PD", "TEST", 37, 39], ["CD4", "TEST", 56, 59], ["CD8+ lymphocytes", "PROBLEM", 65, 81], ["disease outcome", "PROBLEM", 117, 132], ["CD8+ lymphocytes", "OBSERVATION", 65, 81]]], ["Specifically, in untreated patients with HIV, high PD-1 expression has been shown to correlate with a decrease in CD4+ T lymphocytes during both acute and chronic infection.", [["T lymphocytes", "ANATOMY", 119, 132], ["acute and chronic infection", "DISEASE", 145, 172], ["patients", "ORGANISM", 27, 35], ["PD-1", "GENE_OR_GENE_PRODUCT", 51, 55], ["CD4", "GENE_OR_GENE_PRODUCT", 114, 117], ["T lymphocytes", "CELL", 119, 132], ["CD4", "PROTEIN", 114, 117], ["T lymphocytes", "CELL_TYPE", 119, 132], ["patients", "SPECIES", 27, 35], ["HIV", "SPECIES", 41, 44], ["HIV", "SPECIES", 41, 44], ["HIV", "PROBLEM", 41, 44], ["high PD", "PROBLEM", 46, 53], ["a decrease in CD4", "PROBLEM", 100, 117], ["T lymphocytes", "PROBLEM", 119, 132], ["both acute and chronic infection", "PROBLEM", 140, 172], ["decrease", "OBSERVATION_MODIFIER", 102, 110], ["CD4", "OBSERVATION", 114, 117], ["lymphocytes", "ANATOMY", 121, 132], ["both", "OBSERVATION_MODIFIER", 140, 144], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["chronic", "OBSERVATION_MODIFIER", 155, 162], ["infection", "OBSERVATION", 163, 172]]], ["7 8 15 Similar to PD-1 upregulation, overexpression of CTLA-4 on CD4+ T lymphocytes more frequently correlates with progressive disease.", [["T lymphocytes", "ANATOMY", 70, 83], ["PD-1", "GENE_OR_GENE_PRODUCT", 18, 22], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 55, 61], ["CD4", "GENE_OR_GENE_PRODUCT", 65, 68], ["T lymphocytes", "CELL", 70, 83], ["CTLA-4", "PROTEIN", 55, 61], ["CD4", "PROTEIN", 65, 68], ["T lymphocytes", "CELL_TYPE", 70, 83], ["PD", "TEST", 18, 20], ["CTLA", "TEST", 55, 59], ["T lymphocytes", "PROBLEM", 70, 83], ["progressive disease", "PROBLEM", 116, 135], ["lymphocytes", "OBSERVATION", 72, 83], ["progressive", "OBSERVATION_MODIFIER", 116, 127], ["disease", "OBSERVATION", 128, 135]]], ["7 8 16 HIV persistence can be reversed by ICI in vitro, 7 8 17 and in preclinical animal models, T cell exhaustion is ameliorated by PD-1 blockade.", [["T cell", "ANATOMY", 97, 103], ["ICI", "CHEMICAL", 42, 45], ["ICI", "CHEMICAL", 42, 45], ["HIV", "ORGANISM", 7, 10], ["ICI", "SIMPLE_CHEMICAL", 42, 45], ["T cell", "CELL", 97, 103], ["PD-1", "GENE_OR_GENE_PRODUCT", 133, 137], ["HIV", "SPECIES", 7, 10], ["T cell exhaustion", "PROBLEM", 97, 114]]], ["18 Together, the above discussed pathomechanism and preliminary experimental data warrant studies regarding safety and efficacy of ICI in HIV-infected patients.", [["ICI", "CHEMICAL", 131, 134], ["HIV-infected", "DISEASE", 138, 150], ["ICI", "CHEMICAL", 131, 134], ["ICI", "SIMPLE_CHEMICAL", 131, 134], ["HIV", "ORGANISM", 138, 141], ["patients", "ORGANISM", 151, 159], ["HIV", "SPECIES", 138, 141], ["patients", "SPECIES", 151, 159], ["HIV", "SPECIES", 138, 141], ["preliminary experimental data", "TEST", 52, 81], ["studies", "TEST", 90, 97], ["ICI", "TREATMENT", 131, 134]]], ["Interestingly, even though patients living with HIV on HAART have a life expectancy similar to the general population, these patients still have an increased risk to develop cancer.", [["cancer", "ANATOMY", 174, 180], ["cancer", "DISEASE", 174, 180], ["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 125, 133], ["cancer", "CANCER", 174, 180], ["patients", "SPECIES", 27, 35], ["HIV", "SPECIES", 48, 51], ["patients", "SPECIES", 125, 133], ["HIV", "SPECIES", 48, 51], ["HAART", "TREATMENT", 55, 60], ["cancer", "PROBLEM", 174, 180], ["cancer", "OBSERVATION", 174, 180]]], ["19 20 In this context, initial observations on HIV-positive cancer patients treated with ICI are emerging.", [["cancer", "ANATOMY", 60, 66], ["HIV-positive cancer", "DISEASE", 47, 66], ["ICI", "CHEMICAL", 89, 92], ["ICI", "CHEMICAL", 89, 92], ["HIV", "ORGANISM", 47, 50], ["cancer", "CANCER", 60, 66], ["patients", "ORGANISM", 67, 75], ["ICI", "SIMPLE_CHEMICAL", 89, 92], ["HIV", "SPECIES", 47, 50], ["patients", "SPECIES", 67, 75], ["HIV", "SPECIES", 47, 50], ["HIV-positive cancer", "PROBLEM", 47, 66], ["ICI", "TREATMENT", 89, 92], ["cancer", "OBSERVATION", 60, 66]]], ["In a systematic review, of 73 HIVinfected patients who received ICI therapy for advanced cancer, anti-PD-1 monotherapy was the most frequently employed regimen (n=62).", [["cancer", "ANATOMY", 89, 95], ["ICI", "CHEMICAL", 64, 67], ["cancer", "DISEASE", 89, 95], ["anti-PD-1", "CHEMICAL", 97, 106], ["ICI", "CHEMICAL", 64, 67], ["patients", "ORGANISM", 42, 50], ["ICI", "SIMPLE_CHEMICAL", 64, 67], ["cancer", "CANCER", 89, 95], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 97, 106], ["patients", "SPECIES", 42, 50], ["ICI therapy", "TREATMENT", 64, 75], ["advanced cancer", "PROBLEM", 80, 95], ["anti-PD-1 monotherapy", "TREATMENT", 97, 118], ["cancer", "OBSERVATION", 89, 95]]], ["19 In this cohort, grade III or higher irAEs were observed in 8.6% of patients.", [["irAEs", "DISEASE", 39, 44], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["grade III or higher irAEs", "PROBLEM", 19, 44]]], ["HIV remained suppressed in 93% of patients and CD4+ lymphocyte count increased in patients with available pretreatment and post-treatment HIV load and CD4 cell count data, respectively.", [["CD4+ lymphocyte", "ANATOMY", 47, 62], ["CD4 cell", "ANATOMY", 151, 159], ["HIV", "ORGANISM", 0, 3], ["patients", "ORGANISM", 34, 42], ["CD4", "GENE_OR_GENE_PRODUCT", 47, 50], ["lymphocyte", "CELL", 52, 62], ["patients", "ORGANISM", 82, 90], ["CD4 cell", "CELL", 151, 159], ["CD4", "PROTEIN", 47, 50], ["CD4", "PROTEIN", 151, 154], ["HIV", "SPECIES", 0, 3], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 82, 90], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 138, 141], ["HIV", "PROBLEM", 0, 3], ["CD4", "TEST", 47, 50], ["lymphocyte count", "TEST", 52, 68], ["available pretreatment", "TREATMENT", 96, 118], ["post-treatment HIV load", "TEST", 123, 146], ["CD4 cell count data", "TEST", 151, 170], ["suppressed", "OBSERVATION_MODIFIER", 13, 23], ["lymphocyte count", "OBSERVATION", 52, 68]]], ["None of the previous studies reported the occurrence of immune reactivation inflammatory syndrome during ICI therapy.", [["ICI", "CHEMICAL", 105, 108], ["ICI", "CHEMICAL", 105, 108], ["ICI", "SIMPLE_CHEMICAL", 105, 108], ["the previous studies", "TEST", 8, 28], ["immune reactivation inflammatory syndrome", "PROBLEM", 56, 97], ["ICI therapy", "TREATMENT", 105, 116], ["immune reactivation", "OBSERVATION", 56, 75], ["inflammatory syndrome", "OBSERVATION", 76, 97]]], ["19 Similar to the safety profile, efficacy of ICI was favorable with an objective response of 63% in Kaposi sarcoma, 30% in non-small cell lung carcinoma, and 27% in melanoma.", [["Kaposi sarcoma", "ANATOMY", 101, 115], ["non-small cell lung carcinoma", "ANATOMY", 124, 153], ["melanoma", "ANATOMY", 166, 174], ["ICI", "CHEMICAL", 46, 49], ["Kaposi sarcoma", "DISEASE", 101, 115], ["non-small cell lung carcinoma", "DISEASE", 124, 153], ["melanoma", "DISEASE", 166, 174], ["ICI", "CHEMICAL", 46, 49], ["ICI", "SIMPLE_CHEMICAL", 46, 49], ["Kaposi sarcoma", "CANCER", 101, 115], ["non-small cell lung carcinoma", "CANCER", 124, 153], ["melanoma", "CANCER", 166, 174], ["ICI", "TREATMENT", 46, 49], ["an objective response", "TEST", 69, 90], ["Kaposi sarcoma", "PROBLEM", 101, 115], ["non-small cell lung carcinoma", "PROBLEM", 124, 153], ["melanoma", "PROBLEM", 166, 174], ["Kaposi sarcoma", "OBSERVATION", 101, 115], ["non-small cell", "OBSERVATION", 124, 138], ["lung", "ANATOMY", 139, 143], ["carcinoma", "OBSERVATION", 144, 153], ["27%", "OBSERVATION_MODIFIER", 159, 162], ["melanoma", "OBSERVATION", 166, 174]]], ["19 Prompted by these encouraging results, phase I and II trials investigating ICIs in HIV-infected patients with advanced solid tumors and lymphomas are currently conducted.", [["solid tumors", "ANATOMY", 122, 134], ["lymphomas", "ANATOMY", 139, 148], ["ICIs", "CHEMICAL", 78, 82], ["HIV-infected", "DISEASE", 86, 98], ["solid tumors", "DISEASE", 122, 134], ["lymphomas", "DISEASE", 139, 148], ["ICIs", "SIMPLE_CHEMICAL", 78, 82], ["HIV", "ORGANISM", 86, 89], ["patients", "ORGANISM", 99, 107], ["solid tumors", "CANCER", 122, 134], ["lymphomas", "CANCER", 139, 148], ["HIV", "SPECIES", 86, 89], ["patients", "SPECIES", 99, 107], ["HIV", "SPECIES", 86, 89], ["ICIs", "PROBLEM", 78, 82], ["advanced solid tumors", "PROBLEM", 113, 134], ["lymphomas", "PROBLEM", 139, 148], ["advanced", "OBSERVATION_MODIFIER", 113, 121], ["solid", "OBSERVATION_MODIFIER", 122, 127], ["tumors", "OBSERVATION", 128, 134], ["lymphomas", "OBSERVATION", 139, 148]]], ["21 22 Accordingly, a task force formed by the American Society of Clinical Oncology (ASCO) recently recommended the inclusion of HIV-infected patients in oncology trials, particularly patients with CD4+ counts higher than 350 cells/\u00b5L, thus representing a group of patients with intact immunological function and survival comparable with the general population.", [["cells", "ANATOMY", 226, 231], ["HIV-infected", "DISEASE", 129, 141], ["HIV", "ORGANISM", 129, 132], ["patients", "ORGANISM", 142, 150], ["patients", "ORGANISM", 184, 192], ["CD4", "GENE_OR_GENE_PRODUCT", 198, 201], ["patients", "ORGANISM", 265, 273], ["CD4", "PROTEIN", 198, 201], ["patients", "SPECIES", 142, 150], ["patients", "SPECIES", 184, 192], ["patients", "SPECIES", 265, 273], ["HIV", "SPECIES", 129, 132], ["HIV", "PROBLEM", 129, 132], ["CD4+ counts", "TEST", 198, 209]]], ["23 Moreover, data from the first clinical trial investigating the safety, tolerability and pharmacokinetics of CTLA-4 inhibition (ipilimumab)HIV INFECTIONOpen access in patients with chronic HIV infection in the absence of concurrent malignancies were recently reported.", [["malignancies", "ANATOMY", 234, 246], ["CTLA-4", "CHEMICAL", 111, 117], ["ipilimumab", "CHEMICAL", 130, 140], ["chronic HIV infection", "DISEASE", 183, 204], ["malignancies", "DISEASE", 234, 246], ["ipilimumab", "CHEMICAL", 130, 140], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 111, 117], ["ipilimumab", "SIMPLE_CHEMICAL", 130, 140], ["patients", "ORGANISM", 169, 177], ["malignancies", "CANCER", 234, 246], ["patients", "SPECIES", 169, 177], ["HIV", "SPECIES", 191, 194], ["HIV", "SPECIES", 141, 144], ["HIV", "SPECIES", 191, 194], ["CTLA-4 inhibition (ipilimumab)", "TREATMENT", 111, 141], ["HIV INFECTIONOpen access", "TREATMENT", 141, 165], ["chronic HIV infection", "PROBLEM", 183, 204], ["concurrent malignancies", "PROBLEM", 223, 246], ["chronic", "OBSERVATION_MODIFIER", 183, 190], ["HIV", "OBSERVATION_MODIFIER", 191, 194], ["infection", "OBSERVATION", 195, 204], ["malignancies", "OBSERVATION", 234, 246]]], ["24 Although only based on a limited number of patients (n=24), this study did not reveal any safety concerns that would preclude further investigation of using CLTA-4 inhibition to enhance the immune response against HIV.", [["patients", "ORGANISM", 46, 54], ["CLTA-4", "GENE_OR_GENE_PRODUCT", 160, 166], ["HIV", "ORGANISM", 217, 220], ["patients", "SPECIES", 46, 54], ["HIV", "SPECIES", 217, 220], ["HIV", "SPECIES", 217, 220], ["this study", "TEST", 63, 73], ["further investigation", "TEST", 129, 150], ["CLTA-4 inhibition", "TREATMENT", 160, 177], ["HIV", "PROBLEM", 217, 220]]], ["One patient who developed facial palsy received medium dose prednisone; still, no worsening of his HIV infection was observed.", [["facial", "ANATOMY", 26, 32], ["facial palsy", "DISEASE", 26, 38], ["prednisone", "CHEMICAL", 60, 70], ["HIV infection", "DISEASE", 99, 112], ["prednisone", "CHEMICAL", 60, 70], ["patient", "ORGANISM", 4, 11], ["prednisone", "SIMPLE_CHEMICAL", 60, 70], ["HIV", "ORGANISM", 99, 102], ["patient", "SPECIES", 4, 11], ["HIV", "SPECIES", 99, 102], ["facial palsy", "PROBLEM", 26, 38], ["medium dose prednisone", "TREATMENT", 48, 70], ["his HIV infection", "PROBLEM", 95, 112], ["facial", "ANATOMY", 26, 32], ["palsy", "OBSERVATION", 33, 38], ["no", "UNCERTAINTY", 79, 81], ["worsening", "OBSERVATION_MODIFIER", 82, 91], ["HIV", "OBSERVATION_MODIFIER", 99, 102], ["infection", "OBSERVATION", 103, 112]]], ["24 Furthermore, in a randomized, doubleblind, placebo-controlled, phase I dose-escalating study testing PD-1 inhibition (nivolumab) in HAART-treated HIV-infected adults without concurrent cancer (n=8), even a single, low-dose infusion appeared to enhance HIV-specific immunity.", [["cancer", "ANATOMY", 188, 194], ["nivolumab", "CHEMICAL", 121, 130], ["HIV-infected", "DISEASE", 149, 161], ["cancer", "DISEASE", 188, 194], ["HIV-specific immunity", "DISEASE", 255, 276], ["PD-1", "GENE_OR_GENE_PRODUCT", 104, 108], ["nivolumab", "SIMPLE_CHEMICAL", 121, 130], ["HIV", "ORGANISM", 149, 152], ["adults", "ORGANISM", 162, 168], ["cancer", "CANCER", 188, 194], ["HIV", "ORGANISM", 255, 258], ["HIV", "SPECIES", 149, 152], ["HIV", "SPECIES", 149, 152], ["HIV", "SPECIES", 255, 258], ["placebo", "TREATMENT", 46, 53], ["phase I dose-escalating study testing PD", "TREATMENT", 66, 106], ["nivolumab", "TREATMENT", 121, 130], ["HAART", "TREATMENT", 135, 140], ["HIV", "PROBLEM", 149, 152], ["concurrent cancer", "PROBLEM", 177, 194], ["a single, low-dose infusion", "TREATMENT", 207, 234], ["cancer", "OBSERVATION", 188, 194]]], ["25 In summary, the exclusion of HIV-infected patients from oncology ICI trials appears to be neither supported by evidence from basic research nor early clinical trials.", [["HIV-infected", "DISEASE", 32, 44], ["ICI", "CHEMICAL", 68, 71], ["HIV", "ORGANISM", 32, 35], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["HIV", "SPECIES", 32, 35], ["HIV", "PROBLEM", 32, 35], ["oncology ICI trials", "TREATMENT", 59, 78]]], ["On the contrary, many lines of evidence suggest that ICI could be employed to improve HIV-specific immunity and thus contribute to HIV remission or even possible cure strategies.", [["ICI", "CHEMICAL", 53, 56], ["ICI", "CHEMICAL", 53, 56], ["ICI", "SIMPLE_CHEMICAL", 53, 56], ["HIV", "ORGANISM", 86, 89], ["HIV", "ORGANISM", 131, 134], ["HIV", "SPECIES", 86, 89], ["HIV", "SPECIES", 86, 89], ["HIV", "SPECIES", 131, 134], ["ICI", "TREATMENT", 53, 56], ["HIV", "PROBLEM", 86, 89], ["HIV remission", "PROBLEM", 131, 144], ["cure strategies", "TREATMENT", 162, 177]]], ["23 26 27 However, the mechanisms regulating HIV persistence are complex and not yet fully understood, leading to the hypothesis that a combined treatment approach including ICI and cytokines will be required to accomplish such complete remissions.", [["ICI", "CHEMICAL", 173, 176], ["ICI", "CHEMICAL", 173, 176], ["HIV", "ORGANISM", 44, 47], ["ICI", "SIMPLE_CHEMICAL", 173, 176], ["cytokines", "PROTEIN", 181, 190], ["HIV", "SPECIES", 44, 47], ["a combined treatment approach", "TREATMENT", 133, 162], ["ICI", "TREATMENT", 173, 176], ["cytokines", "TREATMENT", 181, 190], ["HIV", "OBSERVATION", 44, 47]]], ["28 HEPATITIS B AND C Viral caused hepatitis is one of the leading causes of morbidity and death worldwide.", [["Viral caused hepatitis", "DISEASE", 21, 43], ["death", "DISEASE", 90, 95], ["HEPATITIS B AND C Viral caused hepatitis", "PROBLEM", 3, 43], ["morbidity", "PROBLEM", 76, 85], ["death", "PROBLEM", 90, 95], ["HEPATITIS", "OBSERVATION", 3, 12], ["hepatitis", "OBSERVATION", 34, 43], ["morbidity", "OBSERVATION", 76, 85]]], ["HBV and HCV account for the majority of viral-hepatitis-related mortality, mostly attributable to cirrhosis and hepatocellular carcinoma.", [["hepatocellular carcinoma", "ANATOMY", 112, 136], ["viral-hepatitis", "DISEASE", 40, 55], ["cirrhosis", "DISEASE", 98, 107], ["hepatocellular carcinoma", "DISEASE", 112, 136], ["HBV", "ORGANISM", 0, 3], ["HCV", "ORGANISM", 8, 11], ["hepatocellular carcinoma", "CANCER", 112, 136], ["HBV", "SPECIES", 0, 3], ["HCV", "SPECIES", 8, 11], ["HBV", "PROBLEM", 0, 3], ["HCV", "PROBLEM", 8, 11], ["viral-hepatitis", "PROBLEM", 40, 55], ["cirrhosis", "PROBLEM", 98, 107], ["hepatocellular carcinoma", "PROBLEM", 112, 136], ["HCV", "OBSERVATION", 8, 11], ["viral", "OBSERVATION", 40, 45], ["hepatitis", "OBSERVATION", 46, 55], ["cirrhosis", "OBSERVATION", 98, 107], ["hepatocellular", "ANATOMY", 112, 126], ["carcinoma", "OBSERVATION", 127, 136]]], ["To date, it is still a challenge to achieve complete HBV clearance or to prevent HCV relapse once directly acting antiviral treatment regimens failed.", [["HBV", "ORGANISM", 53, 56], ["HCV", "ORGANISM", 81, 84], ["HBV", "SPECIES", 53, 56], ["HCV", "SPECIES", 81, 84], ["complete HBV clearance", "TREATMENT", 44, 66], ["HCV relapse", "PROBLEM", 81, 92], ["antiviral treatment regimens", "TREATMENT", 114, 142]]], ["29 One important constraint for the use of ICI in patients with concomitant virus hepatitis for treatment of cancer is the possible occurrence of immune-mediated hepatotoxicity, a frequent irAE caused by ICI.", [["cancer", "ANATOMY", 109, 115], ["ICI", "CHEMICAL", 43, 46], ["hepatitis", "DISEASE", 82, 91], ["cancer", "DISEASE", 109, 115], ["hepatotoxicity", "DISEASE", 162, 176], ["irAE", "DISEASE", 189, 193], ["ICI", "CHEMICAL", 204, 207], ["ICI", "CHEMICAL", 43, 46], ["ICI", "CHEMICAL", 204, 207], ["ICI", "SIMPLE_CHEMICAL", 43, 46], ["patients", "ORGANISM", 50, 58], ["cancer", "CANCER", 109, 115], ["irAE", "CANCER", 189, 193], ["ICI", "SIMPLE_CHEMICAL", 204, 207], ["patients", "SPECIES", 50, 58], ["ICI", "TREATMENT", 43, 46], ["concomitant virus hepatitis", "PROBLEM", 64, 91], ["cancer", "PROBLEM", 109, 115], ["immune-mediated hepatotoxicity", "PROBLEM", 146, 176], ["cancer", "OBSERVATION", 109, 115], ["hepatotoxicity", "OBSERVATION", 162, 176]]], ["This notion is particularly troublesome, as an immune-mediated hepatitis may pose a significant diagnostic challenge in patients with underlying viral or autoimmune hepatitis.", [["hepatitis", "DISEASE", 63, 72], ["viral or autoimmune hepatitis", "DISEASE", 145, 174], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["an immune-mediated hepatitis", "PROBLEM", 44, 72], ["underlying viral or autoimmune hepatitis", "PROBLEM", 134, 174], ["hepatitis", "OBSERVATION", 63, 72], ["viral", "OBSERVATION", 145, 150], ["autoimmune hepatitis", "OBSERVATION", 154, 174]]], ["[30] [31] [32] Pu et al 33 recently published a comprehensive review on 186 cancer patients with concurrent HBV or HCV infection who had received ICI treatment.", [["cancer", "ANATOMY", 76, 82], ["cancer", "DISEASE", 76, 82], ["HBV or HCV infection", "DISEASE", 108, 128], ["ICI", "CHEMICAL", 146, 149], ["ICI", "CHEMICAL", 146, 149], ["cancer", "CANCER", 76, 82], ["patients", "ORGANISM", 83, 91], ["HBV", "ORGANISM", 108, 111], ["HCV", "ORGANISM", 115, 118], ["ICI", "SIMPLE_CHEMICAL", 146, 149], ["patients", "SPECIES", 83, 91], ["HBV", "SPECIES", 108, 111], ["HCV", "SPECIES", 115, 118], ["concurrent HBV", "PROBLEM", 97, 111], ["HCV infection", "PROBLEM", 115, 128], ["ICI treatment", "TREATMENT", 146, 159], ["HBV", "OBSERVATION", 108, 111], ["HCV", "OBSERVATION", 115, 118]]], ["33 About 20% of patients developed an increase of hepatic transaminases which was higher than those reported in ICI-treated cancer patients without concurrent viral hepatitis.", [["hepatic", "ANATOMY", 50, 57], ["cancer", "ANATOMY", 124, 130], ["ICI", "CHEMICAL", 112, 115], ["cancer", "DISEASE", 124, 130], ["viral hepatitis", "DISEASE", 159, 174], ["ICI", "CHEMICAL", 112, 115], ["patients", "ORGANISM", 16, 24], ["hepatic", "ORGAN", 50, 57], ["ICI", "SIMPLE_CHEMICAL", 112, 115], ["cancer", "CANCER", 124, 130], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 131, 139], ["an increase of hepatic transaminases", "PROBLEM", 35, 71], ["concurrent viral hepatitis", "PROBLEM", 148, 174], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["hepatic", "ANATOMY", 50, 57], ["transaminases", "OBSERVATION", 58, 71], ["cancer", "OBSERVATION", 124, 130], ["without", "UNCERTAINTY", 140, 147], ["viral hepatitis", "OBSERVATION", 159, 174]]], ["33 All grade 3 or 4 toxicities were reversible by means of antiviral treatment or corticosteroids without necessitating a discontinuation of ICI.", [["toxicities", "DISEASE", 20, 30], ["ICI", "CHEMICAL", 141, 144], ["ICI", "CHEMICAL", 141, 144], ["ICI", "SIMPLE_CHEMICAL", 141, 144], ["All grade 3 or 4 toxicities", "PROBLEM", 3, 30], ["antiviral treatment", "TREATMENT", 59, 78], ["corticosteroids", "TREATMENT", 82, 97], ["a discontinuation of ICI", "TREATMENT", 120, 144], ["grade 3", "OBSERVATION_MODIFIER", 7, 14], ["antiviral treatment", "OBSERVATION", 59, 78]]], ["Importantly, no negative influence on infection status was reported in patients receiving corticosteroids.", [["infection", "DISEASE", 38, 47], ["corticosteroids", "CHEMICAL", 90, 105], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["infection status", "PROBLEM", 38, 54], ["corticosteroids", "TREATMENT", 90, 105], ["no", "UNCERTAINTY", 13, 15], ["negative", "OBSERVATION_MODIFIER", 16, 24], ["influence", "OBSERVATION_MODIFIER", 25, 34], ["infection", "OBSERVATION", 38, 47]]], ["33 It should be mentioned, however, that ICI should be withhold once an irAE is encountered requiring immunosuppressive drugs; but, ICI may be resumed once the irAE has resolved.", [["ICI", "CHEMICAL", 41, 44], ["ICI", "CHEMICAL", 132, 135], ["ICI", "CHEMICAL", 41, 44], ["ICI", "CHEMICAL", 132, 135], ["ICI", "SIMPLE_CHEMICAL", 41, 44], ["ICI", "SIMPLE_CHEMICAL", 132, 135], ["ICI", "TREATMENT", 41, 44], ["immunosuppressive drugs", "TREATMENT", 102, 125], ["ICI", "TREATMENT", 132, 135]]], ["Importantly, the incidence of other adverse events in this particular patient population was not significantly increased when compared with ICI-treated cancer patients without chronic viral hepatitis.", [["cancer", "ANATOMY", 152, 158], ["ICI", "CHEMICAL", 140, 143], ["cancer", "DISEASE", 152, 158], ["chronic viral hepatitis", "DISEASE", 176, 199], ["ICI", "CHEMICAL", 140, 143], ["patient", "ORGANISM", 70, 77], ["ICI", "SIMPLE_CHEMICAL", 140, 143], ["cancer", "CANCER", 152, 158], ["patients", "ORGANISM", 159, 167], ["patient", "SPECIES", 70, 77], ["patients", "SPECIES", 159, 167], ["other adverse events", "PROBLEM", 30, 50], ["ICI", "TEST", 140, 143], ["chronic viral hepatitis", "PROBLEM", 176, 199], ["significantly", "OBSERVATION_MODIFIER", 97, 110], ["increased", "OBSERVATION_MODIFIER", 111, 120], ["cancer", "OBSERVATION", 152, 158], ["without", "UNCERTAINTY", 168, 175], ["chronic", "OBSERVATION_MODIFIER", 176, 183], ["viral hepatitis", "OBSERVATION", 184, 199]]], ["Based on a recent publication reviewing the available data on the use of ICI in cancer patients with hepatitis, it is recommended that all patients scheduled to receive ICI should be screened for HBV and HCV, and in patients who are tested positive, prophylactic antiviral treatment is indicated.", [["cancer", "ANATOMY", 80, 86], ["ICI", "CHEMICAL", 73, 76], ["cancer", "DISEASE", 80, 86], ["hepatitis", "DISEASE", 101, 110], ["ICI", "CHEMICAL", 169, 172], ["ICI", "CHEMICAL", 73, 76], ["ICI", "CHEMICAL", 169, 172], ["ICI", "SIMPLE_CHEMICAL", 73, 76], ["cancer", "CANCER", 80, 86], ["patients", "ORGANISM", 87, 95], ["patients", "ORGANISM", 139, 147], ["ICI", "SIMPLE_CHEMICAL", 169, 172], ["HBV", "ORGANISM", 196, 199], ["HCV", "ORGANISM", 204, 207], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 216, 224], ["HBV", "SPECIES", 196, 199], ["HCV", "SPECIES", 204, 207], ["ICI", "TREATMENT", 73, 76], ["hepatitis", "PROBLEM", 101, 110], ["ICI", "TREATMENT", 169, 172], ["HBV", "PROBLEM", 196, 199], ["HCV", "PROBLEM", 204, 207], ["prophylactic antiviral treatment", "TREATMENT", 250, 282], ["cancer", "OBSERVATION", 80, 86]]], ["Unfortunately, however, it is currently unclear for how long the prophylactic treatment should be continued.", [["the prophylactic treatment", "TREATMENT", 61, 87]]], ["Primary prophylaxis should also be considered in patients with chronic HBV infection, if not already on treatment.", [["HBV infection", "DISEASE", 71, 84], ["patients", "ORGANISM", 49, 57], ["HBV", "ORGANISM", 71, 74], ["patients", "SPECIES", 49, 57], ["HBV", "SPECIES", 71, 74], ["Primary prophylaxis", "TREATMENT", 0, 19], ["chronic HBV infection", "PROBLEM", 63, 84], ["treatment", "TREATMENT", 104, 113], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["HBV", "OBSERVATION", 71, 74], ["infection", "OBSERVATION", 75, 84]]], ["Liver function tests and viral load should routinely be monitored in virus positive patients.", [["Liver", "ANATOMY", 0, 5], ["Liver", "ORGAN", 0, 5], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["Liver function tests", "TEST", 0, 20], ["viral load", "TEST", 25, 35], ["viral load", "OBSERVATION", 25, 35]]], ["34 35 It is well known that HBV-specific exhaustion of T cells is maintained by ongoing HBV-antigen stimulation.", [["T cells", "ANATOMY", 55, 62], ["HBV", "ORGANISM", 28, 31], ["T cells", "CELL", 55, 62], ["HBV", "ORGANISM", 88, 91], ["antigen", "GENE_OR_GENE_PRODUCT", 92, 99], ["T cells", "CELL_TYPE", 55, 62], ["HBV", "SPECIES", 28, 31], ["HBV", "SPECIES", 88, 91], ["HBV", "PROBLEM", 28, 31], ["T cells", "PROBLEM", 55, 62], ["HBV", "OBSERVATION", 28, 31]]], ["Furthermore, PD-L1/2 expression, secretion of immunosuppressive cytokines, for example, IL-10 and transforming growth factor (TGF-\u00df), dysfunction of dendritic cells, enhanced numbers of PD-1+ NK cells, Tregs, and myeloidderived suppressor cells negatively influence HBV-specific T cell immunity.", [["dendritic cells", "ANATOMY", 149, 164], ["PD-1+ NK cells", "ANATOMY", 186, 200], ["Tregs", "ANATOMY", 202, 207], ["myeloidderived suppressor cells", "ANATOMY", 213, 244], ["T cell", "ANATOMY", 279, 285], ["PD-L1", "GENE_OR_GENE_PRODUCT", 13, 18], ["2", "GENE_OR_GENE_PRODUCT", 19, 20], ["IL-10", "GENE_OR_GENE_PRODUCT", 88, 93], ["transforming growth factor", "GENE_OR_GENE_PRODUCT", 98, 124], ["TGF-\u00df", "GENE_OR_GENE_PRODUCT", 126, 131], ["dendritic cells", "CELL", 149, 164], ["PD-1", "GENE_OR_GENE_PRODUCT", 186, 190], ["Tregs", "CELL", 202, 207], ["myeloidderived suppressor cells", "CELL", 213, 244], ["HBV", "ORGANISM", 266, 269], ["T cell", "CELL", 279, 285], ["immunosuppressive cytokines", "PROTEIN", 46, 73], ["IL-10", "PROTEIN", 88, 93], ["transforming growth factor", "PROTEIN", 98, 124], ["TGF-\u00df", "PROTEIN", 126, 131], ["dendritic cells", "CELL_TYPE", 149, 164], ["NK cells", "CELL_TYPE", 192, 200], ["Tregs", "CELL_TYPE", 202, 207], ["myeloidderived suppressor cells", "CELL_TYPE", 213, 244], ["HBV", "SPECIES", 266, 269], ["PD", "TEST", 13, 15], ["L1/2 expression", "TREATMENT", 16, 31], ["immunosuppressive cytokines", "TREATMENT", 46, 73], ["IL", "TEST", 88, 90], ["transforming growth factor", "TEST", 98, 124], ["TGF", "TEST", 126, 129], ["dysfunction of dendritic cells", "PROBLEM", 134, 164], ["PD", "TEST", 186, 188], ["NK cells", "TEST", 192, 200], ["Tregs", "TEST", 202, 207], ["myeloidderived suppressor cells", "PROBLEM", 213, 244], ["HBV", "TEST", 266, 269], ["L1", "ANATOMY", 16, 18], ["dendritic cells", "OBSERVATION", 149, 164], ["NK cells", "OBSERVATION", 192, 200], ["suppressor cells", "OBSERVATION", 228, 244]]], ["6 8 34 35 Similar to HBV infection, chronic HCV infection is also associated with increased PD-1 and TIM-3 expression as another marker for T cell exhaustion.", [["T cell", "ANATOMY", 140, 146], ["HBV infection", "DISEASE", 21, 34], ["HCV infection", "DISEASE", 44, 57], ["HBV", "ORGANISM", 21, 24], ["HCV", "ORGANISM", 44, 47], ["PD-1", "GENE_OR_GENE_PRODUCT", 92, 96], ["TIM-3", "GENE_OR_GENE_PRODUCT", 101, 106], ["T cell", "CELL", 140, 146], ["TIM", "PROTEIN", 101, 104], ["HBV", "SPECIES", 21, 24], ["HCV", "SPECIES", 44, 47], ["HBV infection", "PROBLEM", 21, 34], ["chronic HCV infection", "PROBLEM", 36, 57], ["increased PD", "PROBLEM", 82, 94], ["T cell exhaustion", "PROBLEM", 140, 157], ["HBV", "OBSERVATION_MODIFIER", 21, 24], ["infection", "OBSERVATION", 25, 34], ["chronic", "OBSERVATION_MODIFIER", 36, 43], ["HCV", "OBSERVATION_MODIFIER", 44, 47], ["infection", "OBSERVATION", 48, 57]]], ["36 37 Although direct-acting antiviral regimens for HCV-infected patients have shown great overall success, thereby placing the need for therapeutic alternatives into perspective, the application of ICI to treat therapy-resistant chronic HCV infection is appealing.", [["HCV-infected", "DISEASE", 52, 64], ["ICI", "CHEMICAL", 199, 202], ["HCV infection", "DISEASE", 238, 251], ["ICI", "CHEMICAL", 199, 202], ["HCV", "ORGANISM", 52, 55], ["patients", "ORGANISM", 65, 73], ["ICI", "SIMPLE_CHEMICAL", 199, 202], ["HCV", "ORGANISM", 238, 241], ["patients", "SPECIES", 65, 73], ["HCV", "SPECIES", 52, 55], ["HCV", "SPECIES", 238, 241], ["direct-acting antiviral regimens", "TREATMENT", 15, 47], ["HCV", "PROBLEM", 52, 55], ["therapeutic alternatives", "TREATMENT", 137, 161], ["ICI", "TREATMENT", 199, 202], ["therapy", "TREATMENT", 212, 219], ["resistant chronic HCV infection", "PROBLEM", 220, 251], ["chronic", "OBSERVATION_MODIFIER", 230, 237], ["HCV", "OBSERVATION_MODIFIER", 238, 241], ["infection", "OBSERVATION", 242, 251]]], ["28 29 36 38 39 Gardiner et al 40 recently reported a phase I proof-of-concept trial demonstrating that PD-1 inhibition through nivolumab resulted in prolonged suppression of HCV replication in some patients with chronic infection.", [["nivolumab", "CHEMICAL", 127, 136], ["chronic infection", "DISEASE", 212, 229], ["nivolumab", "CHEMICAL", 127, 136], ["PD-1", "GENE_OR_GENE_PRODUCT", 103, 107], ["nivolumab", "SIMPLE_CHEMICAL", 127, 136], ["HCV", "ORGANISM", 174, 177], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["HCV", "SPECIES", 174, 177], ["PD", "TREATMENT", 103, 105], ["nivolumab", "TREATMENT", 127, 136], ["HCV replication", "TREATMENT", 174, 189], ["chronic infection", "PROBLEM", 212, 229], ["HCV", "OBSERVATION", 174, 177], ["chronic", "OBSERVATION_MODIFIER", 212, 219], ["infection", "OBSERVATION", 220, 229]]], ["Based on these encouraging results, further exploration of PD-1 pathway inhibition is warranted for other chronic viral diseases, possibly in combination with direct-acting antiviral regimens.", [["chronic viral diseases", "DISEASE", 106, 128], ["PD-1", "GENE_OR_GENE_PRODUCT", 59, 63], ["further exploration", "TEST", 36, 55], ["PD-1 pathway inhibition", "TREATMENT", 59, 82], ["other chronic viral diseases", "PROBLEM", 100, 128], ["direct-acting antiviral regimens", "TREATMENT", 159, 191], ["chronic", "OBSERVATION_MODIFIER", 106, 113], ["viral", "OBSERVATION", 114, 119]]], ["40 However, similar to the situation for HBV infection, the number of clinical trials assessing ICI in chronic HCV infection remain limited.", [["HBV infection", "DISEASE", 41, 54], ["ICI", "CHEMICAL", 96, 99], ["chronic HCV infection", "DISEASE", 103, 124], ["ICI", "CHEMICAL", 96, 99], ["HBV", "ORGANISM", 41, 44], ["ICI", "SIMPLE_CHEMICAL", 96, 99], ["HBV", "SPECIES", 41, 44], ["HCV", "SPECIES", 111, 114], ["HBV infection", "PROBLEM", 41, 54], ["clinical trials", "TREATMENT", 70, 85], ["ICI", "TREATMENT", 96, 99], ["chronic HCV infection", "PROBLEM", 103, 124], ["infection", "OBSERVATION", 45, 54], ["chronic", "OBSERVATION_MODIFIER", 103, 110], ["HCV", "OBSERVATION_MODIFIER", 111, 114], ["infection", "OBSERVATION", 115, 124]]], ["36 41-43 Taken together, ICI appears to be safe and effective in cancer patients with concurrent HBV or HCV.", [["cancer", "ANATOMY", 65, 71], ["ICI", "CHEMICAL", 25, 28], ["cancer", "DISEASE", 65, 71], ["ICI", "CHEMICAL", 25, 28], ["ICI", "SIMPLE_CHEMICAL", 25, 28], ["cancer", "CANCER", 65, 71], ["patients", "ORGANISM", 72, 80], ["HBV", "ORGANISM", 97, 100], ["HCV", "ORGANISM", 104, 107], ["patients", "SPECIES", 72, 80], ["HBV", "SPECIES", 97, 100], ["HCV", "SPECIES", 104, 107], ["concurrent HBV", "PROBLEM", 86, 100], ["HCV", "PROBLEM", 104, 107], ["HCV", "OBSERVATION", 104, 107]]], ["Thus, HBV and HCV infection should not contraindicate ICI.", [["HCV infection", "DISEASE", 14, 27], ["ICI", "CHEMICAL", 54, 57], ["ICI", "CHEMICAL", 54, 57], ["HBV", "ORGANISM", 6, 9], ["HCV", "ORGANISM", 14, 17], ["ICI", "SIMPLE_CHEMICAL", 54, 57], ["HBV", "SPECIES", 6, 9], ["HCV", "SPECIES", 14, 17], ["HBV", "PROBLEM", 6, 9], ["HCV infection", "PROBLEM", 14, 27], ["ICI", "PROBLEM", 54, 57], ["HBV", "OBSERVATION", 6, 9], ["HCV", "OBSERVATION_MODIFIER", 14, 17], ["infection", "OBSERVATION", 18, 27]]], ["34 35 Even though the risk of virus reactivation and virus-related hepatotoxicity appears to be low, it is recommended that patients with active HBV or HCV should routinely be monitored and treated with antiviral agents if indicated, in particular in patients receiving immunosuppressive medication for ICI-induced irAE.", [["hepatotoxicity", "DISEASE", 67, 81], ["ICI", "CHEMICAL", 303, 306], ["irAE", "DISEASE", 315, 319], ["ICI", "CHEMICAL", 303, 306], ["patients", "ORGANISM", 124, 132], ["HBV", "ORGANISM", 145, 148], ["HCV", "ORGANISM", 152, 155], ["patients", "ORGANISM", 251, 259], ["ICI", "SIMPLE_CHEMICAL", 303, 306], ["patients", "SPECIES", 124, 132], ["patients", "SPECIES", 251, 259], ["HBV", "SPECIES", 145, 148], ["HCV", "SPECIES", 152, 155], ["virus reactivation", "PROBLEM", 30, 48], ["virus", "PROBLEM", 53, 58], ["hepatotoxicity", "PROBLEM", 67, 81], ["active HBV", "PROBLEM", 138, 148], ["HCV", "PROBLEM", 152, 155], ["antiviral agents", "TREATMENT", 203, 219], ["immunosuppressive medication", "TREATMENT", 270, 298], ["ICI-induced irAE", "TREATMENT", 303, 319], ["virus reactivation", "OBSERVATION", 30, 48]]], ["33 Since PD-1 plays a significant role in the natural history of both HBV-induced and HCV-induced hepatitis, there is a rationale for the use of ICI in these conditions.", [["HBV-induced and HCV-induced hepatitis", "DISEASE", 70, 107], ["ICI", "CHEMICAL", 145, 148], ["ICI", "CHEMICAL", 145, 148], ["PD-1", "GENE_OR_GENE_PRODUCT", 9, 13], ["HBV", "ORGANISM", 70, 73], ["HCV", "ORGANISM", 86, 89], ["ICI", "SIMPLE_CHEMICAL", 145, 148], ["HBV", "SPECIES", 70, 73], ["HCV", "SPECIES", 86, 89], ["both HBV", "PROBLEM", 65, 73], ["HCV", "PROBLEM", 86, 89], ["hepatitis", "PROBLEM", 98, 107], ["ICI", "TREATMENT", 145, 148], ["HBV", "OBSERVATION", 70, 73], ["HCV", "OBSERVATION", 86, 89], ["hepatitis", "OBSERVATION", 98, 107]]], ["Initial studies indicate that anti-PD-1 treatment is safe in chronic HBV and HCV infection, but further trials are needed to determine whether ICI can be used to gain HBV long-term remission.", [["anti-PD-1", "CHEMICAL", 30, 39], ["chronic HBV and HCV infection", "DISEASE", 61, 90], ["ICI", "CHEMICAL", 143, 146], ["ICI", "CHEMICAL", 143, 146], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 30, 39], ["HBV", "ORGANISM", 69, 72], ["HCV", "ORGANISM", 77, 80], ["ICI", "SIMPLE_CHEMICAL", 143, 146], ["HBV", "SPECIES", 69, 72], ["HCV", "SPECIES", 77, 80], ["HBV", "SPECIES", 167, 170], ["Initial studies", "TEST", 0, 15], ["anti-PD-1 treatment", "TREATMENT", 30, 49], ["chronic HBV", "PROBLEM", 61, 72], ["HCV infection", "PROBLEM", 77, 90], ["ICI", "TREATMENT", 143, 146], ["HBV long-term remission", "TREATMENT", 167, 190], ["chronic", "OBSERVATION_MODIFIER", 61, 68], ["HBV", "OBSERVATION", 69, 72], ["HCV", "OBSERVATION_MODIFIER", 77, 80], ["infection", "OBSERVATION", 81, 90]]], ["36 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY Progressive multifocal leukoencephalopathy (PML) is a rare, often lethal disease of the central nervous system caused by the JC polyomavirus (JCV).", [["central nervous system", "ANATOMY", 134, 156], ["Progressive multifocal leukoencephalopathy", "DISEASE", 46, 88], ["PML", "DISEASE", 90, 93], ["disease of the central nervous system", "DISEASE", 119, 156], ["PML", "CANCER", 90, 93], ["central nervous system", "ANATOMICAL_SYSTEM", 134, 156], ["JC polyomavirus", "ORGANISM", 171, 186], ["JCV", "ORGANISM", 188, 191], ["JC polyomavirus", "SPECIES", 171, 186], ["JCV", "SPECIES", 188, 191], ["PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY Progressive multifocal leukoencephalopathy", "PROBLEM", 3, 88], ["PML", "PROBLEM", 90, 93], ["often lethal disease of the central nervous system", "PROBLEM", 106, 156], ["the JC polyomavirus", "PROBLEM", 167, 186], ["PROGRESSIVE", "OBSERVATION_MODIFIER", 3, 14], ["MULTIFOCAL", "OBSERVATION_MODIFIER", 15, 25], ["LEUKOENCEPHALOPATHY", "OBSERVATION_MODIFIER", 26, 45], ["Progressive", "OBSERVATION_MODIFIER", 46, 57], ["multifocal", "OBSERVATION_MODIFIER", 58, 68], ["leukoencephalopathy", "OBSERVATION", 69, 88], ["lethal", "OBSERVATION_MODIFIER", 112, 118], ["disease", "OBSERVATION", 119, 126], ["central", "ANATOMY_MODIFIER", 134, 141], ["nervous system", "ANATOMY", 142, 156], ["JC polyomavirus", "OBSERVATION", 171, 186]]], ["44 In general, JCV Open access infection is indolent and asymptomatic, but may become symptomatic and fatal in immunocompromised patients, for example, patients infected with HIV, lymphoproliferative malignancies or those undergoing immunosuppressive therapies.", [["lymphoproliferative malignancies", "ANATOMY", 180, 212], ["infection", "DISEASE", 31, 40], ["HIV", "DISEASE", 175, 178], ["lymphoproliferative malignancies", "DISEASE", 180, 212], ["JCV", "ORGANISM", 15, 18], ["patients", "ORGANISM", 129, 137], ["patients", "ORGANISM", 152, 160], ["HIV", "ORGANISM", 175, 178], ["lymphoproliferative malignancies", "CANCER", 180, 212], ["patients", "SPECIES", 129, 137], ["patients", "SPECIES", 152, 160], ["HIV", "SPECIES", 175, 178], ["JCV", "SPECIES", 15, 18], ["HIV", "SPECIES", 175, 178], ["indolent", "PROBLEM", 44, 52], ["asymptomatic", "PROBLEM", 57, 69], ["symptomatic", "PROBLEM", 86, 97], ["HIV", "PROBLEM", 175, 178], ["lymphoproliferative malignancies", "PROBLEM", 180, 212], ["immunosuppressive therapies", "TREATMENT", 233, 260], ["infection", "OBSERVATION", 31, 40], ["indolent", "OBSERVATION_MODIFIER", 44, 52], ["may become", "UNCERTAINTY", 75, 85], ["symptomatic", "OBSERVATION_MODIFIER", 86, 97], ["fatal", "OBSERVATION_MODIFIER", 102, 107], ["lymphoproliferative malignancies", "OBSERVATION", 180, 212]]], ["45 46 Currently, no proven therapeutic strategy for this disease has been established.", [["this disease", "PROBLEM", 52, 64]]], ["Based on evidence that T cell exhaustion might affect the course of JCV infections, ICIs are currently tested for treatment of PML.", [["T cell", "ANATOMY", 23, 29], ["PML", "ANATOMY", 127, 130], ["JCV infections", "DISEASE", 68, 82], ["PML", "DISEASE", 127, 130], ["T cell", "CELL", 23, 29], ["JCV", "ORGANISM", 68, 71], ["ICIs", "SIMPLE_CHEMICAL", 84, 88], ["PML", "CANCER", 127, 130], ["JCV", "SPECIES", 68, 71], ["T cell exhaustion", "PROBLEM", 23, 40], ["JCV infections", "PROBLEM", 68, 82], ["ICIs", "TREATMENT", 84, 88], ["treatment", "TREATMENT", 114, 123], ["PML", "PROBLEM", 127, 130], ["cell exhaustion", "OBSERVATION", 25, 40], ["PML", "OBSERVATION", 127, 130]]], ["47 For example, Cortese et al 48 assessed the safety and efficacy of PD-1 inhibition by pembrolizumab with different predisposing conditions (n=8).", [["pembrolizumab", "CHEMICAL", 88, 101], ["pembrolizumab", "CHEMICAL", 88, 101], ["PD-1", "GENE_OR_GENE_PRODUCT", 69, 73], ["pembrolizumab", "SIMPLE_CHEMICAL", 88, 101], ["PD", "TREATMENT", 69, 71], ["pembrolizumab", "TREATMENT", 88, 101], ["different predisposing conditions", "PROBLEM", 107, 140]]], ["In this small cohort, five patients achieved a clinical benefit or stabilization of PML and a decrease in JCV viral load.", [["PML", "DISEASE", 84, 87], ["patients", "ORGANISM", 27, 35], ["PML", "CANCER", 84, 87], ["JCV", "ORGANISM", 106, 109], ["patients", "SPECIES", 27, 35], ["JCV", "SPECIES", 106, 109], ["PML", "PROBLEM", 84, 87], ["a decrease in JCV viral load", "PROBLEM", 92, 120], ["small", "OBSERVATION_MODIFIER", 8, 13], ["PML", "OBSERVATION", 84, 87], ["decrease", "OBSERVATION_MODIFIER", 94, 102], ["JCV viral load", "OBSERVATION", 106, 120]]], ["Contrasting results were observed in another study, three kidney transplant recipients suffering from PML were treated with nivolumab and all three patients died within 8 weeks with evidence of disease progression.", [["kidney", "ANATOMY", 58, 64], ["PML", "ANATOMY", 102, 105], ["PML", "DISEASE", 102, 105], ["nivolumab", "CHEMICAL", 124, 133], ["nivolumab", "CHEMICAL", 124, 133], ["kidney", "ORGAN", 58, 64], ["recipients", "ORGANISM", 76, 86], ["PML", "CANCER", 102, 105], ["nivolumab", "SIMPLE_CHEMICAL", 124, 133], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["another study", "TEST", 37, 50], ["three kidney transplant recipients", "TREATMENT", 52, 86], ["PML", "PROBLEM", 102, 105], ["nivolumab", "TREATMENT", 124, 133], ["disease progression", "PROBLEM", 194, 213], ["kidney", "ANATOMY", 58, 64], ["transplant", "OBSERVATION", 65, 75], ["PML", "OBSERVATION", 102, 105], ["evidence of", "UNCERTAINTY", 182, 193], ["disease", "OBSERVATION", 194, 201]]], ["49 As an explanation for this adverse outcome, 48 the authors speculate that immunosuppressive therapy (ie, calcineurin inhibitors) might have led to persistent T cell dysfunction and lymphopenia.", [["T cell", "ANATOMY", 161, 167], ["T cell dysfunction", "DISEASE", 161, 179], ["lymphopenia", "DISEASE", 184, 195], ["calcineurin", "GENE_OR_GENE_PRODUCT", 108, 119], ["T cell", "CELL", 161, 167], ["this adverse outcome", "PROBLEM", 25, 45], ["immunosuppressive therapy", "TREATMENT", 77, 102], ["calcineurin inhibitors", "TREATMENT", 108, 130], ["persistent T cell dysfunction", "PROBLEM", 150, 179], ["lymphopenia", "PROBLEM", 184, 195], ["persistent", "OBSERVATION_MODIFIER", 150, 160], ["T cell dysfunction", "OBSERVATION", 161, 179], ["lymphopenia", "OBSERVATION", 184, 195]]], ["The authors further point out that patients with severe lymphopenia also did not respond favorably to ICI treatment.", [["lymphopenia", "DISEASE", 56, 67], ["ICI", "CHEMICAL", 102, 105], ["ICI", "CHEMICAL", 102, 105], ["patients", "ORGANISM", 35, 43], ["ICI", "SIMPLE_CHEMICAL", 102, 105], ["patients", "SPECIES", 35, 43], ["severe lymphopenia", "PROBLEM", 49, 67], ["ICI treatment", "TREATMENT", 102, 115], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["lymphopenia", "OBSERVATION", 56, 67]]], ["Hence, they concluded that ICI may be ineffective in such patients.", [["ICI", "CHEMICAL", 27, 30], ["ICI", "CHEMICAL", 27, 30], ["ICI", "SIMPLE_CHEMICAL", 27, 30], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["ICI", "TREATMENT", 27, 30]]], ["48 49 In contrast, a number of case reports describe favorable outcomes for patients with PML receiving ICI.", [["PML", "ANATOMY", 90, 93], ["PML", "DISEASE", 90, 93], ["ICI", "CHEMICAL", 104, 107], ["ICI", "CHEMICAL", 104, 107], ["patients", "ORGANISM", 76, 84], ["PML", "CANCER", 90, 93], ["ICI", "SIMPLE_CHEMICAL", 104, 107], ["patients", "SPECIES", 76, 84], ["PML", "PROBLEM", 90, 93], ["ICI", "TREATMENT", 104, 107]]], ["For example, Hoang et al 50 described a biopsy-confirmed PML case in which the PD-1 inhibitor nivolumab seems to have stimulated immune activation resulting in effective disease control in the patient with a concomitant hematological malignancy.", [["hematological malignancy", "ANATOMY", 220, 244], ["nivolumab", "CHEMICAL", 94, 103], ["hematological malignancy", "DISEASE", 220, 244], ["nivolumab", "CHEMICAL", 94, 103], ["PML", "CANCER", 57, 60], ["PD-1", "GENE_OR_GENE_PRODUCT", 79, 83], ["nivolumab", "SIMPLE_CHEMICAL", 94, 103], ["patient", "ORGANISM", 193, 200], ["hematological malignancy", "CANCER", 220, 244], ["patient", "SPECIES", 193, 200], ["a biopsy", "TEST", 38, 46], ["PML case", "PROBLEM", 57, 65], ["the PD-1 inhibitor nivolumab", "TREATMENT", 75, 103], ["stimulated immune activation", "PROBLEM", 118, 146], ["effective disease control", "TREATMENT", 160, 185], ["a concomitant hematological malignancy", "PROBLEM", 206, 244], ["PML", "OBSERVATION", 57, 60], ["effective", "OBSERVATION_MODIFIER", 160, 169], ["disease", "OBSERVATION", 170, 177], ["hematological", "ANATOMY", 220, 233], ["malignancy", "OBSERVATION", 234, 244]]], ["[50] [51] [52] Together, at present, there are few studies on the safety and/or efficacy of ICI in patients with PML.", [["PML", "ANATOMY", 113, 116], ["ICI", "CHEMICAL", 92, 95], ["PML", "DISEASE", 113, 116], ["ICI", "CHEMICAL", 92, 95], ["ICI", "SIMPLE_CHEMICAL", 92, 95], ["patients", "ORGANISM", 99, 107], ["PML", "CANCER", 113, 116], ["patients", "SPECIES", 99, 107], ["ICI", "TREATMENT", 92, 95], ["PML", "PROBLEM", 113, 116], ["PML", "OBSERVATION", 113, 116]]], ["The available studies do not show consistent results which, might be due to the great heterogeneity of predisposing conditions leading to PML.", [["PML", "ANATOMY", 138, 141], ["PML", "DISEASE", 138, 141], ["PML", "CANCER", 138, 141], ["The available studies", "TEST", 0, 21], ["predisposing conditions", "PROBLEM", 103, 126], ["PML", "PROBLEM", 138, 141], ["PML", "OBSERVATION", 138, 141]]], ["Despite these difficulties, the present data suggest that the underlying cause of immunosuppression, pretreatment, and laboratory parameters, such as lymphopenia, have relevant effects on the success of ICI therapy of PML.", [["PML", "ANATOMY", 218, 221], ["lymphopenia", "DISEASE", 150, 161], ["ICI", "CHEMICAL", 203, 206], ["PML", "DISEASE", 218, 221], ["ICI", "CHEMICAL", 203, 206], ["ICI", "SIMPLE_CHEMICAL", 203, 206], ["PML", "CANCER", 218, 221], ["these difficulties", "PROBLEM", 8, 26], ["immunosuppression", "TREATMENT", 82, 99], ["pretreatment", "TREATMENT", 101, 113], ["laboratory parameters", "TEST", 119, 140], ["lymphopenia", "PROBLEM", 150, 161], ["ICI therapy", "TREATMENT", 203, 214], ["PML", "PROBLEM", 218, 221], ["immunosuppression", "OBSERVATION", 82, 99]]], ["This notion may be extrapolated to ICI treatment of cancer in patients with PML.", [["cancer", "ANATOMY", 52, 58], ["PML", "ANATOMY", 76, 79], ["ICI", "CHEMICAL", 35, 38], ["cancer", "DISEASE", 52, 58], ["PML", "DISEASE", 76, 79], ["ICI", "CHEMICAL", 35, 38], ["ICI", "SIMPLE_CHEMICAL", 35, 38], ["cancer", "CANCER", 52, 58], ["patients", "ORGANISM", 62, 70], ["PML", "CANCER", 76, 79], ["patients", "SPECIES", 62, 70], ["ICI treatment", "TREATMENT", 35, 48], ["cancer", "PROBLEM", 52, 58], ["PML", "PROBLEM", 76, 79], ["may be", "UNCERTAINTY", 12, 18], ["cancer", "OBSERVATION", 52, 58]]], ["To the best of our knowledge, however, there exist no definite data on patients with PML receiving ICI treatment because of coexisting cancer.", [["PML", "ANATOMY", 85, 88], ["cancer", "ANATOMY", 135, 141], ["PML", "DISEASE", 85, 88], ["ICI", "CHEMICAL", 99, 102], ["cancer", "DISEASE", 135, 141], ["ICI", "CHEMICAL", 99, 102], ["patients", "ORGANISM", 71, 79], ["PML", "CANCER", 85, 88], ["ICI", "SIMPLE_CHEMICAL", 99, 102], ["cancer", "CANCER", 135, 141], ["patients", "SPECIES", 71, 79], ["PML", "PROBLEM", 85, 88], ["ICI treatment", "TREATMENT", 99, 112], ["coexisting cancer", "PROBLEM", 124, 141], ["no definite", "UNCERTAINTY", 51, 62], ["coexisting", "OBSERVATION_MODIFIER", 124, 134], ["cancer", "OBSERVATION", 135, 141]]], ["Of course, the use of immunosuppressive comedication for ICI-induced irAEs is challenging in this particular patient population.", [["ICI", "CHEMICAL", 57, 60], ["irAEs", "DISEASE", 69, 74], ["ICI", "CHEMICAL", 57, 60], ["ICI", "SIMPLE_CHEMICAL", 57, 60], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["immunosuppressive comedication", "TREATMENT", 22, 52], ["ICI-induced irAEs", "TREATMENT", 57, 74]]], ["Thus, prospective studies are necessary to determine whether ICIs are a safe and effective approach for PML and PML-associated cancers.INFLUENZAInfluenza, a highly contagious respiratory disease, is responsible for a significant economic burden on the healthcare systems.", [["PML", "ANATOMY", 104, 107], ["PML", "ANATOMY", 112, 115], ["cancers", "ANATOMY", 127, 134], ["respiratory", "ANATOMY", 175, 186], ["PML", "DISEASE", 104, 107], ["PML", "DISEASE", 112, 115], ["cancers", "DISEASE", 127, 134], ["respiratory disease", "DISEASE", 175, 194], ["ICIs", "SIMPLE_CHEMICAL", 61, 65], ["PML", "CANCER", 104, 107], ["PML", "GENE_OR_GENE_PRODUCT", 112, 115], ["cancers", "CANCER", 127, 134], ["prospective studies", "TEST", 6, 25], ["a safe and effective approach", "TREATMENT", 70, 99], ["PML", "PROBLEM", 104, 107], ["PML", "PROBLEM", 112, 115], ["associated cancers.INFLUENZAInfluenza", "PROBLEM", 116, 153], ["a highly contagious respiratory disease", "PROBLEM", 155, 194], ["a significant economic burden on the healthcare systems", "PROBLEM", 215, 270], ["PML", "OBSERVATION", 112, 115], ["cancers", "OBSERVATION", 127, 134], ["highly", "OBSERVATION_MODIFIER", 157, 163], ["contagious", "OBSERVATION_MODIFIER", 164, 174], ["respiratory disease", "OBSERVATION", 175, 194], ["significant", "OBSERVATION_MODIFIER", 217, 228], ["economic", "OBSERVATION_MODIFIER", 229, 237], ["burden", "OBSERVATION", 238, 244]]], ["The co-circulating influenza A (subtype: H1N1, H3N2) and B (lineage: Victoria, Yamagata) viruses cause seasonal epidemics which affect a major part of the global population annually and cause more than 645,000 influenza-associated deaths worldwide.", [["influenza A", "DISEASE", 19, 30], ["influenza", "DISEASE", 210, 219], ["deaths", "DISEASE", 231, 237], ["co-circulating influenza A (subtype: H1N1, H3N2", "ORGANISM", 4, 51], ["Yamagata) viruses", "ORGANISM", 79, 96], ["H1N1", "PROBLEM", 41, 45], ["H3N2", "PROBLEM", 47, 51], ["seasonal epidemics", "PROBLEM", 103, 121], ["influenza", "PROBLEM", 210, 219], ["influenza", "OBSERVATION", 19, 28]]], ["53 54 Since patients with cancer are at higher risk of influenza-associated complications, vaccination, the primary preventive tool against influenza, is recommended.", [["cancer", "ANATOMY", 26, 32], ["cancer", "DISEASE", 26, 32], ["influenza", "DISEASE", 55, 64], ["influenza", "DISEASE", 140, 149], ["patients", "ORGANISM", 12, 20], ["cancer", "CANCER", 26, 32], ["patients", "SPECIES", 12, 20], ["cancer", "PROBLEM", 26, 32], ["influenza", "PROBLEM", 55, 64], ["associated complications", "PROBLEM", 65, 89], ["vaccination", "TREATMENT", 91, 102], ["influenza", "PROBLEM", 140, 149], ["cancer", "OBSERVATION", 26, 32], ["influenza", "OBSERVATION", 55, 64], ["complications", "OBSERVATION", 76, 89]]], ["Particularly, ICI-treated patients produce robust humoral and cellular immune responses.", [["cellular", "ANATOMY", 62, 70], ["ICI", "CHEMICAL", 14, 17], ["ICI", "CHEMICAL", 14, 17], ["ICI", "SIMPLE_CHEMICAL", 14, 17], ["patients", "ORGANISM", 26, 34], ["cellular", "CELL", 62, 70], ["patients", "SPECIES", 26, 34], ["cellular immune", "OBSERVATION", 62, 77]]], ["Still it is important to note that Bersanelli et al 53 reported that the post-vaccination occurrence of the influenza syndrome (fever \u226538\u00b0C and the presence of at least one respiratory symptom together with generalized symptoms) was significantly increased in patients with cancer receiving ICI.", [["cancer", "ANATOMY", 274, 280], ["influenza syndrome", "DISEASE", 108, 126], ["fever", "DISEASE", 128, 133], ["cancer", "DISEASE", 274, 280], ["ICI", "CHEMICAL", 291, 294], ["ICI", "CHEMICAL", 291, 294], ["C", "GENE_OR_GENE_PRODUCT", 138, 139], ["patients", "ORGANISM", 260, 268], ["cancer", "CANCER", 274, 280], ["ICI", "SIMPLE_CHEMICAL", 291, 294], ["patients", "SPECIES", 260, 268], ["the influenza syndrome", "PROBLEM", 104, 126], ["fever", "PROBLEM", 128, 133], ["one respiratory symptom", "PROBLEM", 169, 192], ["generalized symptoms", "PROBLEM", 207, 227], ["cancer", "PROBLEM", 274, 280], ["ICI", "TREATMENT", 291, 294], ["influenza syndrome", "OBSERVATION", 108, 126], ["increased", "OBSERVATION_MODIFIER", 247, 256], ["cancer", "OBSERVATION", 274, 280]]], ["In this study, the lack of efficacy of vaccination was more pronounced among the elderly.", [["this study", "TEST", 3, 13], ["vaccination", "TREATMENT", 39, 50]]], ["53 Importantly, influenza vaccination did not negatively impact the efficacy of the anticancer effects of ICI treatment.", [["anticancer", "ANATOMY", 84, 94], ["influenza", "DISEASE", 16, 25], ["ICI", "CHEMICAL", 106, 109], ["ICI", "CHEMICAL", 106, 109], ["anticancer", "CANCER", 84, 94], ["ICI", "SIMPLE_CHEMICAL", 106, 109], ["influenza vaccination", "PROBLEM", 16, 37], ["ICI treatment", "TREATMENT", 106, 119]]], ["Moreover, the same authors reported that ICI-treated cancer patients who received influenza vaccination and/or developed influenza syndrome showed longer overall survival.", [["cancer", "ANATOMY", 53, 59], ["ICI", "CHEMICAL", 41, 44], ["cancer", "DISEASE", 53, 59], ["influenza syndrome", "DISEASE", 121, 139], ["ICI", "CHEMICAL", 41, 44], ["ICI", "SIMPLE_CHEMICAL", 41, 44], ["cancer", "CANCER", 53, 59], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["ICI", "PROBLEM", 41, 44], ["influenza vaccination", "TREATMENT", 82, 103], ["influenza syndrome", "PROBLEM", 121, 139]]], ["The effect of immunosuppressive therapy for ICI-induced irAE on the influenza syndrome was not addressed in these studies.", [["ICI", "CHEMICAL", 44, 47], ["irAE", "CHEMICAL", 56, 60], ["influenza syndrome", "DISEASE", 68, 86], ["ICI", "CHEMICAL", 44, 47], ["ICI", "SIMPLE_CHEMICAL", 44, 47], ["immunosuppressive therapy", "TREATMENT", 14, 39], ["ICI", "TREATMENT", 44, 47], ["the influenza syndrome", "PROBLEM", 64, 86], ["these studies", "TEST", 108, 121], ["immunosuppressive therapy", "OBSERVATION", 14, 39], ["influenza syndrome", "OBSERVATION", 68, 86]]], ["54 In rare cases, influenza infection and vaccination are associated with the occurrence of organ-specific autoimmune conditions, such as Guillain-Barr\u00e9 syndrome, a rapid onset muscle weakness caused by the immune system attacking peripheral nerves.", [["organ", "ANATOMY", 92, 97], ["muscle", "ANATOMY", 177, 183], ["immune system", "ANATOMY", 207, 220], ["peripheral nerves", "ANATOMY", 231, 248], ["influenza infection", "DISEASE", 18, 37], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 138, 161], ["muscle weakness", "DISEASE", 177, 192], ["organ", "ORGAN", 92, 97], ["Guillain-Barr\u00e9", "ORGANISM", 138, 152], ["muscle", "ORGAN", 177, 183], ["immune system", "ANATOMICAL_SYSTEM", 207, 220], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 231, 248], ["influenza infection", "PROBLEM", 18, 37], ["vaccination", "TREATMENT", 42, 53], ["organ-specific autoimmune conditions", "PROBLEM", 92, 128], ["Barr\u00e9 syndrome", "PROBLEM", 147, 161], ["a rapid onset muscle weakness", "PROBLEM", 163, 192], ["rare", "OBSERVATION_MODIFIER", 6, 10], ["cases", "OBSERVATION", 11, 16], ["influenza", "OBSERVATION_MODIFIER", 18, 27], ["infection", "OBSERVATION", 28, 37], ["autoimmune", "OBSERVATION", 107, 117], ["Barr\u00e9 syndrome", "OBSERVATION", 147, 161], ["rapid", "OBSERVATION_MODIFIER", 165, 170], ["muscle", "ANATOMY", 177, 183], ["weakness", "OBSERVATION", 184, 192], ["nerves", "ANATOMY", 242, 248]]], ["The risk of influenza vaccine-induced Guillain-Barr\u00e9 syndrome is extremely small.", [["influenza", "DISEASE", 12, 21], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 38, 61], ["Guillain-Barr\u00e9", "ORGANISM", 38, 52], ["influenza vaccine", "TREATMENT", 12, 29], ["Barr\u00e9 syndrome", "PROBLEM", 47, 61], ["influenza", "OBSERVATION", 12, 21], ["Barr\u00e9 syndrome", "OBSERVATION", 47, 61], ["extremely", "OBSERVATION_MODIFIER", 65, 74], ["small", "OBSERVATION_MODIFIER", 75, 80]]], ["Notably, however, Yuen et al 55 reported a patient with previous post-vaccination Guillain-Barr\u00e9 syndrome who developed a fatal reactivation following the initiation of ICI.", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 82, 105], ["ICI", "CHEMICAL", 169, 172], ["ICI", "CHEMICAL", 169, 172], ["patient", "ORGANISM", 43, 50], ["Guillain-Barr\u00e9", "ORGANISM", 82, 96], ["ICI", "SIMPLE_CHEMICAL", 169, 172], ["patient", "SPECIES", 43, 50], ["Barr\u00e9 syndrome", "PROBLEM", 91, 105], ["a fatal reactivation", "PROBLEM", 120, 140], ["ICI", "TREATMENT", 169, 172], ["fatal", "OBSERVATION_MODIFIER", 122, 127], ["reactivation", "OBSERVATION", 128, 140]]], ["Indeed, the hypothesis that influenza vaccination may induce adverse immune responses in ICI-treated patients is corroborated by results from animal experiments showing increased T cell responses to viral antigens under PD-1 inhibition.", [["T cell", "ANATOMY", 179, 185], ["influenza", "DISEASE", 28, 37], ["ICI", "CHEMICAL", 89, 92], ["ICI", "CHEMICAL", 89, 92], ["ICI", "SIMPLE_CHEMICAL", 89, 92], ["patients", "ORGANISM", 101, 109], ["T cell", "CELL", 179, 185], ["PD-1", "GENE_OR_GENE_PRODUCT", 220, 224], ["viral antigens", "PROTEIN", 199, 213], ["patients", "SPECIES", 101, 109], ["influenza vaccination", "TREATMENT", 28, 49], ["adverse immune responses", "PROBLEM", 61, 85], ["animal experiments", "TEST", 142, 160], ["increased T cell responses", "PROBLEM", 169, 195], ["increased T cell", "OBSERVATION", 169, 185]]], ["56 Moreover, it has been suggested that vaccines may stimulate an overwhelming expansion of autoreactive T lymphocytes which cross-recognize vaccines as well as self-antigens.", [["T lymphocytes", "ANATOMY", 105, 118], ["autoreactive T lymphocytes", "CELL", 92, 118], ["autoreactive T lymphocytes", "CELL_TYPE", 92, 118], ["vaccines", "TREATMENT", 40, 48], ["autoreactive T lymphocytes", "PROBLEM", 92, 118], ["vaccines", "TREATMENT", 141, 149], ["autoreactive T lymphocytes", "OBSERVATION", 92, 118]]], ["57 58 L\u00e4ubli et al 59 reported a small cohort of ICI-treated cancer patients that had received influenza vaccinations and subsequently experienced higher rates of irAEs than expected (n=23).", [["cancer", "ANATOMY", 61, 67], ["ICI", "CHEMICAL", 49, 52], ["cancer", "DISEASE", 61, 67], ["irAEs", "DISEASE", 163, 168], ["ICI", "CHEMICAL", 49, 52], ["ICI", "SIMPLE_CHEMICAL", 49, 52], ["cancer", "CANCER", 61, 67], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["influenza vaccinations", "TREATMENT", 95, 117], ["small", "OBSERVATION_MODIFIER", 33, 38], ["cancer", "OBSERVATION", 61, 67]]], ["Later studies investigating larger patient cohorts did not confirm such an increase of frequency or severity of irAEs in patients on ICI who previously received influenza vaccination.", [["irAEs", "DISEASE", 112, 117], ["ICI", "CHEMICAL", 133, 136], ["ICI", "CHEMICAL", 133, 136], ["patient", "ORGANISM", 35, 42], ["patients", "ORGANISM", 121, 129], ["ICI", "SIMPLE_CHEMICAL", 133, 136], ["patient", "SPECIES", 35, 42], ["patients", "SPECIES", 121, 129], ["Later studies", "TEST", 0, 13], ["severity of irAEs", "PROBLEM", 100, 117], ["ICI", "TREATMENT", 133, 136], ["influenza vaccination", "TREATMENT", 161, 182], ["larger", "OBSERVATION_MODIFIER", 28, 34]]], ["57 60-65 The data of Chong et al 57 do not indicate an increase in incidence or severity of irAE in patients with cancer on ICI who received influenza vaccinations.", [["cancer", "ANATOMY", 114, 120], ["irAE", "DISEASE", 92, 96], ["cancer", "DISEASE", 114, 120], ["ICI", "CHEMICAL", 124, 127], ["patients", "ORGANISM", 100, 108], ["cancer", "CANCER", 114, 120], ["patients", "SPECIES", 100, 108], ["severity of irAE", "PROBLEM", 80, 96], ["cancer", "PROBLEM", 114, 120], ["ICI", "TREATMENT", 124, 127], ["influenza vaccinations", "TREATMENT", 141, 163], ["increase", "OBSERVATION_MODIFIER", 55, 63], ["cancer", "OBSERVATION", 114, 120]]], ["Twenty per cent (75/370) of patients experienced a new irAE (any grade), of those 48% received corticosteroids or other immunosuppressants.", [["irAE", "DISEASE", 55, 59], ["corticosteroids", "CHEMICAL", 95, 110], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["a new irAE", "PROBLEM", 49, 59], ["corticosteroids", "TREATMENT", 95, 110], ["other immunosuppressants", "TREATMENT", 114, 138]]], ["In the latter subgroup, no negative influence on vaccination outcome was reported.", [["no", "UNCERTAINTY", 24, 26], ["negative", "OBSERVATION_MODIFIER", 27, 35], ["influence", "OBSERVATION_MODIFIER", 36, 45]]], ["57 In this context, the study of Awadalla et al 65 should be pointed out.", [["the study", "TEST", 20, 29]]], ["They actually demonstrated that the administration of a influenza vaccination was not correlated with an increased risk of subsequent myocarditis among patients on ICI.", [["influenza", "DISEASE", 56, 65], ["myocarditis", "DISEASE", 134, 145], ["ICI", "CHEMICAL", 164, 167], ["ICI", "CHEMICAL", 164, 167], ["patients", "ORGANISM", 152, 160], ["ICI", "SIMPLE_CHEMICAL", 164, 167], ["patients", "SPECIES", 152, 160], ["a influenza vaccination", "TREATMENT", 54, 77], ["subsequent myocarditis", "PROBLEM", 123, 145], ["ICI", "TREATMENT", 164, 167], ["myocarditis", "OBSERVATION", 134, 145]]], ["Indeed, rates of vaccination were lower among patients who did develop ICI-induced myocarditis, and the vaccination was associated with a lower risk of other irAEs, in particular ICI-induced pneumonitis.", [["ICI", "CHEMICAL", 71, 74], ["myocarditis", "DISEASE", 83, 94], ["irAEs", "DISEASE", 158, 163], ["ICI", "CHEMICAL", 179, 182], ["pneumonitis", "DISEASE", 191, 202], ["ICI", "CHEMICAL", 71, 74], ["ICI", "CHEMICAL", 179, 182], ["patients", "ORGANISM", 46, 54], ["ICI", "SIMPLE_CHEMICAL", 71, 74], ["ICI", "SIMPLE_CHEMICAL", 179, 182], ["patients", "SPECIES", 46, 54], ["vaccination", "TREATMENT", 17, 28], ["ICI", "PROBLEM", 71, 74], ["myocarditis", "PROBLEM", 83, 94], ["other irAEs", "PROBLEM", 152, 163], ["pneumonitis", "PROBLEM", 191, 202], ["myocarditis", "OBSERVATION", 83, 94], ["irAEs", "OBSERVATION", 158, 163], ["pneumonitis", "OBSERVATION", 191, 202]]], ["65 Unfortunately, there is little data available whether ICI would be beneficial in the management of severe influenza cases.Open accessIn this context, Yu et al 66 reported that influenza infection substantially increases the number of highly PD-1 positive innate lymphoid cells in the lungs of mice.", [["lymphoid cells", "ANATOMY", 265, 279], ["lungs", "ANATOMY", 287, 292], ["ICI", "CHEMICAL", 57, 60], ["influenza", "DISEASE", 109, 118], ["influenza infection", "DISEASE", 179, 198], ["ICI", "CHEMICAL", 57, 60], ["ICI", "SIMPLE_CHEMICAL", 57, 60], ["influenza", "ORGANISM", 179, 188], ["PD-1", "GENE_OR_GENE_PRODUCT", 244, 248], ["lymphoid cells", "CELL", 265, 279], ["lungs", "ORGAN", 287, 292], ["mice", "ORGANISM", 296, 300], ["innate lymphoid cells", "CELL_TYPE", 258, 279], ["mice", "SPECIES", 296, 300], ["mice", "SPECIES", 296, 300], ["ICI", "TREATMENT", 57, 60], ["severe influenza cases", "PROBLEM", 102, 124], ["influenza infection", "PROBLEM", 179, 198], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["influenza", "OBSERVATION", 109, 118], ["influenza", "OBSERVATION_MODIFIER", 179, 188], ["infection", "OBSERVATION", 189, 198], ["innate lymphoid cells", "OBSERVATION", 258, 279], ["lungs", "ANATOMY", 287, 292]]], ["Anti-PD-1 treatment resulted in reduction of total lung innate lymphoid cells with almost complete loss of PD-1 highly positive cells.", [["lung innate lymphoid cells", "ANATOMY", 51, 77], ["cells", "ANATOMY", 128, 133], ["Anti-PD-1", "CHEMICAL", 0, 9], ["Anti-PD-1", "GENE_OR_GENE_PRODUCT", 0, 9], ["lung innate lymphoid cells", "CELL", 51, 77], ["PD-1", "GENE_OR_GENE_PRODUCT", 107, 111], ["cells", "CELL", 128, 133], ["lung innate lymphoid cells", "CELL_TYPE", 51, 77], ["PD-1 highly positive cells", "CELL_LINE", 107, 133], ["Anti-PD", "TREATMENT", 0, 7], ["1 treatment", "TREATMENT", 8, 19], ["total lung innate lymphoid cells", "PROBLEM", 45, 77], ["almost complete loss of PD", "PROBLEM", 83, 109], ["reduction", "OBSERVATION_MODIFIER", 32, 41], ["total", "OBSERVATION_MODIFIER", 45, 50], ["lung", "ANATOMY", 51, 55], ["innate lymphoid cells", "OBSERVATION", 56, 77], ["positive cells", "OBSERVATION", 119, 133]]], ["Hence, they suggested that anti-PD-1 treatment may provide an effective approach for both disease prevention and treatment.", [["anti-PD-1", "CHEMICAL", 27, 36], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 27, 36], ["anti-PD-1 treatment", "TREATMENT", 27, 46], ["an effective approach", "TREATMENT", 59, 80], ["both disease prevention", "TREATMENT", 85, 108], ["treatment", "TREATMENT", 113, 122]]], ["66COVID-19In March 2020, the COVID-19 outbreak, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), was officially proclaimed a pandemic by the WHO.", [["acute respiratory syndrome coronavirus", "DISEASE", 78, 116], ["severe acute respiratory syndrome coronavirus", "SPECIES", 71, 116], ["SARS-COV-2", "SPECIES", 120, 130], ["the COVID", "TEST", 25, 34], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 67, 116], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["respiratory syndrome", "OBSERVATION", 84, 104]]], ["Up through end of April, 2020, almost 3 million cases of COVID-19 were confirmed with more than 200,000 deaths reported worldwide.", [["deaths", "DISEASE", 104, 110], ["COVID", "TREATMENT", 57, 62]]], ["67 COVID-19 is predominantly characterized by high fever, dry cough, fatigue, and eventually pneumonia, and can cause death in severe cases.", [["fever", "DISEASE", 51, 56], ["dry cough", "DISEASE", 58, 67], ["fatigue", "DISEASE", 69, 76], ["pneumonia", "DISEASE", 93, 102], ["death", "DISEASE", 118, 123], ["COVID", "TEST", 3, 8], ["high fever", "PROBLEM", 46, 56], ["dry cough", "PROBLEM", 58, 67], ["fatigue", "PROBLEM", 69, 76], ["pneumonia", "PROBLEM", 93, 102], ["death in severe cases", "PROBLEM", 118, 139], ["high", "OBSERVATION_MODIFIER", 46, 50], ["fever", "OBSERVATION", 51, 56], ["dry", "OBSERVATION_MODIFIER", 58, 61], ["cough", "OBSERVATION", 62, 67], ["pneumonia", "OBSERVATION", 93, 102], ["severe", "OBSERVATION_MODIFIER", 127, 133]]], ["To date, most published data on COVID-19 have been generated in China.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 32, 40], ["COVID-19", "DNA", 32, 40], ["COVID", "TEST", 32, 37]]], ["In 14% of confirmed cases, the course of disease was severe and in 5% critical.", [["disease", "PROBLEM", 41, 48], ["disease", "OBSERVATION", 41, 48], ["severe", "OBSERVATION_MODIFIER", 53, 59]]], ["The so-called case fatality rate (CFR) was as high as 1%, thereby being much greater than the CFR usually observed in seasonal influenza (approximately 0.1%).", [["influenza", "DISEASE", 127, 136], ["CFR", "TEST", 34, 37], ["seasonal influenza", "PROBLEM", 118, 136], ["influenza", "OBSERVATION", 127, 136]]], ["However, current infection rates as well as CFR still have to be considered with caution.", [["infection", "DISEASE", 17, 26], ["current infection rates", "PROBLEM", 9, 32], ["CFR", "TEST", 44, 47], ["infection", "OBSERVATION", 17, 26]]], ["68 Risk for severe disease and death is strongly associated with older age (in particular >70 years), cardiovascular disease, diabetes, obesity, chronic respiratory disease, hypertension, and cancer.", [["cardiovascular", "ANATOMY", 102, 116], ["respiratory", "ANATOMY", 153, 164], ["cancer", "ANATOMY", 192, 198], ["death", "DISEASE", 31, 36], ["cardiovascular disease", "DISEASE", 102, 124], ["diabetes", "DISEASE", 126, 134], ["obesity", "DISEASE", 136, 143], ["chronic respiratory disease", "DISEASE", 145, 172], ["hypertension", "DISEASE", 174, 186], ["cancer", "DISEASE", 192, 198], ["cancer", "CANCER", 192, 198], ["severe disease", "PROBLEM", 12, 26], ["death", "PROBLEM", 31, 36], ["cardiovascular disease", "PROBLEM", 102, 124], ["diabetes", "PROBLEM", 126, 134], ["obesity", "PROBLEM", 136, 143], ["chronic respiratory disease", "PROBLEM", 145, 172], ["hypertension", "PROBLEM", 174, 186], ["cancer", "PROBLEM", 192, 198], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["disease", "OBSERVATION", 19, 26], ["cardiovascular", "ANATOMY", 102, 116], ["disease", "OBSERVATION", 117, 124], ["diabetes", "OBSERVATION", 126, 134], ["obesity", "OBSERVATION", 136, 143], ["chronic", "OBSERVATION_MODIFIER", 145, 152], ["respiratory disease", "OBSERVATION", 153, 172], ["hypertension", "OBSERVATION", 174, 186], ["cancer", "OBSERVATION", 192, 198]]], ["[68] [69] [70] Laboratory predictors for severe and fatal disease predominantly include elevated lactate dehydrogenase, pro-calcitonin, and D-dimers, increased serum levels of cytokines IL-6, IL-10 and tumor necrosis factor-\u03b1 (TNF-\u03b1), as well as decreased lymphocyte counts, particularly CD8+ T and NK cells.", [["serum", "ANATOMY", 160, 165], ["lymphocyte", "ANATOMY", 256, 266], ["CD8+ T", "ANATOMY", 288, 294], ["NK cells", "ANATOMY", 299, 307], ["lactate", "CHEMICAL", 97, 104], ["necrosis", "DISEASE", 208, 216], ["lactate", "CHEMICAL", 97, 104], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 97, 118], ["pro-calcitonin", "SIMPLE_CHEMICAL", 120, 134], ["D-dimers", "SIMPLE_CHEMICAL", 140, 148], ["serum", "ORGANISM_SUBSTANCE", 160, 165], ["IL-6", "GENE_OR_GENE_PRODUCT", 186, 190], ["IL-10", "GENE_OR_GENE_PRODUCT", 192, 197], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 202, 225], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 227, 232], ["lymphocyte", "CELL", 256, 266], ["CD8", "GENE_OR_GENE_PRODUCT", 288, 291], ["NK cells", "CELL", 299, 307], ["lactate dehydrogenase", "PROTEIN", 97, 118], ["pro-calcitonin", "PROTEIN", 120, 134], ["cytokines", "PROTEIN", 176, 185], ["IL-6", "PROTEIN", 186, 190], ["IL-10", "PROTEIN", 192, 197], ["tumor necrosis factor-\u03b1", "PROTEIN", 202, 225], ["TNF", "PROTEIN", 227, 230], ["CD8+ T and NK cells", "CELL_TYPE", 288, 307], ["Laboratory predictors", "TEST", 15, 36], ["severe and fatal disease", "PROBLEM", 41, 65], ["elevated lactate dehydrogenase", "PROBLEM", 88, 118], ["pro-calcitonin", "TEST", 120, 134], ["D-dimers", "PROBLEM", 140, 148], ["increased serum levels", "PROBLEM", 150, 172], ["cytokines IL", "TEST", 176, 188], ["IL", "TEST", 192, 194], ["tumor necrosis factor", "PROBLEM", 202, 223], ["TNF", "TEST", 227, 230], ["decreased lymphocyte counts", "PROBLEM", 246, 273], ["CD8", "TEST", 288, 291], ["fatal disease", "OBSERVATION", 52, 65], ["elevated", "OBSERVATION_MODIFIER", 88, 96], ["lactate dehydrogenase", "OBSERVATION", 97, 118], ["tumor", "OBSERVATION_MODIFIER", 202, 207], ["necrosis", "OBSERVATION", 208, 216], ["decreased lymphocyte counts", "OBSERVATION", 246, 273], ["NK cells", "OBSERVATION", 299, 307]]], ["[69] [70] [71] [72] Indeed, Biao et al 71 recently demonstrated that the number of total T lymphocytes in the peripheral blood was significantly decreased in patients with COVID-19.", [["T lymphocytes", "ANATOMY", 89, 102], ["peripheral blood", "ANATOMY", 110, 126], ["T lymphocytes", "CELL", 89, 102], ["peripheral blood", "ORGANISM_SUBSTANCE", 110, 126], ["patients", "ORGANISM", 158, 166], ["T lymphocytes", "CELL_TYPE", 89, 102], ["patients", "SPECIES", 158, 166], ["Biao et al", "TEST", 28, 38], ["total T lymphocytes", "TEST", 83, 102], ["the peripheral blood", "TEST", 106, 126], ["COVID", "TEST", 172, 177], ["peripheral", "ANATOMY_MODIFIER", 110, 120], ["blood", "ANATOMY", 121, 126], ["significantly", "OBSERVATION_MODIFIER", 131, 144], ["decreased", "OBSERVATION_MODIFIER", 145, 154]]], ["This was particularly pronounced in older patients and in patients who needed intensive care unit (ICU) treatment.", [["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 58, 66], ["ICU) treatment", "TREATMENT", 99, 113], ["pronounced", "OBSERVATION_MODIFIER", 22, 32]]], ["Importantly, lymphopenia was negatively associated with patient survival.", [["lymphopenia", "DISEASE", 13, 24], ["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["lymphopenia", "PROBLEM", 13, 24], ["lymphopenia", "OBSERVATION", 13, 24]]], ["Biao et al [69] [70] [71] also showed that T cell counts of patients who recovered increased, while IL-6, IL-10 and TNF-\u03b1 levels decreased.", [["T cell", "ANATOMY", 43, 49], ["T cell", "CELL", 43, 49], ["patients", "ORGANISM", 60, 68], ["IL-6", "GENE_OR_GENE_PRODUCT", 100, 104], ["IL-10", "GENE_OR_GENE_PRODUCT", 106, 111], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 116, 121], ["TNF", "PROTEIN", 116, 119], ["patients", "SPECIES", 60, 68], ["T cell counts", "TEST", 43, 56], ["IL", "TEST", 100, 102], ["IL", "TEST", 106, 108], ["TNF", "TEST", 116, 119]]], ["71 Since the cytokine increases were paralleled by a decrease in lymphocytes, Diao et al 71 speculated that elevated proinflammatory cytokines may promote the reduction of T lymphocytes in patients with COVID-19.", [["lymphocytes", "ANATOMY", 65, 76], ["T lymphocytes", "ANATOMY", 172, 185], ["reduction of T lymphocytes", "DISEASE", 159, 185], ["lymphocytes", "CELL", 65, 76], ["T lymphocytes", "CELL", 172, 185], ["patients", "ORGANISM", 189, 197], ["cytokine", "PROTEIN", 13, 21], ["lymphocytes", "CELL_TYPE", 65, 76], ["proinflammatory cytokines", "PROTEIN", 117, 142], ["T lymphocytes", "CELL_TYPE", 172, 185], ["patients", "SPECIES", 189, 197], ["the cytokine increases", "PROBLEM", 9, 31], ["a decrease in lymphocytes", "PROBLEM", 51, 76], ["elevated proinflammatory cytokines", "PROBLEM", 108, 142], ["the reduction of T lymphocytes", "PROBLEM", 155, 185], ["COVID", "TEST", 203, 208], ["decrease", "OBSERVATION_MODIFIER", 53, 61], ["lymphocytes", "ANATOMY", 65, 76], ["elevated", "OBSERVATION_MODIFIER", 108, 116], ["proinflammatory cytokines", "OBSERVATION", 117, 142], ["reduction", "OBSERVATION_MODIFIER", 159, 168], ["T lymphocytes", "OBSERVATION", 172, 185]]], ["However, this observation has to be substantiated in future studies.", [["future studies", "TEST", 53, 67]]], ["71 Additionally, as assessed by flow cytometry of peripheral blood, T cells of severely affected patients are characterized by a much higher PD-1 expression than healthy controls.", [["peripheral blood", "ANATOMY", 50, 66], ["T cells", "ANATOMY", 68, 75], ["peripheral blood", "ORGANISM_SUBSTANCE", 50, 66], ["T cells", "CELL", 68, 75], ["patients", "ORGANISM", 97, 105], ["PD-1", "GENE_OR_GENE_PRODUCT", 141, 145], ["T cells", "CELL_TYPE", 68, 75], ["patients", "SPECIES", 97, 105], ["flow cytometry", "TEST", 32, 46], ["peripheral blood", "TEST", 50, 66], ["severely affected patients", "PROBLEM", 79, 105], ["peripheral", "ANATOMY_MODIFIER", 50, 60], ["blood", "ANATOMY", 61, 66]]], ["71 Specifically, enhanced PD-1 and Tim-3 expression on T cells was observed when patients progressed from prodromal to symptomatic stages, indicating that T lymphocyte exhaustion-similar to other viral infections-is a hallmark of COVID-19 as well.", [["T cells", "ANATOMY", 55, 62], ["T lymphocyte", "ANATOMY", 155, 167], ["viral infections", "DISEASE", 196, 212], ["PD-1", "GENE_OR_GENE_PRODUCT", 26, 30], ["Tim-3", "GENE_OR_GENE_PRODUCT", 35, 40], ["T cells", "CELL", 55, 62], ["patients", "ORGANISM", 81, 89], ["T lymphocyte", "CELL", 155, 167], ["T cells", "CELL_TYPE", 55, 62], ["patients", "SPECIES", 81, 89], ["enhanced PD", "TEST", 17, 28], ["Tim", "TEST", 35, 38], ["prodromal to symptomatic stages", "PROBLEM", 106, 137], ["T lymphocyte exhaustion", "PROBLEM", 155, 178], ["other viral infections", "PROBLEM", 190, 212], ["COVID", "TEST", 230, 235], ["lymphocyte exhaustion", "OBSERVATION", 157, 178], ["viral", "OBSERVATION_MODIFIER", 196, 201], ["infections", "OBSERVATION", 202, 212]]], ["The expression of critical inhibitory checkpoint proteins of T cell exhaustion, including PD-1 and Tim-3, and the increase of TNF-\u03b1, IL-10 and other cytokines (which actually all may modulate the expression of PD-1 and Tim-3) are likely to mediate T cell lymphopenia in patients with COVID-19 through programmed cell death.", [["T cell", "ANATOMY", 61, 67], ["T cell", "ANATOMY", 248, 254], ["cell", "ANATOMY", 312, 316], ["lymphopenia", "DISEASE", 255, 266], ["COVID-19", "CHEMICAL", 284, 292], ["death", "DISEASE", 317, 322], ["T cell", "CELL", 61, 67], ["PD-1", "GENE_OR_GENE_PRODUCT", 90, 94], ["Tim-3", "GENE_OR_GENE_PRODUCT", 99, 104], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 126, 131], ["IL-10", "GENE_OR_GENE_PRODUCT", 133, 138], ["PD-1", "GENE_OR_GENE_PRODUCT", 210, 214], ["Tim-3", "GENE_OR_GENE_PRODUCT", 219, 224], ["T cell", "CELL", 248, 254], ["patients", "ORGANISM", 270, 278], ["cell", "CELL", 312, 316], ["inhibitory checkpoint proteins", "PROTEIN", 27, 57], ["Tim-3", "PROTEIN", 99, 104], ["TNF", "PROTEIN", 126, 129], ["IL-10", "PROTEIN", 133, 138], ["cytokines", "PROTEIN", 149, 158], ["Tim", "PROTEIN", 219, 222], ["patients", "SPECIES", 270, 278], ["T cell exhaustion", "PROBLEM", 61, 78], ["PD", "TEST", 90, 92], ["Tim", "TEST", 99, 102], ["TNF", "TEST", 126, 129], ["IL", "TEST", 133, 135], ["other cytokines", "PROBLEM", 143, 158], ["PD", "TEST", 210, 212], ["T cell lymphopenia", "PROBLEM", 248, 266], ["COVID", "TEST", 284, 289], ["programmed cell death", "PROBLEM", 301, 322], ["cell exhaustion", "OBSERVATION", 63, 78], ["increase", "OBSERVATION_MODIFIER", 114, 122], ["likely to mediate", "UNCERTAINTY", 230, 247], ["T cell lymphopenia", "OBSERVATION", 248, 266], ["cell death", "OBSERVATION", 312, 322]]], ["73 To date, very limited data are available addressing the clinical outcome of ICI-treated cancer patients also suffering from COVID-19 infection.", [["cancer", "ANATOMY", 91, 97], ["ICI", "CHEMICAL", 79, 82], ["cancer", "DISEASE", 91, 97], ["COVID-19", "CHEMICAL", 127, 135], ["infection", "DISEASE", 136, 145], ["ICI", "CHEMICAL", 79, 82], ["ICI", "SIMPLE_CHEMICAL", 79, 82], ["cancer", "CANCER", 91, 97], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["COVID-19 infection", "PROBLEM", 127, 145], ["infection", "OBSERVATION", 136, 145]]], ["[74] [75] [76] [77] The blockade of PD-1+ on CD8+ lymphocytes by ICI treatment might be reasonable in patients with COVID-19 in order to abrogate functional T cell exhaustion and restore vigorous T lymphocytic cytotoxicity against both the tumor and the viral antigens.", [["CD8+ lymphocytes", "ANATOMY", 45, 61], ["T cell", "ANATOMY", 157, 163], ["T lymphocytic", "ANATOMY", 196, 209], ["tumor", "ANATOMY", 240, 245], ["ICI", "CHEMICAL", 65, 68], ["COVID-19", "CHEMICAL", 116, 124], ["tumor", "DISEASE", 240, 245], ["ICI", "CHEMICAL", 65, 68], ["COVID-19", "CHEMICAL", 116, 124], ["[74] [75] [76] [77]", "SIMPLE_CHEMICAL", 0, 19], ["PD-1", "GENE_OR_GENE_PRODUCT", 36, 40], ["CD8", "GENE_OR_GENE_PRODUCT", 45, 48], ["ICI", "SIMPLE_CHEMICAL", 65, 68], ["patients", "ORGANISM", 102, 110], ["T cell", "CELL", 157, 163], ["T lymphocytic", "CANCER", 196, 209], ["tumor", "CANCER", 240, 245], ["CD8", "PROTEIN", 45, 48], ["lymphocytes", "CELL_TYPE", 50, 61], ["viral antigens", "PROTEIN", 254, 268], ["patients", "SPECIES", 102, 110], ["PD", "TEST", 36, 38], ["CD8", "TEST", 45, 48], ["lymphocytes", "PROBLEM", 50, 61], ["ICI treatment", "TREATMENT", 65, 78], ["COVID", "TEST", 116, 121], ["functional T cell exhaustion", "PROBLEM", 146, 174], ["vigorous T lymphocytic cytotoxicity", "PROBLEM", 187, 222], ["the tumor", "PROBLEM", 236, 245], ["the viral antigens", "PROBLEM", 250, 268], ["cell exhaustion", "OBSERVATION", 159, 174], ["tumor", "OBSERVATION", 240, 245], ["viral antigens", "OBSERVATION", 254, 268]]], ["However, as discussed by Chiappelli et al, 75 this may work only at the initial and intermediate stage when PD-1 expression on cytotoxic T cells ranges between low and medium levels.", [["cytotoxic T cells", "ANATOMY", 127, 144], ["PD-1", "GENE_OR_GENE_PRODUCT", 108, 112], ["cytotoxic T cells", "CELL", 127, 144], ["cytotoxic T cells", "CELL_TYPE", 127, 144], ["PD", "TEST", 108, 110], ["cytotoxic T cells", "TEST", 127, 144], ["medium levels", "OBSERVATION_MODIFIER", 168, 181]]], ["At the more advanced stage, when PD-1 expression is high on CD8+ T lymphocytes, T lymphocyte exhaustion is likely irreversible, and thus, ICI will no longer have an effect.", [["CD8+", "ANATOMY", 60, 64], ["T lymphocytes", "ANATOMY", 65, 78], ["T lymphocyte", "ANATOMY", 80, 92], ["ICI", "CHEMICAL", 138, 141], ["ICI", "CHEMICAL", 138, 141], ["PD-1", "GENE_OR_GENE_PRODUCT", 33, 37], ["CD8", "GENE_OR_GENE_PRODUCT", 60, 63], ["T lymphocytes", "CELL", 65, 78], ["T lymphocyte", "CELL", 80, 92], ["ICI", "SIMPLE_CHEMICAL", 138, 141], ["CD8", "PROTEIN", 60, 63], ["T lymphocytes", "CELL_TYPE", 65, 78], ["T lymphocyte", "CELL_TYPE", 80, 92], ["PD", "TEST", 33, 35], ["T lymphocyte exhaustion", "PROBLEM", 80, 103], ["ICI", "TREATMENT", 138, 141], ["lymphocytes", "ANATOMY", 67, 78], ["lymphocyte exhaustion", "OBSERVATION", 82, 103], ["likely", "UNCERTAINTY", 107, 113], ["irreversible", "OBSERVATION_MODIFIER", 114, 126]]], ["75 The excess of cytokines is also of great significance with respect to the cytokine release syndrome (CRS, 'cytokine storm'), a phenomenon of massive inflammatory reaction, where cytokines (eg, IL-6, IL-10, TNF-\u03b1) are rapidly produced in large amounts in response to infectious agents.", [["CRS", "DISEASE", 104, 107], ["IL-6", "GENE_OR_GENE_PRODUCT", 196, 200], ["IL-10", "GENE_OR_GENE_PRODUCT", 202, 207], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 209, 214], ["cytokines", "PROTEIN", 17, 26], ["cytokine", "PROTEIN", 77, 85], ["cytokine", "PROTEIN", 110, 118], ["cytokines", "PROTEIN", 181, 190], ["IL-10", "PROTEIN", 202, 207], ["TNF", "PROTEIN", 209, 212], ["the cytokine release syndrome", "PROBLEM", 73, 102], ["CRS", "PROBLEM", 104, 107], ["massive inflammatory reaction", "PROBLEM", 144, 173], ["cytokines (eg", "TREATMENT", 181, 194], ["IL", "TEST", 196, 198], ["IL", "TEST", 202, 204], ["infectious agents", "TREATMENT", 269, 286], ["cytokines", "OBSERVATION", 17, 26], ["massive", "OBSERVATION_MODIFIER", 144, 151], ["inflammatory reaction", "OBSERVATION", 152, 173], ["large", "OBSERVATION_MODIFIER", 240, 245], ["amounts", "OBSERVATION_MODIFIER", 246, 253], ["infectious agents", "OBSERVATION", 269, 286]]], ["71 Similar to SARS-COV and the Middle East respiratory syndrome (MERS-COV), SARS-COV-2 is associated with increased amounts of proinflammatory cytokines in the serum, which are suspected to cause pulmonary inflammation and extensive lung damage.", [["serum", "ANATOMY", 160, 165], ["pulmonary", "ANATOMY", 196, 205], ["lung", "ANATOMY", 233, 237], ["SARS-COV", "DISEASE", 14, 22], ["respiratory syndrome", "DISEASE", 43, 63], ["SARS", "DISEASE", 76, 80], ["pulmonary inflammation", "DISEASE", 196, 218], ["lung damage", "DISEASE", 233, 244], ["COV-2", "CELL", 81, 86], ["serum", "ORGANISM_SUBSTANCE", 160, 165], ["pulmonary", "ORGAN", 196, 205], ["lung", "ORGAN", 233, 237], ["proinflammatory cytokines", "PROTEIN", 127, 152], ["Middle East respiratory syndrome (MERS-COV", "SPECIES", 31, 73], ["SARS", "PROBLEM", 14, 18], ["COV", "PROBLEM", 19, 22], ["the Middle East respiratory syndrome", "PROBLEM", 27, 63], ["SARS", "PROBLEM", 76, 80], ["proinflammatory cytokines in the serum", "PROBLEM", 127, 165], ["pulmonary inflammation", "PROBLEM", 196, 218], ["extensive lung damage", "PROBLEM", 223, 244], ["SARS", "OBSERVATION", 14, 18], ["Middle", "ANATOMY_MODIFIER", 31, 37], ["respiratory syndrome", "OBSERVATION", 43, 63], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["amounts", "OBSERVATION_MODIFIER", 116, 123], ["proinflammatory cytokines", "OBSERVATION", 127, 152], ["suspected to cause", "UNCERTAINTY", 177, 195], ["pulmonary", "ANATOMY", 196, 205], ["inflammation", "OBSERVATION", 206, 218], ["extensive", "OBSERVATION_MODIFIER", 223, 232], ["lung", "ANATOMY", 233, 237], ["damage", "OBSERVATION", 238, 244]]], ["72 However, unlike SARS-COV and MERS-COV, SARS-COV-2 infection appears to be associated with the activation of both T helper 1 (Th-1) and Th-2 lymphocytes.", [["Th-2 lymphocytes", "ANATOMY", 138, 154], ["SARS", "DISEASE", 42, 46], ["infection", "DISEASE", 53, 62], ["MERS-COV", "GENE_OR_GENE_PRODUCT", 32, 40], ["COV-2", "CELL", 47, 52], ["T helper 1", "GENE_OR_GENE_PRODUCT", 116, 126], ["Th-1", "GENE_OR_GENE_PRODUCT", 128, 132], ["Th-2 lymphocytes", "CELL", 138, 154], ["T helper 1 (Th-1) and Th-2 lymphocytes", "CELL_TYPE", 116, 154], ["unlike SARS", "PROBLEM", 12, 23], ["MERS", "PROBLEM", 32, 36], ["COV", "PROBLEM", 37, 40], ["SARS", "PROBLEM", 42, 46], ["COV-2 infection", "PROBLEM", 47, 62], ["SARS", "OBSERVATION", 19, 23], ["lymphocytes", "ANATOMY", 143, 154]]], ["SARS-COV-2 predominantly targets epithelial cells of the respiratory tract, leading to severe alveolar damage.", [["epithelial cells", "ANATOMY", 33, 49], ["respiratory tract", "ANATOMY", 57, 74], ["alveolar", "ANATOMY", 94, 102], ["SARS", "DISEASE", 0, 4], ["alveolar damage", "DISEASE", 94, 109], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["epithelial cells", "CELL", 33, 49], ["respiratory tract", "ORGANISM_SUBDIVISION", 57, 74], ["alveolar", "TISSUE", 94, 102], ["SARS-COV-2", "DNA", 0, 10], ["epithelial cells", "CELL_TYPE", 33, 49], ["SARS", "TEST", 0, 4], ["epithelial cells of the respiratory tract", "PROBLEM", 33, 74], ["severe alveolar damage", "PROBLEM", 87, 109], ["epithelial cells", "OBSERVATION", 33, 49], ["respiratory tract", "ANATOMY", 57, 74], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["alveolar", "ANATOMY_MODIFIER", 94, 102], ["damage", "OBSERVATION", 103, 109]]], ["However, COVID-19 also shows evidence for changes in the lung stroma, suggesting that also pulmonary fibrosis is induced at some time point.", [["lung stroma", "ANATOMY", 57, 68], ["pulmonary", "ANATOMY", 91, 100], ["pulmonary fibrosis", "DISEASE", 91, 109], ["COVID-19", "CHEMICAL", 9, 17], ["lung stroma", "TISSUE", 57, 68], ["pulmonary", "ORGAN", 91, 100], ["COVID-19", "DNA", 9, 17], ["COVID", "TEST", 9, 14], ["changes in the lung stroma", "PROBLEM", 42, 68], ["pulmonary fibrosis", "PROBLEM", 91, 109], ["evidence for", "UNCERTAINTY", 29, 41], ["lung", "ANATOMY", 57, 61], ["stroma", "OBSERVATION", 62, 68], ["pulmonary", "ANATOMY", 91, 100], ["fibrosis", "OBSERVATION", 101, 109]]], ["58 Moreover, similar to SARS-COV and MERS-COV, SARS-COV-2 may also pose the risk of autoimmunity due to cross-reactivity of the induced immune reaction to both viral (eg, spike surface proteins) and host protein epitopes.", [["surface", "ANATOMY", 177, 184], ["SARS", "DISEASE", 24, 28], ["SARS", "DISEASE", 47, 51], ["autoimmunity", "DISEASE", 84, 96], ["MERS-COV", "GENE_OR_GENE_PRODUCT", 37, 45], ["SARS-COV-2", "CELL", 47, 57], ["spike surface proteins", "GENE_OR_GENE_PRODUCT", 171, 193], ["viral (eg, spike surface proteins", "PROTEIN", 160, 193], ["host protein epitopes", "PROTEIN", 199, 220], ["SARS", "PROBLEM", 24, 28], ["MERS", "PROBLEM", 37, 41], ["COV", "PROBLEM", 42, 45], ["SARS", "PROBLEM", 47, 51], ["autoimmunity", "PROBLEM", 84, 96], ["cross-reactivity", "PROBLEM", 104, 120], ["the induced immune reaction", "PROBLEM", 124, 151], ["both viral (eg", "PROBLEM", 155, 169], ["spike surface proteins", "PROBLEM", 171, 193], ["host protein epitopes", "PROBLEM", 199, 220]]], ["Lyons-Weiler 58 recently hypothesized that based on homology with human proteins, such pathogenic priming involving autoimmunity might also occur with SARS-COV-2.", [["autoimmunity", "DISEASE", 116, 128], ["human", "ORGANISM", 66, 71], ["human proteins", "PROTEIN", 66, 80], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71], ["human proteins", "TREATMENT", 66, 80], ["autoimmunity", "PROBLEM", 116, 128]]], ["Similar to the results of previous SARS-COV animal experiments, Agrawall et al 78 reported that mice vaccinated against MERS-COV developed severe Th-2driven immunopathologies in the lung following postvaccination MERS-COV challenge.", [["lung", "ANATOMY", 182, 186], ["SARS", "DISEASE", 35, 39], ["mice", "ORGANISM", 96, 100], ["MERS-COV", "ORGANISM", 120, 128], ["lung", "ORGAN", 182, 186], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 96, 100], ["previous SARS", "TEST", 26, 39], ["MERS", "PROBLEM", 120, 124], ["COV", "PROBLEM", 125, 128], ["severe Th-2driven immunopathologies in the lung", "PROBLEM", 139, 186], ["COV challenge", "TREATMENT", 218, 231], ["severe", "OBSERVATION_MODIFIER", 139, 145], ["lung", "ANATOMY", 182, 186]]], ["58 78 Given the data existing so far on possible autoimmunity particular in the advanced stage of COVID-19, the administration of ICI could pose the risk of immune overactivation and aggravation of autoimmune processes.COVID-19Similar to the 'cytokine storm' observed in patients with advanced COVID-19, CRS has been observed in rare cases as irAEs in patients receiving ICI.", [["autoimmunity", "DISEASE", 49, 61], ["ICI", "CHEMICAL", 130, 133], ["CRS", "DISEASE", 304, 307], ["irAEs", "DISEASE", 343, 348], ["ICI", "CHEMICAL", 371, 374], ["ICI", "CHEMICAL", 130, 133], ["ICI", "CHEMICAL", 371, 374], ["COVID-19", "CELL", 98, 106], ["ICI", "SIMPLE_CHEMICAL", 130, 133], ["COVID-19Similar", "GENE_OR_GENE_PRODUCT", 219, 234], ["patients", "ORGANISM", 271, 279], ["patients", "ORGANISM", 352, 360], ["ICI", "SIMPLE_CHEMICAL", 371, 374], ["COVID", "PROTEIN", 219, 224], ["cytokine", "PROTEIN", 243, 251], ["patients", "SPECIES", 271, 279], ["patients", "SPECIES", 352, 360], ["autoimmunity", "PROBLEM", 49, 61], ["COVID", "TEST", 98, 103], ["ICI", "TREATMENT", 130, 133], ["immune overactivation", "PROBLEM", 157, 178], ["aggravation of autoimmune processes", "PROBLEM", 183, 218], ["COVID", "TEST", 219, 224], ["the 'cytokine storm", "TREATMENT", 238, 257], ["advanced COVID", "TEST", 285, 299], ["CRS", "PROBLEM", 304, 307], ["ICI", "TREATMENT", 371, 374], ["immune overactivation", "OBSERVATION", 157, 178], ["autoimmune", "OBSERVATION", 198, 208]]], ["79 80 Furthermore, one of the observed irAE of anti-PD-1-based ICI is autoimmune pneumonitis, which may occur in up to 5% of all treated patients.", [["anti-PD-1", "CHEMICAL", 47, 56], ["ICI", "CHEMICAL", 63, 66], ["autoimmune pneumonitis", "DISEASE", 70, 92], ["ICI", "CHEMICAL", 63, 66], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 47, 56], ["ICI", "SIMPLE_CHEMICAL", 63, 66], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["anti-PD", "TEST", 47, 54], ["autoimmune pneumonitis", "PROBLEM", 70, 92], ["autoimmune", "OBSERVATION_MODIFIER", 70, 80], ["pneumonitis", "OBSERVATION", 81, 92]]], ["[79] [80] [81] Patients with non-small Open access cell lung cancer treated with ICI may even experience autoimmune pneumonitis in up to 20% of cases.", [["non-small Open access cell lung cancer", "ANATOMY", 29, 67], ["Open access cell lung cancer", "DISEASE", 39, 67], ["ICI", "CHEMICAL", 81, 84], ["autoimmune pneumonitis", "DISEASE", 105, 127], ["ICI", "CHEMICAL", 81, 84], ["Patients", "ORGANISM", 15, 23], ["non-small Open access cell lung cancer", "CANCER", 29, 67], ["ICI", "SIMPLE_CHEMICAL", 81, 84], ["Patients", "SPECIES", 15, 23], ["non-small Open access cell lung cancer", "PROBLEM", 29, 67], ["ICI", "TREATMENT", 81, 84], ["autoimmune pneumonitis", "PROBLEM", 105, 127], ["non-small", "OBSERVATION_MODIFIER", 29, 38], ["Open", "OBSERVATION_MODIFIER", 39, 43], ["access cell", "OBSERVATION", 44, 55], ["lung", "ANATOMY", 56, 60], ["cancer", "OBSERVATION", 61, 67], ["autoimmune", "OBSERVATION_MODIFIER", 105, 115], ["pneumonitis", "OBSERVATION", 116, 127]]], ["81 Since the clinical symptoms and radiographic findings in irAEinduced pneumonitis are similar to those of COVID-19 pneumonitis, it may be in some cases difficult to arrive at proper diagnostic conclusions as the basis for appropriate management.", [["pneumonitis", "DISEASE", 72, 83], ["pneumonitis", "DISEASE", 117, 128], ["the clinical symptoms", "PROBLEM", 9, 30], ["radiographic findings", "TEST", 35, 56], ["irAEinduced pneumonitis", "PROBLEM", 60, 83], ["COVID-19 pneumonitis", "PROBLEM", 108, 128], ["appropriate management", "TREATMENT", 224, 246], ["pneumonitis", "OBSERVATION", 72, 83], ["pneumonitis", "OBSERVATION", 117, 128]]], ["The occurrence of irAEs frequently necessitates the use of systemic corticosteroids or other immunosuppressive/immunomodulating agents such as mycophenolate acid or TNF-\u03b1 blockers.", [["irAEs", "DISEASE", 18, 23], ["mycophenolate acid", "CHEMICAL", 143, 161], ["mycophenolate acid", "CHEMICAL", 143, 161], ["mycophenolate acid", "SIMPLE_CHEMICAL", 143, 161], ["TNF-\u03b1 blockers", "SIMPLE_CHEMICAL", 165, 179], ["TNF", "PROTEIN", 165, 168], ["irAEs", "PROBLEM", 18, 23], ["systemic corticosteroids", "TREATMENT", 59, 83], ["other immunosuppressive", "TREATMENT", 87, 110], ["immunomodulating agents", "TREATMENT", 111, 134], ["mycophenolate acid", "TREATMENT", 143, 161], ["TNF", "TREATMENT", 165, 168], ["\u03b1 blockers", "TREATMENT", 169, 179], ["irAEs", "OBSERVATION", 18, 23]]], ["Whether the use of systemic corticosteroids is harmful in the setting of COVID-19 is unclear.", [["corticosteroids", "CHEMICAL", 28, 43], ["COVID-19", "CHEMICAL", 73, 81], ["corticosteroids", "CHEMICAL", 28, 43], ["COVID-19", "CHEMICAL", 73, 81], ["systemic corticosteroids", "TREATMENT", 19, 43], ["COVID", "TEST", 73, 78]]], ["The use of glucocorticoids in patients with SARS-COV-associated and MERS-COVassociated pneumonitis is still controversial because of divergent clinical outcomes reported in the existing literature.", [["glucocorticoids", "CHEMICAL", 11, 26], ["SARS-COV", "DISEASE", 44, 52], ["pneumonitis", "DISEASE", 87, 98], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["glucocorticoids", "TREATMENT", 11, 26], ["SARS", "PROBLEM", 44, 48], ["COV", "PROBLEM", 49, 52], ["MERS", "PROBLEM", 68, 72], ["COVassociated pneumonitis", "PROBLEM", 73, 98], ["divergent clinical outcomes", "PROBLEM", 133, 160], ["glucocorticoids", "OBSERVATION", 11, 26], ["pneumonitis", "OBSERVATION", 87, 98]]], ["82 Still, high-dose glucocorticoids are one of the most frequently used adjuncts in acute respiratory distress syndrome, even though the effectiveness of steroids in the management of acute lung injury is ambiguous.", [["respiratory", "ANATOMY", 90, 101], ["lung", "ANATOMY", 190, 194], ["glucocorticoids", "CHEMICAL", 20, 35], ["respiratory distress syndrome", "DISEASE", 90, 119], ["steroids", "CHEMICAL", 154, 162], ["acute lung injury", "DISEASE", 184, 201], ["steroids", "CHEMICAL", 154, 162], ["steroids", "SIMPLE_CHEMICAL", 154, 162], ["lung", "ORGAN", 190, 194], ["high-dose glucocorticoids", "TREATMENT", 10, 35], ["acute respiratory distress syndrome", "PROBLEM", 84, 119], ["steroids", "TREATMENT", 154, 162], ["acute lung injury", "PROBLEM", 184, 201], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["respiratory distress syndrome", "OBSERVATION", 90, 119], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["lung", "ANATOMY", 190, 194], ["injury", "OBSERVATION", 195, 201]]], ["82 This is also true for COVID-19.", [["COVID-19", "CHEMICAL", 25, 33], ["COVID", "TEST", 25, 30]]], ["Nevertheless, it seems that early and short-time use of low-dose methylprednisolone may be one feasible approach in SARS-COV-2-related pneumonitis and respiratory distress syndrome.", [["respiratory", "ANATOMY", 151, 162], ["methylprednisolone", "CHEMICAL", 65, 83], ["SARS", "DISEASE", 116, 120], ["pneumonitis", "DISEASE", 135, 146], ["respiratory distress syndrome", "DISEASE", 151, 180], ["methylprednisolone", "CHEMICAL", 65, 83], ["methylprednisolone", "SIMPLE_CHEMICAL", 65, 83], ["low-dose methylprednisolone", "TREATMENT", 56, 83], ["SARS", "PROBLEM", 116, 120], ["COV", "TEST", 121, 124], ["pneumonitis", "PROBLEM", 135, 146], ["respiratory distress syndrome", "PROBLEM", 151, 180], ["pneumonitis", "OBSERVATION", 135, 146], ["respiratory", "OBSERVATION", 151, 162], ["distress syndrome", "OBSERVATION", 163, 180]]], ["83 Hence, possible ICI-induced irAEs could be safely managed with methylprednisolone in the setting of COVID-19.", [["ICI", "CHEMICAL", 19, 22], ["irAEs", "DISEASE", 31, 36], ["methylprednisolone", "CHEMICAL", 66, 84], ["ICI", "CHEMICAL", 19, 22], ["methylprednisolone", "CHEMICAL", 66, 84], ["COVID-19", "CHEMICAL", 103, 111], ["ICI", "SIMPLE_CHEMICAL", 19, 22], ["methylprednisolone", "SIMPLE_CHEMICAL", 66, 84], ["ICI-induced irAEs", "PROBLEM", 19, 36], ["methylprednisolone", "TREATMENT", 66, 84], ["COVID", "TEST", 103, 108]]], ["Based on the observation of cytokine excess (eg, TNF-\u03b1), during advanced stages of COVID-19, one may speculate that TNF-\u03b1 blockers such as infliximab may not only be beneficial for the management of ICI-induced irAEs, but also for COVID-19.", [["infliximab", "CHEMICAL", 139, 149], ["ICI", "CHEMICAL", 199, 202], ["irAEs", "DISEASE", 211, 216], ["COVID-19", "CHEMICAL", 83, 91], ["ICI", "CHEMICAL", 199, 202], ["COVID-19", "CHEMICAL", 231, 239], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 49, 54], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 116, 121], ["infliximab", "SIMPLE_CHEMICAL", 139, 149], ["ICI", "SIMPLE_CHEMICAL", 199, 202], ["irAEs", "PATHOLOGICAL_FORMATION", 211, 216], ["cytokine", "PROTEIN", 28, 36], ["TNF", "PROTEIN", 49, 52], ["TNF", "PROTEIN", 116, 119], ["cytokine excess", "PROBLEM", 28, 43], ["TNF", "TEST", 49, 52], ["COVID", "TEST", 83, 88], ["TNF-\u03b1 blockers", "TREATMENT", 116, 130], ["infliximab", "TREATMENT", 139, 149], ["ICI", "TREATMENT", 199, 202], ["COVID", "TEST", 231, 236]]], ["84 Notably, cytokine IL-6 antibodies (eg, tocilizumab) are currently under intense investigation in patients with COVID-19.", [["tocilizumab", "CHEMICAL", 42, 53], ["IL-6 antibodies", "GENE_OR_GENE_PRODUCT", 21, 36], ["tocilizumab", "SIMPLE_CHEMICAL", 42, 53], ["patients", "ORGANISM", 100, 108], ["cytokine IL-6 antibodies", "PROTEIN", 12, 36], ["patients", "SPECIES", 100, 108], ["cytokine IL", "TEST", 12, 23], ["tocilizumab", "TREATMENT", 42, 53], ["COVID", "TEST", 114, 119]]], ["Tocilizumab is already approved in the USA to manage CRS occurring after chimeric antigen receptor T cell treatment.", [["T cell", "ANATOMY", 99, 105], ["Tocilizumab", "CHEMICAL", 0, 11], ["CRS", "DISEASE", 53, 56], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["Tocilizumab", "TREATMENT", 0, 11], ["CRS", "PROBLEM", 53, 56], ["chimeric antigen receptor T cell treatment", "TREATMENT", 73, 115]]], ["82 Notably, it has been demonstrated that tocilizumab is effective in the management of irAEs occurring in ICI-treated patients who are refractory to corticosteroids.", [["tocilizumab", "CHEMICAL", 42, 53], ["irAEs", "DISEASE", 88, 93], ["ICI", "CHEMICAL", 107, 110], ["ICI", "CHEMICAL", 107, 110], ["corticosteroids", "CHEMICAL", 150, 165], ["tocilizumab", "SIMPLE_CHEMICAL", 42, 53], ["irAEs", "CANCER", 88, 93], ["ICI", "SIMPLE_CHEMICAL", 107, 110], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["tocilizumab", "TREATMENT", 42, 53], ["irAEs", "PROBLEM", 88, 93], ["corticosteroids", "TREATMENT", 150, 165], ["tocilizumab", "OBSERVATION", 42, 53]]], ["82 Furthermore, there is currently an ongoing phase II trial investigating a combination of tocilizumab with anti-PD-1/CTLA-4 therapy in order to diminish irAEs in unresectable stage III or stage IV melanoma patients (NCT03999749).", [["unresectable stage III", "ANATOMY", 164, 186], ["melanoma", "ANATOMY", 199, 207], ["tocilizumab", "CHEMICAL", 92, 103], ["anti-PD-1/CTLA-4", "CHEMICAL", 109, 125], ["melanoma", "DISEASE", 199, 207], ["tocilizumab", "SIMPLE_CHEMICAL", 92, 103], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 109, 118], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 119, 125], ["stage IV melanoma", "CANCER", 190, 207], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216], ["tocilizumab", "TREATMENT", 92, 103], ["anti-PD", "TREATMENT", 109, 116], ["CTLA", "TREATMENT", 119, 123], ["therapy", "TREATMENT", 126, 133], ["unresectable stage III", "PROBLEM", 164, 186], ["stage IV melanoma", "PROBLEM", 190, 207], ["unresectable", "OBSERVATION_MODIFIER", 164, 176], ["stage III", "OBSERVATION_MODIFIER", 177, 186], ["stage IV", "OBSERVATION_MODIFIER", 190, 198], ["melanoma", "OBSERVATION", 199, 207]]], ["84 A novel approach to ICI in cancer and viral infections, particularly COVID-19, represents CD200 checkpoint reversal.", [["cancer", "ANATOMY", 30, 36], ["ICI", "CHEMICAL", 23, 26], ["cancer", "DISEASE", 30, 36], ["viral infections", "DISEASE", 41, 57], ["ICI", "CHEMICAL", 23, 26], ["ICI", "SIMPLE_CHEMICAL", 23, 26], ["cancer", "CANCER", 30, 36], ["CD200", "GENE_OR_GENE_PRODUCT", 93, 98], ["CD200", "PROTEIN", 93, 98], ["A novel approach to ICI", "TREATMENT", 3, 26], ["cancer", "PROBLEM", 30, 36], ["viral infections", "PROBLEM", 41, 57], ["COVID", "TEST", 72, 77], ["CD200 checkpoint reversal", "TREATMENT", 93, 118], ["cancer", "OBSERVATION", 30, 36], ["viral infections", "OBSERVATION", 41, 57], ["CD200 checkpoint reversal", "OBSERVATION", 93, 118]]], ["85 The CD200 immune checkpoint causes suppression of the secretion of proinflammatory cytokines, that is, IL-2 and IFN-\u04af, and enhances the production of myeloidderived suppressor cells and Tregs that are implicated in impaired antitumor and antiviral immune responses.", [["myeloidderived suppressor cells", "ANATOMY", 153, 184], ["Tregs", "ANATOMY", 189, 194], ["antitumor", "ANATOMY", 227, 236], ["CD200", "GENE_OR_GENE_PRODUCT", 7, 12], ["IL-2", "GENE_OR_GENE_PRODUCT", 106, 110], ["IFN-\u04af", "GENE_OR_GENE_PRODUCT", 115, 120], ["myeloidderived suppressor cells", "CELL", 153, 184], ["Tregs", "CELL", 189, 194], ["antitumor", "CANCER", 227, 236], ["CD200", "PROTEIN", 7, 12], ["proinflammatory cytokines", "PROTEIN", 70, 95], ["IFN", "PROTEIN", 115, 118], ["myeloidderived suppressor cells", "CELL_TYPE", 153, 184], ["Tregs", "CELL_TYPE", 189, 194], ["The CD200 immune checkpoint", "TREATMENT", 3, 30], ["the secretion of proinflammatory cytokines", "PROBLEM", 53, 95], ["IL", "TEST", 106, 108], ["IFN", "TEST", 115, 118], ["myeloidderived suppressor cells", "PROBLEM", 153, 184], ["impaired antitumor", "PROBLEM", 218, 236], ["proinflammatory cytokines", "OBSERVATION", 70, 95], ["suppressor cells", "OBSERVATION", 168, 184], ["impaired antitumor", "OBSERVATION", 218, 236]]], ["85 Anti-CD200 targeted treatments have shown promising effects in animal models accompanied by downregulation of inhibitory PD-1 receptors.", [["PD-1 receptors", "GENE_OR_GENE_PRODUCT", 124, 138], ["inhibitory PD-1 receptors", "PROTEIN", 113, 138], ["Anti-CD200 targeted treatments", "TREATMENT", 3, 33], ["inhibitory PD", "TREATMENT", 113, 126]]], ["85 In a murine coronavirus model, the checkpoint inhibitory CD200-CD200R1 system has been demonstrated to downregulate the single strand RNA virus sensor toll-like receptor seven in myeloid-derived cells and respective interventions restored IFN-\u04af levels resulting in enhanced virus elimination.", [["myeloid-derived cells", "ANATOMY", 182, 203], ["murine", "ORGANISM", 8, 14], ["CD200", "GENE_OR_GENE_PRODUCT", 60, 65], ["CD200R1", "GENE_OR_GENE_PRODUCT", 66, 73], ["toll-like receptor", "GENE_OR_GENE_PRODUCT", 154, 172], ["myeloid-derived cells", "CELL", 182, 203], ["IFN-\u04af", "GENE_OR_GENE_PRODUCT", 242, 247], ["CD200", "PROTEIN", 60, 65], ["CD200R1", "PROTEIN", 66, 73], ["toll-like receptor seven", "PROTEIN", 154, 178], ["myeloid-derived cells", "CELL_TYPE", 182, 203], ["IFN", "PROTEIN", 242, 245], ["murine", "SPECIES", 8, 14], ["murine coronavirus", "SPECIES", 8, 26], ["a murine coronavirus model", "TREATMENT", 6, 32], ["the checkpoint inhibitory CD200-CD200R1 system", "TREATMENT", 34, 80], ["respective interventions", "TREATMENT", 208, 232], ["IFN-\u04af levels", "TEST", 242, 254], ["enhanced virus elimination", "PROBLEM", 268, 294], ["myeloid", "ANATOMY", 182, 189]]], ["86 87 Together, experience and evidence are growing with regard to the use of ICI in patients with the novel infectious disease COVID-19.", [["ICI", "CHEMICAL", 78, 81], ["ICI", "CHEMICAL", 78, 81], ["ICI", "SIMPLE_CHEMICAL", 78, 81], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["ICI", "TREATMENT", 78, 81], ["the novel infectious disease COVID", "PROBLEM", 99, 133], ["infectious", "OBSERVATION", 109, 119]]], ["In comparison to chemotherapeutic regimens ICI cannot be considered immunosuppressive.", [["ICI", "CHEMICAL", 43, 46], ["ICI", "CHEMICAL", 43, 46], ["ICI", "SIMPLE_CHEMICAL", 43, 46], ["chemotherapeutic regimens ICI", "TREATMENT", 17, 46]]], ["Hematological irAEs caused by ICI are very infrequent, with only few cases reported.", [["irAEs", "DISEASE", 14, 19], ["ICI", "CHEMICAL", 30, 33], ["ICI", "CHEMICAL", 30, 33], ["ICI", "SIMPLE_CHEMICAL", 30, 33], ["Hematological irAEs", "PROBLEM", 0, 19]]], ["In a metaanalysis of 9324 patients, the frequency of neutropenia was smaller than 1%.", [["neutropenia", "DISEASE", 53, 64], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["neutropenia", "PROBLEM", 53, 64], ["neutropenia", "OBSERVATION", 53, 64]]], ["88 Previously reported reactivation of viral infections (ie, cytomegalovirus, hepatitis B) under ICI therapy were mostly observed following immunosuppressive treatment of irAEs.", [["viral infections", "DISEASE", 39, 55], ["cytomegalovirus, hepatitis B", "DISEASE", 61, 89], ["ICI", "CHEMICAL", 97, 100], ["ICI", "CHEMICAL", 97, 100], ["cytomegalovirus", "ORGANISM", 61, 76], ["hepatitis B", "ORGANISM", 78, 89], ["ICI", "SIMPLE_CHEMICAL", 97, 100], ["irAEs", "SIMPLE_CHEMICAL", 171, 176], ["viral infections", "PROBLEM", 39, 55], ["cytomegalovirus", "PROBLEM", 61, 76], ["hepatitis B", "TREATMENT", 78, 89], ["ICI therapy", "TREATMENT", 97, 108], ["immunosuppressive treatment", "TREATMENT", 140, 167], ["irAEs", "PROBLEM", 171, 176], ["reactivation", "OBSERVATION_MODIFIER", 23, 35], ["viral infections", "OBSERVATION", 39, 55]]], ["Hence, it does not appear reasonable to assume that patients undergoing ICI are at higher risk of becoming infected by SARS-COV-2 or other infectious agents compared with patients without ICI treatment.", [["ICI", "CHEMICAL", 72, 75], ["SARS", "DISEASE", 119, 123], ["ICI", "CHEMICAL", 188, 191], ["ICI", "CHEMICAL", 72, 75], ["ICI", "CHEMICAL", 188, 191], ["patients", "ORGANISM", 52, 60], ["ICI", "SIMPLE_CHEMICAL", 72, 75], ["patients", "ORGANISM", 171, 179], ["ICI", "SIMPLE_CHEMICAL", 188, 191], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 171, 179], ["ICI", "TREATMENT", 72, 75], ["SARS", "PROBLEM", 119, 123], ["COV", "TEST", 124, 127], ["other infectious agents", "TREATMENT", 133, 156], ["ICI treatment", "TREATMENT", 188, 201], ["infected", "OBSERVATION", 107, 115]]], ["76 On the basis of preliminary basic research data and clinical observations in patients with COVID-19, one may assume that ICI could safely be employed in cancer patients with a SARS-CoV-2 infection and even COVID-19.", [["cancer", "ANATOMY", 156, 162], ["ICI", "CHEMICAL", 124, 127], ["cancer", "DISEASE", 156, 162], ["SARS-CoV-2 infection", "DISEASE", 179, 199], ["ICI", "CHEMICAL", 124, 127], ["patients", "ORGANISM", 80, 88], ["ICI", "SIMPLE_CHEMICAL", 124, 127], ["cancer", "CANCER", 156, 162], ["patients", "ORGANISM", 163, 171], ["CoV-2", "ORGANISM", 184, 189], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 163, 171], ["preliminary basic research data", "TEST", 19, 50], ["COVID", "TEST", 94, 99], ["ICI", "TREATMENT", 124, 127], ["a SARS-CoV-2 infection", "PROBLEM", 177, 199], ["COVID", "TEST", 209, 214]]], ["As long as there is no clear evidence, however, it remains a caseby-case scenario depending on many factors discussed above, particularly with respect to how advanced the cancer and/or COVID-19 are.", [["cancer", "ANATOMY", 171, 177], ["cancer", "DISEASE", 171, 177], ["cancer", "CANCER", 171, 177], ["the cancer", "PROBLEM", 167, 177], ["no", "UNCERTAINTY", 20, 22], ["cancer", "OBSERVATION", 171, 177]]], ["76 89 92 Notably, ICI may even represent an effective approach in the management of COVID-19 patients without cancer.", [["cancer", "ANATOMY", 110, 116], ["ICI", "CHEMICAL", 18, 21], ["cancer", "DISEASE", 110, 116], ["patients", "ORGANISM", 93, 101], ["cancer", "CANCER", 110, 116], ["patients", "SPECIES", 93, 101], ["COVID", "TEST", 84, 89], ["cancer", "PROBLEM", 110, 116], ["without", "UNCERTAINTY", 102, 109], ["cancer", "OBSERVATION", 110, 116]]], ["71 73 76 79 Additionally, a combination of ICI with an anti-IL-6 antibody is an attractive approach to reduce the risks of both irAEs and possible cytokine excess frequently observed in severe COVID-19 cases.", [["ICI", "CHEMICAL", 43, 46], ["irAEs", "DISEASE", 128, 133], ["COVID", "DISEASE", 193, 198], ["ICI", "CHEMICAL", 43, 46], ["ICI", "SIMPLE_CHEMICAL", 43, 46], ["anti-IL-6 antibody", "GENE_OR_GENE_PRODUCT", 55, 73], ["anti-IL-6 antibody", "PROTEIN", 55, 73], ["cytokine", "PROTEIN", 147, 155], ["ICI", "TREATMENT", 43, 46], ["an anti-IL-6 antibody", "TREATMENT", 52, 73], ["an attractive approach", "TREATMENT", 77, 99], ["both irAEs", "PROBLEM", 123, 133], ["cytokine excess", "PROBLEM", 147, 162]]], ["93 A study following this strategy is currently recruiting patients.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["A study", "TEST", 3, 10], ["this strategy", "TREATMENT", 21, 34]]], ["The objective of this prospective, controlled, randomized, multicenter study is to compare the efficacy of the combined administration of a chloroquine analog, nivolumab, and tocilizumab versus standard of care in patients with advanced or metastatic cancer who have COVID-19 and are not eligible to a resuscitation unit ( ClinicalTrials. gov: NCT04333914).", [["metastatic cancer", "ANATOMY", 240, 257], ["chloroquine", "CHEMICAL", 140, 151], ["nivolumab", "CHEMICAL", 160, 169], ["tocilizumab", "CHEMICAL", 175, 186], ["cancer", "DISEASE", 251, 257], ["chloroquine", "CHEMICAL", 140, 151], ["nivolumab", "CHEMICAL", 160, 169], ["chloroquine", "SIMPLE_CHEMICAL", 140, 151], ["nivolumab", "SIMPLE_CHEMICAL", 160, 169], ["tocilizumab", "SIMPLE_CHEMICAL", 175, 186], ["patients", "ORGANISM", 214, 222], ["metastatic cancer", "CANCER", 240, 257], ["patients", "SPECIES", 214, 222], ["multicenter study", "TEST", 59, 76], ["a chloroquine analog", "TREATMENT", 138, 158], ["nivolumab", "TREATMENT", 160, 169], ["tocilizumab", "TREATMENT", 175, 186], ["advanced or metastatic cancer", "PROBLEM", 228, 257], ["COVID", "TEST", 267, 272], ["a resuscitation unit ( ClinicalTrials", "TREATMENT", 300, 337], ["metastatic", "OBSERVATION_MODIFIER", 240, 250], ["cancer", "OBSERVATION", 251, 257]]], ["Patients will be randomized into two different cohorts: (1) asymptomatic or mild symptoms: chloroquine analog versus nivolumab versus standard of care (1:1:1); (2) moderate/severe symptoms: chloroquine analog versus tocilizumab versus standard of care (1:1:1).", [["chloroquine", "CHEMICAL", 91, 102], ["nivolumab", "CHEMICAL", 117, 126], ["chloroquine", "CHEMICAL", 190, 201], ["tocilizumab", "CHEMICAL", 216, 227], ["chloroquine", "CHEMICAL", 91, 102], ["nivolumab", "CHEMICAL", 117, 126], ["chloroquine", "CHEMICAL", 190, 201], ["Patients", "ORGANISM", 0, 8], ["chloroquine", "SIMPLE_CHEMICAL", 91, 102], ["nivolumab", "SIMPLE_CHEMICAL", 117, 126], ["chloroquine", "SIMPLE_CHEMICAL", 190, 201], ["tocilizumab", "SIMPLE_CHEMICAL", 216, 227], ["Patients", "SPECIES", 0, 8], ["asymptomatic", "PROBLEM", 60, 72], ["mild symptoms", "PROBLEM", 76, 89], ["chloroquine analog", "TREATMENT", 91, 109], ["nivolumab versus standard of care", "TREATMENT", 117, 150], ["moderate/severe symptoms", "PROBLEM", 164, 188], ["chloroquine analog", "TREATMENT", 190, 208], ["tocilizumab", "TREATMENT", 216, 227], ["mild", "OBSERVATION_MODIFIER", 76, 80], ["moderate", "OBSERVATION_MODIFIER", 164, 172], ["severe", "OBSERVATION_MODIFIER", 173, 179]]], ["It has to be stressed, however, that hydroxychloroquine use has been reported to be ineffective or even associated with higher mortality and therefore should only be considered in the context of well-designed controlled and regulatory approved clinical trials.", [["hydroxychloroquine", "CHEMICAL", 37, 55], ["hydroxychloroquine", "CHEMICAL", 37, 55], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 37, 55], ["hydroxychloroquine", "TREATMENT", 37, 55]]], ["Furthermore, two protocols have been registered at ClinicalTrials. gov investigating ICI in COVID-19 patients without cancer: In a phase II randomized trial, the protocol CORIMUNO19-NIVO will evaluate the efficacy and safety of nivolumab alone versus standard of care in COVID-19 patients hospitalized in an ICU (NCT04343144), and in an open-label, controlled, single-center pilot study, nivolumab will be employed in adult patients with COVID-19 aiming to investigate the Open access efficacy and safety of nivolumab in relation to viral clearance (NCT04356508).CONCLUSIONSBased on the data presented in this review and in line with the recommendations of the Study Group for Infections in Compromised Hosts, we assume that PD-1/ PD-L1-and/or CTLA-4-based ICI treatment does not seem to independently enhance the risk of infection or cause more virulent course of disease.", [["cancer", "ANATOMY", 118, 124], ["ICI", "CHEMICAL", 85, 88], ["cancer", "DISEASE", 118, 124], ["nivolumab", "CHEMICAL", 228, 237], ["nivolumab", "CHEMICAL", 388, 397], ["nivolumab", "CHEMICAL", 508, 517], ["Infections", "DISEASE", 677, 687], ["CTLA-4", "CHEMICAL", 744, 750], ["ICI", "CHEMICAL", 757, 760], ["infection", "DISEASE", 822, 831], ["ICI", "CHEMICAL", 85, 88], ["nivolumab", "CHEMICAL", 228, 237], ["nivolumab", "CHEMICAL", 388, 397], ["nivolumab", "CHEMICAL", 508, 517], ["ICI", "CHEMICAL", 757, 760], ["ICI", "SIMPLE_CHEMICAL", 85, 88], ["patients", "ORGANISM", 101, 109], ["cancer", "CANCER", 118, 124], ["nivolumab", "SIMPLE_CHEMICAL", 228, 237], ["patients", "ORGANISM", 280, 288], ["nivolumab", "SIMPLE_CHEMICAL", 388, 397], ["patients", "ORGANISM", 424, 432], ["nivolumab", "SIMPLE_CHEMICAL", 508, 517], ["PD-1", "GENE_OR_GENE_PRODUCT", 725, 729], ["PD-L1", "GENE_OR_GENE_PRODUCT", 731, 736], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 744, 750], ["ICI", "SIMPLE_CHEMICAL", 757, 760], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 280, 288], ["patients", "SPECIES", 424, 432], ["cancer", "PROBLEM", 118, 124], ["the protocol CORIMUNO19", "TREATMENT", 158, 181], ["nivolumab", "TREATMENT", 228, 237], ["pilot study", "TEST", 375, 386], ["nivolumab", "TREATMENT", 388, 397], ["COVID", "TREATMENT", 438, 443], ["Open access efficacy", "TREATMENT", 473, 493], ["nivolumab", "TREATMENT", 508, 517], ["viral clearance", "TEST", 533, 548], ["Infections", "PROBLEM", 677, 687], ["PD", "TEST", 725, 727], ["PD", "TEST", 731, 733], ["L1", "TEST", 734, 736], ["CTLA", "TEST", 744, 748], ["based ICI treatment", "TREATMENT", 751, 770], ["infection", "PROBLEM", 822, 831], ["disease", "PROBLEM", 865, 872], ["without", "UNCERTAINTY", 110, 117], ["cancer", "OBSERVATION", 118, 124], ["infection", "OBSERVATION", 822, 831]]], ["27 Hence, the above discussed viral infections should not be considered as contraindications per se for patients who are scheduled for or are on ICI.", [["viral infections", "DISEASE", 30, 46], ["ICI", "CHEMICAL", 145, 148], ["ICI", "CHEMICAL", 145, 148], ["patients", "ORGANISM", 104, 112], ["ICI", "SIMPLE_CHEMICAL", 145, 148], ["patients", "SPECIES", 104, 112], ["viral infections", "PROBLEM", 30, 46], ["ICI", "TREATMENT", 145, 148]]], ["Over the course of ICI treatment, however, supportive immunosuppressive therapies may be required to treat ICI-associated irAEs, which in turn may increase the risk of new or reactivation of persisting viral infections.", [["ICI", "CHEMICAL", 19, 22], ["ICI", "CHEMICAL", 107, 110], ["irAEs", "DISEASE", 122, 127], ["viral infections", "DISEASE", 202, 218], ["ICI", "CHEMICAL", 19, 22], ["ICI", "CHEMICAL", 107, 110], ["ICI", "SIMPLE_CHEMICAL", 19, 22], ["ICI", "SIMPLE_CHEMICAL", 107, 110], ["ICI treatment", "TREATMENT", 19, 32], ["supportive immunosuppressive therapies", "TREATMENT", 43, 81], ["ICI", "TREATMENT", 107, 110], ["associated irAEs", "PROBLEM", 111, 127], ["persisting viral infections", "PROBLEM", 191, 218], ["new", "OBSERVATION_MODIFIER", 168, 171], ["persisting", "OBSERVATION_MODIFIER", 191, 201], ["viral", "OBSERVATION_MODIFIER", 202, 207], ["infections", "OBSERVATION", 208, 218]]], ["Hence, physicians caring for patients receiving immunosuppressants for treatment of ICI-induced irAEs should maintain close surveillance for the occurrence of symptoms or signs suggestive of new infection or worsening of preexisting viral infections.", [["ICI", "CHEMICAL", 84, 87], ["irAEs", "DISEASE", 96, 101], ["infection", "DISEASE", 195, 204], ["viral infections", "DISEASE", 233, 249], ["ICI", "CHEMICAL", 84, 87], ["patients", "ORGANISM", 29, 37], ["ICI", "SIMPLE_CHEMICAL", 84, 87], ["patients", "SPECIES", 29, 37], ["immunosuppressants", "TREATMENT", 48, 66], ["treatment", "TREATMENT", 71, 80], ["ICI-induced irAEs", "TREATMENT", 84, 101], ["symptoms", "PROBLEM", 159, 167], ["signs", "PROBLEM", 171, 176], ["new infection", "PROBLEM", 191, 204], ["preexisting viral infections", "PROBLEM", 221, 249], ["suggestive of", "UNCERTAINTY", 177, 190], ["new", "OBSERVATION_MODIFIER", 191, 194], ["infection", "OBSERVATION", 195, 204], ["worsening", "OBSERVATION_MODIFIER", 208, 217], ["viral", "OBSERVATION_MODIFIER", 233, 238], ["infections", "OBSERVATION", 239, 249]]], ["27 For almost all aforementioned viral infections, there are convincing data that disease-associated T cell exhaustion is a fundamental immune escape mechanism.", [["T cell", "ANATOMY", 101, 107], ["viral infections", "DISEASE", 33, 49], ["T cell", "CELL", 101, 107], ["almost all aforementioned viral infections", "PROBLEM", 7, 49], ["disease", "PROBLEM", 82, 89], ["T cell exhaustion", "PROBLEM", 101, 118], ["viral", "OBSERVATION_MODIFIER", 33, 38], ["infections", "OBSERVATION", 39, 49], ["cell exhaustion", "OBSERVATION", 103, 118], ["immune escape", "OBSERVATION", 136, 149]]], ["Accordingly, increasing lines of evidence suggest that ICIs represent not only an effective antitumor treatment regimen in such patients but also a potential approach in the management of the viral infection per se.CONCLUSIONSContributors TG conceived of the review article and collected the literature.", [["antitumor", "ANATOMY", 92, 101], ["viral infection", "DISEASE", 192, 207], ["TG", "DISEASE", 239, 241], ["ICIs", "SIMPLE_CHEMICAL", 55, 59], ["antitumor", "CANCER", 92, 101], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["increasing lines", "TREATMENT", 13, 29], ["ICIs", "TREATMENT", 55, 59], ["an effective antitumor treatment regimen", "TREATMENT", 79, 119], ["the management", "TREATMENT", 170, 184], ["the viral infection", "PROBLEM", 188, 207], ["effective", "OBSERVATION_MODIFIER", 82, 91], ["antitumor", "OBSERVATION", 92, 101], ["viral", "OBSERVATION_MODIFIER", 192, 197], ["infection", "OBSERVATION", 198, 207]]], ["TG, JR, and CHS provided the extraction and interpretation of scientific data and drafted the initial manuscript.", [["TG", "DISEASE", 0, 2], ["the extraction", "TREATMENT", 25, 39], ["scientific data", "TEST", 62, 77]]], ["JCB assisted with design and scientific review.", [["JCB", "CHEMICAL", 0, 3]]], ["All authors contributed to manuscript editing, proofread and have approved the final manuscript.CONCLUSIONSFunding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.CONCLUSIONSCompeting interests TG has received speakers and/or advisory board honoraria from BMS, Sanofi-Genzyme, MSD, Novartis Pharma, Roche, Abbvie, Almirall, Janssen, Lilly, Pfizer, Pierre Fabre, Merck-Serono, outside the submitted work.", [["TG", "DISEASE", 287, 289], ["honoraria", "ORGANISM", 334, 343], ["MSD", "ANATOMY", 370, 373]]], ["JCB is receiving speaker's bureau honoraria from Amgen, Pfizer, Merck-Serono, Recordati and Sanofi, is a paid consultant/advisory board member for Boehringer Ingelheim, eTheRNA, In ProTher, MerckSerono, Pfizer, 4SC and Sanofi.", [["JCB", "CHEMICAL", 0, 3], ["MerckSerono", "TREATMENT", 190, 201], ["Sanofi", "TREATMENT", 219, 225]]], ["His group receives research grants from Bristol-Myers Squibb, Merck Serono, HTG, IQVIA, and Alcedis.Patient consent for publication Not required.Provenance and peer review Not commissioned; externally peer reviewed.Patient consent for publication Not required.Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made.", [["HTG", "DISEASE", 76, 79], ["Patient", "SPECIES", 100, 107], ["Patient", "SPECIES", 215, 222], ["Merck Serono", "TREATMENT", 62, 74], ["Alcedis", "TREATMENT", 92, 99], ["Open access", "TREATMENT", 260, 271]]], ["0/.ORCID iDsThilo Gambichler http:// orcid. org/ 0000-0001-7862-3695 J\u00fcrgen Christian Becker http:// orcid. org/ 0000-0001-9183-653X", [["org/ 0000-0001-7862-3695 J\u00fcrgen Christian Becker http:// orcid.", "SPECIES", 44, 107], ["org/ 0000-0001-9183-653X", "SPECIES", 108, 132]]]], "3941bfed937029a31746847f195aeb98631f8d0d": [["IntroductionRelationships between virus infection mechanisms and lipid rafts had often been studied in complexes with caveolae [1, 2] .", [["lipid rafts", "ANATOMY", 65, 76], ["caveolae", "ANATOMY", 118, 126], ["infection", "DISEASE", 40, 49], ["caveolae", "CELLULAR_COMPONENT", 118, 126], ["virus infection mechanisms", "PROBLEM", 34, 60], ["lipid rafts", "TREATMENT", 65, 76]]], ["Lipid rafts, membrane microdomains enriched in cholesterol, and sphingolipids represented by GM1 and globotriaosylceramide (Gb3Cer) were defined at the Keystone Symposium on Lipid Rafts and Cell Function (March [23] [24] [25] [26] [27] [28] 2006 in Steamboat Springs, CO) as follows: \"Membrane rafts are small (10-200 nm) , heterogeneous, highly dynamic, steroland sphingolipid-enriched domains that compartmentalize cellular processes.", [["Lipid rafts", "ANATOMY", 0, 11], ["membrane microdomains", "ANATOMY", 13, 34], ["Cell", "ANATOMY", 190, 194], ["Membrane rafts", "ANATOMY", 285, 299], ["cellular", "ANATOMY", 417, 425], ["cholesterol", "CHEMICAL", 47, 58], ["globotriaosylceramide", "CHEMICAL", 101, 122], ["cholesterol", "CHEMICAL", 47, 58], ["sphingolipids", "CHEMICAL", 64, 77], ["globotriaosylceramide", "CHEMICAL", 101, 122], ["steroland", "CHEMICAL", 355, 364], ["Lipid rafts", "CELLULAR_COMPONENT", 0, 11], ["membrane microdomains", "CELLULAR_COMPONENT", 13, 34], ["cholesterol", "SIMPLE_CHEMICAL", 47, 58], ["sphingolipids", "SIMPLE_CHEMICAL", 64, 77], ["GM1", "SIMPLE_CHEMICAL", 93, 96], ["globotriaosylceramide", "SIMPLE_CHEMICAL", 101, 122], ["Gb3Cer", "SIMPLE_CHEMICAL", 124, 130], ["Lipid Rafts", "SIMPLE_CHEMICAL", 174, 185], ["Cell", "CELL", 190, 194], ["Membrane", "CELLULAR_COMPONENT", 285, 293], ["steroland", "SIMPLE_CHEMICAL", 355, 364], ["sphingolipid", "SIMPLE_CHEMICAL", 365, 377], ["cellular", "CELL", 417, 425], ["steroland sphingolipid-enriched domains", "PROTEIN", 355, 394], ["Lipid rafts", "TREATMENT", 0, 11], ["membrane microdomains", "TREATMENT", 13, 34], ["sphingolipids", "TEST", 64, 77], ["globotriaosylceramide (Gb3Cer)", "TREATMENT", 101, 131], ["Lipid Rafts", "TREATMENT", 174, 185], ["Steamboat Springs", "TEST", 249, 266], ["Membrane rafts", "TEST", 285, 299], ["heterogeneous, highly dynamic, steroland sphingolipid-enriched domains", "PROBLEM", 324, 394], ["membrane microdomains", "OBSERVATION", 13, 34], ["Membrane rafts", "ANATOMY", 285, 299], ["small", "OBSERVATION_MODIFIER", 304, 309], ["heterogeneous", "OBSERVATION_MODIFIER", 324, 337], ["highly", "OBSERVATION_MODIFIER", 339, 345], ["dynamic", "OBSERVATION_MODIFIER", 346, 353], ["enriched domains", "OBSERVATION", 378, 394], ["cellular processes", "OBSERVATION", 417, 435]]], ["Small rafts can sometimes be stabilized to form larger platforms through protein-protein and proteinlipid interactions.\"", [["protein-protein", "PROTEIN", 73, 88], ["Small rafts", "PROBLEM", 0, 11], ["rafts", "OBSERVATION", 6, 11]]], ["This definition led to the term \"lipid raft\" being discarded in favor of the term \"membrane raft\".", [["lipid raft", "ANATOMY", 33, 43], ["membrane raft", "ANATOMY", 83, 96], ["membrane raft", "CELLULAR_COMPONENT", 83, 96], ["the term \"lipid raft", "TREATMENT", 23, 43], ["lipid raft", "OBSERVATION", 33, 43]]], ["The term \"membrane raft\" underlies the concept that both proteins and lipids, rather than solely lipid-driven interactions, play an important role in the formation of these membrane microdomains.", [["membrane raft", "ANATOMY", 10, 23], ["membrane microdomains", "ANATOMY", 173, 194], ["membrane raft", "CELLULAR_COMPONENT", 10, 23], ["lipids", "SIMPLE_CHEMICAL", 70, 76], ["lipid", "SIMPLE_CHEMICAL", 97, 102], ["membrane microdomains", "CELLULAR_COMPONENT", 173, 194], ["The term \"membrane raft", "PROBLEM", 0, 23], ["membrane raft", "OBSERVATION", 10, 23], ["membrane microdomains", "OBSERVATION", 173, 194]]], ["The caveola, a cholesterol/sphingolipid-rich small pit, depression, or invagination, is a site on the cell surface that provides a platform for proteins and lipids to interact and transmit signals.", [["pit", "ANATOMY", 51, 54], ["cell surface", "ANATOMY", 102, 114], ["cholesterol", "CHEMICAL", 15, 26], ["depression", "DISEASE", 56, 66], ["cholesterol", "CHEMICAL", 15, 26], ["sphingolipid", "CHEMICAL", 27, 39], ["caveola", "CANCER", 4, 11], ["cholesterol", "SIMPLE_CHEMICAL", 15, 26], ["sphingolipid", "SIMPLE_CHEMICAL", 27, 39], ["cell surface", "CELLULAR_COMPONENT", 102, 114], ["lipids", "SIMPLE_CHEMICAL", 157, 163], ["a cholesterol/sphingolipid", "TEST", 13, 39], ["small pit", "PROBLEM", 45, 54], ["depression", "PROBLEM", 56, 66], ["invagination", "PROBLEM", 71, 83], ["cholesterol", "OBSERVATION_MODIFIER", 15, 26], ["sphingolipid", "ANATOMY", 27, 39], ["rich", "OBSERVATION_MODIFIER", 40, 44], ["small", "OBSERVATION_MODIFIER", 45, 50], ["pit", "OBSERVATION_MODIFIER", 51, 54], ["depression", "OBSERVATION", 56, 66], ["invagination", "OBSERVATION", 71, 83]]], ["In the symposium, the range of 10-200 nm, which was adopted as the size of membraneRole of Membrane Rafts in Virus EntryThe involvement of membrane rafts in virus entry has been evaluated by the effects of raft-disrupting reagents on virus infection and by the effects of cholesterol-removing reagents such as methyl-\u03b2-cyclodextrin and cholesterol synthesis inhibitors such as nystatin.", [["membrane rafts", "ANATOMY", 139, 153], ["raft", "ANATOMY", 206, 210], ["infection", "DISEASE", 240, 249], ["cholesterol", "CHEMICAL", 272, 283], ["methyl-\u03b2-cyclodextrin", "CHEMICAL", 310, 331], ["cholesterol", "CHEMICAL", 336, 347], ["nystatin", "CHEMICAL", 377, 385], ["cholesterol", "CHEMICAL", 272, 283], ["methyl-\u03b2-cyclodextrin", "CHEMICAL", 310, 331], ["cholesterol", "CHEMICAL", 336, 347], ["nystatin", "CHEMICAL", 377, 385], ["membrane rafts", "CELLULAR_COMPONENT", 139, 153], ["cholesterol", "SIMPLE_CHEMICAL", 272, 283], ["methyl-\u03b2-cyclodextrin", "SIMPLE_CHEMICAL", 310, 331], ["cholesterol", "SIMPLE_CHEMICAL", 336, 347], ["nystatin", "SIMPLE_CHEMICAL", 377, 385], ["Membrane Rafts", "TREATMENT", 91, 105], ["membrane rafts in virus entry", "PROBLEM", 139, 168], ["raft-disrupting reagents", "TREATMENT", 206, 230], ["virus infection", "PROBLEM", 234, 249], ["cholesterol-removing reagents", "TREATMENT", 272, 301], ["methyl-\u03b2-cyclodextrin", "TREATMENT", 310, 331], ["cholesterol synthesis inhibitors", "TREATMENT", 336, 368], ["nystatin", "TREATMENT", 377, 385], ["size", "OBSERVATION_MODIFIER", 67, 71], ["Membrane Rafts", "OBSERVATION", 91, 105], ["membrane rafts", "OBSERVATION", 139, 153]]], ["Inhibition of virus infection by cholesterol depletion is generally recovered by the addition of exogenous cholesterol without affecting virus binding to cellular receptors.", [["cellular", "ANATOMY", 154, 162], ["infection", "DISEASE", 20, 29], ["cholesterol", "CHEMICAL", 33, 44], ["cholesterol", "CHEMICAL", 107, 118], ["cholesterol", "CHEMICAL", 33, 44], ["cholesterol", "CHEMICAL", 107, 118], ["cholesterol", "SIMPLE_CHEMICAL", 33, 44], ["cholesterol", "SIMPLE_CHEMICAL", 107, 118], ["cellular", "CELL", 154, 162], ["cellular receptors", "PROTEIN", 154, 172], ["virus infection", "PROBLEM", 14, 29], ["cholesterol depletion", "PROBLEM", 33, 54], ["exogenous cholesterol", "TREATMENT", 97, 118], ["affecting virus binding", "PROBLEM", 127, 150], ["virus", "OBSERVATION_MODIFIER", 14, 19], ["infection", "OBSERVATION", 20, 29], ["cholesterol depletion", "OBSERVATION", 33, 54]]], ["Traditional examinations of membrane raft function in virus entry have been performed by biochemical methods for detection of viral proteins and viral cellular receptors within a detergent-insoluble fraction after virus attachment and during virus infection or colocalization of these proteins and receptors with specific raft markers such as caveolin-1, flotillin, and GM1.", [["membrane raft", "ANATOMY", 28, 41], ["cellular", "ANATOMY", 151, 159], ["raft", "ANATOMY", 322, 326], ["infection", "DISEASE", 248, 257], ["membrane raft", "CELLULAR_COMPONENT", 28, 41], ["cellular", "CELL", 151, 159], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 343, 353], ["flotillin", "GENE_OR_GENE_PRODUCT", 355, 364], ["GM1", "GENE_OR_GENE_PRODUCT", 370, 373], ["viral proteins", "PROTEIN", 126, 140], ["viral cellular receptors", "PROTEIN", 145, 169], ["raft markers", "PROTEIN", 322, 334], ["caveolin-1", "PROTEIN", 343, 353], ["flotillin", "PROTEIN", 355, 364], ["GM1", "PROTEIN", 370, 373], ["Traditional examinations of membrane raft function", "TEST", 0, 50], ["biochemical methods", "TEST", 89, 108], ["viral proteins", "PROBLEM", 126, 140], ["viral cellular receptors", "PROBLEM", 145, 169], ["a detergent-insoluble fraction", "TREATMENT", 177, 207], ["virus attachment", "PROBLEM", 214, 230], ["virus infection", "PROBLEM", 242, 257], ["these proteins", "PROBLEM", 279, 293], ["specific raft markers", "TEST", 313, 334], ["caveolin", "TEST", 343, 351], ["flotillin", "TREATMENT", 355, 364], ["viral cellular", "OBSERVATION", 145, 159]]], ["Molecular biological examinations of the role of a caveola-dependent endocytic pathway in virus entry have also been performed by inhibition of caveola formation using RNA interference (RNAi) and dominant-negative protein expression for normal caveolin-1 knockdown.Entry of Enveloped VirusesEntry processes of enveloped viruses associated with membrane rafts have been evaluated for lymphocytic choriomeningitis virus (LCMV; Arenaviridae) [4] , coronaviruses including severe acute respiratory syndrome coronavirus (SARS-CoV) (Coronaviridae) [5] [6] [7] [8] [9] [10] [11] , Ebola virus (Filoviridae) [12] [13] [14] , Marburg virus (Filoviridae) [12, 15] , West Nile virus (WNV; Flaviviridae) [16] , dengue virus (DEN; Flaviviridae) [17] [18] [19] [20] , Japanese encephalitis virus (JEV; Flaviviridae) [19, 21] , human hepatitis C virus (HCV; Flaviviridae) [22, 23] , Epstein-Barr virus (EBV; herpesviridae) [24, 25] , herpes simplex virus-1 (HSV-1; herpesviridae) [26, 27] including porcine herpesvirus-1 pseudorabies virus [28] , human herpesvirus-6 (HHV-6; Herpesviridae) [29] , human herpesvirus-8 of Kaposi's sarcoma-associated herpesvirus (HHV-8; Herpesviridae) [30, 31] , influenza virus (Orthomyxoviridae) [32] [33] [34] [35] [36] [37] , vaccinia virus (Poxviridae) [38] , human immunodeficiency virus (HIV; Retroviridae) [39] [40] [41] [42] [43] [44] [45] , human T lymphotropic virus 1 (HTLV-1; Retroviridae) [46, 47] , Semliki Forest virus (Togaviridae) [48] [49] [50] [51] , and Sindbis virus (Togaviridae) [51, 52] .Entry of Enveloped VirusesThe majority of enveloped viruses release viral internal genomes and proteins into the intracellular compartment through fusion processes induced by viral surface proteins between viral and cellular membranes immediately after virus attachment to receptors or the endocytic pathway.Entry of Enveloped VirusesHuman coronavirus, a pathogen causing 10-30% of all common colds manifesting upper respiratory and gastrointestinal symptoms, enters cells through caveola-dependent endocytosis after attachment to the viral receptor CD13 within membrane rafts.", [["caveola", "ANATOMY", 144, 151], ["membrane rafts", "ANATOMY", 344, 358], ["intracellular compartment", "ANATOMY", 1642, 1667], ["surface", "ANATOMY", 1710, 1717], ["cellular membranes", "ANATOMY", 1745, 1763], ["respiratory", "ANATOMY", 1946, 1957], ["gastrointestinal", "ANATOMY", 1962, 1978], ["cells", "ANATOMY", 1996, 2001], ["membrane rafts", "ANATOMY", 2091, 2105], ["lymphocytic choriomeningitis virus", "DISEASE", 383, 417], ["acute respiratory syndrome coronavirus", "DISEASE", 476, 514], ["Coronaviridae) [5] [6] [7] [8] [9] [10] [11] , Ebola virus (Filoviridae) [12] [13] [14] ,", "CHEMICAL", 527, 616], ["Marburg virus", "DISEASE", 617, 630], ["dengue virus (DEN; Flaviviridae) [17] [18] [19] [20", "CHEMICAL", 699, 750], ["Japanese encephalitis virus (JEV; Flaviviridae)", "DISEASE", 754, 801], ["human hepatitis C virus (HCV; Flaviviridae)", "DISEASE", 813, 856], ["Epstein-Barr virus (EBV; herpesviridae", "DISEASE", 868, 906], ["herpes simplex virus", "DISEASE", 919, 939], ["Kaposi's sarcoma", "DISEASE", 1105, 1121], ["influenza virus", "DISEASE", 1179, 1194], ["Orthomyxoviridae) [32] [33] [34] [35] [36] [37] ,", "CHEMICAL", 1196, 1245], ["vaccinia virus", "DISEASE", 1246, 1260], ["human immunodeficiency virus (HIV; Retroviridae) [39] [40] [41] [42] [43] [44", "CHEMICAL", 1281, 1358], ["Sindbis virus", "DISEASE", 1491, 1504], ["VirusesHuman coronavirus", "DISEASE", 1856, 1880], ["colds", "DISEASE", 1922, 1927], ["respiratory and gastrointestinal symptoms", "DISEASE", 1946, 1987], ["caveola", "GENE_OR_GENE_PRODUCT", 51, 58], ["caveola", "SIMPLE_CHEMICAL", 144, 151], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 244, 254], ["enveloped viruses", "ORGANISM", 310, 327], ["membrane rafts", "CELLULAR_COMPONENT", 344, 358], ["lymphocytic choriomeningitis virus", "ORGANISM", 383, 417], ["LCMV", "ORGANISM", 419, 423], ["Arenaviridae) [4", "ORGANISM", 425, 441], ["coronaviruses", "ORGANISM", 445, 458], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 469, 514], ["SARS-CoV", "ORGANISM", 516, 524], ["Coronaviridae) [5] [6] [7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 527, 571], ["Ebola virus", "ORGANISM", 574, 585], ["Marburg virus", "ORGANISM", 617, 630], ["Filoviridae", "ORGANISM", 632, 643], ["West Nile virus", "ORGANISM", 656, 671], ["WNV; Flaviviridae) [16]", "ORGANISM", 673, 696], ["dengue virus", "ORGANISM", 699, 711], ["DEN; Flaviviridae) [17] [18] [19] [20", "ORGANISM", 713, 750], ["Japanese encephalitis virus", "ORGANISM", 754, 781], ["JEV; Flaviviridae", "ORGANISM", 783, 800], ["human", "ORGANISM", 813, 818], ["hepatitis C virus", "ORGANISM", 819, 836], ["HCV; Flaviviridae", "ORGANISM", 838, 855], ["Epstein-Barr virus", "ORGANISM", 868, 886], ["EBV", "ORGANISM", 888, 891], ["herpesviridae) [24, 25] ,", "ORGANISM", 893, 918], ["herpes simplex virus-1", "ORGANISM", 919, 941], ["HSV-1; herpesviridae", "ORGANISM", 943, 963], ["porcine herpesvirus-1 pseudorabies virus [28]", "ORGANISM", 984, 1029], ["human herpesvirus-6", "ORGANISM", 1032, 1051], ["HHV-6; Herpesviridae) [29]", "ORGANISM", 1053, 1079], ["human herpesvirus-8", "ORGANISM", 1082, 1101], ["Kaposi's sarcoma-associated herpesvirus", "ORGANISM", 1105, 1144], ["HHV-8; Herpesviridae", "ORGANISM", 1146, 1166], ["influenza virus", "ORGANISM", 1179, 1194], ["vaccinia virus", "ORGANISM", 1246, 1260], ["Poxviridae) [38", "ORGANISM", 1262, 1277], ["human immunodeficiency virus", "ORGANISM", 1281, 1309], ["HIV", "ORGANISM", 1311, 1314], ["human T lymphotropic virus 1", "ORGANISM", 1367, 1395], ["HTLV-1", "ORGANISM", 1397, 1403], ["; Retroviridae", "ORGANISM", 1403, 1417], ["Semliki Forest virus", "ORGANISM", 1430, 1450], ["Sindbis virus", "ORGANISM", 1491, 1504], ["Enveloped Viruses", "ORGANISM", 1538, 1555], ["enveloped viruses", "ORGANISM", 1571, 1588], ["intracellular compartment", "CELLULAR_COMPONENT", 1642, 1667], ["cellular membranes", "CELLULAR_COMPONENT", 1745, 1763], ["Enveloped VirusesHuman coronavirus", "ORGANISM", 1846, 1880], ["colds", "ORGANISM_SUBDIVISION", 1922, 1927], ["gastrointestinal", "ORGAN", 1962, 1978], ["cells", "CELL", 1996, 2001], ["caveola", "GENE_OR_GENE_PRODUCT", 2010, 2017], ["CD13", "GENE_OR_GENE_PRODUCT", 2079, 2083], ["membrane rafts", "CELLULAR_COMPONENT", 2091, 2105], ["caveolin", "PROTEIN", 244, 252], ["viral internal genomes", "DNA", 1597, 1619], ["viral surface proteins", "PROTEIN", 1704, 1726], ["viral receptor", "PROTEIN", 2064, 2078], ["CD13", "PROTEIN", 2079, 2083], ["lymphocytic choriomeningitis virus", "SPECIES", 383, 417], ["coronavirus", "SPECIES", 503, 514], ["Ebola virus", "SPECIES", 574, 585], ["Marburg virus", "SPECIES", 617, 630], ["West Nile virus", "SPECIES", 656, 671], ["dengue virus", "SPECIES", 699, 711], ["Japanese encephalitis virus", "SPECIES", 754, 781], ["human", "SPECIES", 813, 818], ["hepatitis C virus", "SPECIES", 819, 836], ["Epstein-Barr virus", "SPECIES", 868, 886], ["herpes simplex virus-1", "SPECIES", 919, 941], ["HSV-1", "SPECIES", 943, 948], ["porcine herpesvirus-1 pseudorabies virus", "SPECIES", 984, 1024], ["human", "SPECIES", 1032, 1037], ["herpesvirus-6", "SPECIES", 1038, 1051], ["HHV-6", "SPECIES", 1053, 1058], ["human", "SPECIES", 1082, 1087], ["herpesvirus-8", "SPECIES", 1088, 1101], ["Kaposi's sarcoma-associated herpesvirus", "SPECIES", 1105, 1144], ["HHV-8", "SPECIES", 1146, 1151], ["influenza virus", "SPECIES", 1179, 1194], ["vaccinia virus", "SPECIES", 1246, 1260], ["human immunodeficiency virus", "SPECIES", 1281, 1309], ["HIV", "SPECIES", 1311, 1314], ["human", "SPECIES", 1367, 1372], ["T lymphotropic virus 1", "SPECIES", 1373, 1395], ["HTLV-1", "SPECIES", 1397, 1403], ["Semliki Forest virus", "SPECIES", 1430, 1450], ["Sindbis virus", "SPECIES", 1491, 1504], ["VirusesHuman coronavirus", "SPECIES", 1856, 1880], ["lymphocytic choriomeningitis virus", "SPECIES", 383, 417], ["LCMV", "SPECIES", 419, 423], ["severe acute respiratory syndrome coronavirus", "SPECIES", 469, 514], ["SARS-CoV", "SPECIES", 516, 524], ["Ebola virus", "SPECIES", 574, 585], ["Marburg virus", "SPECIES", 617, 630], ["West Nile virus", "SPECIES", 656, 671], ["WNV", "SPECIES", 673, 676], ["dengue virus", "SPECIES", 699, 711], ["DEN", "SPECIES", 713, 716], ["Japanese encephalitis virus", "SPECIES", 754, 781], ["JEV", "SPECIES", 783, 786], ["human hepatitis C virus", "SPECIES", 813, 836], ["HCV", "SPECIES", 838, 841], ["Epstein-Barr virus", "SPECIES", 868, 886], ["EBV", "SPECIES", 888, 891], ["herpes simplex virus-1", "SPECIES", 919, 941], ["HSV-1", "SPECIES", 943, 948], ["porcine herpesvirus-1 pseudorabies virus", "SPECIES", 984, 1024], ["human herpesvirus-6 (HHV-6", "SPECIES", 1032, 1058], ["human herpesvirus-8", "SPECIES", 1082, 1101], ["Kaposi's sarcoma-associated herpesvirus (HHV-8", "SPECIES", 1105, 1151], ["vaccinia virus", "SPECIES", 1246, 1260], ["human immunodeficiency virus", "SPECIES", 1281, 1309], ["HIV", "SPECIES", 1311, 1314], ["human T lymphotropic virus 1", "SPECIES", 1367, 1395], ["HTLV-1", "SPECIES", 1397, 1403], ["Semliki Forest virus", "SPECIES", 1430, 1450], ["Sindbis virus", "SPECIES", 1491, 1504], ["VirusesHuman coronavirus", "SPECIES", 1856, 1880], ["Molecular biological examinations", "TEST", 0, 33], ["caveola formation", "TREATMENT", 144, 161], ["RNA interference", "TEST", 168, 184], ["enveloped viruses", "PROBLEM", 310, 327], ["membrane rafts", "TREATMENT", 344, 358], ["lymphocytic choriomeningitis virus", "PROBLEM", 383, 417], ["coronaviruses", "PROBLEM", 445, 458], ["severe acute respiratory syndrome", "PROBLEM", 469, 502], ["coronavirus (SARS-CoV) (Coronaviridae)", "TREATMENT", 503, 541], ["Ebola virus (Filoviridae)", "TREATMENT", 574, 599], ["Marburg virus (Filoviridae)", "TREATMENT", 617, 644], ["dengue virus", "PROBLEM", 699, 711], ["Japanese encephalitis virus", "PROBLEM", 754, 781], ["Flaviviridae", "TEST", 788, 800], ["human hepatitis C virus", "PROBLEM", 813, 836], ["HCV", "TEST", 838, 841], ["Flaviviridae", "TEST", 843, 855], ["Epstein", "TEST", 868, 875], ["Barr virus", "TEST", 876, 886], ["EBV", "TEST", 888, 891], ["herpesviridae", "TEST", 893, 906], ["herpes simplex virus", "TEST", 919, 939], ["HSV", "TEST", 943, 946], ["herpesviridae", "TEST", 950, 963], ["porcine herpesvirus", "TEST", 984, 1003], ["pseudorabies virus", "TEST", 1006, 1024], ["human herpesvirus", "TEST", 1032, 1049], ["HHV", "TEST", 1053, 1056], ["Herpesviridae", "TEST", 1060, 1073], ["human herpesvirus", "TEST", 1082, 1099], ["Kaposi's sarcoma", "PROBLEM", 1105, 1121], ["herpesvirus (HHV", "TEST", 1133, 1149], ["Herpesviridae", "TEST", 1153, 1166], ["influenza virus (Orthomyxoviridae)", "TEST", 1179, 1213], ["vaccinia virus (Poxviridae)", "TEST", 1246, 1273], ["human immunodeficiency virus", "PROBLEM", 1281, 1309], ["Retroviridae", "TEST", 1316, 1328], ["human T lymphotropic virus", "TEST", 1367, 1393], ["HTLV", "TEST", 1397, 1401], ["Retroviridae", "TEST", 1405, 1417], ["Semliki Forest virus (Togaviridae)", "TEST", 1430, 1464], ["Sindbis virus", "TEST", 1491, 1504], ["Enveloped Viruses", "PROBLEM", 1538, 1555], ["enveloped viruses", "PROBLEM", 1571, 1588], ["viral internal genomes", "PROBLEM", 1597, 1619], ["fusion processes", "PROBLEM", 1676, 1692], ["viral surface proteins", "PROBLEM", 1704, 1726], ["viral and cellular membranes", "PROBLEM", 1735, 1763], ["virus attachment to receptors", "TREATMENT", 1782, 1811], ["Enveloped VirusesHuman coronavirus", "PROBLEM", 1846, 1880], ["a pathogen", "PROBLEM", 1882, 1892], ["all common colds", "PROBLEM", 1911, 1927], ["upper respiratory and gastrointestinal symptoms", "PROBLEM", 1940, 1987], ["caveola-dependent endocytosis", "TREATMENT", 2010, 2039], ["negative protein expression", "OBSERVATION", 205, 232], ["Viruses", "OBSERVATION", 284, 291], ["enveloped viruses", "OBSERVATION", 310, 327], ["severe", "OBSERVATION_MODIFIER", 469, 475], ["acute", "OBSERVATION_MODIFIER", 476, 481], ["respiratory syndrome", "OBSERVATION", 482, 502], ["sarcoma", "OBSERVATION", 1114, 1121], ["Enveloped", "OBSERVATION_MODIFIER", 1538, 1547], ["Viruses", "OBSERVATION", 1548, 1555], ["enveloped", "OBSERVATION_MODIFIER", 1571, 1580], ["viruses", "OBSERVATION", 1581, 1588], ["viral internal genomes", "OBSERVATION", 1597, 1619], ["intracellular compartment", "OBSERVATION", 1642, 1667], ["fusion processes", "OBSERVATION", 1676, 1692], ["viral surface proteins", "OBSERVATION", 1704, 1726], ["viral", "OBSERVATION", 1735, 1740], ["cellular membranes", "OBSERVATION", 1745, 1763], ["Enveloped", "OBSERVATION_MODIFIER", 1846, 1855], ["VirusesHuman coronavirus", "OBSERVATION", 1856, 1880], ["upper", "ANATOMY_MODIFIER", 1940, 1945], ["respiratory", "ANATOMY", 1946, 1957], ["gastrointestinal", "ANATOMY", 1962, 1978], ["dependent", "OBSERVATION_MODIFIER", 2018, 2027], ["endocytosis", "OBSERVATION", 2028, 2039], ["membrane rafts", "OBSERVATION", 2091, 2105]]], ["It has been shown that virus infection is inhibited by caveola destruction using a cholesterolremoving reagent and an RNAi method for caveolin-1 [5] .", [["infection", "DISEASE", 29, 38], ["caveola", "SIMPLE_CHEMICAL", 55, 62], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 134, 144], ["caveolin", "PROTEIN", 134, 142], ["virus infection", "PROBLEM", 23, 38], ["caveola destruction", "PROBLEM", 55, 74], ["a cholesterolremoving reagent", "TREATMENT", 81, 110], ["an RNAi method", "TREATMENT", 115, 129], ["caveolin", "TEST", 134, 142], ["virus", "OBSERVATION_MODIFIER", 23, 28], ["infection", "OBSERVATION", 29, 38]]], ["Mouse hepatitis virus (MHV) of murine coronaviruses binds to nonraft membranes but moves to raft membranes for virus entry and fusion processes.", [["nonraft membranes", "ANATOMY", 61, 78], ["raft membranes", "ANATOMY", 92, 106], ["Mouse hepatitis virus", "DISEASE", 0, 21], ["Mouse hepatitis virus", "ORGANISM", 0, 21], ["MHV", "ORGANISM", 23, 26], ["murine", "ORGANISM", 31, 37], ["coronaviruses", "ORGANISM", 38, 51], ["nonraft membranes", "CELLULAR_COMPONENT", 61, 78], ["raft membranes", "CELLULAR_COMPONENT", 92, 106], ["Mouse hepatitis virus", "SPECIES", 0, 21], ["murine", "SPECIES", 31, 37], ["Mouse hepatitis virus", "SPECIES", 0, 21], ["MHV", "SPECIES", 23, 26], ["murine coronaviruses", "SPECIES", 31, 51], ["Mouse hepatitis virus", "PROBLEM", 0, 21], ["murine coronaviruses binds", "PROBLEM", 31, 57], ["nonraft membranes", "PROBLEM", 61, 78], ["virus entry and fusion processes", "TREATMENT", 111, 143], ["hepatitis virus", "OBSERVATION", 6, 21], ["fusion processes", "OBSERVATION", 127, 143]]], ["Membrane rafts are not incorporated into the MHV virion and are not associated with the spike (S) protein of MHV on the Golgi body membrane, which is the site of virus assembly and budding.", [["Membrane rafts", "ANATOMY", 0, 14], ["Golgi body membrane", "ANATOMY", 120, 139], ["Membrane rafts", "CELLULAR_COMPONENT", 0, 14], ["MHV virion", "ORGANISM", 45, 55], ["MHV", "GENE_OR_GENE_PRODUCT", 109, 112], ["Golgi body membrane", "CELLULAR_COMPONENT", 120, 139], ["spike (S) protein", "PROTEIN", 88, 105], ["MHV", "PROTEIN", 109, 112], ["MHV", "SPECIES", 45, 48], ["MHV", "SPECIES", 109, 112], ["Membrane rafts", "TREATMENT", 0, 14], ["the spike (S) protein of MHV on the Golgi body membrane", "PROBLEM", 84, 139], ["rafts", "OBSERVATION", 9, 14], ["MHV virion", "OBSERVATION", 45, 55], ["not associated with", "UNCERTAINTY", 64, 83], ["MHV", "OBSERVATION", 109, 112], ["Golgi body membrane", "OBSERVATION", 120, 139], ["virus", "OBSERVATION", 162, 167]]], ["Membrane rafts are therefore not required for the virus release process [6, 7] .", [["Membrane rafts", "ANATOMY", 0, 14], ["Membrane rafts", "CELLULAR_COMPONENT", 0, 14], ["Membrane rafts", "TREATMENT", 0, 14], ["the virus release process", "PROBLEM", 46, 71]]], ["SARS-CoV, the most extensively researched human coronavirus that causes severe acute respiratory syndrome (SARS), associates with membrane rafts as an entry platform via the viral spike (S) protein after binding to the viral receptor angiotensin-converting enzyme 2 (ACE2) within rafts of Vero E6 cells [8, 10] .", [["membrane rafts", "ANATOMY", 130, 144], ["rafts", "ANATOMY", 280, 285], ["Vero E6 cells", "ANATOMY", 289, 302], ["SARS", "DISEASE", 0, 4], ["coronavirus", "DISEASE", 48, 59], ["acute respiratory syndrome", "DISEASE", 79, 105], ["SARS", "DISEASE", 107, 111], ["angiotensin", "CHEMICAL", 234, 245], ["SARS-CoV", "ORGANISM", 0, 8], ["human", "ORGANISM", 42, 47], ["membrane", "CELLULAR_COMPONENT", 130, 138], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 234, 265], ["ACE2", "GENE_OR_GENE_PRODUCT", 267, 271], ["Vero E6 cells", "CELL", 289, 302], ["viral spike (S) protein", "PROTEIN", 174, 197], ["viral receptor angiotensin-converting enzyme 2", "PROTEIN", 219, 265], ["ACE2", "PROTEIN", 267, 271], ["Vero E6 cells", "CELL_LINE", 289, 302], ["human", "SPECIES", 42, 47], ["coronavirus", "SPECIES", 48, 59], ["SARS-CoV", "SPECIES", 0, 8], ["human coronavirus", "SPECIES", 42, 59], ["human coronavirus", "PROBLEM", 42, 59], ["severe acute respiratory syndrome", "PROBLEM", 72, 105], ["membrane rafts", "PROBLEM", 130, 144], ["an entry platform", "TEST", 148, 165], ["the viral spike", "PROBLEM", 170, 185], ["the viral receptor angiotensin", "TEST", 215, 245], ["enzyme", "TEST", 257, 263], ["ACE2", "TEST", 267, 271], ["Vero E6 cells", "TEST", 289, 302], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["respiratory syndrome", "OBSERVATION", 85, 105], ["viral spike", "OBSERVATION", 174, 185], ["Vero E6 cells", "OBSERVATION", 289, 302]]], ["Moreover, SARS-CoV and feline infectious peritonitis virus (FIPV), a coronavirus causing lethal chronic disease in cats, enter cells through a clathrin-independent and caveola-independent pathway because both dominant-negative protein expressions of Eps15 (required for the clathrin-dependent pathway) and caveolin-1 have no effect on virus infectivity and no colocalization of caveolin-1 is observed with viral proteins during virus entry.", [["cells", "ANATOMY", 127, 132], ["SARS", "DISEASE", 10, 14], ["infectious peritonitis", "DISEASE", 30, 52], ["coronavirus", "DISEASE", 69, 80], ["chronic disease", "DISEASE", 96, 111], ["SARS-CoV", "ORGANISM", 10, 18], ["feline infectious peritonitis virus", "ORGANISM", 23, 58], ["FIPV", "ORGANISM", 60, 64], ["cats", "ORGANISM", 115, 119], ["cells", "CELL", 127, 132], ["clathrin", "GENE_OR_GENE_PRODUCT", 143, 151], ["caveola", "GENE_OR_GENE_PRODUCT", 168, 175], ["Eps15", "GENE_OR_GENE_PRODUCT", 250, 255], ["clathrin", "GENE_OR_GENE_PRODUCT", 274, 282], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 306, 316], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 378, 388], ["clathrin", "PROTEIN", 143, 151], ["Eps15", "PROTEIN", 250, 255], ["clathrin", "PROTEIN", 274, 282], ["caveolin-1", "PROTEIN", 306, 316], ["caveolin-1", "PROTEIN", 378, 388], ["viral proteins", "PROTEIN", 406, 420], ["feline infectious peritonitis virus", "SPECIES", 23, 58], ["coronavirus", "SPECIES", 69, 80], ["cats", "SPECIES", 115, 119], ["SARS-CoV", "SPECIES", 10, 18], ["feline infectious peritonitis virus", "SPECIES", 23, 58], ["FIPV", "SPECIES", 60, 64], ["SARS", "PROBLEM", 10, 14], ["CoV", "PROBLEM", 15, 18], ["feline infectious peritonitis virus (FIPV", "PROBLEM", 23, 64], ["a coronavirus", "PROBLEM", 67, 80], ["lethal chronic disease in cats", "PROBLEM", 89, 119], ["Eps15", "TEST", 250, 255], ["the clathrin-dependent pathway", "TREATMENT", 270, 300], ["caveolin", "TEST", 306, 314], ["virus infectivity", "PROBLEM", 335, 352], ["viral proteins during virus entry", "PROBLEM", 406, 439], ["infectious", "OBSERVATION_MODIFIER", 30, 40], ["peritonitis", "OBSERVATION", 41, 52], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["disease", "OBSERVATION", 104, 111]]], ["However, inhibition of virus infection by cholesterol depletion indicates the importance of raft-mediated endocytosis for the entry process of these viruses [9, 11] .", [["raft", "ANATOMY", 92, 96], ["infection", "DISEASE", 29, 38], ["cholesterol", "CHEMICAL", 42, 53], ["cholesterol", "CHEMICAL", 42, 53], ["cholesterol", "SIMPLE_CHEMICAL", 42, 53], ["raft", "CELLULAR_COMPONENT", 92, 96], ["virus infection", "PROBLEM", 23, 38], ["cholesterol depletion", "PROBLEM", 42, 63], ["raft-mediated endocytosis", "PROBLEM", 92, 117], ["these viruses", "PROBLEM", 143, 156], ["virus infection", "OBSERVATION", 23, 38], ["cholesterol depletion", "OBSERVATION", 42, 63], ["viruses", "OBSERVATION", 149, 156]]], ["Taken together, results of studies indicate that raft-mediated endocytosis associated with cholesterol is distinctly different from caveolin-1-dependent endocytosis.Entry of Enveloped VirusesEbola virus and Marburg virus, two of the most pathogenic viruses in humans and nonhuman primates that cause severe hemorrhagic fever with mortality rates reaching 90%, enter host cells through folate receptor-\u03b1 (FR\u03b1) as a viral coreceptor, which is a glycosyl phosphatidylinositol-(GPI-) 4 Biochemistry Research International anchored protein within membrane rafts [53] .", [["raft", "ANATOMY", 49, 53], ["cells", "ANATOMY", 371, 376], ["membrane rafts", "ANATOMY", 542, 556], ["cholesterol", "CHEMICAL", 91, 102], ["Ebola virus", "DISEASE", 191, 202], ["Marburg virus", "DISEASE", 207, 220], ["hemorrhagic fever", "DISEASE", 307, 324], ["folate", "CHEMICAL", 385, 391], ["cholesterol", "CHEMICAL", 91, 102], ["folate", "CHEMICAL", 385, 391], ["glycosyl", "CHEMICAL", 443, 451], ["phosphatidylinositol", "CHEMICAL", 452, 472], ["raft", "CELLULAR_COMPONENT", 49, 53], ["cholesterol", "SIMPLE_CHEMICAL", 91, 102], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 132, 142], ["Enveloped Viruses", "ORGANISM", 174, 191], ["Ebola virus", "ORGANISM", 191, 202], ["Marburg virus", "ORGANISM", 207, 220], ["humans", "ORGANISM", 260, 266], ["nonhuman primates", "ORGANISM", 271, 288], ["host cells", "CELL", 366, 376], ["folate receptor-\u03b1", "GENE_OR_GENE_PRODUCT", 385, 402], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 404, 407], ["phosphatidylinositol", "SIMPLE_CHEMICAL", 452, 472], ["membrane", "CELLULAR_COMPONENT", 542, 550], ["caveolin-1", "PROTEIN", 132, 142], ["host cells", "CELL_TYPE", 366, 376], ["folate receptor", "PROTEIN", 385, 400], ["\u03b1", "PROTEIN", 401, 402], ["FR\u03b1", "PROTEIN", 404, 407], ["viral coreceptor", "PROTEIN", 414, 430], ["glycosyl phosphatidylinositol-(GPI-) 4 Biochemistry Research International anchored protein", "PROTEIN", 443, 534], ["Ebola virus", "SPECIES", 191, 202], ["Marburg virus", "SPECIES", 207, 220], ["humans", "SPECIES", 260, 266], ["Ebola virus", "SPECIES", 191, 202], ["Marburg virus", "SPECIES", 207, 220], ["humans", "SPECIES", 260, 266], ["studies", "TEST", 27, 34], ["raft-mediated endocytosis", "PROBLEM", 49, 74], ["cholesterol", "TEST", 91, 102], ["caveolin", "TEST", 132, 140], ["dependent endocytosis", "PROBLEM", 143, 164], ["Enveloped VirusesEbola virus", "PROBLEM", 174, 202], ["Marburg virus", "PROBLEM", 207, 220], ["severe hemorrhagic fever", "PROBLEM", 300, 324], ["mortality rates", "TEST", 330, 345], ["folate receptor", "TEST", 385, 400], ["a viral coreceptor", "PROBLEM", 412, 430], ["a glycosyl phosphatidylinositol", "TREATMENT", 441, 472], ["endocytosis", "OBSERVATION", 63, 74], ["-1-dependent", "OBSERVATION_MODIFIER", 140, 152], ["endocytosis", "OBSERVATION", 153, 164], ["Enveloped", "OBSERVATION_MODIFIER", 174, 183], ["Viruses", "OBSERVATION", 184, 191], ["most pathogenic", "OBSERVATION_MODIFIER", 233, 248], ["viruses", "OBSERVATION", 249, 256], ["severe", "OBSERVATION_MODIFIER", 300, 306], ["hemorrhagic", "OBSERVATION_MODIFIER", 307, 318], ["fever", "OBSERVATION", 319, 324]]], ["The severe pathogenesis of these viruses in humans makes studies on the infection mechanism difficult to perform using intact viruses.", [["infection", "DISEASE", 72, 81], ["humans", "ORGANISM", 44, 50], ["humans", "SPECIES", 44, 50], ["humans", "SPECIES", 44, 50], ["The severe pathogenesis of these viruses", "PROBLEM", 0, 40], ["the infection mechanism", "PROBLEM", 68, 91], ["intact viruses", "PROBLEM", 119, 133], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["pathogenesis", "OBSERVATION", 11, 23], ["viruses", "OBSERVATION", 33, 40], ["viruses", "OBSERVATION", 126, 133]]], ["Results of studies using pseudotypes possessing these viral proteins suggest that filoviruses utilize acidified endosomes for vial entry [54, 55] .", [["endosomes", "ANATOMY", 112, 121], ["filoviruses", "GENE_OR_GENE_PRODUCT", 82, 93], ["endosomes", "CELLULAR_COMPONENT", 112, 121], ["viral proteins", "PROTEIN", 54, 68], ["studies", "TEST", 11, 18], ["pseudotypes", "TREATMENT", 25, 36], ["these viral proteins", "PROBLEM", 48, 68], ["vial entry", "TEST", 126, 136]]], ["Inhibitory effects of a cholesterol-removing reagent and a cholesterol synthesis inhibitor on viral infectivity have demonstrated the requirement of membrane rafts in filovirus entry [12, 15] .", [["membrane rafts", "ANATOMY", 149, 163], ["cholesterol", "CHEMICAL", 24, 35], ["cholesterol", "CHEMICAL", 59, 70], ["cholesterol", "CHEMICAL", 24, 35], ["cholesterol", "CHEMICAL", 59, 70], ["cholesterol", "SIMPLE_CHEMICAL", 24, 35], ["cholesterol", "SIMPLE_CHEMICAL", 59, 70], ["membrane rafts", "CELLULAR_COMPONENT", 149, 163], ["a cholesterol", "TREATMENT", 22, 35], ["removing reagent", "TREATMENT", 36, 52], ["a cholesterol synthesis inhibitor", "TREATMENT", 57, 90], ["viral infectivity", "PROBLEM", 94, 111], ["membrane rafts", "TREATMENT", 149, 163], ["membrane rafts", "OBSERVATION", 149, 163]]], ["The entry process of pseudotypes and virus-like particles bearing glycoproteins of Zaire Ebola virus and Lake Victoria Marburg virus appears to occur through multiple pathways including dynamin-dependent (clathrin-dependent and caveoladependent endocytosis) and dynamin-independent pathways such as macropinocytosis that is enhanced by Axl, a plasma membrane-associated Tyro3/Axl/Mer (TAM) family member, although Axl is not a receptor for filoviruses [14] .", [["plasma membrane", "ANATOMY", 343, 358], ["Ebola virus", "DISEASE", 89, 100], ["virus-like particles", "ORGANISM", 37, 57], ["Zaire Ebola virus", "ORGANISM", 83, 100], ["Lake Victoria Marburg virus", "ORGANISM", 105, 132], ["dynamin", "GENE_OR_GENE_PRODUCT", 186, 193], ["clathrin", "GENE_OR_GENE_PRODUCT", 205, 213], ["caveoladependent", "GENE_OR_GENE_PRODUCT", 228, 244], ["dynamin", "GENE_OR_GENE_PRODUCT", 262, 269], ["Axl", "GENE_OR_GENE_PRODUCT", 336, 339], ["plasma membrane", "CELLULAR_COMPONENT", 343, 358], ["Tyro3", "GENE_OR_GENE_PRODUCT", 370, 375], ["Axl", "GENE_OR_GENE_PRODUCT", 376, 379], ["Mer", "GENE_OR_GENE_PRODUCT", 380, 383], ["TAM", "GENE_OR_GENE_PRODUCT", 385, 388], ["Axl", "GENE_OR_GENE_PRODUCT", 414, 417], ["dynamin", "PROTEIN", 186, 193], ["clathrin", "PROTEIN", 205, 213], ["dynamin", "PROTEIN", 262, 269], ["Axl", "PROTEIN", 336, 339], ["plasma membrane-associated Tyro3/Axl/Mer (TAM) family member", "PROTEIN", 343, 403], ["Axl", "PROTEIN", 414, 417], ["Zaire Ebola virus", "SPECIES", 83, 100], ["Victoria Marburg virus", "SPECIES", 110, 132], ["Zaire Ebola virus", "SPECIES", 83, 100], ["Lake Victoria Marburg virus", "SPECIES", 105, 132], ["pseudotypes", "PROBLEM", 21, 32], ["virus", "PROBLEM", 37, 42], ["Zaire Ebola virus", "PROBLEM", 83, 100], ["Lake Victoria Marburg virus", "PROBLEM", 105, 132], ["dynamin-dependent (clathrin-dependent", "PROBLEM", 186, 223], ["caveoladependent endocytosis", "PROBLEM", 228, 256], ["dynamin-independent pathways", "PROBLEM", 262, 290], ["macropinocytosis", "PROBLEM", 299, 315], ["a plasma membrane", "TEST", 341, 358], ["Tyro3/Axl/Mer (TAM)", "TREATMENT", 370, 389], ["filoviruses", "PROBLEM", 440, 451], ["pseudotypes", "OBSERVATION", 21, 32], ["virus", "OBSERVATION", 37, 42], ["particles", "OBSERVATION_MODIFIER", 48, 57], ["Zaire", "OBSERVATION_MODIFIER", 83, 88], ["Ebola virus", "OBSERVATION", 89, 100], ["dependent", "OBSERVATION_MODIFIER", 194, 203]]], ["Ebola fusion peptide, a hydrophobic helical domain that belongs to the GP2 membrane fusion protein of Ebola virus, is sensitive to interaction with membrane rafts, suggesting the involvement of membrane rafts in the fusion process of Ebola virus during entry into cells [13] .Entry of Enveloped VirusesFlaviviruses enter cells through receptor-mediated endocytosis and are delivered into acidic endosomes, leading to release of viral genomic RNA into the cytoplasm by uncoating of the virion.", [["membrane rafts", "ANATOMY", 148, 162], ["membrane rafts", "ANATOMY", 194, 208], ["cells", "ANATOMY", 264, 269], ["cells", "ANATOMY", 321, 326], ["acidic endosomes", "ANATOMY", 388, 404], ["cytoplasm", "ANATOMY", 455, 464], ["virion", "ANATOMY", 485, 491], ["Ebola", "DISEASE", 0, 5], ["Ebola", "DISEASE", 234, 239], ["Ebola", "ORGANISM", 0, 5], ["GP2", "GENE_OR_GENE_PRODUCT", 71, 74], ["Ebola virus", "ORGANISM", 102, 113], ["membrane rafts", "CELLULAR_COMPONENT", 148, 162], ["membrane rafts", "CELLULAR_COMPONENT", 194, 208], ["Ebola virus", "ORGANISM", 234, 245], ["cells", "CELL", 264, 269], ["cells", "CELL", 321, 326], ["acidic endosomes", "CELLULAR_COMPONENT", 388, 404], ["cytoplasm", "ORGANISM_SUBSTANCE", 455, 464], ["virion", "CELLULAR_COMPONENT", 485, 491], ["hydrophobic helical domain", "PROTEIN", 24, 50], ["GP2 membrane fusion protein", "PROTEIN", 71, 98], ["viral genomic RNA", "RNA", 428, 445], ["Ebola virus", "SPECIES", 102, 113], ["Ebola virus", "SPECIES", 234, 245], ["Ebola virus", "SPECIES", 102, 113], ["Ebola virus", "SPECIES", 234, 245], ["Ebola fusion peptide", "TREATMENT", 0, 20], ["a hydrophobic helical domain", "PROBLEM", 22, 50], ["Ebola virus", "PROBLEM", 102, 113], ["membrane rafts", "TREATMENT", 148, 162], ["membrane rafts", "PROBLEM", 194, 208], ["Ebola virus", "PROBLEM", 234, 245], ["Enveloped VirusesFlaviviruses", "PROBLEM", 285, 314], ["receptor-mediated endocytosis", "TREATMENT", 335, 364], ["viral genomic RNA", "PROBLEM", 428, 445], ["Ebola virus", "OBSERVATION", 102, 113], ["membrane rafts", "OBSERVATION", 148, 162], ["membrane rafts", "OBSERVATION", 194, 208], ["Ebola virus", "OBSERVATION", 234, 245], ["Enveloped", "OBSERVATION_MODIFIER", 285, 294], ["Viruses", "OBSERVATION", 295, 302], ["endocytosis", "OBSERVATION", 353, 364], ["viral genomic RNA", "OBSERVATION", 428, 445]]], ["Severe disease caused by WNV infection is manifested as neurological symptoms such as meningitis, encephalitis, and poliomyelitis.", [["neurological", "ANATOMY", 56, 68], ["WNV infection", "DISEASE", 25, 38], ["meningitis", "DISEASE", 86, 96], ["encephalitis", "DISEASE", 98, 110], ["poliomyelitis", "DISEASE", 116, 129], ["WNV", "ORGANISM", 25, 28], ["WNV", "SPECIES", 25, 28], ["Severe disease", "PROBLEM", 0, 14], ["WNV infection", "PROBLEM", 25, 38], ["neurological symptoms", "PROBLEM", 56, 77], ["meningitis", "PROBLEM", 86, 96], ["encephalitis", "PROBLEM", 98, 110], ["poliomyelitis", "PROBLEM", 116, 129], ["disease", "OBSERVATION", 7, 14], ["WNV", "OBSERVATION_MODIFIER", 25, 28], ["infection", "OBSERVATION", 29, 38], ["meningitis", "OBSERVATION", 86, 96], ["encephalitis", "OBSERVATION", 98, 110], ["poliomyelitis", "OBSERVATION", 116, 129]]], ["A nonpathogenic laboratory strain of WNV (Sarafend strain) binds to \u03b1 V \u03b2 3 integrin as a viral receptor and enters cells through a clathrin-dependent endocytic pathway and activation of focal adhesion kinase (FAK) [56, 57] .", [["cells", "ANATOMY", 116, 121], ["WNV", "ORGANISM", 37, 40], ["Sarafend strain", "ORGANISM", 42, 57], ["\u03b1 V \u03b2 3 integrin", "GENE_OR_GENE_PRODUCT", 68, 84], ["cells", "CELL", 116, 121], ["clathrin", "GENE_OR_GENE_PRODUCT", 132, 140], ["focal adhesion kinase", "GENE_OR_GENE_PRODUCT", 187, 208], ["FAK", "GENE_OR_GENE_PRODUCT", 210, 213], ["\u03b1 V \u03b2 3 integrin", "PROTEIN", 68, 84], ["viral receptor", "PROTEIN", 90, 104], ["clathrin", "PROTEIN", 132, 140], ["focal adhesion kinase", "PROTEIN", 187, 208], ["FAK", "PROTEIN", 210, 213], ["WNV", "SPECIES", 37, 40], ["A nonpathogenic laboratory strain of WNV", "PROBLEM", 0, 40], ["a viral receptor", "TREATMENT", 88, 104], ["a clathrin", "TREATMENT", 130, 140], ["focal adhesion kinase", "PROBLEM", 187, 208], ["nonpathogenic", "OBSERVATION_MODIFIER", 2, 15], ["laboratory strain", "OBSERVATION", 16, 33], ["focal", "OBSERVATION_MODIFIER", 187, 192], ["adhesion kinase", "OBSERVATION", 193, 208]]], ["However, NY385-99 strain of WNV utilizes a raft-mediated endocytic pathway that is not associated with \u03b1 V \u03b2 3 integrin and FAK activation [16] .", [["raft", "ANATOMY", 43, 47], ["NY385-99", "CHEMICAL", 9, 17], ["WNV", "DISEASE", 28, 31], ["NY385-99", "CHEMICAL", 9, 17], ["NY385-99 strain", "ORGANISM", 9, 24], ["WNV", "ORGANISM", 28, 31], ["raft", "CELLULAR_COMPONENT", 43, 47], ["\u03b1 V \u03b2 3 integrin", "GENE_OR_GENE_PRODUCT", 103, 119], ["FAK", "GENE_OR_GENE_PRODUCT", 124, 127], ["\u03b1 V \u03b2 3 integrin", "PROTEIN", 103, 119], ["FAK", "PROTEIN", 124, 127], ["WNV", "SPECIES", 28, 31], ["NY385", "TEST", 9, 14], ["WNV", "PROBLEM", 28, 31]]], ["Use of membrane rafts in the entry process depends on the virus strain.Entry of Enveloped VirusesDEN, an important arthropod-borne human pathogen, is clinically manifested from a simple self-limited febrile illness known as dengue fever to a hemorrhagic fever and potentially fatal hemorrhagic shock syndrome.", [["membrane rafts", "ANATOMY", 7, 21], ["VirusesDEN", "CHEMICAL", 90, 100], ["febrile illness", "DISEASE", 199, 214], ["dengue fever", "DISEASE", 224, 236], ["hemorrhagic fever", "DISEASE", 242, 259], ["hemorrhagic shock", "DISEASE", 282, 299], ["membrane rafts", "CELLULAR_COMPONENT", 7, 21], ["VirusesDEN", "GENE_OR_GENE_PRODUCT", 90, 100], ["human", "ORGANISM", 131, 136], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["membrane rafts", "TREATMENT", 7, 21], ["the virus strain", "PROBLEM", 54, 70], ["a simple self-limited febrile illness", "PROBLEM", 177, 214], ["dengue fever", "PROBLEM", 224, 236], ["a hemorrhagic fever", "PROBLEM", 240, 259], ["fatal hemorrhagic shock syndrome", "PROBLEM", 276, 308], ["membrane rafts", "OBSERVATION", 7, 21], ["Enveloped", "OBSERVATION_MODIFIER", 80, 89], ["VirusesDEN", "OBSERVATION", 90, 100], ["hemorrhagic", "OBSERVATION_MODIFIER", 242, 253], ["fever", "OBSERVATION", 254, 259], ["potentially", "UNCERTAINTY", 264, 275], ["fatal", "OBSERVATION_MODIFIER", 276, 281], ["hemorrhagic", "OBSERVATION_MODIFIER", 282, 293], ["shock syndrome", "OBSERVATION", 294, 308]]], ["Reported candidates of the DEN receptor for the entry process include dendritic cell-specific ICAM 3-grabbing nonintegrin (DC-SIGN) [58] , heparan sulfate [59] , heat shock proteins (HSPs) [18] , and neolactotetraosylceramide [60] .", [["dendritic cell", "ANATOMY", 70, 84], ["DEN", "CHEMICAL", 27, 30], ["heparan sulfate", "CHEMICAL", 139, 154], ["neolactotetraosylceramide", "CHEMICAL", 200, 225], ["sulfate", "CHEMICAL", 147, 154], ["neolactotetraosylceramide", "CHEMICAL", 200, 225], ["DEN receptor", "GENE_OR_GENE_PRODUCT", 27, 39], ["dendritic cell", "CELL", 70, 84], ["ICAM 3", "GENE_OR_GENE_PRODUCT", 94, 100], ["nonintegrin", "GENE_OR_GENE_PRODUCT", 110, 121], ["DC-SIGN", "SIMPLE_CHEMICAL", 123, 130], ["heparan sulfate [59]", "SIMPLE_CHEMICAL", 139, 159], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 162, 181], ["HSPs", "GENE_OR_GENE_PRODUCT", 183, 187], ["neolactotetraosylceramide", "SIMPLE_CHEMICAL", 200, 225], ["DEN receptor", "PROTEIN", 27, 39], ["dendritic cell", "CELL_TYPE", 70, 84], ["ICAM 3", "PROTEIN", 94, 100], ["grabbing nonintegrin", "PROTEIN", 101, 121], ["DC", "PROTEIN", 123, 125], ["SIGN", "PROTEIN", 126, 130], ["heparan sulfate [59] , heat shock proteins", "PROTEIN", 139, 181], ["HSPs", "PROTEIN", 183, 187], ["the DEN receptor", "TREATMENT", 23, 39], ["the entry process", "PROBLEM", 44, 61], ["dendritic cell", "PROBLEM", 70, 84], ["specific ICAM", "TEST", 85, 98], ["heparan sulfate", "TREATMENT", 139, 154], ["heat shock proteins (HSPs)", "TREATMENT", 162, 188], ["neolactotetraosylceramide", "TREATMENT", 200, 225], ["dendritic cell", "OBSERVATION", 70, 84]]], ["HSP90 and HSP70 are part of a receptor complex of DEN and are associated with membrane rafts essential for virus entry into neuroblastoma cells and human monocytes/macrophages [18, 19] .", [["membrane rafts", "ANATOMY", 78, 92], ["neuroblastoma cells", "ANATOMY", 124, 143], ["monocytes", "ANATOMY", 154, 163], ["macrophages", "ANATOMY", 164, 175], ["HSP90", "GENE_OR_GENE_PRODUCT", 0, 5], ["HSP70", "GENE_OR_GENE_PRODUCT", 10, 15], ["DEN", "SIMPLE_CHEMICAL", 50, 53], ["membrane rafts", "CELLULAR_COMPONENT", 78, 92], ["neuroblastoma cells", "CELL", 124, 143], ["human", "ORGANISM", 148, 153], ["monocytes", "CELL", 154, 163], ["macrophages", "CELL", 164, 175], ["HSP90", "PROTEIN", 0, 5], ["HSP70", "PROTEIN", 10, 15], ["receptor complex", "PROTEIN", 30, 46], ["neuroblastoma cells", "CELL_TYPE", 124, 143], ["human monocytes", "CELL_TYPE", 148, 163], ["macrophages", "CELL_TYPE", 164, 175], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["HSP90", "TEST", 0, 5], ["HSP70", "TEST", 10, 15], ["a receptor complex of DEN", "PROBLEM", 28, 53], ["membrane rafts", "TREATMENT", 78, 92], ["virus entry into neuroblastoma cells", "PROBLEM", 107, 143], ["human monocytes/macrophages", "TEST", 148, 175], ["neuroblastoma cells", "OBSERVATION", 124, 143], ["macrophages", "ANATOMY", 164, 175]]], ["DC-SIGN is present in membrane rafts [61] , and neolactotetraosylceramide is a sphingolipid within membrane rafts.", [["membrane rafts", "ANATOMY", 22, 36], ["membrane rafts", "ANATOMY", 99, 113], ["neolactotetraosylceramide", "CHEMICAL", 48, 73], ["neolactotetraosylceramide", "CHEMICAL", 48, 73], ["sphingolipid", "CHEMICAL", 79, 91], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 0, 7], ["membrane rafts", "CELLULAR_COMPONENT", 22, 36], ["neolactotetraosylceramide", "SIMPLE_CHEMICAL", 48, 73], ["sphingolipid", "SIMPLE_CHEMICAL", 79, 91], ["membrane rafts", "CELLULAR_COMPONENT", 99, 113], ["DC", "CELL_TYPE", 0, 2], ["SIGN", "PROTEIN", 3, 7], ["neolactotetraosylceramide", "TREATMENT", 48, 73], ["membrane rafts", "OBSERVATION", 99, 113]]], ["One of risk factors of hemorrhagic fever and fatal hemorrhagic shock syndrome after secondary infection with a serotype different from the primary infection is probably antibody-dependent enhancement (ADE), which can be explained by the hypothesis that preexisting nonneutralizing antibodies will generate immune complexes with a new serotype secondary-infecting DEN, leading to enhancement of the capacity to infect macrophages and other Fc \u03a5 receptor-(Fc \u03a5 -) bearing cells.", [["macrophages", "ANATOMY", 417, 428], ["cells", "ANATOMY", 470, 475], ["hemorrhagic fever", "DISEASE", 23, 40], ["hemorrhagic shock", "DISEASE", 51, 68], ["infection", "DISEASE", 94, 103], ["primary infection", "DISEASE", 139, 156], ["DEN", "CHEMICAL", 363, 366], ["DEN", "ORGANISM", 363, 366], ["macrophages", "CELL", 417, 428], ["Fc \u03a5 receptor", "GENE_OR_GENE_PRODUCT", 439, 452], ["cells", "CELL", 470, 475], ["nonneutralizing antibodies", "PROTEIN", 265, 291], ["immune complexes", "PROTEIN", 306, 322], ["macrophages", "CELL_TYPE", 417, 428], ["Fc \u03a5 receptor-(Fc \u03a5 -) bearing cells", "CELL_LINE", 439, 475], ["hemorrhagic fever", "PROBLEM", 23, 40], ["fatal hemorrhagic shock syndrome", "PROBLEM", 45, 77], ["secondary infection", "PROBLEM", 84, 103], ["a serotype", "PROBLEM", 109, 119], ["the primary infection", "PROBLEM", 135, 156], ["antibody-dependent enhancement", "PROBLEM", 169, 199], ["preexisting nonneutralizing antibodies", "PROBLEM", 253, 291], ["immune complexes", "PROBLEM", 306, 322], ["infecting DEN", "PROBLEM", 353, 366], ["the capacity", "PROBLEM", 394, 406], ["macrophages", "TEST", 417, 428], ["receptor", "TEST", 444, 452], ["hemorrhagic", "OBSERVATION_MODIFIER", 23, 34], ["fever", "OBSERVATION", 35, 40], ["fatal", "OBSERVATION_MODIFIER", 45, 50], ["hemorrhagic", "OBSERVATION_MODIFIER", 51, 62], ["shock syndrome", "OBSERVATION", 63, 77], ["secondary", "OBSERVATION_MODIFIER", 84, 93], ["infection", "OBSERVATION", 94, 103], ["serotype different", "OBSERVATION_MODIFIER", 111, 129], ["primary", "OBSERVATION_MODIFIER", 139, 146], ["infection", "OBSERVATION", 147, 156], ["probably", "UNCERTAINTY", 160, 168], ["antibody", "OBSERVATION_MODIFIER", 169, 177], ["dependent", "OBSERVATION_MODIFIER", 178, 187], ["enhancement", "OBSERVATION_MODIFIER", 188, 199], ["bearing cells", "OBSERVATION", 462, 475]]], ["The ADE of DEN-4 infection in the human myelomonocyte cell line U937 has been suggested to require membrane rafts [20] .", [["myelomonocyte cell line U937", "ANATOMY", 40, 68], ["membrane rafts", "ANATOMY", 99, 113], ["DEN-4", "CHEMICAL", 11, 16], ["infection", "DISEASE", 17, 26], ["U937", "CHEMICAL", 64, 68], ["DEN-4", "CHEMICAL", 11, 16], ["DEN-4", "ORGANISM", 11, 16], ["human", "ORGANISM", 34, 39], ["myelomonocyte cell line U937", "CELL", 40, 68], ["membrane", "CELLULAR_COMPONENT", 99, 107], ["human myelomonocyte cell line U937", "CELL_LINE", 34, 68], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39], ["DEN", "PROBLEM", 11, 14], ["4 infection", "PROBLEM", 15, 26], ["the human myelomonocyte cell line", "TREATMENT", 30, 63], ["membrane rafts", "TREATMENT", 99, 113], ["DEN", "OBSERVATION", 11, 14], ["infection", "OBSERVATION", 17, 26]]], ["The entry process of JEV, the leading cause of acute encephalitis in South-East Asia, also requires membrane rafts in neural stem/progenitor cells [19, 21] , possibly via the putative receptor HSP70 [62] and heparin sulfate [63] like DEN.", [["membrane rafts", "ANATOMY", 100, 114], ["neural stem/progenitor cells", "ANATOMY", 118, 146], ["JEV", "DISEASE", 21, 24], ["encephalitis", "DISEASE", 53, 65], ["heparin sulfate", "CHEMICAL", 208, 223], ["DEN", "CHEMICAL", 234, 237], ["sulfate", "CHEMICAL", 216, 223], ["DEN", "CHEMICAL", 234, 237], ["JEV", "ORGANISM", 21, 24], ["membrane rafts", "CELLULAR_COMPONENT", 100, 114], ["neural stem/progenitor cells", "CELL", 118, 146], ["HSP70", "GENE_OR_GENE_PRODUCT", 193, 198], ["heparin sulfate [63]", "SIMPLE_CHEMICAL", 208, 228], ["DEN", "SIMPLE_CHEMICAL", 234, 237], ["neural stem/progenitor cells", "CELL_TYPE", 118, 146], ["HSP70", "PROTEIN", 193, 198], ["JEV", "SPECIES", 21, 24], ["JEV", "PROBLEM", 21, 24], ["acute encephalitis", "PROBLEM", 47, 65], ["membrane rafts", "TREATMENT", 100, 114], ["heparin sulfate", "TREATMENT", 208, 223], ["JEV", "OBSERVATION", 21, 24], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["encephalitis", "OBSERVATION", 53, 65], ["membrane rafts", "OBSERVATION", 100, 114], ["neural stem", "ANATOMY", 118, 129]]], ["The phosphatidylinositol-3 kinase (PI3K)/Akt pathway is activated through membrane rafts as a signal platform during early JEV infection, resulting in increased production of the infectious progeny viruses [21] .Entry of Enveloped VirusesHCV is a major cause of chronic liver disease, including chronic hepatitis, hepatic steatosis, cirrhosis, and hepatocellular carcinoma.", [["membrane rafts", "ANATOMY", 74, 88], ["liver", "ANATOMY", 270, 275], ["hepatic", "ANATOMY", 314, 321], ["hepatocellular carcinoma", "ANATOMY", 348, 372], ["JEV infection", "DISEASE", 123, 136], ["chronic liver disease", "DISEASE", 262, 283], ["chronic hepatitis, hepatic steatosis", "DISEASE", 295, 331], ["cirrhosis", "DISEASE", 333, 342], ["hepatocellular carcinoma", "DISEASE", 348, 372], ["phosphatidylinositol", "CHEMICAL", 4, 24], ["phosphatidylinositol-3 kinase", "GENE_OR_GENE_PRODUCT", 4, 33], ["PI3K", "GENE_OR_GENE_PRODUCT", 35, 39], ["Akt", "GENE_OR_GENE_PRODUCT", 41, 44], ["membrane rafts", "CELLULAR_COMPONENT", 74, 88], ["JEV", "ORGANISM", 123, 126], ["Enveloped VirusesHCV", "ORGANISM", 221, 241], ["liver", "ORGAN", 270, 275], ["hepatic", "ORGAN", 314, 321], ["hepatocellular carcinoma", "CANCER", 348, 372], ["phosphatidylinositol-3 kinase", "PROTEIN", 4, 33], ["PI3K", "PROTEIN", 35, 39], ["Akt", "PROTEIN", 41, 44], ["JEV", "SPECIES", 123, 126], ["The phosphatidylinositol", "TEST", 0, 24], ["Akt pathway", "TEST", 41, 52], ["a signal platform", "PROBLEM", 92, 109], ["early JEV infection", "PROBLEM", 117, 136], ["the infectious progeny viruses", "PROBLEM", 175, 205], ["chronic liver disease", "PROBLEM", 262, 283], ["chronic hepatitis", "PROBLEM", 295, 312], ["hepatic steatosis", "PROBLEM", 314, 331], ["cirrhosis", "PROBLEM", 333, 342], ["hepatocellular carcinoma", "PROBLEM", 348, 372], ["JEV infection", "OBSERVATION", 123, 136], ["increased", "OBSERVATION_MODIFIER", 151, 160], ["production", "OBSERVATION_MODIFIER", 161, 171], ["infectious", "OBSERVATION_MODIFIER", 179, 189], ["progeny viruses", "OBSERVATION", 190, 205], ["Enveloped", "OBSERVATION_MODIFIER", 221, 230], ["VirusesHCV", "OBSERVATION", 231, 241], ["chronic", "OBSERVATION_MODIFIER", 262, 269], ["liver", "ANATOMY", 270, 275], ["disease", "OBSERVATION", 276, 283], ["chronic", "OBSERVATION_MODIFIER", 295, 302], ["hepatitis", "OBSERVATION", 303, 312], ["hepatic", "ANATOMY", 314, 321], ["steatosis", "OBSERVATION", 322, 331], ["cirrhosis", "OBSERVATION", 333, 342], ["hepatocellular", "ANATOMY", 348, 362], ["carcinoma", "OBSERVATION", 363, 372]]], ["A cholesterol-removing reagent has an inhibitory effect on HCV entry through the virus receptor CD81 within membrane rafts [22] .", [["membrane rafts", "ANATOMY", 108, 122], ["cholesterol", "CHEMICAL", 2, 13], ["cholesterol", "CHEMICAL", 2, 13], ["cholesterol", "SIMPLE_CHEMICAL", 2, 13], ["HCV", "ORGANISM", 59, 62], ["CD81", "GENE_OR_GENE_PRODUCT", 96, 100], ["membrane rafts", "CELLULAR_COMPONENT", 108, 122], ["virus receptor CD81", "PROTEIN", 81, 100], ["HCV", "SPECIES", 59, 62], ["A cholesterol", "TEST", 0, 13], ["reagent", "TREATMENT", 23, 30], ["an inhibitory effect", "PROBLEM", 35, 55], ["HCV entry", "PROBLEM", 59, 68], ["the virus receptor CD81", "TREATMENT", 77, 100]]], ["Sphingomyelin hydrolysis shows a strong inhibitory effect on HCV entry, because ceramide enrichment of the plasma membrane leads to a decreased level of CD81 at the cell surface membrane by enhancement of CD81 internalization [23] .", [["plasma membrane", "ANATOMY", 107, 122], ["cell surface membrane", "ANATOMY", 165, 186], ["Sphingomyelin", "CHEMICAL", 0, 13], ["ceramide", "CHEMICAL", 80, 88], ["Sphingomyelin", "CHEMICAL", 0, 13], ["ceramide", "CHEMICAL", 80, 88], ["Sphingomyelin", "SIMPLE_CHEMICAL", 0, 13], ["HCV", "ORGANISM", 61, 64], ["ceramide", "SIMPLE_CHEMICAL", 80, 88], ["plasma membrane", "CELLULAR_COMPONENT", 107, 122], ["CD81", "GENE_OR_GENE_PRODUCT", 153, 157], ["cell surface membrane", "CELLULAR_COMPONENT", 165, 186], ["CD81", "GENE_OR_GENE_PRODUCT", 205, 209], ["CD81", "PROTEIN", 153, 157], ["CD81", "PROTEIN", 205, 209], ["HCV", "SPECIES", 61, 64], ["Sphingomyelin hydrolysis", "PROBLEM", 0, 24], ["a strong inhibitory effect", "PROBLEM", 31, 57], ["HCV entry", "PROBLEM", 61, 70], ["ceramide enrichment of the plasma membrane", "PROBLEM", 80, 122], ["a decreased level of CD81", "PROBLEM", 132, 157], ["CD81 internalization", "PROBLEM", 205, 225], ["decreased", "OBSERVATION_MODIFIER", 134, 143], ["CD81 internalization", "OBSERVATION", 205, 225]]], ["Thus, the entry process of HCV through CD81 is partially dependent on some major raft components, such as cholesterol and sphingomyelin, at the cell surface membrane.Entry of Enveloped VirusesEBV is a human herpesvirus causing infectious mononucleosis and is associated with a variety of human lymphocytic and epithelial neoplasms, including Burkitt's lymphoma and nasopharyngeal carcinoma.", [["raft", "ANATOMY", 81, 85], ["cell surface membrane", "ANATOMY", 144, 165], ["lymphocytic", "ANATOMY", 294, 305], ["epithelial neoplasms", "ANATOMY", 310, 330], ["Burkitt's lymphoma", "ANATOMY", 342, 360], ["nasopharyngeal carcinoma", "ANATOMY", 365, 389], ["cholesterol", "CHEMICAL", 106, 117], ["sphingomyelin", "CHEMICAL", 122, 135], ["herpesvirus", "DISEASE", 207, 218], ["infectious mononucleosis", "DISEASE", 227, 251], ["neoplasms", "DISEASE", 321, 330], ["Burkitt's lymphoma", "DISEASE", 342, 360], ["nasopharyngeal carcinoma", "DISEASE", 365, 389], ["cholesterol", "CHEMICAL", 106, 117], ["sphingomyelin", "CHEMICAL", 122, 135], ["HCV", "ORGANISM", 27, 30], ["CD81", "GENE_OR_GENE_PRODUCT", 39, 43], ["raft components", "CELLULAR_COMPONENT", 81, 96], ["cholesterol", "SIMPLE_CHEMICAL", 106, 117], ["sphingomyelin", "SIMPLE_CHEMICAL", 122, 135], ["cell surface membrane", "CELLULAR_COMPONENT", 144, 165], ["VirusesEBV", "GENE_OR_GENE_PRODUCT", 185, 195], ["human", "ORGANISM", 201, 206], ["herpesvirus", "ORGANISM", 207, 218], ["human", "ORGANISM", 288, 293], ["lymphocytic", "CANCER", 294, 305], ["epithelial neoplasms", "CANCER", 310, 330], ["Burkitt's lymphoma", "CANCER", 342, 360], ["nasopharyngeal carcinoma", "CANCER", 365, 389], ["CD81", "PROTEIN", 39, 43], ["Enveloped VirusesEBV", "PROTEIN", 175, 195], ["human", "SPECIES", 201, 206], ["human", "SPECIES", 288, 293], ["HCV", "SPECIES", 27, 30], ["human herpesvirus", "SPECIES", 201, 218], ["human", "SPECIES", 288, 293], ["HCV through CD81", "PROBLEM", 27, 43], ["partially dependent", "PROBLEM", 47, 66], ["a human herpesvirus", "PROBLEM", 199, 218], ["infectious mononucleosis", "PROBLEM", 227, 251], ["human lymphocytic and epithelial neoplasms", "PROBLEM", 288, 330], ["Burkitt's lymphoma", "PROBLEM", 342, 360], ["nasopharyngeal carcinoma", "PROBLEM", 365, 389], ["HCV", "OBSERVATION", 27, 30], ["partially", "OBSERVATION_MODIFIER", 47, 56], ["dependent", "OBSERVATION_MODIFIER", 57, 66], ["some", "OBSERVATION_MODIFIER", 70, 74], ["major", "OBSERVATION_MODIFIER", 75, 80], ["raft components", "OBSERVATION", 81, 96], ["cholesterol", "OBSERVATION_MODIFIER", 106, 117], ["sphingomyelin", "OBSERVATION_MODIFIER", 122, 135], ["cell", "ANATOMY_MODIFIER", 144, 148], ["surface", "ANATOMY_MODIFIER", 149, 156], ["membrane", "ANATOMY_MODIFIER", 157, 165], ["infectious", "OBSERVATION_MODIFIER", 227, 237], ["human lymphocytic", "OBSERVATION", 288, 305], ["epithelial neoplasms", "OBSERVATION", 310, 330], ["Burkitt's lymphoma", "OBSERVATION", 342, 360], ["nasopharyngeal", "ANATOMY", 365, 379], ["carcinoma", "OBSERVATION", 380, 389]]], ["EBV can recognize human complement receptor type 2 (CR2), also known as CD21, on the cell surface membrane of B lymphocytes [24, 64] .", [["cell surface membrane", "ANATOMY", 85, 106], ["B lymphocytes", "ANATOMY", 110, 123], ["EBV", "ORGANISM", 0, 3], ["human", "ORGANISM", 18, 23], ["complement receptor type 2", "GENE_OR_GENE_PRODUCT", 24, 50], ["CR2", "GENE_OR_GENE_PRODUCT", 52, 55], ["CD21", "GENE_OR_GENE_PRODUCT", 72, 76], ["cell surface membrane", "CELLULAR_COMPONENT", 85, 106], ["B lymphocytes", "CELL", 110, 123], ["human complement receptor type 2", "PROTEIN", 18, 50], ["CR2", "PROTEIN", 52, 55], ["CD21", "PROTEIN", 72, 76], ["B lymphocytes", "CELL_TYPE", 110, 123], ["human", "SPECIES", 18, 23], ["EBV", "SPECIES", 0, 3], ["human", "SPECIES", 18, 23], ["lymphocytes", "ANATOMY", 112, 123]]], ["Complexes of CD21 with CD19 and palmitoylated CD81 are present in membrane rafts.", [["membrane rafts", "ANATOMY", 66, 80], ["CD21", "GENE_OR_GENE_PRODUCT", 13, 17], ["CD19", "GENE_OR_GENE_PRODUCT", 23, 27], ["CD81", "GENE_OR_GENE_PRODUCT", 46, 50], ["membrane rafts", "CELLULAR_COMPONENT", 66, 80], ["CD21", "PROTEIN", 13, 17], ["CD19", "PROTEIN", 23, 27], ["palmitoylated CD81", "PROTEIN", 32, 50], ["CD19", "TEST", 23, 27], ["palmitoylated CD81", "PROBLEM", 32, 50], ["CD21", "OBSERVATION", 13, 17], ["palmitoylated CD81", "OBSERVATION", 32, 50], ["membrane rafts", "OBSERVATION", 66, 80]]], ["CD19/CD21/CD81 complexes in part stabilize B-cell antigen receptor (BCR) within membrane rafts, thus leading to enhancement of BCR-mediated signaling [25] .Entry of Enveloped VirusesHSV, belonging to the family of alphaherpesvirus, is a pathogen causing mucosal lesions of the mouth and genital organs in humans.", [["B-cell", "ANATOMY", 43, 49], ["membrane rafts", "ANATOMY", 80, 94], ["mucosal lesions", "ANATOMY", 254, 269], ["mouth", "ANATOMY", 277, 282], ["genital organs", "ANATOMY", 287, 301], ["mucosal lesions of the mouth", "DISEASE", 254, 282], ["CD19", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD21", "GENE_OR_GENE_PRODUCT", 5, 9], ["CD81", "GENE_OR_GENE_PRODUCT", 10, 14], ["B-cell antigen receptor", "GENE_OR_GENE_PRODUCT", 43, 66], ["BCR", "GENE_OR_GENE_PRODUCT", 68, 71], ["membrane rafts", "CELLULAR_COMPONENT", 80, 94], ["BCR", "GENE_OR_GENE_PRODUCT", 127, 130], ["VirusesHSV", "GENE_OR_GENE_PRODUCT", 175, 185], ["alphaherpesvirus", "GENE_OR_GENE_PRODUCT", 214, 230], ["mucosal lesions", "PATHOLOGICAL_FORMATION", 254, 269], ["mouth", "ORGANISM_SUBDIVISION", 277, 282], ["genital organs", "ORGAN", 287, 301], ["humans", "ORGANISM", 305, 311], ["CD19", "PROTEIN", 0, 4], ["CD21", "PROTEIN", 5, 9], ["CD81 complexes", "PROTEIN", 10, 24], ["B-cell antigen receptor", "PROTEIN", 43, 66], ["BCR", "PROTEIN", 68, 71], ["BCR", "PROTEIN", 127, 130], ["Enveloped VirusesHSV", "PROTEIN", 165, 185], ["humans", "SPECIES", 305, 311], ["humans", "SPECIES", 305, 311], ["CD19", "TEST", 0, 4], ["CD21", "TEST", 5, 9], ["CD81 complexes", "TEST", 10, 24], ["B-cell antigen receptor", "TEST", 43, 66], ["membrane rafts", "TEST", 80, 94], ["enhancement of BCR", "PROBLEM", 112, 130], ["alphaherpesvirus", "PROBLEM", 214, 230], ["a pathogen", "PROBLEM", 235, 245], ["mucosal lesions of the mouth and genital organs in humans", "PROBLEM", 254, 311], ["membrane rafts", "OBSERVATION", 80, 94], ["Enveloped", "OBSERVATION_MODIFIER", 165, 174], ["VirusesHSV", "OBSERVATION", 175, 185], ["lesions", "OBSERVATION", 262, 269], ["mouth", "ANATOMY", 277, 282], ["genital organs", "ANATOMY", 287, 301]]], ["HSV binds to and enters host cells through complicated processes involving the essential viral glycoproteins B (gB), gD, gH, and gL and multiple cellular molecules including the tumor necrosis factor receptor (TNFR) family [65] , nectin-1 or nectin-2 (two members of the immunoglobulin superfamily) [66] , paired immunoglobulin-like type 2 receptor (PILR) [67] , and a particular type of modified HSPGs [68, 69] .", [["cells", "ANATOMY", 29, 34], ["cellular", "ANATOMY", 145, 153], ["tumor", "DISEASE", 178, 183], ["HSV", "ORGANISM", 0, 3], ["host cells", "CELL", 24, 34], ["B", "GENE_OR_GENE_PRODUCT", 109, 110], ["gB", "GENE_OR_GENE_PRODUCT", 112, 114], ["gD", "GENE_OR_GENE_PRODUCT", 117, 119], ["gH", "GENE_OR_GENE_PRODUCT", 121, 123], ["gL", "GENE_OR_GENE_PRODUCT", 129, 131], ["tumor necrosis factor receptor", "GENE_OR_GENE_PRODUCT", 178, 208], ["TNFR", "GENE_OR_GENE_PRODUCT", 210, 214], ["nectin-1", "GENE_OR_GENE_PRODUCT", 230, 238], ["nectin-2", "GENE_OR_GENE_PRODUCT", 242, 250], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 271, 285], ["immunoglobulin-like type 2 receptor", "GENE_OR_GENE_PRODUCT", 313, 348], ["PILR", "GENE_OR_GENE_PRODUCT", 350, 354], ["HSPGs", "GENE_OR_GENE_PRODUCT", 397, 402], ["host cells", "CELL_TYPE", 24, 34], ["essential viral glycoproteins B", "PROTEIN", 79, 110], ["gB", "PROTEIN", 112, 114], ["gD", "PROTEIN", 117, 119], ["gH", "PROTEIN", 121, 123], ["gL", "PROTEIN", 129, 131], ["cellular molecules", "PROTEIN", 145, 163], ["tumor necrosis factor receptor (TNFR) family", "PROTEIN", 178, 222], ["nectin-1", "PROTEIN", 230, 238], ["nectin-2", "PROTEIN", 242, 250], ["immunoglobulin superfamily", "PROTEIN", 271, 297], ["paired immunoglobulin-like type 2 receptor", "PROTEIN", 306, 348], ["PILR", "PROTEIN", 350, 354], ["HSPGs", "PROTEIN", 397, 402], ["HSV", "SPECIES", 0, 3], ["HSV binds", "PROBLEM", 0, 9], ["complicated processes", "PROBLEM", 43, 64], ["gH", "TEST", 121, 123], ["multiple cellular molecules", "PROBLEM", 136, 163], ["the tumor necrosis", "PROBLEM", 174, 192], ["nectin", "TEST", 230, 236], ["the immunoglobulin superfamily", "TEST", 267, 297], ["paired immunoglobulin", "TEST", 306, 327], ["host cells", "OBSERVATION", 24, 34], ["viral glycoproteins", "OBSERVATION", 89, 108], ["gH", "ANATOMY", 121, 123], ["gL", "ANATOMY", 129, 131], ["multiple", "OBSERVATION_MODIFIER", 136, 144], ["cellular molecules", "OBSERVATION", 145, 163], ["tumor necrosis", "OBSERVATION", 178, 192]]], ["The association of TNFR with membrane rafts is essential for tumor necrosis factor alpha-(TNF\u03b1-) mediated nuclear factor-kappaB (NF-\u03baB) activation [70] .", [["membrane rafts", "ANATOMY", 29, 43], ["tumor", "DISEASE", 61, 66], ["necrosis", "DISEASE", 67, 75], ["TNFR", "GENE_OR_GENE_PRODUCT", 19, 23], ["membrane", "CELLULAR_COMPONENT", 29, 37], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 61, 88], ["TNF\u03b1-", "GENE_OR_GENE_PRODUCT", 90, 95], ["nuclear factor-kappaB", "GENE_OR_GENE_PRODUCT", 106, 127], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 129, 134], ["TNFR", "PROTEIN", 19, 23], ["tumor necrosis factor alpha", "PROTEIN", 61, 88], ["TNF\u03b1-) mediated nuclear factor-kappaB", "PROTEIN", 90, 127], ["NF-\u03baB", "PROTEIN", 129, 134], ["membrane rafts", "TREATMENT", 29, 43], ["tumor necrosis", "PROBLEM", 61, 75], ["alpha", "TEST", 83, 88], ["TNF", "TEST", 90, 93], ["nuclear factor", "TEST", 106, 120], ["TNFR", "OBSERVATION", 19, 23], ["membrane rafts", "OBSERVATION", 29, 43], ["essential for", "UNCERTAINTY", 47, 60], ["tumor", "OBSERVATION_MODIFIER", 61, 66], ["necrosis", "OBSERVATION", 67, 75]]], ["Similarly, the association of HSPG with membrane rafts is correlated with protein kinase C alpha (PKC\u03b1) activation [71] .", [["membrane rafts", "ANATOMY", 40, 54], ["HSPG", "GENE_OR_GENE_PRODUCT", 30, 34], ["membrane rafts", "CELLULAR_COMPONENT", 40, 54], ["protein kinase C alpha", "GENE_OR_GENE_PRODUCT", 74, 96], ["PKC\u03b1", "GENE_OR_GENE_PRODUCT", 98, 102], ["HSPG", "PROTEIN", 30, 34], ["protein kinase C alpha", "PROTEIN", 74, 96], ["PKC\u03b1", "PROTEIN", 98, 102], ["membrane rafts", "TREATMENT", 40, 54], ["protein kinase", "TEST", 74, 88], ["HSPG", "OBSERVATION_MODIFIER", 30, 34], ["membrane rafts", "OBSERVATION", 40, 54]]], ["Nectin-1 binding to gD of HSV-1 is not associated with membrane rafts either before or during HSV-1 infection in several cell lines.", [["membrane rafts", "ANATOMY", 55, 69], ["cell lines", "ANATOMY", 121, 131], ["infection", "DISEASE", 100, 109], ["Nectin-1", "GENE_OR_GENE_PRODUCT", 0, 8], ["HSV-1", "ORGANISM", 26, 31], ["membrane rafts", "CELLULAR_COMPONENT", 55, 69], ["HSV-1", "ORGANISM", 94, 99], ["cell lines", "CELL", 121, 131], ["Nectin", "PROTEIN", 0, 6], ["gD", "PROTEIN", 20, 22], ["HSV-1", "SPECIES", 26, 31], ["HSV-1", "SPECIES", 94, 99], ["Nectin", "TREATMENT", 0, 6], ["HSV", "PROBLEM", 26, 29], ["membrane rafts", "PROBLEM", 55, 69], ["HSV", "PROBLEM", 94, 97], ["1 infection", "PROBLEM", 98, 109], ["several cell lines", "TREATMENT", 113, 131], ["infection", "OBSERVATION", 100, 109], ["several cell lines", "OBSERVATION", 113, 131]]], ["In the absence of \u03b1 V \u03b2 3 -integrin, HSV-1 utilizes raft-independent and dynamin2-independent pathways to reach the intracellular neutral pH compartment, where the viral envelope fuses with the plasma membrane [27] .", [["raft", "ANATOMY", 52, 56], ["intracellular", "ANATOMY", 116, 129], ["plasma membrane", "ANATOMY", 194, 209], ["\u03b1 V \u03b2 3 -integrin", "GENE_OR_GENE_PRODUCT", 18, 35], ["HSV-1", "GENE_OR_GENE_PRODUCT", 37, 42], ["raft", "CELLULAR_COMPONENT", 52, 56], ["dynamin2", "GENE_OR_GENE_PRODUCT", 73, 81], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 116, 129], ["plasma membrane", "CELLULAR_COMPONENT", 194, 209], ["\u03b1 V \u03b2 3", "PROTEIN", 18, 25], ["integrin", "PROTEIN", 27, 35], ["HSV-1", "PROTEIN", 37, 42], ["dynamin2", "PROTEIN", 73, 81], ["HSV", "TEST", 37, 40], ["the plasma membrane", "TEST", 190, 209]]], ["The gB, but not gC, gD, or gH, of HSV-1 is associated with membrane rafts after virus attachment and during virus entry.", [["membrane rafts", "ANATOMY", 59, 73], ["gB", "GENE_OR_GENE_PRODUCT", 4, 6], ["gC", "GENE_OR_GENE_PRODUCT", 16, 18], ["gD", "GENE_OR_GENE_PRODUCT", 20, 22], ["gH", "GENE_OR_GENE_PRODUCT", 27, 29], ["HSV-1", "GENE_OR_GENE_PRODUCT", 34, 39], ["membrane rafts", "CELLULAR_COMPONENT", 59, 73], ["gB", "PROTEIN", 4, 6], ["gC", "PROTEIN", 16, 18], ["gD", "PROTEIN", 20, 22], ["gH", "PROTEIN", 27, 29], ["HSV-1", "PROTEIN", 34, 39], ["HSV-1", "SPECIES", 34, 39], ["The gB", "TEST", 0, 6], ["HSV", "TEST", 34, 37], ["membrane rafts", "PROBLEM", 59, 73], ["virus attachment", "PROBLEM", 80, 96], ["gB", "ANATOMY", 4, 6], ["not", "UNCERTAINTY", 12, 15], ["gC", "OBSERVATION", 16, 18], ["HSV", "OBSERVATION", 34, 37]]], ["Moreover, a cholesterol-removing reagent results in inhibition of HSV-1 and pseudorabies virus entry [26, 28] .", [["cholesterol", "CHEMICAL", 12, 23], ["cholesterol", "CHEMICAL", 12, 23], ["cholesterol", "SIMPLE_CHEMICAL", 12, 23], ["HSV-1", "ORGANISM", 66, 71], ["pseudorabies virus", "ORGANISM", 76, 94], ["HSV-1", "SPECIES", 66, 71], ["pseudorabies virus", "SPECIES", 76, 94], ["HSV-1", "SPECIES", 66, 71], ["pseudorabies virus", "SPECIES", 76, 94], ["a cholesterol", "TEST", 10, 23], ["HSV", "TEST", 66, 69], ["pseudorabies virus entry", "TEST", 76, 100]]], ["These findings indicate that gB may interact with a cellular molecule within membrane rafts that may serve as a platform for HSV-1 entry and cell signaling.", [["cellular", "ANATOMY", 52, 60], ["membrane rafts", "ANATOMY", 77, 91], ["cell", "ANATOMY", 141, 145], ["gB", "GENE_OR_GENE_PRODUCT", 29, 31], ["cellular", "CELL", 52, 60], ["membrane rafts", "CELLULAR_COMPONENT", 77, 91], ["HSV-1", "GENE_OR_GENE_PRODUCT", 125, 130], ["cell", "CELL", 141, 145], ["gB", "PROTEIN", 29, 31], ["cellular molecule", "PROTEIN", 52, 69], ["HSV-1", "SPECIES", 125, 130], ["gB", "PROBLEM", 29, 31], ["a cellular molecule within membrane rafts", "PROBLEM", 50, 91], ["HSV", "TEST", 125, 128], ["membrane rafts", "OBSERVATION", 77, 91]]], ["Also, \u03b1 V \u03b2 3 -integrin expression on nectin-1-positive cells allows HSV-1 to enter cells Biochemistry Research International 5 through a raft-dependent and dynamin2-dependent pathway and reach the intracellular acidic compartment, where the viral envelope fuses with the plasma membrane.", [["nectin-1-positive cells", "ANATOMY", 38, 61], ["cells", "ANATOMY", 84, 89], ["intracellular acidic compartment", "ANATOMY", 198, 230], ["plasma membrane", "ANATOMY", 272, 287], ["\u03b1 V \u03b2 3 -integrin", "GENE_OR_GENE_PRODUCT", 6, 23], ["nectin-1", "GENE_OR_GENE_PRODUCT", 38, 46], ["HSV-1", "ORGANISM", 69, 74], ["cells", "CELL", 84, 89], ["raft", "CELLULAR_COMPONENT", 138, 142], ["dynamin2", "GENE_OR_GENE_PRODUCT", 157, 165], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 198, 211], ["acidic compartment", "CELLULAR_COMPONENT", 212, 230], ["plasma membrane", "CELLULAR_COMPONENT", 272, 287], ["integrin", "PROTEIN", 15, 23], ["nectin-1-positive cells", "CELL_LINE", 38, 61], ["dynamin2", "PROTEIN", 157, 165], ["HSV-1", "SPECIES", 69, 74], ["nectin", "TEST", 38, 44], ["HSV", "TEST", 69, 72], ["a raft-dependent and dynamin2-dependent pathway", "TREATMENT", 136, 183], ["the plasma membrane", "TREATMENT", 268, 287], ["intracellular", "ANATOMY_MODIFIER", 198, 211], ["acidic compartment", "OBSERVATION", 212, 230], ["viral envelope", "OBSERVATION", 242, 256], ["plasma membrane", "OBSERVATION", 272, 287]]], ["The pathway dictated by \u03b1 V \u03b2 3 -integrin utilizes membrane rafts, the platforms for a number of Toll-like receptors, suggesting that \u03b1 V \u03b2 3 -integrin functions as a sentinel of innate immunity [27] .Entry of Enveloped VirusesHHV-6, a betaherpesvirus related to human herpesvirus 7 and human cytomegalovirus, is a human pathogen of emerging clinical significance.", [["membrane rafts", "ANATOMY", 51, 65], ["VirusesHHV-6", "CHEMICAL", 220, 232], ["human herpesvirus 7 and human cytomegalovirus", "DISEASE", 263, 308], ["\u03b1 V \u03b2 3 -integrin", "GENE_OR_GENE_PRODUCT", 24, 41], ["membrane rafts", "CELLULAR_COMPONENT", 51, 65], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 97, 116], ["\u03b1 V \u03b2 3 -integrin", "GENE_OR_GENE_PRODUCT", 134, 151], ["VirusesHHV-6", "ORGANISM", 220, 232], ["human herpesvirus 7", "ORGANISM", 263, 282], ["human", "ORGANISM", 287, 292], ["cytomegalovirus", "ORGANISM", 293, 308], ["human", "ORGANISM", 315, 320], ["\u03b1 V \u03b2 3", "PROTEIN", 24, 31], ["integrin", "PROTEIN", 33, 41], ["Toll-like receptors", "PROTEIN", 97, 116], ["\u03b1 V \u03b2 3", "PROTEIN", 134, 141], ["integrin", "PROTEIN", 143, 151], ["human", "SPECIES", 263, 268], ["herpesvirus", "SPECIES", 269, 280], ["human", "SPECIES", 287, 292], ["cytomegalovirus", "SPECIES", 293, 308], ["human", "SPECIES", 315, 320], ["Enveloped VirusesHHV-6", "SPECIES", 210, 232], ["human herpesvirus 7", "SPECIES", 263, 282], ["human cytomegalovirus", "SPECIES", 287, 308], ["human", "SPECIES", 315, 320], ["membrane rafts", "TREATMENT", 51, 65], ["Enveloped VirusesHHV", "TEST", 210, 230], ["a betaherpesvirus", "PROBLEM", 234, 251], ["human herpesvirus", "PROBLEM", 263, 280], ["human cytomegalovirus", "PROBLEM", 287, 308], ["cytomegalovirus", "OBSERVATION", 293, 308]]], ["Human CD46, a cellular receptor for HHV-6, is not associated with membrane rafts in uninfected cells.", [["cellular", "ANATOMY", 14, 22], ["membrane rafts", "ANATOMY", 66, 80], ["cells", "ANATOMY", 95, 100], ["Human", "ORGANISM", 0, 5], ["CD46", "GENE_OR_GENE_PRODUCT", 6, 10], ["cellular", "CELL", 14, 22], ["HHV-6", "GENE_OR_GENE_PRODUCT", 36, 41], ["membrane rafts", "CELLULAR_COMPONENT", 66, 80], ["cells", "CELL", 95, 100], ["Human CD46", "PROTEIN", 0, 10], ["cellular receptor", "PROTEIN", 14, 31], ["HHV-6", "PROTEIN", 36, 41], ["uninfected cells", "CELL_TYPE", 84, 100], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["a cellular receptor", "TEST", 12, 31], ["HHV", "PROBLEM", 36, 39], ["membrane rafts in uninfected cells", "PROBLEM", 66, 100], ["not associated with", "UNCERTAINTY", 46, 65], ["membrane rafts", "OBSERVATION", 66, 80], ["uninfected cells", "OBSERVATION", 84, 100]]], ["However, after virus attachment, CD46 is localized to membrane rafts.", [["membrane rafts", "ANATOMY", 54, 68], ["CD46", "GENE_OR_GENE_PRODUCT", 33, 37], ["membrane rafts", "CELLULAR_COMPONENT", 54, 68], ["CD46", "PROTEIN", 33, 37], ["virus attachment", "PROBLEM", 15, 31], ["CD46", "PROBLEM", 33, 37], ["membrane rafts", "OBSERVATION", 54, 68]]], ["When membrane rafts are disrupted by a cholesterol-removing reagent or rescued by addition of exogenous cholesterol, the entry process of HHV-6 is inhibited or partially recovered, respectively.", [["membrane rafts", "ANATOMY", 5, 19], ["cholesterol", "CHEMICAL", 39, 50], ["cholesterol", "CHEMICAL", 104, 115], ["cholesterol", "CHEMICAL", 39, 50], ["cholesterol", "CHEMICAL", 104, 115], ["membrane rafts", "CELLULAR_COMPONENT", 5, 19], ["cholesterol", "SIMPLE_CHEMICAL", 39, 50], ["cholesterol", "SIMPLE_CHEMICAL", 104, 115], ["HHV-6", "GENE_OR_GENE_PRODUCT", 138, 143], ["HHV-6", "PROTEIN", 138, 143], ["a cholesterol-removing reagent", "TREATMENT", 37, 67], ["exogenous cholesterol", "TREATMENT", 94, 115], ["HHV", "PROBLEM", 138, 141], ["exogenous cholesterol", "OBSERVATION", 94, 115]]], ["Membrane rafts appear to play an important role in the HHV-6 entry process as an entry site on the host cell surface [29] .Entry of Enveloped VirusesHHV-8, the most recently identified member of human gammaherpesviruses, is consistently identified in all forms of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.", [["Membrane rafts", "ANATOMY", 0, 14], ["cell surface", "ANATOMY", 104, 116], ["Kaposi's sarcoma", "ANATOMY", 264, 280], ["primary effusion lymphoma", "ANATOMY", 282, 307], ["Kaposi's sarcoma", "DISEASE", 264, 280], ["primary effusion lymphoma", "DISEASE", 282, 307], ["Castleman's disease", "DISEASE", 326, 345], ["Membrane rafts", "CELLULAR_COMPONENT", 0, 14], ["HHV-6", "GENE_OR_GENE_PRODUCT", 55, 60], ["cell surface", "CELLULAR_COMPONENT", 104, 116], ["VirusesHHV-8", "ORGANISM", 142, 154], ["human", "ORGANISM", 195, 200], ["gammaherpesviruses", "CANCER", 201, 219], ["Kaposi's sarcoma", "CANCER", 264, 280], ["primary effusion lymphoma", "CANCER", 282, 307], ["Castleman's disease", "CANCER", 326, 345], ["Enveloped VirusesHHV-8", "DNA", 132, 154], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 195, 200], ["Membrane rafts", "PROBLEM", 0, 14], ["Enveloped VirusesHHV", "TEST", 132, 152], ["human gammaherpesviruses", "PROBLEM", 195, 219], ["Kaposi's sarcoma", "PROBLEM", 264, 280], ["primary effusion lymphoma", "PROBLEM", 282, 307], ["multicentric Castleman's disease", "PROBLEM", 313, 345], ["Enveloped", "OBSERVATION_MODIFIER", 132, 141], ["VirusesHHV", "OBSERVATION", 142, 152], ["human gammaherpesviruses", "OBSERVATION", 195, 219], ["Kaposi", "OBSERVATION", 264, 270], ["sarcoma", "OBSERVATION", 273, 280], ["effusion lymphoma", "OBSERVATION", 290, 307], ["multicentric", "OBSERVATION_MODIFIER", 313, 325], ["Castleman", "OBSERVATION", 326, 335]]], ["Reduced HHV-8 infection and decreased cellular signals associated with the virus infection by raft disruption suggest that membrane rafts in microvascular dermal endothelial cells are required for HHV-8 infection and gene expression, due to their potential roles in the modulation of HHV-8-induced PI3K, RhoA-GTPase, and Diaphanous-2 (a RhoA-GTPase-activated adaptor molecule involved in microtubule activation) signal molecules, which play roles in virus entry processes after receptor binding [30] .", [["cellular", "ANATOMY", 38, 46], ["raft", "ANATOMY", 94, 98], ["membrane rafts", "ANATOMY", 123, 137], ["microvascular dermal endothelial cells", "ANATOMY", 141, 179], ["microtubule", "ANATOMY", 388, 399], ["infection", "DISEASE", 14, 23], ["infection", "DISEASE", 81, 90], ["infection", "DISEASE", 203, 212], ["HHV-8", "ORGANISM", 8, 13], ["cellular", "CELL", 38, 46], ["membrane rafts", "CELLULAR_COMPONENT", 123, 137], ["microvascular dermal endothelial cells", "CELL", 141, 179], ["HHV-8", "ORGANISM", 197, 202], ["HHV-8", "GENE_OR_GENE_PRODUCT", 284, 289], ["PI3K", "GENE_OR_GENE_PRODUCT", 298, 302], ["RhoA", "GENE_OR_GENE_PRODUCT", 304, 308], ["GTPase", "GENE_OR_GENE_PRODUCT", 309, 315], ["Diaphanous-2", "GENE_OR_GENE_PRODUCT", 321, 333], ["RhoA", "GENE_OR_GENE_PRODUCT", 337, 341], ["GTPase-activated adaptor molecule", "GENE_OR_GENE_PRODUCT", 342, 375], ["microtubule", "CELLULAR_COMPONENT", 388, 399], ["microvascular dermal endothelial cells", "CELL_TYPE", 141, 179], ["HHV-8", "PROTEIN", 284, 289], ["PI3K", "PROTEIN", 298, 302], ["RhoA", "PROTEIN", 304, 308], ["GTPase", "PROTEIN", 309, 315], ["Diaphanous-2", "PROTEIN", 321, 333], ["RhoA", "PROTEIN", 337, 341], ["GTPase", "PROTEIN", 342, 348], ["activated adaptor molecule", "PROTEIN", 349, 375], ["microtubule", "PROTEIN", 388, 399], ["signal molecules", "PROTEIN", 412, 428], ["HHV-8", "SPECIES", 8, 13], ["HHV-8", "SPECIES", 197, 202], ["Reduced HHV", "PROBLEM", 0, 11], ["8 infection", "PROBLEM", 12, 23], ["decreased cellular signals", "PROBLEM", 28, 54], ["the virus infection", "PROBLEM", 71, 90], ["raft disruption", "PROBLEM", 94, 109], ["membrane rafts in microvascular dermal endothelial cells", "PROBLEM", 123, 179], ["HHV", "PROBLEM", 197, 200], ["8 infection", "PROBLEM", 201, 212], ["gene expression", "PROBLEM", 217, 232], ["HHV", "TEST", 284, 287], ["RhoA", "TEST", 304, 308], ["Diaphanous", "TEST", 321, 331], ["a RhoA", "TEST", 335, 341], ["activated adaptor molecule", "TREATMENT", 349, 375], ["signal molecules", "PROBLEM", 412, 428], ["HHV", "OBSERVATION", 8, 11], ["8 infection", "OBSERVATION_MODIFIER", 12, 23], ["decreased", "OBSERVATION_MODIFIER", 28, 37], ["cellular signals", "OBSERVATION", 38, 54], ["virus infection", "OBSERVATION", 75, 90], ["raft disruption", "OBSERVATION", 94, 109], ["membrane rafts", "OBSERVATION", 123, 137], ["microvascular dermal", "ANATOMY", 141, 161], ["endothelial cells", "OBSERVATION", 162, 179]]], ["Although activation of these signals involved in actin dynamics plays an important role in the entry process and endosomal sorting of HHV-8, the virus enters cells mainly through a clathrin-dependent pathway, but not a raft-dependent pathway, in endothelial cells [31] .Entry of Enveloped VirusesInfluenza viruses, highly transmittable pathogens of severe acute respiratory symptoms in various animals including humans, avians, and swines, enter host cells through multiple pathways including clathrin-independent endocytosis, caveola-independent endocytosis, and macropinocytosis depending on the cell type [33, [35] [36] [37] after binding of a viral envelope glycoprotein, hemagglutinin (HA), to glycoconjugates containing sialic acid on the cell surface [72, 73] .", [["endosomal", "ANATOMY", 113, 122], ["cells", "ANATOMY", 158, 163], ["raft", "ANATOMY", 219, 223], ["endothelial cells", "ANATOMY", 246, 263], ["respiratory", "ANATOMY", 362, 373], ["avians", "ANATOMY", 420, 426], ["swines", "ANATOMY", 432, 438], ["cells", "ANATOMY", 451, 456], ["cell", "ANATOMY", 598, 602], ["cell surface", "ANATOMY", 745, 757], ["Influenza viruses", "DISEASE", 296, 313], ["acute respiratory symptoms", "DISEASE", 356, 382], ["sialic acid", "CHEMICAL", 726, 737], ["sialic acid", "CHEMICAL", 726, 737], ["actin", "GENE_OR_GENE_PRODUCT", 49, 54], ["endosomal", "CELLULAR_COMPONENT", 113, 122], ["HHV-8", "GENE_OR_GENE_PRODUCT", 134, 139], ["cells", "CELL", 158, 163], ["clathrin", "GENE_OR_GENE_PRODUCT", 181, 189], ["raft", "CELLULAR_COMPONENT", 219, 223], ["endothelial cells", "CELL", 246, 263], ["Enveloped Viruses", "ORGANISM", 279, 296], ["Influenza viruses", "ORGANISM", 296, 313], ["humans", "ORGANISM", 412, 418], ["host cells", "CELL", 446, 456], ["clathrin", "GENE_OR_GENE_PRODUCT", 493, 501], ["caveola", "SIMPLE_CHEMICAL", 527, 534], ["cell", "CELL", 598, 602], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 676, 689], ["sialic acid", "SIMPLE_CHEMICAL", 726, 737], ["cell surface", "CELLULAR_COMPONENT", 745, 757], ["actin", "PROTEIN", 49, 54], ["HHV-8", "PROTEIN", 134, 139], ["clathrin", "PROTEIN", 181, 189], ["endothelial cells", "CELL_TYPE", 246, 263], ["host cells", "CELL_TYPE", 446, 456], ["clathrin", "PROTEIN", 493, 501], ["viral envelope glycoprotein", "PROTEIN", 647, 674], ["hemagglutinin", "PROTEIN", 676, 689], ["HA", "PROTEIN", 691, 693], ["Influenza", "SPECIES", 296, 305], ["humans", "SPECIES", 412, 418], ["humans", "SPECIES", 412, 418], ["HHV", "TEST", 134, 137], ["the virus enters cells", "PROBLEM", 141, 163], ["a clathrin-dependent pathway", "TREATMENT", 179, 207], ["Enveloped VirusesInfluenza viruses", "PROBLEM", 279, 313], ["severe acute respiratory symptoms", "PROBLEM", 349, 382], ["clathrin", "TREATMENT", 493, 501], ["independent endocytosis", "PROBLEM", 502, 525], ["caveola", "TEST", 527, 534], ["independent endocytosis", "PROBLEM", 535, 558], ["macropinocytosis", "PROBLEM", 564, 580], ["the cell type", "TEST", 594, 607], ["a viral envelope glycoprotein", "TREATMENT", 645, 674], ["hemagglutinin (HA)", "TREATMENT", 676, 694], ["sialic acid", "TEST", 726, 737], ["the cell surface", "TEST", 741, 757], ["endothelial cells", "OBSERVATION", 246, 263], ["Enveloped", "OBSERVATION_MODIFIER", 279, 288], ["VirusesInfluenza viruses", "OBSERVATION", 289, 313], ["severe", "OBSERVATION_MODIFIER", 349, 355], ["acute", "OBSERVATION_MODIFIER", 356, 361], ["respiratory symptoms", "OBSERVATION", 362, 382]]], ["The viruses carried to late endosomes acquire fusion activity of HA given by its low-pH-dependent conformation change, leading to membrane fusion between the virus and endosomes.", [["late endosomes", "ANATOMY", 23, 37], ["membrane", "ANATOMY", 130, 138], ["endosomes", "ANATOMY", 168, 177], ["late endosomes", "CELLULAR_COMPONENT", 23, 37], ["membrane", "CELLULAR_COMPONENT", 130, 138], ["endosomes", "CELLULAR_COMPONENT", 168, 177], ["HA", "PROTEIN", 65, 67], ["The viruses", "PROBLEM", 0, 11], ["HA", "PROBLEM", 65, 67], ["its low-pH", "PROBLEM", 77, 87], ["dependent conformation change", "PROBLEM", 88, 117], ["membrane fusion", "TREATMENT", 130, 145], ["the virus and endosomes", "PROBLEM", 154, 177], ["viruses", "OBSERVATION", 4, 11], ["fusion activity", "OBSERVATION", 46, 61], ["membrane fusion", "OBSERVATION", 130, 145]]], ["The viral ribonucleoprotein (RNP) complexes including the viral RNA genome are then released to the cytoplasm of host cells by proton influx of viral ion channel M2 protein that requires binding with cholesterol [32, 74] .", [["cytoplasm", "ANATOMY", 100, 109], ["cells", "ANATOMY", 118, 123], ["cholesterol", "CHEMICAL", 200, 211], ["cholesterol", "CHEMICAL", 200, 211], ["RNP", "CELLULAR_COMPONENT", 29, 32], ["cytoplasm", "ORGANISM_SUBSTANCE", 100, 109], ["host cells", "CELL", 113, 123], ["proton", "SIMPLE_CHEMICAL", 127, 133], ["cholesterol", "SIMPLE_CHEMICAL", 200, 211], ["viral ribonucleoprotein (RNP) complexes", "PROTEIN", 4, 43], ["viral RNA genome", "DNA", 58, 74], ["host cells", "CELL_TYPE", 113, 123], ["viral ion channel M2 protein", "PROTEIN", 144, 172], ["The viral ribonucleoprotein (RNP) complexes", "TREATMENT", 0, 43], ["the viral RNA genome", "PROBLEM", 54, 74], ["viral ion channel M2 protein", "TREATMENT", 144, 172], ["cholesterol", "TEST", 200, 211], ["viral ribonucleoprotein", "OBSERVATION", 4, 27], ["viral RNA genome", "OBSERVATION", 58, 74], ["host cells", "OBSERVATION", 113, 123]]], ["HA concentration to membrane rafts provides a sufficient amount of HA for the progeny virus envelope so that it can express efficient fusion activity for cellular membranes [34] .", [["membrane rafts", "ANATOMY", 20, 34], ["cellular membranes", "ANATOMY", 154, 172], ["HA", "GENE_OR_GENE_PRODUCT", 0, 2], ["membrane rafts", "CELLULAR_COMPONENT", 20, 34], ["HA", "GENE_OR_GENE_PRODUCT", 67, 69], ["cellular", "CELL", 154, 162], ["HA concentration to membrane rafts", "PROBLEM", 0, 34], ["HA", "PROBLEM", 67, 69], ["the progeny virus envelope", "PROBLEM", 74, 100], ["cellular membranes", "PROBLEM", 154, 172], ["membrane rafts", "OBSERVATION", 20, 34]]], ["Influenza virus and capsid-like core particles of hepatitis B virus (Hepadnaviridae) can also internalize through clathrindependent endocytosis alone without the use of membrane rafts [75] .Entry of Enveloped VirusesVaccinia virus had been established as a vaccine that eradicated smallpox disease.", [["membrane rafts", "ANATOMY", 169, 183], ["hepatitis B", "DISEASE", 50, 61], ["smallpox disease", "DISEASE", 281, 297], ["Influenza virus", "ORGANISM", 0, 15], ["capsid", "ORGANISM", 20, 26], ["hepatitis B virus", "ORGANISM", 50, 67], ["Hepadnaviridae", "ORGANISM", 69, 83], ["membrane rafts", "CELLULAR_COMPONENT", 169, 183], ["Enveloped Viruses", "ORGANISM", 199, 216], ["Vaccinia virus", "ORGANISM", 216, 230], ["Influenza virus", "SPECIES", 0, 15], ["hepatitis B virus", "SPECIES", 50, 67], ["Vaccinia virus", "SPECIES", 216, 230], ["Influenza virus", "SPECIES", 0, 15], ["hepatitis B virus", "SPECIES", 50, 67], ["Vaccinia virus", "SPECIES", 216, 230], ["Influenza virus", "PROBLEM", 0, 15], ["capsid", "TEST", 20, 26], ["hepatitis B virus (Hepadnaviridae)", "TREATMENT", 50, 84], ["clathrindependent endocytosis", "PROBLEM", 114, 143], ["membrane rafts", "TREATMENT", 169, 183], ["Enveloped VirusesVaccinia virus", "PROBLEM", 199, 230], ["a vaccine", "TREATMENT", 255, 264], ["smallpox disease", "PROBLEM", 281, 297], ["virus", "OBSERVATION", 10, 15], ["hepatitis", "OBSERVATION", 50, 59], ["Enveloped", "OBSERVATION_MODIFIER", 199, 208], ["Viruses", "OBSERVATION", 209, 216]]], ["Immediately after virus infection, the viral envelope proteins A14, A17L, and D8L, but not H3L, are present in membrane rafts on the cell surface.", [["membrane rafts", "ANATOMY", 111, 125], ["cell surface", "ANATOMY", 133, 145], ["infection", "DISEASE", 24, 33], ["A14", "GENE_OR_GENE_PRODUCT", 63, 66], ["A17L", "GENE_OR_GENE_PRODUCT", 68, 72], ["D8L", "GENE_OR_GENE_PRODUCT", 78, 81], ["H3L", "GENE_OR_GENE_PRODUCT", 91, 94], ["membrane rafts", "CELLULAR_COMPONENT", 111, 125], ["cell surface", "CELLULAR_COMPONENT", 133, 145], ["viral envelope proteins", "PROTEIN", 39, 62], ["A14", "PROTEIN", 63, 66], ["A17L", "PROTEIN", 68, 72], ["D8L", "PROTEIN", 78, 81], ["H3L", "PROTEIN", 91, 94], ["virus infection", "PROBLEM", 18, 33], ["the viral envelope proteins", "TEST", 35, 62], ["A17L", "TEST", 68, 72], ["D8L", "TREATMENT", 78, 81], ["H3L", "PROBLEM", 91, 94], ["infection", "OBSERVATION", 24, 33], ["membrane rafts", "OBSERVATION", 111, 125], ["cell surface", "OBSERVATION", 133, 145]]], ["Initial attachment of the virus to viral receptor glycosaminoglycans is not required for such membrane raft formation.", [["membrane raft", "ANATOMY", 94, 107], ["glycosaminoglycans", "GENE_OR_GENE_PRODUCT", 50, 68], ["membrane raft", "CELLULAR_COMPONENT", 94, 107], ["the virus", "TREATMENT", 22, 31], ["viral receptor glycosaminoglycans", "TREATMENT", 35, 68], ["such membrane raft formation", "PROBLEM", 89, 117], ["raft formation", "OBSERVATION", 103, 117]]], ["On the other hand, cholesterol-containing membrane raft formation with these viral envelope proteins is observed when vaccinia virus penetrates into a wide variety of mammalian cells from different hosts [38] .Entry of Enveloped VirusesHIV-1, a pathogen causing long-term and chronic disease that gradually progresses to acquired immunodeficiency syndrome, binds to viral receptor CD4 on the cell surface by the viral envelope glycoprotein gp120.", [["membrane raft", "ANATOMY", 42, 55], ["cells", "ANATOMY", 177, 182], ["cell surface", "ANATOMY", 392, 404], ["cholesterol", "CHEMICAL", 19, 30], ["acquired immunodeficiency syndrome", "DISEASE", 321, 355], ["cholesterol", "CHEMICAL", 19, 30], ["cholesterol", "SIMPLE_CHEMICAL", 19, 30], ["membrane raft", "CELLULAR_COMPONENT", 42, 55], ["vaccinia virus", "ORGANISM", 118, 132], ["mammalian cells", "CELL", 167, 182], ["VirusesHIV-1", "GENE_OR_GENE_PRODUCT", 229, 241], ["CD4", "GENE_OR_GENE_PRODUCT", 381, 384], ["cell surface", "CELLULAR_COMPONENT", 392, 404], ["gp120", "GENE_OR_GENE_PRODUCT", 440, 445], ["viral envelope proteins", "PROTEIN", 77, 100], ["mammalian cells", "CELL_TYPE", 167, 182], ["viral receptor CD4", "PROTEIN", 366, 384], ["viral envelope glycoprotein gp120", "PROTEIN", 412, 445], ["vaccinia virus", "SPECIES", 118, 132], ["VirusesHIV-1", "SPECIES", 229, 241], ["cholesterol-containing membrane raft formation", "TREATMENT", 19, 65], ["these viral envelope proteins", "PROBLEM", 71, 100], ["vaccinia virus penetrates", "PROBLEM", 118, 143], ["a pathogen", "PROBLEM", 243, 253], ["long-term", "PROBLEM", 262, 271], ["chronic disease", "PROBLEM", 276, 291], ["acquired immunodeficiency syndrome", "PROBLEM", 321, 355], ["the cell surface", "TREATMENT", 388, 404], ["the viral envelope glycoprotein gp120", "TREATMENT", 408, 445], ["membrane raft", "OBSERVATION", 42, 55], ["mammalian cells", "OBSERVATION", 167, 182], ["long-term", "OBSERVATION_MODIFIER", 262, 271], ["chronic", "OBSERVATION_MODIFIER", 276, 283], ["disease", "OBSERVATION", 284, 291], ["immunodeficiency syndrome", "OBSERVATION", 330, 355]]], ["Conformational change of gp120 after receptor binding leads to interaction with viral coreceptors, chemokine receptor CXCR4 or CCR5, and a subsequent conformational change of the viral envelope glycoprotein gp41 that confers membrane fusion activity [76] [77] [78] .", [["membrane", "ANATOMY", 225, 233], ["gp120", "GENE_OR_GENE_PRODUCT", 25, 30], ["CXCR4", "GENE_OR_GENE_PRODUCT", 118, 123], ["CCR5", "GENE_OR_GENE_PRODUCT", 127, 131], ["membrane", "CELLULAR_COMPONENT", 225, 233], ["gp120", "PROTEIN", 25, 30], ["viral coreceptors", "PROTEIN", 80, 97], ["chemokine receptor", "PROTEIN", 99, 117], ["CXCR4", "PROTEIN", 118, 123], ["CCR5", "PROTEIN", 127, 131], ["viral envelope glycoprotein gp41", "PROTEIN", 179, 211], ["Conformational change of gp120 after receptor binding", "TREATMENT", 0, 53], ["viral coreceptors", "TREATMENT", 80, 97], ["chemokine receptor CXCR4", "TREATMENT", 99, 123], ["CCR5", "TEST", 127, 131], ["a subsequent conformational change", "PROBLEM", 137, 171], ["the viral envelope glycoprotein gp41", "TREATMENT", 175, 211]]], ["Approximately 11-18% of CCR5 in human adenocarcinoma cells, 90-95% of CD4 in H9 leukemic T cells, and 50-66% of CD4 in peripheral blood mononuclear cells (PBMCs) are detected in membrane rafts [79, 80] , whereas CXCR4 is almost entirely absent in membrane rafts of human embryonic kidney 293T cells, H9 leukemic T cells and PBMCs [39, 80] .", [["adenocarcinoma cells", "ANATOMY", 38, 58], ["CD4", "ANATOMY", 70, 73], ["H9 leukemic T cells", "ANATOMY", 77, 96], ["CD4", "ANATOMY", 112, 115], ["peripheral blood mononuclear cells", "ANATOMY", 119, 153], ["PBMCs", "ANATOMY", 155, 160], ["membrane rafts", "ANATOMY", 178, 192], ["membrane rafts", "ANATOMY", 247, 261], ["embryonic kidney 293T cells", "ANATOMY", 271, 298], ["H9 leukemic T cells", "ANATOMY", 300, 319], ["PBMCs", "ANATOMY", 324, 329], ["adenocarcinoma", "DISEASE", 38, 52], ["CCR5", "GENE_OR_GENE_PRODUCT", 24, 28], ["human", "ORGANISM", 32, 37], ["adenocarcinoma cells", "CELL", 38, 58], ["CD4", "GENE_OR_GENE_PRODUCT", 70, 73], ["H9 leukemic T cells", "CELL", 77, 96], ["CD4", "GENE_OR_GENE_PRODUCT", 112, 115], ["peripheral blood mononuclear cells", "CELL", 119, 153], ["PBMCs", "CELL", 155, 160], ["membrane rafts", "CELLULAR_COMPONENT", 178, 192], ["CXCR4", "GENE_OR_GENE_PRODUCT", 212, 217], ["membrane rafts", "CELLULAR_COMPONENT", 247, 261], ["human", "ORGANISM", 265, 270], ["embryonic kidney 293T cells", "CELL", 271, 298], ["H9 leukemic T cells", "CELL", 300, 319], ["PBMCs", "CELL", 324, 329], ["CCR5", "PROTEIN", 24, 28], ["human adenocarcinoma cells", "CELL_TYPE", 32, 58], ["CD4", "PROTEIN", 70, 73], ["H9 leukemic T cells", "CELL_LINE", 77, 96], ["CD4", "PROTEIN", 112, 115], ["peripheral blood mononuclear cells", "CELL_TYPE", 119, 153], ["PBMCs", "CELL_TYPE", 155, 160], ["CXCR4", "PROTEIN", 212, 217], ["human embryonic kidney 293T cells", "CELL_LINE", 265, 298], ["H9 leukemic T cells", "CELL_LINE", 300, 319], ["PBMCs", "CELL_TYPE", 324, 329], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 265, 270], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 265, 270], ["CCR5 in human adenocarcinoma cells", "TEST", 24, 58], ["CD4", "TEST", 70, 73], ["H9 leukemic T cells", "TEST", 77, 96], ["CD4", "TEST", 112, 115], ["peripheral blood mononuclear cells", "TEST", 119, 153], ["PBMCs", "TEST", 155, 160], ["membrane rafts", "TEST", 178, 192], ["CXCR4", "TEST", 212, 217], ["H9 leukemic T cells", "PROBLEM", 300, 319], ["PBMCs", "TEST", 324, 329], ["adenocarcinoma cells", "OBSERVATION", 38, 58], ["H9 leukemic T cells", "OBSERVATION", 77, 96], ["peripheral", "ANATOMY_MODIFIER", 119, 129], ["blood", "ANATOMY", 130, 135], ["mononuclear cells", "OBSERVATION", 136, 153], ["membrane rafts", "OBSERVATION", 178, 192], ["absent", "OBSERVATION", 237, 243], ["membrane rafts", "OBSERVATION", 247, 261], ["kidney", "ANATOMY", 281, 287], ["293T cells", "OBSERVATION", 288, 298]]], ["However, recent research indicates that the viral clustering of coreceptor CXCR4 in membrane rafts on 293T cells (not human glioma NP2 and human rhabdosarcoma TE671), rather than that of the viral receptor CD4, is the key step for the entry process of HIV-1 [44] .", [["membrane rafts", "ANATOMY", 84, 98], ["293T cells", "ANATOMY", 102, 112], ["glioma NP2", "ANATOMY", 124, 134], ["rhabdosarcoma TE671", "ANATOMY", 145, 164], ["CXCR4", "GENE_OR_GENE_PRODUCT", 75, 80], ["membrane rafts", "CELLULAR_COMPONENT", 84, 98], ["293T cells", "CELL", 102, 112], ["human", "ORGANISM", 118, 123], ["glioma NP2", "CELL", 124, 134], ["human", "ORGANISM", 139, 144], ["rhabdosarcoma TE671", "CELL", 145, 164], ["CD4", "GENE_OR_GENE_PRODUCT", 206, 209], ["HIV-1", "ORGANISM", 252, 257], ["coreceptor CXCR4", "PROTEIN", 64, 80], ["293T cells", "CELL_LINE", 102, 112], ["human glioma NP2", "CELL_LINE", 118, 134], ["human rhabdosarcoma TE671", "CELL_LINE", 139, 164], ["viral receptor CD4", "PROTEIN", 191, 209], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 139, 144], ["HIV-1", "SPECIES", 252, 257], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 139, 144], ["HIV-1", "SPECIES", 252, 257], ["coreceptor CXCR4 in membrane rafts", "TREATMENT", 64, 98], ["human glioma", "PROBLEM", 118, 130], ["the viral receptor CD4", "PROBLEM", 187, 209], ["HIV", "PROBLEM", 252, 255], ["viral", "OBSERVATION_MODIFIER", 44, 49], ["coreceptor CXCR4", "OBSERVATION", 64, 80]]], ["Interactions between CD4 and CCR5, which occur outside membrane rafts, have been postulated to influence susceptibility to the entry process of CCR5-tropic HIV [81] .", [["membrane rafts", "ANATOMY", 55, 69], ["CD4", "GENE_OR_GENE_PRODUCT", 21, 24], ["CCR5", "GENE_OR_GENE_PRODUCT", 29, 33], ["membrane rafts", "CELLULAR_COMPONENT", 55, 69], ["CCR5", "GENE_OR_GENE_PRODUCT", 144, 148], ["CD4", "PROTEIN", 21, 24], ["CCR5", "PROTEIN", 29, 33], ["CCR5", "PROTEIN", 144, 148], ["CCR5", "TEST", 29, 33]]], ["A recent study has demonstrated that CD4 and CCR5 in macrophages are partitioned to membrane rafts and has suggested that macrophage membrane cholesterol is required for the entry process of HIV, implicating involvement of membrane rafts [43] .", [["macrophages", "ANATOMY", 53, 64], ["membrane rafts", "ANATOMY", 84, 98], ["macrophage membrane", "ANATOMY", 122, 141], ["membrane rafts", "ANATOMY", 223, 237], ["cholesterol", "CHEMICAL", 142, 153], ["cholesterol", "CHEMICAL", 142, 153], ["CD4", "GENE_OR_GENE_PRODUCT", 37, 40], ["CCR5", "GENE_OR_GENE_PRODUCT", 45, 49], ["macrophages", "CELL", 53, 64], ["membrane rafts", "CELLULAR_COMPONENT", 84, 98], ["macrophage membrane", "CELLULAR_COMPONENT", 122, 141], ["cholesterol", "SIMPLE_CHEMICAL", 142, 153], ["HIV", "ORGANISM", 191, 194], ["membrane", "CELLULAR_COMPONENT", 223, 231], ["CD4", "PROTEIN", 37, 40], ["CCR5", "PROTEIN", 45, 49], ["macrophages", "CELL_TYPE", 53, 64], ["HIV", "SPECIES", 191, 194], ["A recent study", "TEST", 0, 14], ["CD4", "TEST", 37, 40], ["macrophage membrane cholesterol", "TEST", 122, 153], ["HIV", "PROBLEM", 191, 194], ["membrane rafts", "PROBLEM", 223, 237], ["CD4", "OBSERVATION", 37, 40], ["membrane rafts", "OBSERVATION", 84, 98], ["macrophage membrane cholesterol", "OBSERVATION", 122, 153]]], ["Additionally, glycosphingolipids abundantly present in membrane rafts of host cells, such as Gb3Cer, GM3 gaglioside, and galactosylceramide, have been shown to be involved in the interaction with viral glycoproteins and in the virus entry process [45, [82] [83] [84] [85] .", [["membrane rafts", "ANATOMY", 55, 69], ["cells", "ANATOMY", 78, 83], ["galactosylceramide", "CHEMICAL", 121, 139], ["galactosylceramide", "CHEMICAL", 121, 139], ["membrane rafts", "CELLULAR_COMPONENT", 55, 69], ["host cells", "CELL", 73, 83], ["Gb3Cer", "GENE_OR_GENE_PRODUCT", 93, 99], ["GM3 gaglioside", "GENE_OR_GENE_PRODUCT", 101, 115], ["galactosylceramide", "GENE_OR_GENE_PRODUCT", 121, 139], ["host cells", "CELL_TYPE", 73, 83], ["Gb3Cer", "PROTEIN", 93, 99], ["viral glycoproteins", "PROTEIN", 196, 215], ["glycosphingolipids", "TREATMENT", 14, 32], ["Gb3Cer", "TEST", 93, 99], ["GM3 gaglioside", "TREATMENT", 101, 115], ["galactosylceramide", "TREATMENT", 121, 139], ["viral glycoproteins", "PROBLEM", 196, 215], ["membrane rafts", "OBSERVATION", 55, 69], ["host cells", "OBSERVATION", 73, 83]]], ["The presence of Gb3Cer within membrane rafts in glomerular cells, but not tubular cells, may play a role in HIV nephropathy through binding of gp120 [86] .", [["membrane rafts", "ANATOMY", 30, 44], ["glomerular cells", "ANATOMY", 48, 64], ["tubular cells", "ANATOMY", 74, 87], ["nephropathy", "DISEASE", 112, 123], ["Gb3Cer", "GENE_OR_GENE_PRODUCT", 16, 22], ["membrane rafts", "CELLULAR_COMPONENT", 30, 44], ["glomerular cells", "CELL", 48, 64], ["tubular cells", "CELL", 74, 87], ["HIV", "ORGANISM", 108, 111], ["gp120", "GENE_OR_GENE_PRODUCT", 143, 148], ["Gb3Cer", "PROTEIN", 16, 22], ["glomerular cells", "CELL_TYPE", 48, 64], ["tubular cells", "CELL_TYPE", 74, 87], ["gp120", "PROTEIN", 143, 148], ["HIV", "SPECIES", 108, 111], ["Gb3Cer within membrane rafts in glomerular cells", "PROBLEM", 16, 64], ["tubular cells", "PROBLEM", 74, 87], ["HIV nephropathy", "PROBLEM", 108, 123], ["membrane rafts", "OBSERVATION", 30, 44], ["glomerular cells", "ANATOMY", 48, 64], ["not", "UNCERTAINTY", 70, 73], ["tubular cells", "OBSERVATION", 74, 87]]], ["However, HIV-1 entry into primary human brain microvascular endothelial cells appears to be a raft-independent mechanism associated with proteoglycans such as cellassociated heparin sulfate and chondroitin sulfate [87] .Entry of Enveloped VirusesHTLV-1, an oncogenic pathogen causing human adult T cell leukemia, enters host cells through glucose transporter 1 (GLUT-1) [88] that is targeted to membrane rafts for glucose deprivation [89] .", [["brain microvascular endothelial cells", "ANATOMY", 40, 77], ["raft", "ANATOMY", 94, 98], ["adult T cell leukemia", "ANATOMY", 290, 311], ["cells", "ANATOMY", 325, 330], ["membrane rafts", "ANATOMY", 395, 409], ["heparin sulfate", "CHEMICAL", 174, 189], ["chondroitin sulfate", "CHEMICAL", 194, 213], ["adult T cell leukemia", "DISEASE", 290, 311], ["glucose", "CHEMICAL", 339, 346], ["glucose", "CHEMICAL", 414, 421], ["chondroitin sulfate", "CHEMICAL", 194, 213], ["glucose", "CHEMICAL", 339, 346], ["glucose", "CHEMICAL", 414, 421], ["HIV-1", "ORGANISM", 9, 14], ["human", "ORGANISM", 34, 39], ["brain microvascular endothelial cells", "CELL", 40, 77], ["proteoglycans", "SIMPLE_CHEMICAL", 137, 150], ["cellassociated heparin sulfate", "SIMPLE_CHEMICAL", 159, 189], ["chondroitin sulfate [87]", "SIMPLE_CHEMICAL", 194, 218], ["VirusesHTLV-1", "ORGANISM", 239, 252], ["human", "ORGANISM", 284, 289], ["T cell leukemia", "CANCER", 296, 311], ["host cells", "CELL", 320, 330], ["glucose transporter 1", "GENE_OR_GENE_PRODUCT", 339, 360], ["GLUT-1", "GENE_OR_GENE_PRODUCT", 362, 368], ["membrane rafts", "CELLULAR_COMPONENT", 395, 409], ["glucose", "SIMPLE_CHEMICAL", 414, 421], ["primary human brain microvascular endothelial cells", "CELL_TYPE", 26, 77], ["host cells", "CELL_TYPE", 320, 330], ["glucose transporter 1 (GLUT-1", "PROTEIN", 339, 368], ["HIV-1", "SPECIES", 9, 14], ["human", "SPECIES", 34, 39], ["VirusesHTLV-1", "SPECIES", 239, 252], ["human", "SPECIES", 284, 289], ["HIV-1", "SPECIES", 9, 14], ["human", "SPECIES", 34, 39], ["Enveloped VirusesHTLV-1", "SPECIES", 229, 252], ["human", "SPECIES", 284, 289], ["HIV", "TEST", 9, 12], ["proteoglycans", "TREATMENT", 137, 150], ["cellassociated heparin sulfate", "TREATMENT", 159, 189], ["chondroitin sulfate", "TREATMENT", 194, 213], ["Enveloped VirusesHTLV", "TEST", 229, 250], ["an oncogenic pathogen", "PROBLEM", 254, 275], ["human adult T cell leukemia", "PROBLEM", 284, 311], ["glucose transporter", "TEST", 339, 358], ["GLUT", "TEST", 362, 366], ["glucose deprivation", "TEST", 414, 433], ["brain", "ANATOMY", 40, 45], ["microvascular endothelial cells", "OBSERVATION", 46, 77], ["cell leukemia", "OBSERVATION", 298, 311]]], ["Inhibition of vial entry and syncytium formation of the infected cells by a cholesterol-removing reagent suggests the involvement of membrane rafts in the entry and fusion processes of HTLV-1 [46, 47] .Entry of Enveloped VirusesAlphaviruses such as Semliki Forest virus and Sindbis virus, arthropod-borne pathogens of infectious arthritis and rashes being the most commonly observed, require cholesterol for the virus entry process and especially for the membrane fusion process between the virus and the endosome triggered by low pH of acidic endosomes [48, 49, 52] .", [["syncytium", "ANATOMY", 29, 38], ["cells", "ANATOMY", 65, 70], ["membrane rafts", "ANATOMY", 133, 147], ["membrane", "ANATOMY", 455, 463], ["endosome", "ANATOMY", 505, 513], ["acidic endosomes", "ANATOMY", 537, 553], ["cholesterol", "CHEMICAL", 76, 87], ["Sindbis virus", "DISEASE", 274, 287], ["infectious arthritis", "DISEASE", 318, 338], ["rashes", "DISEASE", 343, 349], ["cholesterol", "CHEMICAL", 392, 403], ["cholesterol", "CHEMICAL", 76, 87], ["cholesterol", "CHEMICAL", 392, 403], ["syncytium", "CELLULAR_COMPONENT", 29, 38], ["cells", "CELL", 65, 70], ["cholesterol", "SIMPLE_CHEMICAL", 76, 87], ["membrane rafts", "CELLULAR_COMPONENT", 133, 147], ["HTLV-1", "ORGANISM", 185, 191], ["Enveloped Viruses", "ORGANISM", 211, 228], ["Semliki Forest virus", "ORGANISM", 249, 269], ["Sindbis virus", "ORGANISM", 274, 287], ["cholesterol", "SIMPLE_CHEMICAL", 392, 403], ["membrane", "CELLULAR_COMPONENT", 455, 463], ["endosome", "CELLULAR_COMPONENT", 505, 513], ["acidic endosomes", "CELLULAR_COMPONENT", 537, 553], ["infected cells", "CELL_TYPE", 56, 70], ["Semliki Forest virus", "SPECIES", 249, 269], ["Sindbis virus", "SPECIES", 274, 287], ["HTLV-1", "SPECIES", 185, 191], ["Semliki Forest virus", "SPECIES", 249, 269], ["Sindbis virus", "SPECIES", 274, 287], ["Inhibition of vial entry", "TREATMENT", 0, 24], ["the infected cells", "PROBLEM", 52, 70], ["a cholesterol-removing reagent", "TREATMENT", 74, 104], ["membrane rafts", "TREATMENT", 133, 147], ["Enveloped VirusesAlphaviruses", "PROBLEM", 211, 240], ["Semliki Forest virus", "TREATMENT", 249, 269], ["Sindbis virus", "PROBLEM", 274, 287], ["infectious arthritis", "PROBLEM", 318, 338], ["rashes", "PROBLEM", 343, 349], ["cholesterol", "TREATMENT", 392, 403], ["the virus entry process", "PROBLEM", 408, 431], ["the membrane fusion process", "TREATMENT", 451, 478], ["the virus", "PROBLEM", 487, 496], ["low pH of acidic endosomes", "PROBLEM", 527, 553], ["vial entry", "OBSERVATION", 14, 24], ["infected cells", "OBSERVATION", 56, 70], ["membrane rafts", "OBSERVATION", 133, 147], ["Enveloped", "OBSERVATION_MODIFIER", 211, 220], ["Viruses", "OBSERVATION", 221, 228], ["Semliki Forest virus", "OBSERVATION", 249, 269], ["Sindbis virus", "OBSERVATION", 274, 287], ["infectious", "OBSERVATION_MODIFIER", 318, 328], ["arthritis", "OBSERVATION", 329, 338]]], ["Direct binding of E1 fusion protein of Semliki Forest 6 Biochemistry Research International virus to cholesterol promotes viral fusion and infection in a cholesterol-dependent manner, unlike flaviviruses such as DEN and yellow fever virus, which show no significant binding of viral fusion proteins to cholesterol [90] .", [["cholesterol", "CHEMICAL", 101, 112], ["infection", "DISEASE", 139, 148], ["cholesterol", "CHEMICAL", 154, 165], ["DEN", "CHEMICAL", 212, 215], ["yellow fever", "DISEASE", 220, 232], ["cholesterol", "CHEMICAL", 302, 313], ["cholesterol", "CHEMICAL", 101, 112], ["cholesterol", "CHEMICAL", 154, 165], ["cholesterol", "CHEMICAL", 302, 313], ["E1", "GENE_OR_GENE_PRODUCT", 18, 20], ["Semliki Forest 6", "ORGANISM", 39, 55], ["International virus", "ORGANISM", 78, 97], ["cholesterol", "SIMPLE_CHEMICAL", 101, 112], ["cholesterol", "SIMPLE_CHEMICAL", 154, 165], ["DEN", "ORGANISM", 212, 215], ["yellow fever virus", "ORGANISM", 220, 238], ["cholesterol", "SIMPLE_CHEMICAL", 302, 313], ["E1 fusion protein", "PROTEIN", 18, 35], ["viral fusion proteins", "PROTEIN", 277, 298], ["yellow fever virus", "SPECIES", 220, 238], ["yellow fever virus", "SPECIES", 220, 238], ["E1 fusion protein", "TREATMENT", 18, 35], ["Semliki Forest", "TREATMENT", 39, 53], ["International virus to cholesterol promotes viral fusion", "TREATMENT", 78, 134], ["infection", "PROBLEM", 139, 148], ["flaviviruses", "PROBLEM", 191, 203], ["DEN", "PROBLEM", 212, 215], ["yellow fever virus", "PROBLEM", 220, 238], ["significant binding of viral fusion proteins", "PROBLEM", 254, 298], ["cholesterol", "TEST", 302, 313], ["viral fusion", "OBSERVATION", 122, 134], ["infection", "OBSERVATION", 139, 148], ["flaviviruses", "OBSERVATION", 191, 203], ["no", "UNCERTAINTY", 251, 253], ["viral fusion", "OBSERVATION", 277, 289]]], ["However, alphaviruses may not require membrane rafts for cholesteroldependent promotion of fusion with target membrane [51] .", [["membrane rafts", "ANATOMY", 38, 52], ["membrane", "ANATOMY", 110, 118], ["membrane rafts", "CELLULAR_COMPONENT", 38, 52], ["cholesteroldependent", "SIMPLE_CHEMICAL", 57, 77], ["alphaviruses", "PROBLEM", 9, 21], ["membrane rafts", "TREATMENT", 38, 52], ["cholesteroldependent promotion of fusion", "TREATMENT", 57, 97]]], ["Similarly, the entry process of lymphocytic choriomeningitis virus (LCMV; Arenaviridae) is also known to be raft independent but to require membrane cholesterol [4] .", [["membrane", "ANATOMY", 140, 148], ["lymphocytic choriomeningitis virus", "DISEASE", 32, 66], ["cholesterol", "CHEMICAL", 149, 160], ["cholesterol", "CHEMICAL", 149, 160], ["lymphocytic choriomeningitis virus", "ORGANISM", 32, 66], ["LCMV", "ORGANISM", 68, 72], ["Arenaviridae", "ORGANISM", 74, 86], ["membrane", "CELLULAR_COMPONENT", 140, 148], ["lymphocytic choriomeningitis virus", "SPECIES", 32, 66], ["lymphocytic choriomeningitis virus", "SPECIES", 32, 66], ["LCMV", "SPECIES", 68, 72], ["lymphocytic choriomeningitis virus", "PROBLEM", 32, 66], ["membrane cholesterol", "TREATMENT", 140, 160], ["lymphocytic choriomeningitis virus", "OBSERVATION", 32, 66]]], ["Cholesterol dependence may not necessarily be linked to the function of membrane rafts for the virus entry process.Entry of Nonenveloped VirusesEntry processes of nonenveloped viruses associated with membrane rafts have been investigated for species C human adenovirus (HAdV; Adenoviridae) [91, 92] , Coxsackie virus A9, B3, and B4 (Picornaviridae) [93] [94] [95] [96] , echovirus types 1 and 11 (Picornaviridae) [97] [98] [99] [100] [101] [102] , enterovirus (Picornaviridae) [98] , Rhinovirus (Picornaviridae) [103] , BK virus (Papovaviridae) [104] [105] [106] , bovine papillomavirus (Papovaviridae) [107] , human papillomavirus (HPV; Papovaviridae) [108] [109] [110] [111] [112] [113] [114] [115] [116] , JC virus (Papovaviridae) [117] , simian virus 40 (SV40; Papovaviridae) [118] [119] [120] [121] [122] [123] [124] [125] [126] , bluetongue virus (Reoviridae) [127] , and Rotavirus (Reoviridae) [128] [129] [130] .Entry of Nonenveloped VirusesHAdV, a common pathogen of acute respiratory disease and epidemic keratoconjunctivitis, is frequently used as viral vectors for gene therapy, most of which are serotype 5 that generally utilize a clathrin-dependent endocytic pathway.", [["membrane rafts", "ANATOMY", 72, 86], ["membrane rafts", "ANATOMY", 200, 214], ["respiratory", "ANATOMY", 982, 993], ["[93] [94] [95] [96] , echovirus types 1 and 11 (Picornaviridae) [97] [98] [99] [100] [101] [102] , enterovirus (Picornaviridae) [98] , Rhinovirus", "CHEMICAL", 349, 494], ["bovine papillomavirus", "DISEASE", 565, 586], ["human papillomavirus", "DISEASE", 611, 631], ["[122] [123] [124] [125] [126] ,", "CHEMICAL", 804, 835], ["bluetongue virus", "DISEASE", 836, 852], ["acute respiratory disease", "DISEASE", 976, 1001], ["keratoconjunctivitis", "DISEASE", 1015, 1035], ["Cholesterol", "CHEMICAL", 0, 11], ["Cholesterol", "SIMPLE_CHEMICAL", 0, 11], ["membrane rafts", "CELLULAR_COMPONENT", 72, 86], ["nonenveloped viruses", "ORGANISM", 163, 183], ["membrane rafts", "CELLULAR_COMPONENT", 200, 214], ["C human adenovirus", "ORGANISM", 250, 268], ["HAdV; Adenoviridae) [91, 92", "ORGANISM", 270, 297], ["Coxsackie virus A9", "ORGANISM", 301, 319], ["B3", "GENE_OR_GENE_PRODUCT", 321, 323], ["B4", "GENE_OR_GENE_PRODUCT", 329, 331], ["echovirus types 1", "ORGANISM", 371, 388], ["enterovirus", "ORGANISM", 448, 459], ["Rhinovirus", "ORGANISM", 484, 494], ["BK virus", "ORGANISM", 520, 528], ["bovine papillomavirus", "ORGANISM", 565, 586], ["human", "ORGANISM", 611, 616], ["papillomavirus", "ORGANISM", 617, 631], ["HPV", "ORGANISM", 633, 636], ["JC virus", "ORGANISM", 709, 717], ["simian virus 40", "ORGANISM", 742, 757], ["SV40", "ORGANISM", 759, 763], ["bluetongue virus", "ORGANISM", 836, 852], ["Nonenveloped VirusesHAdV", "ORGANISM", 929, 953], ["serotype 5", "ORGANISM", 1109, 1119], ["clathrin", "GENE_OR_GENE_PRODUCT", 1145, 1153], ["Nonenveloped VirusesHAdV", "PROTEIN", 929, 953], ["clathrin", "PROTEIN", 1145, 1153], ["C", "SPECIES", 250, 251], ["human", "SPECIES", 252, 257], ["Coxsackie virus", "SPECIES", 301, 316], ["BK virus", "SPECIES", 520, 528], ["bovine", "SPECIES", 565, 571], ["papillomavirus", "SPECIES", 572, 586], ["human", "SPECIES", 611, 616], ["papillomavirus", "SPECIES", 617, 631], ["simian virus", "SPECIES", 742, 754], ["bluetongue virus", "SPECIES", 836, 852], ["C human adenovirus", "SPECIES", 250, 268], ["Coxsackie virus A9", "SPECIES", 301, 319], ["BK virus", "SPECIES", 520, 528], ["bovine papillomavirus", "SPECIES", 565, 586], ["human papillomavirus", "SPECIES", 611, 631], ["HPV", "SPECIES", 633, 636], ["JC virus", "SPECIES", 709, 717], ["simian virus 40", "SPECIES", 742, 757], ["bluetongue virus", "SPECIES", 836, 852], ["Cholesterol dependence", "PROBLEM", 0, 22], ["the virus entry process", "PROBLEM", 91, 114], ["nonenveloped viruses", "PROBLEM", 163, 183], ["membrane rafts", "TREATMENT", 200, 214], ["species C human adenovirus (HAdV; Adenoviridae)", "TREATMENT", 242, 289], ["Coxsackie virus A9", "TREATMENT", 301, 319], ["B4 (Picornaviridae)", "TREATMENT", 329, 348], ["echovirus types", "TEST", 371, 386], ["enterovirus (Picornaviridae)", "TREATMENT", 448, 476], ["Rhinovirus (Picornaviridae)", "TREATMENT", 484, 511], ["BK virus (Papovaviridae)", "TREATMENT", 520, 544], ["bovine papillomavirus (Papovaviridae)", "TREATMENT", 565, 602], ["human papillomavirus (HPV; Papovaviridae)", "TREATMENT", 611, 652], ["JC virus (Papovaviridae)", "TEST", 709, 733], ["simian virus", "TEST", 742, 754], ["Papovaviridae", "TEST", 765, 778], ["bluetongue virus", "TEST", 836, 852], ["Reoviridae", "TEST", 854, 864], ["Rotavirus (Reoviridae", "TREATMENT", 878, 899], ["acute respiratory disease", "PROBLEM", 976, 1001], ["epidemic keratoconjunctivitis", "PROBLEM", 1006, 1035], ["viral vectors", "TREATMENT", 1059, 1072], ["gene therapy", "TREATMENT", 1077, 1089], ["a clathrin", "TREATMENT", 1143, 1153], ["may not necessarily be", "UNCERTAINTY", 23, 45], ["Nonenveloped", "OBSERVATION_MODIFIER", 124, 136], ["Viruses", "OBSERVATION", 137, 144], ["nonenveloped viruses", "OBSERVATION", 163, 183], ["membrane rafts", "OBSERVATION", 200, 214], ["Nonenveloped VirusesHAdV", "OBSERVATION", 929, 953], ["common", "OBSERVATION_MODIFIER", 957, 963], ["pathogen", "OBSERVATION_MODIFIER", 964, 972], ["acute", "OBSERVATION_MODIFIER", 976, 981], ["respiratory disease", "OBSERVATION", 982, 1001], ["epidemic", "OBSERVATION_MODIFIER", 1006, 1014], ["keratoconjunctivitis", "OBSERVATION", 1015, 1035]]], ["Initial interaction of HAdV with the cellular coxsackievirus and adenovirus receptor (CAR) and heparin sulfate glycosaminoglycans [131] is followed by interaction of the RGD motif of the virus with \u03b1 V \u03b2 3 , \u03b1 V \u03b2 5 , \u03b1 M \u03b2 2 , and \u03b1 5 \u03b2 1 integrins, resulting in clathrin-dependent entry of HAdV into hematopoietic cells.", [["cellular", "ANATOMY", 37, 45], ["hematopoietic cells", "ANATOMY", 302, 321], ["heparin", "CHEMICAL", 95, 102], ["sulfate", "CHEMICAL", 103, 110], ["HAdV", "ORGANISM", 23, 27], ["cellular coxsackievirus", "ORGANISM", 37, 60], ["adenovirus receptor", "GENE_OR_GENE_PRODUCT", 65, 84], ["CAR", "GENE_OR_GENE_PRODUCT", 86, 89], ["heparin sulfate glycosaminoglycans", "SIMPLE_CHEMICAL", 95, 129], ["\u03b1 V \u03b2 3", "GENE_OR_GENE_PRODUCT", 198, 205], ["\u03b1 V \u03b2 5", "GENE_OR_GENE_PRODUCT", 208, 215], ["\u03b1 M \u03b2 2", "GENE_OR_GENE_PRODUCT", 218, 225], ["\u03b1 5 \u03b2 1 integrins", "GENE_OR_GENE_PRODUCT", 232, 249], ["clathrin", "GENE_OR_GENE_PRODUCT", 264, 272], ["HAdV", "ORGANISM", 292, 296], ["hematopoietic cells", "CELL", 302, 321], ["cellular coxsackievirus and adenovirus receptor", "PROTEIN", 37, 84], ["CAR", "PROTEIN", 86, 89], ["RGD motif", "PROTEIN", 170, 179], ["\u03b1 V \u03b2 3", "PROTEIN", 198, 205], ["\u03b1 V \u03b2 5", "PROTEIN", 208, 215], ["\u03b1 M \u03b2 2", "DNA", 218, 225], ["\u03b1 5 \u03b2 1 integrins", "DNA", 232, 249], ["clathrin", "PROTEIN", 264, 272], ["hematopoietic cells", "CELL_TYPE", 302, 321], ["HAdV", "PROBLEM", 23, 27], ["the cellular coxsackievirus", "PROBLEM", 33, 60], ["adenovirus receptor (CAR) and heparin sulfate glycosaminoglycans", "TREATMENT", 65, 129], ["the RGD motif", "TEST", 166, 179], ["the virus", "TEST", 183, 192], ["\u03b1", "TEST", 232, 233], ["integrins", "TEST", 240, 249], ["clathrin", "TEST", 264, 272], ["coxsackievirus", "OBSERVATION", 46, 60], ["hematopoietic cells", "OBSERVATION", 302, 321]]], ["In contrast, mature B-cell plasmocytes and Chinese hamster ovary (CHO) cells, which are CAR-negative cell lines, are permissive to HAdV2, HAdV4, and HAdV5, probably through a clathrin-independent and caveola/raft-dependent endocytic pathway [91, 92] .Entry of Nonenveloped VirusesCoxsackievirus A9 infection is one of the most frequent causes of aseptic meningitis and causes various symptoms such as flaccid paralysis, respiratory disease, and chronic myocarditis.", [["B-cell plasmocytes", "ANATOMY", 20, 38], ["hamster ovary (CHO) cells", "ANATOMY", 51, 76], ["cell lines", "ANATOMY", 101, 111], ["raft", "ANATOMY", 208, 212], ["flaccid", "ANATOMY", 401, 408], ["respiratory", "ANATOMY", 420, 431], ["Coxsackievirus A9 infection", "DISEASE", 280, 307], ["meningitis", "DISEASE", 354, 364], ["flaccid paralysis", "DISEASE", 401, 418], ["respiratory disease", "DISEASE", 420, 439], ["myocarditis", "DISEASE", 453, 464], ["B-cell plasmocytes", "CELL", 20, 38], ["Chinese hamster ovary (CHO) cells", "CELL", 43, 76], ["CAR", "GENE_OR_GENE_PRODUCT", 88, 91], ["cell lines", "CELL", 101, 111], ["HAdV2", "GENE_OR_GENE_PRODUCT", 131, 136], ["HAdV4", "GENE_OR_GENE_PRODUCT", 138, 143], ["HAdV5", "GENE_OR_GENE_PRODUCT", 149, 154], ["clathrin", "GENE_OR_GENE_PRODUCT", 175, 183], ["caveola", "GENE_OR_GENE_PRODUCT", 200, 207], ["raft", "CELLULAR_COMPONENT", 208, 212], ["Nonenveloped VirusesCoxsackievirus A9", "ORGANISM", 260, 297], ["mature B-cell plasmocytes", "CELL_TYPE", 13, 38], ["Chinese hamster ovary (CHO) cells", "CELL_LINE", 43, 76], ["CAR-negative cell lines", "CELL_LINE", 88, 111], ["HAdV2", "PROTEIN", 131, 136], ["HAdV4", "PROTEIN", 138, 143], ["HAdV5", "PROTEIN", 149, 154], ["clathrin", "PROTEIN", 175, 183], ["Chinese hamster", "SPECIES", 43, 58], ["HAdV2", "SPECIES", 131, 136], ["Coxsackievirus A9", "SPECIES", 280, 297], ["Chinese hamster ovary (CHO) cells", "TREATMENT", 43, 76], ["cell lines", "TREATMENT", 101, 111], ["HAdV4", "PROBLEM", 138, 143], ["HAdV5", "PROBLEM", 149, 154], ["caveola/raft", "TEST", 200, 212], ["Nonenveloped VirusesCoxsackievirus A9 infection", "PROBLEM", 260, 307], ["aseptic meningitis", "PROBLEM", 346, 364], ["various symptoms", "PROBLEM", 376, 392], ["flaccid paralysis", "PROBLEM", 401, 418], ["respiratory disease", "PROBLEM", 420, 439], ["chronic myocarditis", "PROBLEM", 445, 464], ["mature", "OBSERVATION_MODIFIER", 13, 19], ["B-cell plasmocytes", "OBSERVATION", 20, 38], ["hamster ovary", "ANATOMY", 51, 64], ["negative cell lines", "OBSERVATION", 92, 111], ["raft", "ANATOMY_MODIFIER", 208, 212], ["Nonenveloped", "OBSERVATION_MODIFIER", 260, 272], ["Viruses", "OBSERVATION_MODIFIER", 273, 280], ["Coxsackievirus", "OBSERVATION_MODIFIER", 280, 294], ["A9 infection", "OBSERVATION", 295, 307], ["most frequent", "OBSERVATION_MODIFIER", 322, 335], ["aseptic", "OBSERVATION_MODIFIER", 346, 353], ["meningitis", "OBSERVATION", 354, 364], ["flaccid", "OBSERVATION_MODIFIER", 401, 408], ["paralysis", "OBSERVATION", 409, 418], ["respiratory disease", "OBSERVATION", 420, 439], ["chronic", "OBSERVATION_MODIFIER", 445, 452], ["myocarditis", "OBSERVATION", 453, 464]]], ["This virus utilizes \u03b1 V \u03b2 3 integrin as a viral receptor, glucose-regulated protein 78 (GRP78) as a viral coreceptor, and accessory molecule major histocompatibility complex class I (MHC-I) for the entry process.", [["glucose", "CHEMICAL", 58, 65], ["glucose", "CHEMICAL", 58, 65], ["\u03b1 V \u03b2 3 integrin", "GENE_OR_GENE_PRODUCT", 20, 36], ["glucose-regulated protein 78", "GENE_OR_GENE_PRODUCT", 58, 86], ["GRP78", "GENE_OR_GENE_PRODUCT", 88, 93], ["accessory molecule major histocompatibility complex class I", "GENE_OR_GENE_PRODUCT", 122, 181], ["MHC-I", "GENE_OR_GENE_PRODUCT", 183, 188], ["\u03b1 V \u03b2 3 integrin", "PROTEIN", 20, 36], ["viral receptor", "PROTEIN", 42, 56], ["glucose-regulated protein 78", "PROTEIN", 58, 86], ["GRP78", "PROTEIN", 88, 93], ["viral coreceptor", "PROTEIN", 100, 116], ["accessory molecule major histocompatibility complex class I", "PROTEIN", 122, 181], ["MHC", "PROTEIN", 183, 186], ["I", "PROTEIN", 187, 188], ["a viral receptor", "TEST", 40, 56], ["glucose", "TEST", 58, 65], ["a viral coreceptor", "TEST", 98, 116], ["the entry process", "PROBLEM", 194, 211]]], ["Receptor molecules \u03b1 V \u03b2 3 integrin and GRP78 as well as MHC-I are concentrated as a virus entry site in membrane rafts following virus infection.", [["membrane rafts", "ANATOMY", 105, 119], ["infection", "DISEASE", 136, 145], ["\u03b1 V \u03b2 3 integrin", "GENE_OR_GENE_PRODUCT", 19, 35], ["GRP78", "GENE_OR_GENE_PRODUCT", 40, 45], ["MHC-I", "GENE_OR_GENE_PRODUCT", 57, 62], ["membrane rafts", "CELLULAR_COMPONENT", 105, 119], ["Receptor molecules", "PROTEIN", 0, 18], ["\u03b1 V \u03b2 3 integrin", "PROTEIN", 19, 35], ["GRP78", "PROTEIN", 40, 45], ["MHC-I", "PROTEIN", 57, 62], ["virus entry site", "DNA", 85, 101], ["Receptor molecules", "TEST", 0, 18], ["integrin and GRP78", "TREATMENT", 27, 45], ["a virus entry site", "PROBLEM", 83, 101], ["virus infection", "PROBLEM", 130, 145], ["virus", "OBSERVATION", 85, 90], ["membrane rafts", "OBSERVATION", 105, 119], ["virus infection", "OBSERVATION", 130, 145]]], ["The relationship between activation of Raf/mitogen-activated protein kinase (MAPK) within rafts during infection and virus entry is unclear [93, 94] .", [["rafts", "ANATOMY", 90, 95], ["infection", "DISEASE", 103, 112], ["Raf/mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 39, 75], ["MAPK", "GENE_OR_GENE_PRODUCT", 77, 81], ["rafts", "CELLULAR_COMPONENT", 90, 95], ["Raf/mitogen-activated protein kinase", "PROTEIN", 39, 75], ["MAPK", "PROTEIN", 77, 81], ["Raf/mitogen", "TREATMENT", 39, 50], ["activated protein kinase", "TREATMENT", 51, 75], ["infection", "PROBLEM", 103, 112], ["virus entry", "PROBLEM", 117, 128], ["infection", "OBSERVATION", 103, 112]]], ["Coxsackievirus B4 is a human pathogen causing insulin-dependent diabetes mellitus, also known as type I diabetes, by progressive destruction of pancreatic \u03b2 cells.", [["pancreatic \u03b2 cells", "ANATOMY", 144, 162], ["diabetes mellitus", "DISEASE", 64, 81], ["type I diabetes", "DISEASE", 97, 112], ["Coxsackievirus B4", "ORGANISM", 0, 17], ["human", "ORGANISM", 23, 28], ["insulin", "GENE_OR_GENE_PRODUCT", 46, 53], ["pancreatic \u03b2 cells", "CELL", 144, 162], ["pancreatic \u03b2 cells", "CELL_TYPE", 144, 162], ["Coxsackievirus B4", "SPECIES", 0, 17], ["human", "SPECIES", 23, 28], ["Coxsackievirus B4", "SPECIES", 0, 17], ["human", "SPECIES", 23, 28], ["Coxsackievirus B4", "PROBLEM", 0, 17], ["a human pathogen", "PROBLEM", 21, 37], ["insulin-dependent diabetes mellitus", "PROBLEM", 46, 81], ["type I diabetes", "PROBLEM", 97, 112], ["progressive destruction of pancreatic \u03b2 cells", "PROBLEM", 117, 162], ["insulin-dependent", "OBSERVATION_MODIFIER", 46, 63], ["diabetes mellitus", "OBSERVATION", 64, 81], ["diabetes", "OBSERVATION", 104, 112], ["progressive", "OBSERVATION_MODIFIER", 117, 128], ["destruction", "OBSERVATION", 129, 140], ["pancreatic", "ANATOMY", 144, 154], ["\u03b2 cells", "OBSERVATION", 155, 162]]], ["Attachment of this virus to viral receptor molecules, CAR and CD55, seems to induce the recruitment of these molecules into membrane rafts.", [["membrane rafts", "ANATOMY", 124, 138], ["CAR", "GENE_OR_GENE_PRODUCT", 54, 57], ["CD55", "GENE_OR_GENE_PRODUCT", 62, 66], ["membrane rafts", "CELLULAR_COMPONENT", 124, 138], ["viral receptor molecules", "PROTEIN", 28, 52], ["CAR", "PROTEIN", 54, 57], ["CD55", "PROTEIN", 62, 66], ["this virus", "PROBLEM", 14, 24], ["membrane rafts", "OBSERVATION", 124, 138]]], ["Internalization of Coxsackievirus B4 rapidly to the Golgi apparatus is independent of clathrin and appears to be dependent on membrane rafts.", [["Golgi apparatus", "ANATOMY", 52, 67], ["membrane rafts", "ANATOMY", 126, 140], ["Coxsackievirus B4", "ORGANISM", 19, 36], ["Golgi", "CELLULAR_COMPONENT", 52, 57], ["clathrin", "GENE_OR_GENE_PRODUCT", 86, 94], ["membrane rafts", "CELLULAR_COMPONENT", 126, 140], ["clathrin", "PROTEIN", 86, 94], ["Coxsackievirus B4", "SPECIES", 19, 36], ["Coxsackievirus B4", "PROBLEM", 19, 36], ["clathrin", "TREATMENT", 86, 94], ["dependent on membrane rafts", "PROBLEM", 113, 140], ["Coxsackievirus", "OBSERVATION", 19, 33], ["B4", "OBSERVATION_MODIFIER", 34, 36], ["Golgi apparatus", "OBSERVATION", 52, 67], ["appears to be", "UNCERTAINTY", 99, 112], ["dependent", "OBSERVATION_MODIFIER", 113, 122], ["membrane rafts", "OBSERVATION", 126, 140]]], ["However, it has been suggested that CAR can also follow the clathrin-mediated pathway [95] .", [["CAR", "GENE_OR_GENE_PRODUCT", 36, 39], ["clathrin", "GENE_OR_GENE_PRODUCT", 60, 68], ["CAR", "PROTEIN", 36, 39], ["clathrin", "PROTEIN", 60, 68]]], ["Coxsackievirus B3 is a human pathogen causing febrile illness, meningitis, and myocarditis.", [["Coxsackievirus B3", "DISEASE", 0, 17], ["febrile illness", "DISEASE", 46, 61], ["meningitis", "DISEASE", 63, 73], ["myocarditis", "DISEASE", 79, 90], ["Coxsackievirus B3", "ORGANISM", 0, 17], ["human", "ORGANISM", 23, 28], ["Coxsackievirus B3", "SPECIES", 0, 17], ["human", "SPECIES", 23, 28], ["Coxsackievirus B3", "SPECIES", 0, 17], ["human", "SPECIES", 23, 28], ["Coxsackievirus B3", "PROBLEM", 0, 17], ["a human pathogen", "PROBLEM", 21, 37], ["febrile illness", "PROBLEM", 46, 61], ["meningitis", "PROBLEM", 63, 73], ["myocarditis", "PROBLEM", 79, 90], ["meningitis", "OBSERVATION", 63, 73], ["myocarditis", "OBSERVATION", 79, 90]]], ["Coxsackievirus B3 Nancy strain cannot bind to the glycosylphosphatidylinositol-(GPI-) anchored complement regulatory protein decay-accelerating factor (DAF), but RD strain, a DAFbinding derivative of Nancy strain, can.", [["glycosylphosphatidylinositol", "CHEMICAL", 50, 78], ["Coxsackievirus B3", "ORGANISM", 0, 17], ["Nancy strain", "ORGANISM", 18, 30], ["decay-accelerating factor", "GENE_OR_GENE_PRODUCT", 125, 150], ["DAF", "GENE_OR_GENE_PRODUCT", 152, 155], ["Nancy strain", "ORGANISM", 200, 212], ["glycosylphosphatidylinositol-(GPI-) anchored complement regulatory protein decay-accelerating factor", "PROTEIN", 50, 150], ["DAF", "PROTEIN", 152, 155], ["Coxsackievirus B3 Nancy", "SPECIES", 0, 23], ["Coxsackievirus B3 Nancy strain", "SPECIES", 0, 30], ["Coxsackievirus B3 Nancy strain", "PROBLEM", 0, 30], ["the glycosylphosphatidylinositol", "TEST", 46, 78], ["GPI", "TEST", 80, 83], ["anchored complement regulatory protein decay", "PROBLEM", 86, 130], ["accelerating factor (DAF", "PROBLEM", 131, 155], ["RD strain", "PROBLEM", 162, 171], ["Nancy strain", "PROBLEM", 200, 212]]], ["Coxsackievirus B3 RD strain possessing the ability of DAF binding enters polarized human intestinal Coca-2 cells through a caveola-dependent but dynamin-independent pathway that requires DAFmediated tyrosine kinase signals, whereas entry of this strain into nonpolarized HeLa CCL-2 cells requires dynamin and membrane rafts with CAR but not clathrin or caveolin, indicating that the entry pathway of this virus is dependent on cell type such as polarized and nonpolarized cell lines and that the requirement of membrane rafts differs significantly from that of caveolin for virus entry.", [["intestinal Coca-2 cells", "ANATOMY", 89, 112], ["HeLa CCL-2 cells", "ANATOMY", 271, 287], ["membrane rafts", "ANATOMY", 309, 323], ["cell", "ANATOMY", 427, 431], ["cell lines", "ANATOMY", 472, 482], ["membrane rafts", "ANATOMY", 511, 525], ["tyrosine", "CHEMICAL", 199, 207], ["tyrosine", "CHEMICAL", 199, 207], ["Coxsackievirus B3 RD strain", "ORGANISM", 0, 27], ["DAF", "GENE_OR_GENE_PRODUCT", 54, 57], ["human", "ORGANISM", 83, 88], ["intestinal Coca-2 cells", "CELL", 89, 112], ["caveola", "SIMPLE_CHEMICAL", 123, 130], ["dynamin", "GENE_OR_GENE_PRODUCT", 145, 152], ["DAFmediated tyrosine kinase", "GENE_OR_GENE_PRODUCT", 187, 214], ["HeLa CCL-2 cells", "CELL", 271, 287], ["dynamin", "GENE_OR_GENE_PRODUCT", 297, 304], ["membrane rafts", "CELLULAR_COMPONENT", 309, 323], ["CAR", "GENE_OR_GENE_PRODUCT", 329, 332], ["clathrin", "GENE_OR_GENE_PRODUCT", 341, 349], ["caveolin", "GENE_OR_GENE_PRODUCT", 353, 361], ["cell type", "CELL", 427, 436], ["cell lines", "CELL", 472, 482], ["membrane rafts", "CELLULAR_COMPONENT", 511, 525], ["caveolin", "GENE_OR_GENE_PRODUCT", 561, 569], ["DAF", "PROTEIN", 54, 57], ["polarized human intestinal Coca-2 cells", "CELL_LINE", 73, 112], ["dynamin", "PROTEIN", 145, 152], ["DAFmediated tyrosine kinase", "PROTEIN", 187, 214], ["nonpolarized HeLa CCL-2 cells", "CELL_LINE", 258, 287], ["dynamin", "PROTEIN", 297, 304], ["CAR", "PROTEIN", 329, 332], ["clathrin", "PROTEIN", 341, 349], ["caveolin", "PROTEIN", 353, 361], ["polarized and nonpolarized cell lines", "CELL_LINE", 445, 482], ["caveolin", "PROTEIN", 561, 569], ["Coxsackievirus B3", "SPECIES", 0, 17], ["human", "SPECIES", 83, 88], ["Coxsackievirus B3 RD strain", "SPECIES", 0, 27], ["human", "SPECIES", 83, 88], ["Coxsackievirus B3 RD strain", "PROBLEM", 0, 27], ["DAF binding", "PROBLEM", 54, 65], ["DAFmediated tyrosine kinase signals", "TEST", 187, 222], ["nonpolarized HeLa CCL", "TREATMENT", 258, 279], ["dynamin and membrane rafts", "TREATMENT", 297, 323], ["CAR", "TREATMENT", 329, 332], ["caveolin", "TREATMENT", 353, 361], ["this virus", "PROBLEM", 400, 410], ["polarized and nonpolarized cell lines", "TREATMENT", 445, 482], ["membrane rafts", "TREATMENT", 511, 525], ["intestinal", "ANATOMY", 89, 99], ["nonpolarized cell lines", "OBSERVATION", 459, 482], ["membrane rafts", "OBSERVATION", 511, 525]]], ["Coxsackievirus B3 Nancy strain possessing no ability of DAF binding utilizes an entry mechanism similar to that of the RD strain in HeLa CCL2 cells, suggesting no influence of DAF binding on virus entry into HeLa CCL2 cells [96] .Entry of Nonenveloped VirusesEchovirus type 1 and a number of enteroviruses including echovirus type 11 cause nerve paralysis, cerebral meningitis, respiratory symptoms, and anathema.", [["HeLa CCL2 cells", "ANATOMY", 132, 147], ["HeLa CCL2 cells", "ANATOMY", 208, 223], ["nerve", "ANATOMY", 340, 345], ["cerebral", "ANATOMY", 357, 365], ["respiratory", "ANATOMY", 378, 389], ["enteroviruses", "DISEASE", 292, 305], ["echovirus type 11", "DISEASE", 316, 333], ["nerve paralysis", "DISEASE", 340, 355], ["cerebral meningitis", "DISEASE", 357, 376], ["respiratory symptoms", "DISEASE", 378, 398], ["anathema", "DISEASE", 404, 412], ["Coxsackievirus B3 Nancy strain", "ORGANISM", 0, 30], ["DAF", "GENE_OR_GENE_PRODUCT", 56, 59], ["HeLa CCL2 cells", "CELL", 132, 147], ["DAF", "GENE_OR_GENE_PRODUCT", 176, 179], ["HeLa CCL2 cells", "CELL", 208, 223], ["Echovirus type 1", "GENE_OR_GENE_PRODUCT", 259, 275], ["echovirus type 11", "ORGANISM", 316, 333], ["nerve", "ORGAN", 340, 345], ["cerebral", "ORGAN", 357, 365], ["DAF", "PROTEIN", 56, 59], ["HeLa CCL2 cells", "CELL_LINE", 132, 147], ["DAF", "PROTEIN", 176, 179], ["HeLa CCL2 cells", "CELL_LINE", 208, 223], ["Coxsackievirus B3 Nancy", "SPECIES", 0, 23], ["Coxsackievirus B3 Nancy strain", "SPECIES", 0, 30], ["VirusesEchovirus type 1", "SPECIES", 252, 275], ["Coxsackievirus", "PROBLEM", 0, 14], ["DAF binding", "PROBLEM", 56, 67], ["the RD strain in HeLa CCL2 cells", "PROBLEM", 115, 147], ["DAF binding", "PROBLEM", 176, 187], ["HeLa CCL2 cells", "TEST", 208, 223], ["Nonenveloped VirusesEchovirus type 1", "PROBLEM", 239, 275], ["enteroviruses", "PROBLEM", 292, 305], ["echovirus type", "PROBLEM", 316, 330], ["nerve paralysis", "PROBLEM", 340, 355], ["cerebral meningitis", "PROBLEM", 357, 376], ["respiratory symptoms", "PROBLEM", 378, 398], ["anathema", "PROBLEM", 404, 412], ["HeLa CCL2 cells", "OBSERVATION", 132, 147], ["no", "UNCERTAINTY", 160, 162], ["Nonenveloped", "OBSERVATION_MODIFIER", 239, 251], ["VirusesEchovirus", "OBSERVATION", 252, 268], ["enteroviruses", "OBSERVATION", 292, 305], ["nerve", "ANATOMY", 340, 345], ["paralysis", "OBSERVATION", 346, 355], ["cerebral", "ANATOMY", 357, 365], ["meningitis", "OBSERVATION", 366, 376], ["respiratory symptoms", "OBSERVATION", 378, 398]]], ["These viruses utilize \u03b1 2 \u03b2 1 integrin and DAF on the cell surface as the respective receptors, which induce caveola-dependent and membrane raft-dependent endocytosis [97] [98] [99] [100] [101] .", [["cell surface", "ANATOMY", 54, 66], ["membrane raft", "ANATOMY", 131, 144], ["\u03b1 2 \u03b2 1 integrin", "GENE_OR_GENE_PRODUCT", 22, 38], ["DAF", "GENE_OR_GENE_PRODUCT", 43, 46], ["cell surface", "CELLULAR_COMPONENT", 54, 66], ["caveola", "SIMPLE_CHEMICAL", 109, 116], ["membrane raft", "CELLULAR_COMPONENT", 131, 144], ["\u03b1 2 \u03b2 1 integrin", "PROTEIN", 22, 38], ["DAF", "PROTEIN", 43, 46], ["1 integrin", "TREATMENT", 28, 38], ["the cell surface", "TREATMENT", 50, 66], ["caveola", "TEST", 109, 116], ["dependent endocytosis", "PROBLEM", 145, 166]]], ["However, a recent study has suggested that binding of clustered \u03b1 2 \u03b2 1 integrin with echovirus type 1 initiates a unique entry pathway that is p21-activated kinase 1 (Pak1), GTP-binding protein Rac1, PI3K, phospholipase C (PLC) and actin-dependent but clathirin and caveolaindependent and that can sort cargo to caveosomes [102] .Entry of Nonenveloped VirusesRhinoviruses, general pathogens of cold and acute respiratory symptoms, colocalize with ceramide-enriched membrane platforms during infection.", [["respiratory", "ANATOMY", 410, 421], ["membrane", "ANATOMY", 466, 474], ["Rhinoviruses", "DISEASE", 360, 372], ["ceramide", "CHEMICAL", 448, 456], ["infection", "DISEASE", 492, 501], ["GTP", "CHEMICAL", 175, 178], ["clathirin", "CHEMICAL", 253, 262], ["ceramide", "CHEMICAL", 448, 456], ["\u03b1 2 \u03b2 1 integrin", "GENE_OR_GENE_PRODUCT", 64, 80], ["echovirus type 1", "GENE_OR_GENE_PRODUCT", 86, 102], ["p21-activated kinase 1", "GENE_OR_GENE_PRODUCT", 144, 166], ["Pak1", "GENE_OR_GENE_PRODUCT", 168, 172], ["GTP-binding protein", "GENE_OR_GENE_PRODUCT", 175, 194], ["Rac1", "GENE_OR_GENE_PRODUCT", 195, 199], ["PI3K", "GENE_OR_GENE_PRODUCT", 201, 205], ["phospholipase C", "GENE_OR_GENE_PRODUCT", 207, 222], ["PLC", "GENE_OR_GENE_PRODUCT", 224, 227], ["actin", "GENE_OR_GENE_PRODUCT", 233, 238], ["clathirin", "GENE_OR_GENE_PRODUCT", 253, 262], ["caveolaindependent", "SIMPLE_CHEMICAL", 267, 285], ["ceramide", "SIMPLE_CHEMICAL", 448, 456], ["membrane", "CELLULAR_COMPONENT", 466, 474], ["\u03b1 2 \u03b2 1 integrin", "PROTEIN", 64, 80], ["echovirus type 1", "PROTEIN", 86, 102], ["p21-activated kinase 1", "PROTEIN", 144, 166], ["Pak1", "PROTEIN", 168, 172], ["GTP-binding protein", "PROTEIN", 175, 194], ["Rac1", "PROTEIN", 195, 199], ["PI3K", "PROTEIN", 201, 205], ["phospholipase C", "PROTEIN", 207, 222], ["PLC", "PROTEIN", 224, 227], ["actin", "PROTEIN", 233, 238], ["clathirin", "PROTEIN", 253, 262], ["a recent study", "TEST", 9, 23], ["echovirus type 1", "PROBLEM", 86, 102], ["p21", "TEST", 144, 147], ["activated kinase", "TEST", 148, 164], ["Pak1", "TEST", 168, 172], ["GTP-binding protein Rac1", "TEST", 175, 199], ["PI3K", "TEST", 201, 205], ["phospholipase C (PLC", "TREATMENT", 207, 227], ["actin-dependent", "PROBLEM", 233, 248], ["clathirin", "TREATMENT", 253, 262], ["caveolaindependent", "TREATMENT", 267, 285], ["Nonenveloped VirusesRhinoviruses", "PROBLEM", 340, 372], ["cold", "PROBLEM", 395, 399], ["acute respiratory symptoms", "PROBLEM", 404, 430], ["ceramide", "TREATMENT", 448, 456], ["enriched membrane platforms", "TREATMENT", 457, 484], ["infection", "PROBLEM", 492, 501], ["Nonenveloped", "OBSERVATION_MODIFIER", 340, 352], ["VirusesRhinoviruses", "OBSERVATION", 353, 372], ["acute", "OBSERVATION_MODIFIER", 404, 409], ["respiratory symptoms", "OBSERVATION", 410, 430], ["enriched membrane platforms", "OBSERVATION", 457, 484], ["infection", "OBSERVATION", 492, 501]]], ["Rhinoviruses induce microtubule-and microfilament-mediated translocation of acid sphingomyelinase from an intracellular compartment onto the extracellular leaflet of the cell membrane.", [["microtubule", "ANATOMY", 20, 31], ["microfilament", "ANATOMY", 36, 49], ["intracellular compartment", "ANATOMY", 106, 131], ["extracellular leaflet", "ANATOMY", 141, 162], ["cell membrane", "ANATOMY", 170, 183], ["Rhinoviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["microtubule", "CELLULAR_COMPONENT", 20, 31], ["microfilament", "CELLULAR_COMPONENT", 36, 49], ["sphingomyelinase", "GENE_OR_GENE_PRODUCT", 81, 97], ["intracellular compartment", "CELLULAR_COMPONENT", 106, 131], ["extracellular leaflet", "CELLULAR_COMPONENT", 141, 162], ["cell membrane", "CELLULAR_COMPONENT", 170, 183], ["microtubule", "PROTEIN", 20, 31], ["acid sphingomyelinase", "PROTEIN", 76, 97], ["Rhinoviruses", "PROBLEM", 0, 12], ["microtubule", "TEST", 20, 31], ["acid sphingomyelinase", "PROBLEM", 76, 97], ["microtubule", "OBSERVATION_MODIFIER", 20, 31], ["acid sphingomyelinase", "OBSERVATION", 76, 97], ["intracellular", "ANATOMY_MODIFIER", 106, 119], ["compartment", "ANATOMY_MODIFIER", 120, 131], ["extracellular leaflet", "OBSERVATION", 141, 162], ["cell membrane", "OBSERVATION", 170, 183]]], ["The enzymatic activity of acid sphingomyelinase hydrolyzes sphingomyelin to ceramide in the cell membrane, finally leading to the formation of large ceramide-enriched membrane platforms.", [["cell membrane", "ANATOMY", 92, 105], ["membrane", "ANATOMY", 167, 175], ["sphingomyelin", "CHEMICAL", 59, 72], ["ceramide", "CHEMICAL", 76, 84], ["ceramide", "CHEMICAL", 149, 157], ["sphingomyelin", "CHEMICAL", 59, 72], ["ceramide", "CHEMICAL", 76, 84], ["ceramide", "CHEMICAL", 149, 157], ["acid sphingomyelinase", "SIMPLE_CHEMICAL", 26, 47], ["sphingomyelin", "SIMPLE_CHEMICAL", 59, 72], ["ceramide", "SIMPLE_CHEMICAL", 76, 84], ["cell membrane", "CELLULAR_COMPONENT", 92, 105], ["ceramide", "SIMPLE_CHEMICAL", 149, 157], ["membrane", "CELLULAR_COMPONENT", 167, 175], ["acid sphingomyelinase", "PROTEIN", 26, 47], ["acid sphingomyelinase hydrolyzes sphingomyelin", "TREATMENT", 26, 72], ["activity", "OBSERVATION_MODIFIER", 14, 22], ["cell membrane", "OBSERVATION", 92, 105], ["large", "OBSERVATION_MODIFIER", 143, 148], ["ceramide", "OBSERVATION_MODIFIER", 149, 157], ["enriched membrane platforms", "OBSERVATION", 158, 185]]], ["Genetic and pharmacological prevention of acid sphingomyelinase has shown the involvement of ceramide-enriched membrane platforms in Rhinovirus entry [103] .", [["membrane", "ANATOMY", 111, 119], ["ceramide", "CHEMICAL", 93, 101], ["ceramide", "CHEMICAL", 93, 101], ["acid sphingomyelinase", "SIMPLE_CHEMICAL", 42, 63], ["ceramide", "SIMPLE_CHEMICAL", 93, 101], ["membrane", "CELLULAR_COMPONENT", 111, 119], ["Rhinovirus", "SIMPLE_CHEMICAL", 133, 143], ["acid sphingomyelinase", "PROTEIN", 42, 63], ["acid sphingomyelinase", "PROBLEM", 42, 63], ["enriched membrane platforms", "OBSERVATION", 102, 129]]], ["Although previous studies have shown the existence of many receptors for Rhinovirus entry, ninety percent of human Rhinovirus immunogenic variants use intercellular adhesion molecule-1 (ICAM-1) as a receptor [132] [133] [134] , which is known to be a component of ganglioside GM1-containing membrane rafts [135] .Entry of Nonenveloped VirusesHPVs are well-established pathogens causing cervical cancer and have also been implicated as pathogens in other epithelial cancers, including head and neck cancers.", [["membrane rafts", "ANATOMY", 291, 305], ["cervical cancer", "ANATOMY", 386, 401], ["epithelial cancers", "ANATOMY", 454, 472], ["head and neck cancers", "ANATOMY", 484, 505], ["cervical cancer", "DISEASE", 386, 401], ["epithelial cancers", "DISEASE", 454, 472], ["head and neck cancers", "DISEASE", 484, 505], ["ganglioside", "CHEMICAL", 264, 275], ["Rhinovirus", "GENE_OR_GENE_PRODUCT", 73, 83], ["human", "ORGANISM", 109, 114], ["intercellular adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 151, 184], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 186, 192], ["ganglioside GM1", "GENE_OR_GENE_PRODUCT", 264, 279], ["membrane", "CELLULAR_COMPONENT", 291, 299], ["VirusesHPVs", "GENE_OR_GENE_PRODUCT", 335, 346], ["cervical cancer", "CANCER", 386, 401], ["epithelial cancers", "CANCER", 454, 472], ["head and neck cancers", "CANCER", 484, 505], ["intercellular adhesion molecule-1", "PROTEIN", 151, 184], ["ICAM", "PROTEIN", 186, 190], ["ganglioside GM1", "PROTEIN", 264, 279], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["previous studies", "TEST", 9, 25], ["Rhinovirus entry", "PROBLEM", 73, 89], ["human Rhinovirus immunogenic variants", "PROBLEM", 109, 146], ["intercellular adhesion molecule", "TEST", 151, 182], ["ICAM", "TEST", 186, 190], ["ganglioside GM1", "TEST", 264, 279], ["Nonenveloped VirusesHPVs", "PROBLEM", 322, 346], ["cervical cancer", "PROBLEM", 386, 401], ["other epithelial cancers", "PROBLEM", 448, 472], ["head and neck cancers", "PROBLEM", 484, 505], ["ganglioside GM1", "OBSERVATION", 264, 279], ["Nonenveloped", "OBSERVATION_MODIFIER", 322, 334], ["VirusesHPVs", "OBSERVATION", 335, 346], ["cervical", "ANATOMY", 386, 394], ["cancer", "OBSERVATION", 395, 401], ["epithelial", "ANATOMY_MODIFIER", 454, 464], ["cancers", "OBSERVATION", 465, 472], ["head", "ANATOMY", 484, 488], ["neck", "ANATOMY", 493, 497], ["cancers", "OBSERVATION", 498, 505]]], ["Over 100 different types of HPV, including types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 , and 68 as high-risk carcinogenic HPVs and types 6, 11, 32, 34, 40, 42, 43, 44, 53, 54, 55, 61, 70, 72, 73, 81, 83, 84, 89 , and Pap155 as low-risk HPVs, have been identified.", [["carcinogenic HPVs", "DISEASE", 122, 139], ["HPVs", "DISEASE", 249, 253], ["HPV", "ORGANISM", 28, 31], ["HPVs", "ORGANISM", 135, 139], ["40", "GENE_OR_GENE_PRODUCT", 165, 167], ["43", "GENE_OR_GENE_PRODUCT", 173, 175], ["53", "GENE_OR_GENE_PRODUCT", 181, 183], ["55", "GENE_OR_GENE_PRODUCT", 189, 191], ["Pap155", "GENE_OR_GENE_PRODUCT", 230, 236], ["HPVs", "ORGANISM", 249, 253], ["types 6, 11, 32, 34, 40, 42, 43, 44, 53, 54, 55, 61, 70, 72, 73, 81, 83, 84, 89 , and Pap155", "DNA", 144, 236], ["HPV", "SPECIES", 28, 31], ["HPV", "TEST", 28, 31], ["Pap155", "TEST", 230, 236], ["low-risk HPVs", "PROBLEM", 240, 253], ["HPV", "OBSERVATION", 28, 31], ["carcinogenic HPVs", "OBSERVATION", 122, 139]]], ["In most cases, type 16 is the primary etiologic agent for anogenital malignancies, particularly cervical cancer [136] .", [["anogenital malignancies", "ANATOMY", 58, 81], ["cervical cancer", "ANATOMY", 96, 111], ["anogenital malignancies", "DISEASE", 58, 81], ["cervical cancer", "DISEASE", 96, 111], ["anogenital malignancies", "CANCER", 58, 81], ["cervical cancer", "CANCER", 96, 111], ["anogenital malignancies", "PROBLEM", 58, 81], ["cervical cancer", "PROBLEM", 96, 111], ["cervical", "ANATOMY", 96, 104], ["cancer", "OBSERVATION", 105, 111]]], ["Increased expression of HPV type 18 by addition of cholesterol suggests involvement of the HPV infection cycle in membrane rafts [109] .", [["membrane rafts", "ANATOMY", 114, 128], ["cholesterol", "CHEMICAL", 51, 62], ["HPV infection", "DISEASE", 91, 104], ["cholesterol", "CHEMICAL", 51, 62], ["HPV type 18", "ORGANISM", 24, 35], ["cholesterol", "SIMPLE_CHEMICAL", 51, 62], ["HPV", "ORGANISM", 91, 94], ["membrane rafts", "CELLULAR_COMPONENT", 114, 128], ["HPV type", "PROBLEM", 24, 32], ["cholesterol", "TREATMENT", 51, 62], ["the HPV infection", "PROBLEM", 87, 104], ["HPV infection", "OBSERVATION", 91, 104]]], ["The entry process of HPV begins with viral binding to specifically modified heparan sulfate proteoglycans (HPSGs), most likely syndecans.", [["heparan sulfate", "CHEMICAL", 76, 91], ["HPV", "ORGANISM", 21, 24], ["heparan sulfate proteoglycans", "SIMPLE_CHEMICAL", 76, 105], ["HPSGs", "SIMPLE_CHEMICAL", 107, 112], ["syndecans", "SIMPLE_CHEMICAL", 127, 136], ["heparan sulfate proteoglycans", "PROTEIN", 76, 105], ["HPSGs", "PROTEIN", 107, 112], ["HPV", "SPECIES", 21, 24], ["HPV", "PROBLEM", 21, 24], ["viral binding", "PROBLEM", 37, 50], ["modified heparan sulfate proteoglycans", "TREATMENT", 67, 105], ["HPV", "OBSERVATION", 21, 24], ["most likely", "UNCERTAINTY", 115, 126]]], ["In addition, \u03b16 integrin and laminin 5 have been suggested to be transient receptors for HPV.", [["\u03b16 integrin", "GENE_OR_GENE_PRODUCT", 13, 24], ["laminin 5", "GENE_OR_GENE_PRODUCT", 29, 38], ["HPV", "ORGANISM", 89, 92], ["\u03b16 integrin", "PROTEIN", 13, 24], ["laminin 5", "PROTEIN", 29, 38], ["HPV", "SPECIES", 89, 92], ["\u03b16 integrin and laminin", "TREATMENT", 13, 36], ["HPV", "PROBLEM", 89, 92]]], ["Although association of HSPGs with membrane rafts has been shown [71] , binding of HPV type 33 pseudovirus to HSPGs is followed by delayed caveola-independent endocytosis [110] .", [["membrane rafts", "ANATOMY", 35, 49], ["HSPGs", "GENE_OR_GENE_PRODUCT", 24, 29], ["membrane rafts", "CELLULAR_COMPONENT", 35, 49], ["HPV type 33 pseudovirus", "ORGANISM", 83, 106], ["HSPGs", "GENE_OR_GENE_PRODUCT", 110, 115], ["HSPGs", "PROTEIN", 24, 29], ["HSPGs", "PROTEIN", 110, 115], ["HPV type 33 pseudovirus", "SPECIES", 83, 106], ["membrane rafts", "PROBLEM", 35, 49], ["HPV type 33 pseudovirus to HSPGs", "PROBLEM", 83, 115]]], ["Interestingly, the entry process of HPV types 16 and 58 involves clathrin-dependent endocytosis, whereas that of HPV type 31 involves caveola-dependent endocytosis, indicating that HPVs use distinct routes for entry into COS-7 cells (a monkey kidney cell line) [111] .", [["COS-7 cells", "ANATOMY", 221, 232], ["kidney cell line", "ANATOMY", 243, 259], ["HPVs", "DISEASE", 181, 185], ["HPV", "ORGANISM", 36, 39], ["58", "GENE_OR_GENE_PRODUCT", 53, 55], ["clathrin", "GENE_OR_GENE_PRODUCT", 65, 73], ["HPV type 31", "ORGANISM", 113, 124], ["caveola", "GENE_OR_GENE_PRODUCT", 134, 141], ["HPVs", "ORGANISM", 181, 185], ["COS-7 cells", "CELL", 221, 232], ["monkey", "ORGANISM", 236, 242], ["kidney cell line", "CELL", 243, 259], ["[111]", "CELL", 261, 266], ["clathrin", "PROTEIN", 65, 73], ["COS-7 cells", "CELL_LINE", 221, 232], ["monkey kidney cell line", "CELL_LINE", 236, 259], ["HPV types", "TEST", 36, 45], ["clathrin-dependent endocytosis", "PROBLEM", 65, 95], ["HPV type", "TEST", 113, 121], ["caveola-dependent endocytosis", "PROBLEM", 134, 163], ["HPVs", "PROBLEM", 181, 185], ["entry into COS", "TEST", 210, 224], ["a monkey kidney cell line", "TREATMENT", 234, 259], ["dependent", "OBSERVATION_MODIFIER", 74, 83], ["endocytosis", "OBSERVATION", 84, 95], ["dependent endocytosis", "OBSERVATION", 142, 163], ["kidney", "ANATOMY", 243, 249], ["cell line", "OBSERVATION", 250, 259]]], ["In human keratinocytes (a natural host cell type of HPVs), remarkably slow entry and initiation of HPV type 31 early infection require both caveolin-1 and dynamin-2 (entry half-time of approximately 14 h), different from fast clathrin-dependent endocytosis of HPV type 16 (entry half-time of 4 h) [114] .", [["keratinocytes", "ANATOMY", 9, 22], ["cell", "ANATOMY", 39, 43], ["HPVs", "ANATOMY", 52, 56], ["infection", "DISEASE", 117, 126], ["human", "ORGANISM", 3, 8], ["keratinocytes", "CELL", 9, 22], ["cell type", "CELL", 39, 48], ["HPVs", "CELL", 52, 56], ["HPV type 31", "ORGANISM", 99, 110], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 140, 150], ["dynamin-2", "GENE_OR_GENE_PRODUCT", 155, 164], ["clathrin", "GENE_OR_GENE_PRODUCT", 226, 234], ["HPV type 16", "ORGANISM", 260, 271], ["human keratinocytes", "CELL_TYPE", 3, 22], ["caveolin-1", "PROTEIN", 140, 150], ["dynamin-2", "PROTEIN", 155, 164], ["clathrin", "PROTEIN", 226, 234], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["human keratinocytes", "PROBLEM", 3, 22], ["HPVs", "PROBLEM", 52, 56], ["slow entry", "PROBLEM", 70, 80], ["HPV type 31 early infection", "PROBLEM", 99, 126], ["both caveolin", "TREATMENT", 135, 148], ["dynamin", "TEST", 155, 162], ["keratinocytes", "OBSERVATION", 9, 22], ["natural host cell", "OBSERVATION_MODIFIER", 26, 43], ["infection", "OBSERVATION", 117, 126]]], ["Both HPV types 16 and 31 require the acidic compartment of the endosomal pathway, where low pH induces a conformational change in the HPV capsid to promote viral genome uncoating.", [["endosomal", "ANATOMY", 63, 72], ["HPV", "ORGANISM", 5, 8], ["endosomal", "CELLULAR_COMPONENT", 63, 72], ["HPV", "ORGANISM", 134, 137], ["low pH", "PROBLEM", 88, 94], ["a conformational change", "PROBLEM", 103, 126], ["the HPV capsid", "TREATMENT", 130, 144], ["viral genome uncoating", "PROBLEM", 156, 178], ["viral genome uncoating", "OBSERVATION", 156, 178]]], ["Binding of and infection with HPV type 16, but not HPV type 31, require HPSGs in human keratinocytes.", [["keratinocytes", "ANATOMY", 87, 100], ["infection", "DISEASE", 15, 24], ["HPV type 16", "ORGANISM", 30, 41], ["HPV type 31", "ORGANISM", 51, 62], ["HPSGs", "GENE_OR_GENE_PRODUCT", 72, 77], ["human", "ORGANISM", 81, 86], ["keratinocytes", "CELL", 87, 100], ["HPSGs", "PROTEIN", 72, 77], ["human keratinocytes", "CELL_TYPE", 81, 100], ["human", "SPECIES", 81, 86], ["HPV type 16", "SPECIES", 30, 41], ["human", "SPECIES", 81, 86], ["infection", "PROBLEM", 15, 24], ["HPV type 16", "PROBLEM", 30, 41], ["HPSGs in human keratinocytes", "TREATMENT", 72, 100], ["infection", "OBSERVATION", 15, 24]]], ["The different mechanisms of these two HPV types may reflect the distinct binding requirement [115] .", [["HPV", "ORGANISM", 38, 41], ["the distinct binding requirement", "PROBLEM", 60, 92], ["HPV", "OBSERVATION", 38, 41], ["distinct", "OBSERVATION_MODIFIER", 64, 72], ["binding requirement", "OBSERVATION", 73, 92]]], ["However, in COS-7 cells, and 293TT cells (a simian virus 40 large T antigen-transformed human kidney cell line), HPV type 31, like HPV type 16, enters the cells through a clathrin-dependent pathway rather than a caveola-dependent pathway as described above [113] .", [["COS-7 cells", "ANATOMY", 12, 23], ["293TT cells", "ANATOMY", 29, 40], ["kidney cell line", "ANATOMY", 94, 110], ["cells", "ANATOMY", 155, 160], ["COS-7 cells", "CELL", 12, 23], ["293TT cells", "CELL", 29, 40], ["simian virus 40", "ORGANISM", 44, 59], ["large T antigen", "GENE_OR_GENE_PRODUCT", 60, 75], ["human", "ORGANISM", 88, 93], ["kidney cell line", "CELL", 94, 110], ["HPV type 31", "ORGANISM", 113, 124], ["HPV type 16", "ORGANISM", 131, 142], ["cells", "CELL", 155, 160], ["clathrin", "GENE_OR_GENE_PRODUCT", 171, 179], ["caveola", "GENE_OR_GENE_PRODUCT", 212, 219], ["COS-7 cells", "CELL_LINE", 12, 23], ["293TT cells", "CELL_LINE", 29, 40], ["transformed human kidney cell line", "CELL_LINE", 76, 110], ["clathrin", "PROTEIN", 171, 179], ["simian virus", "SPECIES", 44, 56], ["human", "SPECIES", 88, 93], ["simian virus", "SPECIES", 44, 56], ["human", "SPECIES", 88, 93], ["HPV type 31", "SPECIES", 113, 124], ["293TT cells", "PROBLEM", 29, 40], ["a simian virus", "TEST", 42, 56], ["large T antigen", "TEST", 60, 75], ["human kidney cell line", "TEST", 88, 110], ["HPV type", "TEST", 113, 121], ["a clathrin-dependent pathway", "TREATMENT", 169, 197], ["a caveola-dependent pathway", "TREATMENT", 210, 237], ["kidney", "ANATOMY", 94, 100], ["cell line", "OBSERVATION", 101, 110]]], ["HPV type 16 also uses a novel endocytic pathway associated with tetraspanins CD63 and CD151 in HeLa cells, independently of clathrin and caveolin [116] .", [["HeLa cells", "ANATOMY", 95, 105], ["HPV type 16", "ORGANISM", 0, 11], ["CD63", "GENE_OR_GENE_PRODUCT", 77, 81], ["CD151", "GENE_OR_GENE_PRODUCT", 86, 91], ["HeLa cells", "CELL", 95, 105], ["clathrin", "GENE_OR_GENE_PRODUCT", 124, 132], ["caveolin [116]", "GENE_OR_GENE_PRODUCT", 137, 151], ["tetraspanins", "PROTEIN", 64, 76], ["CD63", "PROTEIN", 77, 81], ["CD151", "PROTEIN", 86, 91], ["HeLa cells", "CELL_LINE", 95, 105], ["clathrin", "PROTEIN", 124, 132], ["caveolin", "PROTEIN", 137, 145], ["a novel endocytic pathway", "PROBLEM", 22, 47], ["tetraspanins CD63", "TREATMENT", 64, 81], ["CD151 in HeLa cells", "TREATMENT", 86, 105]]], ["Complexes of tetraspanins CD63 and CD151 with \u03b16 integrin and laminin through \u03b24 palmitoylation of these tetraspanins induce assembly of cholesterol-associated microdomains that are distinct from membrane rafts [137, 138] .", [["microdomains", "ANATOMY", 160, 172], ["membrane rafts", "ANATOMY", 196, 210], ["cholesterol", "CHEMICAL", 137, 148], ["cholesterol", "CHEMICAL", 137, 148], ["CD63", "GENE_OR_GENE_PRODUCT", 26, 30], ["CD151", "GENE_OR_GENE_PRODUCT", 35, 40], ["\u03b16 integrin", "GENE_OR_GENE_PRODUCT", 46, 57], ["laminin", "GENE_OR_GENE_PRODUCT", 62, 69], ["\u03b24", "GENE_OR_GENE_PRODUCT", 78, 80], ["tetraspanins", "GENE_OR_GENE_PRODUCT", 105, 117], ["cholesterol", "SIMPLE_CHEMICAL", 137, 148], ["membrane rafts", "CELLULAR_COMPONENT", 196, 210], ["tetraspanins", "PROTEIN", 13, 25], ["CD63", "PROTEIN", 26, 30], ["CD151", "PROTEIN", 35, 40], ["\u03b16 integrin", "PROTEIN", 46, 57], ["laminin", "PROTEIN", 62, 69], ["tetraspanins", "PROTEIN", 105, 117], ["CD63", "TEST", 26, 30], ["CD151", "TEST", 35, 40], ["\u03b16 integrin", "TREATMENT", 46, 57], ["laminin", "TREATMENT", 62, 69], ["these tetraspanins", "TREATMENT", 99, 117], ["cholesterol-associated microdomains", "PROBLEM", 137, 172], ["cholesterol", "OBSERVATION", 137, 148], ["microdomains", "ANATOMY_MODIFIER", 160, 172], ["membrane rafts", "OBSERVATION", 196, 210]]], ["These tetraspanin-enriched microdomains may serve as an entry platform of HPV type 16.", [["microdomains", "ANATOMY", 27, 39], ["tetraspanin", "GENE_OR_GENE_PRODUCT", 6, 17], ["microdomains", "CELLULAR_COMPONENT", 27, 39], ["HPV type 16", "ORGANISM", 74, 85], ["tetraspanin", "PROTEIN", 6, 17], ["These tetraspanin-enriched microdomains", "TREATMENT", 0, 39]]], ["The different entry routes for HPV types 16 and 31 might result from different host cell types, such as human keratinocytes, COS-7 cells and 293TT cells, and from dependency of HPV lifecycles on cell differentiation.", [["cell", "ANATOMY", 84, 88], ["keratinocytes", "ANATOMY", 110, 123], ["COS-7 cells", "ANATOMY", 125, 136], ["293TT cells", "ANATOMY", 141, 152], ["cell", "ANATOMY", 195, 199], ["HPV", "ORGANISM", 31, 34], ["host cell", "CELL", 79, 88], ["human", "ORGANISM", 104, 109], ["keratinocytes", "CELL", 110, 123], ["COS-7 cells", "CELL", 125, 136], ["293TT cells", "CELL", 141, 152], ["HPV", "ORGANISM", 177, 180], ["cell", "CELL", 195, 199], ["human keratinocytes", "CELL_TYPE", 104, 123], ["COS-7 cells", "CELL_LINE", 125, 136], ["293TT cells", "CELL_LINE", 141, 152], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["HPV", "SPECIES", 177, 180], ["HPV types", "TEST", 31, 40], ["different host cell types", "PROBLEM", 69, 94], ["human keratinocytes", "TEST", 104, 123], ["COS", "TEST", 125, 128], ["293TT cells", "PROBLEM", 141, 152], ["HPV lifecycles", "PROBLEM", 177, 191], ["host cell types", "OBSERVATION", 79, 94], ["cell differentiation", "OBSERVATION", 195, 215]]], ["Although the involvement of distinct endocytic pathways in HPV typedependent pathogenicity remains unclear, results obtained from human keratinocytes, a natural host cell line of HPVs, may be close to the truth of the entry process.", [["keratinocytes", "ANATOMY", 136, 149], ["cell line", "ANATOMY", 166, 175], ["HPVs", "ANATOMY", 179, 183], ["HPVs", "DISEASE", 179, 183], ["HPV typedependent", "ORGANISM", 59, 76], ["human", "ORGANISM", 130, 135], ["keratinocytes", "CELL", 136, 149], ["cell line", "CELL", 166, 175], ["HPVs", "ORGANISM", 179, 183], ["human keratinocytes", "CELL_TYPE", 130, 149], ["human", "SPECIES", 130, 135], ["HPV", "SPECIES", 59, 62], ["human", "SPECIES", 130, 135], ["HPV typedependent pathogenicity", "PROBLEM", 59, 90], ["human keratinocytes", "PROBLEM", 130, 149], ["HPVs", "PROBLEM", 179, 183], ["distinct", "OBSERVATION_MODIFIER", 28, 36], ["endocytic", "OBSERVATION_MODIFIER", 37, 46], ["host cell line", "OBSERVATION", 161, 175], ["HPVs", "OBSERVATION", 179, 183], ["entry process", "OBSERVATION", 218, 231]]], ["BK virus, a pathogen of an infectious complication termed polyomavirus-associated nephropathy in renal transplant recipients, enters Vero cells and human renal proximal tubular epithelial cells by a slow caveola-dependent and clathrinindependent pathway in a pH-dependent manner [104] [105] [106] .", [["renal transplant", "ANATOMY", 97, 113], ["Vero cells", "ANATOMY", 133, 143], ["renal proximal tubular epithelial cells", "ANATOMY", 154, 193], ["BK", "CHEMICAL", 0, 2], ["nephropathy", "DISEASE", 82, 93], ["BK virus", "ORGANISM", 0, 8], ["polyomavirus", "ORGANISM", 58, 70], ["renal", "ORGAN", 97, 102], ["Vero cells", "CELL", 133, 143], ["human", "ORGANISM", 148, 153], ["renal proximal tubular epithelial cells", "CELL", 154, 193], ["Vero cells", "CELL_LINE", 133, 143], ["human renal proximal tubular epithelial cells", "CELL_TYPE", 148, 193], ["BK virus", "SPECIES", 0, 8], ["human", "SPECIES", 148, 153], ["BK virus", "SPECIES", 0, 8], ["human", "SPECIES", 148, 153], ["BK virus", "PROBLEM", 0, 8], ["an infectious complication", "PROBLEM", 24, 50], ["polyomavirus", "PROBLEM", 58, 70], ["associated nephropathy", "PROBLEM", 71, 93], ["renal transplant recipients", "TREATMENT", 97, 124], ["enters Vero cells", "PROBLEM", 126, 143], ["human renal proximal tubular epithelial cells", "PROBLEM", 148, 193], ["a slow caveola-dependent and clathrinindependent pathway", "PROBLEM", 197, 253], ["virus", "OBSERVATION", 3, 8], ["infectious", "OBSERVATION_MODIFIER", 27, 37], ["polyomavirus", "OBSERVATION", 58, 70], ["nephropathy", "OBSERVATION", 82, 93], ["renal", "ANATOMY", 97, 102], ["transplant recipients", "OBSERVATION", 103, 124], ["Vero cells", "OBSERVATION", 133, 143], ["human", "ANATOMY_MODIFIER", 148, 153], ["renal", "ANATOMY", 154, 159], ["proximal", "ANATOMY_MODIFIER", 160, 168], ["tubular", "ANATOMY_MODIFIER", 169, 176], ["epithelial cells", "OBSERVATION", 177, 193], ["dependent", "OBSERVATION_MODIFIER", 212, 221]]], ["JC virus and bovine papillomavirus enter cells through clathrin-dependent endocytosis and are subsequently transported from early endosomes to caveolar vesicles and then carried by a slow caveola-dependent pathway [107, 117] .Entry of Nonenveloped VirusesCaveola-dependent endocytosis has been studied mostly by analysis of cell entry of polyomaviruses represented by of SV40, which causes cancer in some animals through repression of tumor suppressor p53 [139] .", [["cells", "ANATOMY", 41, 46], ["early endosomes", "ANATOMY", 124, 139], ["caveolar vesicles", "ANATOMY", 143, 160], ["cell", "ANATOMY", 324, 328], ["cancer", "ANATOMY", 390, 396], ["tumor", "ANATOMY", 435, 440], ["cancer", "DISEASE", 390, 396], ["tumor", "DISEASE", 435, 440], ["JC virus", "ORGANISM", 0, 8], ["bovine", "ORGANISM", 13, 19], ["papillomavirus", "ORGANISM", 20, 34], ["cells", "CELL", 41, 46], ["clathrin", "GENE_OR_GENE_PRODUCT", 55, 63], ["early endosomes", "CELLULAR_COMPONENT", 124, 139], ["caveolar vesicles", "CELLULAR_COMPONENT", 143, 160], ["caveola", "GENE_OR_GENE_PRODUCT", 188, 195], ["Nonenveloped Viruses", "ORGANISM", 235, 255], ["Caveola", "GENE_OR_GENE_PRODUCT", 255, 262], ["cell", "CELL", 324, 328], ["polyomaviruses", "ORGANISM", 338, 352], ["SV40", "ORGANISM", 371, 375], ["cancer", "CANCER", 390, 396], ["tumor", "CANCER", 435, 440], ["p53", "GENE_OR_GENE_PRODUCT", 452, 455], ["clathrin", "PROTEIN", 55, 63], ["tumor suppressor p53 [139]", "PROTEIN", 435, 461], ["JC virus", "SPECIES", 0, 8], ["bovine", "SPECIES", 13, 19], ["papillomavirus", "SPECIES", 20, 34], ["JC virus", "SPECIES", 0, 8], ["bovine papillomavirus", "SPECIES", 13, 34], ["JC virus", "PROBLEM", 0, 8], ["bovine papillomavirus enter cells", "PROBLEM", 13, 46], ["dependent endocytosis", "PROBLEM", 64, 85], ["a slow caveola-dependent pathway", "PROBLEM", 181, 213], ["Nonenveloped VirusesCaveola-dependent endocytosis", "PROBLEM", 235, 284], ["polyomaviruses", "PROBLEM", 338, 352], ["cancer", "PROBLEM", 390, 396], ["tumor suppressor p53", "PROBLEM", 435, 455], ["bovine papillomavirus", "OBSERVATION", 13, 34], ["dependent", "OBSERVATION_MODIFIER", 64, 73], ["endocytosis", "OBSERVATION", 74, 85], ["caveolar vesicles", "ANATOMY", 143, 160], ["Nonenveloped", "OBSERVATION_MODIFIER", 235, 247], ["Viruses", "OBSERVATION", 248, 255], ["dependent", "OBSERVATION_MODIFIER", 263, 272], ["endocytosis", "OBSERVATION", 273, 284], ["cancer", "OBSERVATION", 390, 396], ["tumor", "OBSERVATION", 435, 440]]], ["After SV40 attaches to MHC-I on the cell surface, caveola and caveolin-1 are recruited to the association site of SV40 [140, 141] .", [["cell surface", "ANATOMY", 36, 48], ["SV40", "ORGANISM", 6, 10], ["MHC-I", "GENE_OR_GENE_PRODUCT", 23, 28], ["cell surface", "CELLULAR_COMPONENT", 36, 48], ["caveola", "CELLULAR_COMPONENT", 50, 57], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 62, 72], ["SV40", "ORGANISM", 114, 118], ["MHC-I", "PROTEIN", 23, 28], ["caveola and caveolin-1", "PROTEIN", 50, 72], ["association site", "DNA", 94, 110], ["the cell surface", "TREATMENT", 32, 48], ["caveola and caveolin", "TREATMENT", 50, 70], ["SV40", "TEST", 114, 118]]], ["Then virusincorporated caveola undergoes budding from the cellular membrane after activation of tyrosine kinases, actin skeleton depolymerization, actin tail formation, and dynamin accumulation around the association site [121, 123] .", [["cellular membrane", "ANATOMY", 58, 75], ["tail", "ANATOMY", 153, 157], ["tyrosine", "CHEMICAL", 96, 104], ["tyrosine", "CHEMICAL", 96, 104], ["caveola", "GENE_OR_GENE_PRODUCT", 23, 30], ["cellular membrane", "CELLULAR_COMPONENT", 58, 75], ["tyrosine", "AMINO_ACID", 96, 104], ["actin", "GENE_OR_GENE_PRODUCT", 114, 119], ["actin", "GENE_OR_GENE_PRODUCT", 147, 152], ["dynamin", "GENE_OR_GENE_PRODUCT", 173, 180], ["tyrosine kinases", "PROTEIN", 96, 112], ["actin", "PROTEIN", 114, 119], ["actin", "PROTEIN", 147, 152], ["dynamin", "PROTEIN", 173, 180], ["virusincorporated caveola", "TREATMENT", 5, 30], ["tyrosine kinases", "TREATMENT", 96, 112], ["actin skeleton depolymerization", "TREATMENT", 114, 145], ["actin tail formation", "PROBLEM", 147, 167], ["dynamin accumulation", "PROBLEM", 173, 193], ["cellular membrane", "OBSERVATION", 58, 75], ["tyrosine kinases", "OBSERVATION", 96, 112], ["skeleton depolymerization", "OBSERVATION", 120, 145], ["actin tail", "OBSERVATION", 147, 157], ["dynamin accumulation", "OBSERVATION", 173, 193]]], ["Finaly, caveola carries the virus to the endoplasmic reticulum (ER) along cellular microtubules.", [["endoplasmic reticulum", "ANATOMY", 41, 62], ["ER", "ANATOMY", 64, 66], ["cellular microtubules", "ANATOMY", 74, 95], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 41, 62], ["ER", "GENE_OR_GENE_PRODUCT", 64, 66], ["cellular microtubules", "CELLULAR_COMPONENT", 74, 95], ["ER", "PROTEIN", 64, 66], ["virus", "OBSERVATION", 28, 33], ["endoplasmic reticulum", "ANATOMY", 41, 62], ["cellular microtubules", "OBSERVATION", 74, 95]]], ["SV40 receptor MHC-I is not localized in membrane rafts, but attachment induces association of the virus with caveola [118] [119] [120] [121] [122] or ganglioside GM1 that is enriched in membrane rafts as a viral receptor [124, 125] .", [["membrane rafts", "ANATOMY", 40, 54], ["membrane rafts", "ANATOMY", 186, 200], ["caveola [118] [119] [120] [121] [122", "CHEMICAL", 109, 145], ["ganglioside", "CHEMICAL", 150, 161], ["SV40", "ORGANISM", 0, 4], ["MHC-I", "GENE_OR_GENE_PRODUCT", 14, 19], ["membrane rafts", "CELLULAR_COMPONENT", 40, 54], ["ganglioside GM1", "SIMPLE_CHEMICAL", 150, 165], ["membrane rafts", "CELLULAR_COMPONENT", 186, 200], ["SV40 receptor MHC-I", "PROTEIN", 0, 19], ["viral receptor", "PROTEIN", 206, 220], ["the virus", "PROBLEM", 94, 103], ["caveola", "TEST", 109, 116], ["ganglioside GM1", "TEST", 150, 165], ["a viral receptor", "TEST", 204, 220], ["membrane rafts", "OBSERVATION", 40, 54], ["membrane rafts", "OBSERVATION", 186, 200]]], ["As for other polyomaviruses, BK virus and JC virus, but not mouse polyomavirus, have been reported to use caveoladependent endocytosis for the entry process [104-106, 117, 142] .", [["polyomaviruses", "ORGANISM", 13, 27], ["BK virus", "ORGANISM", 29, 37], ["JC virus", "ORGANISM", 42, 50], ["mouse", "ORGANISM", 60, 65], ["polyomavirus", "ORGANISM", 66, 78], ["BK virus", "SPECIES", 29, 37], ["JC virus", "SPECIES", 42, 50], ["mouse", "SPECIES", 60, 65], ["BK virus", "SPECIES", 29, 37], ["JC virus", "SPECIES", 42, 50], ["mouse", "SPECIES", 60, 65], ["other polyomaviruses", "PROBLEM", 7, 27], ["BK virus", "PROBLEM", 29, 37], ["JC virus", "PROBLEM", 42, 50], ["mouse polyomavirus", "PROBLEM", 60, 78], ["polyomaviruses", "OBSERVATION", 13, 27], ["JC virus", "OBSERVATION", 42, 50], ["polyomavirus", "OBSERVATION", 66, 78]]], ["Bluetongue virus-1 can infect baby hamster kidney (BHK) cells through an entry process that is clathrin dependent and cholesterol dependent but requires dynamin [127] .Entry of Nonenveloped VirusesRotaviruses, pathogens of severe diarrhea in infants and young children, recognize several molecules on the epithelial cell surface, including glycolipids, N-glycoproteins, HSC70 protein, and \u03b1 V \u03b2 3 integrin localized in membrane rafts [128, 129] .Role of Membrane Rafts in Virus Genome Replication, Assembly, and BuddingEvaluation of the role of membrane rafts in viral assembly and budding has been performed by examining the inhibitory effect of progeny virus formation and production when membrane rafts are disrupted by a cholesterol-removing reagent or a cholesterol synthesis inhibitor.", [["hamster kidney (BHK) cells", "ANATOMY", 35, 61], ["epithelial cell surface", "ANATOMY", 305, 328], ["membrane rafts", "ANATOMY", 419, 433], ["Membrane", "ANATOMY", 454, 462], ["membrane rafts", "ANATOMY", 545, 559], ["membrane rafts", "ANATOMY", 691, 705], ["Bluetongue virus-1", "CHEMICAL", 0, 18], ["cholesterol", "CHEMICAL", 118, 129], ["diarrhea", "DISEASE", 230, 238], ["cholesterol", "CHEMICAL", 725, 736], ["cholesterol", "CHEMICAL", 759, 770], ["cholesterol", "CHEMICAL", 118, 129], ["cholesterol", "CHEMICAL", 725, 736], ["cholesterol", "CHEMICAL", 759, 770], ["Bluetongue virus-1", "ORGANISM", 0, 18], ["baby hamster kidney", "CELL", 30, 49], ["BHK) cells", "CELL", 51, 61], ["clathrin", "GENE_OR_GENE_PRODUCT", 95, 103], ["cholesterol", "SIMPLE_CHEMICAL", 118, 129], ["dynamin", "GENE_OR_GENE_PRODUCT", 153, 160], ["infants", "ORGANISM", 242, 249], ["children", "ORGANISM", 260, 268], ["epithelial cell surface", "CELLULAR_COMPONENT", 305, 328], ["N-glycoproteins", "GENE_OR_GENE_PRODUCT", 353, 368], ["HSC70", "GENE_OR_GENE_PRODUCT", 370, 375], ["\u03b1 V \u03b2 3 integrin", "GENE_OR_GENE_PRODUCT", 389, 405], ["membrane rafts", "CELLULAR_COMPONENT", 419, 433], ["membrane rafts", "CELLULAR_COMPONENT", 545, 559], ["progeny virus", "ORGANISM", 647, 660], ["membrane rafts", "CELLULAR_COMPONENT", 691, 705], ["cholesterol", "SIMPLE_CHEMICAL", 725, 736], ["cholesterol", "SIMPLE_CHEMICAL", 759, 770], ["baby hamster kidney (BHK) cells", "CELL_LINE", 30, 61], ["clathrin", "PROTEIN", 95, 103], ["N-glycoproteins", "PROTEIN", 353, 368], ["HSC70 protein", "PROTEIN", 370, 383], ["\u03b1 V \u03b2 3 integrin", "PROTEIN", 389, 405], ["Bluetongue virus-1", "SPECIES", 0, 18], ["hamster", "SPECIES", 35, 42], ["infants", "SPECIES", 242, 249], ["children", "SPECIES", 260, 268], ["Bluetongue virus-1", "SPECIES", 0, 18], ["hamster", "SPECIES", 35, 42], ["BHK", "SPECIES", 51, 54], ["Bluetongue virus", "PROBLEM", 0, 16], ["an entry process", "PROBLEM", 70, 86], ["clathrin dependent", "PROBLEM", 95, 113], ["cholesterol dependent", "PROBLEM", 118, 139], ["Nonenveloped VirusesRotaviruses", "PROBLEM", 177, 208], ["severe diarrhea", "PROBLEM", 223, 238], ["the epithelial cell surface", "TEST", 301, 328], ["glycolipids", "TEST", 340, 351], ["HSC70 protein", "TEST", 370, 383], ["V", "TEST", 391, 392], ["integrin localized in membrane rafts", "TEST", 397, 433], ["Membrane Rafts", "TREATMENT", 454, 468], ["Virus Genome Replication", "TREATMENT", 472, 496], ["BuddingEvaluation", "TEST", 512, 529], ["membrane rafts", "TREATMENT", 545, 559], ["progeny virus formation", "PROBLEM", 647, 670], ["a cholesterol", "TEST", 723, 736], ["reagent", "TREATMENT", 746, 753], ["a cholesterol synthesis inhibitor", "TREATMENT", 757, 790], ["kidney", "ANATOMY", 43, 49], ["entry process", "OBSERVATION", 73, 86], ["clathrin dependent", "OBSERVATION", 95, 113], ["cholesterol dependent", "OBSERVATION", 118, 139], ["Nonenveloped", "OBSERVATION_MODIFIER", 177, 189], ["VirusesRotaviruses", "OBSERVATION", 190, 208], ["severe", "OBSERVATION_MODIFIER", 223, 229], ["diarrhea", "OBSERVATION", 230, 238], ["epithelial cell", "ANATOMY", 305, 320], ["Membrane Rafts", "OBSERVATION", 454, 468], ["Virus Genome", "OBSERVATION", 472, 484], ["membrane rafts", "OBSERVATION", 545, 559], ["progeny virus", "OBSERVATION", 647, 660]]], ["In cholesterol-depleted infected cells, impaired virus formations and productions are recovered by the addition of exogenous cholesterol.", [["cells", "ANATOMY", 33, 38], ["cholesterol", "CHEMICAL", 3, 14], ["cholesterol", "CHEMICAL", 125, 136], ["cholesterol", "CHEMICAL", 3, 14], ["cholesterol", "CHEMICAL", 125, 136], ["cholesterol", "SIMPLE_CHEMICAL", 3, 14], ["cells", "CELL", 33, 38], ["cholesterol", "SIMPLE_CHEMICAL", 125, 136], ["cholesterol-depleted infected cells", "CELL_TYPE", 3, 38], ["cholesterol", "TEST", 3, 14], ["depleted infected cells", "PROBLEM", 15, 38], ["impaired virus formations", "PROBLEM", 40, 65], ["cholesterol", "OBSERVATION_MODIFIER", 3, 14], ["depleted", "OBSERVATION_MODIFIER", 15, 23], ["infected cells", "OBSERVATION", 24, 38], ["impaired", "OBSERVATION_MODIFIER", 40, 48], ["virus formations", "OBSERVATION", 49, 65], ["exogenous cholesterol", "OBSERVATION", 115, 136]]], ["General biochemical methods have also been used to determine whether several viral structural proteins during the process of virus formation and assembly are colocalized with the detergent-insoluble fraction or a representative raft-marker such as caveolin-1, flotillin, or GM1.", [["raft", "ANATOMY", 228, 232], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 248, 258], ["flotillin", "GENE_OR_GENE_PRODUCT", 260, 269], ["GM1", "GENE_OR_GENE_PRODUCT", 274, 277], ["viral structural proteins", "PROTEIN", 77, 102], ["caveolin-1", "PROTEIN", 248, 258], ["flotillin", "PROTEIN", 260, 269], ["GM1", "PROTEIN", 274, 277], ["General biochemical methods", "TEST", 0, 27], ["several viral structural proteins", "PROBLEM", 69, 102], ["virus formation", "PROBLEM", 125, 140], ["caveolin", "TEST", 248, 256], ["flotillin", "TREATMENT", 260, 269], ["GM1", "PROBLEM", 274, 277], ["virus", "OBSERVATION", 125, 130]]], ["Raftdependent virus budding and replication have also been evaluated by examining the inhibitory effect of caveola formation using an RNAi method and dominant-negative protein expression for normal caveolin-1 knockdown.", [["caveola", "ANATOMY", 107, 114], ["Raftdependent virus", "ORGANISM", 0, 19], ["caveola", "SIMPLE_CHEMICAL", 107, 114], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 198, 208], ["caveolin", "PROTEIN", 198, 206], ["Raftdependent virus", "SPECIES", 0, 19], ["Raftdependent virus budding", "TREATMENT", 0, 27], ["caveola formation", "TREATMENT", 107, 124], ["an RNAi method", "TEST", 131, 145]]], ["If the raftassociation sites have been identified in the viral structural proteins, it is possible to generate mutated viral proteins that do not associate with membrane rafts.", [["raftassociation sites", "ANATOMY", 7, 28], ["membrane rafts", "ANATOMY", 161, 175], ["membrane rafts", "CELLULAR_COMPONENT", 161, 175], ["raftassociation sites", "DNA", 7, 28], ["viral structural proteins", "PROTEIN", 57, 82], ["mutated viral proteins", "PROTEIN", 111, 133], ["the raftassociation sites", "PROBLEM", 3, 28], ["the viral structural proteins", "PROBLEM", 53, 82], ["mutated viral proteins", "PROBLEM", 111, 133], ["membrane rafts", "PROBLEM", 161, 175], ["membrane rafts", "OBSERVATION", 161, 175]]], ["Then evaluation of virus assembly and budding in membrane rafts can also be performed by measuring intracellular transport or incorporation rate of these mutated proteins into virus particles or characterization of viruses possessing these mutated proteins generated by established reverse genetics methods.", [["membrane rafts", "ANATOMY", 49, 63], ["intracellular", "ANATOMY", 99, 112], ["membrane rafts", "CELLULAR_COMPONENT", 49, 63], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 99, 112], ["mutated proteins", "PROTEIN", 154, 170], ["mutated proteins", "PROTEIN", 240, 256], ["evaluation", "TEST", 5, 15], ["virus", "PROBLEM", 19, 24], ["intracellular transport", "TEST", 99, 122], ["incorporation rate", "TEST", 126, 144], ["these mutated proteins into virus particles", "PROBLEM", 148, 191], ["viruses", "PROBLEM", 215, 222], ["virus", "OBSERVATION", 19, 24]]], ["When virus budding of enveloped viruses occurs in membrane rafts, colocalization of the budded virus and a raft marker on the cell surface membrane can be observed by using an electronic microscope.Genome Replication, Assembly, and Budding of Enveloped VirusesThe role of membrane rafts in viral RNA synthesis of enveloped viruses has been investigated for hepatitis C virus (HCV; Flaviviridae) [86, [143] [144] [145] [146] [147] , DEN [148, 149] , JEV [148] , and respiratory syncytial virus (RSV; Paramyxoviridae) [150, 151] .", [["membrane rafts", "ANATOMY", 50, 64], ["raft", "ANATOMY", 107, 111], ["cell surface membrane", "ANATOMY", 126, 147], ["membrane rafts", "ANATOMY", 272, 286], ["hepatitis C", "DISEASE", 357, 368], ["respiratory syncytial virus", "DISEASE", 465, 492], ["membrane rafts", "CELLULAR_COMPONENT", 50, 64], ["budded virus", "ORGANISM", 88, 100], ["raft", "CELLULAR_COMPONENT", 107, 111], ["cell surface membrane", "CELLULAR_COMPONENT", 126, 147], ["membrane rafts", "CELLULAR_COMPONENT", 272, 286], ["hepatitis C virus", "ORGANISM", 357, 374], ["HCV; Flaviviridae", "ORGANISM", 376, 393], ["JEV", "ORGANISM", 449, 452], ["respiratory syncytial virus", "ORGANISM", 465, 492], ["RSV", "ORGANISM", 494, 497], ["viral RNA", "RNA", 290, 299], ["hepatitis C virus", "SPECIES", 357, 374], ["respiratory syncytial virus", "SPECIES", 465, 492], ["hepatitis C virus", "SPECIES", 357, 374], ["HCV", "SPECIES", 376, 379], ["respiratory syncytial virus", "SPECIES", 465, 492], ["RSV", "SPECIES", 494, 497], ["enveloped viruses", "PROBLEM", 22, 39], ["the budded virus", "PROBLEM", 84, 100], ["the cell surface membrane", "TREATMENT", 122, 147], ["an electronic microscope", "TEST", 173, 197], ["Genome Replication", "TREATMENT", 198, 216], ["membrane rafts", "TREATMENT", 272, 286], ["viral RNA synthesis", "TREATMENT", 290, 309], ["enveloped viruses", "PROBLEM", 313, 330], ["hepatitis C virus", "PROBLEM", 357, 374], ["JEV", "TEST", 449, 452], ["respiratory syncytial virus", "PROBLEM", 465, 492], ["enveloped", "OBSERVATION_MODIFIER", 22, 31], ["viruses", "OBSERVATION", 32, 39], ["membrane rafts", "OBSERVATION", 50, 64], ["budded virus", "OBSERVATION", 88, 100], ["raft marker", "OBSERVATION", 107, 118], ["cell surface", "OBSERVATION", 126, 138], ["viral RNA", "OBSERVATION", 290, 299], ["respiratory syncytial", "ANATOMY", 465, 486]]], ["Association of HCV nonstructural (NS) proteins with cholesterol-enriched membrane rafts in the Golgi-derived membrane results in the formation of the replication complexes (distinct particle structures of about 0.7 \u03bcm in size) for HCV RNA synthesis [86, 143, 144] .", [["membrane rafts", "ANATOMY", 73, 87], ["Golgi", "ANATOMY", 95, 100], ["membrane", "ANATOMY", 109, 117], ["cholesterol", "CHEMICAL", 52, 63], ["cholesterol", "CHEMICAL", 52, 63], ["HCV nonstructural (NS) proteins", "GENE_OR_GENE_PRODUCT", 15, 46], ["cholesterol", "SIMPLE_CHEMICAL", 52, 63], ["membrane rafts", "CELLULAR_COMPONENT", 73, 87], ["Golgi", "CELLULAR_COMPONENT", 95, 100], ["membrane", "CELLULAR_COMPONENT", 109, 117], ["HCV nonstructural (NS) proteins", "PROTEIN", 15, 46], ["replication complexes", "PROTEIN", 150, 171], ["HCV RNA", "RNA", 231, 238], ["HCV", "SPECIES", 15, 18], ["HCV", "SPECIES", 231, 234], ["HCV nonstructural (NS) proteins", "PROBLEM", 15, 46], ["cholesterol", "TEST", 52, 63], ["enriched membrane rafts", "TREATMENT", 64, 87], ["the replication complexes", "PROBLEM", 146, 171], ["HCV RNA synthesis", "TEST", 231, 248], ["HCV", "OBSERVATION", 15, 18], ["membrane rafts", "OBSERVATION", 73, 87], ["derived membrane", "OBSERVATION", 101, 117], ["replication complexes", "OBSERVATION", 150, 171], ["distinct", "OBSERVATION_MODIFIER", 173, 181], ["particle", "OBSERVATION_MODIFIER", 182, 190]]], ["A lipophilic longchain base compound, NA255, has been identified as a smallmolecule HCV replication inhibitor from a secondary fungal metabolite.", [["NA255", "CHEMICAL", 38, 43], ["NA255", "CHEMICAL", 38, 43], ["NA255", "SIMPLE_CHEMICAL", 38, 43], ["HCV", "SPECIES", 84, 87], ["A lipophilic longchain base compound", "PROBLEM", 0, 36], ["a smallmolecule HCV replication inhibitor", "TREATMENT", 68, 109], ["a secondary fungal metabolite", "PROBLEM", 115, 144], ["lipophilic", "OBSERVATION_MODIFIER", 2, 12], ["HCV", "OBSERVATION", 84, 87], ["fungal metabolite", "OBSERVATION", 127, 144]]], ["NA255 disrupts the association of HCV NS proteins with membrane rafts by prevention of the de novo synthesis of sphingolipids, major membrane raft components [145] .", [["membrane rafts", "ANATOMY", 55, 69], ["membrane raft", "ANATOMY", 133, 146], ["NA255", "CHEMICAL", 0, 5], ["sphingolipids", "CHEMICAL", 112, 125], ["NA255", "SIMPLE_CHEMICAL", 0, 5], ["HCV NS proteins", "GENE_OR_GENE_PRODUCT", 34, 49], ["membrane rafts", "CELLULAR_COMPONENT", 55, 69], ["sphingolipids", "SIMPLE_CHEMICAL", 112, 125], ["membrane raft", "CELLULAR_COMPONENT", 133, 146], ["NA255", "PROTEIN", 0, 5], ["HCV NS proteins", "PROTEIN", 34, 49], ["major membrane raft components", "PROTEIN", 127, 157], ["HCV", "SPECIES", 34, 37], ["HCV NS proteins", "TREATMENT", 34, 49], ["membrane rafts", "TREATMENT", 55, 69], ["the de novo synthesis of sphingolipids", "TREATMENT", 87, 125], ["membrane rafts", "OBSERVATION", 55, 69]]], ["The sphingomyelin-binding domain of HCV RNAdependent RNA polymerase is the membrane raft localization domain of viral nonstructural protein NS5B [146] .", [["membrane raft", "ANATOMY", 75, 88], ["sphingomyelin", "CHEMICAL", 4, 17], ["sphingomyelin", "CHEMICAL", 4, 17], ["sphingomyelin", "SIMPLE_CHEMICAL", 4, 17], ["HCV", "ORGANISM", 36, 39], ["membrane raft", "CELLULAR_COMPONENT", 75, 88], ["sphingomyelin-binding domain", "PROTEIN", 4, 32], ["HCV RNAdependent RNA polymerase", "PROTEIN", 36, 67], ["membrane raft localization domain", "PROTEIN", 75, 108], ["viral nonstructural protein NS5B", "PROTEIN", 112, 144], ["HCV", "SPECIES", 36, 39], ["The sphingomyelin-binding domain", "TREATMENT", 0, 32], ["HCV RNAdependent RNA polymerase", "TREATMENT", 36, 67], ["viral nonstructural protein NS5B", "TEST", 112, 144], ["viral nonstructural protein NS5B", "OBSERVATION", 112, 144]]], ["Since cholesterol-depleted or sphingomyelin-hydrolyzed virus has a defect in cellular internalization but not cell attachment, incorporation of cholesterol and sphingolipid into HCV particles also plays an important role in virus maturation and infectivity.", [["cellular", "ANATOMY", 77, 85], ["cell", "ANATOMY", 110, 114], ["cholesterol", "CHEMICAL", 6, 17], ["sphingomyelin", "CHEMICAL", 30, 43], ["cholesterol", "CHEMICAL", 144, 155], ["sphingolipid", "CHEMICAL", 160, 172], ["cholesterol", "CHEMICAL", 6, 17], ["sphingomyelin", "CHEMICAL", 30, 43], ["cholesterol", "CHEMICAL", 144, 155], ["sphingolipid", "CHEMICAL", 160, 172], ["cholesterol", "SIMPLE_CHEMICAL", 6, 17], ["sphingomyelin", "SIMPLE_CHEMICAL", 30, 43], ["cellular", "CELL", 77, 85], ["cell", "CELL", 110, 114], ["cholesterol", "SIMPLE_CHEMICAL", 144, 155], ["sphingolipid", "SIMPLE_CHEMICAL", 160, 172], ["HCV particles", "ORGANISM", 178, 191], ["HCV", "SPECIES", 178, 181], ["cholesterol", "TEST", 6, 17], ["sphingomyelin", "PROBLEM", 30, 43], ["hydrolyzed virus", "PROBLEM", 44, 60], ["a defect in cellular internalization", "PROBLEM", 65, 101], ["cell attachment", "PROBLEM", 110, 125], ["incorporation of cholesterol and sphingolipid into HCV particles", "PROBLEM", 127, 191], ["depleted", "OBSERVATION", 18, 26], ["sphingomyelin", "ANATOMY", 30, 43], ["hydrolyzed virus", "OBSERVATION", 44, 60], ["defect", "OBSERVATION", 67, 73], ["cellular internalization", "OBSERVATION", 77, 101], ["not", "UNCERTAINTY", 106, 109], ["cell attachment", "OBSERVATION", 110, 125]]], ["Although newly synthesized structural proteins of HCV localize into membrane rafts on the cellular membrane of infected cells, it is unclear whether these membrane rafts are derived from lipids on the viral particles or not.", [["membrane rafts", "ANATOMY", 68, 82], ["cellular membrane", "ANATOMY", 90, 107], ["cells", "ANATOMY", 120, 125], ["membrane rafts", "ANATOMY", 155, 169], ["HCV", "ORGANISM", 50, 53], ["membrane rafts", "CELLULAR_COMPONENT", 68, 82], ["cellular membrane", "CELLULAR_COMPONENT", 90, 107], ["cells", "CELL", 120, 125], ["membrane rafts", "CELLULAR_COMPONENT", 155, 169], ["lipids", "SIMPLE_CHEMICAL", 187, 193], ["structural proteins", "PROTEIN", 27, 46], ["infected cells", "CELL_TYPE", 111, 125], ["HCV", "SPECIES", 50, 53], ["HCV", "PROBLEM", 50, 53], ["infected cells", "PROBLEM", 111, 125], ["these membrane rafts", "PROBLEM", 149, 169], ["HCV", "OBSERVATION", 50, 53], ["membrane rafts", "OBSERVATION", 68, 82], ["cellular membrane", "OBSERVATION", 90, 107], ["infected cells", "OBSERVATION", 111, 125], ["membrane rafts", "OBSERVATION", 155, 169]]], ["Alternatively, membrane rafts may serve as a budding site of HCV in the ER [147] .Genome Replication, Assembly, and Budding of Enveloped VirusesOn the cell surface and in the viral RNA replication complexes, membrane rafts are associated with the NS1 of all four DEN serotypes and JEV.", [["membrane rafts", "ANATOMY", 15, 29], ["cell surface", "ANATOMY", 151, 163], ["membrane rafts", "ANATOMY", 208, 222], ["JEV", "DISEASE", 281, 284], ["membrane rafts", "CELLULAR_COMPONENT", 15, 29], ["HCV", "ORGANISM", 61, 64], ["ER", "GENE_OR_GENE_PRODUCT", 72, 74], ["VirusesOn", "GENE_OR_GENE_PRODUCT", 137, 146], ["cell surface", "CELLULAR_COMPONENT", 151, 163], ["membrane rafts", "CELLULAR_COMPONENT", 208, 222], ["NS1", "GENE_OR_GENE_PRODUCT", 247, 250], ["DEN serotypes", "ORGANISM", 263, 276], ["JEV", "ORGANISM", 281, 284], ["ER", "PROTEIN", 72, 74], ["viral RNA replication complexes", "PROTEIN", 175, 206], ["NS1", "PROTEIN", 247, 250], ["HCV", "SPECIES", 61, 64], ["JEV", "SPECIES", 281, 284], ["membrane rafts", "TREATMENT", 15, 29], ["HCV", "PROBLEM", 61, 64], ["Genome Replication", "TREATMENT", 82, 100], ["Enveloped VirusesOn the cell surface", "TREATMENT", 127, 163], ["the viral RNA replication complexes", "TREATMENT", 171, 206], ["membrane rafts", "TREATMENT", 208, 222], ["membrane rafts", "OBSERVATION", 15, 29], ["HCV", "OBSERVATION", 61, 64], ["cell surface", "OBSERVATION", 151, 163], ["viral RNA", "OBSERVATION", 175, 184], ["replication complexes", "OBSERVATION", 185, 206], ["membrane rafts", "OBSERVATION", 208, 222]]], ["Efficient viral RNA replication of flaviviruses requires NS1, which can be found in the cell as a monomer associated with cellular organelle membranes and colocalized with the viral replication complex and as a dimer in a membrane GPI-anchored form colocalized with membrane rafts, and it is also secreted as a hexamer from infected cells [148, 149] .Genome Replication, Assembly, and Budding of Enveloped VirusesHuman RSV is a major pathogen of severe lower respiratory tract disease in infants, children, immunosuppressed individuals, and the elderly.", [["cell", "ANATOMY", 88, 92], ["cellular organelle membranes", "ANATOMY", 122, 150], ["membrane", "ANATOMY", 222, 230], ["membrane rafts", "ANATOMY", 266, 280], ["cells", "ANATOMY", 333, 338], ["lower respiratory tract", "ANATOMY", 453, 476], ["lower respiratory tract disease", "DISEASE", 453, 484], ["NS1", "GENE_OR_GENE_PRODUCT", 57, 60], ["cell", "CELL", 88, 92], ["cellular", "CELLULAR_COMPONENT", 122, 130], ["organelle membranes", "CELLULAR_COMPONENT", 131, 150], ["membrane", "CELLULAR_COMPONENT", 222, 230], ["membrane rafts", "CELLULAR_COMPONENT", 266, 280], ["cells", "CELL", 333, 338], ["Enveloped VirusesHuman RSV", "ORGANISM", 396, 422], ["lower", "ORGANISM_SUBDIVISION", 453, 458], ["respiratory tract", "ORGANISM_SUBDIVISION", 459, 476], ["infants", "ORGANISM", 488, 495], ["children", "ORGANISM", 497, 505], ["NS1", "PROTEIN", 57, 60], ["viral replication complex", "PROTEIN", 176, 201], ["dimer", "PROTEIN", 211, 216], ["membrane GPI-anchored form", "PROTEIN", 222, 248], ["infected cells", "CELL_TYPE", 324, 338], ["infants", "SPECIES", 488, 495], ["children", "SPECIES", 497, 505], ["RSV", "SPECIES", 419, 422], ["Efficient viral RNA replication of flaviviruses", "PROBLEM", 0, 47], ["NS1", "TREATMENT", 57, 60], ["cellular organelle membranes", "PROBLEM", 122, 150], ["the viral replication complex", "PROBLEM", 172, 201], ["a membrane GPI", "TEST", 220, 234], ["membrane rafts", "TREATMENT", 266, 280], ["infected cells", "PROBLEM", 324, 338], ["Enveloped VirusesHuman RSV", "PROBLEM", 396, 422], ["severe lower respiratory tract disease", "PROBLEM", 446, 484], ["viral RNA replication", "OBSERVATION", 10, 31], ["flaviviruses", "OBSERVATION", 35, 47], ["organelle membranes", "OBSERVATION", 131, 150], ["viral replication", "OBSERVATION", 176, 193], ["membrane rafts", "OBSERVATION", 266, 280], ["severe", "OBSERVATION_MODIFIER", 446, 452], ["lower", "ANATOMY_MODIFIER", 453, 458], ["respiratory tract", "ANATOMY", 459, 476]]], ["The viral proteins, nucleoprotein (N), phosphoprotein (P), large polymerase subunit (L), matrix protein (M) and M2-1, are located in membrane rafts in virus-infected cells.", [["membrane rafts", "ANATOMY", 133, 147], ["cells", "ANATOMY", 166, 171], ["nucleoprotein (N)", "GENE_OR_GENE_PRODUCT", 20, 37], ["large polymerase subunit (L)", "GENE_OR_GENE_PRODUCT", 59, 87], ["matrix protein (M)", "GENE_OR_GENE_PRODUCT", 89, 107], ["M2-1", "GENE_OR_GENE_PRODUCT", 112, 116], ["membrane rafts", "CELLULAR_COMPONENT", 133, 147], ["cells", "CELL", 166, 171], ["viral proteins", "PROTEIN", 4, 18], ["nucleoprotein (N), phosphoprotein (P)", "PROTEIN", 20, 57], ["large polymerase subunit", "PROTEIN", 59, 83], ["L", "PROTEIN", 85, 86], ["matrix protein", "PROTEIN", 89, 103], ["M", "PROTEIN", 105, 106], ["M2", "PROTEIN", 112, 114], ["1", "PROTEIN", 115, 116], ["virus-infected cells", "CELL_TYPE", 151, 171], ["The viral proteins", "TEST", 0, 18], ["nucleoprotein", "TEST", 20, 33], ["phosphoprotein", "TEST", 39, 53], ["large polymerase subunit (L), matrix protein", "TEST", 59, 103], ["M2", "TEST", 112, 114], ["infected cells", "PROBLEM", 157, 171], ["viral proteins", "OBSERVATION", 4, 18], ["M2", "ANATOMY", 112, 114], ["membrane rafts", "OBSERVATION", 133, 147], ["virus", "OBSERVATION", 151, 156], ["infected cells", "OBSERVATION", 157, 171]]], ["Viral RNP complexes are formed by interactions of viral genomic RNA with N, P, L, and M2-1 proteins.", [["M2-1", "GENE_OR_GENE_PRODUCT", 86, 90], ["Viral RNP complexes", "PROTEIN", 0, 19], ["viral genomic RNA", "RNA", 50, 67], ["N, P, L, and M2-1 proteins", "PROTEIN", 73, 99], ["Viral RNP complexes", "PROBLEM", 0, 19], ["viral genomic RNA", "PROBLEM", 50, 67], ["P", "TEST", 76, 77], ["M2", "TEST", 86, 88], ["RNP complexes", "OBSERVATION", 6, 19], ["viral genomic RNA", "OBSERVATION", 50, 67], ["M2", "ANATOMY", 86, 88]]], ["The association of viral RNP complexes with membrane rafts leads to efficient RNA polymerase activity that may require interaction with cellular factor HSP70 (one of the viral receptor candidates) in a raft-dependent and ATP-dependent manner [150, 151] .Genome Replication, Assembly, and Budding of Enveloped VirusesThe role of membrane rafts in the assembly and budding of enveloped viruses has been investigated in Ebola virus [12, 152] , Marburg virus [12] , WNV [153] , murine cytomegalovirus (MCMV; Herpesviridae) [154] , HSV [155, 156] , HHV-6 [157] , influenza virus [34, 40, [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] , measles virus (Paramyxoviridae) [40, 172, 173] , Newcastle disease virus (NDV; Paramyxoviridae) [174, 175] , RSV [150, 151, [176] [177] [178] [179] , Sendai virus (Paramyxoviridae) [180, 181] , HIV-1 [40, [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] , HTLV-1 [202] , and vesicular stomatitis virus (VSV; Rhabdoviridae) [203, 204] .Genome Replication, Assembly, and Budding of Enveloped VirusesEbola virus and Marburg virus use membrane rafts bearing viral glycoproteins as a platform for budding from host cells, in addition to entry.", [["membrane rafts", "ANATOMY", 44, 58], ["cellular", "ANATOMY", 136, 144], ["raft", "ANATOMY", 202, 206], ["membrane rafts", "ANATOMY", 328, 342], ["membrane rafts", "ANATOMY", 1171, 1185], ["cells", "ANATOMY", 1250, 1255], ["ATP", "CHEMICAL", 221, 224], ["Ebola virus", "DISEASE", 417, 428], ["murine cytomegalovirus", "DISEASE", 474, 496], ["influenza virus", "DISEASE", 558, 573], ["[165] [166] [167] [168] [169] [170] [171] ,", "CHEMICAL", 625, 668], ["measles virus", "DISEASE", 669, 682], ["Newcastle disease virus", "DISEASE", 718, 741], ["HTLV-1 [202", "CHEMICAL", 996, 1007], ["vesicular stomatitis virus", "DISEASE", 1015, 1041], ["Ebola", "DISEASE", 1137, 1142], ["ATP", "CHEMICAL", 221, 224], ["membrane rafts", "CELLULAR_COMPONENT", 44, 58], ["cellular", "CELL", 136, 144], ["HSP70", "GENE_OR_GENE_PRODUCT", 152, 157], ["raft", "CELLULAR_COMPONENT", 202, 206], ["ATP", "SIMPLE_CHEMICAL", 221, 224], ["membrane rafts", "CELLULAR_COMPONENT", 328, 342], ["Ebola virus", "ORGANISM", 417, 428], ["Marburg virus [12]", "ORGANISM", 441, 459], ["WNV [153]", "ORGANISM", 462, 471], ["murine", "ORGANISM", 474, 480], ["cytomegalovirus", "ORGANISM", 481, 496], ["MCMV", "ORGANISM", 498, 502], ["Herpesviridae) [154]", "ORGANISM", 504, 524], ["HSV", "ORGANISM", 527, 530], ["HHV-6 [157", "ORGANISM", 544, 554], ["influenza virus", "ORGANISM", 558, 573], ["measles virus", "ORGANISM", 669, 682], ["Newcastle disease virus", "ORGANISM", 718, 741], ["NDV", "ORGANISM", 743, 746], ["RSV", "ORGANISM", 778, 781], ["Sendai virus", "ORGANISM", 819, 831], ["HIV-1", "ORGANISM", 863, 868], ["HTLV-1", "ORGANISM", 996, 1002], ["vesicular stomatitis virus", "ORGANISM", 1015, 1041], ["VSV", "ORGANISM", 1043, 1046], ["Budding of Enveloped Viruses", "ORGANISM", 1109, 1137], ["Ebola virus", "ORGANISM", 1137, 1148], ["Marburg virus", "ORGANISM", 1153, 1166], ["membrane rafts", "CELLULAR_COMPONENT", 1171, 1185], ["host cells", "CELL", 1245, 1255], ["viral RNP complexes", "PROTEIN", 19, 38], ["RNA polymerase", "PROTEIN", 78, 92], ["cellular factor", "PROTEIN", 136, 151], ["HSP70", "PROTEIN", 152, 157], ["viral receptor candidates", "PROTEIN", 170, 195], ["viral glycoproteins", "PROTEIN", 1194, 1213], ["host cells", "CELL_TYPE", 1245, 1255], ["Ebola virus", "SPECIES", 417, 428], ["Marburg virus", "SPECIES", 441, 454], ["murine", "SPECIES", 474, 480], ["cytomegalovirus", "SPECIES", 481, 496], ["MCMV", "SPECIES", 498, 502], ["influenza virus", "SPECIES", 558, 573], ["measles virus", "SPECIES", 669, 682], ["Newcastle disease virus", "SPECIES", 718, 741], ["NDV", "SPECIES", 743, 746], ["Sendai virus", "SPECIES", 819, 831], ["HIV-1", "SPECIES", 863, 868], ["vesicular stomatitis virus", "SPECIES", 1015, 1041], ["Ebola virus", "SPECIES", 1137, 1148], ["Marburg virus", "SPECIES", 1153, 1166], ["Ebola virus", "SPECIES", 417, 428], ["Marburg virus", "SPECIES", 441, 454], ["WNV", "SPECIES", 462, 465], ["murine cytomegalovirus", "SPECIES", 474, 496], ["MCMV", "SPECIES", 498, 502], ["HSV", "SPECIES", 527, 530], ["HHV-6", "SPECIES", 544, 549], ["measles virus", "SPECIES", 669, 682], ["Newcastle disease virus", "SPECIES", 718, 741], ["NDV", "SPECIES", 743, 746], ["RSV", "SPECIES", 778, 781], ["Sendai virus", "SPECIES", 819, 831], ["HIV-1", "SPECIES", 863, 868], ["HTLV-1", "SPECIES", 996, 1002], ["vesicular stomatitis virus", "SPECIES", 1015, 1041], ["VSV", "SPECIES", 1043, 1046], ["Ebola virus", "SPECIES", 1137, 1148], ["Marburg virus", "SPECIES", 1153, 1166], ["viral RNP complexes", "PROBLEM", 19, 38], ["membrane rafts", "TREATMENT", 44, 58], ["efficient RNA polymerase activity", "PROBLEM", 68, 101], ["cellular factor HSP70", "TEST", 136, 157], ["the viral receptor candidates", "TREATMENT", 166, 195], ["membrane rafts", "TREATMENT", 328, 342], ["enveloped viruses", "PROBLEM", 374, 391], ["Ebola virus", "PROBLEM", 417, 428], ["Marburg virus", "TEST", 441, 454], ["WNV", "TEST", 462, 465], ["murine cytomegalovirus", "TEST", 474, 496], ["MCMV", "TEST", 498, 502], ["Herpesviridae", "TEST", 504, 517], ["HSV", "TEST", 527, 530], ["HHV", "TEST", 544, 547], ["influenza virus", "TEST", 558, 573], ["measles virus (Paramyxoviridae)", "TEST", 669, 700], ["Newcastle disease virus", "PROBLEM", 718, 741], ["Paramyxoviridae", "TEST", 748, 763], ["RSV", "TEST", 778, 781], ["Sendai virus (Paramyxoviridae)", "TEST", 819, 849], ["HIV", "TEST", 863, 866], ["HTLV", "TEST", 996, 1000], ["vesicular stomatitis virus", "PROBLEM", 1015, 1041], ["VSV", "TEST", 1043, 1046], ["Rhabdoviridae", "TEST", 1048, 1061], ["Genome Replication", "TREATMENT", 1075, 1093], ["Enveloped VirusesEbola virus", "PROBLEM", 1120, 1148], ["Marburg virus use membrane rafts", "TREATMENT", 1153, 1185], ["viral glycoproteins", "TREATMENT", 1194, 1213], ["budding from host cells", "PROBLEM", 1232, 1255], ["viral RNP complexes", "OBSERVATION", 19, 38], ["membrane rafts", "OBSERVATION", 44, 58], ["RNA polymerase activity", "OBSERVATION", 78, 101], ["vesicular stomatitis", "ANATOMY", 1015, 1035], ["host cells", "OBSERVATION", 1245, 1255]]], ["Hence, released virus particles incorporate the raft-associated molecule GM1 but not transferrin receptor, a protein absent from membrane rafts [12] .", [["raft", "ANATOMY", 48, 52], ["membrane rafts", "ANATOMY", 129, 143], ["raft", "CELLULAR_COMPONENT", 48, 52], ["GM1", "GENE_OR_GENE_PRODUCT", 73, 76], ["transferrin receptor", "GENE_OR_GENE_PRODUCT", 85, 105], ["membrane rafts", "CELLULAR_COMPONENT", 129, 143], ["raft-associated molecule", "PROTEIN", 48, 72], ["GM1", "PROTEIN", 73, 76], ["transferrin receptor", "PROTEIN", 85, 105], ["released virus particles", "PROBLEM", 7, 31], ["associated molecule GM1", "PROBLEM", 53, 76], ["transferrin receptor", "TEST", 85, 105], ["a protein", "TEST", 107, 116], ["virus", "OBSERVATION", 16, 21], ["molecule GM1", "OBSERVATION", 64, 76], ["membrane rafts", "OBSERVATION", 129, 143]]], ["The matrix protein VP40 of Ebola virus, which plays an essential role in virus assembly and budding, oligomerizes in membrane rafts.", [["membrane rafts", "ANATOMY", 117, 131], ["matrix", "CELLULAR_COMPONENT", 4, 10], ["VP40", "GENE_OR_GENE_PRODUCT", 19, 23], ["Ebola virus", "ORGANISM", 27, 38], ["membrane rafts", "CELLULAR_COMPONENT", 117, 131], ["matrix protein VP40", "PROTEIN", 4, 23], ["Ebola virus", "SPECIES", 27, 38], ["Ebola virus", "SPECIES", 27, 38], ["The matrix protein VP40", "TREATMENT", 0, 23], ["Ebola virus", "PROBLEM", 27, 38], ["Ebola virus", "OBSERVATION", 27, 38], ["membrane rafts", "OBSERVATION", 117, 131]]], ["The cellular TSG101 protein, a component of the vacuolar protein sorting machinery, actively targets along with VP40 to membrane rafts at the cell surface, by binding of VP40 with a PTAP motif of TSG101.", [["cellular", "ANATOMY", 4, 12], ["vacuolar", "ANATOMY", 48, 56], ["membrane rafts", "ANATOMY", 120, 134], ["cell surface", "ANATOMY", 142, 154], ["cellular", "CELL", 4, 12], ["TSG101", "GENE_OR_GENE_PRODUCT", 13, 19], ["vacuolar", "CELLULAR_COMPONENT", 48, 56], ["VP40", "GENE_OR_GENE_PRODUCT", 112, 116], ["membrane rafts", "CELLULAR_COMPONENT", 120, 134], ["cell surface", "CELLULAR_COMPONENT", 142, 154], ["VP40", "GENE_OR_GENE_PRODUCT", 170, 174], ["TSG101", "GENE_OR_GENE_PRODUCT", 196, 202], ["cellular TSG101 protein", "PROTEIN", 4, 27], ["vacuolar protein sorting machinery", "PROTEIN", 48, 82], ["VP40", "PROTEIN", 112, 116], ["VP40", "PROTEIN", 170, 174], ["PTAP motif", "PROTEIN", 182, 192], ["TSG101", "DNA", 196, 202], ["The cellular TSG101 protein", "TEST", 0, 27], ["VP40 to membrane rafts", "TREATMENT", 112, 134], ["a PTAP motif of TSG101", "TREATMENT", 180, 202], ["cellular", "OBSERVATION", 4, 12], ["TSG101 protein", "OBSERVATION", 13, 27], ["vacuolar protein sorting machinery", "OBSERVATION", 48, 82], ["cell surface", "OBSERVATION", 142, 154]]], ["Thus, budding complexes containing VP40 and TSG101 accumulate in membrane rafts to promote virus budding [152] .Genome Replication, Assembly, and Budding of Enveloped VirusesWNV spreads from the blood stream to the central nervous system and peripheral tissues across endothelial cells.", [["membrane rafts", "ANATOMY", 65, 79], ["blood stream", "ANATOMY", 195, 207], ["central nervous system", "ANATOMY", 215, 237], ["peripheral tissues", "ANATOMY", 242, 260], ["endothelial cells", "ANATOMY", 268, 285], ["budding", "CELLULAR_COMPONENT", 6, 13], ["VP40", "GENE_OR_GENE_PRODUCT", 35, 39], ["TSG101", "GENE_OR_GENE_PRODUCT", 44, 50], ["membrane rafts", "CELLULAR_COMPONENT", 65, 79], ["blood", "ORGANISM_SUBSTANCE", 195, 200], ["central nervous system", "ANATOMICAL_SYSTEM", 215, 237], ["peripheral tissues", "TISSUE", 242, 260], ["endothelial cells", "CELL", 268, 285], ["budding complexes", "PROTEIN", 6, 23], ["VP40", "PROTEIN", 35, 39], ["TSG101", "PROTEIN", 44, 50], ["endothelial cells", "CELL_TYPE", 268, 285], ["budding complexes", "PROBLEM", 6, 23], ["VP40", "PROBLEM", 35, 39], ["membrane rafts", "TREATMENT", 65, 79], ["the blood stream", "TEST", 191, 207], ["membrane rafts", "OBSERVATION", 65, 79], ["virus", "OBSERVATION", 91, 96], ["central", "ANATOMY_MODIFIER", 215, 222], ["nervous system", "ANATOMY", 223, 237], ["peripheral tissues", "ANATOMY", 242, 260], ["endothelial cells", "OBSERVATION", 268, 285]]], ["Virus-like particles of highly virulent WNV NY99 6-LP strain are transported from the apical side to basolateral side of endothelial cells as the virus budding site in a raft-dependent manner, whereas those of low-virulent WNV Eg101 strain are hardly transported.", [["apical side", "ANATOMY", 86, 97], ["basolateral", "ANATOMY", 101, 112], ["endothelial cells", "ANATOMY", 121, 138], ["raft", "ANATOMY", 170, 174], ["Virus-like particles", "ORGANISM", 0, 20], ["WNV", "ORGANISM", 40, 43], ["NY99 6-LP strain", "ORGANISM", 44, 60], ["apical side", "CELLULAR_COMPONENT", 86, 97], ["basolateral side", "CELLULAR_COMPONENT", 101, 117], ["endothelial cells", "CELL", 121, 138], ["raft", "CELLULAR_COMPONENT", 170, 174], ["WNV Eg101 strain", "ORGANISM", 223, 239], ["endothelial cells", "CELL_TYPE", 121, 138], ["virus budding site", "DNA", 146, 164], ["WNV", "SPECIES", 40, 43], ["Virus", "TEST", 0, 5], ["LP strain", "PROBLEM", 51, 60], ["endothelial cells", "PROBLEM", 121, 138], ["the virus budding site", "PROBLEM", 142, 164], ["particles", "OBSERVATION_MODIFIER", 11, 20], ["highly", "OBSERVATION_MODIFIER", 24, 30], ["virulent", "OBSERVATION_MODIFIER", 31, 39], ["WNV", "OBSERVATION", 40, 43], ["apical", "ANATOMY_MODIFIER", 86, 92], ["basolateral", "ANATOMY_MODIFIER", 101, 112], ["endothelial cells", "OBSERVATION", 121, 138], ["virus", "OBSERVATION", 146, 151]]], ["Membrane rafts may be involved in a transport pathway for basolateral destinations of WNV within endothelial cells [153] .Genome Replication, Assembly, and Budding of Enveloped VirusesMCMV (belonging to the betaherpesvirus UL78 family) M78 protein, a 7-transmembrane receptor homologue, traffics to the surface membrane of infected cells, but is rapidly and constitutively internalized through both clathrin-dependent and caveola/raft-dependent pathways.", [["Membrane rafts", "ANATOMY", 0, 14], ["basolateral", "ANATOMY", 58, 69], ["endothelial cells", "ANATOMY", 97, 114], ["surface membrane", "ANATOMY", 303, 319], ["cells", "ANATOMY", 332, 337], ["raft", "ANATOMY", 430, 434], ["Membrane rafts", "CELLULAR_COMPONENT", 0, 14], ["WNV", "ORGANISM", 86, 89], ["endothelial cells", "CELL", 97, 114], ["VirusesMCMV", "GENE_OR_GENE_PRODUCT", 177, 188], ["UL78", "GENE_OR_GENE_PRODUCT", 223, 227], ["M78", "GENE_OR_GENE_PRODUCT", 236, 239], ["surface membrane", "CELLULAR_COMPONENT", 303, 319], ["cells", "CELL", 332, 337], ["clathrin", "GENE_OR_GENE_PRODUCT", 399, 407], ["caveola", "GENE_OR_GENE_PRODUCT", 422, 429], ["raft", "CELLULAR_COMPONENT", 430, 434], ["endothelial cells", "CELL_TYPE", 97, 114], ["Enveloped VirusesMCMV", "PROTEIN", 167, 188], ["betaherpesvirus UL78 family", "PROTEIN", 207, 234], ["M78 protein", "PROTEIN", 236, 247], ["7-transmembrane receptor homologue", "PROTEIN", 251, 285], ["infected cells", "CELL_TYPE", 323, 337], ["clathrin", "PROTEIN", 399, 407], ["WNV", "SPECIES", 86, 89], ["WNV", "PROBLEM", 86, 89], ["protein", "TEST", 240, 247], ["transmembrane receptor homologue", "TREATMENT", 253, 285], ["infected cells", "PROBLEM", 323, 337], ["infected cells", "OBSERVATION", 323, 337]]], ["Such an M78 subcellular localization may contribute to the incorporation of M78 into the viral envelope during virus maturation [154] .Genome Replication, Assembly, and Budding of Enveloped VirusesSix envelope glycoproteins, gH, gL, gQ1, gQ2, g, and gB, of HHV-6 are present in membrane rafts during the course of virus maturation.", [["subcellular", "ANATOMY", 12, 23], ["membrane rafts", "ANATOMY", 278, 292], ["M78", "GENE_OR_GENE_PRODUCT", 8, 11], ["M78", "GENE_OR_GENE_PRODUCT", 76, 79], ["gH", "GENE_OR_GENE_PRODUCT", 225, 227], ["gL", "GENE_OR_GENE_PRODUCT", 229, 231], ["gQ1", "GENE_OR_GENE_PRODUCT", 233, 236], ["gQ2", "GENE_OR_GENE_PRODUCT", 238, 241], ["g", "GENE_OR_GENE_PRODUCT", 243, 244], ["gB", "GENE_OR_GENE_PRODUCT", 250, 252], ["HHV-6", "ORGANISM", 257, 262], ["membrane rafts", "CELLULAR_COMPONENT", 278, 292], ["M78", "PROTEIN", 76, 79], ["envelope glycoproteins", "PROTEIN", 201, 223], ["gH", "PROTEIN", 225, 227], ["gL", "PROTEIN", 229, 231], ["gQ1", "PROTEIN", 233, 236], ["gQ2", "PROTEIN", 238, 241], ["g", "PROTEIN", 243, 244], ["gB", "PROTEIN", 250, 252], ["HHV-6", "PROTEIN", 257, 262], ["HHV-6", "SPECIES", 257, 262], ["Genome Replication", "TREATMENT", 135, 153], ["gH", "TEST", 225, 227], ["gL", "TEST", 229, 231], ["HHV", "PROBLEM", 257, 260], ["virus maturation", "TREATMENT", 314, 330], ["gB", "ANATOMY", 250, 252], ["membrane rafts", "OBSERVATION", 278, 292]]], ["GM1, a representative raft marker, is incorporated into mature virus particles along with these viral envelope glycoproteins, indicating that HHV-6 may assemble through membrane rafts [157] .Genome Replication, Assembly, and Budding of Enveloped VirusesThe HSV tegument contains the less-abundant virus particle host shutoff (vhs) protein encoded by the HSV late gene UL41, which enhances the turnover of all kinetics of viral mRNA and is likely to be important in the increased removal of immediate-early and early viral transcripts to facilitate the switch to late gene expression.", [["raft", "ANATOMY", 22, 26], ["membrane rafts", "ANATOMY", 169, 183], ["GM1", "GENE_OR_GENE_PRODUCT", 0, 3], ["raft", "CELLULAR_COMPONENT", 22, 26], ["HHV-6", "ORGANISM", 142, 147], ["membrane", "CELLULAR_COMPONENT", 169, 177], ["Enveloped Viruses", "ORGANISM", 236, 253], ["HSV tegument", "ORGANISM", 257, 269], ["vhs", "GENE_OR_GENE_PRODUCT", 326, 329], ["HSV", "ORGANISM", 354, 357], ["UL41", "GENE_OR_GENE_PRODUCT", 368, 372], ["GM1", "PROTEIN", 0, 3], ["viral envelope glycoproteins", "PROTEIN", 96, 124], ["HHV-6", "PROTEIN", 142, 147], ["virus particle host shutoff (vhs) protein", "PROTEIN", 297, 338], ["HSV late gene UL41", "DNA", 354, 372], ["viral mRNA", "RNA", 421, 431], ["immediate-early and early viral transcripts", "RNA", 490, 533], ["HSV", "SPECIES", 257, 260], ["HSV", "SPECIES", 354, 357], ["a representative raft marker", "TEST", 5, 33], ["mature virus particles", "PROBLEM", 56, 78], ["these viral envelope glycoproteins", "PROBLEM", 90, 124], ["HHV", "PROBLEM", 142, 145], ["Genome Replication", "TREATMENT", 191, 209], ["Enveloped Viruses", "PROBLEM", 236, 253], ["The HSV tegument", "TEST", 253, 269], ["the HSV late gene UL41", "PROBLEM", 350, 372], ["viral mRNA", "PROBLEM", 421, 431], ["the increased removal", "TREATMENT", 465, 486], ["early viral transcripts", "TREATMENT", 510, 533], ["raft marker", "OBSERVATION", 22, 33], ["mature", "OBSERVATION_MODIFIER", 56, 62], ["virus particles", "OBSERVATION", 63, 78], ["Viruses", "OBSERVATION", 246, 253], ["virus particle", "OBSERVATION", 297, 311], ["viral mRNA", "OBSERVATION", 421, 431], ["likely to be", "UNCERTAINTY", 439, 451], ["viral transcripts", "OBSERVATION", 516, 533]]], ["Only a small proportion of total cellular vhs proteins are associated with membrane rafts.", [["cellular", "ANATOMY", 33, 41], ["membrane rafts", "ANATOMY", 75, 89], ["cellular", "CELL", 33, 41], ["membrane rafts", "CELLULAR_COMPONENT", 75, 89], ["vhs proteins", "PROTEIN", 42, 54], ["total cellular vhs proteins", "PROBLEM", 27, 54], ["membrane rafts", "PROBLEM", 75, 89], ["small", "OBSERVATION_MODIFIER", 7, 12], ["proportion", "OBSERVATION_MODIFIER", 13, 23], ["total cellular", "OBSERVATION", 27, 41], ["vhs proteins", "OBSERVATION", 42, 54], ["associated with", "UNCERTAINTY", 59, 74], ["membrane rafts", "OBSERVATION", 75, 89]]], ["Nevertheless, a large proportion of the vhs proteins exist in HSV-containing cytoplasmic organelles, indicating that membrane rafts may correlate with assembly of vhs protein into the tegument [155] .", [["cytoplasmic organelles", "ANATOMY", 77, 99], ["membrane rafts", "ANATOMY", 117, 131], ["tegument", "ANATOMY", 184, 192], ["vhs", "GENE_OR_GENE_PRODUCT", 40, 43], ["HSV", "ORGANISM", 62, 65], ["cytoplasmic organelles", "CELLULAR_COMPONENT", 77, 99], ["membrane rafts", "CELLULAR_COMPONENT", 117, 131], ["vhs", "GENE_OR_GENE_PRODUCT", 163, 166], ["vhs proteins", "PROTEIN", 40, 52], ["vhs protein", "PROTEIN", 163, 174], ["HSV", "SPECIES", 62, 65], ["the vhs proteins", "TEST", 36, 52], ["HSV", "PROBLEM", 62, 65], ["cytoplasmic organelles", "PROBLEM", 77, 99], ["membrane rafts", "PROBLEM", 117, 131], ["large", "OBSERVATION_MODIFIER", 16, 21], ["HSV", "OBSERVATION", 62, 65], ["cytoplasmic organelles", "OBSERVATION", 77, 99], ["membrane rafts", "OBSERVATION", 117, 131]]], ["The UL11 and UL51 gene products of HSV are membrane-associated tegument proteins that are incorporated into the HSV envelope during virus maturation.", [["membrane", "ANATOMY", 43, 51], ["tegument", "ANATOMY", 63, 71], ["UL11", "GENE_OR_GENE_PRODUCT", 4, 8], ["UL51", "GENE_OR_GENE_PRODUCT", 13, 17], ["HSV", "ORGANISM", 35, 38], ["membrane", "CELLULAR_COMPONENT", 43, 51], ["HSV envelope", "ORGANISM", 112, 124], ["UL11 and UL51 gene products", "PROTEIN", 4, 31], ["membrane-associated tegument proteins", "PROTEIN", 43, 80], ["HSV", "SPECIES", 35, 38], ["HSV", "SPECIES", 112, 115], ["The UL11", "TEST", 0, 8], ["HSV", "PROBLEM", 35, 38], ["tegument proteins", "PROBLEM", 63, 80], ["the HSV envelope", "PROBLEM", 108, 124], ["virus maturation", "TREATMENT", 132, 148], ["HSV", "OBSERVATION", 35, 38], ["tegument proteins", "OBSERVATION", 63, 80]]], ["HSV UL11 is associated with cholesteroland glycosphingolipid-enriched membrane rafts through its posttranslational myristoylation and palmitoylation into the Golgi apparatus, but UL51, which is only palmitoylated, has no association with the membrane rafts.", [["membrane rafts", "ANATOMY", 70, 84], ["Golgi apparatus", "ANATOMY", 158, 173], ["membrane rafts", "ANATOMY", 242, 256], ["HSV", "ORGANISM", 0, 3], ["UL11", "GENE_OR_GENE_PRODUCT", 4, 8], ["cholesteroland", "SIMPLE_CHEMICAL", 28, 42], ["membrane rafts", "CELLULAR_COMPONENT", 70, 84], ["Golgi apparatus", "CELLULAR_COMPONENT", 158, 173], ["UL51", "GENE_OR_GENE_PRODUCT", 179, 183], ["membrane rafts", "CELLULAR_COMPONENT", 242, 256], ["HSV UL11", "PROTEIN", 0, 8], ["UL51", "PROTEIN", 179, 183], ["HSV", "SPECIES", 0, 3], ["HSV UL11", "TEST", 0, 8], ["cholesteroland glycosphingolipid", "TREATMENT", 28, 60], ["enriched membrane rafts", "TREATMENT", 61, 84], ["its posttranslational myristoylation", "TREATMENT", 93, 129], ["the membrane rafts", "PROBLEM", 238, 256], ["enriched membrane rafts", "OBSERVATION", 61, 84], ["posttranslational myristoylation", "OBSERVATION", 97, 129], ["Golgi apparatus", "OBSERVATION", 158, 173], ["no association with", "UNCERTAINTY", 218, 237], ["membrane rafts", "OBSERVATION", 242, 256]]], ["UL11 and UL51 appear to function at different steps in progeny virus maturation [156] .", [["UL11", "GENE_OR_GENE_PRODUCT", 0, 4], ["UL51", "GENE_OR_GENE_PRODUCT", 9, 13], ["progeny virus", "ORGANISM", 55, 68], ["UL11", "PROTEIN", 0, 4], ["UL51", "PROTEIN", 9, 13], ["UL11", "TEST", 0, 4]]], ["Involvement of membrane rafts in HSV assembly and budding remains to be clarified.Genome Replication, Assembly, and Budding of Enveloped VirusesInfluenza virus particles consist of vial RNP with two spike envelope glycoproteins, HA and neuraminidase (NA), and ion channel M2 protein on the outer surface and internal M1 protein and nonstructural NS2 protein on the inner surface.", [["membrane rafts", "ANATOMY", 15, 29], ["outer surface", "ANATOMY", 290, 303], ["inner surface", "ANATOMY", 365, 378], ["membrane rafts", "CELLULAR_COMPONENT", 15, 29], ["HSV", "ORGANISM", 33, 36], ["Enveloped Viruses", "ORGANISM", 127, 144], ["Influenza virus", "ORGANISM", 144, 159], ["HA", "GENE_OR_GENE_PRODUCT", 229, 231], ["neuraminidase (NA)", "GENE_OR_GENE_PRODUCT", 236, 254], ["ion channel M2", "GENE_OR_GENE_PRODUCT", 260, 274], ["outer surface", "CELLULAR_COMPONENT", 290, 303], ["inner surface", "CELLULAR_COMPONENT", 365, 378], ["vial RNP", "PROTEIN", 181, 189], ["spike envelope glycoproteins", "PROTEIN", 199, 227], ["HA", "PROTEIN", 229, 231], ["neuraminidase", "PROTEIN", 236, 249], ["NA", "PROTEIN", 251, 253], ["ion channel M2 protein", "PROTEIN", 260, 282], ["internal M1 protein", "PROTEIN", 308, 327], ["nonstructural NS2 protein", "PROTEIN", 332, 357], ["Influenza virus", "SPECIES", 144, 159], ["HSV", "SPECIES", 33, 36], ["Influenza virus", "SPECIES", 144, 159], ["membrane rafts", "PROBLEM", 15, 29], ["HSV", "PROBLEM", 33, 36], ["Genome Replication", "TREATMENT", 82, 100], ["Enveloped VirusesInfluenza virus particles", "PROBLEM", 127, 169], ["vial RNP", "TREATMENT", 181, 189], ["two spike envelope glycoproteins", "PROBLEM", 195, 227], ["HA", "PROBLEM", 229, 231], ["neuraminidase (NA)", "TEST", 236, 254], ["membrane rafts", "OBSERVATION", 15, 29], ["Viruses", "OBSERVATION", 137, 144], ["internal M1", "ANATOMY", 308, 319], ["nonstructural NS2 protein", "OBSERVATION", 332, 357], ["inner", "OBSERVATION_MODIFIER", 365, 370], ["surface", "OBSERVATION_MODIFIER", 371, 378]]], ["Membrane rafts are associated with the transmembrane domains and cytoplasmic tails of HA [162] and NA [162, 163] and with the short transmembrane domains of M2 [74, 169, 205] and NP [164] , but not M1.", [["Membrane rafts", "ANATOMY", 0, 14], ["transmembrane", "ANATOMY", 39, 52], ["cytoplasmic", "ANATOMY", 65, 76], ["transmembrane", "ANATOMY", 132, 145], ["Membrane rafts", "CELLULAR_COMPONENT", 0, 14], ["transmembrane", "CELLULAR_COMPONENT", 39, 52], ["cytoplasmic", "ORGANISM_SUBSTANCE", 65, 76], ["HA [162]", "GENE_OR_GENE_PRODUCT", 86, 94], ["M2", "GENE_OR_GENE_PRODUCT", 157, 159], ["transmembrane domains", "PROTEIN", 39, 60], ["cytoplasmic tails", "PROTEIN", 65, 82], ["transmembrane domains", "PROTEIN", 132, 153], ["M2", "PROTEIN", 157, 159], ["M1", "PROTEIN", 198, 200], ["Membrane rafts", "PROBLEM", 0, 14], ["the transmembrane domains", "PROBLEM", 35, 60], ["cytoplasmic tails of HA", "PROBLEM", 65, 88], ["NA", "TEST", 99, 101], ["the short transmembrane domains", "TEST", 122, 153], ["NP", "TEST", 179, 181], ["M1", "ANATOMY", 198, 200]]], ["These domains of HA and M2 contain palmitoylated cysteine residues that are required for hydrophobic interactions with lipids and cholesterol of membrane rafts.", [["membrane rafts", "ANATOMY", 145, 159], ["cholesterol", "CHEMICAL", 130, 141], ["cysteine", "CHEMICAL", 49, 57], ["cholesterol", "CHEMICAL", 130, 141], ["HA", "GENE_OR_GENE_PRODUCT", 17, 19], ["M2", "GENE_OR_GENE_PRODUCT", 24, 26], ["cysteine", "AMINO_ACID", 49, 57], ["lipids", "SIMPLE_CHEMICAL", 119, 125], ["cholesterol", "SIMPLE_CHEMICAL", 130, 141], ["membrane rafts", "CELLULAR_COMPONENT", 145, 159], ["M2", "PROTEIN", 24, 26], ["HA", "PROBLEM", 17, 19], ["palmitoylated cysteine residues", "TREATMENT", 35, 66], ["lipids", "TREATMENT", 119, 125], ["cholesterol of membrane rafts", "TREATMENT", 130, 159], ["M2", "ANATOMY_MODIFIER", 24, 26], ["palmitoylated cysteine residues", "OBSERVATION", 35, 66], ["membrane rafts", "OBSERVATION", 145, 159]]], ["M2 also possesses a putative cholesterol recognition/interaction amino acid consensus (CRAC) motif in addition to palmitoylation of its amphiphilic helix.", [["cholesterol", "CHEMICAL", 29, 40], ["amino acid", "CHEMICAL", 65, 75], ["cholesterol", "CHEMICAL", 29, 40], ["amino acid", "CHEMICAL", 65, 75], ["M2", "GENE_OR_GENE_PRODUCT", 0, 2], ["cholesterol", "SIMPLE_CHEMICAL", 29, 40], ["amino acid", "AMINO_ACID", 65, 75], ["M2", "PROTEIN", 0, 2], ["interaction amino acid consensus (CRAC) motif", "PROTEIN", 53, 98], ["a putative cholesterol recognition", "PROBLEM", 18, 52], ["interaction amino acid consensus", "PROBLEM", 53, 85], ["CRAC) motif", "TREATMENT", 87, 98], ["palmitoylation of its amphiphilic helix", "TREATMENT", 114, 153]]], ["The targeting to membrane rafts of M2 requires the palmitoylation but not the CRAC motif [171] .", [["membrane rafts", "ANATOMY", 17, 31], ["membrane", "CELLULAR_COMPONENT", 17, 25], ["M2", "GENE_OR_GENE_PRODUCT", 35, 37], ["M2", "PROTEIN", 35, 37], ["CRAC motif", "PROTEIN", 78, 88], ["the palmitoylation", "TREATMENT", 47, 65], ["M2", "OBSERVATION_MODIFIER", 35, 37]]], ["Although the transmembrane domains and the cytoplasmic tails of NA are essential for the association with rafts, there is no evidence that NA contains palmitoylated cysteine residues.", [["transmembrane", "ANATOMY", 13, 26], ["cytoplasmic", "ANATOMY", 43, 54], ["rafts", "ANATOMY", 106, 111], ["NA", "CHEMICAL", 64, 66], ["NA", "CHEMICAL", 139, 141], ["cysteine", "CHEMICAL", 165, 173], ["transmembrane", "CELLULAR_COMPONENT", 13, 26], ["cytoplasmic", "ORGANISM_SUBSTANCE", 43, 54], ["NA", "GENE_OR_GENE_PRODUCT", 64, 66], ["rafts", "CELLULAR_COMPONENT", 106, 111], ["NA", "SIMPLE_CHEMICAL", 139, 141], ["cysteine", "AMINO_ACID", 165, 173], ["transmembrane domains", "PROTEIN", 13, 34], ["cytoplasmic tails", "PROTEIN", 43, 60], ["the transmembrane domains", "TEST", 9, 34], ["palmitoylated cysteine residues", "TREATMENT", 151, 182], ["cytoplasmic", "OBSERVATION_MODIFIER", 43, 54], ["tails", "OBSERVATION_MODIFIER", 55, 60], ["no evidence", "UNCERTAINTY", 122, 133], ["palmitoylated cysteine residues", "OBSERVATION", 151, 182]]], ["The mechanism by which NP associates with rafts remains unknown.", [["rafts", "ANATOMY", 42, 47], ["NP", "GENE_OR_GENE_PRODUCT", 23, 25], ["rafts", "CELLULAR_COMPONENT", 42, 47]]], ["HA, NA, NP, and M2 independently use membrane rafts together with each apical targeting signal sequence for the apical sorting process, leading to efficient preferential budding and release of progeny viruses from the apical surface membrane.", [["membrane rafts", "ANATOMY", 37, 51], ["apical", "ANATOMY", 71, 77], ["apical", "ANATOMY", 112, 118], ["apical surface membrane", "ANATOMY", 218, 241], ["NA", "CHEMICAL", 4, 6], ["HA", "GENE_OR_GENE_PRODUCT", 0, 2], ["NA", "SIMPLE_CHEMICAL", 4, 6], ["M2", "GENE_OR_GENE_PRODUCT", 16, 18], ["membrane rafts", "CELLULAR_COMPONENT", 37, 51], ["apical surface membrane", "CELLULAR_COMPONENT", 218, 241], ["apical targeting signal sequence", "PROTEIN", 71, 103], ["HA", "PROBLEM", 0, 2], ["membrane rafts", "TREATMENT", 37, 51], ["the apical sorting process", "PROBLEM", 108, 134], ["apical", "ANATOMY_MODIFIER", 112, 118], ["progeny viruses", "OBSERVATION", 193, 208], ["apical", "ANATOMY_MODIFIER", 218, 224], ["surface", "ANATOMY_MODIFIER", 225, 232]]], ["However, membrane rafts are not necessarily required for apical sorting of these viral proteins, indicating that apical sorting machineries of these viral proteins also exist outside their membrane rafts [158, [160] [161] [162] 164] .", [["membrane rafts", "ANATOMY", 9, 23], ["apical", "ANATOMY", 57, 63], ["apical", "ANATOMY", 113, 119], ["membrane rafts", "ANATOMY", 189, 203], ["membrane rafts", "CELLULAR_COMPONENT", 9, 23], ["apical", "CELLULAR_COMPONENT", 57, 63], ["membrane rafts", "CELLULAR_COMPONENT", 189, 203], ["viral proteins", "PROTEIN", 81, 95], ["viral proteins", "PROTEIN", 149, 163], ["apical sorting", "TEST", 57, 71], ["these viral proteins", "PROBLEM", 75, 95], ["these viral proteins", "TEST", 143, 163], ["membrane rafts", "OBSERVATION", 9, 23], ["not necessarily", "UNCERTAINTY", 28, 43], ["viral proteins", "OBSERVATION", 81, 95], ["apical", "ANATOMY_MODIFIER", 113, 119], ["viral proteins", "OBSERVATION", 149, 163]]], ["For example, cellular protein VIP17/MAL, a raftassociated protein, is involved in apical transport of HA in dog kidney MDCK cells [206] .", [["cellular", "ANATOMY", 13, 21], ["apical", "ANATOMY", 82, 88], ["kidney MDCK cells", "ANATOMY", 112, 129], ["cellular", "CELL", 13, 21], ["VIP17", "GENE_OR_GENE_PRODUCT", 30, 35], ["MAL", "GENE_OR_GENE_PRODUCT", 36, 39], ["apical", "CELLULAR_COMPONENT", 82, 88], ["HA", "GENE_OR_GENE_PRODUCT", 102, 104], ["dog kidney MDCK cells", "CELL", 108, 129], ["cellular protein", "PROTEIN", 13, 29], ["VIP17", "PROTEIN", 30, 35], ["MAL", "PROTEIN", 36, 39], ["raftassociated protein", "PROTEIN", 43, 65], ["HA", "PROTEIN", 102, 104], ["dog kidney MDCK cells", "CELL_LINE", 108, 129], ["dog", "SPECIES", 108, 111], ["cellular protein VIP17", "TEST", 13, 35], ["a raftassociated protein", "PROBLEM", 41, 65], ["HA", "PROBLEM", 102, 104], ["MDCK cells", "TEST", 119, 129], ["apical", "ANATOMY_MODIFIER", 82, 88]]], ["M1, a non-raft protein, is incorporated into membrane rafts through its interactions with cytoplasmic tails of both HA and M2, which facilitate the recruitment of internal viral proteins and viral RNP to the cell surface membrane for efficient virus assembly and budding [162, 207] .", [["membrane rafts", "ANATOMY", 45, 59], ["cytoplasmic", "ANATOMY", 90, 101], ["cell surface membrane", "ANATOMY", 208, 229], ["M1", "GENE_OR_GENE_PRODUCT", 0, 2], ["membrane rafts", "CELLULAR_COMPONENT", 45, 59], ["cytoplasmic", "ORGANISM_SUBSTANCE", 90, 101], ["HA", "GENE_OR_GENE_PRODUCT", 116, 118], ["M2", "GENE_OR_GENE_PRODUCT", 123, 125], ["cell surface membrane", "CELLULAR_COMPONENT", 208, 229], ["M1", "PROTEIN", 0, 2], ["non-raft protein", "PROTEIN", 6, 22], ["cytoplasmic tails", "PROTEIN", 90, 107], ["HA", "PROTEIN", 116, 118], ["M2", "PROTEIN", 123, 125], ["internal viral proteins", "PROTEIN", 163, 186], ["viral RNP", "PROTEIN", 191, 200], ["a non-raft protein", "TEST", 4, 22], ["both HA and M2", "PROBLEM", 111, 125], ["internal viral proteins", "PROBLEM", 163, 186], ["viral RNP", "TREATMENT", 191, 200], ["the cell surface membrane", "TREATMENT", 204, 229], ["membrane rafts", "OBSERVATION", 45, 59], ["tails", "OBSERVATION_MODIFIER", 102, 107], ["M2", "ANATOMY", 123, 125], ["viral RNP", "OBSERVATION", 191, 200]]], ["Although M1 has been believed to play a critical role in viral assembly and budding [208, 209] , recent studies have indicated that HA, NA, and M2, but not M1, are required for assembly and budding of influenza virus particles [167, 169] .Genome Replication, Assembly, and Budding of Enveloped VirusesGM-95 cells are mutant cells of mouse B16 melanoma that cannot synthesize major glycosphingolipids including gangliosides due to lack of ceramide glycosyltransferase gene, the first enzyme of glucosylceramide series synthesis.", [["VirusesGM-95 cells", "ANATOMY", 294, 312], ["cells", "ANATOMY", 324, 329], ["B16 melanoma", "ANATOMY", 339, 351], ["B16 melanoma", "DISEASE", 339, 351], ["ceramide", "CHEMICAL", 438, 446], ["ceramide", "CHEMICAL", 438, 446], ["glucosylceramide", "CHEMICAL", 493, 509], ["M1", "GENE_OR_GENE_PRODUCT", 9, 11], ["HA", "GENE_OR_GENE_PRODUCT", 132, 134], ["NA", "GENE_OR_GENE_PRODUCT", 136, 138], ["M2", "GENE_OR_GENE_PRODUCT", 144, 146], ["M1", "GENE_OR_GENE_PRODUCT", 156, 158], ["influenza virus", "ORGANISM", 201, 216], ["VirusesGM-95 cells", "CELL", 294, 312], ["mutant cells", "CELL", 317, 329], ["mouse", "ORGANISM", 333, 338], ["B16 melanoma", "CANCER", 339, 351], ["gangliosides", "GENE_OR_GENE_PRODUCT", 410, 422], ["ceramide glycosyltransferase", "GENE_OR_GENE_PRODUCT", 438, 466], ["glucosylceramide", "SIMPLE_CHEMICAL", 493, 509], ["M1", "PROTEIN", 9, 11], ["M2", "PROTEIN", 144, 146], ["M1", "PROTEIN", 156, 158], ["Enveloped VirusesGM-95 cells", "CELL_LINE", 284, 312], ["mutant cells", "CELL_TYPE", 317, 329], ["ceramide glycosyltransferase gene", "DNA", 438, 471], ["influenza virus", "SPECIES", 201, 216], ["mouse", "SPECIES", 333, 338], ["mouse", "SPECIES", 333, 338], ["recent studies", "TEST", 97, 111], ["HA, NA, and M2", "PROBLEM", 132, 146], ["influenza virus particles", "PROBLEM", 201, 226], ["Enveloped VirusesGM", "TEST", 284, 303], ["mutant cells", "PROBLEM", 317, 329], ["mouse B16 melanoma", "PROBLEM", 333, 351], ["gangliosides", "TREATMENT", 410, 422], ["ceramide glycosyltransferase gene", "TREATMENT", 438, 471], ["glucosylceramide series synthesis", "TREATMENT", 493, 526], ["M2", "ANATOMY", 144, 146], ["mouse B16 melanoma", "OBSERVATION", 333, 351]]], ["GM-95 cells can be infected by influenza A viruses and produce infectious progeny viruses, regardless of the absence of major glycosphingolipids [73] .", [["GM-95 cells", "ANATOMY", 0, 11], ["GM-95", "CHEMICAL", 0, 5], ["influenza A viruses", "DISEASE", 31, 50], ["infectious progeny viruses", "DISEASE", 63, 89], ["GM-95 cells", "CELL", 0, 11], ["influenza A viruses", "ORGANISM", 31, 50], ["GM-95 cells", "CELL_LINE", 0, 11], ["influenza A viruses", "SPECIES", 31, 50], ["GM", "TEST", 0, 2], ["influenza A viruses", "PROBLEM", 31, 50], ["infectious progeny viruses", "PROBLEM", 63, 89], ["infectious", "OBSERVATION_MODIFIER", 63, 73]]], ["Since gangliosides are major components of rafts and viral receptors, it has been suggested that they are not absolutely necessary for the influenza virus lifecycle.", [["rafts", "ANATOMY", 43, 48], ["gangliosides", "GENE_OR_GENE_PRODUCT", 6, 18], ["rafts", "CELLULAR_COMPONENT", 43, 48], ["influenza virus", "ORGANISM", 139, 154], ["viral receptors", "PROTEIN", 53, 68], ["influenza virus", "SPECIES", 139, 154], ["the influenza virus lifecycle", "PROBLEM", 135, 164], ["major", "OBSERVATION_MODIFIER", 23, 28], ["components", "OBSERVATION_MODIFIER", 29, 39], ["rafts", "OBSERVATION_MODIFIER", 43, 48], ["viral receptors", "OBSERVATION", 53, 68]]], ["This suggestion for virus assembly and budding is supported by evidence that infectious progeny viruses can be produced from cells infected with mutant viruses possessing HA and NA that lack the ability to interact with membrane rafts by mutations of their raft-binding domains [34, 163] and that membrane raft disruption enhances virus budding from MDCK cells [168] .", [["cells", "ANATOMY", 125, 130], ["membrane rafts", "ANATOMY", 220, 234], ["raft", "ANATOMY", 257, 261], ["membrane raft", "ANATOMY", 297, 310], ["MDCK cells", "ANATOMY", 350, 360], ["NA", "CHEMICAL", 178, 180], ["cells", "CELL", 125, 130], ["mutant viruses", "ORGANISM", 145, 159], ["HA", "GENE_OR_GENE_PRODUCT", 171, 173], ["membrane rafts", "CELLULAR_COMPONENT", 220, 234], ["membrane raft", "CELLULAR_COMPONENT", 297, 310], ["MDCK cells", "CELL", 350, 360], ["raft-binding domains", "PROTEIN", 257, 277], ["MDCK cells", "CELL_LINE", 350, 360], ["virus", "PROBLEM", 20, 25], ["infectious progeny viruses", "PROBLEM", 77, 103], ["mutant viruses possessing HA", "PROBLEM", 145, 173], ["membrane rafts", "TREATMENT", 220, 234], ["that membrane raft disruption enhances virus budding", "PROBLEM", 292, 344], ["MDCK cells", "TEST", 350, 360], ["suggestion for", "UNCERTAINTY", 5, 19], ["virus", "OBSERVATION", 20, 25], ["infectious", "OBSERVATION_MODIFIER", 77, 87], ["raft disruption", "OBSERVATION", 306, 321], ["enhances virus", "OBSERVATION", 322, 336]]], ["How membrane rafts help the influenza virus lifecycle needs to be addressed in future studies.", [["membrane rafts", "ANATOMY", 4, 18], ["membrane rafts", "CELLULAR_COMPONENT", 4, 18], ["influenza virus", "ORGANISM", 28, 43], ["the influenza virus lifecycle", "TREATMENT", 24, 53]]], ["The concentration and clustering of HA and NA in the same membrane rafts facilitate efficient incorporation of these raft-associated viral proteins into the progeny viral membrane during the budding process [34, 163] , because progeny virus particles are selectively budded together with membrane rafts from the cell surface [159] .", [["membrane rafts", "ANATOMY", 58, 72], ["raft", "ANATOMY", 117, 121], ["membrane", "ANATOMY", 171, 179], ["membrane rafts", "ANATOMY", 288, 302], ["cell surface", "ANATOMY", 312, 324], ["NA", "CHEMICAL", 43, 45], ["HA", "GENE_OR_GENE_PRODUCT", 36, 38], ["NA", "SIMPLE_CHEMICAL", 43, 45], ["membrane rafts", "CELLULAR_COMPONENT", 58, 72], ["raft", "CELLULAR_COMPONENT", 117, 121], ["viral membrane", "CELLULAR_COMPONENT", 165, 179], ["progeny virus particles", "ORGANISM", 227, 250], ["membrane rafts", "CELLULAR_COMPONENT", 288, 302], ["cell surface", "CELLULAR_COMPONENT", 312, 324], ["raft-associated viral proteins", "PROTEIN", 117, 147], ["The concentration", "TREATMENT", 0, 17], ["HA", "PROBLEM", 36, 38], ["NA in the same membrane rafts", "TREATMENT", 43, 72], ["viral proteins", "PROBLEM", 133, 147], ["progeny virus particles", "PROBLEM", 227, 250], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["HA", "OBSERVATION_MODIFIER", 36, 38], ["viral proteins", "OBSERVATION", 133, 147], ["progeny viral membrane", "OBSERVATION", 157, 179], ["membrane rafts", "OBSERVATION", 288, 302]]], ["At that time, M2 is distributed in a different type of membrane rafts from those associated with HA and NA or is located in non-raft compartments on the cell surface, resulting in poor incorporation into the progeny viral membrane [165] .", [["membrane rafts", "ANATOMY", 55, 69], ["non-raft compartments", "ANATOMY", 124, 145], ["cell surface", "ANATOMY", 153, 165], ["membrane", "ANATOMY", 222, 230], ["NA", "CHEMICAL", 104, 106], ["M2", "GENE_OR_GENE_PRODUCT", 14, 16], ["membrane rafts", "CELLULAR_COMPONENT", 55, 69], ["HA", "GENE_OR_GENE_PRODUCT", 97, 99], ["NA", "SIMPLE_CHEMICAL", 104, 106], ["non-raft compartments", "CELLULAR_COMPONENT", 124, 145], ["cell surface", "CELLULAR_COMPONENT", 153, 165], ["M2", "PROTEIN", 14, 16], ["membrane rafts", "PROBLEM", 55, 69], ["HA", "PROBLEM", 97, 99], ["NA", "PROBLEM", 104, 106], ["M2", "OBSERVATION_MODIFIER", 14, 16], ["distributed", "OBSERVATION_MODIFIER", 20, 31], ["membrane rafts", "OBSERVATION", 55, 69], ["cell surface", "OBSERVATION", 153, 165], ["poor incorporation", "OBSERVATION", 180, 198], ["viral membrane", "OBSERVATION", 216, 230]]], ["On the other hand, a study has shown that M2 interacts with membrane rafts associated with HA dependent on an intact actin cytoskeleton and thereby M2 targets to the raft lipid-enriched zone, the viral budding site on the cell surface membrane, organized by HA [170] .", [["membrane rafts", "ANATOMY", 60, 74], ["cytoskeleton", "ANATOMY", 123, 135], ["raft", "ANATOMY", 166, 170], ["cell surface membrane", "ANATOMY", 222, 243], ["M2", "GENE_OR_GENE_PRODUCT", 42, 44], ["membrane rafts", "CELLULAR_COMPONENT", 60, 74], ["HA", "GENE_OR_GENE_PRODUCT", 91, 93], ["actin", "GENE_OR_GENE_PRODUCT", 117, 122], ["cytoskeleton", "CELLULAR_COMPONENT", 123, 135], ["M2", "GENE_OR_GENE_PRODUCT", 148, 150], ["raft", "CELLULAR_COMPONENT", 166, 170], ["zone", "CELLULAR_COMPONENT", 186, 190], ["cell surface membrane", "CELLULAR_COMPONENT", 222, 243], ["M2", "PROTEIN", 42, 44], ["actin", "PROTEIN", 117, 122], ["M2", "PROTEIN", 148, 150], ["viral budding site", "DNA", 196, 214], ["a study", "TEST", 19, 26], ["membrane rafts", "PROBLEM", 60, 74], ["HA dependent", "PROBLEM", 91, 103], ["the viral budding site", "PROBLEM", 192, 214], ["membrane rafts", "OBSERVATION", 60, 74], ["actin cytoskeleton", "OBSERVATION", 117, 135], ["enriched zone", "OBSERVATION", 177, 190], ["viral budding", "OBSERVATION", 196, 209]]], ["Disruption of membrane rafts results in decreased infectious progeny virus production concomitantly with enhancement of the release total infectious and noninfectious virus particles from infected cells [168] .", [["membrane rafts", "ANATOMY", 14, 28], ["cells", "ANATOMY", 197, 202], ["membrane rafts", "CELLULAR_COMPONENT", 14, 28], ["cells", "CELL", 197, 202], ["infected cells", "CELL_TYPE", 188, 202], ["Disruption of membrane rafts", "PROBLEM", 0, 28], ["decreased infectious progeny virus production", "PROBLEM", 40, 85], ["the release total infectious and noninfectious virus particles", "PROBLEM", 120, 182], ["infected cells", "PROBLEM", 188, 202], ["membrane rafts", "OBSERVATION", 14, 28], ["decreased", "OBSERVATION_MODIFIER", 40, 49], ["infectious", "OBSERVATION_MODIFIER", 50, 60], ["progeny virus", "OBSERVATION", 61, 74], ["total", "OBSERVATION_MODIFIER", 132, 137], ["infectious", "OBSERVATION", 138, 148], ["noninfectious", "OBSERVATION_MODIFIER", 153, 166], ["infected cells", "OBSERVATION", 188, 202]]], ["Taken together, the results of studies indicate that the role of membrane rafts in the influenza virus lifecycle is contribution to an efficient incorporation of raft-associated viral proteins into the progeny viral membrane and pinchingoff of virus particles from the plasma membrane.Genome Replication, Assembly, and Budding of Enveloped VirusesIn infected cells, the tight association of newly synthesized HA transferred to the cell surface with membrane rafts stimulates cellular Raf/MEK/ERK signaling of the MAPK pathway through PKC\u03b1 activation.", [["membrane rafts", "ANATOMY", 65, 79], ["raft", "ANATOMY", 162, 166], ["membrane", "ANATOMY", 216, 224], ["plasma membrane", "ANATOMY", 269, 284], ["cells", "ANATOMY", 359, 364], ["cell surface", "ANATOMY", 431, 443], ["membrane rafts", "ANATOMY", 449, 463], ["cellular", "ANATOMY", 475, 483], ["influenza", "DISEASE", 87, 96], ["membrane rafts", "CELLULAR_COMPONENT", 65, 79], ["influenza virus", "ORGANISM", 87, 102], ["raft", "CELLULAR_COMPONENT", 162, 166], ["viral membrane", "CELLULAR_COMPONENT", 210, 224], ["plasma membrane", "CELLULAR_COMPONENT", 269, 284], ["cells", "CELL", 359, 364], ["HA", "GENE_OR_GENE_PRODUCT", 409, 411], ["cell surface", "CELLULAR_COMPONENT", 431, 443], ["membrane rafts", "CELLULAR_COMPONENT", 449, 463], ["cellular", "CELL", 475, 483], ["Raf", "GENE_OR_GENE_PRODUCT", 484, 487], ["MEK", "GENE_OR_GENE_PRODUCT", 488, 491], ["ERK", "GENE_OR_GENE_PRODUCT", 492, 495], ["MAPK", "GENE_OR_GENE_PRODUCT", 513, 517], ["PKC\u03b1", "GENE_OR_GENE_PRODUCT", 534, 538], ["raft-associated viral proteins", "PROTEIN", 162, 192], ["infected cells", "CELL_TYPE", 350, 364], ["HA", "PROTEIN", 409, 411], ["Raf", "PROTEIN", 484, 487], ["MEK", "PROTEIN", 488, 491], ["ERK", "PROTEIN", 492, 495], ["MAPK", "PROTEIN", 513, 517], ["PKC\u03b1", "PROTEIN", 534, 538], ["influenza virus", "SPECIES", 87, 102], ["studies", "TEST", 31, 38], ["membrane rafts", "TREATMENT", 65, 79], ["the influenza virus lifecycle", "PROBLEM", 83, 112], ["viral proteins", "PROBLEM", 178, 192], ["virus particles", "PROBLEM", 244, 259], ["Enveloped Viruses", "PROBLEM", 330, 347], ["infected cells", "PROBLEM", 350, 364], ["newly synthesized HA", "PROBLEM", 391, 411], ["membrane rafts", "TREATMENT", 449, 463], ["cellular Raf", "TEST", 475, 487], ["the MAPK pathway", "TEST", 509, 525], ["membrane rafts", "OBSERVATION", 65, 79], ["influenza virus", "OBSERVATION", 87, 102], ["viral proteins", "OBSERVATION", 178, 192], ["progeny viral membrane", "OBSERVATION", 202, 224], ["virus particles", "OBSERVATION", 244, 259], ["plasma membrane", "OBSERVATION", 269, 284], ["Viruses", "OBSERVATION", 340, 347], ["infected cells", "OBSERVATION", 350, 364], ["tight", "OBSERVATION_MODIFIER", 370, 375], ["membrane rafts", "OBSERVATION", 449, 463]]], ["MPAK activation induces nuclear export of viral RNP compexes from the nucleus to the cytoplasm, leading to enhanced production of infectious progeny viruses [166] .", [["nuclear", "ANATOMY", 24, 31], ["nucleus", "ANATOMY", 70, 77], ["cytoplasm", "ANATOMY", 85, 94], ["MPAK", "CHEMICAL", 0, 4], ["MPAK", "GENE_OR_GENE_PRODUCT", 0, 4], ["nuclear", "CELLULAR_COMPONENT", 24, 31], ["nucleus", "CELLULAR_COMPONENT", 70, 77], ["cytoplasm", "ORGANISM_SUBSTANCE", 85, 94], ["MPAK", "PROTEIN", 0, 4], ["viral RNP", "PROTEIN", 42, 51], ["viral RNP compexes", "PROBLEM", 42, 60], ["infectious progeny viruses", "PROBLEM", 130, 156], ["viral RNP", "OBSERVATION", 42, 51], ["nucleus", "ANATOMY", 70, 77], ["infectious", "OBSERVATION_MODIFIER", 130, 140]]], ["Our recent study has shown that sulfatide, 3-O-sulfated galactosylceramide, is required for efficient virus replication and that association of newly synthesized HA transferred to the infected cell surface with sulfatide induces nuclear export of viral RNP complexes from the nucleus to the cytoplasm, leading to enhanced production of infectious progeny viruses [210] .", [["cell surface", "ANATOMY", 193, 205], ["nuclear", "ANATOMY", 229, 236], ["nucleus", "ANATOMY", 276, 283], ["cytoplasm", "ANATOMY", 291, 300], ["sulfatide", "CHEMICAL", 32, 41], ["3-O-sulfated galactosylceramide", "CHEMICAL", 43, 74], ["sulfatide", "CHEMICAL", 211, 220], ["sulfatide", "CHEMICAL", 32, 41], ["3-O-sulfated galactosylceramide", "CHEMICAL", 43, 74], ["sulfatide", "SIMPLE_CHEMICAL", 32, 41], ["3-O-sulfated galactosylceramide", "SIMPLE_CHEMICAL", 43, 74], ["HA", "GENE_OR_GENE_PRODUCT", 162, 164], ["cell surface", "CELLULAR_COMPONENT", 193, 205], ["sulfatide", "SIMPLE_CHEMICAL", 211, 220], ["nuclear", "CELLULAR_COMPONENT", 229, 236], ["nucleus", "CELLULAR_COMPONENT", 276, 283], ["cytoplasm", "ORGANISM_SUBSTANCE", 291, 300], ["viral RNP complexes", "PROTEIN", 247, 266], ["Our recent study", "TEST", 0, 16], ["sulfatide", "TREATMENT", 32, 41], ["3-O-sulfated galactosylceramide", "TREATMENT", 43, 74], ["efficient virus replication", "TREATMENT", 92, 119], ["newly synthesized HA", "PROBLEM", 144, 164], ["sulfatide", "TREATMENT", 211, 220], ["viral RNP complexes", "PROBLEM", 247, 266], ["infectious progeny viruses", "PROBLEM", 336, 362], ["infected cell", "OBSERVATION", 184, 197], ["viral RNP complexes", "OBSERVATION", 247, 266], ["nucleus", "ANATOMY", 276, 283], ["infectious", "OBSERVATION_MODIFIER", 336, 346]]], ["Thus, association of HA with sulfatide may trigger MAPK activation that enhances nuclear export of viral RNP complexes.", [["nuclear", "ANATOMY", 81, 88], ["sulfatide", "CHEMICAL", 29, 38], ["sulfatide", "CHEMICAL", 29, 38], ["HA", "GENE_OR_GENE_PRODUCT", 21, 23], ["sulfatide", "SIMPLE_CHEMICAL", 29, 38], ["MAPK", "GENE_OR_GENE_PRODUCT", 51, 55], ["nuclear", "CELLULAR_COMPONENT", 81, 88], ["MAPK", "PROTEIN", 51, 55], ["viral RNP complexes", "PROTEIN", 99, 118], ["HA", "PROBLEM", 21, 23], ["sulfatide", "TREATMENT", 29, 38], ["MAPK activation", "PROBLEM", 51, 66], ["viral RNP complexes", "PROBLEM", 99, 118], ["viral RNP complexes", "OBSERVATION", 99, 118]]], ["Some studies have shown that existence of sulfatide associated with membrane rafts [211, 212] , but lipid composition in the purified influenza virus envelope propagated in embryonated eggs does not contain any acidic glycosphingolipids including sulfatide [162] .", [["membrane rafts", "ANATOMY", 68, 82], ["eggs", "ANATOMY", 185, 189], ["sulfatide", "CHEMICAL", 42, 51], ["sulfatide", "CHEMICAL", 247, 256], ["sulfatide", "CHEMICAL", 42, 51], ["sulfatide", "CHEMICAL", 247, 256], ["sulfatide", "SIMPLE_CHEMICAL", 42, 51], ["membrane rafts", "CELLULAR_COMPONENT", 68, 82], ["lipid", "SIMPLE_CHEMICAL", 100, 105], ["influenza virus envelope", "ORGANISM", 134, 158], ["sulfatide", "SIMPLE_CHEMICAL", 247, 256], ["influenza virus", "SPECIES", 134, 149], ["Some studies", "TEST", 0, 12], ["sulfatide", "PROBLEM", 42, 51], ["membrane rafts", "PROBLEM", 68, 82], ["lipid composition", "TREATMENT", 100, 117], ["the purified influenza virus envelope", "TREATMENT", 121, 158], ["embryonated eggs", "PROBLEM", 173, 189]]], ["Further investigation is needed to determine whether enhanced nuclear export of viral RNP is triggered by raft-associated or non-raft sulfatide.Genome Replication, Assembly, and Budding of Enveloped VirusesMeasles virus is a pathogen of an acute respiratory disease and causes the death of over one million children each year, principally because of virus-induced immunosuppression of lymphocyte function.", [["nuclear", "ANATOMY", 62, 69], ["raft", "ANATOMY", 106, 110], ["respiratory", "ANATOMY", 246, 257], ["lymphocyte", "ANATOMY", 385, 395], ["Measles virus", "DISEASE", 206, 219], ["acute respiratory disease", "DISEASE", 240, 265], ["death", "DISEASE", 281, 286], ["nuclear", "CELLULAR_COMPONENT", 62, 69], ["raft", "CELLULAR_COMPONENT", 106, 110], ["sulfatide", "SIMPLE_CHEMICAL", 134, 143], ["Enveloped Viruses", "ORGANISM", 189, 206], ["Measles virus", "ORGANISM", 206, 219], ["children", "ORGANISM", 307, 315], ["lymphocyte", "CELL", 385, 395], ["viral RNP", "PROTEIN", 80, 89], ["Measles virus", "SPECIES", 206, 219], ["children", "SPECIES", 307, 315], ["Measles virus", "SPECIES", 206, 219], ["Further investigation", "TEST", 0, 21], ["viral RNP", "PROBLEM", 80, 89], ["non-raft sulfatide", "TREATMENT", 125, 143], ["Enveloped VirusesMeasles virus", "PROBLEM", 189, 219], ["an acute respiratory disease", "PROBLEM", 237, 265], ["virus", "PROBLEM", 350, 355], ["lymphocyte function", "PROBLEM", 385, 404], ["viral RNP", "OBSERVATION", 80, 89], ["Enveloped", "OBSERVATION_MODIFIER", 189, 198], ["Viruses", "OBSERVATION", 199, 206], ["acute", "OBSERVATION_MODIFIER", 240, 245], ["respiratory disease", "OBSERVATION", 246, 265], ["lymphocyte function", "OBSERVATION", 385, 404]]], ["Membrane rafts act as a platform of the virus assembly process but not the budding process.", [["Membrane rafts", "ANATOMY", 0, 14], ["Membrane rafts", "CELLULAR_COMPONENT", 0, 14], ["Membrane rafts", "TREATMENT", 0, 14], ["the virus assembly process", "PROBLEM", 36, 62], ["the budding process", "PROBLEM", 71, 90], ["virus", "OBSERVATION", 40, 45]]], ["The transmembrane domain of the viral surface fusion (F) protein has two palmitoylated cysteines, which probably interact with membrane rafts [213] .", [["transmembrane", "ANATOMY", 4, 17], ["surface", "ANATOMY", 38, 45], ["membrane rafts", "ANATOMY", 127, 141], ["cysteines", "CHEMICAL", 87, 96], ["membrane", "CELLULAR_COMPONENT", 127, 135], ["transmembrane domain", "PROTEIN", 4, 24], ["viral surface fusion (F) protein", "PROTEIN", 32, 64], ["the viral surface fusion", "TREATMENT", 28, 52], ["two palmitoylated cysteines", "PROBLEM", 69, 96], ["viral surface", "OBSERVATION", 32, 45], ["palmitoylated cysteines", "OBSERVATION", 73, 96]]], ["The F protein is synthesized as an inactive precursor (F 0 ) that is proteolytically cleaved in the trans-Golgi network and thereby converted to the biologically active form, disulfide-linked subunits F 1 and F 2 .", [["Golgi network", "ANATOMY", 106, 119], ["disulfide", "CHEMICAL", 175, 184], ["F protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["F 1", "GENE_OR_GENE_PRODUCT", 201, 204], ["F 2", "GENE_OR_GENE_PRODUCT", 209, 212], ["F protein", "PROTEIN", 4, 13], ["F 0", "PROTEIN", 55, 58], ["trans-Golgi network", "PROTEIN", 100, 119], ["disulfide-linked subunits F 1", "PROTEIN", 175, 204], ["F 2", "PROTEIN", 209, 212], ["The F protein", "TEST", 0, 13]]], ["After transport of two mature viral envelope glycoproteins, hemagglutinin (H) and F proteins, to the trans-Golgi network, they are preferentially incorporated into membrane rafts, but the F 0 precursor is not.", [["membrane rafts", "ANATOMY", 164, 178], ["hemagglutinin (H)", "GENE_OR_GENE_PRODUCT", 60, 77], ["F proteins", "GENE_OR_GENE_PRODUCT", 82, 92], ["membrane rafts", "CELLULAR_COMPONENT", 164, 178], ["F 0", "GENE_OR_GENE_PRODUCT", 188, 191], ["mature viral envelope glycoproteins", "PROTEIN", 23, 58], ["hemagglutinin (H) and F proteins", "PROTEIN", 60, 92], ["trans-Golgi network", "PROTEIN", 101, 120], ["F 0 precursor", "PROTEIN", 188, 201], ["two mature viral envelope glycoproteins", "TREATMENT", 19, 58], ["viral envelope glycoproteins", "OBSERVATION", 30, 58], ["membrane rafts", "OBSERVATION", 164, 178]]], ["Internal structural proteins, M and N, interact with membrane rafts possibly through acylation of saturated chains, regardless of the presence of the two viral envelope glycoproteins.", [["membrane rafts", "ANATOMY", 53, 67], ["membrane rafts", "CELLULAR_COMPONENT", 53, 67], ["Internal structural proteins", "PROTEIN", 0, 28], ["N", "PROTEIN", 36, 37], ["viral envelope glycoproteins", "PROTEIN", 154, 182], ["membrane rafts", "TREATMENT", 53, 67], ["acylation of saturated chains", "TREATMENT", 85, 114], ["the two viral envelope glycoproteins", "PROBLEM", 146, 182], ["structural proteins", "OBSERVATION", 9, 28], ["membrane rafts", "OBSERVATION", 53, 67]]], ["The nonstructural V protein remains excluded from rafts during the course of virus infection.", [["rafts", "ANATOMY", 50, 55], ["infection", "DISEASE", 83, 92], ["nonstructural V protein", "GENE_OR_GENE_PRODUCT", 4, 27], ["rafts", "CELLULAR_COMPONENT", 50, 55], ["nonstructural V protein", "PROTEIN", 4, 27], ["The nonstructural V protein", "TEST", 0, 27], ["virus infection", "PROBLEM", 77, 92], ["nonstructural V protein", "OBSERVATION", 4, 27], ["infection", "OBSERVATION", 83, 92]]], ["Although the M protein can interact with the cytoplasmic tail of the F protein in H-F complexes, it can also bind to plasma membranes and the N protein, thereafter in turn binding to the viral internal structural proteins, P and L. Eventually, M-RNP complexes (composed of viral internal proteins N, P, and L with viral RNA) interact with the surface membrane through the M protein associated with membrane rafts and with H-F complexes associated with membrane rafts through the F protein, resulting in efficient assembly of measles virus prior to the budding process [172, 173] .Genome Replication, Assembly, and Budding of Enveloped VirusesNDV is a highly contagious pathogen of zoonotic bird disease affecting many domestic and wild avian species.", [["cytoplasmic tail", "ANATOMY", 45, 61], ["plasma membranes", "ANATOMY", 117, 133], ["surface membrane", "ANATOMY", 343, 359], ["membrane rafts", "ANATOMY", 398, 412], ["membrane rafts", "ANATOMY", 452, 466], ["zoonotic bird disease", "DISEASE", 681, 702], ["M protein", "GENE_OR_GENE_PRODUCT", 13, 22], ["cytoplasmic", "ORGANISM_SUBSTANCE", 45, 56], ["H-F", "GENE_OR_GENE_PRODUCT", 82, 85], ["plasma membranes", "CELLULAR_COMPONENT", 117, 133], ["M-RNP", "GENE_OR_GENE_PRODUCT", 244, 249], ["surface membrane", "CELLULAR_COMPONENT", 343, 359], ["M protein", "GENE_OR_GENE_PRODUCT", 372, 381], ["membrane rafts", "CELLULAR_COMPONENT", 398, 412], ["H-F complexes", "GENE_OR_GENE_PRODUCT", 422, 435], ["membrane rafts", "CELLULAR_COMPONENT", 452, 466], ["F protein", "GENE_OR_GENE_PRODUCT", 479, 488], ["measles virus", "ORGANISM", 525, 538], ["Enveloped VirusesNDV", "ORGANISM", 625, 645], ["M protein", "PROTEIN", 13, 22], ["cytoplasmic tail", "PROTEIN", 45, 61], ["F protein", "PROTEIN", 69, 78], ["H-F complexes", "PROTEIN", 82, 95], ["N protein", "PROTEIN", 142, 151], ["viral internal structural proteins", "PROTEIN", 187, 221], ["P", "PROTEIN", 223, 224], ["L.", "PROTEIN", 229, 231], ["M", "PROTEIN", 244, 245], ["RNP complexes", "PROTEIN", 246, 259], ["viral internal proteins", "PROTEIN", 273, 296], ["N", "PROTEIN", 297, 298], ["P", "PROTEIN", 300, 301], ["L", "PROTEIN", 307, 308], ["viral RNA", "RNA", 314, 323], ["M protein", "PROTEIN", 372, 381], ["H-F complexes", "PROTEIN", 422, 435], ["F protein", "PROTEIN", 479, 488], ["measles virus", "SPECIES", 525, 538], ["the M protein", "TEST", 9, 22], ["the N protein", "TEST", 138, 151], ["M-RNP complexes", "TREATMENT", 244, 259], ["viral internal proteins", "TREATMENT", 273, 296], ["viral RNA)", "PROBLEM", 314, 324], ["the surface membrane", "TREATMENT", 339, 359], ["the M protein", "TREATMENT", 368, 381], ["membrane rafts", "TREATMENT", 398, 412], ["H-F complexes", "PROBLEM", 422, 435], ["membrane rafts", "TREATMENT", 452, 466], ["measles virus", "PROBLEM", 525, 538], ["zoonotic bird disease", "PROBLEM", 681, 702], ["viral RNA", "OBSERVATION", 314, 323], ["membrane rafts", "OBSERVATION", 398, 412], ["highly", "OBSERVATION_MODIFIER", 651, 657], ["contagious", "OBSERVATION_MODIFIER", 658, 668], ["zoonotic bird disease", "OBSERVATION", 681, 702], ["wild avian species", "OBSERVATION", 731, 749]]], ["The assembly and budding of infectious progeny viruses preferentially occur in membrane rafts that interact with the cortical cytoskeleton [174] .", [["membrane rafts", "ANATOMY", 79, 93], ["cortical cytoskeleton", "ANATOMY", 117, 138], ["infectious progeny viruses", "ORGANISM", 28, 54], ["membrane rafts", "CELLULAR_COMPONENT", 79, 93], ["cortical cytoskeleton", "CELLULAR_COMPONENT", 117, 138], ["infectious progeny viruses", "PROBLEM", 28, 54], ["infectious", "OBSERVATION_MODIFIER", 28, 38], ["progeny viruses", "OBSERVATION", 39, 54], ["membrane rafts", "OBSERVATION", 79, 93]]], ["Furthermore, intact membrane raft domains in the infected cells, but not in the virus envelopes, facilitate the proper formation or maintenance of the viral surface hemagglutinin-neuraminidase (HN) and F glycoprotein complexes (required for virus-cell membrane fusion) and the incorporation of the HN-F complexes into the viral surface, leading to the initiation of membrane fusion between the virus and cell [175] .Genome Replication, Assembly, and Budding of Enveloped VirusesHuman RSV is a major cause of severe lower respiratory tract disease in young children, the elderly, and immunosuppressed adults.", [["membrane raft", "ANATOMY", 20, 33], ["cells", "ANATOMY", 58, 63], ["surface", "ANATOMY", 157, 164], ["cell membrane", "ANATOMY", 247, 260], ["surface", "ANATOMY", 328, 335], ["membrane", "ANATOMY", 366, 374], ["cell", "ANATOMY", 404, 408], ["lower respiratory tract", "ANATOMY", 515, 538], ["lower respiratory tract disease", "DISEASE", 515, 546], ["membrane raft", "CELLULAR_COMPONENT", 20, 33], ["cells", "CELL", 58, 63], ["hemagglutinin-neuraminidase (HN)", "GENE_OR_GENE_PRODUCT", 165, 197], ["F glycoprotein", "GENE_OR_GENE_PRODUCT", 202, 216], ["cell membrane", "CELLULAR_COMPONENT", 247, 260], ["HN-F", "GENE_OR_GENE_PRODUCT", 298, 302], ["membrane", "CELLULAR_COMPONENT", 366, 374], ["cell", "CELL", 404, 408], ["Enveloped VirusesHuman RSV", "ORGANISM", 461, 487], ["lower", "ORGANISM_SUBDIVISION", 515, 520], ["respiratory tract", "ORGANISM_SUBDIVISION", 521, 538], ["children", "ORGANISM", 556, 564], ["membrane raft domains", "PROTEIN", 20, 41], ["infected cells", "CELL_TYPE", 49, 63], ["viral surface hemagglutinin-neuraminidase (HN) and F glycoprotein complexes", "PROTEIN", 151, 226], ["HN-F complexes", "PROTEIN", 298, 312], ["children", "SPECIES", 556, 564], ["RSV", "SPECIES", 484, 487], ["intact membrane raft domains", "PROBLEM", 13, 41], ["the infected cells", "PROBLEM", 45, 63], ["the virus envelopes", "PROBLEM", 76, 95], ["the viral surface hemagglutinin", "TREATMENT", 147, 178], ["neuraminidase (HN) and F glycoprotein complexes", "TREATMENT", 179, 226], ["virus-cell membrane fusion", "TREATMENT", 241, 267], ["membrane fusion", "TREATMENT", 366, 381], ["Enveloped VirusesHuman RSV", "PROBLEM", 461, 487], ["severe lower respiratory tract disease", "PROBLEM", 508, 546], ["intact membrane", "OBSERVATION_MODIFIER", 13, 28], ["raft domains", "OBSERVATION", 29, 41], ["infected cells", "OBSERVATION", 49, 63], ["virus", "OBSERVATION", 80, 85], ["viral surface", "OBSERVATION", 322, 335], ["severe", "OBSERVATION_MODIFIER", 508, 514], ["lower", "ANATOMY_MODIFIER", 515, 520], ["respiratory tract", "ANATOMY", 521, 538]]], ["The viral envelope attachment G protein and the internal M and N proteins of RSV are present in membrane rafts.", [["membrane rafts", "ANATOMY", 96, 110], ["viral envelope attachment G protein", "GENE_OR_GENE_PRODUCT", 4, 39], ["RSV", "ORGANISM", 77, 80], ["membrane rafts", "CELLULAR_COMPONENT", 96, 110], ["viral envelope attachment G protein", "PROTEIN", 4, 39], ["internal M and N proteins", "PROTEIN", 48, 73], ["RSV", "SPECIES", 77, 80], ["The viral envelope attachment G protein", "TEST", 0, 39], ["RSV", "PROBLEM", 77, 80], ["viral envelope", "OBSERVATION", 4, 18], ["internal", "ANATOMY_MODIFIER", 48, 56], ["RSV", "OBSERVATION", 77, 80], ["membrane rafts", "OBSERVATION", 96, 110]]], ["Caveolin, a raft marker, is present in the RSV envelope.", [["raft", "ANATOMY", 12, 16], ["Caveolin", "GENE_OR_GENE_PRODUCT", 0, 8], ["raft", "CELLULAR_COMPONENT", 12, 16], ["RSV", "ORGANISM", 43, 46], ["Caveolin", "PROTEIN", 0, 8], ["RSV", "SPECIES", 43, 46], ["Caveolin", "TREATMENT", 0, 8], ["a raft marker", "TEST", 10, 23], ["raft marker", "OBSERVATION", 12, 23], ["RSV envelope", "OBSERVATION", 43, 55]]], ["RSV infection induces cellular distribution of phosphocaveolin-1 that is enriched at sites of attachment of the actin cytoskeleton.", [["cellular", "ANATOMY", 22, 30], ["cytoskeleton", "ANATOMY", 118, 130], ["RSV infection", "DISEASE", 0, 13], ["RSV", "ORGANISM", 0, 3], ["cellular", "CELL", 22, 30], ["phosphocaveolin-1", "GENE_OR_GENE_PRODUCT", 47, 64], ["actin", "GENE_OR_GENE_PRODUCT", 112, 117], ["cytoskeleton", "CELLULAR_COMPONENT", 118, 130], ["phosphocaveolin-1", "PROTEIN", 47, 64], ["actin", "PROTEIN", 112, 117], ["RSV", "SPECIES", 0, 3], ["RSV infection", "PROBLEM", 0, 13], ["phosphocaveolin-1", "PROBLEM", 47, 64], ["infection", "OBSERVATION", 4, 13], ["cellular", "OBSERVATION_MODIFIER", 22, 30], ["distribution", "OBSERVATION_MODIFIER", 31, 43], ["enriched", "OBSERVATION_MODIFIER", 73, 81], ["actin cytoskeleton", "OBSERVATION", 112, 130]]], ["Therefore, RSV assembly at the plasma membrane is shown to occur in specialized membrane rafts that contain a high content of caveolin [176, 177] .", [["plasma membrane", "ANATOMY", 31, 46], ["membrane rafts", "ANATOMY", 80, 94], ["RSV", "ORGANISM", 11, 14], ["plasma membrane", "CELLULAR_COMPONENT", 31, 46], ["membrane rafts", "CELLULAR_COMPONENT", 80, 94], ["caveolin", "GENE_OR_GENE_PRODUCT", 126, 134], ["caveolin", "PROTEIN", 126, 134], ["RSV", "SPECIES", 11, 14], ["RSV", "PROBLEM", 11, 14], ["RSV", "OBSERVATION", 11, 14], ["membrane rafts", "OBSERVATION", 80, 94], ["high content", "OBSERVATION_MODIFIER", 110, 122]]], ["The cytoplasmic tail of F protein plays an essential role in its cellular localization and production of infectious progeny viruses, dependently on interaction of F protein with membrane rafts [178] .", [["cytoplasmic", "ANATOMY", 4, 15], ["cellular", "ANATOMY", 65, 73], ["membrane rafts", "ANATOMY", 178, 192], ["cytoplasmic", "ORGANISM_SUBSTANCE", 4, 15], ["F", "GENE_OR_GENE_PRODUCT", 24, 25], ["cellular", "CELL", 65, 73], ["F protein", "GENE_OR_GENE_PRODUCT", 163, 172], ["membrane rafts", "CELLULAR_COMPONENT", 178, 192], ["cytoplasmic tail", "PROTEIN", 4, 20], ["F protein", "PROTEIN", 24, 33], ["F protein", "PROTEIN", 163, 172], ["infectious progeny viruses", "PROBLEM", 105, 131], ["cytoplasmic", "OBSERVATION_MODIFIER", 4, 15], ["tail", "OBSERVATION_MODIFIER", 16, 20], ["essential", "OBSERVATION_MODIFIER", 43, 52], ["infectious", "OBSERVATION_MODIFIER", 105, 115], ["progeny viruses", "OBSERVATION", 116, 131]]], ["Moreover, like the function of HIV-1 Nef [192] , RSV infection facilitates production of phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol 3,4,5-triphosphate (PIP3) in the lipid composition of membrane rafts within virus inclusion bodies through lipid kinases containing PI3K.", [["membrane rafts", "ANATOMY", 213, 227], ["RSV infection", "DISEASE", 49, 62], ["phosphatidylinositol 4,5-bisphosphate", "CHEMICAL", 89, 126], ["phosphatidylinositol 3,4,5-triphosphate", "CHEMICAL", 138, 177], ["phosphatidylinositol 4,5-bisphosphate", "CHEMICAL", 89, 126], ["PIP2", "CHEMICAL", 128, 132], ["phosphatidylinositol 3,4,5-triphosphate", "CHEMICAL", 138, 177], ["PIP3", "CHEMICAL", 179, 183], ["HIV-1", "ORGANISM", 31, 36], ["Nef", "ORGANISM", 37, 40], ["RSV", "ORGANISM", 49, 52], ["phosphatidylinositol 4,5-bisphosphate", "SIMPLE_CHEMICAL", 89, 126], ["PIP2", "SIMPLE_CHEMICAL", 128, 132], ["phosphatidylinositol 3,4,5-triphosphate", "SIMPLE_CHEMICAL", 138, 177], ["PIP3", "SIMPLE_CHEMICAL", 179, 183], ["lipid", "SIMPLE_CHEMICAL", 192, 197], ["membrane rafts", "CELLULAR_COMPONENT", 213, 227], ["lipid kinases", "GENE_OR_GENE_PRODUCT", 266, 279], ["PI3K", "GENE_OR_GENE_PRODUCT", 291, 295], ["Nef", "PROTEIN", 37, 40], ["phosphatidylinositol 4,5-bisphosphate", "PROTEIN", 89, 126], ["PIP2", "PROTEIN", 128, 132], ["PIP3", "PROTEIN", 179, 183], ["lipid kinases", "PROTEIN", 266, 279], ["PI3K", "PROTEIN", 291, 295], ["HIV-1", "SPECIES", 31, 36], ["HIV-1", "SPECIES", 31, 36], ["RSV", "SPECIES", 49, 52], ["HIV", "TEST", 31, 34], ["RSV infection", "PROBLEM", 49, 62], ["phosphatidylinositol", "TEST", 89, 109], ["bisphosphate (PIP2", "TREATMENT", 114, 132], ["phosphatidylinositol", "TEST", 138, 158], ["triphosphate (PIP3)", "TREATMENT", 165, 184], ["the lipid composition of membrane rafts", "TREATMENT", 188, 227], ["lipid kinases", "TREATMENT", 266, 279], ["infection", "OBSERVATION", 53, 62], ["membrane rafts", "OBSERVATION", 213, 227]]], ["This change plays an important role in the assembly and budding processes of progeny virus [179] .Genome Replication, Assembly, and Budding of Enveloped VirusesSendai virus, also known as murine parainfluenza virus type 1, is a highly transmissible pathogen of respiratory tract infection in mice, hamsters, guinea pigs, rats, and occasionally pigs.", [["respiratory tract", "ANATOMY", 261, 278], ["Sendai virus", "DISEASE", 160, 172], ["parainfluenza virus", "DISEASE", 195, 214], ["respiratory tract infection", "DISEASE", 261, 288], ["progeny virus", "ORGANISM", 77, 90], ["Enveloped Viruses", "ORGANISM", 143, 160], ["Sendai virus", "ORGANISM", 160, 172], ["murine", "ORGANISM", 188, 194], ["parainfluenza virus type 1", "ORGANISM", 195, 221], ["respiratory tract", "ORGANISM_SUBDIVISION", 261, 278], ["mice", "ORGANISM", 292, 296], ["hamsters", "ORGANISM", 298, 306], ["guinea pigs", "ORGANISM", 308, 319], ["rats", "ORGANISM", 321, 325], ["pigs", "ORGANISM", 344, 348], ["Sendai virus", "SPECIES", 160, 172], ["murine", "SPECIES", 188, 194], ["parainfluenza virus type 1", "SPECIES", 195, 221], ["mice", "SPECIES", 292, 296], ["hamsters", "SPECIES", 298, 306], ["guinea pigs", "SPECIES", 308, 319], ["rats", "SPECIES", 321, 325], ["pigs", "SPECIES", 344, 348], ["Sendai virus", "SPECIES", 160, 172], ["murine parainfluenza virus type 1", "SPECIES", 188, 221], ["mice", "SPECIES", 292, 296], ["hamsters", "SPECIES", 298, 306], ["progeny virus", "PROBLEM", 77, 90], ["Genome Replication", "TREATMENT", 98, 116], ["Enveloped VirusesSendai virus", "PROBLEM", 143, 172], ["murine parainfluenza virus type 1", "PROBLEM", 188, 221], ["respiratory tract infection", "PROBLEM", 261, 288], ["Sendai virus", "OBSERVATION", 160, 172], ["parainfluenza virus", "OBSERVATION", 195, 214], ["highly", "OBSERVATION_MODIFIER", 228, 234], ["transmissible", "OBSERVATION_MODIFIER", 235, 248], ["pathogen", "OBSERVATION_MODIFIER", 249, 257], ["respiratory tract", "ANATOMY", 261, 278], ["infection", "OBSERVATION", 279, 288]]], ["The two viral envelope proteins, HN protein and F protein, interact with membrane rafts.", [["membrane rafts", "ANATOMY", 73, 87], ["HN protein", "GENE_OR_GENE_PRODUCT", 33, 43], ["F protein", "GENE_OR_GENE_PRODUCT", 48, 57], ["membrane rafts", "CELLULAR_COMPONENT", 73, 87], ["viral envelope proteins", "PROTEIN", 8, 31], ["HN protein", "PROTEIN", 33, 43], ["F protein", "PROTEIN", 48, 57], ["The two viral envelope proteins", "PROBLEM", 0, 31], ["membrane rafts", "TREATMENT", 73, 87], ["viral envelope proteins", "OBSERVATION", 8, 31], ["membrane rafts", "OBSERVATION", 73, 87]]], ["The viral internal M protein appears to have no direct association with membrane rafts.", [["membrane rafts", "ANATOMY", 72, 86], ["membrane rafts", "CELLULAR_COMPONENT", 72, 86], ["viral internal M protein", "PROTEIN", 4, 28], ["The viral internal M protein", "TEST", 0, 28], ["membrane rafts", "TREATMENT", 72, 86], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["internal M protein", "OBSERVATION", 10, 28], ["membrane rafts", "OBSERVATION", 72, 86]]], ["When mature HN-F complexes specifically interact with M proteins through both the cytoplasmic tail and the transmembrane domain of F protein, the HN-F-M complexes are localized in membrane rafts, where the viral proteins have been suggested to be assembled [180] .", [["cytoplasmic tail", "ANATOMY", 82, 98], ["transmembrane", "ANATOMY", 107, 120], ["membrane rafts", "ANATOMY", 180, 194], ["HN-F", "GENE_OR_GENE_PRODUCT", 12, 16], ["M proteins", "GENE_OR_GENE_PRODUCT", 54, 64], ["cytoplasmic tail", "CELLULAR_COMPONENT", 82, 98], ["F protein", "GENE_OR_GENE_PRODUCT", 131, 140], ["HN-F-M", "GENE_OR_GENE_PRODUCT", 146, 152], ["membrane rafts", "CELLULAR_COMPONENT", 180, 194], ["mature HN-F complexes", "PROTEIN", 5, 26], ["M proteins", "PROTEIN", 54, 64], ["cytoplasmic tail", "PROTEIN", 82, 98], ["transmembrane domain", "PROTEIN", 107, 127], ["F protein", "PROTEIN", 131, 140], ["HN-F-M complexes", "PROTEIN", 146, 162], ["viral proteins", "PROTEIN", 206, 220], ["the viral proteins", "TEST", 202, 220], ["cytoplasmic tail", "ANATOMY", 82, 98], ["membrane rafts", "OBSERVATION", 180, 194]]], ["However, further study led to the conclusion that the virus assembly complexes found in membrane rafts did not constitute a direct precursor of virus particle budding [181] .", [["membrane rafts", "ANATOMY", 88, 102], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["virus assembly complexes", "PROTEIN", 54, 78], ["further study", "TEST", 9, 22], ["the virus assembly complexes", "PROBLEM", 50, 78], ["a direct precursor of virus particle budding", "PROBLEM", 122, 166]]], ["Two possible routes, raft dependent and raft independent, seem to be involved in Sendai virus assembly.Genome Replication, Assembly, and Budding of Enveloped VirusesHIV-1 uses membrane rafts as a platform for viral assembly and budding [182, 188] .", [["raft", "ANATOMY", 21, 25], ["membrane rafts", "ANATOMY", 176, 190], ["Sendai virus", "ORGANISM", 81, 93], ["HIV-1", "ORGANISM", 165, 170], ["membrane rafts", "CELLULAR_COMPONENT", 176, 190], ["HIV", "SPECIES", 165, 168], ["Sendai virus", "SPECIES", 81, 93], ["HIV-1", "SPECIES", 165, 170], ["Sendai virus", "PROBLEM", 81, 93], ["Genome Replication", "TREATMENT", 103, 121], ["Enveloped VirusesHIV", "PROBLEM", 148, 168], ["membrane rafts", "TREATMENT", 176, 190], ["raft dependent", "OBSERVATION", 21, 35], ["Sendai virus", "OBSERVATION", 81, 93]]], ["Modification of the N-terminus of HIV-1 Gag protein with myristic acid is required for HIV-1 assembly and budding [214] .", [["myristic acid", "CHEMICAL", 57, 70], ["myristic acid", "CHEMICAL", 57, 70], ["HIV-1", "ORGANISM", 34, 39], ["Gag", "GENE_OR_GENE_PRODUCT", 40, 43], ["myristic acid", "SIMPLE_CHEMICAL", 57, 70], ["HIV-1", "ORGANISM", 87, 92], ["N-terminus", "PROTEIN", 20, 30], ["HIV-1 Gag protein", "PROTEIN", 34, 51], ["HIV-1", "SPECIES", 34, 39], ["HIV-1", "SPECIES", 87, 92], ["HIV-1", "SPECIES", 34, 39], ["HIV-1", "SPECIES", 87, 92], ["HIV", "TEST", 34, 37], ["myristic acid", "TEST", 57, 70], ["HIV", "PROBLEM", 87, 90]]], ["Gag protein interacts with the plasma membrane through associations between its myristic acids and membrane rafts, leading to its incorporation into HIV-1 particles as an internal structural protein [188] .", [["plasma membrane", "ANATOMY", 31, 46], ["membrane rafts", "ANATOMY", 99, 113], ["myristic acids", "CHEMICAL", 80, 94], ["myristic acids", "CHEMICAL", 80, 94], ["Gag", "GENE_OR_GENE_PRODUCT", 0, 3], ["plasma membrane", "CELLULAR_COMPONENT", 31, 46], ["myristic acids", "SIMPLE_CHEMICAL", 80, 94], ["membrane rafts", "CELLULAR_COMPONENT", 99, 113], ["HIV-1", "ORGANISM", 149, 154], ["Gag protein", "PROTEIN", 0, 11], ["HIV-1", "SPECIES", 149, 154], ["HIV-1", "SPECIES", 149, 154], ["its myristic acids", "TREATMENT", 76, 94], ["membrane rafts", "TREATMENT", 99, 113], ["an internal structural protein", "TEST", 168, 198], ["myristic acids", "OBSERVATION", 80, 94], ["membrane rafts", "OBSERVATION", 99, 113]]], ["During the budding process, Gag-Gag interactions (Gag multimerization) occur through the N-terminus of the viral nucleocapsid (NC domain).", [["N", "CHEMICAL", 89, 90], ["Gag", "GENE_OR_GENE_PRODUCT", 28, 31], ["Gag", "GENE_OR_GENE_PRODUCT", 32, 35], ["Gag", "GENE_OR_GENE_PRODUCT", 50, 53], ["Gag", "PROTEIN", 28, 31], ["Gag", "PROTEIN", 32, 35], ["Gag", "PROTEIN", 50, 53], ["N-terminus", "PROTEIN", 89, 99], ["viral nucleocapsid", "PROTEIN", 107, 125], ["NC domain", "PROTEIN", 127, 136], ["the budding process", "PROBLEM", 7, 26], ["Gag interactions", "PROBLEM", 32, 48], ["the viral nucleocapsid (NC domain", "TREATMENT", 103, 136], ["viral nucleocapsid", "OBSERVATION", 107, 125]]], ["Lower-ordered Gag multimerization, but not higher-order Gag multimerization, may enhance or stabilize Gag-membrane and Gag-raft interactions.", [["Gag-raft", "ANATOMY", 119, 127], ["Gag", "GENE_OR_GENE_PRODUCT", 14, 17], ["Gag-membrane", "SIMPLE_CHEMICAL", 102, 114], ["Gag", "PROTEIN", 14, 17], ["Gag", "PROTEIN", 56, 59], ["ordered Gag multimerization", "TREATMENT", 6, 33], ["Gag multimerization", "PROBLEM", 56, 75], ["Gag-membrane", "PROBLEM", 102, 114], ["Gag multimerization", "OBSERVATION", 14, 33]]], ["Whether membrane rafts are responsible for increasing Gag-Gag interaction is unclear [186] .", [["membrane rafts", "ANATOMY", 8, 22], ["membrane rafts", "CELLULAR_COMPONENT", 8, 22], ["Gag", "GENE_OR_GENE_PRODUCT", 54, 57], ["Gag", "GENE_OR_GENE_PRODUCT", 58, 61], ["Gag", "PROTEIN", 54, 57], ["Gag", "PROTEIN", 58, 61], ["membrane rafts", "PROBLEM", 8, 22], ["increasing Gag", "PROBLEM", 43, 57], ["Gag interaction", "PROBLEM", 58, 73], ["membrane rafts", "OBSERVATION", 8, 22]]], ["The viral envelope glycoprotein complexes (composed of gp120 and gp41) are incorporated into the HIV-1 envelope together with membrane rafts by interactions of Gag with the cytoplasmic tail of gp41, which stabilize the gp120-gp41 interactions.", [["membrane rafts", "ANATOMY", 126, 140], ["cytoplasmic tail", "ANATOMY", 173, 189], ["gp120", "GENE_OR_GENE_PRODUCT", 55, 60], ["gp41", "GENE_OR_GENE_PRODUCT", 65, 69], ["HIV-1", "ORGANISM", 97, 102], ["membrane rafts", "CELLULAR_COMPONENT", 126, 140], ["Gag", "GENE_OR_GENE_PRODUCT", 160, 163], ["cytoplasmic", "ORGANISM_SUBSTANCE", 173, 184], ["gp41", "GENE_OR_GENE_PRODUCT", 193, 197], ["gp120", "GENE_OR_GENE_PRODUCT", 219, 224], ["gp41", "GENE_OR_GENE_PRODUCT", 225, 229], ["viral envelope glycoprotein complexes", "PROTEIN", 4, 41], ["gp120", "PROTEIN", 55, 60], ["gp41", "PROTEIN", 65, 69], ["Gag", "PROTEIN", 160, 163], ["cytoplasmic tail", "PROTEIN", 173, 189], ["gp41", "PROTEIN", 193, 197], ["gp120", "PROTEIN", 219, 224], ["gp41", "PROTEIN", 225, 229], ["HIV-1", "SPECIES", 97, 102], ["HIV-1", "SPECIES", 97, 102], ["The viral envelope glycoprotein complexes", "TREATMENT", 0, 41], ["gp120 and gp41", "TREATMENT", 55, 69], ["membrane rafts", "TREATMENT", 126, 140], ["viral envelope glycoprotein complexes", "OBSERVATION", 4, 41]]], ["Palmitoylation in cytoplasmic tails of gp41 is required for interactions with rafts but not for interactions between gp41 and Gag protein.", [["cytoplasmic", "ANATOMY", 18, 29], ["cytoplasmic", "ORGANISM_SUBSTANCE", 18, 29], ["gp41", "GENE_OR_GENE_PRODUCT", 39, 43], ["gp41", "GENE_OR_GENE_PRODUCT", 117, 121], ["Gag", "GENE_OR_GENE_PRODUCT", 126, 129], ["cytoplasmic tails", "PROTEIN", 18, 35], ["gp41", "PROTEIN", 39, 43], ["gp41", "PROTEIN", 117, 121], ["Gag protein", "PROTEIN", 126, 137], ["Palmitoylation in cytoplasmic tails of gp41", "TREATMENT", 0, 43], ["cytoplasmic tails", "OBSERVATION", 18, 35]]], ["Moreover, although associations of rafts with both gp41 and Gag protein are not essential for HIV-1 assembly, infectious progeny virus production, and surface trafficking of the viral proteins [185, 189, 190] , the quantal interaction of Gag with cholesterol-enriched rafts facilitates HIV-1 particle production by enhancement of both Gag-membrane interaction and Gag multimerization [193, 194] .", [["surface", "ANATOMY", 151, 158], ["rafts", "ANATOMY", 268, 273], ["membrane", "ANATOMY", 339, 347], ["cholesterol", "CHEMICAL", 247, 258], ["cholesterol", "CHEMICAL", 247, 258], ["rafts", "CELLULAR_COMPONENT", 35, 40], ["gp41", "GENE_OR_GENE_PRODUCT", 51, 55], ["Gag", "GENE_OR_GENE_PRODUCT", 60, 63], ["HIV-1", "ORGANISM", 94, 99], ["infectious progeny virus", "ORGANISM", 110, 134], ["Gag", "GENE_OR_GENE_PRODUCT", 238, 241], ["cholesterol", "SIMPLE_CHEMICAL", 247, 258], ["rafts", "CELLULAR_COMPONENT", 268, 273], ["HIV-1", "ORGANISM", 286, 291], ["Gag", "GENE_OR_GENE_PRODUCT", 335, 338], ["membrane", "CELLULAR_COMPONENT", 339, 347], ["gp41", "PROTEIN", 51, 55], ["Gag protein", "PROTEIN", 60, 71], ["viral proteins", "PROTEIN", 178, 192], ["Gag", "PROTEIN", 238, 241], ["Gag", "PROTEIN", 335, 338], ["Gag", "PROTEIN", 364, 367], ["HIV-1", "SPECIES", 94, 99], ["HIV-1", "SPECIES", 286, 291], ["HIV-1", "SPECIES", 94, 99], ["HIV-1", "SPECIES", 286, 291], ["both gp41 and Gag protein", "TEST", 46, 71], ["HIV", "PROBLEM", 94, 97], ["infectious progeny virus production", "PROBLEM", 110, 145], ["the viral proteins", "TEST", 174, 192], ["Gag", "TEST", 238, 241], ["cholesterol", "TEST", 247, 258], ["HIV", "PROBLEM", 286, 289], ["infectious", "OBSERVATION_MODIFIER", 110, 120], ["both Gag", "ANATOMY", 330, 338]]], ["Interactions of Gag protein with Annexin 2 at the PIP2-enriched membrane rafts also increase virus production [196] .Genome Replication, Assembly, and Budding of Enveloped VirusesThe Nef protein encoded by primate lentiviruses facilitates virus replication and thus increases the pathogenic potential of HIV.", [["membrane rafts", "ANATOMY", 64, 78], ["Gag", "GENE_OR_GENE_PRODUCT", 16, 19], ["Annexin 2", "GENE_OR_GENE_PRODUCT", 33, 42], ["PIP2", "GENE_OR_GENE_PRODUCT", 50, 54], ["membrane rafts", "CELLULAR_COMPONENT", 64, 78], ["Enveloped Viruses", "ORGANISM", 162, 179], ["Nef", "GENE_OR_GENE_PRODUCT", 183, 186], ["primate lentiviruses", "ORGANISM", 206, 226], ["HIV", "ORGANISM", 304, 307], ["Gag protein", "PROTEIN", 16, 27], ["Annexin 2", "PROTEIN", 33, 42], ["PIP2", "PROTEIN", 50, 54], ["Nef protein", "PROTEIN", 183, 194], ["HIV", "SPECIES", 304, 307], ["HIV", "SPECIES", 304, 307], ["Gag protein", "TEST", 16, 27], ["Annexin", "TREATMENT", 33, 40], ["the PIP2-enriched membrane rafts", "TREATMENT", 46, 78], ["increase virus production", "PROBLEM", 84, 109], ["Genome Replication", "TREATMENT", 117, 135], ["Enveloped Viruses", "PROBLEM", 162, 179], ["The Nef protein", "TREATMENT", 179, 194], ["virus replication", "TREATMENT", 239, 256], ["HIV", "PROBLEM", 304, 307], ["membrane rafts", "OBSERVATION", 64, 78]]], ["The myristoylated N-terminus and its neighboring basic arginine and lysine residues of Nef increase viral transcription and HIV-1 infectivity through interactions with GM1-and cholesterol-enriched membrane rafts, where Nef binds to both the plasma membrane and the viral structural proteins and participates directly in formation of the budding scaffold, leading to incorporation of Nef into the virus particles, concomitantly with viral structural proteins [183, 184, 187] .", [["membrane rafts", "ANATOMY", 197, 211], ["plasma membrane", "ANATOMY", 241, 256], ["arginine", "CHEMICAL", 55, 63], ["lysine", "CHEMICAL", 68, 74], ["cholesterol", "CHEMICAL", 176, 187], ["N", "CHEMICAL", 18, 19], ["arginine", "CHEMICAL", 55, 63], ["lysine", "CHEMICAL", 68, 74], ["cholesterol", "CHEMICAL", 176, 187], ["arginine", "AMINO_ACID", 55, 63], ["lysine", "AMINO_ACID", 68, 74], ["Nef", "GENE_OR_GENE_PRODUCT", 87, 90], ["HIV-1", "ORGANISM", 124, 129], ["GM1", "GENE_OR_GENE_PRODUCT", 168, 171], ["cholesterol", "SIMPLE_CHEMICAL", 176, 187], ["membrane rafts", "CELLULAR_COMPONENT", 197, 211], ["Nef", "GENE_OR_GENE_PRODUCT", 219, 222], ["plasma membrane", "CELLULAR_COMPONENT", 241, 256], ["Nef", "GENE_OR_GENE_PRODUCT", 383, 386], ["myristoylated N-terminus", "PROTEIN", 4, 28], ["Nef", "PROTEIN", 87, 90], ["GM1", "PROTEIN", 168, 171], ["Nef", "PROTEIN", 219, 222], ["viral structural proteins", "PROTEIN", 265, 290], ["Nef", "PROTEIN", 383, 386], ["viral structural proteins", "PROTEIN", 432, 457], ["HIV-1", "SPECIES", 124, 129], ["HIV-1", "SPECIES", 124, 129], ["The myristoylated N-terminus", "TREATMENT", 0, 28], ["its neighboring basic arginine and lysine residues", "TREATMENT", 33, 83], ["Nef increase viral transcription", "TREATMENT", 87, 119], ["HIV", "PROBLEM", 124, 127], ["GM1", "TEST", 168, 171], ["cholesterol-enriched membrane rafts", "TREATMENT", 176, 211], ["Nef binds", "PROBLEM", 219, 228], ["the plasma membrane", "TEST", 237, 256], ["the viral structural proteins", "PROBLEM", 261, 290], ["the budding scaffold", "PROBLEM", 333, 353], ["Nef into the virus particles", "PROBLEM", 383, 411], ["viral structural proteins", "TEST", 432, 457], ["lysine residues", "OBSERVATION", 68, 83], ["increase", "OBSERVATION_MODIFIER", 91, 99], ["viral transcription", "OBSERVATION", 100, 119], ["membrane rafts", "OBSERVATION", 197, 211], ["plasma membrane", "ANATOMY", 241, 256], ["viral structural proteins", "OBSERVATION", 265, 290], ["budding scaffold", "OBSERVATION", 337, 353]]], ["The N-terminus of Nef determines its differential membrane avidity and its preferential incorporation into a specific membrane raft for surface membranes or for subcellular membranes [191] , which Nef itself has the ability to regulate by modulating the lipid composition of the virus envelope and host cell membrane rafts through, for example, activation of lipid kinases such as PI3K [192] .", [["membrane", "ANATOMY", 50, 58], ["membrane raft", "ANATOMY", 118, 131], ["surface membranes", "ANATOMY", 136, 153], ["subcellular membranes", "ANATOMY", 161, 182], ["cell membrane rafts", "ANATOMY", 303, 322], ["Nef", "GENE_OR_GENE_PRODUCT", 18, 21], ["membrane", "CELLULAR_COMPONENT", 50, 58], ["membrane raft", "CELLULAR_COMPONENT", 118, 131], ["surface membranes", "CELLULAR_COMPONENT", 136, 153], ["subcellular membranes", "CELLULAR_COMPONENT", 161, 182], ["Nef", "GENE_OR_GENE_PRODUCT", 197, 200], ["cell membrane rafts", "CELLULAR_COMPONENT", 303, 322], ["lipid kinases", "GENE_OR_GENE_PRODUCT", 359, 372], ["PI3K [192]", "GENE_OR_GENE_PRODUCT", 381, 391], ["N-terminus", "PROTEIN", 4, 14], ["Nef", "PROTEIN", 18, 21], ["Nef", "PROTEIN", 197, 200], ["lipid kinases", "PROTEIN", 359, 372], ["PI3K [192]", "PROTEIN", 381, 391], ["its differential membrane avidity", "PROBLEM", 33, 66], ["a specific membrane raft", "TREATMENT", 107, 131], ["surface membranes", "TREATMENT", 136, 153], ["subcellular membranes", "PROBLEM", 161, 182], ["the virus envelope", "PROBLEM", 275, 293], ["host cell membrane rafts", "TREATMENT", 298, 322], ["lipid kinases", "TEST", 359, 372], ["host cell membrane rafts", "OBSERVATION", 298, 322]]], ["HIV-1 release from certain cell lines is enhanced by the viral Vpu protein, which is partitioned into membrane rafts.", [["cell lines", "ANATOMY", 27, 37], ["membrane rafts", "ANATOMY", 102, 116], ["HIV-1", "ORGANISM", 0, 5], ["cell lines", "CELL", 27, 37], ["Vpu", "GENE_OR_GENE_PRODUCT", 63, 66], ["membrane rafts", "CELLULAR_COMPONENT", 102, 116], ["cell lines", "CELL_LINE", 27, 37], ["viral Vpu protein", "PROTEIN", 57, 74], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["certain cell lines", "TREATMENT", 19, 37], ["the viral Vpu protein", "TEST", 53, 74], ["certain cell lines", "OBSERVATION", 19, 37], ["viral Vpu protein", "OBSERVATION", 57, 74], ["membrane rafts", "OBSERVATION", 102, 116]]], ["Transmembrane mutants of the Vpu protein have impaired HIV-1 particle release function due to deficiency of raft association but still maintain the ability to down regulate CD4 [200] .", [["raft", "ANATOMY", 108, 112], ["Vpu", "GENE_OR_GENE_PRODUCT", 29, 32], ["HIV-1", "ORGANISM", 55, 60], ["raft", "CELLULAR_COMPONENT", 108, 112], ["CD4", "GENE_OR_GENE_PRODUCT", 173, 176], ["Transmembrane mutants", "PROTEIN", 0, 21], ["Vpu protein", "PROTEIN", 29, 40], ["CD4", "PROTEIN", 173, 176], ["HIV-1", "SPECIES", 55, 60], ["HIV-1", "SPECIES", 55, 60], ["Transmembrane mutants", "PROBLEM", 0, 21], ["the Vpu protein", "TEST", 25, 40], ["impaired HIV", "PROBLEM", 46, 58], ["deficiency of raft association", "PROBLEM", 94, 124]]], ["For HIV-1 assembly and budding, membrane rafts are also associated with cellular factors such as human cellular cystidine deaminase APOBEC3G (hA3G), BST-2/ CD317/HM1.24 (tetherin), caveolin-1, and tetraspanins. hA3G inhibits infectivity of progeny virus particles by its incorporation into virus particles through its association with membrane rafts [195, 201] .", [["membrane rafts", "ANATOMY", 32, 46], ["cellular", "ANATOMY", 72, 80], ["cellular", "ANATOMY", 103, 111], ["membrane rafts", "ANATOMY", 335, 349], ["cystidine", "CHEMICAL", 112, 121], ["HIV-1", "ORGANISM", 4, 9], ["membrane rafts", "CELLULAR_COMPONENT", 32, 46], ["cellular", "CELL", 72, 80], ["human", "ORGANISM", 97, 102], ["cellular cystidine deaminase", "GENE_OR_GENE_PRODUCT", 103, 131], ["APOBEC3G", "GENE_OR_GENE_PRODUCT", 132, 140], ["hA3G", "GENE_OR_GENE_PRODUCT", 142, 146], ["BST-2", "GENE_OR_GENE_PRODUCT", 149, 154], ["CD317", "GENE_OR_GENE_PRODUCT", 156, 161], ["HM1.24", "GENE_OR_GENE_PRODUCT", 162, 168], ["tetherin", "GENE_OR_GENE_PRODUCT", 170, 178], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 181, 191], ["tetraspanins", "GENE_OR_GENE_PRODUCT", 197, 209], ["hA3G", "GENE_OR_GENE_PRODUCT", 211, 215], ["progeny virus particles", "ORGANISM", 240, 263], ["membrane rafts", "CELLULAR_COMPONENT", 335, 349], ["cellular factors", "PROTEIN", 72, 88], ["human cellular cystidine deaminase", "PROTEIN", 97, 131], ["APOBEC3G", "PROTEIN", 132, 140], ["hA3G", "PROTEIN", 142, 146], ["BST-2", "PROTEIN", 149, 154], ["CD317", "PROTEIN", 156, 161], ["HM1.24", "PROTEIN", 162, 168], ["tetherin", "PROTEIN", 170, 178], ["caveolin-1", "PROTEIN", 181, 191], ["tetraspanins", "PROTEIN", 197, 209], ["hA3G", "PROTEIN", 211, 215], ["HIV-1", "SPECIES", 4, 9], ["human", "SPECIES", 97, 102], ["HIV-1", "SPECIES", 4, 9], ["human", "SPECIES", 97, 102], ["HIV", "PROBLEM", 4, 7], ["budding, membrane rafts", "PROBLEM", 23, 46], ["cellular factors", "PROBLEM", 72, 88], ["BST", "TEST", 149, 152], ["CD317", "TEST", 156, 161], ["tetherin", "TEST", 170, 178], ["caveolin", "TEST", 181, 189], ["tetraspanins", "TREATMENT", 197, 209], ["infectivity of progeny virus particles", "PROBLEM", 225, 263], ["membrane rafts", "OBSERVATION", 32, 46], ["infectivity", "OBSERVATION_MODIFIER", 225, 236], ["progeny virus", "OBSERVATION", 240, 253]]], ["Tetherin also exerts antiviral activity against HIV-1 and other enveloped viruses as an interferon-inducible factor of the innate immune system by inhibition of progeny virus particle release from the cell surface.", [["cell surface", "ANATOMY", 201, 213], ["Tetherin", "GENE_OR_GENE_PRODUCT", 0, 8], ["HIV-1", "ORGANISM", 48, 53], ["cell surface", "CELLULAR_COMPONENT", 201, 213], ["Tetherin", "PROTEIN", 0, 8], ["interferon-inducible factor", "PROTEIN", 88, 115], ["HIV-1", "SPECIES", 48, 53], ["HIV-1", "SPECIES", 48, 53], ["Tetherin", "TREATMENT", 0, 8], ["HIV-1", "PROBLEM", 48, 53], ["other enveloped viruses", "PROBLEM", 58, 81], ["the innate immune system", "TREATMENT", 119, 143], ["progeny virus particle", "TREATMENT", 161, 183], ["antiviral activity", "OBSERVATION", 21, 39], ["viruses", "OBSERVATION", 74, 81], ["cell surface", "OBSERVATION", 201, 213]]], ["Viral propagation among T cells proceeds by direct cellto-cell transmission through membrane raft-enriched synapses colocalized with tetherin, which counteracts the viral Vpu protein partitioned to membrane rafts, involved in virus release [199] .", [["T cells", "ANATOMY", 24, 31], ["cellto-cell", "ANATOMY", 51, 62], ["membrane raft", "ANATOMY", 84, 97], ["synapses", "ANATOMY", 107, 115], ["membrane rafts", "ANATOMY", 198, 212], ["T cells", "CELL", 24, 31], ["cellto-cell", "CELL", 51, 62], ["membrane raft", "CELLULAR_COMPONENT", 84, 97], ["synapses", "CELLULAR_COMPONENT", 107, 115], ["tetherin", "GENE_OR_GENE_PRODUCT", 133, 141], ["Vpu", "GENE_OR_GENE_PRODUCT", 171, 174], ["membrane rafts", "CELLULAR_COMPONENT", 198, 212], ["T cells", "CELL_TYPE", 24, 31], ["tetherin", "PROTEIN", 133, 141], ["viral Vpu protein", "PROTEIN", 165, 182], ["Viral propagation among T cells", "PROBLEM", 0, 31], ["direct cellto", "TEST", 44, 57], ["membrane raft", "TREATMENT", 84, 97], ["tetherin", "TREATMENT", 133, 141], ["the viral Vpu protein", "TREATMENT", 161, 182], ["membrane rafts", "TREATMENT", 198, 212], ["enriched synapses", "OBSERVATION", 98, 115], ["viral Vpu", "OBSERVATION", 165, 174], ["membrane rafts", "OBSERVATION", 198, 212]]], ["HIV-1 infection enhances the expression of caveolin-1, a major protein of membrane rafts.", [["membrane rafts", "ANATOMY", 74, 88], ["infection", "DISEASE", 6, 15], ["HIV-1", "ORGANISM", 0, 5], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 43, 53], ["membrane rafts", "CELLULAR_COMPONENT", 74, 88], ["caveolin-1", "PROTEIN", 43, 53], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["1 infection", "PROBLEM", 4, 15], ["caveolin", "TEST", 43, 51], ["infection", "OBSERVATION", 6, 15], ["membrane rafts", "OBSERVATION", 74, 88]]], ["Although membrane rafts have been shown to contribute to assembly and budding processes of HIV-1, expression of caveolin-1 causes a reduction of virus production in macrophages [198] .", [["membrane rafts", "ANATOMY", 9, 23], ["macrophages", "ANATOMY", 165, 176], ["membrane rafts", "CELLULAR_COMPONENT", 9, 23], ["HIV-1", "ORGANISM", 91, 96], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 112, 122], ["macrophages", "CELL", 165, 176], ["caveolin-1", "PROTEIN", 112, 122], ["macrophages", "CELL_TYPE", 165, 176], ["HIV-1", "SPECIES", 91, 96], ["HIV-1", "SPECIES", 91, 96], ["membrane rafts", "PROBLEM", 9, 23], ["HIV", "PROBLEM", 91, 94], ["caveolin", "TREATMENT", 112, 120], ["a reduction of virus production in macrophages", "PROBLEM", 130, 176], ["virus production", "OBSERVATION", 145, 161]]], ["This suggests that caveolin-1 may contribute to persistent infection in macrophages and that a caveolin-dependent raft, caveola, is not necessarily an advantage for the HIV-1 lifecycle.", [["macrophages", "ANATOMY", 72, 83], ["raft", "ANATOMY", 114, 118], ["infection", "DISEASE", 59, 68], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 19, 29], ["macrophages", "CELL", 72, 83], ["caveolin", "GENE_OR_GENE_PRODUCT", 95, 103], ["raft", "CELLULAR_COMPONENT", 114, 118], ["HIV-1", "ORGANISM", 169, 174], ["caveolin-1", "PROTEIN", 19, 29], ["macrophages", "CELL_TYPE", 72, 83], ["caveolin", "PROTEIN", 95, 103], ["HIV-1", "SPECIES", 169, 174], ["HIV-1", "SPECIES", 169, 174], ["persistent infection in macrophages", "PROBLEM", 48, 83], ["a caveolin-dependent raft", "TREATMENT", 93, 118], ["the HIV", "TEST", 165, 172], ["may contribute to", "UNCERTAINTY", 30, 47], ["persistent", "OBSERVATION_MODIFIER", 48, 58], ["infection", "OBSERVATION", 59, 68], ["macrophages", "OBSERVATION", 72, 83], ["not necessarily", "UNCERTAINTY", 132, 147]]], ["A tetraspanin-enriched microdomain is a unique type of protein-based microdomain, clearly distinct from membrane rafts.", [["microdomain", "ANATOMY", 23, 34], ["microdomain", "ANATOMY", 69, 80], ["membrane rafts", "ANATOMY", 104, 118], ["tetraspanin", "GENE_OR_GENE_PRODUCT", 2, 13], ["microdomain", "CELLULAR_COMPONENT", 23, 34], ["membrane rafts", "CELLULAR_COMPONENT", 104, 118], ["tetraspanin", "PROTEIN", 2, 13], ["enriched microdomain", "OBSERVATION", 14, 34], ["membrane rafts", "OBSERVATION", 104, 118]]], ["Tetraspanins CD9, raft-associated CD55, and raft marker GM1 are concentrated at the virus assembly site.", [["raft", "ANATOMY", 18, 22], ["raft", "ANATOMY", 44, 48], ["CD9", "GENE_OR_GENE_PRODUCT", 13, 16], ["raft", "CELLULAR_COMPONENT", 18, 22], ["CD55", "GENE_OR_GENE_PRODUCT", 34, 38], ["raft", "CELLULAR_COMPONENT", 44, 48], ["GM1", "GENE_OR_GENE_PRODUCT", 56, 59], ["Tetraspanins", "PROTEIN", 0, 12], ["CD9", "PROTEIN", 13, 16], ["raft", "PROTEIN", 18, 22], ["CD55", "PROTEIN", 34, 38], ["raft marker GM1", "PROTEIN", 44, 59], ["virus assembly site", "DNA", 84, 103], ["Tetraspanins CD9", "TEST", 0, 16], ["raft", "TEST", 18, 22], ["CD55", "TEST", 34, 38], ["raft marker GM1", "PROBLEM", 44, 59], ["CD55", "OBSERVATION", 34, 38], ["virus", "OBSERVATION", 84, 89]]], ["This recruitment and confinement of CD9 are partially dependent on cholesterol, whereas those of CD55 are completely dependent on cholesterol.", [["cholesterol", "CHEMICAL", 67, 78], ["cholesterol", "CHEMICAL", 130, 141], ["cholesterol", "CHEMICAL", 67, 78], ["cholesterol", "CHEMICAL", 130, 141], ["CD9", "GENE_OR_GENE_PRODUCT", 36, 39], ["cholesterol", "SIMPLE_CHEMICAL", 67, 78], ["CD55", "GENE_OR_GENE_PRODUCT", 97, 101], ["cholesterol", "SIMPLE_CHEMICAL", 130, 141], ["CD9", "PROTEIN", 36, 39], ["CD55", "PROTEIN", 97, 101], ["partially dependent on cholesterol", "PROBLEM", 44, 78]]], ["HIV-1 assembly creates specialized microdomains for recruiting components of both membrane rafts and tetraspanin-enriched microdomains [197] .", [["microdomains", "ANATOMY", 35, 47], ["membrane rafts", "ANATOMY", 82, 96], ["microdomains", "ANATOMY", 122, 134], ["HIV-1", "ORGANISM", 0, 5], ["membrane rafts", "CELLULAR_COMPONENT", 82, 96], ["tetraspanin", "GENE_OR_GENE_PRODUCT", 101, 112], ["membrane rafts", "PROTEIN", 82, 96], ["tetraspanin", "PROTEIN", 101, 112], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["both membrane rafts", "TREATMENT", 77, 96], ["tetraspanin-enriched microdomains", "TREATMENT", 101, 134], ["both", "ANATOMY_MODIFIER", 77, 81], ["membrane rafts", "OBSERVATION", 82, 96]]], ["As for retroviruses other than HIV, HTLV-1 assembly, but not budding and surface trafficking, is also inhibited by a decrease of Gag associations with membrane rafts by interferon \u03b1-2a treatment [202] .Genome Replication, Assembly, and Budding of Enveloped VirusesVSV budding is known to occur at membrane microdomains containing the viral envelope G glycoproteins, some of which are 100-150 nm in size and smaller than the virus envelope (approximately 100-150 nm) and others of which extended in size to a maximum of 300-400 nm from the tip of the virus budding site [203, 204] .", [["surface", "ANATOMY", 73, 80], ["membrane rafts", "ANATOMY", 151, 165], ["membrane microdomains", "ANATOMY", 297, 318], ["interferon \u03b1-2a", "CHEMICAL", 169, 184], ["retroviruses", "ORGANISM", 7, 19], ["HTLV-1", "ORGANISM", 36, 42], ["budding", "CELLULAR_COMPONENT", 61, 68], ["surface", "CELLULAR_COMPONENT", 73, 80], ["Gag", "GENE_OR_GENE_PRODUCT", 129, 132], ["membrane rafts", "CELLULAR_COMPONENT", 151, 165], ["interferon \u03b1-2a", "GENE_OR_GENE_PRODUCT", 169, 184], ["VirusesVSV", "GENE_OR_GENE_PRODUCT", 257, 267], ["membrane microdomains", "CELLULAR_COMPONENT", 297, 318], ["envelope G glycoproteins", "GENE_OR_GENE_PRODUCT", 340, 364], ["Gag", "PROTEIN", 129, 132], ["interferon", "PROTEIN", 169, 179], ["viral envelope G glycoproteins", "PROTEIN", 334, 364], ["HIV", "SPECIES", 31, 34], ["HTLV-1", "SPECIES", 36, 42], ["HIV", "SPECIES", 31, 34], ["HTLV-1", "SPECIES", 36, 42], ["retroviruses", "PROBLEM", 7, 19], ["HIV", "PROBLEM", 31, 34], ["HTLV", "PROBLEM", 36, 40], ["membrane rafts", "TREATMENT", 151, 165], ["Enveloped VirusesVSV budding", "PROBLEM", 247, 275], ["the viral envelope G glycoproteins", "TREATMENT", 330, 364], ["the virus envelope", "PROBLEM", 420, 438], ["viral envelope G glycoproteins", "OBSERVATION_MODIFIER", 334, 364], ["size", "OBSERVATION_MODIFIER", 398, 402], ["smaller", "OBSERVATION_MODIFIER", 407, 414], ["virus", "OBSERVATION", 424, 429], ["size", "OBSERVATION_MODIFIER", 498, 502], ["tip", "OBSERVATION_MODIFIER", 539, 542], ["virus", "OBSERVATION", 550, 555]]], ["However, immunoelectron microscopy observation did not confirm that gold-labeled G protein-containing microdomains are equivalent to lipid-enriched membrane rafts.", [["microdomains", "ANATOMY", 102, 114], ["membrane rafts", "ANATOMY", 148, 162], ["gold", "CHEMICAL", 68, 72], ["G protein", "GENE_OR_GENE_PRODUCT", 81, 90], ["lipid", "SIMPLE_CHEMICAL", 133, 138], ["membrane rafts", "CELLULAR_COMPONENT", 148, 162], ["G protein", "PROTEIN", 81, 90], ["immunoelectron microscopy observation", "TEST", 9, 46], ["gold-labeled G protein", "TEST", 68, 90], ["microdomains", "PROBLEM", 102, 114], ["lipid-enriched membrane rafts", "TREATMENT", 133, 162], ["enriched membrane rafts", "OBSERVATION", 139, 162]]], ["Furthermore, such microdomains of 300-400 nm in size are too large for the definition of raft microdomains of 10-200 nm in size [3] .", [["microdomains", "ANATOMY", 18, 30], ["raft microdomains", "ANATOMY", 89, 106], ["microdomains", "CELLULAR_COMPONENT", 18, 30], ["raft microdomains", "CELLULAR_COMPONENT", 89, 106], ["such microdomains", "TEST", 13, 30], ["size", "OBSERVATION_MODIFIER", 48, 52], ["too large", "OBSERVATION_MODIFIER", 57, 66], ["raft", "ANATOMY_MODIFIER", 89, 93], ["size", "OBSERVATION_MODIFIER", 123, 127]]], ["A recent study has also shown that most G proteins of wildtype VSV were not incorporated into membrane rafts in infected osteoclasts [215] .", [["membrane rafts", "ANATOMY", 94, 108], ["osteoclasts", "ANATOMY", 121, 132], ["G proteins", "GENE_OR_GENE_PRODUCT", 40, 50], ["wildtype VSV", "ORGANISM", 54, 66], ["membrane rafts", "CELLULAR_COMPONENT", 94, 108], ["osteoclasts", "CELL", 121, 132], ["G proteins", "PROTEIN", 40, 50], ["infected osteoclasts", "CELL_TYPE", 112, 132], ["VSV", "SPECIES", 63, 66], ["A recent study", "TEST", 0, 14], ["wildtype VSV", "PROBLEM", 54, 66], ["infected osteoclasts", "PROBLEM", 112, 132], ["membrane rafts", "OBSERVATION", 94, 108], ["infected osteoclasts", "OBSERVATION", 112, 132]]], ["Relevance of membrane rafts on VSV infection will be settled in future studies.Genome Replication, Assembly, and Budding of Nonenveloped VirusesThe role of membrane rafts in intracellular assembly of nonenveloped viruses has been investigated only in bluetongue virus [216] and Rotavirus [130, [217] [218] [219] [220] , belonging to the family Reoviridae.", [["membrane rafts", "ANATOMY", 13, 27], ["membrane rafts", "ANATOMY", 156, 170], ["intracellular", "ANATOMY", 174, 187], ["VSV infection", "DISEASE", 31, 44], ["membrane rafts", "CELLULAR_COMPONENT", 13, 27], ["VSV", "ORGANISM", 31, 34], ["membrane rafts", "CELLULAR_COMPONENT", 156, 170], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 174, 187], ["bluetongue virus", "ORGANISM", 251, 267], ["membrane rafts", "PROTEIN", 156, 170], ["bluetongue virus", "SPECIES", 251, 267], ["VSV", "SPECIES", 31, 34], ["bluetongue virus", "SPECIES", 251, 267], ["membrane rafts", "TREATMENT", 13, 27], ["VSV infection", "PROBLEM", 31, 44], ["nonenveloped viruses", "PROBLEM", 200, 220], ["bluetongue virus", "PROBLEM", 251, 267], ["Rotavirus", "TEST", 278, 287], ["membrane rafts", "OBSERVATION", 13, 27], ["VSV infection", "OBSERVATION", 31, 44], ["Viruses", "OBSERVATION", 137, 144], ["membrane rafts", "OBSERVATION", 156, 170]]], ["Association of SNARE (soluble N-ethylmaleimide-sensitive fusion attachment protein receptor) domain in the bluetongue virus outer capsid VP5 with membrane rafts may play an important role in its membrane targeting and virus assembly [216] .", [["membrane rafts", "ANATOMY", 146, 160], ["membrane", "ANATOMY", 195, 203], ["N-ethylmaleimide", "CHEMICAL", 30, 46], ["N-ethylmaleimide", "CHEMICAL", 30, 46], ["SNARE", "GENE_OR_GENE_PRODUCT", 15, 20], ["soluble N-ethylmaleimide-sensitive fusion attachment protein receptor", "GENE_OR_GENE_PRODUCT", 22, 91], ["bluetongue virus", "ORGANISM", 107, 123], ["VP5", "GENE_OR_GENE_PRODUCT", 137, 140], ["membrane rafts", "CELLULAR_COMPONENT", 146, 160], ["membrane", "CELLULAR_COMPONENT", 195, 203], ["SNARE", "PROTEIN", 15, 20], ["soluble N-ethylmaleimide-sensitive fusion attachment protein receptor) domain", "PROTEIN", 22, 99], ["bluetongue virus outer capsid VP5", "PROTEIN", 107, 140], ["bluetongue virus", "SPECIES", 107, 123], ["bluetongue virus", "SPECIES", 107, 123], ["SNARE (soluble N-ethylmaleimide", "TREATMENT", 15, 46], ["sensitive fusion attachment protein receptor", "TREATMENT", 47, 91], ["the bluetongue virus outer capsid VP5", "TREATMENT", 103, 140], ["membrane rafts", "TREATMENT", 146, 160], ["SNARE", "OBSERVATION", 15, 20], ["capsid VP5", "OBSERVATION", 130, 140], ["membrane rafts", "OBSERVATION", 146, 160]]], ["Rotavirus replication occurs at large inclusions (known as viroplasms) in the cell cytoplasm, which are sites for replication of viral RNA and assembly of double-layered particles.", [["viroplasms", "ANATOMY", 59, 69], ["cell cytoplasm", "ANATOMY", 78, 92], ["Rotavirus", "DISEASE", 0, 9], ["Rotavirus", "ORGANISM", 0, 9], ["cell", "CELLULAR_COMPONENT", 78, 82], ["cytoplasm", "ORGANISM_SUBSTANCE", 83, 92], ["viral RNA", "RNA", 129, 138], ["Rotavirus replication", "PROBLEM", 0, 21], ["large inclusions", "PROBLEM", 32, 48], ["the cell cytoplasm", "PROBLEM", 74, 92], ["viral RNA", "PROBLEM", 129, 138], ["double-layered particles", "TREATMENT", 155, 179], ["large", "OBSERVATION_MODIFIER", 32, 37], ["inclusions", "OBSERVATION", 38, 48], ["cell cytoplasm", "OBSERVATION", 78, 92], ["viral RNA", "OBSERVATION", 129, 138], ["double-layered particles", "OBSERVATION_MODIFIER", 155, 179]]], ["These particles are transferred across the ER membrane by interactions of the viral capsid protein VP6 with the nonstructural transmembrane glycoprotein NSP4, which has been characterized as an ER intracellular receptor and a viral enterotoxin for intestinal cells.", [["ER membrane", "ANATOMY", 43, 54], ["intracellular", "ANATOMY", 197, 210], ["intestinal cells", "ANATOMY", 248, 264], ["ER membrane", "CELLULAR_COMPONENT", 43, 54], ["VP6", "GENE_OR_GENE_PRODUCT", 99, 102], ["NSP4", "GENE_OR_GENE_PRODUCT", 153, 157], ["ER", "GENE_OR_GENE_PRODUCT", 194, 196], ["intestinal cells", "CELL", 248, 264], ["ER", "PROTEIN", 43, 45], ["viral capsid protein", "PROTEIN", 78, 98], ["VP6", "PROTEIN", 99, 102], ["nonstructural transmembrane glycoprotein", "PROTEIN", 112, 152], ["NSP4", "PROTEIN", 153, 157], ["ER intracellular receptor", "PROTEIN", 194, 219], ["viral enterotoxin", "PROTEIN", 226, 243], ["intestinal cells", "CELL_TYPE", 248, 264], ["the viral capsid protein VP6", "TREATMENT", 74, 102], ["the nonstructural transmembrane glycoprotein NSP4", "PROBLEM", 108, 157], ["an ER intracellular receptor", "TEST", 191, 219], ["a viral enterotoxin", "TREATMENT", 224, 243], ["intestinal cells", "PROBLEM", 248, 264], ["particles", "OBSERVATION", 6, 15], ["intestinal cells", "OBSERVATION", 248, 264]]], ["During transfer across the ER, the virus acquires a transient lipid envelope that is finally lost and replaced by viral surface spike proteins, VP4 and VP7.", [["ER", "ANATOMY", 27, 29], ["surface", "ANATOMY", 120, 127], ["ER", "GENE_OR_GENE_PRODUCT", 27, 29], ["VP4", "GENE_OR_GENE_PRODUCT", 144, 147], ["VP7", "GENE_OR_GENE_PRODUCT", 152, 155], ["ER", "PROTEIN", 27, 29], ["viral surface spike proteins", "PROTEIN", 114, 142], ["VP4", "PROTEIN", 144, 147], ["VP7", "PROTEIN", 152, 155], ["the virus", "PROBLEM", 31, 40], ["a transient lipid envelope", "PROBLEM", 50, 76], ["viral surface spike proteins", "PROBLEM", 114, 142], ["VP4", "TEST", 144, 147], ["VP7", "TEST", 152, 155], ["virus", "OBSERVATION", 35, 40], ["transient", "OBSERVATION_MODIFIER", 52, 61], ["lipid envelope", "OBSERVATION", 62, 76]]], ["In this process, the involvement of transient enveloped particles in membrane rafts is highly questionable since rafts are thought to be absent from the ER.", [["membrane rafts", "ANATOMY", 69, 83], ["rafts", "ANATOMY", 113, 118], ["ER", "ANATOMY", 153, 155], ["membrane rafts", "CELLULAR_COMPONENT", 69, 83], ["rafts", "CELLULAR_COMPONENT", 113, 118], ["ER", "GENE_OR_GENE_PRODUCT", 153, 155], ["ER", "PROTEIN", 153, 155], ["transient enveloped particles in membrane rafts", "PROBLEM", 36, 83], ["transient", "OBSERVATION_MODIFIER", 36, 45], ["enveloped", "OBSERVATION_MODIFIER", 46, 55], ["particles", "OBSERVATION_MODIFIER", 56, 65], ["membrane rafts", "OBSERVATION", 69, 83], ["thought to be", "UNCERTAINTY", 123, 136]]], ["Association of VP4 with membrane rafts in the extrareticular compartment facilitates rotavirus morphogenesis as a final assembly platform and apical targeting toward the release process [130, 217, 218] .", [["membrane rafts", "ANATOMY", 24, 38], ["extrareticular compartment", "ANATOMY", 46, 72], ["apical", "ANATOMY", 142, 148], ["VP4", "GENE_OR_GENE_PRODUCT", 15, 18], ["membrane rafts", "CELLULAR_COMPONENT", 24, 38], ["extrareticular compartment", "CELLULAR_COMPONENT", 46, 72], ["rotavirus", "ORGANISM", 85, 94], ["VP4", "PROTEIN", 15, 18], ["rotavirus", "SPECIES", 85, 94], ["VP4", "PROBLEM", 15, 18], ["membrane rafts", "TREATMENT", 24, 38], ["rotavirus morphogenesis", "PROBLEM", 85, 108], ["membrane rafts", "OBSERVATION", 24, 38], ["extrareticular", "ANATOMY_MODIFIER", 46, 60], ["rotavirus morphogenesis", "OBSERVATION", 85, 108], ["apical", "ANATOMY_MODIFIER", 142, 148]]], ["The rafttype membrane microdomains associated with VP4 are significantly dependent on raft heterogeneity of cell lines [219] .", [["rafttype membrane microdomains", "ANATOMY", 4, 34], ["raft", "ANATOMY", 86, 90], ["cell lines", "ANATOMY", 108, 118], ["rafttype membrane microdomains", "CELLULAR_COMPONENT", 4, 34], ["VP4", "GENE_OR_GENE_PRODUCT", 51, 54], ["cell lines", "CELL", 108, 118], ["VP4", "PROTEIN", 51, 54], ["cell lines", "CELL_LINE", 108, 118], ["The rafttype membrane microdomains", "TREATMENT", 0, 34], ["VP4", "PROBLEM", 51, 54], ["significantly dependent", "PROBLEM", 59, 82], ["cell lines", "PROBLEM", 108, 118], ["membrane microdomains", "OBSERVATION", 13, 34], ["significantly", "OBSERVATION_MODIFIER", 59, 72], ["dependent", "OBSERVATION_MODIFIER", 73, 82], ["raft", "OBSERVATION_MODIFIER", 86, 90], ["heterogeneity", "OBSERVATION_MODIFIER", 91, 104], ["cell lines", "OBSERVATION", 108, 118]]], ["Moreover, N-glycosylation of NSP4 is processed in the Golgi network through caveola-dependent Golgi networkbypassing transport [220] .Role of Membrane Rafts in Virus-Induced Signal TransductionsViral replication efficiency, viral infection sites, and viral infectious diseases are frequently controlled by membrane rafts in host cells and immune cells.", [["Golgi network", "ANATOMY", 54, 67], ["Golgi", "ANATOMY", 94, 99], ["Membrane", "ANATOMY", 142, 150], ["membrane rafts", "ANATOMY", 306, 320], ["cells", "ANATOMY", 329, 334], ["immune cells", "ANATOMY", 339, 351], ["viral infection", "DISEASE", 224, 239], ["infectious diseases", "DISEASE", 257, 276], ["NSP4", "GENE_OR_GENE_PRODUCT", 29, 33], ["Golgi network", "CELLULAR_COMPONENT", 54, 67], ["caveola", "SIMPLE_CHEMICAL", 76, 83], ["Golgi", "CELLULAR_COMPONENT", 94, 99], ["Virus", "ORGANISM", 160, 165], ["membrane rafts", "CELLULAR_COMPONENT", 306, 320], ["host cells", "CELL", 324, 334], ["immune cells", "CELL", 339, 351], ["NSP4", "PROTEIN", 29, 33], ["host cells", "CELL_TYPE", 324, 334], ["immune cells", "CELL_TYPE", 339, 351], ["N-glycosylation of NSP4", "TREATMENT", 10, 33], ["Membrane Rafts in Virus", "TREATMENT", 142, 165], ["Viral replication efficiency", "PROBLEM", 194, 222], ["viral infection sites", "PROBLEM", 224, 245], ["viral infectious diseases", "PROBLEM", 251, 276], ["immune cells", "PROBLEM", 339, 351], ["Membrane Rafts", "OBSERVATION", 142, 156], ["Viral replication efficiency", "OBSERVATION", 194, 222], ["viral", "OBSERVATION_MODIFIER", 224, 229], ["infection", "OBSERVATION", 230, 239], ["viral", "OBSERVATION_MODIFIER", 251, 256], ["infectious", "OBSERVATION", 257, 267], ["membrane rafts", "OBSERVATION", 306, 320], ["host cells", "OBSERVATION", 324, 334], ["immune cells", "OBSERVATION", 339, 351]]], ["Membrane rafts also act as a scaffold of various cellular signal transductions.", [["Membrane rafts", "ANATOMY", 0, 14], ["cellular", "ANATOMY", 49, 57], ["Membrane rafts", "CELLULAR_COMPONENT", 0, 14], ["cellular", "CELL", 49, 57], ["Membrane rafts", "TREATMENT", 0, 14], ["various cellular signal transductions", "PROBLEM", 41, 78], ["cellular signal transductions", "OBSERVATION", 49, 78]]], ["Involvement of membrane rafts in many viral infectious diseases often results from up-or downregulation of cellular signal transductions associated with cell proliferation, apoptosis, cell differentiation, immune response, and so on.", [["membrane rafts", "ANATOMY", 15, 29], ["cellular", "ANATOMY", 107, 115], ["cell", "ANATOMY", 153, 157], ["cell", "ANATOMY", 184, 188], ["viral infectious diseases", "DISEASE", 38, 63], ["membrane rafts", "CELLULAR_COMPONENT", 15, 29], ["cellular", "CELL", 107, 115], ["cell", "CELL", 153, 157], ["cell", "CELL", 184, 188], ["membrane rafts", "PROBLEM", 15, 29], ["many viral infectious diseases", "PROBLEM", 33, 63], ["cellular signal transductions", "PROBLEM", 107, 136], ["cell proliferation", "PROBLEM", 153, 171], ["apoptosis", "PROBLEM", 173, 182], ["cell differentiation", "PROBLEM", 184, 204], ["membrane rafts", "OBSERVATION", 15, 29], ["many", "OBSERVATION_MODIFIER", 33, 37], ["viral", "OBSERVATION_MODIFIER", 38, 43], ["infectious", "OBSERVATION", 44, 54], ["cellular signal transductions", "OBSERVATION", 107, 136], ["cell proliferation", "OBSERVATION", 153, 171], ["cell differentiation", "OBSERVATION", 184, 204], ["immune response", "OBSERVATION", 206, 221]]], ["HTLV-1 Tax1 protein recruits I\u03baB kinases (IKKs) to membrane rafts for persistent activation of NF-\u03baB, which enhances T-cell proliferation, thereby contributing to HTLV-1-induced T-cell leukemia [221] .Role of Membrane Rafts in Virus-Induced Signal TransductionsFlaviviruses DEN type 2 and JEV activate the raft-dependent PI3K/Akt pathway that induces antiapoptosis in order to protect infected cells from early apoptotic cell death.", [["membrane rafts", "ANATOMY", 51, 65], ["T-cell", "ANATOMY", 117, 123], ["T-cell leukemia", "ANATOMY", 178, 193], ["Membrane", "ANATOMY", 209, 217], ["raft", "ANATOMY", 306, 310], ["cells", "ANATOMY", 394, 399], ["cell", "ANATOMY", 421, 425], ["T-cell leukemia", "DISEASE", 178, 193], ["death", "DISEASE", 426, 431], ["HTLV-1", "ORGANISM", 0, 6], ["Tax1", "GENE_OR_GENE_PRODUCT", 7, 11], ["I\u03baB kinases", "GENE_OR_GENE_PRODUCT", 29, 40], ["IKKs", "GENE_OR_GENE_PRODUCT", 42, 46], ["membrane rafts", "CELLULAR_COMPONENT", 51, 65], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 95, 100], ["T-cell", "CELL", 117, 123], ["HTLV-1", "ORGANISM", 163, 169], ["T-cell leukemia", "CANCER", 178, 193], ["Virus", "ORGANISM", 227, 232], ["DEN type 2", "GENE_OR_GENE_PRODUCT", 274, 284], ["JEV", "ORGANISM", 289, 292], ["raft", "CELLULAR_COMPONENT", 306, 310], ["PI3K", "GENE_OR_GENE_PRODUCT", 321, 325], ["Akt", "GENE_OR_GENE_PRODUCT", 326, 329], ["cells", "CELL", 394, 399], ["cell", "CELL", 421, 425], ["HTLV-1 Tax1 protein", "PROTEIN", 0, 19], ["I\u03baB kinases", "PROTEIN", 29, 40], ["IKKs", "PROTEIN", 42, 46], ["NF-\u03baB", "PROTEIN", 95, 100], ["PI3K", "PROTEIN", 321, 325], ["Akt", "PROTEIN", 326, 329], ["infected cells", "CELL_TYPE", 385, 399], ["HTLV-1", "SPECIES", 0, 6], ["HTLV-1", "SPECIES", 163, 169], ["JEV", "SPECIES", 289, 292], ["HTLV", "TEST", 0, 4], ["Tax1 protein", "TEST", 7, 19], ["IKKs", "TEST", 42, 46], ["membrane rafts", "TEST", 51, 65], ["persistent activation of NF", "PROBLEM", 70, 97], ["HTLV", "TEST", 163, 167], ["T-cell leukemia", "PROBLEM", 178, 193], ["Membrane Rafts in Virus", "TREATMENT", 209, 232], ["Signal TransductionsFlaviviruses DEN type 2", "TREATMENT", 241, 284], ["JEV activate", "TREATMENT", 289, 301], ["the raft", "TEST", 302, 310], ["dependent PI3K/Akt pathway", "TREATMENT", 311, 337], ["antiapoptosis", "PROBLEM", 351, 364], ["infected cells", "PROBLEM", 385, 399], ["early apoptotic cell death", "PROBLEM", 405, 431], ["cell proliferation", "OBSERVATION", 119, 137], ["cell leukemia", "OBSERVATION", 180, 193], ["Membrane Rafts", "OBSERVATION", 209, 223], ["infected cells", "OBSERVATION", 385, 399], ["early", "OBSERVATION_MODIFIER", 405, 410], ["apoptotic cell death", "OBSERVATION", 411, 431]]], ["However, this signaling is not essential for flavivirus replication.", [["flavivirus", "SPECIES", 45, 55], ["flavivirus replication", "PROBLEM", 45, 67], ["not essential for", "UNCERTAINTY", 27, 44], ["flavivirus", "OBSERVATION", 45, 55]]], ["A balance between apoptotic and antiapoptotic signaling, which is triggered by the interplay between host and virus, controls the outcome of flavivirus infection [17] .", [["flavivirus infection", "DISEASE", 141, 161], ["flavivirus", "ORGANISM", 141, 151], ["antiapoptotic signaling", "PROBLEM", 32, 55], ["flavivirus infection", "PROBLEM", 141, 161], ["balance", "OBSERVATION", 2, 9], ["antiapoptotic signaling", "OBSERVATION", 32, 55]]], ["DEN NS1, which can be found in membrane rafts on the host cell surface, increases NF-\u03baB transcriptional activities by facilitating nuclear translocation of NF-\u03baB p65 protein in HepG2 cells, suggesting a possible contribution to DEN pathogenicity [149] .", [["membrane rafts", "ANATOMY", 31, 45], ["cell surface", "ANATOMY", 58, 70], ["nuclear", "ANATOMY", 131, 138], ["HepG2 cells", "ANATOMY", 177, 188], ["DEN", "CHEMICAL", 228, 231], ["DEN NS1", "ORGANISM", 0, 7], ["membrane rafts", "CELLULAR_COMPONENT", 31, 45], ["cell surface", "CELLULAR_COMPONENT", 58, 70], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 82, 87], ["nuclear", "CELLULAR_COMPONENT", 131, 138], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 156, 165], ["HepG2 cells", "CELL", 177, 188], ["DEN", "SIMPLE_CHEMICAL", 228, 231], ["DEN NS1", "PROTEIN", 0, 7], ["NF-\u03baB", "PROTEIN", 82, 87], ["NF-\u03baB p65 protein", "PROTEIN", 156, 173], ["HepG2 cells", "CELL_LINE", 177, 188], ["DEN NS1", "PROBLEM", 0, 7], ["HepG2 cells", "TEST", 177, 188], ["DEN pathogenicity", "PROBLEM", 228, 245], ["membrane rafts", "OBSERVATION", 31, 45], ["host cell", "OBSERVATION_MODIFIER", 53, 62], ["surface", "OBSERVATION_MODIFIER", 63, 70], ["suggesting a possible", "UNCERTAINTY", 190, 211]]], ["In JEV-infected microglia, the integrity of membrane rafts and the activation of Src-related Ras/Raf/ERK cascades participate in NF-\u03baB activation and consequent TNF\u03b1 and interleukin-1 beta (IL-1\u03b2) expression.", [["microglia", "ANATOMY", 16, 25], ["membrane rafts", "ANATOMY", 44, 58], ["JEV-infected", "DISEASE", 3, 15], ["JEV", "ORGANISM", 3, 6], ["microglia", "CELL", 16, 25], ["membrane rafts", "CELLULAR_COMPONENT", 44, 58], ["Ras", "GENE_OR_GENE_PRODUCT", 93, 96], ["Raf", "GENE_OR_GENE_PRODUCT", 97, 100], ["ERK", "GENE_OR_GENE_PRODUCT", 101, 104], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 129, 134], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 161, 165], ["interleukin-1 beta", "GENE_OR_GENE_PRODUCT", 170, 188], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 190, 195], ["microglia", "CELL_TYPE", 16, 25], ["Src-related Ras", "PROTEIN", 81, 96], ["Raf", "PROTEIN", 97, 100], ["ERK", "PROTEIN", 101, 104], ["NF-\u03baB", "PROTEIN", 129, 134], ["TNF\u03b1", "PROTEIN", 161, 165], ["JEV", "SPECIES", 3, 6], ["JEV", "PROBLEM", 3, 6], ["infected microglia", "PROBLEM", 7, 25], ["Src-related Ras", "TREATMENT", 81, 96], ["Raf", "PROBLEM", 97, 100], ["ERK cascades", "PROBLEM", 101, 113], ["consequent TNF\u03b1", "TREATMENT", 150, 165], ["interleukin", "TREATMENT", 170, 181], ["beta (IL", "TREATMENT", 184, 192], ["JEV", "OBSERVATION", 3, 6], ["infected microglia", "OBSERVATION", 7, 25], ["membrane rafts", "OBSERVATION", 44, 58]]], ["These signal activations and cytokine expressions caused by JEV infection may play a critical role in neuronal cell death [222] .Role of Membrane Rafts in Virus-Induced Signal TransductionsThe partitioning of measles virus F protein into high buoyant density-membrane rafts activates an alternative pathway of human complement independently of CD46 and CD55, which regulate the complement activation and do not exist in the same rafts as the F protein.", [["neuronal cell", "ANATOMY", 102, 115], ["Membrane", "ANATOMY", 137, 145], ["membrane rafts", "ANATOMY", 259, 273], ["rafts", "ANATOMY", 429, 434], ["JEV infection", "DISEASE", 60, 73], ["neuronal cell death", "DISEASE", 102, 121], ["JEV", "ORGANISM", 60, 63], ["neuronal cell", "CELL", 102, 115], ["Virus", "ORGANISM", 155, 160], ["measles virus F", "GENE_OR_GENE_PRODUCT", 209, 224], ["membrane rafts", "CELLULAR_COMPONENT", 259, 273], ["human", "ORGANISM", 310, 315], ["CD46", "GENE_OR_GENE_PRODUCT", 344, 348], ["CD55", "GENE_OR_GENE_PRODUCT", 353, 357], ["rafts", "CELLULAR_COMPONENT", 429, 434], ["F", "GENE_OR_GENE_PRODUCT", 442, 443], ["cytokine", "PROTEIN", 29, 37], ["measles virus F protein", "PROTEIN", 209, 232], ["CD46", "PROTEIN", 344, 348], ["CD55", "PROTEIN", 353, 357], ["F protein", "PROTEIN", 442, 451], ["measles virus", "SPECIES", 209, 222], ["human", "SPECIES", 310, 315], ["JEV", "SPECIES", 60, 63], ["measles virus", "SPECIES", 209, 222], ["human", "SPECIES", 310, 315], ["cytokine expressions", "PROBLEM", 29, 49], ["JEV infection", "PROBLEM", 60, 73], ["Membrane Rafts in Virus", "TREATMENT", 137, 160], ["measles virus F protein", "TREATMENT", 209, 232], ["high buoyant density-membrane rafts", "TREATMENT", 238, 273], ["CD46 and CD55", "TREATMENT", 344, 357], ["JEV infection", "OBSERVATION", 60, 73], ["neuronal cell death", "OBSERVATION", 102, 121], ["Membrane Rafts", "OBSERVATION", 137, 151], ["high buoyant", "OBSERVATION_MODIFIER", 238, 250], ["membrane rafts", "OBSERVATION", 259, 273]]], ["Thus, measles virus infection induces inflammatory response through alternative complement activation [223] .", [["measles virus infection", "DISEASE", 6, 29], ["measles virus", "ORGANISM", 6, 19], ["measles virus", "SPECIES", 6, 19], ["measles virus infection", "PROBLEM", 6, 29], ["inflammatory response", "PROBLEM", 38, 59], ["inflammatory", "OBSERVATION_MODIFIER", 38, 50]]], ["Measles virus-induced immunosuppression also results from signal transduction alteration such as PI3K present in membrane rafts of T cells [224] .Role of Membrane Rafts in Virus-Induced Signal TransductionsHSV-1 infection is implicated in Alzheimer's disease susceptibility by virus binding to HSPGs, nectin receptors, \u03b12macrolgobulin, blood-borne lipoproteins, and apolipoprotein E. Cholesterol reduction on the plasma membrane by a cholesterol synthesis inhibitor has been linked to a decrease in the risk for development of Alzheimer's dementia.", [["membrane rafts", "ANATOMY", 113, 127], ["T cells", "ANATOMY", 131, 138], ["Membrane", "ANATOMY", 154, 162], ["blood", "ANATOMY", 336, 341], ["plasma membrane", "ANATOMY", 413, 428], ["infection", "DISEASE", 212, 221], ["Alzheimer's disease", "DISEASE", 239, 258], ["cholesterol", "CHEMICAL", 434, 445], ["Alzheimer's dementia", "DISEASE", 527, 547], ["Cholesterol", "CHEMICAL", 384, 395], ["cholesterol", "CHEMICAL", 434, 445], ["Measles virus", "ORGANISM", 0, 13], ["PI3K", "GENE_OR_GENE_PRODUCT", 97, 101], ["membrane rafts", "CELLULAR_COMPONENT", 113, 127], ["T cells", "CELL", 131, 138], ["Virus", "ORGANISM", 172, 177], ["HSV-1", "ORGANISM", 206, 211], ["HSPGs", "GENE_OR_GENE_PRODUCT", 294, 299], ["nectin receptors", "GENE_OR_GENE_PRODUCT", 301, 317], ["\u03b12macrolgobulin", "GENE_OR_GENE_PRODUCT", 319, 334], ["blood", "ORGANISM_SUBSTANCE", 336, 341], ["apolipoprotein E.", "SIMPLE_CHEMICAL", 366, 383], ["Cholesterol", "SIMPLE_CHEMICAL", 384, 395], ["plasma membrane", "CELLULAR_COMPONENT", 413, 428], ["cholesterol", "SIMPLE_CHEMICAL", 434, 445], ["PI3K", "PROTEIN", 97, 101], ["T cells", "CELL_TYPE", 131, 138], ["HSPGs", "PROTEIN", 294, 299], ["nectin receptors", "PROTEIN", 301, 317], ["\u03b12macrolgobulin", "PROTEIN", 319, 334], ["blood-borne lipoproteins", "PROTEIN", 336, 360], ["HSV-1", "SPECIES", 206, 211], ["Measles virus", "SPECIES", 0, 13], ["HSV-1", "SPECIES", 206, 211], ["Measles virus", "PROBLEM", 0, 13], ["immunosuppression", "TREATMENT", 22, 39], ["signal transduction alteration", "PROBLEM", 58, 88], ["Membrane Rafts", "TREATMENT", 154, 168], ["HSV", "TEST", 206, 209], ["1 infection", "PROBLEM", 210, 221], ["Alzheimer's disease susceptibility", "PROBLEM", 239, 273], ["virus binding", "PROBLEM", 277, 290], ["HSPGs", "TEST", 294, 299], ["nectin receptors", "TEST", 301, 317], ["\u03b12macrolgobulin", "TEST", 319, 334], ["blood-borne lipoproteins", "TEST", 336, 360], ["apolipoprotein E. Cholesterol reduction", "TREATMENT", 366, 405], ["the plasma membrane", "TREATMENT", 409, 428], ["a cholesterol synthesis inhibitor", "TREATMENT", 432, 465], ["Alzheimer's dementia", "PROBLEM", 527, 547], ["Membrane Rafts", "OBSERVATION", 154, 168], ["infection", "OBSERVATION", 212, 221], ["decrease", "OBSERVATION_MODIFIER", 487, 495], ["Alzheimer", "OBSERVATION", 527, 536]]], ["Since HSV-1 uptake into cells is dependent on cholesterol and membrane rafts, cholesterol reduction may decrease the availability of raft-dependent pathways to spread HSV-1 in the brain [225, 226] .", [["cells", "ANATOMY", 24, 29], ["membrane rafts", "ANATOMY", 62, 76], ["raft", "ANATOMY", 133, 137], ["brain", "ANATOMY", 180, 185], ["cholesterol", "CHEMICAL", 46, 57], ["cholesterol", "CHEMICAL", 78, 89], ["cholesterol", "CHEMICAL", 46, 57], ["cholesterol", "CHEMICAL", 78, 89], ["HSV-1", "ORGANISM", 6, 11], ["cells", "CELL", 24, 29], ["cholesterol", "SIMPLE_CHEMICAL", 46, 57], ["membrane rafts", "CELLULAR_COMPONENT", 62, 76], ["cholesterol", "SIMPLE_CHEMICAL", 78, 89], ["raft", "CELLULAR_COMPONENT", 133, 137], ["HSV-1", "ORGANISM", 167, 172], ["brain", "ORGAN", 180, 185], ["HSV-1", "SPECIES", 6, 11], ["HSV-1", "SPECIES", 167, 172], ["HSV", "TEST", 6, 9], ["1 uptake into cells", "PROBLEM", 10, 29], ["cholesterol and membrane rafts", "TREATMENT", 46, 76], ["cholesterol reduction", "TREATMENT", 78, 99], ["HSV", "TEST", 167, 170], ["dependent", "OBSERVATION_MODIFIER", 33, 42], ["membrane rafts", "OBSERVATION", 62, 76], ["brain", "ANATOMY", 180, 185]]], ["Tyrosine kinase-interacting protein (Tip) of lymphotropic herpesvirus saimiri (HVS) downregulates T-cell receptor (TCR) and CD4 expression on the cell surface through its targeting to membrane rafts in T cells.", [["T-cell", "ANATOMY", 98, 104], ["cell surface", "ANATOMY", 146, 158], ["membrane rafts", "ANATOMY", 184, 198], ["T cells", "ANATOMY", 202, 209], ["Tyrosine", "CHEMICAL", 0, 8], ["Tyrosine", "CHEMICAL", 0, 8], ["Tyrosine kinase-interacting protein", "GENE_OR_GENE_PRODUCT", 0, 35], ["Tip", "GENE_OR_GENE_PRODUCT", 37, 40], ["lymphotropic herpesvirus saimiri", "ORGANISM", 45, 77], ["HVS", "ORGANISM", 79, 82], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 98, 113], ["TCR", "GENE_OR_GENE_PRODUCT", 115, 118], ["CD4", "GENE_OR_GENE_PRODUCT", 124, 127], ["cell surface", "CELLULAR_COMPONENT", 146, 158], ["membrane rafts", "CELLULAR_COMPONENT", 184, 198], ["T cells", "CELL", 202, 209], ["Tyrosine kinase-interacting protein", "PROTEIN", 0, 35], ["Tip", "PROTEIN", 37, 40], ["T-cell receptor", "PROTEIN", 98, 113], ["TCR", "PROTEIN", 115, 118], ["CD4", "PROTEIN", 124, 127], ["T cells", "CELL_TYPE", 202, 209], ["lymphotropic herpesvirus saimiri", "SPECIES", 45, 77], ["lymphotropic herpesvirus saimiri", "SPECIES", 45, 77], ["HVS", "SPECIES", 79, 82], ["Tyrosine kinase", "TEST", 0, 15], ["interacting protein", "PROBLEM", 16, 35], ["lymphotropic herpesvirus saimiri (HVS", "TREATMENT", 45, 82], ["T-cell receptor", "TREATMENT", 98, 113], ["TCR", "TEST", 115, 118], ["CD4 expression", "PROBLEM", 124, 138], ["the cell surface", "TREATMENT", 142, 158], ["lymphotropic herpesvirus", "OBSERVATION", 45, 69]]], ["Tip is required for cellular membrane deformation of T cells but not for viral replication, which induces lymphoma in primates [227] .", [["cellular membrane", "ANATOMY", 20, 37], ["T cells", "ANATOMY", 53, 60], ["lymphoma", "ANATOMY", 106, 114], ["lymphoma", "DISEASE", 106, 114], ["Tip", "GENE_OR_GENE_PRODUCT", 0, 3], ["cellular membrane", "CELLULAR_COMPONENT", 20, 37], ["T cells", "CELL", 53, 60], ["lymphoma", "CANCER", 106, 114], ["Tip", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 53, 60], ["Tip", "TREATMENT", 0, 3], ["cellular membrane deformation of T cells", "TREATMENT", 20, 60], ["viral replication", "PROBLEM", 73, 90], ["lymphoma", "PROBLEM", 106, 114], ["required for", "UNCERTAINTY", 7, 19], ["cellular membrane deformation", "OBSERVATION", 20, 49], ["T cells", "OBSERVATION", 53, 60], ["not for", "UNCERTAINTY", 65, 72], ["viral replication", "OBSERVATION", 73, 90], ["lymphoma", "OBSERVATION", 106, 114]]], ["HHV-8 encodes two RING finger E3 ubiquitin ligases (MIR1 and MIR2) that mediate ubiquitination and degradation of cellular proteins important for immune response.", [["cellular", "ANATOMY", 114, 122], ["HHV-8", "ORGANISM", 0, 5], ["MIR1", "GENE_OR_GENE_PRODUCT", 52, 56], ["MIR2", "GENE_OR_GENE_PRODUCT", 61, 65], ["cellular", "CELL", 114, 122], ["HHV-8", "DNA", 0, 5], ["RING finger E3 ubiquitin ligases", "PROTEIN", 18, 50], ["MIR1", "PROTEIN", 52, 56], ["MIR2", "PROTEIN", 61, 65], ["cellular proteins", "PROTEIN", 114, 131], ["HHV-8", "SPECIES", 0, 5], ["HHV", "TEST", 0, 3], ["two RING finger E3 ubiquitin ligases", "TREATMENT", 14, 50], ["MIR1 and MIR2)", "TREATMENT", 52, 66], ["cellular proteins", "TREATMENT", 114, 131], ["immune response", "PROBLEM", 146, 161], ["ubiquitin ligases", "OBSERVATION", 33, 50]]], ["Many of the MIR substrates are believed to be present in membrane rafts.", [["membrane rafts", "ANATOMY", 57, 71], ["membrane rafts", "CELLULAR_COMPONENT", 57, 71], ["the MIR substrates", "TREATMENT", 8, 26], ["believed to be", "UNCERTAINTY", 31, 45], ["membrane rafts", "OBSERVATION", 57, 71]]], ["Function of MIR2 is required for its palmitoylation, which is known as a posttranslational modification that enhances recruitment of transmembrane proteins into membrane rafts.", [["transmembrane", "ANATOMY", 133, 146], ["membrane rafts", "ANATOMY", 161, 175], ["MIR2", "GENE_OR_GENE_PRODUCT", 12, 16], ["transmembrane", "CELLULAR_COMPONENT", 133, 146], ["membrane rafts", "CELLULAR_COMPONENT", 161, 175], ["MIR2", "PROTEIN", 12, 16], ["transmembrane proteins", "PROTEIN", 133, 155], ["its palmitoylation", "PROBLEM", 33, 51], ["a posttranslational modification", "PROBLEM", 71, 103], ["membrane rafts", "OBSERVATION", 161, 175]]], ["MIR2 function may play an important role in immune evasion of the virus and resultant persistent viral infection by MIR2-mediated downregulation of MHC-I and platelet endothelial cell adhesion molecule 1 (PECAM-1) [228] .Role of Membrane Rafts in Virus-Induced Signal TransductionsGM1 expression and asialo-GM1 expression in membrane rafts of T cells and natural killer (NK) cells are differentially regulated by these cells in the context of RSV infection.", [["Membrane", "ANATOMY", 229, 237], ["membrane rafts", "ANATOMY", 325, 339], ["T cells", "ANATOMY", 343, 350], ["natural killer (NK) cells", "ANATOMY", 355, 380], ["cells", "ANATOMY", 419, 424], ["viral infection", "DISEASE", 97, 112], ["RSV infection", "DISEASE", 443, 456], ["MIR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["MIR2", "GENE_OR_GENE_PRODUCT", 116, 120], ["MHC-I", "GENE_OR_GENE_PRODUCT", 148, 153], ["platelet endothelial cell adhesion molecule 1", "GENE_OR_GENE_PRODUCT", 158, 203], ["PECAM-1", "GENE_OR_GENE_PRODUCT", 205, 212], ["Virus", "ORGANISM", 247, 252], ["asialo-GM1", "GENE_OR_GENE_PRODUCT", 300, 310], ["membrane rafts", "CELLULAR_COMPONENT", 325, 339], ["T cells", "CELL", 343, 350], ["natural killer (NK) cells", "CELL", 355, 380], ["cells", "CELL", 419, 424], ["RSV", "ORGANISM", 443, 446], ["MIR2", "PROTEIN", 0, 4], ["MIR2", "PROTEIN", 116, 120], ["MHC-I", "PROTEIN", 148, 153], ["platelet endothelial cell adhesion molecule 1", "PROTEIN", 158, 203], ["PECAM", "PROTEIN", 205, 210], ["GM1", "PROTEIN", 307, 310], ["T cells", "CELL_TYPE", 343, 350], ["natural killer (NK) cells", "CELL_TYPE", 355, 380], ["RSV", "SPECIES", 443, 446], ["immune evasion", "TREATMENT", 44, 58], ["the virus", "PROBLEM", 62, 71], ["resultant persistent viral infection", "PROBLEM", 76, 112], ["MIR2", "TEST", 116, 120], ["platelet endothelial cell adhesion molecule", "TEST", 158, 201], ["PECAM", "TEST", 205, 210], ["Membrane Rafts", "TREATMENT", 229, 243], ["asialo", "TEST", 300, 306], ["T cells", "PROBLEM", 343, 350], ["RSV infection", "PROBLEM", 443, 456], ["persistent", "OBSERVATION_MODIFIER", 86, 96], ["viral", "OBSERVATION_MODIFIER", 97, 102], ["infection", "OBSERVATION", 103, 112], ["platelet endothelial cell adhesion", "OBSERVATION", 158, 192], ["Membrane Rafts", "OBSERVATION", 229, 243], ["RSV", "OBSERVATION_MODIFIER", 443, 446], ["infection", "OBSERVATION", 447, 456]]], ["Asialo-GM1 may increase RSV clearance by increasing IFN-\u03b3 levels in mouse lungs [229] .Role of Membrane Rafts in Virus-Induced Signal TransductionsThe pseudorabies virus Us9 protein interacts with membrane rafts and then promotes targeting of viral structural proteins to neuronal axons.", [["lungs", "ANATOMY", 74, 79], ["Membrane", "ANATOMY", 95, 103], ["membrane rafts", "ANATOMY", 197, 211], ["neuronal axons", "ANATOMY", 272, 286], ["Asialo", "CHEMICAL", 0, 6], ["Asialo-GM1", "SIMPLE_CHEMICAL", 0, 10], ["RSV", "ORGANISM", 24, 27], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 52, 57], ["mouse", "ORGANISM", 68, 73], ["lungs", "ORGAN", 74, 79], ["Virus", "ORGANISM", 113, 118], ["pseudorabies virus", "ORGANISM", 151, 169], ["Us9", "GENE_OR_GENE_PRODUCT", 170, 173], ["membrane rafts", "CELLULAR_COMPONENT", 197, 211], ["neuronal axons", "CELLULAR_COMPONENT", 272, 286], ["IFN", "PROTEIN", 52, 55], ["\u03b3", "PROTEIN", 56, 57], ["pseudorabies virus Us9 protein", "PROTEIN", 151, 181], ["viral structural proteins", "PROTEIN", 243, 268], ["mouse", "SPECIES", 68, 73], ["pseudorabies virus", "SPECIES", 151, 169], ["RSV", "SPECIES", 24, 27], ["mouse", "SPECIES", 68, 73], ["pseudorabies virus", "SPECIES", 151, 169], ["Asialo-GM1", "TREATMENT", 0, 10], ["RSV clearance", "PROBLEM", 24, 37], ["increasing IFN", "TREATMENT", 41, 55], ["Membrane Rafts in Virus", "TREATMENT", 95, 118], ["The pseudorabies virus", "TREATMENT", 147, 169], ["membrane rafts", "TREATMENT", 197, 211], ["viral structural proteins", "PROBLEM", 243, 268], ["lungs", "ANATOMY", 74, 79], ["Membrane Rafts", "OBSERVATION", 95, 109], ["membrane rafts", "OBSERVATION", 197, 211], ["viral structural proteins", "OBSERVATION", 243, 268]]], ["Consequently, the virus spreads from presynaptic to postsynaptic neurons and cells of the mammalian nervous systems [108] .Role of Membrane Rafts in Virus-Induced Signal TransductionsRaft-dependent phagocytosis of HCV-infected apoptotic vesicles containing viral double-strand RNA (dsRNA) is required for maturation of human monocyte-derived dendritic cells (MoDCs).", [["presynaptic", "ANATOMY", 37, 48], ["postsynaptic neurons", "ANATOMY", 52, 72], ["cells", "ANATOMY", 77, 82], ["mammalian nervous systems", "ANATOMY", 90, 115], ["Membrane", "ANATOMY", 131, 139], ["vesicles", "ANATOMY", 237, 245], ["monocyte-derived dendritic cells", "ANATOMY", 325, 357], ["MoDCs", "ANATOMY", 359, 364], ["neurons", "CELL", 65, 72], ["cells", "CELL", 77, 82], ["nervous", "ANATOMICAL_SYSTEM", 100, 107], ["Virus", "ORGANISM", 149, 154], ["Raft", "GENE_OR_GENE_PRODUCT", 183, 187], ["HCV", "ORGANISM", 214, 217], ["apoptotic vesicles", "CELLULAR_COMPONENT", 227, 245], ["human", "ORGANISM", 319, 324], ["monocyte-derived dendritic cells", "CELL", 325, 357], ["MoDCs", "CELL", 359, 364], ["postsynaptic neurons", "CELL_TYPE", 52, 72], ["viral double-strand RNA", "RNA", 257, 280], ["human monocyte-derived dendritic cells", "CELL_TYPE", 319, 357], ["MoDCs", "CELL_TYPE", 359, 364], ["human", "SPECIES", 319, 324], ["HCV", "SPECIES", 214, 217], ["human", "SPECIES", 319, 324], ["the virus spreads", "PROBLEM", 14, 31], ["Membrane Rafts in Virus", "PROBLEM", 131, 154], ["dependent phagocytosis", "PROBLEM", 188, 210], ["HCV", "PROBLEM", 214, 217], ["infected apoptotic vesicles", "PROBLEM", 218, 245], ["viral double-strand RNA (dsRNA", "TREATMENT", 257, 287], ["human monocyte", "TEST", 319, 333], ["postsynaptic neurons", "OBSERVATION", 52, 72], ["mammalian nervous", "ANATOMY", 90, 107], ["Membrane Rafts", "OBSERVATION", 131, 145], ["HCV", "OBSERVATION", 214, 217], ["infected", "OBSERVATION_MODIFIER", 218, 226], ["apoptotic vesicles", "OBSERVATION", 227, 245], ["viral", "OBSERVATION_MODIFIER", 257, 262], ["double", "OBSERVATION_MODIFIER", 263, 269], ["strand RNA", "OBSERVATION_MODIFIER", 270, 280], ["dendritic cells", "OBSERVATION", 342, 357]]], ["However, HCV JFH1 strain, which can efficiently replicate in cell culture, does not directly stimulate MoDCs for activation of T cells and NK cells [230] .", [["cell culture", "ANATOMY", 61, 73], ["MoDCs", "ANATOMY", 103, 108], ["T cells", "ANATOMY", 127, 134], ["NK cells", "ANATOMY", 139, 147], ["HCV JFH1", "ORGANISM", 9, 17], ["strain", "ORGANISM", 18, 24], ["cell", "CELL", 61, 65], ["MoDCs", "GENE_OR_GENE_PRODUCT", 103, 108], ["T cells", "CELL", 127, 134], ["NK cells", "CELL", 139, 147], ["MoDCs", "PROTEIN", 103, 108], ["T cells", "CELL_TYPE", 127, 134], ["NK cells", "CELL_TYPE", 139, 147], ["HCV", "SPECIES", 9, 12], ["HCV JFH1 strain", "PROBLEM", 9, 24], ["cell culture", "TEST", 61, 73], ["NK cells", "PROBLEM", 139, 147]]], ["HCV envelope E2 protein attenuates interleukin-2 (IL-2) production at the level of secretion by its interaction with tetraspanin CD81 coreceptor and sequent recruitment of protein kinase C beta (PKC\u03b2), which is essential for IL-2 secretion, to membrane rafts in peripheral blood mononuclear cells.", [["membrane rafts", "ANATOMY", 244, 258], ["peripheral blood mononuclear cells", "ANATOMY", 262, 296], ["E2", "CHEMICAL", 13, 15], ["HCV", "ORGANISM", 0, 3], ["interleukin-2", "GENE_OR_GENE_PRODUCT", 35, 48], ["IL-2", "GENE_OR_GENE_PRODUCT", 50, 54], ["tetraspanin CD81", "GENE_OR_GENE_PRODUCT", 117, 133], ["protein kinase C beta", "GENE_OR_GENE_PRODUCT", 172, 193], ["PKC\u03b2", "GENE_OR_GENE_PRODUCT", 195, 199], ["IL-2", "GENE_OR_GENE_PRODUCT", 225, 229], ["membrane", "CELLULAR_COMPONENT", 244, 252], ["peripheral blood mononuclear cells", "CELL", 262, 296], ["HCV envelope E2 protein", "PROTEIN", 0, 23], ["tetraspanin CD81 coreceptor", "PROTEIN", 117, 144], ["protein kinase C beta", "PROTEIN", 172, 193], ["PKC\u03b2", "PROTEIN", 195, 199], ["IL", "PROTEIN", 225, 227], ["peripheral blood mononuclear cells", "CELL_TYPE", 262, 296], ["HCV", "SPECIES", 0, 3], ["HCV envelope E2 protein", "TEST", 0, 23], ["interleukin", "TEST", 35, 46], ["tetraspanin CD81 coreceptor", "TREATMENT", 117, 144], ["protein kinase C beta (PKC\u03b2)", "TEST", 172, 200], ["IL", "TEST", 225, 227], ["peripheral", "ANATOMY_MODIFIER", 262, 272], ["blood", "ANATOMY", 273, 278], ["mononuclear cells", "OBSERVATION", 279, 296]]], ["The ability of the E2 protein to attenuate IL-2 and IFN-\u03b3 secretion has been suggested to contribute to a mechanism for HCV to evade the human immune response and to establish persistent infection [231] .Role of Membrane Rafts in Virus-Induced Signal TransductionsAntibodies against SARS-CoV spike domain2 (S2) in patient sera can cross-react with human lung epithelial cells through annexin A2, which has been identified as one of the candidate proteins of the autoantigen.", [["Membrane", "ANATOMY", 212, 220], ["sera", "ANATOMY", 322, 326], ["lung epithelial cells", "ANATOMY", 354, 375], ["E2", "CHEMICAL", 19, 21], ["infection", "DISEASE", 187, 196], ["E2", "GENE_OR_GENE_PRODUCT", 19, 21], ["IL-2", "GENE_OR_GENE_PRODUCT", 43, 47], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 52, 57], ["HCV", "ORGANISM", 120, 123], ["human", "ORGANISM", 137, 142], ["Virus", "ORGANISM", 230, 235], ["SARS-CoV spike domain2", "GENE_OR_GENE_PRODUCT", 283, 305], ["S2", "GENE_OR_GENE_PRODUCT", 307, 309], ["patient", "ORGANISM", 314, 321], ["sera", "ORGANISM_SUBSTANCE", 322, 326], ["human", "ORGANISM", 348, 353], ["lung epithelial cells", "CELL", 354, 375], ["annexin A2", "GENE_OR_GENE_PRODUCT", 384, 394], ["E2 protein", "PROTEIN", 19, 29], ["IFN", "PROTEIN", 52, 55], ["\u03b3", "PROTEIN", 56, 57], ["Virus-Induced Signal TransductionsAntibodies", "PROTEIN", 230, 274], ["SARS-CoV spike domain2", "PROTEIN", 283, 305], ["S2", "PROTEIN", 307, 309], ["human lung epithelial cells", "CELL_TYPE", 348, 375], ["annexin A2", "PROTEIN", 384, 394], ["autoantigen", "PROTEIN", 462, 473], ["human", "SPECIES", 137, 142], ["patient", "SPECIES", 314, 321], ["human", "SPECIES", 348, 353], ["HCV", "SPECIES", 120, 123], ["human", "SPECIES", 137, 142], ["SARS-CoV", "SPECIES", 283, 291], ["human", "SPECIES", 348, 353], ["the E2 protein", "TREATMENT", 15, 29], ["IL", "TEST", 43, 45], ["IFN", "TREATMENT", 52, 55], ["HCV", "PROBLEM", 120, 123], ["persistent infection", "PROBLEM", 176, 196], ["Membrane Rafts in Virus", "TREATMENT", 212, 235], ["Signal TransductionsAntibodies", "TEST", 244, 274], ["SARS", "PROBLEM", 283, 287], ["CoV spike domain2 (S2) in patient sera", "PROBLEM", 288, 326], ["human lung epithelial cells", "PROBLEM", 348, 375], ["annexin A2", "TEST", 384, 394], ["persistent", "OBSERVATION_MODIFIER", 176, 186], ["infection", "OBSERVATION", 187, 196], ["Membrane Rafts", "OBSERVATION", 212, 226], ["lung", "ANATOMY", 354, 358], ["epithelial cells", "OBSERVATION", 359, 375]]], ["SARS-CoV-induced cytokines interlekin-6 (IL-6) and INF\u03b3 stimulate surface expression and raft distribution of annexin A2 in human lung type II epithelial A549 cells and increase the binding capability of anti-S2 antibodies to human lung epithelial cells.", [["surface", "ANATOMY", 66, 73], ["raft", "ANATOMY", 89, 93], ["lung type II epithelial A549 cells", "ANATOMY", 130, 164], ["lung epithelial cells", "ANATOMY", 232, 253], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["interlekin-6", "GENE_OR_GENE_PRODUCT", 27, 39], ["IL-6", "GENE_OR_GENE_PRODUCT", 41, 45], ["INF\u03b3", "GENE_OR_GENE_PRODUCT", 51, 55], ["surface", "CELLULAR_COMPONENT", 66, 73], ["raft", "CELLULAR_COMPONENT", 89, 93], ["annexin A2", "GENE_OR_GENE_PRODUCT", 110, 120], ["human", "ORGANISM", 124, 129], ["lung type II epithelial A549 cells", "CELL", 130, 164], ["anti-S2 antibodies", "GENE_OR_GENE_PRODUCT", 204, 222], ["human", "ORGANISM", 226, 231], ["lung epithelial cells", "CELL", 232, 253], ["SARS-CoV-induced cytokines", "PROTEIN", 0, 26], ["interlekin-6 (IL-6", "PROTEIN", 27, 45], ["INF\u03b3", "PROTEIN", 51, 55], ["annexin A2", "PROTEIN", 110, 120], ["human lung type II epithelial A549 cells", "CELL_LINE", 124, 164], ["anti-S2 antibodies", "PROTEIN", 204, 222], ["human lung epithelial cells", "CELL_TYPE", 226, 253], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 226, 231], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["cytokines", "TEST", 17, 26], ["interlekin", "TEST", 27, 37], ["IL", "TEST", 41, 43], ["annexin A2 in human lung type II epithelial A549 cells", "PROBLEM", 110, 164], ["the binding capability", "TEST", 178, 200], ["anti-S2 antibodies", "TEST", 204, 222], ["annexin A2", "OBSERVATION", 110, 120], ["lung", "ANATOMY", 130, 134], ["epithelial A549 cells", "OBSERVATION", 143, 164], ["lung", "ANATOMY", 232, 236], ["epithelial cells", "OBSERVATION", 237, 253]]], ["The upregulated expression and raft targeting of annexin A2 and the cross-reactivity of anti-S2 antibodies to annexin A2 may contribute to the pathogenesis of SARS disease [232] .Role of Membrane Rafts in Virus-Induced Signal TransductionsRhinovirus serotype 39 colocalizes with Src kinases, PI3K, and the serine threonine kinase Akt in membrane rafts in the context of virus infection.", [["raft", "ANATOMY", 31, 35], ["Membrane", "ANATOMY", 187, 195], ["membrane rafts", "ANATOMY", 337, 351], ["annexin A2", "CHEMICAL", 110, 120], ["SARS disease", "DISEASE", 159, 171], ["infection", "DISEASE", 376, 385], ["serine", "CHEMICAL", 306, 312], ["threonine", "CHEMICAL", 313, 322], ["raft", "CELLULAR_COMPONENT", 31, 35], ["annexin A2", "GENE_OR_GENE_PRODUCT", 49, 59], ["anti-S2 antibodies", "GENE_OR_GENE_PRODUCT", 88, 106], ["annexin A2", "GENE_OR_GENE_PRODUCT", 110, 120], ["Virus", "ORGANISM", 205, 210], ["Src", "GENE_OR_GENE_PRODUCT", 279, 282], ["PI3K", "GENE_OR_GENE_PRODUCT", 292, 296], ["serine", "AMINO_ACID", 306, 312], ["threonine kinase", "SIMPLE_CHEMICAL", 313, 329], ["Akt", "GENE_OR_GENE_PRODUCT", 330, 333], ["membrane rafts", "CELLULAR_COMPONENT", 337, 351], ["annexin A2", "PROTEIN", 49, 59], ["anti-S2 antibodies", "PROTEIN", 88, 106], ["annexin A2", "PROTEIN", 110, 120], ["Src kinases", "PROTEIN", 279, 290], ["PI3K", "PROTEIN", 292, 296], ["serine threonine kinase", "PROTEIN", 306, 329], ["Akt", "PROTEIN", 330, 333], ["annexin A2", "TREATMENT", 49, 59], ["the cross-reactivity", "TEST", 64, 84], ["anti-S2 antibodies to annexin A2", "PROBLEM", 88, 120], ["SARS disease", "PROBLEM", 159, 171], ["Membrane Rafts in Virus", "TREATMENT", 187, 210], ["Rhinovirus serotype", "TEST", 239, 258], ["Src kinases", "TEST", 279, 290], ["PI3K", "TEST", 292, 296], ["the serine threonine kinase", "TREATMENT", 302, 329], ["Akt in membrane rafts", "TREATMENT", 330, 351], ["virus infection", "PROBLEM", 370, 385], ["upregulated", "OBSERVATION_MODIFIER", 4, 15], ["expression", "OBSERVATION", 16, 26], ["raft", "OBSERVATION_MODIFIER", 31, 35], ["Membrane Rafts", "OBSERVATION", 187, 201], ["membrane rafts", "OBSERVATION", 337, 351], ["virus", "OBSERVATION_MODIFIER", 370, 375], ["infection", "OBSERVATION", 376, 385]]], ["Src and PI3K are upstream activators of Akt and the interleukin-8 (IL-8) promoter.", [["Src", "GENE_OR_GENE_PRODUCT", 0, 3], ["PI3K", "GENE_OR_GENE_PRODUCT", 8, 12], ["Akt", "GENE_OR_GENE_PRODUCT", 40, 43], ["interleukin-8", "GENE_OR_GENE_PRODUCT", 52, 65], ["IL-8", "GENE_OR_GENE_PRODUCT", 67, 71], ["Src", "PROTEIN", 0, 3], ["PI3K", "PROTEIN", 8, 12], ["Akt and the interleukin-8 (IL-8) promoter", "DNA", 40, 81], ["Src", "TEST", 0, 3], ["PI3K", "TEST", 8, 12], ["Akt", "TEST", 40, 43], ["the interleukin-8 (IL-8) promoter", "TREATMENT", 48, 81], ["PI3K", "ANATOMY", 8, 12]]], ["Rhinovirus infection activates these kinases and sequent IL-8 expression, which exacerbates asthma and chronic obstructive pulmonary disease [233] .Role of Membrane Rafts in Virus-Induced Signal TransductionsPersistent HPV infection results in transformation of epithelial cells that induces cellular polarity disturbance, which is implicated in MAL and BENE, components of the membrane raft's machinery for apical sorting of membrane proteins.", [["pulmonary", "ANATOMY", 123, 132], ["Membrane", "ANATOMY", 156, 164], ["epithelial cells", "ANATOMY", 262, 278], ["cellular", "ANATOMY", 292, 300], ["membrane raft", "ANATOMY", 378, 391], ["apical", "ANATOMY", 408, 414], ["membrane", "ANATOMY", 426, 434], ["infection", "DISEASE", 11, 20], ["asthma", "DISEASE", 92, 98], ["chronic obstructive pulmonary disease", "DISEASE", 103, 140], ["HPV infection", "DISEASE", 219, 232], ["IL-8", "GENE_OR_GENE_PRODUCT", 57, 61], ["pulmonary", "ORGAN", 123, 132], ["Virus", "ORGANISM", 174, 179], ["HPV", "ORGANISM", 219, 222], ["epithelial cells", "CELL", 262, 278], ["cellular", "CELL", 292, 300], ["MAL", "GENE_OR_GENE_PRODUCT", 346, 349], ["BENE", "GENE_OR_GENE_PRODUCT", 354, 358], ["membrane raft", "CELLULAR_COMPONENT", 378, 391], ["apical", "CELLULAR_COMPONENT", 408, 414], ["membrane", "CELLULAR_COMPONENT", 426, 434], ["kinases", "PROTEIN", 37, 44], ["IL-8", "PROTEIN", 57, 61], ["epithelial cells", "CELL_TYPE", 262, 278], ["MAL", "PROTEIN", 346, 349], ["BENE", "PROTEIN", 354, 358], ["membrane proteins", "PROTEIN", 426, 443], ["HPV", "SPECIES", 219, 222], ["Rhinovirus infection", "PROBLEM", 0, 20], ["these kinases", "TEST", 31, 44], ["sequent IL", "TREATMENT", 49, 59], ["asthma", "PROBLEM", 92, 98], ["chronic obstructive pulmonary disease", "PROBLEM", 103, 140], ["Membrane Rafts in Virus", "TREATMENT", 156, 179], ["Persistent HPV infection", "PROBLEM", 208, 232], ["epithelial cells", "PROBLEM", 262, 278], ["cellular polarity disturbance", "PROBLEM", 292, 321], ["the membrane raft's machinery", "TREATMENT", 374, 403], ["apical sorting of membrane proteins", "PROBLEM", 408, 443], ["infection", "OBSERVATION", 11, 20], ["asthma", "OBSERVATION", 92, 98], ["chronic", "OBSERVATION_MODIFIER", 103, 110], ["obstructive", "OBSERVATION_MODIFIER", 111, 122], ["pulmonary", "ANATOMY", 123, 132], ["disease", "OBSERVATION", 133, 140], ["Membrane Rafts", "OBSERVATION", 156, 170], ["Persistent", "OBSERVATION_MODIFIER", 208, 218], ["HPV infection", "OBSERVATION", 219, 232], ["epithelial cells", "OBSERVATION", 262, 278], ["cellular polarity disturbance", "OBSERVATION", 292, 321], ["apical", "ANATOMY_MODIFIER", 408, 414], ["membrane proteins", "OBSERVATION", 426, 443]]], ["Down-regulation of MAL and BENE genes in the context of HPV infection may play an important role in development of human cervical squamous cell cancer [112] .", [["cervical squamous cell cancer", "ANATOMY", 121, 150], ["HPV infection", "DISEASE", 56, 69], ["cervical squamous cell cancer", "DISEASE", 121, 150], ["MAL", "GENE_OR_GENE_PRODUCT", 19, 22], ["BENE", "GENE_OR_GENE_PRODUCT", 27, 31], ["HPV", "ORGANISM", 56, 59], ["human", "ORGANISM", 115, 120], ["cervical squamous cell cancer", "CANCER", 121, 150], ["MAL and BENE genes", "DNA", 19, 37], ["human", "SPECIES", 115, 120], ["HPV", "SPECIES", 56, 59], ["human", "SPECIES", 115, 120], ["MAL and BENE genes", "PROBLEM", 19, 37], ["HPV infection", "PROBLEM", 56, 69], ["human cervical squamous cell cancer", "PROBLEM", 115, 150], ["infection", "OBSERVATION", 60, 69], ["cervical", "ANATOMY", 121, 129], ["squamous cell cancer", "OBSERVATION", 130, 150]]], ["The \"early\" gene oncoproteins E6 and E7 of high-risk HPV are known to be invariably expressed in cervical cancers by inducing several signal alterations such as p53 inactivation, apoptosis suppression, telomerase activation, and cell adhesion disruption [234] .", [["cervical cancers", "ANATOMY", 97, 113], ["cell", "ANATOMY", 229, 233], ["cervical cancers", "DISEASE", 97, 113], ["E6", "GENE_OR_GENE_PRODUCT", 30, 32], ["E7", "GENE_OR_GENE_PRODUCT", 37, 39], ["HPV", "ORGANISM", 53, 56], ["cervical cancers", "CANCER", 97, 113], ["p53", "GENE_OR_GENE_PRODUCT", 161, 164], ["telomerase", "GENE_OR_GENE_PRODUCT", 202, 212], ["cell", "CELL", 229, 233], ["\"early\" gene oncoproteins", "PROTEIN", 4, 29], ["E6", "PROTEIN", 30, 32], ["E7", "PROTEIN", 37, 39], ["p53", "PROTEIN", 161, 164], ["telomerase", "PROTEIN", 202, 212], ["HPV", "SPECIES", 53, 56], ["high-risk HPV", "PROBLEM", 43, 56], ["cervical cancers", "PROBLEM", 97, 113], ["several signal alterations", "PROBLEM", 126, 152], ["p53 inactivation", "PROBLEM", 161, 177], ["apoptosis suppression", "PROBLEM", 179, 200], ["telomerase activation", "PROBLEM", 202, 223], ["cell adhesion disruption", "PROBLEM", 229, 253], ["cervical", "ANATOMY", 97, 105], ["cancers", "OBSERVATION", 106, 113], ["cell adhesion", "OBSERVATION", 229, 242]]], ["The additional oncoprotein E5 of high-risk HPV type 16 increases expression and association of both GM1 and caveolin-1, components of membrane rafts, on the cell surface.", [["membrane rafts", "ANATOMY", 134, 148], ["cell surface", "ANATOMY", 157, 169], ["E5", "GENE_OR_GENE_PRODUCT", 27, 29], ["HPV type 16", "ORGANISM", 43, 54], ["GM1", "GENE_OR_GENE_PRODUCT", 100, 103], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 108, 118], ["membrane rafts", "CELLULAR_COMPONENT", 134, 148], ["cell surface", "CELLULAR_COMPONENT", 157, 169], ["oncoprotein E5", "PROTEIN", 15, 29], ["GM1", "PROTEIN", 100, 103], ["caveolin-1", "PROTEIN", 108, 118], ["membrane rafts", "PROTEIN", 134, 148], ["The additional oncoprotein E5", "TEST", 0, 29], ["membrane rafts", "PROBLEM", 134, 148], ["the cell surface", "TREATMENT", 153, 169], ["oncoprotein E5", "OBSERVATION_MODIFIER", 15, 29], ["both", "ANATOMY_MODIFIER", 95, 99], ["GM1", "ANATOMY", 100, 103], ["membrane rafts", "OBSERVATION", 134, 148], ["cell surface", "OBSERVATION", 157, 169]]], ["This up-regulation of membrane rafts helps HPV immune evasion by suppression of cytotoxic T lymphocytes and enhances proliferative signaling of epidermal growth factor (EGF) possibly through localization of the EGF receptor with membrane rafts [235] .Role of Membrane Rafts in Prion InfectionInvolvement of membrane rafts in infectious particle prion (PrP) infection has been reported [236] [237] [238] [239] [240] [241] [242] .", [["membrane rafts", "ANATOMY", 22, 36], ["cytotoxic T lymphocytes", "ANATOMY", 80, 103], ["membrane rafts", "ANATOMY", 229, 243], ["Membrane", "ANATOMY", 259, 267], ["membrane rafts", "ANATOMY", 307, 321], ["Prion Infection", "DISEASE", 277, 292], ["infectious particle prion (PrP) infection", "DISEASE", 325, 366], ["[236] [237] [238] [239] [240] [241] [242]", "CHEMICAL", 385, 426], ["membrane rafts", "CELLULAR_COMPONENT", 22, 36], ["HPV", "ORGANISM", 43, 46], ["cytotoxic T lymphocytes", "CELL", 80, 103], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 144, 167], ["EGF", "GENE_OR_GENE_PRODUCT", 169, 172], ["EGF receptor", "GENE_OR_GENE_PRODUCT", 211, 223], ["membrane", "CELLULAR_COMPONENT", 229, 237], ["membrane rafts", "CELLULAR_COMPONENT", 307, 321], ["infectious particle prion", "GENE_OR_GENE_PRODUCT", 325, 350], ["PrP", "GENE_OR_GENE_PRODUCT", 352, 355], ["cytotoxic T lymphocytes", "CELL_TYPE", 80, 103], ["epidermal growth factor", "PROTEIN", 144, 167], ["EGF", "PROTEIN", 169, 172], ["EGF receptor", "PROTEIN", 211, 223], ["HPV", "SPECIES", 43, 46], ["membrane rafts", "TREATMENT", 22, 36], ["HPV immune evasion", "TREATMENT", 43, 61], ["cytotoxic T lymphocytes", "PROBLEM", 80, 103], ["epidermal growth factor (EGF)", "PROBLEM", 144, 173], ["membrane rafts", "PROBLEM", 229, 243], ["Membrane Rafts", "TREATMENT", 259, 273], ["membrane rafts", "PROBLEM", 307, 321], ["infectious particle prion (PrP) infection", "PROBLEM", 325, 366], ["cytotoxic T lymphocytes", "OBSERVATION", 80, 103], ["proliferative", "OBSERVATION_MODIFIER", 117, 130], ["epidermal", "OBSERVATION_MODIFIER", 144, 153], ["growth", "OBSERVATION_MODIFIER", 154, 160], ["Membrane Rafts", "OBSERVATION", 259, 273], ["Prion Infection", "OBSERVATION", 277, 292], ["membrane rafts", "OBSERVATION", 307, 321], ["infectious", "OBSERVATION_MODIFIER", 325, 335]]], ["PrP is an infectious protein that does not have a genome, unlike viruses.", [["PrP", "GENE_OR_GENE_PRODUCT", 0, 3], ["PrP", "PROTEIN", 0, 3], ["an infectious protein", "PROBLEM", 7, 28], ["infectious", "OBSERVATION", 10, 20], ["viruses", "OBSERVATION", 65, 72]]], ["PrP Sc , the protease-resistant isoform of the host normal prion protein PrP c , is the infectious component causing fetal neurodegenerative transmissible spongiform encephalopathies, called Creutzfeldt-Jakob disease in humans.", [["fetal", "ANATOMY", 117, 122], ["neurodegenerative transmissible spongiform encephalopathies", "DISEASE", 123, 182], ["Creutzfeldt-Jakob disease", "DISEASE", 191, 216], ["PrP Sc", "GENE_OR_GENE_PRODUCT", 0, 6], ["PrP c", "GENE_OR_GENE_PRODUCT", 73, 78], ["Creutzfeldt-Jakob", "ORGANISM", 191, 208], ["humans", "ORGANISM", 220, 226], ["PrP Sc", "PROTEIN", 0, 6], ["protease-resistant isoform", "PROTEIN", 13, 39], ["prion protein", "PROTEIN", 59, 72], ["PrP c", "PROTEIN", 73, 78], ["humans", "SPECIES", 220, 226], ["humans", "SPECIES", 220, 226], ["PrP Sc", "TREATMENT", 0, 6], ["the protease", "TREATMENT", 9, 21], ["the infectious component", "PROBLEM", 84, 108], ["fetal neurodegenerative transmissible spongiform encephalopathies", "PROBLEM", 117, 182], ["Jakob disease in humans", "PROBLEM", 203, 226], ["infectious", "OBSERVATION_MODIFIER", 88, 98], ["fetal", "ANATOMY", 117, 122], ["neurodegenerative transmissible", "OBSERVATION", 123, 154], ["spongiform encephalopathies", "OBSERVATION", 155, 182], ["disease", "OBSERVATION", 209, 216]]], ["PrP c , which contains a conserved N-terminal cationic domain that stimulates a raft-dependent pathway, internalizes in neuroblastoma N2a cells through a clathrin-independent pathway associated with Arf6 [241] and raft-dependent macropinocytosis [240] .", [["raft", "ANATOMY", 80, 84], ["neuroblastoma N2a cells", "ANATOMY", 120, 143], ["raft", "ANATOMY", 214, 218], ["neuroblastoma", "DISEASE", 120, 133], ["N", "CHEMICAL", 35, 36], ["PrP c", "GENE_OR_GENE_PRODUCT", 0, 5], ["raft", "CELLULAR_COMPONENT", 80, 84], ["neuroblastoma N2a cells", "CELL", 120, 143], ["clathrin", "GENE_OR_GENE_PRODUCT", 154, 162], ["Arf6", "GENE_OR_GENE_PRODUCT", 199, 203], ["raft", "CELLULAR_COMPONENT", 214, 218], ["PrP c", "PROTEIN", 0, 5], ["N-terminal cationic domain", "PROTEIN", 35, 61], ["neuroblastoma N2a cells", "CELL_LINE", 120, 143], ["clathrin", "PROTEIN", 154, 162], ["Arf6", "PROTEIN", 199, 203], ["a conserved N-terminal cationic domain", "TREATMENT", 23, 61], ["dependent pathway", "PROBLEM", 85, 102], ["neuroblastoma N2a cells", "PROBLEM", 120, 143], ["Arf6", "TEST", 199, 203], ["raft-dependent macropinocytosis", "PROBLEM", 214, 245], ["neuroblastoma N2a cells", "OBSERVATION", 120, 143], ["dependent", "OBSERVATION_MODIFIER", 219, 228], ["macropinocytosis", "OBSERVATION", 229, 245]]], ["On the other hand, PrP c internalizes in Fischer rat thyroid (FRT) cells by cooperation of clathrin-dependent and raft-dependent pathways.", [["thyroid (FRT) cells", "ANATOMY", 53, 72], ["raft", "ANATOMY", 114, 118], ["PrP c", "GENE_OR_GENE_PRODUCT", 19, 24], ["Fischer rat", "ORGANISM", 41, 52], ["thyroid (FRT) cells", "CELL", 53, 72], ["clathrin", "GENE_OR_GENE_PRODUCT", 91, 99], ["raft", "CELLULAR_COMPONENT", 114, 118], ["PrP c", "PROTEIN", 19, 24], ["Fischer rat thyroid (FRT) cells", "CELL_LINE", 41, 72], ["clathrin", "PROTEIN", 91, 99], ["rat", "SPECIES", 49, 52], ["PrP c internalizes", "TEST", 19, 37], ["clathrin", "TEST", 91, 99], ["thyroid", "ANATOMY", 53, 60]]], ["This internalization does not affect caveolin expression in FRT cells, which do not express caveolin-1 and do not have any caveolae.", [["FRT cells", "ANATOMY", 60, 69], ["caveolae", "ANATOMY", 123, 131], ["caveolin", "GENE_OR_GENE_PRODUCT", 37, 45], ["FRT cells", "CELL", 60, 69], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 92, 102], ["caveolae", "CELLULAR_COMPONENT", 123, 131], ["caveolin", "PROTEIN", 37, 45], ["FRT cells", "CELL_LINE", 60, 69], ["caveolin-1", "PROTEIN", 92, 102], ["caveolin expression in FRT cells", "PROBLEM", 37, 69], ["FRT cells", "OBSERVATION", 60, 69]]], ["These findings indicate that pathways of PrP c internalization are dependent on cell type and that the raft-dependent pathway distinctly differs from the caveola-dependent pathway [242] .", [["cell", "ANATOMY", 80, 84], ["raft", "ANATOMY", 103, 107], ["PrP c", "GENE_OR_GENE_PRODUCT", 41, 46], ["cell type", "CELL", 80, 89], ["raft", "CELLULAR_COMPONENT", 103, 107], ["caveola", "GENE_OR_GENE_PRODUCT", 154, 161], ["PrP c", "PROTEIN", 41, 46], ["PrP c internalization", "TREATMENT", 41, 62], ["dependent on cell type", "PROBLEM", 67, 89]]], ["Association of PrP C with cholesterol-enriched membrane rafts enhances correct protein folding of PrP c conformation.", [["membrane rafts", "ANATOMY", 47, 61], ["cholesterol", "CHEMICAL", 26, 37], ["cholesterol", "CHEMICAL", 26, 37], ["PrP C", "GENE_OR_GENE_PRODUCT", 15, 20], ["cholesterol", "SIMPLE_CHEMICAL", 26, 37], ["membrane rafts", "CELLULAR_COMPONENT", 47, 61], ["PrP c conformation", "GENE_OR_GENE_PRODUCT", 98, 116], ["PrP C", "PROTEIN", 15, 20], ["PrP c", "PROTEIN", 98, 103], ["PrP C", "PROBLEM", 15, 20], ["cholesterol-enriched membrane rafts", "TREATMENT", 26, 61], ["PrP c conformation", "TREATMENT", 98, 116], ["membrane rafts", "OBSERVATION", 47, 61], ["protein folding", "OBSERVATION", 79, 94]]], ["Cholesterol [236] [237] [238] .", [["Cholesterol [236] [237] [238", "CHEMICAL", 0, 28], ["Cholesterol", "CHEMICAL", 0, 11], ["Cholesterol", "SIMPLE_CHEMICAL", 0, 11], ["Cholesterol", "TEST", 0, 11]]], ["GPI-anchored HSPG glypican-1 directly interacts with both PrP c and PrP Sc and targets these to membrane rafts.", [["membrane rafts", "ANATOMY", 96, 110], ["GPI-anchored HSPG glypican-1", "GENE_OR_GENE_PRODUCT", 0, 28], ["PrP c", "GENE_OR_GENE_PRODUCT", 58, 63], ["PrP Sc", "GENE_OR_GENE_PRODUCT", 68, 74], ["membrane rafts", "CELLULAR_COMPONENT", 96, 110], ["GPI-anchored HSPG glypican-1", "PROTEIN", 0, 28], ["PrP c", "PROTEIN", 58, 63], ["PrP Sc", "PROTEIN", 68, 74], ["GPI", "TEST", 0, 3], ["anchored HSPG glypican", "TREATMENT", 4, 26], ["both PrP c", "TREATMENT", 53, 63], ["PrP Sc", "TREATMENT", 68, 74]]], ["Targeting of both prions through glypican-1 facilitates favorable interaction of PrP Sc with PrP c within membrane rafts, which are believed to be the conversion sites of PrP c to PrP Sc , suggesting a critical role of glypican-1 in the pathogenesis of prion disease [243] .", [["membrane rafts", "ANATOMY", 106, 120], ["prion disease", "DISEASE", 253, 266], ["glypican-1", "GENE_OR_GENE_PRODUCT", 33, 43], ["PrP Sc", "GENE_OR_GENE_PRODUCT", 81, 87], ["PrP c", "GENE_OR_GENE_PRODUCT", 93, 98], ["membrane rafts", "CELLULAR_COMPONENT", 106, 120], ["PrP c", "GENE_OR_GENE_PRODUCT", 171, 176], ["PrP Sc", "GENE_OR_GENE_PRODUCT", 180, 186], ["glypican-1", "GENE_OR_GENE_PRODUCT", 219, 229], ["glypican-1", "PROTEIN", 33, 43], ["PrP Sc", "PROTEIN", 81, 87], ["PrP c", "PROTEIN", 93, 98], ["PrP c", "PROTEIN", 171, 176], ["PrP Sc", "PROTEIN", 180, 186], ["glypican-1", "PROTEIN", 219, 229], ["glypican", "TEST", 33, 41], ["PrP Sc", "TREATMENT", 81, 87], ["PrP c within membrane rafts", "TREATMENT", 93, 120], ["PrP c to PrP Sc", "TREATMENT", 171, 186], ["prion disease", "PROBLEM", 253, 266], ["membrane rafts", "OBSERVATION", 106, 120]]], ["PrP c is associated with membrane rafts in membrane-derived microvesicles of human plasma that are important modulators of cell-to-cell communication.", [["membrane rafts", "ANATOMY", 25, 39], ["membrane", "ANATOMY", 43, 51], ["microvesicles", "ANATOMY", 60, 73], ["plasma", "ANATOMY", 83, 89], ["cell", "ANATOMY", 123, 127], ["cell", "ANATOMY", 131, 135], ["PrP c", "GENE_OR_GENE_PRODUCT", 0, 5], ["membrane rafts", "CELLULAR_COMPONENT", 25, 39], ["membrane", "CELLULAR_COMPONENT", 43, 51], ["microvesicles", "CELL", 60, 73], ["human", "ORGANISM", 77, 82], ["plasma", "ORGANISM_SUBSTANCE", 83, 89], ["cell", "CELL", 123, 127], ["cell", "CELL", 131, 135], ["PrP c", "PROTEIN", 0, 5], ["membrane-derived microvesicles", "CELL_TYPE", 43, 73], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["membrane rafts in membrane", "PROBLEM", 25, 51], ["human plasma", "TEST", 77, 89]]], ["Membrane-derived microvesicles bearing PrP c within membrane rafts may contribute to intercellular diffusion, intracellular signaling, and neuroinvasion of PrP c [244] .", [["Membrane", "ANATOMY", 0, 8], ["microvesicles", "ANATOMY", 17, 30], ["membrane rafts", "ANATOMY", 52, 66], ["intercellular", "ANATOMY", 85, 98], ["intracellular", "ANATOMY", 110, 123], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["microvesicles", "CELL", 17, 30], ["PrP c", "GENE_OR_GENE_PRODUCT", 39, 44], ["membrane rafts", "CELLULAR_COMPONENT", 52, 66], ["intercellular", "IMMATERIAL_ANATOMICAL_ENTITY", 85, 98], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 110, 123], ["PrP c [244]", "GENE_OR_GENE_PRODUCT", 156, 167], ["PrP c", "PROTEIN", 39, 44], ["PrP", "PROTEIN", 156, 159], ["PrP c within membrane rafts", "TREATMENT", 39, 66], ["intercellular diffusion", "PROBLEM", 85, 108], ["intracellular signaling", "TEST", 110, 133], ["microvesicles bearing PrP", "OBSERVATION", 17, 42], ["membrane rafts", "OBSERVATION", 52, 66], ["may contribute to", "UNCERTAINTY", 67, 84], ["intercellular diffusion", "OBSERVATION", 85, 108]]], ["The property of the GPI anchor attached to PrP Sc has been reported to affect the binding of PrP Sc to neurons, distribution to membrane rafts, and conversion of endogenous PrP c in GT1 neuronal cells [245] .", [["neurons", "ANATOMY", 103, 110], ["membrane rafts", "ANATOMY", 128, 142], ["neuronal cells", "ANATOMY", 186, 200], ["GPI", "GENE_OR_GENE_PRODUCT", 20, 23], ["PrP Sc", "GENE_OR_GENE_PRODUCT", 43, 49], ["PrP Sc", "GENE_OR_GENE_PRODUCT", 93, 99], ["neurons", "CELL", 103, 110], ["membrane rafts", "CELLULAR_COMPONENT", 128, 142], ["PrP c", "GENE_OR_GENE_PRODUCT", 173, 178], ["GT1 neuronal cells", "CELL", 182, 200], ["GPI anchor", "PROTEIN", 20, 30], ["PrP Sc", "PROTEIN", 43, 49], ["PrP Sc", "PROTEIN", 93, 99], ["PrP c", "PROTEIN", 173, 178], ["GT1 neuronal cells", "CELL_LINE", 182, 200], ["the GPI anchor", "TREATMENT", 16, 30], ["PrP Sc", "TREATMENT", 43, 49], ["endogenous PrP c in GT1 neuronal cells", "TREATMENT", 162, 200], ["neurons", "ANATOMY", 103, 110], ["membrane rafts", "OBSERVATION", 128, 142]]], ["Moreover, the increased level of glycosphingolipid GM1 (an essential raft marker) on fibroblast cells by a mouse parvovirus (Parvoviridae) infection may promote prion infection through the incorporation of exogenous PrP Sc into membrane rafts [239] .ConclusionMany studies have suggested the involvement of membrane rafts in cell entry, genome replication, assembly, budding, and virus-associated diseases of enveloped and nonenveloped viruses (summarized in Tables 1, 2, 3, and 4).", [["raft", "ANATOMY", 69, 73], ["fibroblast cells", "ANATOMY", 85, 101], ["membrane rafts", "ANATOMY", 228, 242], ["membrane rafts", "ANATOMY", 307, 321], ["cell", "ANATOMY", 325, 329], ["infection", "DISEASE", 139, 148], ["prion infection", "DISEASE", 161, 176], ["glycosphingolipid GM1", "GENE_OR_GENE_PRODUCT", 33, 54], ["raft", "CELLULAR_COMPONENT", 69, 73], ["fibroblast cells", "CELL", 85, 101], ["mouse parvovirus", "ORGANISM", 107, 123], ["Parvoviridae)", "ORGANISM", 125, 138], ["PrP Sc", "GENE_OR_GENE_PRODUCT", 216, 222], ["membrane rafts", "CELLULAR_COMPONENT", 228, 242], ["membrane rafts", "CELLULAR_COMPONENT", 307, 321], ["cell", "CELL", 325, 329], ["genome", "CELLULAR_COMPONENT", 337, 343], ["glycosphingolipid GM1", "PROTEIN", 33, 54], ["fibroblast cells", "CELL_TYPE", 85, 101], ["PrP Sc", "PROTEIN", 216, 222], ["mouse", "SPECIES", 107, 112], ["parvovirus", "SPECIES", 113, 123], ["mouse parvovirus", "SPECIES", 107, 123], ["the increased level of glycosphingolipid GM1", "PROBLEM", 10, 54], ["an essential raft marker", "TREATMENT", 56, 80], ["fibroblast cells", "TREATMENT", 85, 101], ["a mouse parvovirus (Parvoviridae) infection", "TREATMENT", 105, 148], ["prion infection", "PROBLEM", 161, 176], ["exogenous PrP Sc into membrane rafts", "TREATMENT", 206, 242], ["Many studies", "TEST", 260, 272], ["membrane rafts", "PROBLEM", 307, 321], ["genome replication", "PROBLEM", 337, 355], ["virus", "PROBLEM", 380, 385], ["associated diseases", "PROBLEM", 386, 405], ["nonenveloped viruses", "PROBLEM", 423, 443], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["glycosphingolipid GM1", "OBSERVATION", 33, 54], ["fibroblast cells", "OBSERVATION", 85, 101], ["prion infection", "OBSERVATION", 161, 176], ["membrane rafts", "OBSERVATION", 307, 321], ["cell entry", "OBSERVATION", 325, 335], ["genome replication", "OBSERVATION", 337, 355], ["nonenveloped", "OBSERVATION_MODIFIER", 423, 435], ["viruses", "OBSERVATION", 436, 443]]], ["Paradoxically, some recent studies have shown that membrane rafts are not necessarily required for efficient viral replication.", [["membrane rafts", "ANATOMY", 51, 65], ["membrane rafts", "CELLULAR_COMPONENT", 51, 65], ["some recent studies", "TEST", 15, 34], ["membrane rafts", "PROBLEM", 51, 65], ["efficient viral replication", "TREATMENT", 99, 126], ["membrane rafts", "OBSERVATION", 51, 65], ["not necessarily", "UNCERTAINTY", 70, 85]]], ["For the virus entry process, many viruses use several dif- ferent pathways, not only caveola/raft-dependent but also clathrin-dependent or another endocytic pathway such as macropinocytosis.", [["raft", "ANATOMY", 93, 97], ["caveola", "GENE_OR_GENE_PRODUCT", 85, 92], ["raft", "CELLULAR_COMPONENT", 93, 97], ["clathrin", "GENE_OR_GENE_PRODUCT", 117, 125], ["clathrin", "PROTEIN", 117, 125], ["the virus entry process", "PROBLEM", 4, 27], ["many viruses", "PROBLEM", 29, 41], ["macropinocytosis", "PROBLEM", 173, 189], ["virus", "OBSERVATION", 8, 13], ["viruses", "OBSERVATION", 34, 41], ["raft", "OBSERVATION", 93, 97], ["macropinocytosis", "OBSERVATION", 173, 189]]], ["Additionally, the caveola-dependent pathway does not necessarily correspond to the raft-dependent one, suggesting the existence of other complicated pathways associated with caveolae and membrane rafts.", [["raft", "ANATOMY", 83, 87], ["caveolae", "ANATOMY", 174, 182], ["membrane rafts", "ANATOMY", 187, 201], ["caveola", "GENE_OR_GENE_PRODUCT", 18, 25], ["raft", "CELLULAR_COMPONENT", 83, 87], ["caveolae", "CELLULAR_COMPONENT", 174, 182], ["membrane rafts", "CELLULAR_COMPONENT", 187, 201], ["caveolae and membrane rafts", "TREATMENT", 174, 201], ["dependent", "OBSERVATION_MODIFIER", 26, 35], ["pathway", "OBSERVATION", 36, 43], ["does not necessarily", "UNCERTAINTY", 44, 64], ["raft", "OBSERVATION", 83, 87], ["dependent", "OBSERVATION_MODIFIER", 88, 97], ["membrane rafts", "OBSERVATION", 187, 201]]], ["For the assembly and budding processes of many enveloped viruses, membrane raft disruption on host cells facilitates formation and production of progeny virus particles with less infectivity and lower viral components.", [["membrane raft", "ANATOMY", 66, 79], ["cells", "ANATOMY", 99, 104], ["membrane raft", "CELLULAR_COMPONENT", 66, 79], ["host cells", "CELL", 94, 104], ["host cells", "CELL_TYPE", 94, 104], ["the assembly and budding processes", "PROBLEM", 4, 38], ["many enveloped viruses", "PROBLEM", 42, 64], ["membrane raft disruption", "PROBLEM", 66, 90], ["host cells", "PROBLEM", 94, 104], ["progeny virus particles", "PROBLEM", 145, 168], ["less infectivity and lower viral components", "PROBLEM", 174, 217], ["many", "OBSERVATION_MODIFIER", 42, 46], ["enveloped", "OBSERVATION_MODIFIER", 47, 56], ["viruses", "OBSERVATION", 57, 64], ["membrane raft disruption", "OBSERVATION", 66, 90], ["host cells", "OBSERVATION", 94, 104], ["progeny virus", "OBSERVATION", 145, 158], ["less infectivity", "OBSERVATION_MODIFIER", 174, 190], ["lower", "OBSERVATION_MODIFIER", 195, 200], ["viral components", "OBSERVATION", 201, 217]]], ["Also, membrane rafts are not necessarily essential for cellular membrane targeting of viral structural proteins.", [["membrane rafts", "ANATOMY", 6, 20], ["cellular membrane", "ANATOMY", 55, 72], ["membrane rafts", "CELLULAR_COMPONENT", 6, 20], ["cellular membrane", "CELLULAR_COMPONENT", 55, 72], ["viral structural proteins", "PROTEIN", 86, 111], ["viral structural proteins", "PROBLEM", 86, 111], ["membrane rafts", "OBSERVATION", 6, 20], ["not necessarily", "UNCERTAINTY", 25, 40], ["viral structural proteins", "OBSERVATION", 86, 111]]], ["For virus assembly and budding, membrane rafts are more likely to provide progeny virus particles with greater infectivity because of the concentration and efficient incorporation of viral structural components from the assembly and budding sites to the virus particles.", [["membrane rafts", "ANATOMY", 32, 46], ["membrane rafts", "CELLULAR_COMPONENT", 32, 46], ["virus", "PROBLEM", 4, 9], ["progeny virus particles", "PROBLEM", 74, 97], ["greater infectivity", "PROBLEM", 103, 122], ["the concentration", "PROBLEM", 134, 151], ["viral structural components", "PROBLEM", 183, 210], ["the virus particles", "PROBLEM", 250, 269], ["membrane rafts", "OBSERVATION", 32, 46], ["more likely", "UNCERTAINTY", 51, 62], ["greater infectivity", "OBSERVATION_MODIFIER", 103, 122], ["viral structural components", "OBSERVATION", 183, 210]]], ["Similarly, concentration of viral polymerases into membrane rafts acts as a platform of more efficient replication and transcription of viral genomes.", [["membrane rafts", "ANATOMY", 51, 65], ["membrane rafts", "CELLULAR_COMPONENT", 51, 65], ["viral polymerases", "PROTEIN", 28, 45], ["viral genomes", "DNA", 136, 149], ["viral polymerases into membrane rafts", "TREATMENT", 28, 65], ["viral genomes", "PROBLEM", 136, 149], ["viral polymerases", "OBSERVATION", 28, 45], ["viral genomes", "OBSERVATION", 136, 149]]], ["Furthermore, the use of several endocytic pathways provides an advantage for virus entry into a wider range of hosts, cell lines, and tissues or can allow the virus to be assigned to an alternative pathway when one pathway does not work.", [["cell lines", "ANATOMY", 118, 128], ["tissues", "ANATOMY", 134, 141], ["cell lines", "CELL", 118, 128], ["tissues", "TISSUE", 134, 141], ["cell lines", "CELL_LINE", 118, 128], ["virus entry", "TREATMENT", 77, 88], ["cell lines", "TREATMENT", 118, 128], ["the virus", "PROBLEM", 155, 164], ["cell lines", "OBSERVATION", 118, 128]]], ["Concentration of viral fusion proteins in raft-associated receptors or caveola/raftdependent endocytosis may enhance membrane fusion between the virus and cell, leading to efficient release of viral internal proteins and genomes to the cytoplasm at an early stage of virus infection.", [["raft", "ANATOMY", 42, 46], ["membrane", "ANATOMY", 117, 125], ["cell", "ANATOMY", 155, 159], ["cytoplasm", "ANATOMY", 236, 245], ["infection", "DISEASE", 273, 282], ["raft", "CELLULAR_COMPONENT", 42, 46], ["caveola", "GENE_OR_GENE_PRODUCT", 71, 78], ["raftdependent", "GENE_OR_GENE_PRODUCT", 79, 92], ["membrane", "CELLULAR_COMPONENT", 117, 125], ["cell", "CELL", 155, 159], ["cytoplasm", "ORGANISM_SUBSTANCE", 236, 245], ["viral fusion proteins", "PROTEIN", 17, 38], ["raft-associated receptors", "PROTEIN", 42, 67], ["viral internal proteins", "PROTEIN", 193, 216], ["viral fusion proteins", "TREATMENT", 17, 38], ["associated receptors", "PROBLEM", 47, 67], ["caveola/raftdependent endocytosis", "PROBLEM", 71, 104], ["membrane fusion", "PROBLEM", 117, 132], ["the virus and cell", "PROBLEM", 141, 159], ["viral internal proteins", "PROBLEM", 193, 216], ["the cytoplasm", "PROBLEM", 232, 245], ["virus infection", "PROBLEM", 267, 282], ["viral fusion", "OBSERVATION", 17, 29], ["raftdependent endocytosis", "OBSERVATION", 79, 104], ["membrane fusion", "OBSERVATION", 117, 132], ["viral", "OBSERVATION", 193, 198], ["early stage", "OBSERVATION_MODIFIER", 252, 263], ["virus infection", "OBSERVATION", 267, 282]]], ["Taken together, the results indicate that membrane rafts are not essential for viral life cycles.", [["membrane rafts", "ANATOMY", 42, 56], ["membrane rafts", "CELLULAR_COMPONENT", 42, 56], ["membrane rafts", "PROBLEM", 42, 56], ["viral life cycles", "TREATMENT", 79, 96], ["membrane rafts", "OBSERVATION", 42, 56]]], ["Viruses probably take advantage of membrane rafts for more efficiency of virus entry, viral genome replication, and virus particle production.", [["membrane rafts", "ANATOMY", 35, 49], ["membrane rafts", "CELLULAR_COMPONENT", 35, 49], ["Viruses", "PROBLEM", 0, 7], ["membrane rafts", "TREATMENT", 35, 49], ["virus entry", "PROBLEM", 73, 84], ["viral genome replication", "PROBLEM", 86, 110], ["virus particle production", "PROBLEM", 116, 141], ["viral genome replication", "OBSERVATION", 86, 110]]], ["Viruses also induce many raft-mediated cellular signals which relate to characteristic symptoms of the viral diseases.ConclusionMany studies on the involvement of membrane rafts in viral infection cycles and viral infectious diseases have been performed by classical approaches (cholesterol-disrupting reagent treatments, detergent-insoluble fractionization, and microscopic observation of colocalization with raft markers) and by recent molecular biological approaches (RNAi and dominant negative expression against representative raft components).", [["raft", "ANATOMY", 25, 29], ["cellular", "ANATOMY", 39, 47], ["membrane rafts", "ANATOMY", 163, 177], ["raft", "ANATOMY", 410, 414], ["raft", "ANATOMY", 532, 536], ["viral diseases", "DISEASE", 103, 117], ["viral infection", "DISEASE", 181, 196], ["viral infectious diseases", "DISEASE", 208, 233], ["cholesterol", "CHEMICAL", 279, 290], ["cholesterol", "CHEMICAL", 279, 290], ["raft", "CELLULAR_COMPONENT", 25, 29], ["cellular", "CELL", 39, 47], ["membrane rafts", "CELLULAR_COMPONENT", 163, 177], ["cholesterol", "SIMPLE_CHEMICAL", 279, 290], ["raft markers", "PROTEIN", 410, 422], ["Viruses", "PROBLEM", 0, 7], ["many raft-mediated cellular signals", "PROBLEM", 20, 55], ["characteristic symptoms", "PROBLEM", 72, 95], ["the viral diseases", "PROBLEM", 99, 117], ["membrane rafts", "TREATMENT", 163, 177], ["viral infection cycles", "PROBLEM", 181, 203], ["viral infectious diseases", "PROBLEM", 208, 233], ["cholesterol", "TEST", 279, 290], ["disrupting reagent treatments", "TREATMENT", 291, 320], ["insoluble fractionization", "TREATMENT", 332, 357], ["microscopic observation", "TEST", 363, 386], ["many", "OBSERVATION_MODIFIER", 20, 24], ["raft", "OBSERVATION_MODIFIER", 25, 29], ["cellular signals", "OBSERVATION", 39, 55], ["viral diseases", "OBSERVATION", 103, 117], ["membrane rafts", "OBSERVATION", 163, 177], ["viral infection", "OBSERVATION", 181, 196]]], ["However, since various types of microdomains, such as raft-dependent, caveola-dependent, cholesterol-dependent, and other specialized microdomains, have been shown to have independent heterogeneous properties, evaluation of respective functions of distinct membrane rafts and microdomains would be difficult by experiments using only common approaches to study membrane rafts.", [["microdomains", "ANATOMY", 32, 44], ["raft", "ANATOMY", 54, 58], ["microdomains", "ANATOMY", 134, 146], ["membrane rafts", "ANATOMY", 257, 271], ["microdomains", "ANATOMY", 276, 288], ["membrane rafts", "ANATOMY", 361, 375], ["cholesterol", "CHEMICAL", 89, 100], ["cholesterol", "CHEMICAL", 89, 100], ["microdomains", "CELLULAR_COMPONENT", 32, 44], ["raft", "CELLULAR_COMPONENT", 54, 58], ["caveola", "SIMPLE_CHEMICAL", 70, 77], ["cholesterol", "SIMPLE_CHEMICAL", 89, 100], ["microdomains", "CELLULAR_COMPONENT", 134, 146], ["membrane rafts", "CELLULAR_COMPONENT", 257, 271], ["microdomains", "CELLULAR_COMPONENT", 276, 288], ["membrane rafts", "CELLULAR_COMPONENT", 361, 375], ["caveola-dependent, cholesterol-dependent", "PROBLEM", 70, 110], ["microdomains", "OBSERVATION", 32, 44], ["dependent", "OBSERVATION_MODIFIER", 59, 68], ["dependent", "OBSERVATION_MODIFIER", 78, 87], ["cholesterol", "OBSERVATION_MODIFIER", 89, 100], ["dependent", "OBSERVATION_MODIFIER", 101, 110], ["microdomains", "OBSERVATION", 134, 146], ["heterogeneous", "OBSERVATION_MODIFIER", 184, 197], ["distinct", "OBSERVATION_MODIFIER", 248, 256], ["membrane rafts", "OBSERVATION", 257, 271]]], ["Further study will require new approaches for elucidating the functions of distinct membrane microdomains.", [["membrane microdomains", "ANATOMY", 84, 105], ["membrane microdomains", "CELLULAR_COMPONENT", 84, 105], ["Further study", "TEST", 0, 13], ["new approaches", "TREATMENT", 27, 41], ["distinct membrane microdomains", "PROBLEM", 75, 105], ["distinct", "OBSERVATION_MODIFIER", 75, 83], ["membrane microdomains", "OBSERVATION", 84, 105]]], ["An understanding of the role of membrane rafts in viral lifecycle may contribute to elucidation of essential cellular functions Biochemistry Research International 15 of membrane rafts and to development of new antiviral chemotherapy against viral replications and viral infectious diseases.", [["membrane rafts", "ANATOMY", 32, 46], ["cellular", "ANATOMY", 109, 117], ["membrane rafts", "ANATOMY", 170, 184], ["viral infectious diseases", "DISEASE", 265, 290], ["membrane rafts", "CELLULAR_COMPONENT", 32, 46], ["cellular", "CELL", 109, 117], ["membrane rafts", "CELLULAR_COMPONENT", 170, 184], ["membrane rafts", "TREATMENT", 32, 46], ["membrane rafts", "TREATMENT", 170, 184], ["new antiviral chemotherapy", "TREATMENT", 207, 233], ["viral replications", "TREATMENT", 242, 260], ["viral infectious diseases", "PROBLEM", 265, 290], ["new", "OBSERVATION_MODIFIER", 207, 210], ["antiviral chemotherapy", "OBSERVATION", 211, 233], ["viral", "OBSERVATION_MODIFIER", 265, 270], ["infectious", "OBSERVATION", 271, 281]]]]}